<SEC-DOCUMENT>0001628280-23-027335.txt : 20230803
<SEC-HEADER>0001628280-23-027335.hdr.sgml : 20230803
<ACCEPTANCE-DATETIME>20230803171614
ACCESSION NUMBER:		0001628280-23-027335
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		123
CONFORMED PERIOD OF REPORT:	20230531
FILED AS OF DATE:		20230803
DATE AS OF CHANGE:		20230803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANGIODYNAMICS INC
		CENTRAL INDEX KEY:			0001275187
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				113146460
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50761
		FILM NUMBER:		231141194

	BUSINESS ADDRESS:	
		STREET 1:		14 PLAZA DRIVE
		CITY:			LATHAM
		STATE:			NY
		ZIP:			12110
		BUSINESS PHONE:		5187981215

	MAIL ADDRESS:	
		STREET 1:		14 PLAZA DRIVE
		CITY:			LATHAM
		STATE:			NY
		ZIP:			12110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ango-20230531.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:9980962c-8c03-489b-926a-266c60a03003,g:4284608e-2675-438a-ad4d-4e46a03d6c06,d:0c89ef540c7d4512afc87ee33fb4f1eb--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ango="http://www.angiodynamics.com/20230531" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ango-20230531</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-31">0001275187</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-32">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-51" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-412">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="c-51" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-610">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="c-120" name="us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-612">http://www.angiodynamics.com/20230531#AcquisitionRestructuringAndOtherItemsNet</ix:nonNumeric><ix:nonNumeric contextRef="c-44" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-877">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="c-166" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-908">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-8" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-972">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-973">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-976">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-8" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-977">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-980">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-8" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-981">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ango-20230531.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ango:PlacementAndEvaluationUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ango:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-27</xbrli:startDate><xbrli:endDate>2021-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-27</xbrli:startDate><xbrli:endDate>2021-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ango:DialysisProductPortfolioAndBioSentryBiopsyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ango:RevenueBasedPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ango:RevenueBasedPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ango:RevenueBasedPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ango:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ango:RevenueBasedPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ango:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ango:OarTracTrademarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ango:RadiaDyneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ango:PlacementAndEvaluationUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ango:PlacementAndEvaluationUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>ango:unit</xbrli:measure></xbrli:unit><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ango:ProductTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ango:ProductTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ango:EximoMedicalLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ango:EximoMedicalLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ango:TaxPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ango:TaxPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ango:TaxPeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ango:TaxPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ango:TaxPeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-30</xbrli:startDate><xbrli:endDate>2022-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-03</xbrli:startDate><xbrli:endDate>2019-06-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-30</xbrli:startDate><xbrli:endDate>2022-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-30</xbrli:startDate><xbrli:endDate>2022-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="covenant"><xbrli:measure>ango:covenant</xbrli:measure></xbrli:unit><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ango:RevolvingFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2014-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-29</xbrli:startDate><xbrli:endDate>2014-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>ango:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockAndIncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-03</xbrli:startDate><xbrli:endDate>2022-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:TwoThousandAndFourStockAndIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceShareAndRestrictedStockUnitAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceShareAndRestrictedStockUnitAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceShareAndRestrictedStockUnitAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceSharesIncludingThreeYearMarketConditionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceSharesIncludingThreeYearMarketConditionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceSharesIncludingThreeYearMarketConditionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceSharesIncludingThreeYearMarketConditionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ango:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ango:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ango:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ango:SalesandMarketingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ango:SalesandMarketingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ango:SalesandMarketingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employees"><xbrli:measure>ango:Employees</xbrli:measure></xbrli:unit><xbrli:unit id="working_hour"><xbrli:measure>ango:working_hour</xbrli:measure></xbrli:unit><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-03</xbrli:startDate><xbrli:endDate>2022-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ango:CrBardIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-11</xbrli:startDate><xbrli:endDate>2012-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ango:TheDelawareActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-10</xbrli:startDate><xbrli:endDate>2015-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ango:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ango:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ango:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:NetAssetsGeographicAreaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:LegalCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:LegalCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:LegalCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:MergersandAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:MergersandAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:MergersandAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:TransitionServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:TransitionServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:TransitionServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:DivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:DivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:DivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:IntangibleImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:IntangibleImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:IntangibleImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:IsraeliInnovationAuthorityPrepaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:IsraeliInnovationAuthorityPrepaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:IsraeliInnovationAuthorityPrepaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:ManufacturingRelocationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:ManufacturingRelocationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:ManufacturingRelocationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:SettlementExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-08</xbrli:startDate><xbrli:endDate>2023-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001275187</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"> UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.087%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.087%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">May 31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">0-50761</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.087%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">AngioDynamics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="ango-20230531_g1.gif" alt="angologoa21.gif" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:422px"/></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">11-3146460</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">14 Plaza Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Latham</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">New York</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">12110</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">518</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">795-1400</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">ANGO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Title of Class)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.087%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:1pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"><tr><td style="width:1.0%"></td><td style="width:19.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="f-24">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-25">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="f-26">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-27">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;padding-left:18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of November&#160;30, 2022, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-1" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-28">450,329,930</ix:nonFraction> computed by reference to the last sale price of the common stock on that date as reported by The NASDAQ Global Select Market.</span></div><div style="margin-top:3pt;padding-left:18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of August 2, 2023 there were <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-29">39,671,221</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</span></div><div style="margin-top:3pt;padding-left:18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:18pt"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-30" continuedAt="i5d9eb58dd67748508cf4ebd82f2efa5b" escape="true">DOCUMENTS INCORPORATED BY REFERENCE</ix:nonNumeric></span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i5d9eb58dd67748508cf4ebd82f2efa5b">The information required for Part III of this Annual Report on Form 10-K is incorporated by reference to the registrant&#8217;s Proxy Statement for its 2023 Annual Meeting of Stockholders to be filed within 120 days of the registrant's fiscal year ended May&#160;31, 2023.</ix:continuation> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AngioDynamics, Inc. and Subsidiaries</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part I:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_16">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_19">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_22">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_25">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_28">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part II:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_34">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_37">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_37">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_40">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_43">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_43">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_46">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_46">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_49">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_49">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_52">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_52">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_55">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_55">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_58">Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_58">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part III:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_64">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_64">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_67">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_67">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_70">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_70">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_73">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_73">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_76">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_76">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part IV:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_82">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_82">49</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_10"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise indicated in this report, "AngioDynamics," the "Company," "we," "our" or "us" refers to AngioDynamics, Inc and our consolidated subsidiaries.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Regarding Forward-Looking Statements</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This annual report on Form 10-K, including the sections entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," &#8220;projects&#8221;, "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses.  Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the Securities and Exchange Commission (the "SEC").</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this annual report on Form 10-K will prove to be accurate.  In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this report. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Regarding Trademarks</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes trademarks, tradenames and service marks that are our property or the property of other third parties. Solely for convenience, such trademarks and tradenames sometimes appear without any &#8220;&#8482;&#8221; or &#8220;&#174;&#8221; symbol. However, failure to include such symbols is not intended to suggest, in any way, that we will not assert our rights or the rights of any applicable licensor, to these trademarks and tradenames.  For a complete listing of all our trademarks, tradenames and service marks please visit www.angiodynamics.com/IP.</span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_13"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HISTORY</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AngioDynamics was founded in Queensbury, N.Y., U.S., in 1988 and began manufacturing and shipping product in the early 1990s.  The Company is headquartered in Latham, N.Y., with manufacturing primarily out of the Queensbury facility.  Initially dedicated to the research and development of products used in interventional radiology, the Company soon became well established as a producer of diagnostic catheters for non-coronary angiography and thrombolytic delivery systems.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grew over the following years as a result of acquisitions of companies including RITA Medical Systems in January 2007, Oncobionic in May 2008, the assets of Diomed in June 2008, Vortex Medical, Inc. in October 2012, the assets of Microsulis Medical Limited in January 2013, and Clinical Devices in August 2013. These acquisitions added product lines </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including ablation and NanoKnife systems, vascular access products, angiographic products and accessories, dialysis products, drainage products, thrombolytic products, embolization products and venous products.  In May 2012, the Company acquired Navilyst Medical's Fluid Management business, which the Company sold in May 2019 to Medline Industries, Inc. pursuant to an asset purchase agreement. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company acquired the BioSentry product line from Surgical Specialties, LLC.  In September 2018, the Company acquired RadiaDyne, which included endorectal and vaginal balloons.  On October 2, 2019, the Company acquired Eximo Medical, Ltd., a pre-commercial stage medical device company and its proprietary 355nm laser atherectomy technology (now called Auryon), which treats Peripheral Artery Disease.  On December 17, 2019, the Company acquired the C3 Wave tip location asset from Medical Components Inc.  On July 27, 2021, AngioDynamics acquired the Camaro Support Catheter asset from QX Medical, LLC.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AngioDynamics is publicly traded on the NASDAQ stock exchange under the symbol ANGO.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRODUCTS</span></div><div style="text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our product offerings fall within two segments, Med Tech and Med Device.  All products discussed below have been cleared for sale in the United States by the Food and Drug Administration.  International regulatory clearances vary by product and jurisdiction.</span></div><div style="text-indent:21.6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Med Tech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-indent:21.6pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Auryon </span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Auryon Atherectomy System is one of our latest advancements in peripheral arterial disease.  The Auryon system is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Additionally, the Auryon system includes aspiration which enhances the safety of the procedure. Regardless of lesion type, the Auryon system provides safety and efficacy. The Auryon system is indicated for use in the treatment, including atherectomy, of infrainguinal stenoses and occlusions, including in-stent restenosis (ISR), and to aspirate thrombus adjacent to stenoses in native and stented infrainguinal arteries.</span></div></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"><div style="margin-bottom:9pt;text-indent:21.6pt"><img src="ango-20230531_g2.jpg" alt="Auryon.jpg" style="height:183px;margin-bottom:5pt;vertical-align:text-bottom;width:284px"/></div></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Thrombectomy</span></div><div><span><br/></span></div><div style="text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Thrombus Management portfolio includes the AlphaVac Mechanical Thrombectomy System, AngioVac venous drainage cannula and circuit, as well as catheter directed thrombolytic devices, including the Uni-Fuse system, the Uni-Fuse+ system, the Pulse Spray system and SpeedLyser infusion catheters. AngioDynamics offers a range of options when treating thrombus and removing fresh, soft thrombi or emboli.</span></div><div style="text-indent:21.6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AngioVac</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:45.614%"><div style="margin-bottom:6pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AngioVac venous drainage system includes a Venous Drainage Cannula and Extracorporeal Circuit. The cannula is indicated for use as a venous drainage cannula and for removal of fresh, soft thrombi or emboli during extracorporeal bypass. The AngioVac circuit is indicated for use in procedures requiring extracorporeal circulatory support for periods of up to six hours. AngioVac devices are for use with other manufacturers&#8217; off-the-shelf pump, filter and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. </span></div></div><div style="display:inline-block;max-width:8.771%;min-width:7.771%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:45.615%"><div style="margin-bottom:9pt;text-indent:21.6pt"><img src="ango-20230531_g3.jpg" alt="AngioVac.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:209px"/></div></div></div><div style="text-indent:21.6pt"><span><br/></span></div><div style="text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AngioVac venous drainage cannula is a 22 French flat coil-reinforced cannula designed with a proprietary self-expanding nitinol reinforced funnel shaped distal tip. The funnel shaped tip enhances venous drainage flow when the distal tip is exposed by retracting the sheath, helps prevent clogging of the cannula with commonly encountered undesirable intravascular material, and facilitates embolic removal of such extraneous material.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AlphaVac </span></div><div><span><br/></span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"><div style="text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AlphaVac System is an emergent mechanical aspiration device that eliminates the need for perfusionist support.  AlphaVac is offered in both a 22 French flat coil-reinforced cannula and an 18 French braided reinforced cannula each designed with a proprietary self-expanding nitinol reinforced funnel shaped distal tip.  AlphaVac is indicated for the non-surgical removal of thrombi or emboli from vasculature as well as aspiration of contrast media and other fluids from the vasculature.  The cannula is intended for use in the venous system.  The handle is indicated as a vacuum source for the AlphaVac MMA system.</span></div></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                </span><img src="ango-20230531_g4.gif" alt="AlphaVac-Logo-and-Handle.gif" style="height:215px;margin-bottom:5pt;vertical-align:text-bottom;width:215px"/></div></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Thrombolytic Catheters</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins and surgical bypass grafts. AngioDynamics&#8217; Uni-Fuse infusion catheter features pressure response outlets, a proprietary slit technology that provides a consistent, even distribution of fluid volume along the entire length of the infusion pattern, designed to provide an advantage over standard side-hole catheters.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer the Pulse-Spray infusion system for high pressure, pulsed delivery of lytic agents designed to shorten treatment time, and the SpeedLyser infusion system built for dialysis grafts and fistulas.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NanoKnife</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NanoKnife IRE Ablation System is an alternative to traditional thermal ablation that received 510(k) clearance from the Food and Drug Administration for the surgical ablation of soft tissue. The system utilizes low energy direct current electrical pulses to permanently open pores in target cell membranes.&#160;These permanent pores or nano-scale defects in the cell membranes result in cell death.&#160;The treated tissue is then removed by the body&#8217;s natural processes in a matter of weeks, mimicking natural cell death.&#160;Unlike other ablation technologies, the NanoKnife System does not achieve tissue ablation using thermal energy.</span></div></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><img src="ango-20230531_g5.jpg" alt="nanoknifepicturea07.jpg" style="height:164px;margin-bottom:5pt;vertical-align:text-bottom;width:329px"/></div></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NanoKnife System consists of two major components: a Low Energy Direct Current, or LEDC Generator and needle-like electrode probes.&#160;Up to six (6)&#160;electrode probes can be placed into or around the targeted soft tissue.&#160;Once the probes are in place, the user enters the appropriate parameters for voltage, number of pulses, interval between pulses, and the pulse length into the generator user interface.&#160;The generator then delivers a series of short electric pulses between each electrode probe. The energy delivery is hyperechoic and can be monitored under real-time ultrasound.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Med Device</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Peripheral Products (Core)</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer a comprehensive portfolio for minimally invasive peripheral products.  Product categories include an extensive line of angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters and coaxial micro-introducer kits.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Angiographic Products and Accessories</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Angiographic products and accessories are used during peripheral diagnostic and interventional procedures. These products permit physicians to reach targeted locations to deliver contrast media for visualization purposes and therapeutic agents and devices, such as percutaneous transluminal angioplasty (PTA) balloons. Angiographic products consist of angiographic catheters and guidewires.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our angiographic catheter line includes the following brands, all with radiopaque tips to assure excellent visibility under fluoroscopy:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Soft-Vu flush catheters are available in flush and selective varieties.  Flush catheters are used in procedures where a high flow of contrast is required for &#8220;big picture&#8221; diagnostics. Anomalies discovered through a flush angiogram may require further investigation into a vessel of interest. Soft-Vu selective catheters are used to gain access to smaller or more distal vessels and advance the catheter or wire into the diseased section.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accu-Vu sizing catheters feature radiopaque marker bands at the distal portion of the catheter to provide a highly accurate measurement of the patient&#8217;s anatomy. This enables precise measurement for interventional devices such as stents.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mariner catheters have a hydrophilic coating that, when combined with water, reduces friction. This makes insertion potentially easier and more comfortable for the patient, and can also be used for advancing through tortuous anatomy.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AngioDynamics guidewires include Nit-Vu (featuring a kink-resistant NiTi alloy core facilitating smooth navigation through tortuous vasculature and accurate wire control) and Polytetrafluoroethylene (PTFE) Coated diagnostic guidewires (fixed core and movable core).</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AngioDynamics catheters and guidewires are available in more than 500 tip configurations and lengths.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drainage Products</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drainage products percutaneously drain abscesses and other fluid pockets. An abscess is a tender inflamed mass that typically must be drained by a physician. AngioDynamics offers two brands of drainage catheters for multi-purpose/general, nephrostomy and biliary drainage: Total Abscession and Exodus. Each offer features and benefits depending on case presentation and physician preferences.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Micro Access Kits</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Micro Access kits provide interventional physicians a smaller introducer system for minimally-invasive procedures. Our Micro Access product line provides physicians with the means to choose from the wide selection of configurations, including guidewire, needle and introducer options. Two lines are available in stiff/standard, 10cm or 15cm and echogenic for visibility under ultrasound guidance: Micro Introducer Kit and Ministick Max.</span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:0.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">BioFlo</span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"><div style="margin-bottom:0.9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AngioDynamics offers the BioFlo catheter, the only catheter on the market with Endexo Technology, a material more resistant to thrombus accumulation, in vitro (based on platelet count). Endexo Technology is a permanent and non-eluting polymer that is &#8220;blended&#8221; into the polyurethane from which the catheter is made. It is present throughout the catheter, including the extraluminal, intraluminal and cut catheter surface of the tip. Endexo Technology remains present for the life of the catheter.  The BioFlo catheter&#8217;s long-term durability and efficacy is intended to provide clinicians a high degree of safety and confidence in providing better patient care and improved patient outcomes. BioFlo catheters are available across the Vascular Access family of products, including PICCs, midlines, ports and dialysis catheters.</span></div></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><img src="ango-20230531_g6.jpg" alt="bioflopicturea05.jpg" style="height:164px;margin-bottom:5pt;vertical-align:text-bottom;width:329px"/></div></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Midlines</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Midline catheters are inserted via the same veins used for PICC placement in the middle third of the upper arm; however, the midline catheter is advanced and placed so that the catheter tip is level or near the level of the axilla and distal to the shoulder.  Our Midline product is a BioFlo Midline Catheter which incorporates Endexo Technology and is an effective solution to preserving a patient&#8217;s peripheral access.  It provides a cost-effective alternative to multiple IV site rotations for patients who need short-term venous access.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PICCs</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A peripherally inserted central catheter, or PICC, is a long thin catheter that is inserted into a peripheral vein, typically in the upper arm, and advanced until the catheter tip terminates in a large vein in the chest near the heart to obtain intravenous access. PICCs can typically be used for prolonged periods of time and provide an alternative to central venous catheters. Our PICC product offerings include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">BioFlo PICC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our BioFlo PICC line is the only power injectable PICC available that incorporates Endexo Technology into the manufacturing and design of the catheter. Advanced features such as large lumen diameters allow the BioFlo PICC to deliver the power injection flow rates required for contrast-enhanced Computed Tomography (CT) scans compatible with up to 325 psi CT injections.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Xcela PICC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Xcela PICC line is designed to provide a high degree of safety, ease and confidence in patient care. Advanced features such as large lumen diameters allow the Xcela PICC to deliver the power injection flow rates required for contrast-enhanced CTs compatible with up to 325 psi CT injections.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">PASV Valve Technology: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PASV Valve Technology is available in both BioFlo and Xcela lines and is designed to automatically resist backflow and reduce blood reflux that could lead to catheter-related complications.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">C3 Wave PICC tip location system</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The C3 Wave system is our innovative, wireless, app-based ECG system which eliminates the need for a confirmatory chest x-ray of PICC tip placement, allowing greater patient access to the Company&#8217;s proprietary BioFlo PICCs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Ports </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ports are implantable devices utilized for the central venous administration of a variety of medical therapies and for blood sampling and diagnostic purposes. Central venous access facilitates a more systemic delivery of treatment agents, while mitigating certain harsh side effects of certain treatment protocols and eliminating the need for repeated access to peripheral veins. Depending upon needle gauge size and the port size, a port can be utilized for up to approximately 2,000 accesses once implanted in the body. Our ports are used primarily in systemic or regional short- and long-term cancer treatment protocols that require frequent infusions of highly concentrated or toxic medications (such as chemotherapy agents, antibiotics or analgesics) and frequent blood samplings. Our port products and accessories include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">BioFlo Port</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our BioFlo Port was the first port available featuring a catheter with Endexo Technology. Advanced features of the BioFlo Port include multiple profile and catheter options, a large septum area for ease of access and the ability to administer contrast through a CT injection for purposes of imaging.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">SmartPort, SmartPort+, SmartPort Plastic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The SmartPort power-injectable port with Vortex technology offers the ability for a clinician to access a vein for both the delivery of medications or fluids and for administering power-</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injected contrast to perform a CT scan. The ability to access a port for power-injected contrast studies eliminates the need for additional needle sticks in the patient&#8217;s arm and wrist veins. Once implanted, repeated access to the bloodstream can be accomplished with greater ease and less discomfort. Our SmartPort port line is available in standard, mini and low-profiles to accommodate more patient anatomies.  The SmartPort+ port line combines Vortex technology with BioFlo catheters.  In addition to the three titanium port body sizes, there is a plastic port body.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Vortex:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Vortex port technology line of ports features a clear-flow port technology that, we believe, revolutionized port design. With its rounded chamber, the Vortex port is designed to have no sludge-harboring corners or dead spaces. This product line consists of titanium, plastic and dual-lumen offerings.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">PASV Valve Technology: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PASV Valve Technology is designed to automatically resist backflow and reduce blood reflux that could lead to catheter-related complications.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dialysis Products</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market an extensive line of dialysis products that provide short and long-term vascular access for dialysis patients. Dialysis, or cleaning of the blood, is necessary in conditions such as acute renal failure, chronic renal failure and end-stage renal disease (ESRD). We currently offer a variety of dialysis catheters, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">BioFlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DuraMax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our BioFlo DuraMax dialysis catheter is the only dialysis catheter with Endexo Technology. Advanced features of the BioFlo DuraMax dialysis catheter include large inner diameter lumens designed for long term patency, a proprietary guidewire lumen to facilitate catheter exchanges and Curved Tip Technology that allows the catheter to self-center in the Superior Vena Cava (SVC).</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">DuraMax:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The DuraMax catheter is a stepped-tip catheter designed to improve ease of use, dialysis efficiency and overall patient outcomes.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, AngioDynamics also offers other renal therapies, including our DuraFlow Chronic Hemodialysis Catheter, Acute Dialysis Catheter, EVENMORE Chronic Hemodialysis Catheter, EMBOSAFE Valved Splitable Sheath Dilator and Perchik Button Suture Retention Device.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Venous Insufficiency</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VenaCure EVLT laser system</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our VenaCure EVLT system products are used in endovascular laser procedures to treat superficial venous disease (varicose veins). Superficial venous disease is a malfunction of one or more valves in the leg&#160;veins whereby blood refluxes or does not return to the heart, thereby pooling in the legs and leading to symptoms such as pain, swelling and ulcerations. The VenaCure EVLT system uses laser energy to stop the reflux by ablating (collapsing and destroying) the affected vein. Blood is then re-routed to other healthy veins.</span></div></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"><div style="margin-bottom:9pt;text-indent:9pt"><img src="ango-20230531_g7.jpg" alt="venacureevltpicturea07.jpg" style="height:158px;margin-bottom:5pt;vertical-align:text-bottom;width:322px"/></div></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The procedure is minimally invasive and generally takes less than an hour, typically allowing the patient to quickly return to normal activities.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VenaCure EVLT system is sold as a system that includes diode laser hardware and procedure kits which include disposable laser fiber components, an access sheath, access wires and needles. Our VenaCure EVLT 1470 nanometer wavelength laser allows physicians to more efficiently heat the vein wall using lower power settings thereby reducing the risk of collateral&#160;damage. The NeverTouch tip fiber eliminates laser tip contact with the vein wall, which in turn minimizes perforations of the vein wall that typically result in less pain and bruising as compared to traditional bare-tip fibers. The NeverTouch tip also maximizes ultrasonic visibility, making it easier for physicians to use. Procedure kits are available in a variety of lengths and configurations to accommodate varied patient anatomies.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VenaCure EVLT system comes with a comprehensive physician training program and extensive marketing support.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Microwave Ablation </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solero Microwave Tissue Ablation (MTA) System</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solero MTA System features the Solero Microwave (MW) Generator and the specially designed Solero MW Applicators. The solid state Solero MW Generator with a 2.45 GHz operating frequency can power up to 140W for optimized power delivery and fast ablations. The Solero MW Applicator&#8217;s optimized ceramic tip diffuses MW energy nearly spherically, and its patented cooling channel with thermocouple provides real-time monitoring to help protect non-targeted tissue during the ablation. In addition, the Solero MTA System offers physicians scalability with a single applicator designed for multiple, predictable ablation volumes by varying time and wattage. Solero is a single applicator system able to complete up to a 5 cm ablation in six (6) minutes at maximum power.  </span></div></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><img src="ango-20230531_g8.jpg" alt="solerowhitea05.jpg" style="height:164px;margin-bottom:5pt;vertical-align:text-bottom;width:329px"/></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span><br/></span></div></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solero MTA System and Accessories are indicated for the ablation of soft tissue during open procedures. The Solero MTA System is not intended for cardiac use.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Radiofrequency Ablation </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">StarBurst Radiofrequency Ablation Devices</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Radiofrequency Ablation (RFA) products use radiofrequency energy to provide a minimally invasive approach to ablating solid cancerous or benign tumors. Our StarBurst Radiofrequency Ablation devices deliver radiofrequency energy to raise the temperature of cells above 45-50&#176;C, causing cellular death. The physician inserts the disposable needle electrode device into the targeted body tissue, typically under ultrasound, CT or Magnetic Resonance Imaging (MRI) guidance. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the procedure, our system automatically adjusts the amount of energy delivered in order to maintain the temperature necessary to ablate the targeted tissue. For a typical 5 cm ablation using our StarBurst Xli-enhanced disposable device, the ablation process takes approximately ten (10) minutes. The RFA system consists of a radiofrequency generator and a family of disposable devices.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to thermal ablation systems and the NanoKnife Ablation System, AngioDynamics also offers Habib 4X Surgical Resection devices that are used in minimally invasive laparoscopic surgery procedures in surgical specialties such as Hepato-Biliary, GI, Surgical Oncology, Transplant Surgery and Urology (Partial Nephrectomy Resections). It is clinically indicated to assist in coagulation of tissue during intraoperative and laparoscopic procedures.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">BioSentry Tract Sealant System</span></div></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BioSentry Tract Sealant System deploys a self-expanding hydrogel plug into the pleural space following a percutaneous lung biopsy, creating an airtight seal that closes the pleural puncture.  Depth markings&#160;provide accurate and consistent placement based on CT-guided measurements, while the depth adjustment wheel&#160;and&#160;locking mechanisms&#160;ensure proper plug deployment.  The hydrogel plug is made from a synthetic tissue-friendly polymer that fully reabsorbs into the body and the coaxial adapter mates with a coaxial needle to ensure a proper fit and delivery of the plug.  The BioSentry Tract Sealant System is indicated for sealing pleural punctures to significantly reduce the risk of pneumothoraxes (air leaks) associated with percutaneous, transthoracic needle lung biopsies and to provide accuracy in marking a biopsy location for visualization during surgical resection.  </span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">IsoLoc Endorectal Balloon</span></div></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IsoLoc Endorectal Balloon's unique, customer-driven design is the result of collaborations with Radiation Oncologists, Therapists and Physicists with one goal in mind, to create a new standard for endorectal balloons (ERB) in the oncology space.   </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design of the IsoLoc device not only addresses patient comfort, but also simplifies three challenging clinical scenarios that many physicians face when using radiation therapy for and/or in relation to the prostate.  First, its' gas-release tip removes rectal gas and reduces prostate motion for gaseous patients.  Secondly, the structure of the ERB aids in defining the anatomy for difficult planning scenarios with post-radical patients.  Lastly, the IsoLoc device repositions and lifts the bowel in patients that have a low-lying bowel.  </span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"></div></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Alatus Vaginal Balloon Packing System</span></div></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Alatus device was developed with the patient's comfort in mind and to assist the physician to move healthy tissue away from the radiation treatment field.  Prior to the Alatus device, the clinician would push gauze into the vagina to move the bladder and bowel away from the radiation treatment field.  Inserting gauze into the vagina can be uncomfortable before treatment and unpleasant at the end of treatment as it tends to dry out before removing. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESEARCH &amp; DEVELOPMENT </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growth depends in large part on the continuous introduction of new and innovative products, together with ongoing enhancements to our existing products. This happens through internal product development, technology licensing, strategic alliances and acquisitions.  Our research and development (R&amp;D) teams work closely with our marketing teams, sales force and regulatory and compliance teams to incorporate customer feedback into our development and design process. We believe that we have a reputation among interventional physicians as a strong partner for developing high quality products because of our tradition of close physician collaboration, dedicated market focus, responsiveness and execution capabilities for product development and commercialization.  We recognize the importance of, and intend to continue to make investments in R&amp;D.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITION</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We encounter significant competition across our product lines and in each market in which our products are sold. These markets are characterized by rapid change resulting from technological advances, scientific discoveries and changing customer needs and expectations. We face competitors, ranging from large manufacturers with multiple business lines, to small manufacturers that offer a limited selection of products.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary device competitors include: Boston Scientific Corporation; Cook Medical; Medical Components, Inc. (MedComp); TeleFlex Medical; Becton Dickinson; Medtronic; Merit Medical; Terumo Medical Corporation; Johnson and Johnson; Philips Healthcare; Inari Medical; Varian Medical Systems and Total Vein Systems.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our products compete primarily based on their quality, clinical outcomes, ease of use, reliability, physician familiarity and cost-effectiveness. In the current environment of managed care, which is characterized by economically motivated buyers, consolidation among health care providers, increased competition and declining reimbursement rates, we have been increasingly required to compete on the basis of price. We believe that our continued competitive success will depend upon our ability to develop or acquire scientifically advanced technology, apply our technology cost-effectively across product lines and markets, attract and retain skilled personnel, obtain patent or other protection for our products, obtain required regulatory and reimbursement approvals, manufacture and successfully market our products either directly or through third parties, and maintain sufficient inventory to meet customer demand.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALES AND MARKETING</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our broad line of quality devices in the United States primarily through a direct sales force and internationally through a combination of direct sales and distributor relationships.  We support our customers and sales organization with a marketing staff that includes product managers, customer service representatives and other marketing specialists.  We focus our sales and marketing efforts on interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANUFACTURING</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture certain proprietary components and products and then assemble, inspect, test and package our finished products. By designing and manufacturing many of our products from raw materials, and assembling and testing our subassemblies and products, we believe that we are able to maintain better quality control, ensure compliance with applicable regulatory standards and our internal specifications, and limit outside access to our proprietary technology. We have custom-designed proprietary manufacturing and processing equipment and have developed proprietary enhancements for existing production machinery.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture many of our products from two owned manufacturing properties, one in Queensbury, NY and one small facility in Glens Falls, NY, providing capabilities which include manufacturing, service, offices, engineering and research and we lease distribution warehouses.  The manufacturing facilities are registered with the FDA and have been certified to ISO 13485 standards. ISO 13485 is a quality system standard that satisfies European Union regulatory requirements, thus allowing us to market and sell our products in European Union countries. AngioDynamics is certified under the Medical Device Single Audit Program ("MDSAP") which allows a recognized auditing organization to conduct a single regulatory audit of a medical device manufacturer to satisfy the relevant requirements of the regulatory authorities participating in the program.  International partners that are participating in the MDSAP include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Therapeutic Goods Administration of Australia</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Brazil&#8217;s Ag&#234;ncia Nacional de Vigil&#226;ncia Sanit&#225;ria</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health Canada</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Japan&#8217;s Ministry of Health, Labour and Welfare, and the Japanese Pharmaceuticals and Medical Devices Agency</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. Food and Drug Administration</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing facilities are subject to periodic inspections by regulatory authorities to ensure compliance with domestic and non-U.S. regulatory requirements. See &#8220;Government Regulation&#8221; section of this Item 1 for additional information. See Part I, Item 2 "Properties" in this Annual Report on Form 10-K for details on each manufacturing location.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal year 2022, AngioDynamics entered into a supply agreement with Precision Concepts, Costa Rica S.A., a Costa Rica corporation, with its principal place of business in Alajuela, Costa Rica.  Precision Concepts is manufacturing, storing, and handling certain products for the Company and is registered with the FDA and certified to the ISO 13485 standard.  The Company also relies on third party manufacturers for the manufacturing of certain products.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BACKLOG</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically kept sufficient inventory on hand to ship product within 24-48 hours of order receipt to meet customer demand.  In fiscal year 2023, the Company's ability to manufacture products, the reliability of our supply chain, labor shortages, backlog and inflation (including the cost and availability of raw materials, direct labor and shipping) have impacted our business and resulted in a backlog of $2.7 million at the end of the fourth quarter.  We continue to focus on meeting the demand for our product and working towards standard inventory and backlog levels in fiscal year 2024.  See Part I, Item 1A "Risk Factors" in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents, trademarks and other proprietary rights are very important to our business. We also rely upon trade secrets, manufacturing know-how, technological innovations and licensing opportunities to maintain and improve our competitive position. We regularly monitor and review third-party proprietary rights, including patents and patent applications, as available, to aid in the development of our intellectual property strategy, avoid infringement of third-party proprietary rights, and identify licensing opportunities.  The Company owns an extensive portfolio of patents and patent applications in the United States and in certain foreign countries. The portfolio also includes exclusive licenses to third party patents and applications.  Most of our products are sold under the AngioDynamics trade name or trademark. Additionally, products are sold under product trademarks and/or registered product trademarks owned by AngioDynamics, Inc., or an affiliate or subsidiary. Some products contain trademarks of companies other than AngioDynamics.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part I, Item&#160;3 "Legal Proceedings" and Note 17 to the consolidated financial statements in this Annual Report on Form 10-K for additional details on litigation regarding proprietary technology.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LITIGATION</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in an industry characterized by extensive patent litigation. Patent litigation can result in significant damage awards and injunctions that could prevent the manufacture and sale of affected products, or result in significant royalty payments in order to continue selling those products. The medical device industry is also susceptible to significant product liability claims. These claims may be brought by individuals seeking relief on their own behalf or purporting to represent a class. In addition, product liability claims may be asserted against us in the future based on events we are not aware of at the present time. At any given time, we are involved in a number of product liability actions. For additional information, see both Part I, Item&#160;3 "Legal Proceedings" and Note 17 to the consolidated financial statements in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNMENT REGULATION</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we manufacture and market are subject to regulation by the United States Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act, or FDCA, and international regulations in our specific target markets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">United States FDA Regulation</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a new medical device can be introduced into the market, a manufacturer generally must obtain marketing clearance or approval from the FDA through either a 510(k) submission (a premarket notification) or a premarket approval application (PMA).</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 510(k) clearance procedure is available only if a manufacturer can establish that its device is &#8220;substantially equivalent&#8221; in intended use and in safety and effectiveness to a &#8220;predicate device,&#8221; which is (i) a device that has been cleared through the 510(k) clearance process;  (ii) a device that was legally marketed prior to May 28, 1976 (preamendments device); (iii) a device that was originally on the U.S. market as a Class III device (Premarket approval) and later downclassified to Class II or I; (iv) or a 510(k) exempt device.  After a device receives 510(k) clearance, any modification that could significantly affect </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its safety or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance. The 510(k) clearance procedure including questions and responses may take up to 12 months. In some cases, supporting clinical data may be required. The FDA may determine that a new or modified device is not substantially equivalent to a predicate device or may require that additional information, including clinical data, be submitted before a determination is made, either of which could significantly delay the introduction of a new or modified device. If a device cannot demonstrate substantial equivalence, it may be subject to either a De Novo 510(k) submission or a PMA.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PMA application procedure is more comprehensive than the 510(k) procedure and typically takes more time to complete. The PMA application must be supported by scientific evidence providing pre-clinical and clinical data relating to the safety and efficacy of the device and must include other information about the device and its components, design, manufacturing, and labeling. The FDA will approve a PMA application only if reasonable assurance that the device is safe and effective for its intended use can be provided. As part of the PMA application review, the FDA will inspect the manufacturer&#8217;s facilities for compliance with its Quality System Regulation, or QSR. As part of the PMA approval the FDA may place restrictions on the device, such as requiring additional patient follow-up for an indefinite period of time. If the FDA&#8217;s evaluation of the PMA application or the manufacturing facility is not favorable, the FDA may deny approval of the PMA application or issue a &#8220;not approvable&#8221; letter. The FDA may also require additional clinical trials, which can delay the PMA approval process by several years. After the PMA is approved, if significant changes are made to a device, its manufacturing or labeling, a PMA supplement containing additional information must be filed for prior FDA approval.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our products have been introduced into the market using the 510(k) procedure.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA submissions require extensive validations and testing which requires a significant amount of time and financial resources. Recent changes in both regulations and FDA perspectives have increased both time and testing requirements, which have caused and are expected to continue to cause significant delays and increased costs for clearances and approvals. The increased focus by the FDA on such issues as chemical identification of all colorants, non-acceptance of certain colorants (certain forms of carbon black) and other concerns, continue to cause challenges and delays. In addition, changes to existing products call into question previously approved devices and result in additional costs for testing and material analysis.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The devices manufactured by us are also subject to the QSR, which imposes elaborate testing, control, documentation and other quality assurance procedures on our manufacturing facilities. Every phase of production, including raw materials, components and subassembly, manufacturing, testing, quality control, labeling, tracing of customers after distribution and follow-up and reporting of complaint information is governed by the FDA&#8217;s QSR. Device manufacturers are required to register their facilities and list their products with the FDA and certain state agencies. The FDA periodically inspects manufacturing facilities and, if there are alleged violations, the operator of a facility must correct them or satisfactorily demonstrate the absence of the violations or face regulatory action. Failure to maintain compliance with the QSR may result in the issuance of one or more Forms 483 or warning letters and could potentially result in a consent decree. Failure to maintain the QSR appropriately could result in the issuance of further warning letters. In addition, non-compliance with applicable FDA requirements can result in, among other things, fines, injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, failure of the FDA to grant marketing approvals, inability to obtain clearances or approvals for products, withdrawal of marketing approvals, a recommendation by the FDA to disallow us to enter into government contracts, and/or criminal prosecutions. The FDA also has the authority to request repair, replacement or refund of the cost of any device manufactured or distributed by us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other U.S. Regulatory Bodies</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our products are subject to a variety of federal, state and local laws in those jurisdictions where our products are, or will be, marketed.  We and our products are also subject to a variety of federal, state and local laws relating to matters such as safe working conditions, manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances. In addition, we are subject to various federal and state laws governing our relationships with the physicians and others who purchase or make referrals for our products. For instance, federal law prohibits payments of any form that are intended to induce a referral for any item payable under Medicare, Medicaid or any other federal healthcare program. Many states have similar laws. There can be no assurance that we will not be required to incur significant costs to comply with such laws and regulations now or in the future, or that such laws or regulations will not have a material adverse effect upon our ability to do business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">International Regulation</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internationally, all of our current products are considered medical devices under applicable regulatory regimes, and we anticipate that this will be true for all of our future products. Sales of medical devices are subject to regulatory requirements in many countries. The regulatory review process may vary greatly from country to country.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to distribute and sell products into the European Union as well as a number of other countries including many Central European Free Trade Agreement participants, Scandinavian, and Middle Eastern countries, a CE Mark is required. New </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products must be compliant with the Medical Device Regulation ("MDR") as of May 2021 and previously CE Marked products must become compliant when their certification expires, with a transition period ending December 2027 for higher classification devices, or December 2028 for lower classification devices. Products with an expiring certification must be in distribution before certification expiration dates to continue to be sold. Clinical evaluations of products under MDR requires more information than previously required. All devices must have current clinical literature that specifically addresses data-driven safety and performance criteria, and legacy devices often require additional biocompatibility, bench testing and redesign to address changes in standards over time. Additionally, there can be extended time frames under MDR for product certifications that can be 12-18 months or longer.  During that time period, significant design modifications cannot be made.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar regulations are in place for Canada, Japan, China, Brazil and most other countries.  In some cases, we rely on our international distributors to obtain regulatory approvals, complete product registrations, comply with clinical trial requirements and complete those steps that are customarily taken in the applicable jurisdictions.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales of medical devices manufactured in the United States that are not approved or cleared by the FDA for use in the United States, or are banned or deviate from lawful performance standards, are subject to FDA export requirements. Before exporting such products to a foreign country, we must first comply with the FDA&#8217;s regulatory procedures for exporting unapproved devices.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining approval to distribute medical products is costly and time-consuming in virtually all the major markets where we sell medical devices. We cannot assure that any new medical devices we develop will be cleared, approved or certified in a timely or cost-effective manner or cleared, approved or certified at all. There can be no assurance that new laws or regulations regarding the release or sale of medical devices will not delay or prevent sale of our current or future products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THIRD-PARTY REIMBURSEMENT AND ANTI-FRAUD AND CORRUPT PRACTICES REGULATION</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The delivery of our devices is subject to regulation by the Department of Health and Human Services (HHS) and comparable state and non-U.S. agencies responsible for reimbursement and regulation of health care items and services. U.S. laws and regulations are imposed primarily in conjunction with the Medicare and Medicaid programs, as well as the government&#8217;s interest in regulating the quality and cost of health care. Foreign governments also impose regulations in conjunction with their health care reimbursement programs and the delivery of health care items and services.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal health care laws apply when we or customers submit claims for items or services that are reimbursed under Medicare, Medicaid, or other federally-funded health care programs. The principal U.S. federal laws include: (1) the Anti-kickback Statute which prohibits offers to pay or receive remuneration of any kind for the purpose of inducing or rewarding referrals of items or services reimbursable by a federal health care program, subject to certain safe harbor exceptions; (2) the False Claims Act which prohibits the submission of false or otherwise improper claims for payment to a federally-funded health care program, including claims resulting from a violation of the Anti-kickback Statute; (3) the Stark law which prohibits physicians from referring Medicare or Medicaid patients to a provider that bills these programs for the provision of certain designated health services if the physician (or a member of the physician&#8217;s immediate family) has a financial relationship with that provider; and (4) health care fraud statutes that prohibit false statements and improper claims to any third-party payer. There are often similar state false claims, anti-kickback, and anti-self-referral and insurance laws that apply to state-funded Medicaid and other health care programs and private third-party payers. In addition, the U.S. Foreign Corrupt Practices Act (FCPA) can be used to prosecute companies in the U.S. for arrangements with physicians or other parties outside the U.S. if the physician or party is a government official of another country and the arrangement violates the law of that country.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">International</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The delivery of our devices in any market is subject to evolving regulation by the EU Medical Device Regulations, notified bodies and comparable nation-specific bodies responsible for reimbursement and regulation of health care items and services.  Our success in international markets will depend largely upon the availability of reimbursement from the national public health payers as well as private, third party payors, through which healthcare providers are paid in those markets. Reimbursement and healthcare payment systems vary significantly by country. The main types of healthcare payment systems are government sponsored healthcare and private insurance. Reimbursement approval must be obtained individually in each country in which our products are marketed. Outside the U.S., we maintain a healthcare economics team that works directly with providers, our distributors and health systems to obtain reimbursement approval in the countries in which they will use or sell our products. There can be no assurance that reimbursement approvals will be received.  See Part I. Item&#160;1A "Risk Factors" in this Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSURANCE</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product liability insurance coverage is limited to a maximum of $10 million per product liability claim and an annual aggregate policy limit of $10 million, subject to a self-insured retention of $500,000 per occurrence and $2 million in the aggregate. The policy covers, subject to policy conditions and exclusions, claims of bodily injury and property damage from any product sold or manufactured by us.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that this level of coverage is adequate. We may not be able to sustain or maintain this level of coverage and cannot assure you that adequate insurance coverage will continue to be available on commercially reasonable terms, or at all. A successful product liability claim or other claim, with respect to uninsured or underinsured liabilities, could have a material adverse effect on our business.  See Part I. Item&#160;1A "Risk Factors" in this Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ENVIRONMENTAL, HEALTH AND SAFETY</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain hazardous and potentially hazardous substances used in connection with our operations. Our operations are also subject to laws and regulations related to occupational health and safety. We maintain safety, training and maintenance programs as part of our ongoing efforts to ensure compliance with applicable laws and regulations.  Although we believe that we have complied with environmental, health and safety laws and regulations in all material respects and, to date, have not been required to take any action to correct any noncompliance, there can be no assurance that we will not be required to incur significant costs to comply with environmental regulations in the future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EMPLOYEES</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;31, 2023, we had approximately 815 full time employees.  None of our employees are represented by a labor union and we have never experienced a work stoppage.  In the highly competitive medical technology industry, we consider attracting, developing, engaging and retaining high performing talent in positions critical to our long-term growth strategy including but not limited to technical, operational, marketing, sales, research and development, and management.  Our ability to recruit and retain such talent depends on several factors, including culture, compensation and benefits, talent development, career opportunities, recognition and work environment.  Our goal is to create a diverse and inclusive culture that encourages an environment where employees feel welcomed, respected and valued.  We are an equal opportunity/affirmative action employer committed to making employment decisions without regard to race, religion, ethnicity or national origin, gender, sexual orientation, gender identity or expression, age, disability, protected veteran status or any other characteristics protected by law.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The engagement of our workforce is crucial to delivering on our competitive strategy, and we place high importance on informed and engaged employees.  We communicate frequently and transparently with our employees through a variety of communication methods, including video and written communications, town hall meetings and our company intranet.  As a result of the COVID-19 pandemic, we also further strengthened our communication platforms.  Our employee communications during the pandemic have kept our employees informed on critical priorities, important actions being taken by management in response to the pandemic and continued efforts to protect employee health, safety and well-being.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Officers of the Company</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information with respect to our executive officers.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:19.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.911%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James C. Clemmer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stephen A. Trowbridge</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chad T. Campbell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and General Manager, Vascular Access and Oncology </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Centea</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and General Manager, Endovascular Therapies</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David D. Helsel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Global Operations and Research and Development</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laura Piccinini</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and General Manager, International</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">James C. Clemmer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> became our President and Chief Executive Officer (CEO) in April 2016. Prior to joining AngioDynamics, Mr.&#160;Clemmer served as President of the $1.8 billion medical supplies segment at Covidien plc. where he directed the strategic and day-to-day operations for global business divisions that collectively manufactured 23 different product categories. In addition, he managed global manufacturing, research and development, operational excellence, business development and all other functions associated with the medical supplies business. Prior to his role at Covidien, Mr. Clemmer served as Group President at Kendall Healthcare (which was acquired by Tyco International in 1994), where he managed the U.S. business across five divisions and built the strategic plan for the medical supplies segment before Covidien was spun off from Tyco. Mr. Clemmer began his career at Sage Products, Inc. Mr. Clemmer currently serves on the Board of Directors for </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AngioDynamics and previously served on the Board of Directors for Lantheus Medical Imaging. Mr. Clemmer is a graduate of the Massachusetts College of Liberal Arts, where he served as interim president from August 2015 until March 2016.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stephen A. Trowbridge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was appointed Executive Vice President and Chief Financial Officer (CFO) in February 2020, having served as Interim Chief Financial Officer since October 2019. Prior to his appointment as CFO, he served as the Company&#8217;s Senior Vice President and General Counsel. He joined AngioDynamics in June 2008 as Corporate Counsel.  In addition to serving as the Company&#8217;s CFO and managing the finance functions, Mr. Trowbridge also managed the Legal function on an interim basis until January 30, 2021.  Prior to AngioDynamics, Mr. Trowbridge served as Corporate Counsel at Philips Healthcare and Intermagnetics General Corporation.  Mr. Trowbridge began his career with Cadwalader, Wickersham &amp; Taft LLP in the firm&#8217;s Mergers and Acquisitions and Securities Group. Mr. Trowbridge received a Bachelor of Science in Science and Technology Studies from Rensselaer Polytechnic Institute, a Juris Doctor from the University of Pennsylvania Law School, and a Master of Business Administration from Duke University&#8217;s Fuqua School of Business.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chad T. Campbell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> joined AngioDynamics in May 2016 as the Senior Vice President and General Manager for Vascular Access.  As of October 2021, Mr. Campbell assumed responsibility of the Oncology Global Business Unit in addition to his role of General Manager for Vascular Access. In his role, Mr. Campbell oversees research and development and global commercialization of the Global Business Unit&#8217;s portfolio. Mr. Campbell joined AngioDynamics from Medtronic where he served as the Vice President of Marketing for the Patient Care and Safety business after serving as the Vice President of Marketing for the SharpSafety business at Covidien (Medtronic). During his tenure at Covidien, Mr. Campbell also held roles including Director of Marketing, Area Vice President of Sales, Region Manager, Product Manager and Account Manager. Mr. Campbell received a Bachelor of Arts from the University of Kentucky.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scott Centea</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> joined AngioDynamics in 2005 as a sales representative serving the Carolinas.  During his tenure, he has served in a variety of positions with increased responsibility including Vice President of Corporate Accounts where he was in charge of leading a team of individuals to execute Health System Purchasing Contracts.  From there Mr. Centea assumed the role of Vice President of Marketing for Endovascular Therapies, before being promoted into his most recent and current role as Senior Vice President/General Manager of Endovascular Therapies and Peripheral Artery Disease.  Mr. Centea currently holds board positions with the American Venous Forum (AVF) and the Capital District American Heart Association.  Mr. Centea holds a Bachelor of Arts in Communications from Newberry College. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">David D. Helsel </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">currently serves as Senior Vice President of Global Operations and Research and Development and has been with AngioDynamics since December 2017.  Prior to joining AngioDynamics he was Senior Vice President, Global Supply Chain, at Hill-Rom Holdings for almost three years.  Before that, Mr. Helsel worked at Haemonetics for three years where he served as Executive Vice President for Global Manufacturing and also spent almost nineteen years in various positions with increasing responsibility at Covidien, including Vice President of Operations for the Surgical Solutions Division and Medical Supplies Division.  An expert in Lean and Six Sigma, Mr. Helsel also served as Global Director of Operational Excellence, supporting sixty-three manufacturing facilities.  Mr. Helsel holds a Bachelor of Science in Mechanical Engineering from LeTourneau University.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Laura Piccinini</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> joined AngioDynamics as Senior Vice President and General Manager for International in June 2021.  Ms. Piccinini brings more than 25 years of experience in leadership roles in the medical device industry, with an extensive background in the field of respiratory and surgical care.  From June 2020 to June 2021, she served as CEO and a member of the Board of Directors for Respiratory Motion, Inc.  Prior to that, from 2017 to 2020, she served as Global Head of Commercial Operations for the Implants business unit at Nobel Biocare Systems, then a Danaher subsidiary now part of Envista Holdings.  From 2015 to 2017, Ms. Piccinini served as President of EMEA at Covidien and prior to that at Stryker.  Ms. Piccinini is a graduate of the Parma University of Medicine, where she received a nursing degree with specializations in ICU, Anesthesia, and First Aid as a Helicopter Flight Coordinator.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVAILABLE INFORMATION</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters is located at 14 Plaza Drive, Latham, New&#160;York 12110. Our phone number is (518)&#160;795-1400. Our website is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.angiodynamics.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available, free-of-charge through our website, our Annual Reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file or furnish such materials to the SEC.  In addition, our website includes, among other things, charters of the various committees of our Board of Directors and our code of conduct and ethics applicable to all employees, officers and directors.  Within the time period required by the SEC, we will post on our website any amendment to the code of conduct and ethics and any waiver applicable to any executive officer, director or senior financial officer.  We use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.  Accordingly, investors should monitor our website, in addition to following our press releases, SEC filings and public conference calls and webcasts.  We use these channels as well </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as social media and blogs to communicate with the public about our company, our services and other issues.  It is possible that the information we post on social media and blogs could be deemed to be material information.  Therefore, we encourage investors, the media, and others interested in our Company to review the information we post on the social media channels and blogs listed on our website.  Any stockholder also may obtain copies of these documents, free of charge, by sending a request in writing to our Corporate headquarters, Attention: Saleem Cheeks. Information on our website or connected to our website is not incorporated by reference into this Annual Report on Form&#160;10-K.  </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information contained in this Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission, the following risk factors should be considered carefully by investors in evaluating our business.  Our financial and operating results are subject to a number of risks and uncertainties, including those set forth below, many of which are not within our control. Our business, financial condition, results of operations and/or liquidity could be materially and adversely affected by any of these risks or by additional risks not presently known to us or that we currently deem immaterial.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR BUSINESS AND INDUSTRY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition in the medical device industry which continues to experience consolidation. We may be unable to compete effectively with respect to technological innovation and price which may have a material adverse effect on our revenues, financial condition, results of operations and/or liquidity.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets for our products are highly competitive and we expect competition to continue to intensify. The medical device industry is characterized by rapid technological change, frequent product introductions and evolving customer requirements.  Our customers consider many factors when choosing products, including technology, features and benefits, quality, reliability, ease of use, clinical or economic outcomes, availability, price and customer service. We face competition globally from a wide range of companies, many of whom have substantially greater financial, marketing and other resources than us.  We may not be able to compete effectively, and we may lose market share to our competitors.  Our primary device competitors include: Boston Scientific Corporation; Cook Medical; Medical Components, Inc. (MedComp); TeleFlex Medical; Becton Dickinson; Medtronic; Merit Medical; Terumo Medical Corporation; Johnson and Johnson; Philips Healthcare; Inari Medical; Varian Medical Systems and Total Vein Systems.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may succeed in adapting faster than us to changing customer needs or requirements, in developing and introducing technologies and products earlier, in obtaining patent protection (which could create barriers to market entry for us) or regulatory clearance earlier, or in commercializing new products or technologies more rapidly than us. Our competitors may also develop products and technologies that are superior to ours or that otherwise could render our products obsolete or noncompetitive.  The trend of increased consolidation in the medical technology industry has resulted in companies with greater scale and market power, intensifying competition and increasing pricing pressure. We may also face competition from providers of other medical therapies, such as pharmaceutical companies, that may offer non-surgical therapies for conditions that are currently, or in the future may be, treated using our products. If we are not able to compete effectively, our market share and revenue may decline.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the increasing purchasing power of health systems, group purchasing organizations (&#8220;GPOs&#8221;) and integrated health delivery networks (&#8220;IDNs&#8221;), together with increased competition and declining reimbursement rates, has resulted increasingly with the Company competing on the basis of price. Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain market prices for our products or obtain or maintain contract positions with major GPOs and IDNs, which could adversely impact our profitability.  Also, sales through a GPO or IDN can be significant to our business and our inability to retain contracts with our customers, or acquire additional contracts, could have a material adverse effect on our business, financial condition, results of operations and/or liquidity.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our inability to continue to effectively develop, acquire and/or market new products and technologies could have a material adverse effect on our business, financial condition and/or results of operations.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our devices is characterized by rapid technological change, new product introductions, technological improvements, changes in physician requirements and evolving industry standards. Product life cycles are relatively short because medical device manufacturers continually develop more effective and less expensive versions of existing devices in response to physician demand.  We engage in product development and improvement programs to maintain and improve our competitive position. Our products are technologically complex and these programs involve significant planning, market studies, investment in research and development, clinical trials and regulatory clearances or approvals and may require more time and expense than anticipated to bring such products to market. We may not, however, be successful in enhancing existing products, or developing new products or technologies that will achieve regulatory approval, be developed or manufactured in a cost-effective manner, obtain appropriate intellectual property protection or receive market acceptance. We also may be unable to recover all or a meaningful part of our investment in these products or technologies. Additionally, there can be no assurance that the size of the markets in which we compete will increase above existing levels or not decline, that we will be able to maintain, gain or regain market share or that we can compete effectively on the basis of price or that the number of procedures in which our products are used will increase above existing levels or not decline. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, the future prospects of many of our high growth products, such as the NanoKnife system, the AngioVac system, the AlphaVac system and the Auryon system, rely on continued market development and continued generation of clinical data pursuant to clinical trials conducted by us, our competitors or other third parties. If the results of these trials are not what we expect or fail to generate meaningful clinical data, it may adversely impact our ability to obtain product approvals.  If any of these products fail to achieve clinical acceptance or are perceived unfavorably by the market, it could severely limit our ability to drive revenue growth, which could have a material adverse effect on our business, financial condition, results of operations and/or liquidity. See Risk Factor titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Our business and prospects rely heavily upon our ability to successfully complete clinical trials, including, but not limited to, our NanoKnife DIRECT clinical study, our NanoKnife PRESERVE clinical study, AlphaVac APEX-AV clinical study and clinical studies for AngioVac.  We may choose to, or may be required to, suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed.&#8221;</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we expect to continue to engage in business development activities which includes selectively evaluating and pursuing the acquisition of complementary businesses, technologies and products. These activities may result in substantial investment of our time and financial resources and competition for targets may be significant.  We may not be able to identify appropriate acquisition candidates, consummate transactions, obtain agreements with favorable terms or obtain any necessary financing or regulatory approvals. Further, once a business is acquired, any inability to successfully integrate the business or achieve anticipated cost savings or operating synergies, decreases in customer loyalty or product orders, failure to retain and develop its workforce, failure to establish and maintain appropriate controls, higher or unanticipated expenses, or unknown or contingent liabilities could adversely affect our ability to realize the anticipated benefits of any acquisition. The evaluation and integration of an acquired business, whether or not successful, requires significant efforts which may result in additional expenses and divert the attention of our management and technical personnel from other projects. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we proceed with one or more significant acquisitions in which the consideration consists of cash, a substantial portion of our available cash could be used to consummate the acquisitions. If we consummate one or more acquisitions in which the consideration consists of capital stock, our stockholders could suffer significant dilution of their interest in us. In addition, we could incur or assume significant amounts of indebtedness in connection with acquisitions. These transactions are inherently risky and may not enhance our financial position or results of operations or create value for our shareholders as they are based on projections and assumptions which are uncertain and subject to change and there can be no assurance that any past or future transaction will be successful. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to develop and successfully manufacture and launch new products, generate satisfactory clinical results, provide sufficient economic value, enhance existing products, or identify, acquire and integrate complementary businesses, technologies and products or if we experience a decrease in market size or market share or declines in average selling price or procedural volumes, or otherwise fail to compete effectively, we may not achieve our growth goals, which could have a material adverse effect on our business, financial condition and/or results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not maintain our reputation with interventional physicians, interventional and surgical oncologists, and critical care nurses, our growth will be limited and our business could be harmed.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians typically influence the medical device purchasing decisions of the hospitals and other healthcare institutions in which they practice. Consequently, our reputation with interventional physicians, interventional and surgical oncologists, and critical care nurses is crucial to our continued growth. We believe that we have built a positive reputation based on the quality of our products, our physician-driven product development efforts, our marketing and training efforts and our presence at medical society meetings. Any actual or perceived diminution in the quality of our products, or our failure or inability to maintain these other efforts, could damage our reputation with interventional physicians, interventional and surgical oncologists, and critical care nurses, and cause our growth to be limited and our business to be harmed, which could have a material adverse effect on our business, financial condition, results of operations and/or liquidity.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and prospects rely heavily upon our ability to successfully complete clinical trials, including, but not limited to, our NanoKnife DIRECT clinical study, our NanoKnife PRESERVE clinical study, AlphaVac APEX-AV clinical study and clinical studies for AngioVac.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may choose to, or may be required to, suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials must be conducted in accordance with the applicable laws and regulations in the jurisdictions in which the clinical trials are conducted, including FDA&#8217;s current Good Clinical Practices. The clinical trials are subject to oversight by the FDA, regulatory agencies in other jurisdictions, ethics committees and institutional review boards at the medical institutions where the clinical trials are conducted. Clinical trial protocols may require a large number of patients to be enrolled in the trials. Patient enrollment is a function of many factors, including the size of the patient population for the target indication, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proximity of patients to clinical sites, the eligibility criteria for the trial, the existence of competing clinical trials and the availability of alternative or new treatments. Clinical trials may be suspended by the FDA or by a regulatory agency in another jurisdiction at any time if the FDA or the regulatory agency finds deficiencies in the conduct of these trials or it is believed that these trials expose patients to unacceptable health risks.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, the FDA or regulatory agencies in other jurisdictions might delay or terminate our clinical trials for various reasons, including insufficient patient enrollment, fatalities, unforeseen adverse side effects by enrolled patients or the development of new therapies that require us to revise or amend our clinical trial protocols. Patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive follow-up to assess safety and effectiveness, if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts or if they participate in contemporaneous clinical trials of competing products. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on contract research organizations, or CROs, with respect to conducting our clinical trials.  We may experience significant cost overruns associated with, and we may encounter difficulties managing, these CROs.  Termination of our clinical trials or significant delays in completing our clinical trials could have a material adverse effect on our business, financial condition, results of operations and/or liquidity.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to convince customers that our products can improve the cost structure of their business, our revenue growth and profitability may be materially and adversely impacted.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide initiatives to contain healthcare costs have led governments and the private sector to enact cost containment efforts as a means of managing the growth of health care utilization.  Common techniques include policies on price regulation, competitive pricing, bidding and tender mechanics, coverage and payment, comparative effectiveness of therapies, technology assessments, and managed-care arrangements.  These changes are causing the marketplace to put increased emphasis on the delivery of more cost-effective medical devices and therapies. Government programs, including Medicare and Medicaid, private health care insurance, and managed-care plans have attempted to control costs by limiting the amount of reimbursement they will pay for particular procedures or treatments, tying reimbursement to outcomes, shifting to population health management, and other mechanisms designed to constrain utilization and contain costs. Simultaneously, hospitals are redefining their role in health care delivery as many assume much more risk and control of the total cost of patient care.  To successfully make this transformation, health systems are consolidating, purchasing or partnering with physicians and post-acute care providers, while also narrowing networks thus allowing greater control over outcomes.  This has created an increasing level of price sensitivity among customers for our products and could have a material adverse effect on our business, financial condition, results of operations and/or liquidity. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on single and limited source suppliers which subjects our business and results of operations to risks of supplier business interruptions.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently purchase significant amounts of several key products, raw materials and product components from single and limited source suppliers and anticipate that we will do so for future products as well. Any delays in delivery of or shortages in those or other products and components (like we experienced during our 2022 and 2023 fiscal year) could interrupt and delay manufacturing of our products, lead to backlogs and result in the cancellation of orders for our products. Any or all of these suppliers could discontinue the manufacture or supply of these products, raw materials and/or components at any time. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to FDA and other business considerations, we may not be able to identify and integrate alternative sources of supply in a timely fashion or at all. Any transition to alternate suppliers may result in production delays and increased costs and may limit our ability to deliver products to our customers. Furthermore, if we are unable to identify alternative sources of supply, we would have to modify our products to use substitute components, which may cause delays in shipments, backlogs, increased prices for our products or increased design and manufacturing costs.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we purchase certain products as a distributor for the manufacturer of those products.  Any constraint or interruption in the supply of raw materials, other product components or finished products that we distribute could materially impact our ability to sell products, and have a material adverse effect on our business, financial condition, results of operations and/or liquidity.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are heavily dependent on third-party distributors to generate a substantial portion of our international revenues and are at the risk of these distributors also selling for our competitors, failing to be financially viable and failing to effectively distribute our products in compliance with applicable laws.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of North America we rely heavily on third party distributors, either on a country-by-country basis or on a multi-country, regional basis, to market, sell and distribute our products where we do not have a direct sales and marketing presence (including, among others, China, Japan, Brazil, the Middle East and many European countries). As such, our revenue, if any, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depends on the terms of such arrangements and the distributors&#8217; efforts. These efforts may turn out not to be sufficient and our third-party distributors may not effectively sell our products.  International distributors accounted for approximately 72% of international revenues for the fiscal year ended May&#160;31, 2023.  International sales grew 12% in fiscal year 2023 as we continued to develop and foster partnerships with distributors such as Healthcare 21, Cardiva and Mediplast.  If we are unable to maintain our relationships or establish direct sales capabilities on acceptable terms or at all, we may lose significant revenue or be unable to achieve our growth aspirations.  In certain circumstances, distributors may also sell competing products, or products for competing diagnostic modalities, and may have incentives to shift sales towards those competing products. As a result, we cannot assure you that our international distributors will increase or maintain our current levels of unit sales or increase or maintain our current unit pricing, which, in turn, could have a material adverse effect on our business, financial condition, results of operations and/or liquidity.  In addition, there is a risk that our distributors will not be financially viable due to current economic and/or regulatory events in their respective countries or remit payments to us in a timely manner. If our distributors fail to comply with applicable laws or fail to effectively market and sell our products, our financial condition and results of operations could be materially and adversely impacted.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to secure adequate reimbursement for our products could materially impair our ability to grow revenue and drive profitability.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are used in medical procedures and purchased principally by hospitals or physicians which typically bill various third-party payors, such as governmental programs (e.g., Medicare, Medicaid and comparable foreign programs), private insurance plans and managed care plans, for the healthcare services provided to their patients. The ability of our customers to obtain appropriate reimbursement for products and services from third-party payors is critical to the success of medical device companies because it affects which products customers purchase and the prices they are willing to pay. In general, a third-party payor only covers a medical product or procedure when the plan administrator is satisfied that the product or procedure improves health outcomes, including quality of life or functional ability, in a safe and cost-effective manner. Even if a device has received clearance or approval for marketing by the FDA, there is no assurance that third-party payors, including Medicare and managed care companies, will cover the cost of the device and related procedures.  Even if coverage is available, third-party payors may place restrictions on the circumstances where they provide coverage or may offer reimbursement that is not sufficient to cover the cost of our products.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors who cover the cost of medical products or equipment, in addition to allowing a general charge for the procedure, often maintain lists of exclusive suppliers or approved lists of products deemed to be cost-effective. If our products are not on approved lists of third-party payors, healthcare providers must determine if the additional cost and effort required in obtaining prior authorization, and the uncertainty of actually obtaining coverage, is justified by any perceived clinical benefits from using our products.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, the advent of contracted fixed rates per procedure has made it difficult to receive reimbursement for disposable products, even if the use of these products improves clinical outcomes. In addition, many third-party payors are moving to managed care systems in which providers contract to provide comprehensive healthcare for a fixed cost per person. Managed care providers often attempt to control the cost of healthcare by authorizing fewer elective surgical procedures. Under current prospective payment systems, such as the diagnosis related group system and the hospital out-patient prospective payment system, both of which are used by Medicare and in many managed care systems used by private third-party payors, the cost of our products will be incorporated into the overall cost of a procedure and not be separately reimbursed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If hospitals and physicians cannot obtain adequate reimbursement for our products or the procedures in which they are used, this could have a material adverse effect on our business, financial condition, results of operations and/or liquidity.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement varies by country and can significantly impact the acceptance of new technology. Implementation of healthcare reforms in the United States and in other countries may limit, reduce or eliminate reimbursement for our products and adversely affect both our pricing flexibility and the demand for our products. Even when we develop a promising new product, we may find limited demand for the product unless reimbursement approval is obtained from private and governmental third-party payors. Changes in healthcare systems in the United States or elsewhere in a manner that significantly reduces reimbursement for procedures using our medical devices or denies coverage for these procedures, or adverse decisions relating to our products by administrators of these systems in coverage or reimbursement issues, would have an adverse impact on the acceptance of our products and the prices which our customers are willing to pay for them.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a product liability claim is brought against us or our product liability insurance coverage is inadequate, our business could be harmed.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design, manufacture and marketing of the types of medical devices we sell entail an inherent risk of product liability. Our products are used by physicians to treat seriously ill patients. We are periodically subject to product liability claims, and patients or customers may in the future bring claims against us in a number of circumstances and for a number of reasons, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including if our products were misused, if a component of our product fails, if our manufacture or design was flawed, if the product produced unsatisfactory results or if the instructions for use and operating manuals and disclosure of product related risks for our products were found to be inadequate. In addition, individuals or groups seeking to represent a class may file suit against us. The outcome of litigation, particularly class action lawsuits, is difficult to assess or quantify. Plaintiffs in these types of lawsuits often seek recovery of very large or indeterminate amounts, including not only actual damages, but also punitive damages. The magnitude of the potential losses relating to these lawsuits may remain unknown for substantial periods of time.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry a product liability policy with a limit of $10.0 million per product liability claim and an aggregate policy limit of $10.0 million, subject to a self-insured retention of $0.5 million per occurrence and $2.0 million in the aggregate. We believe, based on claims made against us in the past, our existing product liability insurance coverage is reasonably adequate to protect us from any liabilities we might incur. However, there is no assurance that this coverage will be sufficient to satisfy any claim made against us. In addition, we may not be able to continue to maintain adequate coverage at a reasonable cost and on reasonable terms, if at all. Any product liability claim brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing any coverage in the future. Additionally, if one or more product liability claims is brought against us for uninsured liabilities or is in excess of our insurance coverage, our financial condition, results of operations and/or liquidity could be negatively impacted. Further, such claims may require us to recall some of our products, which could result in significant costs to us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be exposed to risks associated with product line divestitures as we may never realize the expected benefits and could cause operational disruptions with personnel, systems and infrastructure changes.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with Merit Medical Systems, Inc. pursuant to which Merit acquired the dialysis product portfolio and BioSentry tract sealant system biopsy businesses for $100.0&#160;million in cash.  The Company and Merit entered into various agreements to facilitate the transition to Merit, including a Transactions Services Agreement and Contract Manufacturing Agreement. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This divestiture along with potential future divestitures of certain product lines will allow us to transform ourselves into a high growth, highly profitable, medical technology company.  If we are unable to achieve our growth and profitability objectives due to competition, lack of acceptance of our products, failure to generate favorable clinical data or gain regulatory approvals, or other risks as described in this section, or due to other events, we will not be successful in transforming our business and may not see the appropriate market valuation.  The divestiture of product lines will impact revenue, earnings and cash flows, which over time we expect to replace by investing in higher margin revenue streams.  There is a risk that we will be unable to replace the revenue, earnings and cash flow that these product lines generated, or that the cost of such will be higher than expected. If we are unable to achieve our profit and growth objectives, such failure will be exacerbated by the loss of revenue, earnings and cash flow generated by our divested product lines and could materially impact our financial position and results of operations, resulting in a decline in our stock price.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of product lines could require us to restructure significant personnel, systems and infrastructure.  In some instances, we may enter into short term transition service arrangements, under which the parties perform certain services for each other pending establishment of new processes and systems. Although these transitions are thoroughly planned, it is not unlikely in a transaction of this complexity that disruptions could occur.  If disruptions to our financial controls, IT, administrative support, manufacturing or regulatory processes occur, and if such disruptions prove to be more severe than our planning anticipated, this could have a material adverse effect on our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International and national economic and industry conditions constantly change, and could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition and results of operation are affected by many changing economic, industry and other conditions beyond our control.  Actual or potential changes in international, national, regional and local economic, business and financial conditions, including recession, high inflation and trade protection measures, creditworthiness of our customers, may negatively affect consumer preferences, perceptions, spending patterns or demographic trends, any of which could adversely affect our business, financial condition, results of operations and/or liquidity.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to macro-economic fluctuations in the U.S. and worldwide economy. Concerns about consumer and investor confidence, volatile corporate profits and reduced capital spending, international conflicts, terrorist and military activity, civil unrest and pandemic illness could reduce customer orders or cause customer order cancellations. In addition, political and social turmoil may put further pressure on economic conditions in the United States and abroad. The global economy has been periodically impacted by the effects of global economic downturns (such as those recently related to COVID-19). There can be no assurance that there will not be further such events or deterioration in the global economy. These economic conditions make it more difficult for us to accurately forecast and plan our future business activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility in the cost of raw materials, components, freight and energy increases the costs of producing and distributing our products. New laws or regulations adopted in response to climate change could also increase energy and transportation costs, as well as the costs of certain raw materials and components. Increases in oil prices may increase our packaging and transportation costs. Recently, the costs of labor, raw materials, transportation, construction, services, and energy necessary for the production and distribution of our products have increased significantly. While we have implemented cost containment measures, selective price increases and taken other actions to offset these inflationary pressures in our supply chain, we may not be able to completely offset all the increases in our operational costs, any of which could adversely affect our business, financial condition, results of operations and/or liquidity.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales outside the U.S. accounted for approximately 17% of our net sales during our fiscal year ended May&#160;31, 2023.  We anticipate that sales from international operations will continue to represent a significant portion of our total sales, and we intend to continue our expansion into emerging and/or faster-growing markets outside the U.S.  Our sales and profitability from our international operations are subject to risks and uncertainties that could have a material adverse effect on our business, financial condition and/or results of operations, many of which we cannot predict, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in currency exchange rates which may, in some instances affect spending behavior and reduce cash flows and revenue outside the U.S.;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">healthcare reform legislation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple non-U.S. regulatory requirements that are subject to change and could restrict our ability to manufacture and sell our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">local product preferences and product requirements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer-term receivables than are typical in the U.S. and/or the ability to obtain payment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade protection measures and import or export licensing requirements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">less intellectual property protection in some countries outside the U.S. than exists in the U.S.;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different labor regulations and workforce instability;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential payment of U.S. income taxes on earnings of certain foreign subsidiaries subject to U.S. taxation upon repatriation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expiration and non-renewal of foreign tax rulings;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential negative consequences from changes in or interpretation of tax laws, including changes in our effective tax rate or the applicable tax rate in one or more jurisdictions; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic instability and inflation, recession or interest rate fluctuations.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Russia&#8217;s invasion and military attacks on Ukraine have triggered significant sanctions from U.S. and European leaders. These events may escalate and have created increasingly volatile global economic conditions. Resulting changes in U.S. trade policy could trigger retaliatory actions by Russia, its allies and other affected countries, including China, resulting in a &#8220;trade war.&#8221; A trade war could result in increased costs for raw materials we use in our manufacturing and could result in Russia and other foreign governments imposing tariffs on products that we export outside the U.S. or otherwise limiting our ability to sell our products abroad. These increased costs could have a material adverse effect on our business, financial condition and results of operations. Furthermore, if the conflict between Russia and Ukraine continues for a long period of time, or if other countries, including the U.S., become further involved in the conflict, we could face material adverse effects on our business, financial condition, results of operations and/or liquidity.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be harmed if we cannot hire or retain qualified personnel.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends upon our ability to attract and retain highly qualified personnel, including managerial, sales, and technical personnel. We compete for key personnel with other companies, healthcare institutions, academic institutions, government entities and other organizations. We do not have written employment agreements with our executive officers, other than the CEO. Our ability to maintain and expand our business may be impaired if we are unable to retain our current key personnel or hire or retain other qualified personnel in the future, including personnel for our manufacturing facilities and field based sales employees.  If we are not able to hire and retain personnel in our manufacturing facilities, we may not meet our production demand.  We have experienced labor shortages in fiscal years 2022 and 2023 that significantly contributed to the backlog.  In addition, our sales force is highly talented and we face intense competition in our industry for sales personnel which could have an adverse effect on our business and revenue if there is significant turnover. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage our growth profitably, our business, financial results and stock price could suffer.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial results will depend in part on our ability to profitably manage our growth. Management will need to maintain existing customers and attract new customers, recruit, retain and effectively manage employees, as well as expand operations and integrate customer support and financial control systems. If integration-related expenses and capital expenditure </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements are greater than anticipated or if we are unable to manage our growth profitably, our financial results and the market price of our common stock may decline.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years we have begun to implement operational excellence initiatives which include a number of restructuring, realignment and cost reduction initiatives.  We may not realize the benefits of these initiatives to the extent or on the timing we anticipated and the ongoing difficulties in implementing these measures may be greater than anticipated and/or offset by inflationary pressures, which could cause us to incur additional costs or result in business disruptions like the backlogs we have experienced in fiscal years 2022 and 2023. In addition, if these measures are not successful or sustainable, we may undertake additional realignment and cost reduction efforts, which could result in significant additional expenses and adversely impact our ability to achieve our other strategic goals and business plans.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to attract additional capital necessary to expand our business or may incur additional indebtedness which, together with our current indebtedness levels, could impose operating and financial restrictions on us as a result of debt service obligations which could significantly limit our ability to execute our business strategy or curtail our growth.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional capital to expand our business. If cash generated internally is insufficient to fund capital requirements, we may require additional debt or equity financing. In addition, we may require financing to fund any significant acquisitions we may seek to make. Disruptions in the capital markets and increases in the cost of capital have previously resulted, and could again result, in volatility, decreased liquidity, and widening of credit spreads, which could make needed financing either unavailable or available on terms unsatisfactory to us which could result in significant stockholder dilution.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may incur additional indebtedness or draw additional amounts on our existing credit facilities in the future subject to limitations contained in the agreements governing our debt.  The interest rate on potential borrowings could be a floating rate which could expose us to the risk of increased interest expense in the future.  The terms of indebtedness could require us to comply with certain financial maintenance covenants. In addition, the terms of our existing indebtedness include, and any future indebtedness could include, covenants restricting or limiting our ability to take certain actions. These covenants could adversely affect our ability to obtain additional financing, to finance future operations, to pursue certain business opportunities or take certain corporate actions. The covenants could also restrict our flexibility in planning for changes in our business and the industry and could make us more vulnerable to economic downturns and adverse developments, could limit our flexibility in planning for, or reacting to, changes and opportunities in the markets in which we compete, could place us at a competitive disadvantage compared to our competitors that have less debt or could require us to dedicate a substantial portion of our cash flow to service our debt.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to meet our cash requirements, including our debt service obligations, could be dependent upon our operating performance, which would be subject to general economic and competitive conditions and to financial, business and other factors affecting our operations, many of which could be beyond our control. We cannot provide assurance that our business operations would generate sufficient cash flows from operations to fund potential cash requirements and debt service obligations. If our operating results, cash flow or capital resources prove inadequate, we could face substantial liquidity problems and might be required to dispose of material assets or operations to meet our debt and other obligations. If we incurred indebtedness and were unable to service our debt, we could be forced to reduce or delay planned expansions and capital expenditures, sell assets, restructure or refinance our debt or seek additional equity capital, and we could be unable to take any of these actions on satisfactory terms or in a timely manner. Further, any of these actions may not be sufficient to allow us to service our potential debt obligations or could have an adverse impact on our business. Our potential debt agreements could limit our ability to take certain of these actions. Our failure to generate sufficient operating cash flow to pay our potential debts or to successfully undertake any of these actions could have a material adverse effect on us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflationary pressure and unfavorable economic conditions could negatively affect our operations and business.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A significant deterioration in economic conditions, including economic slowdowns or recessions, increased unemployment levels, inflationary pressures or disruptions to credit and capital markets, could lead to decreased consumer confidence and spending and availability of credit.  For example, in 2022 and continuing into 2023, the United States and other certain foreign countries have experienced a rapid increase in inflation levels.  Such heightened inflationary levels may negatively impact demand for our products and increase our costs.  Additionally, we finance a portion of our portfolio with unhedged floating- rate debt from our Credit Agreement.  The rapid increase in inflation during fiscal year 2023 led to a rapid increase in market interest rates, which materially increased the interest rate on our floating rate debt.   In addition, if rates continue to increase, we may incur significant additional expense and adversely impact our ability to achieve our other strategic goals and business plans.    </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our goodwill, intangible assets and fixed assets are subject to potential impairment; we have recorded significant goodwill impairment charges and may be required to record additional charges to future earnings if our goodwill or intangible assets become impaired.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our assets consists of goodwill, intangible assets and fixed assets, the carrying value of which may be reduced if we determine that those assets are impaired, including intangible assets from recent acquisitions.  During the fourth quarter of fiscal year 2021, the Company made the decision to abandon the OARtrac product technology and trademark.  This resulted in an impairment charge of $14.0&#160;million.  The impairment charge is recorded in "Acquisition, restructuring and other items, net", on the Consolidated Statements of Operations (see Note 19, "Acquisition, restructuring and other items, net" set forth in the Notes in the consolidated financial statements included in this Annual Report on Form 10-K).</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our intangible and fixed assets have finite useful lives and are amortized or depreciated over their useful lives on either a straight-line basis or over the expected period of benefit or as revenues are earned from the sales of the related products. The underlying assumptions regarding the estimated useful lives of these intangible assets are reviewed quarterly and more often if an event or circumstance occurs making it likely that the carrying value of the assets may not be recoverable and are adjusted through accelerated amortization if necessary.  Whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable, we test intangible assets for impairment based on estimates of future cash flows. Factors that may be considered a change in circumstances indicating that the carrying value of our intangible assets and/or goodwill may not be recoverable include a decline in stock price and market capitalization, slower growth rates in our industry or our own operations and/or other materially adverse events that have implications on the profitability of our business.  When testing for impairment of definite-lived intangible assets held for use, the Company groups assets at the lowest level for which cash flows are separately identifiable. The Company operates as a single asset group.  If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise.  Prior to the first quarter of fiscal year 2023, the Company managed its operations as one reporting unit.  At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as two operating segments and two reporting units, namely Med Tech and Med Device (see Note 18 "Segment and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K).  The annual goodwill impairment review performed in April 2023 and 2022 indicated no goodwill impairments.  As of May&#160;31, 2023, the Company concluded that the sale of the dialysis product portfolio and BioSentry tract sealant system biopsy businesses to Merit Medical Systems, Inc. was a triggering event for the Med Device report unit.  The Company utilized the income approach to determine the fair value of the remaining Med Device reporting unit.  Based on the results of this evaluation, the Company recorded a goodwill impairment charge of $14.5 million for the year ended May&#160;31, 2023 to write down the carrying value of the Med Device reporting unit to fair value.  If actual results differ from the assumptions and estimates used in the goodwill and intangible asset calculations, we could incur future impairment or amortization charges, which could negatively impact our financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be limited in our ability to utilize, or may not be able to utilize, net operating loss carryforwards to reduce our future tax liability.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IRC Section 382 and related provisions contain rules that limit for U.S. federal income tax purposes the ability of a Company that undergoes an &#8220;ownership change&#8221; to utilize its net operating loss carryforwards and certain other tax attributes existing as of the date of such ownership change.  Our Federal net operating loss carryforwards as of May&#160;31, 2023 after considering IRC Section 382 limitations are $169.7 million.  The expiration of the Federal net operating loss carryforwards is as follows: $5.2 million between 2023 and 2024, $79.4 million between 2028 and 2037 and $85.1 million indefinitely.  Our state net operating loss carryforwards as of May&#160;31, 2023 after considering remaining IRC Section 382 limitations are $24.1 million which expire in various years from 2029 to 2042.  Future ownership changes within the meaning of IRC Section 382 may also subject our tax loss carryforwards to annual limitations which would restrict our ability to use them to offset our taxable income in periods following the ownership changes.  See Note 10, "Income Taxes" set forth in our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended May&#160;31, 2023 for a further discussion of our tax loss carryovers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A cyber-attack or other breach of our, our distributors, or our supply chain partners' information technology systems could have a material adverse effect on our business, financial condition and/or results of operations.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology systems to process, transmit, and store electronic information in our day-to-day operations. Similar to other large multi-national companies, the size and complexity of our information technology systems makes them vulnerable to cyber-attacks, malicious intrusions, breakdowns, destruction, losses of data privacy, or other significant disruptions. Our distributors and supply chain partners face similar risks.  Our information systems require an ongoing commitment of resources to maintain, protect, and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards, the increasing need to protect patient and customer information, and changing customer patterns. In addition, third parties may attempt to gain </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">access into our systems or products or those of our supply chain partners to obtain data relating to patients or our proprietary information. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure by us, our distributors, or our supply chain partners to maintain or protect information technology systems and data integrity, including from cyber-attacks, ransomware, intrusions or other breaches, could result in the unauthorized access to supply chain partners or vendors and personally identifiable information, theft of intellectual property, misappropriation of assets, or otherwise compromise confidential or proprietary information and disrupt operations of our Company, our distributors, or our supply chain partners. Any of these events, in turn, may cause us to lose existing customers, have difficulty preventing, detecting, and controlling fraud, have disputes with customers, our supply chain partners, physicians, and other health care professionals, be subject to legal claims and liability, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach or theft of intellectual property, or suffer other adverse consequences, any of which could have a material adverse effect on our business, financial condition and/or results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any disaster at our manufacturing facilities or those of our suppliers could disrupt our ability to manufacture our products for a substantial amount of time. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct manufacturing and assembly at facilities in Queensbury, New York, Glens Falls, New York, and other third parties in Costa Rica, Israel, Latvia, China and other locations. It would be difficult, expensive and time-consuming to transfer resources from one facility to the other and/or replace or repair these facilities or manufacturing equipment if they were significantly affected by a disaster. Additionally, we might be forced to rely on third-party manufacturers or delay production of our products. Insurance for damage to our properties and the disruption of our business from disasters may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. If one of our principal suppliers were to experience a similar disaster, uninsured loss or under-insured loss, we might not be able to obtain adequate alternative sources of supplies or products. Any significant uninsured loss, prolonged or repeated disruption, or inability to operate experienced by us or any of our principal suppliers could cause significant harm to our business, financial condition, results of operations and/or liquidity.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our organizational documents and Delaware law may discourage or prevent a change of control, even if an acquisition would be beneficial to our stockholders, which could cause our stock price to decline and prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that may enable our management to resist a change in control.  For example, our Board of Directors is classified so that not all members of our Board of Directors are elected at one time and our Board of Directors is authorized, without prior stockholder approval, to create and issue &#8220;blank check&#8221; preferred stock with rights senior to those of our common stock and stockholder action by written consent is prohibited. We are also subject to the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These provisions may discourage, delay or prevent a change in the ownership of our Company or a change in our management. In addition, these provisions could limit the price that investors would be willing to pay in the future for shares of our common stock. Any delay or prevention of a change of control transaction or changes in our Board of Directors could cause the market price of our common stock to decline. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic has negatively impacted our business and operations around the world and may continue to materially and adversely impact our business, operations and financial results.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has created significant disruption and uncertainty in the global economy and has negatively impacted our business and results of operations and financial condition during fiscal years  2021, 2022 and 2023.  Although the impact of COVID-19 and the resulting measures decreased during 2023, they have the potential to continue to negatively impact our business, results of operations and financial condition in the future.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous national, international, state and local jurisdictions have imposed, and others in the future may impose, a variety of government orders and restrictions for their residents to control the spread of COVID-19. Such orders or restrictions may cause significant alteration of our operations, work stoppages, slowdowns and delays, travel restrictions and event cancellations, among other effects, thereby significantly and negatively impacting our operations. Other disruptions or potential disruptions include: (i) restrictions on our personnel and personnel of business partners to travel and access customers for training and case support&#894; (ii) reductions in spending by our customers; (iii) delays in clearance, approvals or certifications by regulatory bodies&#894; (iv) diversion of or limitations on employee resources that would otherwise be focused on the operations of our business, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people&#894; (v) reductions in our sales team, including through layoffs, furloughs or other losses of sales representatives&#894; (vi) additional government requirements or other incremental mitigation efforts that may further impact our or our suppliers&#8217; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capacity to manufacture our products; (vii) disruption of our research and development activities; and (viii) delays in ongoing studies and pre-clinical trials.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, elective procedures that use our products significantly decreased in number during fiscal year 2021, as health care organizations around the world prioritized the treatment of patients with COVID-19 and reduced spending in other areas.  We experienced a similar impact to procedure volumes with the resurgence of COVID-19 in fiscal year 2022 which continued through fiscal year 2023.  For example in fiscal year 2021, U.S. governmental authorities had recommended, and in certain cases required, that elective, deferrable, specialty and other procedures and appointments, be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 so that limited resources and personnel could be focused on the treatment of infected patients. Many of these procedures that use our products were suspended or postponed at times during fiscal years 2021, 2022 and 2023.  Similarly, our clinical trials were impacted by COVID-19 as hospitals prioritized treating these patients.  It is unclear when or if other resurgences of COVID-19, or increased spread of its variants, may again cause a rise in infections and result in authorities and/or customers imposing restrictions that could adversely affect our business, financial condition, results of operations and/or liquidity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, most of the hospitals and clinics that purchase our products have instituted strict procedures at their facilities in an effort to prevent the spread of COVID-19, including restrictions on sales representatives entering these facilities. This has been, and currently remains, a major impediment to our sales efforts, as supporting existing customers and acquiring new customers is much more difficult in this environment. These restrictions have had an effect on our sales and, until they are lifted, our business, operations and financial results will continue to be adversely impacted.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These challenges and restrictions will likely continue for the duration of the pandemic, which is uncertain, and may even continue beyond the pandemic. Many areas have relaxed restrictions from time-to-time and have resumed business operations, but a resurgence in infections or mutations of the coronavirus that causes COVID-19 could cause authorities and/or our customers to reinstate such restrictions or impose additional restrictions. All of these factors also may cause or contribute to disruptions and delays in our logistics and supply chain. The extent to which the COVID-19 pandemic impacts our business, operations and financial results will depend on future developments that are uncertain and cannot be predicted, including new information that may emerge concerning the severity and spread of the virus and the actions by government entities, our customers and other parties to contain the virus or treat its impact, among others. To the extent the COVID-19 pandemic adversely affects our business, operations and financial results, it may also have the effect of heightening other risks described herein, such as those relating to general economic conditions, demand for our products, relationships with suppliers and sales efforts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be negatively impacted by Environmental, Social and Governance (ESG), climate change and other sustainability-related matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Governments, investors, customers, employees and other stakeholders are increasingly focusing on corporate ESG practices and disclosures, including risks associated with climate change and expectations in this area are rapidly evolving.  Shifts in weather patterns caused by climate change are expected to increase the frequency and severity of adverse weather conditions such as hurricanes, tornadoes, earthquakes, wildfires, droughts, extreme temperatures or flooding, which could cause or contribute to reduced workforce availability, increased production and distribution costs and disruptions and delays in our logistics and supply chain/operations as well as the operations of our customers. The increasing attention to corporate ESG initiatives and ESG risks could result in reduced demand for products, reduced profits and increased investigations and litigation. If we are unable to satisfy any new criteria by which our ESG practices may be assessed, investors may conclude that our policies and/or actions with respect to ESG matters and risks are inadequate. If we fail or are perceived to have failed to accurately disclose our progress on such initiatives or goals, our reputation, business, financial condition and results of operations could be adversely impacted.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO THE REGULATORY ENVIRONMENT</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to a comprehensive system of federal, state and international laws and regulations, and we could be the subject of investigations, enforcement actions or face lawsuits and monetary or equitable judgments.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in many parts of the world, and our operations are affected by complex state, federal and international laws relating to healthcare, environmental protection, antitrust, anti-corruption, anti-bribery, fraud and abuse, export control, tax, employment and laws regarding privacy, personally identifiable information and protected health information, including, for example, the Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;), various FDA and international regulations relating to, among other things, the development, quality assurance, manufacturing, importation, distribution, marketing and sale of, and billing for, our products, the federal Anti-Kickback Statute and Federal False Claims Act (Note 17), the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and similar anti-bribery laws in international jurisdictions, including the UK Anti-Bribery Act, the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), General Data Protection Regulation (&#8220;GDPR&#8221;), domestic and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreign data protection, data security and privacy laws, laws related to the collection, storage, use and disclosure of personal data and laws and regulations relating to sanctions and money laundering. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with these laws and regulatory standards, allegations of such non-compliance or the discovery of previously unknown problems with a product or manufacturer: (i) could result in FDA Form-483 notices and/or warning letters or the foreign equivalent, fines, delays or suspensions of regulatory clearances, investigations, detainment, seizures or recalls of products (with the attendant expenses), the banning of a particular device, an order to replace or refund the cost of any device previously manufactured or distributed, operating restrictions and/or civil or criminal prosecution, and/or penalties, as well as decreased sales as a result of negative publicity and product liability claims; (ii) could expose us to breach of contract claims, fines and penalties, costs for remediation and harm to our reputation; (iii) could result in criminal or civil sanctions, including substantial fines, imprisonment and exclusion from participation in healthcare programs such as Medicare and Medicaid and health programs outside the United States; and (iv) could otherwise disrupt our business and could have a material adverse effect on our business, financial condition, results of operations and/or liquidity.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is under continued scrutiny from state, federal and international governments, including with respect to industry practices in the area of sales and marketing. Certain states, including Massachusetts, have recently passed or are considering legislation restricting our interactions with health care providers and requiring disclosure of many payments to them. The federal government has recently introduced similar legislation, which may or may not preempt state laws. If our marketing, sales or other activities fail to comply with the FDA&#8217;s or other comparable foreign regulatory agencies&#8217; regulations or guidelines, or other applicable laws, we may be subject to warnings from the FDA or investigations or enforcement actions from the FDA, Medicare, the Office of Inspector General of the U.S. Department of Health and Human Services or other government agencies or enforcement bodies. We anticipate that the government will continue to scrutinize our industry closely, and that additional regulation by governmental authorities may increase compliance costs, increase exposure to litigation and may have other adverse effects to our operations. The Company&#8217;s failure to comply with any marketing or sales regulations or any other applicable regulatory requirements could adversely affect our business, results of operations, financial condition and/or liquidity. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, lawsuits by or otherwise involving employees, customers, licensors, licensees, suppliers, vendors, business partners, distributors, shareholders or competitors with respect to how we conduct our business could be very costly and could substantially disrupt our business. The occurrence of an adverse monetary or equitable judgment or a large expenditure in connection with a settlement of any of these matters could have a material adverse effect on our business, financial condition, results of operations and/or liquidity.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or some of our suppliers fail to comply with the FDA&#8217;s Quality System Regulation, or QSR, and other applicable post-market requirements, our manufacturing operations could be disrupted, our product sales and profitability could suffer, and we may be subject to a wide variety of FDA enforcement actions.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing processes and those of some of our suppliers must comply with the FDA&#8217;s Quality System Regulation, or QSR, which governs the methods used in, and the facilities and controls used for, the design, testing, manufacture, control, quality assurance, installation, servicing, labeling, packaging, storage and shipping of medical devices, and with current medical device adverse event reporting regulations, and similar foreign rules and regulations. The FDA enforces the QSR through unannounced inspections. Despite our training and compliance programs, our internal control policies and procedures may not always protect us from negligent, reckless or criminal acts committed by our employees or agents. If we, or one of our suppliers, fail a QSR inspection, or if a corrective action plan adopted by us or one of our suppliers is not sufficient, the FDA may bring an enforcement action, and our operations could be disrupted and our manufacturing delayed. We are also subject to the FDA&#8217;s general prohibition against promoting our products for unapproved or &#8220;off-label&#8221; uses, the FDA&#8217;s adverse event reporting requirements and the FDA&#8217;s reporting requirements for field correction or product removals. The FDA has recently placed increased emphasis on its scrutiny of compliance with the QSR and these other post-market requirements. In addition, most other countries require us and our suppliers to comply with manufacturing and quality assurance standards for medical devices that are similar to those in force in the United States before marketing and selling our products in those countries. If we, or our suppliers, should fail to do so, we would lose our ability to market and sell our products in those countries.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot obtain and maintain marketing clearance or approval from governmental agencies, we will not be able to sell our products.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are medical devices that are subject to extensive regulation in the United States and in the foreign countries in which they are sold. Unless an exemption applies, each medical device that we wish to market in the United States must receive either 510(k) clearance or Pre-Market Approval (&#8220;PMA&#8221;) from the FDA before the product can be sold. Either process can be lengthy and expensive. The FDA&#8217;s 510(k) clearance procedure, also known as &#8220;premarket notification,&#8221; is the process we have used for our current products. This process usually takes from four to twelve months from the date the premarket </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">notification is submitted to the FDA, but may take significantly longer. Even after a device receives regulatory approval it remains subject to significant regulatory and quality requirements, such as manufacturing, recordkeeping, renewal, recertification or reporting and other post market approval requirements, which may include clinical, laboratory or other studies. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product approvals by the FDA and other foreign regulators can be withdrawn due to failure to comply with regulatory standards or the occurrence of unforeseen problems following initial approval or may be re-classified to a higher regulatory classification, such as requiring a PMA for a previously cleared 510(k) device. The PMA process is much more costly, lengthy and uncertain. It generally takes from one to three years from the date the application is submitted to, and filed with the FDA, and may take even longer. In addition, any modification to an FDA-cleared medical device that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, requires a new FDA 510(k) clearance or, possibly, a PMA. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory regimes in other countries similarly require approval or clearance prior to our marketing or selling products in those countries. We rely on our distributors to obtain regulatory clearances or approvals of our products outside of the United States. If we are unable to obtain additional clearances or approvals needed to market existing or new products in the United States or elsewhere or obtain these clearances or approvals in a timely fashion or at all, or if our existing clearances are revoked, our revenues and profitability may decline.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, we intend to obtain Medical Device Regulation ("MDR")  approvals for our principal products sold in the European Union ("EU") ahead of expiration dates; however for multiple reasons, including but not limited to changing business strategies, labor shortages and contract resources, administrative delays, increased costs of obtaining MDR certification, availability of necessary data and notified body capacity, certain products may not be fully compliant at the time of CE mark expiration. The additional time and resources required to obtain MDR certification has been a significant factor in, and will likely continue to influence, our decisions whether to discontinue sales and distribution of certain products in the EU.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complying with and obtaining regulatory approval in foreign countries, including our efforts to comply with the requirements of the MDR, have and will likely continue to lead to additional uncertainty, risk, expense and delay in commercializing products in certain foreign jurisdictions, which could have a material adverse effect on our business, financial condition and/or results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may be subject to product recalls, which may harm our reputation and divert managerial and financial resources.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar governmental authorities in other countries have the authority to order mandatory recall of our products or order their removal from the market if there are material deficiencies or defects in design, manufacture, installation, servicing or labeling of the product, or if the governmental entity finds that our products would cause serious adverse health consequences. A government mandated recall, voluntary recall or field action by us could occur as a result of component failures, manufacturing errors or design defects, including labeling defects. Any recall of our products may harm our reputation with customers and divert managerial, engineering and financial resources.  There is no assurance that we will not incur warranty or repair costs, be subject to liability claims for damages related to product defects, or experience manufacturing, shipping or other delays or interruptions as a result of these defects in the future. Our insurance policies may not provide sufficient protection should a claim be asserted.  A recall of any of our products could harm our reputation, divert managerial and financial resources and have a material adverse effect on our business, financial condition, results of operations and/or liquidity.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to fines, penalties, injunctions or costly investigations if we are determined to be promoting the use of our products for unapproved or &#8220;off-label&#8221; uses.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are incorrect in our belief that our promotional materials and training methods regarding the use of our products are conducted in compliance with regulations of the FDA and other applicable regulations, and the FDA determines that our promotional materials or training constitutes promotion of an unapproved use, the FDA could request that we modify our training or promotional materials or subject us to regulatory enforcement actions, including the issuance of a warning letter, injunction, seizure, civil fine and criminal penalties.  It is also possible that other federal, state or foreign enforcement authorities might take action if they consider promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.  Any of these results could have a material adverse effect on our business, financial condition, results of operations and/or liquidity.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations governing the export of our products could adversely impact our business.  If the U.S. government imposes strict sanctions on Iran, our revenue could be impacted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control (OFAC), and the Bureau of Industry and Security at the U.S. Department of Commerce (BIS), administer certain laws and regulations that restrict U.S. persons and, in some instances, non-U.S. persons, in conducting activities, transacting business with or making investments in certain countries, governments, entities and individuals subject to U.S. economic sanctions. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our international operations, we are subject to such laws and regulations, which are complex, restrict our business dealings with certain countries and individuals, and are constantly changing. Further restrictions may be enacted, amended, enforced or interpreted in a manner that materially impacts our operations.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2023 we generated $1.2 million of revenue for sales to distributors doing business in Iran.  We continuously review our ability to sell products to distributors that conduct business in Iran in accordance with all applicable U.S. laws.  If laws, rules or regulations of the United States, with respect to doing business in or with parties that do business in Iran, change to restrict our ability to generate revenue in Iran, our revenue could decline, impacting our results of operations.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we have limited business dealings in countries subject to comprehensive sanctions.  These business dealings may expose us to a heightened risk of violating applicable sanctions regulations. Violations of these regulations are punishable by civil penalties, including fines, denial of export privileges, injunctions, asset seizures, debarment from government contracts, revocations or restrictions of licenses, and/or criminal fines and imprisonment. We have established policies and procedures designed to assist with our compliance with such laws and regulations. However, there can be no assurance that our policies and procedures will effectively prevent us from violating these regulations in every transaction in which we may engage, and such a violation could adversely affect our reputation, business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO INTELLECTUAL PROPERTY</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to adequately protect our intellectual property rights, we may not be able to generate revenues from new or existing products and our business may suffer.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on obtaining, maintaining and enforcing our patents, trademarks and other proprietary rights, and our ability to avoid infringing the proprietary rights of others. We rely upon patent, trade secret, copyright, know-how and trademark laws, as well as license agreements and contractual provisions, to establish our intellectual property rights and protect our products. However, no assurances can be made that any pending or future patent applications will result in the issuance of patents, that any current or future patents issued to, or licensed by us, will not be challenged or circumvented by our competitors, or that our patents will not be found invalid.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent positions of medical device companies, including our Company, are uncertain and involve complex and evolving legal and factual questions. The coverage sought in a patent application can be denied or significantly reduced either before or after the patent is issued. Consequently, there can be no assurance that any of our pending patent applications will result in an issued patent. There is also no assurance that any existing or future patent will provide significant protection or commercial advantage, or whether any existing or future patent will be circumvented by a more basic patent, thus requiring us to obtain a license to produce and sell the product. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we rely on trade secret protection for certain unpatented aspects of our proprietary technology. There can be no assurance that others will not independently develop or otherwise acquire substantially equivalent proprietary information or techniques, that others will not gain access to our proprietary technology or disclose such technology, or that we can meaningfully protect our trade secrets. We have a policy of requiring key employees and consultants to execute confidentiality agreements upon the commencement of an employment or consulting relationship with us. Our confidentiality agreements also require our employees to assign to us all rights to any inventions made or conceived during their employment with us. We also generally require our consultants to assign to us any inventions made during the course of their engagement by us. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for us in the event of unauthorized use, transfer or disclosure of confidential information or inventions. If we are not able to adequately protect our intellectual property, our market share, financial condition and results of operations may suffer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties claim that our products infringe their intellectual property rights, we may be forced to expend significant financial resources and management time defending against such actions and our financial condition and our results of operations could suffer.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may claim that our products infringe their patents and other intellectual property rights. Identifying third-party patent rights can be particularly difficult because, in general, patent applications can be maintained in secrecy for at least 18 months after their earliest priority date, and publication of discoveries in the scientific or patent literature often lag behind actual discoveries. Some companies in the medical device industry have used intellectual property infringement litigation to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gain a competitive advantage. If a competitor were to challenge our patents, licenses or other intellectual property rights, or assert that our products infringe its patent or other intellectual property rights, we could incur substantial litigation costs, be forced to make expensive changes to our product design, pay royalties or other fees to license rights in order to continue manufacturing and selling our products, or pay substantial damages. Third-party infringement claims, regardless of their outcome, would not only consume our financial resources but also divert our management&#8217;s time and effort. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such claims could also cause our customers or potential customers to purchase competitors&#8217; products or defer or limit their purchase or use of our affected products until resolution of the claim. See Part I, Item 3 "Legal Proceedings" of this report for additional details on litigation regarding proprietary technology.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR STOCK PRICE</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future operating results are difficult to predict and may vary significantly from quarter to quarter, which may adversely affect the price of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing introduction of new products and services that affect our overall product mix make the prediction of future operating results difficult. You should not rely on our past results as any indication of future operating results. The price of our common stock will likely fall in the event that our operating results do not meet the expectations of analysts and investors. Comparisons of our quarterly operating results are an unreliable indication of our future performance because they are likely to vary significantly based on many factors, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of sales of our products and services in our markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to introduce new products or services and enhancements in a timely manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for and acceptance of our products and services;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our competition and the introduction of alternative products or services;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to command favorable pricing for our products and services;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the growth of the market for our devices and services;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expansion and rate of success of our direct sales force in the United States and internationally and our independent distributors internationally;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions relating to ongoing FDA compliance;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to integrate acquired assets or companies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of intellectual property disputes;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and timing of orders from independent distributors or customers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the attraction and retention of key personnel, particularly in sales and marketing, regulatory, manufacturing and research and development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated delays or an inability to control costs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic conditions, including inflationary pressure, as well as those specific to our customers and markets; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seasonal fluctuations in revenue due to the elective nature of some procedures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price may be volatile, which may cause the value of our stock to decline or subject us to a securities class action litigation.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock price may be volatile and could be subject to wide fluctuations in price in response to various factors, many of which are beyond our control, attributable to outside factors and/or unrelated to operating performance. Such factors may include comments by securities analysts or other third parties, including blogs, articles, message boards and social and other media coverage which may not be attributable to us and may not be reliable or accurate.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NASDAQ Stock Market and medical devices companies in particular have experienced substantial price and volume volatility that is often seemingly unrelated to the operating performance of the companies. These broad market fluctuations may cause the trading price of our common stock to decline. In the past, securities class action litigation has often been brought against a company after a period of volatility in the market price of its common stock.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_19"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unresolved Staff Comments.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_22"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Properties.</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended May&#160;31, 2023, we operated in the following locations:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:31.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purpose</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approx.<br/>Sq. Ft.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property<br/>Type</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latham, NY</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate headquarters</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glens Falls, NY</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Queensbury, NY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Queensbury, NY</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marlborough, MA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amsterdam, NL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rehovot, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we lease sales offices in various other jurisdictions.  </span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_25"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding legal proceedings is included in Note 17 to our consolidated financial statements in this Annual Report on Form 10-K.</span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_28"></div><div style="margin-bottom:4pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mine Safety Disclosures.</span></div><div style="text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_34"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities.</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Global Select Market tier of the NASDAQ Stock Market LLC, under the symbol &#8220;ANGO.&#8221;</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth, for the fiscal quarters indicated, the high and low sale prices for our common stock as reported by the NASDAQ Stock Market.</span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">High</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Low</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended May 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth Quarter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third Quarter</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Quarter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale Price</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">High</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Low</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended May 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth Quarter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third Quarter</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Quarter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Quarter</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August 2, 2023, there were 169 holders of record of our common stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not declare any cash dividends on our common stock during our last three fiscal years. We do not anticipate paying any cash dividends on our common stock for the foreseeable future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Graph</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below matches AngioDynamics, Inc.&#8217;s cumulative 5-year total shareholder return on common stock with the cumulative total returns of the NASDAQ Composite index, the RDG SmallCap Medical Devices index, S&amp;P 500 Health Care index and the NASDAQ Medical Equipment index. The graph tracks the performance of a $100 investment in our common stock and in each index (with the reinvestment of all dividends) from May 31, 2018 to May&#160;31, 2023. The stock price performance included in this graph is not necessarily indicative of future stock price performance.</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:24.75pt"><img src="ango-20230531_g9.jpg" alt="5 Year Total Return Graph.jpg" style="height:542px;margin-bottom:5pt;vertical-align:text-bottom;width:651px"/></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_37"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">[Reserved]</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_40"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Conditions and Results of Operations.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information should be read together with the audited consolidated financial statements and the notes thereto and other information included elsewhere in this annual report on Form 10-K.  This discussion may contain forward-looking statements related to future events and our future financial performance that are based on current expectation and are subject to risks and uncertainties.  Our actual results may differ materially from those anticipated in any forward-looking statements as a result of many factors, including those set forth in Part I, Item 1A, "Risk Factors" and "Disclosure Regarding Forward-Looking Statements" included in this Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Company and Market </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Many of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or long-term use.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations cross a variety of markets. Our financial performance is impacted by changing market dynamics, which have included an emergence of value-based purchasing by healthcare providers, consolidation of healthcare providers, the increased role of the consumer in health care decision-making and an aging population, among others. In addition, our growth is impacted by changes within our sector, such as the merging of competitors to gain scale and influence; changes in the regulatory environment for medical device; and fluctuations in the global economy. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions of our product offerings are created through internal and external product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in research and development activities and selective business development opportunities to provide growth opportunities. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products in the United States primarily through a direct sales force, and outside the U.S. through a combination of direct sales and distributor relationships. Our end users include interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.  We expect our businesses to grow in both sales and profitability by expanding geographically, penetrating new markets, introducing new products and increasing our presence internationally.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 global pandemic has impacted our business and may continue to pose future risks with the emergence of new variants.  Even with the public health actions that have been taken to reduce the spread of the virus, the market continues to experience disruptions with respect to consumer demand, hospital operating procedures and workflow, trends that may continue.  The Company's ability to manufacture products, the reliability of our supply chain, labor shortages, backlog and inflation (including the cost and availability of raw materials, direct labor and shipping) have impacted our business, trends that may continue.  Accordingly, management continues to evaluate the Company&#8217;s liquidity position, communicate with and monitor the actions of our customers and suppliers, and review our near-term financial performance.  </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing with the first quarter of fiscal year 2023, the Company began to manage its operations through two segments, Med Tech and Med Device to align with the transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Company repaid all amounts outstanding under its then existing credit agreement and entered into a new Credit Agreement that provides for a $75.0&#160;million Revolving Facility and a $30.0&#160;million Delayed Draw Term Loan.  As of May&#160;31, 2023, $25.0 million was drawn on the Revolving Facility and $25.0 million was drawn on the Delayed Draw Term Loan.  See Note 12 "Long-Term Debt" set forth in the Notes to the consolidated financial statements. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal year 2023, the Company was in discussions with Merit Medical Systems, Inc. ("Merit") to sell the dialysis product portfolio and BioSentry tract sealant system biopsy businesses.  This qualified for held for sale accounting as of May&#160;31, 2023.  On June 8, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with Merit Medical Systems, Inc. pursuant to which Merit acquired the dialysis product portfolio and BioSentry tract sealant system biopsy businesses for $100.0&#160;million in cash subject to the terms and conditions of the Asset Purchase Agreement.  The Company and Merit entered into various agreements to facilitate the transition to Merit, including a Transactions Services Agreement and Contract Manufacturing Agreement.  The Company determined that the sale of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">businesses did not constitute a strategic shift that had a major effect on the Company&#8217;s operations or financial results and as a result, this transaction will not be classified as discontinued operations.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;31, 2023, the Company concluded that the sale of the dialysis product portfolio and BioSentry tract sealant system biopsy businesses to Merit Medical Systems, Inc. was a triggering event for the Med Device reporting unit.  The Company utilized the income approach to determine the fair value of the remaining Med Device reporting unit.  Based on the results of this evaluation, the Company recorded a goodwill impairment charge of $14.5 million for the year ended May&#160;31, 2023 to write down the carrying value of the Med Device reporting unit to fair value. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the operating performance of our business, management focuses on revenue, gross margin, operating income, earnings per share and cash flow from operations. A summary of these key financial metrics for the year ended May&#160;31, 2023 compared to the year ended May&#160;31, 2022 follows: </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended May&#160;31, 2023:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue increased by 7.1% to $338.8 million </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Med Tech growth of 22.8% and Med Device growth of 1.9%</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gross profit decreased by 100 bps to 51.4% </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss increased by $25.9 million to $52.4 million</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss per share increased by $0.65 to a loss of $1.33</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash flow from operations increased by $7.3 million resulting in cash provided by operations of $0.1 million </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Med Tech business, comprised of Auryon, the Thrombectomy platform and NanoKnife grew 22.8% in fiscal year 2023.  The growth in Auryon, AlphaVac and NanoKnife disposables was partially offset by continued softness in AngioVac.  Our Med Device business grew 1.9% in fiscal year 2023 driven by growth in Core, Dialysis, Ports and Microwave products. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Strategic Initiatives to Drive Growth</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is focused on its ongoing transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company that delivers unique and innovative health care solutions.  The Company believes that this transformation will enable the Company to shift the portfolio from the mature, lower-growth markets where we have competed in the past by investing in technology and products that provide access to larger and faster growing markets.  As such, we believe the growth in the near to mid-term will continue to be driven by our high technology products including Auryon, Mechanical Thrombectomy (which includes AngioVac and AlphaVac) and NanoKnife.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the year, we introduced strategic moves designed to streamline our business, improve our overall business operations and position ourselves for growth. Those initiatives included:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Product development process.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company continued its disciplined product development process which is intended to improve the Company&#8217;s ability to bring new products to market.  This included:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Pathway expansion for Auryon in arterial thrombectomy and full market release of the hyrodphilic coated catheters;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">FDA clearance of the AlphaVac F18 thrombectomy system;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Enrollment of patients in the APEX IDE study for the use of AlphaVac F18 to treat pulmonary embolism; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Continued enrollment of patients in the PRESERVE study for the use of NanoKnife in the prostate.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Value Creation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To create value and drive future growth, the Company plans to practice dispassionate portfolio optimization and continue to focus on areas of compelling unmet needs including those that are patient-centric and evidenced-based.  In addition, the Company continues to pursue targeted global expansion opportunities.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are summarized in Note 1 "Basis of Presentation, Business Description and Summary of Significant Accounting Policies" in the consolidated financial statements included in this Form 10-K. While all of these significant accounting policies affect the reporting of our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require us to use a greater degree of judgment and/or estimates. Actual results may differ from those estimates. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements.  The Company&#8217;s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights.  As part of its assessment of each contract, the Company evaluates certain factors including the customer&#8217;s ability to pay (or credit risk).  For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction prices of products are typically based on contracted rates.  Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer, net of any variable consideration described below.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation.  Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation.  The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company&#8217;s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company&#8217;s manufacturing site or delivery to the customer&#8217;s named location, based on the contractual shipping terms of a contract.  In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company typically invoices customers upon satisfaction of identified performance obligations.  As the Company&#8217;s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into agreements to place placement and evaluation units (&#8220;units&#8221;) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer&#8217;s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units.  In these arrangements, revenue recognized for the sale of the disposables is not allocated between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers.  These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides certain customers with rebates and allowances that are explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.  The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets.  These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes.  The Company is also required to pay administrative fees to group purchasing organizations. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally offers customers a limited right of return.  Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge.  To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date.  The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized.  The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls.  During the year ended May&#160;31, 2023, such product returns were not material.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A receivable is generally recognized in the period the Company ships the product.  Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition.  Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers.  In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company&#8217;s </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inventories are stated at the lower of cost or net realizable value based on the first-in, first-out cost method and consist of raw materials, work in process and finished goods.  Appropriate consideration is given to deterioration, obsolescence, expiring and other factors in evaluating net realizable value.  When we evaluate inventory for excess quantities and obsolescence, we utilize historical product usage experience and expected demand for establishing our reserve estimates. Our actual product usage may vary from the historical experience and estimating demand is inherently difficult which may result in us recording excess and obsolete inventory amounts that do not match the required amounts.  An increase to inventory reserves results in a corresponding increase in cost of revenue. Inventories are written off against the reserve when they are physically disposed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions and Contingent Consideration</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the purchase price of acquired companies to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values.  The estimates used to value the net assets acquired are based in part on historical experience and information obtained from the management of the acquired company.  The Company generally values the identifiable intangible assets acquired using a discounted cash flow model.  The significant estimates used in valuing certain of the intangible assets include, but are not limited to: future expected cash flows of the asset, discount rates to determine the present value of the future cash flows, attrition rates of customers, royalty rates and expected technology life cycles.  The Company also estimates the useful lives of the intangible assets based on the expected period over which the Company anticipates generating economic benefit from the asset. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s estimates of fair value are based on assumptions believed to be reasonable at that time.  If management made different estimates or judgments, material differences in the fair values of the net assets acquired may result.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones.  The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations).  Projected revenues are based on the Company&#8217;s most recent internal operational budgets and long-range strategic plans.  The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies.  Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements.  Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within operating expenses in the Consolidated Statements of Operations.  Contingent consideration payments made soon after the acquisition date are classified as investing activities in the Consolidated Statements of Cash Flows.  Contingent consideration payments not made soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the Consolidated Statements of Cash Flows, and amounts paid in excess of the original acquisition date fair value are reported as operating activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill, indefinite lived intangible assets and in process research and development ("IP R&amp;D") are amortized over their estimated useful lives, which range between two to eighteen years, on a straight-line basis over the expected period of benefit.  The Company periodically reviews the estimated useful lives of intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Such conditions could include significant adverse changes in the business climate, current-period operating or cash flow losses, significant declines in forecasted operations, or a current expectation that an asset group will be disposed of before the end of its useful life.  When testing for impairment of definite-lived intangible assets held for use, the Company groups assets at the lowest level for which cash flows are separately identifiable.  Prior to the first quarter of fiscal year 2023, the Company managed its operations as one reporting unit.  At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as two operating segments and two reporting units, namely Med Tech and Med Device (see Note 18 "Segment and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K).  The Company operates as two reporting units and two asset groups.  If a triggering event is deemed to exist, the Company performs an undiscounted operating cash flow analysis to determine if an impairment exists.  If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise.  Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated costs were based on respective fair market values at the date of acquisition.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For goodwill, the impairment test requires a comparison of the estimated fair value of each reporting unit to which the goodwill is assigned to the carrying value of the assets and liabilities of those reporting units. The determination of reporting units also requires management judgment. The Company considers whether a reporting unit exists within a reportable segment based on the availability of discrete financial information. The Company operates as two operating segments with two reporting units and consequently evaluates goodwill for impairment based on an evaluation of the fair value of each reporting unit. If the carrying value of the reporting units exceed the fair value, the carrying value is reduced to its fair value through an adjustment to the goodwill balance, resulting in an impairment charge. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed in Note 9, "Goodwill and Intangible Assets" set forth in the Notes to our consolidated financial statements included in this Annual Report on Form 10-K, the Company recorded a goodwill impairment loss of $14.5 million for the year ended May&#160;31, 2023 as the fair value of the Med Device reporting unit was less than its carrying value. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no adjustments to goodwill for the Med Tech reporting unit for the year ended May&#160;31, 2023 other than foreign currency translation adjustments. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the years ended May&#160;31, 2023 and 2022 </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal year ended May&#160;31, 2023, the Company reported a net loss of $52.4 million, or a loss of $1.33 per diluted share, on net sales of $338.8 million compared to a net loss of $26.5 million, or a loss of $0.68 per diluted share, on net sales of $316.2 million in fiscal year 2022. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Sales</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Net sales are derived from the sale of our products and related freight charges, less discounts, rebates and returns. </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Sales </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Med Tech</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Med Device </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,752&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,219&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,533&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Sales by Geography</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,752&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended May&#160;31, 2023, net sales increased $22.5 million to $338.8 million compared to the year ended May&#160;31, 2022.  At May&#160;31, 2023, the Company had a backlog of $2.7 million compared to $8.4 million at the end of May&#160;31, 2022.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Med Tech business net sales increased $18.0 million for the year ended May&#160;31, 2023 compared to the prior year.  The change in sales from the prior year was primarily driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased Auryon sales of $12.0 million; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Growth in the thrombectomy platform of $3.0 million, which was driven by growth in the mechanical thrombectomy platform in AlphaVac sales of $5.0 million, partially offset by softness in AngioVac; and  </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased NanoKnife sales of $3.0 million, which was driven by NanoKnife disposable sales in the U.S. and internationally which increased $3.3 million due to increased case volume.  This increase was partially offset by decreased NanoKnife capital sales in the U.S.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Med Device business net sales increased $4.6 million for the year ended May&#160;31, 2023 compared to the prior year.  The backlog, which primarily impacted sales of Core and Vascular Access products, was $2.7 million at May&#160;31, 2023 compared to $8.4 million at May&#160;31, 2022.  The change in sales from the prior year was primarily driven by:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:0.9pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Core, Dialysis, Ports and Microwave sales of $5.4 million, $5.2 million, $1.4 million and $1.0 million, respectively.  These increases were partially offset by decreased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Venous, PICCs, Midlines and other Oncology and Vascular Access sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $3.6 million, $2.4 million, $0.8 million and $1.6 million, respectively.</span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$ Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit % of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit % of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit % of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Gross profit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Company gross profit increased by $8.5 million compared to the prior year.  The change from the prior year was primarily driven by:&#160;&#160;&#160;&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sales volume, which positively impacted gross profit by $13.2 million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Production volume and other incentives which positively impacted gross profit by $11.3 million</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Price and mix, which negatively impacted gross profit by $4.9 million; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Inflationary costs on raw materials, labor shortages and freight costs, which negatively impacted gross profit by $8.1 million; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Incremental depreciation on placement units of $2.2 million; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">A benefit of $0.8 million that was recorded as a result of the employee retention credit that the Company filed for under the provision of the CARES Act in the prior year.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Med Tech segment gross profit increased by $9.4 million compared to the prior year.  The change from the prior year was primarily driven by:&#160;&#160;&#160;&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sales volume, which positively impacted gross profit by $13.9 million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Production volume, manufacturing and other incentives which positively impacted gross profit by $2.1 million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pricing pressures and mix, which negatively impacted gross profit by $4.7 million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Inflationary costs on raw materials, labor shortages and freight costs, which negatively impacted gross profit by $0.5 million; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Incremental depreciation on placement units of $1.3 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Med Device segment gross profit decreased by $0.9 million compared to the prior year.  The change from the prior year was primarily driven by:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sales volume, which positively impacted gross profit by $2.1 million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Production volume, manufacturing and other incentives which positively impacted gross profit by $8.6 million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pricing pressures and mix, which negatively impacted gross profit by $3.7 million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Inflationary costs on raw materials, labor shortages and freight costs, which negatively impacted gross profit by $7.6 million; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Incremental depreciation on placement units of $0.3 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Expenses and Other Income (expense)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(856)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and development expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Research and development (&#8220;R&amp;D&#8221;) expense includes internal and external costs to develop new products, enhance existing products, validate new and enhanced products, manage clinical, regulatory and medical affairs.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense decreased $0.9 million compared to the prior year.  The change from the prior year was primarily driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The timing of certain projects and clinical spend associated with the ongoing clinical trials, which decreased R&amp;D expense by $1.1 million; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compensation and benefits expenses, which decreased $0.3 million; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A benefit of $0.5 million that was recorded as a result of the employee retention credit that the Company filed for under the provision of the CARES Act in the prior year.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sales and marketing expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Sales and marketing (&#8220;S&amp;M&#8221;) expense consists primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S&amp;M expense increased by $8.9 million compared to the prior year.  The change from the prior year was primarily driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Additional headcount from the build-out of the Auryon and mechanical thrombectomy sales and marketing teams, which increased compensation and benefits expense by $3.1 million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Travel, meeting, tradeshow and other selling expenses, which increased $3.7 million; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other fixed expenses (utilities, insurance, depreciation, etc.), which decreased $0.6 million; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A benefit of $2.8 million that was recorded as a result of the employee retention credit that the Company file for under the provision of the CARES Act in the prior year.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - General and administrative (&#8220;G&amp;A&#8221;) expense includes executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G&amp;A expense increased by $1.6 million compared to the prior year.  The change from the prior year was primarily driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compensation and benefits expense, which decreased $0.5 million; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other outside consultant spend for legal and IT which increased $1.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(668)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, restructuring and other items, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,478)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,778)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amortization of intangibles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Represents the amount of amortization expense that was taken on intangible assets held by the Company.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amortization expense decreased $0.7 million compared to the prior year.  The decrease is due to assets that became fully amortized in fiscal year 2023. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Represents the impairment charge taken on goodwill.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company recorded a non-cash goodwill impairment charge of $14.5 million for the year ended May&#160;31, 2023 as the fair value of the Med Device reporting unit was less than its carrying value.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change in fair value of contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The change in the fair value for the year ended May&#160;31, 2023 is related to the Eximo contingent consideration and the increased probability of achieving the revenue milestones.  The first revenue milestone was achieved in May 2023 and will be paid in the first quarter of fiscal year 2024.  </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition, restructuring and other items, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Acquisition, restructuring and other items, net represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition, restructuring and other items, net increased by $6.6 million compared to the prior year.  The change from the prior year was primarily driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Legal expense, related to litigation that is outside of the normal course of business, which increased $2.4 million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mergers and acquisition expense related to legal fees, which increased $0.3 million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing relocation expense related to the move of certain manufacturing lines to Costa Rica, which increased $0.4 million;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other expenses (mainly severance associated with organizational changes), which decreased $0.1 million; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The payment to the Israeli Innovation Authority of $3.5 million related to grant funds that were provided to Eximo to develop the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020.  These grant funds were fully repaid in the first quarter of fiscal year 2023 to satisfy the obligation which was otherwise being paid as a royalty based on a percentage of sales.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Other expense includes interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The change in other expe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nse of $1.8 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to the prior year, is primarily due to increased interest expense of $2.1 million and unrealized foreign currency fluctuations of $0.2 million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,995)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,402)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our effective tax rate was a benefit of 3.7% for fiscal year 2023 compared with an effective tax rate benefit of 11.4% for the prior year.  The current year and prior year effective tax rates differ from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation), goodwill impairment and the impact of stock-based compensation.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal year 2016, except the naked credit deferred tax liability. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&amp;D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of May&#160;31, 2023. The Company will continue to assess the level of the valuation allowance required.  If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company&#8217;s results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review our liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 global pandemic.  We believe that our current cash on hand provides sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and cash equivalents totaled $44.6 million as of May&#160;31, 2023, compared with $28.8 million as of May&#160;31, 2022.  As of May&#160;31, 2023 and 2022, total debt outstanding related to the Credit Agreement was $50.0 million ($25.0 million on the Revolving Facility and $25.0 million on the Delayed Draw Term Loan) and $25.0 million, respectively.  The fair value of the contingent consideration liability as of May&#160;31, 2023 was $19.3 million. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our cash flows for the years ended May&#160;31, 2023 and 2022:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(518)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,795&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,336)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended May&#160;31, 2023 and 2022, cash flows consisted of the following:</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash provided by (used in) operating activities:</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended May&#160;31, 2023 and 2022:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss of $52.4 million and $26.5 million, respectively, plus the non-cash items, primarily driven by depreciation and amortization, goodwill impairment and stock-based compensation, along with the changes in working capital below, contributed to cash provided by operations of $0.1 million for the year ended May&#160;31, 2023 and cash used in operations of $7.2 million for the year ended May&#160;31, 2022.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For the year ended May&#160;31, 2023, working capital was unfavorably impacted by increased accounts receivable and inventory on hand of $1.3 million and $8.2 million, respectively. This was partially offset by increased accounts payable and accrued liabilities of $2.1 million. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For the year ended May&#160;31, 2022, working capital was unfavorably impacted by increased accounts receivable, inventory on hand and prepaids of $17.2 million, $2.8 million and $5.0 million respectively. This was partially offset by increased accounts payable and accrued liabilities of $3.9 million. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash used in investing activities:</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended May&#160;31, 2023 and 2022:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$3.8 million and $4.3 million, respectively, of cash was used for fixed asset additions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$5.4 million and $11.4 million, respectively, of cash was used for Auryon placement and evaluation unit additions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.5 million of cash was used for the acquisition of an exclusive license in the first quarter of fiscal year 2023; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$3.6 million of cash was used for the QX Medical asset acquisition in the first quarter of fiscal year 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash provided by financing activities:</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended May&#160;31, 2023 and 2022:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$70.0 million in proceeds on long-term debt less the repayment of $45.0 million associated with the new Credit Agreement in the first quarter of fiscal year 2023.  The $25.0 million draw on the Delayed Draw Term Loan associated with the new Credit Agreement is to fund the historical and planned fiscal year 2023 purchases of Auryon placement and evaluation units.  See Note 12 "Long-Term Debt" set forth in the Notes to the consolidated financial statements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.8 million of deferred financing costs associated with the new Credit Agreement; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$5.0 million draw on the Revolving Facility in the first quarter of fiscal year 2022 for the QX Medical asset acquisition; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.2 million and $2.7 million, respectively, of proceeds from stock option and ESPP activity.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On August 30, 2022, the Company repaid all amounts outstanding under its then existing credit agreement and entered into a new Credit Agreement that provides for a $75.0 million Revolving Facility and a $30.0 million Delayed Draw Term Loan, and also includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million.  The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. One financial covenant requires us to maintain a fixed charge coverage ratio of not less than 1.25 to 1.00. The other financial covenant requires us to maintain a total leverage ratio of not greater than 3.00 to 1.00. The total leverage ratio is based upon our trailing twelve months total adjusted EBITDA (as defined in the Credit Agreement). The amount that we can borrow under our Credit Agreement is directly based on our leverage ratio. The interest rate at May&#160;31, 2023 applicable to each was 6.73%. The Company was in compliance with the Credit Agreement covenants as of May&#160;31, 2023.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of fiscal year 2023 and in connection with the new Credit Agreement, the Company drew $25.0 million on the Revolving Facility. The Company also drew $25.0 million on the Delayed Draw Term Loan to fund the historical and planned fiscal year 2023 purchases of Auryon placement and evaluation units for total long-term debt outstanding of $50.0 million. In the first quarter of fiscal year 2022, the Company made a $5.0 million draw on the Revolving Facility in conjunction with the QX Medical asset acquisition. We believe that our current cash balance, together with cash generated from operations and access to our Revolving Facility, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make acquisitions of other businesses or technologies in the future for cash, we may require external financing.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to fiscal year 2023, on June 8, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with Merit Medical Systems, Inc. ("Merit") pursuant to which Merit acquired the dialysis product portfolio and BioSentry tract sealant system biopsy businesses.  The Company and Merit entered into various agreements to facilitate the transition to Merit, including a Transactions Services Agreement and Contract Manufacturing Agreement.  The purchase price for the asset sale was $100.0 million in cash subject to the terms and conditions of the Asset Purchase Agreement.  In conjunction with the Asset Purchase Agreement, on June 8, 2023, AngioDynamics used a portion of the consideration received to repay all amounts owed under AngioDynamics&#8217; existing Credit Agreement, dated as of August 30, 2022, and as a result, the Credit Agreement was extinguished. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual obligations as of May&#160;31, 2023 are set forth in the table below (in thousands).  We have no variable interest entities or other off-balance sheet obligations.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash payments due by period as of May&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less&#160;than<br/>One&#160;Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-3&#160;Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3-5&#160;Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">After&#160;5<br/>Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual Obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt and interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related future obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,054&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,280&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Operating leases include short-term leases that are not recorded on our Consolidated Balance Sheets under ASU No. 2016-02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) The inventory purchase obligations are not reflected on our Consolidated Balance Sheets under accounting principles generally accepted in the United States of America.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) Acquisition-related future obligations include scheduled minimum payments and contingent payments based upon achievement of performance measures or milestones such as sales or profitability targets, the achievement of research and development objectives or the receipt of regulatory approvals.  The amount represents the undiscounted value of contingent liabilities recorded on the balance sheet.  Timing of payments are as contractually scheduled, or where contingent, the Company's best estimate of payment timing.</span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the years ended May&#160;31, 2022 and 2021 </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For management discussion and analysis of our 2022 financial results and liquidity compared with 2021, see Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended May&#160;31, 2022 filed on July 22, 2022. </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 of the Notes to the consolidated financial statements for Recently Issued Accounting Pronouncements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOREIGN CURRENCY EXCHANGE RATE RISK</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from changes in currency exchange rates, as well as interest rate fluctuations on our credit facility and investments that could impact our results of operations and financial position.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact sales in currencies other than the U.S. Dollar, particularly the Euro, British pound and Canadian dollar. Approximately 4.7% of our sales in fiscal year 2023 were denominated in foreign currencies. We do not have expenses denominated in foreign currencies at the level of our sales and as a result, our profitability is exposed to currency fluctuations.  When the U.S. Dollar strengthens, our sales and gross profit will be negatively impacted.  In addition, we have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period, with the offset to changes presented as a component of Other (Expense) Income.  Significant non-functional balances include accounts receivable due from some of our international customers.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTEREST RATE RISK</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the Revolving Facility and  Delayed Draw Term Loan is based, at the Company's option, on a rate equal to (i) the Secured Overnight Financing Rate ("SOFR") plus 0.10% (subject to a floor of 0%), or (ii) if the Company elects to treat a borrowing as an ABR Borrowing, an alternate base rate based on SOFR, plus, in each case, an applicable margin of 1.25%, 1.50% or 1.75%, depending on the leverage ratio.  If any amounts are not paid when due, such overdue amounts will bear interest at an amount generally equal to 2.0% plus the existing loan rate.  The Credit Agreement also carries a commitment fee in the case of the Revolving Facility, and a ticking fee, in the case of the Delayed Draw Term Loans of 0.20% to 0.25% per annum on the unused portion.   As of May&#160;31, 2023, there was $25.0&#160;million outstanding on the Delayed Draw Term Loan and $25.0&#160;million outstanding on the Revolving Facility and the interest rate at May&#160;31, 2023 was 6.73%.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONCENTRATION OF CREDIT RISK</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, our Revolving Facility and trade accounts receivable.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash and cash equivalents at various institutions and performs periodic evaluations of the relative credit standings of these financial institutions to ensure their credit worthiness.  In addition, the Credit Agreement is structured across three investment grade banks.  The Company has the ability to draw equally amongst the five banks which limits the concentration of credit risk of one institution.  </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentration of credit risk with respect to trade accounts receivable is limited due to the large number of customers that purchase products from the Company.  No single customer represents more than 10% of total sales.  The Company monitors the creditworthiness of its customers.  As the Company&#8217;s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.  Although the Company does not currently foresee a significant credit risk associated with the outstanding accounts receivable, repayment is dependent upon the financial stability of our customers.</span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_46"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Financial Statements and Supplementary Data.</span></div><div style="margin-bottom:13pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statements and supplementary data required by Part II, Item&#160;8 are included in Part IV of this report and indexed under Item&#160;15 (a)&#160;(1) and (2) of this report, and are incorporated by reference into this Item&#160;8.&#160;</span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_49"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_52"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting for our Company. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States and includes those policies and procedures that:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States, and that our receipts and expenditures are being made only in accordance with authorizations of our management and members of our Board of Directors; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has assessed the effectiveness of our internal control over financial reporting as of May&#160;31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013).  Based on this evaluation, management concluded that our internal control over financial reporting was effective as of May&#160;31, 2023.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of May&#160;31, 2023 has been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report which appears herein.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting for the fiscal year ended May&#160;31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Shareholders and the Board of Directors of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AngioDynamics, Inc.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Latham, New York </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the internal control over financial reporting of AngioDynamics, Inc. and subsidiaries (the &#8220;Company&#8221;) as of May&#160;31, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of May&#160;31, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> issued by COSO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended May&#160;31, 2023, of the Company and our report dated August 3, 2023, expressed an unqualified opinion on those financial statements.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Deloitte &amp; Touche LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Boston, Massachusetts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">August 3, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div><span><br/></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_55"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Jurisdictions that Prevent Inspections.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information required by Part III is omitted from this Annual Report on Form 10-K because we will file a definitive proxy statement within 120 days after the end of our fiscal year end pursuant to Regulation 14A (the &#8220;Proxy Statement&#8221;) for our Annual Meeting of Stockholders, currently scheduled for October&#160;2023. The information included in the Proxy Statement under the respective headings noted below is incorporated herein by reference.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Directors, Executive Officers and Corporate Governance.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required in this Annual Report on Form 10-K with respect to Executive Officers is contained in the discussion titled &#8220;Executive Officers of the Company&#8221; in Part I of this Annual Report on Form 10-K. The balance of the information required by Item&#160;10 is incorporated herein by reference to our Proxy Statement under the heading &#8220;Election of Directors&#8221;.&#160;</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_67"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Compensation.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this caption is incorporated herein by reference to our Proxy Statement under the heading &#8220;Executive Compensation&#8221;.&#160;</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_70"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this caption is incorporated herein by reference to our Proxy Statement under the heading &#8220;Ownership of Securities&#8221;.&#160;</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_73"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Relationships and Related Transactions, and Director Independence.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this caption is incorporated herein by reference to our Proxy Statement under the heading &#8220;Certain Relationships and Related Transactions&#8221;.&#160;</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_76"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principal Accounting Fees and Services.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this caption is incorporated herein by reference to our Proxy Statement under the headings &#8220;Audit Matters&#8212;Principal Accounting Fees and Services and&#8212;Policy on Audit Committee Pre-approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm&#8221;.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV</span></div><div><span><br/></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_82"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exhibits, Financial Statement Schedules.</span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_85"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements</span></div><div style="margin-top:5pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following consolidated financial statements and supplementary data of Registrant and its subsidiaries required by Part II, Item&#160;8, are included in Part IV of this report:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:87.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_94">Report of Independent Registered Public Accounting Firm (PCAOB I</a></span><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_94">D</a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_94"> </a><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-35">34</ix:nonNumeric><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_94">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_94">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_97">Consolidated Statements of Operations&#8212;Year ended May&#160;31, 2023, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_97">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_100">Consolidated Statements of Comprehensive Loss - Year ended May&#160;31, 2023, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_100">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_103">Consolidated Balance Sheets&#8212;May 31, 2023 and May 31, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_103">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_106">Consolidated Statements of Stockholders&#8217; Equity&#8212;Year ended May&#160;31, 2023, 2022 and&#160;2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_106">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_109">Consolidated Statements of Cash Flows&#8212;Year ended May&#160;31, 2023, 2022 and&#160;2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_109">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_112">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_112">58</a></span></div></td></tr></table></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_88"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Statement Schedules</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following consolidated financial statement schedule is included in Part IV of this report:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:94.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_220">Schedule II&#8212;Valuation and qualifying accounts</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_220">81</a></span></div></td></tr></table></div><div style="margin-top:4pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules are omitted because they are not applicable, not required, or because the required information is included in the consolidated financial statements or notes thereto.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_91"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:94.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_223">(b) Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0c89ef540c7d4512afc87ee33fb4f1eb_223">82</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:91%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the Shareholders and the Board of Directors of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AngioDynamics, Inc.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Latham, New York</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:91%">Opinion on the Financial Statements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">We have audited the accompanying consolidated balance sheets of AngioDynamics, Inc. and subsidiaries (the "Company") as of May&#160;31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), stockholders' equity, and cash flows, for each of the three years in the period ended May&#160;31, 2023, and the related notes and the schedule listed in the Index at Item 15 (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of May&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended May&#160;31, 2023, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of May&#160;31, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated August 3, 2023, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:91%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:91%">Critical Audit Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:91%">Inventories &#8211; Excess Quantities and Obsolescence &#8212; Refer to Notes 1 &amp; 6</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:91%">Critical Audit Matter Description</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">The Company evaluates inventory each reporting period for excess quantities and obsolescence, establishing reserves when necessary based upon historical experience, assessment of economic conditions, and expected demand. Once recorded, these reserves are considered permanent adjustments to the carrying value of inventory. As of May&#160;31, 2023, the Company has inventories of $55.3 million, net of excess quantities and obsolescence reserves.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We identified the reserve for excess quantities and obsolete inventory as a critical audit matter because of the significant estimates and assumptions management makes to quantify and to record the reserve, including the determination of expected demand. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate the methodology and the reasonableness of assumptions including expected demand.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:91%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Our audit procedures related to the reserve for excess quantities and obsolete inventory including management&#8217;s estimate of expected demand, included the following, among others:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the design and effectiveness of controls over inventory, including those over the estimation of reserves for excess quantities and obsolescence.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We evaluated the reasonableness of the Company's excess and obsolete inventory policy, considering historical experience and the underlying assumptions. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the calculation of the excess and obsolete reserve pursuant to the Company's policy, on a sample basis, including the completeness and accuracy of the data used in the calculation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We performed a retrospective review by comparing management&#8217;s prior year projections of future demand by product, with actual product sales in the current year to identify potential bias in the inventory reserve.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We held discussions with senior financial and operating management to determine whether any strategic, regulatory, or operational changes in the business were consistent with the projections of future demand that were utilized as the basis for the reserves recorded.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:91%">Valuation of Goodwill for the Med Device Reporting Unit - Refer to Notes 1 &amp; 9</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At May 31, 2023, the Company's goodwill specific to the Med Device reporting unit was $40 million. As discussed in Note 1 of the consolidated financial statements, goodwill is not amortized but rather is tested for impairment at least annually or more frequently if impairment indicators arise. In connection with the Company&#8217;s determination that assets held for sale criteria was met as of May 31, 2023 with regard to a portion of its Med Device reporting unit, the Company identified a triggering event requiring further assessment relating to the recoverability of its goodwill and therefore after performing its annual test on its measurement date of April 30, 2023, performed an updated goodwill impairment test as of May 31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company determined the amount of goodwill attributable to the disposal group and to the portion of the remaining Med Device reporting unit on a relative fair value basis. The Company recorded a goodwill impairment charge of $14.5 million relating to its Med Device reporting unit for the year ended May 31, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Auditing the annual goodwill impairment involves significant audit effort, as well as a degree of complexity and auditor judgment due to the estimation required in determining the fair value of the reporting units or components thereof. In particular, the fair value estimates involve judgmental assumptions including the amount and timing of expected future cash flows from revenue growth rates, EBITA margins, weighting of fair values, and discount rates. The audit effort involved the use of professionals with specialized skill and knowledge.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The primary procedures we performed to address this critical audit matter included:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the effectiveness of internal controls over the Company&#8217;s annual goodwill impairment analysis and its conclusions related to its updated goodwill assessment as of May 31, 2023. This included controls over management&#8217;s review of the revenue growth rates, EBITA margins, weighting of the fair values, and discount rates used in the valuation models.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We performed risk assessment procedures over the Company&#8217;s goodwill impairment analysis, and evaluated the sensitivity of certain business assumptions, including  </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Revenue growth rates </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">EBITA margins </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Weighting of fair values</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Discount rates used in the valuation models</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We considered the historical accuracy of management's estimates and evaluated the forecasts for reasonableness, comparing to historical results and internal communications to management and the Board of Directors, as well as information generated from analyst and industry reports for the Company and certain of its peer companies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the assistance of our fair value specialists, we evaluated the revenue growth rates, EBITA margins, weighting of fair values, and discount rates and reasonableness of the valuation methodology, including testing the underlying source information and the mathematical accuracy of the calculations, and developing a range of independent estimates and comparing to those selected by management.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We considered the existence of contradictory evidence based on consideration of internal communication to management and the Board of Directors, Company press releases, and analysts' reports, as well as any changes within the business.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-36">Deloitte &amp; Touche LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-37">Boston, Massachusetts</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">August 3, 2023  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 2016.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AngioDynamics, Inc. and Subsidiaries</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-38">338,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-39">316,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-40">291,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of sales (exclusive of intangible amortization)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-41">164,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-42">150,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-43">134,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-44">174,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-45">165,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-46">156,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-47">29,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-48">30,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-49">36,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-50">104,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-51">95,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-52">81,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-53">40,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-54">38,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-55">35,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-56">18,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-57">19,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-58">18,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-59">14,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ango:ChangeInFairValueOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-62">2,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ango:ChangeInFairValueOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-63">1,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ango:ChangeInFairValueOfContingentConsideration" scale="3" id="f-64">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, restructuring and other items, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="3" id="f-65">15,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="3" id="f-66">9,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="3" id="f-67">20,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-68">225,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-69">194,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-70">192,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-71">51,181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-72">28,471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-73">35,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-74">2,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-75">688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-76">861</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-77">554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-78">790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-79">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expenses, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ango:OtherNonoperatingIncomeExpenseAndInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-80">3,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="ango:OtherNonoperatingIncomeExpenseAndInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-81">1,478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="ango:OtherNonoperatingIncomeExpenseAndInterestExpense" scale="3" id="f-82">769</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-83">54,437</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-84">29,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-85">36,052</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-86">1,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-87">3,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-88">4,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-89"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-90">52,442</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-91">26,547</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-92">31,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per share</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-93">1.33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-94">0.68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-95">0.82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-96">1.33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-97">0.68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-98">0.82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-99">39,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-100">39,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-101">38,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-102">39,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-103">39,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-104">38,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AngioDynamics, Inc. and Subsidiaries</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-105">52,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-106">26,547</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-107">31,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), before tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-108">6,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-109">1,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-110">4,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-111">6,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-112">1,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-113">4,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense) related to items of other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="3" id="f-114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="3" id="f-115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="3" id="f-116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-117">6,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-118">1,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-119">4,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total comprehensive loss, net of tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-120">58,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-121">28,343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-122">27,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:17pt;margin-top:12pt"><span><br/></span></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AngioDynamics, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-123">44,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-124">28,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-125">2,150</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-126">1,939</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-127">52,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-128">52,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-129">55,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-130">51,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-131">4,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-132">10,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-133">6,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="3" id="f-134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-135">163,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-136">143,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-137">44,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-138">45,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-139">111,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-140">152,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-141">159,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-142">201,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-143">10,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-144">10,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-145">43,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-147">532,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-148">552,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-149">40,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-150">28,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-151">26,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-152">34,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-153">14,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-154">8,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-155">2,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-156">2,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-157">83,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-158">74,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-159">49,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-160">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-161">12,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-162">16,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-163">4,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-164">8,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-165">3,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-166">4,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-167">154,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-168">128,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 17)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-169"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-8" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-170"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-171"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-172">0.01</ix:nonFraction></ix:nonFraction> per share, <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-173"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-174">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-175"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-176"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-177"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-178">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-181"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-182">0.01</ix:nonFraction></ix:nonFraction> per share, <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-183"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-184">75,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-185">39,981,422</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-186">39,541,173</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-187">39,611,422</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-188">39,171,173</ix:nonFraction> shares outstanding at May 31, 2023 and 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-189">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-190">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-191">599,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-192">586,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-193">210,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-194">158,413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-195"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-196">370,000</ix:nonFraction></ix:nonFraction> shares, at cost at May 31, 2023 and 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="f-197">5,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="f-198">5,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-199">4,723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-200">1,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Stockholders' Equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-201">378,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-202">424,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities and Stockholders' Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-203">532,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-204">552,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AngioDynamics, Inc. and Subsidiaries</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.675%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional<br/>paid in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at May 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-205">38,448,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-206">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-207">561,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-208">100,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-209">1,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-210">370,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-211">5,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-212">454,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-213">31,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-214">31,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-215">123,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-216">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-217">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-218">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/cancellation of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-219">184,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-220">223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-221">223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-222">164,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-223">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-224">1,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-225">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-226">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-227">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-228">4,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-229">4,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at May 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-230">38,920,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-231">377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-232">573,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-233">131,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-234">3,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-235">370,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-236">5,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-237">439,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-238">26,547</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-239">26,547</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-240">162,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-241">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-242">2,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-243">2,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/cancellation of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-244">299,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-245">1,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-246">1,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/cancellation of performance share units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-247">59,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-248">98,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-249">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-250">1,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-251">1,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-252">10,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-253">10,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-254">1,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-255">1,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at May 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-256">39,541,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-257">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-258">586,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-259">158,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-260">1,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-261">370,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-262">5,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-263">424,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-264"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-265">52,442</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-266">52,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-267">21,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-268">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-269">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-270">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/cancellation of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-271">239,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-272">720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-273">720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/cancellation  of performance share units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-274">29,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-275">312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-276">312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-277">149,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-278">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-279">2,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-280">2,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-281">11,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-282">11,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-283">6,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-284">6,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at May 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-285">39,981,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-286">382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-287">599,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-288">210,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-289">4,723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-290">370,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-291">5,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-292">378,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AngioDynamics, Inc. and Subsidiaries</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-293"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-294">52,442</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-295">26,547</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-296">31,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-297">30,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-298">29,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-299">25,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ango:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-300">2,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ango:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-301">2,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ango:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-302">2,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-303">14,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-306">11,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-307">10,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-308">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ango:ChangeInFairValueOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-309">2,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ango:ChangeInFairValueOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-310">1,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ango:ChangeInFairValueOfContingentConsideration" scale="3" id="f-311">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ango:DeferredIncomeTaxRelatedToOperatingActivity" format="ixt:num-dot-decimal" scale="3" id="f-312">2,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="ango:DeferredIncomeTaxRelatedToOperatingActivity" format="ixt:num-dot-decimal" scale="3" id="f-313">3,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="ango:DeferredIncomeTaxRelatedToOperatingActivity" format="ixt:num-dot-decimal" scale="3" id="f-314">4,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in accounts receivable allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-315">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-316">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-317">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="f-318">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="f-319">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="f-320">14,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-321">513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-322">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-323">147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-324">1,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-325">17,151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-326">4,162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-327">8,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-328">2,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-329">11,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-330">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-331">5,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-332">3,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-333">2,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-334">3,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-335">4,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="f-336">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-337">7,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-338">24,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-339">3,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-340">4,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-341">5,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to placement and evaluation units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ango:IncreaseInPlacementAndEvaluationUnits" format="ixt:num-dot-decimal" scale="3" id="f-342">5,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ango:IncreaseInPlacementAndEvaluationUnits" format="ixt:num-dot-decimal" scale="3" id="f-343">11,410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ango:IncreaseInPlacementAndEvaluationUnits" format="ixt:num-dot-decimal" scale="3" id="f-344">8,524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-346">3,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ango:PaymentsToAcquireIntangibleAssetsNetOfCashAcquired" scale="3" id="f-348">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ango:PaymentsToAcquireIntangibleAssetsNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ango:PaymentsToAcquireIntangibleAssetsNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-351">9,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-352">19,307</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-353">13,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of and borrowings on long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-354">70,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-357">45,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-359">20,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from borrowings on long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-361">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs on long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-363">751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options and employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ango:ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" format="ixt:num-dot-decimal" scale="3" id="f-366">1,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ango:ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" format="ixt:num-dot-decimal" scale="3" id="f-367">2,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ango:ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" format="ixt:num-dot-decimal" scale="3" id="f-368">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-369">25,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-370">7,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-371">16,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-372">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-373">518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-374">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-375">15,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-376">19,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-377">6,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-378">28,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-379">48,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-380">54,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-381">44,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-382">28,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-383">48,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AngioDynamics, Inc. and Subsidiaries</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS&#8212;(Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in accounts payable for purchases of fixed assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="3" id="f-384">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="3" id="f-385">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="3" id="f-386">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid during the year for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="3" id="f-387">2,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestPaid" scale="3" id="f-388">562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestPaid" scale="3" id="f-389">731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-390">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-391">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-392">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:90pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:90pt;text-align:center"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AngioDynamics, Inc. and Subsidiaries</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_115"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.  <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-393" continuedAt="i43b64171cbde41609037fcc050a2cc5e" escape="true">BASIS OF PRESENTATION, BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_118"></div><ix:continuation id="i43b64171cbde41609037fcc050a2cc5e" continuedAt="ic3ddfde8202141519ae2b71d649ec32b"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-394" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Description of Business</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, (collectively, the "Company", "we", "our", or "us").  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving the quality of life for patients.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Principles</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements and accompanying notes have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP").</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of AngioDynamics and its subsidiaries (all of which are wholly owned).  All intercompany balances and transactions have been eliminated.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates.</span></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_121"></div><ix:continuation id="ic3ddfde8202141519ae2b71d649ec32b" continuedAt="i22ed4345e6b8494d98e3c60a842d89d8"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-395" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all unrestricted highly liquid investments with an initial maturity of <ix:nonNumeric contextRef="c-1" name="ango:ShortTermInvestmentsMaturityPeriod" id="f-396">less than three months</ix:nonNumeric> at the date of purchase to be cash equivalents. The Company maintains cash and cash equivalent balances with financial institutions in the United States in excess of amounts insured by the Federal Deposit Insurance Corporation.</span></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_124"></div><ix:continuation id="i22ed4345e6b8494d98e3c60a842d89d8" continuedAt="i751bcec1f0194ce989a1565b84f656da"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-397" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Instruments</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the Company's cash and cash equivalents, accounts receivable, accounts payable and long-term debt approximates fair value due to the short-term nature or market interest rates of these items. The Company bases the fair value of short-term investments on quoted market prices or other relevant information generated by market transactions involving identical or comparable assets. The Company measures and records derivative financial instruments at fair value. See Note 5, "Fair Value of Financial Instruments" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K, for further discussion of financial instruments that are carried at fair value on a recurring and nonrecurring basis.</span></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_127"></div><ix:continuation id="i751bcec1f0194ce989a1565b84f656da" continuedAt="icdc90aa7979047c29b581f8aeb5e8cd8"><ix:nonNumeric contextRef="c-1" name="us-gaap:ReceivablesPolicyTextBlock" id="f-398" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, principally trade receivables, are generally due within <ix:nonNumeric contextRef="c-51" name="ango:AccountsReceivableDuePeriod" format="ixt-sec:durday" id="f-399">30</ix:nonNumeric> to <ix:nonNumeric contextRef="c-52" name="ango:AccountsReceivableDuePeriod" format="ixt-sec:durday" id="f-400">90</ix:nonNumeric> days and are stated at amounts due from customers, net of an allowance for estimated sales returns and doubtful accounts. The Company performs ongoing credit evaluations of customers and adjusts credit limits based upon payment history and the customer&#8217;s current creditworthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers, and a provision for estimated credit losses is maintained based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they are determined to be uncollectible.</span></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_130"></div><ix:continuation id="icdc90aa7979047c29b581f8aeb5e8cd8" continuedAt="i79edbcb720534bfc9684a5add437af27"><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-401" continuedAt="iae6d14bae5f248e08099ceb1b057d876" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inventories are stated at the lower of cost or net realizable value based on the first-in, first-out cost method and consist of raw materials, work in process and finished goods.  The standard cost of finished goods and work-in-process inventory is composed of material, labor and manufacturing overhead, which approximates actual cost. In addition to stating inventory at the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i79edbcb720534bfc9684a5add437af27" continuedAt="ieb5749c2c9624c379707f53e66fdfa41"><ix:continuation id="iae6d14bae5f248e08099ceb1b057d876">lower of cost or net realizable value, we also evaluate inventory each reporting period for excess quantities and obsolescence, establishing reserves when necessary based upon historical experience, assessment of economic conditions and expected demand. Once recorded, these reserves are considered permanent adjustments to the carrying value of inventory. An increase to inventory reserves results in a corresponding increase in cost of revenue. Inventories are written off against the reserve when they are physically disposed.</ix:continuation></ix:continuation></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_133"></div><ix:continuation id="ieb5749c2c9624c379707f53e66fdfa41" continuedAt="i867536c9464d4f90b04cbf35ef47fad0"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-402" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets.  Placement and evaluation units represent capital equipment placed at customer locations under placement or evaluation agreements for which depreciation expense is included in cost of sales on the Consolidated Statements of Operations.  <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-403" continuedAt="ib4b4e528e2dc4f25bea6d15e54de743f" escape="true">Refer below for useful lives by category:</ix:nonNumeric></span></div><div style="margin-bottom:4pt;text-align:center"><ix:continuation id="ib4b4e528e2dc4f25bea6d15e54de743f" continuedAt="i097b08ca81ac42b8b05f7ed397b1ff99"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated useful lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-53" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-404">4</ix:nonNumeric> to <ix:nonNumeric contextRef="c-54" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-405">39</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-55" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-406">2</ix:nonNumeric> to <ix:nonNumeric contextRef="c-56" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-407">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-57" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-408">5</ix:nonNumeric> to <ix:nonNumeric contextRef="c-58" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-409">8</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placement and evaluation units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-59" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-410">5</ix:nonNumeric> years</span></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates property, plant and equipment for impairment periodically to determine if changes in circumstances or the occurrence of events suggest the carrying value of the asset or asset group may not be recoverable. Expenditures for repairs and maintenance are charged to expense as incurred. Renewals and betterments are capitalized.</span></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_136"></div><ix:continuation id="i867536c9464d4f90b04cbf35ef47fad0" continuedAt="id512a5b0b16b4609a4bbedaa2b094d70"><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-411" continuedAt="id719110e8e80423f9578422e5c7686bc" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill, indefinite lived intangible assets and in process research and development ("IP R&amp;D") are amortized over their estimated useful lives, which range between <span style="-sec-ix-hidden:f-412">two</span> to <ix:nonNumeric contextRef="c-52" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-413">eighteen years</ix:nonNumeric>, on a straight-line basis over the expected period of benefit.  The Company periodically reviews the estimated useful lives of intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Such conditions could include significant adverse changes in the business climate, current-period operating or cash flow losses, significant declines in forecasted operations, or a current expectation that an asset group will be disposed of before the end of its useful life.  When testing for impairment of definite-lived intangible assets held for use, the Company groups assets at the lowest level for which cash flows are separately identifiable.  Prior to the first quarter of fiscal year 2023, the Company managed its operations as one reporting unit.  At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-414">two</ix:nonFraction> operating segments and <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-415">two</ix:nonFraction> reporting units, namely Med Tech and Med Device (see Note 18 "Segments and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K).  The Company operates as two reporting units and two asset groups.  If a triggering event is deemed to exist, the Company performs an undiscounted operating cash flow analysis to determine if an impairment exists.  If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise.  Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated costs were based on respective fair market values at the date of acquisition.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id719110e8e80423f9578422e5c7686bc">  For goodwill, the impairment test requires a comparison of the estimated fair value of each reporting unit to which the goodwill is assigned to the carrying value of the assets and liabilities of those reporting units. The determination of reporting units also requires management judgment. The Company considers whether a reporting unit exists within a reportable segment based on the availability of discrete financial information. The Company operates as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="f-416">two</ix:nonFraction> operating segments with <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-417">two</ix:nonFraction> reporting units and consequently evaluates goodwill for impairment based on an evaluation of the fair value of each reporting unit. If the carrying value of the reporting units exceed the fair value, the carrying value is reduced to its fair value through an adjustment to the goodwill balance, resulting in an impairment charge.</ix:continuation> </span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed in Note 9, "Goodwill and Intangible Assets" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K, the Company recorded a goodwill impairment loss of $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-418">14.5</ix:nonFraction> million for the year ended May&#160;31, 2023 as the fair value of the Med Device reporting unit was less than its carrying value. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id512a5b0b16b4609a4bbedaa2b094d70" continuedAt="i02747a07ac0c4b47854be1971f7f4188"><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-419" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the liability for contingent consideration recorded on the acquisition date for a business combination is based on probability weighted estimated cash flow streams, discounted back to present value using a discount rate determined in accordance with accepted valuation methods and reflective of the risk associated with the estimated cash flow streams. The liability for contingent consideration is remeasured to fair value at each reporting period with changes recorded in earnings until the contingency is resolved.</span></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_142"></div><ix:continuation id="i02747a07ac0c4b47854be1971f7f4188" continuedAt="i98825990ea79418798e281a158a191e6"><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-420" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers control of promised goods or services to its customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those goods and services.&#160;See Note 4, &#8220;Revenue from Contracts with Customers&#8221; set forth in the Notes to our consolidated financial statements included in this Annual Report on Form 10-K for further discussion on revenue.</span></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_145"></div><ix:continuation id="i98825990ea79418798e281a158a191e6" continuedAt="ib18fbfcfe1604b2281f877b4f57fb8ac"><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-421" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs, including salaries, consulting fees, building costs, utilities and administrative expenses that are related to developing new products, enhancing existing products, validating new and enhanced products, managing clinical, regulatory and medical affairs are expensed as incurred.</span></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_148"></div><ix:continuation id="ib18fbfcfe1604b2281f877b4f57fb8ac" continuedAt="i189b3a8b43484083b62a24f8b13a0d55"><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-422" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates income tax expense for each jurisdiction in which it operates. This involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. The Company periodically evaluates deferred tax assets, capital loss carryforwards and tax credit carryforwards to determine their recoverability based primarily on the Company's ability to generate future taxable income and capital gains.  Where it is more-likely-than-not these will not be recovered, the Company estimates a valuation allowance and records a corresponding additional tax expense in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes and measures uncertain tax positions taken or expected to be taken in a tax return utilizing a two-step approach. The Company first determines if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is that the Company measures the tax benefit as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes on the Consolidated Statements of Operations.</span></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_151"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i189b3a8b43484083b62a24f8b13a0d55" continuedAt="ie195028327e348e3a991724f429d2b5c"><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-423" continuedAt="i728bd01bc79c40949fccc41b36a66455" escape="true">Stock-Based Compensation</ix:nonNumeric></ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie195028327e348e3a991724f429d2b5c" continuedAt="i3b7adf3905ab483a8a5b211b396aee2b"><ix:continuation id="i728bd01bc79c40949fccc41b36a66455">Stock-based compensation expense reflects the fair value of stock-based awards measured at the grant date and recognized over the relevant service period.  The expense recognized includes the impact of forfeitures as they occur.  The Company estimates the fair value of each stock-based award on the measurement date using either the current market price of the stock, the Black-Scholes option valuation model, or the Monte Carlo Simulation valuation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or restricted stock units, a risk-free interest rate and dividend yield. The Company recognizes stock-based compensation expense related to options, restricted stock units and market based performance stock units on a straight-line basis over the service period of the award, which is generally <ix:nonNumeric contextRef="c-61" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-424">4</ix:nonNumeric> years for options and restricted stock units and <ix:nonNumeric contextRef="c-62" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-425">3</ix:nonNumeric> years for market based performance stock units.</ix:continuation></ix:continuation> </span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_154"></div><ix:continuation id="i3b7adf3905ab483a8a5b211b396aee2b" continuedAt="i0f3ecec6ee5f487bb1aaada83cce9327"><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-426" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company's foreign subsidiaries is the local currency in which the subsidiary operates. For foreign operations where the local currency is considered to be the functional currency, the Company translates assets and liabilities into U.S. dollars at the exchange rate on the balance sheet date. The Company translates income and expense items at average rates of exchange prevailing during each period. The Company accumulates translation adjustments in accumulated other comprehensive loss, a component of stockholders&#8217; equity.</span></div><div style="text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Transaction gains or losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in Other income (expense), net in the Consolidated Statements of Operations as incurred.</span></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_157"></div><div style="margin-bottom:9pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0f3ecec6ee5f487bb1aaada83cce9327" continuedAt="i489a9a56e27344df978d6b2df61ef4a1"><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-427" continuedAt="ic9d23d0e65b0404d853c7ea20432d3ce" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to market risks, including changes in foreign currency and interest rates. The Company periodically enters into certain derivative financial instruments to hedge the underlying economic exposure. </span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i489a9a56e27344df978d6b2df61ef4a1" continuedAt="i6f82c746989f421cbb7386be6c6884d6"><ix:continuation id="ic9d23d0e65b0404d853c7ea20432d3ce">Derivative instruments are presented in the consolidated financial statements at their fair value. Changes in the fair value of derivative financial instruments are either recognized periodically in income or in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss) depending on whether the derivative financial instrument qualifies for hedge accounting and, if so, whether it qualifies as a fair value or cash flow hedge. Generally, the changes in the fair value of derivatives accounted for as fair value hedges are recorded in income along with the portions of the changes in the fair value of hedged items that relate to the hedged risks. Changes in the fair value of derivatives accounted for as cash flow hedges, to the extent they are effective as hedges, are recorded in accumulated other comprehensive income (loss).  There were no derivative instruments held by the Company as of May 31, 2023 and 2022.</ix:continuation></ix:continuation>  </span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_160"></div><ix:continuation id="i6f82c746989f421cbb7386be6c6884d6"><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="f-428" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various legal proceedings that arise in the ordinary course of business, including patent infringement and product liability matters. The Company records accruals for contingencies when it is probable the liability has been incurred and the amount can be reasonably estimated.  Legal fees are expensed as incurred. Insurance recoveries related to potential claims are recognized up to the amount of the recorded liability when coverage is confirmed and the estimated recoveries are probable of payment. These recoveries are not netted against the related liabilities for financial statement presentation.</span></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_163"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-429" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="f-430" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements - Adopted</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:20.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Consolidated Financial Statements</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ASU 2021-10,&#160; Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company adopted the new standard in the first quarter of fiscal year 2023 and it did not have an impact on the Company's consolidated financial statements.</span></td></tr></table></div><div style="margin-top:9pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:20.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Consolidated Financial Statements</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2021-08,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span></div><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">This ASU</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. </span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company plans to adopt the new standard in the first quarter of fiscal year 2024 and does not expect there to be a material impact to the consolidated financial statements.</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.  <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-431" continuedAt="i2a9d7ab809c4438a895e133e8efecb76" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i2a9d7ab809c4438a895e133e8efecb76" continuedAt="i710fac178f204b94a499707f904ae7da">Camaro Support Catheter Asset Acquisition</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i710fac178f204b94a499707f904ae7da">On July 27, 2021, the Company acquired the Camaro support catheter (rebranded as Syntrax) from QX Medical, LLC for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-432">4.0</ix:nonFraction>&#160;million, which included an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-433">3.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-434">0.4</ix:nonFraction>&#160;million in purchase price holdbacks, along with $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="ango:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-435">1.0</ix:nonFraction>&#160;million of potential future contingent consideration related to revenue milestones. This acquisition supports the Auryon product family and the Company's strategic plan.  The Company accounted for this acquisition as an asset purchase.  The Company recorded the amount paid at closing as inventory and fixed assets of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="ango:AssetAcquisitionInventoryAndFixedAssets" format="ixt:num-dot-decimal" scale="6" id="f-436">0.1</ix:nonFraction>&#160;million and an intangible asset product technology of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="f-437">3.9</ix:nonFraction>&#160;million.  The intangible asset will be amortized over <ix:nonNumeric contextRef="c-63" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-438">15</ix:nonNumeric> years.  The contingent consideration is comprised of revenue milestones and will be accounted for when the contingency is resolved or becomes probable and reasonably estimable.</ix:continuation>  </span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_1908"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.  <ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-439" continuedAt="ia5dbaced1b0541ba9872b86a76ca309f" escape="true">ASSETS HELD FOR SALE </ix:nonNumeric></span></div><ix:continuation id="ia5dbaced1b0541ba9872b86a76ca309f"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal year 2023, the Company was in discussions with Merit to sell the dialysis product portfolio and BioSentry tract sealant system biopsy businesses.  This qualified for held for sale accounting and the Company determined that the fair value of the net assets being sold exceeded the carrying value as of May&#160;31, 2023.  The transaction was finalized on June 8, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="f-440" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the major classes of assets held for sale:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of May 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" format="ixt:num-dot-decimal" scale="3" id="f-441">4,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-442">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total current assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-443">6,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="3" id="f-444">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-445">17,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-446">25,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total non-current assets held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-447">43,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_169"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.  <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-448" continuedAt="i561ca32da63246d48fff432518bee317" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-449" continuedAt="i1026b20dd75d4f2fbdda4c300603c01b" escape="true">REVENUE FROM CONTRACTS WITH CUSTOMERS</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i561ca32da63246d48fff432518bee317" continuedAt="i0308baf1805a4fd2a6aa95fce5465ae7"><ix:continuation id="i1026b20dd75d4f2fbdda4c300603c01b" continuedAt="i31c50af6b4254af58e3423c8fdf0bcac"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one primary revenue stream which is the sales of its products.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-450" continuedAt="i43079c1900194a9288a506b68e1ca812" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize net sales by Med Tech, Med Device and by geography: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-451">84,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-452">12,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-453">96,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-454">69,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-455">8,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-456">78,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-457">198,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-458">43,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-459">242,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-460">196,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-461">41,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-462">237,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-463">282,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-464">56,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-465">338,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-466">265,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-467">50,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-468">316,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0308baf1805a4fd2a6aa95fce5465ae7" continuedAt="i6034c1e1b8eb4a9c861d86ecc003ccc0"><div style="margin-bottom:9pt"><ix:continuation id="i43079c1900194a9288a506b68e1ca812"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:54.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-469">46,440</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-470">9,291</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-471">55,731</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-472">190,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-473">44,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-474">235,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-475">237,043</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-476">53,967</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-477">291,010</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings.  The Company's products are generally used in minimally invasive, image-guided procedures.  Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use.  The Company sells its products to its distributors and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.  </span></div><ix:continuation id="i31c50af6b4254af58e3423c8fdf0bcac" continuedAt="i733c9877d0e842058e1d34de4c413e8e"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts and Performance Obligations</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements.  The Company&#8217;s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights.  As part of its assessment of each contract, the Company evaluates certain factors including the customer&#8217;s ability to pay (or credit risk).  For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Price and Allocation to Performance Obligations</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction prices of products are typically based on contracted rates.  Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer, net of any variable consideration as described below. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation.  Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation.  The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company&#8217;s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company&#8217;s manufacturing site or delivery to the customer&#8217;s named location, based on the shipping terms of a contract.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company typically invoices customers upon satisfaction of identified performance obligations.  As the Company&#8217;s standard payment terms are <ix:nonNumeric contextRef="c-51" name="ango:RevenuePerformanceObligationPaymentTerm" format="ixt-sec:durday" id="f-478">30</ix:nonNumeric> to <ix:nonNumeric contextRef="c-52" name="ango:RevenuePerformanceObligationPaymentTerm" format="ixt-sec:durday" id="f-479">90</ix:nonNumeric> days from invoicing, the Company does not provide any significant financing to its customers.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company enters into agreements to place placement and evaluation units (&#8220;units&#8221;) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer&#8217;s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units.  In these arrangements, revenue recognized for the sale of the disposables is not allocated between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6034c1e1b8eb4a9c861d86ecc003ccc0"><ix:continuation id="i733c9877d0e842058e1d34de4c413e8e" continuedAt="i9b653d29879840749b9b09917b98d664"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts between the Company and its customers.  These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and Allowances:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides certain customers with rebates and allowances that are explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.  The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets.  These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes.  The Company is also required to pay administrative fees to group purchasing organizations. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Returns: The Company generally offers customers a limited right of return.  Product returns after <ix:nonNumeric contextRef="c-1" name="ango:ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval" format="ixt-sec:durday" id="f-480">30</ix:nonNumeric> days must be pre-approved by the Company and customers may be subject to a <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="ango:ContractwithCustomerRightofReturnRestockingCharge" scale="-2" id="f-481">20</ix:nonFraction>% restocking charge.  To be accepted, a returned product must be unadulterated, undamaged and have at least <ix:nonNumeric contextRef="c-1" name="ango:ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn" format="ixt-sec:durwordsen" id="f-482">twelve months</ix:nonNumeric> remaining prior to its expiration date.  The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized.  The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls.  During the year ended May&#160;31, 2023, such product returns were not material.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances with Customers</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A receivable is generally recognized in the period the Company ships the product.  Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition.  Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers.  In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company&#8217;s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-483" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company&#8217;s receivables, contract assets and contract liabilities with customers:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-484">52,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-485">52,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="3" id="f-486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="3" id="f-487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="f-488">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="f-489">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended May&#160;31, 2023 and 2022, the Company had additions to contract liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="f-490">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="f-491">2.2</ix:nonFraction>&#160;million, respectively.  This was offset by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ango:CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod" format="ixt:num-dot-decimal" scale="6" id="f-492">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ango:CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod" format="ixt:num-dot-decimal" scale="6" id="f-493">2.1</ix:nonFraction>&#160;million in revenue that was recognized during the years ended May&#160;31, 2023 and 2022, respectively.  </span></div><ix:continuation id="i9b653d29879840749b9b09917b98d664"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs to Obtain or Fulfill a Customer Contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs.  The Company&#8217;s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time.  However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products.  Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer.  Amounts charged to customers for shipping are recorded in net sales.</span></div></ix:continuation></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_172"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.  <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-494" continuedAt="ib991f46c02b3453e8de602a6277c79b7" escape="true">FAIR VALUE OF FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="ib991f46c02b3453e8de602a6277c79b7" continuedAt="i71789b29ab2842c99cb6826d55f46d15"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value.  The three levels of the hierarchy are defined as follows:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i71789b29ab2842c99cb6826d55f46d15" continuedAt="i21137fe4f0444439b313ba138f5ded88"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs to the valuation methodology are unobservable inputs based on management&#8217;s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to their immediate or short-term maturities.  The recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-495" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements using inputs considered as:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at May 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration for acquisition earn outs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-498">19,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-499">19,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Financial Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-502">19,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-503">19,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements using inputs considered as:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at May 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration for acquisition earn outs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-504">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-505">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-506">16,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-507">16,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Financial Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-509">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-510">16,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-511">16,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, 2 and 3 for the years ended May&#160;31, 2023 and 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-512" continuedAt="ibf9803722b6949c98462cb0928af6fed" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the changes in fair value components of Level 3 instruments:    </span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial&#160;Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-513">16,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in present value of contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:num-dot-decimal" scale="3" id="f-514">2,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency gain from remeasurement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ango:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement" scale="3" id="f-515">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-516">19,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial&#160;Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-517">15,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ango:ChangeInFairValueOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-518">1,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency loss from remeasurement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="ango:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement" scale="3" id="f-519">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-520">16,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ibf9803722b6949c98462cb0928af6fed">(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i21137fe4f0444439b313ba138f5ded88"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liability for Acquisition Earn Outs</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements which is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="f-521" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of May&#160;31, 2023:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:25.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue based payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-522">19,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" id="f-523">5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-100" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-524">80</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-101" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-525">100</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At May&#160;31, 2023, the amount of undiscounted future contingent consideration that the Company expects to pay as a result of all completed acquisitions is approximately $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="ango:UndiscountedContingentConsiderationFairValueFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-526">20.0</ix:nonFraction> million.  The milestones, including revenue projections and technical milestones, associated with the contingent consideration must be reached in future periods ranging from fiscal years 2024 to 2029 in order for the associated consideration to be paid. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Items Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-527">14.5</ix:nonFraction> million for the year ended May&#160;31, 2023 to write down the carrying value of the Med Device reporting unit to fair value. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal year 2021, the Company made the decision to abandon the OARtrac product technology and trademark.  This resulted in an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-528">14.0</ix:nonFraction>&#160;million.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other items measured at fair value on a nonrecurring basis during the year ended May&#160;31, 2023 or May&#160;31, 2022.</span></div></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_175"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.  <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-529" continuedAt="i32703354a2c240f7b8ba6511e0fb7a32" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="i32703354a2c240f7b8ba6511e0fb7a32" continuedAt="i84011d55908e43dea1905d959bd254f3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-530" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method).  Inventories consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-531">28,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-532">28,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-533">6,708</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-534">7,186</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-535">19,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-536">15,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-537">55,325</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-538">51,392</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i84011d55908e43dea1905d959bd254f3">The Company periodically reviews inventory for both obsolescence and loss of value.  The Company makes assumptions about the future demand for and market value of the inventory.  Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow moving inventory.  The total inventory reserve at May&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="f-539">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="f-540">3.7</ix:nonFraction> million, respectively.</ix:continuation>  </span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_178"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.  <ix:nonNumeric contextRef="c-1" name="ango:PrepaidExpensesAndOtherTextBlock" id="f-541" continuedAt="i820c05f3aadb46b78272327a27bb0afb" escape="true">PREPAID EXPENSES AND OTHER</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i820c05f3aadb46b78272327a27bb0afb" continuedAt="ib2005033f1e9419a831c833bcdbf4735"><ix:nonNumeric contextRef="c-1" name="ango:PrepaidExpensesAndOtherTableTextBlock" id="f-542" continuedAt="ie2920fe27c0d4ab68b1f9fbceab2bc75" escape="true">Prepaid expenses and other consisted of the following:</ix:nonNumeric></ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><ix:continuation id="ib2005033f1e9419a831c833bcdbf4735"><ix:continuation id="ie2920fe27c0d4ab68b1f9fbceab2bc75"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:PrepaidDeposits" scale="3" id="f-543">894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ango:PrepaidDeposits" format="ixt:num-dot-decimal" scale="3" id="f-544">2,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Retention Tax Credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:PrepaidEmployeeTaxCredit" format="ixt:fixed-zero" scale="3" id="f-545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ango:PrepaidEmployeeTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-546">4,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:SoftwareLicenses" format="ixt:num-dot-decimal" scale="3" id="f-547">1,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ango:SoftwareLicenses" format="ixt:num-dot-decimal" scale="3" id="f-548">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:PrepaidLicenseeFees" scale="3" id="f-549">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ango:PrepaidLicenseeFees" scale="3" id="f-550">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade shows</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:TradeShows" scale="3" id="f-551">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ango:TradeShows" scale="3" id="f-552">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidRent" scale="3" id="f-553">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PrepaidRent" scale="3" id="f-554">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:PrepaidIncomeandOtherTaxes" scale="3" id="f-555">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ango:PrepaidIncomeandOtherTaxes" scale="3" id="f-556">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-557">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-558">2,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-559">4,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-560">10,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_181"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.  <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-561" continuedAt="idfa833ce80714107a4f04c4a03ffb666" escape="true">PROPERTY, PLANT AND EQUIPMENT, NET</ix:nonNumeric></span></div><ix:continuation id="i097b08ca81ac42b8b05f7ed397b1ff99"><ix:continuation id="idfa833ce80714107a4f04c4a03ffb666" continuedAt="ic54b9cc1b70d467bb45e01e4d835c623"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-562">29,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-563">29,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-564">27,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-565">27,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-566">17,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-567">15,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placement and evaluation units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-568">26,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-569">21,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-570">2,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-571">2,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-572">102,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-573">95,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-574">59,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-575">51,069</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:PropertyPlantAndEquipmentExcludingLandAndLandImprovements" format="ixt:num-dot-decimal" scale="3" id="f-576">43,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ango:PropertyPlantAndEquipmentExcludingLandAndLandImprovements" format="ixt:num-dot-decimal" scale="3" id="f-577">44,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LandAndLandImprovements" scale="3" id="f-578">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LandAndLandImprovements" scale="3" id="f-579">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-580">44,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-581">45,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic54b9cc1b70d467bb45e01e4d835c623">Depreciation expense for fiscal years 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-582">11.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-583">7.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-584">5.7</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_184"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.  <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-585" continuedAt="iaae44a3a8578419f9984b7574329beb9" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="iaae44a3a8578419f9984b7574329beb9" continuedAt="i438117c294c143e086b51e790a0c68a2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically performed its annual goodwill assessment during the third quarter of each fiscal year.  During the fourth quarter of fiscal year 2022, the Company changed its annual impairment assessment date from December 31 to April 30 to more closely align the impairment assessment date with the Company's long term planning and forecasting process.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the first quarter of fiscal year 2023, the Company managed its operations as <ix:nonFraction unitRef="unit" contextRef="c-4" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-586"><ix:nonFraction unitRef="unit" contextRef="c-4" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-587">one</ix:nonFraction></ix:nonFraction> reporting unit.  At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as <ix:nonFraction unitRef="unit" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-588">two</ix:nonFraction> operating segments and <ix:nonFraction unitRef="unit" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-589">two</ix:nonFraction> reporting units, namely Med Tech and Med Device (see Note 18 "Segments and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K).  As a result of this change, goodwill was required to be allocated to each reporting unit and an interim goodwill impairment assessment was performed at the Company and reporting unit levels.  To determine the fair value of the individual reporting units and the entire company as of June 1, 2022, the Company utilized the income approach.  The income approach is based on the projected cash flows discounted to their present value using discount rates, that in the Company's judgment, consider the timing and risk of the forecasted cash flows using internally developed forecasts and assumptions.  Under the income approach, the discount rate used is the average estimated value of a market participant&#8217;s cost of capital and debt, derived using customary market metrics.  Other significant assumptions include revenue growth rates, profitability projections, and terminal value growth rates.  The market approach was also considered; however, the income approach was chosen as the Company determined it is a better representation of both the Med Tech and Med Device reporting units' projected long-term performance. The fair value of each </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i438117c294c143e086b51e790a0c68a2" continuedAt="i3c2cee99b1794a069a17276e06909ff9"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting unit and the Company as a whole was assessed to determine if there was any impairment.  The Company compared each reporting unit's fair value to the adjusted carrying value to conclude that there was no impairment for either reporting unit or the Company as a whole.  The adjusted carrying value of each reporting unit was used to calculate the Company's book value to compare to its market capitalization at the assessment date.  Based on the results of this evaluation, there were no adjustments to goodwill for either reporting unit or the Company as a whole as of August 31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's annual testing for impairment of goodwill was completed as of April 30, 2023.  To determine the fair value of the <ix:nonFraction unitRef="unit" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="f-590">two</ix:nonFraction> reporting units as of April 30, 2023, the Company utilized the income approach for Med Tech and a combination of the income approach and market approach for Med Device.  The income approach is based on the projected cash flows discounted to their present value using discount rates, that in the Company's judgment, consider the timing and risk of the forecasted cash flows using internally developed forecasts and assumptions.  Under the income approach, the discount rate used is the average estimated value of a market participant&#8217;s cost of capital and debt, derived using customary market metrics.  Other significant assumptions include revenue growth rates, profitability projections, and terminal value growth rates.  The market approach estimates fair values based on the determination of appropriate publicly traded market comparison companies and market multiples of revenue and earnings derived from those companies with similar operating and investment characteristics.  The market approach was also considered; however, the income approach was chosen as the Company determined it is a better representation of the Med Tech reporting units' projected long-term performance.  For Med Device, both the income and market approaches were considered.  The fair value of each reporting unit was assessed to determine if there was any impairment.  The Company compared each reporting unit's fair value to the adjusted carrying value to conclude that there was no impairment for either reporting unit.  Based on the results of this evaluation, there were no adjustments to goodwill for either reporting unit as of April 30, 2023.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the sale of the dialysis product portfolio and BioSentry tract sealant system biopsy businesses to Merit Medical Systems, Inc. was a triggering event for the Med Device report unit.  As the Company concluded that this was the sale of a business, goodwill was allocated to the sale based on the relative fair value of the dialysis and BioSentry businesses and is included in assets held for sale as of May&#160;31, 2023.  To determine the fair value of the remaining Med Device reporting unit as of May&#160;31, 2023, the Company utilized the income approach, as it was determined to be a better representation of the remaining Med Device reporting unit's projected long-term performance. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the results of this evaluation, the Company recorded a goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-591">14.5</ix:nonFraction> million for the year ended May&#160;31, 2023 to write down the carrying value of the Med Device reporting unit to fair value. The impairment loss is disclosed separately on the face of the accompanying consolidated statements of operations.  </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no adjustments to goodwill for the Med Tech reporting unit for the year ended May&#160;31, 2023 other than foreign currency translation adjustments.  There were no adjustments to goodwill for the year ended May&#160;31, 2022 other than foreign currency translation adjustments.   </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-592" escape="true"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill for each reporting unit is allocated as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended May 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance June 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-593">160,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-594">40,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-595">201,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" id="f-596">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-597">14,549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-598">14,549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets held for sale </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" id="f-599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-600">25,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-601">25,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-602">1,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" id="f-603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-604">1,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance May 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-605">159,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" id="f-606">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-607">159,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though the Company determined that there was <ix:nonFraction unitRef="usd" contextRef="c-118" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-608"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-609">no</ix:nonFraction></ix:nonFraction> goodwill impairment as of April 30, 2023 for the Med Tech reporting unit, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of April 30, 2024.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definite Lived Intangible Assets</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill are amortized over their estimated useful lives on a straight-line basis. Useful lives range from <span style="-sec-ix-hidden:f-610">two</span> to <ix:nonNumeric contextRef="c-52" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-611">eighteen years</ix:nonNumeric>.  The Company periodically reviews, and adjusts, if necessary, the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3c2cee99b1794a069a17276e06909ff9"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the triggering event for the Med Device reporting unit as of May&#160;31, 2023, long-lived assets were tested for impairment.  As a result of the undiscounted cash flow analysis that was performed, there were no impairments identified as of May&#160;31, 2023.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal year 2021, the Company made the decision to abandon the OARtrac product technology and trademark.  This resulted in an <span style="-sec-ix-hidden:f-612">impairment charge</span> of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-613">14.0</ix:nonFraction>&#160;million.  The impairment charge is recorded in "Acquisition, restructuring and other items, net", on the Consolidated Statements of Operations (see Note 19 "Acquisition, restructuring and other items, net" as set forth in the Notes to the consolidated financial statements in this Annual Report on Form 10-K).  </span></div><ix:nonNumeric contextRef="c-1" name="ango:ScheduleOfIntangibleAssetsTableTextBlock" id="f-614" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;carrying<br/>value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net&#160;carrying<br/>value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-615">211,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-616">118,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-617">93,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-618">57,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-619">40,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-620">16,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-621">7,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-622">6,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-623">790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-624">4,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-625">4,674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-626">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-627">281,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-628">170,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-629">111,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;carrying<br/>value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net&#160;carrying<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-630">239,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-631">112,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-632">127,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-633">60,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-634">38,003</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-635">22,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-636">9,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-637">7,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-638">2,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-639">4,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-640">4,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-641">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-642">314,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-643">161,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-644">152,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-645">18.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-646">19.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-647">18.1</ix:nonFraction> million for fiscal years 2023, 2022 and 2021, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-648" escape="true"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-649">14,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-650">14,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-651">14,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-652">14,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-653">10,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-654">43,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-655">111,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_187"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.  <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-656" continuedAt="i21df169cc72a413380bfc1a9411073cd" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i21df169cc72a413380bfc1a9411073cd" continuedAt="i288a2227f2a047cd9c31bd3fdc63dd67"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-657" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss before income tax benefit are as follows:</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-658">45,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-659">28,495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-660">31,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-661">9,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-662">1,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-663">4,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-664">54,437</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-665">29,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-666">36,052</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i288a2227f2a047cd9c31bd3fdc63dd67" continuedAt="ia9f3144a24b3405e8e142066e50b1d3a"><div style="margin-bottom:9pt;text-indent:21.6pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-667" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit is comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-668">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-669">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-670">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-671">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-672">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-673">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-674">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-675">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-676">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-677">207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-678">3,415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-679">3,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-680">2,104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-681">293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-682">1,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-683">2,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-684">3,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-685">4,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-686">1,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-687">3,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-688">4,504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-689" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences that give rise to deferred tax assets and liabilities are summarized as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-690">40,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-691">40,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-692">4,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-693">4,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state R&amp;D tax credit carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-694">7,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-695">6,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="f-696">724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="f-697">853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses incurred not currently deductible</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" format="ixt:num-dot-decimal" scale="3" id="f-698">6,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" format="ixt:num-dot-decimal" scale="3" id="f-699">1,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="f-700">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="f-701">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-702">59,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-703">54,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-704">46,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-705">50,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-706">46,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-707">50,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-708">25,759</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-709">20,203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-710">12,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-711">15,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability in the U.S. as of May&#160;31, 2023 and 2022 principally relates to tax amortization of intangibles that have an indefinite reversal period for book purposes, also known as a &#8220;naked credit deferred tax liability&#8221;, that cannot be considered as a source of income to recover the deferred tax asset.  In addition, included in the net deferred tax liability as of May&#160;31, 2023 and 2022 is a net deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="ango:DeferredTaxLiabilitiesPurchaseAccountingAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-712">5.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="ango:DeferredTaxLiabilitiesPurchaseAccountingAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-713">8.8</ix:nonFraction>&#160;million, respectively that was related to the stock acquisition of Eximo Medical Ltd. primarily related to book intangibles partially offset by tax net operating losses and capitalized R&amp;D expenditures.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's U.S. Federal net operating loss carryforwards as of May&#160;31, 2023 after considering IRC Section&#160;382 limitations are $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="ango:OperatingLossCarryforwardsAmountAfterLimitationOfUse" format="ixt:num-dot-decimal" scale="6" id="f-714">169.7</ix:nonFraction> million. The expiration of the Federal net operating loss carryforwards are as follows: $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-715">5.2</ix:nonFraction> million between 2023 and 2024, $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="ango:OperatingLossCarryforwardsAmountAfterLimitationOfUse" format="ixt:num-dot-decimal" scale="6" id="f-716">79.4</ix:nonFraction> million between 2028 and 2037 and $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="ango:OperatingLossCarryforwardsAmountAfterLimitationOfUse" format="ixt:num-dot-decimal" scale="6" id="f-717">85.1</ix:nonFraction> million indefinitely.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's state net operating loss carryforwards as of May&#160;31, 2023 after considering remaining IRC Section&#160;382 limitations are $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-718">24.1</ix:nonFraction> million which expire in various years from 2029 to 2042.  The Company has Israel tax net operating losses of $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-719">16.3</ix:nonFraction>&#160;million that can be carried forward indefinitely.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2018, except for the Global Intangible Low-Taxed Income, the Company will no longer record United States federal income tax on its share of the income of its foreign subsidiaries, nor will it record a benefit for foreign tax credits related to that income.  Upon distribution of these earnings in the form of dividends or otherwise, the Company would be subject to withholding taxes payable, where applicable, to foreign countries, but would have no further federal income tax liability.  The Company intends to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of May&#160;31, 2023, as well as all subsequent earnings generated by all of our foreign subsidiaries.  Determining the amount of unrecognized deferred tax liability related to any additional outside basis difference in these entities is not practical.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia9f3144a24b3405e8e142066e50b1d3a"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly assesses its ability to realize its deferred tax assets.  Assessing the realization of deferred tax assets requires significant management judgment.  In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity.  Evidence the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal year 2016, except the naked credit deferred tax liability.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&amp;D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of May&#160;31, 2023.  The Company will continue to assess the level of the valuation allowance required.  If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company&#8217;s results of operations.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-720" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated income tax expense has differed from the amount that would be provided by applying the U.S. Federal statutory income tax rate to the Company's income before income taxes for the following reasons:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit at federal statutory tax rate of 21.0%, 21.0% and 21.0%, respectively</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-721">11,432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-722">6,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-723">7,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of Federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-724">353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-725">536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-726">462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Non-U.S. operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ango:IncomeTaxReconciliationEffectOfForeignOperations" scale="3" id="f-727">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ango:IncomeTaxReconciliationEffectOfForeignOperations" scale="3" id="f-728">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="ango:IncomeTaxReconciliationEffectOfForeignOperations" scale="3" id="f-729">293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="f-730">991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="f-731">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-732">1,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meals and entertainment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="f-733">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="f-734">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="f-735">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:num-dot-decimal" scale="3" id="f-736">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="3" id="f-737">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="3" id="f-738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ango:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" scale="3" id="f-739">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ango:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" scale="3" id="f-740">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ango:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" scale="3" id="f-741">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-742">5,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-743">3,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-744">3,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ango:IncomeTaxReconciliationEffectofEliminationofASC718APICPool" scale="3" id="f-745">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ango:IncomeTaxReconciliationEffectofEliminationofASC718APICPool" format="ixt:num-dot-decimal" scale="3" id="f-746">1,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="ango:IncomeTaxReconciliationEffectofEliminationofASC718APICPool" scale="3" id="f-747">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-748">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-749">412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-750">455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-751">1,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-752">3,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-753">4,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-754" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending amount of unrecognized tax benefits:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits balance at June 1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="f-755">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="f-756">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="f-757">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in gross amounts of tax positions related to prior years due to U.S. tax reform</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-758">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-759">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-760">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease due to lapse in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="f-761">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="f-762">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="f-763">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits balance at May 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="f-764">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="f-765">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="f-766">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:4pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above includes unrecognized tax benefits associated with the calculation of limitations placed on the utilization of tax attributes related to an acquired company. If recognized, $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="f-767">0.5</ix:nonFraction> million would result in adjustments to other tax accounts. &#160; </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense. There are <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-768"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-769">no</ix:nonFraction></ix:nonFraction> accrued interest and penalties recognized in the Consolidated Balance Sheets as of May&#160;31, 2023 and May&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business the Company is subject to examination by taxing authorities throughout the world.  Fiscal years 2020 through 2022 remain open to examination by the various tax authorities. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not anticipate that the amount of unrecognized tax benefits will significantly change in the next twelve months.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:21.6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.  <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-770" continuedAt="i303da8c2073b4367b6ba0e431bb902ed" escape="true">ACCRUED LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="i303da8c2073b4367b6ba0e431bb902ed"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-771" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-772">9,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-773">20,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-774">7,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-775">3,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-776">2,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-777">2,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:AccruedResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="f-778">1,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ango:AccruedResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="f-779">1,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued severance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestructuringReserveCurrent" scale="3" id="f-780">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RestructuringReserveCurrent" scale="3" id="f-781">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and franchise taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="f-782">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="f-783">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="f-784">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="f-785">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-786">4,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-787">5,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-788">26,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-789">34,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_193"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.  <ix:nonNumeric contextRef="c-1" name="us-gaap:LongTermDebtTextBlock" id="f-790" continuedAt="ibb91b57a892f42c3bcecfa2010f1008d" escape="true">LONG-TERM DEBT</ix:nonNumeric></span></div><ix:continuation id="ibb91b57a892f42c3bcecfa2010f1008d" continuedAt="i878bbc02d2fd4a41a0f0e91b75d901de"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Company repaid all amounts outstanding under its then existing credit agreement and entered into a new Credit Agreement (the "Credit Agreement") with its lenders, JPMorgan Chase Bank, N.A., as Administrative Agent, sole bookrunner, and sole lead arranger, and Bank of America, N.A. and KeyBank National Association, as Syndication Agents. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for a $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-791">75.0</ix:nonFraction>&#160;million secured revolving credit facility (the "Revolving Facility") and a $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-792">30.0</ix:nonFraction>&#160;million delayed draw term loan (the "Delayed Draw Term Loan"), and also includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="ango:LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature" format="ixt:num-dot-decimal" scale="6" id="f-793">75.0</ix:nonFraction>&#160;million.&#160; Each exercise of such expansion feature must be drawn in $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-794">5.0</ix:nonFraction>&#160;million increments.  The proceeds of the Revolving Facility may be used for general corporate purposes, including permitted acquisitions.  The proceeds of the Delayed Draw Term Loan may be used for general corporate purposes, including primarily to finance the manufacturing costs of the Auryon laser capital equipment.  </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement has a <ix:nonNumeric contextRef="c-141" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-795">five-year</ix:nonNumeric> maturity.  Interest on the Revolving Facility and  Delayed Draw Term Loan will be based, at the Company's option, on a rate equal to (i) the Secured Overnight Financing Rate ("SOFR") plus <ix:nonFraction unitRef="number" contextRef="c-142" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-796">0.10</ix:nonFraction>% (subject to a floor of <ix:nonFraction unitRef="number" contextRef="c-143" decimals="INF" name="ango:DebtInstrumentFloorInterestRate" scale="-2" id="f-797">0</ix:nonFraction>%), or (ii) if the Company elects to treat a borrowing as an ABR Borrowing, an alternate base rate based on SOFR, plus, in each case, an applicable margin of <ix:nonFraction unitRef="number" contextRef="c-144" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-798">1.25</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-145" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-799">1.50</ix:nonFraction>% or <ix:nonFraction unitRef="number" contextRef="c-146" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-800">1.75</ix:nonFraction>%, depending on the leverage ratio.  If any amounts are not paid when due, such overdue amounts will bear interest at an amount generally equal to <ix:nonFraction unitRef="number" contextRef="c-147" decimals="INF" name="ango:DebtInstrumentDebtDefaultInterestRateIncrease" scale="-2" id="f-801">2.0</ix:nonFraction>% plus the existing loan rate.  The Credit Agreement also carries a commitment fee in the case of the Revolving Facility, and a ticking fee, in the case of the Delayed Draw Term Loans of <ix:nonFraction unitRef="number" contextRef="c-51" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="f-802">0.20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-52" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="f-803">0.25</ix:nonFraction>% per annum on the unused portion.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations under the Credit Agreement are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the &#8220;Guarantors&#8221;). All obligations of the Company and the Guarantors under the Credit Agreement are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, <ix:nonFraction unitRef="covenant" contextRef="c-148" decimals="INF" name="ango:LineOfCreditFacilityNumberOfCovenants" format="ixt-sec:numwordsen" scale="0" id="f-804">two</ix:nonFraction> quarterly financial covenants as follows:&#160;</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than <ix:nonFraction unitRef="number" contextRef="c-147" decimals="INF" name="ango:DebtInstrumentCovenantTermsMaximumTotalLeverageRatio" scale="0" id="f-805">3.00</ix:nonFraction> to 1.00 (during certain periods following material acquisitions the ratio shall be increased to <ix:nonFraction unitRef="number" contextRef="c-147" decimals="INF" name="ango:DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions" scale="0" id="f-806">3.50</ix:nonFraction> to 1.00). </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures* to&#160;consolidated interest expense* paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than <ix:nonFraction unitRef="number" contextRef="c-147" decimals="INF" name="ango:DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio" scale="0" id="f-807">1.25</ix:nonFraction> to 1.00. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* The definitions of consolidated total indebtedness, consolidated EBITDA, consolidated capital expenditures and consolidated interest expense are specifically defined in the credit agreement included as an exhibit to Form 8-K filed on August 31, 2022.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-808" continuedAt="i82d3d86be5374b21a117f4d20dd86d98" escape="true">As of May&#160;31, 2023 there was $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-809">25.0</ix:nonFraction>&#160;million outstanding on the Revolving Facility and $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-810">25.0</ix:nonFraction>&#160;million outstanding on the Delayed Draw Term Loan and the interest rate at May&#160;31, 2023 applicable to each was <ix:nonFraction unitRef="number" contextRef="c-149" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="f-811">6.73</ix:nonFraction>%.  As of May&#160;31, 2023 and May&#160;31, 2022, the carrying value of long-term debt approximated its fair market value.  </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i878bbc02d2fd4a41a0f0e91b75d901de"><div style="margin-bottom:9pt"><ix:continuation id="i82d3d86be5374b21a117f4d20dd86d98"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:85.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-812">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delayed Draw Term Loan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-813">25,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debit issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="f-814">182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total long-term debt</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-815">49,818</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was in compliance with the Credit Agreement covenants as of May&#160;31, 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2023, AngioDynamics used a portion of the consideration received from the sale of the dialysis and BioSentry businesses to repay all amounts owed under AngioDynamics&#8217; existing Credit Agreement, and as a result, the Credit Agreement was extinguished.  Pursuant to the terms of the Credit Agreement, AngioDynamics had the option to repay this facility prior to the maturity date without penalty.</span></div></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_196"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.  <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-816" continuedAt="i47286c7e72394d639825db01aa1fb21b" escape="true">RETIREMENT PLANS</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i47286c7e72394d639825db01aa1fb21b">The Company has a 401(k) plan under which eligible employees can defer a portion of their compensation, part of which is matched by the Company. Matching contributions were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-817">4.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-818">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-819">3.8</ix:nonFraction> million in 2023, 2022 and 2021, respectively. There are also various immaterial foreign retirement plans.</ix:continuation> </span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_199"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.  <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-820" continuedAt="ic9e899eac8574d6ca9d5e64cd44c9463" escape="true">STOCKHOLDERS&#8217; EQUITY </ix:nonNumeric></span></div><ix:continuation id="ic9e899eac8574d6ca9d5e64cd44c9463" continuedAt="id6c866eec11444a3b8072f9c701f7f6f"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalization</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2014, the Board of Directors approved the Amended and Restated Certificate of Incorporation (the &#8220;Amended Certificate&#8221;). Under the Amended Certificate, the authorized capital stock is <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="ango:CapitalStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-821">80,000,000</ix:nonFraction> shares, consisting of <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-822">75,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-823">.01</ix:nonFraction> per share and <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-824">5,000,000</ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-825">.01</ix:nonFraction> per share. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="c-153" decimals="INF" name="ango:CommonStockVotesPerShare" format="ixt-sec:numwordsen" scale="0" id="f-826">one</ix:nonFraction> vote for each share held. Subject to preferences applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably dividends, if any, as may be declared by the Board of Directors out of funds legally available for dividend payments. If the Company liquidates, dissolves, or winds up, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities and liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no pre-emptive rights or rights to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Company may designate in the future.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has the authority to (i)&#160;issue the undesignated preferred stock in one or more series, (ii)&#160;determine the powers, preferences and rights and the qualifications, limitations or restrictions granted to or imposed upon any wholly un-issued series of undesignated preferred stock and (iii)&#160;fix the number of shares constituting any series and the designation of the series, without any further vote or action by the Company's stockholders.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2020, the Company's shareholders approved the 2020 Stock and Incentive Award Plan (the &#8220;2020 Plan&#8221;).  The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance share units, performance shares and other incentive awards to the Company's employees, directors and other service providers.  On November 3, 2022 the Company's shareholders approved an amendment to the 2020 Plan to increase the reserve of shares of common stock available for future grants by <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-827">1,950,000</ix:nonFraction> shares.  As of May&#160;31, 2023, there remained approximately <ix:nonFraction unitRef="shares" contextRef="c-155" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-828">2.9</ix:nonFraction> million shares available for future grants under the 2020 Plan. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of the 2020 Plan, equity awards were issued under the 2004 Stock and Incentive Award Plan (the &#8220;2004 Plan&#8221;).  The adoption of the 2020 Plan did not impact the administration of equity awards issued under the 2004 Plan but following the adoption of the 2020 Plan, equity award grants are no longer made under the 2004 Plan.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id6c866eec11444a3b8072f9c701f7f6f" continuedAt="i41777f5834c24c9d8c09a2d8895c80cc"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-829" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock option activity for the fiscal year ended May&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year - June 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-830">2,346,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-831">17.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-832">187,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-833">21.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-834">47,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-835">14.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-836">79,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-837">20.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-838">200,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-839">12.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year - May 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-840">2,206,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-841">17.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-842">5.89</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="f-843">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at year-end</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-844">1,408,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-845">17.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-846">4.77</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="3" id="f-847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options expected to vest in future periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-848">798,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-849">19.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-850">7.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="f-851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are granted at exercise prices equal to the quoted market price of common stock at the date of the grant. Options vest <ix:nonFraction unitRef="number" contextRef="c-61" decimals="2" name="ango:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage" scale="-2" id="f-852">25</ix:nonFraction>%&#160;per year over <ix:nonNumeric contextRef="c-61" name="ango:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1" format="ixt-sec:durwordsen" id="f-853">four years</ix:nonNumeric> for employees.  Stock options granted prior to May 1, 2007 and after June 1, 2017 expire on the tenth anniversary of the grant date.  Stock options granted between May 1, 2007 through May 31, 2017 expire on the seventh anniversary of the grant date. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of each stock option grant at the date of grant using a Black-Scholes option pricing model.  The weighted average grant-date fair value of options granted during the years ended May&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-854">9.27</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-855">9.57</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-856">3.97</ix:nonFraction>, respectively.  The following assumptions were used in arriving at the fair value of options granted during 2023, 2022 and 2021, respectively:  risk-free interest rates of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-857">3.20</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-858">0.92</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-859">0.34</ix:nonFraction>%; expected volatility of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-860">44</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-861">41</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-862">39</ix:nonFraction>%; and expected lives of <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-863">5.14</ix:nonNumeric> years, <ix:nonNumeric contextRef="c-4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-864">5.05</ix:nonNumeric> years, and <ix:nonNumeric contextRef="c-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-865">4.96</ix:nonNumeric> years.  The Company does not declare dividends therefore a dividend yield of zero was used for the years ended May&#160;31, 2023, 2022 and 2021.  Risk-free interest rates reflect the yield on zero-coupon U.S. Treasury bonds whose maturity period equals the expected term of the option.  Expected volatilities are based on the historical volatility of the Company's stock.  The expected option lives are based on historical experience of employee exercise behavior. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised during the years ended May&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-866">0.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-867">1.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-868">0.8</ix:nonFraction> million, respectively.  As of May&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-869">3.9</ix:nonFraction> million of total unrecognized compensation cost related to non-vested options, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-870">2</ix:nonNumeric> years. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash received from option exercises during 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-871">0.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-872">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-873">1.9</ix:nonFraction> million, respectively.  Due to the valuation allowance there was <ix:nonFraction unitRef="usd" contextRef="c-61" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-874"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-875"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-876">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> tax benefit realized from stock option exercises during the years ended May&#160;31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit and Performance Share Awards</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock units to certain employees under the 2020 Plan, and historically under the 2004 Plan, which give the recipients the right to receive shares of Company stock upon vesting. The restricted stock unit awards vest in <span style="-sec-ix-hidden:f-877">four</span> equal annual installments beginning on the first anniversary of the grant date.  Restricted stock unit awards granted to directors vest&#160;over <ix:nonNumeric contextRef="c-44" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-878">one year</ix:nonNumeric>. Unvested restricted stock unit awards will be forfeited if the recipient ceases to be employed by the Company. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="f-879" continuedAt="i4608815284f84374ba8d61a82d46a5ef" escape="true">The following table summarizes information about restricted stock unit activity for the year ended May&#160;31, 2023:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="i4608815284f84374ba8d61a82d46a5ef" continuedAt="i1f31593c84844990a8f9ca2e72898ce1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted&#160;Average Grant-Date&#160;Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at beginning of year, June 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-880">670,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-158" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-881">18.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-882">379,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-44" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-883">19.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-884">275,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-44" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-885">20.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-886">38,562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-44" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-887">19.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at end of year, May 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-159" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-888">736,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="c-159" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-889"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock unit is the market price of Company stock on the date of grant.  The weighted average grant date fair value of restricted stock units granted during the years ended May&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-44" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-890">19.99</ix:nonFraction>, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i41777f5834c24c9d8c09a2d8895c80cc" continuedAt="iec70a1f7b34547d6be7c5d6674202941"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-891">26.24</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-892">10.40</ix:nonFraction>, respectively.  The total intrinsic value of restricted stock units (meaning the fair value of the units on the date of vest) vesting during the years ended May&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-893">5.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-894">8.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-895">2.1</ix:nonFraction> million,&#160;respectively.  As of May&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-896">9.1</ix:nonFraction> million of total unrecognized compensation cost related to non-vested restricted stock awards, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-44" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-897">2</ix:nonNumeric> years.   </span></div><div style="text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company grants performance share awards to certain employees under the 2020 Plan, and historically under the 2004 Plan, which gives the recipients the right to receive shares of Company stock if certain criteria is met.  </span></div><div style="text-indent:21.6pt"><span><br/></span></div><ix:continuation id="i1f31593c84844990a8f9ca2e72898ce1"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The following table summarizes information about performance unit award activity for the year ended May&#160;31, 2023:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance Unit Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted&#160;Average Grant-Date&#160;Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at beginning of year, June 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-898">449,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-163" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-899">17.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-900">175,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-164" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-901">21.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-902">45,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-164" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-903">20.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-904">31,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-164" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-905">20.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at end of year, May 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-165" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-906">548,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-165" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-907">19.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2023, 2022 and 2021, the Company granted performance unit awards.  Performance unit awards subject to vesting are based on the Company's level of attainment of the performance targets which are set for each of the <span style="-sec-ix-hidden:f-908">three</span> performance years along with continued employment of the grantee.  At the end of the <ix:nonNumeric contextRef="c-166" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-909">three year</ix:nonNumeric> period, the vested shares are subject to modification based on the Company&#8217;s TSR targets relative to the percentage appreciation of a specified index of companies for the respective <ix:nonNumeric contextRef="c-166" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-910">three-year</ix:nonNumeric> period. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to estimate the fair value of such awards, a Monte Carlo Simulation valuation model on the date of the grant was used.  For the years ended May&#160;31, 2023, 2022 and 2021, the weighted average grant date fair market value for new grants was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-167" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-911">23.71</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-168" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-912">28.93</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-913">9.72</ix:nonFraction>, respectively.  Compensation cost is recognized over the performance period which is typically <ix:nonNumeric contextRef="c-166" name="ango:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod" format="ixt-sec:durwordsen" id="f-914">three years</ix:nonNumeric>.  As of May&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-915">2.4</ix:nonFraction> million of unrecognized compensation cost which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-166" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-916">1</ix:nonNumeric> year. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-917" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represents the break out of stock-based compensation included in the Company's Consolidated Statement of Operations:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-918">793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-919">827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-920">768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-921">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-922">1,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-923">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-924">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-925">2,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-926">1,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-927">5,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-928">5,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-929">5,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-930">11,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-931">10,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-932">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax benefit on the compensation expense recognized for all stock-based compensation arrangements was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-933">2.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-934">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-935">2.0</ix:nonFraction> million for the years ended May&#160;31, 2023, 2022 and 2021, respectively.  The income tax benefit for 2023, 2022 and 2021 are negated by the full valuation allowance recorded against the deferred tax assets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employee Stock Purchase Plan (the &#8220;Stock Purchase Plan&#8221;) provides a means by which employees (the &#8220;participants&#8221;) are given an opportunity to purchase the Company's common stock through payroll deductions.  A total of  <ix:nonFraction unitRef="shares" contextRef="c-182" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-936">5,000,000</ix:nonFraction> shares of common stock have been reserved for issuance under the Stock Purchase Plan.  Shares are offered through <ix:nonFraction unitRef="employees" contextRef="c-183" decimals="INF" name="ango:NumberOfSharePurchasePeriod" format="ixt-sec:numwordsen" scale="0" id="f-937">two</ix:nonFraction> purchase periods, each with duration of approximately <ix:nonNumeric contextRef="c-183" name="ango:SharePurchasePeriod" format="ixt-sec:durmonth" id="f-938">6</ix:nonNumeric> months, commencing on the first business day of the first and third fiscal quarters. An employee is eligible to participate in an offering period if, on the first day of an offering period, he or she has been employed in a full-time capacity for at least <ix:nonNumeric contextRef="c-183" name="ango:EmployeePlanParticipatingEligibilityPeriod" format="ixt-sec:durwordsen" id="f-939">six months</ix:nonNumeric>, with a customary working schedule of <ix:nonFraction unitRef="working_hour" contextRef="c-183" decimals="INF" name="ango:SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible" scale="0" id="f-940">20</ix:nonFraction> or more hours per week and more than <ix:nonNumeric contextRef="c-183" name="ango:SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible" format="ixt-sec:durwordsen" id="f-941">five months</ix:nonNumeric> in a calendar year. Employees who own stock possessing <ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="ango:EmployeePlanParticipatingEligibilityThresholdPercentage" scale="-2" id="f-942">5</ix:nonFraction>% or more of the total combined voting power or value of all classes of stock are not eligible to participate in the Stock Purchase Plan. The purchase price of the shares of common stock acquired on each purchase date will be the lower of (i)&#160;<ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="ango:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod" scale="-2" id="f-943">85</ix:nonFraction>% of the fair market value of a share of common </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iec70a1f7b34547d6be7c5d6674202941"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock on the first day of the offering period or (ii)&#160;<ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-944">85</ix:nonFraction>% of the fair market value of a share of common stock on the last day of the purchase period, subject to adjustments made by the Board of Directors. The Stock Purchase Plan is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423 of the Internal Revenue Code.  During the years ended May 31, 2017, 2019 and 2021, an additional <ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-945">500,000</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-185" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-946">1,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-186" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-947">500,000</ix:nonFraction> shares of the Company's common stock, respectively, were reserved for issuance under the Stock Purchase Plan.   On November 3, 2022 the Company's shareholders approved an amendment to the employee stock purchase plan to increase the reserve of shares of common stock available for future grants by <ix:nonFraction unitRef="shares" contextRef="c-187" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-948">1,000,000</ix:nonFraction> shares. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to calculate the purchase date fair value of the shares issued under the Stock Purchase Plan and recognize expense related to shares purchased ratably over the offering period.  During the years ended May&#160;31, 2023, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-949">149,778</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-186" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-950">98,586</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-188" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-951">164,194</ix:nonFraction> shares, respectively, were issued at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="f-952">13.67</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="f-953">19.02</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="f-954">7.95</ix:nonFraction>, respectively, under the Stock Purchase Plan.  As of May&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-182" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-955">3.2</ix:nonFraction> million shares remained available for future purchases under the Stock Purchase Plan.</span></div></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_202"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.  <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-956" continuedAt="i6ea744df32eb47cba05ef84f5c496567" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i6ea744df32eb47cba05ef84f5c496567"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share are based on the weighted average number of common shares outstanding.  In addition, diluted earnings per share include the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive.  In periods with a net loss, stock options and restricted stock units are not included in the computation of basic loss per share as the impact would be anti-dilutive.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="f-957" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles basic to diluted weighted average shares outstanding:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-958">39,480,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-959">39,009,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-960">38,342,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="f-961">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="f-962">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="f-963">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-964">39,480,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-965">39,009,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-966">38,342,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities excluded as their inclusion would be anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-967">3,491,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-968">3,465,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-969">3,285,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_205"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.  <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-970" continuedAt="i318117592d1945b79c37018006702992" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i318117592d1945b79c37018006702992" continuedAt="i503c38def35b4f1a9a96c3fc8a663730"><div style="margin-bottom:9pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception of the contract.  The Company has operating leases for buildings, primarily for office space, R&amp;D, manufacturing and warehousing.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date.  Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised.  The Company recognizes lease expense for these leases on a straight-line basis over the lease term.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected the three practical expedients that permit an entity to (a) not reassess whether expired or existing contracts contain leases, (b) not reassess lease classification for existing or expired leases, and (c) not consider whether previously capitalized initial direct costs would be appropriate under the new standard. Further, the Company has elected to not recognize leases with terms of 12 months or less on the balance sheet, and elected to account for lease and non-lease components as a single component for certain classes of assets.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ango:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-971" continuedAt="i11e65df8160f4e9d80dac909458fc7a2" escape="true">The following table presents supplemental balance sheet information related to leases:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i503c38def35b4f1a9a96c3fc8a663730"><div style="margin-bottom:4pt;text-align:center"><ix:continuation id="i11e65df8160f4e9d80dac909458fc7a2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-972"><span style="-sec-ix-hidden:f-973">Other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-974">5,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-975">6,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-976"><span style="-sec-ix-hidden:f-977">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-978">1,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-979">2,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-980"><span style="-sec-ix-hidden:f-981">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-982">3,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-983">4,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-984">5,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-985">7,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.  The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term.  <ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-986" continuedAt="ic9158dcd3f6d4145a4e8f15bd7441fd1" escape="true">The following table presents the weighted average remaining lease term and discount rate:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><ix:continuation id="ic9158dcd3f6d4145a4e8f15bd7441fd1" continuedAt="i95e7150e653f47babf6ae5bd31ce2e92"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-987">3.05</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-988">3.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-989">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-990">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-991" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the lease liabilities for each of the following fiscal years is:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-992">2,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-993">1,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-994">1,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-995">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="f-996">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-997">5,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-998">358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-999">5,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1000">1,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1001">3,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended May&#160;31, 2023 and May 31, 2022, the Company recognized operating lease expense, which includes immaterial short-term leases, of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1002">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1003">2.8</ix:nonFraction>&#160;million, respectively.  <ix:continuation id="i95e7150e653f47babf6ae5bd31ce2e92" continuedAt="i2920258dc7b64c1daa5cc20d0a6351ed">The expenses on the Consolidated Statement of Operations were classified as follows:</ix:continuation></span></div><div style="margin-bottom:9pt;text-align:center"><ix:continuation id="i2920258dc7b64c1daa5cc20d0a6351ed" continuedAt="i170bbd5af9754940b95450a5a13c56fa"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="f-1004">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="f-1005">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="f-1006">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="f-1007">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="f-1008">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="f-1009">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1010">1,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1011">1,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1012">2,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1013">2,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div><ix:continuation id="i170bbd5af9754940b95450a5a13c56fa"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow and other information related to leases:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1014">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1015">2,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-1016">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-1017">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.  <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1018" continuedAt="ica8dba6d75eb41048cf13c3386cb7b4a" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ica8dba6d75eb41048cf13c3386cb7b4a" continuedAt="ia7bbeab573eb4785902bd02fc97b68ee"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Contingencies </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCommitmentsTableTextBlock" id="f-1019" escape="true"><div style="margin-bottom:7pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's other future commitments and contingencies as of May&#160;31, 2023: </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028 and thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="3" id="f-1020">3,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1021">3,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PurchaseObligationDueInSecondYear" format="ixt:fixed-zero" scale="3" id="f-1022">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PurchaseObligationDueInThirdYear" format="ixt:fixed-zero" scale="3" id="f-1023">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PurchaseObligationDueInFourthYear" format="ixt:fixed-zero" scale="3" id="f-1024">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:PurchaseObligationToBePaidAfterYearFour" format="ixt:fixed-zero" scale="3" id="f-1025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:Royalties" format="ixt:num-dot-decimal" scale="3" id="f-1026">39,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:RoyaltiesDueInFirstYear" format="ixt:num-dot-decimal" scale="3" id="f-1027">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:RoyaltiesDueinSecondYear" format="ixt:num-dot-decimal" scale="3" id="f-1028">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:RoyaltiesDueinThirdYear" format="ixt:num-dot-decimal" scale="3" id="f-1029">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:RoyaltiesDueinFourthYear" format="ixt:num-dot-decimal" scale="3" id="f-1030">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:RoyaltiesDueAfterFourthYear" format="ixt:num-dot-decimal" scale="3" id="f-1031">25,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="3" id="f-1032">43,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractualObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1033">6,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractualObligationDueInSecondYear" format="ixt:num-dot-decimal" scale="3" id="f-1034">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractualObligationDueInThirdYear" format="ixt:num-dot-decimal" scale="3" id="f-1035">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractualObligationDueInFourthYear" format="ixt:num-dot-decimal" scale="3" id="f-1036">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ango:ContractualObligationToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1037">25,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) The non-cancelable inventory purchase obligations are not reflected on the Consolidated Balance Sheets under accounting principles generally accepted in the United States of America.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) These are future minimum royalty payments.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business.  The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated.  The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred.  However, the Company cannot predict the outcome of any litigation or the potential for future litigation.</span></div><div style="margin-bottom:0.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.R. Bard, Inc. v. AngioDynamics, Inc.</span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2012, C.R. Bard, Inc. (&#8220;Bard&#8221;) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on <ix:nonFraction unitRef="unit" contextRef="c-193" decimals="INF" name="ango:NumberOfPatentsAssertedForReexamination" format="ixt-sec:numwordsen" id="f-1038">three</ix:nonFraction> U.S. patents held by Bard (US Patent Nos. 7,785,302 ("302"), 7,959,615 (&#8220;615&#8221;) and 7,947,022 ("022")).  The case was stayed pending reexamination in the US Patent and Trademark Office ("USPTO").  Following the reexamination proceedings, and the parties&#8217; related appeals to the Federal Circuit which resulted in further proceedings at the USPTO, certain claims of the 615 patent were held invalid, while the remaining claims of the 615 patent and the other <ix:nonFraction unitRef="unit" contextRef="c-193" decimals="INF" name="ango:NumberOfPatentsUpheldOverPriorArtReferences" format="ixt-sec:numwordsen" id="f-1039">two</ix:nonFraction> patents were upheld over the prior art references considered in the reexamination proceedings.  Thereafter, the case was transferred from the District of Utah to the United States District Court for the District of Delaware (&#8220;District of Delaware&#8221;).  On July 22, 2021, in another case against a different defendant, the District of Utah invalidated multiple claims of the &#8216;302, &#8216;022, and &#8216;615 Patents under 35 USC &#167;101, including claims asserted against the Company.  On December 27, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal from the Utah Decision.  On February 17, 2023, the Federal Circuit Reversed-in-Part, Vacated-in-Part, and Remanded the Utah Decision.  The District of Delaware lifted the stay on February 28, 2023 and held a status conference on March 23, 2023.  A scheduling order has been entered, and a jury trial is currently scheduled for April 29, 2024. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.  </span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 10, 2015, Bard and Bard Peripheral Vascular filed suit in the District of Delaware claiming certain of the Company's implantable port products infringe on <ix:nonFraction unitRef="unit" contextRef="c-194" decimals="INF" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" id="f-1040">three</ix:nonFraction> U.S. patents held by Bard (US Patent Nos. 8,475,417, 8,545,460, 8,805,478).  The case proceeded through trial which began on March 4, 2019.  At the close of Bard&#8217;s case, the Court granted the Company's oral motion for judgment as a matter of law as well as its motions for summary judgment on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed.  Bard appealed the judgment to the Federal Circuit and on November 10, 2020, the Federal Circuit reversed the judgment in part with respect to Section 101 (subject matter eligibility), and vacated and remanded the trial court&#8217;s invalidity and non-infringement judgments.  Following remand from the Federal Circuit, a jury trial commenced in the District of Delaware beginning November 14, 2022.  On November 22, 2022, a jury entered a verdict finding that certain of the Company&#8217;s implantable port products infringe certain claims of U.S. patents held by Bard. The issue of damages was bifurcated by the Court during trial and was not determined by the jury.  On Jun</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e 1, 2023, following post-trial briefing, the Court issued its decision on the Company&#8217;s Renewed Judgement as a Matter of Law.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Court held the asserted patent claims were invalid as anticipated, indefinite, ineligible, and not willfully infringed.  The Court entered Judgment the same day in favor of the Company.  Bard has filed a Notice of Appeal to the Federal Circuit. The Company maintains its belief that Bard&#8217;s claims are without merit.  The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.</span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2021, Bard filed suit in the District of Delaware asserting certain of the Company&#8217;s port products (including certain related infusion sets) infringe U.S. Patent Nos. 8,025,639, 9,603,992 and 9,603,993.   On December 27, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal of the Utah decision invalidating </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:0.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia7bbeab573eb4785902bd02fc97b68ee">multiple claims of the &#8216;302, &#8216;022, and &#8216;615 patents under 35 USC &#167;101. Following the Federal Circuit&#8217;s decision on appeal, the District of Delaware lifted the stay on February 28, 2023, and held a scheduling conference on March 23, 2023. A scheduling order has been entered, and a jury trial is currently scheduled for June 9, 2025. The Company maintains its belief that Bard's claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.</ix:continuation></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_211"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.  <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1041" continuedAt="i20a8df5246e042bba4e5b9a88722ffbc" escape="true">SEGMENTS AND GEOGRAPHIC INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i20a8df5246e042bba4e5b9a88722ffbc" continuedAt="i815dca2632994f6fa4b5fc8ede6ea135"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly reviews its segments and the approach used by the chief operating decision maker, the President and Chief Executive Officer ("CEO"), and management to evaluate performance and allocate resources.  Prior to the first quarter of fiscal year 2023, the Company considered the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis.  Commencing with the first quarter of fiscal year 2023, the Company began to manage its operations through <ix:nonFraction unitRef="unit" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1042">two</ix:nonFraction> segments, Med Tech and Med Device to align with the transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company.  The CEO evaluates these <ix:nonFraction unitRef="unit" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1043">two</ix:nonFraction> segments based on net sales and gross margin to, among other items, allocate resources and assess performance.  Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions.  The CEO evaluates all other elements of profitability, investment and cash flow metrics on a consolidated global basis due to shared infrastructure and resources. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company manages its assets on a total company basis, not by operating segment; therefore, the CEO does not review any asset information by operating segment and, accordingly, asset information is not reported or evaluated by operating segment.  Total assets were $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-1044">532.6</ix:nonFraction> million as of May&#160;31, 2023. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes net sales and gross margin by Med Tech and Med Device including prior periods during which the Company considered the business to be a single operating segment, in order to conform to the current period presentation:</span></div><div style="margin-bottom:9pt"><ix:nonNumeric contextRef="c-1" name="ango:ScheduleOfNetRevenueByProductGroupTableTextBlock" id="f-1045" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1046">96,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1047">78,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1048">55,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1049">61,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1050">52,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1051">39,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross Margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-69" decimals="3" name="ango:GrossMarginPercentage" scale="-2" id="f-1052">64.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-72" decimals="3" name="ango:GrossMarginPercentage" scale="-2" id="f-1053">66.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="3" name="ango:GrossMarginPercentage" scale="-2" id="f-1054">71.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1055">242,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1056">237,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1057">235,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1058">112,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1059">113,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1060">117,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross Margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-60" decimals="3" name="ango:GrossMarginPercentage" scale="-2" id="f-1061">46.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="3" name="ango:GrossMarginPercentage" scale="-2" id="f-1062">47.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="3" name="ango:GrossMarginPercentage" scale="-2" id="f-1063">49.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1064">338,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1065">316,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1066">291,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1067">174,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1068">165,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1069">156,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross Margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ango:GrossMarginPercentage" scale="-2" id="f-1070">51.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="ango:GrossMarginPercentage" scale="-2" id="f-1071">52.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="ango:GrossMarginPercentage" scale="-2" id="f-1072">53.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic information</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="f-1073" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes net sales by geographic area based on external customer location:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales by Geography</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1074">282,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1075">265,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1076">237,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1077">56,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1078">50,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1079">53,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1080">338,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1081">316,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1082">291,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i815dca2632994f6fa4b5fc8ede6ea135">For fiscal years 2023, 2022 and 2021, international sales as a percentage of total net sales were <ix:nonFraction unitRef="number" contextRef="c-198" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1083">17</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-199" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1084">16</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-200" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1085">19</ix:nonFraction>%, respectively. Sales to any one country outside the U.S., as determined by shipment destination, did not comprise a material portion of net sales in any of the last three fiscal years. In addition, no one customer represents more than 10% of consolidated net sales.  <ix:nonFraction unitRef="number" contextRef="c-201" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1086">85</ix:nonFraction>% of long-lived assets are located within the United States.</ix:continuation>  </span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_214"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.  <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-1087" continuedAt="ib3d48eb283e942c4b8e46b1694b87d66" escape="true">ACQUISITION, RESTRUCTURING AND OTHER ITEMS, NET</ix:nonNumeric></span></div><ix:continuation id="ib3d48eb283e942c4b8e46b1694b87d66" continuedAt="i79419fb79e0445aea6e2ecaa233dcec8"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-1088" continuedAt="i5031f230fd0643e2b2b4be602589ad13" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition, restructuring and other items, net consisted of:</span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="3" id="f-1089">9,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="3" id="f-1090">7,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="3" id="f-1091">6,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mergers and acquisitions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" scale="3" id="f-1092">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" scale="3" id="f-1093">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" scale="3" id="f-1094">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transition service agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:fixed-zero" scale="3" id="f-1095">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:fixed-zero" scale="3" id="f-1096">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" sign="-" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="3" id="f-1097">1,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:fixed-zero" scale="3" id="f-1098">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:fixed-zero" scale="3" id="f-1099">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" scale="3" id="f-1100">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible and other asset impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:fixed-zero" scale="3" id="f-1101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:fixed-zero" scale="3" id="f-1102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="3" id="f-1103">13,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israeli Innovation Authority prepayment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="3" id="f-1104">3,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:fixed-zero" scale="3" id="f-1105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:fixed-zero" scale="3" id="f-1106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing Relocation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="3" id="f-1107">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" scale="3" id="f-1108">644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:fixed-zero" scale="3" id="f-1109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" scale="3" id="f-1110">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" scale="3" id="f-1111">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" scale="3" id="f-1112">756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="3" id="f-1113">15,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="3" id="f-1114">9,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="3" id="f-1115">20,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Legal expenses related to litigation that is outside the normal course of business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5) During the fourth quarter of fiscal year 2021, the Company made the decision to abandon the OARtrac product technology and trademark.  This resulted in an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-1116">14.0</ix:nonFraction>&#160;million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6) I</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n the first quarter of fiscal year 2023, a $<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:PaymentsForPreviousAcquisition" format="ixt:num-dot-decimal" scale="6" id="f-1117">3.5</ix:nonFraction>&#160;million payment was made to the Israeli Innovation Authority to fully satisfy the obligation related to grant funds that were provided to Eximo for development of the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020. </span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i5031f230fd0643e2b2b4be602589ad13">(7) Expenses to relocate certain manufacturing lines from Queensbury, NY to Alajuela, Costa Rica.</ix:continuation> </span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i79419fb79e0445aea6e2ecaa233dcec8">Included in legal for fiscal year 2021 is a $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="ango:AcquisitionRestructuringAndOtherItemsNet" format="ixt:num-dot-decimal" scale="6" id="f-1118">1.0</ix:nonFraction>&#160;million settlement expense. The settlement received partially offset legal expenses paid related to the settlement proceedings.</ix:continuation> </span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_217"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.  <ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="f-1119" continuedAt="i05cfbd02783f42ddab8933085f67e094" escape="true">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</ix:nonNumeric></span></div><ix:continuation id="i05cfbd02783f42ddab8933085f67e094"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-1120" escape="true"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of accumulated other comprehensive income (loss), net of tax, are as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation gain (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1121">3,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1122">1,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1123">1,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1124">1,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1125">6,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1126">6,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1127">4,723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_1901"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21.  <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1128" continuedAt="i971c8c9381634b2c9e0dae3895eb6564" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i971c8c9381634b2c9e0dae3895eb6564" continuedAt="i798c68e051374a92ada53226f827773c">On June 8, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with Merit Medical Systems, Inc. pursuant to which Merit acquired the dialysis product portfolio and BioSentry tract sealant system biopsy businesses for $<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="us-gaap:ProceedsFromSaleOfOtherAssets1" format="ixt:num-dot-decimal" scale="6" id="f-1129">100.0</ix:nonFraction>&#160;million in cash.  The Company and Merit entered into various agreements to facilitate the transition to Merit, including a Transactions Services Agreement and Contract Manufacturing Agreement.  The Company determined that the sale of the businesses did not constitute a strategic shift that had a major effect on the Company&#8217;s operations or financial results and as a result, this transaction will not be classified as discontinued operations.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i798c68e051374a92ada53226f827773c">On June 8, 2023, AngioDynamics used a portion of the consideration received in connection with the Transaction to repay all amounts owed under AngioDynamics&#8217; existing Credit Agreement, dated as of August 30, 2022, with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and KeyBank National Association, as co-syndication agents, and JPMorgan Chase Bank N.A., as sole bookrunner and sole lead arranger, and as a result, the Credit Agreement was extinguished. Pursuant to the terms of the Credit Agreement, AngioDynamics had the option to repay this facility prior to the maturity date without penalty.</ix:continuation></span></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_220"></div><div style="margin-top:18pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AngioDynamics, Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="f-1130" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SCHEDULE&#160;II&#160;-VALUATION&#160;AND&#160;QUALIFYING&#160; ACCOUNTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance&#160;at Beginning of&#160;Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions&#160;- Charged&#160;to costs and expenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance&#160;at End&#160;of&#160;Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended May&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for deferred tax asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1131">13,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-1132">3,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="3" id="f-1133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1134">17,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns and doubtful accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1135">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-1136">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-1137">2,064</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1138">1,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended May&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for deferred tax asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1139">17,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-1140">3,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="3" id="f-1141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1142">20,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns and doubtful accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1143">1,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="f-1144">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="f-1145">323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1146">1,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended May&#160;31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for deferred tax asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1147">20,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-1148">5,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="3" id="f-1149">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1150">25,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns and doubtful accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1151">1,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="f-1152">457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="f-1153">246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1154">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="margin-bottom:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of Exhibits </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000091412112000534/an26859490-ex2_1.htm">Stock Purchase Agreement, dated as of October 8, 2012, by and among AngioDynamics, Inc., Vortex Medical, Inc. (&#8220;Vortex&#8221;), the stockholders of Vortex set forth on the signature pages thereto, the option holders of Vortex set forth on the signature pages thereto and CHTP Management Services, Inc., as sellers&#8217; representative.</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 12, 2012</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000091412119000934/an53548547-2_1.htm">Asset Purchase Agreement dated as of April 17, 2019 by and between AngioDynamics, Inc. and Medline Industries Inc.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 18, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1275187/000114036123029854/brhc20054314_ex2-1.htm">Asset Purchase Agreement dated as of June 8, 2023 by and between AngioDynamics, Inc. and Merit Medical Systems, Inc. </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000119312505198180/dex31.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 7, 2005</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000127518715000018/ex31253115.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of AngioDynamics, Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2015</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000091412115000548/an33460072-ex3_1.htm">Second Amended and Restated By-Laws, effective October 16, 2015.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 21, 2015</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000127518718000016/angoproxy-53118.htm">AngioDynamics, Inc. 2004 Stock and Incentive Award Plan (as amended).</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEF 14A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 30, 2018</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.6</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000127518717000034/a83117-exx101.htm">AngioDynamics 2017 Total Shareholder Return Performance Unit Agreement Program.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 29, 2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000127518718000011/ex1017totalshareholderretu.htm">AngioDynamics 2018 Total Shareholder Return Performance Unit Agreement Program.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 23, 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1275187/000127518720000005/psuawardagreement.htm">AngioDynamics 2019 Total Shareholder Return Performance Unit Agreement Program.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 8, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1275187/000127518720000028/angoproxy-53120.htm">AngioDynamics, Inc. 2020 Stock and Incentive Award Plan</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEF 14A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 3, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1275187/000127518720000028/angoproxy-53120.htm">AngioDynamics, Inc. Employee Stock Purchase Plan (as amended).</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEF 14A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 3, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000119312504169832/dex101.htm">Form of Non-Statutory Stock Option Agreement pursuant to the AngioDynamics, Inc. Stock and Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 12, 2004</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000127518718000011/ex1031stockoptionagreement.htm">Form of Non-Statutory Stock Option Agreement pursuant to the AngioDynamics, Inc. Stock and Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 23, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000127518716000037/ex102-2016psuagreement.htm">Form of 2016 Performance Share Award Agreement pursuant to the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 5, 2016</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000127518717000034/a83117-exx102.htm">Form of 2017 Performance Share Award Agreement pursuant to the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 29, 2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000127518718000011/ex1045performanceunitaward.htm">Form of 2018 Performance Share Award Agreement pursuant to the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 23, 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1275187/000127518721000005/ango-20201130.htm">Form of 2020 Performance Share Award Agreement pursuant to the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 8, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001275187/000127518721000023/ango-20210831.htm#ic69966880990446bb6eee699ec835b1f_118">Form of Performance Share Award Agreement pursuant to the 2020 Stock and Incentive Award Plan</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000116923205002637/d63831_ex10-3.htm">Form of Restricted Stock Award Agreement pursuant to the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 12, 2005</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1056421/0001012870-00-002503-index.html">Rita Medical Systems, Inc. 1994 Incentive Stock Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2000</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of Exhibits </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1052958/0000950144-98-001576-index.html">Horizon Medical Products, Inc. 1998 Stock Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 13, 1998</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1056421/000101287000003359/0001012870-00-003359-index.htm">Rita Medical Systems, Inc. 2000 Stock Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1056421/000114420405021015/v021182_ex99-2.htm">Rita Medical Systems, Inc. 2000 Directors&#8217; Stock Plan, as amended on June 8, 2005.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 8, 2005</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1056421/000114420405021015/v021182_ex99-1.htm">Rita Medical Systems, Inc. 2005 Stock and Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 8, 2005</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000116923206002370/d68040_ex10-1.htm">Form of Indemnification Agreement of AngioDynamics, Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 12, 2006</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000091412116001069/an35192888-ex10_1.htm">Employment Agreement, dated April 1, 2016, between AngioDynamics, Inc. and James C. Clemmer.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000091412116001069/an35192888-ex10_2.htm">Change in Control Agreement, dated April 1, 2016, between AngioDynamics, Inc. and James C. Clemmer.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2016</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1275187/000127518720000024/formofseveranceagreeme.htm">Form of Severance Agreement of AngioDynamics, Inc.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000127518715000011/ex101353114a.htm">Form of Change in Control Agreement.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 12, 2015</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000091412116001069/an35192888-ex10_3.htm">Performance Share Award Agreement, with a grant date of April 4, 2016, between AngioDynamics, Inc. and James C. Clemmer.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000091412116001069/an35192888-ex10_4.htm">AngioDynamics, Inc. Total Shareholder Return Performance Share Award Program - Performance Period Ending July 2019.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2016</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000091412116001069/an35192888-ex10_5.htm">Stock Option Award Agreement, with a grant date of April 4, 2016, between AngioDynamics, Inc. and James C. Clemmer.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000091412116001069/an35192888-ex10_6.htm">Restricted Stock Unit Award Agreement, with a grant date of April 4, 2016, between AngioDynamics, Inc. and James C. Clemmer.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2016</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000091412116001150/an35296029-ex10_1.htm">Separation Agreement and General Release, dated April 22, 2016, between AngioDynamics, Inc. and Joseph M. DeVivo.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 27, 2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1275187/000091412121000581/an55676910-8ki.htm">Amended and Restated Change in Control Agreement, by and between AngioDynamics, Inc. and James C. Clemmer.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1275187/000091412121000581/an55676910-8ki.htm">Form of Amended and Restated Change in Control Agreement with AngioDynamics, Inc.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1275187/000116923206002370/d68040_ex14.htm">Code of Ethics.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex2105312023.htm">Subsidiaries </a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex23angio2023consentofdelo.htm">Consent of Deloitte &amp; Touche LLP, an independent registered public accounting firm.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3115312310-k.htm">Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3125312310-k.htm">Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3215312310-k.htm">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3225312310-k.htm">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Schema Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Calculation Linkbase Documents</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Labels Linkbase Documents</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Presentation Linkbase Documents</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i0c89ef540c7d4512afc87ee33fb4f1eb_226"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:4.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANGIODYNAMICS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OWARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ONNELLY&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Howard W. Donnelly,<br/>Chairman of the Board, Director</span></td></tr></table></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OWARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ONNELLY&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Howard W. Donnelly,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chairman of the Board, Director</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LEMMER&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">James C. Clemmer,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">President, Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TEPHEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ROWBRIDGE</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stephen A. Trowbridge,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Executive Vice President, Chief Financial Officer,<br/>(Principal Financial and Accounting Officer)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ESLEY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OHNSON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wesley E. Johnson, Jr.,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Director</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ENNIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> S. M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ETENY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dennis S. Meteny,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Director</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> S. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EED</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jan S. Reed,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Director</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ILEEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> O. A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UEN</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eileen O. Auen,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Director</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AREN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICITRA</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Karen A. Licitra,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Director</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARNOFF</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael E. Tarnoff,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Director</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;LORINDA A. BURGESS</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lorinda A. Burgess</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Director</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>2
<FILENAME>ex2105312023.htm
<DESCRIPTION>EX-21
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if9bce3a6052c47028d37897994f1830d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Subsidiaries of AngioDynamics, Inc. </font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.856%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Subsidiary</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">State of Incorporation or Organization</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AngioDynamics UK Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AngioDynamics Netherlands B. V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RITA Medical Systems, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AngioDynamics France, SARL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AngioDynamics Canada Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AngioDynamics Medical Brasil Servicos de Marketing Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RadiaDyne LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eximo Medical, Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AngioDynamics VA LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>3
<FILENAME>ex23angio2023consentofdelo.htm
<DESCRIPTION>EX-23
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7347e6e2829847ab90aef34fa68276a4_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We consent to the incorporation by reference in Registration Statement Nos. 333-120057, 333-138456, 333-140627, 333-161355, 333-162844, 333-170619, 333-190640, 333-203441, 333-229814, 333-252209 and 333-26915</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">on Form S-8 of our reports dated August 3, 2023, relating to the financial statements of AngioDynamics Inc. and the effectiveness of AngioDynamics Inc.'s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended May&#160;31, 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Deloitte &#38; Touche LLP </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 3, 2023 </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex3115312310-k.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i553918a547cb43f8bf5cc8fb3c433ab0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, James C. Clemmer, certify that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this annual report on Form 10-K of AngioDynamics, Inc.&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:33.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:33.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:33.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:33.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:9pt;text-indent:-27pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:33.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:33.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Date&#58; August 3, 2023 </font></div><div style="margin-top:9pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; S &#47; JAMES C. CLEMMER</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James C. Clemmer, President,</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex3125312310-k.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib4335f459a0842809211002f28aef3f4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Stephen A. Trowbridge, certify that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this annual report on Form 10-K of AngioDynamics, Inc.&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:33.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:33.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:33.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:33.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:9pt;text-indent:-27pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:33.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:33.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Date&#58; August 3, 2023 </font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; S &#47; STEPHEN A. TROWBRIDGE</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stephen A. Trowbridge, Executive Vice President,</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div style="padding-left:2.25pt;padding-right:2.25pt"><font><br></font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex3215312310-k.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic4a2e5cc55a94bd684c17076a4d36f94_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO TITLE 18,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">UNITED STATES CODE, SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, James C. Clemmer, President, Chief Executive Officer and Director of ANGIODYNAMICS, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section&#160;1350, that, to the best of my knowledge&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:2.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the annual report on Form 10-K of the Company for the fiscal year ended May&#160;31, 2023 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))&#59; and</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:2.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div style="margin-bottom:1pt;padding-left:2.25pt"><font><br></font></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Date&#58; August 3, 2023 </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47; JAMES C. CLEMMER</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James C. Clemmer, President,</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex3225312310-k.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2a1ac2e6b5da4521b24b1f0aa07bf2c5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Exhibit 32.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO TITLE 18,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">UNITED STATES CODE, SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Stephen A. Trowbridge, Chief Financial Officer of ANGIODYNAMICS, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section&#160;1350, that, to the best of my knowledge&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:2.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the annual report on Form 10-K of the Company for the fiscal year ended May&#160;31, 2023 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:2.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Date&#58; August 3, 2023 </font></div><div style="margin-top:9pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47; STEPHEN A. TROWBRIDGE</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stephen A. Trowbridge, Executive Vice President,</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ango-20230531.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:9980962c-8c03-489b-926a-266c60a03003,g:4284608e-2675-438a-ad4d-4e46a03d6c06-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ango="http://www.angiodynamics.com/20230531" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.angiodynamics.com/20230531">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ango-20230531_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ango-20230531_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ango-20230531_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ango-20230531_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.angiodynamics.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.angiodynamics.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsComprehensiveIncomeLoss" roleURI="http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss">
        <link:definition>0000004 - Statement - Consolidated Statements Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.angiodynamics.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000005 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPolicies" roleURI="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Basis of Presentation, Business Description and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.angiodynamics.com/role/Acquisitions">
        <link:definition>0000010 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsHeldForSale" roleURI="http://www.angiodynamics.com/role/AssetsHeldForSale">
        <link:definition>0000011 - Disclosure - Assets Held For Sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromContractswithCustomers" roleURI="http://www.angiodynamics.com/role/RevenuefromContractswithCustomers">
        <link:definition>0000012 - Disclosure - Revenue from Contracts with Customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://www.angiodynamics.com/role/FairValueofFinancialInstruments">
        <link:definition>0000013 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.angiodynamics.com/role/Inventories">
        <link:definition>0000014 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOther" roleURI="http://www.angiodynamics.com/role/PrepaidExpensesandOther">
        <link:definition>0000015 - Disclosure - Prepaid Expenses and Other</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNet" roleURI="http://www.angiodynamics.com/role/PropertyPlantandEquipmentNet">
        <link:definition>0000016 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000017 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.angiodynamics.com/role/IncomeTaxes">
        <link:definition>0000018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.angiodynamics.com/role/AccruedLiabilities">
        <link:definition>0000019 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.angiodynamics.com/role/LongTermDebt">
        <link:definition>0000020 - Disclosure - Long Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlans" roleURI="http://www.angiodynamics.com/role/RetirementPlans">
        <link:definition>0000021 - Disclosure - Retirement Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.angiodynamics.com/role/StockholdersEquity">
        <link:definition>0000022 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.angiodynamics.com/role/EarningsPerShare">
        <link:definition>0000023 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.angiodynamics.com/role/Leases">
        <link:definition>0000024 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.angiodynamics.com/role/CommitmentsandContingencies">
        <link:definition>0000025 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsandGeographicInformation" roleURI="http://www.angiodynamics.com/role/SegmentsandGeographicInformation">
        <link:definition>0000026 - Disclosure - Segments and Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionRestructuringandOtherItemsnet" roleURI="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnet">
        <link:definition>0000027 - Disclosure - Acquisition, Restructuring and Other Items, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>0000028 - Disclosure - Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.angiodynamics.com/role/SubsequentEvents">
        <link:definition>0000029 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ValuationandQualifyingAccounts" roleURI="http://www.angiodynamics.com/role/ValuationandQualifyingAccounts">
        <link:definition>0000030 - Disclosure - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000031 - Disclosure - Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000032 - Disclosure - Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsHeldForSaleTables" roleURI="http://www.angiodynamics.com/role/AssetsHeldForSaleTables">
        <link:definition>0000033 - Disclosure - Assets Held For Sale (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromContractswithCustomersTables" roleURI="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersTables">
        <link:definition>0000034 - Disclosure - Revenue from Contracts with Customers (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsTables" roleURI="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsTables">
        <link:definition>0000035 - Disclosure - Fair Value of Financial Instruments Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.angiodynamics.com/role/InventoriesTables">
        <link:definition>0000036 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherTables" roleURI="http://www.angiodynamics.com/role/PrepaidExpensesandOtherTables">
        <link:definition>0000037 - Disclosure - Prepaid Expenses and Other (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetTables" roleURI="http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetTables">
        <link:definition>0000038 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000039 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.angiodynamics.com/role/IncomeTaxesTables">
        <link:definition>0000040 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.angiodynamics.com/role/AccruedLiabilitiesTables">
        <link:definition>0000041 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.angiodynamics.com/role/LongTermDebtTables">
        <link:definition>0000042 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.angiodynamics.com/role/StockholdersEquityTables">
        <link:definition>0000043 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.angiodynamics.com/role/EarningsPerShareTables">
        <link:definition>0000044 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.angiodynamics.com/role/LeasesTables">
        <link:definition>0000045 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.angiodynamics.com/role/CommitmentsAndContingenciesTables">
        <link:definition>0000046 - Disclosure - Commitments And Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsandGeographicInformationTables" roleURI="http://www.angiodynamics.com/role/SegmentsandGeographicInformationTables">
        <link:definition>0000047 - Disclosure - Segments and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionRestructuringandOtherItemsnetTables" roleURI="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetTables">
        <link:definition>0000048 - Disclosure - Acquisition, Restructuring and Other Items, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>0000049 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual">
        <link:definition>0000050 - Disclosure - Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails">
        <link:definition>0000051 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsHeldForSaleDetails" roleURI="http://www.angiodynamics.com/role/AssetsHeldForSaleDetails">
        <link:definition>0000052 - Disclosure - Assets Held For Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromContractswithCustomersDisaggregationofRevenueDetails" roleURI="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails">
        <link:definition>0000053 - Disclosure - Revenue from Contracts with Customers - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromContractswithCustomersDetails" roleURI="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails">
        <link:definition>0000054 - Disclosure - Revenue from Contracts with Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromContractswithCustomersRevenuefromContractswithCustomersContractAssetsandLiabilitiesDetails" roleURI="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersRevenuefromContractswithCustomersContractAssetsandLiabilitiesDetails">
        <link:definition>0000055 - Disclosure - Revenue from Contracts with Customers Revenue from Contracts with Customers - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails" roleURI="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails">
        <link:definition>0000056 - Disclosure - Fair Value of Financial Instruments Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails2" roleURI="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails2">
        <link:definition>0000057 - Disclosure - Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3" roleURI="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3">
        <link:definition>0000058 - Disclosure - Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.angiodynamics.com/role/InventoriesDetails">
        <link:definition>0000059 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherDetails" roleURI="http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails">
        <link:definition>0000060 - Disclosure - Prepaid Expenses and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetDetails" roleURI="http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails">
        <link:definition>0000061 - Disclosure - Property, Plant, and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsGoodwillRollforwardDetails" roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails">
        <link:definition>0000062 - Disclosure - Goodwill and Intangible Assets - Goodwill Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>0000063 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails" roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails">
        <link:definition>0000064 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails" roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails">
        <link:definition>0000065 - Disclosure - Goodwill and Intangible Assets - Expected Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofLossDetails" roleURI="http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails">
        <link:definition>0000066 - Disclosure - Income Taxes - Components of Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxBenefitDetails" roleURI="http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails">
        <link:definition>0000067 - Disclosure - Income Taxes - Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000068 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000069 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxRateReconciliationDetails" roleURI="http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails">
        <link:definition>0000070 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>0000071 - Disclosure - Income Taxes Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.angiodynamics.com/role/AccruedLiabilitiesDetails">
        <link:definition>0000072 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNarrativeDetails" roleURI="http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails">
        <link:definition>0000073 - Disclosure - Long Term Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtLongTermDebtScheduleDetails" roleURI="http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails">
        <link:definition>0000074 - Disclosure - Long Term Debt - Long Term Debt Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlansDetails" roleURI="http://www.angiodynamics.com/role/RetirementPlansDetails">
        <link:definition>0000075 - Disclosure - Retirement Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000076 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.angiodynamics.com/role/StockholdersEquityDetails">
        <link:definition>0000077 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails2" roleURI="http://www.angiodynamics.com/role/StockholdersEquityDetails2">
        <link:definition>0000078 - Disclosure - Stockholders' Equity (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCompensationExpenseDetails" roleURI="http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails">
        <link:definition>0000079 - Disclosure - Stockholders' Equity - Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.angiodynamics.com/role/EarningsPerShareDetails">
        <link:definition>0000080 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.angiodynamics.com/role/LeasesDetails">
        <link:definition>0000081 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>0000082 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLiabilityMaturityScheduleDetails" roleURI="http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails">
        <link:definition>0000083 - Disclosure - Leases - Liability Maturity Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLiabilityMaturityScheduleDetails_1" roleURI="http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1">
        <link:definition>0000083 - Disclosure - Leases - Liability Maturity Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalStatementofOperationsInformationDetails" roleURI="http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails">
        <link:definition>0000084 - Disclosure - Leases - Supplemental Statement of Operations Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>0000085 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleDetails" roleURI="http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails">
        <link:definition>0000086 - Disclosure - Commitments and Contingencies - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleDetails_1" roleURI="http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails_1">
        <link:definition>0000086 - Disclosure - Commitments and Contingencies - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>0000087 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsandGeographicInformationNarrativeDetails" roleURI="http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails">
        <link:definition>0000088 - Disclosure - Segments and Geographic Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsandGeographicInformationSalesbyProductCategoryDetails" roleURI="http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails">
        <link:definition>0000089 - Disclosure - Segments and Geographic Information - Sales by Product Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsandGeographicInformationSaleforGeographicAreasDetails" roleURI="http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails">
        <link:definition>0000090 - Disclosure - Segments and Geographic Information - Sale for Geographic Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionRestructuringandOtherItemsnetScheduleDetails" roleURI="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails">
        <link:definition>0000091 - Disclosure - Acquisition, Restructuring and Other Items, net - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionRestructuringandOtherItemsnetNarrativeDetails" roleURI="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetNarrativeDetails">
        <link:definition>0000092 - Disclosure - Acquisition, Restructuring and Other Items, net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>0000093 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.angiodynamics.com/role/SubsequentEventsDetails">
        <link:definition>0000094 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ValuationandQualifyingAccountsDetails" roleURI="http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails">
        <link:definition>0000095 - Disclosure - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ango_EmployeePlanParticipatingEligibilityPeriod" abstract="false" name="EmployeePlanParticipatingEligibilityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ango_IncomeTaxReconciliationEffectOfForeignOperations" abstract="false" name="IncomeTaxReconciliationEffectOfForeignOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" abstract="true" name="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ango_ScheduleOfIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleOfIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ango_DeferredIncomeTaxRelatedToOperatingActivity" abstract="false" name="DeferredIncomeTaxRelatedToOperatingActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_TaxPeriodThreeMember" abstract="true" name="TaxPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_ScheduleofIncomeTaxLineItems" abstract="true" name="ScheduleofIncomeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval" abstract="false" name="ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ango_RevolvingFacilityMember" abstract="true" name="RevolvingFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_PrepaidIncomeandOtherTaxes" abstract="false" name="PrepaidIncomeandOtherTaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_CapitalStockSharesAuthorized" abstract="false" name="CapitalStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ango_MedTechMember" abstract="true" name="MedTechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_ManufacturingRelocationMember" abstract="true" name="ManufacturingRelocationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_SharePurchasePeriod" abstract="false" name="SharePurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ango_AcquisitionRestructuringAndOtherItemsNet" abstract="false" name="AcquisitionRestructuringAndOtherItemsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_Royalties" abstract="false" name="Royalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_PerformanceSharesIncludingThreeYearMarketConditionMember" abstract="true" name="PerformanceSharesIncludingThreeYearMarketConditionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_IsraeliInnovationAuthorityPrepaymentMember" abstract="true" name="IsraeliInnovationAuthorityPrepaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired" abstract="false" name="PaymentsToAcquireIntangibleAssetsNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_ResearchAndDevelopmentMember" abstract="true" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_DebtInstrumentDebtDefaultInterestRateIncrease" abstract="false" name="DebtInstrumentDebtDefaultInterestRateIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment" abstract="false" name="DeferredTaxLiabilitiesPurchaseAccountingAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions" abstract="false" name="DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ango_StockAndIncentiveAwardPlan2020Member" abstract="true" name="StockAndIncentiveAwardPlan2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_CommonStockVotesPerShare" abstract="false" name="CommonStockVotesPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio" abstract="false" name="DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ango_TaxPeriodTwoMember" abstract="true" name="TaxPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_LineOfCreditFacilityNumberOfCovenants" abstract="false" name="LineOfCreditFacilityNumberOfCovenants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ango_ProductTechnologiesMember" abstract="true" name="ProductTechnologiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_AccruedResearchAndDevelopmentCurrent" abstract="false" name="AccruedResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_RevenueBasedPaymentMember" abstract="true" name="RevenueBasedPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract" abstract="true" name="FairValueLiabilitiesMeasuredOnRecurringBasisAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ango_CashPaidDuringPeriodAbstract" abstract="true" name="CashPaidDuringPeriodAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ango_MergersandAcquisitionsMember" abstract="true" name="MergersandAcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_PrepaidLicenseeFees" abstract="false" name="PrepaidLicenseeFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_PurchaseObligationToBePaidAfterYearFour" abstract="false" name="PurchaseObligationToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_DebtInstrumentFloorInterestRate" abstract="false" name="DebtInstrumentFloorInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ango_MedDeviceMember" abstract="true" name="MedDeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_TaxPeriodOneMember" abstract="true" name="TaxPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_PrepaidDeposits" abstract="false" name="PrepaidDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_RoyaltiesDueinFourthYear" abstract="false" name="RoyaltiesDueinFourthYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure" abstract="false" name="UndiscountedContingentConsiderationFairValueFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_NumberOfPatentsUpheldOverPriorArtReferences" abstract="false" name="NumberOfPatentsUpheldOverPriorArtReferences" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool" abstract="false" name="IncomeTaxReconciliationEffectofEliminationofASC718APICPool" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_RoyaltiesDueinThirdYear" abstract="false" name="RoyaltiesDueinThirdYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_TheDelawareActionMember" abstract="true" name="TheDelawareActionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_PrepaidExpensesAndOtherTableTextBlock" abstract="false" name="PrepaidExpensesAndOtherTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ango_TransitionServiceAgreementMember" abstract="true" name="TransitionServiceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember" abstract="true" name="TwoThousandAndFourStockAndIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_SalesandMarketingMember" abstract="true" name="SalesandMarketingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_IntangibleImpairmentMember" abstract="true" name="IntangibleImpairmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_StockPurchasePlanMember" abstract="true" name="StockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_OarTracTrademarkMember" abstract="true" name="OarTracTrademarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_TaxPeriodFourMember" abstract="true" name="TaxPeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_PrepaidExpensesAndOtherTextBlock" abstract="false" name="PrepaidExpensesAndOtherTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements" abstract="false" name="PropertyPlantAndEquipmentExcludingLandAndLandImprovements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_DivestitureMember" abstract="true" name="DivestitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_InternationalMember" abstract="true" name="InternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_SoftwareLicenses" abstract="false" name="SoftwareLicenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio" abstract="false" name="DebtInstrumentCovenantTermsMaximumTotalLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ango_RoyaltiesDueinSecondYear" abstract="false" name="RoyaltiesDueinSecondYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_NumberOfSharePurchasePeriod" abstract="false" name="NumberOfSharePurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ango_ContractwithCustomerRightofReturnRestockingCharge" abstract="false" name="ContractwithCustomerRightofReturnRestockingCharge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod" abstract="false" name="CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_RetirementPlansTextualAbstract" abstract="true" name="RetirementPlansTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ango_NumberOfPatentsAssertedForReexamination" abstract="false" name="NumberOfPatentsAssertedForReexamination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ango_RoyaltiesDueInFirstYear" abstract="false" name="RoyaltiesDueInFirstYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn" abstract="false" name="ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember" abstract="true" name="AllowanceForSalesReturnsAndDoubtfulAccountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_LegalCostsMember" abstract="true" name="LegalCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_TradeShows" abstract="false" name="TradeShows" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_RadiaDyneMember" abstract="true" name="RadiaDyneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_PrepaidEmployeeTaxCredit" abstract="false" name="PrepaidEmployeeTaxCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_PerformanceShareAndRestrictedStockUnitAwardsMember" abstract="true" name="PerformanceShareAndRestrictedStockUnitAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ango_IncomeTaxesTextualAbstract" abstract="true" name="IncomeTaxesTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ango_MeasurementInputProbabilityofPaymentMember" abstract="true" name="MeasurementInputProbabilityofPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember" abstract="true" name="QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse" abstract="false" name="OperatingLossCarryforwardsAmountAfterLimitationOfUse" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_SettlementExpenseMember" abstract="true" name="SettlementExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_AccountsReceivableDuePeriod" abstract="false" name="AccountsReceivableDuePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ango_DialysisProductPortfolioAndBioSentryBiopsyMember" abstract="true" name="DialysisProductPortfolioAndBioSentryBiopsyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" abstract="false" name="ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_ShortTermInvestmentsMaturityPeriod" abstract="false" name="ShortTermInvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ango_EximoMedicalLtd.Member" abstract="true" name="EximoMedicalLtd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_RevenuePerformanceObligationPaymentTerm" abstract="false" name="RevenuePerformanceObligationPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ango_OtherNonoperatingIncomeExpenseAndInterestExpense" abstract="false" name="OtherNonoperatingIncomeExpenseAndInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_ChangeInFairValueOfContingentConsideration" abstract="false" name="ChangeInFairValueOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_ScheduleOfNetRevenueByProductGroupTableTextBlock" abstract="false" name="ScheduleOfNetRevenueByProductGroupTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ango_PlacementAndEvaluationUnitsMember" abstract="true" name="PlacementAndEvaluationUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_EmployeePlanParticipatingEligibilityThresholdPercentage" abstract="false" name="EmployeePlanParticipatingEligibilityThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ango_GrossMarginPercentage" abstract="false" name="GrossMarginPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ango_IncreaseInPlacementAndEvaluationUnits" abstract="false" name="IncreaseInPlacementAndEvaluationUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_AssetAcquisitionInventoryAndFixedAssets" abstract="false" name="AssetAcquisitionInventoryAndFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_RoyaltiesDueAfterFourthYear" abstract="false" name="RoyaltiesDueAfterFourthYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_ContractualObligationToBePaidAfterYearFour" abstract="false" name="ContractualObligationToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ango_CrBardIncMember" abstract="true" name="CrBardIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ango_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ango-20230531_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:9980962c-8c03-489b-926a-266c60a03003,g:4284608e-2675-438a-ad4d-4e46a03d6c06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ango-20230531.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a80abea3-9b3f-4ddb-86f5-96c00d21ccc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AcquisitionRestructuringAndOtherItemsNet_49b6eda6-d32b-4bdf-920b-164d03dbb629" xlink:href="ango-20230531.xsd#ango_AcquisitionRestructuringAndOtherItemsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a80abea3-9b3f-4ddb-86f5-96c00d21ccc6" xlink:to="loc_ango_AcquisitionRestructuringAndOtherItemsNet_49b6eda6-d32b-4bdf-920b-164d03dbb629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9055aed9-49cd-4e77-90f1-3eb925e3c8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a80abea3-9b3f-4ddb-86f5-96c00d21ccc6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9055aed9-49cd-4e77-90f1-3eb925e3c8df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_506f2779-5edd-4b74-826b-ed05567afd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a80abea3-9b3f-4ddb-86f5-96c00d21ccc6" xlink:to="loc_us-gaap_SellingAndMarketingExpense_506f2779-5edd-4b74-826b-ed05567afd8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9a99de9f-7159-4974-bc54-f1f3f6aa9ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a80abea3-9b3f-4ddb-86f5-96c00d21ccc6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9a99de9f-7159-4974-bc54-f1f3f6aa9ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_bce15260-ebe1-4218-a7f4-ddc2cdada61a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a80abea3-9b3f-4ddb-86f5-96c00d21ccc6" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_bce15260-ebe1-4218-a7f4-ddc2cdada61a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ChangeInFairValueOfContingentConsideration_930d4f52-47d5-4f9e-a1f1-da3db6286f07" xlink:href="ango-20230531.xsd#ango_ChangeInFairValueOfContingentConsideration"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a80abea3-9b3f-4ddb-86f5-96c00d21ccc6" xlink:to="loc_ango_ChangeInFairValueOfContingentConsideration_930d4f52-47d5-4f9e-a1f1-da3db6286f07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_838fc625-0e30-426b-b114-76671a516f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a80abea3-9b3f-4ddb-86f5-96c00d21ccc6" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_838fc625-0e30-426b-b114-76671a516f54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_OtherNonoperatingIncomeExpenseAndInterestExpense_95229553-674d-4126-aa97-1babc9ade7f0" xlink:href="ango-20230531.xsd#ango_OtherNonoperatingIncomeExpenseAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_00a296c6-b690-4c64-a79c-e17760ef1668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ango_OtherNonoperatingIncomeExpenseAndInterestExpense_95229553-674d-4126-aa97-1babc9ade7f0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_00a296c6-b690-4c64-a79c-e17760ef1668" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a6a3187d-34a7-4232-adb2-bdb3584a3306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ango_OtherNonoperatingIncomeExpenseAndInterestExpense_95229553-674d-4126-aa97-1babc9ade7f0" xlink:to="loc_us-gaap_InterestExpense_a6a3187d-34a7-4232-adb2-bdb3584a3306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3892a10f-28d5-401e-a788-ca221987feca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4173b2f1-1e7e-4fa2-926a-356d3505dcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3892a10f-28d5-401e-a788-ca221987feca" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4173b2f1-1e7e-4fa2-926a-356d3505dcbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_66682632-dacf-4d07-b99b-cf9e162358e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3892a10f-28d5-401e-a788-ca221987feca" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_66682632-dacf-4d07-b99b-cf9e162358e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_fde46ff2-9449-4779-9c7a-bb5e862e008b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c2ea1b13-d1d4-4b7f-a22c-4f33be915ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_fde46ff2-9449-4779-9c7a-bb5e862e008b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c2ea1b13-d1d4-4b7f-a22c-4f33be915ede" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_eb7c8c15-4d5f-4086-a9e0-f7ca5821fe64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_fde46ff2-9449-4779-9c7a-bb5e862e008b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_eb7c8c15-4d5f-4086-a9e0-f7ca5821fe64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_70769b24-94cc-43e9-8166-35406f0173f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_41f769b0-8cea-44ce-9712-e9baa520aaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_70769b24-94cc-43e9-8166-35406f0173f7" xlink:to="loc_us-gaap_OperatingExpenses_41f769b0-8cea-44ce-9712-e9baa520aaf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_a0a4d6d6-2b98-4669-8147-54bee8944ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_70769b24-94cc-43e9-8166-35406f0173f7" xlink:to="loc_us-gaap_GrossProfit_a0a4d6d6-2b98-4669-8147-54bee8944ee5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ango-20230531.xsd#ConsolidatedStatementsComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_f0bd6c93-7333-4455-910e-a9202b3ab57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_eb6abc86-bc5a-4a7a-8376-38f2a03d5896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_f0bd6c93-7333-4455-910e-a9202b3ab57b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_eb6abc86-bc5a-4a7a-8376-38f2a03d5896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3ce5b13d-35ad-454e-be5f-381a73c885a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_afce554c-ba42-4ef9-a673-a0fea2eb6c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3ce5b13d-35ad-454e-be5f-381a73c885a0" xlink:to="loc_us-gaap_NetIncomeLoss_afce554c-ba42-4ef9-a673-a0fea2eb6c34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fbf8bbae-4a0d-4c6c-b5e7-814b38d41843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3ce5b13d-35ad-454e-be5f-381a73c885a0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fbf8bbae-4a0d-4c6c-b5e7-814b38d41843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f0d54c6e-3848-4465-8638-8e463cf1374a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_81430cb7-351a-4b25-8702-456d7a797947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f0d54c6e-3848-4465-8638-8e463cf1374a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_81430cb7-351a-4b25-8702-456d7a797947" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_4267abe7-bbe9-4679-870f-6ed494b08c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f0d54c6e-3848-4465-8638-8e463cf1374a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_4267abe7-bbe9-4679-870f-6ed494b08c0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ango-20230531.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d9345dc6-05de-4992-b68b-ef2303c05e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_688731d2-72cf-49be-8b7d-22c5841d3fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d9345dc6-05de-4992-b68b-ef2303c05e40" xlink:to="loc_us-gaap_LiabilitiesCurrent_688731d2-72cf-49be-8b7d-22c5841d3fa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ff21301a-d3e5-4603-9406-f7dac3f7b690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d9345dc6-05de-4992-b68b-ef2303c05e40" xlink:to="loc_us-gaap_LongTermDebt_ff21301a-d3e5-4603-9406-f7dac3f7b690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_8ccf321d-7232-448a-8818-c9300a896896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d9345dc6-05de-4992-b68b-ef2303c05e40" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_8ccf321d-7232-448a-8818-c9300a896896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_f59bc8fb-e35d-40c3-90dd-b3c0acbe9a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d9345dc6-05de-4992-b68b-ef2303c05e40" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_f59bc8fb-e35d-40c3-90dd-b3c0acbe9a8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ed971479-45fb-423a-b7b6-57dc1f87beef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d9345dc6-05de-4992-b68b-ef2303c05e40" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ed971479-45fb-423a-b7b6-57dc1f87beef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_38ee8e7e-912c-448b-80c6-60be98ec18d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0033a2ab-2ed2-4899-9c4e-116393a23c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38ee8e7e-912c-448b-80c6-60be98ec18d3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0033a2ab-2ed2-4899-9c4e-116393a23c9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1574af94-86e0-484b-a14a-b3acbae114dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38ee8e7e-912c-448b-80c6-60be98ec18d3" xlink:to="loc_us-gaap_InventoryNet_1574af94-86e0-484b-a14a-b3acbae114dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_a6683673-ab74-4e36-b232-e6d7cd0d9a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38ee8e7e-912c-448b-80c6-60be98ec18d3" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_a6683673-ab74-4e36-b232-e6d7cd0d9a7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1723392b-498e-4561-9911-21b86eff80b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38ee8e7e-912c-448b-80c6-60be98ec18d3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1723392b-498e-4561-9911-21b86eff80b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6f06445c-ef64-439a-8daa-05a268b24edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38ee8e7e-912c-448b-80c6-60be98ec18d3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6f06445c-ef64-439a-8daa-05a268b24edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b72aadc8-a01e-4b2f-812e-30e660d2fd88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_07ef5b86-4421-48e5-a2c5-390ddc732c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b72aadc8-a01e-4b2f-812e-30e660d2fd88" xlink:to="loc_us-gaap_Liabilities_07ef5b86-4421-48e5-a2c5-390ddc732c62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c50bb215-5366-4410-a2fb-781e3f2369b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b72aadc8-a01e-4b2f-812e-30e660d2fd88" xlink:to="loc_us-gaap_StockholdersEquity_c50bb215-5366-4410-a2fb-781e3f2369b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_84ae97b9-c1d6-4674-9ec0-d172dc558073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b72aadc8-a01e-4b2f-812e-30e660d2fd88" xlink:to="loc_us-gaap_CommitmentsAndContingencies_84ae97b9-c1d6-4674-9ec0-d172dc558073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff7f4f4b-6c86-4772-9022-57b62a0badba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a2edd0dc-c49e-4dc8-86e6-9ec1a6fb1d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff7f4f4b-6c86-4772-9022-57b62a0badba" xlink:to="loc_us-gaap_PreferredStockValue_a2edd0dc-c49e-4dc8-86e6-9ec1a6fb1d0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5ae331c6-8013-4244-a44e-57477acec7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff7f4f4b-6c86-4772-9022-57b62a0badba" xlink:to="loc_us-gaap_CommonStockValue_5ae331c6-8013-4244-a44e-57477acec7f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_96e938f9-90e0-4ea3-9299-93dc42854fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff7f4f4b-6c86-4772-9022-57b62a0badba" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_96e938f9-90e0-4ea3-9299-93dc42854fd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_11e8b080-73be-4cb1-a2ea-8976c9eeb353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff7f4f4b-6c86-4772-9022-57b62a0badba" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_11e8b080-73be-4cb1-a2ea-8976c9eeb353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_7a4b6f66-60f5-4d20-bac9-c11e3eaca1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff7f4f4b-6c86-4772-9022-57b62a0badba" xlink:to="loc_us-gaap_TreasuryStockValue_7a4b6f66-60f5-4d20-bac9-c11e3eaca1b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_300c87f7-032c-40b8-91e6-96435e5eebf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff7f4f4b-6c86-4772-9022-57b62a0badba" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_300c87f7-032c-40b8-91e6-96435e5eebf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a277293c-8037-4e08-a2b4-914c6ed9cef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6a390837-9d05-49a7-b11c-c20ddc666c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a277293c-8037-4e08-a2b4-914c6ed9cef1" xlink:to="loc_us-gaap_AccountsPayableCurrent_6a390837-9d05-49a7-b11c-c20ddc666c37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_642e79e3-74f1-4f6e-bee4-af0b915f3cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a277293c-8037-4e08-a2b4-914c6ed9cef1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_642e79e3-74f1-4f6e-bee4-af0b915f3cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1f1146df-4b52-4c4e-8549-2272decf311b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a277293c-8037-4e08-a2b4-914c6ed9cef1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1f1146df-4b52-4c4e-8549-2272decf311b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c266516d-3c79-4c57-9deb-eea452a7bae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a277293c-8037-4e08-a2b4-914c6ed9cef1" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c266516d-3c79-4c57-9deb-eea452a7bae8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1c1b2069-cf67-41af-9c5c-a3b970b6bcbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7ff037d4-801f-4702-9d3c-ec9fc6c39a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c1b2069-cf67-41af-9c5c-a3b970b6bcbf" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7ff037d4-801f-4702-9d3c-ec9fc6c39a3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5b976aca-23f0-491f-ae2c-4b4198d12468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c1b2069-cf67-41af-9c5c-a3b970b6bcbf" xlink:to="loc_us-gaap_Goodwill_5b976aca-23f0-491f-ae2c-4b4198d12468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_e8ad39f1-1529-4fc3-a6dc-45c055e903fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c1b2069-cf67-41af-9c5c-a3b970b6bcbf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_e8ad39f1-1529-4fc3-a6dc-45c055e903fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_78cebcb4-a886-414b-94a3-48641dc94536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c1b2069-cf67-41af-9c5c-a3b970b6bcbf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_78cebcb4-a886-414b-94a3-48641dc94536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3878d910-d202-4922-b525-b668bb488060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c1b2069-cf67-41af-9c5c-a3b970b6bcbf" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3878d910-d202-4922-b525-b668bb488060" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c1f31fb6-7313-4e14-adfe-993b43c806b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c1b2069-cf67-41af-9c5c-a3b970b6bcbf" xlink:to="loc_us-gaap_AssetsCurrent_c1f31fb6-7313-4e14-adfe-993b43c806b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ango-20230531.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_NoncashLeaseExpense_729eaa50-65ab-45a8-aec3-0846eb60ebfa" xlink:href="ango-20230531.xsd#ango_NoncashLeaseExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_ango_NoncashLeaseExpense_729eaa50-65ab-45a8-aec3-0846eb60ebfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_780c66d7-3fb4-4f21-b0be-2aa652294134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_us-gaap_NetIncomeLoss_780c66d7-3fb4-4f21-b0be-2aa652294134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_36cd87b9-810e-4c0a-8944-de4f4e8131b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_36cd87b9-810e-4c0a-8944-de4f4e8131b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_1e2da41d-d1a1-4071-8e86-776e7842368c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_1e2da41d-d1a1-4071-8e86-776e7842368c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c39dda9f-37de-4c81-b5aa-f8b2d558620e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c39dda9f-37de-4c81-b5aa-f8b2d558620e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d61fd9fe-5086-4baa-83c9-027799ebf1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_us-gaap_DepreciationAndAmortization_d61fd9fe-5086-4baa-83c9-027799ebf1cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c1769f7b-cd38-46a8-8e74-8dd46373f74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_us-gaap_ShareBasedCompensation_c1769f7b-cd38-46a8-8e74-8dd46373f74e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d4ac0d24-5eaf-4f00-8bd2-d1185ab2fba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d4ac0d24-5eaf-4f00-8bd2-d1185ab2fba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ChangeInFairValueOfContingentConsideration_d485889d-965a-40b0-b3fb-670b79e46cb0" xlink:href="ango-20230531.xsd#ango_ChangeInFairValueOfContingentConsideration"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_ango_ChangeInFairValueOfContingentConsideration_d485889d-965a-40b0-b3fb-670b79e46cb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f936f55e-7861-4a28-b49e-7d04ca3b1b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f936f55e-7861-4a28-b49e-7d04ca3b1b39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_db24cd77-8ed1-4eab-aa28-cc3a6238cddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_db24cd77-8ed1-4eab-aa28-cc3a6238cddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_5b1f0fd3-14e9-4ad1-88d5-0a0297ac2b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_5b1f0fd3-14e9-4ad1-88d5-0a0297ac2b85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0373607-a07b-46f0-a790-81f5e5ab5791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0373607-a07b-46f0-a790-81f5e5ab5791" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DeferredIncomeTaxRelatedToOperatingActivity_d2257213-e99a-426d-a047-659fe2cd3d27" xlink:href="ango-20230531.xsd#ango_DeferredIncomeTaxRelatedToOperatingActivity"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dcd8c2b0-8a67-46ff-80a8-7912338ac014" xlink:to="loc_ango_DeferredIncomeTaxRelatedToOperatingActivity_d2257213-e99a-426d-a047-659fe2cd3d27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b8f310a-ef0a-4a76-a149-dd074b687fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_c5ca27f0-39a6-4377-b910-c23c981c31ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b8f310a-ef0a-4a76-a149-dd074b687fb6" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_c5ca27f0-39a6-4377-b910-c23c981c31ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7401cd1d-1d5e-4c28-85d5-33fe1ee70ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b8f310a-ef0a-4a76-a149-dd074b687fb6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7401cd1d-1d5e-4c28-85d5-33fe1ee70ef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_aaf7f596-102f-43b7-84d9-221d9e9a03d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b8f310a-ef0a-4a76-a149-dd074b687fb6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_aaf7f596-102f-43b7-84d9-221d9e9a03d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_2065b72b-73f6-4c99-8cc1-5d772daa8b4d" xlink:href="ango-20230531.xsd#ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b8f310a-ef0a-4a76-a149-dd074b687fb6" xlink:to="loc_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_2065b72b-73f6-4c99-8cc1-5d772daa8b4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e6a6c9cb-e1ba-4a5b-a67e-ff4d2950ca85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b8f310a-ef0a-4a76-a149-dd074b687fb6" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e6a6c9cb-e1ba-4a5b-a67e-ff4d2950ca85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_420992fb-3c06-4102-96af-c5686a3ec88d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IncreaseInPlacementAndEvaluationUnits_4789392d-875e-4813-9b56-91eaeba71fd6" xlink:href="ango-20230531.xsd#ango_IncreaseInPlacementAndEvaluationUnits"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_420992fb-3c06-4102-96af-c5686a3ec88d" xlink:to="loc_ango_IncreaseInPlacementAndEvaluationUnits_4789392d-875e-4813-9b56-91eaeba71fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b0d9dee9-dce2-4e96-a435-875c3e9ec898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_420992fb-3c06-4102-96af-c5686a3ec88d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b0d9dee9-dce2-4e96-a435-875c3e9ec898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_82dbc582-b627-418e-b1b1-49e7436471d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_420992fb-3c06-4102-96af-c5686a3ec88d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_82dbc582-b627-418e-b1b1-49e7436471d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired_438ce415-170a-4464-b224-af63ddb2bffb" xlink:href="ango-20230531.xsd#ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_420992fb-3c06-4102-96af-c5686a3ec88d" xlink:to="loc_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired_438ce415-170a-4464-b224-af63ddb2bffb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93507d24-93e0-4a8f-9cd4-3281fe23c07b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5da536c3-4f98-48b3-a1df-50fe86210010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93507d24-93e0-4a8f-9cd4-3281fe23c07b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5da536c3-4f98-48b3-a1df-50fe86210010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a767e8f-d4f6-4e89-9fdf-a10eff53a072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93507d24-93e0-4a8f-9cd4-3281fe23c07b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a767e8f-d4f6-4e89-9fdf-a10eff53a072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e0882071-5e16-46f2-a0a8-d88c6fc8086e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93507d24-93e0-4a8f-9cd4-3281fe23c07b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e0882071-5e16-46f2-a0a8-d88c6fc8086e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7105a2e3-d494-4523-a22a-408ef09a669c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93507d24-93e0-4a8f-9cd4-3281fe23c07b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7105a2e3-d494-4523-a22a-408ef09a669c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AssetsHeldForSaleDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AssetsHeldForSaleDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/AssetsHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_dec3227c-4e97-4f9f-afef-0df0c2458e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_b14baea4-ef74-4cc6-91b6-53585688f787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_dec3227c-4e97-4f9f-afef-0df0c2458e42" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_b14baea4-ef74-4cc6-91b6-53585688f787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_22d8aef5-6fe3-4c04-8a3c-6e0b0027ce21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_dec3227c-4e97-4f9f-afef-0df0c2458e42" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_22d8aef5-6fe3-4c04-8a3c-6e0b0027ce21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_db4ba564-b195-444c-9130-7436aba3836a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_dec3227c-4e97-4f9f-afef-0df0c2458e42" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_db4ba564-b195-444c-9130-7436aba3836a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5cfd2b93-6ca0-440b-9187-18c7af161096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_87229598-9794-4298-95cc-b260def08075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5cfd2b93-6ca0-440b-9187-18c7af161096" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_87229598-9794-4298-95cc-b260def08075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_a2288cb7-4b7f-458e-a36f-f96eaba4778b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5cfd2b93-6ca0-440b-9187-18c7af161096" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_a2288cb7-4b7f-458e-a36f-f96eaba4778b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_eb0c2c4b-448e-4d4b-96a1-485fb5f20f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_51cc7b8b-fa2e-4377-8c50-21e194e6ee2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_eb0c2c4b-448e-4d4b-96a1-485fb5f20f88" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_51cc7b8b-fa2e-4377-8c50-21e194e6ee2b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_74a9bdc5-bff9-405f-a64e-ec0ed3a8f7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_3e017ff1-855b-493b-b705-78e9e41e2cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_74a9bdc5-bff9-405f-a64e-ec0ed3a8f7a9" xlink:to="loc_us-gaap_InventoryRawMaterials_3e017ff1-855b-493b-b705-78e9e41e2cba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_954a68f8-cdc5-4d8a-bc5d-d9bdb9c6c771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_74a9bdc5-bff9-405f-a64e-ec0ed3a8f7a9" xlink:to="loc_us-gaap_InventoryWorkInProcess_954a68f8-cdc5-4d8a-bc5d-d9bdb9c6c771" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_65aa1839-584a-418d-a44a-74f932a030df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_74a9bdc5-bff9-405f-a64e-ec0ed3a8f7a9" xlink:to="loc_us-gaap_InventoryFinishedGoods_65aa1839-584a-418d-a44a-74f932a030df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#PrepaidExpensesandOtherDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7142a81-1b6d-46b8-aadf-846f1a59a59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidEmployeeTaxCredit_a245851b-c8cf-4f56-9e5e-1e3796de327d" xlink:href="ango-20230531.xsd#ango_PrepaidEmployeeTaxCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7142a81-1b6d-46b8-aadf-846f1a59a59d" xlink:to="loc_ango_PrepaidEmployeeTaxCredit_a245851b-c8cf-4f56-9e5e-1e3796de327d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent_a8e84baa-4372-4539-8d9f-3746f84f2a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7142a81-1b6d-46b8-aadf-846f1a59a59d" xlink:to="loc_us-gaap_PrepaidRent_a8e84baa-4372-4539-8d9f-3746f84f2a73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TradeShows_f3417639-322f-48a8-bb24-a21557cd9896" xlink:href="ango-20230531.xsd#ango_TradeShows"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7142a81-1b6d-46b8-aadf-846f1a59a59d" xlink:to="loc_ango_TradeShows_f3417639-322f-48a8-bb24-a21557cd9896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidDeposits_d9e65cbc-b65c-4e93-8554-cbf06db4f794" xlink:href="ango-20230531.xsd#ango_PrepaidDeposits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7142a81-1b6d-46b8-aadf-846f1a59a59d" xlink:to="loc_ango_PrepaidDeposits_d9e65cbc-b65c-4e93-8554-cbf06db4f794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidIncomeandOtherTaxes_6f8813d5-9240-4a65-8430-6d6703af53bd" xlink:href="ango-20230531.xsd#ango_PrepaidIncomeandOtherTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7142a81-1b6d-46b8-aadf-846f1a59a59d" xlink:to="loc_ango_PrepaidIncomeandOtherTaxes_6f8813d5-9240-4a65-8430-6d6703af53bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidLicenseeFees_51e5cf35-9695-4507-b95d-fc514ea7cfd5" xlink:href="ango-20230531.xsd#ango_PrepaidLicenseeFees"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7142a81-1b6d-46b8-aadf-846f1a59a59d" xlink:to="loc_ango_PrepaidLicenseeFees_51e5cf35-9695-4507-b95d-fc514ea7cfd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_57480f05-f24a-4067-80ae-bfdb6e62d86d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7142a81-1b6d-46b8-aadf-846f1a59a59d" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_57480f05-f24a-4067-80ae-bfdb6e62d86d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SoftwareLicenses_d831c119-638f-4a72-b433-6e39517c2157" xlink:href="ango-20230531.xsd#ango_SoftwareLicenses"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7142a81-1b6d-46b8-aadf-846f1a59a59d" xlink:to="loc_ango_SoftwareLicenses_d831c119-638f-4a72-b433-6e39517c2157" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#PropertyPlantandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements_41dd09da-ac98-4e76-a4ed-d70670ba696e" xlink:href="ango-20230531.xsd#ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9bc03f9d-4044-4fd8-bf82-01619d192daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements_41dd09da-ac98-4e76-a4ed-d70670ba696e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9bc03f9d-4044-4fd8-bf82-01619d192daf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e9dfe374-825e-4218-b725-1708ba85fd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements_41dd09da-ac98-4e76-a4ed-d70670ba696e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e9dfe374-825e-4218-b725-1708ba85fd9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_314cbbcc-9b63-465e-b317-f65757e090c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovements_fba43fab-30d6-4373-9292-1f475da833b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_314cbbcc-9b63-465e-b317-f65757e090c2" xlink:to="loc_us-gaap_LandAndLandImprovements_fba43fab-30d6-4373-9292-1f475da833b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements_4b81a643-2c2a-4023-b7e3-34cb6fd84857" xlink:href="ango-20230531.xsd#ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_314cbbcc-9b63-465e-b317-f65757e090c2" xlink:to="loc_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements_4b81a643-2c2a-4023-b7e3-34cb6fd84857" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6ad8141d-b239-4870-9bda-c1212299b2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_289c76a5-36dc-4f0b-a953-038fd9711e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6ad8141d-b239-4870-9bda-c1212299b2c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_289c76a5-36dc-4f0b-a953-038fd9711e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9b5abc4d-7bbf-48df-ad82-3f6ff4545aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6ad8141d-b239-4870-9bda-c1212299b2c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9b5abc4d-7bbf-48df-ad82-3f6ff4545aed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5210d2b1-ad5e-4ac7-abee-e4058a382119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_73e63375-d4bb-4e89-85ff-29baa393f452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5210d2b1-ad5e-4ac7-abee-e4058a382119" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_73e63375-d4bb-4e89-85ff-29baa393f452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_76b43bd8-3022-4664-933a-7f0f0add06f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5210d2b1-ad5e-4ac7-abee-e4058a382119" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_76b43bd8-3022-4664-933a-7f0f0add06f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dce4d8dd-91e6-40cd-9ffc-d8c79515729e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5210d2b1-ad5e-4ac7-abee-e4058a382119" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dce4d8dd-91e6-40cd-9ffc-d8c79515729e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d16d2377-55b6-4eaa-90ca-09f5129d7bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5210d2b1-ad5e-4ac7-abee-e4058a382119" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d16d2377-55b6-4eaa-90ca-09f5129d7bdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2ddf79e3-f142-40af-9a53-b57524e30917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5210d2b1-ad5e-4ac7-abee-e4058a382119" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2ddf79e3-f142-40af-9a53-b57524e30917" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_71ca8f28-50a6-459e-81eb-a2bb5aab1977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5210d2b1-ad5e-4ac7-abee-e4058a382119" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_71ca8f28-50a6-459e-81eb-a2bb5aab1977" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#IncomeTaxesComponentsofLossDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_307295f7-d9b9-4ad9-9940-a4bd7891dbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4f78e3b5-31e4-4ad6-9715-2848c692c89e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_307295f7-d9b9-4ad9-9940-a4bd7891dbae" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4f78e3b5-31e4-4ad6-9715-2848c692c89e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_bd1fcca6-ce7e-4978-b31c-f92ddef006ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_307295f7-d9b9-4ad9-9940-a4bd7891dbae" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_bd1fcca6-ce7e-4978-b31c-f92ddef006ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#IncomeTaxesIncomeTaxBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c43ce035-d35c-4723-bbd3-dacab1fbeea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6adfb54a-1dda-436b-968d-9f94e307f4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c43ce035-d35c-4723-bbd3-dacab1fbeea2" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6adfb54a-1dda-436b-968d-9f94e307f4d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a5c475d9-85e4-4107-bcb3-1441a4a35c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c43ce035-d35c-4723-bbd3-dacab1fbeea2" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a5c475d9-85e4-4107-bcb3-1441a4a35c61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4d2b71b8-f2b1-4527-8240-9fa4bb62404f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_55d56b60-0293-4688-aa66-b8f596de8b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4d2b71b8-f2b1-4527-8240-9fa4bb62404f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_55d56b60-0293-4688-aa66-b8f596de8b79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8d16c0c2-5a0d-4276-8ad2-c4105541a3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4d2b71b8-f2b1-4527-8240-9fa4bb62404f" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8d16c0c2-5a0d-4276-8ad2-c4105541a3f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_56210258-2b94-4e9f-9286-de148dc2b4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_642e9f79-5a9c-4659-b7df-41649a3a8636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_56210258-2b94-4e9f-9286-de148dc2b4b1" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_642e9f79-5a9c-4659-b7df-41649a3a8636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_23d69174-9afa-42fa-a7d7-21fbaf60c814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_56210258-2b94-4e9f-9286-de148dc2b4b1" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_23d69174-9afa-42fa-a7d7-21fbaf60c814" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_93ab8ed5-90c4-4083-9073-61525d6f6cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c2bbf7dc-2b3a-411a-a775-ed09ca524e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_93ab8ed5-90c4-4083-9073-61525d6f6cfe" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c2bbf7dc-2b3a-411a-a775-ed09ca524e73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f25696f9-a329-40ec-88d5-5de34e4254d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5a799c68-06dc-4965-8def-a74a0adf46e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f25696f9-a329-40ec-88d5-5de34e4254d9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5a799c68-06dc-4965-8def-a74a0adf46e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0055e411-6d08-4b16-a22c-67390a6fb717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f25696f9-a329-40ec-88d5-5de34e4254d9" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0055e411-6d08-4b16-a22c-67390a6fb717" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_fd16fb47-7574-4720-8846-20d5ae3e35ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f25696f9-a329-40ec-88d5-5de34e4254d9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_fd16fb47-7574-4720-8846-20d5ae3e35ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_408f1fff-81f3-45a2-9d27-5bdd4c1027f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e58604f2-d113-4d33-ab7f-a919e41e60ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_408f1fff-81f3-45a2-9d27-5bdd4c1027f6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e58604f2-d113-4d33-ab7f-a919e41e60ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_843910c4-2b18-4ccb-bdad-1a8f5fefbcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_408f1fff-81f3-45a2-9d27-5bdd4c1027f6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_843910c4-2b18-4ccb-bdad-1a8f5fefbcb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_16c951bf-a30d-4f3a-90e5-8575dbd63c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_408f1fff-81f3-45a2-9d27-5bdd4c1027f6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_16c951bf-a30d-4f3a-90e5-8575dbd63c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_c62f0ea4-130b-473b-b5dc-8214301e418f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_408f1fff-81f3-45a2-9d27-5bdd4c1027f6" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_c62f0ea4-130b-473b-b5dc-8214301e418f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_b6347a87-a9d5-4e0b-b7da-02624f4a793c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_408f1fff-81f3-45a2-9d27-5bdd4c1027f6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_b6347a87-a9d5-4e0b-b7da-02624f4a793c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_ca723dc2-ece2-45b8-a57a-d84d9986b40d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_408f1fff-81f3-45a2-9d27-5bdd4c1027f6" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_ca723dc2-ece2-45b8-a57a-d84d9986b40d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#IncomeTaxesIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_588d1df7-33a6-4aee-a2b7-4699ae6ebc31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IncomeTaxReconciliationEffectOfForeignOperations_ed4495ea-cb77-4723-bca5-03ee687347a9" xlink:href="ango-20230531.xsd#ango_IncomeTaxReconciliationEffectOfForeignOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_588d1df7-33a6-4aee-a2b7-4699ae6ebc31" xlink:to="loc_ango_IncomeTaxReconciliationEffectOfForeignOperations_ed4495ea-cb77-4723-bca5-03ee687347a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_841b399d-5a53-48f1-a743-dd27775a7fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_588d1df7-33a6-4aee-a2b7-4699ae6ebc31" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_841b399d-5a53-48f1-a743-dd27775a7fae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_598aac38-5880-41ed-a1f9-b28a401f8dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_588d1df7-33a6-4aee-a2b7-4699ae6ebc31" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_598aac38-5880-41ed-a1f9-b28a401f8dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_f6cc2db7-b70d-471a-bfea-ea0683e797e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_588d1df7-33a6-4aee-a2b7-4699ae6ebc31" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_f6cc2db7-b70d-471a-bfea-ea0683e797e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool_a76ace28-0394-4a23-97d2-b3814af83412" xlink:href="ango-20230531.xsd#ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_588d1df7-33a6-4aee-a2b7-4699ae6ebc31" xlink:to="loc_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool_a76ace28-0394-4a23-97d2-b3814af83412" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6638b217-ca00-4483-b8bc-1de83b6b35d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_588d1df7-33a6-4aee-a2b7-4699ae6ebc31" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6638b217-ca00-4483-b8bc-1de83b6b35d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_01f017f8-bfcd-4087-80a1-8680e5482d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_588d1df7-33a6-4aee-a2b7-4699ae6ebc31" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_01f017f8-bfcd-4087-80a1-8680e5482d4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_c0e55210-19ba-4279-9e1e-9fb4021a4022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_588d1df7-33a6-4aee-a2b7-4699ae6ebc31" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_c0e55210-19ba-4279-9e1e-9fb4021a4022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_f8933048-f116-452c-b4ec-b2f444de03ce" xlink:href="ango-20230531.xsd#ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_588d1df7-33a6-4aee-a2b7-4699ae6ebc31" xlink:to="loc_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_f8933048-f116-452c-b4ec-b2f444de03ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_f71bc843-feb8-4a83-85e0-8abebb5b318a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_588d1df7-33a6-4aee-a2b7-4699ae6ebc31" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_f71bc843-feb8-4a83-85e0-8abebb5b318a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3afd4334-49f7-45c6-8d6f-947049729375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e5dec9e3-c463-4782-b6dd-98a28b4159f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3afd4334-49f7-45c6-8d6f-947049729375" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e5dec9e3-c463-4782-b6dd-98a28b4159f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_f6d6655a-ae26-45dc-849a-060b9982250a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3afd4334-49f7-45c6-8d6f-947049729375" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_f6d6655a-ae26-45dc-849a-060b9982250a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_7aec0cc3-adf8-4728-a359-4d05cf87d8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3afd4334-49f7-45c6-8d6f-947049729375" xlink:to="loc_us-gaap_RestructuringReserveCurrent_7aec0cc3-adf8-4728-a359-4d05cf87d8a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_53890567-7671-437a-bbf8-c55564cba54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3afd4334-49f7-45c6-8d6f-947049729375" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_53890567-7671-437a-bbf8-c55564cba54f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_06c8cc36-24bf-4c4b-a55f-b50f855c2708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3afd4334-49f7-45c6-8d6f-947049729375" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_06c8cc36-24bf-4c4b-a55f-b50f855c2708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_92ba6170-b3a7-4c3e-ad28-eadabfa614a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3afd4334-49f7-45c6-8d6f-947049729375" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_92ba6170-b3a7-4c3e-ad28-eadabfa614a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AccruedResearchAndDevelopmentCurrent_d0acc90e-ab54-478a-a7e4-0b9a5341a96a" xlink:href="ango-20230531.xsd#ango_AccruedResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3afd4334-49f7-45c6-8d6f-947049729375" xlink:to="loc_ango_AccruedResearchAndDevelopmentCurrent_d0acc90e-ab54-478a-a7e4-0b9a5341a96a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_926f5a97-fcf9-45da-8326-d08c8a15ffad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3afd4334-49f7-45c6-8d6f-947049729375" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_926f5a97-fcf9-45da-8326-d08c8a15ffad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#LongTermDebtLongTermDebtScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fd5007c3-ac18-4b53-a95c-cde90e5ab909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5b134a11-34ba-44c2-8285-c1c993a063ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_fd5007c3-ac18-4b53-a95c-cde90e5ab909" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5b134a11-34ba-44c2-8285-c1c993a063ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0ac8bf52-abd9-4d9d-b2cb-de3b02e8ad21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_fd5007c3-ac18-4b53-a95c-cde90e5ab909" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0ac8bf52-abd9-4d9d-b2cb-de3b02e8ad21" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_36a32a7e-bb9c-40c6-b267-43eb3c374fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b0629d0c-3bf0-46e1-821c-72e965aaabbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_36a32a7e-bb9c-40c6-b267-43eb3c374fc9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b0629d0c-3bf0-46e1-821c-72e965aaabbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7808b316-1463-4486-a6f6-08a47dedd021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_36a32a7e-bb9c-40c6-b267-43eb3c374fc9" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7808b316-1463-4486-a6f6-08a47dedd021" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3e018aa3-b5e9-449b-b248-11e680f003d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7dd213fa-9af2-4625-9821-184e653d094b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_3e018aa3-b5e9-449b-b248-11e680f003d8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7dd213fa-9af2-4625-9821-184e653d094b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_44c03170-0505-4eb0-b981-72025483c237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_3e018aa3-b5e9-449b-b248-11e680f003d8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_44c03170-0505-4eb0-b981-72025483c237" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#LeasesLiabilityMaturityScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_554feabf-fb17-4a1d-b43d-318ebeefd9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4f6744b1-1eb1-4589-8d8a-14add52e346c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_554feabf-fb17-4a1d-b43d-318ebeefd9ba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4f6744b1-1eb1-4589-8d8a-14add52e346c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6b70e917-b056-42f7-aed1-97431a17c865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_554feabf-fb17-4a1d-b43d-318ebeefd9ba" xlink:to="loc_us-gaap_OperatingLeaseLiability_6b70e917-b056-42f7-aed1-97431a17c865" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1" xlink:type="simple" xlink:href="ango-20230531.xsd#LeasesLiabilityMaturityScheduleDetails_1"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da0b7d0d-d259-4993-8f05-ae0111ac0ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_49a8c49a-5d95-4026-bbb6-76463493cff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da0b7d0d-d259-4993-8f05-ae0111ac0ef0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_49a8c49a-5d95-4026-bbb6-76463493cff7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_716a34e6-0a68-4e24-a262-5dcbe87abfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da0b7d0d-d259-4993-8f05-ae0111ac0ef0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_716a34e6-0a68-4e24-a262-5dcbe87abfd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_398b1cd8-06c4-4c48-b7ed-8bd2eedea319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da0b7d0d-d259-4993-8f05-ae0111ac0ef0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_398b1cd8-06c4-4c48-b7ed-8bd2eedea319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_de0d3132-bc5a-443c-bae4-bc3059862f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da0b7d0d-d259-4993-8f05-ae0111ac0ef0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_de0d3132-bc5a-443c-bae4-bc3059862f92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_71f57a6e-b9aa-42b6-8b8f-9b0d8fd1afe5" xlink:href="ango-20230531.xsd#ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da0b7d0d-d259-4993-8f05-ae0111ac0ef0" xlink:to="loc_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_71f57a6e-b9aa-42b6-8b8f-9b0d8fd1afe5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#CommitmentsandContingenciesScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_546caadb-e716-442f-9e08-1768287305bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueinFourthYear_b746c0a7-bff9-46ee-8c90-7047b3838376" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueinFourthYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInFourthYear_546caadb-e716-442f-9e08-1768287305bf" xlink:to="loc_ango_RoyaltiesDueinFourthYear_b746c0a7-bff9-46ee-8c90-7047b3838376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_c5c48194-8a3a-49af-bc60-60dc8a50ab15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInFourthYear_546caadb-e716-442f-9e08-1768287305bf" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_c5c48194-8a3a-49af-bc60-60dc8a50ab15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_cebe62c7-4488-494d-91cc-df19d47cbb48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_Royalties_fb198de3-78d2-400d-8b09-d0868ea10b44" xlink:href="ango-20230531.xsd#ango_Royalties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_cebe62c7-4488-494d-91cc-df19d47cbb48" xlink:to="loc_ango_Royalties_fb198de3-78d2-400d-8b09-d0868ea10b44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_7fbb3ee5-e38f-4e3b-a89c-be1b88b058ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_cebe62c7-4488-494d-91cc-df19d47cbb48" xlink:to="loc_us-gaap_PurchaseObligation_7fbb3ee5-e38f-4e3b-a89c-be1b88b058ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_6913f7db-d7e2-4ac5-bd23-3392ac6c99e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueinThirdYear_326ecf36-d8f2-4f2b-a9c9-bfcdcbcf7949" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueinThirdYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear_6913f7db-d7e2-4ac5-bd23-3392ac6c99e6" xlink:to="loc_ango_RoyaltiesDueinThirdYear_326ecf36-d8f2-4f2b-a9c9-bfcdcbcf7949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_da2dc311-2b6b-4e4c-ae5a-099605982e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear_6913f7db-d7e2-4ac5-bd23-3392ac6c99e6" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_da2dc311-2b6b-4e4c-ae5a-099605982e08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_Royalties_d0b71fc7-e1a2-4d04-812b-32bc0092104f" xlink:href="ango-20230531.xsd#ango_Royalties"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueInFirstYear_872ab63f-65a4-40e4-8d5f-ed8fc26a0218" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueInFirstYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ango_Royalties_d0b71fc7-e1a2-4d04-812b-32bc0092104f" xlink:to="loc_ango_RoyaltiesDueInFirstYear_872ab63f-65a4-40e4-8d5f-ed8fc26a0218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueinSecondYear_dea75e3d-b0a1-40c8-bb2f-14204e5b869f" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueinSecondYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ango_Royalties_d0b71fc7-e1a2-4d04-812b-32bc0092104f" xlink:to="loc_ango_RoyaltiesDueinSecondYear_dea75e3d-b0a1-40c8-bb2f-14204e5b869f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueAfterFourthYear_56d70972-8591-4c93-aa71-647bc264e900" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueAfterFourthYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ango_Royalties_d0b71fc7-e1a2-4d04-812b-32bc0092104f" xlink:to="loc_ango_RoyaltiesDueAfterFourthYear_56d70972-8591-4c93-aa71-647bc264e900" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueinThirdYear_774c1964-29bd-4a7f-bc15-fa7d2dc87c4f" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueinThirdYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ango_Royalties_d0b71fc7-e1a2-4d04-812b-32bc0092104f" xlink:to="loc_ango_RoyaltiesDueinThirdYear_774c1964-29bd-4a7f-bc15-fa7d2dc87c4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueinFourthYear_a147ae8b-8354-477b-a92b-090f59aa12e9" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueinFourthYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ango_Royalties_d0b71fc7-e1a2-4d04-812b-32bc0092104f" xlink:to="loc_ango_RoyaltiesDueinFourthYear_a147ae8b-8354-477b-a92b-090f59aa12e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_d8184aa0-d750-4cfe-bf32-c5101b40419e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueinSecondYear_5d2c98ee-b30b-4ffe-a274-b9d6ac147991" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueinSecondYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear_d8184aa0-d750-4cfe-bf32-c5101b40419e" xlink:to="loc_ango_RoyaltiesDueinSecondYear_5d2c98ee-b30b-4ffe-a274-b9d6ac147991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_92ea80a4-2644-4fee-8ba7-e7c5753dc9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear_d8184aa0-d750-4cfe-bf32-c5101b40419e" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_92ea80a4-2644-4fee-8ba7-e7c5753dc9c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ContractualObligationToBePaidAfterYearFour_89cba944-0101-4896-beaa-6e322d6a85dd" xlink:href="ango-20230531.xsd#ango_ContractualObligationToBePaidAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PurchaseObligationToBePaidAfterYearFour_b4e9761b-f6f4-4fed-a197-7d88d02c32bb" xlink:href="ango-20230531.xsd#ango_PurchaseObligationToBePaidAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ango_ContractualObligationToBePaidAfterYearFour_89cba944-0101-4896-beaa-6e322d6a85dd" xlink:to="loc_ango_PurchaseObligationToBePaidAfterYearFour_b4e9761b-f6f4-4fed-a197-7d88d02c32bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueAfterFourthYear_dece1e0a-c96a-41c2-acf1-e2ba0d914d1c" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueAfterFourthYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ango_ContractualObligationToBePaidAfterYearFour_89cba944-0101-4896-beaa-6e322d6a85dd" xlink:to="loc_ango_RoyaltiesDueAfterFourthYear_dece1e0a-c96a-41c2-acf1-e2ba0d914d1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_91c5ff3a-ef53-47c2-8ac2-f3a030c941bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PurchaseObligationToBePaidAfterYearFour_53d4434d-5ec5-4af3-957c-061ed59b0cd4" xlink:href="ango-20230531.xsd#ango_PurchaseObligationToBePaidAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_91c5ff3a-ef53-47c2-8ac2-f3a030c941bb" xlink:to="loc_ango_PurchaseObligationToBePaidAfterYearFour_53d4434d-5ec5-4af3-957c-061ed59b0cd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_11cdc711-d0fe-419e-b7fb-7da2e2193c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_91c5ff3a-ef53-47c2-8ac2-f3a030c941bb" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_11cdc711-d0fe-419e-b7fb-7da2e2193c86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_e299b3de-a29b-465a-aef2-a6a3fc106b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_91c5ff3a-ef53-47c2-8ac2-f3a030c941bb" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_e299b3de-a29b-465a-aef2-a6a3fc106b45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_965d8483-4b03-4b34-949d-b4f530762afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_91c5ff3a-ef53-47c2-8ac2-f3a030c941bb" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_965d8483-4b03-4b34-949d-b4f530762afb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_d888e522-adea-432c-a7ba-24df015aee26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_91c5ff3a-ef53-47c2-8ac2-f3a030c941bb" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_d888e522-adea-432c-a7ba-24df015aee26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_1feea92c-3c00-4215-b753-4a7339d66256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_7333a482-7ffd-418f-8f1e-7caab93e660e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_1feea92c-3c00-4215-b753-4a7339d66256" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_7333a482-7ffd-418f-8f1e-7caab93e660e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueInFirstYear_1b49bf6b-6da0-4536-b0b5-15a461679411" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueInFirstYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_1feea92c-3c00-4215-b753-4a7339d66256" xlink:to="loc_ango_RoyaltiesDueInFirstYear_1b49bf6b-6da0-4536-b0b5-15a461679411" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails_1" xlink:type="simple" xlink:href="ango-20230531.xsd#CommitmentsandContingenciesScheduleDetails_1"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_abd3a522-8416-4592-ae14-802d0d67ed5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_bf86f2a7-e576-469b-803c-6bf1ae325cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_abd3a522-8416-4592-ae14-802d0d67ed5d" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_bf86f2a7-e576-469b-803c-6bf1ae325cc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_dff9c0f5-d75f-428d-b2cd-28cdbd380b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_abd3a522-8416-4592-ae14-802d0d67ed5d" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_dff9c0f5-d75f-428d-b2cd-28cdbd380b5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_3033efc6-98f8-47cd-bb77-84d8df25b3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_abd3a522-8416-4592-ae14-802d0d67ed5d" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_3033efc6-98f8-47cd-bb77-84d8df25b3c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ContractualObligationToBePaidAfterYearFour_0b504c68-7b15-4984-b4bd-0b85ae3fd47b" xlink:href="ango-20230531.xsd#ango_ContractualObligationToBePaidAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_abd3a522-8416-4592-ae14-802d0d67ed5d" xlink:to="loc_ango_ContractualObligationToBePaidAfterYearFour_0b504c68-7b15-4984-b4bd-0b85ae3fd47b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_df12ae33-c56f-4f08-84e3-50b3904e2aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_abd3a522-8416-4592-ae14-802d0d67ed5d" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_df12ae33-c56f-4f08-84e3-50b3904e2aa7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_cf396678-41d7-481f-a225-bd93b1eb2607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_6d3448b4-1849-4396-bb4f-56b94e2730c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_cf396678-41d7-481f-a225-bd93b1eb2607" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_6d3448b4-1849-4396-bb4f-56b94e2730c9" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ango-20230531_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:9980962c-8c03-489b-926a-266c60a03003,g:4284608e-2675-438a-ad4d-4e46a03d6c06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ango-20230531.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ib430224770794f318760ef9765dbde20_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_228964e1-9245-4274-aff3-00802ed28309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_228964e1-9245-4274-aff3-00802ed28309" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8ec96d04-0c8c-47a4-8ff3-6fabd11deff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8ec96d04-0c8c-47a4-8ff3-6fabd11deff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9a16956f-f3b6-4fb4-9fb1-13c2da17eb62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockholdersEquity_9a16956f-f3b6-4fb4-9fb1-13c2da17eb62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_bdbae424-14d7-4d97-a3e3-61f21c035052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_TreasuryStockCommonShares_bdbae424-14d7-4d97-a3e3-61f21c035052" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e559d25f-d97c-4e77-888b-5e9978d3c267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_NetIncomeLoss_e559d25f-d97c-4e77-888b-5e9978d3c267" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3984fab5-2ddf-4c23-949b-f315e3c8ec41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3984fab5-2ddf-4c23-949b-f315e3c8ec41" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1f70e55c-46d9-4c40-ba79-c38b010a2a90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1f70e55c-46d9-4c40-ba79-c38b010a2a90" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_e8abe218-b902-4073-8c6e-66919eb3086d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_e8abe218-b902-4073-8c6e-66919eb3086d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_993edc90-75e8-4f75-b8e7-c48c52afc3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_993edc90-75e8-4f75-b8e7-c48c52afc3f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f021b7a0-fdbe-47e8-a601-44524b45ebc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f021b7a0-fdbe-47e8-a601-44524b45ebc3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ef98cd39-ff08-44c0-8a4e-a2724b12cfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ef98cd39-ff08-44c0-8a4e-a2724b12cfdf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d6039f49-9e69-4010-9432-c423d4bc5f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d6039f49-9e69-4010-9432-c423d4bc5f49" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ccca056f-2c2f-4449-9893-962050c13836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ccca056f-2c2f-4449-9893-962050c13836" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ec628f1-1871-4c86-9ed5-9a66a8ab541c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8c795dfa-027c-40b9-8f35-b4e8a0c8f2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b25218d2-778a-4675-89bd-5f841a271159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_25968907-cbeb-42b2-a26b-38021fcf0686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_228964e1-9245-4274-aff3-00802ed28309" xlink:to="loc_us-gaap_StatementTable_25968907-cbeb-42b2-a26b-38021fcf0686" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2e665b7b-2389-4abd-ad4d-aa44af5328d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_25968907-cbeb-42b2-a26b-38021fcf0686" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2e665b7b-2389-4abd-ad4d-aa44af5328d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e665b7b-2389-4abd-ad4d-aa44af5328d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e665b7b-2389-4abd-ad4d-aa44af5328d2" xlink:to="loc_us-gaap_EquityComponentDomain_2e665b7b-2389-4abd-ad4d-aa44af5328d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e665b7b-2389-4abd-ad4d-aa44af5328d2" xlink:to="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b8eb7353-ff5b-4107-bff4-6852c0233e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:to="loc_us-gaap_CommonStockMember_b8eb7353-ff5b-4107-bff4-6852c0233e74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d09919c9-189f-478f-8944-73328a057482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d09919c9-189f-478f-8944-73328a057482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_12cd3cf4-f233-44b2-9e79-063a2c9c6d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:to="loc_us-gaap_RetainedEarningsMember_12cd3cf4-f233-44b2-9e79-063a2c9c6d23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a1dd705b-75a3-44c1-b881-0870b7f35b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a1dd705b-75a3-44c1-b881-0870b7f35b51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_d5c993fb-20cf-4b26-8220-7be84e17d021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:to="loc_us-gaap_TreasuryStockCommonMember_d5c993fb-20cf-4b26-8220-7be84e17d021" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_98cd963b-a047-44b0-b608-fd44bf6d22b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_25968907-cbeb-42b2-a26b-38021fcf0686" xlink:to="loc_us-gaap_AwardTypeAxis_98cd963b-a047-44b0-b608-fd44bf6d22b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98cd963b-a047-44b0-b608-fd44bf6d22b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_98cd963b-a047-44b0-b608-fd44bf6d22b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98cd963b-a047-44b0-b608-fd44bf6d22b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_368b3b49-e4d5-4f44-8ded-6a735108e41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_98cd963b-a047-44b0-b608-fd44bf6d22b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_368b3b49-e4d5-4f44-8ded-6a735108e41b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f42998d9-b0a4-4438-82e4-ebf688b7d1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_368b3b49-e4d5-4f44-8ded-6a735108e41b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f42998d9-b0a4-4438-82e4-ebf688b7d1f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_19090691-08e0-4050-8b28-36a2107f8277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_368b3b49-e4d5-4f44-8ded-6a735108e41b" xlink:to="loc_us-gaap_PerformanceSharesMember_19090691-08e0-4050-8b28-36a2107f8277" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" xlink:href="ango-20230531.xsd#BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual" xlink:type="extended" id="i108f2b0db4004062bf8b2274540452d6_BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ShortTermInvestmentsMaturityPeriod_cc3b6c96-06a2-4c5c-bd4e-e67a95bb107e" xlink:href="ango-20230531.xsd#ango_ShortTermInvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_ango_ShortTermInvestmentsMaturityPeriod_cc3b6c96-06a2-4c5c-bd4e-e67a95bb107e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AccountsReceivableDuePeriod_f57a5c7d-6c38-4c84-a929-ed2b66ae61e5" xlink:href="ango-20230531.xsd#ango_AccountsReceivableDuePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_ango_AccountsReceivableDuePeriod_f57a5c7d-6c38-4c84-a929-ed2b66ae61e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_635728eb-db29-4f86-b733-de61e2d9ce1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_635728eb-db29-4f86-b733-de61e2d9ce1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_832fddb1-6d86-4d8b-bb1b-3800fa163119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_832fddb1-6d86-4d8b-bb1b-3800fa163119" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_82eb0c15-b56d-4ab1-bd95-f472332268bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_82eb0c15-b56d-4ab1-bd95-f472332268bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_bfced91c-4516-4fd8-a723-ead33fec38a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_us-gaap_NumberOfReportingUnits_bfced91c-4516-4fd8-a723-ead33fec38a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_89f101d8-a83c-433f-8b3d-033013337a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_us-gaap_NumberOfOperatingSegments_89f101d8-a83c-433f-8b3d-033013337a94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69d335d7-7b80-445d-96af-56a2e8719b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69d335d7-7b80-445d-96af-56a2e8719b53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa9f4f9-3cdf-4ef1-a246-f52d536ac281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69d335d7-7b80-445d-96af-56a2e8719b53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa9f4f9-3cdf-4ef1-a246-f52d536ac281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2aa9f4f9-3cdf-4ef1-a246-f52d536ac281_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa9f4f9-3cdf-4ef1-a246-f52d536ac281" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2aa9f4f9-3cdf-4ef1-a246-f52d536ac281_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66d72f52-c7c0-4da6-b708-da0438570c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa9f4f9-3cdf-4ef1-a246-f52d536ac281" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66d72f52-c7c0-4da6-b708-da0438570c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_fc242fd8-0fa5-41c9-80d4-8998440a534c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66d72f52-c7c0-4da6-b708-da0438570c88" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_fc242fd8-0fa5-41c9-80d4-8998440a534c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3dec3fb0-4e62-4f88-8bc0-595de38b3445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66d72f52-c7c0-4da6-b708-da0438570c88" xlink:to="loc_us-gaap_ComputerEquipmentMember_3dec3fb0-4e62-4f88-8bc0-595de38b3445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_9a8cd825-497f-4ed1-9c8a-8c2d45afe452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66d72f52-c7c0-4da6-b708-da0438570c88" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_9a8cd825-497f-4ed1-9c8a-8c2d45afe452" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PlacementAndEvaluationUnitsMember_8732bb05-aa8b-4f28-9438-012fd3d1fa3e" xlink:href="ango-20230531.xsd#ango_PlacementAndEvaluationUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66d72f52-c7c0-4da6-b708-da0438570c88" xlink:to="loc_ango_PlacementAndEvaluationUnitsMember_8732bb05-aa8b-4f28-9438-012fd3d1fa3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_82eba331-6fcb-42b8-92d0-b29c868f5d56" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69d335d7-7b80-445d-96af-56a2e8719b53" xlink:to="loc_srt_RangeAxis_82eba331-6fcb-42b8-92d0-b29c868f5d56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82eba331-6fcb-42b8-92d0-b29c868f5d56_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_82eba331-6fcb-42b8-92d0-b29c868f5d56" xlink:to="loc_srt_RangeMember_82eba331-6fcb-42b8-92d0-b29c868f5d56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d10f7d3-7b7c-4982-8f79-66c17f6c3d4d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_82eba331-6fcb-42b8-92d0-b29c868f5d56" xlink:to="loc_srt_RangeMember_6d10f7d3-7b7c-4982-8f79-66c17f6c3d4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3f5ee6c4-0c51-4875-a99e-90c4deaab8ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d10f7d3-7b7c-4982-8f79-66c17f6c3d4d" xlink:to="loc_srt_MinimumMember_3f5ee6c4-0c51-4875-a99e-90c4deaab8ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_06c036a2-3279-483b-9a71-f73ee0948160" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d10f7d3-7b7c-4982-8f79-66c17f6c3d4d" xlink:to="loc_srt_MaximumMember_06c036a2-3279-483b-9a71-f73ee0948160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_745a17c0-39a3-4f96-be0f-68b6eda54ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69d335d7-7b80-445d-96af-56a2e8719b53" xlink:to="loc_us-gaap_AwardTypeAxis_745a17c0-39a3-4f96-be0f-68b6eda54ba1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_745a17c0-39a3-4f96-be0f-68b6eda54ba1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_745a17c0-39a3-4f96-be0f-68b6eda54ba1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_745a17c0-39a3-4f96-be0f-68b6eda54ba1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bff58d6b-a2c7-49a3-95a7-28da6e0530bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_745a17c0-39a3-4f96-be0f-68b6eda54ba1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bff58d6b-a2c7-49a3-95a7-28da6e0530bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fa4ce534-b71e-48b7-9468-010c5be6d03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bff58d6b-a2c7-49a3-95a7-28da6e0530bf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fa4ce534-b71e-48b7-9468-010c5be6d03a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0e573514-16c5-404f-9cd7-ae382c4479a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bff58d6b-a2c7-49a3-95a7-28da6e0530bf" xlink:to="loc_us-gaap_RestrictedStockMember_0e573514-16c5-404f-9cd7-ae382c4479a5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="i0e26034a2c9549f8a7b99e3343d458d8_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_e9414af0-017c-48e4-9e0a-ba19002ebf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_e9414af0-017c-48e4-9e0a-ba19002ebf15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b577f671-dbe3-4317-a0d6-74884d5bfd66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b577f671-dbe3-4317-a0d6-74884d5bfd66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e2f169f1-f094-4d36-9228-4117e50e79ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e2f169f1-f094-4d36-9228-4117e50e79ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount_cc7d4080-ea50-4b51-8909-0f1ddaa9e51d" xlink:href="ango-20230531.xsd#ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount_cc7d4080-ea50-4b51-8909-0f1ddaa9e51d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AssetAcquisitionInventoryAndFixedAssets_f5496156-0bd1-4118-a29e-ea2fe07e9471" xlink:href="ango-20230531.xsd#ango_AssetAcquisitionInventoryAndFixedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_ango_AssetAcquisitionInventoryAndFixedAssets_f5496156-0bd1-4118-a29e-ea2fe07e9471" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_d9ae6769-0fcb-45c5-8c64-6996d49d271d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_d9ae6769-0fcb-45c5-8c64-6996d49d271d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_4ea40c1e-d70f-45ec-b6a6-9c245fb0fa20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_4ea40c1e-d70f-45ec-b6a6-9c245fb0fa20" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dfa0feb6-1a7a-4110-b690-dd2b69cfb98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dfa0feb6-1a7a-4110-b690-dd2b69cfb98a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ed37308-dac8-47bc-80e2-85f5edff6232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dfa0feb6-1a7a-4110-b690-dd2b69cfb98a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ed37308-dac8-47bc-80e2-85f5edff6232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7ed37308-dac8-47bc-80e2-85f5edff6232_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ed37308-dac8-47bc-80e2-85f5edff6232" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7ed37308-dac8-47bc-80e2-85f5edff6232_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d41098d2-36a7-4fd5-8254-d036313d6941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ed37308-dac8-47bc-80e2-85f5edff6232" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d41098d2-36a7-4fd5-8254-d036313d6941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_f2ba11c9-bfbd-4c2c-a803-6f9bfe8626ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d41098d2-36a7-4fd5-8254-d036313d6941" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_f2ba11c9-bfbd-4c2c-a803-6f9bfe8626ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_68071df0-6cce-4a6f-9182-c965e962d98f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dfa0feb6-1a7a-4110-b690-dd2b69cfb98a" xlink:to="loc_us-gaap_AssetAcquisitionAxis_68071df0-6cce-4a6f-9182-c965e962d98f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_68071df0-6cce-4a6f-9182-c965e962d98f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_68071df0-6cce-4a6f-9182-c965e962d98f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_68071df0-6cce-4a6f-9182-c965e962d98f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_51c379e9-c414-4321-ad53-ffa6308443c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_68071df0-6cce-4a6f-9182-c965e962d98f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_51c379e9-c414-4321-ad53-ffa6308443c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember_b9b48e2e-c31d-4792-8f14-3686366401a3" xlink:href="ango-20230531.xsd#ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_51c379e9-c414-4321-ad53-ffa6308443c5" xlink:to="loc_ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember_b9b48e2e-c31d-4792-8f14-3686366401a3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AssetsHeldForSaleDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AssetsHeldForSaleDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/AssetsHeldForSaleDetails" xlink:type="extended" id="i652b9298290f4a8d8afbb6b566ec990c_AssetsHeldForSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_dfcab527-a7ad-4adf-b4c0-77eaac99b418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_114a2755-69af-4801-b614-3b47c32f82f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_dfcab527-a7ad-4adf-b4c0-77eaac99b418" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_114a2755-69af-4801-b614-3b47c32f82f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_94b8e8ee-190c-4891-a2a3-75fe1e29600c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_114a2755-69af-4801-b614-3b47c32f82f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_94b8e8ee-190c-4891-a2a3-75fe1e29600c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_dd97e6c0-bc96-4f4c-97df-14360234f618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_114a2755-69af-4801-b614-3b47c32f82f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_dd97e6c0-bc96-4f4c-97df-14360234f618" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_b3718d5e-6061-43e3-b92a-4713577dd058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_114a2755-69af-4801-b614-3b47c32f82f7" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_b3718d5e-6061-43e3-b92a-4713577dd058" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1fc01674-45a3-42e6-bd9c-6e36cbd68c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_dfcab527-a7ad-4adf-b4c0-77eaac99b418" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1fc01674-45a3-42e6-bd9c-6e36cbd68c29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_ccff14b1-48c5-4591-8d6d-41e0d8db54b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1fc01674-45a3-42e6-bd9c-6e36cbd68c29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_ccff14b1-48c5-4591-8d6d-41e0d8db54b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_f8b54b51-f914-4c5d-ad90-033c32433a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1fc01674-45a3-42e6-bd9c-6e36cbd68c29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_f8b54b51-f914-4c5d-ad90-033c32433a05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_01150cdb-ed91-4338-89e9-6cde4cb9c192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1fc01674-45a3-42e6-bd9c-6e36cbd68c29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_01150cdb-ed91-4338-89e9-6cde4cb9c192" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_5b734e7b-692d-4c90-a61b-ea836d12ca55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1fc01674-45a3-42e6-bd9c-6e36cbd68c29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_5b734e7b-692d-4c90-a61b-ea836d12ca55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5931d8db-e30e-4838-946c-6488207de0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_dfcab527-a7ad-4adf-b4c0-77eaac99b418" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5931d8db-e30e-4838-946c-6488207de0ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_009e6b8e-4f0c-4fb6-8905-34d69aab927a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5931d8db-e30e-4838-946c-6488207de0ff" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_009e6b8e-4f0c-4fb6-8905-34d69aab927a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_009e6b8e-4f0c-4fb6-8905-34d69aab927a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_009e6b8e-4f0c-4fb6-8905-34d69aab927a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_009e6b8e-4f0c-4fb6-8905-34d69aab927a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c9294a7f-d5ec-422a-a962-477811968188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_009e6b8e-4f0c-4fb6-8905-34d69aab927a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c9294a7f-d5ec-422a-a962-477811968188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DialysisProductPortfolioAndBioSentryBiopsyMember_3d266dc1-d3ad-456c-9742-b769480bc876" xlink:href="ango-20230531.xsd#ango_DialysisProductPortfolioAndBioSentryBiopsyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c9294a7f-d5ec-422a-a962-477811968188" xlink:to="loc_ango_DialysisProductPortfolioAndBioSentryBiopsyMember_3d266dc1-d3ad-456c-9742-b769480bc876" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_fbd96ffa-4d53-4f67-a9bd-f471d825b1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5931d8db-e30e-4838-946c-6488207de0ff" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_fbd96ffa-4d53-4f67-a9bd-f471d825b1e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_fbd96ffa-4d53-4f67-a9bd-f471d825b1e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_fbd96ffa-4d53-4f67-a9bd-f471d825b1e1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_fbd96ffa-4d53-4f67-a9bd-f471d825b1e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_15d670c3-3435-4ecc-9295-639528afa2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_fbd96ffa-4d53-4f67-a9bd-f471d825b1e1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_15d670c3-3435-4ecc-9295-639528afa2e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_a274b043-4812-4271-b3e0-0164ef8f3744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_15d670c3-3435-4ecc-9295-639528afa2e0" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_a274b043-4812-4271-b3e0-0164ef8f3744" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#RevenuefromContractswithCustomersDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails" xlink:type="extended" id="i04dc4f6677a24a1b94556b5b227f3e5a_RevenuefromContractswithCustomersDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_adbdf563-7e8c-433e-9f5e-865f3dfb254f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85ff1b29-5c60-4e03-a1e6-9ab078bdcb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_adbdf563-7e8c-433e-9f5e-865f3dfb254f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85ff1b29-5c60-4e03-a1e6-9ab078bdcb75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_43e5d381-d4c7-41e6-b625-e84f916497c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_adbdf563-7e8c-433e-9f5e-865f3dfb254f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_43e5d381-d4c7-41e6-b625-e84f916497c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0dc83f8b-ab71-49b4-8abc-d782056b4299" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_43e5d381-d4c7-41e6-b625-e84f916497c3" xlink:to="loc_srt_ProductOrServiceAxis_0dc83f8b-ab71-49b4-8abc-d782056b4299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0dc83f8b-ab71-49b4-8abc-d782056b4299_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0dc83f8b-ab71-49b4-8abc-d782056b4299" xlink:to="loc_srt_ProductsAndServicesDomain_0dc83f8b-ab71-49b4-8abc-d782056b4299_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7fb43eaa-12f7-45d1-b709-e6377e6efdf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0dc83f8b-ab71-49b4-8abc-d782056b4299" xlink:to="loc_srt_ProductsAndServicesDomain_7fb43eaa-12f7-45d1-b709-e6377e6efdf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedTechMember_1ddf1cf2-708c-4369-9481-4dfbbaa58d10" xlink:href="ango-20230531.xsd#ango_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7fb43eaa-12f7-45d1-b709-e6377e6efdf3" xlink:to="loc_ango_MedTechMember_1ddf1cf2-708c-4369-9481-4dfbbaa58d10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedDeviceMember_3904a9a6-1515-4ef5-a31c-01a1c81ea775" xlink:href="ango-20230531.xsd#ango_MedDeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7fb43eaa-12f7-45d1-b709-e6377e6efdf3" xlink:to="loc_ango_MedDeviceMember_3904a9a6-1515-4ef5-a31c-01a1c81ea775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_934d047f-3c40-47b9-b9c5-981cecaf2694" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_43e5d381-d4c7-41e6-b625-e84f916497c3" xlink:to="loc_srt_StatementGeographicalAxis_934d047f-3c40-47b9-b9c5-981cecaf2694" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_934d047f-3c40-47b9-b9c5-981cecaf2694_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_934d047f-3c40-47b9-b9c5-981cecaf2694" xlink:to="loc_srt_SegmentGeographicalDomain_934d047f-3c40-47b9-b9c5-981cecaf2694_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f419af17-e9bd-48f2-a6c1-160925db5aac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_934d047f-3c40-47b9-b9c5-981cecaf2694" xlink:to="loc_srt_SegmentGeographicalDomain_f419af17-e9bd-48f2-a6c1-160925db5aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ec8ebbe1-d29f-4a29-be5c-94351f26e86f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f419af17-e9bd-48f2-a6c1-160925db5aac" xlink:to="loc_country_US_ec8ebbe1-d29f-4a29-be5c-94351f26e86f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1db87593-72e9-4559-9c7e-a39a4cee5470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f419af17-e9bd-48f2-a6c1-160925db5aac" xlink:to="loc_us-gaap_NonUsMember_1db87593-72e9-4559-9c7e-a39a4cee5470" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#RevenuefromContractswithCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails" xlink:type="extended" id="i704a6732530746c5bfcf668313c5864d_RevenuefromContractswithCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevenuePerformanceObligationPaymentTerm_e7a38870-f99e-46c3-a389-b409e92ec5d4" xlink:href="ango-20230531.xsd#ango_RevenuePerformanceObligationPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:to="loc_ango_RevenuePerformanceObligationPaymentTerm_e7a38870-f99e-46c3-a389-b409e92ec5d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval_6ad33410-f9d8-4062-9498-92f6985ffe36" xlink:href="ango-20230531.xsd#ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:to="loc_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval_6ad33410-f9d8-4062-9498-92f6985ffe36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ContractwithCustomerRightofReturnRestockingCharge_4e71b8af-1e55-4e7f-b384-6358dadf0879" xlink:href="ango-20230531.xsd#ango_ContractwithCustomerRightofReturnRestockingCharge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:to="loc_ango_ContractwithCustomerRightofReturnRestockingCharge_4e71b8af-1e55-4e7f-b384-6358dadf0879" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn_f823f186-9bc0-4b20-9c4e-8ae58ba9dd89" xlink:href="ango-20230531.xsd#ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:to="loc_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn_f823f186-9bc0-4b20-9c4e-8ae58ba9dd89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_ffec5c15-15dd-47c0-bcc0-d42102b1fa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_ffec5c15-15dd-47c0-bcc0-d42102b1fa4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod_dad89be0-2533-4ef5-832b-2a28cc7af945" xlink:href="ango-20230531.xsd#ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:to="loc_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod_dad89be0-2533-4ef5-832b-2a28cc7af945" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c335af7c-d3a9-45ab-9865-c29393296af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c335af7c-d3a9-45ab-9865-c29393296af1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_213ed350-4d2f-474b-baf7-8435509732a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c335af7c-d3a9-45ab-9865-c29393296af1" xlink:to="loc_srt_RangeAxis_213ed350-4d2f-474b-baf7-8435509732a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_213ed350-4d2f-474b-baf7-8435509732a5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_213ed350-4d2f-474b-baf7-8435509732a5" xlink:to="loc_srt_RangeMember_213ed350-4d2f-474b-baf7-8435509732a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54fbc75a-da71-4061-93fb-3bf68f11309d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_213ed350-4d2f-474b-baf7-8435509732a5" xlink:to="loc_srt_RangeMember_54fbc75a-da71-4061-93fb-3bf68f11309d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_77000dd8-9266-4566-9b95-e05b0a714521" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_54fbc75a-da71-4061-93fb-3bf68f11309d" xlink:to="loc_srt_MinimumMember_77000dd8-9266-4566-9b95-e05b0a714521" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7b647004-fc8a-4f51-b5da-4d5b87793a95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_54fbc75a-da71-4061-93fb-3bf68f11309d" xlink:to="loc_srt_MaximumMember_7b647004-fc8a-4f51-b5da-4d5b87793a95" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="extended" id="i6886989014274d0699d3f36c13783b8e_FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_74452f01-584a-420e-8ff6-94ea33cc6f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_58a7b516-bbd7-48ad-a863-0cb0a046f7da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_74452f01-584a-420e-8ff6-94ea33cc6f25" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_58a7b516-bbd7-48ad-a863-0cb0a046f7da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e09505e1-09e1-4130-82ba-0356ee0c8320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_58a7b516-bbd7-48ad-a863-0cb0a046f7da" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e09505e1-09e1-4130-82ba-0356ee0c8320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_727aeaf0-63d8-4eef-8afa-57f7818e2f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_58a7b516-bbd7-48ad-a863-0cb0a046f7da" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_727aeaf0-63d8-4eef-8afa-57f7818e2f54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de52d03-722b-463e-b65f-29a459419607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_74452f01-584a-420e-8ff6-94ea33cc6f25" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de52d03-722b-463e-b65f-29a459419607" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a00b99-b4bb-4d62-a303-dfc2e0712e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de52d03-722b-463e-b65f-29a459419607" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a00b99-b4bb-4d62-a303-dfc2e0712e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_25a00b99-b4bb-4d62-a303-dfc2e0712e9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a00b99-b4bb-4d62-a303-dfc2e0712e9b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_25a00b99-b4bb-4d62-a303-dfc2e0712e9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ea6608c-989a-4ef0-a8b9-4e7e6a712866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a00b99-b4bb-4d62-a303-dfc2e0712e9b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ea6608c-989a-4ef0-a8b9-4e7e6a712866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1671004d-8b2a-49e8-b780-de87b525538e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ea6608c-989a-4ef0-a8b9-4e7e6a712866" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1671004d-8b2a-49e8-b780-de87b525538e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_055dd970-96da-4d5e-b25f-893f20fffb70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de52d03-722b-463e-b65f-29a459419607" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_055dd970-96da-4d5e-b25f-893f20fffb70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_055dd970-96da-4d5e-b25f-893f20fffb70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_055dd970-96da-4d5e-b25f-893f20fffb70" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_055dd970-96da-4d5e-b25f-893f20fffb70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d59693b-a37c-407e-9894-8ef4adeed778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_055dd970-96da-4d5e-b25f-893f20fffb70" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d59693b-a37c-407e-9894-8ef4adeed778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_713d351d-62f9-4c40-a38a-ca67dbbcb199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d59693b-a37c-407e-9894-8ef4adeed778" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_713d351d-62f9-4c40-a38a-ca67dbbcb199" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2f35de42-6a35-451a-b1da-76aef1583a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d59693b-a37c-407e-9894-8ef4adeed778" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2f35de42-6a35-451a-b1da-76aef1583a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_96901342-da46-4d75-b53e-14aa23f56439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d59693b-a37c-407e-9894-8ef4adeed778" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_96901342-da46-4d75-b53e-14aa23f56439" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3" xlink:type="simple" xlink:href="ango-20230531.xsd#FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3" xlink:type="extended" id="i0809a0a917a246b3b13cf28a4b8ece54_FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03c65cb6-789e-49db-9d4e-0c65b2c3d5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract_dcada634-3c43-42a0-9273-40621d7187be" xlink:href="ango-20230531.xsd#ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03c65cb6-789e-49db-9d4e-0c65b2c3d5ab" xlink:to="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract_dcada634-3c43-42a0-9273-40621d7187be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4e9060a-d57c-456d-ba64-71ade5661a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract_dcada634-3c43-42a0-9273-40621d7187be" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4e9060a-d57c-456d-ba64-71ade5661a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a59b97eb-657f-47b6-bd89-c970ab334a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract_dcada634-3c43-42a0-9273-40621d7187be" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a59b97eb-657f-47b6-bd89-c970ab334a6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8af8188b-48e8-40ff-a23c-0944e8d60180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract_dcada634-3c43-42a0-9273-40621d7187be" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_8af8188b-48e8-40ff-a23c-0944e8d60180" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure_f8fdc57f-6286-464b-b8df-cd61a0c765d6" xlink:href="ango-20230531.xsd#ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03c65cb6-789e-49db-9d4e-0c65b2c3d5ab" xlink:to="loc_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure_f8fdc57f-6286-464b-b8df-cd61a0c765d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_2948f924-6569-430c-af5d-d3430c4fde01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03c65cb6-789e-49db-9d4e-0c65b2c3d5ab" xlink:to="loc_us-gaap_AssetImpairmentCharges_2948f924-6569-430c-af5d-d3430c4fde01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03c65cb6-789e-49db-9d4e-0c65b2c3d5ab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_5f03c0b5-0754-417b-8b4b-23025319dc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_5f03c0b5-0754-417b-8b4b-23025319dc5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_5f03c0b5-0754-417b-8b4b-23025319dc5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_5f03c0b5-0754-417b-8b4b-23025319dc5f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_5f03c0b5-0754-417b-8b4b-23025319dc5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_8969abce-17b3-4a66-82f8-2ea3d0aff6de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_5f03c0b5-0754-417b-8b4b-23025319dc5f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_8969abce-17b3-4a66-82f8-2ea3d0aff6de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevenueBasedPaymentMember_6a020742-3b79-451c-91d6-e69997cd2432" xlink:href="ango-20230531.xsd#ango_RevenueBasedPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8969abce-17b3-4a66-82f8-2ea3d0aff6de" xlink:to="loc_ango_RevenueBasedPaymentMember_6a020742-3b79-451c-91d6-e69997cd2432" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_bf15ed05-9570-4bb0-bd6d-ea9cdc84cef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_ValuationTechniqueAxis_bf15ed05-9570-4bb0-bd6d-ea9cdc84cef3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_bf15ed05-9570-4bb0-bd6d-ea9cdc84cef3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_bf15ed05-9570-4bb0-bd6d-ea9cdc84cef3" xlink:to="loc_us-gaap_ValuationTechniqueDomain_bf15ed05-9570-4bb0-bd6d-ea9cdc84cef3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_7c67d394-9403-4094-8fa2-194636d70fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_bf15ed05-9570-4bb0-bd6d-ea9cdc84cef3" xlink:to="loc_us-gaap_ValuationTechniqueDomain_7c67d394-9403-4094-8fa2-194636d70fbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_46ca8f0f-0b95-40c7-8dcf-315030db9233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_7c67d394-9403-4094-8fa2-194636d70fbe" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_46ca8f0f-0b95-40c7-8dcf-315030db9233" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevenueBasedPaymentMember_a68cfcf2-26ec-49ec-9e95-4af4e719ff95" xlink:href="ango-20230531.xsd#ango_RevenueBasedPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_7c67d394-9403-4094-8fa2-194636d70fbe" xlink:to="loc_ango_RevenueBasedPaymentMember_a68cfcf2-26ec-49ec-9e95-4af4e719ff95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be5540c4-62bd-43c2-bba8-3b9c22858ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be5540c4-62bd-43c2-bba8-3b9c22858ec6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be5540c4-62bd-43c2-bba8-3b9c22858ec6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be5540c4-62bd-43c2-bba8-3b9c22858ec6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be5540c4-62bd-43c2-bba8-3b9c22858ec6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_488d605e-5fd4-4d7a-8183-909c47fa6d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be5540c4-62bd-43c2-bba8-3b9c22858ec6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_488d605e-5fd4-4d7a-8183-909c47fa6d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_370cc8b3-e568-40f2-a71c-28c0478d49ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_488d605e-5fd4-4d7a-8183-909c47fa6d9a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_370cc8b3-e568-40f2-a71c-28c0478d49ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_15559741-1322-4750-b5e8-977fb1a1a1a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_srt_RangeAxis_15559741-1322-4750-b5e8-977fb1a1a1a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_15559741-1322-4750-b5e8-977fb1a1a1a5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_15559741-1322-4750-b5e8-977fb1a1a1a5" xlink:to="loc_srt_RangeMember_15559741-1322-4750-b5e8-977fb1a1a1a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b1b3da7-ae21-46f6-a9d2-26c4b033a379" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_15559741-1322-4750-b5e8-977fb1a1a1a5" xlink:to="loc_srt_RangeMember_9b1b3da7-ae21-46f6-a9d2-26c4b033a379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_29176cd7-98e3-4f80-936d-3637b778167b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9b1b3da7-ae21-46f6-a9d2-26c4b033a379" xlink:to="loc_srt_MinimumMember_29176cd7-98e3-4f80-936d-3637b778167b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_774ebfa4-c4e3-4eec-8018-f4d15befcd23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9b1b3da7-ae21-46f6-a9d2-26c4b033a379" xlink:to="loc_srt_MaximumMember_774ebfa4-c4e3-4eec-8018-f4d15befcd23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bb1ba9b7-5fd1-4a47-a20f-c51d76a9c93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bb1ba9b7-5fd1-4a47-a20f-c51d76a9c93a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bb1ba9b7-5fd1-4a47-a20f-c51d76a9c93a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bb1ba9b7-5fd1-4a47-a20f-c51d76a9c93a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bb1ba9b7-5fd1-4a47-a20f-c51d76a9c93a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_84210078-ec8f-45b9-bd6c-258e40c3af97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bb1ba9b7-5fd1-4a47-a20f-c51d76a9c93a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_84210078-ec8f-45b9-bd6c-258e40c3af97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_010502a6-8112-4c1f-a655-a6d9e60a4c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_84210078-ec8f-45b9-bd6c-258e40c3af97" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_010502a6-8112-4c1f-a655-a6d9e60a4c74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9adb1d7d-49d4-4ffd-be16-2fcf0ecf5061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9adb1d7d-49d4-4ffd-be16-2fcf0ecf5061" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9adb1d7d-49d4-4ffd-be16-2fcf0ecf5061_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9adb1d7d-49d4-4ffd-be16-2fcf0ecf5061" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9adb1d7d-49d4-4ffd-be16-2fcf0ecf5061_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d114a0e3-02ee-41c2-9cd3-dbdfe716f269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9adb1d7d-49d4-4ffd-be16-2fcf0ecf5061" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d114a0e3-02ee-41c2-9cd3-dbdfe716f269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_05655a92-321f-4a43-8693-04dc64b450a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d114a0e3-02ee-41c2-9cd3-dbdfe716f269" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_05655a92-321f-4a43-8693-04dc64b450a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MeasurementInputProbabilityofPaymentMember_adbb4517-fb3f-41c0-9032-a231b00cf6cb" xlink:href="ango-20230531.xsd#ango_MeasurementInputProbabilityofPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d114a0e3-02ee-41c2-9cd3-dbdfe716f269" xlink:to="loc_ango_MeasurementInputProbabilityofPaymentMember_adbb4517-fb3f-41c0-9032-a231b00cf6cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eb550303-05c5-4c84-8556-e522e157171d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eb550303-05c5-4c84-8556-e522e157171d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb550303-05c5-4c84-8556-e522e157171d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eb550303-05c5-4c84-8556-e522e157171d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb550303-05c5-4c84-8556-e522e157171d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_924d276c-3968-4b1c-b1f1-5fefabc523a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eb550303-05c5-4c84-8556-e522e157171d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_924d276c-3968-4b1c-b1f1-5fefabc523a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RadiaDyneMember_1b52e4d3-591e-43a4-9217-b9ae9c7145d8" xlink:href="ango-20230531.xsd#ango_RadiaDyneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_924d276c-3968-4b1c-b1f1-5fefabc523a6" xlink:to="loc_ango_RadiaDyneMember_1b52e4d3-591e-43a4-9217-b9ae9c7145d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43caf2b7-1ab2-455e-b7d9-36a0d1fd26bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43caf2b7-1ab2-455e-b7d9-36a0d1fd26bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43caf2b7-1ab2-455e-b7d9-36a0d1fd26bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43caf2b7-1ab2-455e-b7d9-36a0d1fd26bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43caf2b7-1ab2-455e-b7d9-36a0d1fd26bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2a68fc-17ac-45d4-ad4f-6a9fd63a20ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43caf2b7-1ab2-455e-b7d9-36a0d1fd26bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2a68fc-17ac-45d4-ad4f-6a9fd63a20ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_OarTracTrademarkMember_fed10cc6-498d-49e4-9bdf-d85b3ddd6f76" xlink:href="ango-20230531.xsd#ango_OarTracTrademarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2a68fc-17ac-45d4-ad4f-6a9fd63a20ea" xlink:to="loc_ango_OarTracTrademarkMember_fed10cc6-498d-49e4-9bdf-d85b3ddd6f76" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#PropertyPlantandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="extended" id="i08330422d2f64ddeb7cd6b2180dbf23c_PropertyPlantandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2a5d017e-74c3-4b31-9e91-8caff7506937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2a5d017e-74c3-4b31-9e91-8caff7506937" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e20af68b-ef59-4b99-80dc-1a680544412d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e20af68b-ef59-4b99-80dc-1a680544412d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c3dca89d-d739-4aa1-a633-0663db7548a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c3dca89d-d739-4aa1-a633-0663db7548a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements_acfcec94-5511-4626-ae46-9f53967c7135" xlink:href="ango-20230531.xsd#ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:to="loc_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements_acfcec94-5511-4626-ae46-9f53967c7135" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovements_a77c8e78-7633-4eb7-a4a1-f88951751191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:to="loc_us-gaap_LandAndLandImprovements_a77c8e78-7633-4eb7-a4a1-f88951751191" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1738c42f-ff86-4446-b1e4-c36e742c15c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1738c42f-ff86-4446-b1e4-c36e742c15c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_42ab4b46-1558-49f7-8987-998b014b7a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2a5d017e-74c3-4b31-9e91-8caff7506937" xlink:to="loc_us-gaap_Depreciation_42ab4b46-1558-49f7-8987-998b014b7a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18505618-f6db-4b9c-9d70-068647161170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2a5d017e-74c3-4b31-9e91-8caff7506937" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18505618-f6db-4b9c-9d70-068647161170" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b86a9c3d-cd0e-4875-994f-0f68e10c8be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18505618-f6db-4b9c-9d70-068647161170" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b86a9c3d-cd0e-4875-994f-0f68e10c8be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b86a9c3d-cd0e-4875-994f-0f68e10c8be6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b86a9c3d-cd0e-4875-994f-0f68e10c8be6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b86a9c3d-cd0e-4875-994f-0f68e10c8be6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b86a9c3d-cd0e-4875-994f-0f68e10c8be6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_c2937552-aa8e-4214-88db-4fde40735286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_c2937552-aa8e-4214-88db-4fde40735286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_490e9164-64d7-4bb7-9aae-3ac0a8833651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:to="loc_us-gaap_ComputerEquipmentMember_490e9164-64d7-4bb7-9aae-3ac0a8833651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_3dfd5b88-7194-4472-b8bd-2e76ff0b6bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_3dfd5b88-7194-4472-b8bd-2e76ff0b6bf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PlacementAndEvaluationUnitsMember_48552c69-e0a2-4869-89b7-d5454befe5b8" xlink:href="ango-20230531.xsd#ango_PlacementAndEvaluationUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:to="loc_ango_PlacementAndEvaluationUnitsMember_48552c69-e0a2-4869-89b7-d5454befe5b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_a7cdf008-77d4-4435-ac5c-46de44d02b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:to="loc_us-gaap_ConstructionInProgressMember_a7cdf008-77d4-4435-ac5c-46de44d02b24" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#GoodwillandIntangibleAssetsGoodwillRollforwardDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails" xlink:type="extended" id="i9275725729144b2b8717a6c4df4707b7_GoodwillandIntangibleAssetsGoodwillRollforwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f546826f-573f-40c8-9789-d7a172db0105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_4bbdb386-125f-4525-b163-9ca461481baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_f546826f-573f-40c8-9789-d7a172db0105" xlink:to="loc_us-gaap_GoodwillRollForward_4bbdb386-125f-4525-b163-9ca461481baa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_eb9cdcdb-801d-4dae-be56-89c5456e8668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_4bbdb386-125f-4525-b163-9ca461481baa" xlink:to="loc_us-gaap_Goodwill_eb9cdcdb-801d-4dae-be56-89c5456e8668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0427ccc2-14d5-4190-a16e-a4d6ac5927ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_4bbdb386-125f-4525-b163-9ca461481baa" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0427ccc2-14d5-4190-a16e-a4d6ac5927ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_62e48942-1fcd-413c-a78f-e82120e133c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_4bbdb386-125f-4525-b163-9ca461481baa" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_62e48942-1fcd-413c-a78f-e82120e133c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_dccf8c46-93b8-4ba3-b00b-478799b643eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_4bbdb386-125f-4525-b163-9ca461481baa" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_dccf8c46-93b8-4ba3-b00b-478799b643eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_79c28bd2-03c1-40e9-b95a-f42f512aef7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_d6cfb8bd-4ca5-4e29-89a7-1d421a9961c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_f546826f-573f-40c8-9789-d7a172db0105" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_d6cfb8bd-4ca5-4e29-89a7-1d421a9961c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7e1a44dd-f733-4202-b855-eb91ea73c85d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d6cfb8bd-4ca5-4e29-89a7-1d421a9961c8" xlink:to="loc_srt_ProductOrServiceAxis_7e1a44dd-f733-4202-b855-eb91ea73c85d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e1a44dd-f733-4202-b855-eb91ea73c85d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7e1a44dd-f733-4202-b855-eb91ea73c85d" xlink:to="loc_srt_ProductsAndServicesDomain_7e1a44dd-f733-4202-b855-eb91ea73c85d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a3ab044-1fc1-4654-a601-1185ad9d4626" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7e1a44dd-f733-4202-b855-eb91ea73c85d" xlink:to="loc_srt_ProductsAndServicesDomain_5a3ab044-1fc1-4654-a601-1185ad9d4626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedTechMember_ef3b2912-de8f-475f-8666-4edf3c1b6e17" xlink:href="ango-20230531.xsd#ango_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a3ab044-1fc1-4654-a601-1185ad9d4626" xlink:to="loc_ango_MedTechMember_ef3b2912-de8f-475f-8666-4edf3c1b6e17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedDeviceMember_448b21be-f70f-460f-abbf-30c0eddfbe2b" xlink:href="ango-20230531.xsd#ango_MedDeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a3ab044-1fc1-4654-a601-1185ad9d4626" xlink:to="loc_ango_MedDeviceMember_448b21be-f70f-460f-abbf-30c0eddfbe2b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended" id="id56f6c0fdd7747779b7b8be57e43b37b_GoodwillandIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_ac1a9439-8646-409f-bfd2-88d07a6fe3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_NumberOfReportingUnits_ac1a9439-8646-409f-bfd2-88d07a6fe3a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7b78c506-f7c8-4201-a325-b5ad9a4d7f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7b78c506-f7c8-4201-a325-b5ad9a4d7f83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e4e1c922-9e0e-438c-a22d-4f52b415fff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e4e1c922-9e0e-438c-a22d-4f52b415fff8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_080a3f71-f316-452b-9911-c59844486ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_080a3f71-f316-452b-9911-c59844486ae8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_5fa68ea3-47fa-4a86-ae01-c1e716945ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_5fa68ea3-47fa-4a86-ae01-c1e716945ce6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c4e56dbc-372b-4966-b332-cc37a0f8e4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c4e56dbc-372b-4966-b332-cc37a0f8e4ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3d220553-8531-44b3-9789-9d0bf23a32d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3d220553-8531-44b3-9789-9d0bf23a32d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d44b0593-2725-4553-9329-065fe2e05809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d44b0593-2725-4553-9329-065fe2e05809" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a0b768d-593f-4d92-9f9e-f75a01f32ea6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d44b0593-2725-4553-9329-065fe2e05809" xlink:to="loc_srt_RangeAxis_3a0b768d-593f-4d92-9f9e-f75a01f32ea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3a0b768d-593f-4d92-9f9e-f75a01f32ea6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3a0b768d-593f-4d92-9f9e-f75a01f32ea6" xlink:to="loc_srt_RangeMember_3a0b768d-593f-4d92-9f9e-f75a01f32ea6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_645a9370-8103-4490-8eff-3dd3a4440e7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3a0b768d-593f-4d92-9f9e-f75a01f32ea6" xlink:to="loc_srt_RangeMember_645a9370-8103-4490-8eff-3dd3a4440e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_51b26b93-f000-4ab2-91d5-87fcfa152174" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_645a9370-8103-4490-8eff-3dd3a4440e7b" xlink:to="loc_srt_MinimumMember_51b26b93-f000-4ab2-91d5-87fcfa152174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5faa72f2-8632-4935-99c6-66723f3fcdb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_645a9370-8103-4490-8eff-3dd3a4440e7b" xlink:to="loc_srt_MaximumMember_5faa72f2-8632-4935-99c6-66723f3fcdb0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended" id="i22c8389fc5f84f51855fd6d430b41ef7_GoodwillandIntangibleAssetsIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b0b46258-0975-453d-93d4-d2ed01d94250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5acd2eab-9730-4af0-ab56-4ef8041c3999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b0b46258-0975-453d-93d4-d2ed01d94250" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5acd2eab-9730-4af0-ab56-4ef8041c3999" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4dea449f-678f-41a8-9d87-a70ee2bb492f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b0b46258-0975-453d-93d4-d2ed01d94250" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4dea449f-678f-41a8-9d87-a70ee2bb492f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_773eeff7-9c95-41b9-bfd3-f4b235fd7a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b0b46258-0975-453d-93d4-d2ed01d94250" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_773eeff7-9c95-41b9-bfd3-f4b235fd7a0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c896d03-30cd-4011-8a6f-a18a20cd1601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b0b46258-0975-453d-93d4-d2ed01d94250" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c896d03-30cd-4011-8a6f-a18a20cd1601" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_62c378e7-5204-4960-b5f3-dbd8805e8645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c896d03-30cd-4011-8a6f-a18a20cd1601" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_62c378e7-5204-4960-b5f3-dbd8805e8645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62c378e7-5204-4960-b5f3-dbd8805e8645_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_62c378e7-5204-4960-b5f3-dbd8805e8645" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62c378e7-5204-4960-b5f3-dbd8805e8645_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8434c62f-028f-46e0-81b8-448b05e91ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_62c378e7-5204-4960-b5f3-dbd8805e8645" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8434c62f-028f-46e0-81b8-448b05e91ef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ProductTechnologiesMember_d4807603-61c7-4542-a35c-7a5edfd7fec0" xlink:href="ango-20230531.xsd#ango_ProductTechnologiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8434c62f-028f-46e0-81b8-448b05e91ef1" xlink:to="loc_ango_ProductTechnologiesMember_d4807603-61c7-4542-a35c-7a5edfd7fec0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_8205e2ed-648b-4cef-824b-a2e4891644ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8434c62f-028f-46e0-81b8-448b05e91ef1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_8205e2ed-648b-4cef-824b-a2e4891644ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_92a2c940-8020-4512-9826-cba9506fcbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8434c62f-028f-46e0-81b8-448b05e91ef1" xlink:to="loc_us-gaap_TrademarksMember_92a2c940-8020-4512-9826-cba9506fcbd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_46121d83-cae4-42f4-bea1-050d20094269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8434c62f-028f-46e0-81b8-448b05e91ef1" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_46121d83-cae4-42f4-bea1-050d20094269" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="ic8c93ee70d0a4f56bc3a95cfba8671bb_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ango_ScheduleofIncomeTaxLineItems_ee603ea7-d48c-4d40-b409-f80e1dc4fa4f" xlink:href="ango-20230531.xsd#ango_ScheduleofIncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:href="ango-20230531.xsd#ango_IncomeTaxesTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ango_ScheduleofIncomeTaxLineItems_ee603ea7-d48c-4d40-b409-f80e1dc4fa4f" xlink:to="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment_31890979-e39f-4eca-87cc-e3c7a999f7d7" xlink:href="ango-20230531.xsd#ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:to="loc_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment_31890979-e39f-4eca-87cc-e3c7a999f7d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse_4d69c8b3-20eb-43f0-a3e0-a8191333dcd3" xlink:href="ango-20230531.xsd#ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:to="loc_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse_4d69c8b3-20eb-43f0-a3e0-a8191333dcd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_406ea132-fa1e-4475-b17c-f0a58ac03737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_406ea132-fa1e-4475-b17c-f0a58ac03737" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_20a220b5-e8de-498d-8ed5-354792d6b99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_20a220b5-e8de-498d-8ed5-354792d6b99f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cf2d1898-1afd-42e9-af83-7d24f642722e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:to="loc_us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cf2d1898-1afd-42e9-af83-7d24f642722e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_85df5f7f-488f-49a3-8633-4e7df90aec77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_85df5f7f-488f-49a3-8633-4e7df90aec77" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_fcf69cdd-0df8-40a0-9d25-c763a3eb6ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ango_ScheduleofIncomeTaxLineItems_ee603ea7-d48c-4d40-b409-f80e1dc4fa4f" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_fcf69cdd-0df8-40a0-9d25-c763a3eb6ead" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_217f2d47-a686-41a9-b681-7def10d15c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fcf69cdd-0df8-40a0-9d25-c763a3eb6ead" xlink:to="loc_us-gaap_TaxPeriodAxis_217f2d47-a686-41a9-b681-7def10d15c6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_217f2d47-a686-41a9-b681-7def10d15c6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_217f2d47-a686-41a9-b681-7def10d15c6a" xlink:to="loc_us-gaap_TaxPeriodDomain_217f2d47-a686-41a9-b681-7def10d15c6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_0e93ec67-e287-4567-8e2f-6721b6e2a2be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_217f2d47-a686-41a9-b681-7def10d15c6a" xlink:to="loc_us-gaap_TaxPeriodDomain_0e93ec67-e287-4567-8e2f-6721b6e2a2be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TaxPeriodOneMember_c77953ab-ef69-4bc2-b79a-20a8a88a5026" xlink:href="ango-20230531.xsd#ango_TaxPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_0e93ec67-e287-4567-8e2f-6721b6e2a2be" xlink:to="loc_ango_TaxPeriodOneMember_c77953ab-ef69-4bc2-b79a-20a8a88a5026" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TaxPeriodTwoMember_26a93470-03b1-4227-8b8b-d63821472126" xlink:href="ango-20230531.xsd#ango_TaxPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_0e93ec67-e287-4567-8e2f-6721b6e2a2be" xlink:to="loc_ango_TaxPeriodTwoMember_26a93470-03b1-4227-8b8b-d63821472126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TaxPeriodFourMember_97484d6a-6eb3-48fd-a39a-aa660cf35e62" xlink:href="ango-20230531.xsd#ango_TaxPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_0e93ec67-e287-4567-8e2f-6721b6e2a2be" xlink:to="loc_ango_TaxPeriodFourMember_97484d6a-6eb3-48fd-a39a-aa660cf35e62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TaxPeriodThreeMember_4a9b186e-2f73-47c2-ba11-2df4ba30b810" xlink:href="ango-20230531.xsd#ango_TaxPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_0e93ec67-e287-4567-8e2f-6721b6e2a2be" xlink:to="loc_ango_TaxPeriodThreeMember_4a9b186e-2f73-47c2-ba11-2df4ba30b810" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_295a5314-4d84-4b05-80c3-a83623e5e517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fcf69cdd-0df8-40a0-9d25-c763a3eb6ead" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_295a5314-4d84-4b05-80c3-a83623e5e517" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_295a5314-4d84-4b05-80c3-a83623e5e517_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_295a5314-4d84-4b05-80c3-a83623e5e517" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_295a5314-4d84-4b05-80c3-a83623e5e517_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9b8075a7-7a8e-4c2a-8ba8-e0f3a907e408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_295a5314-4d84-4b05-80c3-a83623e5e517" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9b8075a7-7a8e-4c2a-8ba8-e0f3a907e408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6cf3e349-bc57-4509-b51b-811c203868fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9b8075a7-7a8e-4c2a-8ba8-e0f3a907e408" xlink:to="loc_us-gaap_DomesticCountryMember_6cf3e349-bc57-4509-b51b-811c203868fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_25d3a03d-0734-4d06-a17c-13cdc4df114d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9b8075a7-7a8e-4c2a-8ba8-e0f3a907e408" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_25d3a03d-0734-4d06-a17c-13cdc4df114d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IsraelTaxAuthorityMember_cb69b127-5f16-4fb9-9361-b8332ab012b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9b8075a7-7a8e-4c2a-8ba8-e0f3a907e408" xlink:to="loc_us-gaap_IsraelTaxAuthorityMember_cb69b127-5f16-4fb9-9361-b8332ab012b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b327b751-86e8-4c53-8fd8-18e1775b4add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fcf69cdd-0df8-40a0-9d25-c763a3eb6ead" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b327b751-86e8-4c53-8fd8-18e1775b4add" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b327b751-86e8-4c53-8fd8-18e1775b4add_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b327b751-86e8-4c53-8fd8-18e1775b4add" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b327b751-86e8-4c53-8fd8-18e1775b4add_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88ae947b-087c-4504-a4d1-ba389e9028aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b327b751-86e8-4c53-8fd8-18e1775b4add" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88ae947b-087c-4504-a4d1-ba389e9028aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EximoMedicalLtd.Member_270482af-e66e-4dff-9f8f-24eb906049df" xlink:href="ango-20230531.xsd#ango_EximoMedicalLtd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88ae947b-087c-4504-a4d1-ba389e9028aa" xlink:to="loc_ango_EximoMedicalLtd.Member_270482af-e66e-4dff-9f8f-24eb906049df" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#LongTermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" xlink:type="extended" id="i6495d1e7276e4b5d8024d9ea819c3c28_LongTermDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_27547d7f-b37b-4e31-b64f-729e4cb9ba17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_27547d7f-b37b-4e31-b64f-729e4cb9ba17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature_7971c2d2-873c-4fb9-bedc-d58e0c8bd539" xlink:href="ango-20230531.xsd#ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature_7971c2d2-873c-4fb9-bedc-d58e0c8bd539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_475beef9-8665-47c1-b890-d0a630f70987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_475beef9-8665-47c1-b890-d0a630f70987" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentDebtDefaultInterestRateIncrease_9604bb3d-2026-4fdc-846a-4c01c8ff3e8c" xlink:href="ango-20230531.xsd#ango_DebtInstrumentDebtDefaultInterestRateIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_DebtInstrumentDebtDefaultInterestRateIncrease_9604bb3d-2026-4fdc-846a-4c01c8ff3e8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_eedf546d-b72b-4e7a-a418-0d0cdc04b38f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_eedf546d-b72b-4e7a-a418-0d0cdc04b38f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_LineOfCreditFacilityNumberOfCovenants_7bb96fad-1c92-45e8-9aa1-08040464a6f9" xlink:href="ango-20230531.xsd#ango_LineOfCreditFacilityNumberOfCovenants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_LineOfCreditFacilityNumberOfCovenants_7bb96fad-1c92-45e8-9aa1-08040464a6f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio_9c274182-04d4-4446-b352-f4814fa2e57a" xlink:href="ango-20230531.xsd#ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio_9c274182-04d4-4446-b352-f4814fa2e57a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions_c7794e4d-3efa-48c1-9906-d6c9713e281d" xlink:href="ango-20230531.xsd#ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions_c7794e4d-3efa-48c1-9906-d6c9713e281d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio_c3873515-b31f-4e44-9cc3-14d7fb61102a" xlink:href="ango-20230531.xsd#ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio_c3873515-b31f-4e44-9cc3-14d7fb61102a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_6fc051aa-401d-49b6-8ffd-9f186fea1158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_6fc051aa-401d-49b6-8ffd-9f186fea1158" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_0bcceb4d-d089-4282-9572-c0e5786d416d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_DebtInstrumentTerm_0bcceb4d-d089-4282-9572-c0e5786d416d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8dd7fc10-76e6-4568-9a97-1f8f28916da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8dd7fc10-76e6-4568-9a97-1f8f28916da2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ec5992ce-4e1a-4a4a-abfe-4858fa418da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ec5992ce-4e1a-4a4a-abfe-4858fa418da6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentFloorInterestRate_c303b64d-be40-4915-a44d-757c6673d7a5" xlink:href="ango-20230531.xsd#ango_DebtInstrumentFloorInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_DebtInstrumentFloorInterestRate_c303b64d-be40-4915-a44d-757c6673d7a5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_efa712e6-a35b-43fd-ae02-389f3dec6479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_LineOfCredit_efa712e6-a35b-43fd-ae02-389f3dec6479" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_71750ec5-3e8d-4eff-bed8-480b9d5fdd84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_LongTermDebt_71750ec5-3e8d-4eff-bed8-480b9d5fdd84" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fabdb0fb-cbce-4635-b527-481af827be5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_DebtInstrumentTable_fabdb0fb-cbce-4635-b527-481af827be5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_85578d6a-a859-4e51-a849-13e05aea5b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fabdb0fb-cbce-4635-b527-481af827be5a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_85578d6a-a859-4e51-a849-13e05aea5b32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_85578d6a-a859-4e51-a849-13e05aea5b32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85578d6a-a859-4e51-a849-13e05aea5b32" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_85578d6a-a859-4e51-a849-13e05aea5b32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_42821bd2-9555-4752-bdf0-cb0ed061590d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85578d6a-a859-4e51-a849-13e05aea5b32" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_42821bd2-9555-4752-bdf0-cb0ed061590d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6415959f-213f-4c8d-b812-fab7ba47fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_42821bd2-9555-4752-bdf0-cb0ed061590d" xlink:to="loc_us-gaap_LineOfCreditMember_6415959f-213f-4c8d-b812-fab7ba47fd07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f234a88e-367d-4db6-b881-bb2e21bb9a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fabdb0fb-cbce-4635-b527-481af827be5a" xlink:to="loc_us-gaap_CreditFacilityAxis_f234a88e-367d-4db6-b881-bb2e21bb9a8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f234a88e-367d-4db6-b881-bb2e21bb9a8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f234a88e-367d-4db6-b881-bb2e21bb9a8f" xlink:to="loc_us-gaap_CreditFacilityDomain_f234a88e-367d-4db6-b881-bb2e21bb9a8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c2940d3f-9517-4499-a9cc-19485b0bf0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f234a88e-367d-4db6-b881-bb2e21bb9a8f" xlink:to="loc_us-gaap_CreditFacilityDomain_c2940d3f-9517-4499-a9cc-19485b0bf0e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_529ee02e-b32f-4902-bab5-9e65e36e2ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c2940d3f-9517-4499-a9cc-19485b0bf0e7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_529ee02e-b32f-4902-bab5-9e65e36e2ba5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d78bd2d4-c89f-4b7d-865f-9630e7444b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c2940d3f-9517-4499-a9cc-19485b0bf0e7" xlink:to="loc_us-gaap_SecuredDebtMember_d78bd2d4-c89f-4b7d-865f-9630e7444b7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2248dd82-f8a6-414b-8d88-5674b893bba9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fabdb0fb-cbce-4635-b527-481af827be5a" xlink:to="loc_srt_RangeAxis_2248dd82-f8a6-414b-8d88-5674b893bba9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2248dd82-f8a6-414b-8d88-5674b893bba9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2248dd82-f8a6-414b-8d88-5674b893bba9" xlink:to="loc_srt_RangeMember_2248dd82-f8a6-414b-8d88-5674b893bba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea1c4818-5353-443e-baad-8e8ba5b309f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2248dd82-f8a6-414b-8d88-5674b893bba9" xlink:to="loc_srt_RangeMember_ea1c4818-5353-443e-baad-8e8ba5b309f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e6812cc5-7a65-40c5-8672-4d424bba6d0c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ea1c4818-5353-443e-baad-8e8ba5b309f7" xlink:to="loc_srt_MinimumMember_e6812cc5-7a65-40c5-8672-4d424bba6d0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0ca540d9-1be4-40cd-b8bd-e64a96c1b9d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ea1c4818-5353-443e-baad-8e8ba5b309f7" xlink:to="loc_srt_MaximumMember_0ca540d9-1be4-40cd-b8bd-e64a96c1b9d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6c31a571-6253-4403-aa36-e8d963c19d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fabdb0fb-cbce-4635-b527-481af827be5a" xlink:to="loc_us-gaap_VariableRateAxis_6c31a571-6253-4403-aa36-e8d963c19d3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6c31a571-6253-4403-aa36-e8d963c19d3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_6c31a571-6253-4403-aa36-e8d963c19d3d" xlink:to="loc_us-gaap_VariableRateDomain_6c31a571-6253-4403-aa36-e8d963c19d3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d37faed8-646b-4a11-be65-7b9ae62590a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_6c31a571-6253-4403-aa36-e8d963c19d3d" xlink:to="loc_us-gaap_VariableRateDomain_d37faed8-646b-4a11-be65-7b9ae62590a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_0b2a1aae-21f8-4ec2-b823-16f9f5f2fe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_d37faed8-646b-4a11-be65-7b9ae62590a9" xlink:to="loc_us-gaap_BaseRateMember_0b2a1aae-21f8-4ec2-b823-16f9f5f2fe5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_78e8524d-8b30-442e-832a-ba9a0450476c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_d37faed8-646b-4a11-be65-7b9ae62590a9" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_78e8524d-8b30-442e-832a-ba9a0450476c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#LongTermDebtLongTermDebtScheduleDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails" xlink:type="extended" id="ie06e0e2a9f0f4b61891da098e79b6797_LongTermDebtLongTermDebtScheduleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a998ed0f-3c22-4d8e-86ce-c6645fc75047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0d9bfe3d-17d9-45fb-88ce-f8ed85c2a617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a998ed0f-3c22-4d8e-86ce-c6645fc75047" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0d9bfe3d-17d9-45fb-88ce-f8ed85c2a617" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8647d651-87fe-4590-970a-cb091465c4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a998ed0f-3c22-4d8e-86ce-c6645fc75047" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8647d651-87fe-4590-970a-cb091465c4ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b80fc91d-8df6-424d-9f44-374067b75cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a998ed0f-3c22-4d8e-86ce-c6645fc75047" xlink:to="loc_us-gaap_LongTermDebt_b80fc91d-8df6-424d-9f44-374067b75cff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0498a261-e282-41cb-bddf-37311185e1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a998ed0f-3c22-4d8e-86ce-c6645fc75047" xlink:to="loc_us-gaap_DebtInstrumentTable_0498a261-e282-41cb-bddf-37311185e1c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_142f80c3-4ecb-4dd0-9322-ab9763891665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0498a261-e282-41cb-bddf-37311185e1c2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_142f80c3-4ecb-4dd0-9322-ab9763891665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_142f80c3-4ecb-4dd0-9322-ab9763891665_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_142f80c3-4ecb-4dd0-9322-ab9763891665" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_142f80c3-4ecb-4dd0-9322-ab9763891665_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_667e9df8-b9b7-40c4-937d-f55d05a76da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_142f80c3-4ecb-4dd0-9322-ab9763891665" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_667e9df8-b9b7-40c4-937d-f55d05a76da2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_3490d48a-7ccc-489a-a960-2c10e0669685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_667e9df8-b9b7-40c4-937d-f55d05a76da2" xlink:to="loc_us-gaap_LineOfCreditMember_3490d48a-7ccc-489a-a960-2c10e0669685" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_15e071ff-46f4-48c9-85d5-aae5fdec33d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_667e9df8-b9b7-40c4-937d-f55d05a76da2" xlink:to="loc_us-gaap_LoansPayableMember_15e071ff-46f4-48c9-85d5-aae5fdec33d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6379ad83-0f1f-4470-9fe5-3da259429161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0498a261-e282-41cb-bddf-37311185e1c2" xlink:to="loc_us-gaap_DebtInstrumentAxis_6379ad83-0f1f-4470-9fe5-3da259429161" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6379ad83-0f1f-4470-9fe5-3da259429161_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6379ad83-0f1f-4470-9fe5-3da259429161" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6379ad83-0f1f-4470-9fe5-3da259429161_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fad38654-2784-42fa-ada2-5392fe2fe47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6379ad83-0f1f-4470-9fe5-3da259429161" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fad38654-2784-42fa-ada2-5392fe2fe47e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevolvingFacilityMember_02b2133b-5e06-4ea3-90cd-82fa96e9e6b2" xlink:href="ango-20230531.xsd#ango_RevolvingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fad38654-2784-42fa-ada2-5392fe2fe47e" xlink:to="loc_ango_RevolvingFacilityMember_02b2133b-5e06-4ea3-90cd-82fa96e9e6b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f266aefc-519a-44a3-8cec-6c3bf0e04312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0498a261-e282-41cb-bddf-37311185e1c2" xlink:to="loc_us-gaap_CreditFacilityAxis_f266aefc-519a-44a3-8cec-6c3bf0e04312" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f266aefc-519a-44a3-8cec-6c3bf0e04312_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f266aefc-519a-44a3-8cec-6c3bf0e04312" xlink:to="loc_us-gaap_CreditFacilityDomain_f266aefc-519a-44a3-8cec-6c3bf0e04312_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2a01fd18-165f-4974-99ac-39f5d329038c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f266aefc-519a-44a3-8cec-6c3bf0e04312" xlink:to="loc_us-gaap_CreditFacilityDomain_2a01fd18-165f-4974-99ac-39f5d329038c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ae725ba4-0700-462f-b480-27292b7ddbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2a01fd18-165f-4974-99ac-39f5d329038c" xlink:to="loc_us-gaap_SecuredDebtMember_ae725ba4-0700-462f-b480-27292b7ddbf1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i3ef88e5d3b5140c49ee1c05484b8049a_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CapitalStockSharesAuthorized_bca13f8e-45f8-4bce-b4d5-86320e39a471" xlink:href="ango-20230531.xsd#ango_CapitalStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_CapitalStockSharesAuthorized_bca13f8e-45f8-4bce-b4d5-86320e39a471" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e58cfd34-a7d6-4b69-a5b4-b84a6019b2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e58cfd34-a7d6-4b69-a5b4-b84a6019b2a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ecb2710e-7f0f-400d-8e36-81b4df70f6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ecb2710e-7f0f-400d-8e36-81b4df70f6fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4d81e0e5-a9dd-4ef7-974f-4f1b5c318e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4d81e0e5-a9dd-4ef7-974f-4f1b5c318e3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_dfb662bc-00eb-4443-b1d1-985af3d6ea1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_dfb662bc-00eb-4443-b1d1-985af3d6ea1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CommonStockVotesPerShare_3c996854-a004-4c17-be16-93cc1eeeb2f8" xlink:href="ango-20230531.xsd#ango_CommonStockVotesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_CommonStockVotesPerShare_3c996854-a004-4c17-be16-93cc1eeeb2f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_28966329-efb2-40a3-9a00-742da21e0914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_28966329-efb2-40a3-9a00-742da21e0914" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage_734613d6-0bbb-444b-878f-6ebde62078f5" xlink:href="ango-20230531.xsd#ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage_734613d6-0bbb-444b-878f-6ebde62078f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1_196334b2-d98b-44fe-8b7f-a9a7614e90f9" xlink:href="ango-20230531.xsd#ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1_196334b2-d98b-44fe-8b7f-a9a7614e90f9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_84784755-8589-4d34-9b60-3aa921ef842e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_84784755-8589-4d34-9b60-3aa921ef842e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fbb3b9cd-732e-4e34-9cf3-b8712805903e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fbb3b9cd-732e-4e34-9cf3-b8712805903e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8455130b-06a6-4403-953e-4bf5582f8a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8455130b-06a6-4403-953e-4bf5582f8a2a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0db727c2-072c-4da5-8487-4635f68aa488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0db727c2-072c-4da5-8487-4635f68aa488" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1bfb4aa4-2aa9-4f5b-8584-d7034b9330b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1bfb4aa4-2aa9-4f5b-8584-d7034b9330b2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cf377705-e849-456b-b1f5-aea5d6cad641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cf377705-e849-456b-b1f5-aea5d6cad641" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a83ed4e7-aa14-4f6f-9c65-cc4af158144a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a83ed4e7-aa14-4f6f-9c65-cc4af158144a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_07b16c38-7ee1-4231-9c57-7ce6abe415c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_07b16c38-7ee1-4231-9c57-7ce6abe415c8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_352148d9-a358-4b3a-abf6-37423a0eab84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_352148d9-a358-4b3a-abf6-37423a0eab84" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69b847d3-76b1-4d29-b0ba-3435b3784a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69b847d3-76b1-4d29-b0ba-3435b3784a2b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f93d3229-e27a-450a-a339-0d5e52308b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f93d3229-e27a-450a-a339-0d5e52308b6a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_572cd612-5eb4-4424-9eed-72d43160327f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_572cd612-5eb4-4424-9eed-72d43160327f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f88b0f5-b05a-421e-bc16-2411f679d273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f88b0f5-b05a-421e-bc16-2411f679d273" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod_798f609e-fb1b-4c54-a5e3-803bee87a291" xlink:href="ango-20230531.xsd#ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod_798f609e-fb1b-4c54-a5e3-803bee87a291" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_38146c48-e021-4d85-a7f3-2d57c43818ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_38146c48-e021-4d85-a7f3-2d57c43818ad" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_730b9af3-d8ed-4761-86bc-fd4e9d4f12d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_730b9af3-d8ed-4761-86bc-fd4e9d4f12d5" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_NumberOfSharePurchasePeriod_9ea256d9-9a8a-4910-be23-0f6862214da9" xlink:href="ango-20230531.xsd#ango_NumberOfSharePurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_NumberOfSharePurchasePeriod_9ea256d9-9a8a-4910-be23-0f6862214da9" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharePurchasePeriod_8c7a1b65-0676-40c0-9b68-2b4644221f91" xlink:href="ango-20230531.xsd#ango_SharePurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_SharePurchasePeriod_8c7a1b65-0676-40c0-9b68-2b4644221f91" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EmployeePlanParticipatingEligibilityPeriod_bd62463b-a44a-4a8b-b21b-f2db9102bb6c" xlink:href="ango-20230531.xsd#ango_EmployeePlanParticipatingEligibilityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_EmployeePlanParticipatingEligibilityPeriod_bd62463b-a44a-4a8b-b21b-f2db9102bb6c" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible_1db370ab-8960-49be-8ae2-455d1a8bd2a3" xlink:href="ango-20230531.xsd#ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible_1db370ab-8960-49be-8ae2-455d1a8bd2a3" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible_0204540c-cb41-414d-bec1-46179519f7dd" xlink:href="ango-20230531.xsd#ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible_0204540c-cb41-414d-bec1-46179519f7dd" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EmployeePlanParticipatingEligibilityThresholdPercentage_ebe88cec-ba04-44bf-8714-37b069268d70" xlink:href="ango-20230531.xsd#ango_EmployeePlanParticipatingEligibilityThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_EmployeePlanParticipatingEligibilityThresholdPercentage_ebe88cec-ba04-44bf-8714-37b069268d70" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod_50a2a664-64fa-4374-bf14-b78e92fab3b8" xlink:href="ango-20230531.xsd#ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod_50a2a664-64fa-4374-bf14-b78e92fab3b8" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4ab5fc89-20d5-438a-84df-e48de2e15825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4ab5fc89-20d5-438a-84df-e48de2e15825" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_516ca3e8-a5ae-4263-a727-6784b78eb63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_516ca3e8-a5ae-4263-a727-6784b78eb63e" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6c39cc56-e9c3-4526-aa5b-a96814b75539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6c39cc56-e9c3-4526-aa5b-a96814b75539" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_23e1ebc3-73cf-48fa-ac03-ebd9259ec542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_23e1ebc3-73cf-48fa-ac03-ebd9259ec542" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d5cb9dac-ce33-45be-a93e-28cff0740ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d5cb9dac-ce33-45be-a93e-28cff0740ee5" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_bc70f301-ae4f-4dd2-85eb-f8583a6ee2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_bc70f301-ae4f-4dd2-85eb-f8583a6ee2b6" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_ebd9e0fd-d5a2-4db4-a54e-244827e81ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_ebd9e0fd-d5a2-4db4-a54e-244827e81ba6" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_6efcc407-3eb7-4346-a3cd-f4ac35e91508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_6efcc407-3eb7-4346-a3cd-f4ac35e91508" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fdca4444-39ab-4de5-b244-484981fdd7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_6efcc407-3eb7-4346-a3cd-f4ac35e91508" xlink:to="loc_us-gaap_PlanNameAxis_fdca4444-39ab-4de5-b244-484981fdd7eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fdca4444-39ab-4de5-b244-484981fdd7eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_fdca4444-39ab-4de5-b244-484981fdd7eb" xlink:to="loc_us-gaap_PlanNameDomain_fdca4444-39ab-4de5-b244-484981fdd7eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4e20cfbc-b61e-43c9-88fb-9cd362d17b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_fdca4444-39ab-4de5-b244-484981fdd7eb" xlink:to="loc_us-gaap_PlanNameDomain_4e20cfbc-b61e-43c9-88fb-9cd362d17b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember_c58d5b86-22bb-41ba-a592-5369bfd66392" xlink:href="ango-20230531.xsd#ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4e20cfbc-b61e-43c9-88fb-9cd362d17b48" xlink:to="loc_ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember_c58d5b86-22bb-41ba-a592-5369bfd66392" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_StockPurchasePlanMember_18ec1062-5e55-4fbd-bb5f-9c4117401b1f" xlink:href="ango-20230531.xsd#ango_StockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4e20cfbc-b61e-43c9-88fb-9cd362d17b48" xlink:to="loc_ango_StockPurchasePlanMember_18ec1062-5e55-4fbd-bb5f-9c4117401b1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_StockAndIncentiveAwardPlan2020Member_e9a393cb-d34f-4f85-84a3-f5cbc7ea1208" xlink:href="ango-20230531.xsd#ango_StockAndIncentiveAwardPlan2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4e20cfbc-b61e-43c9-88fb-9cd362d17b48" xlink:to="loc_ango_StockAndIncentiveAwardPlan2020Member_e9a393cb-d34f-4f85-84a3-f5cbc7ea1208" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EmployeeStockPurchasePlanMember_11c10f6d-3765-4350-897c-2a55940c20ac" xlink:href="ango-20230531.xsd#ango_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4e20cfbc-b61e-43c9-88fb-9cd362d17b48" xlink:to="loc_ango_EmployeeStockPurchasePlanMember_11c10f6d-3765-4350-897c-2a55940c20ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_ed2503d0-4d61-409b-bc01-00713d4cc0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_6efcc407-3eb7-4346-a3cd-f4ac35e91508" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_ed2503d0-4d61-409b-bc01-00713d4cc0a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ed2503d0-4d61-409b-bc01-00713d4cc0a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_ed2503d0-4d61-409b-bc01-00713d4cc0a5" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ed2503d0-4d61-409b-bc01-00713d4cc0a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4c7297d3-0365-40c1-931d-6e487ab4f27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_ed2503d0-4d61-409b-bc01-00713d4cc0a5" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4c7297d3-0365-40c1-931d-6e487ab4f27b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2043236a-ce03-4758-9eee-b5ee6e8d61a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4c7297d3-0365-40c1-931d-6e487ab4f27b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2043236a-ce03-4758-9eee-b5ee6e8d61a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7662577c-38fd-40f6-982d-bfbc3961d89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_6efcc407-3eb7-4346-a3cd-f4ac35e91508" xlink:to="loc_us-gaap_AwardTypeAxis_7662577c-38fd-40f6-982d-bfbc3961d89d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7662577c-38fd-40f6-982d-bfbc3961d89d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7662577c-38fd-40f6-982d-bfbc3961d89d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7662577c-38fd-40f6-982d-bfbc3961d89d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ff94a68-3880-4291-a7f2-0a9131b39f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7662577c-38fd-40f6-982d-bfbc3961d89d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ff94a68-3880-4291-a7f2-0a9131b39f5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3a0a0079-017a-43e5-82c6-43740a29b7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ff94a68-3880-4291-a7f2-0a9131b39f5b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3a0a0079-017a-43e5-82c6-43740a29b7e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b09c2f3e-1a0c-4a5f-99e8-6f6c8148f9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ff94a68-3880-4291-a7f2-0a9131b39f5b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b09c2f3e-1a0c-4a5f-99e8-6f6c8148f9c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PerformanceShareAndRestrictedStockUnitAwardsMember_2ddde8b4-b199-4019-be8b-a4da3253b422" xlink:href="ango-20230531.xsd#ango_PerformanceShareAndRestrictedStockUnitAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ff94a68-3880-4291-a7f2-0a9131b39f5b" xlink:to="loc_ango_PerformanceShareAndRestrictedStockUnitAwardsMember_2ddde8b4-b199-4019-be8b-a4da3253b422" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PerformanceSharesIncludingThreeYearMarketConditionMember_a2da4378-d9ba-42e5-b689-55c4948d73d8" xlink:href="ango-20230531.xsd#ango_PerformanceSharesIncludingThreeYearMarketConditionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ff94a68-3880-4291-a7f2-0a9131b39f5b" xlink:to="loc_ango_PerformanceSharesIncludingThreeYearMarketConditionMember_a2da4378-d9ba-42e5-b689-55c4948d73d8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/StockholdersEquityDetails2" xlink:type="simple" xlink:href="ango-20230531.xsd#StockholdersEquityDetails2"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/StockholdersEquityDetails2" xlink:type="extended" id="i5e8c2fe6dce34ef6acab95bf8da34beb_StockholdersEquityDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5fb4507-6f4c-4f8c-8f89-bc5139f502cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c35e7af-bf38-4684-a8b0-3a3f182f5fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5fb4507-6f4c-4f8c-8f89-bc5139f502cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c35e7af-bf38-4684-a8b0-3a3f182f5fb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1aff90d7-3903-47d9-bf03-383d410bcfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c35e7af-bf38-4684-a8b0-3a3f182f5fb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1aff90d7-3903-47d9-bf03-383d410bcfc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1f042967-f1b3-4c27-aa44-ce033f39e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c35e7af-bf38-4684-a8b0-3a3f182f5fb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1f042967-f1b3-4c27-aa44-ce033f39e58f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_83e3c342-0851-4ca2-8de0-6341173d3fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c35e7af-bf38-4684-a8b0-3a3f182f5fb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_83e3c342-0851-4ca2-8de0-6341173d3fb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_32854ca6-a83a-4734-a93e-668de265b5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c35e7af-bf38-4684-a8b0-3a3f182f5fb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_32854ca6-a83a-4734-a93e-668de265b5ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f95c607f-d156-4bdb-b036-8bbcf0531245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67f62d09-a815-40c3-9ae1-28895d4822e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5fb4507-6f4c-4f8c-8f89-bc5139f502cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67f62d09-a815-40c3-9ae1-28895d4822e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6df28d28-3762-4afc-8617-2a0873bedea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67f62d09-a815-40c3-9ae1-28895d4822e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6df28d28-3762-4afc-8617-2a0873bedea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52587297-59ab-4c42-9b4b-6c4946c24c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67f62d09-a815-40c3-9ae1-28895d4822e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52587297-59ab-4c42-9b4b-6c4946c24c48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_798aff5d-9c98-48fa-973f-80d51cfe368a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67f62d09-a815-40c3-9ae1-28895d4822e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_798aff5d-9c98-48fa-973f-80d51cfe368a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0fa2d1ea-79bb-4415-acf4-6fa4f6fe765b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67f62d09-a815-40c3-9ae1-28895d4822e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0fa2d1ea-79bb-4415-acf4-6fa4f6fe765b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb2f933c-a834-4399-bd30-b8e2ef132901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ba6a24-3a90-403e-9e71-2e1c9e8fe833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5fb4507-6f4c-4f8c-8f89-bc5139f502cb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ba6a24-3a90-403e-9e71-2e1c9e8fe833" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b038d0ee-db44-452c-a34b-c27168c5c4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ba6a24-3a90-403e-9e71-2e1c9e8fe833" xlink:to="loc_us-gaap_AwardTypeAxis_b038d0ee-db44-452c-a34b-c27168c5c4b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b038d0ee-db44-452c-a34b-c27168c5c4b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b038d0ee-db44-452c-a34b-c27168c5c4b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b038d0ee-db44-452c-a34b-c27168c5c4b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0600b6d-a154-4d0e-b44e-e501baf356a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b038d0ee-db44-452c-a34b-c27168c5c4b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0600b6d-a154-4d0e-b44e-e501baf356a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5188e95e-3749-47a7-964e-3270bb7c3a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0600b6d-a154-4d0e-b44e-e501baf356a6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5188e95e-3749-47a7-964e-3270bb7c3a21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d934b143-5568-4a0d-94aa-e7d27a0a5996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0600b6d-a154-4d0e-b44e-e501baf356a6" xlink:to="loc_us-gaap_PerformanceSharesMember_d934b143-5568-4a0d-94aa-e7d27a0a5996" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#StockholdersEquityCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails" xlink:type="extended" id="i85e33c66619241bbae7765648c65218d_StockholdersEquityCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b50d8538-7b96-41e4-8adb-2d1785875f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b2748b55-c885-4077-9a28-5de84b88bf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b50d8538-7b96-41e4-8adb-2d1785875f9d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b2748b55-c885-4077-9a28-5de84b88bf3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67409461-ec9b-46ac-a56f-c8ac857198d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b50d8538-7b96-41e4-8adb-2d1785875f9d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67409461-ec9b-46ac-a56f-c8ac857198d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a98b8e55-96c7-40c0-907f-f4b0c851aded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67409461-ec9b-46ac-a56f-c8ac857198d4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a98b8e55-96c7-40c0-907f-f4b0c851aded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a98b8e55-96c7-40c0-907f-f4b0c851aded_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a98b8e55-96c7-40c0-907f-f4b0c851aded" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a98b8e55-96c7-40c0-907f-f4b0c851aded_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_25206aa2-98fc-4693-a89a-f4a8def612cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a98b8e55-96c7-40c0-907f-f4b0c851aded" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_25206aa2-98fc-4693-a89a-f4a8def612cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_9a8effd3-d239-4950-985b-1a39595466ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25206aa2-98fc-4693-a89a-f4a8def612cc" xlink:to="loc_us-gaap_CostOfSalesMember_9a8effd3-d239-4950-985b-1a39595466ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ResearchAndDevelopmentMember_22d5c047-db52-4a2d-bfb2-9f417d14be23" xlink:href="ango-20230531.xsd#ango_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25206aa2-98fc-4693-a89a-f4a8def612cc" xlink:to="loc_ango_ResearchAndDevelopmentMember_22d5c047-db52-4a2d-bfb2-9f417d14be23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SalesandMarketingMember_9562be16-c39e-42da-a432-29c3e63bc509" xlink:href="ango-20230531.xsd#ango_SalesandMarketingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25206aa2-98fc-4693-a89a-f4a8def612cc" xlink:to="loc_ango_SalesandMarketingMember_9562be16-c39e-42da-a432-29c3e63bc509" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2f801c26-0c5e-4d2f-a177-45ecc4ea94d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25206aa2-98fc-4693-a89a-f4a8def612cc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2f801c26-0c5e-4d2f-a177-45ecc4ea94d3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#LeasesSupplementalStatementofOperationsInformationDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails" xlink:type="extended" id="ia126586691de495799ca3a1a7c67cabc_LeasesSupplementalStatementofOperationsInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c477c5eb-ed90-49e9-9783-64232bfd02d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_9a9690dd-f3cf-4183-a142-9bd9c9bf47ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c477c5eb-ed90-49e9-9783-64232bfd02d1" xlink:to="loc_us-gaap_OperatingLeaseExpense_9a9690dd-f3cf-4183-a142-9bd9c9bf47ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f0db3952-9e3f-4995-bf8a-c3e1db81da3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c477c5eb-ed90-49e9-9783-64232bfd02d1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f0db3952-9e3f-4995-bf8a-c3e1db81da3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3e8426dc-aa1e-427a-92a1-bcb0c8d42098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f0db3952-9e3f-4995-bf8a-c3e1db81da3e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3e8426dc-aa1e-427a-92a1-bcb0c8d42098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3e8426dc-aa1e-427a-92a1-bcb0c8d42098_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3e8426dc-aa1e-427a-92a1-bcb0c8d42098" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3e8426dc-aa1e-427a-92a1-bcb0c8d42098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_39e2cd2c-d5df-41cd-b766-71f714c1caa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3e8426dc-aa1e-427a-92a1-bcb0c8d42098" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_39e2cd2c-d5df-41cd-b766-71f714c1caa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_7ff5a784-e248-4c28-8e47-b00b494e615b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_39e2cd2c-d5df-41cd-b766-71f714c1caa7" xlink:to="loc_us-gaap_CostOfSalesMember_7ff5a784-e248-4c28-8e47-b00b494e615b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e242fda3-bb91-4b49-934c-08cbf991df34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_39e2cd2c-d5df-41cd-b766-71f714c1caa7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e242fda3-bb91-4b49-934c-08cbf991df34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_d9b9da44-fe1c-4a77-b090-a57fcd3d1b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_39e2cd2c-d5df-41cd-b766-71f714c1caa7" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_d9b9da44-fe1c-4a77-b090-a57fcd3d1b90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a1f3475b-9d93-49fb-8a95-5dfaa2a733ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_39e2cd2c-d5df-41cd-b766-71f714c1caa7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a1f3475b-9d93-49fb-8a95-5dfaa2a733ba" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i00d552977fb54f3795beebc0b09e2540_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_41a93c04-4e22-41d3-8f81-2dfed6236a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_NumberOfPatentsAssertedForReexamination_3209ca7a-5811-4752-bfc1-5160ec819990" xlink:href="ango-20230531.xsd#ango_NumberOfPatentsAssertedForReexamination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_41a93c04-4e22-41d3-8f81-2dfed6236a56" xlink:to="loc_ango_NumberOfPatentsAssertedForReexamination_3209ca7a-5811-4752-bfc1-5160ec819990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_NumberOfPatentsUpheldOverPriorArtReferences_86fad2f3-a506-4bfc-8ccb-3ec47061f9a2" xlink:href="ango-20230531.xsd#ango_NumberOfPatentsUpheldOverPriorArtReferences"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_41a93c04-4e22-41d3-8f81-2dfed6236a56" xlink:to="loc_ango_NumberOfPatentsUpheldOverPriorArtReferences_86fad2f3-a506-4bfc-8ccb-3ec47061f9a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_1b94d459-e972-4592-bc8e-4071e87adc22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_41a93c04-4e22-41d3-8f81-2dfed6236a56" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_1b94d459-e972-4592-bc8e-4071e87adc22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_f595dff0-04c8-4b32-8575-7db11b31bb15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_41a93c04-4e22-41d3-8f81-2dfed6236a56" xlink:to="loc_us-gaap_LossContingenciesTable_f595dff0-04c8-4b32-8575-7db11b31bb15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_08cd1b82-bda7-41b6-8858-a3ddf638ddd3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f595dff0-04c8-4b32-8575-7db11b31bb15" xlink:to="loc_srt_LitigationCaseAxis_08cd1b82-bda7-41b6-8858-a3ddf638ddd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_08cd1b82-bda7-41b6-8858-a3ddf638ddd3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_08cd1b82-bda7-41b6-8858-a3ddf638ddd3" xlink:to="loc_srt_LitigationCaseTypeDomain_08cd1b82-bda7-41b6-8858-a3ddf638ddd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a46d144a-fb33-43fb-81ad-6f7be51cd211" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_08cd1b82-bda7-41b6-8858-a3ddf638ddd3" xlink:to="loc_srt_LitigationCaseTypeDomain_a46d144a-fb33-43fb-81ad-6f7be51cd211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CrBardIncMember_a2f0ac88-a1d6-4753-9d85-9284fb6b4376" xlink:href="ango-20230531.xsd#ango_CrBardIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a46d144a-fb33-43fb-81ad-6f7be51cd211" xlink:to="loc_ango_CrBardIncMember_a2f0ac88-a1d6-4753-9d85-9284fb6b4376" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TheDelawareActionMember_3f1bee30-1084-42b9-bf17-777d0ba2eccb" xlink:href="ango-20230531.xsd#ango_TheDelawareActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a46d144a-fb33-43fb-81ad-6f7be51cd211" xlink:to="loc_ango_TheDelawareActionMember_3f1bee30-1084-42b9-bf17-777d0ba2eccb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#SegmentsandGeographicInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails" xlink:type="extended" id="iaf0bf1c4b6354409bb8cd77e289f898d_SegmentsandGeographicInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_458b7576-7e16-47ed-8260-bd40fe96cf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_210f8b33-2fab-4e81-b94b-b7a36ebf3455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_458b7576-7e16-47ed-8260-bd40fe96cf3e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_210f8b33-2fab-4e81-b94b-b7a36ebf3455" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_47c195aa-fde7-48ee-abbb-5d51b3dced23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_458b7576-7e16-47ed-8260-bd40fe96cf3e" xlink:to="loc_us-gaap_Assets_47c195aa-fde7-48ee-abbb-5d51b3dced23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_68846c47-2233-4d2c-ba3d-00548ec59356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_458b7576-7e16-47ed-8260-bd40fe96cf3e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_68846c47-2233-4d2c-ba3d-00548ec59356" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76e02ea2-ec7b-4739-93a1-356476f9c5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_458b7576-7e16-47ed-8260-bd40fe96cf3e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76e02ea2-ec7b-4739-93a1-356476f9c5ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9b672a7a-4557-4f64-ab9a-c5bdec143be2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76e02ea2-ec7b-4739-93a1-356476f9c5ce" xlink:to="loc_srt_StatementGeographicalAxis_9b672a7a-4557-4f64-ab9a-c5bdec143be2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9b672a7a-4557-4f64-ab9a-c5bdec143be2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9b672a7a-4557-4f64-ab9a-c5bdec143be2" xlink:to="loc_srt_SegmentGeographicalDomain_9b672a7a-4557-4f64-ab9a-c5bdec143be2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_33042117-e365-40cc-982b-7045fc94b560" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9b672a7a-4557-4f64-ab9a-c5bdec143be2" xlink:to="loc_srt_SegmentGeographicalDomain_33042117-e365-40cc-982b-7045fc94b560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_94084c03-0921-448a-9e99-9d0396183524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_33042117-e365-40cc-982b-7045fc94b560" xlink:to="loc_us-gaap_NonUsMember_94084c03-0921-448a-9e99-9d0396183524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_48d7182c-bc5b-422c-a743-65ae948232ea" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_33042117-e365-40cc-982b-7045fc94b560" xlink:to="loc_country_US_48d7182c-bc5b-422c-a743-65ae948232ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_71b92898-d22e-4e86-971f-3807319dfd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76e02ea2-ec7b-4739-93a1-356476f9c5ce" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_71b92898-d22e-4e86-971f-3807319dfd4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_71b92898-d22e-4e86-971f-3807319dfd4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_71b92898-d22e-4e86-971f-3807319dfd4d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_71b92898-d22e-4e86-971f-3807319dfd4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1ed3ecf8-417a-4a94-a4f9-ecd74cc985d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_71b92898-d22e-4e86-971f-3807319dfd4d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1ed3ecf8-417a-4a94-a4f9-ecd74cc985d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_05b1ad24-7e9a-409a-8681-a0edd5763440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1ed3ecf8-417a-4a94-a4f9-ecd74cc985d3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_05b1ad24-7e9a-409a-8681-a0edd5763440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAssetsGeographicAreaMember_b8065ffe-68b6-4c34-8069-58e7ff068566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetAssetsGeographicAreaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1ed3ecf8-417a-4a94-a4f9-ecd74cc985d3" xlink:to="loc_us-gaap_NetAssetsGeographicAreaMember_b8065ffe-68b6-4c34-8069-58e7ff068566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_80e047d6-c60f-42f9-a542-c9d0a248c1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76e02ea2-ec7b-4739-93a1-356476f9c5ce" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_80e047d6-c60f-42f9-a542-c9d0a248c1d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_80e047d6-c60f-42f9-a542-c9d0a248c1d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_80e047d6-c60f-42f9-a542-c9d0a248c1d0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_80e047d6-c60f-42f9-a542-c9d0a248c1d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_62da4209-03ef-48e3-98f3-018fa411d946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_80e047d6-c60f-42f9-a542-c9d0a248c1d0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_62da4209-03ef-48e3-98f3-018fa411d946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_54c6b35d-0929-4f2c-bb58-888536f16d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_62da4209-03ef-48e3-98f3-018fa411d946" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_54c6b35d-0929-4f2c-bb58-888536f16d0f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#SegmentsandGeographicInformationSalesbyProductCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails" xlink:type="extended" id="ie86e286db3b047699187f6c93fc2e4f6_SegmentsandGeographicInformationSalesbyProductCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_b259ffc1-470c-4b3e-9c50-67f29c5aab68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0260c65f-470c-404e-ab9e-22013ea6bec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b259ffc1-470c-4b3e-9c50-67f29c5aab68" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0260c65f-470c-404e-ab9e-22013ea6bec5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_adc2286d-9e05-41c3-a59d-6e734357f389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b259ffc1-470c-4b3e-9c50-67f29c5aab68" xlink:to="loc_us-gaap_GrossProfit_adc2286d-9e05-41c3-a59d-6e734357f389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_GrossMarginPercentage_e70d0a4a-97c0-4a60-b5fa-d33427f45249" xlink:href="ango-20230531.xsd#ango_GrossMarginPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b259ffc1-470c-4b3e-9c50-67f29c5aab68" xlink:to="loc_ango_GrossMarginPercentage_e70d0a4a-97c0-4a60-b5fa-d33427f45249" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a5d930aa-7f00-44ba-91df-7a93133c9f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b259ffc1-470c-4b3e-9c50-67f29c5aab68" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a5d930aa-7f00-44ba-91df-7a93133c9f8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9afe7992-84ca-4c0a-b105-6080b1fab2a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a5d930aa-7f00-44ba-91df-7a93133c9f8d" xlink:to="loc_srt_ProductOrServiceAxis_9afe7992-84ca-4c0a-b105-6080b1fab2a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9afe7992-84ca-4c0a-b105-6080b1fab2a0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9afe7992-84ca-4c0a-b105-6080b1fab2a0" xlink:to="loc_srt_ProductsAndServicesDomain_9afe7992-84ca-4c0a-b105-6080b1fab2a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8f400a14-711c-4222-8b8f-40f063a3871e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9afe7992-84ca-4c0a-b105-6080b1fab2a0" xlink:to="loc_srt_ProductsAndServicesDomain_8f400a14-711c-4222-8b8f-40f063a3871e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedTechMember_96543562-46aa-4347-a76b-72aac3737c86" xlink:href="ango-20230531.xsd#ango_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8f400a14-711c-4222-8b8f-40f063a3871e" xlink:to="loc_ango_MedTechMember_96543562-46aa-4347-a76b-72aac3737c86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedDeviceMember_40a6a287-5d54-4c70-b7ab-2243be7621b2" xlink:href="ango-20230531.xsd#ango_MedDeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8f400a14-711c-4222-8b8f-40f063a3871e" xlink:to="loc_ango_MedDeviceMember_40a6a287-5d54-4c70-b7ab-2243be7621b2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#SegmentsandGeographicInformationSaleforGeographicAreasDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails" xlink:type="extended" id="i10ae32f0fad243029b95af30ca2208d6_SegmentsandGeographicInformationSaleforGeographicAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_04b6b395-2f84-4364-bc02-ba60386e8064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_374fdd80-20df-43c2-a8e2-d38dfc990c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_04b6b395-2f84-4364-bc02-ba60386e8064" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_374fdd80-20df-43c2-a8e2-d38dfc990c10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_513afdf4-33df-40d6-8c08-cb58a75c0039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_04b6b395-2f84-4364-bc02-ba60386e8064" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_513afdf4-33df-40d6-8c08-cb58a75c0039" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_af031897-0096-46c1-9411-7fe860e99680" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_513afdf4-33df-40d6-8c08-cb58a75c0039" xlink:to="loc_srt_StatementGeographicalAxis_af031897-0096-46c1-9411-7fe860e99680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_af031897-0096-46c1-9411-7fe860e99680_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_af031897-0096-46c1-9411-7fe860e99680" xlink:to="loc_srt_SegmentGeographicalDomain_af031897-0096-46c1-9411-7fe860e99680_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3603ac44-b0be-43e5-a108-69660537527b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_af031897-0096-46c1-9411-7fe860e99680" xlink:to="loc_srt_SegmentGeographicalDomain_3603ac44-b0be-43e5-a108-69660537527b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7a928337-78aa-4835-8fbb-8acebb345e82" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3603ac44-b0be-43e5-a108-69660537527b" xlink:to="loc_country_US_7a928337-78aa-4835-8fbb-8acebb345e82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_InternationalMember_4b3c42dc-1422-4f1d-b4f1-fda76fb9b1d7" xlink:href="ango-20230531.xsd#ango_InternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3603ac44-b0be-43e5-a108-69660537527b" xlink:to="loc_ango_InternationalMember_4b3c42dc-1422-4f1d-b4f1-fda76fb9b1d7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AcquisitionRestructuringandOtherItemsnetScheduleDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails" xlink:type="extended" id="ifda11dcfdb8a49efbeed76e1585804c8_AcquisitionRestructuringandOtherItemsnetScheduleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9d086507-b58f-410f-9ac6-bb2ee5cd35d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AcquisitionRestructuringAndOtherItemsNet_7d80eb20-def8-426f-9533-6d09f1f4313d" xlink:href="ango-20230531.xsd#ango_AcquisitionRestructuringAndOtherItemsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9d086507-b58f-410f-9ac6-bb2ee5cd35d5" xlink:to="loc_ango_AcquisitionRestructuringAndOtherItemsNet_7d80eb20-def8-426f-9533-6d09f1f4313d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_61da4949-401e-462f-9eb5-bcec07d9aac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9d086507-b58f-410f-9ac6-bb2ee5cd35d5" xlink:to="loc_us-gaap_AssetImpairmentCharges_61da4949-401e-462f-9eb5-bcec07d9aac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForPreviousAcquisition_7623a46b-c52e-4f14-aae2-674b5ed06c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPreviousAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9d086507-b58f-410f-9ac6-bb2ee5cd35d5" xlink:to="loc_us-gaap_PaymentsForPreviousAcquisition_7623a46b-c52e-4f14-aae2-674b5ed06c66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ef4ada78-3af0-46dd-80ad-076f1a62f931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9d086507-b58f-410f-9ac6-bb2ee5cd35d5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ef4ada78-3af0-46dd-80ad-076f1a62f931" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8610d4bc-518f-48d0-a9b4-83b51fd83aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ef4ada78-3af0-46dd-80ad-076f1a62f931" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8610d4bc-518f-48d0-a9b4-83b51fd83aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_8610d4bc-518f-48d0-a9b4-83b51fd83aac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8610d4bc-518f-48d0-a9b4-83b51fd83aac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_8610d4bc-518f-48d0-a9b4-83b51fd83aac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8610d4bc-518f-48d0-a9b4-83b51fd83aac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_LegalCostsMember_0d071c8c-efaa-4838-936f-76b8fc9d92f3" xlink:href="ango-20230531.xsd#ango_LegalCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_LegalCostsMember_0d071c8c-efaa-4838-936f-76b8fc9d92f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MergersandAcquisitionsMember_9100324f-78d9-46bb-9a62-d02b8000da78" xlink:href="ango-20230531.xsd#ango_MergersandAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_MergersandAcquisitionsMember_9100324f-78d9-46bb-9a62-d02b8000da78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TransitionServiceAgreementMember_27925e8d-7da1-4314-8d35-e260c16dd953" xlink:href="ango-20230531.xsd#ango_TransitionServiceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_TransitionServiceAgreementMember_27925e8d-7da1-4314-8d35-e260c16dd953" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DivestitureMember_c6013b9d-3f89-43aa-9a38-2399354efd9b" xlink:href="ango-20230531.xsd#ango_DivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_DivestitureMember_c6013b9d-3f89-43aa-9a38-2399354efd9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IntangibleImpairmentMember_01a0df22-8b2a-45d9-a140-e5dbdc5f4373" xlink:href="ango-20230531.xsd#ango_IntangibleImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_IntangibleImpairmentMember_01a0df22-8b2a-45d9-a140-e5dbdc5f4373" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IsraeliInnovationAuthorityPrepaymentMember_dbb5fbd4-2b0d-4d9d-9f45-eea7593c9c56" xlink:href="ango-20230531.xsd#ango_IsraeliInnovationAuthorityPrepaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_IsraeliInnovationAuthorityPrepaymentMember_dbb5fbd4-2b0d-4d9d-9f45-eea7593c9c56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ManufacturingRelocationMember_b9322a79-c397-4126-8aa1-b6efb92615c1" xlink:href="ango-20230531.xsd#ango_ManufacturingRelocationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_ManufacturingRelocationMember_b9322a79-c397-4126-8aa1-b6efb92615c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_2ba4b876-bbff-4c9f-b229-a0b7bb9349bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_us-gaap_OtherRestructuringMember_2ba4b876-bbff-4c9f-b229-a0b7bb9349bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0586b46e-0b7d-4c28-908e-15565340b555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ef4ada78-3af0-46dd-80ad-076f1a62f931" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0586b46e-0b7d-4c28-908e-15565340b555" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0586b46e-0b7d-4c28-908e-15565340b555_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0586b46e-0b7d-4c28-908e-15565340b555" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0586b46e-0b7d-4c28-908e-15565340b555_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94b99e46-5bd7-4be3-bcdb-6614caeb1015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0586b46e-0b7d-4c28-908e-15565340b555" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94b99e46-5bd7-4be3-bcdb-6614caeb1015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RadiaDyneMember_fba146e0-ff5a-47c4-86bf-1e17ae711314" xlink:href="ango-20230531.xsd#ango_RadiaDyneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94b99e46-5bd7-4be3-bcdb-6614caeb1015" xlink:to="loc_ango_RadiaDyneMember_fba146e0-ff5a-47c4-86bf-1e17ae711314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ada71f5-adcb-4e0b-88fc-6123e2b9d88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ef4ada78-3af0-46dd-80ad-076f1a62f931" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ada71f5-adcb-4e0b-88fc-6123e2b9d88c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7ada71f5-adcb-4e0b-88fc-6123e2b9d88c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ada71f5-adcb-4e0b-88fc-6123e2b9d88c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7ada71f5-adcb-4e0b-88fc-6123e2b9d88c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9103920f-9dce-400c-bcec-23b6fe7e0764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ada71f5-adcb-4e0b-88fc-6123e2b9d88c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9103920f-9dce-400c-bcec-23b6fe7e0764" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_OarTracTrademarkMember_2166b13c-17ce-4da5-8045-51a0126d280a" xlink:href="ango-20230531.xsd#ango_OarTracTrademarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9103920f-9dce-400c-bcec-23b6fe7e0764" xlink:to="loc_ango_OarTracTrademarkMember_2166b13c-17ce-4da5-8045-51a0126d280a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AcquisitionRestructuringandOtherItemsnetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetNarrativeDetails" xlink:type="extended" id="id5dbbbaa95044db2b1d26b4cb598e52a_AcquisitionRestructuringandOtherItemsnetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6bf3550e-b33e-40da-8f72-40e6c33fd451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AcquisitionRestructuringAndOtherItemsNet_79fd3610-2091-4d50-a138-d2a3dce86860" xlink:href="ango-20230531.xsd#ango_AcquisitionRestructuringAndOtherItemsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6bf3550e-b33e-40da-8f72-40e6c33fd451" xlink:to="loc_ango_AcquisitionRestructuringAndOtherItemsNet_79fd3610-2091-4d50-a138-d2a3dce86860" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b97a6d19-58ed-4a81-bcc1-bb1235dd0de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6bf3550e-b33e-40da-8f72-40e6c33fd451" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b97a6d19-58ed-4a81-bcc1-bb1235dd0de7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_25c4f202-1cbd-4a34-8470-b8d68eb1cf40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b97a6d19-58ed-4a81-bcc1-bb1235dd0de7" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_25c4f202-1cbd-4a34-8470-b8d68eb1cf40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_25c4f202-1cbd-4a34-8470-b8d68eb1cf40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_25c4f202-1cbd-4a34-8470-b8d68eb1cf40" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_25c4f202-1cbd-4a34-8470-b8d68eb1cf40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_80390d57-b012-4a6b-9f83-055e15c475c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_25c4f202-1cbd-4a34-8470-b8d68eb1cf40" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_80390d57-b012-4a6b-9f83-055e15c475c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SettlementExpenseMember_3475ab08-21f2-45ff-9ccb-5f2ba5e167ac" xlink:href="ango-20230531.xsd#ango_SettlementExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_80390d57-b012-4a6b-9f83-055e15c475c8" xlink:to="loc_ango_SettlementExpenseMember_3475ab08-21f2-45ff-9ccb-5f2ba5e167ac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="ie36937e5476e49e0b81ccadf75722afa_AccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_885ac517-3a3c-4c00-be6a-757d8904eee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_f592769b-cde7-473e-b71c-8c36af4c74ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_885ac517-3a3c-4c00-be6a-757d8904eee8" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_f592769b-cde7-473e-b71c-8c36af4c74ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d0dd9336-27a9-43b3-90a3-a3377c59220e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_f592769b-cde7-473e-b71c-8c36af4c74ac" xlink:to="loc_us-gaap_StockholdersEquity_d0dd9336-27a9-43b3-90a3-a3377c59220e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_ad20533c-4295-464e-925b-3ee540bdf046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_f592769b-cde7-473e-b71c-8c36af4c74ac" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_ad20533c-4295-464e-925b-3ee540bdf046" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d803fe27-8985-48f0-b008-0a44563df280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_f592769b-cde7-473e-b71c-8c36af4c74ac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d803fe27-8985-48f0-b008-0a44563df280" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_19ac1f4a-08fa-4c65-ad77-8d3f9a72736f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_842197dc-47d3-440a-a9ba-2a1c0464f45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_885ac517-3a3c-4c00-be6a-757d8904eee8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_842197dc-47d3-440a-a9ba-2a1c0464f45d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8e98c979-ca63-4871-be03-bfed57bc7efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_842197dc-47d3-440a-a9ba-2a1c0464f45d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8e98c979-ca63-4871-be03-bfed57bc7efe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8e98c979-ca63-4871-be03-bfed57bc7efe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8e98c979-ca63-4871-be03-bfed57bc7efe" xlink:to="loc_us-gaap_EquityComponentDomain_8e98c979-ca63-4871-be03-bfed57bc7efe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dc4bbc0e-d51b-4084-b032-9283ef59977d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8e98c979-ca63-4871-be03-bfed57bc7efe" xlink:to="loc_us-gaap_EquityComponentDomain_dc4bbc0e-d51b-4084-b032-9283ef59977d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9d22b8f5-6f0c-4dba-aff2-707f2c7cbabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dc4bbc0e-d51b-4084-b032-9283ef59977d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9d22b8f5-6f0c-4dba-aff2-707f2c7cbabc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/SubsequentEventsDetails" xlink:type="extended" id="i001b64a59db2432299b9d76db0eaa6b7_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_03577fc2-b9b8-4ed1-9405-bb49bf7ea5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssets1_7205e9cb-a921-420f-bfca-b557b837496c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_03577fc2-b9b8-4ed1-9405-bb49bf7ea5ee" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssets1_7205e9cb-a921-420f-bfca-b557b837496c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f53d3407-d486-4794-81ef-455d4a69a2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_03577fc2-b9b8-4ed1-9405-bb49bf7ea5ee" xlink:to="loc_us-gaap_SubsequentEventTable_f53d3407-d486-4794-81ef-455d4a69a2ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4f60936f-ef9c-4319-95f1-d71cd79abe50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f53d3407-d486-4794-81ef-455d4a69a2ed" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4f60936f-ef9c-4319-95f1-d71cd79abe50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4f60936f-ef9c-4319-95f1-d71cd79abe50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4f60936f-ef9c-4319-95f1-d71cd79abe50" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4f60936f-ef9c-4319-95f1-d71cd79abe50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b20dbe7c-de5b-41a4-b5f4-2d35daadb9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4f60936f-ef9c-4319-95f1-d71cd79abe50" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b20dbe7c-de5b-41a4-b5f4-2d35daadb9d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7e2d046e-0566-4797-88b1-9159a3422e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b20dbe7c-de5b-41a4-b5f4-2d35daadb9d3" xlink:to="loc_us-gaap_SubsequentEventMember_7e2d046e-0566-4797-88b1-9159a3422e63" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#ValuationandQualifyingAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails" xlink:type="extended" id="icafa3a97fd1b4cb8909b348e5aba1a8b_ValuationandQualifyingAccountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_314ee58c-bea9-429e-aa4e-0bed9cabd443" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_9f8b3ef4-1e2b-4320-8785-87ffa5982b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_314ee58c-bea9-429e-aa4e-0bed9cabd443" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_9f8b3ef4-1e2b-4320-8785-87ffa5982b94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d23548b5-5acf-437e-84d3-1e223d1f8f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_9f8b3ef4-1e2b-4320-8785-87ffa5982b94" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d23548b5-5acf-437e-84d3-1e223d1f8f89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_ebdbfca0-ec95-4bb0-bf24-bdd790252996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_9f8b3ef4-1e2b-4320-8785-87ffa5982b94" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_ebdbfca0-ec95-4bb0-bf24-bdd790252996" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_0758cb37-6cad-4f1a-8201-d959a81aaa57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_9f8b3ef4-1e2b-4320-8785-87ffa5982b94" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_0758cb37-6cad-4f1a-8201-d959a81aaa57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_b1fc9205-f9dd-4ebf-8acb-b4ef44bfe7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d22fdf6a-01fc-4d9b-9386-a0ab2f4b7e81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_314ee58c-bea9-429e-aa4e-0bed9cabd443" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d22fdf6a-01fc-4d9b-9386-a0ab2f4b7e81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ac8f622e-6095-472b-b7cf-887139ad6341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d22fdf6a-01fc-4d9b-9386-a0ab2f4b7e81" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ac8f622e-6095-472b-b7cf-887139ad6341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_ac8f622e-6095-472b-b7cf-887139ad6341_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ac8f622e-6095-472b-b7cf-887139ad6341" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_ac8f622e-6095-472b-b7cf-887139ad6341_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1838c7a0-82cf-4763-b727-a9a551490296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ac8f622e-6095-472b-b7cf-887139ad6341" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1838c7a0-82cf-4763-b727-a9a551490296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_55ab5aa6-940f-4b54-bdb9-114629103e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1838c7a0-82cf-4763-b727-a9a551490296" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_55ab5aa6-940f-4b54-bdb9-114629103e24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember_2e9026f4-f604-4e18-9605-bedad285e260" xlink:href="ango-20230531.xsd#ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1838c7a0-82cf-4763-b727-a9a551490296" xlink:to="loc_ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember_2e9026f4-f604-4e18-9605-bedad285e260" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AcquisitionRestructuringAndOtherItemsNet_d9a7993a-ec74-4a12-b732-940f39ba2f9f" xlink:href="ango-20230531.xsd#ango_AcquisitionRestructuringAndOtherItemsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_ango_AcquisitionRestructuringAndOtherItemsNet_d9a7993a-ec74-4a12-b732-940f39ba2f9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ango-20230531_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:9980962c-8c03-489b-926a-266c60a03003,g:4284608e-2675-438a-ad4d-4e46a03d6c06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_6b8cf616-74bf-47b9-9af3-372d38a68220_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_eaa8ca68-f373-4137-9b0a-36a8218fef4b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_113c6736-2bd1-42ee-948f-7f8b545c6df4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_442ad4c1-dbca-4792-ac0a-b1524df9eb58_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_52bac82f-a83a-4b5b-a794-1d1eb1f33980_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non U.S.</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7c91dce8-f59d-43b5-b250-398b83cf844d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_91b0d261-2ad6-4a10-89d4-c8ac587fdbd7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in accounts receivable allowances</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_b8cbd249-032d-4b10-a3e9-391e5ee8d6a7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_01cb255f-1842-43ea-81af-caadb7e89cab_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_02fef2ce-1753-408b-a635-85ede46332d7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure_da594c5b-a8fe-4716-a233-168b12f3cdee_verboseLabel_en-US" xlink:label="lab_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential amount of undiscounted future contingent consideration</link:label>
    <link:label id="lab_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure_label_en-US" xlink:label="lab_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted Contingent Consideration Fair Value Fair Value Disclosure</link:label>
    <link:label id="lab_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure_documentation_en-US" xlink:label="lab_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted contingent consideration fair value fair value disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure" xlink:href="ango-20230531.xsd#ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure" xlink:to="lab_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_4dc4c0de-2990-43d2-8837-7cffbb487edd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_00fb32b4-4314-4539-912f-436121b4e061_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_821214f9-ef3d-4662-b4cf-f1fda3d64b8b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_717039c0-1a45-48eb-90bf-2c879e38953a_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_f580c4ae-8432-4ad9-8e92-77a10ef27f48_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_MergersandAcquisitionsMember_80f75de6-6f94-484c-a6ae-572d5e0275cd_terseLabel_en-US" xlink:label="lab_ango_MergersandAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers and acquisitions</link:label>
    <link:label id="lab_ango_MergersandAcquisitionsMember_label_en-US" xlink:label="lab_ango_MergersandAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers and Acquisitions [Member]</link:label>
    <link:label id="lab_ango_MergersandAcquisitionsMember_documentation_en-US" xlink:label="lab_ango_MergersandAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers and Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MergersandAcquisitionsMember" xlink:href="ango-20230531.xsd#ango_MergersandAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_MergersandAcquisitionsMember" xlink:to="lab_ango_MergersandAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_PrepaidEmployeeTaxCredit_2518d1a4-d800-4bde-acdb-684e2bf3f7d8_terseLabel_en-US" xlink:label="lab_ango_PrepaidEmployeeTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Retention Tax Credit</link:label>
    <link:label id="lab_ango_PrepaidEmployeeTaxCredit_label_en-US" xlink:label="lab_ango_PrepaidEmployeeTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Employee Tax Credit</link:label>
    <link:label id="lab_ango_PrepaidEmployeeTaxCredit_documentation_en-US" xlink:label="lab_ango_PrepaidEmployeeTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Employee Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidEmployeeTaxCredit" xlink:href="ango-20230531.xsd#ango_PrepaidEmployeeTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_PrepaidEmployeeTaxCredit" xlink:to="lab_ango_PrepaidEmployeeTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_0c39e493-8fa2-454d-b8c5-10a74b890ab9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_668258c2-02f9-4c1c-b9a7-986699578893_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_5689ebbf-0915-49b3-8cd4-37c35150aadd_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_CrBardIncMember_cae0e98b-964a-4667-8412-c5e10214d993_terseLabel_en-US" xlink:label="lab_ango_CrBardIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C.R. Bard, Inc.</link:label>
    <link:label id="lab_ango_CrBardIncMember_label_en-US" xlink:label="lab_ango_CrBardIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cr Bard Inc [Member]</link:label>
    <link:label id="lab_ango_CrBardIncMember_documentation_en-US" xlink:label="lab_ango_CrBardIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C.R. Bard, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CrBardIncMember" xlink:href="ango-20230531.xsd#ango_CrBardIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_CrBardIncMember" xlink:to="lab_ango_CrBardIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_386156c4-b0c7-4f71-a984-c2a2d69bde44_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_a3d4140a-8173-460d-8bf7-5680166ac3f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_af2f0451-4c5e-44c5-8221-67f56fa6981f_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_ecf3a1e9-fb5c-469a-9eac-6ac28564ec75_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_9f5c38a5-7570-4dab-9d81-b17a8f1b80fe_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ManufacturingRelocationMember_393b6357-925c-4944-a4d0-dfe4325d4167_terseLabel_en-US" xlink:label="lab_ango_ManufacturingRelocationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Relocation</link:label>
    <link:label id="lab_ango_ManufacturingRelocationMember_label_en-US" xlink:label="lab_ango_ManufacturingRelocationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Relocation [Member]</link:label>
    <link:label id="lab_ango_ManufacturingRelocationMember_documentation_en-US" xlink:label="lab_ango_ManufacturingRelocationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Relocation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ManufacturingRelocationMember" xlink:href="ango-20230531.xsd#ango_ManufacturingRelocationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ManufacturingRelocationMember" xlink:to="lab_ango_ManufacturingRelocationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_679b9354-7091-481a-b2fe-23b02da858da_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5b8d7e0d-bf29-40fc-91a8-874f34445d12_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn_1cde617b-37a4-46cb-8f37-9491c213a4de_terseLabel_en-US" xlink:label="lab_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restocking charge period (months)</link:label>
    <link:label id="lab_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn_label_en-US" xlink:label="lab_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Right of Return, Minimum Remaining Product Life Prior to Return</link:label>
    <link:label id="lab_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn_documentation_en-US" xlink:label="lab_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Right of Return, Minimum Remaining Product Life Prior to Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn" xlink:href="ango-20230531.xsd#ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn" xlink:to="lab_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8c5b765b-22b4-4b54-bf14-9060eb0781f0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c6b84f4b-3fbb-45ea-acbc-4d771ddcde6e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_01da8356-4f7b-4954-bade-7b7e2694328a_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f04dfca9-6f22-495d-9d6d-8e59fc6dd3d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eb5d72df-2a74-470b-be91-0d2560b076ce_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_edeb5d58-6bdb-407d-b6a7-ac011f4bb6c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9a8b8511-e5d1-4d1d-aa05-5db6546d3dfd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_740c4f48-0347-4141-bd8b-dd496d5768a7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net sales for geographic areas</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_963de177-8647-482d-b267-5f12e56eb76e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_PlacementAndEvaluationUnitsMember_7da04327-f227-49ec-abd3-42e2746dcea1_terseLabel_en-US" xlink:label="lab_ango_PlacementAndEvaluationUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement and evaluation units</link:label>
    <link:label id="lab_ango_PlacementAndEvaluationUnitsMember_label_en-US" xlink:label="lab_ango_PlacementAndEvaluationUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement And Evaluation Units [Member]</link:label>
    <link:label id="lab_ango_PlacementAndEvaluationUnitsMember_documentation_en-US" xlink:label="lab_ango_PlacementAndEvaluationUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement And Evaluation Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PlacementAndEvaluationUnitsMember" xlink:href="ango-20230531.xsd#ango_PlacementAndEvaluationUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_PlacementAndEvaluationUnitsMember" xlink:to="lab_ango_PlacementAndEvaluationUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_7ead5907-5c29-495f-9f33-743033945b86_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease due to lapse in statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_85a8b01b-ab6c-48aa-b5c6-bf00a64b4bcf_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_e239ba4e-0734-4594-85cb-5728726fc1e4_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_DebtInstrumentFloorInterestRate_92c64eec-b1e7-4a9a-b155-557b1e3f979a_terseLabel_en-US" xlink:label="lab_ango_DebtInstrumentFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Floor Interest Rate</link:label>
    <link:label id="lab_ango_DebtInstrumentFloorInterestRate_label_en-US" xlink:label="lab_ango_DebtInstrumentFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Floor Interest Rate</link:label>
    <link:label id="lab_ango_DebtInstrumentFloorInterestRate_documentation_en-US" xlink:label="lab_ango_DebtInstrumentFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Floor Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentFloorInterestRate" xlink:href="ango-20230531.xsd#ango_DebtInstrumentFloorInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_DebtInstrumentFloorInterestRate" xlink:to="lab_ango_DebtInstrumentFloorInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_e7ba75c8-15ee-47a8-a3d4-83ca80ecc9c7_verboseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_8273bd90-69e0-40c4-ae0a-49ecb22720e4_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_AccruedResearchAndDevelopmentCurrent_e5a5c958-663a-43ce-a46e-4880255656f9_terseLabel_en-US" xlink:label="lab_ango_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ango_AccruedResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_ango_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development, Current</link:label>
    <link:label id="lab_ango_AccruedResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_ango_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AccruedResearchAndDevelopmentCurrent" xlink:href="ango-20230531.xsd#ango_AccruedResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_AccruedResearchAndDevelopmentCurrent" xlink:to="lab_ango_AccruedResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6e49ed29-841f-4bba-94e1-522e3646ee79_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8b8ac87d-e187-4758-a2fb-02981473ee92_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9e397243-7880-48a0-8c17-5f4b98cc907e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_69772884-cc56-4110-9900-2c5d673c9fbc_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_AcquisitionRestructuringAndOtherItemsNet_686cf81d-f345-4f89-930d-3150175ad0fe_verboseLabel_en-US" xlink:label="lab_ango_AcquisitionRestructuringAndOtherItemsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, restructuring and other items, net</link:label>
    <link:label id="lab_ango_AcquisitionRestructuringAndOtherItemsNet_cfe1f51b-102a-4910-a370-373a1383a984_terseLabel_en-US" xlink:label="lab_ango_AcquisitionRestructuringAndOtherItemsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ango_AcquisitionRestructuringAndOtherItemsNet_label_en-US" xlink:label="lab_ango_AcquisitionRestructuringAndOtherItemsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Restructuring and Other Items Net</link:label>
    <link:label id="lab_ango_AcquisitionRestructuringAndOtherItemsNet_documentation_en-US" xlink:label="lab_ango_AcquisitionRestructuringAndOtherItemsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Restructuring And Other Items Net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AcquisitionRestructuringAndOtherItemsNet" xlink:href="ango-20230531.xsd#ango_AcquisitionRestructuringAndOtherItemsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_AcquisitionRestructuringAndOtherItemsNet" xlink:to="lab_ango_AcquisitionRestructuringAndOtherItemsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_bfe2bd10-a880-4e5a-8bf9-3168e01b973f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_d5a01fc4-757a-404d-9f11-b0868baaa1e3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5bbc124a-b09c-4b3d-87fc-a83be3af5152_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities excluded as their inclusion would be anti-dilutive</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_b774f433-1ddc-4dd7-b610-9f1559ac7cd9_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_bb315ca3-8a85-444e-bfba-27b40e2a137a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_PrepaidIncomeandOtherTaxes_ec5cfa9b-09d6-4a5a-a37f-5f2f784b3807_terseLabel_en-US" xlink:label="lab_ango_PrepaidIncomeandOtherTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid taxes</link:label>
    <link:label id="lab_ango_PrepaidIncomeandOtherTaxes_label_en-US" xlink:label="lab_ango_PrepaidIncomeandOtherTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Income and Other Taxes</link:label>
    <link:label id="lab_ango_PrepaidIncomeandOtherTaxes_documentation_en-US" xlink:label="lab_ango_PrepaidIncomeandOtherTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Income and Other Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidIncomeandOtherTaxes" xlink:href="ango-20230531.xsd#ango_PrepaidIncomeandOtherTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_PrepaidIncomeandOtherTaxes" xlink:to="lab_ango_PrepaidIncomeandOtherTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_1d16200c-8f64-4267-b978-3e265ea257ff_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_68a86e7f-38ca-46bc-9c67-fb57bb78bde9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b508be08-8da0-4a67-ada1-2c307489ccb0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_07ce385f-ab82-43de-a0f2-2bc960580872_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_8007e291-b31b-494f-b24f-b061a6ab5e79_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_52bc0c80-9d5f-4576-972d-a18d1b44a2cf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_d8fa0681-a6e3-4043-873f-a307ae582e00_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_RoyaltiesDueAfterFourthYear_f111739d-516d-497e-8927-c09211916459_terseLabel_en-US" xlink:label="lab_ango_RoyaltiesDueAfterFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_ango_RoyaltiesDueAfterFourthYear_label_en-US" xlink:label="lab_ango_RoyaltiesDueAfterFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Due After Fourth Year</link:label>
    <link:label id="lab_ango_RoyaltiesDueAfterFourthYear_documentation_en-US" xlink:label="lab_ango_RoyaltiesDueAfterFourthYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Due After Fourth Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueAfterFourthYear" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueAfterFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_RoyaltiesDueAfterFourthYear" xlink:to="lab_ango_RoyaltiesDueAfterFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_c21c9b98-eb14-4c4c-aa8f-b9b7985c7bb9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_86377f05-1b1b-48a5-9b34-0b1a449acf13_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_907be3b8-d948-48e8-a1db-fb2a0bbda3c0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_5bcbaca6-0f5e-4507-b3b6-7cf47a91c2c6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_22389aec-2fcd-4d36-a5c2-5e1d4a729ef2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_805863af-2619-431f-be7d-467cbc58e39d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price Forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_da1cc277-93a6-4298-b972-db947127bb8f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_6c46a4b9-fa70-4a01-a182-529bd864c0e2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_7c474f7e-54a6-403c-8190-4054e22fe40e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a4fdb381-0bcc-47bd-9dd2-2ea3a3327f8c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_499b08a2-b8ad-45cd-b0f8-2f6424c7db72_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6266d988-ef19-4a4f-aa8a-af9cf30e83d6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8452a115-854a-4705-9d5e-ee93dfeca795_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_PrepaidExpensesAndOtherTextBlock_546697cb-d338-41b5-bf13-9c87c4c3c9a3_verboseLabel_en-US" xlink:label="lab_ango_PrepaidExpensesAndOtherTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREPAID EXPENSES AND OTHER</link:label>
    <link:label id="lab_ango_PrepaidExpensesAndOtherTextBlock_label_en-US" xlink:label="lab_ango_PrepaidExpensesAndOtherTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other [Text Block]</link:label>
    <link:label id="lab_ango_PrepaidExpensesAndOtherTextBlock_documentation_en-US" xlink:label="lab_ango_PrepaidExpensesAndOtherTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidExpensesAndOtherTextBlock" xlink:href="ango-20230531.xsd#ango_PrepaidExpensesAndOtherTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_PrepaidExpensesAndOtherTextBlock" xlink:to="lab_ango_PrepaidExpensesAndOtherTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_b0dc8d55-53f0-4318-a1ee-4c2493f88054_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d09c034f-54c9-49bf-a21c-8758e705cdfc_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ScheduleofIncomeTaxLineItems_81ddb792-7825-406e-8d90-77ae23cb8360_verboseLabel_en-US" xlink:label="lab_ango_ScheduleofIncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_ango_ScheduleofIncomeTaxLineItems_label_en-US" xlink:label="lab_ango_ScheduleofIncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax [Line Items]</link:label>
    <link:label id="lab_ango_ScheduleofIncomeTaxLineItems_documentation_en-US" xlink:label="lab_ango_ScheduleofIncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ScheduleofIncomeTaxLineItems" xlink:href="ango-20230531.xsd#ango_ScheduleofIncomeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ScheduleofIncomeTaxLineItems" xlink:to="lab_ango_ScheduleofIncomeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_PrepaidExpensesAndOtherTableTextBlock_ffc8655e-4afd-4245-add9-4e9ba1a1fe17_verboseLabel_en-US" xlink:label="lab_ango_PrepaidExpensesAndOtherTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_ango_PrepaidExpensesAndOtherTableTextBlock_label_en-US" xlink:label="lab_ango_PrepaidExpensesAndOtherTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other [Table Text Block]</link:label>
    <link:label id="lab_ango_PrepaidExpensesAndOtherTableTextBlock_documentation_en-US" xlink:label="lab_ango_PrepaidExpensesAndOtherTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidExpensesAndOtherTableTextBlock" xlink:href="ango-20230531.xsd#ango_PrepaidExpensesAndOtherTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_PrepaidExpensesAndOtherTableTextBlock" xlink:to="lab_ango_PrepaidExpensesAndOtherTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ChangeInFairValueOfContingentConsideration_860f0de2-91c5-4fa0-8900-126e54d2d5f0_verboseLabel_en-US" xlink:label="lab_ango_ChangeInFairValueOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_ango_ChangeInFairValueOfContingentConsideration_label_en-US" xlink:label="lab_ango_ChangeInFairValueOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_ango_ChangeInFairValueOfContingentConsideration_documentation_en-US" xlink:label="lab_ango_ChangeInFairValueOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expense charged against earnings in the period resulting from remeasurement to fair value of contingent earn out liabilities related to acquisitions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ChangeInFairValueOfContingentConsideration" xlink:href="ango-20230531.xsd#ango_ChangeInFairValueOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ChangeInFairValueOfContingentConsideration" xlink:to="lab_ango_ChangeInFairValueOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_887c5068-6af8-439b-84bc-b7a3adaef8ad_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_TaxPeriodOneMember_521de9bf-b48c-43b4-9ae9-5386cd1fdb8e_terseLabel_en-US" xlink:label="lab_ango_TaxPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2022 and 2023</link:label>
    <link:label id="lab_ango_TaxPeriodOneMember_label_en-US" xlink:label="lab_ango_TaxPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period One [Member]</link:label>
    <link:label id="lab_ango_TaxPeriodOneMember_documentation_en-US" xlink:label="lab_ango_TaxPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TaxPeriodOneMember" xlink:href="ango-20230531.xsd#ango_TaxPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_TaxPeriodOneMember" xlink:to="lab_ango_TaxPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_cc0f7ad4-6036-4e57-98fe-64eb4d55a027_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_67bbeaf6-67cd-419b-8707-1d80aeeef728_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1109633-76ad-4d93-8535-92adb0a9ace0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e755bc49-fb99-4df2-a14c-8b7f1ca798b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_GrossMarginPercentage_450e1176-6836-4eae-84ce-c562c51c27f0_terseLabel_en-US" xlink:label="lab_ango_GrossMarginPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Margin</link:label>
    <link:label id="lab_ango_GrossMarginPercentage_label_en-US" xlink:label="lab_ango_GrossMarginPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Margin, Percentage</link:label>
    <link:label id="lab_ango_GrossMarginPercentage_documentation_en-US" xlink:label="lab_ango_GrossMarginPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Margin, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_GrossMarginPercentage" xlink:href="ango-20230531.xsd#ango_GrossMarginPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_GrossMarginPercentage" xlink:to="lab_ango_GrossMarginPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f66b8a3a-4507-4670-9627-312a88d3612e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b25db8b6-e4f3-439d-bb6a-3534194aeaf5_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_67ea017d-0a8e-42eb-b5c9-5a428c11a4af_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_RoyaltiesDueinThirdYear_9bb45800-9f5c-4add-b187-db53985b077f_terseLabel_en-US" xlink:label="lab_ango_RoyaltiesDueinThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ango_RoyaltiesDueinThirdYear_label_en-US" xlink:label="lab_ango_RoyaltiesDueinThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Due in Third Year</link:label>
    <link:label id="lab_ango_RoyaltiesDueinThirdYear_documentation_en-US" xlink:label="lab_ango_RoyaltiesDueinThirdYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Due in Third Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueinThirdYear" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueinThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_RoyaltiesDueinThirdYear" xlink:to="lab_ango_RoyaltiesDueinThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_bf15fa9b-cf1a-46b4-a060-0ab0f3b04b7f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_EmployeePlanParticipatingEligibilityThresholdPercentage_b41cac64-4c87-4bd3-a34b-81cd8f1a0341_verboseLabel_en-US" xlink:label="lab_ango_EmployeePlanParticipatingEligibilityThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees ownership threshold</link:label>
    <link:label id="lab_ango_EmployeePlanParticipatingEligibilityThresholdPercentage_label_en-US" xlink:label="lab_ango_EmployeePlanParticipatingEligibilityThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Plan Participating Eligibility Threshold Percentage</link:label>
    <link:label id="lab_ango_EmployeePlanParticipatingEligibilityThresholdPercentage_documentation_en-US" xlink:label="lab_ango_EmployeePlanParticipatingEligibilityThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership threshold for participating plan eligibility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EmployeePlanParticipatingEligibilityThresholdPercentage" xlink:href="ango-20230531.xsd#ango_EmployeePlanParticipatingEligibilityThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_EmployeePlanParticipatingEligibilityThresholdPercentage" xlink:to="lab_ango_EmployeePlanParticipatingEligibilityThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_bbca831a-82d1-4d4a-8256-be2a043b1904_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_AccountsReceivableDuePeriod_a3fac16a-dbe8-49ee-a337-df90c83ac298_verboseLabel_en-US" xlink:label="lab_ango_AccountsReceivableDuePeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivables period due</link:label>
    <link:label id="lab_ango_AccountsReceivableDuePeriod_label_en-US" xlink:label="lab_ango_AccountsReceivableDuePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Due Period</link:label>
    <link:label id="lab_ango_AccountsReceivableDuePeriod_documentation_en-US" xlink:label="lab_ango_AccountsReceivableDuePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable due period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AccountsReceivableDuePeriod" xlink:href="ango-20230531.xsd#ango_AccountsReceivableDuePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_AccountsReceivableDuePeriod" xlink:to="lab_ango_AccountsReceivableDuePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ee5522bd-91b3-43ad-8199-6e1b5e23d6f0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_42065990-c37d-4759-8dee-13ba73c63fe5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59beef8c-460a-40d3-9c22-fdb3ae9d59c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_8569f19e-cc80-4131-9434-748049472c97_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IsraelTaxAuthorityMember_4605939c-6d4a-4982-8a7c-358c19089a04_terseLabel_en-US" xlink:label="lab_us-gaap_IsraelTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Israel</link:label>
    <link:label id="lab_us-gaap_IsraelTaxAuthorityMember_label_en-US" xlink:label="lab_us-gaap_IsraelTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Israel Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IsraelTaxAuthorityMember" xlink:to="lab_us-gaap_IsraelTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c29767a-e2ca-4c9b-a0d6-e901c12615b4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_bd8f3fdd-0768-480d-9819-c78093fadcc2_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_RevenueBasedPaymentMember_10b996e7-90d7-445a-aa0f-065051eb3173_terseLabel_en-US" xlink:label="lab_ango_RevenueBasedPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue based payments</link:label>
    <link:label id="lab_ango_RevenueBasedPaymentMember_label_en-US" xlink:label="lab_ango_RevenueBasedPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Based Payment [Member]</link:label>
    <link:label id="lab_ango_RevenueBasedPaymentMember_documentation_en-US" xlink:label="lab_ango_RevenueBasedPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Based Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevenueBasedPaymentMember" xlink:href="ango-20230531.xsd#ango_RevenueBasedPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_RevenueBasedPaymentMember" xlink:to="lab_ango_RevenueBasedPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_18f9fda8-f8b3-4077-a9af-5337d6826acd_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b525775b-744d-4dc8-94bc-4348d224a3ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_54f1e83a-b619-46d6-b4d1-57b58508bf41_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1a75dd89-09e1-4f82-83e6-6c1afae1cde8_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f714d13c-0be9-4832-bd94-b15acf283304_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d2adecc4-6b57-4884-afe1-981269679d0a_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_fb1ceb15-22b6-430c-8a7a-af7661bda417_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fb4dc1e4-4f49-4625-a153-a08fa1b0385f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15b4487f-b030-41a5-862c-90bc912faa09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_1424e4b8-e1c0-4649-bf8b-30d602810988_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_23623563-5840-42d8-942d-8c98a6591530_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_e80a9711-e2a5-4fcf-9f98-0f0eac3b750c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_c162179e-44b1-46a5-b2c3-a5170fd0e67e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_21f8b074-c0c1-4bb9-8978-4ee5a02e12df_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovements_ee120bef-ae21-405d-a38a-0908354697a7_verboseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and land improvements</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovements_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and Land Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovements" xlink:to="lab_us-gaap_LandAndLandImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_989a11e0-4e04-47dd-a60d-3ae33af85893_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Two, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_aa848709-79b3-44a4-8c7c-d45a16ec438a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_3185b3c0-a4b0-4546-af0e-4b04f67a5cf0_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3f0aae85-d7a5-476a-9593-60a663c0024c_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_6ea73b7e-7610-4d3b-b068-e522ad01ec01_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bedd8006-ba46-4cb8-96c5-d8e00d9d579d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e79ecca4-1c57-40e3-86ef-74d41a0dc04c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested compensation, weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4173e68e-aa04-4980-9d0d-f5fff3bd2f99_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant-Date Fair Value Beginning Balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cf95c8c8-0902-4289-a30d-08ed3adee161_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant-Date Fair Value Ending Balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_cd4eea7f-de2c-4c60-8675-8d9b3e821fa7_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_eb6f6309-a4e1-4d3e-9d50-26ccff7402c8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3fd2cc4f-f904-4e73-8db9-69233e3e1120_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a56fa639-37e0-4e36-b1eb-24818b35806c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_813c0ab9-ae72-416d-b6d8-a544ecc23b8e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in gross amounts of tax positions related to prior years due to U.S. tax reform</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_7faa1ad2-fbd7-4745-8224-31a5203d4e32_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d8f4d216-49f3-4666-836b-56c7738c2ca7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_SalesandMarketingMember_9e497d27-fbc8-4d18-b11b-2a6d7232ef65_terseLabel_en-US" xlink:label="lab_ango_SalesandMarketingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_ango_SalesandMarketingMember_label_en-US" xlink:label="lab_ango_SalesandMarketingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and Marketing [Member]</link:label>
    <link:label id="lab_ango_SalesandMarketingMember_documentation_en-US" xlink:label="lab_ango_SalesandMarketingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and Marketing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SalesandMarketingMember" xlink:href="ango-20230531.xsd#ango_SalesandMarketingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_SalesandMarketingMember" xlink:to="lab_ango_SalesandMarketingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_60829131-7b94-4f94-bc53-7ed0fb54e1ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_b59debef-0120-4a22-8b8f-846ad37e0a69_verboseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ScheduleOfNetRevenueByProductGroupTableTextBlock_7eb8a70f-f66f-4311-a5fa-b62a343ad2ca_verboseLabel_en-US" xlink:label="lab_ango_ScheduleOfNetRevenueByProductGroupTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of total net sales by product category</link:label>
    <link:label id="lab_ango_ScheduleOfNetRevenueByProductGroupTableTextBlock_label_en-US" xlink:label="lab_ango_ScheduleOfNetRevenueByProductGroupTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Revenue by Product Group [Table Text Block]</link:label>
    <link:label id="lab_ango_ScheduleOfNetRevenueByProductGroupTableTextBlock_documentation_en-US" xlink:label="lab_ango_ScheduleOfNetRevenueByProductGroupTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net revenue by product group.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ScheduleOfNetRevenueByProductGroupTableTextBlock" xlink:href="ango-20230531.xsd#ango_ScheduleOfNetRevenueByProductGroupTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ScheduleOfNetRevenueByProductGroupTableTextBlock" xlink:to="lab_ango_ScheduleOfNetRevenueByProductGroupTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_964e5207-546f-45b3-af1c-53ad4fe2d3fe_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRent_8bdc1f5e-b6db-464d-9585-9a83b69b3a17_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent</link:label>
    <link:label id="lab_us-gaap_PrepaidRent_label_en-US" xlink:label="lab_us-gaap_PrepaidRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRent" xlink:to="lab_us-gaap_PrepaidRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_33ad945b-0342-40f2-a37e-add24dfa175c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_7dff6b81-0938-4f30-9c3c-5dbc2d9afa54_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_StockPurchasePlanMember_9ebd6a86-11f6-419e-bac5-3276d291f9be_terseLabel_en-US" xlink:label="lab_ango_StockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Plan</link:label>
    <link:label id="lab_ango_StockPurchasePlanMember_label_en-US" xlink:label="lab_ango_StockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_ango_StockPurchasePlanMember_documentation_en-US" xlink:label="lab_ango_StockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_StockPurchasePlanMember" xlink:href="ango-20230531.xsd#ango_StockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_StockPurchasePlanMember" xlink:to="lab_ango_StockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_022efa9e-6c91-44b1-9967-e6f3d215f459_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ec45cf26-d3af-4265-8d9f-03374860d68e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_e1822188-f109-4b34-842b-e31010a8fd84_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_NumberOfPatentsAssertedForReexamination_50c5ad92-7f2d-4a37-863b-faf723d8564a_terseLabel_en-US" xlink:label="lab_ango_NumberOfPatentsAssertedForReexamination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of petitions filed for reexamination of patents</link:label>
    <link:label id="lab_ango_NumberOfPatentsAssertedForReexamination_label_en-US" xlink:label="lab_ango_NumberOfPatentsAssertedForReexamination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Patents Asserted for Reexamination</link:label>
    <link:label id="lab_ango_NumberOfPatentsAssertedForReexamination_documentation_en-US" xlink:label="lab_ango_NumberOfPatentsAssertedForReexamination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents asserted for reexamination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_NumberOfPatentsAssertedForReexamination" xlink:href="ango-20230531.xsd#ango_NumberOfPatentsAssertedForReexamination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_NumberOfPatentsAssertedForReexamination" xlink:to="lab_ango_NumberOfPatentsAssertedForReexamination" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_EximoMedicalLtd.Member_ccea0a1d-4d15-40e6-9251-6ef6bb326232_terseLabel_en-US" xlink:label="lab_ango_EximoMedicalLtd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eximo Medical, Ltd.</link:label>
    <link:label id="lab_ango_EximoMedicalLtd.Member_label_en-US" xlink:label="lab_ango_EximoMedicalLtd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eximo Medical, Ltd. [Member]</link:label>
    <link:label id="lab_ango_EximoMedicalLtd.Member_documentation_en-US" xlink:label="lab_ango_EximoMedicalLtd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eximo Medical, Ltd. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EximoMedicalLtd.Member" xlink:href="ango-20230531.xsd#ango_EximoMedicalLtd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_EximoMedicalLtd.Member" xlink:to="lab_ango_EximoMedicalLtd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3270fff7-3313-444a-ab6d-16f015d78211_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_61818b53-47fa-4a8e-b2b4-2210b6ced037_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_bdb33146-521e-4447-9697-e00d04dcb335_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember_910d1e24-9bb5-4ddd-ba8f-514c4615917f_terseLabel_en-US" xlink:label="lab_ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for sales returns and doubtful accounts</link:label>
    <link:label id="lab_ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember_label_en-US" xlink:label="lab_ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Sales Returns and Doubtful Accounts [Member]</link:label>
    <link:label id="lab_ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember_documentation_en-US" xlink:label="lab_ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Sales Returns and Doubtful Accounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember" xlink:href="ango-20230531.xsd#ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember" xlink:to="lab_ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_28abae58-ea86-4649-8768-d40df2667ede_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e8c73d5f-96b9-4e03-8f2d-566ea62ad99e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_50c3c2ca-6d0c-4c8a-8b83-346441296346_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_270c8a02-b94a-476e-8eed-f1948730c961_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and franchise taxes</link:label>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_label_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_2545f1bd-20ee-4010-8f8a-65e4100855a4_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3e3a0b69-af1f-470a-84d5-b97b3e445472_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b06bd507-895c-4ad1-81e4-a7e9c8e20eb5_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c8da1bc1-cfa2-432c-acb6-4a32afe1f17f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_35591083-932e-421a-9766-4f7eba1786ec_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense) related to items of other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_041b1f50-8cb8-4b6a-ad04-084a29020919_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_eabb27f6-f51a-459b-9ce3-5ce8fc770fef_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3970080a-39a5-48e3-a445-63bb8bee3e23_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_9a682d51-c2e6-478a-b2d4-8976e7a91e34_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset product technology</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_aec55ac9-0f47-4789-be2b-26860f11be88_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_72631732-2c45-4868-b774-7ded06b87b4a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_DialysisProductPortfolioAndBioSentryBiopsyMember_474ecc05-f9a2-4238-8d32-2da975e9fef7_terseLabel_en-US" xlink:label="lab_ango_DialysisProductPortfolioAndBioSentryBiopsyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dialysis Product Portfolio And BioSentry Biopsy</link:label>
    <link:label id="lab_ango_DialysisProductPortfolioAndBioSentryBiopsyMember_label_en-US" xlink:label="lab_ango_DialysisProductPortfolioAndBioSentryBiopsyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dialysis Product Portfolio And BioSentry Biopsy [Member]</link:label>
    <link:label id="lab_ango_DialysisProductPortfolioAndBioSentryBiopsyMember_documentation_en-US" xlink:label="lab_ango_DialysisProductPortfolioAndBioSentryBiopsyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dialysis Product Portfolio And BioSentry Biopsy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DialysisProductPortfolioAndBioSentryBiopsyMember" xlink:href="ango-20230531.xsd#ango_DialysisProductPortfolioAndBioSentryBiopsyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_DialysisProductPortfolioAndBioSentryBiopsyMember" xlink:to="lab_ango_DialysisProductPortfolioAndBioSentryBiopsyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0fef9289-0b13-4016-977d-6fe6732e2474_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_9cb78c79-ddf4-4f76-ab0d-618dd6868509_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c21386f2-69c6-47fb-934e-3e61738cb729_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_01aea78b-a574-4387-88db-f1047e3d03f4_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_95df6dce-468c-41f3-9b52-bc64a65ec8e7_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3931f2a8-467f-4d45-a398-759604d3fb67_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a8b61fdf-c521-458a-9752-dc750cfbae61_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_f15e90c2-461e-45b9-9605-b4baa173d836_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_193254fa-47ca-412d-bef4-87470af0a626_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_e13d5a48-532b-4cec-860a-65393b665d6f_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements_70fc71d2-4c24-47ca-ae43-7426a522efb2_totalLabel_en-US" xlink:label="lab_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment excluding land and land improvements</link:label>
    <link:label id="lab_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements_label_en-US" xlink:label="lab_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant and Equipment Excluding Land and Land Improvements</link:label>
    <link:label id="lab_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements_documentation_en-US" xlink:label="lab_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property plant and equipment excluding land and land improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements" xlink:href="ango-20230531.xsd#ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements" xlink:to="lab_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_06a21598-329d-436b-80ef-4f75d5994c55_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b7233056-f16d-4419-98ba-5d2772cf5baa_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income tax (benefit) provision analyzed by category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b20b2b4-917b-4d38-9c22-d36d9126334e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_PrepaidLicenseeFees_93a69692-2c81-4fda-8753-32e1614478f6_verboseLabel_en-US" xlink:label="lab_ango_PrepaidLicenseeFees" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees</link:label>
    <link:label id="lab_ango_PrepaidLicenseeFees_label_en-US" xlink:label="lab_ango_PrepaidLicenseeFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Licensee Fees</link:label>
    <link:label id="lab_ango_PrepaidLicenseeFees_documentation_en-US" xlink:label="lab_ango_PrepaidLicenseeFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount as of the balance sheet date of prepaid licensee fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidLicenseeFees" xlink:href="ango-20230531.xsd#ango_PrepaidLicenseeFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_PrepaidLicenseeFees" xlink:to="lab_ango_PrepaidLicenseeFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3d318ed2-9531-40c6-85ec-c27a1b20d15d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of recognition for costs not yet recognized (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1c73a6ce-7b0e-48a7-b5db-de71c1dfd6ac_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, Option exercisable at year end</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_CapitalStockSharesAuthorized_3c6c55e7-8d59-4e55-986b-f01f0f7a9c56_verboseLabel_en-US" xlink:label="lab_ango_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized capital stock (shares)</link:label>
    <link:label id="lab_ango_CapitalStockSharesAuthorized_label_en-US" xlink:label="lab_ango_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock Shares Authorized</link:label>
    <link:label id="lab_ango_CapitalStockSharesAuthorized_documentation_en-US" xlink:label="lab_ango_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital stock shares authorized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CapitalStockSharesAuthorized" xlink:href="ango-20230531.xsd#ango_CapitalStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_CapitalStockSharesAuthorized" xlink:to="lab_ango_CapitalStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_13b4a189-b275-479d-82e2-561d38b045a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_5d2ff7c3-64aa-4326-9789-b8eac6bff8fd_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software and equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_80fde754-cfdf-439f-95d4-4b6c68eeb6a8_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement_c29a5171-f44c-431f-b71d-1929c6b24590_terseLabel_en-US" xlink:label="lab_ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency gain from remeasurement</link:label>
    <link:label id="lab_ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement_label_en-US" xlink:label="lab_ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Currency Gain (Loss) From Remeasurement</link:label>
    <link:label id="lab_ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement_documentation_en-US" xlink:label="lab_ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Currency Gain (Loss) From Remeasurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement" xlink:href="ango-20230531.xsd#ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement" xlink:to="lab_ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_db59a862-8402-40ac-a782-64e0d654f117_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_331409f6-9af0-41a8-9369-80214ab09af4_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c7447e29-930b-4f60-b2e4-cb0c5c95e4a8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_4b641993-0f57-4b38-8cb9-07d874fe0c2b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average price of share issued</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_MeasurementInputProbabilityofPaymentMember_013c7e3b-6eee-4925-89c9-117f7ffcf4eb_terseLabel_en-US" xlink:label="lab_ango_MeasurementInputProbabilityofPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability of Payment</link:label>
    <link:label id="lab_ango_MeasurementInputProbabilityofPaymentMember_label_en-US" xlink:label="lab_ango_MeasurementInputProbabilityofPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability of Payment [Member]</link:label>
    <link:label id="lab_ango_MeasurementInputProbabilityofPaymentMember_documentation_en-US" xlink:label="lab_ango_MeasurementInputProbabilityofPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability of Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MeasurementInputProbabilityofPaymentMember" xlink:href="ango-20230531.xsd#ango_MeasurementInputProbabilityofPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_MeasurementInputProbabilityofPaymentMember" xlink:to="lab_ango_MeasurementInputProbabilityofPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_bafa5d4f-b0d0-474c-992b-a465a9bd1064_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_1ba59888-06f2-4fde-a925-ef0b01227208_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_b8e722f2-b0c7-4c8d-991b-083c2b7028ce_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_898796f3-fa99-461d-98e8-d76506d22422_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_DeferredIncomeTaxRelatedToOperatingActivity_a4d6709c-e4d2-4ccd-80b5-5dd9e28014dc_verboseLabel_en-US" xlink:label="lab_ango_DeferredIncomeTaxRelatedToOperatingActivity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax provision</link:label>
    <link:label id="lab_ango_DeferredIncomeTaxRelatedToOperatingActivity_label_en-US" xlink:label="lab_ango_DeferredIncomeTaxRelatedToOperatingActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Related To Operating Activity</link:label>
    <link:label id="lab_ango_DeferredIncomeTaxRelatedToOperatingActivity_documentation_en-US" xlink:label="lab_ango_DeferredIncomeTaxRelatedToOperatingActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities related to components of deferred income tax assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DeferredIncomeTaxRelatedToOperatingActivity" xlink:href="ango-20230531.xsd#ango_DeferredIncomeTaxRelatedToOperatingActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_DeferredIncomeTaxRelatedToOperatingActivity" xlink:to="lab_ango_DeferredIncomeTaxRelatedToOperatingActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_62ae3acc-23c8-4c15-b91a-b8e5af7c9cdd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7a148225-f3b4-44a1-b660-9abf37b825dc_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RETIREMENT PLANS</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_SettlementExpenseMember_5703ca02-3cb4-4843-b4cf-78d0ce100046_terseLabel_en-US" xlink:label="lab_ango_SettlementExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Expense</link:label>
    <link:label id="lab_ango_SettlementExpenseMember_label_en-US" xlink:label="lab_ango_SettlementExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Expense [Member]</link:label>
    <link:label id="lab_ango_SettlementExpenseMember_documentation_en-US" xlink:label="lab_ango_SettlementExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SettlementExpenseMember" xlink:href="ango-20230531.xsd#ango_SettlementExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_SettlementExpenseMember" xlink:to="lab_ango_SettlementExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1950010e-c2a3-44ea-8ec2-213ff2cf94a7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_8e9dbdb1-8849-4df3-b3a6-761d8379db6d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a7c39fe7-3038-4eda-9989-eb1bb95cfe80_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a5cd9364-f853-4ac4-a098-dfea0f282a70_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_4915ba96-71fe-4ad0-9fb2-8ed3df75125a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9f65acb1-cd50-4d26-88ea-e2b28826df67_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f0441f3a-4b73-4a73-af82-c121f9db87c8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_IntangibleImpairmentMember_7e9dce07-d151-4736-b0d6-074399b365e5_terseLabel_en-US" xlink:label="lab_ango_IntangibleImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible and other asset impairment</link:label>
    <link:label id="lab_ango_IntangibleImpairmentMember_label_en-US" xlink:label="lab_ango_IntangibleImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Impairment [Member]</link:label>
    <link:label id="lab_ango_IntangibleImpairmentMember_documentation_en-US" xlink:label="lab_ango_IntangibleImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Impairment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IntangibleImpairmentMember" xlink:href="ango-20230531.xsd#ango_IntangibleImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_IntangibleImpairmentMember" xlink:to="lab_ango_IntangibleImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_RoyaltiesDueInFirstYear_22655311-2fee-4110-aa64-43773f0f1a6b_terseLabel_en-US" xlink:label="lab_ango_RoyaltiesDueInFirstYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ango_RoyaltiesDueInFirstYear_label_en-US" xlink:label="lab_ango_RoyaltiesDueInFirstYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Due In First Year</link:label>
    <link:label id="lab_ango_RoyaltiesDueInFirstYear_documentation_en-US" xlink:label="lab_ango_RoyaltiesDueInFirstYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Due In First Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueInFirstYear" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueInFirstYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_RoyaltiesDueInFirstYear" xlink:to="lab_ango_RoyaltiesDueInFirstYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e969e867-7d6a-4e6a-9130-1ed06c1809d3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_NumberOfPatentsUpheldOverPriorArtReferences_447914c3-3033-4d00-8a86-25e1f9d46fd1_terseLabel_en-US" xlink:label="lab_ango_NumberOfPatentsUpheldOverPriorArtReferences" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents upheld over prior art references</link:label>
    <link:label id="lab_ango_NumberOfPatentsUpheldOverPriorArtReferences_label_en-US" xlink:label="lab_ango_NumberOfPatentsUpheldOverPriorArtReferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patents Upheld Over Prior Art References</link:label>
    <link:label id="lab_ango_NumberOfPatentsUpheldOverPriorArtReferences_documentation_en-US" xlink:label="lab_ango_NumberOfPatentsUpheldOverPriorArtReferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patents Upheld Over Prior Art References</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_NumberOfPatentsUpheldOverPriorArtReferences" xlink:href="ango-20230531.xsd#ango_NumberOfPatentsUpheldOverPriorArtReferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_NumberOfPatentsUpheldOverPriorArtReferences" xlink:to="lab_ango_NumberOfPatentsUpheldOverPriorArtReferences" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_d4230ae9-4a33-4a0c-8c6d-138c05955688_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91717630-3c8a-4346-813b-8c7f6502ec6e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6525e226-1391-4bd9-9193-acd9925718f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_f6620111-6fe1-426c-b833-27ab81616652_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_3352aac9-9e4f-4054-bfe3-c2d5007f1e92_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_TransitionServiceAgreementMember_b1b98347-95b1-4407-a77f-0b142fab4802_terseLabel_en-US" xlink:label="lab_ango_TransitionServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition service agreement</link:label>
    <link:label id="lab_ango_TransitionServiceAgreementMember_label_en-US" xlink:label="lab_ango_TransitionServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Service Agreement [Member]</link:label>
    <link:label id="lab_ango_TransitionServiceAgreementMember_documentation_en-US" xlink:label="lab_ango_TransitionServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Service Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TransitionServiceAgreementMember" xlink:href="ango-20230531.xsd#ango_TransitionServiceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_TransitionServiceAgreementMember" xlink:to="lab_ango_TransitionServiceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_11ba1058-6b7d-47c9-b119-096513482739_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE OF FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_36799004-3466-4df6-907a-67dee4474d55_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and State net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0312d1b0-7ca8-4636-bf97-d53eea9e31bd_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_649b0b34-cb70-43f4-9e5c-4a248de37a0b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_866b5e73-55f3-4bf3-94a9-69d2c9345bb2_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_74065c57-f684-458e-94b8-01b72efaf203_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, treasure shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_b6d45dff-09ff-4f17-982d-cb0b455595a7_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment_e61d796c-92f9-4f9b-99a4-1f68f2d425c0_terseLabel_en-US" xlink:label="lab_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, purchase accounting adjustment</link:label>
    <link:label id="lab_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment_label_en-US" xlink:label="lab_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Purchase Accounting Adjustment</link:label>
    <link:label id="lab_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment_documentation_en-US" xlink:label="lab_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Purchase Accounting Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment" xlink:href="ango-20230531.xsd#ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment" xlink:to="lab_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_07c5a53b-fbe9-451b-a812-f1d33a913ecd_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a11cfacf-e578-4f7f-a6a4-999cfd613eb8_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6638e6c6-2979-4ed5-b073-983dd11056fb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non U.S.</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_e4d716fc-78f7-46cc-87ac-239a27c3962f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_2d6d0983-2096-4097-ac3b-9c9af52f3dcd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses incurred not currently deductible</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_45622a32-d7fc-4fb0-a702-0b32c5cc3137_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9a210929-b1e7-474c-ba6b-82abb34f9943_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock Award Units, Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f4caa7a9-1e93-48a3-8d59-3c0dd723db3f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_cb0927d7-e9c2-417d-aa4b-3ef366909668_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_88f9debf-fc5e-4120-bc64-0b323c433b32_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_37469e9a-ecd6-402c-b205-4319a977c9fb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Options expected to vest in future periods (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_2bdd181f-783d-4ecf-92b0-356c22254b07_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_255b4de6-430c-4fa5-b096-cbaca3253596_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_1a01023e-4ed4-4e16-9cbb-7e74f6ec4054_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_13aa042c-f808-4f27-b966-33bc971fdc3a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_5bbb7865-6190-47bd-b1de-2ba7fb98e827_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION, BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_aff59a58-1067-4ac1-8438-066a7040d00f_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0facaa55-4000-4cd6-84d1-55aa741c28a8_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_974ca84f-3ede-4744-ac65-255126ae2463_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_d839991f-be35-4ad1-be6d-df6134a0cdee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_52ab1739-481d-4a1c-95df-1083daaf636f_terseLabel_en-US" xlink:label="lab_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and employee stock purchase plan</link:label>
    <link:label id="lab_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_label_en-US" xlink:label="lab_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments), Issuance Of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:label id="lab_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_documentation_en-US" xlink:label="lab_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments), Issuance Of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:href="ango-20230531.xsd#ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:to="lab_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4e9eaf42-94b8-4ce2-b4b7-be48a918898c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares reserved for issuance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_EmployeeStockPurchasePlanMember_9d7bbaca-6f40-45e4-987e-cb1e663a8d8f_terseLabel_en-US" xlink:label="lab_ango_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_ango_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_ango_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_ango_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_ango_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EmployeeStockPurchasePlanMember" xlink:href="ango-20230531.xsd#ango_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_EmployeeStockPurchasePlanMember" xlink:to="lab_ango_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_LegalCostsMember_0b14469b-b6e1-4764-be2b-9c359f0f6801_terseLabel_en-US" xlink:label="lab_ango_LegalCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal</link:label>
    <link:label id="lab_ango_LegalCostsMember_label_en-US" xlink:label="lab_ango_LegalCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs [Member]</link:label>
    <link:label id="lab_ango_LegalCostsMember_documentation_en-US" xlink:label="lab_ango_LegalCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_LegalCostsMember" xlink:href="ango-20230531.xsd#ango_LegalCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_LegalCostsMember" xlink:to="lab_ango_LegalCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio_5689f7de-1117-4d31-ac29-e0eac8dff653_terseLabel_en-US" xlink:label="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, maximum leverage ratio of total indebtedness to adjusted EBITDA</link:label>
    <link:label id="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio_label_en-US" xlink:label="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio</link:label>
    <link:label id="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio_documentation_en-US" xlink:label="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio" xlink:href="ango-20230531.xsd#ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio" xlink:to="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dbc6ccb5-351f-45a8-8573-ce5f2299fd7c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4ed3829e-bdc8-4f88-8d6d-fe90781e5a38_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_ef9fb6ad-9dfb-422b-ae6d-3a9cabfd5c0e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_3a9c50db-ad49-4a6d-9805-6a67ffcc5dfa_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_de1b7a95-170b-4c91-91eb-5768d03bb7af_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_f284dcca-353f-499a-8526-1594bcd29ae0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_eed5ce1f-0e57-40b4-a884-0eb940185a0c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_16931052-5a54-40c0-ac63-4c5ee28e3679_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_18b1ddbf-1f16-4423-bb04-e82fecd6073e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_163361c6-c1a1-4d8e-9472-a19eb79a1342_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c9514f6c-2ca2-4288-9a12-48d35d4d77bf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c0d60289-b576-4326-b986-0c2fe16e9902_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of restricted stock awards vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_63d8bb5b-5f57-4f56-ba98-70cfe2160135_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_61005911-62d7-4073-9510-ed2ff5cbc427_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_PrepaidDeposits_f38e7f4d-e30b-41a9-ae9d-9b98eaf32ec0_terseLabel_en-US" xlink:label="lab_ango_PrepaidDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits</link:label>
    <link:label id="lab_ango_PrepaidDeposits_label_en-US" xlink:label="lab_ango_PrepaidDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Deposits</link:label>
    <link:label id="lab_ango_PrepaidDeposits_documentation_en-US" xlink:label="lab_ango_PrepaidDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidDeposits" xlink:href="ango-20230531.xsd#ango_PrepaidDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_PrepaidDeposits" xlink:to="lab_ango_PrepaidDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_4ff7e7a7-3681-47e6-887e-d41593855909_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_795d9ad0-b248-48b8-916d-0588d21f307d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e0413111-7b83-424f-8a3b-a0de296622d8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2ea95872-1249-41f7-818e-f06c33166080_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_230baf92-c5bb-4793-9579-995149fe3085_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant-Date Fair Value, Cancelled (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_0d91eb56-b3bb-46e6-8984-df11d8565610_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1f4ca996-5fe2-49f0-a5f4-6bb2f5f868d3_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7646717c-1d2a-4cef-93ff-901494657a88_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherOwnershipInterestsTable_2fc1bc2a-02d1-4445-977f-4583d1b51e34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Ownership Interests [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherOwnershipInterestsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Ownership Interests [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:to="lab_us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9cbd82aa-711b-47d0-a7fe-35b41baa573e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_374b8d13-6290-4a2d-a878-d56c9a8ae63e_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_82f826c5-30ca-4c50-a072-200f5af0ae86_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_b9b35c84-e9d1-4073-921f-1f25e4770bf9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a98cd7b7-1d3f-4166-aebf-59c9ad15481e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_SoftwareLicenses_319c35ad-5c6c-439e-b03c-1db0926ecb57_verboseLabel_en-US" xlink:label="lab_ango_SoftwareLicenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software licenses</link:label>
    <link:label id="lab_ango_SoftwareLicenses_label_en-US" xlink:label="lab_ango_SoftwareLicenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Licenses</link:label>
    <link:label id="lab_ango_SoftwareLicenses_documentation_en-US" xlink:label="lab_ango_SoftwareLicenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount as of the balance sheet date of payments made for software licenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SoftwareLicenses" xlink:href="ango-20230531.xsd#ango_SoftwareLicenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_SoftwareLicenses" xlink:to="lab_ango_SoftwareLicenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForPreviousAcquisition_74681ce9-7a8d-4f27-9319-1d368c515a39_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForPreviousAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsForPreviousAcquisition_label_en-US" xlink:label="lab_us-gaap_PaymentsForPreviousAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Previous Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForPreviousAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPreviousAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForPreviousAcquisition" xlink:to="lab_us-gaap_PaymentsForPreviousAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_681e523c-d477-4bc7-9c29-85f4ff4f3628_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d199ba01-b35c-49bb-8bd4-7d6cf9ec050c_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_87ffc27c-23e1-40df-8b28-a6b814ed2d83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3921092f-139f-41d4-aaf2-412bb7df67b6_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/cancellation of common stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_b0377443-d933-44f6-aa49-6903c17193bd_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_25c6415d-9934-447e-943b-17a0aa5c71e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of common stock available to be issued (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_693d0683-5bb3-465b-a683-c7abec3ad1b2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration for acquisition earn outs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_54444fbd-19d9-4e65-93da-6a95cc5d1d9b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue based payments</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_82b8231d-0216-4775-a114-a15b52e8c9d3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_c6a33f3a-78ec-4b15-82a6-d96329a0ccdb_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b193c0d0-baa9-440c-916e-3d360c5bce85_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_ed200ec3-2e6b-4eae-b5e1-c10b56681049_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets Held For Sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_34ac9389-893c-42d0-b68f-478e5745e825_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant-Date Fair Value, Vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_OtherNonoperatingIncomeExpenseAndInterestExpense_34e1ea07-67bf-44c1-9591-0281142c6012_totalLabel_en-US" xlink:label="lab_ango_OtherNonoperatingIncomeExpenseAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expenses, net</link:label>
    <link:label id="lab_ango_OtherNonoperatingIncomeExpenseAndInterestExpense_label_en-US" xlink:label="lab_ango_OtherNonoperatingIncomeExpenseAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) And Interest Expense</link:label>
    <link:label id="lab_ango_OtherNonoperatingIncomeExpenseAndInterestExpense_documentation_en-US" xlink:label="lab_ango_OtherNonoperatingIncomeExpenseAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) And Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_OtherNonoperatingIncomeExpenseAndInterestExpense" xlink:href="ango-20230531.xsd#ango_OtherNonoperatingIncomeExpenseAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_OtherNonoperatingIncomeExpenseAndInterestExpense" xlink:to="lab_ango_OtherNonoperatingIncomeExpenseAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b5d3f133-a18b-4bef-a2bc-7b8491d650d6_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4cd9874d-6648-4971-bef2-b020e78bed09_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8311a6f2-61db-40cd-9920-492d2304706a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_417f4e7f-8b5d-4b30-9804-4870dc86d14b_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state R&amp;D tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_5ba322c3-09f0-4e5d-b390-11bbc8a044ac_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3b946da0-a155-40da-891f-3ef51eef4fe5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_acf9e3a6-1b87-4ff6-8121-e498487b4d5a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember_847f6160-22bf-42cf-a5af-968262d85394_terseLabel_en-US" xlink:label="lab_ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QX Medical, LLC Camaro Support Catheter Asset Acquisition</link:label>
    <link:label id="lab_ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember_label_en-US" xlink:label="lab_ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QX Medical, LLC Camaro Support Catheter Asset Acquisition [Member]</link:label>
    <link:label id="lab_ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember_documentation_en-US" xlink:label="lab_ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QX Medical, LLC Camaro Support Catheter Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember" xlink:href="ango-20230531.xsd#ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember" xlink:to="lab_ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0f17eaad-849b-4a12-9ea5-21bed217cba5_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0d2ab178-7fbf-4a23-b092-53f3819fd473_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3bdb3c77-813f-4259-9de6-d7cadd3a13f9_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $2,150 and $1,939, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cbbce9f2-5e03-436b-af18-0831c68460b8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8826783-ef72-4c94-b842-70830907c62c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2e0a57ce-0861-4392-b10f-b20f231ea3e4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_a83a752c-e25f-4293-892c-9a62c990b8eb_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ProductTechnologiesMember_aefde08a-155d-41c7-84ea-cb37042d1369_terseLabel_en-US" xlink:label="lab_ango_ProductTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product technologies</link:label>
    <link:label id="lab_ango_ProductTechnologiesMember_label_en-US" xlink:label="lab_ango_ProductTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Technologies [Member]</link:label>
    <link:label id="lab_ango_ProductTechnologiesMember_documentation_en-US" xlink:label="lab_ango_ProductTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product technologies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ProductTechnologiesMember" xlink:href="ango-20230531.xsd#ango_ProductTechnologiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ProductTechnologiesMember" xlink:to="lab_ango_ProductTechnologiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_6f517e7b-72c6-4bcc-ba72-d40eab2b9a32_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_CashPaidDuringPeriodAbstract_f167d615-c556-4ac7-92c5-402e2dbcf5ba_verboseLabel_en-US" xlink:label="lab_ango_CashPaidDuringPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the year for:</link:label>
    <link:label id="lab_ango_CashPaidDuringPeriodAbstract_label_en-US" xlink:label="lab_ango_CashPaidDuringPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During Period [Abstract]</link:label>
    <link:label id="lab_ango_CashPaidDuringPeriodAbstract_documentation_en-US" xlink:label="lab_ango_CashPaidDuringPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During Period [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CashPaidDuringPeriodAbstract" xlink:href="ango-20230531.xsd#ango_CashPaidDuringPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_CashPaidDuringPeriodAbstract" xlink:to="lab_ango_CashPaidDuringPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_02af5517-6a34-4f55-9683-053a03d3e499_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_71172179-12f7-4f50-8627-a87be00bcaa5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, Options exercisable at year end (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_e7d6a8d9-c0fa-4bea-862f-6a4b17928ef9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before tax expense:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a7bb8ac3-2fd8-4647-bb4a-1d65896afe76_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price Expired (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a8d05bef-2446-495f-ada6-b97e9eea0457_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_570a13f1-ccaf-43b2-9629-c494ef43e744_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3bbe07aa-a0ed-446a-a599-e354e1dae306_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_6e81e0ea-f118-4724-8ff0-373a13c17ceb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of and borrowings on long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Other Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b9d5206-b42c-41a1-9649-1517fdf2fbde_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested compensation (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ed5f0a1b-7346-43c6-b885-ad876130ece5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock Award Units Beginning Balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9c67bc1e-1a1b-4594-9d01-85393d9b7804_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock Award Units Ending Balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_49990f6f-343f-4670-a0ff-0dcf351e366a_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_297bfe9f-a96e-45a9-b82a-48d5aaca46e6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_f372e8d0-760a-4ffe-b3c6-1db27084d8a1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_374fec5f-d566-4b4f-acaf-fea203e42feb_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;carrying value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_77bd4b16-88ef-439f-8d81-cb8623bdef5b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_5e093b0e-a079-4356-85fb-4523f509ec33_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_01e8b5aa-2e56-45bf-bfbe-cb449edcef63_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0c8fa77e-8afb-4bde-9ddd-292ce2aaf3c7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_9a81988d-33b0-4cf0-8d01-4c0a8663ec3e_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_84d44b6e-cbbc-4c82-87a4-7e3a165ba48e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_d3608c12-de4c-4748-8384-c20e7b6dcbca_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHESIVE INCOME (LOSS)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_f0de3672-fa0b-40c6-96bc-e0c27ffba310_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_e023db64-2f10-40a3-85f6-a325d005c5a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_08ea01ee-5865-4118-adc3-b13d337c8434_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, Options expected to vest in future periods (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_3178052b-c6e3-4b1a-b2d6-052880396a4a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_199b3111-b937-4585-952e-baa6f7eceaf7_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_484c8633-83d0-4b06-8eaf-66176a8c93f8_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3af111cc-209c-47f0-b1c2-fce6620a50f0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_AssetsAndLiabilitiesLesseeTableTextBlock_a86466e9-e072-4236-bb8b-8e33cb31cf57_terseLabel_en-US" xlink:label="lab_ango_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental balance sheet information</link:label>
    <link:label id="lab_ango_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_ango_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_ango_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_ango_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="ango-20230531.xsd#ango_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_ango_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_df1aaeba-2257-4dc7-93c4-a8311eaa58a5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule summarizes stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_IncreaseInPlacementAndEvaluationUnits_ee6d4dfd-963b-4bb1-9c0d-3335162bf7ae_negatedTerseLabel_en-US" xlink:label="lab_ango_IncreaseInPlacementAndEvaluationUnits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to placement and evaluation units</link:label>
    <link:label id="lab_ango_IncreaseInPlacementAndEvaluationUnits_label_en-US" xlink:label="lab_ango_IncreaseInPlacementAndEvaluationUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Placement And Evaluation Units</link:label>
    <link:label id="lab_ango_IncreaseInPlacementAndEvaluationUnits_documentation_en-US" xlink:label="lab_ango_IncreaseInPlacementAndEvaluationUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Placement And Evaluation Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IncreaseInPlacementAndEvaluationUnits" xlink:href="ango-20230531.xsd#ango_IncreaseInPlacementAndEvaluationUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_IncreaseInPlacementAndEvaluationUnits" xlink:to="lab_ango_IncreaseInPlacementAndEvaluationUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_63d7d504-3b97-464d-9e42-b8a9aa9f989d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_a1811283-3dae-47b5-b0c9-7c4e5a6590df_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_8e3dd4bf-3aeb-4b1d-8410-219f42ee5c00_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_43fe72e8-85d2-444f-b3e1-932161194240_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear" xlink:to="lab_us-gaap_ContractualObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9cda77da-124c-40aa-9303-f9a771396f74_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_TaxPeriodFourMember_7c470bbd-d26f-408c-a6b3-ff7d7084a2b1_terseLabel_en-US" xlink:label="lab_ango_TaxPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_ango_TaxPeriodFourMember_label_en-US" xlink:label="lab_ango_TaxPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period Four [Member]</link:label>
    <link:label id="lab_ango_TaxPeriodFourMember_documentation_en-US" xlink:label="lab_ango_TaxPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TaxPeriodFourMember" xlink:href="ango-20230531.xsd#ango_TaxPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_TaxPeriodFourMember" xlink:to="lab_ango_TaxPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_796022af-04d4-448f-b854-0e07f9998d5f_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature_47701f22-3b89-4ad5-98c0-5598c263845f_terseLabel_en-US" xlink:label="lab_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible increase in borrowing capacity</link:label>
    <link:label id="lab_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature_label_en-US" xlink:label="lab_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity, Accordian Feature</link:label>
    <link:label id="lab_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature_documentation_en-US" xlink:label="lab_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity, Accordian Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature" xlink:href="ango-20230531.xsd#ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature" xlink:to="lab_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_80669d3b-c938-458d-bc09-dfa749deeb75_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_61a54a2f-7ec1-4a9d-826f-19d629c4d64b_verboseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_RevenuePerformanceObligationPaymentTerm_b9cf7f79-fd5e-486a-a306-1c586110be3c_terseLabel_en-US" xlink:label="lab_ango_RevenuePerformanceObligationPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation payment term (days)</link:label>
    <link:label id="lab_ango_RevenuePerformanceObligationPaymentTerm_label_en-US" xlink:label="lab_ango_RevenuePerformanceObligationPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Term</link:label>
    <link:label id="lab_ango_RevenuePerformanceObligationPaymentTerm_documentation_en-US" xlink:label="lab_ango_RevenuePerformanceObligationPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevenuePerformanceObligationPaymentTerm" xlink:href="ango-20230531.xsd#ango_RevenuePerformanceObligationPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_RevenuePerformanceObligationPaymentTerm" xlink:to="lab_ango_RevenuePerformanceObligationPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b2dcb523-19e9-49cd-b011-f3a8e4a851e3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1f2572d3-750f-4f5c-8cff-a973934c9b94_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_eb16f8a6-4717-48ea-a0a2-6c2478c64833_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_20a681c7-8cde-4b74-8292-cdd1ee1d31de_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_788737ac-5253-44d4-bd09-7cb1db19c44d_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance June 1, 2022</link:label>
    <link:label id="lab_us-gaap_Goodwill_a4722044-1191-41e3-b1cc-e78706e5dbc9_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance May 31, 2023</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_fd94f594-252e-44b1-8cbc-3b55934b30da_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Financial Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_c6b332a2-5a0f-4af8-bcad-50c779245564_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20b7750b-26ea-44f6-b227-e0f25758af82_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_57cecd56-59b6-4399-9d03-9a90fe234438_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_EmployeePlanParticipatingEligibilityPeriod_cc9d7155-6c74-4d10-b3b4-2e40e7ffcf28_verboseLabel_en-US" xlink:label="lab_ango_EmployeePlanParticipatingEligibilityPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee eligible in participating in offering period</link:label>
    <link:label id="lab_ango_EmployeePlanParticipatingEligibilityPeriod_label_en-US" xlink:label="lab_ango_EmployeePlanParticipatingEligibilityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Plan Participating Eligibility Period</link:label>
    <link:label id="lab_ango_EmployeePlanParticipatingEligibilityPeriod_documentation_en-US" xlink:label="lab_ango_EmployeePlanParticipatingEligibilityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee plan participating eligibility period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EmployeePlanParticipatingEligibilityPeriod" xlink:href="ango-20230531.xsd#ango_EmployeePlanParticipatingEligibilityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_EmployeePlanParticipatingEligibilityPeriod" xlink:to="lab_ango_EmployeePlanParticipatingEligibilityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c5d11391-4ad9-47f0-9e6e-3b421563636f_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_c9185ec6-6ccd-4a7a-befb-7f5b4156602a_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL AND INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible_03fa12d3-e315-4601-96c5-da4a4e55268a_terseLabel_en-US" xlink:label="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of working months to be eligible</link:label>
    <link:label id="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible_label_en-US" xlink:label="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Working Months Per Year to be Eligible</link:label>
    <link:label id="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible_documentation_en-US" xlink:label="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Working Months Per Year to be Eligible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible" xlink:href="ango-20230531.xsd#ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible" xlink:to="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3c5864f7-c4d8-455b-877c-e178f88454ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_03c67ca4-0300-442e-bd78-b9d8a22c3826_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_156ec585-adbe-4847-9e06-8b52b929c933_verboseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_9c153e5a-1e56-43bd-9f71-b78caf4c545a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment, Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6c3e10ce-8b75-454d-92e1-2db6d397e20e_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4bbe1c0e-c33a-4444-9820-43a457daebe6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1214b6b0-40a6-4df1-a6e0-c7201d370d10_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f209da95-6f14-4faa-9501-99b6c8380bed_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8b048882-cc47-4f41-a933-e2dbce73fce3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dc21aa34-c412-4496-8f3a-8d3f43ce69ae_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_dd630474-bbf1-4159-a00c-7f5ec9e2c990_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0283dc4c-652c-4421-9c02-399896480ad6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_cfce1f37-1fc5-48e3-9cea-dcb0c4d35259_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments and disposals</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_aa1db539-9993-4b0f-b910-298d62602789_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_IncomeTaxesTextualAbstract_2b752a17-8b2c-4c9e-9030-e2032c1dde3e_verboseLabel_en-US" xlink:label="lab_ango_IncomeTaxesTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes (Textual) [Abstract]</link:label>
    <link:label id="lab_ango_IncomeTaxesTextualAbstract_label_en-US" xlink:label="lab_ango_IncomeTaxesTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes (Textual) [Abstract]</link:label>
    <link:label id="lab_ango_IncomeTaxesTextualAbstract_documentation_en-US" xlink:label="lab_ango_IncomeTaxesTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes (Textual) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IncomeTaxesTextualAbstract" xlink:href="ango-20230531.xsd#ango_IncomeTaxesTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_IncomeTaxesTextualAbstract" xlink:to="lab_ango_IncomeTaxesTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ad131ad8-1499-4981-b913-585795bc66db_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_eb4d7daa-4f92-460c-a4f8-fb204f9cd837_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5dff2b1d-3575-4c65-ab4e-1289d7408a4b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_NoncashLeaseExpense_6537b674-2747-46b0-b538-b3d0308dce3c_terseLabel_en-US" xlink:label="lab_ango_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_ango_NoncashLeaseExpense_label_en-US" xlink:label="lab_ango_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_ango_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_ango_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_NoncashLeaseExpense" xlink:href="ango-20230531.xsd#ango_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_NoncashLeaseExpense" xlink:to="lab_ango_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_cc24dea7-a200-413a-a852-7405ae6f710c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (exclusive of intangible amortization)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_964497df-fdf1-42ee-a38b-258b50068b27_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a41960d3-faa3-4bbe-b077-8f2f0c7a9138_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bf7b7717-6cd7-4b30-967b-7c99aedf1727_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_727cc3d2-cd4c-4643-b9c0-52e755a3abf7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool_0b46df13-f98c-471d-a83d-3708ad425a71_negatedTerseLabel_en-US" xlink:label="lab_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool_label_en-US" xlink:label="lab_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Effect of Elimination of ASC 718 APIC Pool</link:label>
    <link:label id="lab_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool_documentation_en-US" xlink:label="lab_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Effect of Elimination of ASC 718 APIC Pool</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool" xlink:href="ango-20230531.xsd#ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool" xlink:to="lab_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_028dae49-19ce-4b92-9252-da317e6c9836_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_04ae3b25-2af4-4c56-b739-ea90a529530a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_RevolvingFacilityMember_4be48b29-6320-4f23-a82f-5f7567113f65_terseLabel_en-US" xlink:label="lab_ango_RevolvingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Facility</link:label>
    <link:label id="lab_ango_RevolvingFacilityMember_label_en-US" xlink:label="lab_ango_RevolvingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Facility [Member]</link:label>
    <link:label id="lab_ango_RevolvingFacilityMember_documentation_en-US" xlink:label="lab_ango_RevolvingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevolvingFacilityMember" xlink:href="ango-20230531.xsd#ango_RevolvingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_RevolvingFacilityMember" xlink:to="lab_ango_RevolvingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_767f42a7-7e6a-496a-b76d-c0bf0251f1fa_verboseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income tax (benefit) provision analyzed by category</link:label>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_0a7800a7-2b13-4dee-98c1-a6564132f8f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_cf29e44b-44a2-445c-92bc-ba7f74547dca_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and building improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_a0761dd6-e681-428d-9cd2-22045900e322_verboseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and building improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_9a198dd4-be1f-48ed-8744-10f38b5347ae_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_6dbe2519-08a8-491a-b665-42361535747f_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_bad3f0ae-0e1c-4adf-8a35-b245f4bed0b3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.01 per share, 75,000,000 shares authorized; 39,981,422 and 39,541,173 shares issued and 39,611,422 and 39,171,173 shares outstanding at May 31, 2023 and 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval_ed3df035-a504-45d8-96b9-52949a3448b9_terseLabel_en-US" xlink:label="lab_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of return period (days)</link:label>
    <link:label id="lab_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval_label_en-US" xlink:label="lab_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Right of Return, Product Return Period After Purchase Date Requiring Pre-Approval</link:label>
    <link:label id="lab_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval_documentation_en-US" xlink:label="lab_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Right of Return, Product Return Period After Purchase Date Requiring Pre-Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval" xlink:href="ango-20230531.xsd#ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval" xlink:to="lab_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_178b5a22-f8db-472d-8ad5-3ba8ad673520_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod_ec6e4d0e-92bb-45ac-87a2-56f1b84b0b6b_terseLabel_en-US" xlink:label="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance period</link:label>
    <link:label id="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod_label_en-US" xlink:label="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Compensation Cost Probable Recognition Performance Period</link:label>
    <link:label id="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod_documentation_en-US" xlink:label="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Compensation Cost Probable Recognition Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod" xlink:href="ango-20230531.xsd#ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod" xlink:to="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9bf25117-4dba-4d3b-a415-9f4d899a5381_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_2a3cff31-02a7-4183-aa09-74af088fe029_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_f7f670d6-1f08-4b9d-985b-bb8b36bb89a3_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e8e2e7ca-f7f3-49ee-b0bf-3e4a724aadf9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants in the period, weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fdde518c-07f7-46e6-8603-545bc51c9c31_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant-Date Fair Value, Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage_759b48c6-9168-472c-8dcb-e8fc16d81fdd_verboseLabel_en-US" xlink:label="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of grants to employees vesting</link:label>
    <link:label id="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage_label_en-US" xlink:label="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Award Granted to Employees Vesting Percentage</link:label>
    <link:label id="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage_documentation_en-US" xlink:label="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award award granted to employees vesting percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage" xlink:href="ango-20230531.xsd#ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage" xlink:to="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_e097911c-fdda-4201-9d0c-a6c0158eb433_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_cc5c235a-458f-4395-8217-cf91faecbeed_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets and liabilities measured on recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0efee7c4-9412-4be4-89fc-152bd607989a_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Options exercisable at year end</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_9808a620-c90e-4ab7-a5e7-2696442c96d1_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_TradeShows_18bb25b4-9bb2-45c9-b94d-69e4b70d0f09_terseLabel_en-US" xlink:label="lab_ango_TradeShows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade shows</link:label>
    <link:label id="lab_ango_TradeShows_label_en-US" xlink:label="lab_ango_TradeShows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Shows</link:label>
    <link:label id="lab_ango_TradeShows_documentation_en-US" xlink:label="lab_ango_TradeShows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount as of the balance sheet date of payments made in advance related to trade shows.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TradeShows" xlink:href="ango-20230531.xsd#ango_TradeShows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_TradeShows" xlink:to="lab_ango_TradeShows" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d715fea9-df53-4950-ae31-7e63fdd2ace7_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_b49a1866-cb23-4f13-9416-2efe8f2b7cae_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a671c12-a571-48c5-8598-5014976e98da_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02eb3769-56d0-44ed-9a07-a0d6ec561531_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_IncomeTaxReconciliationEffectOfForeignOperations_cc91aec0-6e6e-41f6-bca0-b032fc79e84f_verboseLabel_en-US" xlink:label="lab_ango_IncomeTaxReconciliationEffectOfForeignOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of Non-U.S. operations</link:label>
    <link:label id="lab_ango_IncomeTaxReconciliationEffectOfForeignOperations_label_en-US" xlink:label="lab_ango_IncomeTaxReconciliationEffectOfForeignOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Effect of Foreign Operations</link:label>
    <link:label id="lab_ango_IncomeTaxReconciliationEffectOfForeignOperations_documentation_en-US" xlink:label="lab_ango_IncomeTaxReconciliationEffectOfForeignOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference, between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to the impact of non US operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IncomeTaxReconciliationEffectOfForeignOperations" xlink:href="ango-20230531.xsd#ango_IncomeTaxReconciliationEffectOfForeignOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_IncomeTaxReconciliationEffectOfForeignOperations" xlink:to="lab_ango_IncomeTaxReconciliationEffectOfForeignOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4005e218-b10f-4f55-a9fd-4675bc75c730_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_53606a79-bd35-4bb2-aba9-e76960ad2527_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear" xlink:to="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_d1eb9156-afdc-4449-81de-c34dd60bd571_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_50be80df-0888-4fe6-bef7-8472410ebf3c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d40011ca-5169-49c5-bd57-110f76d58611_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_42f0ec28-ad90-4c74-a696-ee24bd23f249_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9d59bbea-cca6-43bb-b5d4-116421350274_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4010b774-22a1-4a8f-9928-31307654c26c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_0c2a2379-d92c-487f-850e-91f2e17d6784_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in present value of contingent consideration (1)</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bff1cdf3-bc01-4798-b12e-74022e5d4921_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, Option expected to vest in future periods</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_c368cbdb-694b-4341-b5bc-9072edefbc50_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7f736e1f-6609-45e3-b444-32efa594447a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_0d18e174-a6d6-41dd-8a98-a649c7c61ca8_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired_d8f95a30-0db0-4fbd-931c-e697d39c55f5_negatedLabel_en-US" xlink:label="lab_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of intangibles</link:label>
    <link:label id="lab_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired_label_en-US" xlink:label="lab_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Intangible Assets Net Of Cash Acquired</link:label>
    <link:label id="lab_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired_documentation_en-US" xlink:label="lab_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow associated with the acquisition of intangible assets, net of cash acquired from the purchase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired" xlink:href="ango-20230531.xsd#ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired" xlink:to="lab_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_9ffd6ca8-c4ce-4363-b176-fb4689c1c50c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_c975f6d0-0fee-4072-96ec-d353e14c7e69_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_60ffa797-0e25-469c-a82c-deaec2e84c97_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_967f3792-22ee-43b3-a813-d626babfe9c1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3f16d766-b59f-48e1-a335-63477b5fad96_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of intangible assets other than goodwill (years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_34b8c9b0-2570-41bd-a915-983d62288241_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_f55397cd-a47a-4f95-9c36-fd7ad9135c0b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cbf00f42-1da2-40ba-b3f5-89fbfb413b09_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_a6d703f7-11c1-4328-b435-6916001958a3_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_df6083e6-a33e-4c65-b8c5-056560e7eda1_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_58a6b444-f942-4dff-a57b-90b289dec9a0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_0f6172fa-dce7-43ed-a9c4-0fc2766ddcd3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings on long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c0498e0c-ef21-4276-a3eb-92c0454a3876_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1b69934f-5b35-4de3-b291-606e4ab821b5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_898f55b1-6658-4296-adc4-c16049269884_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_7c96cd01-71e9-4ab2-a56f-f429f705a24e_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ScheduleOfIntangibleAssetsTableTextBlock_d4bae46c-8847-4e49-a140-af8820339e43_verboseLabel_en-US" xlink:label="lab_ango_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ango_ScheduleOfIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_ango_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_ango_ScheduleOfIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_ango_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ScheduleOfIntangibleAssetsTableTextBlock" xlink:href="ango-20230531.xsd#ango_ScheduleOfIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="lab_ango_ScheduleOfIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_231f5458-2368-4e88-9c31-f1231fdf26ea_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued severance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveCurrent" xlink:to="lab_us-gaap_RestructuringReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_fc095e91-8a24-414d-b93b-13573d105f7a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_1baebbd1-c325-4c1f-8dc5-4187f6af514a_verboseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7a9a3a7f-dd7b-4819-99c7-e38c0da722be_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_d052ccff-50ac-4c94-aa6c-452d8eced708_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligations</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_809fb762-787b-44cd-8318-97b2dc58ce78_verboseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_321e1a05-941a-4aad-9016-a68fa3a10921_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_62ef2ea1-a8a9-4fcc-bb55-797fba20d262_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_93cfd8ec-754e-4cfb-96a4-bde2fe99aed9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_InternationalMember_8b35cad7-b9c7-4fa1-948c-2ba68b45d0d7_verboseLabel_en-US" xlink:label="lab_ango_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_ango_InternationalMember_label_en-US" xlink:label="lab_ango_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_ango_InternationalMember_documentation_en-US" xlink:label="lab_ango_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_InternationalMember" xlink:href="ango-20230531.xsd#ango_InternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_InternationalMember" xlink:to="lab_ango_InternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_d9fc3f5d-3f5a-498a-b9ae-d18f54b0c627_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Meals and entertainment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_d639acf3-8720-4927-9dce-6ae2c97cb5ad_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_00e2f241-02b3-441e-b29e-c6e2a0663a18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Options exercisable at year-end (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2e30c735-7672-43b4-b141-b47e27b08be0_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fair market value of a share of common stock on the last day of the offering period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_566fe530-78b8-4eab-95aa-5d31d06e6056_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_a446c133-87f4-4c8e-87ed-026930a56915_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOwnershipInterestsLineItems_57c86ef0-c09e-436e-9322-a5748ece660e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOwnershipInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Ownership Interests [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherOwnershipInterestsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherOwnershipInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Ownership Interests [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOwnershipInterestsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems" xlink:to="lab_us-gaap_OtherOwnershipInterestsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_85bd40d8-0bcd-489c-9987-bfc475daf1b2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2029 and thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_336a5e3e-864a-4d56-a480-f7526b5d3d2b_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions&#160;- Charged&#160;to costs and expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_4769e2ac-c868-4b5b-a699-7ead4b5853fa_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5b305ef6-2d7d-4d62-baf9-c007adf084c3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock under Employee Stock Purchase Plan, Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_085d7d1b-e0dc-4a65-9b6e-9f2e13420d77_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares to be offered under the Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_DivestitureMember_f7ab25c4-e1df-405a-b751-233770ebf8c8_terseLabel_en-US" xlink:label="lab_ango_DivestitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestiture</link:label>
    <link:label id="lab_ango_DivestitureMember_label_en-US" xlink:label="lab_ango_DivestitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestiture [Member]</link:label>
    <link:label id="lab_ango_DivestitureMember_documentation_en-US" xlink:label="lab_ango_DivestitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DivestitureMember" xlink:href="ango-20230531.xsd#ango_DivestitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_DivestitureMember" xlink:to="lab_ango_DivestitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ContractualObligationToBePaidAfterYearFour_41c7f3b1-d260-4953-84da-5ab675e71286_totalLabel_en-US" xlink:label="lab_ango_ContractualObligationToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_ango_ContractualObligationToBePaidAfterYearFour_label_en-US" xlink:label="lab_ango_ContractualObligationToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ango_ContractualObligationToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ango_ContractualObligationToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ContractualObligationToBePaidAfterYearFour" xlink:href="ango-20230531.xsd#ango_ContractualObligationToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ContractualObligationToBePaidAfterYearFour" xlink:to="lab_ango_ContractualObligationToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e6d74fa6-8ea7-4a75-bfd2-268faa693f99_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Outstanding at beginning of year (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a3344f6e-7003-4896-a45d-49af1c10691e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Outstanding at end of year (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_761060aa-5a30-49fc-8405-8ce44e1c7e40_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized debit issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract_14c66211-bebf-4273-98b5-5ca1913ec473_verboseLabel_en-US" xlink:label="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary showing the recurring fair value measurements of the contingent consideration liability</link:label>
    <link:label id="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract_label_en-US" xlink:label="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Liabilities Measured on Recurring Basis [Abstract]</link:label>
    <link:label id="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract_documentation_en-US" xlink:label="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Liabilities Measured On Recurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:href="ango-20230531.xsd#ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:to="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_LineOfCreditFacilityNumberOfCovenants_265d1457-3c6c-4011-9486-743243821db6_terseLabel_en-US" xlink:label="lab_ango_LineOfCreditFacilityNumberOfCovenants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of financial covenants</link:label>
    <link:label id="lab_ango_LineOfCreditFacilityNumberOfCovenants_label_en-US" xlink:label="lab_ango_LineOfCreditFacilityNumberOfCovenants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Number Of Covenants</link:label>
    <link:label id="lab_ango_LineOfCreditFacilityNumberOfCovenants_documentation_en-US" xlink:label="lab_ango_LineOfCreditFacilityNumberOfCovenants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Number Of Covenants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_LineOfCreditFacilityNumberOfCovenants" xlink:href="ango-20230531.xsd#ango_LineOfCreditFacilityNumberOfCovenants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_LineOfCreditFacilityNumberOfCovenants" xlink:to="lab_ango_LineOfCreditFacilityNumberOfCovenants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_c640173d-ea24-4cc8-a7c1-4ac8e51f2ba1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6ca19ec3-1b47-4ea6-b0e2-dd3a8360c79d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTableTextBlock_c44b4f6b-4d79-4bba-9401-402212602c6d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTableTextBlock" xlink:to="lab_us-gaap_OtherCommitmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_18d99996-30af-4993-b4de-609b95e11285_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Description of Business</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_04aa50eb-a71b-4e80-84df-5a1073ae83b0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_14016e6d-ef3b-4626-8cab-3329c4d78567_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_dbbffeb4-61c9-4a3b-9b7c-a4a9b10a9cd5_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_25348555-598c-4ef3-bb6b-1525091abbd2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions_35dc1931-7f55-4bc6-b9d1-070308e039f5_terseLabel_en-US" xlink:label="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, maximum leverage ratio of total indebtedness to adjusted EBITDA, following material acquisitions</link:label>
    <link:label id="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions_label_en-US" xlink:label="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio, Subsequent To Material Acquisitions</link:label>
    <link:label id="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions_documentation_en-US" xlink:label="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio, Subsequent To Material Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions" xlink:href="ango-20230531.xsd#ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions" xlink:to="lab_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_b8b1a8c3-0a7a-4d39-a5e3-57b80857eb55_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_73887964-7a71-4523-8831-f31683d6db71_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected amortization expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_b8419089-6ba3-4345-ad83-8bdf950f6b03_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_173b8085-89aa-4b92-a513-cdd43a373ba6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_36ccec90-8cec-46fe-b37c-f906e36f85af_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, 370,000 shares, at cost at May 31, 2023 and 2022, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_00f4c6bd-0703-4a9d-9056-67e9c695e29c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_MedDeviceMember_dcd3434a-e355-42d6-83ee-a16270418233_terseLabel_en-US" xlink:label="lab_ango_MedDeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Med Device</link:label>
    <link:label id="lab_ango_MedDeviceMember_label_en-US" xlink:label="lab_ango_MedDeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Med Device [Member]</link:label>
    <link:label id="lab_ango_MedDeviceMember_documentation_en-US" xlink:label="lab_ango_MedDeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Med Device</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedDeviceMember" xlink:href="ango-20230531.xsd#ango_MedDeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_MedDeviceMember" xlink:to="lab_ango_MedDeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_2390a58d-7cfa-4eab-9a18-848de308c20c_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFourthYear" xlink:to="lab_us-gaap_ContractualObligationDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_39f6568c-6565-402c-a70b-f11821ff7b54_verboseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowances</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a79c21e2-ccf6-45c6-94bc-65ee45c783d3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9d8fe446-d2ab-4a4d-8ae0-4d88917ef38b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock Award Units, Cancelled (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_41e0511b-e9c9-4a3f-9fbc-a0e6ffcba69c_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_a11b4add-170c-4190-b90b-eaddf4db9f30_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_71fc683c-a3eb-4270-ba4f-0f6517bd94f0_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_230eb40d-397b-496d-ab5e-e13f78258427_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_98b4e0ea-7010-4de1-9774-a3e8e61a9bca_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITION, RESTRUCTURING AND OTHER ITEMS, NET</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2bbd9bb7-b0bd-4ca1-b5c7-216b6531dd53_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f4a093a4-0c62-4aad-8f09-5fd316755d43_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_58e33f04-2fcc-4ec2-92ae-f3328f238673_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, net of current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f697ff32-9cf3-4e35-b960-35ff8509eb07_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_42cd8113-e8d9-4bdb-a281-b3a2510e3f57_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6c1eb762-bd32-46fd-875a-e6c5ea30659c_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_8344237c-49e2-4b3d-bcc0-3f610a263702_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_967e1457-83c2-4f2c-bd50-366a62eb4560_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_0d94e014-4baa-463a-a9f7-577ac46f408a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_Royalties_ee9f398a-f896-43a0-b72b-025736e19bcf_totalLabel_en-US" xlink:label="lab_ango_Royalties" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ango_Royalties_label_en-US" xlink:label="lab_ango_Royalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_ango_Royalties_documentation_en-US" xlink:label="lab_ango_Royalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_Royalties" xlink:href="ango-20230531.xsd#ango_Royalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_Royalties" xlink:to="lab_ango_Royalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cf4d4ea1-7baf-4f61-af7e-111e03a57d9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_eee5c9ca-53cd-4efb-a6ea-6a8cc6472adb_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_7c382a62-5178-4135-acdb-483d12c10b4b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_50871e72-1762-4aa9-997d-649c822ac854_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_cfd360b7-fbe4-4b56-bcb0-9d40dd3c8b38_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_9c473817-1da4-459f-afd4-ccf005b93621_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_1bdd2ff6-9b62-4b59-a8d9-6aa6cc028722_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_218ebc22-7b97-47b2-882b-8f19dc85bfc1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_08f09fd7-7676-4829-96df-2d81a5150dd0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_fbcf3ab3-fd0d-4781-b091-f95c6a0e0399_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_e1af4811-1f91-49f8-8b58-2940ed5d0443_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f7185c0b-560a-436b-b6ec-cefb53b16420_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_08bc51f6-87f5-4fed-8540-7a5558831512_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net&#160;carrying value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ResearchAndDevelopmentMember_d5366e0b-7b69-4568-b95c-3af90bc96e97_terseLabel_en-US" xlink:label="lab_ango_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ango_ResearchAndDevelopmentMember_label_en-US" xlink:label="lab_ango_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Member]</link:label>
    <link:label id="lab_ango_ResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_ango_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ResearchAndDevelopmentMember" xlink:href="ango-20230531.xsd#ango_ResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ResearchAndDevelopmentMember" xlink:to="lab_ango_ResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fc1ec4fc-5136-4291-b4e3-e6cb68d92dbc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service, compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_CommonStockVotesPerShare_9e9338f5-50bc-4464-af64-132a9af70018_terseLabel_en-US" xlink:label="lab_ango_CommonStockVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, votes per share</link:label>
    <link:label id="lab_ango_CommonStockVotesPerShare_label_en-US" xlink:label="lab_ango_CommonStockVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Votes Per Share</link:label>
    <link:label id="lab_ango_CommonStockVotesPerShare_documentation_en-US" xlink:label="lab_ango_CommonStockVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Votes Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CommonStockVotesPerShare" xlink:href="ango-20230531.xsd#ango_CommonStockVotesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_CommonStockVotesPerShare" xlink:to="lab_ango_CommonStockVotesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_dea6fd59-e0ff-4e33-b44b-1282320ef605_verboseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a3ed8b2a-78f4-4136-9f37-901a9c3214b5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule summarizes stock option activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_14b49712-dac6-44de-87eb-1dda55643f6c_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT, NET</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_TaxPeriodThreeMember_de738c30-b41f-44cd-90aa-491940063307_terseLabel_en-US" xlink:label="lab_ango_TaxPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2020 To 2040</link:label>
    <link:label id="lab_ango_TaxPeriodThreeMember_label_en-US" xlink:label="lab_ango_TaxPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period Three [Member]</link:label>
    <link:label id="lab_ango_TaxPeriodThreeMember_documentation_en-US" xlink:label="lab_ango_TaxPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TaxPeriodThreeMember" xlink:href="ango-20230531.xsd#ango_TaxPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_TaxPeriodThreeMember" xlink:to="lab_ango_TaxPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_5e0e4908-a3bf-45b0-9bbe-c2c1ec473ddf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_2d7b087c-b878-4eab-92ab-274406a9f632_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_22c2e0aa-dd8a-4a92-8532-451d222922a5_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6bad3275-3e8e-43f5-91a8-588c1f2a87b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Outstanding at end of year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ba856a3b-ffcb-459f-afbb-bb0649aeef12_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_058a0d13-4924-4bb7-9c1d-2e4217fbbc51_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7d6766d6-0bd8-4cfe-9193-79f0a9080ee2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod_bc6cf41e-2530-4215-9008-2577c069b0b2_verboseLabel_en-US" xlink:label="lab_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fair market value of a share of common stock on the first day of the offering period</link:label>
    <link:label id="lab_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod_label_en-US" xlink:label="lab_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Purchase Price of Common Stock Percent on First Day of Offering Period</link:label>
    <link:label id="lab_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod_documentation_en-US" xlink:label="lab_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award purchase price of common stock percent on first day of offering period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod" xlink:href="ango-20230531.xsd#ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod" xlink:to="lab_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_09d53ce1-bd87-41dc-8ab7-c399b29435d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of unrecognized tax benefits reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_12642b7f-dabb-4e7b-88fc-dc10c42b167f_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_06910e30-d41b-4064-a5b9-3d6ad9fe247a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_RadiaDyneMember_9da06cff-c73e-4fd5-a23e-6cdf83309410_terseLabel_en-US" xlink:label="lab_ango_RadiaDyneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RadiaDyne</link:label>
    <link:label id="lab_ango_RadiaDyneMember_label_en-US" xlink:label="lab_ango_RadiaDyneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RadiaDyne [Member]</link:label>
    <link:label id="lab_ango_RadiaDyneMember_documentation_en-US" xlink:label="lab_ango_RadiaDyneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RadiaDyne [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RadiaDyneMember" xlink:href="ango-20230531.xsd#ango_RadiaDyneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_RadiaDyneMember" xlink:to="lab_ango_RadiaDyneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_c06579f4-5dbc-497b-b657-2866eee7f403_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_SharePurchasePeriod_4c89c3db-0a6a-4519-be20-e7f6e508b453_verboseLabel_en-US" xlink:label="lab_ango_SharePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of purchase of shares</link:label>
    <link:label id="lab_ango_SharePurchasePeriod_label_en-US" xlink:label="lab_ango_SharePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Period</link:label>
    <link:label id="lab_ango_SharePurchasePeriod_documentation_en-US" xlink:label="lab_ango_SharePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharePurchasePeriod" xlink:href="ango-20230531.xsd#ango_SharePurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_SharePurchasePeriod" xlink:to="lab_ango_SharePurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9cd98869-f730-4b70-a854-80b71ee937ac_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6a6ef18a-b7df-4d6a-ad13-dc2311e5c729_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/cancellation of common stock units, Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_5e8103b7-9019-4f52-88a7-cc586159e501_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs on long-term debt</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7e7dbbdf-4308-4544-83cf-f6e738f62d4c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f9b2846d-39a0-431c-8c58-7f3ab3bd1d52_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_AssetAcquisitionInventoryAndFixedAssets_0532cc03-7a5a-437b-a94a-080786b8c3fd_terseLabel_en-US" xlink:label="lab_ango_AssetAcquisitionInventoryAndFixedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and fixed assets</link:label>
    <link:label id="lab_ango_AssetAcquisitionInventoryAndFixedAssets_label_en-US" xlink:label="lab_ango_AssetAcquisitionInventoryAndFixedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Inventory And Fixed Assets</link:label>
    <link:label id="lab_ango_AssetAcquisitionInventoryAndFixedAssets_documentation_en-US" xlink:label="lab_ango_AssetAcquisitionInventoryAndFixedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Inventory And Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AssetAcquisitionInventoryAndFixedAssets" xlink:href="ango-20230531.xsd#ango_AssetAcquisitionInventoryAndFixedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_AssetAcquisitionInventoryAndFixedAssets" xlink:to="lab_ango_AssetAcquisitionInventoryAndFixedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_ce55c04d-6b32-452f-a3f9-67827e6befc3_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENTS AND GEOGRAPHIC INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_fa185dc9-28b6-462b-993f-3508ddfd904b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance&#160;at Beginning of&#160;Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_3f0579a1-4ea3-4041-b2e4-61e49b6a04f0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance&#160;at End&#160;of&#160;Period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_aa27e5db-a4c0-479d-8532-fc0419a24036_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_42aa0a15-e292-425b-988e-84be085120b3_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_a30376fc-d8fd-4215-85db-098067c762d2_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76eb92bf-eaa9-4d58-8105-03c96c0eb3be_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7a11d0c4-2422-4b6c-9502-9f3612476d7b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bf842d6-88c7-4bf2-af60-4c95a83e646d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_43058278-5822-492b-be36-a7a379509e16_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_d45ac371-02cc-4bba-8107-84238b331afa_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_ada9a92d-2ffd-4cb5-b28d-3dbbe5ebaf9c_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_fcc2ce29-c458-4acd-ac0b-87e7a983b3a4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_47b9af75-9834-42f2-b47b-44874e235e5b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1bc747ab-e70f-4d6f-993c-5c0ee533675c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Option expected to vest in future periods</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_3195385d-aadc-4e82-a9f4-c0e61bc2ee4a_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c16344a6-c538-487e-8901-2de1b62031a8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2602eaa-20d4-40af-9999-5f57908a4b38_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8452824c-c7f3-417e-a064-e50972b59f51_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_c9a21273-7bb5-4fc0-8604-6d37fd5448d8_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_75dd9df8-d517-4bf4-a618-80c095a93373_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2b942522-01c6-47c9-9179-58152e94121a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_ab6e4048-35c8-4fbe-900d-57137ac92786_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_PerformanceShareAndRestrictedStockUnitAwardsMember_16c01e9c-c2cc-4a4a-9816-586c70a44a58_verboseLabel_en-US" xlink:label="lab_ango_PerformanceShareAndRestrictedStockUnitAwardsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share and Restricted Stock Unit Awards</link:label>
    <link:label id="lab_ango_PerformanceShareAndRestrictedStockUnitAwardsMember_label_en-US" xlink:label="lab_ango_PerformanceShareAndRestrictedStockUnitAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share and Restricted Stock Unit Awards [Member]</link:label>
    <link:label id="lab_ango_PerformanceShareAndRestrictedStockUnitAwardsMember_documentation_en-US" xlink:label="lab_ango_PerformanceShareAndRestrictedStockUnitAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share and Restricted Stock Unit Awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PerformanceShareAndRestrictedStockUnitAwardsMember" xlink:href="ango-20230531.xsd#ango_PerformanceShareAndRestrictedStockUnitAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_PerformanceShareAndRestrictedStockUnitAwardsMember" xlink:to="lab_ango_PerformanceShareAndRestrictedStockUnitAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_a5399f3a-2a12-4c40-a78f-643403948f66_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_925bbc46-fd53-4386-837b-edf1256d5a08_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_854b286c-83ff-41af-b74f-8879eac1b9fb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a3c07f55-ebe9-4708-aa56-5b97f4967537_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation pre tax amount</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8edb4da0-b44e-4c60-bebf-c2adc4fbfb37_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 17)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c032ff11-eb0d-41fb-b263-4dfc8ec2fbb1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47b071d8-534e-4d11-97da-1c135f2fac07_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, Outstanding at beginning of year (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10ef16bf-e1ff-4b7e-963b-3a30497e0c19_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, Outstanding at end of year (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_8806e889-3d9b-46e0-9f8b-708ec678c3a2_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_c4949e9a-24a6-46f8-b680-241eaf52de77_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d6d6e949-9822-4087-8501-0628bbe52a75_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_38903f72-f8dc-44d9-b1fc-1510a5a8eba6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_749f96bf-fb6f-4dd3-9610-87aa795dd3b1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_4f6d10c4-3de3-455e-9661-255b25c26ec2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28612546-8a2e-41a4-8988-694170d1e882_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_d5e3df43-80fe-433e-b613-782f11216982_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_95ad9fb7-6e23-4c31-83c3-8979eea23870_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for deferred tax asset</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio_dd0babee-507f-442d-a460-a283d7c007ce_terseLabel_en-US" xlink:label="lab_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum fixed charge coverage ratio</link:label>
    <link:label id="lab_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio_label_en-US" xlink:label="lab_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Minimum Fixed Charge Coverage Ratio</link:label>
    <link:label id="lab_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio_documentation_en-US" xlink:label="lab_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Minimum Fixed Charge Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio" xlink:href="ango-20230531.xsd#ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio" xlink:to="lab_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ccf7452a-7837-4ba0-b6d8-f1c9fe07fd44_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_d15bd673-84fc-4508-9013-9c788628771c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1b46f20f-358d-4780-b389-e0a4006b5b95_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_92330d80-1a03-41d0-a02b-621279191b06_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_e73a9c12-51ce-4592-9b83-617c3e917afc_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_514c48a8-4dc6-4a95-9e25-8b78a2813b4b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_5f7c44cf-2b66-49e6-a6e4-fbe5b3491bae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_c84ae613-3690-4591-9268-007e0371d910_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1_6ba3f886-24b2-43a6-89d4-00e091406683_verboseLabel_en-US" xlink:label="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option grants to employees vesting period</link:label>
    <link:label id="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1_label_en-US" xlink:label="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Award Granted to Employees Vesting Period 1</link:label>
    <link:label id="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1_documentation_en-US" xlink:label="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award award granted to employees vesting period1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1" xlink:href="ango-20230531.xsd#ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1" xlink:to="lab_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8d7a39da-223b-444d-b3d9-d66230630f45_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_f88e3e05-6b5b-4d1d-a15c-ea38835c9f07_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_941127e0-a87d-4950-a2da-9c8cb7dad01f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE FROM CONTRACTS WITH CUSTOMERS</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_2fde495f-af10-4dae-a351-9b3c5cea5201_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_37aac26c-4f5a-4fd7-811c-36289134f0c5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9c7bd5bf-325d-43b8-a7b0-88f0c81211e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_7444fb74-ef8e-4c8f-9d10-2117d917d049_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11ad70d3-fa31-4b3d-b69d-f8f85e2917a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_RetirementPlansTextualAbstract_b59a6703-517c-4815-a1e7-b5e58443dfff_verboseLabel_en-US" xlink:label="lab_ango_RetirementPlansTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plans (Textual) [Abstract]</link:label>
    <link:label id="lab_ango_RetirementPlansTextualAbstract_label_en-US" xlink:label="lab_ango_RetirementPlansTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plans (Textual) [Abstract]</link:label>
    <link:label id="lab_ango_RetirementPlansTextualAbstract_documentation_en-US" xlink:label="lab_ango_RetirementPlansTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plans (Textual) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RetirementPlansTextualAbstract" xlink:href="ango-20230531.xsd#ango_RetirementPlansTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_RetirementPlansTextualAbstract" xlink:to="lab_ango_RetirementPlansTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_ed1f2c46-0376-47d5-b858-cd6797c69db8_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c0cb2af2-5d16-406c-bc93-7d3274a7934c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_dff1e2ef-65e0-4363-b1df-80a9fd9f9bbc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term (years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_70e35984-8ff7-4817-b10a-f6c52694aece_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of deferred tax asset and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember_c1ccc2e3-3bfa-40aa-a003-022b005d7bb5_verboseLabel_en-US" xlink:label="lab_ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2004 Stock and Incentive Award Plan</link:label>
    <link:label id="lab_ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember_label_en-US" xlink:label="lab_ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand and Four Stock and Incentive Award Plan [Member]</link:label>
    <link:label id="lab_ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand and Four Stock and Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember" xlink:href="ango-20230531.xsd#ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember" xlink:to="lab_ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f05cc4f0-f19f-4af3-9393-86eff445648d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_62cbb7df-ff77-46cc-a984-a3416b882b1b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_OarTracTrademarkMember_a9a2432e-109f-4023-8d0e-c7ac0b4423a0_terseLabel_en-US" xlink:label="lab_ango_OarTracTrademarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OarTrac trademark</link:label>
    <link:label id="lab_ango_OarTracTrademarkMember_label_en-US" xlink:label="lab_ango_OarTracTrademarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OarTrac Trademark [Member]</link:label>
    <link:label id="lab_ango_OarTracTrademarkMember_documentation_en-US" xlink:label="lab_ango_OarTracTrademarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OarTrac Trademark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_OarTracTrademarkMember" xlink:href="ango-20230531.xsd#ango_OarTracTrademarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_OarTracTrademarkMember" xlink:to="lab_ango_OarTracTrademarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_49e3c87f-be5b-480e-962f-e0a481d87587_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_81bcb8ea-5317-4fb0-a453-f6dc99a8bce4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_90daa7f6-a2b6-4ffd-8c1c-2feccc0fe05c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_434c188c-f66f-4ddb-9143-64e0fab4a203_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_b0d2ed22-f8a2-406f-b1d5-2c7d1f7094f8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of income (loss) before income tax provision</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6d358e81-80c7-4787-9f20-64fa674a99e7_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f7f139ec-0533-45be-9288-573682523513_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_92effc58-7c22-4601-bb53-49cd1d3cb711_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3f3fbbcb-90ee-479d-b84e-28b5cc834420_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_0d0a4ac3-8319-42bd-a577-98793e51073f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Tax Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ab3b6f38-954f-40ea-86c0-10ee3b0fc914_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7f2ddad2-f85a-4465-bdf3-f52246c34b5a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_0404232a-a8c5-4225-a161-9af7c0eb806d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_72c681a1-46fd-4b68-a723-2eac86c9d4e8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_e60530b5-fe95-45a9-a5bc-3e3f8ae520e7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_227b7926-639c-4e43-bda0-6264b2e48fbd_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b171139d-bb0b-435b-9cfb-d490f7bed86a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvanceRoyaltiesAbstract_0223ada7-3cad-4bc5-9d76-879816660600_terseLabel_en-US" xlink:label="lab_us-gaap_AdvanceRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_AdvanceRoyaltiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdvanceRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Royalties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract" xlink:to="lab_us-gaap_AdvanceRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fdec6854-b952-4d23-a194-f79eeef5b18d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ec8d4441-5485-44b5-b559-2656331c3a57_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_22fa8692-2781-418e-ab6f-21510564bb31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_b2b7c1bf-c419-4ed5-808e-6cc0314b242d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_09ce5840-c4cf-4c3a-bc47-cb86eed8c2f4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_PurchaseObligationToBePaidAfterYearFour_4925cb78-e9b8-4d30-95bf-7099740bf89f_terseLabel_en-US" xlink:label="lab_ango_PurchaseObligationToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_ango_PurchaseObligationToBePaidAfterYearFour_label_en-US" xlink:label="lab_ango_PurchaseObligationToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ango_PurchaseObligationToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ango_PurchaseObligationToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PurchaseObligationToBePaidAfterYearFour" xlink:href="ango-20230531.xsd#ango_PurchaseObligationToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_PurchaseObligationToBePaidAfterYearFour" xlink:to="lab_ango_PurchaseObligationToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_d1db110e-70dd-4e01-8608-6707cfc0fab4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_43569cd6-88e5-4169-9765-0f4961de705c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5cc0a62a-15ff-4a7d-99b4-003a875c64f0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ShortTermInvestmentsMaturityPeriod_cce11576-f477-4c98-a262-237867ddf1f6_terseLabel_en-US" xlink:label="lab_ango_ShortTermInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period</link:label>
    <link:label id="lab_ango_ShortTermInvestmentsMaturityPeriod_label_en-US" xlink:label="lab_ango_ShortTermInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Investments Maturity Period</link:label>
    <link:label id="lab_ango_ShortTermInvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_ango_ShortTermInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investments maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ShortTermInvestmentsMaturityPeriod" xlink:href="ango-20230531.xsd#ango_ShortTermInvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ShortTermInvestmentsMaturityPeriod" xlink:to="lab_ango_ShortTermInvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_StockAndIncentiveAwardPlan2020Member_1fc9dce3-9496-40da-87da-a2ff12806586_terseLabel_en-US" xlink:label="lab_ango_StockAndIncentiveAwardPlan2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock And Incentive Award Plan 2020</link:label>
    <link:label id="lab_ango_StockAndIncentiveAwardPlan2020Member_label_en-US" xlink:label="lab_ango_StockAndIncentiveAwardPlan2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock And Incentive Award Plan 2020 [Member]</link:label>
    <link:label id="lab_ango_StockAndIncentiveAwardPlan2020Member_documentation_en-US" xlink:label="lab_ango_StockAndIncentiveAwardPlan2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock And Incentive Award Plan 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_StockAndIncentiveAwardPlan2020Member" xlink:href="ango-20230531.xsd#ango_StockAndIncentiveAwardPlan2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_StockAndIncentiveAwardPlan2020Member" xlink:to="lab_ango_StockAndIncentiveAwardPlan2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_TaxPeriodTwoMember_f74210ff-5a43-427a-a8e1-a6686b802f2c_terseLabel_en-US" xlink:label="lab_ango_TaxPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2028 and 2037</link:label>
    <link:label id="lab_ango_TaxPeriodTwoMember_label_en-US" xlink:label="lab_ango_TaxPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period Two [Member]</link:label>
    <link:label id="lab_ango_TaxPeriodTwoMember_documentation_en-US" xlink:label="lab_ango_TaxPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TaxPeriodTwoMember" xlink:href="ango-20230531.xsd#ango_TaxPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_TaxPeriodTwoMember" xlink:to="lab_ango_TaxPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_73dcc223-78cf-4783-8d43-16663be3d51f_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_ce4d8edd-4776-4969-a074-2c9d177990f5_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_3b6759fb-217a-4cbd-a581-5c56dd1cca8c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_8a5c1ef4-2144-44f5-836c-1b03b07b0b8f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS HELD FOR SALE</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e1f6c369-0cc5-4cb6-9bdf-1f8cd6b86188_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_da654b7a-5739-4316-acf0-8114506fa0fb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee (percentage)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_ContractwithCustomerRightofReturnRestockingCharge_9b084adf-1c26-4b18-9368-4c0e4bc3523a_terseLabel_en-US" xlink:label="lab_ango_ContractwithCustomerRightofReturnRestockingCharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restocking charge (percent)</link:label>
    <link:label id="lab_ango_ContractwithCustomerRightofReturnRestockingCharge_label_en-US" xlink:label="lab_ango_ContractwithCustomerRightofReturnRestockingCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Right of Return, Restocking Charge</link:label>
    <link:label id="lab_ango_ContractwithCustomerRightofReturnRestockingCharge_documentation_en-US" xlink:label="lab_ango_ContractwithCustomerRightofReturnRestockingCharge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Right of Return, Restocking Charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ContractwithCustomerRightofReturnRestockingCharge" xlink:href="ango-20230531.xsd#ango_ContractwithCustomerRightofReturnRestockingCharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_ContractwithCustomerRightofReturnRestockingCharge" xlink:to="lab_ango_ContractwithCustomerRightofReturnRestockingCharge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_f922fd8e-9e1d-4290-8f4a-1ef4a53449c4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_58be8c5d-30a3-4107-a826-3ef47d753364_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_DebtInstrumentDebtDefaultInterestRateIncrease_8f03716e-5730-4cc7-ba2c-7b3f9a48d68a_terseLabel_en-US" xlink:label="lab_ango_DebtInstrumentDebtDefaultInterestRateIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt default interest rate increase (percentage)</link:label>
    <link:label id="lab_ango_DebtInstrumentDebtDefaultInterestRateIncrease_label_en-US" xlink:label="lab_ango_DebtInstrumentDebtDefaultInterestRateIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Interest Rate Increase</link:label>
    <link:label id="lab_ango_DebtInstrumentDebtDefaultInterestRateIncrease_documentation_en-US" xlink:label="lab_ango_DebtInstrumentDebtDefaultInterestRateIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Interest Rate Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentDebtDefaultInterestRateIncrease" xlink:href="ango-20230531.xsd#ango_DebtInstrumentDebtDefaultInterestRateIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_DebtInstrumentDebtDefaultInterestRateIncrease" xlink:to="lab_ango_DebtInstrumentDebtDefaultInterestRateIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f0950dc0-4d15-4906-8b1d-1c800afb659a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability schedule</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f7a0985b-9082-482b-9895-69a39a9c5dff_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_ad567cac-907d-4b83-8341-ca546b746b98_terseLabel_en-US" xlink:label="lab_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible executive compensation</link:label>
    <link:label id="lab_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_label_en-US" xlink:label="lab_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount</link:label>
    <link:label id="lab_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_documentation_en-US" xlink:label="lab_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:href="ango-20230531.xsd#ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:to="lab_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_e0b79872-7815-4d4f-bf75-023de0934cc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_dd3a5ecf-aebd-4a3e-99fc-6f2c622e5bb9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_MedTechMember_bf3b29a3-ba04-4568-9ce2-e26fe691309d_terseLabel_en-US" xlink:label="lab_ango_MedTechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Med Tech</link:label>
    <link:label id="lab_ango_MedTechMember_label_en-US" xlink:label="lab_ango_MedTechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Med Tech [Member]</link:label>
    <link:label id="lab_ango_MedTechMember_documentation_en-US" xlink:label="lab_ango_MedTechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Med Tech</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedTechMember" xlink:href="ango-20230531.xsd#ango_MedTechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_MedTechMember" xlink:to="lab_ango_MedTechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_e00c4538-68af-4f2a-bb0f-454cfe4942af_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_RoyaltiesDueinSecondYear_3b3eb4d2-dac7-4349-90c0-3b9234671fa7_terseLabel_en-US" xlink:label="lab_ango_RoyaltiesDueinSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ango_RoyaltiesDueinSecondYear_label_en-US" xlink:label="lab_ango_RoyaltiesDueinSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Due in Second Year</link:label>
    <link:label id="lab_ango_RoyaltiesDueinSecondYear_documentation_en-US" xlink:label="lab_ango_RoyaltiesDueinSecondYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Due in Second Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueinSecondYear" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueinSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_RoyaltiesDueinSecondYear" xlink:to="lab_ango_RoyaltiesDueinSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_88a514fe-e7a1-497a-9f22-0be1fc61f8e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_59cf7700-d951-4dea-bc43-d8a48554521a_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_ef76e98b-889f-41c0-b0f9-4a2510fab1b2_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e695261e-efd6-4f8a-a2b7-b8d44eedcae8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_ddf00ea9-c3c5-42e8-a0f3-85a379b206f9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory valuation reserve</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_0592fc0c-4a16-4130-83c9-1f61ba3a4240_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_74022ea2-0326-451a-a329-88b23b123850_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_69f1b74f-a1f5-4d76-87a2-276569946595_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_f11ce175-9f07-4c30-8569-df7505fa3027_verboseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_77343cea-61af-4658-82ef-197635a1ed0f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dd477944-7ff4-4bd9-8011-fb75595b3051_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock Award Units, Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_6c091401-489f-42c8-a950-f173d44d68b2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a9a8dbf9-0545-4356-a2b8-c23b1cddd009_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6a7a30b5-db73-4724-ac18-50c57e1ceb5d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c3bded1a-b433-498c-8d77-fefbc6fa848f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares to be offered</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_81655841-a4b6-46c6-b364-06a5bd26ef1e_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:to="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_6bf091ad-64dc-45c8-a77f-fc593cd90502_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award nonvested shares and weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_AuditorInformationAbstract_label_en-US" xlink:label="lab_ango_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_ango_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_ango_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AuditorInformationAbstract" xlink:href="ango-20230531.xsd#ango_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_AuditorInformationAbstract" xlink:to="lab_ango_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_e26b1478-6ed9-4f99-9f4f-61031121a347_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_55a90beb-55fc-4492-aecb-1fc7c1cf3af3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_cfba5a76-f50d-4931-9e1d-ea62194f9187_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_NumberOfSharePurchasePeriod_2629ed9d-5f10-4ac2-96ff-df254782a099_verboseLabel_en-US" xlink:label="lab_ango_NumberOfSharePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase periods</link:label>
    <link:label id="lab_ango_NumberOfSharePurchasePeriod_label_en-US" xlink:label="lab_ango_NumberOfSharePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Share Purchase Period</link:label>
    <link:label id="lab_ango_NumberOfSharePurchasePeriod_documentation_en-US" xlink:label="lab_ango_NumberOfSharePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share purchase period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_NumberOfSharePurchasePeriod" xlink:href="ango-20230531.xsd#ango_NumberOfSharePurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_NumberOfSharePurchasePeriod" xlink:to="lab_ango_NumberOfSharePurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_IsraeliInnovationAuthorityPrepaymentMember_5564190f-efcd-4db4-85f2-ed5a43b427e8_terseLabel_en-US" xlink:label="lab_ango_IsraeliInnovationAuthorityPrepaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Israeli Innovation Authority prepayment</link:label>
    <link:label id="lab_ango_IsraeliInnovationAuthorityPrepaymentMember_label_en-US" xlink:label="lab_ango_IsraeliInnovationAuthorityPrepaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Israeli Innovation Authority Prepayment [Member]</link:label>
    <link:label id="lab_ango_IsraeliInnovationAuthorityPrepaymentMember_documentation_en-US" xlink:label="lab_ango_IsraeliInnovationAuthorityPrepaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Israeli Innovation Authority Prepayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IsraeliInnovationAuthorityPrepaymentMember" xlink:href="ango-20230531.xsd#ango_IsraeliInnovationAuthorityPrepaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_IsraeliInnovationAuthorityPrepaymentMember" xlink:to="lab_ango_IsraeliInnovationAuthorityPrepaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0ab78c18-2196-474c-864b-949079a06bef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_93ded6b3-3401-4e78-8d43-759f58935edb_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ec67b29f-0ccc-43d2-856c-d786c80a303d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_41d52932-9dec-4aac-a30f-80c0c32909a8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of Federal tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2a67be4d-5f28-42a1-a57c-289a7a77c360_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_4f750d23-f156-41d0-844b-700c7a7442c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, Restructuring and Other Items, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_5c38925e-06e5-4d8c-8eb6-566ac89a2ad6_verboseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VALUATION AND QUALIFYING ACCOUNTS</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b30db34a-3ced-426e-a545-46dc6f806c13_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate used in fair value calculation</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6c63e92f-044c-4709-9da0-a80fc51d0e1c_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ead2a2b1-7e1f-4c02-8d6b-0148298dae28_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_b85760bd-bf7b-4ba2-8822-81079e2db3d6_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected amortization expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_15a2e8bf-f7ec-461d-865a-f9e9a3328fc9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1ede6820-4817-42f2-a58e-311fc7083df0_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_d5a431bd-0e4f-4fc5-9809-69af0c587f39_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), before tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d43e96b5-779f-4d67-bc2d-cc16a8b7f511_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;Average Grant-Date&#160;Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63c7af06-36d8-41b7-8a33-d18bd87154ad_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b209962-fcd3-470a-a59c-18ab7a4bc2fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetAssetsGeographicAreaMember_e7673928-b9af-474b-8c2e-b459c0f8db07_terseLabel_en-US" xlink:label="lab_us-gaap_NetAssetsGeographicAreaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Assets, Geographic Area</link:label>
    <link:label id="lab_us-gaap_NetAssetsGeographicAreaMember_label_en-US" xlink:label="lab_us-gaap_NetAssetsGeographicAreaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Assets, Geographic Area [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAssetsGeographicAreaMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetAssetsGeographicAreaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetAssetsGeographicAreaMember" xlink:to="lab_us-gaap_NetAssetsGeographicAreaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ca59a8bd-f398-431b-b595-31d1125f3141_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_1913dde6-a1d5-4f7e-ae9d-13bf2a7cb13c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_a0178373-8a2c-497e-ad65-c1a79371b509_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod_9178e1c4-ff25-44ea-b7d7-48f4d7e20c72_terseLabel_en-US" xlink:label="lab_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized, including current period.</link:label>
    <link:label id="lab_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod_label_en-US" xlink:label="lab_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer With Customer, Liability, Revenue Recognized, Including Current Period</link:label>
    <link:label id="lab_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod_documentation_en-US" xlink:label="lab_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer With Customer, Liability, Revenue Recognized, Including Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod" xlink:href="ango-20230531.xsd#ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod" xlink:to="lab_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1e4468ea-1d62-4049-aac2-5d842021ab3e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c1616dcd-c0ce-4e1f-a9b1-bb0b997d79d9_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a1e3ae96-8c7c-4c60-b5b2-d0d61f1c6c81_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_RoyaltiesDueinFourthYear_6c782d83-d0ef-41df-a5bc-34d2682f9779_terseLabel_en-US" xlink:label="lab_ango_RoyaltiesDueinFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_ango_RoyaltiesDueinFourthYear_label_en-US" xlink:label="lab_ango_RoyaltiesDueinFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Due in Fourth Year</link:label>
    <link:label id="lab_ango_RoyaltiesDueinFourthYear_documentation_en-US" xlink:label="lab_ango_RoyaltiesDueinFourthYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Due in Fourth Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueinFourthYear" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueinFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_RoyaltiesDueinFourthYear" xlink:to="lab_ango_RoyaltiesDueinFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_dc3fe8d6-f3bb-4fa8-8db9-dc5a538dc319_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_637a406e-e324-4fe4-ae68-b489be670325_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_58f019b5-f793-4b20-ab8e-fb578f39ca35_totalLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_c5feb37c-01b8-47eb-9fce-7279c1e36109_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_6ca71ee0-0520-4c6a-ba73-3621f3ede804_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in accounts payable for purchases of fixed assets</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_040f007e-210f-4ece-8e37-ef2e2ff4a69e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit at federal statutory tax rate of 21.0%, 21.0% and 21.0%, respectively</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_98ca099c-b1f4-4014-bc95-86d0692aaf6f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_14f95ca3-90fc-4bce-9154-df9413f43ee3_verboseLabel_en-US" xlink:label="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements using Significant Unobservable Inputs</link:label>
    <link:label id="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_label_en-US" xlink:label="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Liabilities Measured on Recurring Basis Unobservable Input Reconciliation [Abstract]</link:label>
    <link:label id="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_documentation_en-US" xlink:label="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:href="ango-20230531.xsd#ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="lab_ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e418928-8a7c-4433-b48c-d567b1021a21_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_5d4c98f4-b8f8-4351-83cb-86ba2618790a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ea47715a-94b8-4db7-9e49-8570f69f5d86_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f581e350-36ac-4f8b-b5f5-bfaec24c5bd0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7286bb31-377c-4472-bd7a-9dc3e34c5f35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option grants in the period, weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_684aa463-00ea-4d00-ac05-250a1d047ea5_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_de10dffd-368f-40eb-a799-5491a8052efa_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount_dc269061-7926-49e5-bb33-87ea56d28eee_terseLabel_en-US" xlink:label="lab_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future contingent consideration</link:label>
    <link:label id="lab_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="ango-20230531.xsd#ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_4812cc68-0628-40aa-af96-731de91ee5c3_terseLabel_en-US" xlink:label="lab_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ango-20230531.xsd#ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse_19fc942a-1012-4e47-a698-a4d083117235_terseLabel_en-US" xlink:label="lab_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards after considering limitations of use</link:label>
    <link:label id="lab_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse_label_en-US" xlink:label="lab_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Amount After Limitation Of Use</link:label>
    <link:label id="lab_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse_documentation_en-US" xlink:label="lab_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Amount After Limitation Of Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse" xlink:href="ango-20230531.xsd#ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse" xlink:to="lab_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_7b9a068e-6d11-485f-bf57-c47a9b11f699_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_f2022d77-8a53-4bb0-ae8b-1274f56164e5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ab1c5c1f-5be9-4a73-ab44-d8f225a3f619_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_97ce75dd-453a-4e48-a8f3-75ee1633f4ac_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_2ab3bcc0-3b10-4102-9504-30b5217270b7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b2d42797-4dc7-402e-bca7-fb9ed0947277_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherAssets1_42dfef19-5a60-4560-9ef7-33993293684d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherAssets1_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6ec010dc-a69d-4f47-beb6-3b005497ba18_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_597559a4-2412-41a2-a778-32efe710e82c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate at period end (percentage)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_9d2f02b7-f2e9-4685-916a-4930de242ad1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_PerformanceSharesIncludingThreeYearMarketConditionMember_775162ef-1fb0-4d48-92a1-e7a55af82d7a_terseLabel_en-US" xlink:label="lab_ango_PerformanceSharesIncludingThreeYearMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_ango_PerformanceSharesIncludingThreeYearMarketConditionMember_label_en-US" xlink:label="lab_ango_PerformanceSharesIncludingThreeYearMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Including Three-Year Market Condition [Member]</link:label>
    <link:label id="lab_ango_PerformanceSharesIncludingThreeYearMarketConditionMember_documentation_en-US" xlink:label="lab_ango_PerformanceSharesIncludingThreeYearMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Including Three-Year Market Condition [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PerformanceSharesIncludingThreeYearMarketConditionMember" xlink:href="ango-20230531.xsd#ango_PerformanceSharesIncludingThreeYearMarketConditionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_PerformanceSharesIncludingThreeYearMarketConditionMember" xlink:to="lab_ango_PerformanceSharesIncludingThreeYearMarketConditionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible_0d577934-f47c-476a-9c64-db79d89a1f8b_terseLabel_en-US" xlink:label="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of working hours to be eligible (working hour)</link:label>
    <link:label id="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible_label_en-US" xlink:label="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Working Hours Per Week to be Eligible</link:label>
    <link:label id="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible_documentation_en-US" xlink:label="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Working Hours Per Week to be Eligible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible" xlink:href="ango-20230531.xsd#ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible" xlink:to="lab_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible" xlink:type="arc" order="1"/>
    <link:label id="lab_ango_TheDelawareActionMember_2eed6035-192a-4154-a36f-e046a9d57590_terseLabel_en-US" xlink:label="lab_ango_TheDelawareActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Delaware Action</link:label>
    <link:label id="lab_ango_TheDelawareActionMember_label_en-US" xlink:label="lab_ango_TheDelawareActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Delaware Action [Member]</link:label>
    <link:label id="lab_ango_TheDelawareActionMember_documentation_en-US" xlink:label="lab_ango_TheDelawareActionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Delaware Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TheDelawareActionMember" xlink:href="ango-20230531.xsd#ango_TheDelawareActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ango_TheDelawareActionMember" xlink:to="lab_ango_TheDelawareActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_42e40497-e05d-425b-abb1-ffd78cb2220c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reasons for consolidated income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ango-20230531_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:9980962c-8c03-489b-926a-266c60a03003,g:4284608e-2675-438a-ad4d-4e46a03d6c06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.angiodynamics.com/role/CoverPage" xlink:type="simple" xlink:href="ango-20230531.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7195075c-a6af-4597-be44-2df2c365a8c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityCentralIndexKey_7195075c-a6af-4597-be44-2df2c365a8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fc948120-e1a9-4c97-b41a-2c5701be75a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_AmendmentFlag_fc948120-e1a9-4c97-b41a-2c5701be75a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_948fb715-6651-46ea-bd80-5ffd46def392" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_DocumentFiscalYearFocus_948fb715-6651-46ea-bd80-5ffd46def392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_36d6c223-fb98-49b9-8981-39d2eb65a075" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_DocumentFiscalPeriodFocus_36d6c223-fb98-49b9-8981-39d2eb65a075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2c66e404-ec37-4b07-a7e7-361d79d9dbf9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_CurrentFiscalYearEndDate_2c66e404-ec37-4b07-a7e7-361d79d9dbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4fbaf75a-5fb8-43b7-a804-dc626e9cfc77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_DocumentType_4fbaf75a-5fb8-43b7-a804-dc626e9cfc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_1651aa47-f03a-42fb-90af-ae793327d7f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_DocumentAnnualReport_1651aa47-f03a-42fb-90af-ae793327d7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c17ea66c-47b9-4031-ac8f-718c372c57fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_DocumentPeriodEndDate_c17ea66c-47b9-4031-ac8f-718c372c57fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_744a44bf-32a4-4a02-ae36-9f7d6cb18509" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_DocumentTransitionReport_744a44bf-32a4-4a02-ae36-9f7d6cb18509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b36f9e57-867b-4b15-bd68-a9ac8e48ca4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityFileNumber_b36f9e57-867b-4b15-bd68-a9ac8e48ca4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_363c4b4f-3415-4121-991d-627a2972a27e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityRegistrantName_363c4b4f-3415-4121-991d-627a2972a27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4abaf92d-43eb-4ce5-a9f9-8acd8ba5fb02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4abaf92d-43eb-4ce5-a9f9-8acd8ba5fb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3913f929-bd88-4bc7-9159-7a7be23d8c26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityTaxIdentificationNumber_3913f929-bd88-4bc7-9159-7a7be23d8c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1ddbab6e-101a-4f42-bec8-d1b41a342f75" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityAddressAddressLine1_1ddbab6e-101a-4f42-bec8-d1b41a342f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_924602c8-5bd5-470f-96e6-14de36f09b6b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityAddressCityOrTown_924602c8-5bd5-470f-96e6-14de36f09b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c545a5d9-7844-4bb9-b27f-8466046ced2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityAddressStateOrProvince_c545a5d9-7844-4bb9-b27f-8466046ced2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fbd67518-92d1-4a2a-acb9-6d3f75b15129" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityAddressPostalZipCode_fbd67518-92d1-4a2a-acb9-6d3f75b15129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_af1b6698-661f-4890-bcd0-911300375934" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_CityAreaCode_af1b6698-661f-4890-bcd0-911300375934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ac1fc5ca-956d-4905-831d-13e325405a90" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_LocalPhoneNumber_ac1fc5ca-956d-4905-831d-13e325405a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c2b49240-d221-47ae-935f-1a942d25ab44" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_Security12bTitle_c2b49240-d221-47ae-935f-1a942d25ab44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e6ba6404-c7f7-4d19-83c7-678d17117ea8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_TradingSymbol_e6ba6404-c7f7-4d19-83c7-678d17117ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8035a847-36f6-48aa-95fc-66d61776e773" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_SecurityExchangeName_8035a847-36f6-48aa-95fc-66d61776e773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0ae2492c-f1d7-4ff1-9649-a9e1ab5228c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_0ae2492c-f1d7-4ff1-9649-a9e1ab5228c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_fd2d7432-f3a5-4fb4-ad3e-21ea56fd1d99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityVoluntaryFilers_fd2d7432-f3a5-4fb4-ad3e-21ea56fd1d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_210197e3-73e8-4bc4-85f7-bac8c5596ee7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityCurrentReportingStatus_210197e3-73e8-4bc4-85f7-bac8c5596ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_28c85a96-43e0-429f-8bf5-965f72726e4d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityInteractiveDataCurrent_28c85a96-43e0-429f-8bf5-965f72726e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_dcbeb1bd-f670-4155-8506-de4c6f47d84e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntitySmallBusiness_dcbeb1bd-f670-4155-8506-de4c6f47d84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c7fce651-fc12-4697-8cb6-d1db8f667d9a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityEmergingGrowthCompany_c7fce651-fc12-4697-8cb6-d1db8f667d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_22920142-eee9-4c03-b7dd-587aa4041117" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_IcfrAuditorAttestationFlag_22920142-eee9-4c03-b7dd-587aa4041117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8d5da889-7173-41a7-b6de-50a1d5febd0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityShellCompany_8d5da889-7173-41a7-b6de-50a1d5febd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_df19d115-39ff-4083-8b56-7d91be4542e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityPublicFloat_df19d115-39ff-4083-8b56-7d91be4542e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8bf4c9dd-c5f1-4007-8db1-f8ad38826c17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8bf4c9dd-c5f1-4007-8db1-f8ad38826c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c7417ae4-b391-4048-81e1-12e5ee02f43e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c7417ae4-b391-4048-81e1-12e5ee02f43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a614c525-e076-4257-bf13-95dc6bf2ac32" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d326054e-0d7a-4309-ab74-a78ad36350ab" xlink:to="loc_dei_EntityFilerCategory_a614c525-e076-4257-bf13-95dc6bf2ac32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AuditInformation" xlink:type="simple" xlink:href="ango-20230531.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ango_AuditorInformationAbstract_78c44b72-4a32-47e6-9a8b-191c90b5df5a" xlink:href="ango-20230531.xsd#ango_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_38ab90cf-2f43-44dc-a600-92d76b81f747" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_AuditorInformationAbstract_78c44b72-4a32-47e6-9a8b-191c90b5df5a" xlink:to="loc_dei_AuditorName_38ab90cf-2f43-44dc-a600-92d76b81f747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_184db6b2-a9f0-4352-84f8-93ec1f1c8871" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_AuditorInformationAbstract_78c44b72-4a32-47e6-9a8b-191c90b5df5a" xlink:to="loc_dei_AuditorLocation_184db6b2-a9f0-4352-84f8-93ec1f1c8871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_7af80d8a-aa22-4c9f-8ddc-3e3e774b373a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_AuditorInformationAbstract_78c44b72-4a32-47e6-9a8b-191c90b5df5a" xlink:to="loc_dei_AuditorFirmId_7af80d8a-aa22-4c9f-8ddc-3e3e774b373a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ango-20230531.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_5b9e615e-dc68-4205-8d71-025a52a4429b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_52d6ca70-5b8f-49c5-980b-338e7760fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b9e615e-dc68-4205-8d71-025a52a4429b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_52d6ca70-5b8f-49c5-980b-338e7760fc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c13bedd5-9f9e-4098-8c9b-29a3a01cf291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b9e615e-dc68-4205-8d71-025a52a4429b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c13bedd5-9f9e-4098-8c9b-29a3a01cf291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_30c6369e-5aae-4633-904a-7390c1c3f449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b9e615e-dc68-4205-8d71-025a52a4429b" xlink:to="loc_us-gaap_GrossProfit_30c6369e-5aae-4633-904a-7390c1c3f449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d9ef5f03-7b53-4b89-93ad-022187cd9bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b9e615e-dc68-4205-8d71-025a52a4429b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d9ef5f03-7b53-4b89-93ad-022187cd9bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8f7f844b-7a37-42aa-a4a6-b6a95de8dab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9ef5f03-7b53-4b89-93ad-022187cd9bbb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8f7f844b-7a37-42aa-a4a6-b6a95de8dab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_dfd3a9b6-ec07-4aef-b560-4f2f8eda3bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9ef5f03-7b53-4b89-93ad-022187cd9bbb" xlink:to="loc_us-gaap_SellingAndMarketingExpense_dfd3a9b6-ec07-4aef-b560-4f2f8eda3bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8d889fdc-bbf3-493d-bdf9-0323335a9e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9ef5f03-7b53-4b89-93ad-022187cd9bbb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8d889fdc-bbf3-493d-bdf9-0323335a9e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_fc058f91-67e3-419c-ac6d-d1ba693d0f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9ef5f03-7b53-4b89-93ad-022187cd9bbb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_fc058f91-67e3-419c-ac6d-d1ba693d0f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3975eb12-f3e2-489e-92ee-33538969b60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9ef5f03-7b53-4b89-93ad-022187cd9bbb" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_3975eb12-f3e2-489e-92ee-33538969b60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ChangeInFairValueOfContingentConsideration_ccfaa429-eaec-4900-b03f-9fb69a5f3a20" xlink:href="ango-20230531.xsd#ango_ChangeInFairValueOfContingentConsideration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9ef5f03-7b53-4b89-93ad-022187cd9bbb" xlink:to="loc_ango_ChangeInFairValueOfContingentConsideration_ccfaa429-eaec-4900-b03f-9fb69a5f3a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AcquisitionRestructuringAndOtherItemsNet_8bf1d349-4f7c-40f4-943c-10e254966a93" xlink:href="ango-20230531.xsd#ango_AcquisitionRestructuringAndOtherItemsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9ef5f03-7b53-4b89-93ad-022187cd9bbb" xlink:to="loc_ango_AcquisitionRestructuringAndOtherItemsNet_8bf1d349-4f7c-40f4-943c-10e254966a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_529b9bdb-cb04-479f-b46a-f90b81a06343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9ef5f03-7b53-4b89-93ad-022187cd9bbb" xlink:to="loc_us-gaap_OperatingExpenses_529b9bdb-cb04-479f-b46a-f90b81a06343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3c03e4fa-cdfa-4b3e-94e8-012110d8d1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b9e615e-dc68-4205-8d71-025a52a4429b" xlink:to="loc_us-gaap_OperatingIncomeLoss_3c03e4fa-cdfa-4b3e-94e8-012110d8d1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_658ee69d-fc7b-48d3-9dc0-4868a74ec4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b9e615e-dc68-4205-8d71-025a52a4429b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_658ee69d-fc7b-48d3-9dc0-4868a74ec4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f5688dc3-3e2c-4967-859f-0e098eae4ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_658ee69d-fc7b-48d3-9dc0-4868a74ec4eb" xlink:to="loc_us-gaap_InterestExpense_f5688dc3-3e2c-4967-859f-0e098eae4ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0e82e7fa-097e-4eee-968e-b416366c36a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_658ee69d-fc7b-48d3-9dc0-4868a74ec4eb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0e82e7fa-097e-4eee-968e-b416366c36a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_OtherNonoperatingIncomeExpenseAndInterestExpense_d9d36055-de98-49c5-b2d5-8548295a9612" xlink:href="ango-20230531.xsd#ango_OtherNonoperatingIncomeExpenseAndInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_658ee69d-fc7b-48d3-9dc0-4868a74ec4eb" xlink:to="loc_ango_OtherNonoperatingIncomeExpenseAndInterestExpense_d9d36055-de98-49c5-b2d5-8548295a9612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b65006a3-c84f-46d8-985d-ce3c0e145cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b9e615e-dc68-4205-8d71-025a52a4429b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b65006a3-c84f-46d8-985d-ce3c0e145cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1d150d5e-07fd-48c4-8e22-a40d856c8f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b9e615e-dc68-4205-8d71-025a52a4429b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1d150d5e-07fd-48c4-8e22-a40d856c8f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7ad55184-d64b-431b-8b5a-e9edb9e60bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b9e615e-dc68-4205-8d71-025a52a4429b" xlink:to="loc_us-gaap_NetIncomeLoss_7ad55184-d64b-431b-8b5a-e9edb9e60bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_651835d0-5bbb-4c10-96f7-17d74f6a8046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b9e615e-dc68-4205-8d71-025a52a4429b" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_651835d0-5bbb-4c10-96f7-17d74f6a8046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c321469c-72c8-4c74-a504-464e5862f8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_651835d0-5bbb-4c10-96f7-17d74f6a8046" xlink:to="loc_us-gaap_EarningsPerShareBasic_c321469c-72c8-4c74-a504-464e5862f8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2ebdbcd8-4357-46b1-8a12-aa1902af8bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_651835d0-5bbb-4c10-96f7-17d74f6a8046" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2ebdbcd8-4357-46b1-8a12-aa1902af8bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_b1dd4e42-b988-4af1-9d76-76296ef2cb42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b9e615e-dc68-4205-8d71-025a52a4429b" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_b1dd4e42-b988-4af1-9d76-76296ef2cb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_394046ec-3069-4702-9992-4e932e759603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_b1dd4e42-b988-4af1-9d76-76296ef2cb42" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_394046ec-3069-4702-9992-4e932e759603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_51865d9f-fb19-4386-975b-5e35caf76987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_b1dd4e42-b988-4af1-9d76-76296ef2cb42" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_51865d9f-fb19-4386-975b-5e35caf76987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ango-20230531.xsd#ConsolidatedStatementsComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6a1acd4a-b436-49cc-9ed4-cc0b5b01f117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f4bb05ea-4cb4-45fe-9343-29737629c30b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6a1acd4a-b436-49cc-9ed4-cc0b5b01f117" xlink:to="loc_us-gaap_NetIncomeLoss_f4bb05ea-4cb4-45fe-9343-29737629c30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_1679949f-1a2d-430f-9ed2-e8132f670373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6a1acd4a-b436-49cc-9ed4-cc0b5b01f117" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_1679949f-1a2d-430f-9ed2-e8132f670373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0c2568ab-9115-46cf-aa35-1b0a75cba991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_1679949f-1a2d-430f-9ed2-e8132f670373" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0c2568ab-9115-46cf-aa35-1b0a75cba991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_38df4b16-c66e-4aa7-a51b-6694686685e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_1679949f-1a2d-430f-9ed2-e8132f670373" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_38df4b16-c66e-4aa7-a51b-6694686685e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_368c4f85-755a-49e2-9b55-07a7e6647862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6a1acd4a-b436-49cc-9ed4-cc0b5b01f117" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_368c4f85-755a-49e2-9b55-07a7e6647862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2d097bb0-df68-450b-a198-b892f7cc6b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6a1acd4a-b436-49cc-9ed4-cc0b5b01f117" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2d097bb0-df68-450b-a198-b892f7cc6b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4f9c8870-dadb-42ef-9e01-1d1e4b16078a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6a1acd4a-b436-49cc-9ed4-cc0b5b01f117" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4f9c8870-dadb-42ef-9e01-1d1e4b16078a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ango-20230531.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2a4ed5e4-c01c-4921-a32a-dd77dd9085bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f3260c89-f080-4849-9e7b-37de67212f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a4ed5e4-c01c-4921-a32a-dd77dd9085bc" xlink:to="loc_us-gaap_AssetsAbstract_f3260c89-f080-4849-9e7b-37de67212f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c8c89668-0f39-411b-9f85-9238e87e42a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f3260c89-f080-4849-9e7b-37de67212f5c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c8c89668-0f39-411b-9f85-9238e87e42a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5b3b4f37-5116-4152-84d4-6b9019111848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c8c89668-0f39-411b-9f85-9238e87e42a1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5b3b4f37-5116-4152-84d4-6b9019111848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4d13db09-60c8-45b5-8a87-22f631145a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c8c89668-0f39-411b-9f85-9238e87e42a1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4d13db09-60c8-45b5-8a87-22f631145a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cbc7e77a-a42b-4840-b97c-14544bbfbce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c8c89668-0f39-411b-9f85-9238e87e42a1" xlink:to="loc_us-gaap_InventoryNet_cbc7e77a-a42b-4840-b97c-14544bbfbce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_372b71e6-0f07-4973-88f5-11e034249a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c8c89668-0f39-411b-9f85-9238e87e42a1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_372b71e6-0f07-4973-88f5-11e034249a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_059f0ddc-dd2e-4d21-929f-a57a4bd0e730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c8c89668-0f39-411b-9f85-9238e87e42a1" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_059f0ddc-dd2e-4d21-929f-a57a4bd0e730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_754788f9-dc84-487d-8f0f-9d5c2969cbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c8c89668-0f39-411b-9f85-9238e87e42a1" xlink:to="loc_us-gaap_AssetsCurrent_754788f9-dc84-487d-8f0f-9d5c2969cbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_23223e10-9e95-476f-8dc4-6e8ef6d3fd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f3260c89-f080-4849-9e7b-37de67212f5c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_23223e10-9e95-476f-8dc4-6e8ef6d3fd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ede6ddd8-51eb-41de-9d56-31b69b034770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f3260c89-f080-4849-9e7b-37de67212f5c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ede6ddd8-51eb-41de-9d56-31b69b034770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_60ca3e30-93ae-4d3b-ae30-208f93985ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f3260c89-f080-4849-9e7b-37de67212f5c" xlink:to="loc_us-gaap_Goodwill_60ca3e30-93ae-4d3b-ae30-208f93985ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a9746391-4de7-43a8-9105-0002d24dc96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f3260c89-f080-4849-9e7b-37de67212f5c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a9746391-4de7-43a8-9105-0002d24dc96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_f4265699-951b-4061-a0c2-8ea19a1e28b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f3260c89-f080-4849-9e7b-37de67212f5c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_f4265699-951b-4061-a0c2-8ea19a1e28b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f85df152-28cf-49c5-a9b4-edae61849fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f3260c89-f080-4849-9e7b-37de67212f5c" xlink:to="loc_us-gaap_Assets_f85df152-28cf-49c5-a9b4-edae61849fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c7e9e83-9e31-4489-961e-4692d2afd782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a4ed5e4-c01c-4921-a32a-dd77dd9085bc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c7e9e83-9e31-4489-961e-4692d2afd782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2656ae6d-a7c5-4f95-b10f-501e098bd663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c7e9e83-9e31-4489-961e-4692d2afd782" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2656ae6d-a7c5-4f95-b10f-501e098bd663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_89a41069-34a3-4b5c-9178-6c3e585f3ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2656ae6d-a7c5-4f95-b10f-501e098bd663" xlink:to="loc_us-gaap_AccountsPayableCurrent_89a41069-34a3-4b5c-9178-6c3e585f3ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3e82a604-48cb-465c-a387-29853bd8eea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2656ae6d-a7c5-4f95-b10f-501e098bd663" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3e82a604-48cb-465c-a387-29853bd8eea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_3c85c1c8-2451-4e29-be6b-caa99f327e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2656ae6d-a7c5-4f95-b10f-501e098bd663" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_3c85c1c8-2451-4e29-be6b-caa99f327e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_70563ad9-419a-4de9-9c2f-4be42c54a980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2656ae6d-a7c5-4f95-b10f-501e098bd663" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_70563ad9-419a-4de9-9c2f-4be42c54a980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8633c93a-25af-43ba-838c-902098da4553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2656ae6d-a7c5-4f95-b10f-501e098bd663" xlink:to="loc_us-gaap_LiabilitiesCurrent_8633c93a-25af-43ba-838c-902098da4553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_93047307-f464-4119-9d2f-3ba275b88097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c7e9e83-9e31-4489-961e-4692d2afd782" xlink:to="loc_us-gaap_LongTermDebt_93047307-f464-4119-9d2f-3ba275b88097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_f1fb2d50-d489-46b9-ac87-9426109c81f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c7e9e83-9e31-4489-961e-4692d2afd782" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_f1fb2d50-d489-46b9-ac87-9426109c81f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7eeae3ce-4244-42ed-a2e4-caea9e2ccc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c7e9e83-9e31-4489-961e-4692d2afd782" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7eeae3ce-4244-42ed-a2e4-caea9e2ccc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_be673106-bb6e-4b04-b16c-eecdc204546f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c7e9e83-9e31-4489-961e-4692d2afd782" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_be673106-bb6e-4b04-b16c-eecdc204546f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0518d356-56c5-473a-937e-4d19814e874e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c7e9e83-9e31-4489-961e-4692d2afd782" xlink:to="loc_us-gaap_Liabilities_0518d356-56c5-473a-937e-4d19814e874e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_02fc8c91-5e94-427a-936a-0f6d0b09628f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c7e9e83-9e31-4489-961e-4692d2afd782" xlink:to="loc_us-gaap_CommitmentsAndContingencies_02fc8c91-5e94-427a-936a-0f6d0b09628f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5e12a9c8-a7ca-4096-9cdc-b818cf38d535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c7e9e83-9e31-4489-961e-4692d2afd782" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5e12a9c8-a7ca-4096-9cdc-b818cf38d535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_57926fd7-15fc-4f9d-ba5e-e22e83cc2f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5e12a9c8-a7ca-4096-9cdc-b818cf38d535" xlink:to="loc_us-gaap_PreferredStockValue_57926fd7-15fc-4f9d-ba5e-e22e83cc2f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b6347bc7-befa-4d05-a5ec-567e82eaddb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5e12a9c8-a7ca-4096-9cdc-b818cf38d535" xlink:to="loc_us-gaap_CommonStockValue_b6347bc7-befa-4d05-a5ec-567e82eaddb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_06bcb120-41d1-4e78-8f30-dd7d8216daab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5e12a9c8-a7ca-4096-9cdc-b818cf38d535" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_06bcb120-41d1-4e78-8f30-dd7d8216daab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2367f30f-e276-478c-a989-febee1bdd80c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5e12a9c8-a7ca-4096-9cdc-b818cf38d535" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2367f30f-e276-478c-a989-febee1bdd80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_1d504311-ca13-4965-9b86-10145983d8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5e12a9c8-a7ca-4096-9cdc-b818cf38d535" xlink:to="loc_us-gaap_TreasuryStockValue_1d504311-ca13-4965-9b86-10145983d8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f969023b-bc1f-4c85-8eb5-b7dc48b39823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5e12a9c8-a7ca-4096-9cdc-b818cf38d535" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f969023b-bc1f-4c85-8eb5-b7dc48b39823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a471bd34-bec8-42ad-9291-2b992996e094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5e12a9c8-a7ca-4096-9cdc-b818cf38d535" xlink:to="loc_us-gaap_StockholdersEquity_a471bd34-bec8-42ad-9291-2b992996e094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_db203586-72de-43a6-8be1-a80e0eb8885f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c7e9e83-9e31-4489-961e-4692d2afd782" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_db203586-72de-43a6-8be1-a80e0eb8885f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ango-20230531.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ec11df48-3bea-4dbf-98d2-1f278a4574e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7afa8414-c468-40af-bc3d-14b8d757b5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ec11df48-3bea-4dbf-98d2-1f278a4574e6" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7afa8414-c468-40af-bc3d-14b8d757b5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_714a01e4-e9ba-4883-a9d4-30e689aae43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ec11df48-3bea-4dbf-98d2-1f278a4574e6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_714a01e4-e9ba-4883-a9d4-30e689aae43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ae63ebf2-9ea1-417c-8f96-21fd7a98feda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ec11df48-3bea-4dbf-98d2-1f278a4574e6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ae63ebf2-9ea1-417c-8f96-21fd7a98feda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_614b50ac-8870-423b-9994-a47de5c643eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ec11df48-3bea-4dbf-98d2-1f278a4574e6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_614b50ac-8870-423b-9994-a47de5c643eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f9a67413-38cd-4c4c-9721-eb3e8cb11a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ec11df48-3bea-4dbf-98d2-1f278a4574e6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f9a67413-38cd-4c4c-9721-eb3e8cb11a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_73bdb47c-9f4f-4fea-88ae-1e23b60d1c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ec11df48-3bea-4dbf-98d2-1f278a4574e6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_73bdb47c-9f4f-4fea-88ae-1e23b60d1c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e86e96cf-8d36-4918-adb7-8e38b7796309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ec11df48-3bea-4dbf-98d2-1f278a4574e6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e86e96cf-8d36-4918-adb7-8e38b7796309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2a2aaa4b-7d54-4df6-ac41-191a4debddb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ec11df48-3bea-4dbf-98d2-1f278a4574e6" xlink:to="loc_us-gaap_CommonStockSharesIssued_2a2aaa4b-7d54-4df6-ac41-191a4debddb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d2b9e178-c74f-49e7-9af0-e0d8e4f40d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ec11df48-3bea-4dbf-98d2-1f278a4574e6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d2b9e178-c74f-49e7-9af0-e0d8e4f40d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_fa54d87b-612c-4c0f-aa5c-9e1eef81aaec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ec11df48-3bea-4dbf-98d2-1f278a4574e6" xlink:to="loc_us-gaap_TreasuryStockCommonShares_fa54d87b-612c-4c0f-aa5c-9e1eef81aaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ango-20230531.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e0d9ac99-bc86-4a28-9c1c-c894112e2f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_25968907-cbeb-42b2-a26b-38021fcf0686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e0d9ac99-bc86-4a28-9c1c-c894112e2f9d" xlink:to="loc_us-gaap_StatementTable_25968907-cbeb-42b2-a26b-38021fcf0686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2e665b7b-2389-4abd-ad4d-aa44af5328d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25968907-cbeb-42b2-a26b-38021fcf0686" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2e665b7b-2389-4abd-ad4d-aa44af5328d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2e665b7b-2389-4abd-ad4d-aa44af5328d2" xlink:to="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b8eb7353-ff5b-4107-bff4-6852c0233e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:to="loc_us-gaap_CommonStockMember_b8eb7353-ff5b-4107-bff4-6852c0233e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d09919c9-189f-478f-8944-73328a057482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d09919c9-189f-478f-8944-73328a057482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_12cd3cf4-f233-44b2-9e79-063a2c9c6d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:to="loc_us-gaap_RetainedEarningsMember_12cd3cf4-f233-44b2-9e79-063a2c9c6d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a1dd705b-75a3-44c1-b881-0870b7f35b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a1dd705b-75a3-44c1-b881-0870b7f35b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_d5c993fb-20cf-4b26-8220-7be84e17d021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_95f940cb-35ec-493e-bd01-33e2793cdc92" xlink:to="loc_us-gaap_TreasuryStockCommonMember_d5c993fb-20cf-4b26-8220-7be84e17d021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_98cd963b-a047-44b0-b608-fd44bf6d22b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25968907-cbeb-42b2-a26b-38021fcf0686" xlink:to="loc_us-gaap_AwardTypeAxis_98cd963b-a047-44b0-b608-fd44bf6d22b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_368b3b49-e4d5-4f44-8ded-6a735108e41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_98cd963b-a047-44b0-b608-fd44bf6d22b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_368b3b49-e4d5-4f44-8ded-6a735108e41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f42998d9-b0a4-4438-82e4-ebf688b7d1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_368b3b49-e4d5-4f44-8ded-6a735108e41b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f42998d9-b0a4-4438-82e4-ebf688b7d1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_19090691-08e0-4050-8b28-36a2107f8277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_368b3b49-e4d5-4f44-8ded-6a735108e41b" xlink:to="loc_us-gaap_PerformanceSharesMember_19090691-08e0-4050-8b28-36a2107f8277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_228964e1-9245-4274-aff3-00802ed28309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25968907-cbeb-42b2-a26b-38021fcf0686" xlink:to="loc_us-gaap_StatementLineItems_228964e1-9245-4274-aff3-00802ed28309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_228964e1-9245-4274-aff3-00802ed28309" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8ec96d04-0c8c-47a4-8ff3-6fabd11deff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8ec96d04-0c8c-47a4-8ff3-6fabd11deff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9a16956f-f3b6-4fb4-9fb1-13c2da17eb62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockholdersEquity_9a16956f-f3b6-4fb4-9fb1-13c2da17eb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_bdbae424-14d7-4d97-a3e3-61f21c035052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_TreasuryStockCommonShares_bdbae424-14d7-4d97-a3e3-61f21c035052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e559d25f-d97c-4e77-888b-5e9978d3c267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_NetIncomeLoss_e559d25f-d97c-4e77-888b-5e9978d3c267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3984fab5-2ddf-4c23-949b-f315e3c8ec41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3984fab5-2ddf-4c23-949b-f315e3c8ec41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1f70e55c-46d9-4c40-ba79-c38b010a2a90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1f70e55c-46d9-4c40-ba79-c38b010a2a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_e8abe218-b902-4073-8c6e-66919eb3086d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_e8abe218-b902-4073-8c6e-66919eb3086d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_993edc90-75e8-4f75-b8e7-c48c52afc3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_993edc90-75e8-4f75-b8e7-c48c52afc3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f021b7a0-fdbe-47e8-a601-44524b45ebc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f021b7a0-fdbe-47e8-a601-44524b45ebc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ef98cd39-ff08-44c0-8a4e-a2724b12cfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ef98cd39-ff08-44c0-8a4e-a2724b12cfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d6039f49-9e69-4010-9432-c423d4bc5f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d6039f49-9e69-4010-9432-c423d4bc5f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ccca056f-2c2f-4449-9893-962050c13836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ccca056f-2c2f-4449-9893-962050c13836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ec628f1-1871-4c86-9ed5-9a66a8ab541c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_StockholdersEquity_8ec628f1-1871-4c86-9ed5-9a66a8ab541c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8c795dfa-027c-40b9-8f35-b4e8a0c8f2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8c795dfa-027c-40b9-8f35-b4e8a0c8f2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b25218d2-778a-4675-89bd-5f841a271159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_24c39b68-4cf0-485b-9a16-5ea1ddc05300" xlink:to="loc_us-gaap_TreasuryStockCommonShares_b25218d2-778a-4675-89bd-5f841a271159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ango-20230531.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_becc060b-37a0-40b3-ad59-4617edbedd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33f61e7d-6915-487b-b8a7-9a910c4941ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_becc060b-37a0-40b3-ad59-4617edbedd3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33f61e7d-6915-487b-b8a7-9a910c4941ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2ddefa62-63a4-4f62-b753-f584c6f7bcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33f61e7d-6915-487b-b8a7-9a910c4941ce" xlink:to="loc_us-gaap_NetIncomeLoss_2ddefa62-63a4-4f62-b753-f584c6f7bcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c1f3b94a-78f7-4e94-907c-3c0b568d0d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33f61e7d-6915-487b-b8a7-9a910c4941ce" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c1f3b94a-78f7-4e94-907c-3c0b568d0d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_c580dd46-5d58-43b3-9ed2-c2b33d01c76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c1f3b94a-78f7-4e94-907c-3c0b568d0d4f" xlink:to="loc_us-gaap_DepreciationAndAmortization_c580dd46-5d58-43b3-9ed2-c2b33d01c76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_NoncashLeaseExpense_403b4a40-ac16-4bb9-90af-f7480bc56f37" xlink:href="ango-20230531.xsd#ango_NoncashLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c1f3b94a-78f7-4e94-907c-3c0b568d0d4f" xlink:to="loc_ango_NoncashLeaseExpense_403b4a40-ac16-4bb9-90af-f7480bc56f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2690b7c8-3823-46c6-90a3-73c2fa1834f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c1f3b94a-78f7-4e94-907c-3c0b568d0d4f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2690b7c8-3823-46c6-90a3-73c2fa1834f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4a771950-de5c-49f1-a9c2-e80f747ff05e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c1f3b94a-78f7-4e94-907c-3c0b568d0d4f" xlink:to="loc_us-gaap_ShareBasedCompensation_4a771950-de5c-49f1-a9c2-e80f747ff05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ChangeInFairValueOfContingentConsideration_0c91e6de-4c44-4bbd-b1dd-e3c6b0b2bf03" xlink:href="ango-20230531.xsd#ango_ChangeInFairValueOfContingentConsideration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c1f3b94a-78f7-4e94-907c-3c0b568d0d4f" xlink:to="loc_ango_ChangeInFairValueOfContingentConsideration_0c91e6de-4c44-4bbd-b1dd-e3c6b0b2bf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DeferredIncomeTaxRelatedToOperatingActivity_35f4f62e-9afc-4201-9cf0-3285821f99ab" xlink:href="ango-20230531.xsd#ango_DeferredIncomeTaxRelatedToOperatingActivity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c1f3b94a-78f7-4e94-907c-3c0b568d0d4f" xlink:to="loc_ango_DeferredIncomeTaxRelatedToOperatingActivity_35f4f62e-9afc-4201-9cf0-3285821f99ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_f9e27f9f-47fa-4430-872c-d97e42ca9d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c1f3b94a-78f7-4e94-907c-3c0b568d0d4f" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_f9e27f9f-47fa-4430-872c-d97e42ca9d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_cb1585b6-a48b-4380-9756-c618fc9c1b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c1f3b94a-78f7-4e94-907c-3c0b568d0d4f" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_cb1585b6-a48b-4380-9756-c618fc9c1b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9c242898-fb4f-495d-8d5d-b2b4fd169269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c1f3b94a-78f7-4e94-907c-3c0b568d0d4f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9c242898-fb4f-495d-8d5d-b2b4fd169269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0dc57459-5804-434d-8a7c-c8f9ddc7175e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33f61e7d-6915-487b-b8a7-9a910c4941ce" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0dc57459-5804-434d-8a7c-c8f9ddc7175e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6a2437f5-55fc-4b07-84f5-712a5b27143c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0dc57459-5804-434d-8a7c-c8f9ddc7175e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6a2437f5-55fc-4b07-84f5-712a5b27143c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9e3e8510-166a-420f-9956-a4d088df204e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0dc57459-5804-434d-8a7c-c8f9ddc7175e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9e3e8510-166a-420f-9956-a4d088df204e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_87f8752b-c5be-4235-a9a6-d037fe49a028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0dc57459-5804-434d-8a7c-c8f9ddc7175e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_87f8752b-c5be-4235-a9a6-d037fe49a028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_25182f41-15b6-46e5-9252-595b1766e811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0dc57459-5804-434d-8a7c-c8f9ddc7175e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_25182f41-15b6-46e5-9252-595b1766e811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77fc4a57-4f19-4929-9e94-f8ecb6e5096c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33f61e7d-6915-487b-b8a7-9a910c4941ce" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77fc4a57-4f19-4929-9e94-f8ecb6e5096c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2bcf90-cb03-4e91-9157-4b21fd562002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_becc060b-37a0-40b3-ad59-4617edbedd3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2bcf90-cb03-4e91-9157-4b21fd562002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7d36dcfd-4458-4d29-80ce-ca64441dcfec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2bcf90-cb03-4e91-9157-4b21fd562002" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7d36dcfd-4458-4d29-80ce-ca64441dcfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IncreaseInPlacementAndEvaluationUnits_4b2f4cd5-1e9a-42ab-a0da-bdb76c95ce86" xlink:href="ango-20230531.xsd#ango_IncreaseInPlacementAndEvaluationUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2bcf90-cb03-4e91-9157-4b21fd562002" xlink:to="loc_ango_IncreaseInPlacementAndEvaluationUnits_4b2f4cd5-1e9a-42ab-a0da-bdb76c95ce86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_49d234c8-a1af-40ff-bc4a-9432b178e66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2bcf90-cb03-4e91-9157-4b21fd562002" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_49d234c8-a1af-40ff-bc4a-9432b178e66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired_c26483c9-9f2a-4bc2-a978-4d24cbde00b3" xlink:href="ango-20230531.xsd#ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2bcf90-cb03-4e91-9157-4b21fd562002" xlink:to="loc_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired_c26483c9-9f2a-4bc2-a978-4d24cbde00b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_416c366a-9e61-463f-92f1-b732d7ee47de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2bcf90-cb03-4e91-9157-4b21fd562002" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_416c366a-9e61-463f-92f1-b732d7ee47de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f899ea53-c71d-44af-b311-87520cee1974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_becc060b-37a0-40b3-ad59-4617edbedd3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f899ea53-c71d-44af-b311-87520cee1974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_7bee70c1-efad-4298-99f2-62a3c6204d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f899ea53-c71d-44af-b311-87520cee1974" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_7bee70c1-efad-4298-99f2-62a3c6204d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a338ab39-72b7-48af-8f02-4b6f2f558fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f899ea53-c71d-44af-b311-87520cee1974" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a338ab39-72b7-48af-8f02-4b6f2f558fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_cae01ec3-ef42-4561-9369-d8866ac4eba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f899ea53-c71d-44af-b311-87520cee1974" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_cae01ec3-ef42-4561-9369-d8866ac4eba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_13b7b4d1-a74e-4987-aa5d-f5aca1b19e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f899ea53-c71d-44af-b311-87520cee1974" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_13b7b4d1-a74e-4987-aa5d-f5aca1b19e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_ec2b5ab9-2ccf-4186-9cc0-5e518aa8e956" xlink:href="ango-20230531.xsd#ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f899ea53-c71d-44af-b311-87520cee1974" xlink:to="loc_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_ec2b5ab9-2ccf-4186-9cc0-5e518aa8e956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15115804-ae13-4e9c-b2d2-ddede52a87db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f899ea53-c71d-44af-b311-87520cee1974" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15115804-ae13-4e9c-b2d2-ddede52a87db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f910b9af-8539-4ced-ae92-1591dcc9113f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_becc060b-37a0-40b3-ad59-4617edbedd3a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f910b9af-8539-4ced-ae92-1591dcc9113f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5238b9b5-bd3f-4b53-a820-35f180ea7450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_becc060b-37a0-40b3-ad59-4617edbedd3a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5238b9b5-bd3f-4b53-a820-35f180ea7450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_74e6aaf3-d3a5-40d8-8f6e-ff93565de531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_becc060b-37a0-40b3-ad59-4617edbedd3a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_74e6aaf3-d3a5-40d8-8f6e-ff93565de531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_82588345-153f-4abf-90ad-8564bfc87a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_becc060b-37a0-40b3-ad59-4617edbedd3a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_82588345-153f-4abf-90ad-8564bfc87a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4b284cd7-a427-4f59-a46f-1ad859a8dde4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_becc060b-37a0-40b3-ad59-4617edbedd3a" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4b284cd7-a427-4f59-a46f-1ad859a8dde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_49748ca0-dc63-4f82-a41b-39354a8d5147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4b284cd7-a427-4f59-a46f-1ad859a8dde4" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_49748ca0-dc63-4f82-a41b-39354a8d5147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CashPaidDuringPeriodAbstract_fa1b5e41-b5b1-4d83-a560-0999b77bdd9d" xlink:href="ango-20230531.xsd#ango_CashPaidDuringPeriodAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_becc060b-37a0-40b3-ad59-4617edbedd3a" xlink:to="loc_ango_CashPaidDuringPeriodAbstract_fa1b5e41-b5b1-4d83-a560-0999b77bdd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_3a0803ab-7dd2-4845-a52f-394957657560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_CashPaidDuringPeriodAbstract_fa1b5e41-b5b1-4d83-a560-0999b77bdd9d" xlink:to="loc_us-gaap_InterestPaid_3a0803ab-7dd2-4845-a52f-394957657560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_62ec41a8-2060-4385-97dc-2703c8d08dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_CashPaidDuringPeriodAbstract_fa1b5e41-b5b1-4d83-a560-0999b77bdd9d" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_62ec41a8-2060-4385-97dc-2703c8d08dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ango-20230531.xsd#BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_18133cee-310f-49f9-bfdb-8ae00567113a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3815b33d-25d8-467f-a375-5d6de51aec69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18133cee-310f-49f9-bfdb-8ae00567113a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3815b33d-25d8-467f-a375-5d6de51aec69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/Acquisitions" xlink:type="simple" xlink:href="ango-20230531.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_25ea0d2a-1185-42cc-8982-609d2e1d2123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_43b1ce6c-5530-45e3-85d3-9174666eb712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_25ea0d2a-1185-42cc-8982-609d2e1d2123" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_43b1ce6c-5530-45e3-85d3-9174666eb712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AssetsHeldForSale" xlink:type="simple" xlink:href="ango-20230531.xsd#AssetsHeldForSale"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AssetsHeldForSale" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3a4b9d5b-529e-46e5-b490-ab15a399cdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_a3fb3fa4-5591-4526-819e-7c9dddd60b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3a4b9d5b-529e-46e5-b490-ab15a399cdc3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_a3fb3fa4-5591-4526-819e-7c9dddd60b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/RevenuefromContractswithCustomers" xlink:type="simple" xlink:href="ango-20230531.xsd#RevenuefromContractswithCustomers"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/RevenuefromContractswithCustomers" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a5582044-35f9-4177-a3cc-5d0a05d04e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_45dc8c2b-6a46-462c-9fa3-862b798c7b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a5582044-35f9-4177-a3cc-5d0a05d04e23" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_45dc8c2b-6a46-462c-9fa3-862b798c7b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="ango-20230531.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ff2392d7-757e-44c9-89fb-310cae5c48be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1c5301e7-3ece-48a1-978f-78673f0914ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ff2392d7-757e-44c9-89fb-310cae5c48be" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1c5301e7-3ece-48a1-978f-78673f0914ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/Inventories" xlink:type="simple" xlink:href="ango-20230531.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_93500364-c036-4725-bba1-7cab7d958911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_c2297cc4-7b53-4fdc-b5de-96fdf992daae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_93500364-c036-4725-bba1-7cab7d958911" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_c2297cc4-7b53-4fdc-b5de-96fdf992daae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/PrepaidExpensesandOther" xlink:type="simple" xlink:href="ango-20230531.xsd#PrepaidExpensesandOther"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/PrepaidExpensesandOther" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_4c134c4c-0e74-44b3-b47e-e65b8d738401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidExpensesAndOtherTextBlock_755baf9d-21e4-405f-8f81-5dd528a99448" xlink:href="ango-20230531.xsd#ango_PrepaidExpensesAndOtherTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_4c134c4c-0e74-44b3-b47e-e65b8d738401" xlink:to="loc_ango_PrepaidExpensesAndOtherTextBlock_755baf9d-21e4-405f-8f81-5dd528a99448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/PropertyPlantandEquipmentNet" xlink:type="simple" xlink:href="ango-20230531.xsd#PropertyPlantandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8d3865de-80dd-4926-87b3-b0cc5c39f776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_23dadf53-5c6c-46fd-815a-4a46a22faa54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8d3865de-80dd-4926-87b3-b0cc5c39f776" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_23dadf53-5c6c-46fd-815a-4a46a22faa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ango-20230531.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_af2617e5-d60f-4d70-b6fd-0841c5ac78b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a2bd1ae9-b670-4976-8474-74f983d289d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_af2617e5-d60f-4d70-b6fd-0841c5ac78b6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a2bd1ae9-b670-4976-8474-74f983d289d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ango-20230531.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f343e6ce-febf-4bb0-88a4-80ceb977ecb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_dbc8c8a2-4ec3-4f77-92e6-539a22fb7c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f343e6ce-febf-4bb0-88a4-80ceb977ecb7" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_dbc8c8a2-4ec3-4f77-92e6-539a22fb7c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="ango-20230531.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b6998e44-b6e8-4fc9-bf2f-c74701ff2936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_b3c24441-9b2a-4641-9822-0db687f55894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b6998e44-b6e8-4fc9-bf2f-c74701ff2936" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_b3c24441-9b2a-4641-9822-0db687f55894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LongTermDebt" xlink:type="simple" xlink:href="ango-20230531.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_03a7588c-b047-4146-8a2f-9f6fa67c3e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_713f26c1-1a10-4a8f-b6b2-5f1ce6778994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_03a7588c-b047-4146-8a2f-9f6fa67c3e34" xlink:to="loc_us-gaap_LongTermDebtTextBlock_713f26c1-1a10-4a8f-b6b2-5f1ce6778994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/RetirementPlans" xlink:type="simple" xlink:href="ango-20230531.xsd#RetirementPlans"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/RetirementPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2dbd158b-bc6f-437a-8e94-b45da21024f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5e714942-140c-4cfb-909a-582690c565da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2dbd158b-bc6f-437a-8e94-b45da21024f5" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5e714942-140c-4cfb-909a-582690c565da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ango-20230531.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6519b055-d623-40a8-ab90-a2baf4a7fb58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_30f6dfc9-7d79-4f56-b396-725fb714deb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6519b055-d623-40a8-ab90-a2baf4a7fb58" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_30f6dfc9-7d79-4f56-b396-725fb714deb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/EarningsPerShare" xlink:type="simple" xlink:href="ango-20230531.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ff6e8024-af90-49c2-9208-f73cea148c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_5c36ae14-5d38-4a5a-b33e-b1b5e14aa806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ff6e8024-af90-49c2-9208-f73cea148c94" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_5c36ae14-5d38-4a5a-b33e-b1b5e14aa806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/Leases" xlink:type="simple" xlink:href="ango-20230531.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_99c2b144-578b-45ec-acac-4e4e937f95da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_51c483a8-4095-445b-af84-3eada5e1a030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_99c2b144-578b-45ec-acac-4e4e937f95da" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_51c483a8-4095-445b-af84-3eada5e1a030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ango-20230531.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0c32f8c4-1829-421c-a1d4-2f372f4fa6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_655f1157-2f4b-40ea-8f35-b37f21f69b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0c32f8c4-1829-421c-a1d4-2f372f4fa6d4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_655f1157-2f4b-40ea-8f35-b37f21f69b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/SegmentsandGeographicInformation" xlink:type="simple" xlink:href="ango-20230531.xsd#SegmentsandGeographicInformation"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/SegmentsandGeographicInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_702e5d88-c0c8-4635-be4d-0a99f3a7e3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_145c8154-4fb0-4c7c-918c-da21ec761579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_702e5d88-c0c8-4635-be4d-0a99f3a7e3b8" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_145c8154-4fb0-4c7c-918c-da21ec761579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnet" xlink:type="simple" xlink:href="ango-20230531.xsd#AcquisitionRestructuringandOtherItemsnet"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_48153761-ed55-4acb-ab8f-bfc15ef580d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_19bf3a9a-354c-4b74-b86b-2563009c9100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_48153761-ed55-4acb-ab8f-bfc15ef580d8" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_19bf3a9a-354c-4b74-b86b-2563009c9100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ango-20230531.xsd#AccumulatedOtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2257fba6-ebcd-4285-a4d7-5ec9a339fddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_2445e717-d11b-4f14-a296-430066503d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2257fba6-ebcd-4285-a4d7-5ec9a339fddb" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_2445e717-d11b-4f14-a296-430066503d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ango-20230531.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f337e634-cd0b-4314-b584-3c9cbf2b12f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_34f60a0d-29a0-4299-b092-8666105e1a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f337e634-cd0b-4314-b584-3c9cbf2b12f3" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_34f60a0d-29a0-4299-b092-8666105e1a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ValuationandQualifyingAccounts" xlink:type="simple" xlink:href="ango-20230531.xsd#ValuationandQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/ValuationandQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_ac64f826-05e9-4932-9b26-0ad018919a94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_4357d9d2-3e30-4655-b7cb-17455f227331" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_ac64f826-05e9-4932-9b26-0ad018919a94" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_4357d9d2-3e30-4655-b7cb-17455f227331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ango-20230531.xsd#BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0ee34444-8a15-4708-b4cb-7000cca8cc87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0ee34444-8a15-4708-b4cb-7000cca8cc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1bdc317e-97ca-4326-9ece-9e4f63518e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1bdc317e-97ca-4326-9ece-9e4f63518e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3b70dca4-49c1-4508-af2b-0db9056f4e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3b70dca4-49c1-4508-af2b-0db9056f4e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_f095da50-344c-40c9-af84-3ee4b66efb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_f095da50-344c-40c9-af84-3ee4b66efb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_32eb039b-9ebf-4929-95b2-e6c5786581e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_32eb039b-9ebf-4929-95b2-e6c5786581e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fe8d65ea-27a9-4c5e-b311-cb298924e53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fe8d65ea-27a9-4c5e-b311-cb298924e53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_21fb4252-1c64-4429-9108-1290be967083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_21fb4252-1c64-4429-9108-1290be967083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_8fd0e5dd-015f-4846-8706-2b541ec57699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_8fd0e5dd-015f-4846-8706-2b541ec57699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_dd0bb627-b17c-47c6-a34c-f06f0220c77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_dd0bb627-b17c-47c6-a34c-f06f0220c77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d977eb41-dc40-4496-85b4-89962921fb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d977eb41-dc40-4496-85b4-89962921fb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_bbd59469-3cde-41de-9858-6492bd367198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_bbd59469-3cde-41de-9858-6492bd367198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f5ee5b3b-ff6d-495f-aff1-3ea7ce91ca7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f5ee5b3b-ff6d-495f-aff1-3ea7ce91ca7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_050fc9c3-6606-43cb-b8e8-3a90cddbd5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_050fc9c3-6606-43cb-b8e8-3a90cddbd5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_14fcfa09-9e0a-4f3e-9594-69b057fe4079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_14fcfa09-9e0a-4f3e-9594-69b057fe4079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_b4ccacf9-4c1b-495c-9f98-a1036a258dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_b4ccacf9-4c1b-495c-9f98-a1036a258dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_28652024-19ac-4698-a008-a7edbf464bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_28652024-19ac-4698-a008-a7edbf464bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_97c4d4fa-d425-48c6-9882-536ac19abfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b61878ef-f9d6-4f56-94aa-4bc63f8f05fe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_97c4d4fa-d425-48c6-9882-536ac19abfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ango-20230531.xsd#BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bd3ad4f5-e805-45e7-99e2-fee95719c324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1f436d1a-4e62-4e58-84f9-f2c5f63c019a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd3ad4f5-e805-45e7-99e2-fee95719c324" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1f436d1a-4e62-4e58-84f9-f2c5f63c019a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_46e2aaef-08f1-483f-a261-b3cc8fc7ce78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd3ad4f5-e805-45e7-99e2-fee95719c324" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_46e2aaef-08f1-483f-a261-b3cc8fc7ce78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AssetsHeldForSaleTables" xlink:type="simple" xlink:href="ango-20230531.xsd#AssetsHeldForSaleTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AssetsHeldForSaleTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5cbb842c-69a5-4504-b275-e8768c99ed4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_bb9b10b3-7c3a-4b63-99e3-56edbd87a75e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5cbb842c-69a5-4504-b275-e8768c99ed4b" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_bb9b10b3-7c3a-4b63-99e3-56edbd87a75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersTables" xlink:type="simple" xlink:href="ango-20230531.xsd#RevenuefromContractswithCustomersTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a5d374e1-31b4-49c0-b937-3107b2019eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b1f7c40b-6832-4862-a2a3-64a46088c618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a5d374e1-31b4-49c0-b937-3107b2019eeb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b1f7c40b-6832-4862-a2a3-64a46088c618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_74f826b4-4dcd-4987-b21f-45a5375b06ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a5d374e1-31b4-49c0-b937-3107b2019eeb" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_74f826b4-4dcd-4987-b21f-45a5375b06ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="ango-20230531.xsd#FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c0711430-25c6-4165-926d-c62f8b54cfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_22cf9575-8715-45aa-8601-86cf4ef9de93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c0711430-25c6-4165-926d-c62f8b54cfc5" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_22cf9575-8715-45aa-8601-86cf4ef9de93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d454302f-b376-44c6-86f4-0fe68999ae56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c0711430-25c6-4165-926d-c62f8b54cfc5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d454302f-b376-44c6-86f4-0fe68999ae56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_43a22f3c-3431-4913-adbf-cb274b7d66fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c0711430-25c6-4165-926d-c62f8b54cfc5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_43a22f3c-3431-4913-adbf-cb274b7d66fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/InventoriesTables" xlink:type="simple" xlink:href="ango-20230531.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_afeda914-231c-450b-a091-a0396af32ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30d99dfe-dc54-491b-8a14-09f1c9fb2231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_afeda914-231c-450b-a091-a0396af32ed3" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30d99dfe-dc54-491b-8a14-09f1c9fb2231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/PrepaidExpensesandOtherTables" xlink:type="simple" xlink:href="ango-20230531.xsd#PrepaidExpensesandOtherTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/PrepaidExpensesandOtherTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_14cb448f-2b1c-486e-88d0-d822602cdc08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidExpensesAndOtherTableTextBlock_e5e9bff3-6ac7-45a1-a1d3-b04525cd22f9" xlink:href="ango-20230531.xsd#ango_PrepaidExpensesAndOtherTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_14cb448f-2b1c-486e-88d0-d822602cdc08" xlink:to="loc_ango_PrepaidExpensesAndOtherTableTextBlock_e5e9bff3-6ac7-45a1-a1d3-b04525cd22f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetTables" xlink:type="simple" xlink:href="ango-20230531.xsd#PropertyPlantandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e97549ad-766c-490e-b5e1-c218efdfeb83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_70c2a282-f664-454b-a553-73aa9f3b7fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e97549ad-766c-490e-b5e1-c218efdfeb83" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_70c2a282-f664-454b-a553-73aa9f3b7fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ango-20230531.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8ca4857d-bc30-43a7-afdb-f1a75ba9f2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_e1407700-4736-421b-9df2-b11991695cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8ca4857d-bc30-43a7-afdb-f1a75ba9f2c0" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_e1407700-4736-421b-9df2-b11991695cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ScheduleOfIntangibleAssetsTableTextBlock_7b15972e-e669-41e1-b08f-3ec482839773" xlink:href="ango-20230531.xsd#ango_ScheduleOfIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8ca4857d-bc30-43a7-afdb-f1a75ba9f2c0" xlink:to="loc_ango_ScheduleOfIntangibleAssetsTableTextBlock_7b15972e-e669-41e1-b08f-3ec482839773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_70a5a12b-2c6a-4605-aa5e-1d3ebc2f536b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8ca4857d-bc30-43a7-afdb-f1a75ba9f2c0" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_70a5a12b-2c6a-4605-aa5e-1d3ebc2f536b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ango-20230531.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c020d0dd-b990-458b-9a4d-40bbf1010dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_3f13af63-6c3f-464c-8290-0808f89de89c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c020d0dd-b990-458b-9a4d-40bbf1010dc8" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_3f13af63-6c3f-464c-8290-0808f89de89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_bb70f124-0cab-4ffa-a933-96249df9dee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c020d0dd-b990-458b-9a4d-40bbf1010dc8" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_bb70f124-0cab-4ffa-a933-96249df9dee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ea7a0875-3b9c-43f5-895a-871547dc6cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c020d0dd-b990-458b-9a4d-40bbf1010dc8" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ea7a0875-3b9c-43f5-895a-871547dc6cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fd40cfad-e485-46e8-80ca-327eea745a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c020d0dd-b990-458b-9a4d-40bbf1010dc8" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fd40cfad-e485-46e8-80ca-327eea745a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_94d31795-49fd-4a66-9d45-7f86667f70e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c020d0dd-b990-458b-9a4d-40bbf1010dc8" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_94d31795-49fd-4a66-9d45-7f86667f70e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="ango-20230531.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f9b37f00-efd2-493c-bd0b-355f611f7044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ca34125b-6281-47e9-9de4-df3832595143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f9b37f00-efd2-493c-bd0b-355f611f7044" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ca34125b-6281-47e9-9de4-df3832595143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="ango-20230531.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cfe536f5-0d7e-4fc9-bacc-290e2fd3a819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_26f35042-f52a-42c7-970a-61e1912ea297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cfe536f5-0d7e-4fc9-bacc-290e2fd3a819" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_26f35042-f52a-42c7-970a-61e1912ea297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ango-20230531.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5d7b460a-4657-4579-8f17-732ea29404f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e2ffa44e-303a-4131-97df-a43c8a599578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5d7b460a-4657-4579-8f17-732ea29404f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e2ffa44e-303a-4131-97df-a43c8a599578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_b1ae92bf-b5c2-4bd1-ae57-c9996f1c4036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5d7b460a-4657-4579-8f17-732ea29404f1" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_b1ae92bf-b5c2-4bd1-ae57-c9996f1c4036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02e28da5-c418-4a3c-b820-639c433885ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5d7b460a-4657-4579-8f17-732ea29404f1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02e28da5-c418-4a3c-b820-639c433885ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ango-20230531.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ecd62d3c-5803-445e-b17d-66a8c6aaa864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_90515768-ad1a-4553-9a26-b15b657e3cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ecd62d3c-5803-445e-b17d-66a8c6aaa864" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_90515768-ad1a-4553-9a26-b15b657e3cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LeasesTables" xlink:type="simple" xlink:href="ango-20230531.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e58e6468-f89e-4284-8f43-796920896f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AssetsAndLiabilitiesLesseeTableTextBlock_bd933280-2294-4ac1-aaf1-a2b2e31ae4a8" xlink:href="ango-20230531.xsd#ango_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e58e6468-f89e-4284-8f43-796920896f9c" xlink:to="loc_ango_AssetsAndLiabilitiesLesseeTableTextBlock_bd933280-2294-4ac1-aaf1-a2b2e31ae4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_5d3ea55b-d8f8-431f-ac15-c8b24725b4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e58e6468-f89e-4284-8f43-796920896f9c" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_5d3ea55b-d8f8-431f-ac15-c8b24725b4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_43970a44-9290-4c01-abc4-c14377783f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e58e6468-f89e-4284-8f43-796920896f9c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_43970a44-9290-4c01-abc4-c14377783f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/CommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="ango-20230531.xsd#CommitmentsAndContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9a26b856-5fca-4d0e-a80f-7d169e6025ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTableTextBlock_a81b9839-9991-4403-82ca-1656c97fa533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9a26b856-5fca-4d0e-a80f-7d169e6025ae" xlink:to="loc_us-gaap_OtherCommitmentsTableTextBlock_a81b9839-9991-4403-82ca-1656c97fa533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/SegmentsandGeographicInformationTables" xlink:type="simple" xlink:href="ango-20230531.xsd#SegmentsandGeographicInformationTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/SegmentsandGeographicInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6b7ac445-ba90-4a9e-9e09-928963455296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ScheduleOfNetRevenueByProductGroupTableTextBlock_a6d76aef-8688-47bc-b44e-59336abe219f" xlink:href="ango-20230531.xsd#ango_ScheduleOfNetRevenueByProductGroupTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6b7ac445-ba90-4a9e-9e09-928963455296" xlink:to="loc_ango_ScheduleOfNetRevenueByProductGroupTableTextBlock_a6d76aef-8688-47bc-b44e-59336abe219f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_6213076c-e46b-4085-a5e5-e498f13272a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6b7ac445-ba90-4a9e-9e09-928963455296" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_6213076c-e46b-4085-a5e5-e498f13272a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetTables" xlink:type="simple" xlink:href="ango-20230531.xsd#AcquisitionRestructuringandOtherItemsnetTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_46b539c5-433c-49bd-914b-449bfc530584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_bb8e4169-0241-4ec4-92a6-452938035049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_46b539c5-433c-49bd-914b-449bfc530584" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_bb8e4169-0241-4ec4-92a6-452938035049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="ango-20230531.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d2abb763-f691-4685-b12e-0c2d23f63727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_84d5ce70-3c2a-4cde-9aa9-cf95be27718f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d2abb763-f691-4685-b12e-0c2d23f63727" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_84d5ce70-3c2a-4cde-9aa9-cf95be27718f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" xlink:href="ango-20230531.xsd#BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_574a9dad-4a6c-4451-b587-6d1931ef92d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69d335d7-7b80-445d-96af-56a2e8719b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_574a9dad-4a6c-4451-b587-6d1931ef92d1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69d335d7-7b80-445d-96af-56a2e8719b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa9f4f9-3cdf-4ef1-a246-f52d536ac281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69d335d7-7b80-445d-96af-56a2e8719b53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa9f4f9-3cdf-4ef1-a246-f52d536ac281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66d72f52-c7c0-4da6-b708-da0438570c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa9f4f9-3cdf-4ef1-a246-f52d536ac281" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66d72f52-c7c0-4da6-b708-da0438570c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_fc242fd8-0fa5-41c9-80d4-8998440a534c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66d72f52-c7c0-4da6-b708-da0438570c88" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_fc242fd8-0fa5-41c9-80d4-8998440a534c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3dec3fb0-4e62-4f88-8bc0-595de38b3445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66d72f52-c7c0-4da6-b708-da0438570c88" xlink:to="loc_us-gaap_ComputerEquipmentMember_3dec3fb0-4e62-4f88-8bc0-595de38b3445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_9a8cd825-497f-4ed1-9c8a-8c2d45afe452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66d72f52-c7c0-4da6-b708-da0438570c88" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_9a8cd825-497f-4ed1-9c8a-8c2d45afe452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PlacementAndEvaluationUnitsMember_8732bb05-aa8b-4f28-9438-012fd3d1fa3e" xlink:href="ango-20230531.xsd#ango_PlacementAndEvaluationUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66d72f52-c7c0-4da6-b708-da0438570c88" xlink:to="loc_ango_PlacementAndEvaluationUnitsMember_8732bb05-aa8b-4f28-9438-012fd3d1fa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_82eba331-6fcb-42b8-92d0-b29c868f5d56" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69d335d7-7b80-445d-96af-56a2e8719b53" xlink:to="loc_srt_RangeAxis_82eba331-6fcb-42b8-92d0-b29c868f5d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d10f7d3-7b7c-4982-8f79-66c17f6c3d4d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_82eba331-6fcb-42b8-92d0-b29c868f5d56" xlink:to="loc_srt_RangeMember_6d10f7d3-7b7c-4982-8f79-66c17f6c3d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3f5ee6c4-0c51-4875-a99e-90c4deaab8ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d10f7d3-7b7c-4982-8f79-66c17f6c3d4d" xlink:to="loc_srt_MinimumMember_3f5ee6c4-0c51-4875-a99e-90c4deaab8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_06c036a2-3279-483b-9a71-f73ee0948160" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d10f7d3-7b7c-4982-8f79-66c17f6c3d4d" xlink:to="loc_srt_MaximumMember_06c036a2-3279-483b-9a71-f73ee0948160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_745a17c0-39a3-4f96-be0f-68b6eda54ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69d335d7-7b80-445d-96af-56a2e8719b53" xlink:to="loc_us-gaap_AwardTypeAxis_745a17c0-39a3-4f96-be0f-68b6eda54ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bff58d6b-a2c7-49a3-95a7-28da6e0530bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_745a17c0-39a3-4f96-be0f-68b6eda54ba1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bff58d6b-a2c7-49a3-95a7-28da6e0530bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fa4ce534-b71e-48b7-9468-010c5be6d03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bff58d6b-a2c7-49a3-95a7-28da6e0530bf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fa4ce534-b71e-48b7-9468-010c5be6d03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0e573514-16c5-404f-9cd7-ae382c4479a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bff58d6b-a2c7-49a3-95a7-28da6e0530bf" xlink:to="loc_us-gaap_RestrictedStockMember_0e573514-16c5-404f-9cd7-ae382c4479a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69d335d7-7b80-445d-96af-56a2e8719b53" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ShortTermInvestmentsMaturityPeriod_cc3b6c96-06a2-4c5c-bd4e-e67a95bb107e" xlink:href="ango-20230531.xsd#ango_ShortTermInvestmentsMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_ango_ShortTermInvestmentsMaturityPeriod_cc3b6c96-06a2-4c5c-bd4e-e67a95bb107e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AccountsReceivableDuePeriod_f57a5c7d-6c38-4c84-a929-ed2b66ae61e5" xlink:href="ango-20230531.xsd#ango_AccountsReceivableDuePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_ango_AccountsReceivableDuePeriod_f57a5c7d-6c38-4c84-a929-ed2b66ae61e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_635728eb-db29-4f86-b733-de61e2d9ce1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_635728eb-db29-4f86-b733-de61e2d9ce1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_832fddb1-6d86-4d8b-bb1b-3800fa163119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_832fddb1-6d86-4d8b-bb1b-3800fa163119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_82eb0c15-b56d-4ab1-bd95-f472332268bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_82eb0c15-b56d-4ab1-bd95-f472332268bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_bfced91c-4516-4fd8-a723-ead33fec38a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_us-gaap_NumberOfReportingUnits_bfced91c-4516-4fd8-a723-ead33fec38a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_89f101d8-a83c-433f-8b3d-033013337a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_230e84df-6ca8-4b73-ad57-468193acee01" xlink:to="loc_us-gaap_NumberOfOperatingSegments_89f101d8-a83c-433f-8b3d-033013337a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_ead9ecd2-d599-43a7-8218-270f03bc9230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dfa0feb6-1a7a-4110-b690-dd2b69cfb98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_ead9ecd2-d599-43a7-8218-270f03bc9230" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dfa0feb6-1a7a-4110-b690-dd2b69cfb98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ed37308-dac8-47bc-80e2-85f5edff6232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dfa0feb6-1a7a-4110-b690-dd2b69cfb98a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ed37308-dac8-47bc-80e2-85f5edff6232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d41098d2-36a7-4fd5-8254-d036313d6941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ed37308-dac8-47bc-80e2-85f5edff6232" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d41098d2-36a7-4fd5-8254-d036313d6941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_f2ba11c9-bfbd-4c2c-a803-6f9bfe8626ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d41098d2-36a7-4fd5-8254-d036313d6941" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_f2ba11c9-bfbd-4c2c-a803-6f9bfe8626ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_68071df0-6cce-4a6f-9182-c965e962d98f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dfa0feb6-1a7a-4110-b690-dd2b69cfb98a" xlink:to="loc_us-gaap_AssetAcquisitionAxis_68071df0-6cce-4a6f-9182-c965e962d98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_51c379e9-c414-4321-ad53-ffa6308443c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_68071df0-6cce-4a6f-9182-c965e962d98f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_51c379e9-c414-4321-ad53-ffa6308443c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember_b9b48e2e-c31d-4792-8f14-3686366401a3" xlink:href="ango-20230531.xsd#ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_51c379e9-c414-4321-ad53-ffa6308443c5" xlink:to="loc_ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember_b9b48e2e-c31d-4792-8f14-3686366401a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dfa0feb6-1a7a-4110-b690-dd2b69cfb98a" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_e9414af0-017c-48e4-9e0a-ba19002ebf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_e9414af0-017c-48e4-9e0a-ba19002ebf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b577f671-dbe3-4317-a0d6-74884d5bfd66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b577f671-dbe3-4317-a0d6-74884d5bfd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e2f169f1-f094-4d36-9228-4117e50e79ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e2f169f1-f094-4d36-9228-4117e50e79ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount_cc7d4080-ea50-4b51-8909-0f1ddaa9e51d" xlink:href="ango-20230531.xsd#ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount_cc7d4080-ea50-4b51-8909-0f1ddaa9e51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AssetAcquisitionInventoryAndFixedAssets_f5496156-0bd1-4118-a29e-ea2fe07e9471" xlink:href="ango-20230531.xsd#ango_AssetAcquisitionInventoryAndFixedAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_ango_AssetAcquisitionInventoryAndFixedAssets_f5496156-0bd1-4118-a29e-ea2fe07e9471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_d9ae6769-0fcb-45c5-8c64-6996d49d271d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_d9ae6769-0fcb-45c5-8c64-6996d49d271d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_4ea40c1e-d70f-45ec-b6a6-9c245fb0fa20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9264e58c-91ec-48db-adbf-123f78f60b38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_4ea40c1e-d70f-45ec-b6a6-9c245fb0fa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AssetsHeldForSaleDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AssetsHeldForSaleDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AssetsHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_83adced6-1a8b-47bc-99bb-93b8e88e5979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5931d8db-e30e-4838-946c-6488207de0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_83adced6-1a8b-47bc-99bb-93b8e88e5979" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5931d8db-e30e-4838-946c-6488207de0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_009e6b8e-4f0c-4fb6-8905-34d69aab927a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5931d8db-e30e-4838-946c-6488207de0ff" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_009e6b8e-4f0c-4fb6-8905-34d69aab927a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c9294a7f-d5ec-422a-a962-477811968188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_009e6b8e-4f0c-4fb6-8905-34d69aab927a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c9294a7f-d5ec-422a-a962-477811968188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DialysisProductPortfolioAndBioSentryBiopsyMember_3d266dc1-d3ad-456c-9742-b769480bc876" xlink:href="ango-20230531.xsd#ango_DialysisProductPortfolioAndBioSentryBiopsyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c9294a7f-d5ec-422a-a962-477811968188" xlink:to="loc_ango_DialysisProductPortfolioAndBioSentryBiopsyMember_3d266dc1-d3ad-456c-9742-b769480bc876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_fbd96ffa-4d53-4f67-a9bd-f471d825b1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5931d8db-e30e-4838-946c-6488207de0ff" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_fbd96ffa-4d53-4f67-a9bd-f471d825b1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_15d670c3-3435-4ecc-9295-639528afa2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_fbd96ffa-4d53-4f67-a9bd-f471d825b1e1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_15d670c3-3435-4ecc-9295-639528afa2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_a274b043-4812-4271-b3e0-0164ef8f3744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_15d670c3-3435-4ecc-9295-639528afa2e0" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_a274b043-4812-4271-b3e0-0164ef8f3744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_dfcab527-a7ad-4adf-b4c0-77eaac99b418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5931d8db-e30e-4838-946c-6488207de0ff" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_dfcab527-a7ad-4adf-b4c0-77eaac99b418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_114a2755-69af-4801-b614-3b47c32f82f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_dfcab527-a7ad-4adf-b4c0-77eaac99b418" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_114a2755-69af-4801-b614-3b47c32f82f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_94b8e8ee-190c-4891-a2a3-75fe1e29600c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_114a2755-69af-4801-b614-3b47c32f82f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_94b8e8ee-190c-4891-a2a3-75fe1e29600c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_dd97e6c0-bc96-4f4c-97df-14360234f618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_114a2755-69af-4801-b614-3b47c32f82f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_dd97e6c0-bc96-4f4c-97df-14360234f618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_b3718d5e-6061-43e3-b92a-4713577dd058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_114a2755-69af-4801-b614-3b47c32f82f7" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_b3718d5e-6061-43e3-b92a-4713577dd058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1fc01674-45a3-42e6-bd9c-6e36cbd68c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_dfcab527-a7ad-4adf-b4c0-77eaac99b418" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1fc01674-45a3-42e6-bd9c-6e36cbd68c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_ccff14b1-48c5-4591-8d6d-41e0d8db54b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1fc01674-45a3-42e6-bd9c-6e36cbd68c29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_ccff14b1-48c5-4591-8d6d-41e0d8db54b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_f8b54b51-f914-4c5d-ad90-033c32433a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1fc01674-45a3-42e6-bd9c-6e36cbd68c29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_f8b54b51-f914-4c5d-ad90-033c32433a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_01150cdb-ed91-4338-89e9-6cde4cb9c192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1fc01674-45a3-42e6-bd9c-6e36cbd68c29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_01150cdb-ed91-4338-89e9-6cde4cb9c192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_5b734e7b-692d-4c90-a61b-ea836d12ca55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1fc01674-45a3-42e6-bd9c-6e36cbd68c29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_5b734e7b-692d-4c90-a61b-ea836d12ca55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#RevenuefromContractswithCustomersDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_31091964-6e17-4da7-b03b-aae1591b459e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_43e5d381-d4c7-41e6-b625-e84f916497c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_31091964-6e17-4da7-b03b-aae1591b459e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_43e5d381-d4c7-41e6-b625-e84f916497c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0dc83f8b-ab71-49b4-8abc-d782056b4299" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_43e5d381-d4c7-41e6-b625-e84f916497c3" xlink:to="loc_srt_ProductOrServiceAxis_0dc83f8b-ab71-49b4-8abc-d782056b4299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7fb43eaa-12f7-45d1-b709-e6377e6efdf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0dc83f8b-ab71-49b4-8abc-d782056b4299" xlink:to="loc_srt_ProductsAndServicesDomain_7fb43eaa-12f7-45d1-b709-e6377e6efdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedTechMember_1ddf1cf2-708c-4369-9481-4dfbbaa58d10" xlink:href="ango-20230531.xsd#ango_MedTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7fb43eaa-12f7-45d1-b709-e6377e6efdf3" xlink:to="loc_ango_MedTechMember_1ddf1cf2-708c-4369-9481-4dfbbaa58d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedDeviceMember_3904a9a6-1515-4ef5-a31c-01a1c81ea775" xlink:href="ango-20230531.xsd#ango_MedDeviceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7fb43eaa-12f7-45d1-b709-e6377e6efdf3" xlink:to="loc_ango_MedDeviceMember_3904a9a6-1515-4ef5-a31c-01a1c81ea775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_934d047f-3c40-47b9-b9c5-981cecaf2694" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_43e5d381-d4c7-41e6-b625-e84f916497c3" xlink:to="loc_srt_StatementGeographicalAxis_934d047f-3c40-47b9-b9c5-981cecaf2694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f419af17-e9bd-48f2-a6c1-160925db5aac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_934d047f-3c40-47b9-b9c5-981cecaf2694" xlink:to="loc_srt_SegmentGeographicalDomain_f419af17-e9bd-48f2-a6c1-160925db5aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ec8ebbe1-d29f-4a29-be5c-94351f26e86f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f419af17-e9bd-48f2-a6c1-160925db5aac" xlink:to="loc_country_US_ec8ebbe1-d29f-4a29-be5c-94351f26e86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1db87593-72e9-4559-9c7e-a39a4cee5470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f419af17-e9bd-48f2-a6c1-160925db5aac" xlink:to="loc_us-gaap_NonUsMember_1db87593-72e9-4559-9c7e-a39a4cee5470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_adbdf563-7e8c-433e-9f5e-865f3dfb254f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_43e5d381-d4c7-41e6-b625-e84f916497c3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_adbdf563-7e8c-433e-9f5e-865f3dfb254f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85ff1b29-5c60-4e03-a1e6-9ab078bdcb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_adbdf563-7e8c-433e-9f5e-865f3dfb254f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85ff1b29-5c60-4e03-a1e6-9ab078bdcb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#RevenuefromContractswithCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_63c5c9ce-6037-4a93-b4ed-7dce4406f20d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c335af7c-d3a9-45ab-9865-c29393296af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_63c5c9ce-6037-4a93-b4ed-7dce4406f20d" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c335af7c-d3a9-45ab-9865-c29393296af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_213ed350-4d2f-474b-baf7-8435509732a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c335af7c-d3a9-45ab-9865-c29393296af1" xlink:to="loc_srt_RangeAxis_213ed350-4d2f-474b-baf7-8435509732a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54fbc75a-da71-4061-93fb-3bf68f11309d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_213ed350-4d2f-474b-baf7-8435509732a5" xlink:to="loc_srt_RangeMember_54fbc75a-da71-4061-93fb-3bf68f11309d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_77000dd8-9266-4566-9b95-e05b0a714521" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_54fbc75a-da71-4061-93fb-3bf68f11309d" xlink:to="loc_srt_MinimumMember_77000dd8-9266-4566-9b95-e05b0a714521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7b647004-fc8a-4f51-b5da-4d5b87793a95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_54fbc75a-da71-4061-93fb-3bf68f11309d" xlink:to="loc_srt_MaximumMember_7b647004-fc8a-4f51-b5da-4d5b87793a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c335af7c-d3a9-45ab-9865-c29393296af1" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevenuePerformanceObligationPaymentTerm_e7a38870-f99e-46c3-a389-b409e92ec5d4" xlink:href="ango-20230531.xsd#ango_RevenuePerformanceObligationPaymentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:to="loc_ango_RevenuePerformanceObligationPaymentTerm_e7a38870-f99e-46c3-a389-b409e92ec5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval_6ad33410-f9d8-4062-9498-92f6985ffe36" xlink:href="ango-20230531.xsd#ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:to="loc_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval_6ad33410-f9d8-4062-9498-92f6985ffe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ContractwithCustomerRightofReturnRestockingCharge_4e71b8af-1e55-4e7f-b384-6358dadf0879" xlink:href="ango-20230531.xsd#ango_ContractwithCustomerRightofReturnRestockingCharge"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:to="loc_ango_ContractwithCustomerRightofReturnRestockingCharge_4e71b8af-1e55-4e7f-b384-6358dadf0879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn_f823f186-9bc0-4b20-9c4e-8ae58ba9dd89" xlink:href="ango-20230531.xsd#ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:to="loc_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn_f823f186-9bc0-4b20-9c4e-8ae58ba9dd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_ffec5c15-15dd-47c0-bcc0-d42102b1fa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_ffec5c15-15dd-47c0-bcc0-d42102b1fa4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod_dad89be0-2533-4ef5-832b-2a28cc7af945" xlink:href="ango-20230531.xsd#ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_8f40df3e-732a-480f-8004-73998f706f1d" xlink:to="loc_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod_dad89be0-2533-4ef5-832b-2a28cc7af945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersRevenuefromContractswithCustomersContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#RevenuefromContractswithCustomersRevenuefromContractswithCustomersContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/RevenuefromContractswithCustomersRevenuefromContractswithCustomersContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6d80c2e3-1134-4d8a-b3dc-701b0a4f79eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dc6c0f8c-1e66-4e21-826c-5735dd43954d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6d80c2e3-1134-4d8a-b3dc-701b0a4f79eb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dc6c0f8c-1e66-4e21-826c-5735dd43954d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_224138da-3a23-44ef-8b68-cf2dc6e31ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6d80c2e3-1134-4d8a-b3dc-701b0a4f79eb" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_224138da-3a23-44ef-8b68-cf2dc6e31ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1ce51a21-2fce-4e7a-b3e7-69b5600fa92b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6d80c2e3-1134-4d8a-b3dc-701b0a4f79eb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1ce51a21-2fce-4e7a-b3e7-69b5600fa92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5b46fda1-e776-4499-9330-20e464a6703c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de52d03-722b-463e-b65f-29a459419607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5b46fda1-e776-4499-9330-20e464a6703c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de52d03-722b-463e-b65f-29a459419607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a00b99-b4bb-4d62-a303-dfc2e0712e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de52d03-722b-463e-b65f-29a459419607" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a00b99-b4bb-4d62-a303-dfc2e0712e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ea6608c-989a-4ef0-a8b9-4e7e6a712866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a00b99-b4bb-4d62-a303-dfc2e0712e9b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ea6608c-989a-4ef0-a8b9-4e7e6a712866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1671004d-8b2a-49e8-b780-de87b525538e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ea6608c-989a-4ef0-a8b9-4e7e6a712866" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1671004d-8b2a-49e8-b780-de87b525538e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_055dd970-96da-4d5e-b25f-893f20fffb70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de52d03-722b-463e-b65f-29a459419607" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_055dd970-96da-4d5e-b25f-893f20fffb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d59693b-a37c-407e-9894-8ef4adeed778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_055dd970-96da-4d5e-b25f-893f20fffb70" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d59693b-a37c-407e-9894-8ef4adeed778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_713d351d-62f9-4c40-a38a-ca67dbbcb199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d59693b-a37c-407e-9894-8ef4adeed778" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_713d351d-62f9-4c40-a38a-ca67dbbcb199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2f35de42-6a35-451a-b1da-76aef1583a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d59693b-a37c-407e-9894-8ef4adeed778" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2f35de42-6a35-451a-b1da-76aef1583a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_96901342-da46-4d75-b53e-14aa23f56439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d59693b-a37c-407e-9894-8ef4adeed778" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_96901342-da46-4d75-b53e-14aa23f56439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_74452f01-584a-420e-8ff6-94ea33cc6f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de52d03-722b-463e-b65f-29a459419607" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_74452f01-584a-420e-8ff6-94ea33cc6f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_58a7b516-bbd7-48ad-a863-0cb0a046f7da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_74452f01-584a-420e-8ff6-94ea33cc6f25" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_58a7b516-bbd7-48ad-a863-0cb0a046f7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e09505e1-09e1-4130-82ba-0356ee0c8320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_58a7b516-bbd7-48ad-a863-0cb0a046f7da" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e09505e1-09e1-4130-82ba-0356ee0c8320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_727aeaf0-63d8-4eef-8afa-57f7818e2f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_58a7b516-bbd7-48ad-a863-0cb0a046f7da" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_727aeaf0-63d8-4eef-8afa-57f7818e2f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails2" xlink:type="simple" xlink:href="ango-20230531.xsd#FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails2"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1a24e4a7-2afb-4846-bb95-1e4275f2c539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_b87dd67e-3dc2-407b-8ac7-c26aa18f51ce" xlink:href="ango-20230531.xsd#ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1a24e4a7-2afb-4846-bb95-1e4275f2c539" xlink:to="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_b87dd67e-3dc2-407b-8ac7-c26aa18f51ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bcdde167-a2e9-4c0f-bb5e-3232cc8fe33c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_b87dd67e-3dc2-407b-8ac7-c26aa18f51ce" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bcdde167-a2e9-4c0f-bb5e-3232cc8fe33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1044ffe4-55df-4694-a1e2-86a0da2220d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bcdde167-a2e9-4c0f-bb5e-3232cc8fe33c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1044ffe4-55df-4694-a1e2-86a0da2220d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_93f41bf6-3eb8-4ca7-8eef-01791f5a420a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bcdde167-a2e9-4c0f-bb5e-3232cc8fe33c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_93f41bf6-3eb8-4ca7-8eef-01791f5a420a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement_267d56a2-b221-4317-8d66-daecc433a9a7" xlink:href="ango-20230531.xsd#ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bcdde167-a2e9-4c0f-bb5e-3232cc8fe33c" xlink:to="loc_ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement_267d56a2-b221-4317-8d66-daecc433a9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ChangeInFairValueOfContingentConsideration_311b3f3b-7169-4a2c-bb66-547fdc32d9f0" xlink:href="ango-20230531.xsd#ango_ChangeInFairValueOfContingentConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bcdde167-a2e9-4c0f-bb5e-3232cc8fe33c" xlink:to="loc_ango_ChangeInFairValueOfContingentConsideration_311b3f3b-7169-4a2c-bb66-547fdc32d9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_756ae3a6-3e76-41de-aba3-ce0a416fa263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bcdde167-a2e9-4c0f-bb5e-3232cc8fe33c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_756ae3a6-3e76-41de-aba3-ce0a416fa263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3" xlink:type="simple" xlink:href="ango-20230531.xsd#FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a3733488-017f-43cc-921b-2dc8ae5c5412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a3733488-017f-43cc-921b-2dc8ae5c5412" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_5f03c0b5-0754-417b-8b4b-23025319dc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_5f03c0b5-0754-417b-8b4b-23025319dc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_8969abce-17b3-4a66-82f8-2ea3d0aff6de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_5f03c0b5-0754-417b-8b4b-23025319dc5f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_8969abce-17b3-4a66-82f8-2ea3d0aff6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevenueBasedPaymentMember_6a020742-3b79-451c-91d6-e69997cd2432" xlink:href="ango-20230531.xsd#ango_RevenueBasedPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8969abce-17b3-4a66-82f8-2ea3d0aff6de" xlink:to="loc_ango_RevenueBasedPaymentMember_6a020742-3b79-451c-91d6-e69997cd2432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_bf15ed05-9570-4bb0-bd6d-ea9cdc84cef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_ValuationTechniqueAxis_bf15ed05-9570-4bb0-bd6d-ea9cdc84cef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_7c67d394-9403-4094-8fa2-194636d70fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_bf15ed05-9570-4bb0-bd6d-ea9cdc84cef3" xlink:to="loc_us-gaap_ValuationTechniqueDomain_7c67d394-9403-4094-8fa2-194636d70fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_46ca8f0f-0b95-40c7-8dcf-315030db9233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_7c67d394-9403-4094-8fa2-194636d70fbe" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_46ca8f0f-0b95-40c7-8dcf-315030db9233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevenueBasedPaymentMember_a68cfcf2-26ec-49ec-9e95-4af4e719ff95" xlink:href="ango-20230531.xsd#ango_RevenueBasedPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_7c67d394-9403-4094-8fa2-194636d70fbe" xlink:to="loc_ango_RevenueBasedPaymentMember_a68cfcf2-26ec-49ec-9e95-4af4e719ff95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be5540c4-62bd-43c2-bba8-3b9c22858ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be5540c4-62bd-43c2-bba8-3b9c22858ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_488d605e-5fd4-4d7a-8183-909c47fa6d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be5540c4-62bd-43c2-bba8-3b9c22858ec6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_488d605e-5fd4-4d7a-8183-909c47fa6d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_370cc8b3-e568-40f2-a71c-28c0478d49ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_488d605e-5fd4-4d7a-8183-909c47fa6d9a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_370cc8b3-e568-40f2-a71c-28c0478d49ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_15559741-1322-4750-b5e8-977fb1a1a1a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_srt_RangeAxis_15559741-1322-4750-b5e8-977fb1a1a1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b1b3da7-ae21-46f6-a9d2-26c4b033a379" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_15559741-1322-4750-b5e8-977fb1a1a1a5" xlink:to="loc_srt_RangeMember_9b1b3da7-ae21-46f6-a9d2-26c4b033a379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_29176cd7-98e3-4f80-936d-3637b778167b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9b1b3da7-ae21-46f6-a9d2-26c4b033a379" xlink:to="loc_srt_MinimumMember_29176cd7-98e3-4f80-936d-3637b778167b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_774ebfa4-c4e3-4eec-8018-f4d15befcd23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9b1b3da7-ae21-46f6-a9d2-26c4b033a379" xlink:to="loc_srt_MaximumMember_774ebfa4-c4e3-4eec-8018-f4d15befcd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bb1ba9b7-5fd1-4a47-a20f-c51d76a9c93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bb1ba9b7-5fd1-4a47-a20f-c51d76a9c93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_84210078-ec8f-45b9-bd6c-258e40c3af97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bb1ba9b7-5fd1-4a47-a20f-c51d76a9c93a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_84210078-ec8f-45b9-bd6c-258e40c3af97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_010502a6-8112-4c1f-a655-a6d9e60a4c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_84210078-ec8f-45b9-bd6c-258e40c3af97" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_010502a6-8112-4c1f-a655-a6d9e60a4c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9adb1d7d-49d4-4ffd-be16-2fcf0ecf5061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9adb1d7d-49d4-4ffd-be16-2fcf0ecf5061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d114a0e3-02ee-41c2-9cd3-dbdfe716f269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9adb1d7d-49d4-4ffd-be16-2fcf0ecf5061" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d114a0e3-02ee-41c2-9cd3-dbdfe716f269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_05655a92-321f-4a43-8693-04dc64b450a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d114a0e3-02ee-41c2-9cd3-dbdfe716f269" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_05655a92-321f-4a43-8693-04dc64b450a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MeasurementInputProbabilityofPaymentMember_adbb4517-fb3f-41c0-9032-a231b00cf6cb" xlink:href="ango-20230531.xsd#ango_MeasurementInputProbabilityofPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d114a0e3-02ee-41c2-9cd3-dbdfe716f269" xlink:to="loc_ango_MeasurementInputProbabilityofPaymentMember_adbb4517-fb3f-41c0-9032-a231b00cf6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eb550303-05c5-4c84-8556-e522e157171d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eb550303-05c5-4c84-8556-e522e157171d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_924d276c-3968-4b1c-b1f1-5fefabc523a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eb550303-05c5-4c84-8556-e522e157171d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_924d276c-3968-4b1c-b1f1-5fefabc523a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RadiaDyneMember_1b52e4d3-591e-43a4-9217-b9ae9c7145d8" xlink:href="ango-20230531.xsd#ango_RadiaDyneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_924d276c-3968-4b1c-b1f1-5fefabc523a6" xlink:to="loc_ango_RadiaDyneMember_1b52e4d3-591e-43a4-9217-b9ae9c7145d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43caf2b7-1ab2-455e-b7d9-36a0d1fd26bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43caf2b7-1ab2-455e-b7d9-36a0d1fd26bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2a68fc-17ac-45d4-ad4f-6a9fd63a20ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43caf2b7-1ab2-455e-b7d9-36a0d1fd26bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2a68fc-17ac-45d4-ad4f-6a9fd63a20ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_OarTracTrademarkMember_fed10cc6-498d-49e4-9bdf-d85b3ddd6f76" xlink:href="ango-20230531.xsd#ango_OarTracTrademarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2a68fc-17ac-45d4-ad4f-6a9fd63a20ea" xlink:to="loc_ango_OarTracTrademarkMember_fed10cc6-498d-49e4-9bdf-d85b3ddd6f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03c65cb6-789e-49db-9d4e-0c65b2c3d5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ef31838-7f55-42a2-921f-13296d05727b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03c65cb6-789e-49db-9d4e-0c65b2c3d5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract_dcada634-3c43-42a0-9273-40621d7187be" xlink:href="ango-20230531.xsd#ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03c65cb6-789e-49db-9d4e-0c65b2c3d5ab" xlink:to="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract_dcada634-3c43-42a0-9273-40621d7187be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4e9060a-d57c-456d-ba64-71ade5661a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract_dcada634-3c43-42a0-9273-40621d7187be" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4e9060a-d57c-456d-ba64-71ade5661a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a59b97eb-657f-47b6-bd89-c970ab334a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract_dcada634-3c43-42a0-9273-40621d7187be" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a59b97eb-657f-47b6-bd89-c970ab334a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8af8188b-48e8-40ff-a23c-0944e8d60180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract_dcada634-3c43-42a0-9273-40621d7187be" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_8af8188b-48e8-40ff-a23c-0944e8d60180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure_f8fdc57f-6286-464b-b8df-cd61a0c765d6" xlink:href="ango-20230531.xsd#ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03c65cb6-789e-49db-9d4e-0c65b2c3d5ab" xlink:to="loc_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure_f8fdc57f-6286-464b-b8df-cd61a0c765d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_2948f924-6569-430c-af5d-d3430c4fde01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03c65cb6-789e-49db-9d4e-0c65b2c3d5ab" xlink:to="loc_us-gaap_AssetImpairmentCharges_2948f924-6569-430c-af5d-d3430c4fde01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7111d03b-b76e-4a00-8540-066aa7520a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_1dab2a83-f2e2-478c-94e0-f641a82e5e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7111d03b-b76e-4a00-8540-066aa7520a33" xlink:to="loc_us-gaap_InventoryNetAbstract_1dab2a83-f2e2-478c-94e0-f641a82e5e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_3c7c279f-74c0-4c13-95f0-62bbf40ed08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1dab2a83-f2e2-478c-94e0-f641a82e5e73" xlink:to="loc_us-gaap_InventoryRawMaterials_3c7c279f-74c0-4c13-95f0-62bbf40ed08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_2128acc3-61b8-40c1-9a63-4884b343994c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1dab2a83-f2e2-478c-94e0-f641a82e5e73" xlink:to="loc_us-gaap_InventoryWorkInProcess_2128acc3-61b8-40c1-9a63-4884b343994c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_84e8568a-076f-496d-84ac-5358bbae85d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1dab2a83-f2e2-478c-94e0-f641a82e5e73" xlink:to="loc_us-gaap_InventoryFinishedGoods_84e8568a-076f-496d-84ac-5358bbae85d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e349f625-c765-4eae-aa28-64b5f8e4f956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1dab2a83-f2e2-478c-94e0-f641a82e5e73" xlink:to="loc_us-gaap_InventoryNet_e349f625-c765-4eae-aa28-64b5f8e4f956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_16626aac-9441-4274-813d-5da827fae2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7111d03b-b76e-4a00-8540-066aa7520a33" xlink:to="loc_us-gaap_InventoryValuationReserves_16626aac-9441-4274-813d-5da827fae2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#PrepaidExpensesandOtherDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a8e84fc8-ec84-4b9c-a1af-d9e76cbfe75f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_66a79398-4d17-44d8-a264-9d0b8fd5bf12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a8e84fc8-ec84-4b9c-a1af-d9e76cbfe75f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_66a79398-4d17-44d8-a264-9d0b8fd5bf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidDeposits_2cc96899-2d77-44b7-b0c4-0a9be54573ed" xlink:href="ango-20230531.xsd#ango_PrepaidDeposits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_66a79398-4d17-44d8-a264-9d0b8fd5bf12" xlink:to="loc_ango_PrepaidDeposits_2cc96899-2d77-44b7-b0c4-0a9be54573ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidEmployeeTaxCredit_9287798a-9ae3-4d30-8873-7b425fd29f5e" xlink:href="ango-20230531.xsd#ango_PrepaidEmployeeTaxCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_66a79398-4d17-44d8-a264-9d0b8fd5bf12" xlink:to="loc_ango_PrepaidEmployeeTaxCredit_9287798a-9ae3-4d30-8873-7b425fd29f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SoftwareLicenses_7d4f1215-3f7e-44cb-bcbb-3886c20dec00" xlink:href="ango-20230531.xsd#ango_SoftwareLicenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_66a79398-4d17-44d8-a264-9d0b8fd5bf12" xlink:to="loc_ango_SoftwareLicenses_7d4f1215-3f7e-44cb-bcbb-3886c20dec00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidLicenseeFees_6b092dce-9423-4d54-a6a5-1927d8237edd" xlink:href="ango-20230531.xsd#ango_PrepaidLicenseeFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_66a79398-4d17-44d8-a264-9d0b8fd5bf12" xlink:to="loc_ango_PrepaidLicenseeFees_6b092dce-9423-4d54-a6a5-1927d8237edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TradeShows_8bc04444-838b-449e-b128-8523f049ba7f" xlink:href="ango-20230531.xsd#ango_TradeShows"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_66a79398-4d17-44d8-a264-9d0b8fd5bf12" xlink:to="loc_ango_TradeShows_8bc04444-838b-449e-b128-8523f049ba7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent_6aeeb986-c19a-4f3f-96bc-a03380c268eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_66a79398-4d17-44d8-a264-9d0b8fd5bf12" xlink:to="loc_us-gaap_PrepaidRent_6aeeb986-c19a-4f3f-96bc-a03380c268eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PrepaidIncomeandOtherTaxes_8a32eab7-6ca8-4c1e-b44f-8455fd72f251" xlink:href="ango-20230531.xsd#ango_PrepaidIncomeandOtherTaxes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_66a79398-4d17-44d8-a264-9d0b8fd5bf12" xlink:to="loc_ango_PrepaidIncomeandOtherTaxes_8a32eab7-6ca8-4c1e-b44f-8455fd72f251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_cb5c27a2-03f7-42cb-b79a-8e8d68c08787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_66a79398-4d17-44d8-a264-9d0b8fd5bf12" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_cb5c27a2-03f7-42cb-b79a-8e8d68c08787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8258f4e6-5776-4f61-88b6-3e164000740e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_66a79398-4d17-44d8-a264-9d0b8fd5bf12" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8258f4e6-5776-4f61-88b6-3e164000740e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#PropertyPlantandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_836cb27e-019a-4020-91a2-88d203157665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18505618-f6db-4b9c-9d70-068647161170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_836cb27e-019a-4020-91a2-88d203157665" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18505618-f6db-4b9c-9d70-068647161170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b86a9c3d-cd0e-4875-994f-0f68e10c8be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18505618-f6db-4b9c-9d70-068647161170" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b86a9c3d-cd0e-4875-994f-0f68e10c8be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b86a9c3d-cd0e-4875-994f-0f68e10c8be6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_c2937552-aa8e-4214-88db-4fde40735286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_c2937552-aa8e-4214-88db-4fde40735286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_490e9164-64d7-4bb7-9aae-3ac0a8833651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:to="loc_us-gaap_ComputerEquipmentMember_490e9164-64d7-4bb7-9aae-3ac0a8833651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_3dfd5b88-7194-4472-b8bd-2e76ff0b6bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_3dfd5b88-7194-4472-b8bd-2e76ff0b6bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PlacementAndEvaluationUnitsMember_48552c69-e0a2-4869-89b7-d5454befe5b8" xlink:href="ango-20230531.xsd#ango_PlacementAndEvaluationUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:to="loc_ango_PlacementAndEvaluationUnitsMember_48552c69-e0a2-4869-89b7-d5454befe5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_a7cdf008-77d4-4435-ac5c-46de44d02b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee356a3-bffc-4ad1-9fb6-f000bb4b1906" xlink:to="loc_us-gaap_ConstructionInProgressMember_a7cdf008-77d4-4435-ac5c-46de44d02b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2a5d017e-74c3-4b31-9e91-8caff7506937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_18505618-f6db-4b9c-9d70-068647161170" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2a5d017e-74c3-4b31-9e91-8caff7506937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2a5d017e-74c3-4b31-9e91-8caff7506937" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e20af68b-ef59-4b99-80dc-1a680544412d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e20af68b-ef59-4b99-80dc-1a680544412d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c3dca89d-d739-4aa1-a633-0663db7548a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c3dca89d-d739-4aa1-a633-0663db7548a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements_acfcec94-5511-4626-ae46-9f53967c7135" xlink:href="ango-20230531.xsd#ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:to="loc_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements_acfcec94-5511-4626-ae46-9f53967c7135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovements_a77c8e78-7633-4eb7-a4a1-f88951751191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:to="loc_us-gaap_LandAndLandImprovements_a77c8e78-7633-4eb7-a4a1-f88951751191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1738c42f-ff86-4446-b1e4-c36e742c15c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_57fee3ee-1219-46b9-80bb-e132bfb050d9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1738c42f-ff86-4446-b1e4-c36e742c15c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_42ab4b46-1558-49f7-8987-998b014b7a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2a5d017e-74c3-4b31-9e91-8caff7506937" xlink:to="loc_us-gaap_Depreciation_42ab4b46-1558-49f7-8987-998b014b7a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#GoodwillandIntangibleAssetsGoodwillRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e675a768-e768-4c5d-a21d-2bb914c80c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_d6cfb8bd-4ca5-4e29-89a7-1d421a9961c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e675a768-e768-4c5d-a21d-2bb914c80c03" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_d6cfb8bd-4ca5-4e29-89a7-1d421a9961c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7e1a44dd-f733-4202-b855-eb91ea73c85d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d6cfb8bd-4ca5-4e29-89a7-1d421a9961c8" xlink:to="loc_srt_ProductOrServiceAxis_7e1a44dd-f733-4202-b855-eb91ea73c85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a3ab044-1fc1-4654-a601-1185ad9d4626" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7e1a44dd-f733-4202-b855-eb91ea73c85d" xlink:to="loc_srt_ProductsAndServicesDomain_5a3ab044-1fc1-4654-a601-1185ad9d4626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedTechMember_ef3b2912-de8f-475f-8666-4edf3c1b6e17" xlink:href="ango-20230531.xsd#ango_MedTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a3ab044-1fc1-4654-a601-1185ad9d4626" xlink:to="loc_ango_MedTechMember_ef3b2912-de8f-475f-8666-4edf3c1b6e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedDeviceMember_448b21be-f70f-460f-abbf-30c0eddfbe2b" xlink:href="ango-20230531.xsd#ango_MedDeviceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a3ab044-1fc1-4654-a601-1185ad9d4626" xlink:to="loc_ango_MedDeviceMember_448b21be-f70f-460f-abbf-30c0eddfbe2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f546826f-573f-40c8-9789-d7a172db0105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d6cfb8bd-4ca5-4e29-89a7-1d421a9961c8" xlink:to="loc_us-gaap_GoodwillLineItems_f546826f-573f-40c8-9789-d7a172db0105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_4bbdb386-125f-4525-b163-9ca461481baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_f546826f-573f-40c8-9789-d7a172db0105" xlink:to="loc_us-gaap_GoodwillRollForward_4bbdb386-125f-4525-b163-9ca461481baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_eb9cdcdb-801d-4dae-be56-89c5456e8668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_4bbdb386-125f-4525-b163-9ca461481baa" xlink:to="loc_us-gaap_Goodwill_eb9cdcdb-801d-4dae-be56-89c5456e8668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0427ccc2-14d5-4190-a16e-a4d6ac5927ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_4bbdb386-125f-4525-b163-9ca461481baa" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0427ccc2-14d5-4190-a16e-a4d6ac5927ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_62e48942-1fcd-413c-a78f-e82120e133c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_4bbdb386-125f-4525-b163-9ca461481baa" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_62e48942-1fcd-413c-a78f-e82120e133c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_dccf8c46-93b8-4ba3-b00b-478799b643eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_4bbdb386-125f-4525-b163-9ca461481baa" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_dccf8c46-93b8-4ba3-b00b-478799b643eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_79c28bd2-03c1-40e9-b95a-f42f512aef7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_4bbdb386-125f-4525-b163-9ca461481baa" xlink:to="loc_us-gaap_Goodwill_79c28bd2-03c1-40e9-b95a-f42f512aef7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be3159c7-1b53-4ec5-ae6a-fb7f3f16d701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d44b0593-2725-4553-9329-065fe2e05809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be3159c7-1b53-4ec5-ae6a-fb7f3f16d701" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d44b0593-2725-4553-9329-065fe2e05809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a0b768d-593f-4d92-9f9e-f75a01f32ea6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d44b0593-2725-4553-9329-065fe2e05809" xlink:to="loc_srt_RangeAxis_3a0b768d-593f-4d92-9f9e-f75a01f32ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_645a9370-8103-4490-8eff-3dd3a4440e7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3a0b768d-593f-4d92-9f9e-f75a01f32ea6" xlink:to="loc_srt_RangeMember_645a9370-8103-4490-8eff-3dd3a4440e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_51b26b93-f000-4ab2-91d5-87fcfa152174" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_645a9370-8103-4490-8eff-3dd3a4440e7b" xlink:to="loc_srt_MinimumMember_51b26b93-f000-4ab2-91d5-87fcfa152174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5faa72f2-8632-4935-99c6-66723f3fcdb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_645a9370-8103-4490-8eff-3dd3a4440e7b" xlink:to="loc_srt_MaximumMember_5faa72f2-8632-4935-99c6-66723f3fcdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d44b0593-2725-4553-9329-065fe2e05809" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_ac1a9439-8646-409f-bfd2-88d07a6fe3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_NumberOfReportingUnits_ac1a9439-8646-409f-bfd2-88d07a6fe3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7b78c506-f7c8-4201-a325-b5ad9a4d7f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7b78c506-f7c8-4201-a325-b5ad9a4d7f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e4e1c922-9e0e-438c-a22d-4f52b415fff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e4e1c922-9e0e-438c-a22d-4f52b415fff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_080a3f71-f316-452b-9911-c59844486ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_080a3f71-f316-452b-9911-c59844486ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_5fa68ea3-47fa-4a86-ae01-c1e716945ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_5fa68ea3-47fa-4a86-ae01-c1e716945ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c4e56dbc-372b-4966-b332-cc37a0f8e4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c4e56dbc-372b-4966-b332-cc37a0f8e4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3d220553-8531-44b3-9789-9d0bf23a32d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7b8dd87a-83fe-498a-a782-0fdffa55fe2c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3d220553-8531-44b3-9789-9d0bf23a32d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7d16c4ac-94fa-45e2-b69f-93ab2ff78834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c896d03-30cd-4011-8a6f-a18a20cd1601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7d16c4ac-94fa-45e2-b69f-93ab2ff78834" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c896d03-30cd-4011-8a6f-a18a20cd1601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_62c378e7-5204-4960-b5f3-dbd8805e8645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c896d03-30cd-4011-8a6f-a18a20cd1601" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_62c378e7-5204-4960-b5f3-dbd8805e8645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8434c62f-028f-46e0-81b8-448b05e91ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_62c378e7-5204-4960-b5f3-dbd8805e8645" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8434c62f-028f-46e0-81b8-448b05e91ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ProductTechnologiesMember_d4807603-61c7-4542-a35c-7a5edfd7fec0" xlink:href="ango-20230531.xsd#ango_ProductTechnologiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8434c62f-028f-46e0-81b8-448b05e91ef1" xlink:to="loc_ango_ProductTechnologiesMember_d4807603-61c7-4542-a35c-7a5edfd7fec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_8205e2ed-648b-4cef-824b-a2e4891644ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8434c62f-028f-46e0-81b8-448b05e91ef1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_8205e2ed-648b-4cef-824b-a2e4891644ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_92a2c940-8020-4512-9826-cba9506fcbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8434c62f-028f-46e0-81b8-448b05e91ef1" xlink:to="loc_us-gaap_TrademarksMember_92a2c940-8020-4512-9826-cba9506fcbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_46121d83-cae4-42f4-bea1-050d20094269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8434c62f-028f-46e0-81b8-448b05e91ef1" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_46121d83-cae4-42f4-bea1-050d20094269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b0b46258-0975-453d-93d4-d2ed01d94250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c896d03-30cd-4011-8a6f-a18a20cd1601" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b0b46258-0975-453d-93d4-d2ed01d94250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5acd2eab-9730-4af0-ab56-4ef8041c3999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b0b46258-0975-453d-93d4-d2ed01d94250" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5acd2eab-9730-4af0-ab56-4ef8041c3999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4dea449f-678f-41a8-9d87-a70ee2bb492f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b0b46258-0975-453d-93d4-d2ed01d94250" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4dea449f-678f-41a8-9d87-a70ee2bb492f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_773eeff7-9c95-41b9-bfd3-f4b235fd7a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b0b46258-0975-453d-93d4-d2ed01d94250" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_773eeff7-9c95-41b9-bfd3-f4b235fd7a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bbca215b-bf92-4538-876e-429dad49d295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_89553e28-d942-44b7-90f5-99a218241436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bbca215b-bf92-4538-876e-429dad49d295" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_89553e28-d942-44b7-90f5-99a218241436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_783ce4d2-7ea9-40e1-89b4-c7336a5ba1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_89553e28-d942-44b7-90f5-99a218241436" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_783ce4d2-7ea9-40e1-89b4-c7336a5ba1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_73738658-1b9b-4a47-9766-bb258a74ba25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_89553e28-d942-44b7-90f5-99a218241436" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_73738658-1b9b-4a47-9766-bb258a74ba25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7a9b6f84-d774-4202-b8fa-249317aa94dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_89553e28-d942-44b7-90f5-99a218241436" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7a9b6f84-d774-4202-b8fa-249317aa94dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_86c08e01-f714-4f23-b47d-5414000d5f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_89553e28-d942-44b7-90f5-99a218241436" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_86c08e01-f714-4f23-b47d-5414000d5f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1b9600e6-828e-45dc-be6c-2b387f94a400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_89553e28-d942-44b7-90f5-99a218241436" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1b9600e6-828e-45dc-be6c-2b387f94a400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1bd79723-1154-4372-ba48-dc3eb21ec11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_89553e28-d942-44b7-90f5-99a218241436" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1bd79723-1154-4372-ba48-dc3eb21ec11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_94178c5f-127a-4008-b98a-20984915e4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_89553e28-d942-44b7-90f5-99a218241436" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_94178c5f-127a-4008-b98a-20984915e4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#IncomeTaxesComponentsofLossDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b96b799f-578d-43d3-8602-a40d6a4ecffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_b248d6f4-d29b-4b36-ab4c-46d14a461f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b96b799f-578d-43d3-8602-a40d6a4ecffb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_b248d6f4-d29b-4b36-ab4c-46d14a461f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d2ecbe7b-4b3a-49c2-809a-954ba202fefc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_b248d6f4-d29b-4b36-ab4c-46d14a461f9d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d2ecbe7b-4b3a-49c2-809a-954ba202fefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9cdcf0d4-e606-4554-8963-989cd6b686d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_b248d6f4-d29b-4b36-ab4c-46d14a461f9d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9cdcf0d4-e606-4554-8963-989cd6b686d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12c53420-6b0a-435b-8efc-72e07e12e7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_b248d6f4-d29b-4b36-ab4c-46d14a461f9d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12c53420-6b0a-435b-8efc-72e07e12e7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#IncomeTaxesIncomeTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_60a26ff7-8434-413d-abbe-ca49c4cb11a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_c8d17c4b-fee8-4e0a-bf29-5a1170cd8633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_60a26ff7-8434-413d-abbe-ca49c4cb11a9" xlink:to="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_c8d17c4b-fee8-4e0a-bf29-5a1170cd8633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_87b934e5-f2c2-4dc9-b3df-b92dd5d15525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_c8d17c4b-fee8-4e0a-bf29-5a1170cd8633" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_87b934e5-f2c2-4dc9-b3df-b92dd5d15525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a1a33672-0b29-43ed-a867-fe09b690dcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_87b934e5-f2c2-4dc9-b3df-b92dd5d15525" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a1a33672-0b29-43ed-a867-fe09b690dcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7dd380da-c6ab-4e24-b49d-9b74b1ed65fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_87b934e5-f2c2-4dc9-b3df-b92dd5d15525" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7dd380da-c6ab-4e24-b49d-9b74b1ed65fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ae5f5610-5ea5-4c5b-b381-96335dde86d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_87b934e5-f2c2-4dc9-b3df-b92dd5d15525" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ae5f5610-5ea5-4c5b-b381-96335dde86d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_76f95c0b-70d4-4f1a-9f0a-f8becdbd5929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_c8d17c4b-fee8-4e0a-bf29-5a1170cd8633" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_76f95c0b-70d4-4f1a-9f0a-f8becdbd5929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_32fe8d7b-92cf-4c73-8902-f419ae26147f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_76f95c0b-70d4-4f1a-9f0a-f8becdbd5929" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_32fe8d7b-92cf-4c73-8902-f419ae26147f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b9c6ab3e-f275-4230-96fe-9108b7233536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_76f95c0b-70d4-4f1a-9f0a-f8becdbd5929" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b9c6ab3e-f275-4230-96fe-9108b7233536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_be3c40c5-56fc-46e1-a864-9fab9d009c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_76f95c0b-70d4-4f1a-9f0a-f8becdbd5929" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_be3c40c5-56fc-46e1-a864-9fab9d009c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_addb14b3-6806-4e98-bd24-3724a1f617c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_c8d17c4b-fee8-4e0a-bf29-5a1170cd8633" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_addb14b3-6806-4e98-bd24-3724a1f617c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8ef8445c-df02-4d12-884a-0da644b45e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b186a8ff-0aa9-419a-affb-cb96e0fc64f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8ef8445c-df02-4d12-884a-0da644b45e67" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b186a8ff-0aa9-419a-affb-cb96e0fc64f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6cfcb537-0345-40b0-be0b-8d6a4c2f8dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b186a8ff-0aa9-419a-affb-cb96e0fc64f5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6cfcb537-0345-40b0-be0b-8d6a4c2f8dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_cae2abc2-bd96-4a08-bfba-3ddd370a8e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b186a8ff-0aa9-419a-affb-cb96e0fc64f5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_cae2abc2-bd96-4a08-bfba-3ddd370a8e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_88ab4c1e-899b-4669-854f-70b801ad34ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b186a8ff-0aa9-419a-affb-cb96e0fc64f5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_88ab4c1e-899b-4669-854f-70b801ad34ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_bd4c5f70-1517-44bd-8474-c07cad843be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b186a8ff-0aa9-419a-affb-cb96e0fc64f5" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_bd4c5f70-1517-44bd-8474-c07cad843be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_94c8438d-d02d-423b-8e61-05accfa90a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b186a8ff-0aa9-419a-affb-cb96e0fc64f5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_94c8438d-d02d-423b-8e61-05accfa90a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e34f6c29-0352-4346-9199-2cdb97dc7bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b186a8ff-0aa9-419a-affb-cb96e0fc64f5" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e34f6c29-0352-4346-9199-2cdb97dc7bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ca109536-4bed-4ca5-bd5e-aee0973a0ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b186a8ff-0aa9-419a-affb-cb96e0fc64f5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ca109536-4bed-4ca5-bd5e-aee0973a0ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_327c8ea0-8219-4943-9333-35693374f28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8ef8445c-df02-4d12-884a-0da644b45e67" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_327c8ea0-8219-4943-9333-35693374f28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_14583abf-63c1-44cc-89e4-422f0f6ad679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_327c8ea0-8219-4943-9333-35693374f28f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_14583abf-63c1-44cc-89e4-422f0f6ad679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a1f90b89-774c-4d8a-8235-077626c2d869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_327c8ea0-8219-4943-9333-35693374f28f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_a1f90b89-774c-4d8a-8235-077626c2d869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2dfa8d1e-86e7-42ec-bbf0-91b6f1373f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8ef8445c-df02-4d12-884a-0da644b45e67" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2dfa8d1e-86e7-42ec-bbf0-91b6f1373f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_fbee8831-8403-43a1-a4d6-893bfb70c73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8ef8445c-df02-4d12-884a-0da644b45e67" xlink:to="loc_us-gaap_DeferredTaxLiabilities_fbee8831-8403-43a1-a4d6-893bfb70c73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2310e9cc-9bcf-4320-a152-7117e669aa14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_fcf69cdd-0df8-40a0-9d25-c763a3eb6ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2310e9cc-9bcf-4320-a152-7117e669aa14" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_fcf69cdd-0df8-40a0-9d25-c763a3eb6ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_217f2d47-a686-41a9-b681-7def10d15c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fcf69cdd-0df8-40a0-9d25-c763a3eb6ead" xlink:to="loc_us-gaap_TaxPeriodAxis_217f2d47-a686-41a9-b681-7def10d15c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_0e93ec67-e287-4567-8e2f-6721b6e2a2be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_217f2d47-a686-41a9-b681-7def10d15c6a" xlink:to="loc_us-gaap_TaxPeriodDomain_0e93ec67-e287-4567-8e2f-6721b6e2a2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TaxPeriodOneMember_c77953ab-ef69-4bc2-b79a-20a8a88a5026" xlink:href="ango-20230531.xsd#ango_TaxPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_0e93ec67-e287-4567-8e2f-6721b6e2a2be" xlink:to="loc_ango_TaxPeriodOneMember_c77953ab-ef69-4bc2-b79a-20a8a88a5026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TaxPeriodTwoMember_26a93470-03b1-4227-8b8b-d63821472126" xlink:href="ango-20230531.xsd#ango_TaxPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_0e93ec67-e287-4567-8e2f-6721b6e2a2be" xlink:to="loc_ango_TaxPeriodTwoMember_26a93470-03b1-4227-8b8b-d63821472126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TaxPeriodFourMember_97484d6a-6eb3-48fd-a39a-aa660cf35e62" xlink:href="ango-20230531.xsd#ango_TaxPeriodFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_0e93ec67-e287-4567-8e2f-6721b6e2a2be" xlink:to="loc_ango_TaxPeriodFourMember_97484d6a-6eb3-48fd-a39a-aa660cf35e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TaxPeriodThreeMember_4a9b186e-2f73-47c2-ba11-2df4ba30b810" xlink:href="ango-20230531.xsd#ango_TaxPeriodThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_0e93ec67-e287-4567-8e2f-6721b6e2a2be" xlink:to="loc_ango_TaxPeriodThreeMember_4a9b186e-2f73-47c2-ba11-2df4ba30b810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_295a5314-4d84-4b05-80c3-a83623e5e517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fcf69cdd-0df8-40a0-9d25-c763a3eb6ead" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_295a5314-4d84-4b05-80c3-a83623e5e517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9b8075a7-7a8e-4c2a-8ba8-e0f3a907e408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_295a5314-4d84-4b05-80c3-a83623e5e517" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9b8075a7-7a8e-4c2a-8ba8-e0f3a907e408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6cf3e349-bc57-4509-b51b-811c203868fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9b8075a7-7a8e-4c2a-8ba8-e0f3a907e408" xlink:to="loc_us-gaap_DomesticCountryMember_6cf3e349-bc57-4509-b51b-811c203868fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_25d3a03d-0734-4d06-a17c-13cdc4df114d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9b8075a7-7a8e-4c2a-8ba8-e0f3a907e408" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_25d3a03d-0734-4d06-a17c-13cdc4df114d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IsraelTaxAuthorityMember_cb69b127-5f16-4fb9-9361-b8332ab012b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9b8075a7-7a8e-4c2a-8ba8-e0f3a907e408" xlink:to="loc_us-gaap_IsraelTaxAuthorityMember_cb69b127-5f16-4fb9-9361-b8332ab012b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b327b751-86e8-4c53-8fd8-18e1775b4add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fcf69cdd-0df8-40a0-9d25-c763a3eb6ead" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b327b751-86e8-4c53-8fd8-18e1775b4add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88ae947b-087c-4504-a4d1-ba389e9028aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b327b751-86e8-4c53-8fd8-18e1775b4add" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88ae947b-087c-4504-a4d1-ba389e9028aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EximoMedicalLtd.Member_270482af-e66e-4dff-9f8f-24eb906049df" xlink:href="ango-20230531.xsd#ango_EximoMedicalLtd.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88ae947b-087c-4504-a4d1-ba389e9028aa" xlink:to="loc_ango_EximoMedicalLtd.Member_270482af-e66e-4dff-9f8f-24eb906049df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ScheduleofIncomeTaxLineItems_ee603ea7-d48c-4d40-b409-f80e1dc4fa4f" xlink:href="ango-20230531.xsd#ango_ScheduleofIncomeTaxLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_fcf69cdd-0df8-40a0-9d25-c763a3eb6ead" xlink:to="loc_ango_ScheduleofIncomeTaxLineItems_ee603ea7-d48c-4d40-b409-f80e1dc4fa4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:href="ango-20230531.xsd#ango_IncomeTaxesTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_ScheduleofIncomeTaxLineItems_ee603ea7-d48c-4d40-b409-f80e1dc4fa4f" xlink:to="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment_31890979-e39f-4eca-87cc-e3c7a999f7d7" xlink:href="ango-20230531.xsd#ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:to="loc_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment_31890979-e39f-4eca-87cc-e3c7a999f7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse_4d69c8b3-20eb-43f0-a3e0-a8191333dcd3" xlink:href="ango-20230531.xsd#ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:to="loc_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse_4d69c8b3-20eb-43f0-a3e0-a8191333dcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_406ea132-fa1e-4475-b17c-f0a58ac03737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_406ea132-fa1e-4475-b17c-f0a58ac03737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_20a220b5-e8de-498d-8ed5-354792d6b99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_20a220b5-e8de-498d-8ed5-354792d6b99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cf2d1898-1afd-42e9-af83-7d24f642722e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:to="loc_us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cf2d1898-1afd-42e9-af83-7d24f642722e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_85df5f7f-488f-49a3-8633-4e7df90aec77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_IncomeTaxesTextualAbstract_cdf7e3fc-299e-4ed5-9ad5-a3abe41a897a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_85df5f7f-488f-49a3-8633-4e7df90aec77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#IncomeTaxesIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_325b6d97-03fb-4ea4-af3f-55788521ad57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_11d926d9-a743-41df-b03c-4147063e8da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_325b6d97-03fb-4ea4-af3f-55788521ad57" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_11d926d9-a743-41df-b03c-4147063e8da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_f08e0212-f7ba-4db5-92ea-875b90d2998a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_11d926d9-a743-41df-b03c-4147063e8da6" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_f08e0212-f7ba-4db5-92ea-875b90d2998a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_b3faaa01-3191-44cb-89bc-7be80e4d1f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_11d926d9-a743-41df-b03c-4147063e8da6" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_b3faaa01-3191-44cb-89bc-7be80e4d1f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IncomeTaxReconciliationEffectOfForeignOperations_80d4abd5-8198-4976-8d1e-7c87b75d5ecd" xlink:href="ango-20230531.xsd#ango_IncomeTaxReconciliationEffectOfForeignOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_11d926d9-a743-41df-b03c-4147063e8da6" xlink:to="loc_ango_IncomeTaxReconciliationEffectOfForeignOperations_80d4abd5-8198-4976-8d1e-7c87b75d5ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_c90b1270-c3c4-4ab1-86e4-5a3bbdeed273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_11d926d9-a743-41df-b03c-4147063e8da6" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_c90b1270-c3c4-4ab1-86e4-5a3bbdeed273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_95cccba6-8e46-40e3-91ad-f09196030a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_11d926d9-a743-41df-b03c-4147063e8da6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_95cccba6-8e46-40e3-91ad-f09196030a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_4a673557-cb7f-4835-93a6-110112dc551f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_11d926d9-a743-41df-b03c-4147063e8da6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_4a673557-cb7f-4835-93a6-110112dc551f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_0c8d6a5b-4f39-4c04-ab2e-a482fdef224f" xlink:href="ango-20230531.xsd#ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_11d926d9-a743-41df-b03c-4147063e8da6" xlink:to="loc_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_0c8d6a5b-4f39-4c04-ab2e-a482fdef224f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d2ff4f39-29ac-4840-b04a-ced21cd76e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_11d926d9-a743-41df-b03c-4147063e8da6" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d2ff4f39-29ac-4840-b04a-ced21cd76e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool_58380b8f-37ba-42db-860c-3b3149138693" xlink:href="ango-20230531.xsd#ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_11d926d9-a743-41df-b03c-4147063e8da6" xlink:to="loc_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool_58380b8f-37ba-42db-860c-3b3149138693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_c90066f7-1b48-475c-88a7-75d27259bad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_11d926d9-a743-41df-b03c-4147063e8da6" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_c90066f7-1b48-475c-88a7-75d27259bad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4e07e9bb-036e-4129-9a93-683c5917280d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_11d926d9-a743-41df-b03c-4147063e8da6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4e07e9bb-036e-4129-9a93-683c5917280d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#IncomeTaxesIncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_156c1475-2aa3-4124-b893-2654e6079cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_90d16f6f-e45d-419d-a560-84b3c52f5bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_156c1475-2aa3-4124-b893-2654e6079cf4" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_90d16f6f-e45d-419d-a560-84b3c52f5bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c04ccab4-0a0a-4f5b-a77a-3acee20ef2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_90d16f6f-e45d-419d-a560-84b3c52f5bc1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c04ccab4-0a0a-4f5b-a77a-3acee20ef2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_bf0ada64-753d-4cdd-8c9d-71ea98df7045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_90d16f6f-e45d-419d-a560-84b3c52f5bc1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_bf0ada64-753d-4cdd-8c9d-71ea98df7045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_242add9c-1c2c-4de4-bc4e-33de83c97809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_90d16f6f-e45d-419d-a560-84b3c52f5bc1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_242add9c-1c2c-4de4-bc4e-33de83c97809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d48d499b-48a5-47a1-87e7-61220df27a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_90d16f6f-e45d-419d-a560-84b3c52f5bc1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d48d499b-48a5-47a1-87e7-61220df27a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7feee165-785c-42b9-9c01-8a74df9451d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_54a20af2-0182-4682-bdc0-dfc3ba801846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7feee165-785c-42b9-9c01-8a74df9451d2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_54a20af2-0182-4682-bdc0-dfc3ba801846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_abf2a966-6db3-4dba-9402-9005c33b6ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_54a20af2-0182-4682-bdc0-dfc3ba801846" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_abf2a966-6db3-4dba-9402-9005c33b6ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_85199ba7-f07a-48c7-a4fd-5e2b8f36a52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_54a20af2-0182-4682-bdc0-dfc3ba801846" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_85199ba7-f07a-48c7-a4fd-5e2b8f36a52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_ad9975e2-261a-40da-972c-43aa0936dd52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_54a20af2-0182-4682-bdc0-dfc3ba801846" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_ad9975e2-261a-40da-972c-43aa0936dd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AccruedResearchAndDevelopmentCurrent_70f65880-2f00-47b3-acf4-242d3f53b2e7" xlink:href="ango-20230531.xsd#ango_AccruedResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_54a20af2-0182-4682-bdc0-dfc3ba801846" xlink:to="loc_ango_AccruedResearchAndDevelopmentCurrent_70f65880-2f00-47b3-acf4-242d3f53b2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_7d47bd58-0d7b-46b5-997a-bb284f8e3ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_54a20af2-0182-4682-bdc0-dfc3ba801846" xlink:to="loc_us-gaap_RestructuringReserveCurrent_7d47bd58-0d7b-46b5-997a-bb284f8e3ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_2b99d296-cd71-4596-9fc5-da1ff1f67a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_54a20af2-0182-4682-bdc0-dfc3ba801846" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_2b99d296-cd71-4596-9fc5-da1ff1f67a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_fcdcec44-20ad-4382-92c8-8fb2568d99fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_54a20af2-0182-4682-bdc0-dfc3ba801846" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_fcdcec44-20ad-4382-92c8-8fb2568d99fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_934c0a03-7536-49d8-abbf-f814ed05c9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_54a20af2-0182-4682-bdc0-dfc3ba801846" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_934c0a03-7536-49d8-abbf-f814ed05c9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f17ea2aa-ae28-4d8e-ba5a-518d485c5487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_54a20af2-0182-4682-bdc0-dfc3ba801846" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f17ea2aa-ae28-4d8e-ba5a-518d485c5487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#LongTermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f6b44256-bb91-4850-93a6-f5af794c02d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fabdb0fb-cbce-4635-b527-481af827be5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f6b44256-bb91-4850-93a6-f5af794c02d0" xlink:to="loc_us-gaap_DebtInstrumentTable_fabdb0fb-cbce-4635-b527-481af827be5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_85578d6a-a859-4e51-a849-13e05aea5b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fabdb0fb-cbce-4635-b527-481af827be5a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_85578d6a-a859-4e51-a849-13e05aea5b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_42821bd2-9555-4752-bdf0-cb0ed061590d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85578d6a-a859-4e51-a849-13e05aea5b32" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_42821bd2-9555-4752-bdf0-cb0ed061590d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6415959f-213f-4c8d-b812-fab7ba47fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_42821bd2-9555-4752-bdf0-cb0ed061590d" xlink:to="loc_us-gaap_LineOfCreditMember_6415959f-213f-4c8d-b812-fab7ba47fd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f234a88e-367d-4db6-b881-bb2e21bb9a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fabdb0fb-cbce-4635-b527-481af827be5a" xlink:to="loc_us-gaap_CreditFacilityAxis_f234a88e-367d-4db6-b881-bb2e21bb9a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c2940d3f-9517-4499-a9cc-19485b0bf0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f234a88e-367d-4db6-b881-bb2e21bb9a8f" xlink:to="loc_us-gaap_CreditFacilityDomain_c2940d3f-9517-4499-a9cc-19485b0bf0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_529ee02e-b32f-4902-bab5-9e65e36e2ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c2940d3f-9517-4499-a9cc-19485b0bf0e7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_529ee02e-b32f-4902-bab5-9e65e36e2ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d78bd2d4-c89f-4b7d-865f-9630e7444b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c2940d3f-9517-4499-a9cc-19485b0bf0e7" xlink:to="loc_us-gaap_SecuredDebtMember_d78bd2d4-c89f-4b7d-865f-9630e7444b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2248dd82-f8a6-414b-8d88-5674b893bba9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fabdb0fb-cbce-4635-b527-481af827be5a" xlink:to="loc_srt_RangeAxis_2248dd82-f8a6-414b-8d88-5674b893bba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea1c4818-5353-443e-baad-8e8ba5b309f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2248dd82-f8a6-414b-8d88-5674b893bba9" xlink:to="loc_srt_RangeMember_ea1c4818-5353-443e-baad-8e8ba5b309f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e6812cc5-7a65-40c5-8672-4d424bba6d0c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ea1c4818-5353-443e-baad-8e8ba5b309f7" xlink:to="loc_srt_MinimumMember_e6812cc5-7a65-40c5-8672-4d424bba6d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0ca540d9-1be4-40cd-b8bd-e64a96c1b9d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ea1c4818-5353-443e-baad-8e8ba5b309f7" xlink:to="loc_srt_MaximumMember_0ca540d9-1be4-40cd-b8bd-e64a96c1b9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6c31a571-6253-4403-aa36-e8d963c19d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fabdb0fb-cbce-4635-b527-481af827be5a" xlink:to="loc_us-gaap_VariableRateAxis_6c31a571-6253-4403-aa36-e8d963c19d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d37faed8-646b-4a11-be65-7b9ae62590a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_6c31a571-6253-4403-aa36-e8d963c19d3d" xlink:to="loc_us-gaap_VariableRateDomain_d37faed8-646b-4a11-be65-7b9ae62590a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_0b2a1aae-21f8-4ec2-b823-16f9f5f2fe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_d37faed8-646b-4a11-be65-7b9ae62590a9" xlink:to="loc_us-gaap_BaseRateMember_0b2a1aae-21f8-4ec2-b823-16f9f5f2fe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_78e8524d-8b30-442e-832a-ba9a0450476c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_d37faed8-646b-4a11-be65-7b9ae62590a9" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_78e8524d-8b30-442e-832a-ba9a0450476c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fabdb0fb-cbce-4635-b527-481af827be5a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_27547d7f-b37b-4e31-b64f-729e4cb9ba17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_27547d7f-b37b-4e31-b64f-729e4cb9ba17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature_7971c2d2-873c-4fb9-bedc-d58e0c8bd539" xlink:href="ango-20230531.xsd#ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature_7971c2d2-873c-4fb9-bedc-d58e0c8bd539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_475beef9-8665-47c1-b890-d0a630f70987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_475beef9-8665-47c1-b890-d0a630f70987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentDebtDefaultInterestRateIncrease_9604bb3d-2026-4fdc-846a-4c01c8ff3e8c" xlink:href="ango-20230531.xsd#ango_DebtInstrumentDebtDefaultInterestRateIncrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_DebtInstrumentDebtDefaultInterestRateIncrease_9604bb3d-2026-4fdc-846a-4c01c8ff3e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_eedf546d-b72b-4e7a-a418-0d0cdc04b38f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_eedf546d-b72b-4e7a-a418-0d0cdc04b38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_LineOfCreditFacilityNumberOfCovenants_7bb96fad-1c92-45e8-9aa1-08040464a6f9" xlink:href="ango-20230531.xsd#ango_LineOfCreditFacilityNumberOfCovenants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_LineOfCreditFacilityNumberOfCovenants_7bb96fad-1c92-45e8-9aa1-08040464a6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio_9c274182-04d4-4446-b352-f4814fa2e57a" xlink:href="ango-20230531.xsd#ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio_9c274182-04d4-4446-b352-f4814fa2e57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions_c7794e4d-3efa-48c1-9906-d6c9713e281d" xlink:href="ango-20230531.xsd#ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions_c7794e4d-3efa-48c1-9906-d6c9713e281d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio_c3873515-b31f-4e44-9cc3-14d7fb61102a" xlink:href="ango-20230531.xsd#ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio_c3873515-b31f-4e44-9cc3-14d7fb61102a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_6fc051aa-401d-49b6-8ffd-9f186fea1158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_6fc051aa-401d-49b6-8ffd-9f186fea1158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_0bcceb4d-d089-4282-9572-c0e5786d416d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_DebtInstrumentTerm_0bcceb4d-d089-4282-9572-c0e5786d416d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8dd7fc10-76e6-4568-9a97-1f8f28916da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8dd7fc10-76e6-4568-9a97-1f8f28916da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ec5992ce-4e1a-4a4a-abfe-4858fa418da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ec5992ce-4e1a-4a4a-abfe-4858fa418da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DebtInstrumentFloorInterestRate_c303b64d-be40-4915-a44d-757c6673d7a5" xlink:href="ango-20230531.xsd#ango_DebtInstrumentFloorInterestRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_ango_DebtInstrumentFloorInterestRate_c303b64d-be40-4915-a44d-757c6673d7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_efa712e6-a35b-43fd-ae02-389f3dec6479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_LineOfCredit_efa712e6-a35b-43fd-ae02-389f3dec6479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_71750ec5-3e8d-4eff-bed8-480b9d5fdd84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de4e9dc3-2177-4192-866d-fb2af3e6d51e" xlink:to="loc_us-gaap_LongTermDebt_71750ec5-3e8d-4eff-bed8-480b9d5fdd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#LongTermDebtLongTermDebtScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7e762100-c55e-49d5-ba05-f4b5ccc6825f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0498a261-e282-41cb-bddf-37311185e1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7e762100-c55e-49d5-ba05-f4b5ccc6825f" xlink:to="loc_us-gaap_DebtInstrumentTable_0498a261-e282-41cb-bddf-37311185e1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_142f80c3-4ecb-4dd0-9322-ab9763891665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0498a261-e282-41cb-bddf-37311185e1c2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_142f80c3-4ecb-4dd0-9322-ab9763891665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_667e9df8-b9b7-40c4-937d-f55d05a76da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_142f80c3-4ecb-4dd0-9322-ab9763891665" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_667e9df8-b9b7-40c4-937d-f55d05a76da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_3490d48a-7ccc-489a-a960-2c10e0669685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_667e9df8-b9b7-40c4-937d-f55d05a76da2" xlink:to="loc_us-gaap_LineOfCreditMember_3490d48a-7ccc-489a-a960-2c10e0669685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_15e071ff-46f4-48c9-85d5-aae5fdec33d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_667e9df8-b9b7-40c4-937d-f55d05a76da2" xlink:to="loc_us-gaap_LoansPayableMember_15e071ff-46f4-48c9-85d5-aae5fdec33d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6379ad83-0f1f-4470-9fe5-3da259429161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0498a261-e282-41cb-bddf-37311185e1c2" xlink:to="loc_us-gaap_DebtInstrumentAxis_6379ad83-0f1f-4470-9fe5-3da259429161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fad38654-2784-42fa-ada2-5392fe2fe47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6379ad83-0f1f-4470-9fe5-3da259429161" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fad38654-2784-42fa-ada2-5392fe2fe47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RevolvingFacilityMember_02b2133b-5e06-4ea3-90cd-82fa96e9e6b2" xlink:href="ango-20230531.xsd#ango_RevolvingFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fad38654-2784-42fa-ada2-5392fe2fe47e" xlink:to="loc_ango_RevolvingFacilityMember_02b2133b-5e06-4ea3-90cd-82fa96e9e6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f266aefc-519a-44a3-8cec-6c3bf0e04312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0498a261-e282-41cb-bddf-37311185e1c2" xlink:to="loc_us-gaap_CreditFacilityAxis_f266aefc-519a-44a3-8cec-6c3bf0e04312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2a01fd18-165f-4974-99ac-39f5d329038c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f266aefc-519a-44a3-8cec-6c3bf0e04312" xlink:to="loc_us-gaap_CreditFacilityDomain_2a01fd18-165f-4974-99ac-39f5d329038c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ae725ba4-0700-462f-b480-27292b7ddbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2a01fd18-165f-4974-99ac-39f5d329038c" xlink:to="loc_us-gaap_SecuredDebtMember_ae725ba4-0700-462f-b480-27292b7ddbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a998ed0f-3c22-4d8e-86ce-c6645fc75047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0498a261-e282-41cb-bddf-37311185e1c2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a998ed0f-3c22-4d8e-86ce-c6645fc75047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0d9bfe3d-17d9-45fb-88ce-f8ed85c2a617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a998ed0f-3c22-4d8e-86ce-c6645fc75047" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0d9bfe3d-17d9-45fb-88ce-f8ed85c2a617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8647d651-87fe-4590-970a-cb091465c4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a998ed0f-3c22-4d8e-86ce-c6645fc75047" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8647d651-87fe-4590-970a-cb091465c4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b80fc91d-8df6-424d-9f44-374067b75cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a998ed0f-3c22-4d8e-86ce-c6645fc75047" xlink:to="loc_us-gaap_LongTermDebt_b80fc91d-8df6-424d-9f44-374067b75cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/RetirementPlansDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#RetirementPlansDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/RetirementPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_607bfaa6-0d2d-481f-ad64-d7ce1054787c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RetirementPlansTextualAbstract_c9e9065e-9d32-4227-9995-dd60bacf350a" xlink:href="ango-20230531.xsd#ango_RetirementPlansTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_607bfaa6-0d2d-481f-ad64-d7ce1054787c" xlink:to="loc_ango_RetirementPlansTextualAbstract_c9e9065e-9d32-4227-9995-dd60bacf350a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_b03f1c00-7f2d-4992-81d3-e6e66c89e450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ango_RetirementPlansTextualAbstract_c9e9065e-9d32-4227-9995-dd60bacf350a" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_b03f1c00-7f2d-4992-81d3-e6e66c89e450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0d0608b4-5dc3-4065-8fd5-af60ce18e841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_6efcc407-3eb7-4346-a3cd-f4ac35e91508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0d0608b4-5dc3-4065-8fd5-af60ce18e841" xlink:to="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_6efcc407-3eb7-4346-a3cd-f4ac35e91508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fdca4444-39ab-4de5-b244-484981fdd7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_6efcc407-3eb7-4346-a3cd-f4ac35e91508" xlink:to="loc_us-gaap_PlanNameAxis_fdca4444-39ab-4de5-b244-484981fdd7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4e20cfbc-b61e-43c9-88fb-9cd362d17b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_fdca4444-39ab-4de5-b244-484981fdd7eb" xlink:to="loc_us-gaap_PlanNameDomain_4e20cfbc-b61e-43c9-88fb-9cd362d17b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember_c58d5b86-22bb-41ba-a592-5369bfd66392" xlink:href="ango-20230531.xsd#ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4e20cfbc-b61e-43c9-88fb-9cd362d17b48" xlink:to="loc_ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember_c58d5b86-22bb-41ba-a592-5369bfd66392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_StockPurchasePlanMember_18ec1062-5e55-4fbd-bb5f-9c4117401b1f" xlink:href="ango-20230531.xsd#ango_StockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4e20cfbc-b61e-43c9-88fb-9cd362d17b48" xlink:to="loc_ango_StockPurchasePlanMember_18ec1062-5e55-4fbd-bb5f-9c4117401b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_StockAndIncentiveAwardPlan2020Member_e9a393cb-d34f-4f85-84a3-f5cbc7ea1208" xlink:href="ango-20230531.xsd#ango_StockAndIncentiveAwardPlan2020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4e20cfbc-b61e-43c9-88fb-9cd362d17b48" xlink:to="loc_ango_StockAndIncentiveAwardPlan2020Member_e9a393cb-d34f-4f85-84a3-f5cbc7ea1208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EmployeeStockPurchasePlanMember_11c10f6d-3765-4350-897c-2a55940c20ac" xlink:href="ango-20230531.xsd#ango_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4e20cfbc-b61e-43c9-88fb-9cd362d17b48" xlink:to="loc_ango_EmployeeStockPurchasePlanMember_11c10f6d-3765-4350-897c-2a55940c20ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_ed2503d0-4d61-409b-bc01-00713d4cc0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_6efcc407-3eb7-4346-a3cd-f4ac35e91508" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_ed2503d0-4d61-409b-bc01-00713d4cc0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4c7297d3-0365-40c1-931d-6e487ab4f27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_ed2503d0-4d61-409b-bc01-00713d4cc0a5" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4c7297d3-0365-40c1-931d-6e487ab4f27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2043236a-ce03-4758-9eee-b5ee6e8d61a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4c7297d3-0365-40c1-931d-6e487ab4f27b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2043236a-ce03-4758-9eee-b5ee6e8d61a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7662577c-38fd-40f6-982d-bfbc3961d89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_6efcc407-3eb7-4346-a3cd-f4ac35e91508" xlink:to="loc_us-gaap_AwardTypeAxis_7662577c-38fd-40f6-982d-bfbc3961d89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ff94a68-3880-4291-a7f2-0a9131b39f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7662577c-38fd-40f6-982d-bfbc3961d89d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ff94a68-3880-4291-a7f2-0a9131b39f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3a0a0079-017a-43e5-82c6-43740a29b7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ff94a68-3880-4291-a7f2-0a9131b39f5b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3a0a0079-017a-43e5-82c6-43740a29b7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b09c2f3e-1a0c-4a5f-99e8-6f6c8148f9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ff94a68-3880-4291-a7f2-0a9131b39f5b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b09c2f3e-1a0c-4a5f-99e8-6f6c8148f9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PerformanceShareAndRestrictedStockUnitAwardsMember_2ddde8b4-b199-4019-be8b-a4da3253b422" xlink:href="ango-20230531.xsd#ango_PerformanceShareAndRestrictedStockUnitAwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ff94a68-3880-4291-a7f2-0a9131b39f5b" xlink:to="loc_ango_PerformanceShareAndRestrictedStockUnitAwardsMember_2ddde8b4-b199-4019-be8b-a4da3253b422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PerformanceSharesIncludingThreeYearMarketConditionMember_a2da4378-d9ba-42e5-b689-55c4948d73d8" xlink:href="ango-20230531.xsd#ango_PerformanceSharesIncludingThreeYearMarketConditionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ff94a68-3880-4291-a7f2-0a9131b39f5b" xlink:to="loc_ango_PerformanceSharesIncludingThreeYearMarketConditionMember_a2da4378-d9ba-42e5-b689-55c4948d73d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_6efcc407-3eb7-4346-a3cd-f4ac35e91508" xlink:to="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CapitalStockSharesAuthorized_bca13f8e-45f8-4bce-b4d5-86320e39a471" xlink:href="ango-20230531.xsd#ango_CapitalStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_CapitalStockSharesAuthorized_bca13f8e-45f8-4bce-b4d5-86320e39a471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e58cfd34-a7d6-4b69-a5b4-b84a6019b2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e58cfd34-a7d6-4b69-a5b4-b84a6019b2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ecb2710e-7f0f-400d-8e36-81b4df70f6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ecb2710e-7f0f-400d-8e36-81b4df70f6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4d81e0e5-a9dd-4ef7-974f-4f1b5c318e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4d81e0e5-a9dd-4ef7-974f-4f1b5c318e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_dfb662bc-00eb-4443-b1d1-985af3d6ea1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_dfb662bc-00eb-4443-b1d1-985af3d6ea1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CommonStockVotesPerShare_3c996854-a004-4c17-be16-93cc1eeeb2f8" xlink:href="ango-20230531.xsd#ango_CommonStockVotesPerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_CommonStockVotesPerShare_3c996854-a004-4c17-be16-93cc1eeeb2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_28966329-efb2-40a3-9a00-742da21e0914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_28966329-efb2-40a3-9a00-742da21e0914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage_734613d6-0bbb-444b-878f-6ebde62078f5" xlink:href="ango-20230531.xsd#ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage_734613d6-0bbb-444b-878f-6ebde62078f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1_196334b2-d98b-44fe-8b7f-a9a7614e90f9" xlink:href="ango-20230531.xsd#ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1_196334b2-d98b-44fe-8b7f-a9a7614e90f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_84784755-8589-4d34-9b60-3aa921ef842e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_84784755-8589-4d34-9b60-3aa921ef842e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fbb3b9cd-732e-4e34-9cf3-b8712805903e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fbb3b9cd-732e-4e34-9cf3-b8712805903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8455130b-06a6-4403-953e-4bf5582f8a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8455130b-06a6-4403-953e-4bf5582f8a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0db727c2-072c-4da5-8487-4635f68aa488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0db727c2-072c-4da5-8487-4635f68aa488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1bfb4aa4-2aa9-4f5b-8584-d7034b9330b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1bfb4aa4-2aa9-4f5b-8584-d7034b9330b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cf377705-e849-456b-b1f5-aea5d6cad641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cf377705-e849-456b-b1f5-aea5d6cad641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a83ed4e7-aa14-4f6f-9c65-cc4af158144a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a83ed4e7-aa14-4f6f-9c65-cc4af158144a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_07b16c38-7ee1-4231-9c57-7ce6abe415c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_07b16c38-7ee1-4231-9c57-7ce6abe415c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_352148d9-a358-4b3a-abf6-37423a0eab84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_352148d9-a358-4b3a-abf6-37423a0eab84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69b847d3-76b1-4d29-b0ba-3435b3784a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69b847d3-76b1-4d29-b0ba-3435b3784a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f93d3229-e27a-450a-a339-0d5e52308b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f93d3229-e27a-450a-a339-0d5e52308b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_572cd612-5eb4-4424-9eed-72d43160327f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_572cd612-5eb4-4424-9eed-72d43160327f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f88b0f5-b05a-421e-bc16-2411f679d273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f88b0f5-b05a-421e-bc16-2411f679d273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod_798f609e-fb1b-4c54-a5e3-803bee87a291" xlink:href="ango-20230531.xsd#ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod_798f609e-fb1b-4c54-a5e3-803bee87a291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_38146c48-e021-4d85-a7f3-2d57c43818ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_38146c48-e021-4d85-a7f3-2d57c43818ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_730b9af3-d8ed-4761-86bc-fd4e9d4f12d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_730b9af3-d8ed-4761-86bc-fd4e9d4f12d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_NumberOfSharePurchasePeriod_9ea256d9-9a8a-4910-be23-0f6862214da9" xlink:href="ango-20230531.xsd#ango_NumberOfSharePurchasePeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_NumberOfSharePurchasePeriod_9ea256d9-9a8a-4910-be23-0f6862214da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharePurchasePeriod_8c7a1b65-0676-40c0-9b68-2b4644221f91" xlink:href="ango-20230531.xsd#ango_SharePurchasePeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_SharePurchasePeriod_8c7a1b65-0676-40c0-9b68-2b4644221f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EmployeePlanParticipatingEligibilityPeriod_bd62463b-a44a-4a8b-b21b-f2db9102bb6c" xlink:href="ango-20230531.xsd#ango_EmployeePlanParticipatingEligibilityPeriod"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_EmployeePlanParticipatingEligibilityPeriod_bd62463b-a44a-4a8b-b21b-f2db9102bb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible_1db370ab-8960-49be-8ae2-455d1a8bd2a3" xlink:href="ango-20230531.xsd#ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible_1db370ab-8960-49be-8ae2-455d1a8bd2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible_0204540c-cb41-414d-bec1-46179519f7dd" xlink:href="ango-20230531.xsd#ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible_0204540c-cb41-414d-bec1-46179519f7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_EmployeePlanParticipatingEligibilityThresholdPercentage_ebe88cec-ba04-44bf-8714-37b069268d70" xlink:href="ango-20230531.xsd#ango_EmployeePlanParticipatingEligibilityThresholdPercentage"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_EmployeePlanParticipatingEligibilityThresholdPercentage_ebe88cec-ba04-44bf-8714-37b069268d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod_50a2a664-64fa-4374-bf14-b78e92fab3b8" xlink:href="ango-20230531.xsd#ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod_50a2a664-64fa-4374-bf14-b78e92fab3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4ab5fc89-20d5-438a-84df-e48de2e15825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4ab5fc89-20d5-438a-84df-e48de2e15825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_516ca3e8-a5ae-4263-a727-6784b78eb63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_516ca3e8-a5ae-4263-a727-6784b78eb63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6c39cc56-e9c3-4526-aa5b-a96814b75539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6c39cc56-e9c3-4526-aa5b-a96814b75539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_23e1ebc3-73cf-48fa-ac03-ebd9259ec542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_23e1ebc3-73cf-48fa-ac03-ebd9259ec542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d5cb9dac-ce33-45be-a93e-28cff0740ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d5cb9dac-ce33-45be-a93e-28cff0740ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_bc70f301-ae4f-4dd2-85eb-f8583a6ee2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_bc70f301-ae4f-4dd2-85eb-f8583a6ee2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_ebd9e0fd-d5a2-4db4-a54e-244827e81ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_d146b5e8-b0f9-41a3-bf76-6e1a7d2be12c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_ebd9e0fd-d5a2-4db4-a54e-244827e81ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dd5e8108-a519-4b71-b78d-8e7d89caf221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63595bd9-eff2-4c84-a39b-419fd0263a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd5e8108-a519-4b71-b78d-8e7d89caf221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63595bd9-eff2-4c84-a39b-419fd0263a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0c65d2ec-0315-4102-a997-91facb256535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63595bd9-eff2-4c84-a39b-419fd0263a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0c65d2ec-0315-4102-a997-91facb256535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90b09e52-d6aa-4223-ba24-57c4e5154ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63595bd9-eff2-4c84-a39b-419fd0263a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90b09e52-d6aa-4223-ba24-57c4e5154ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e3f07989-e2cc-48ee-b2ba-e96cb8734de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63595bd9-eff2-4c84-a39b-419fd0263a43" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e3f07989-e2cc-48ee-b2ba-e96cb8734de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ce82b2c9-8aa7-4c44-b514-17874f7c8468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63595bd9-eff2-4c84-a39b-419fd0263a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ce82b2c9-8aa7-4c44-b514-17874f7c8468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b5227cd8-c902-4052-b019-9ab9e12c41a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63595bd9-eff2-4c84-a39b-419fd0263a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b5227cd8-c902-4052-b019-9ab9e12c41a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59cac546-96a6-4658-b940-1371afe12efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_63595bd9-eff2-4c84-a39b-419fd0263a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59cac546-96a6-4658-b940-1371afe12efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_37aad7e1-39ae-47f4-843b-ecbe4050497c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd5e8108-a519-4b71-b78d-8e7d89caf221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_37aad7e1-39ae-47f4-843b-ecbe4050497c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f8b42618-02fe-4520-b21c-66759b1568e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd5e8108-a519-4b71-b78d-8e7d89caf221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f8b42618-02fe-4520-b21c-66759b1568e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c3a117be-6aaa-409a-b30f-fc046a9cdc41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd5e8108-a519-4b71-b78d-8e7d89caf221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c3a117be-6aaa-409a-b30f-fc046a9cdc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c2983584-45a0-44be-96cd-b7ce10c01965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c3a117be-6aaa-409a-b30f-fc046a9cdc41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c2983584-45a0-44be-96cd-b7ce10c01965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5cf6b701-bbc1-4170-ae20-f6a3ac4af014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c3a117be-6aaa-409a-b30f-fc046a9cdc41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5cf6b701-bbc1-4170-ae20-f6a3ac4af014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60f99b07-9cb0-4dec-a0f3-598dc1479a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c3a117be-6aaa-409a-b30f-fc046a9cdc41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60f99b07-9cb0-4dec-a0f3-598dc1479a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0fcee266-027b-48ca-9390-282b6a694bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c3a117be-6aaa-409a-b30f-fc046a9cdc41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0fcee266-027b-48ca-9390-282b6a694bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6829cec9-366c-4533-b3ff-06b4565621a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c3a117be-6aaa-409a-b30f-fc046a9cdc41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6829cec9-366c-4533-b3ff-06b4565621a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_993c87ce-e6e4-4a1c-95be-1eb82ef27456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c3a117be-6aaa-409a-b30f-fc046a9cdc41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_993c87ce-e6e4-4a1c-95be-1eb82ef27456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_63112dfd-e0f5-44fa-8d08-129ba1ca4ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd5e8108-a519-4b71-b78d-8e7d89caf221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_63112dfd-e0f5-44fa-8d08-129ba1ca4ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d3793105-5a37-436d-a22c-901ff10fec87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd5e8108-a519-4b71-b78d-8e7d89caf221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d3793105-5a37-436d-a22c-901ff10fec87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6599af76-5b9c-4d75-8701-1c8cdde0e94d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd5e8108-a519-4b71-b78d-8e7d89caf221" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6599af76-5b9c-4d75-8701-1c8cdde0e94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_144caa96-5070-4812-88ca-f9ac9cb0f622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd5e8108-a519-4b71-b78d-8e7d89caf221" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_144caa96-5070-4812-88ca-f9ac9cb0f622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f829c3c6-de08-446a-b240-80536bdbf386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd5e8108-a519-4b71-b78d-8e7d89caf221" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f829c3c6-de08-446a-b240-80536bdbf386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c8a66fc2-8876-48fa-9832-032d93f418e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd5e8108-a519-4b71-b78d-8e7d89caf221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c8a66fc2-8876-48fa-9832-032d93f418e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_af32ce97-ae30-405a-a4ce-7bb7109ce119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd5e8108-a519-4b71-b78d-8e7d89caf221" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_af32ce97-ae30-405a-a4ce-7bb7109ce119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_97d40a6c-f941-4fad-bf1b-07048c2b4333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd5e8108-a519-4b71-b78d-8e7d89caf221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_97d40a6c-f941-4fad-bf1b-07048c2b4333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/StockholdersEquityDetails2" xlink:type="simple" xlink:href="ango-20230531.xsd#StockholdersEquityDetails2"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/StockholdersEquityDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ee70cc1a-36d1-4c5a-a9a7-1e84adf1796e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ba6a24-3a90-403e-9e71-2e1c9e8fe833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ee70cc1a-36d1-4c5a-a9a7-1e84adf1796e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ba6a24-3a90-403e-9e71-2e1c9e8fe833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b038d0ee-db44-452c-a34b-c27168c5c4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ba6a24-3a90-403e-9e71-2e1c9e8fe833" xlink:to="loc_us-gaap_AwardTypeAxis_b038d0ee-db44-452c-a34b-c27168c5c4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0600b6d-a154-4d0e-b44e-e501baf356a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b038d0ee-db44-452c-a34b-c27168c5c4b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0600b6d-a154-4d0e-b44e-e501baf356a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5188e95e-3749-47a7-964e-3270bb7c3a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0600b6d-a154-4d0e-b44e-e501baf356a6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5188e95e-3749-47a7-964e-3270bb7c3a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d934b143-5568-4a0d-94aa-e7d27a0a5996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0600b6d-a154-4d0e-b44e-e501baf356a6" xlink:to="loc_us-gaap_PerformanceSharesMember_d934b143-5568-4a0d-94aa-e7d27a0a5996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5fb4507-6f4c-4f8c-8f89-bc5139f502cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ba6a24-3a90-403e-9e71-2e1c9e8fe833" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5fb4507-6f4c-4f8c-8f89-bc5139f502cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c35e7af-bf38-4684-a8b0-3a3f182f5fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5fb4507-6f4c-4f8c-8f89-bc5139f502cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c35e7af-bf38-4684-a8b0-3a3f182f5fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1aff90d7-3903-47d9-bf03-383d410bcfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c35e7af-bf38-4684-a8b0-3a3f182f5fb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1aff90d7-3903-47d9-bf03-383d410bcfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1f042967-f1b3-4c27-aa44-ce033f39e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c35e7af-bf38-4684-a8b0-3a3f182f5fb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1f042967-f1b3-4c27-aa44-ce033f39e58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_83e3c342-0851-4ca2-8de0-6341173d3fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c35e7af-bf38-4684-a8b0-3a3f182f5fb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_83e3c342-0851-4ca2-8de0-6341173d3fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_32854ca6-a83a-4734-a93e-668de265b5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c35e7af-bf38-4684-a8b0-3a3f182f5fb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_32854ca6-a83a-4734-a93e-668de265b5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f95c607f-d156-4bdb-b036-8bbcf0531245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c35e7af-bf38-4684-a8b0-3a3f182f5fb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f95c607f-d156-4bdb-b036-8bbcf0531245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67f62d09-a815-40c3-9ae1-28895d4822e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5fb4507-6f4c-4f8c-8f89-bc5139f502cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67f62d09-a815-40c3-9ae1-28895d4822e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6df28d28-3762-4afc-8617-2a0873bedea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67f62d09-a815-40c3-9ae1-28895d4822e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6df28d28-3762-4afc-8617-2a0873bedea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52587297-59ab-4c42-9b4b-6c4946c24c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67f62d09-a815-40c3-9ae1-28895d4822e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52587297-59ab-4c42-9b4b-6c4946c24c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_798aff5d-9c98-48fa-973f-80d51cfe368a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67f62d09-a815-40c3-9ae1-28895d4822e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_798aff5d-9c98-48fa-973f-80d51cfe368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0fa2d1ea-79bb-4415-acf4-6fa4f6fe765b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67f62d09-a815-40c3-9ae1-28895d4822e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0fa2d1ea-79bb-4415-acf4-6fa4f6fe765b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb2f933c-a834-4399-bd30-b8e2ef132901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67f62d09-a815-40c3-9ae1-28895d4822e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb2f933c-a834-4399-bd30-b8e2ef132901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#StockholdersEquityCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d2ab7d81-36f3-4171-a19c-d3bf675eac07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67409461-ec9b-46ac-a56f-c8ac857198d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d2ab7d81-36f3-4171-a19c-d3bf675eac07" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67409461-ec9b-46ac-a56f-c8ac857198d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a98b8e55-96c7-40c0-907f-f4b0c851aded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67409461-ec9b-46ac-a56f-c8ac857198d4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a98b8e55-96c7-40c0-907f-f4b0c851aded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_25206aa2-98fc-4693-a89a-f4a8def612cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a98b8e55-96c7-40c0-907f-f4b0c851aded" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_25206aa2-98fc-4693-a89a-f4a8def612cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_9a8effd3-d239-4950-985b-1a39595466ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25206aa2-98fc-4693-a89a-f4a8def612cc" xlink:to="loc_us-gaap_CostOfSalesMember_9a8effd3-d239-4950-985b-1a39595466ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ResearchAndDevelopmentMember_22d5c047-db52-4a2d-bfb2-9f417d14be23" xlink:href="ango-20230531.xsd#ango_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25206aa2-98fc-4693-a89a-f4a8def612cc" xlink:to="loc_ango_ResearchAndDevelopmentMember_22d5c047-db52-4a2d-bfb2-9f417d14be23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SalesandMarketingMember_9562be16-c39e-42da-a432-29c3e63bc509" xlink:href="ango-20230531.xsd#ango_SalesandMarketingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25206aa2-98fc-4693-a89a-f4a8def612cc" xlink:to="loc_ango_SalesandMarketingMember_9562be16-c39e-42da-a432-29c3e63bc509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2f801c26-0c5e-4d2f-a177-45ecc4ea94d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25206aa2-98fc-4693-a89a-f4a8def612cc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2f801c26-0c5e-4d2f-a177-45ecc4ea94d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b50d8538-7b96-41e4-8adb-2d1785875f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67409461-ec9b-46ac-a56f-c8ac857198d4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b50d8538-7b96-41e4-8adb-2d1785875f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b2748b55-c885-4077-9a28-5de84b88bf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b50d8538-7b96-41e4-8adb-2d1785875f9d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b2748b55-c885-4077-9a28-5de84b88bf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_83255a2f-f934-453f-aef1-2b2047c73f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3eff203e-a6e6-44a0-8ee0-269fa5329c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_83255a2f-f934-453f-aef1-2b2047c73f0b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3eff203e-a6e6-44a0-8ee0-269fa5329c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6e4f6a95-93b4-456a-bdc3-0e2e19b8952e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_83255a2f-f934-453f-aef1-2b2047c73f0b" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6e4f6a95-93b4-456a-bdc3-0e2e19b8952e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_29020b69-7911-4e71-823c-4b4bd8f91ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_83255a2f-f934-453f-aef1-2b2047c73f0b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_29020b69-7911-4e71-823c-4b4bd8f91ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1b274ff6-4bb2-4543-96f4-4e93f66e022a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_83255a2f-f934-453f-aef1-2b2047c73f0b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1b274ff6-4bb2-4543-96f4-4e93f66e022a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LeasesDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#LeasesDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1e5f89c6-a580-420e-8044-78a4d2c980f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2e420ca5-810b-4220-97fd-8f2fe723b9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e5f89c6-a580-420e-8044-78a4d2c980f3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2e420ca5-810b-4220-97fd-8f2fe723b9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_6b8ea9ca-ac09-4afa-8cc9-77ba54ca4991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e5f89c6-a580-420e-8044-78a4d2c980f3" xlink:to="loc_us-gaap_OperatingLeaseExpense_6b8ea9ca-ac09-4afa-8cc9-77ba54ca4991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4d7fd65b-0aa7-4fcd-9076-5cf7dd0e514b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e5f89c6-a580-420e-8044-78a4d2c980f3" xlink:to="loc_us-gaap_OperatingLeaseLiability_4d7fd65b-0aa7-4fcd-9076-5cf7dd0e514b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_19295aef-3072-4a3a-98b5-4c84cef2c1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_00ced8d1-1769-4200-8bc9-9feeaaf53155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19295aef-3072-4a3a-98b5-4c84cef2c1e1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_00ced8d1-1769-4200-8bc9-9feeaaf53155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6cd8955-b13f-425f-aa08-7447c64b7382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19295aef-3072-4a3a-98b5-4c84cef2c1e1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6cd8955-b13f-425f-aa08-7447c64b7382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3cd6ba3e-2186-473d-8ba2-182ee58df264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19295aef-3072-4a3a-98b5-4c84cef2c1e1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3cd6ba3e-2186-473d-8ba2-182ee58df264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_edf5127f-1701-4627-bc5c-20214beee5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19295aef-3072-4a3a-98b5-4c84cef2c1e1" xlink:to="loc_us-gaap_OperatingLeaseLiability_edf5127f-1701-4627-bc5c-20214beee5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_035263c8-927b-49f1-9e9d-d9d6660510c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19295aef-3072-4a3a-98b5-4c84cef2c1e1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_035263c8-927b-49f1-9e9d-d9d6660510c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b845e275-24cb-4b4f-bfeb-ba21b1e021df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19295aef-3072-4a3a-98b5-4c84cef2c1e1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b845e275-24cb-4b4f-bfeb-ba21b1e021df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_75403382-bad8-4436-8da5-97bd389472fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19295aef-3072-4a3a-98b5-4c84cef2c1e1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_75403382-bad8-4436-8da5-97bd389472fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0ed63ea8-adb6-41d4-8d19-575654d52bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19295aef-3072-4a3a-98b5-4c84cef2c1e1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0ed63ea8-adb6-41d4-8d19-575654d52bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_313d1933-7a7c-4a15-8df4-b7d619fdd86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19295aef-3072-4a3a-98b5-4c84cef2c1e1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_313d1933-7a7c-4a15-8df4-b7d619fdd86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#LeasesLiabilityMaturityScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7953703f-2b29-424e-b6e0-9a2c340ff9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bb9f0ce3-78ca-4155-9cb0-de2e7e5a77a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7953703f-2b29-424e-b6e0-9a2c340ff9e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bb9f0ce3-78ca-4155-9cb0-de2e7e5a77a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_981fa28f-49bb-4e8d-839d-af183555f8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7953703f-2b29-424e-b6e0-9a2c340ff9e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_981fa28f-49bb-4e8d-839d-af183555f8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3b30652f-2f71-441b-95b6-0022f50c0073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7953703f-2b29-424e-b6e0-9a2c340ff9e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3b30652f-2f71-441b-95b6-0022f50c0073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a487bcad-f40d-4ab4-b030-fa0ae2af072f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7953703f-2b29-424e-b6e0-9a2c340ff9e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a487bcad-f40d-4ab4-b030-fa0ae2af072f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9ab9c7d3-d0b5-4764-9a47-bb50310e082e" xlink:href="ango-20230531.xsd#ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7953703f-2b29-424e-b6e0-9a2c340ff9e3" xlink:to="loc_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9ab9c7d3-d0b5-4764-9a47-bb50310e082e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_86d4e037-e725-41a0-ad96-2e8b02fb399e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7953703f-2b29-424e-b6e0-9a2c340ff9e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_86d4e037-e725-41a0-ad96-2e8b02fb399e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_19211984-3929-4ce2-abe1-9260eed0090d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7953703f-2b29-424e-b6e0-9a2c340ff9e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_19211984-3929-4ce2-abe1-9260eed0090d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_85170f3e-45a2-4c11-a65b-75323c3e20db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7953703f-2b29-424e-b6e0-9a2c340ff9e3" xlink:to="loc_us-gaap_OperatingLeaseLiability_85170f3e-45a2-4c11-a65b-75323c3e20db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f9240daa-ec03-44be-a610-79f8f002046a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7953703f-2b29-424e-b6e0-9a2c340ff9e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f9240daa-ec03-44be-a610-79f8f002046a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f90acd6f-3eb2-4b43-b661-70737a577520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7953703f-2b29-424e-b6e0-9a2c340ff9e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f90acd6f-3eb2-4b43-b661-70737a577520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1" xlink:type="simple" xlink:href="ango-20230531.xsd#LeasesLiabilityMaturityScheduleDetails_1"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#LeasesSupplementalStatementofOperationsInformationDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b95e5a06-1f00-4932-a86f-20ecb75c7a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f0db3952-9e3f-4995-bf8a-c3e1db81da3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b95e5a06-1f00-4932-a86f-20ecb75c7a53" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f0db3952-9e3f-4995-bf8a-c3e1db81da3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3e8426dc-aa1e-427a-92a1-bcb0c8d42098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f0db3952-9e3f-4995-bf8a-c3e1db81da3e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3e8426dc-aa1e-427a-92a1-bcb0c8d42098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_39e2cd2c-d5df-41cd-b766-71f714c1caa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3e8426dc-aa1e-427a-92a1-bcb0c8d42098" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_39e2cd2c-d5df-41cd-b766-71f714c1caa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_7ff5a784-e248-4c28-8e47-b00b494e615b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_39e2cd2c-d5df-41cd-b766-71f714c1caa7" xlink:to="loc_us-gaap_CostOfSalesMember_7ff5a784-e248-4c28-8e47-b00b494e615b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e242fda3-bb91-4b49-934c-08cbf991df34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_39e2cd2c-d5df-41cd-b766-71f714c1caa7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e242fda3-bb91-4b49-934c-08cbf991df34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_d9b9da44-fe1c-4a77-b090-a57fcd3d1b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_39e2cd2c-d5df-41cd-b766-71f714c1caa7" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_d9b9da44-fe1c-4a77-b090-a57fcd3d1b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a1f3475b-9d93-49fb-8a95-5dfaa2a733ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_39e2cd2c-d5df-41cd-b766-71f714c1caa7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a1f3475b-9d93-49fb-8a95-5dfaa2a733ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c477c5eb-ed90-49e9-9783-64232bfd02d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f0db3952-9e3f-4995-bf8a-c3e1db81da3e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_c477c5eb-ed90-49e9-9783-64232bfd02d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_9a9690dd-f3cf-4183-a142-9bd9c9bf47ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c477c5eb-ed90-49e9-9783-64232bfd02d1" xlink:to="loc_us-gaap_OperatingLeaseExpense_9a9690dd-f3cf-4183-a142-9bd9c9bf47ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_96705d70-320b-4568-8629-bafe44c16e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_16f5ae9c-58f0-41de-b371-2542883ca0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_96705d70-320b-4568-8629-bafe44c16e50" xlink:to="loc_us-gaap_OperatingLeasePayments_16f5ae9c-58f0-41de-b371-2542883ca0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9b8101cb-740f-4991-8bf1-89965ac12e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_96705d70-320b-4568-8629-bafe44c16e50" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9b8101cb-740f-4991-8bf1-89965ac12e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#CommitmentsandContingenciesScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2012e41-69cb-45d2-9fb9-1e9193981a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_ea3af8d3-fd7c-4d3a-9155-e4fbe4eda670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2012e41-69cb-45d2-9fb9-1e9193981a41" xlink:to="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_ea3af8d3-fd7c-4d3a-9155-e4fbe4eda670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_aca22a3a-c3f3-46ff-b171-afb42cd7d372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_ea3af8d3-fd7c-4d3a-9155-e4fbe4eda670" xlink:to="loc_us-gaap_PurchaseObligation_aca22a3a-c3f3-46ff-b171-afb42cd7d372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_5b332859-fd8d-4c0d-b21d-a6cf82e6d8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_ea3af8d3-fd7c-4d3a-9155-e4fbe4eda670" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_5b332859-fd8d-4c0d-b21d-a6cf82e6d8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_bfde7c27-fd47-4d66-a971-4e6419fa92e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_ea3af8d3-fd7c-4d3a-9155-e4fbe4eda670" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_bfde7c27-fd47-4d66-a971-4e6419fa92e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_0964fcf0-5271-46e5-b00d-71e27f8472d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_ea3af8d3-fd7c-4d3a-9155-e4fbe4eda670" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_0964fcf0-5271-46e5-b00d-71e27f8472d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_0a26ed37-d3a2-43dd-98c3-5874f8d4f1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_ea3af8d3-fd7c-4d3a-9155-e4fbe4eda670" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_0a26ed37-d3a2-43dd-98c3-5874f8d4f1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_PurchaseObligationToBePaidAfterYearFour_fe51f40e-fea5-4ba8-b6a4-d8be459a1a6e" xlink:href="ango-20230531.xsd#ango_PurchaseObligationToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_ea3af8d3-fd7c-4d3a-9155-e4fbe4eda670" xlink:to="loc_ango_PurchaseObligationToBePaidAfterYearFour_fe51f40e-fea5-4ba8-b6a4-d8be459a1a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_ebfa09a7-01e5-4486-afd8-caab73a9781a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2012e41-69cb-45d2-9fb9-1e9193981a41" xlink:to="loc_us-gaap_AdvanceRoyaltiesAbstract_ebfa09a7-01e5-4486-afd8-caab73a9781a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_Royalties_75ca7808-fec8-43c1-9516-a71f1a136080" xlink:href="ango-20230531.xsd#ango_Royalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_ebfa09a7-01e5-4486-afd8-caab73a9781a" xlink:to="loc_ango_Royalties_75ca7808-fec8-43c1-9516-a71f1a136080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueInFirstYear_f1060829-83f6-4311-8fa3-1627e43d79ed" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueInFirstYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_ebfa09a7-01e5-4486-afd8-caab73a9781a" xlink:to="loc_ango_RoyaltiesDueInFirstYear_f1060829-83f6-4311-8fa3-1627e43d79ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueinSecondYear_02990933-b0ef-4f20-8aab-d446c2a1a77c" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueinSecondYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_ebfa09a7-01e5-4486-afd8-caab73a9781a" xlink:to="loc_ango_RoyaltiesDueinSecondYear_02990933-b0ef-4f20-8aab-d446c2a1a77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueinThirdYear_d373e961-21d4-4d65-b247-9c5b2be8121e" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueinThirdYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_ebfa09a7-01e5-4486-afd8-caab73a9781a" xlink:to="loc_ango_RoyaltiesDueinThirdYear_d373e961-21d4-4d65-b247-9c5b2be8121e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueinFourthYear_0c2d28a4-48a2-493e-983c-f8b64efdff4c" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueinFourthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_ebfa09a7-01e5-4486-afd8-caab73a9781a" xlink:to="loc_ango_RoyaltiesDueinFourthYear_0c2d28a4-48a2-493e-983c-f8b64efdff4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RoyaltiesDueAfterFourthYear_f2dc774b-448d-4c15-a37b-332990f43fda" xlink:href="ango-20230531.xsd#ango_RoyaltiesDueAfterFourthYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_ebfa09a7-01e5-4486-afd8-caab73a9781a" xlink:to="loc_ango_RoyaltiesDueAfterFourthYear_f2dc774b-448d-4c15-a37b-332990f43fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_6af5ca22-71be-4b46-a62c-bb808ed92f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2012e41-69cb-45d2-9fb9-1e9193981a41" xlink:to="loc_us-gaap_ContractualObligation_6af5ca22-71be-4b46-a62c-bb808ed92f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_28117a22-d5ac-45b6-aeac-8a0a069f84c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2012e41-69cb-45d2-9fb9-1e9193981a41" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_28117a22-d5ac-45b6-aeac-8a0a069f84c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_1ee1d934-7a70-4f7b-a785-9592b4be4b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2012e41-69cb-45d2-9fb9-1e9193981a41" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_1ee1d934-7a70-4f7b-a785-9592b4be4b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_a29ca9ff-5142-44b3-bc77-228f4b6ace5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2012e41-69cb-45d2-9fb9-1e9193981a41" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_a29ca9ff-5142-44b3-bc77-228f4b6ace5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_0b20b728-db81-4e03-880c-5edc5e5cde43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2012e41-69cb-45d2-9fb9-1e9193981a41" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_0b20b728-db81-4e03-880c-5edc5e5cde43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ContractualObligationToBePaidAfterYearFour_76df3302-3330-48d0-88db-07f60fbe516d" xlink:href="ango-20230531.xsd#ango_ContractualObligationToBePaidAfterYearFour"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2012e41-69cb-45d2-9fb9-1e9193981a41" xlink:to="loc_ango_ContractualObligationToBePaidAfterYearFour_76df3302-3330-48d0-88db-07f60fbe516d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails_1" xlink:type="simple" xlink:href="ango-20230531.xsd#CommitmentsandContingenciesScheduleDetails_1"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5a6e514a-082f-44da-9937-f17088e738c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_f595dff0-04c8-4b32-8575-7db11b31bb15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5a6e514a-082f-44da-9937-f17088e738c4" xlink:to="loc_us-gaap_LossContingenciesTable_f595dff0-04c8-4b32-8575-7db11b31bb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_08cd1b82-bda7-41b6-8858-a3ddf638ddd3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f595dff0-04c8-4b32-8575-7db11b31bb15" xlink:to="loc_srt_LitigationCaseAxis_08cd1b82-bda7-41b6-8858-a3ddf638ddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a46d144a-fb33-43fb-81ad-6f7be51cd211" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_08cd1b82-bda7-41b6-8858-a3ddf638ddd3" xlink:to="loc_srt_LitigationCaseTypeDomain_a46d144a-fb33-43fb-81ad-6f7be51cd211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_CrBardIncMember_a2f0ac88-a1d6-4753-9d85-9284fb6b4376" xlink:href="ango-20230531.xsd#ango_CrBardIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a46d144a-fb33-43fb-81ad-6f7be51cd211" xlink:to="loc_ango_CrBardIncMember_a2f0ac88-a1d6-4753-9d85-9284fb6b4376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TheDelawareActionMember_3f1bee30-1084-42b9-bf17-777d0ba2eccb" xlink:href="ango-20230531.xsd#ango_TheDelawareActionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a46d144a-fb33-43fb-81ad-6f7be51cd211" xlink:to="loc_ango_TheDelawareActionMember_3f1bee30-1084-42b9-bf17-777d0ba2eccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_41a93c04-4e22-41d3-8f81-2dfed6236a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f595dff0-04c8-4b32-8575-7db11b31bb15" xlink:to="loc_us-gaap_LossContingenciesLineItems_41a93c04-4e22-41d3-8f81-2dfed6236a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_NumberOfPatentsAssertedForReexamination_3209ca7a-5811-4752-bfc1-5160ec819990" xlink:href="ango-20230531.xsd#ango_NumberOfPatentsAssertedForReexamination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_41a93c04-4e22-41d3-8f81-2dfed6236a56" xlink:to="loc_ango_NumberOfPatentsAssertedForReexamination_3209ca7a-5811-4752-bfc1-5160ec819990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_NumberOfPatentsUpheldOverPriorArtReferences_86fad2f3-a506-4bfc-8ccb-3ec47061f9a2" xlink:href="ango-20230531.xsd#ango_NumberOfPatentsUpheldOverPriorArtReferences"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_41a93c04-4e22-41d3-8f81-2dfed6236a56" xlink:to="loc_ango_NumberOfPatentsUpheldOverPriorArtReferences_86fad2f3-a506-4bfc-8ccb-3ec47061f9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_1b94d459-e972-4592-bc8e-4071e87adc22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_41a93c04-4e22-41d3-8f81-2dfed6236a56" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_1b94d459-e972-4592-bc8e-4071e87adc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#SegmentsandGeographicInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_db8e036c-eda6-40eb-970a-00e74eac5254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76e02ea2-ec7b-4739-93a1-356476f9c5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_db8e036c-eda6-40eb-970a-00e74eac5254" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76e02ea2-ec7b-4739-93a1-356476f9c5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9b672a7a-4557-4f64-ab9a-c5bdec143be2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76e02ea2-ec7b-4739-93a1-356476f9c5ce" xlink:to="loc_srt_StatementGeographicalAxis_9b672a7a-4557-4f64-ab9a-c5bdec143be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_33042117-e365-40cc-982b-7045fc94b560" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9b672a7a-4557-4f64-ab9a-c5bdec143be2" xlink:to="loc_srt_SegmentGeographicalDomain_33042117-e365-40cc-982b-7045fc94b560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_94084c03-0921-448a-9e99-9d0396183524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_33042117-e365-40cc-982b-7045fc94b560" xlink:to="loc_us-gaap_NonUsMember_94084c03-0921-448a-9e99-9d0396183524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_48d7182c-bc5b-422c-a743-65ae948232ea" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_33042117-e365-40cc-982b-7045fc94b560" xlink:to="loc_country_US_48d7182c-bc5b-422c-a743-65ae948232ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_71b92898-d22e-4e86-971f-3807319dfd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76e02ea2-ec7b-4739-93a1-356476f9c5ce" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_71b92898-d22e-4e86-971f-3807319dfd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1ed3ecf8-417a-4a94-a4f9-ecd74cc985d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_71b92898-d22e-4e86-971f-3807319dfd4d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1ed3ecf8-417a-4a94-a4f9-ecd74cc985d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_05b1ad24-7e9a-409a-8681-a0edd5763440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1ed3ecf8-417a-4a94-a4f9-ecd74cc985d3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_05b1ad24-7e9a-409a-8681-a0edd5763440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAssetsGeographicAreaMember_b8065ffe-68b6-4c34-8069-58e7ff068566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetAssetsGeographicAreaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1ed3ecf8-417a-4a94-a4f9-ecd74cc985d3" xlink:to="loc_us-gaap_NetAssetsGeographicAreaMember_b8065ffe-68b6-4c34-8069-58e7ff068566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_80e047d6-c60f-42f9-a542-c9d0a248c1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76e02ea2-ec7b-4739-93a1-356476f9c5ce" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_80e047d6-c60f-42f9-a542-c9d0a248c1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_62da4209-03ef-48e3-98f3-018fa411d946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_80e047d6-c60f-42f9-a542-c9d0a248c1d0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_62da4209-03ef-48e3-98f3-018fa411d946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_54c6b35d-0929-4f2c-bb58-888536f16d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_62da4209-03ef-48e3-98f3-018fa411d946" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_54c6b35d-0929-4f2c-bb58-888536f16d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_458b7576-7e16-47ed-8260-bd40fe96cf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_76e02ea2-ec7b-4739-93a1-356476f9c5ce" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_458b7576-7e16-47ed-8260-bd40fe96cf3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_210f8b33-2fab-4e81-b94b-b7a36ebf3455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_458b7576-7e16-47ed-8260-bd40fe96cf3e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_210f8b33-2fab-4e81-b94b-b7a36ebf3455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_47c195aa-fde7-48ee-abbb-5d51b3dced23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_458b7576-7e16-47ed-8260-bd40fe96cf3e" xlink:to="loc_us-gaap_Assets_47c195aa-fde7-48ee-abbb-5d51b3dced23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_68846c47-2233-4d2c-ba3d-00548ec59356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_458b7576-7e16-47ed-8260-bd40fe96cf3e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_68846c47-2233-4d2c-ba3d-00548ec59356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#SegmentsandGeographicInformationSalesbyProductCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_48172e63-eacb-47af-980b-92e780fa4c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a5d930aa-7f00-44ba-91df-7a93133c9f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_48172e63-eacb-47af-980b-92e780fa4c1a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a5d930aa-7f00-44ba-91df-7a93133c9f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9afe7992-84ca-4c0a-b105-6080b1fab2a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a5d930aa-7f00-44ba-91df-7a93133c9f8d" xlink:to="loc_srt_ProductOrServiceAxis_9afe7992-84ca-4c0a-b105-6080b1fab2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8f400a14-711c-4222-8b8f-40f063a3871e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9afe7992-84ca-4c0a-b105-6080b1fab2a0" xlink:to="loc_srt_ProductsAndServicesDomain_8f400a14-711c-4222-8b8f-40f063a3871e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedTechMember_96543562-46aa-4347-a76b-72aac3737c86" xlink:href="ango-20230531.xsd#ango_MedTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8f400a14-711c-4222-8b8f-40f063a3871e" xlink:to="loc_ango_MedTechMember_96543562-46aa-4347-a76b-72aac3737c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MedDeviceMember_40a6a287-5d54-4c70-b7ab-2243be7621b2" xlink:href="ango-20230531.xsd#ango_MedDeviceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8f400a14-711c-4222-8b8f-40f063a3871e" xlink:to="loc_ango_MedDeviceMember_40a6a287-5d54-4c70-b7ab-2243be7621b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_b259ffc1-470c-4b3e-9c50-67f29c5aab68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a5d930aa-7f00-44ba-91df-7a93133c9f8d" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_b259ffc1-470c-4b3e-9c50-67f29c5aab68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0260c65f-470c-404e-ab9e-22013ea6bec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b259ffc1-470c-4b3e-9c50-67f29c5aab68" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0260c65f-470c-404e-ab9e-22013ea6bec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_adc2286d-9e05-41c3-a59d-6e734357f389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b259ffc1-470c-4b3e-9c50-67f29c5aab68" xlink:to="loc_us-gaap_GrossProfit_adc2286d-9e05-41c3-a59d-6e734357f389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_GrossMarginPercentage_e70d0a4a-97c0-4a60-b5fa-d33427f45249" xlink:href="ango-20230531.xsd#ango_GrossMarginPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b259ffc1-470c-4b3e-9c50-67f29c5aab68" xlink:to="loc_ango_GrossMarginPercentage_e70d0a4a-97c0-4a60-b5fa-d33427f45249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#SegmentsandGeographicInformationSaleforGeographicAreasDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cd3c2c39-a746-4eba-9612-bf187987d25b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_513afdf4-33df-40d6-8c08-cb58a75c0039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cd3c2c39-a746-4eba-9612-bf187987d25b" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_513afdf4-33df-40d6-8c08-cb58a75c0039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_af031897-0096-46c1-9411-7fe860e99680" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_513afdf4-33df-40d6-8c08-cb58a75c0039" xlink:to="loc_srt_StatementGeographicalAxis_af031897-0096-46c1-9411-7fe860e99680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3603ac44-b0be-43e5-a108-69660537527b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_af031897-0096-46c1-9411-7fe860e99680" xlink:to="loc_srt_SegmentGeographicalDomain_3603ac44-b0be-43e5-a108-69660537527b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7a928337-78aa-4835-8fbb-8acebb345e82" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3603ac44-b0be-43e5-a108-69660537527b" xlink:to="loc_country_US_7a928337-78aa-4835-8fbb-8acebb345e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_InternationalMember_4b3c42dc-1422-4f1d-b4f1-fda76fb9b1d7" xlink:href="ango-20230531.xsd#ango_InternationalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3603ac44-b0be-43e5-a108-69660537527b" xlink:to="loc_ango_InternationalMember_4b3c42dc-1422-4f1d-b4f1-fda76fb9b1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_04b6b395-2f84-4364-bc02-ba60386e8064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_513afdf4-33df-40d6-8c08-cb58a75c0039" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_04b6b395-2f84-4364-bc02-ba60386e8064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_374fdd80-20df-43c2-a8e2-d38dfc990c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_04b6b395-2f84-4364-bc02-ba60386e8064" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_374fdd80-20df-43c2-a8e2-d38dfc990c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AcquisitionRestructuringandOtherItemsnetScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_01e84019-4c55-4c2a-9912-73f92a4736c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ef4ada78-3af0-46dd-80ad-076f1a62f931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_01e84019-4c55-4c2a-9912-73f92a4736c6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ef4ada78-3af0-46dd-80ad-076f1a62f931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8610d4bc-518f-48d0-a9b4-83b51fd83aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ef4ada78-3af0-46dd-80ad-076f1a62f931" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8610d4bc-518f-48d0-a9b4-83b51fd83aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8610d4bc-518f-48d0-a9b4-83b51fd83aac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_LegalCostsMember_0d071c8c-efaa-4838-936f-76b8fc9d92f3" xlink:href="ango-20230531.xsd#ango_LegalCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_LegalCostsMember_0d071c8c-efaa-4838-936f-76b8fc9d92f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_MergersandAcquisitionsMember_9100324f-78d9-46bb-9a62-d02b8000da78" xlink:href="ango-20230531.xsd#ango_MergersandAcquisitionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_MergersandAcquisitionsMember_9100324f-78d9-46bb-9a62-d02b8000da78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_TransitionServiceAgreementMember_27925e8d-7da1-4314-8d35-e260c16dd953" xlink:href="ango-20230531.xsd#ango_TransitionServiceAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_TransitionServiceAgreementMember_27925e8d-7da1-4314-8d35-e260c16dd953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_DivestitureMember_c6013b9d-3f89-43aa-9a38-2399354efd9b" xlink:href="ango-20230531.xsd#ango_DivestitureMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_DivestitureMember_c6013b9d-3f89-43aa-9a38-2399354efd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IntangibleImpairmentMember_01a0df22-8b2a-45d9-a140-e5dbdc5f4373" xlink:href="ango-20230531.xsd#ango_IntangibleImpairmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_IntangibleImpairmentMember_01a0df22-8b2a-45d9-a140-e5dbdc5f4373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_IsraeliInnovationAuthorityPrepaymentMember_dbb5fbd4-2b0d-4d9d-9f45-eea7593c9c56" xlink:href="ango-20230531.xsd#ango_IsraeliInnovationAuthorityPrepaymentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_IsraeliInnovationAuthorityPrepaymentMember_dbb5fbd4-2b0d-4d9d-9f45-eea7593c9c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_ManufacturingRelocationMember_b9322a79-c397-4126-8aa1-b6efb92615c1" xlink:href="ango-20230531.xsd#ango_ManufacturingRelocationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_ango_ManufacturingRelocationMember_b9322a79-c397-4126-8aa1-b6efb92615c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_2ba4b876-bbff-4c9f-b229-a0b7bb9349bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6d3d10c8-234d-4e39-aea6-771a4fc7a8fd" xlink:to="loc_us-gaap_OtherRestructuringMember_2ba4b876-bbff-4c9f-b229-a0b7bb9349bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0586b46e-0b7d-4c28-908e-15565340b555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ef4ada78-3af0-46dd-80ad-076f1a62f931" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0586b46e-0b7d-4c28-908e-15565340b555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94b99e46-5bd7-4be3-bcdb-6614caeb1015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0586b46e-0b7d-4c28-908e-15565340b555" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94b99e46-5bd7-4be3-bcdb-6614caeb1015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_RadiaDyneMember_fba146e0-ff5a-47c4-86bf-1e17ae711314" xlink:href="ango-20230531.xsd#ango_RadiaDyneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94b99e46-5bd7-4be3-bcdb-6614caeb1015" xlink:to="loc_ango_RadiaDyneMember_fba146e0-ff5a-47c4-86bf-1e17ae711314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ada71f5-adcb-4e0b-88fc-6123e2b9d88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ef4ada78-3af0-46dd-80ad-076f1a62f931" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ada71f5-adcb-4e0b-88fc-6123e2b9d88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9103920f-9dce-400c-bcec-23b6fe7e0764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ada71f5-adcb-4e0b-88fc-6123e2b9d88c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9103920f-9dce-400c-bcec-23b6fe7e0764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_OarTracTrademarkMember_2166b13c-17ce-4da5-8045-51a0126d280a" xlink:href="ango-20230531.xsd#ango_OarTracTrademarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9103920f-9dce-400c-bcec-23b6fe7e0764" xlink:to="loc_ango_OarTracTrademarkMember_2166b13c-17ce-4da5-8045-51a0126d280a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9d086507-b58f-410f-9ac6-bb2ee5cd35d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ef4ada78-3af0-46dd-80ad-076f1a62f931" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_9d086507-b58f-410f-9ac6-bb2ee5cd35d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AcquisitionRestructuringAndOtherItemsNet_7d80eb20-def8-426f-9533-6d09f1f4313d" xlink:href="ango-20230531.xsd#ango_AcquisitionRestructuringAndOtherItemsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9d086507-b58f-410f-9ac6-bb2ee5cd35d5" xlink:to="loc_ango_AcquisitionRestructuringAndOtherItemsNet_7d80eb20-def8-426f-9533-6d09f1f4313d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_61da4949-401e-462f-9eb5-bcec07d9aac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9d086507-b58f-410f-9ac6-bb2ee5cd35d5" xlink:to="loc_us-gaap_AssetImpairmentCharges_61da4949-401e-462f-9eb5-bcec07d9aac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForPreviousAcquisition_7623a46b-c52e-4f14-aae2-674b5ed06c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPreviousAcquisition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9d086507-b58f-410f-9ac6-bb2ee5cd35d5" xlink:to="loc_us-gaap_PaymentsForPreviousAcquisition_7623a46b-c52e-4f14-aae2-674b5ed06c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetNarrativeDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AcquisitionRestructuringandOtherItemsnetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_47f965ce-9522-415a-aa9b-b3b41303f11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b97a6d19-58ed-4a81-bcc1-bb1235dd0de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_47f965ce-9522-415a-aa9b-b3b41303f11e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b97a6d19-58ed-4a81-bcc1-bb1235dd0de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_25c4f202-1cbd-4a34-8470-b8d68eb1cf40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b97a6d19-58ed-4a81-bcc1-bb1235dd0de7" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_25c4f202-1cbd-4a34-8470-b8d68eb1cf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_80390d57-b012-4a6b-9f83-055e15c475c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_25c4f202-1cbd-4a34-8470-b8d68eb1cf40" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_80390d57-b012-4a6b-9f83-055e15c475c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_SettlementExpenseMember_3475ab08-21f2-45ff-9ccb-5f2ba5e167ac" xlink:href="ango-20230531.xsd#ango_SettlementExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_80390d57-b012-4a6b-9f83-055e15c475c8" xlink:to="loc_ango_SettlementExpenseMember_3475ab08-21f2-45ff-9ccb-5f2ba5e167ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6bf3550e-b33e-40da-8f72-40e6c33fd451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b97a6d19-58ed-4a81-bcc1-bb1235dd0de7" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_6bf3550e-b33e-40da-8f72-40e6c33fd451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AcquisitionRestructuringAndOtherItemsNet_79fd3610-2091-4d50-a138-d2a3dce86860" xlink:href="ango-20230531.xsd#ango_AcquisitionRestructuringAndOtherItemsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6bf3550e-b33e-40da-8f72-40e6c33fd451" xlink:to="loc_ango_AcquisitionRestructuringAndOtherItemsNet_79fd3610-2091-4d50-a138-d2a3dce86860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2eb67485-98bc-4ca4-933a-0a5b3b866007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_842197dc-47d3-440a-a9ba-2a1c0464f45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2eb67485-98bc-4ca4-933a-0a5b3b866007" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_842197dc-47d3-440a-a9ba-2a1c0464f45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8e98c979-ca63-4871-be03-bfed57bc7efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_842197dc-47d3-440a-a9ba-2a1c0464f45d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8e98c979-ca63-4871-be03-bfed57bc7efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dc4bbc0e-d51b-4084-b032-9283ef59977d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8e98c979-ca63-4871-be03-bfed57bc7efe" xlink:to="loc_us-gaap_EquityComponentDomain_dc4bbc0e-d51b-4084-b032-9283ef59977d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9d22b8f5-6f0c-4dba-aff2-707f2c7cbabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dc4bbc0e-d51b-4084-b032-9283ef59977d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9d22b8f5-6f0c-4dba-aff2-707f2c7cbabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_885ac517-3a3c-4c00-be6a-757d8904eee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_842197dc-47d3-440a-a9ba-2a1c0464f45d" xlink:to="loc_us-gaap_ClassOfStockLineItems_885ac517-3a3c-4c00-be6a-757d8904eee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_f592769b-cde7-473e-b71c-8c36af4c74ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_885ac517-3a3c-4c00-be6a-757d8904eee8" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_f592769b-cde7-473e-b71c-8c36af4c74ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d0dd9336-27a9-43b3-90a3-a3377c59220e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_f592769b-cde7-473e-b71c-8c36af4c74ac" xlink:to="loc_us-gaap_StockholdersEquity_d0dd9336-27a9-43b3-90a3-a3377c59220e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_ad20533c-4295-464e-925b-3ee540bdf046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_f592769b-cde7-473e-b71c-8c36af4c74ac" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_ad20533c-4295-464e-925b-3ee540bdf046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d803fe27-8985-48f0-b008-0a44563df280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_f592769b-cde7-473e-b71c-8c36af4c74ac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d803fe27-8985-48f0-b008-0a44563df280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_19ac1f4a-08fa-4c65-ad77-8d3f9a72736f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_f592769b-cde7-473e-b71c-8c36af4c74ac" xlink:to="loc_us-gaap_StockholdersEquity_19ac1f4a-08fa-4c65-ad77-8d3f9a72736f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_52839d8f-3fc2-4499-846e-8539c75622ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f53d3407-d486-4794-81ef-455d4a69a2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_52839d8f-3fc2-4499-846e-8539c75622ae" xlink:to="loc_us-gaap_SubsequentEventTable_f53d3407-d486-4794-81ef-455d4a69a2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4f60936f-ef9c-4319-95f1-d71cd79abe50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f53d3407-d486-4794-81ef-455d4a69a2ed" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4f60936f-ef9c-4319-95f1-d71cd79abe50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b20dbe7c-de5b-41a4-b5f4-2d35daadb9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4f60936f-ef9c-4319-95f1-d71cd79abe50" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b20dbe7c-de5b-41a4-b5f4-2d35daadb9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7e2d046e-0566-4797-88b1-9159a3422e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b20dbe7c-de5b-41a4-b5f4-2d35daadb9d3" xlink:to="loc_us-gaap_SubsequentEventMember_7e2d046e-0566-4797-88b1-9159a3422e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_03577fc2-b9b8-4ed1-9405-bb49bf7ea5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f53d3407-d486-4794-81ef-455d4a69a2ed" xlink:to="loc_us-gaap_SubsequentEventLineItems_03577fc2-b9b8-4ed1-9405-bb49bf7ea5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssets1_7205e9cb-a921-420f-bfca-b557b837496c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_03577fc2-b9b8-4ed1-9405-bb49bf7ea5ee" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssets1_7205e9cb-a921-420f-bfca-b557b837496c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="ango-20230531.xsd#ValuationandQualifyingAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_d76088c5-5315-4ff0-8644-5ea63f515cec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d22fdf6a-01fc-4d9b-9386-a0ab2f4b7e81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_d76088c5-5315-4ff0-8644-5ea63f515cec" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d22fdf6a-01fc-4d9b-9386-a0ab2f4b7e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ac8f622e-6095-472b-b7cf-887139ad6341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d22fdf6a-01fc-4d9b-9386-a0ab2f4b7e81" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ac8f622e-6095-472b-b7cf-887139ad6341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1838c7a0-82cf-4763-b727-a9a551490296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_ac8f622e-6095-472b-b7cf-887139ad6341" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1838c7a0-82cf-4763-b727-a9a551490296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_55ab5aa6-940f-4b54-bdb9-114629103e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1838c7a0-82cf-4763-b727-a9a551490296" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_55ab5aa6-940f-4b54-bdb9-114629103e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember_2e9026f4-f604-4e18-9605-bedad285e260" xlink:href="ango-20230531.xsd#ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1838c7a0-82cf-4763-b727-a9a551490296" xlink:to="loc_ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember_2e9026f4-f604-4e18-9605-bedad285e260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_314ee58c-bea9-429e-aa4e-0bed9cabd443" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d22fdf6a-01fc-4d9b-9386-a0ab2f4b7e81" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_314ee58c-bea9-429e-aa4e-0bed9cabd443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_9f8b3ef4-1e2b-4320-8785-87ffa5982b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_314ee58c-bea9-429e-aa4e-0bed9cabd443" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_9f8b3ef4-1e2b-4320-8785-87ffa5982b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d23548b5-5acf-437e-84d3-1e223d1f8f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_9f8b3ef4-1e2b-4320-8785-87ffa5982b94" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d23548b5-5acf-437e-84d3-1e223d1f8f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_ebdbfca0-ec95-4bb0-bf24-bdd790252996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_9f8b3ef4-1e2b-4320-8785-87ffa5982b94" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_ebdbfca0-ec95-4bb0-bf24-bdd790252996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_0758cb37-6cad-4f1a-8201-d959a81aaa57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_9f8b3ef4-1e2b-4320-8785-87ffa5982b94" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_0758cb37-6cad-4f1a-8201-d959a81aaa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_b1fc9205-f9dd-4ebf-8acb-b4ef44bfe7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_9f8b3ef4-1e2b-4320-8785-87ffa5982b94" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_b1fc9205-f9dd-4ebf-8acb-b4ef44bfe7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ango-20230531_g1.gif
<TEXT>
begin 644 ango-20230531_g1.gif
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MZM7:X>'CY_3CYOSBZ>+H\?#Q\_SQ\_#S^
M
M
M
M
M
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M^DJH<JNO.RS)9QW"5[J21+(I)8DH#"" "$!&GAFQQ-[.LP(34$2C5A(%A?+
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MD;P;M>EC2OOZ1\7@42@J#50PT2%9@QH%/21$IPZ%"#<]T>?0N@5ITGHROX5
MA>D#P<604V3LCU+P0M"Q4SWD"-ITBC=MD25E#.TY4XA(0&+,"5Y,T9UZP9Q(
M0"&MESY='5#L#5&MBCTE"7/DPCE<Q[UQ@15(C%/@NY"S*#"I S#=%4FHT!>3
MU(A A8*3 W034X)H4?Y(S)Y9U'3;57VSC6N,G]0@T_C@'1T=B%CSFE:#S#5X
MA$N"U.W9U(P85D*C$.W4'%+=BH);@V]5B&D%3#_0.ZYP-W0CS8:0SBMCMC5
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M6\)/:%O$]1%0$)@Y>+7+/5D-!#N-/"/*95S,Q=P33%F<<<#^E;U<8&%  DO
M@1A$R8T/4%A<@KG<QXU<U[7=X*A<T'7<!4Q8HE#<!]1=M&7"VLV*#MC;(3G0
MMPF"%Y#0DM!2+BTN,)$!2KC=ZK5>@''6Z]7>^-C#T=W>[P7?\#4Y5<4+OL4.
MMSG%PX4(4K X!_4!",T/XQ3?^:7? L+1^L7?B\ RCH#1_/7?_P7@"-K"XP60
M)9@>):@!DMB$]G5?+VW> (;@Z\W>",9?8QP(I*7@#-;@#2:)E,0+!<,..CBA
M'9#8B&"$P87>M;C8%>B"!^;@%][)"8;A[7W(&9WA&\;A%QY0O"  "8","+
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4$1 /#@T,"PH)" <&!00# @$  #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ango-20230531_g2.jpg
<TEXT>
begin 644 ango-20230531_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M;1I_]N'FT<MXNJIN.94M';_=_P#[H?@+_P '%_[<7A/]MW4/@_-X6T_7M/\
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M_P"A;\?_ /?G3O\ Y+I?^'\?PG_Z%OX@?]^=._\ DNOL+_A7/A__ * >C?\
M@#%_\32?\*X\/C_F!Z+_ . ,7_Q-</\ :'#_ /T!S_\ !O\ ]H+^Q^,?^AE2
M_P#!'_W0_+W]LC]IG]C+]O\ \2Z/K'Q:^%/Q)\4:AH-G)86,L6N/I@AA=M[J
M5M-4B5LMSE@3VSBO?X?^"[OPEMX5C3PW\0 L:A5_=:>< >YO,UX;_P %N/\
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MXO[AKF:WT22QC8J%VPV]U/!"G  PL4:*#U(7)).37PC_ ,';'Q]TN#2OA/\
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M=/[)GAWXE>$OV?\ P_I/Q<U3PWKWCS38#:ZAJFAB9;74@AVQSE90&65XPID
M^7>6*X! '?F4J%6V(HZ.7Q1[/NO)G+@XU:=Z535+9^7;Y'I-1OU_"I!TICIN
MKRSN/P6_:/\ ^5K#P_\ ]CGH?_IJAK]ZE')K\U_BG_P1:^(7CS_@L]IG[2=O
MXL\'0^$;'7].U9]*D6X_M%H[:S2!E!">7N+*2/FQ@^M?I4HQ7J9GB*=54O9N
M]H)/U.' TIP<^9;R;^056UG3+?6M*N+.[ACN+6\C:":*1=R2HPVLI'H02/QJ
MS377<*\L[C^<_P#:L^!GQ&_X-\_^"D%A\0O =M-=^ =4N[A_#DTX=;'4]/F(
M>?0[IU)Q)&  I;EA#%,%)1PO[2?L#_\ !4/X2?\ !0WPA#=^"=?@M?$T< EU
M'PMJ,J0ZQII'WLQ9_>1@\"6/<AR.0>![!\:?@9X2_:+^'&I>$?''AW2_$_AO
M5D\NYL+Z(21OZ,IZHZYRKJ0RG!!!&:_)O]IW_@U!MKWQ7)J_P7^)DF@P-*9;
M?2O$T3W!T[<<,(;R'$NT*6 #HSX&&=LDU[SQ.&QD$L4^6HM.:UTUYH\GV-;#
M2;H+FB^G5>A^Q_FDG[K?C7S%_P %#O\ @K%\*/\ @G=X)O)O$FK6NN>-7MVD
MTKPCIUTC:EJ$F,)YG7[-"6QF:08 #;5D8;#^8MM_P0K_ &^-0U86-W\;+./2
MYI3!+<GXE:W*!"25+^3Y W97G9N[XS7L7[(O_!J=X9\(>(K77/C5XYG\:/&X
MN)]!T.-[&RO)05/^D7+DSS(0&!51$6R,M@%3FL#@J3YJU;F7:*=W\^AH\3B9
M^[3IV?=O8^=_^"8/[*?C[_@M5_P4&U+]H/XN1K-X'\/ZK%?7[?966SU6YM\&
MTTBT#97[/ %C:4Y8X #9>=G7]_HQ@>O.:R? ?@/1OACX-TSP[X>TJPT30]%M
MTM+"PLH5AM[2)1A41%P% 'I6NHQ7'CL:\3.Z7+%:)=D=&$PRHPL]6]6^[/SX
M_P"#G+_E%7K'_8T:)_Z5K71?\&X)S_P2#^&O_7_KW_IZO:]&_P""O?[#OB3_
M (*&?L:7WPW\*ZOHNAZM=:QI^HBZU7S?LZI;S"1E/EJS;B!@<8K5_P""4W['
M6O?L$_L.>$OA=XFU32=:UCP_<ZE-/=Z8)!;2"YU"XND"^8 W"S*#D=0<<5M+
M$4_[/5&_O<U[>5C-49?6W4MIRV^=SZ+89%>._MS?L5>$?V^/V<]:^'?C.)A9
MW^+FPOHA^_T>^16$-W%R/F0L<KG#JSH?E8BO8J",BO-IU)0DIP=FCLE%27++
M9G\K?Q<\5?%G_@GU\-_C5^R3XXM[<Z7XDO\ 3M3GAC9_L\%[;7UG=1ZG9,ZJ
M7M[F&T\L@A<G:3M>)U;]JO\ @VF_Y14>&O\ L.ZO_P"E;UV'_!8?_@DKI/\
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M+C0/"D5_HRQOAT@>Y9%6X>,,(V:&(A< D'):LY5$G8TC3OUL?M>'#4M?(?\
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M:9F+;05[*,D<^_45\)^*?A9\0?VBDNO$7Q*\236<FJ$L#=71DN'#1.=BK\S
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MW7R[?''!V_Y_2NPT'X0S2;<0[5/'W:]]T?X310$?NU_*NGTKX=QQ!?W>/PH
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:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ango-20230531_g3.jpg
<TEXT>
begin 644 ango-20230531_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #H 0P# 2(  A$! Q$!_\0
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M;8^F <T$X%1:?="]LXYE!"RH'7(YP1FI6Z5SG>G=7$WY7-"ONKE_C!\4M/\
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MC*LA)]15&\^!-UXE^-G]MZKI5K<:3_;%OJ2I,Z/M\O3KF#)7/)$DJC'3OVH
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MQSPNP_=;OD$5J?\ !*']NSXD?L)_'Y+C2K+4(]%U, 7]C8%[FVD4$?,\7S$
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M;6O[*'@7X+N-?^,?BY-9URX?S5TXR&3[1*/O1M&/G5\D^@K=NO\ @F'\8?\
M@H)XCAUGX+_"F?P1H/DJD>I:]&;7[6F  5#;=PQT.#7[/?LA?\$'_@O^S3=C
M6M=LKGXC>+Y"))M6UYS,=_JL?"#GVK[4T_3X-*LHK:UABM[>!0D<42!4C4=
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MK84XK])K;X ?M :DK^3\'KY%F.[$EW$ #Z_?KT+X;?\ !/S]H7XC>4E[X?\
M#_@R)I%9[B_NO/*+CJJQN3^8HU[$^XNI^=GPY_88\4>.U2\^)>HVNA:#;%<:
M+IS"./V5V'Y8!K]/OV%/^";W_";6NFW5UIIT'P/:*&@C6/RWO0O C"GD*0<E
ML<XZU])?LZ?\$P?"GPQT_P"T^,ISXYUV603/+=+LMH&!R D:X! [;@37T[;V
M\=G D42)%%& J(B[54#H !TJE#N9RKZ6B9?@?P'I'PV\.0:3HEA;Z?86ZX2*
M)<9]R>I/N>:UZ**T.8**** "BBB@ HHHH **** "BBB@ HHHH **** *NLZ-
M:>(M*N+&^MX;NSND,<T,J!DD4]00:^./&G_!!?\ 9\\7>+Y]57PY/8BZF,\U
MM%<R&)B<Y RQP,GH/2OM&B@:;6Q\9Z5_P0?_ &>-.V^9X4%R0Q=C)(?FST'7
MH*W=+_X(J?L\:7LV^!-/D**1EQG)/5OK_C7U?12LA\\CYPT[_@DS\ M,(\OX
M=Z%A0J@- #P!C%;^G_\ !.#X*::J>7\//#>4R039IU/7M7N%%,.9GE5A^Q#\
M)=,=3#\/_#"E<$'[$G88':M.#]D_X;6V=G@KP\F>N+-/KZ5Z%10*[.4LO@9X
M-T[_ %/AC0T^EE'_ (5HP_#CP]!]S0M'7Z64?^%;5% KLSX_">E1#Y=,T]?I
M;H/Z59BTRWA/R6\*_P"[&!4]% "!0O08I:** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ango-20230531_g4.gif
<TEXT>
begin 644 ango-20230531_g4.gif
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M)B4D(R(A(!\>'1P;&AD8%Q85%!,2$1 /#@T,"PH)" <&!00# @$  "'Y!
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MD1<1OOBSD:^#Q+2O\#T1Z[,?F_M7)Y[#_ XO;[]M^+,!_'9 -> %H7[_<TT
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M&?A]&HB$9C  ?=E]'2B5-#  $*"5&I@ 8+D13)F4[U@ 10D%[ZB3<;"12C
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MBP/EK 4@K7T"3 /\? 76O'TZ +P#/-)0<:,]70(Q/(+_9LP$##W,GXP$KEH
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M!4#X1>.B[K[UGCS[?E#]1G#],>N"_T@/ I\XDJ5YBE.QLNR"PK$\QTQPX_B
M0KD_T8+"8,67XPR3M(D1YU!"2XOF#1B]TJ:+"+;K_8+#XK%XT6H%R$K(N<55
M!U7MPA-N!P?FKSN?+V\S]%WEM>T)HIC-)1S&-,RM5#!&#5 %!)XD4%U*"DTU
M;7*2.%3N2$94+H;*".0L(*G"QLK.CORU"=!^$+:EQ=JVU.5R[K88"A]__+*
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MB79]AQQV$U;B(3*Z$?8.CWRI8N&% 2S@'AD50'AABBTR&8N!9QPE#37X/<(
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M+$_0WH'/(U/"XZ@_Y1[Q3H+A_GNG+.!J^UK'%[ZUK\A> 'R2PS126;#**Q>
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MDEW(8E1_ _C"\"Q]Y<(LEL "[\/?^7<)N __^PDL#\_1]=O/](X9V.MZ[6A
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M1L"Z,"_R&B^EQF[7\I[;[BSU B[_)O]LO )MP@+ P(9K*0C OEHNG<"LY5J
M 2! _8:ENYCO^::O^ZXO!F!P!FOP!FMP^Z+OE51 L=9KIJ8K 5C![TXO_YHM
MR9IMR;IPR9XNPBINSNJML7X !B3P#2! OV9 !"2  1B !<#ENQ K!<.O!7-P
M$BOQ$B>Q!\=O",^O#2/J!  MY<JN_ZZP"RONR)HM%YMLSA+ !D0"N()N!W@'
M*R! #EA  )0# 0 Q J@EO#!O")LO_%8P^RKQX/KL'O-Q'^\Q!@PN$PLR!CLQ
M"$>Q%-^IY/YKN:;PS;[P"V\QZ +  (=Q $WNSP( !]QKX>) ( @  J0Q*".
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MIYMVB>EDD$+2"PMADS+ZJ6K . ;3$H4!)]@*&__CDS*4$J=B !&V+U>(68@
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M,M4_7584GVJH:4!"%3%;^E".D6!,G1$ X;&$D$ S;JND)THV.%N]"V%]+A8
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MO62!][R3W<Z2O#/L41&PL<4;4<^='66?+3O4YE";X2C_BQD,#/80,,%B6&-
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M1T\55<;$A-+9 ,$ 1T#&V$9"Q,?&@A@>::DI6<4& \= !08#04?'AH#8P.W
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M,96)T<TT#?]TT-]YI@V 3 :4<0.++)/98MDMU/2%BQF &27,!E>\,@MEEG0
M&1D1L">+'TR$9:%A&<32F!\)N"A, @3T1U=;">JX(X_FS4;/! *,%-N/]D3
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M("K'11L]YY&S+=A,/M$B.:V2N.70I+T+@4NNE-\BEYRX$V$]PT,Z?)?N2U$
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M:W2SFVJTUR2_K&BAH/\ &W1$P356QK,%Q-D0Q:$*(VI@Q<HT8!'/X3,,&C
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M#W0=K0BDA!Z0<<!5[5C83C("GLS0B)R(BH7.49P 9;Y!*SR-)"+)F=!/H42
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M-2!&F\/O%>*/&>/"!DBL6U_1W<GD*7] :/@H^"V 21%$0##$?P.X$!<Z@%O
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MT7$00 0O""##4@.X!0,*'R 5UP10AF)=! M  , 2\"R!EU!P.1*:!79]<@,
M^H@H1 3BI(/;&WGD4=$>&_1&7CJ.E6+)G:GX0,<73O2&9@=:]H!0;S)PP<AK
M6YC6P8*C@%(!!@$ Q] GXQ" !R&OG2&(8&K492.8NP$P*1X:M9*!-=:5B>&J
MR42G77?;")#-<]%)Q^I)SH@C #6P]@KK=^&)-QXZ$$HCYSEBY:?L9S;-0&0R
M_W#Y4]^T",33#W[*VJ'J+PSM<6!$:Q#W+8 )8M2@@\1"F(Z$M[;K[KOP#B.
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MJ X9_Q60Z/FRZ,F)<@YU/R &ZP!$1CC\ (VOF]T4+G*L<CP1 "&RITQG&D=
M-0 "!"A  ?J3L1<83!*!S$D5$F 4GSSO8-);Y-M,%XH J"![%:.*"GKS@@G0
MA8^LU,DT2Q</0Z"PHK590!18HJ$E8 )1=J@6E@0@%$RZ8!:IPN=JU/88L]V
M,&58U*/@9"Y9/0=-UUA-!A8TB$KX\JYKFX3/_+*"E9DH9ALP(@JY>A N=N%(
M*US8H@0@JC&"TVP(FDR<S/E5N%F ,-@D&W\R\)@8DD(P:/W"' 8#'(HAU'B^
MRU4$O-;/WO:6AY'[)W '"A;<'L<L15#H0AE*.8?B#G,9\/]H?DX1DFC-AZ,=
MI>@4$0*-88AQC"7=F($$I-*5*F@CZ5+716G*WO:ZRQ W[8!.W[,]$G2":\C+
M25T64%2?6 F125W84N-1A #4 *K;*T%Q ? L\#G@ ^E)C_FT^X-K)2)&#$
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M ,,U=I &B!^'^):H'J[99AHEC]!&6Z.(*LH;;[OM5JDA$70@')K0+2& >QO
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MQC46E<*]B:VO&MXPAU_Q'R2T2W.'^V>Z#HL,9 '@K32J:;KZL0%VL>$8@ V
MJ';B@,YY;CIN4(A(T$('.+ED( M"PQ",\1D"@'&U'$5 0/7U6HB:!0X"6^,7
M>FK4WL$O?TYQ!NF.E,EF)'2XT1L  -*B+P[P0Q@I%5<&#-!'1'H)'UB^@4V0
M,3[MGM=\RTL?>+E+CZ!FE+SORO-Y$83*H4%E_[E3991\XXN) C8JE@H,(" B
MT%__0B$)K1(PFXR'JK >& $9#H< W!I7P'0GPN&!< VP<>$N;+K#LIZU-]W5
MBT >#@/R<$:LX':&)JGS<=P;GD0D2]D3(P'''XB  U@TG397RUUY5(I#'B?D
M+D;G9@W0H@&LI>07C(5[&F'!D\UXNX#-MDI*$=]V@=H4EYR()E.1G(^^5K0<
M3&&,JQ! \ZCDO*/@2$-KGHX-^OTE'3-E2301D3*D8J1V$WJW'%5?GBF^,)L,
M*>(_)1%2#V-0X+'RO55MM%>Q:AI'V9+D JPTJ3"=:63"I]-FLQ]:TQIK< A%
MU<1P@\XE3$UA6//"*O]D(:V+;G2_C8@7"^BB8T%2ZC)((VX@KC(20T/LA@E$
M*5ZP S3MLZP,-"!"%4E+DE8QQ3%R8&59+$,\/%X<T_J6I$K6MT[(7>XR\A-0
MHMOWNJW<G*8T(]ZU@"N]*\@^$?!C"FP+B<;6C ](XF#@'PC.1Q )YY"\V[IN
M5H9 EJ1Q>P7:NQ!?ZLY"?Q/FV.3S]N,D6(Y -$NZ]W]74[FC#PA 6*I0O[XY
M1'X,CS;IP$<Y[(,(J(\Y G)X1^<.'F&$Y\KJ"A/B4KSJPJ^.;OWK!RNF[(J'
M1!I$$?S 8RK72=>O2?>?MPZCB/T8B(8V489Q@@0 -?Z)N()S_%)[J*8M.T/_
M/"2V@SBH3(,XQ%"H%L(\U$[8W=W1SK*9@05,P$ 0""CA67?=1#/D"*IHB$GX
M7ILP2%4P$@D,P 8HR\<<1:=8 );\&TF<8/8@TE&D2,#D5%(X7/F0WL7!SYZ)
M7L3-C.F='F%\VW<%51&47HBDA!48 2/YS]+,'NU=E>VA!A-N#>\%A\NY'=&I
M!P%LH!007\UI4#G45L^QA52PFC3-U7A8&#9QPLUAWQJR(3M,0+304_?Y$2 M
M Z_5#;)07;2D&#P)@_H)!&X,0FU%U[)P@ ,DH)--"3]-P7%82\_4U(LY0?^1
M0O&$B ,8A0%T@&C@R/@4A17@BX-8CP(N8(%H413Y_T(%?-0$_MWIP1$0=J#R
M\(S-N,07]$B#G%195,^4U! *XE,2C 6<P<4'Q-N.6-=C@$&23,OHC5=NX>!N
M890RH@]ZI0C1_&!-P M+G$0-'<$ML%9ON!("06$3VEXX/@TB%(BGH)54Q$?+
M$=BG%5]:C1HXV$C/S0J#@.'/M9H>[(K>=($5MN$_ F0XV!I@%5M ?1\ L([X
MX<I!T(HI-L[6I9]$T$5NV $^=0-:>,Q+C9TB[0"=\).TA0R(?=@.O@#K-(@+
M.$!*-@ =286UE 4'9$$WJ(P9A$BXF)DHT@Y#JH0OA& QT. R6B-=2-P0=(<=
MU)#, <%B'$$?P* ^A8249/]D<@E):^%#605 !%C>1E3)O6A>C!6!RF"43]V+
MQ'52Z@$A;M6"CDAC-5+B$ 9/1R7))@U7[%E3(9!C[:4<.-YE:B1"VJ&C@:W8
M>P! %FHAS7%AMCF6./0D&,K-&-)-&=[-HMS5>7!"]07D96+F*R245-!0/U@:
M;,&3&#18-9#.K[$%04@%1*:?&V1B;NS&E."# XA*]="FQU1)^]! "@#&:-'0
M!D3&:*C,Y-!;NR#+0S3$'+*"/=B /HT=1^!D[=349HQ/ B13=9SFZ+V;&%BC
M2^ !'7F9JB"&B( 5:]T#4D E3Y!-B,R?N(!1!\!%"8",+-R+$,J;4N@ ^4#C
M6C+_8PY.7(H 6E")7F[QX&H]Q/+09U04CQ$6AILEH2OM)<G=AEX^*"C 1M?\
MY?T41V*Z!UAE$F%^2J@MGCA4!QCNIF/"BO-!&/3AQJL)0F:ZZ(L:$KP1Y!MJ
MS+*Q$300"HX@0=\51R:R6A?)@(0*@C?\FP T6VTBZ70$1_Y@CA*5P9,N0 ,T
M0)-P@'UQP$IZ@4T " ^Q00>XQ0D$XQMN$$_ 17H\I^U8BQ8=A/>5&NG4#U Z
MQ5+ 3S/L!A9Z:"[4T_+@8GZ(&XS8E'K>ATU%E^4%E V,I6HAG@YTAP[4H.\X
M(X'NV9QM9X J68&ZY:0&#3>>H#=2U82JG%UZZB[-DH6Z_UQQE,M[8,"7?>?O
M'=@&D<,R]1P2F*BMX&/0H2%ZO&BN7F8"%$#_L=U<&$"-50"V],7P9(".OD&5
M?=B@$ .V,(B0#JE;G!26O$5<D P)7D_$',&QR0,!0, \2&G#,$!FW80W.,TR
M9, )J$ (6@!&9*1)(>F+V!UMXEW:G=*3ULA'-1*<4@$-],XG[88)QF)B**54
M--(.I 4J]BD^F>!5WD>G&%Q\%B#@V015,(.,A.7Y6"-3D.6C5JJDIMYO#4D8
M6:JE5F#I95Q&C<EH!&*HNNS+SI>A@-.%LFH2&&0PW6G*YNQ@M"H"6"8XL)7R
MR8WR069=G2$_<H(VZ>K28I\\M/^+1"Z 4+37*DQI,3@#6X!8W_U',ZQ%-  I
MM$;K!)P LT7 ]J@K"J0 38%3DKB+5  6:T+  AC  G#*M8PKJ1#A'*QD'P)
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M0&,V+&%5%@3-\Q8%L R80GMVJ%DT..2Q]RK'NFTO/JJH%DPFI^851LLV7V%
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M=CM\_,YX#@[W_;@ZC\TT0XU!@ Z\Z$TC\*_-AG\&$FQ(H,X& X?%WN6X]PX
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M!%2:G+#UDDL;0?K!0([IT+,;1<IY19%"-@RWT"PJ(A>/.O( H<.CD=;3%8J
M>E7===H$I)T%W&F#@'?;,.30...9-\UYNY6!Y$;^R?312C5AD-)*&@0 @7_Y
M8;#!31.8"& &!70P8  *+C #  E$_S '!CA5@ $!"C; 8$@X#1"4 PPL@),+
M,'AH5;,"?#M#"R_ 4.)W*7X)G7-7M(@8 S_0.&]8-M[("2(#*",D','P*U=>
M:O#%ZDMX %#!E DKO####3N,B9=6=K(EQ90A04!P7W)S#)VE10-G+AIO]UI
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MJ (A($!LH=170J2I#/P:&2"803U850,;@$ &M:K?/. 0!G_KPPHS0!2Y>F\
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MR.94.*1SK Q%Z"W,5C GA_0*(1B% '! LV8P@08P8  3(.P,O"3BQ"ZV"EK
MEV$VP%BOIP7L"-CZ(?_TM5G--OO&1F*YP5A6W T@ 1:@),10,=2=9:0#J*P)
MR>")&SR#7C1#^(",N&44I25+,2"%A>1(!># O[G,,(A)C:14/5B/H.& ,^C=
M,X2/:VR>F@Q;$.Q ,)!, %3 82'1_=1#H91#3)2&<T6<SL0#_B11RJU(YQ12
M!FQ.=B2$(U6#43&$/\"2)I1<LA@ ,M@/>A2?7\Q<S"V??M%<#$3=4.A<]'D(
M!TQ ]7D;!J 5 <@5(^F!3_3-@S1 ;2#8J;WA!)A3"8B,["U-ZYE8$<!?863
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M0,,R:!X>K:((<H\N&(,+ZI8OW*3=:8[C,4\;V!82BH:*<)25%1H9=)W]]09
M?.8<061TL(,0@(;&%%JR"-+586564N=6/LH1NE[&\4%WU)XK:0(L+>$N#E4X
M&L<5PN7[R&48T25]\A=>XO\E/49%4&! $)5 ?W(54-1:#^T55@V.SS!F#$Q
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M';%;YO@F:T:3&'Q9?^B<5]'<ID&+F<S1AL0;"[ F:<J)9AP1[[$/[E9>+^Y
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M>\YV//9:&^U%\$*RW-'\DC?A-[A:F,F+MO]OD8\)5[%WI:,#$"_V>.Q*G(%
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M8M&"_XF L@42=*PB7.R(1PL[^M&07H4 9O.[3A@C"&)CP/SP%\]UK(/$T.!
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M>J6";D 5%K@7D\1^[1==<N ]@R8^ 546]Z=HZK8A1O!^_9>'>O@A ]  *5(
M!@"(!0 '"Y  "P !'D(6O^(=M&("S0$0#AB)"! .)09)CA >=, ;!A!2XR*!
MD4$"%= :_\OF2?]"@J-T"3*'"94@0VQ07JKA"V)@@=)0 9=@9(B"#K;A(YG@
M?+W7,+_G@\QF.K#A=,Q11,*  2&!*-6154.4!-:4*U9'(R(1<G?2B^I%'MJW
M?>I615\X9UVX*>)'!=ZB#_S%;[&W%T>GALZV5.G'"A""6'^!@GS'%ABB:(]E
M"@FUA_JXCWD! 0NP &<#7(.(  50  BP -6$ ]D%!YJ6/U48B8_'3Q,0@WK3
M&'E@7&>(.;,T %[@B=A@*I6@ ZAC&C%GB@[G'W"0BTW6?O! .UC2B!;8&']$
M2S-@)H_"$%8U'>E"AA?1@\ (=T&H.67X<+:!C#&A+]7A$EA51/_*M8KD04@U
M861K\I"X5$A8Z%[=UXU@B!]=X 4UHY58! 6Q%H+X,F"&@(=7H6_J&$P$=H:M
M0']KX2.UPG>(5H_C=(\')UG\N)=\>0N%") .D%U.\"4 ,Y#7L0#*L$G ,!T;
M$5I"")$TT#83R7'-8)&.\#1T,$DD9W*3P0%E)!PUXG(;49(FN0\.!$A3PI-1
M\B]CUI);PD:/M%,V,%(:@PZ!L6UF8E5'M8YL6 A^8$)EZ&,M$BYWTB?+2#+:
MUA L 3A0N9PI(08C0%,.@WT&4$AFQ31EIY4UTY5=^95@*05=()IBY&<(D(]X
MX39KR9;1Q3^NL$F(-2UP&2$Y@ /KAI?_1-"7^)F?L "0XR)J)( *?%-- 6"0
M@,@2_V@,9K(2#.AI^B(P&)=1W3*9_],_>:!=9UB-,&!T&V@-C3$  [0!=W4E
ME&.*I10,N546*L$5]^2*\) B5I$C)" *,R Y-^D#LQ$8)B%,JZ*C?@",9V13
M$2&$P4F BU$/(E =6R8"6% O2@J5\ !-T(DL97 O5*DQV8B=6:F=-,.=W:D\
M8!F63U !5#(]Y*F7>'%/Z3D@P(<MK8!@>:=@=.D),3-.=<@A1("6^IFG^MD
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M.[;1Y99W)T=ZMZYJ(8=VF03VF2%Q&[][.0'_$$"WGO$BN 0' @ :E#8=.)H
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M"9NQT- 8S95,"U21_Q)* %6%4.>E');P,!"301O$LOJ &*FINTN5+ZXH0A&
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MT^2(ND@#!'1*LT6  Y3 5%1B8U@ U-R')"0)#RR  #1 !BQ5CK""NMD(@^D
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M!%"J1*@ 6W2  [C(!$  K3AJ-*P,1>A1Q.;;1JJ'A]H$$!A!"TQHI4Y HS:
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M,L8K!T16/.(!V+4A&>^K8& -/^WIP?AMG\1?RI%6H)H ^=WQ.+>=A\@8R4#
ME#XB*E5$-5S(!VS%QW[!RDA4/;3;U3QR!&U. WT !RC" O#P!^A/Q=J7DW2
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MQ,,V#Q;TP'EQ6&WU$.9 SG&;=_B>=\^!&'G-7L3!0$!E"HTX*ZI$3.(-?@
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ML8E<9093 H;R!$ @ "7GD8(F.HHD)"<,EKM[_PY^ZH!;#!HP0/'M5BT"#FQ
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M_QD^-Q@O_69[@7)E])RY 30-H$D(Z"([/PI2+O%E("H00254)3DU-K.9!<1
M$K.IS30T!0T.?& V^7B&#IAB -^T3K'(B4A#EF\)Z?1H2(\JK:IXHT$+*, Y
MN&(/=30 &A7(YU8PH""N<8<L### <C U4$ EP 'CT2%^UE"(+I[M"PQ-"WS.
MD !/?@".!M#IU-; @7DL$:E\[6N&S/(Q)HD@H_Y3YC)7RL;,=0&F,6TK/P@@
MS3O85(XX/8-1"?'-132"=0IQ70=_MLC9,0%J?BWMLR PCOF=,ASKV&)CO"<
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ME97SN<QB05::MBO;K@CGK:GP<[&JND[Y;C8:"MZ$;\]1I]4Q7_G* O]HF!O
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M3=O%<>].G5OUZ@V'=CDT83+@,E,\4B4L "DQX)XWC!L[)LD0$,/ +K_ <(A
M\2C2I$J7,FWJ]&FR"1P3).!IM<I'D %$CH19\M/--Z-T9'KIDFN-F#R$T&P5
MRLV ;A<#7.T9,*C0H1'L0>WK]R_@P(('$_:#Q%NM*'47]_RFY%)7DCE6!8##
MSMV-LYHUJ9U<BI40 &_B=J.Z.(. NWB]Z.5;^#7LV+)GTZZ]S%^DN?UV,NZ8
M=1N#EY'A??5!X,V$3C4T,S]+O+,,>D(X(/]'%?<_H*I7ZXTPP3;X\.+'DR__
MFG3IJKWK_@Z)=CBGR:M$NTF _WE&\^9>H7^N22)L&QQT\X1BUH##Q$] K29
M=]^9]R"$$4HX(86#5/ /@=BM9^!' &R000+OP;?6)^JTD8%*(BR7'W.<=<9)
M*U# <5@N^O"C(2*X^;0==WH!6"&000HY))$0QF+@/OULZ%M6/4$&WW,PH(.
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M+ 8=;WL&/" "YQ0M)-T(?!X1WP:89Q:>Q0]]BQ/"_ BP 0:YKQ3#XX],+HB
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M!>+\G6$B8J,ZKF,V<J,[OB-!5< X^D(PK%D&$)*@60\(FJ,2-B$;PB [!J1
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<EJJIGBJJIJJJKBJKMJJKOBJLQJJLSFILA   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ango-20230531_g5.jpg
<TEXT>
begin 644 ango-20230531_g5.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %* I0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3,M>_5X>8YABI8BK3]HU&[5O+8]+"86C&E"7*KV3N%%%%> >H%%%% !1110
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M'/\ HH>C?]_3_A4D'[67P>N)5C3XAZ)N;@;I]H_,BOQ<YI*Z/]6L/_/+\/\
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M.O@AJ"3>&]9F2QWAI=+N&,EK+SSE"< G^\,'WK]4?V;_ -I7P_\ M%>%VO+
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MRNMCW>.D5U?Z=ST,5C:>%T>K['ZA^(/V@?AMX5E>+5?'&AV<J'#1M>H6!],
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MS7$5*E&2W;U>MFS>6(C@:4(U$]NFUS@/VQOCW<?'#XL7QMKB3_A&M(D>STV
MM\K!3AYL>KD9SUQM%6_V3/V3[_\ :*UJ>]O;A],\):>^RZNXQ^\FDQGRH\\9
MP023T![YKY\8ECD]:]_^%O[;/Q!^#_@NQ\+^';;0XM,M"[*9K(M([,Q9F=MX
MR<G\@*^_K4*U'"JA@K)K37IY^I\M3J4ZE=U,3JC]./ 7[._PZ^&NFQ6>A^$]
M-BV* UQ<0+-/(?5I'!8G\:V/$7PA\$^++&2SU?PGH]];R#!66SCS^! R#[BO
MS;_X>4?%W^YX?_\  !O_ (Y2?\/*/B[_ '/#_P#X -_\<KXYY+F4I<[EKWYF
M?0+,<&ERJ.GH:W[9G[%L'P=L3XQ\&":7PNT@2\LI&+O8ECA6#'DQDD#GD$CK
MFOG_ . _Q<U+X)_$W1_$VGRLL4,HCO(?X9[=CB1"._'(]" :]-\=?MZ?$OXB
M^$-5\-:Q#H4FF:E T$XCL65MI[@[^"*^<J^PP='$/#NCC;-[>J\SP,14I*LJ
MF&T_S/WRTC5+;7-)LM1LY!-:7<*7$,B]&1E#*?R(JW7A/[$/BBX\5?LS^#YK
MI]\UI')8EC_=BD9$_P#'0M>[5^58BE[&K.D_LMK[C[>E/VE.,^Z"BBBL#4**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7^*/_)-
M?%?_ &"KK_T4U=17+_%'_DFGBO\ [!5U_P"BFK2G\<?4B?PL_"JOV"_83_Y-
M4\#?[EW_ .ED]?C[7[!?L)_\FI^!O]R\_P#2R>OT/B3_ '2/^)?DSY3)_P"/
M+T_5'O=%%%?G!]<(0&&",BOSU_;>_8N.GM??$+P%8EK8[I]6TBW3_5]VGB4=
MNI9>W4=Z_0NFNBR(R.H96&"I&017?@L;5P-55*?S7<Y<1AX8F')/_AC\!/T-
M27%S-=3/-/*\TSG+22,68GW)ZU]O_MN?L7GPU)??$'P)9?\ $I8F;5-)@4DV
MQ/+31C^YU)7^'.1QT^&Z_5\)BZ6-I*K2?_ \CX>O0GAYN$S]#O\ @E;_ ,@'
MX@?]?-I_Z!)7,_\ !2KXW:A<^)K/X:Z?<M!IEK"EYJ2H<&>5N8U8_P!U5YQZ
ML/05T_\ P2N_Y /Q _Z^;3_T&2OG_P#X*":/=:;^TYX@N)T817UO:SP,1PRB
M%4./^!(U?,4:<*F>5'/HKKULCV:DY1RV'+U?ZL\3^'OP_P!<^*'BVP\-^';-
MK[5;QB(X\X50!EF8]E !)-?9?AO_ ()9:K<Z='+KWCNUL;UAEK>QL&G1/;>S
MKG\J\K_X)_\ Q3\/?##XU3GQ'+'96VKV#6$-_,0$@E+HXW$_=5MI&?7':OU@
M@GCNH4EAD66)QN61&!5AZ@CK2SK,\7A:RITO=C;>V_WCR[!T*]/GJ:OMV/@K
M_AU7!_T463_P4C_X]2?\.JX/^BC2?^"D?_'J^^JJ7VK6.F1E[R\M[1!U:>54
M'ZFOGO[:S![5/P7^1ZO]G87^3\7_ )GX2>,-!_X17Q;K>BB;[0--OI[/SMNW
M?Y<C)NQDXSC.*]H_91_983]IB7Q(C^(FT#^R! 1MM//\WS-_^VN,;/UKRKXL
M31W'Q2\8RQ.LL4FLWC)(A!5@9W(((ZBOL_\ X)5_\?/Q&_W+'^<]?>YAB*M#
M 2K4W:22_-'S&$I0J8E4Y+34^D?V;/V>=?\ V?+.XTE_'4GB7P[)EXM.N+'R
MS;R'JT;^8V >ZXQGGBO _&'_  4VN?"OBW6]%'@"*X&FWT]GYQU0KO\ +D9-
MV/*.,[<XK[OK\+OB]_R5CQK_ -AN]_\ 1[U\GE%&GF=:I/%KF>GE^5CW,?4G
M@Z<(T'9??^9^MW[+_P"T!)^T5X&O?$,FBKH9M[UK3[.MP9MV%5MV=J_WNF.U
M>QU\@?\ !,C_ )(?K/\ V&9/_1<=?7]>#F%*%'%5*=-629Z>%G*I0C.6[05P
M?QR^)S?!SX6ZYXO33QJC::B/]D:7RA)N=5QNP<?>]*[RO"OVWO\ DV'QM_UQ
MB_\ 1R5CA81J8BG"6S:7XFM:3A2E*.Z3/F]?^"J5RS ?\*ZAY./^0L?_ (U7
MVMXI\;W6A?"G4?%UIIPOKJUTEM36P\TKYA6+S"F[![9&<5^&4?\ K%^HK]W?
M"]I%?^ ](MIT$D$VFPQR(W1E,0!'Y&OIL[P6&P7LG2A:[=]7K:QXV6XBMB.=
M3EML?#'_  ]4N?\ HG4/_@V/_P 9K[6^$?Q&M/BU\.-"\66<8@BU*W$K0!]W
ME/T=,XYPP(_"OQ]_:*^#U]\$?BMK/AVYA9;+S3/I\V#MFMF)*$'N0/E/N#7J
MO[&O[7C_  %U"7P]XB6:[\&WTWF$Q_,]C*>#(H[J>-RCTR.>#VX[)Z%;"JM@
M8Z[[O5?,YL-F%6G6=/$O3;T9^KM%<[X+^(GAKXB:7'J'AO6[+6+5QG=:S!BO
MLR]5/L15OQ-XNT3P;ILFH:[JMGI-E&-S37DRQK^IY_"OA>22ER-:]CZ;FC;F
MOH.\5>(K3PAX9U36[Z18K/3[:2ZE9S@!44L>?PKX/?\ X*IW 8A?AW$5SP?[
M6(_]I5R'[:G[:%O\5+.7P1X)EE'AH2 WVH\H;XJ<A%'7RP<'GJ0.W7YF^$?P
MQU3XP?$+1_"NDIFXOI@LDN,K#$#EY#[*N3[]*^XR[)Z4<.ZV.CY]59>=CYO%
MYA4E55/#/_@L_8OX,_$Z^^*7PBTKQI?:*-$EU"&6X2P\XRXC5F"-NVC[P4-T
MZ,*^/9/^"J-S'(R?\*ZB.TD9_M8__&J^Y--\.VGA#P+!H=@I6RT[3_LL(/7:
MD>T9_*OPFNO^/B7_ 'C_ #KDR;!X7'3K.I#1-6U>B=_,WS#$5\-&FHRU>^WD
M?M7^SG\9'^/'POL_%TFE+HS7$\T/V59_. V-MSNVKU^E>G5\T?\ !/#_ )-C
MT?\ Z_KO_P!&FOI>OG,;3C2Q-2G!62;2/7P\Y5*,)2W:1Q'Q@\8>)/ ?@J[U
MSPSX:7Q7=V8\R;3OM)AD:( EC'A6W,/[O?MSQ7QBW_!5*[1BK?#B)6!P0=6(
M(_\ (-?H(1D8/(K\_OVYOV-_+^W?$?P-8@+S-K&DVZ?B;B,#\V4?4=Z]/*?J
M52?L<7#5[.[^YZG%COK,(^TH2VW6A[A^S'^VMH/[06IW6B7NGKX9\1)F2VLG
MN1*MU& "2C%5^8<Y7'09YYQ])5^!NCZQ>^']4M=2TVZELK^UD6:"XA;:\;@Y
M!!K]7_V/OVM++X]>'UT?6I8[3QO8Q_OX<;5O$ _UT8_]"7L?:NS.,G^J_O\
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M\,-8\1FV\CQ1H-C+=6MY"HWRHBEC"_\ >4@''H3QWK4_83_Y-:\%_P"[<_\
MI3+7NFI:?!JNGW-E<H)+>XB:&1#T96!!'Y&O$G4>"QLI4=.63^Z^QZ48_6,,
ME4UNE^1^!5?<'PU_X)P6/Q&\ Z!XGMOB$\4.JV<=T(ETL-Y99<E<^;S@Y'X5
M\P_'OX37_P %?BEK?AB]3,4,QDLYNTUNQ)C8>^.#Z$$5]&?L3_MG67PKT]/
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M1_R0_6?^PS)_Z+CK[ KB_A7\(/"_P8T&?1_"=@^GZ?-.;AXWF>7+D $Y8D]
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MI^RPR:3W;W]#OP>6^QG[2KJUL%%%%?('OA1110 4444 %%%% !1110 4444
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MKI]-T&73[Z)M'GN9H'YDM)2=G/8XQG\16[:^"K.VN#<ZAY:R2'/V: 8S[8%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ2TMKK5K*+RFD>ZTV]M;4A"<7+/ 8\'L?E8Y[!37I\-B=J@\G'-*Y5B@MO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD) Y/ H 6
MBN&\;_&_P-\.U;^W?$MC:SCI:1RB6X;Z1IEOTKP[QO\ M[:%ID9B\,^'[O59
MVX674'%K']=N&D/_ 'R*\7%9S@,'I5JJ_9:O[D==/"5ZWP19]55F:UXFTGPW
M;-<:KJ=IIT"C)DNIEC'ZFOC6U^*WQU^,UOY>AV=SIMM+UDTVV^S1J/\ KM)D
MG\,&M3P]^QCXJ\3W:W_C+Q$L$S'+-N>\N3_P-S\OX&N&.<5<4D\%0<D^KT7]
M?-'5]2C3_CU$O+=GJ?C#]LCP%X=#)IDEUXEG!P?L$6V(?65]J_EFO _BY^T7
MXK^-/A^YT71]!;3=+SYTES:"2>= O.=WRH/R:OHWPG^R;\/O#$BSSZ=)K=R/
M^6FI2&09]=O _.O6=/T:PTFU6VLK*WM+=1@10Q*BX^@%/ZKF>*_C55!=H_U^
MH>UPE'X(.3\SXI^#^FW5]X!TF^URWFCOI8_FW1[&< D!R.Q8 '\:] A6QMP,
M6[$^]>\>(/!-K?HTEO$L<G]U1@&O.M4\)_9I&#18Q[5]"HN*2;N<-U)W.3_M
M*&/[D %0S7C7;!0NU16K<:"%S@%:DT_PZ&D#22QQKG^(\_E1J4K&IX=TQ[BW
M'RUTR:&MO;O*_P#"*V/#.@LML@6)EB/)ED&W/T'6NJ?2K>2-8V3* YQZ_6JL
M0Y(\NM=#EN&&V-F/TK?L/!,\F#(!&OO7=16\<"XC15'L*DJN4GF[&#9^$;6W
MP9,R']*UX+&"V&(XE7\*GHIV(NPHHHIB"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***YSQ5\1O"_@BU>XU[7]/TJ->OVFX56/L%SDGZ"LZE2%*/-4DDO/
M0J,7)VBKG1T5\[^*?VV/"&EJXT.PO]>(X$Y3[+ ?HTF"1]%->5ZC^TQ\5OB9
M=?8_"VF'3HG.%72;-KB;\99!M'U"5XM;.L'2=HOF?D=U/ 5YZM67F?:E]J%K
MI=K)<WES%:V\8R\LSA%4>Y->5>+/VJ?AWX7AD,>L'7)TX\C2(S.<^[CY!^+5
MX'#^R]\3_B=-'=>+]4^SIG</[4NFNI!](P=B_@!7J_A+]C'P?I CDURYO/$,
MR](Y6\J ?1%_QKF^N9EBM*%'D7>7]?HS;V&%I?Q*EWV1YCXF_;I\0:M<O9>$
M_"T-O+(=L373-=SG/0^7'A<_5ZYQ?!O[0?QNFSJESJ-A8OSB\F%A;J/^N4>&
M;\=U?:GAGP#X=\&Q[-%T6ST[C!:"%0Y^K=3^=;]<,LAQ6,=\?BI-?RQT7]?(
MKZ[2H_P*2]7J?(_@_P#8&LX72?Q/XDFN'/,EOI<8B4^Q<C)^N*]T\&?L^^ /
M :K_ &7X;M#./^7BZ7SI#[Y;./PKT2BO8PN1Y=@]:5)7[O5_C^AR5<;B*WQ2
MT^X;'&L2!$4(JC 51@"G445[IQ!1110 50U'1X=04[AAO[U7Z* .1D\!1R29
M,P _W:U--\*V.G$-Y:RR#HSCI6U12L.[$I:**8@HHHH **** "BBB@ HHHH
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E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ango-20230531_g6.jpg
<TEXT>
begin 644 ango-20230531_g6.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $T F<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA1Q<HP5EHS[KAK$U<5EE.=9W:NK^CT"BBBO(/J HHHH **** "BBB@ HHHH
M*HZAJT.GK\YR?2F:WJ@TNT,A&2>!7*:+CQ-JD@G8^4@W;0>M8SJ<K45NRXQN
MKO8ZC3_$%KJ#;5;9)_=:M2N&\7:/%HT,-S:DQ@MM*Y_6ET#QDZXBNOG3LW<5
MFJW++DJ;E<EUS1.XIKN(U+,< 57748'A\Q9 PQD"N<UCQ"'5@WR*HSY?=OK7
M0Y)&=F0^-O&5KH.BWNHWDC0Z=:Q-+(R@EF"C)P!VKY3LOB-:?M/Z;KVAZKI8
MBL(YMMMY!Y1"?W;*V>6XR3@#G'8U[+XHU ^(%FMI5$D,BE&0]"#QBMKX+_!7
M1_ ]F+BVT^.S1FWQPJ._]X^]80JS=1.F[6*J4J<Z;A55T^AU7PC^%NA?"7P;
M9:+H=KY$2H&ED?'F2N1RSGN:[:DI:ZY2E-N4G=LQITXTXJ$%9(****DL****
M "BBB@ HHHH **** "BBB@ HHHH ***1L[3CK0!XO^TOXQ\)Z7X>MM$\2QW5
MTMZXD$-C(JRH%/W\G/&:^=-%\)_"?QAKUAIUCK>O:;/=S+$B744;J23TW #'
MUKDOC5K&JZM\2M??69"]Y%<M#M_A1%.%4>V,?G7"V-S=PZI:R6'F?;4F5H/+
M&6W@@K@>N<5]UAL&Z-!*,VF]=-C\BQV9K%8R4ITDXIVU6MEYH]/_ &CM<NM!
M\02>!+&V&E>'=(VB&UC/_'P2H/FR'^)CFO"[B3KS7VG\</@N/BK?:'K-QKNE
M^&M:DTZ(7EG?RA7WXSZ]B2*\VTW]BO5]4U2VBC\5Z)=6K./--K/OD"=R%[FH
MP^,H0HI2=GU]3HQF6XNIB9.$;J^FVW16Z6.F_80\37^FP^*X+P-#X:B1;EKV
M8[8891P1D^J\_P# :^EF^.GP]3KXRT8?]O:?XU\0_M'_ !.M/#M@OPK\'Q2:
M;X?TIME])C9)>3#KN[D9Y]Z^:II.M<DL L9)UY/EOT_S/2IYM++81PE-<_+N
M_/LO)'[1Z;J5IK%A!>V-Q'=V<Z"2*>%@R.IZ$$=17Y0_\%2O^3B+'_L"P?\
MH<E?3_\ P3Z^)VL:QI>J>#[NWFN=-TX>?;7F,K"&/,1/N<D?C7S!_P %2O\
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MQA"-/G6YCM8/*>1#E2V22 >]>SDD)/%J26B3/D^+ZD%EDH-ZMJR^9J_LQ_\
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M^B+EOTKYV,ZV'Q+;5Y'VCAAL7@XJ$N6&GRMT/Q4_X9K^*O\ T3WQ%_X+Y/\
M"C_AFOXJ_P#1/?$7_@OD_P *_:;X7_'+P5\8H;I_"NLQ:@]L^V6%@4E7T;:V
M#@^M> ?MP_MF:C^SXUEX;\-Z4[>(KZ/SQJ-Y%_H\4><?)_?;/'H*]*&.KU*G
MLE#4\NIEN&ITO;.H^7R/S8_X9K^*O_1/?$7_ (+Y/\*/^&:_BK_T3WQ%_P""
M^3_"OK?X!_\ !1;Q5XV\;6WA?QS/9V%AJR-:0:K8P;)+6X;B-SR01G^=8GQ
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M(S*ISGK7)B*G)$VIQYF?//[4OA'2_%=C:ZKJ&KII)LI @EFD(B968?*1D<Y
MP1CIZ5\W?VT?LM_I5M<S6EJR>3;6;6ZR&]N!@/%,,$[VXP0>^17M/[3OPO\
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M+8^*=8^+7AW3_!][<6&LW-RJ+<6[$>7'U=F]5"@DY]*^J?V]/CI\(]1NM,\
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M+O[;?,'?_EG%_#$/\:/:)K0.7N)/)<^);H7%X&2W4YBML\?[S>];NEZ2;AL
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M B#L*EKLA!0.>4G(****T("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSKIE4*H X I:*TC%1V(;;W"BBBJ$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 45'-<);H6=@H]ZR+[6MJY#>2GJ?O'Z"I<DMQVN:5Q
M?16[;2=S_P!U>361J/B)RQAM$^?O(W1:YZ_UTD,L1V*>K9Y/XU7T6ZDGOEC
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M]*T;.QAL81'"@11Z58KOI4(T]>IQ2J.04445TF04444 %%%% !1110 4444
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MPL9BO;M1CL@HHHJ#S0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB@"S14:L:DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "HKA0T9!]*** ///%VGP%BVSFN#O+6+KL /K110!26, U(%%%%
M$T*AB :TK>PCD7DM^8HHH NQZ1 1U?\ .K$6C6^>=_YT44 7H=#M?EX;\ZM+
MHMJ/X3^=%% $Z:/;+T0_G5F/2[=>BT44 68]/AZ;:LI9Q#^&BB@"PMN@[5,L
M*^E%% $RQKZ5(J"BB@!^T8I-HQ110 S:/2FL@HHH CVCFCRU]*** &^6OI08
MUR.*** )!&OI3U4>E%% $JJ.E2A1110 ]13Z** "BBB@ HHHH **** "BBB@
7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ango-20230531_g7.jpg
<TEXT>
begin 644 ango-20230531_g7.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #R >4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?\:ZN678PYXKJ7Z*@:^MEMA<&XB%N?\ EJ7&STZ]*?!<1742R0R)+&W1XV#
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M +^/_P#%5Y-\5?"]GX6UZ!=/1H;>>'S!'N)"L"0<$\^AKZ"KQ?X\?\A;2_\
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M/@F\U&_M]/T62[2&X@*>:_E7 B7=E2.0<G '-?HY7QK^S;_R>!\4O^NVI_\
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M;K]Z::2,?C$HK8_X4OX;_N77_?[_ .M72>&?"]CX3LY+6P$@BDD\QO,;<<X
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MZ2"\NKVPTB:"YM[N:(Q/-$ ?.C/ W@)GG')/L*BOOM<=AI>K.T]]-<R27/\
M9;-*I99'4IL9.C(H48/'+'BO.AG<HTN:<+M*[>RMS<KM9ROKM9OF6JWL=4LO
M3G:,K*]N[VOY?C:W78](ANH;B29(I4D>%MDBJP)1L X/H<$'\:EKS"XL9],_
MX2Q+!+N+4'N(Y(PK2L6MR(O,*<\G <9!W<8%31V=P^GS):7TTMI-?62^5;+.
MGD@R@2$.YW<KUP>,=LU<<ZJ)N$J6JYMGV<E;57?PZVVNM+;2\!&RDIZ:=.Z7
M^>G>S/2:*\\CT::UDU&6(WP:SU:WCM%,TA"PL\7F #/*D.^<YZ>U>AUZ^#Q<
M\3S*<.5KSOU:[+K%_*S\EPUZ,:5G&5[_ .2?Z_?<****](Y0HHHH **** "B
MBB@ JOJ&H6VE64]Y>7$=K:0(9)9IG"HB@9))/ %4/%7BS2_!6AW&K:Q=):64
M(Y9NK-V51_$Q[ =:^0_C#\8+GQJKWFMO)H_A:!MUKH^1YEPPSMDF]3_LYP/<
M\UYN-QU+!0O/63V75G;AL+/$RTT75G3?%CXWS_$"&YLM+N9-&\%Q[A<7YRDV
MH =0O=8S^;>PXKX_^*'QF1K<Z1H0%K8QC9^[XW?YQ6#\4OC%>>*IFMX',%DO
M"QH<#%8?PE^#OBCXX^*H]&\/6C3-D-<7<F1!;(?XY&QP.N!U/8&OGZ6%K8VJ
ML1B_E'HO^">]*I3PM/V=+YON<WHNB:QX[UZVTS2;.?4M2O)!'#;PJ69V/^>O
M05^D7[+/[$^E_":.U\2>+4@U?Q:0LD4.-\%@< _+G[T@/\70?P^I]+_9_P#V
M9O"OP!T95TZ(:CK\J;;O6;B,"63U5!SL3_9!^I->O5]33HJ"U/ K8AU-%L%%
M%%=)QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4M6TB#6[
M7[-=&3R"P9DCD9-X_NM@\J<\CH:N*H50 , < "EHK-4X1DYI:O=^FQ7-)I1;
MT04445H2%%%% !1110 4444 %%%% !7(_$?XFZ/\,]'^UZC(9;J7*VMA#S-<
M/Z*.P]6/ K&^*OQDLOA^BZ=91+JWB:X7,&GHV!&I!_>2G^%!CZGMW(^+OBI\
M6?[#U*\U'5+X:OXGF&UI7Y2  DB.-?X5!/ 'KZUXF.S)8=^QI+FJ/IV\V>GA
M<&ZWOU-(_F=+\5?C!/<WQU_Q5<QR7<(/V#1XCF"U4Y(X_B?D98\]N!@#Y)^(
M'Q,U'QEJ$DLTI$9/RH.@%9/BKQ=?>*-0DN+F5I&8Y )KZ:_98_8?O?B*+/Q5
MXYCFTWPTVV6VT_E)[Y>"">Z1D=^I[8X->?A,#*4_;UWS5'^'H>G6Q$*<.2&D
M4>:_LW_LK^)/C]JZ73J^E>%89,76JR+][U2('[[>_1>_8']1/AK\+_#GPD\+
MP:#X9T]+&RCY9OO2S-W>1^K,??IT&  *WM'T:Q\.Z7:Z;IEI#8:?:QB*"VMT
M")&HZ  =*NU]-"FH'S]2K*H]0HHHK4Q"BBB@ HHI!0 M%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A..3P* %KQG
MXK?'(Z7=7/ASPG)#<:ZF5NK^7FWT\8YR>C2?[/0'KZ'GOCM^T59:397NC:%J
M"VRKF.^UM6&R =&CA/\ %+T&1PN>YZ?#/CSXX)<6;:5X?C-G8J-N_P#Y:2_[
M3'U-?/XW&U9/V&#UEU?1?\$]C"X2-O:U]NB[G:?%#XRVGA<WMEH]S)?:G<L7
MO-2F?=++)W.:^<;BXU+Q5JR11QS7U[<R!(XHU+N[$\  <DY[5I^#_!7B'XI>
M*+?1M L9M4U.Z;B-!P!W9B>%4=R>*_3']F?]D70O@79QZIJ/DZUXQD7]Y?[2
M8[;/5(01QZ%R,GV'%3@<OC15]Y/=O=G1B<7I;\#S']EG]A>V\,BS\5_$2VCN
M]7XEM=$?#16W0AI>S/\ [/0=\GI]H*H50 , < "EHKZ",5%61X4IN;NPHHHJ
MB HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%\+JH6:Z7W6/_&NF50H  P*+#<NB&0P);QK'&H55X %2444S,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHJ*>X2W3<QQ0 ^218U+,<"L+4M6+Y5#A/YU'?7S7#'G [+5.&UD
MO)ML8R>[=A1Z%)=65&22YE"@%W/1171:1H:68$LP#S?HOTJYI^FQ6,? RYZL
M>M7*!-W"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5BZD3Y_7M110!E2=_I70:.H
M6S0@ $CTHHH6Q4MR_11102%%%% !1110 4444 %%%% !1110 4444 %%%% !
B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ango-20230531_g8.jpg
<TEXT>
begin 644 ango-20230531_g8.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X0!P17AI9@  34T *@    @ !0,!  4
M   !    2@,"  (    6    4E$0  $    ! 0   %$1  0    !   >PE$2
M  0    !   >P@       8:@  "QCE!H;W1O<VAO<"!)0T,@<')O9FEL90#_
MX@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "
M  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8
M 0    #3+4A0("
M                 !%C<')T   !4    #-D97-C   !A    &QW='!T   !
M\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:
M   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V
M:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,
M  QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0
M9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="
M($E%0S8Q.38V+3(N,0
M                        6%E:(        /-1  $    !%LQ865H@
M                 %A96B        !OH@  ./4   .06%E:(        &*9
M  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE
M8RYC:
M      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O
M;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M        9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N
M(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG
M($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A9
M6B       $P)5@!0    5Q_G;65A<P         !
M     H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9
M !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK$\:_$C0?AU8_:-<U6
MSTV-AE1+)\\G^ZH^9OP!K#$XJCAZ;K8B:A%;N322]6]$:4:-2K-4Z47)O9)7
M?W(VZ*^??&/_  4*\-Z4[1Z-I6HZLR]))2+:(_3.6_-17G^M?\%#?%5V6%CI
M&BV:]MZR3,/QW ?I7YIF?C-PG@Y.'UGVC7\D927_ (%91?R9]=@^ <[KKF]E
MRK^\TOPW_ ^PJ*^(;C]NGX@3$[;S38?9+)3C\\TR']N;XA18W7VGR<_Q62<_
MD!7S_P#Q,%PQ>W)5_P# (_\ R9Z7_$,<WM?FA_X$_P#Y$^X:*^+[#]O_ ,<6
MK#SK?0KH#L]LZY_[Y<5T6C_\%&M2C=?[0\,V,R]S;W31?^A!J]#"^.W"55VG
M5G#_ !0E_P"V\QRUO#G.X*\81EZ27ZV/JZBO _#W_!0GPKJ!5=0TO6-.8_Q*
MJ3(/Q!!_2O0/"O[37@7QB56T\2:?'(_2.Y8VS9]/W@&?PK[/+./N',P:6$QM
M-M]')1?W2L_P/!QG#.:X76M0DEW2NOO5T=Y14=M=1WD*R0R1RQL,JZ,&5A[$
M5)7URDFKH\-W6C"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5XG^VC\7_$/PCT+0IO#]^+&2\GE28F".7>%5
M2/OJ<=3TKVROF[_@HU_R+'AC_KZG_P#0%K\^\5,=B,)PKB\3A*DJ<XJ-I1;B
MU[\5HU9K30^GX-P]*OG-"E6BI1;=TTFG[KW3T/(A^VE\2#_S,"_^"^V_^-T?
M\-I?$G/_ ","_P#@OMO_ (W7EF*.U?Q%_KUQ)_T,*_\ X-G_ /)']"_ZNY3_
M - M/_P"/^1[;\./VN_B#K_Q#T&QNM=62UOM1MX)D^PVZ[T>5589"9&03R.:
M^U*_.'X/?\E:\+_]A>T_]')7Z/5_3_@%G689C@<7/,*\ZKC.*3G*4FE9[<S=
MC\?\2\OPN%Q%".&IQ@G%WY4E?7K9(****_?S\S"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ IEQ<1VD$DLLB1Q1J7=W.U4 Y))[ 4LDBQ(S,
MRJJC)). !7QI^UG^U--\2=2F\/Z#<-'X=MWVS3(<'46'?_KF#T'?J>P'Q/'7
M'&"X8P'UO%>].6D()ZR?Z)?:?3S;2?T'#O#N(S?$^PHZ16LI=$OU;Z+KZ79V
M/Q]_;K^RRS:3X*,;LN4DU21=RY_Z8J>O^\W'H.]?,NNZ]?>)M3EO=1N[B^NY
MCEYIW+NWXFJ>:,9-?PUQ9QMFW$6(]MF-1N-_=@M(1]%^KNWU9_162\/8+*Z7
ML\+'7K)ZR?J_TV\A:3M2T=*^2/;$[4HZ5+!9379_=0RR?[BEJFE\/W]NN9+*
M\C7U:%A_2M(T:DES1B[>A#J13LV5.AHSQ2NIC;# JP]1TI,<UF6% X%(.#2F
M@#7\*^/]=\#S^9H^KZAIS=<03LBGZ@'!_&OO[X%^(;SQ9\'_  [J6H3&XOKR
MR22:4J%+L>IP,#\J_.DG%?H5^S3_ ,D$\*_]@]/ZU_2'T=<;B)9GB<-*I)TU
M3NHW?*GS15TMK^9^4>*>'I+"4JJBN9SM>RO:STOO8[BBBBOZX/Q$**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^;?
M^"C7_(L>%_\ KZG_ /0%KZ2KYN_X*-?\BOX8_P"OJ?\ ] 6OS7Q@_P"2/QOI
M'_TY ^LX%_Y'N']7_P"DR/D\C)HI#TI>HK^ 3^F#H_@]_P E:\+_ /87M/\
MT<E?H]7YP?!\?\7;\+?]A>T_]')7Z/U_6WT;_P#D7XW_ !Q_])9^)^*W^\X?
M_"_S04445_21^3A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^BDY/Y5CB,51H0]I7FHQ75M)?>S2E1J59<E.+;[)79M45Y=K'[9?P[TABO\
M;WVIAVM[660?GMQ^M93?MX> 5;'G:LWN+,\_K7R];Q X:I2Y9X^E?_KY%_DV
M>Q3X9S::O'#3_P# 6OS1[-17D-C^W)\/;MPLFH7UMGO+928'_?(-=5X>_:+\
M#^*'5;/Q/I)D?[J32^0Q_!\&NC!\:9!BY<N&QM*3[*I&_P!U[F.(R',J*O5P
M\TN_*[??8[2BF6]S'=PK)#(DL;C*LC;E8>Q%/KZ5--71Y.VC"BBBF 4444 %
M%%% !1110 5\V_\ !1K_ )%?PQ_U]3_^@+7TE7S;_P %&_\ D5_#'_7U-_Z
MM?FOC!_R1^-](_\ IR!]9P+_ ,CW#^K_ /29'R@1Q2<TO6@U_ )_3)T?P?\
M^2M>%O\ L+VG_HY*_1ZOSA^#_P#R5KPO_P!A>T_]')7Z/5_6WT;_ /D7XW_'
M'_TEGXEXK?[SA_\ "_S04445_21^3A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ;=:S(O GF/V>'/L""Y_$"OESQ[\1M:^)NMM?ZWJ$]]<,3MW'"1#^ZBCA1[
M5AGK7\K<4_2!S3$S=+)(*C3Z2DE*;\[.\8^EI>I^RY-X8X.C%3S"3J2[*ZBO
MU?K=>A[1XD_;N\=ZT[BTETW28VZ"WM@[ ?63=_*N3O?VG/']^^Z3Q5JJD_\
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M.5*4K><I)_@HGZ_EGAOE>'2>)O5EYNR^27ZMGK>N?MO_ !"UAF\O4K/3U/\
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M?Q_ .38I:4N1]XNWX:K\#]-M$UZQ\2Z='>:?>6U]:RC*302"1&_$<5;K\W?
M'Q1U[X8:J+S0]2N+&3(+HK9BF]G0_*WXBOK7]GS]LG3/BC+#I.N+#I&NOA8S
MNQ;WC>BD_=8_W3U[$]*_HO@?QJRK.YQP>-7U>N]$F[PD^T9:6;Z*279-L_+.
M(O#_ !N7Q=?#OVE-;V7O)>:[>:]6D>VT445^TGP 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAU?X&W(M65M2T&9]TMF[8,1/5XC_  GU'0^QYK[.^&GQ9T'XM:(M]HE]'<*
M/-A/RS6Y]'3J/KT/8FOSB%:7A3Q=JG@;6H]0TF^N-/O(?NRPMM./0]B#Z'(-
M?L7A_P",&8\/*.#Q2=;#+[+?O07]QOI_=>G9QU/A.)^!<+FC=>C^[K=^DO\
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M'_%VO"__ &%[3_T<E?H]7YP_!_\ Y*UX6_["]I_Z.2OT>K^MOHW_ /(OQO\
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M9>[+_MY;_P!Y2/YKXVR)99F35)6IS]Z/EW7R?X-!1117Z@?'A7S;_P %&_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *RO&7@C2?B#H<FFZS8P7]G+U21?NG^\IZJP]00:U:*Q
MKX>E7IRHUHJ49*S35TUV:>C1I3J3IS4Z;::V:T:/C_XW_L*ZIX5,VH>%6DUC
M3URQLV_X^H1_L]I /;#>QZUX#/;R6D[Q31O%+&Q5T9=K*1U!'M7Z?5P/Q@_9
MM\,?&6!Y+ZT^RZGMPE_; ),/3=V<>S?@17\Y\;^ >'Q#EB^'9*G+=TY/W7_A
M>\?1W7G%'ZIP]XE5:5J&:+F7\ZW7JNOJK/U9^?@H'2O3?C/^RIXF^#S27+P_
MVIHZG(OK520@_P"FB]4^O(]Z\QSS7\NYODN.RO$O"9A2E3FNDE^*>S79JZ?<
M_8<#F&'QM)5\+-2B^J_7L_)ZBYS28YI>U'7_ !KRSL+N@>(;[PMJL-_IMU<6
M-Y;MNCFA<JRGZC^70U]7_L\_MMVOBU[?1_%S0V&I,0D5^,);W)[!^R,?7[I]
MNE?(F*2OL^#>/,UX;Q/ML#.\&_>@]8R]5T?:2U7FM#P,^X;P6;4O9XF/O+:2
M^)?YKR>GS/U!!R**^/?V6_VOI_!$]OX?\3W$EQHC$1V]VYW26'8!CU:/]5^G
M ^P()TNH$DC=9(Y%#(ZG*L#R"#W!K^X^">.,OXFP7UK!NTHZ3@_BB_/NGTEL
M_)II?SOQ!P[BLHQ'L<0KI_#);-?H^ZZ>EF.HHHK[(\$***KZOJ4>C:5=7DQV
MPVL3S.?15!)_E4SDHQ<I:)#C%MV1\0?MI>/#XT^.5];H^ZUT-%L(AGC<O,A_
M[[)'_ 17DAKUCP%^S+XR^.^KSZPUJ--L=1F>X:\O<H)-[%B47[S=>H&/>O?O
MAY^PEX/\)I')JWVCQ!=+R?.;RH ?9%/_ *$37\.T?#WB;C#,JV;1I>SIUIN2
MG4O%6;TLK.325DFE;3<_HF?%&49%A:>"E/FE"*7+'5W2UN]EKJ[N_D?%MM:R
MWLPCACDED;HL:EF/X"NCT[X+^+M756M_#&O2JW0BQDP?QQ7Z$^'_  CI/A&U
M\K2]-L-.B4?=MX%B'XX%1ZAX_P!!TF7R[K6M)MG_ +LMY&A_(FOT##?1WPM&
M"GF686_PQ45]\I._W(^7J^*5:I+EPF&OZMM_<E^I^?>I?!3QAI,9:X\+Z]&H
MZDV,F!]3BN<NK26RG:.:.2&1>"CJ58?@:_26P^(.@ZK,([77-'N9#T6*\C=C
M^ -+XI\!Z+XZLS#J^EV&I1L,#SX5<CZ'J/J#2Q7T=\+6IN>5X^[_ +T4U\Y1
M>GW,='Q2K4Y<N,PUEY-I_<UK]Z/S5%*.*^K?C#^P'9WL,EYX-N6L[A<M_9]R
M^Z)_9'/*G_>R/<5\O^(_#6H>$-9GT_5+.>QO;=MLD,J[67_$'L1P:_#.+.!<
MXX<JJ&94[1?PSCK"7H^C\FD_*Q^BY+Q'@<UAS82>JWB])+U7ZJZ\RB!7U?\
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M-<<&OO[]D_4?[2_9Z\,OG)CMVA^FR1U'Z 5_1GT<<8XYKB\+TE34O_ 9)?\
MMY^6>*N'3P="M_+)K[U?_P!M/1****_KP_#@HHHH \__ &J/^3?/%'_7H/\
MT-:_/[-?H#^U1_R;YXH_Z]!_Z&M?G\*_COZ1G_(\PW_7I?\ I<S]V\*_^1=5
M_P ?_ML0ZT@X%+1UK^>S]//M/]B+X,1>!/AY'X@N55M4\0QK(K=?)MNJ*/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN>,79Q_WYK\Q\9*KI\'8QKM!??4@CZ_@."EGM!/^\_NC)GR^.13J0G HZU_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P! %'_P7'_(/]9LW_Z"9_\ @3_S/(?^&'?AW_T#;W_P.D_QI?\ AAWX>?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"I]"*3I7\.[:,_H<*?!,]M,LD;,DB$,K*<%2.A%,-'2A-K5!Y'Z!?LT_%O\
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MEE#[;]Y_RQ6LI?);=W9=2<\S:GEN"GBZGV5HN[>R^;_"[/IKX7^!H?AK\/\
M2=#@VE=/MUC=A_RT?J[?BQ)_&MZBBO\ 1O"86EAJ$,-05H02BEV25DODC^5:
MU:=6I*K4=Y2;;?F]6%%%%=!F%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<GNWZMVV75LHHHK[(\$**** "OF[_@HU_P BQX8_Z^I__0%KZ1KYN_X*-?\
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M]]G+?K7V.4?1YSRO)/'UJ=&/6UYR^Y6C_P"3'A8[Q0RZFK8:$IOSM%?>[O\
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M?T5^._C?_@FM^T9\/O!NK:]J6HK'IVBV<M_=,GB0LRQ1(7<@9Y.U3QWKQO\
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MK'_!337OA+XRN/AI\/;O^S=4M8D;6=8CP9K=G4,L$/96V%69^HW #!!- 'Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQC/:@1ZG_P $V/\ @H:O[:7AS4=+UJRM=+\9Z!&DMU';9%O?0D[?/C!)*X;
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M\A\G[>7[47[)/BVQ;QO)KC071WK8^)--'D7J@_,$D"JW'JC\<9]*_3/]D/\
M:ET7]KWX+V/BS1T-K(SFVU"Q=PTEA<J 7C)[C!#*V!E6!P#D#X7_ ."@/_!3
M3X1_M9?LU:KX5TW2?%8U[SX+O2Y[VPACBMY4D7<2RS,1F(R+P#G=5[_@@#XC
MNAK7Q*TGS&-EY%C=B,]%DW3(2/J,9_W11T#J?I51114E'GO[6O\ R:S\2/\
ML6-2_P#262ORY_X(F\_MOV__ & [W_V2OU&_:U_Y-9^)'_8L:E_Z2R5^7/\
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M_M5_MY^&8O$J_P!H1Z]K,VKZFLGS"ZV"2Y=6]59DVD>A-?N3'&L,:JJJJJ,
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M$T#]JK]KG]HF.\\1>&+SQIJ&FPR$%M%TI5M(R.2BA8\,1Z99O6N&_P""GOQ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3G%'_!)']E7QO^RM\.O%VG^-M+ATNZU74HKBV6.[BN/,18MI.8V8#GL:P?\
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MG(=U 4;4<MSZXHZ 5/\ @O;\6=8@\2^"_!,-S-!H<MD^KW,*,0MU-YC1IO\
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MQF_93\:^%_#MJMYK6L6(AM(6E6(2-YB-C<Q"C@'J: /S_P#^""!_XR'\9_\
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MJ!7R7^WY_P $L=%_:XU23Q3H%]#X;\;>6$FEDC+6FJ!0 OG!?F5P  )%!.
M5.!A(IGU9I6JVNN:;;WEC<07EG=1B6&>&021RH1D,K#@@CN*^5_^"S-KX5F_
M8LU237OL8UF*[MSH!?'G_:3*F\1]\&'S-V.,#GH*^,=-_8V_:Z_9N9],\+_\
M)7#IP)*_V%KRM:/S]X1^8",Y[H#4FD?\$Q?VD?VF_%L-YXZFO+%0=C:CXDU@
M74D2=PD:O(_X84$]Q3L2>A?\$ FU#_A.OB0J^9_9?V"S,O79YWF2[/QV^97T
M_P#\%:/@+_PN_P#8YUR>WA\W5O"##7+3:N6*Q B=?H86<X[E%KT/]C[]D;P[
M^QO\*4\-Z&\EY<7$GVG4=1F0++?S8QN('W5 &%4$X'<DDGU#4+"'5;":UN(T
MFM[F-HI8W&5D1A@@CT(.*74?0_!#3/VD=0TS]DO4_A:OG?8]2\1PZVS[OE")
M"R-'C_:<1/\ 5*_3'_@BE\"?^%8_LJR>)KJ'R]1\=7C7@+##"UBS'"/H3YKC
MU$@K\R]<^!2ZW^UM??#KPQ=+J,-QXFDT33[A,LKI]H,:N?8+R3TX)Z5^\?@7
MP=8_#OP5I&@:;'Y.GZ+9Q6-LF/NQQH$7] *<A1/(/VQ?V^_"O[%-]H,/B;2?
M$5__ ,)#',]O)IT,3HOE% P8O(O/SKTS7&^&OV:/@!_P44^%UCX_A\%V]JVM
MF3=<6Q^P7T4J.R,)1 VPOE<_-NR"#WKT3]MK]CG1?VT?A(?#^I7#:;JEC(;K
M2M21-[6<V,'<O&Z-APRY'0$<@5^=VB_L2?M8?L@:Y>6_@4ZLUC</N:;0=2BD
MM;HC@.T,A!W8[M'GWH0SG/\ @IG^P+I?[$7B'P[J'AO7;R^TCQ&TXAMKPK]K
MLI(=A)WJ '4[Q@[001SG(-?H;_P2Q^,VN?'#]C3P[J?B&XFO=4L)I],>[E):
M2[2%\([$\LVTJI8\DJ2>2:^'M'_X)H_M&?M<?$"WU+XF7UUI=NN(Y-0UN_2Y
MFABSDK#!&S8]E^1<GK7Z=_ ;X*:+^SM\)-%\&^'XY%TW18/*5Y,>9.Y)9Y7(
MXW.Y9CCCG P,"A["1^,W_!1(^7^W]\0"WR@:TAR>,#9'7[C0NLD2LK!E8 @@
MY!%?G3_P5%_X)@>,?BS\8;KXB?#VSAUIM9BC_M33!.D-Q'-&@C\V/>0KJRJN
M1D,&!."#QUG_  2F^$WQ\^&_Q%U'_A94/B2'PC%HILK"'5=6$ZVTRRQE!%#Y
MC%1L#C.  ,"CH'4^*O\ @IKX"NOAM^W9XX6^MRT&J7ZZO;[LA;B&=0_!]-V]
M/JIK]&?@[^P+^S7\</ACHOBK0_ NFW6FZU:I<1LFHW9\LD?-&W[[AE;*D=B"
M*WO^"@?_  3]TG]MGPE:30W46B^,-%1ET[470M')&3DP3 <F,GD$9*$D@')!
M^ ]#_8G_ &L/V9]1NK#PE;^*+.UN'R\F@:TGV6Y/3<5$@.?=E!HW ^]M9_X)
MI_LX^'GM5U#P5HMBU_.MK;"?5KJ,W$K?=C3,PW,>RC)-9_\ P4S\':;\/?\
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M8X8(XX885"1QQJ%5%'   X 'I4E !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MANM:Q_QZV(_[:L?Z4WH[ G<UZ*Q_M&N'_EWT\?\  V-(9M>QQ'IH_P"^O\:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ#_R#)_\31_PN'P[C_D(#_OS)_\ $T>TCW#EEV.FHKFO^%O>'L?\A#\H7_\
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M;U%?$*_\'''[&+ X^-FE\?\ 4'U'_P"1Z/\ B(Z_8QSC_A=FEY_[!&H__(]
M'V]17P^/^#CS]C G_DMFE_CH^H__ "/3A_P<=?L8M_S6S2__  3ZC_\ (] '
MV]17Q"?^#CG]C$'_ )+9I?\ X)]1_P#D>@_\'&_[&(7/_"[-*Q_V"-0_^,4
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M_G7]3_\ PYQ_99SG_A0OPS_#18_\*3_ASA^RQG_D@OPSX_Z@T='O!H?RP_\
M#9TW_1*_@'T_Z)Y:?XT+^VA,H.?A3\ >NX9^'EKQ].:_J@_X<Y?LL_\ 1!?A
MGZ?\@:/_  I!_P $<OV65_YH+\,__!-'1[P:'\L!_;0F/_-*O@'G/;X=VG^-
M$?[9\JIM_P"%5_ 0YXR?AY:9_G7]3Y_X(X_LL-_S07X9_P#@FC_PI#_P1O\
MV5R!_P 6%^&?R]/^)-'3U#0_EA;]LV9SS\+/@(O/;X=VG^-*?VTIO+_Y)3\
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MWP*^)^EI9>(OA7X,UJTCE$RQ7>GK(JN 1NP>^"?SKE/^'./[+&,?\*%^&?\
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MKX:OB ?AS:D1$1\/P>,>IKZ(_8E_;-AF_9\L6G^!/[/NHR->SYF'PXMOFP_
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M[8FFFT;;^S]^SXK)&5 ;X=6^ WMQ[FO!_P!@7]L:&X\'^*)+KX&_L_:IC5P
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M)'L.&0GN/3/3%3>+?VY-+U#2)+?POIFJZAJ5PI2)I(=J1D\9P"2WT%)^R/\
M [4/!VH7'B;7HVMKZYC:*VMW'[Q%8Y9W]"< 8ZU^%X7!97/CC!XK@/2#YOK3
MIIJCR:6OM'F>ME'[7*[7N?<5:V*ADE:EGV^GLE*W/?KYV6FKZ71<_:$%ZGQ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGM_&$?RKN//\0Z9XZUY;+J%UI<S0W"2VTB#+1S JP],@C-)'XF9HV)$FYAU
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,_AW=N^9[M_FZX-U,17JU<SW.J.P4444#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ 9=RX(R#P0
M>]?''[6W[-S?##6)/$6BPE?#]\X,L<8_Y!\I/3'_ #S8GCT/']VOL>JNLZ-:
M^(M)N+&^MX[JSO(VBFBD&5D4C!!K.I34U8J,K'YZ^#=?^Q3HFXE5.<D].E>O
M>"_&>/+W,&&>H[UQW[1O[/5_\"?$)N+0RW'AV^ES;7)Y:(\GR9/0CLW\0'J#
M7-^%_%+6TJ@'&#U)Y]LUR1DXOE94HW6A]3^&/%N=IW?4XXK,^#7Q!@\;?%K7
M(M8G:*2QG,%G:3-\JKC[X'3YNN:X#PAXSWI'N?WY./2JGQ"^'DFOZM'XBT6Z
MDL]<M8_E()VS*#G##OZ5UJHUL8\JZGU;>VK:5&TL*-+".6C!Y'T_PJ:RNEN8
MPR-N5AD5XK^SI^U0OB20:#XC5K'6;<^61)_%CN#W'H:]HEL< S6NUE?YM@/R
ML?45T0J*2U,Y1MJBS2]ZJV5\LXPV4D7AD/535H=*-@B[A124I%!08S32,TZB
M@1#)%C_/2HW4-5EES43QX;KFJBR)1*4\&15"ZM^?NGKS]:UY$S56[@W(?RK0
MA'B'[2WP@M_'7A67]RID7+ ]PPKY0\+M-8W[6S_NY;)S$5R?S_+FOT"UO3EO
M;5XG^96!'Z5\6?'/PC_PA7Q/>6-2([R/S.G0BN6I&S-Z<NC.L\'7^1&W W=
M.WM7J'A>7:B]2R\=:\9\%SMY$>6SN.=K<X_&O6O",P=4V^@Y]JSB4STK0GY7
MKZ5UVD\?XUQ>@,<1CD>I]:[#23\PXK:)G(Z"W/ ^E357M#P*L42W-(;!1114
ME!5:\;AJLU5OC@5=/<SJ;',^)FS"W:O"_CHW_$HN <+\C=>YQ7M_B9LQ-_.O
M"OCK,5T6X.5S@]1QG%:R,4>Q?LA0B#]FOPCMSB2R\SG_ &G9OZUZ17!_LOP^
M1^SKX)7^]H]L_P"<8/\ 6N\KG.I;!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^-"FV8?Z/=K_ *N4=/P;VKE/"'CQ9 J^8>H&#VKJ-?\ #^C_ !(T%[/4(8Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPKTAB5!^  J>BBL3J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLRVME;VJY]7DD8\_\ 6B6PH;GT511161N%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC:1:V<8VQVL*0J!V"@ ?RK.1I3+-%%%2:!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,GLQV1#])&_*OHJLY;FM/8****DL**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#K%DDL.Q9F Z@ U[+134$@"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /+_ (KPK-\3
M;<$==*<?^//5CX%Z=M^&.C\;?W2<U+\2HL_$&U;^]ISK_P"/-6G\'+<)\-M+
M']V-<?A4QW"1\^_\%5M(_M']DGXJ;5W-_9$K8QU_T>OC/X9^'4?P=\#_ -W_
M *NT8J3V/''''<U]Z?\ !1BP^U_LJ_$Y?[VB3].O^H:OC'X2Z=_Q;SX(NS-Q
M:<$].W;%4R3]%/A-IRP^%[4;?FV#BNOTZU$6I*=O8UC?"^WV^';;_<%=-#'M
MN0?8T^@7/GW]O?3?M]GH9^;Y6<$CTR*W/V1X?(UGQ,O_ $RL^?\ @,E5?VU8
M?.M='Z\%CG/3D5I?LK($UOQ'A<?N;/)]?EDI]!?:/9J***DL**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ango-20230531_g9.jpg
<TEXT>
begin 644 ango-20230531_g9.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ?I"7X# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M R0"<=>#6'HOQJ^'OB/5+?3=)\>>&=4U&X;;#9V6L6\TTK8SA45R2< ]!VH
M[.BN.UWXS?#_ ,+ZK/I>L^.?#>D:G;D":SOM7MX9H\@,-R,X(R"#R.A%4/\
MAH3X6?\ 12_!_P#X/K7_ ..4 >@45Y__ ,-"?"S_ **7X/\ _!]:_P#QRK&G
M_'3X;:OJ%M8V/Q!\*WM]=2K!!;6^M6TDDLC$*J(H?+,20 !R2: .XHHHH **
MY#Q!\8O 7A/5IM+UOQOX<T;4X=IELM0U:W@FCW*&7<CN",@@C(Y!!K8\,^+M
M"\::<VH>'M:T[7K!9#$;K3+J.YB#@ E=R$C(!''N* ->BBN>\5_$3PIX#:V7
MQ+XGT?PZUT&, U:_BM3+MQNV>8PW8W+G'3(]: .AHKS_ /X:$^%G_12_!_\
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M@CKFN>\4?%/P7X'U".Q\1^+]!T"^DB$Z6VJ:G!;2-&25#A78$J2K#/3*GTH
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M2L?_ (:$^%G_ $4OP?\ ^#ZU_P#CE 'H%%>?_P##0GPL_P"BE^#_ /P?6O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117S_\
MM[?$ZZ^$?[)/Q&U_3[A[74VL%T^TFBX=)+F1(-RGL5$C,#VVT ?FU_P4%_X*
M0>(?B?XLU;P#\,];FT;P%82M:W&J:;*T<^LN!M<^8N"(,[@%4_./F;((4>'?
M [_@GG\;OC]X=@\0Z!X9CT[P_<@-;:GKERMI'<*<?-&IS(Z8.=X7:>Q-<O\
ML8?"6S^.'[4'P]\':E"+C2KS4/M%]"V=LMO!&]Q+&?0.D17_ (%7]'-M;0V=
MO%;V\2001((XXHU"JB@8"@#@ #M0!_.1\?/V.?BU^S+':WOC;PS)::5.X2'6
M+&9;FT\SJ$,B$[&X. X4G!QG%?:W_!+[]OSQ#=>,]-^#WQ&U:XUJRU(>3X?U
M>]D\R>WF )%M(YY=' PA))5@J_=8;?T[^*GPWT?XP?#GQ%X,U^!9]*UJRDLY
M=R!C'N7"R+GHZ-AU/9E![5\B_!G_ ()%_";X6:]I/B#4=<\2>*-=TRYBO+>5
M[I;*".:-@Z.J0@."& /,AZ"@#[D9@BEF(50,DGH*_$K]O[_@HYXA^,WBG5/!
M/PZUFXT7X<V4C6TEY8R-%/K3#*N[N""(#R%C'WA\S9R%7](?^"C'Q,N/A9^Q
M[\0-0LG:._U&V31H'1MI7[2XBD8'J"(VD(QW ^M?BU^Q9\%;3]H#]IKP/X,U
M-&DT:YNFNM1521OMH(VFD0D'(WB/R\CD;Z -7X%?L%_&G]H?14USPMX5\GP_
M)D1:OJUPEI;S8./W>X[I!D$;D4J"""<\5K_&;_@G)\=?@?X>NM?UCPM'J^A6
M:M)<W^@W2W:P(O5WC&) F 26V8 'S$5_0-I^GVNDV-O965M%9V=M&L,-O @2
M.)%&%55'     '3%3LH92",@\$&@#\'_ -B7_@HIXQ_9Q\2:;H/BC4KOQ+\,
MYI$@N+&[D::73(\X\VU).0%ZF+[K ' !.ZOW5T?5K+Q!I-EJFFW,=[IU[ ES
M;7,+;DEB=0R.I[@J00?>OP'_ ."DWP*TWX"_M3ZYIVA6B6&@:W;1:Y8VD:[4
M@64NLB*.@431RX X"D#M7Z9?\$DOB=<_$#]D>QTV]G>>Y\+:G<:,K2'+>2 D
MT0SZ*LVP>@0#M0!^7O\ P4A_Y/:^*7_7[;_^DD%<'^RC\3#\&_VD/AWXM>0P
M6UAJ\ NWSMQ;2GRI_P#R%(]=Y_P4A_Y/:^*7_7[;_P#I)!7(?M-_#?\ X0'5
M/AY?Q1>59^)O NA:U$ /EW&S2&7\3) ['_?H _I#K\-/^"O7Q,'C;]K*;08)
M=]IX4TJVTXJ#E?.D!N)&'OB9%/\ US]J_6C]E3XM0?%#]ESP!XWO;I09M$C.
MH7$C<":!3%<,3Z>9%(:_"?2([K]K']L2W$XDD_X3?Q=OE!ZQ6TUSN;\$B)_!
M: /)_"?_ "-6C?\ 7[#_ .C%K^C/]L3_ )-0^,/_ &*6J?\ I+)7\]6I1I#\
M9+J.-51%U]E55&  +@X %?T*_MB?\FH?&'_L4M4_])9* /YU? ?@C5_B5XTT
M7PKH$"W6M:Q=QV5G"\BQJ\KL%4%F( Y/4FOIRY_X)2_M*00/(G@JSN&7I%'K
MED&;Z;I0/S->7_L4_P#)W'PA_P"QFL?_ $:M?T?4 ?S*^//AM\1OV;?'4%CX
MDTK5_ _BBUQ<6TP<Q28Y DAFC;##.1N1B,@C-?LA_P $P?VQ-4_:3^&^I^&_
M&%VMWXW\+>4LEXPP]_9N,1S/ZR*RLKD=?D)Y8UXS_P %N/%7A6;PK\//#OGV
ML_C6&_FO1$A#36]BT15M_=5>01XSC/E-UV\>3?\ !$VVO6_:&\;7$8?^SH_"
MSQS$#Y?-:[MC'GWVK+C\: /V8SCD\"OYS?VW/C@?V@OVF/&7BJ"X^T:,ES_9
MVDD'*_8X/DC9?9R&D^LAK]G?^"B7QQ_X43^RMXLU&VN/L^MZTG]A:85.&$UP
MK!W7T*1"5P?517Y(?\$W?@):_'W]J'0['5[%+_PUH<,FLZI!*N8Y$CPL4;=B
M&E>+([J&H ZW_@E#\=/^%2_M/V?A^]N/*T3QK#_9$P8X5;H'=:O[DONB'_7<
MU^[%?S2?'+X<:K^S?^T!XG\*1SS6U]X:U<FPNP<2&,,);:8>A,9C?\:_H1_9
MO^,-I\?/@;X.\=VI0-J]@DEU''TBNERD\?T657 ]@* /C_\ X+8?\FV^#?\
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M6^I,H&-K2VZNR_@6(_"@#^9:&%KB:.)!EW8*H]R<5]>?\.G_ -I+_H4-/_\
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M)>#?^Q2A_P#2RZH ^H/^"*G_ ":SXI_['.Z_](;&OO\ KX _X(J?\FL^*?\
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MR@M&WME2I'ID5_3%X-\5:?XZ\(Z)XDTF7S]+UBRAO[67^]%*@=#^3"@#X_\
M^"MWQ@/PX_96N?#]K-Y>I^,;V/2U"G#"W7][.WT(18S[2U^=G_!+/X+_ /"V
MOVL="O[J#S=(\)1-KUR6'RF6,A;=<^OG.C_2-J[/_@L/\8?^$[_:3LO!UK/Y
MFG>#=.6W=5.5^V7 6:8CM]S[.I]"A^@^P/\ @CK\%_\ A!/V>-1\<7D'EZEX
MROS)$S#!^Q6Y:*(?C(;AO<%30!XQ_P %RO\ D*_!O_KCJW_H5G7PW^S_ /LB
M?$W]IRSUJZ^'VC6^JPZ/)%'>-/?0VVQI Q3 D89R$;IZ5]R?\%RO^0K\&_\
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M9_[+<,<LUFP+VK?0+OB'M#7PMX%_8I_X2+_@FGXK^*'V'=XK.I_V]8OL^?\
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M((E) !=F"@9/3DBOK;_AT_\ M)?]"AI__@[M/_CE?,'P]_Y'[PS_ -A.V_\
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M"F.QUVQCNUA8[FA<C$D1/<HX9#[J:_"O_@II_P GQ_$__KM8_P#I!;5^O?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRI(K>^+GQJ\%_ OPC=>(_&VOVFAZ="C,HFD'G7# 9\N&/[TCGLJ@F@#\D_\
M@M7J%O<?M+>$[6(JUQ;^%(?.VG)&Z[NBJGTXY_X%7T9_P1*MYE^ _CRX8GR)
M/$NQ!VW+:PEOT9:_,;]J3X\7O[2_QT\2^/+FW>SAU"98K&Q8[C;VL:A(8SCC
M=M +8X+,Q'6OV^_X)Z? V]^ 7[+/A;0]7M_LNO:EOUG4H&7:T4T^"L;#^\D2
MQ(WNIH _'W_@I#_R>U\4O^OVW_\ 22"O>_V]OAO]L_8>_98\>PQ?-8:!9Z+=
M2*.2LUE'+%GV!@E_%Z\$_P""D/\ R>U\4O\ K]M__22"OTE^)WPW_P"%G_\
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M_P"A0T__ ,'=I_\ '*^2M)_Y"ME_UV3_ -"%?U/4 ?@M_P .G_VDO^A0T_\
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M])L_V*_A?#<:I9P3)9W :.2X16'^ES=030!^<W_#FWX]_P#/YX/_ /!I+_\
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M(Q$S66F^'/L3R8X66>YB=!]2MO+^1H ^U/\ @K!_R9+XO_Z_=._]*XJ^ ?\
M@CKIEMK7[3GB;3KV)9[.[\&7UO/$W1XWN+564_4$U]_?\%8/^3)?%_\ U^Z=
M_P"E<5?!?_!&'_DZ_6_^Q2O/_2JTH ^<_ 6J7?[*O[76F37CLLG@KQ7]FO6Z
M%X8;@Q3C_@48?G_:KV+_ (*R?$\?$+]KS5=.@F6:P\+Z?:Z1"T9RA8J9Y3]=
M\Y4G_8'I4/\ P5>^&_\ P@/[8FO7\47E6?B:QM=:B 'R[BIAE_$R0.Q_WZ\&
M^"7@V]^/7[0?@[P[J$LU_<>(]<MXKZ>1B7:)I 9W)]HPY_"@#ZY_;F^&_P#P
MJ?\ 83_9@\//%Y-TL=S?72$899[F)+B13[AI2O\ P&O9?^"'/_(J_%O_ *_=
M-_\ 1=Q5G_@MY&D/P]^%4<:JB+J5XJJHP !#'@ 56_X(<_\ (J_%O_K]TW_T
M7<4 >"?\%F(/)_:TTQ\Y\WPM9O\ 3]_<K_[+7V=_P1KD5OV2;X*02OB>\#>Q
M\FW/\B*^8/\ @MMX1N;/XU> /%!B866H>'VTY9,?*9+>YDD89]<725WG_!&O
M]H[PKH/A7Q%\)M=U2UTG6[G5CJ^D_:Y!&MZ)(HHI(48\%U,*L%SN82'&=IP
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M&4_0BI: "BBB@#^>O_@I#_R>U\4O^OVW_P#22"OV*_X)X_\ )EOPJ_[!C?\
MH^6OQU_X*0_\GM?%+_K]M_\ TD@K]BO^">/_ "9;\*O^P8W_ */EH ^BJ_G.
M_;NAGM_VPOBVMPQ>0Z].X)'\+8*#\%(K^C&OQ7_X+%? F]\%?'FT^)%M;LVA
M>,+:..:9$.V*^MXUC9&/0;HEC8?WB)/[I- 'Z/?\$\;^VU+]B[X52VKJ\:Z8
MT+%<??2>1''U#*U?15?D9_P2F_;B\-_#?1;CX1?$#5(=$T^2[:[T+6+R0);1
MO)CS+:5SQ&"PWJQXR[@D?+G];H+J&ZMDN(98Y;>10Z2QL&1E(R"".",=Z /-
M?VHM0M]+_9I^*]U=E1;Q^%-4W;C@-FTD 7\20/QK^>/X 6\UY\>/AO;VY(GE
M\2Z:D97KN-U&!^M?IQ_P52_;B\,+\.]0^#O@?5[?7-:U9T37+VPE$D-E;HX8
MP;U.#*[* R@G:H8'!85\F_\ !+'X&7WQ:_:FT376MRV@>#"-9O;AE)7SAD6T
M8/\ ?,N''M$_I0!^\M>*?MK?\FC_ !>_[%F^_P#135[77BG[:W_)H_Q>_P"Q
M9OO_ $4U 'X;_L*_\G@?"3_L8+?^=?T9U_.9^PK_ ,G@?"3_ +&"W_G7]&=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA]X@\!^&[KQ'K.ERW-A>6]BH,GD2!'C<Y(^56C<?66O$_P#@F7^Q7\2OA_\
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MB@#P;]A3P1KOPW_9-^'GAOQ-ID^C:[86LR75C<@"2)C<RL <?[+ _C7O-%%
M!1110!^)_P"W7^QW\:?B1^UE\0_$GAGX=:SK.A7]U"]K?6T:F.51;1*2,M_>
M4C\*_4#]B/P9K?P]_95^'7AWQ'ILVD:YI^GM%=6-P )(F\Z0X./8@_C7N%%
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M_?I/_BJ/^& _VAO^B3^(/^_2?_%5_1310!^.7_!.']DKXP?"C]K+PSXD\7>
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M[288>&9+=%=&]P01^%>G44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]2LX+NTGBNK2XC66&>%P\<B,,JRL.""""".N: )Z*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBOF_\ ;<_: ^(W[/G@OP]JOPW\#_\ "<ZC?Z@UM=6O
MV*YNO)B$;,'Q 01\P R>.: /I"BO)OVB/VC_  Y^S)\)7\=^++>\GMO,CMH;
M*PBW2SW,BL5C&X@*/E8EF.  >IP#W7P^\5CQYX"\->)1:_8AK.F6VHBU,GF>
M3YT2R;-V!NQNQG SCH* -^BBB@ HHHH **^._BE^VIXH\"?MU>#/@?::'I%Q
MX?UN.U>;49A+]KC\T2$[<.%XV#&5[FOL2@ HHHH **** "BODC_@G_\ MC>)
MOVN+/Q]-XCT72=&;P]=VUO;C2Q+B19!*27WNW(\L=,=37UO0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %?F1\=M0D_:S_X*A> ?AU:8O/"GPWVWVI#[T7F
MQE+BXW>S,+6W(_O U^@OQD^)FG_!OX4^*_&^IE39Z'ITUZ8V./-=5/EQ@^KO
MM0>["OQS_87_ &J+CX&>)?'_ ,0M>^&OBOQ_XD\93[SJ^E6Y,2J97DG 8J<E
MY6!.#QY8H ][^W-^QC_P58N4E/V3P1\5E5B?^6:RW3\,>P*WB-_NQS'UK]0Z
M_$[_ (*!_M11?M3>$_#%[:_"CQAX-UOPQ=R3)K&H0$1+;R*-Z%@H*G>D+ D\
M8;UK]2OV/?CC'^T1^SKX.\9M(KZG/:BUU101E;V$^7-D=MS+O _NNM 'R%X1
M_P""J'C'Q-JGC3PCIOPXA\4_$>'6&TWPUH>AQS!)X8S+YUQ<NS-A4")PN,[C
M]T L*6M_\%#?VC/V<_&'A_\ X:"^$>C:-X2UF7:MSHNX2QK\N\I(MS.C,H.[
MRFVL>>1VQ?\ @DOX>M;K]I+]H37'@5KRQG%G%,0-R)->7#.!]3 G_?->M_\
M!9BTBN/V3=,ED0-)!XHLWC;NI,%RI_0F@"MXG_;9^/OQDU#4[S]FKX/VWB;P
M+ITSP#Q1XB_=IJ1C;#M;1M/!E<@C +L>X4\#M_V&/VZM1_:7U_Q/X$\<^&(O
M"'Q(\.(TUS96ZR+%/&L@BE(CDRT3QNR*R,S9W@@]0/;_ -E7P_:>%OV9_A7I
MEE%'#!#X8TYB(T"AI&MT>1R!W9V9CZEB:^'O@HWV;_@LO\5$B_=I)IDV]5&
MV;>S8Y_X$,_6@#[;_::_:6\)_LL?#2?QAXJ::=6E6UL=-M,&XO;A@2(TR0
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M8_L^I:[+I<.H+;DJ\Y:\>T9FQU+0L(_<1@5%_P %N/\ D*_ ;_KMK'_H6GT
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MD>//#T4UI;7F^&XL;@@RVEPAQ)$Q'!P<$'NK*<#.!\%P_P#!5;QGX#:7PO\
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MRKJ1@@CN"*X/X,_ 'P#^SWH-WHWP^\/1^'=-NYA<3PQW$T_F2!0NXM*[-G
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M1^R9XI\.WT>HZ)JSZ5=VES'T=&U12,CLPZ%3R""#R* /U<K\R/CMJ$G[6?\
MP5"\ _#JTQ>>%/AOMOM2'WHO-C*7%QN]F86MN1_>!K]!?C)\3-/^#?PI\5^-
M]3*FST/3IKTQL<>:ZJ?+C!]7?:@]V%?CG^PO^U1<? SQ+X_^(6O?#7Q7X_\
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MM_%WA?Q))%!I6H37+W1C,S&.WE@FDQ)L,J^6T3_=Y*CIO?\ \%N/^0K\!O\
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MP69^-%_X)^"_A?P'ID\MM)XPO9GO9(FQOM+41EHCWP\DT)]Q&PZ$U]9_LN_
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MB6!5D!_NP ]Z_56L?_A#]!_MS^VO[$TW^V,[O[0^R1_:,[=N?,QN^[QUZ<4
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M+<G]RY01R!FP3&KA(I%<C;YB$' (![/Q1_P5<\-?$;PW_P (Y\%/"7BGQ/\
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M%<_@AI?P_N=1\)7^I>)/%DL#"Q\/G2YX7%P1\BS2,HC"AB-VQV. < \5U/\
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M[!?Q>\3_ !U_9<\)^-/&%Y'J'B#4);U;BXB@2%6$=W-&F$0!1A44<#M7T%0
M4444 %%%% !117Y,Q_\ !43Q]\,_VTO%7A?QSJ5MJ'PNT[Q5J6BR016$236=
MLEU)%%,)$4.YC"J2#DLH;^(@T ?K-14-G>0:C9P7=K-'<VL\:RQ30L&21&&5
M92."""""*^)_^"H7[4'Q"_9D\)> [[X?ZK!I5SJU]<P7;3V<5R'5(T90!(IQ
MRQZ4 ?;U%5]/F:XL+:5SEWB5F/N0#7AG[<7[0DO[-/[./B3Q=I\T47B*39IV
MC"90P-W*<*VT\-L0228/!\O!H ][HKX&_P"">O[8GQ&^*7Q-\7_#/XRW$/\
MPEUM86VKZ6JVD5LWDLBO)&P0 $[)H''?!?L*^^: "BOB?]M3]N;Q-\+?B/HO
MP;^#WAZ+Q5\5-81"WG+YD=CY@S&H3(#2%09"7(1%VLV03CRQ?AC_ ,%%[Q!K
M#_$?0+2[9?-_LLM8Y0XXCVBU,1/;[Q'J>] 'Z5T5\"_LF_M[>.M0^-C_  -^
M/_AR'PWX_),5EJ$""%+B4)O$4JABF77)22,[6X &2"?0O^"F?[0GC?\ 9K^
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M6ML'2&ZA5Q'(RQN2\;QN55T8G[RD'J%Y3_@J+^U5\2_V:)OA;%\.M7M]*?Q
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3'P;U+P=XE_9HGTNS6:+4(M2M9'DEM)(B3O523DE#(A'HYQS7T%_P26^._\
MPM;]FF/PM?7 EUSP1.-,96;+M9N"]JY]  )(A[0B@#P']KRZ\3_L<_\ !0JP
M_:%N?#EQXC\#ZS%%$\T0XB;[$MI+#O/$<H""1-V P8@'AL?6?PS_ ."FG[/7
MQ+2%!XW3PO?2 9L_$L#66S/]Z8YA_*2O2/!_[0WPH^/7C3QA\,])U*'Q+J^A
M++#KFCWVF3+$GES&&2-A/&%DVR#!QN'(Y->7_$S_ ()??L]?$GSI4\'OX3OI
M<_Z5X:NFM=O^["=T(_[]T =KXT_9@^%G[07Q5\%_&.:[FU36O#RV[:7?Z-J*
M&UD\BX,\3,4!$F'+?Q8(8BOGK_@M7_R:SX6_['.U_P#2&^KYM^(7P[\;_P#!
M)GXV>#O$/ACQC=>(?AMXCNBM[I\X\KSHXRGFQ3Q@E"XCD#1S* <@\  AOI+_
M (+5_P#)K/A;_L<[7_TAOJ /K3]F7_DVWX4?]BEI/_I'%7>:]H>G^*-%O]'U
M:SAU'2[^![:ZM+A \<T3J59&!Z@@D5P?[,O_ ";;\*/^Q2TG_P!(XJ]*SCD\
M"@#\J?\ @EY<77P;_;(^-WP82XEGT2W-X8#*WWI+*\$,<F,\%XIB3C^ZOIQ^
MBG[0GQ;M/@3\$_&/CR\V,NBZ?)/#')TEN#A((S_ORM&O_ J_.S_@GB__  M+
M_@HK\=?B'IG[WP_&-2,5RG*O]HOT^S\_[4<4C?\  :ZC_@L3\3M2UY?AY\#/
M"\4VH:[XAO$U*YL+49EF&\PVD0'??*93CUB4T 0_\$^?V6Y/BO\ L:_%C4_%
M+^9JWQ9DN$BO;I<L%A+B&X/&<_:FED]]BFNI_P""0'Q@O;OX?>+?@WXBWV_B
M#P1?R/;VLQ^=+:21A+'C_IG.'S_UV45C_#;]H3]JOX6_#_P[X0T;]EDII>AV
M$.GV^ZXDW,L:!=S?-]XXR3W)-?-.B_%3Q[^SI^WUHOQ9^(?@&?X7V'C2]=-4
MTZ1C]G>WFV1W4RL>NV0K<$'^(#L10!]R_P#!6[XI7OP[_9+NM,TZ4PW/BO5(
M-%ED1BKK;E))I<>H80B,CN)37I7_  3]^$^F?"7]DSX?6UC:);WNM:;#KNHS
M;0))KBY19<N>Y5&2,>@0"O$O^"R_@R[\1_LNZ/KEG$9H]!\0V]Q=,O2.WEBE
MAW?]_'A'_ J^C_V,_'EG\1_V5_A?K%G<Q7170;2RN3$<A+B")89E([$/&W%
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M5_91\)Z-::%I47B/X@>(YC!H^DR;F10" TTBI\S#<R*J @LS<'Y37BUKX/\
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M_P#DU#X/?]BEI?\ Z2QUX5_P5Y_Y,VU'_L-6'_H;5[K^QW_R:A\'O^Q2TO\
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M7Z>OM74_\$J_^3'/ /\ UVU+_P!+[BOG[_@L](HUCX H2-YU+42%[D!K'/\
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M\7DBYC\QHWWQ9.R2.10K8P#O7 &#4_[;G[;'B'X,^,/#/PJ^%.A6_BKXK^)
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M*E([N-)/*D=4))1XWVJZY(RZE>"57[!K\P+.-=#_ ."WTL.CGRHK^R9M3CB
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M7>:]H>G^*-%O]'U:SAU'2[^![:ZM+A \<T3J59&!Z@@D5P?[,O\ R;;\*/\
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M&\\26L?C7Q?J,EQ<R/I-ML2R>)Y+= FS:,H$?=C/SD9P*^O?VN/VLM*_9/\
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M+&96DC@CWA!*Z*0SEG.Q$!&6#'.%P?GRXB2+_@N!:LB[3)II9R/XC_8;#)_
M#\JA^+\<?B#_ (+/?#FSUK]Y86=E UFLPW*K)9W,\6T'I^_Y'OS0!UEGHO\
MP4$\%Z''X\U#Q1X5\6F)!=77@,VT N'B'S&%3%;(/, +#"39.!@N>*\P_P""
M6OCY?BI^VU\;O&26+Z8NOV%WJ?V*1][0>=?Q/Y9; SMW8S@9QT%?K!7YE_L'
MZ38Z%_P4G_:4LM.6..SC_M I'$ $CW:C&Q0 = I)&.V* /;/VW/VV/$/P9\8
M>&?A5\*="M_%7Q7\2!3%!."\=DCL5C)0,H+L0Q&Y@JJFYL@BO.]7\+_\%"/!
M^AR^+1XW\'>*9X8O/E\(6MG 92HPVQ"+6/<_W@0LV3@!2QQCYW\6:A\6[_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNS !2M?LM10!\B?\%'OV2=8_:;^&FC:EX../B!X2N'N]*C,XA%Q')L\Z(.2
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MLY+^W>&5HH88O-?:_."L=J,CC*/]!G?MN^%M:U3_ (*6_LZZE9:1?WFG6O\
M8_GWD%L[PQ8U29CN<#"X!!.3T-?I710!\*?\%%OV6?''C/Q1X,^-_P (X9+K
MXB>#=@DL(6S)<V\4C31M$AX=T=I 8^LBR8&2 IYVQ_X+ :-IN@Q6/B7X0>-K
M'Q_Y.&T>"W06\DPX.'D82JI./^63$9QSU/Z&T4 ?!O["/@GX\>/_ (M>*OC9
M\6]2\0>&=$U<2?V3X)N+ZXBMP7VA9&M&;:L<<8V)O7<Q)?L"W+?MG?!7XC_
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MQAC[D+FMJB@ K\RO^"J7A76]?_:(^ 5QI>CZAJ5O;S9FEM+5Y4B_TN _,5!
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MK22DC<2@7.">2G^&W_!1?089-:B^(6@ZS<QKYITF,V1:7N8PKVJ1@]N&7V-
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MBOB'QE^U!\0M'_X*:>$_@[:ZK G@+4+$3W%@;.(R,WV*>7(E*[Q\\:G@]L4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKSP5=ZO/_P (C8VD9%S9,%M_,^TGR5SEMI'S/P#TK]?J_-7_ (+,_P#-"O\
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M)^R#^V?XP\7?%;5_@=\;M!M_#7Q5TF)Y8;BW*I#J:J Y"H"1O\LB0%"5= Q
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MP7!OKS4K22WCCCB0F<.LJC*JN<D J<$ G!H ^)_ ?[37[4O[<6O>(;_X(_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!_P2&T'4_#O[*=W::MIUWI=T?$EXX@O(&A?:8H,':P!QP>?:OMNB@ K\^_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M  0\,6_B+Q#979TZYU"XMI;N26\!(DM[:W0@L48;2S$Y(8!< ,?-=)_X*?\
M[0'P&^(&FZ9\>/A\B:3=CS)(6TQ].O?*) ,L#$^7(%Y^4CD\;EZT ?K;161X
M?\6:3XI\*:=XETN]CNM#U"RCU"VO5R$DMW02))ST!4@\U^.T?_!6S]H;Q1KF
MI1^%?#>@ZG9QRN\45OHEQ<2QPECLW[)>N,<X'- '[045^:'['O[=G[0OQD_:
M,\)>#_'/A&STOPMJ7VO[9=Q:#<VS)Y=G-+'B1W*KF2-!R.<X[UZS_P % /\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSXPD2M@#))QUV'&#^J/A;PSIG@OPUI7A_1;2.PTC2[6.RL[6/[L4,:A44?0
M5J44 %%%% !7F'_-S7_<H?\ M[7I]>8?\W-?]RA_[>T >GT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>8?\W-?]RA_[>UZ?7F'_ #<U_P!RA_[>T >GT444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>8?\W-?]RA_P"WM>GUYA_S<U_W*'_M[0!Z?1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5YA_S<U_W*'_M[7I]>8?\ -S7_ '*'_M[0!Z?1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5YA_S<U_W*'_ +>UZ?7F'_-S7_<H?^WM 'I]%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7F'_-S7_<H?^WM>GUYA_P W-?\ <H?^WM 'I]%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7F'_-S7_<H?\ M[7I]>8?\W-?]RA_[>T >GT444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5YA_S<U_W*'_ +>UZ?7F'_-S7_<H?^WM 'I]
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\P_YN:_[E#_ -O:]/KS#_FYK_N4/_;V@#T^BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
MCN+B*SMY9YY4A@B4O))(P544#)))Z #O7P]^TA_P4$CT^2Z\._"]X[F9<QS>
M(Y%#1J>A%NAX;_KHW'H",-7#B\91P4.>L_EU?H>=CLPP^7T_:5Y6[+J_1'TS
M\9OVB?!/P,TXR^(M3#:BZ;H-)M,27<WIA,_*/]IB![YXK\_?C-^W=X_^)QGL
M=%F_X0W0GROD:=(?M,B_[<_#?@@4=CFOG^ZNM7\9:\\]Q)>:UK5_-EG8M//<
M2,?Q9F-?6GP-_P""=^O>*D@U7XA74GAK36PZZ7;[6O9!_MDY6+Z$,W4$+7Q5
M3'X_-INEAERQ\OU?]?,_.JV9YGGE1T<'%QAY?K+]/S/D;3M,U+Q)JB6EA:76
MJ:C<O\D%O&TTTK'GA0"6-?3_ ,)_^">7COQGY-YXKGA\&Z:V"8I0)[QA[1J=
MJ_\  F!']TU^@7PV^#W@[X1Z6+'PKH-KI:E<27"KNGF]WE;+-]"<#L!795Z>
M%X=IP][$RYGV6B_S_(]C \*4:=IXR7,^RT7W[O\  \1^%O['/PP^%?DW%MH2
MZYJL>#_:.M8N) P[JA 1"#T*J#[U[: %  &!2T5]52HTJ$>6E%)>1]M0P]'#
M1Y*,%%>04445L= 4444 %%%% !1110 4444 >%_M!?LB^#_CM!+?&,:#XJV_
MN]8M(QF0XX$Z<"0=.>&&!@XXK\S_ (O_  2\5_!#Q$=)\3:>80Y)MKZ'+6UT
MH_BC?'/;*G##(R!7[25SOCWX?Z!\3?#-UH'B33HM3TRX',<@^9&QPZ-U5AGA
MAR*^>S')Z6,3G3]V??H_7_,^4S;(*&8)U*7NU._1^O\ G^9^:O[+_P"V9K7P
M5GM]"\0&?7/!;,%$.[=/89/WH2>J^L9./3!SG]-/"/B_1O'GAZSUS0-0AU32
MKQ-\-S V0?4$=0P/!4X((((K\M/VG/V2M=^ >H/J5F9=9\&SR;8-2"_/;DGB
M.<#H>P;[K>Q^4<[^SU^TEXD_9]\1>?I[G4-!N7!O]'F<B.8=-Z'^"0#HP] "
M".*\#!9E7RVI]5QB?*OO7^:_I'S&79OB,GJ_4LP3Y5]Z].Z_I=C]A:*Y3X8_
M$[P_\7/!]GXD\-W@NK"X&&1L"2"0 ;HI%_A<9Z>X(R"">KK[Z,HU(J47=,_3
MX3C4BIP=T]@HHHJBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHILDB0QM)(
MRHB@LS,<  =230 ZBOD7X@?\%-?A!X'^+_ACP;;ZYIVN:3J)E74_$MC?;[72
M64'8'VHPDW$8RK<9R:^I/"OBS1?'&@6>N>'=6LM<T>\3?;W^GSK-#*N<95U)
M!Y!'L010!K45RGQ$^*_@SX2Z3'J?C3Q1I/A>QD;9%-JEVD E;^Z@8Y8^PR:Y
MSX;_ +3GPG^+VJ?V9X.^(.@:_JFTN+"UO4^T,HZLL388@=R!@4 >G445Y7X^
M_:H^$/PO\0'0_%7Q&\.Z+K*LJR6%Q?IYT)8 CS$!)CR"#\V.#F@#U2BLGPMX
MLT3QQH=MK7AS6+#7M'N@3!J&FW*7$$N"0=KH2IP00<'@@TWQ9XPT+P'H-SK?
MB76;#0-'M@#-?ZG<I;P1Y.!EW( )) '/).* -BBO+?A]^U)\(_BKK@T;PG\1
M?#NN:PQ98]/M[Y//EVC+&.,D,X !.5!&!7J5 !1110 5YA_S<U_W*'_M[7I]
M>8?\W-?]RA_[>T >GT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %8'CCQWH/PW\-W6O>(]2ATO2[8?/-,?O'LB@<LQQPH
MR37+_'#X\>&?@-X5;5M>G\V[E!6RTR%AY]VX[*.RCC+'@>Y(!_*SXV_'KQ3\
M>/$IU/Q!=;+6(D6>F0$BWM$/91W8\98\G'H !X.99M3P*Y(ZS[=O4^9S?/*6
M6QY(^]4?3MYO_+J>A_M-?MB:_P#'*YFT?2O.T+P6K_+8JV);S!X><@\^H0?*
M/]H@&O./@S\"?%GQT\1#3/#=CFWC(^UZE/E;:U4]W;'7T498^F 2/2/V8?V/
M-<^.5U#K.K^=H?@I'^:\*XFO,'E( 1T[%SP.VX@@?ISX)\#Z%\.?#=IH/AS3
M8=+TNU&$@A'4]V8GEF/=CDFOF\'EN(S2I]9Q;?*_O?IV1\C@,HQ6=5/KF.DU
M%_>_3LOZ7<\V^ /[*_@_X!V2S6,/]K^)'3;/K=X@\WD<K$O(B3V')[DX%>S4
M45]Y1HTZ$%3I1LD?IE##TL-35*C'EB@HHHK8Z HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH J:MI-EKNFW.G:C:PWUA=1F*>VN$#QR(1@JRG@BOS0_:Z_
M8[NOA!=7'BKPI#+>>"I7S+#DO+IK$_=8]3$3T?MG#=BWZ=5#>6<&H6D]K=01
MW-K.C1RPS*&212,%6!X((.,&O,Q^7TL?3Y9Z-;/M_P  \;,\KHYG2Y*FDEL^
MW_ \C\<?@+\>_$/P#\8)J^D.;G3YBJ:AI<CD17<8/0_W7'.UNH/J"0?UB^$_
MQ8\/?&;P;:^(_#EUY]K+\LT#X$MM* -T4B]F&?H0002"#7P#^V%^QU-\*;BX
M\7^#K>2X\'2MNN;1<N^F,3^9B)Z-_#T/8GQ;X$_';Q#\!?&4>M:+)Y]I+M2_
MTR1B(KN('[I]&&3M;J">X)!^.P>,KY/6>&Q*]S\O->7];GP. Q^(R#$/!XQ>
MY^7FO+NOU/V9HKD/A5\5- ^,7@VS\2>';KS[2<;9(6P);:4 ;HI%'1AGZ$8(
MR"#77U^@PG&I%3@[IGZI3J1JQ4X.Z>P4445984444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7P__ ,%?OB#KG@?]E&&RT::6UB\1:Y;Z3J$\1P?LQAGF://4;VA4'U7<
M#UY^X*\Z_: ^!7AO]H[X5ZQX%\4)(-/OPKQW5OCSK29#NCFC)!PRG\P64\$T
M ?C#\*_V4_A[X\\2?LU:*-8NK\?$2SU5]>NK.X7?:7$2N(XHUQA#$54D,#N)
M)/RD"OT4_P"">O['/Q,_9$?Q38>*?%VC:UX;U94FATS2WG<072MCS09(T W1
M\-@<[4Z[:_-KXL?LB_%W]C3X_>#M-\(:R-?\4Z@+B^\.7?AY&^U.(E(DS"ZG
M#[,_("X8<9/2OO/_ ()P_P#!0+Q-^T)XFU+X;?$JV@_X3"QM9+RUU6" 6YNU
MC<++%-" %25=V<J%! (V@KE@#P3Q5^Q[\8?VO?VX-3O_ (L:'XB\-^ 9KRZ$
M&I!49+?382WV:WA8%D1G!3DCEFD;!.:\\_X*(?L9^'/V+=2\ >)?ASK^LPC4
MIYP$OKE6N+6X@\MTEAD14('S^F5*@YYP/V'^,_QG\*? /X?:EXR\9:DNG:19
M+@ 8,MQ*0=D,29^>1L<#ZDD $C\<_,^)7_!67]IRV=[671O VD,$?R_F@T73
MV?+?,1A[F7;Z99@. B?* ?H-\1OVH_$'A7_@F[:?%R9_L_C+4O#-D(I@@7_3
MKD1P^>J]!@NTP'3  KX6_8 _8!\/?MA> O&/CWX@>(->B<ZF^GV<EA<()9+@
M1I+-<3-*CF3)F3'3)#Y)[?7?_!5?PU9^#OV%;30-#MELM&TG4=+LK>V4Y$5O
M&K)&@)YXP@]>*G_X(Y^5_P ,AR>7]_\ X2.]\SK][9#_ $VT ?*'_!,GXB:_
M\ ?VR/$7P/U._DN-&U*\U#2I;<L1%'J%GYA6=%)^4LL#H<==R9SM%0_\%(O'
MGB#]HW]MK0?@GIVI26^AZ??Z?HMO &)A^VW7EF2Y=0>2@F"<]!&V,;CGFO!(
MW?\ !8"Y^R9_Y*!J!;&?[\WF=?\ @5+J@V_\%@D^V?\ 0_P[?^^E\OI_P'^M
M &I_P4!_8+T#]C;PCX*\>?#SQ!K[;M36PN9;^X0S0W7EM+#/$\2(4/[F3/7!
M"X(K]0/V,_C-=?'W]F?P+XUU$AM6O+-K>_8#&^Y@D:"5\=M[1E\>CBOGK_@L
MQY7_  R7IGF??_X2FS\OK][[/<_TW5O_ /!(L2C]C/1_,SL.KWYCS_=\WM^.
MZ@#[0HHHH *\P_YN:_[E#_V]JUJGQ"\7V6J7EO;?#F]OK:&9XXKI=1A43*&(
M#@'D C!P?6N8\&ZYJGB#]H>6XU?09O#MROA8QK:S3I,647:D/E>,$DC'^S0!
M[91110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI%3@[IA1115%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5\A?\ !3*U^+-A\#+;Q1\)O$&M
M:1>:#=&;5K?1)62:>R90&D&T;CY;*A..BLY/ -?7M% 'X3>&?^"@ UCXI?L_
M^,O'UEJFIZA\-[2^L]2O89%GGU57B989,NR_O#D!RQY(W9)8@>Y_\$R_ 'B'
MXU?M:>.OVA+G0F\/^%II]0GM552(I;J[D;,,38 D$:,^]A_$5XRW'U7\6OV
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M%%=%X#_9S^%OPOUAM6\)?#SPUX>U4EL7VGZ7#%.H8895D"[E4@XV@@>U>BT
M%%%% !7F'_-S7_<H?^WM>GUYA_S<U_W*'_M[0!Z?1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4453U;5['0=,N=1U*[AL+"UC,L]S<.$CC0=
M69CP!2;LKL3:2NRY7Q7^U=^W/!X9^V>$/AS=QW6L<Q7NNQD-%:]BD)Z/)ZOT
M7MD_=\T_:J_;DN_'RW?A3P!/-I_AMLQW6K#,<]\.A5.Z1'_OIN^!D'YH^&OP
MQ\1_%SQ5;>'_  SI[WU]+R[=(H$SS)(W15'K^ R2!7Q.99S*I+ZM@M6]+K\E
M_G]Q^=9OQ!*K+ZIEVK>G,NOE'_/[NYE:3I.L>./$<%C86]UK.MZC/A(TS+-/
M(QR23U)ZDD^Y-?IC^RG^QSIOP5M8/$7B-8=5\;2)D-P\.G CE(O5^QD_!>,E
MNN_9O_9:\.?L_:.)HPFK>*KB/;>:Q(F" <9CA'\"9_%NI[ >V5VY7DRPUJ^(
MUGV[?\$]#)>'XX2V(Q6M3HNB_P W^7XA1117U1]L%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5M2TZUUC3[FQOK:*
M\LKF-HIK>= Z2(PP58'@@CM7Y>_M=?LEW7P1U5_$'AZ*:\\$7DGRL<N^G2$\
M12'J4/\ "Y_W3S@M^I=4]8T>R\0:7=Z;J5K%?:?=QM#/;3J&21&&"I!ZC%>7
MF&7T\?3Y9:26S[?\ \7-,KI9I1Y)Z26S[?\  /R(_9Q_:.UW]GWQ6+JU+W_A
M^[91J.DLV%E7IO3^[(!T/?H>*_6'X?\ Q T+XG>%+'Q%X=ODO],NURKKPR-_
M$CK_  L#P0:_-/\ :V_9)O?@?JDFO:#'-?>![J3"2'+/I[D\12'NO97/7H><
M%N*_9Q_:.UW]GWQ6+JU+W_A^[91J.DLV%E7IO3^[(!T/?H>*^0P..K936>%Q
M2]W\O->1\)EN95\CKO!8U>Y^7FNZ?]:G[!T5SOP_^(&A?$[PI8^(O#M\E_IE
MVN5=>&1OXD=?X6!X(-=%7Z#&2FE*+NF?J49QJ14X.Z84445184444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>8?\ -S7_ '*'_M[7
MI]>8?\W-?]RA_P"WM 'I]%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7F'_-S7_<H?^WM>GUYA_P W
M-?\ <H?^WM 'I]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA,71QM)5J#NG^'DPHHHKI.P**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KS#_FYK_N4/_;VO3Z\P_YN:_[E#_V]H ]/HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!/S-(\+XW$/FQ59?C)_I^9^0/A;X#?$7QKY9T;P5K=Y%)]VX^Q/'"?^VC
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MJ&>YSZ^:Y+#/H"![5Z'17U>&RW"X3^'#7N]7_7H?<8/*<'@4O94U?N]7]_\
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M!^@99FE#,Z?-3TDMUU7_  /,T****]0]D**** "BBB@ HHHH **** "BBB@
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M_&HR.=R@#<?F?X6_%CQ5\&?%EOXC\(ZM-I6I0_*VPYCG3.3'*AX=#CH?8C!
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M HHHH *\P_YN:_[E#_V]KT^O,/\ FYK_ +E#_P!O: /3Z*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#3Y*:UZOJS]&R[+:&6TO9T5KU?5_UV"BBBO0/5"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,/\ FYK_ +E#
M_P!O:]/KS#_FYK_N4/\ V]H ]/HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKZ(^Q/VAOVN/ '[..GLNNW_]H>(73=;Z!IY#W4F>A?M$G^T^,C.T,1BORO\
MVB/VU/B)^T/-/9W][_8/A9F^30-,<K"PSQYS_>F/3[WRY&0JUXO''K?CKQ($
M1;_Q!KVI3\ ;[FYNI6/XL[$_4FOOG]FC_@E[<:@MKK_Q>E>SMSB2/PS8S8E<
M?]/$JGY1_L(=W/WE((KZN&&PF5Q]I6=Y?ULOZ]3[:GA,#DL%5KN\_P ?DOU_
M$^*?A3\$O&WQMUP:7X,\/76LS*0)IHUV6]N#WEE;"(/J<GMDU^A7P/\ ^"57
MAO05M]1^)NL/XEOAAFTC3&:"S0_W6EXDD^H\OZ&OMWPCX-T+P#H-MHGAS2;/
M1-)MAB*TLH1'&OJ<#J3W)Y)Y)K9KQL5G%:M[M+W5^/W_ .1X&,S[$8B\:/N1
M_'[_ /(PO!O@/PY\/-'32O#&AZ?H&G+S]GT^W6%2?4[1\Q]SDFMVBBO!;<G=
MGS,I.3O)W84444A!1110!!?6-MJ5I+:WEO%=6LRE)(9T#HZGJ"IX(^M?.OQ0
M_P""?/P7^)OG3KX</A749.?MGAV06HS_ -<<&+\D!]Z^D:*VIUJE%WIR:.BC
MB*N'?-2DXOR/RL^*W_!*7QSX;66[\"Z]8^+[5>1978%E=_0;B8V^I9?I7R#X
M\^%_B[X7ZF=/\6>'-2\/W62%6^MVC63'=&(VN/=217]"-4-<T#3/$^FS:=K&
MFVFK:?,,26E] LT3_P"\C @_B*]VAG=:&E5<R^YGTN&XBQ%/2O%27W/_ "_
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MH_@_7O$3(-*T34=3+\(+.TDEW<XXV@YYX^M;K(J4=9U'^1T+ANC'6=5_@O\
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M=XF7PI(\RIQ%BY? E'Y?YGYA>)/^"2?B/2?"]Q>Z3XYM-=UJ(;ETO^SS;+*
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M7I]>8?\ -S7_ '*'_M[0!Z?1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%5]0U"UTFQGO;ZYALK.!#)+<7$@CCC4=69B<
M#U-&PKVU98HKY&^,7_!1+PCX1,^G^";1O%VIJ=OVQR8K%#['[TG_  $ 'LU?
M&WQ,_:P^)WQ4DD74_$MQI]@W_,.T@FU@ ]"%.YQ_OLU?/8K/,+AWRQ?._+;[
M_P#*Y\KC>),%A6XP?/+RV^__ "N?J7XT^-W@'X=O)%XB\7:3I=S'RUK)<JTX
M_P"V2Y?]*\5\2?\ !17X4Z*SIIXUK7R#A7L[(1H??,S(0/PS[5^8]E8W6J7:
M6]I;S7ES(<+%"A=V/L!R:]3\*_LG_%SQ@L;V'@75(8GZ2:BJV0QZ_OBN1]*\
M%Y[C<0[8>G]R;?\ 7R/F9<2YCBG;"4?N3D_Z^1]/ZI_P5 LX]PTWX>SS==KW
M6JK'CC@E5B;//;-<CJ?_  4W\83;O[.\(:':CG'VJ6:;'I]UD_\ K^U<YH__
M  3A^*>HK&UW>>'M*!P66XO9'=>>?]7$P)_''O78:7_P3#U^;;_:7CK3;3IN
M^RV,D^.><;F3-'/GE79-?**#VG$E?9-?**_R.1N_^"D7Q4N6S'I_AFUXQB&R
MF/X_-,:P;[]O[XR7:XBUJPLCM(W0:;"3]?G5N17MUG_P2]L8P/M?Q$N)CNR?
M)TA8_E].9FYZ\_I6_8_\$R?!,;#[;XLU^X7=T@6"(X].4;GWH^JYW/>37_;R
M_1A]1XCJ?%-K_MY?HSY/U#]LSXSZEN\[QU=INQG[/;6\/3_<C&*XK7OC9\0?
M$RLNJ^-_$%]&W6&;4IC'_P!\;MHZ#M7Z#Z?_ ,$Y/A19[?.N/$5]C.?M%]&,
M_79$M=AHO[$/P8T7:P\'K>RC_EI>WMQ+GZJ9-OZ4?V/F=7^)5^^38?V!G%?2
MK6^^4G_F?DJS-+(68EW8Y))R2:]$\#_L[_$GXC21C0O!VJ7$+C(NIX3;V^/^
MNLFU/R.:_7/PS\+?!O@ME;0?"FBZ/(O(DLK"*)\^I8+DGW)KJ*Z:7#:O>M4^
MY?J_\CKH<(1O>O6^27ZO_(^ _AA_P31O;AH[KQ_XDCM(NIT[1!OD(]&F<;5/
ML%;ZU]=_#/X!^ ?A%"O_  C'ANSLKH+M:_D7SKIO7,KY;!] 0/:O0:*^CPV6
MX7":TX:]WJ_Z]#Z[!Y3@\#K1IZ]WJ_O_ ,@HHHKTSV HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJNJ:I9Z)IUS?ZC=P
M6%C;(99[JYD$<<2 9+,Q. !ZF@>^B+5>(?M'_M=^!OV;-+*ZQ<_VKXDE3=:^
M'[%P;A^.&D/2)/\ :;D\[0V"*^6/VIO^"G$<'VKPU\'V$LN6BG\4W$657L1;
M1L.?^NCC'HIX:OSR>36_'7B0LQOM?U[4Y^3\]Q<W4S'\6=B?J37TN"R>53]Y
MB-%VZ_\  /KLOR&=6U7%^['MU^?;\_0]+_:$_:G\=?M':T9_$6H&VT:*0M9Z
M%9DI:6X[$C_EH^/XVR>3C XK0_9Q_9!\=_M):BLFCVO]E>&HY-ESX@OD(MTQ
MU6,=97_V5X'&XKG-?5?[*_\ P3)W"S\3_%]>"%E@\*P28/J/M3K_ .BT/IN;
MJM?HEI.D6.@:9;:=IEG;Z?I]K&(H+6UB6.*)!P%55   ]!79BLTI8:/L<(EI
MUZ+_ #_K<[\9G5'!P^KX%+3KT7IW_K<\D_9[_9/\ _LXZ6J^'M/^V:[)'LNM
M>O@'NYLXR%.,1IG^!<#@9W'FO9J**^2J5)U9.<W=GPU6K.M-SJ.[84445F9!
M1110 4444 %%%% !1110 4444 %%%% %;4M-L]8LI;._M(+ZTF&V2WN8Q)&X
M]"I!!_&O%_%_[$GP/\;%VOOAWI5I*W_+320]@0?7$#("?J#7N-%:PJU*6L)-
M>AM3K5:+O3DUZ.Q\8^(/^"5'PBU1R^GZIXGT9L_ZN&\BEC_*2(M_X]WKCK__
M ()$^&9&_P!"^(>K6XW'BXT^*7CL.&7GWK[_ **[8YEBX[5&>C'-\=':J_P?
MYGYNW7_!'^=8R;;XK1RR9X67P^4&/J+D_P JI_\ #H75_P#HIEE_X)W_ /CU
M?I=16W]K8S^?\%_D;_VYC_\ GY^"_P C\T?^'0NK_P#13++_ ,$[_P#QZI+?
M_@D'J+3*)_BA:QQ?Q-'HC.PX[ SC//O7Z544?VMC/Y_P7^0?VYC_ /GY^"_R
M/SLL_P#@D#9H&^U?%.>8_P /DZ$L>/KFX;-;VG?\$C?!D6/M_CS7;GY<'[/;
M0P_-Z\A^.O'ZU]ZT5#S3&/\ Y>?@O\C-YSCY;U?P7^1\9Z=_P2F^#UGS/JOB
MV_)QGSK^!1QUQL@7@_4UU.F_\$U?@/8D>=X<U#4,-N_TG5K@9'I^[9>/U]Z^
MHZ*QEC\5+>H_O,)9EC9;U9?>>":9^PC\!M)4"#X=6$@ (_TJYN;@\G/_ "TD
M:NQTO]FCX2:*P:S^&?A.*0'(D;1K=W&1@X9D)''O7I5%82Q%:7Q3;^;.:6*Q
M$_BJ-_-F)I/@?PYH.W^S- TO3MNW;]DLHXL;?NXVJ.G;TK;HHK!MO5G,Y.6K
M84444A!1110 4444 %%%% !1110 V2-)HVCD17C8%65AD$'J"*^8_C/^P/X$
M^(WGZAX<'_"%ZV^6S91AK.5O]J#("_5"H'7!KZ>HKFQ&&HXJ/)6C=''BL'0Q
MD.3$04E_6SZ'Y"_%3]D7XF?"9I)K_09-7TM/^8GHP:YAQZL -Z#W90/>O)-+
MU>_T&_BO=-O;G3KV(YCN+65HI$/LRD$5^ZM><_$#]G;X<?$^22;Q%X1T^[O)
M,[KV%#;W!]S+&58_B37R>(X<5^;#3MY/_-?Y'PV*X25^?!U+>3_S7^1^;_@O
M]N'XO>#%2(^(UUZV7I#K4"W!_&3B0_B]>Q^'O^"GNLP1HNN^!+&]?H\FGW[V
MXZ]0KI)VSQN_&N]\7?\ !,_P9J<DDGAWQ/JVA,W(BNHTO(E/L/D;'U8_6O)=
M<_X)G^/+5F.D^)M U&,=!<&:W<_@$<9_&N3V.=872#;7JG^9Q+#\18+2$G)>
MJE^>OX'HFJ?M_?"?XD:'+HGCGP!J=YIEP,26LL%O>0@_WOF=2",G# 9& 1ST
M^./C9\-?@GK3/JOPM\1:MH,KDLV@:_9R20KSTCG0NR^RL'Z\L*]$UK]@_P",
MVD;C'X:@U.->KV6HP'_QUG5C^5<U>?LE?&"Q,@D\ ZJVP9/DJDO;/&UCG\*[
M</GV>X%^[%_.+L>AA>)N)<ME[D'\X.S^ZR/E&ZLY[&3RYXFB;_:'7Z>M>V_
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M_#NUSX,.J3+_ ,M=2U"XESTZIO"=O[M>I^'/@'\-?"(7^QO 'AK3G7I+!I4
MD_%]NX_B:[VBN*>(K5/CFW\V>?4Q6(J_'4;^;&0PQV\2Q11K%&HPJ(  !Z "
MGT45SG*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7F'_-S7_<H?^WM>GUYA_P W-?\ <H?^WM 'I]%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML5S+;9Z9QN\S'?\ ,>G/;#/\%+=M>J_RN>C3XHRZ?Q-Q]5_E<_0^BOB;2O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\P_YN:_[E#_V]KT^
MO,/^;FO^Y0_]O: /3Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M &(?VLO$O[+<?C67PA\/AXUUC64M?-N9&F9+*"'S204B4D[FD!+%@!Y8X.:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M. &P!DG@5S'@WP3I?@/]H>6PTB.:.VD\+&=A-,\IW&[53RQ)QA1Q7ME>8?\
M-S7_ '*'_M[0!Z?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110 4444 %%%% !12,P12S$*JC))X KY[^+W[>'P?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E7_A/1-4U
MJPUB]T;3[S5]/#"SU"XM4>XMMPPWER$;DR.N",UJT44 %%%% !1110 4444
M%%%% !1110 5YA_S<U_W*'_M[7I]>8?\W-?]RA_[>T >GT444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %>9?M"?'+2_@)\/;K7KP)<ZC)F#3=/+8-S.1P#
MW"+]YCV ]2 >W\5>*=+\$^'-1UW6KM+'2["%I[BXDZ*H]/4DX  Y)( Y-?D-
M^T5\=M4^/GQ"N-;NM]MI4&8-,T]CQ;P9XSVWMU8^O'0#'A9MF*P-*T?CEM_F
M?-9YFRRVARP?[R6WEY_Y>9PWBGQ/J_C[Q1?ZWJ]S)J.L:E.99I2,L[G@  =
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MWM>GUYA_S<U_W*'_ +>T >GT444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "O,/\ FYK_ +E#_P!O:]/KS#_FYK_N4/\ V]H ]/HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBOF_\ :Q_:XT_X&Z9+H6AO%J'CBZBS'$<-'8*1
MQ+*/[V.53OU/&-W/B,13PM-U:KLD<F*Q5+!TG6K.R7]67F9G[97[6,/P?TB;
MPIX9N5E\:WL6'E0@C3(F'^L;_IH1]U>V=QXP&_-CP_H.L>//$UII6EVT^JZU
MJ4^R*)3NDED8Y))/XDL> ,DFL3Q)XX&I:K>:EJVI/J&I74K33S.QDDD=CDEC
MZ_6NW^$O[6Z? :SN[SPEX2LK_P 77:&)M<UQVD2VB/\ RSA@0K@G&2Y<YX&T
M '=\K2RG-.(L0JCIN-+HWHDO*^[?D?%4<CSGBO%QJ.C*%'HWHDO*^[?=7^Y'
MZE?LQ_LZZ9^S[X)%H#'>>)+X+)JFH*/OL!Q$AZ^6N3CU)).,X&_\0OVB?AG\
M*VE3Q5XVT?2;F/.ZS:Y$ER,?],4W2?\ CM?C=\2/VOOB_P#%7S(]=\<ZDME)
MP;'37%E;E?[K)$%WC_>S7DVGZ;>ZU?):V-K/?WDIPD-O&TDCGV4 DU^L83AV
M%"FH2E:*Z+_-_P"1^X8'A.&%I1ISGRQCT7^;_P C]5/B!_P5:^&WA\2Q>%="
MUGQ9<KG;+(%L;9O3YGW2?G'7SEXX_P""JGQ5\0>9%X>TS0O"L!^Y(D#7=PO_
M  *0[#_W[KR[X?\ ["'QM^(?E26_@JZT6T?K=:\ZV04>I1SYA_!#7TAX%_X)
M%ZA*L<OC+Q_;6Q_CM-#LVFS])I2F/^_9KN]EE>%^)IO[_P %H>E[')<#\;4G
MZ\WX+3\#X]\<?M-_%;XC^8OB#Q]KE[!)]^UCNV@MV^L46U/_ !VO-889+J98
MXD:65SA40%F8GL!W-?L?X'_X)K_!#P>8Y+S1]0\4W"<B36K]R,^NR+RT/T8&
MO?O!_P +O!WP]B6/PQX6T?0 !MSIMC% Q^K*H)/N34RSK#TERT*?Y)$RX@PM
M!<N'I?DE^I^)/@W]DOXQ>/EB?1OAWKDD,I&R>\M_L<39[AYBBD>^<5[=X1_X
M)7_%[7=DFL7GA_PU%GYTN+QIYA]%B1E/_?8K]<**\^IGF(E\"2_$\JKQ'BI?
M!%1_'^ON/S\\(_\ !(OP];A&\4?$'4]0)Y:+2+*.UQ[!Y#+GZ[1]*]J\*_\
M!.;X$^&55I?"UQKLZXQ-JNHSO^:(RH?Q6OIFBO-J9ABJGQ5'\M/R/)J9IC:O
MQ57\M/RL>>>'?V>/A=X2"?V1\//#-E(HP)DTJ$R],<N5+'\37?V]O%:PK%!$
MD,2_=2-0JCZ 5)17%*<IZR=SSI5)U'>;;"BBBH,PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5YA_S<U_W*'_M[7I]>8?\ -S7_ '*'
M_M[0!Z?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\P_P";FO\ N4/_ &]KT^O,/^;FO^Y0_P#;V@#T^BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\P_YN:_[E#_V]KT^O,/^;FO^Y0_]
MO: /3Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BO,/C5^TI\/?@#IIN/%^OPVUXR;X-*MOWU[/Z;(@<@'IN;:OJ17YS
M?'K_ (*=>._B#]HTSP)!_P (+HC97[4C"3495]?,^[%GT0;A_?->CA<OKXK6
M"LN[V/6P>5XG&ZTXVCW>W_!^1^C/QB_:5^'/P)M2WB_Q+;65Z4WQZ7!F:\E]
M,1+E@#_>;"^]?!OQI_X*M>(]<^T6'PTT*/PY:'*KJVJJMQ=D?WEBYCC/^]YG
MX5\,*NK>+M< 47FM:S?2] 'N+BXD8_BSL3]2:^K_ (,?\$R_B=\1?(OO%+0^
M =(?#?Z>OG7K+[6ZD;?I(RD>AKZ2&7X+ KGQ,KOS_1=?Q/K897E^7153%RN_
M/;Y+K^)\R^.OB9XL^)VJ'4/%GB+4O$%WDE7O[EI!'GLBDX0>R@"MGX>? +XC
M?%<H?"?@S6-9@8X%W#;,ML#Z&9L1C\6K];_@_P#L#_"#X11PSCP^OBG6$P3J
M/B$+<G=ZK%@1K@]"%W#CDU]$1QI#&D<:+'&@"JJC  '0 >E8U<[A!<N'AIYZ
M?@<]?B*G37)A:>B[Z+[E_P  _)3P;_P2N^+>O*LNMWV@>&(^\=Q=-<3#Z+$K
M(?\ ONO2[/\ X) 7,D -W\58H)NZ0Z 9%_[Z-RO\J_2.N3U[XM^!_"SNFL>,
M=!TR5/O1W>I0QO\ 3:6SG@\8KR*N=8E:N:BO1?J>%6XBQB]YU%%>B_6Y\!ZG
M_P $@M0BASIWQ1MKJ;^[=:&T*_FL[_RKR?QI_P $P/C/X92272XM%\51*"0N
MFW_ERD>ZSK&,^P)K]([S]K;X/V(<R>/M+;:VT^27EY]MJG(]QQ45K^U]\'+S
M=Y?CS3EV]?-26/\ +<@S^%<\.))1?O5HOUM^ECEI\73@_>KP?JX_I8_%'QQ\
M+O&'PSO!;>*_#&J^'I6;:G]H6CQ+(?\ 88C##W4FM7X8?'KX@?!J\6?P=XKU
M'14#;FM8Y=]LYSGYH7S&WXK7[0S?M%?!CQ98RV%[XU\,WME/^[EMM1GC$3@]
MF63 (^O%>&?$C]B;]G;XU1R77A/6M*\+:K("R7'AG4(9+9CC(W6^XIC':/9]
M:]JAQ#A,0N2M;Y--?=_PY]#AN*L#BE[/$)._9J2^[_ASRWX-?\%8G4PV'Q/\
M,AEX4ZQX?&#]7MW;\RK_ $7M7W+\+_CEX#^-&G?;/!GB>PUQ57=);Q2;+B(?
M]-(6PZ?\"45^4GQI_P""=?Q7^$_GWNF6"^.-#CR1=Z(I:=5]7MS\X/\ N;P.
MYKYJT_4M3\+ZQ'=V-U=Z1JEG)\D]O(T,\+C@X8$,I'YUU3RS"8R//AI6]-5]
MW0[:F3X''Q]I@YV?EJONW1_1517Y$_!G_@IQ\3/A[Y%EXLC@\>Z0GREKP^1?
M*OM.H(;_ (&K$^HK[O\ @W^WA\(_C$L%M#KZ^&=:DP/[+U_;;.6/9)"3&^3T
M ;<?[HS7S^(RW$X?5QNNZU/E\5E&+PFLHW7=:_\ !/H>BD5@RAE.0>012UY9
MXH4444 %%%07E];Z;:R7-W/%:VT8W/-,X1%'J2>!0&Q/17AOQ"_;6^#_ ,.8
MY?M?BVWU6XC_ .7?1Q]J)]MZ_NP?8N*^2OBU_P %9+V99K/X=>%(K0'*KJ>N
M/YCCW6%" "/=F'M58:,L9+DPZYO39>KV7WEX.$L?/DPJY^]MEZO9>C=S]"O&
MGCCP_P##OP_<ZYXFUBTT32;<9DNKR4(N>RCNS'LHR3V!K\Z_VD/^"HU]JOVK
M0OA):MIMH<H_B2_B!GD'0F"%LA!Z,^6P?NJ>:^*?B=\8O&GQEUO^U?&?B*]U
MZ[&?+6X?$4(/41Q* D8XZ*!5GX7_  1\:_&'4A9^%?#]]JIR \L$),<>>[.<
M*H]V('O7UL,!A<OI^WQLE^GHENWY?@?<4\LP654OK.8S6GW7[);R?E;7L<GK
M&LZEXHUBXU'5+VZU75+M]\UU=2M+-,Y[LQ))-=-X.^&6J>*-2M[.WL;J^O)V
MQ#86432S2'TVJ"?R_2OO'X)_\$N[FW^SWWCS6DT]>"^GZ61+<,/[K3$;$_X"
M&^M?</PV^#W@[X1Z;]B\*:#:Z4K*%EN$7=/-_P!=)6RS<]B<#MBOGL?G6-QO
M[K!+V-/^9_$_1?9^>OH?*YGQ!F.8WH9<O84OYW\;_P ,=H^K][R1\+_ ?_@G
M%K.L+;WWC^;_ (1G2AAETBR97O)1_MMRL8/_  )NH(4\U]Y?#[X9>%_A7H:Z
M3X6T:VT>S&-_DKEY2!C=(YRSM[L2:ZBBO!PV!HX5N45>3WD]6_F?-8/+</@V
MYP5YO>3UD_F%%%%>@>H%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO\:_#+_A&=8_Z!5]_P" S_X4?\(SK'_0*OO_  &?_"G_ &'0_G?X#_U<P_\
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M;;_PCWBS0]=+#(&FZC#<$]NB,:Z>N-Q<79H\^491=I*P4445)(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%>9_&#]I#X=? JS:7Q?XEM;&[V[H],A/G7DOIMA7+8/]X@+ZD5\"?'#_ (*I
M^)O$@N--^&FCKX7L6RHU;40L]ZP]5CYCB/UWGN"*]##X#$8K6$=.[V/4PF68
MK&:TXZ=WHOZ]#]"_BU\=/ WP/T;^T?&?B&UTA'!,-LQ+W-QCM'$N7;GC(&!G
MDBOSJ^/W_!4;Q3XP%QI/PTL6\(Z4V4.JW0634)5]5'*0Y'IN;N&%?%FO>(=:
M\;:Y-J6L:A>ZWJ]V_P"\N;R5IYI6/ !9B2?85]1_ 3_@F[\1_BLUMJ7B=#X"
M\.OAM^H1%KZ5?]BWR"OUD*^H#5]+3R_"8&/M,3*[\]ODNI]?2RO Y;'VN+DF
M_/;Y+K^)\M7-UJ_C+7FFN);W7-:OY?FDD9[BXN)&..IRSL?Q-?87P#_X)B>-
M_B MMJOCVY/@?17PWV(H)-1E7TV?=BSZOEAW2OT!^"_[+WPR_9OTMKC0-*AC
MOXXS]H\0:JZR73+CYB92 (U]0@5?45S'Q0_;M^&'P\\ZVL-0D\7:HG M]' >
M$'_:G/R8_P!TL?:O*S#B*G0C:#4%W>_R7_#GB9IQ92PT;4Y*$>[W^2_X<[KX
M+_LT_#OX!V A\(^'H+:]9-DVJW/[Z]F]=TIY /\ =7"^U=?XR^(7AGX>Z?\
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M (98-H^MZEI+ Y!L;N2$]_[I'J?SJOXRU_4OB$WF^)+V76KS@?;KW$MT0!@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%DEYI=_:ZE:/]VXM)EEC;Z,I(J[7\[.@^)M8\*WHO-%U:^T>['2XL+EX)/\
MOI"#7NO@?]OWXX^!?+1/&<NN6J];?7($N]WUD8>;^3UQU,BJ+^'-/UT_S."M
MPU5C_"J)^NG^9^V-%?FGX'_X*Z:I#Y<7C'P!:7?]^ZT.\:#'N(I0^?\ OL5]
M"^!?^"E7P2\8>7'>ZOJ'A6Y?@1ZS8L%SZ>9%YB@>[$5Y53+<72W@WZ:_D>+6
MRC&T?BIM^FOY'U/17*^#_BKX,^(2*WACQ7HNO[AG;IU_%,X]<JK$C\1755YT
MHN+M)6/)E&4':2LPHHHJ20HHHH **** "BBB@ HHHH **:[K&K,S!549+,<
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MZGY\!/TCHHK\ES',:^9UW7KO7HNB79'=""@K(****\PL**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $90ZE6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=.O[_P#X1VYN4,4ECXAC5(9 1AE\S)C*G.,,1G/2OQATGXR65P0FHV<EJ?\
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MW]_R,76G+2",#X\_M8?$[]I"^W^-/$<MQIJ/YD&C68\BQ@/;$2_>([,Y9O\
M:J;]GG]DKXD?M,:PEOX2T1UTE9 EUKU\#%8VWKF3'SL/[B!F]L<U^D?[/_\
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MI/!*H>.6-@RNI&001P01WJ2OS,[ HHHH **** "BBB@ HHHH **** "BBB@
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MRJ ?T%?M;\-?^"6/P(\!>5+J6D:CXTO4Y\[7;UC&&]HH1&A'LP:OI[P?\/\
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MVU#Q)81]+G1)(KZ1E]0L+,Y^C(":Y"/4 M\]A>6UUI.J1C,FG:E UO<I]8W
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M#/E/X3\ Z/87D>-NH3P_:KL?2>4M(/H& KUJO/Q7&UERX.CIWE_DO\RXX?\
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M9;2P/0K#VFE'][E%_P!LY"_E+>WOB#XC>*I+BYEU#Q)XCU:XRSL7N;J[F8X
M[L[$X '6OT/).%9XI+$X[W:?;9OU[+\?3<Y*E91TCN>P_M)_MJ_$O]IK4I4U
M[56TKPT&S;^'-,=H[1!V,G.9GX^\^<$G:%!Q7"_"'X!?$'X\:PVF^!?"U]K\
ML9Q-/$H2W@_ZZ3.1&GL&8$]LU][_ +)O_!)E[R&R\4?&IW@C;$L/A&TEVN1V
M^U2J?E_ZYQG/3+ Y6OTS\+^$]%\$:':Z+X?TJST32;5=D%E80+#%&/95 '^-
M>[CN)L%E</JN604K?^ K]9?UJ9QHRG[TV?E9\-_^",OB_5[5;CQQX\TOPX[
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M!'3H02""?C^(,BEE-7VE/6E+9]GV?Z=SHI5/:*SW.WHHHKY W"BBB@ HHHH
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M,QRRKSGAW!8=?7T]!7HJ_P#!0SX0:6BVMI;ZW]GC&$%MIR)&/8 N,?E7P_\
M\,F_%_\ Z$'5O^^%_P#BJNP_L;_&:>-'7P)>@-TWSP*?Q!D!'XUP5,[SJN[U
M(N3\U)_F6LZSK:-#_P D9]7ZQ_P4V\&PY_LKPCKM[Z?;)(;?T_NM)[_D/PX'
M7O\ @IYK]PK#1? VFV#?PM?WLET/Q"+'_.O--'_X)_\ QCU+'VC1]/TK/_/Y
MJ438Z_\ /(OZ?K7<Z'_P3+\;7#K_ &OXKT&P0]?L:S7+#\&2,>O>L?;YW6VB
MU\DOS']:XCQ&D8M?]NI?F<%XD_;Z^,6O;Q;ZU9:'&QY33;"/@>@:4.P_/->5
M>)?C7X_\8;AK/C/7-0C;.89;^7RN>N$!VC\!7V_X<_X)D^$K/8==\7ZQJA')
M%C#%:*?^^O,./QKU3PS^P]\'/#.Q_P#A%O[5G7_EMJ=W+-GZIN"?^.TO[*S3
M$?QJEO63_2XO[%SK%_[Q5LO.3?X*Z/R952[!5!9B< #J:[7PW\$/B#XP"MH_
M@K7;^)AD31V$@BYZ?.0%_6OV)\-_#OPMX-51H/AO2=%VC -A8Q0G\U4&NAKI
MI\-+_E[5^Y?U^1V4>#UO6K?<OU;_ $/RHT#]@7XQ:TJM<:+9:,K=#J&H1?J(
MRY'Y5Z/H/_!,7Q3<;?[:\::/IX[_ &"WENL?]]>57Z(45Z=/A_!0^)-^K_RL
M>Q3X7RZG\2<O5_Y6/B33_P#@F#H<>/M_CS4+DX&?L^GI#GUZN_\ ];WKHK?_
M ()G_#=8\3^(?%4DF?O1W%L@_(P'^=?7-%=D<HP,=J2_'_,]".0Y;':BOQ?Y
ML^2_^':/PQ_Z#OBW_P #+7_Y&IDO_!-'X:-&PCU_Q6DF/E9KJV8 ^X^SC/YU
M];T5?]E8+_GTB_[$R[_GRCXVNO\ @F3X,9 +?Q=KL3YY,J0N,?0**\Z^)W_!
M-37=#\+W>H>"/$D?B;5X!O31[^ 6?V@#)(2;>RA_0, I/5EK]#J*E91@+IRI
M)_-K\FC&7#^63WI?B_\ ,_GKU[XB7'A#7;W1?$/AW4=&U>QD,-S8W2[)87'\
M+*V".*T/"?Q#T'Q3KEIICWR:(;F01K=ZM^ZMT8\#>Z[M@S_$< =20.:_87]J
MO]B_P+^U5H/_ !-X/['\5VT92P\26<8\^+N$E''FQ9_A8Y&3M*DDG\5/VAOV
M9O'7[,OBYM$\8::4@E+&QU:V!>SOD'\4;XZCC*'#+D9'()_0<MX1X5SN')"$
MJ57LIO[US7O^?YGD5N&L%'51=O4^RI/V$_C"]K'<V&@V.K6TJJ\4UEJUJ4E1
MAD.I:105(QS[UBWG[''QEL5<R>!+YMIVGR9X)?RVR'(]Q7E_[&O_  4'\5_L
MSW5MX?UO[1XI^';/A],=\SV )Y>U9CQUR8R=IYQM)+5^S?PK^+/A3XU>#;/Q
M3X-UB#6M'N1@20G#Q. "8Y$/S(XR,JP!Y!Z$&OC<XX!64S]Z4G![25K?/31_
MTC./"^ J?#.2?JO\C\G[K]EWXM6;!7^'VNL2,_NK1I!^:YJ'_AF?XK_]$]\1
M?^"^3_"OV5HKYC_5NA_S\?X!_JCAO^?LOP/QM@_9A^+%Q*L:_#[7PS=#)9.@
M_,X K=T_]B_XT:D 8? URF5W?Z1=VT/?_;D'/M7ZZT54>&\/]J<OP_R*CPCA
M/M5)?A_D?EQHG_!/'XNZJ1]J@T;1L_\ /]J ;'_?I7KT30?^"86LS,AUKQW8
MV@S\RV%@\^1Z LZ?GBOT#HKKAD."ANF_5_Y6.ZGPQEU/XHN7J_\ *Q\H>%_^
M";_PTTC:^K:AKFO2]UDN$@B/T5%#?^/5[#X3_9E^%G@ED?2? VD)*GW)KJ'[
M5(ON'F+,#[YKTZBO3I8#"T?@II?(]FCEF"P_\.E%?+7[WJ,BA2WC6.)%CC48
M5%& !Z 4^BBN\],**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML#)&@8@D#(SSBNWHH *\P^('[,/PE^*>MC6?%GPZ\.:[J^Y6:_NM/C,\NT8
MDD #2  8PQ(]J]/HH R_#/A?1O!>AVNC>'](L="T>U!6#3]-MDMX(@220L:
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M_P _4]YHJ.">.ZA2:&198I%#)(A!5@>A!'45)7[,FFKH_.]M&%%%%,04444
M%<M\2OAKX?\ BSX2N_#OB2Q6]L+@95N!)#)@[9(V_A<9X/U!R"0>IHJ91C.+
MC)73-Z%>KA:L:]"3C.+NFM&FNJ9^0G[17[,OB/\ 9^UW%T&U/PW<N18ZQ$F$
M?OLD'\$F.W0X)!/.+7[.O[57B?\ 9_U#[-#G6/"\\F^YT>=R I/5X6_Y9O\
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MBOS'-,WQ6;5.>N]%M%;+_@^9VPIJFM HHHKQ#0**** "BBB@ HHHH *^,_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=U8=B/\ /%:M?T71K4\13C5I24HR5TULT?D-2G.E-TZBLUN@HHHK8S"BBB@
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MOP^_:FTL-KMJVD>)X(]EIXCT]%%S&.R2#I+'G^%N1SM*Y)K\=?VEOV+OB/\
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M=Q;31SP2#<DD;!E8>H(ZU+7ZW&2DDT[IGP333LPHHHIB"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZQH]['NCFA99894/Z'T(KS\RX7R?BB#KX;]U6ZM+K_>CL_56?GT/Q',</G_
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MFW2J<K/VIHHHK\9/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;<_S?:*YZZ_:<TU7Q;Z)=2IZRRJA_( UY!I?PS\4ZQM-KH5X5;H\L?E*?Q?
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M5W#O7\[NM:/JW@7Q5>Z9?13:7KFCWCV\T>2LEO/$Y5AD="K+U'I7]-=?D/\
M\%=/V=_^$.^(NF?%72+79I/B;%GJGEK\L5_&GRN?3S8E_P"^HG)^]7Z/P;F7
ML:\L#4?NSU7K_P %?D<F(A=<R/T#_8L_:$C_ &DO@#H7B:>5&\06P_L[6HUP
M-MY&!N? Z"12D@'8/CM7NM?B9_P2Y_:(_P"%/_'J/PKJEUY7AKQILL'WMA(;
MT$_9I/;<6:(_]=%)^[7[9U\[Q!EO]F8Z4(KW):Q]'T^3T]+&M*?/&X4445\T
M;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>=#GU,3D,H^C.?:O;P^?8.MI-N+\]OO_ ,['Y=G'A+Q%EJ=3#QC7C_<?O?\
M@,K/Y1YC[;HKBOA[\:/!'Q5MQ)X5\2V.K/MW-;1R;+A!ZM$V'4>Y%=K7T,)Q
MJ1YH.Z\C\>Q.%KX.JZ.)IN$UNI)IKY/4****LY@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **S]>\0:9X7TFXU/6-0MM+TZW7=+=7<JQQH/=B<5
M\9?'#_@HQ8Z<;C2OAK9+J,XRAUS4(RL*^\41PS_5\#(^ZPKAQ6.H8./-6E;R
MZOY'U60\+YMQ)6]EEM%R2WD](Q]9;?+=]$SZ_P#&?CSP]\.]&DU7Q+K%IHM@
MG_+:ZD"[C_=4=6;_ &5!/M7Q=\9_^"D'%QIOPUTS'5?[<U6/_P >B@_4%_Q2
MOB_QIX]\1?$76I-6\2ZQ=ZSJ#_\ +:ZDW;1_=5>B+_LJ /:O5?@S^QQ\0_C%
MY%Y'8?\ "/:!)AO[4U53&'7UBC^])[$ +_M"OC*V<XO'2]E@H-?G_P #^M3^
ME<L\->'>%:"S#B:O&HUTD^6G?LE\4WY=?Y3R?QAXXU_X@:U)JWB/5[O6=0DX
M,]W*7(']U1T5?]D  >E>Q_!7]BSX@?%XP7T]K_PBWAZ3#?VEJD95Y%]8H>&?
MV)VJ?[U?<OP7_8Q^'WP?\B]:S_X2;Q!'@_VGJB*PC;UBB^ZGL>6']ZO>JZL)
MP\Y/VF-E=]E^K_R^\\3B#Q@A1A]2X:HJ,5HIR5DE_<ALO+F_\!/(?@G^R[X&
M^!EO'-I%A_:&N[<2:U?@/<'/4)QB-?90..I/6OD3_@J!^VT/!NEWGP>\$7^-
M>OHMGB#4+=^;.W8?\>RD=))%/S?W4..K?+[E^WI^V59?LM_#_P"PZ1+#=?$+
M6HF72[1L,+5/NM=RK_=4Y"@_>88Y"MC\/H8=<^(7BO:@N]=\0ZO=%B23+/<S
MR,26)ZEB222?<U^[\)\/4HQ6.KQ4:4-4MDVNK\E^+]#^8<US3&9IB'7Q=5U*
MDMVW=^B_1+1=#I_@7\$_$G[07Q+TGP7X8M_,OKU]TUPX/E6D (\R>0CHJ@_B
M2 .2!7] /P)^"7AS]GOX9Z3X+\,0;+*S3=-<N!YMW.<>9/(>[,?P  4< "OE
MO]DCP'X/_8Y^&9M88X_$OQ$U=$EUK4+<@01L!E;:.0]8X\]5!WMELCY0O4^+
M?BYXD\7[XY[PVEFW'V6TRB$>A.<M^)Q7Y;QYXL92JSPN$G[6,-E#9ONY;6[6
MN_+4^ARGA/'XI*=2/LXOK+?Y+?[['T)XL^,/AKPGOCDO/MUXO'V:SQ(P/HQS
MA?Q.?:O&/%G[0'B#7M\.G;=%M3Q^Y.Z8CW<CC_@('UKSW2-#U#7[L6VG6<U[
M.?X(4+8]SZ#W->N>$OV;[VZV3^(+P64?4VMJ0\GT+?='X;J_GN>>\4\6R=++
MH.G3_NZ+YS?Y)J_8^]CE>1Y"E/%R4I_WM7\HK];^IXW--<:A=&25Y+FXE;EG
M)=W/UZDUW7ACX(>*/$FV1[0:7;-SYM]E"1[)][\P![U]'>&? 6@^$8U&F:;#
M#*!@W##?*?7+GG\.E=!7T>5^&5)-5<UK.3_ECHOG)ZOY)>IY&-XTF_<P-/E7
M>7^2T7WL\D\/_LXZ%I^U]5NKC59!U1?W,?Y [O\ QZO1]&\,:3X>C":;IMM9
M #&Z&(!C]6ZG\:U**_5LOR++,K7^QT(Q?>UW_P"!.[_$^&Q>:8W'/_:*KEY=
M/N6@4445[IY84444 %%%% $%U8VU]'LN;>*X3^[*@8?D:YZ_^&/A34LF;0+$
M$]3#$(C^:XKJ**XZ^#PV*TQ%*,_5)_F=%+$5J'\*;CZ-K\CS6^_9\\(71/E0
M7=G_ -<+@G'_ 'WNK%NOV9=&?/V;5[Z+T\U4?^06O9**^=K<)9%7^/"0^2Y?
M_2;'KT\^S2E\->7SU_.YX1)^R_\ >,?B3_=5K'^9\S^E0+^S#<[AN\01 9Y(
MM2?_ &>O?J*\U\!<.MW^K?\ D\__ )([%Q3FZ_Y??^2Q_P CQ"W_ &8;52/M
M'B":49Y\NU"?S8UT.E_L\^%+!E:<7FH$=5N)MJ_D@7^=>G45W8?@[(<,[PPL
M7ZWE_P"E-G+5XAS2LK2KOY67Y)&7HOA?2/#J%=,TVVLLC!:&(!F^K=3^-:E%
M%?6TJ5.A!4Z45&*Z)67W(\*=2=27--MONPHHHK4S"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#Y#_:F_8=L?B%]K\4^ H8=,\3',MSI@Q';WYZDKVCE/
MK]UCUP<L?SQFAUCP3XB:.1;S1-<TV?D'=#<6\JG\"K U^Y5>'_M'?LJ^&_C]
MIK73!-'\5P1[;;5XDSO Z1S ??3]5[=P?DLTR15[U\+I/MT?^3/Z&X%\4*F5
MJ.69XW4P^RGO*"[/^:/XI;75DO)/V6_VZ[3Q=]D\*_$6XAT_6SB*UUML)!=G
MH%E[1R'^]]UO]DXS]E5^)_Q.^%?B7X0^*)M!\3Z<]C>)\T<@^:*X3/$D;]&4
M_F.A ((KZ'_9<_;@U+X:_9/#'C>2?5_"HQ%!?<O<Z>O0#UDC']W[RC[N0 M<
MF79U*G+ZMCM&M+O]?\_O[GT'&7AC0QU)YSPM:49+F=.+NFN]-_\ MO\ X#TB
M?HKXB\+Z7XLL3::K9QW</\)889#ZJPY!^E>#^-OV>-1TLR7/A^4ZG:]?LTA"
MSJ/;LWZ'V->^>'O$6F>+-&M=6T:_M]3TVZ3S(;JV<.CCV(_(CJ#P:T:[,YX:
MRS/X7Q,/>Z3CI+[^J\G='\\X'-\?D]1PINR3UC+:_73=/TLSX9GM[G2[PQS1
MRVEU$W*NI1T(]CR#7H'A7X\>)/#NR*ZE76;1>-ET?W@'M(.?^^LU]&>)/!NB
M^+H/+U73X;H@860C;(GT<<C\Z\=\6?LV2Q[Y_#U^)5Z_9;SAOH' P?Q ^M?C
M>(X-X@X=J/$Y-6<X_P!W27SB])?CZ'Z#1XARK-X*CF--1?GJOE+=?AZG<^%?
MCGX9\2;(Y[@Z1=GCRKS"H3[/]W\\'VKT&.1945T8.C#(93D$>M?$^O>%]6\,
MW'DZII\]D^< R+\K?[K=#^!JWX:\>:]X1D!TO4IH(\Y,#'?$?JAX_'K7=E_B
M1BL)/ZOG.'U6[2Y9+UB]+_./H<N+X/H5X^URZKH^CU7R:_X)]GT5X7X9_:61
MMD6O:85/0W-B<CZE&/\ (_A7JOASQYH'BQ1_9FIP7$A&?))V2C_@!P?TK];R
MSB7*<WLL+73D_LO27W/?Y7/@L;DV/R^[KTG;NM5]Z_4WZ***^G/%"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "O-_VBO@OIW[07P;\3>!M1*1?VE;'[+=
M.N?LUTIW0R^N%<+G'5=P[UZ116M*K.C4C5INTHNZ]4)JZLS^9;Q)X?U;P#XL
MU+1=3AETW6]'O)+6XCR5>&:)RK8([AEX(^M?O?\ L3?M$0_M*? 31?$,TJMX
MBL0--UJ/@$7<:KF3']V12L@_WB.QKX2_X*[?LW_\(WXPTWXO:-;$:?KA6PUE
M8UXBNT3$4IQVDC7:?]J(=WKQW_@FK^TE_P *(^/5MI&JW9A\)>+2FFWNYOW<
M-P6_T:<^F'8H3T"RL3T%?L>:4H<19/'%T5[\5>WG]J/^7>R."#]E4Y7L?N31
M117XN>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#L17T)7G.K?'SPAIH(BNY]1<?PVL!_FVT?D:XC6/VF[AMRZ5HL<7I)>2E_\
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MDO\ Y)?UH?:P(8 CD4M?)O@7XQ:YX)V6^_\ M+3%X^R7#'Y!_L-U7Z<CVKZ
M\%_%?0/&RI%;7/V6_8<V=R0KD_[/9OPY]A7[%D7&669XE34O9U7]F7_MKV?Y
M^1^>YIP[C<M;FUSP_F7ZKI^7F=E1117WA\N%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>88CU$8(P\@]U7YLE/VHTC2+'P_I=IIFF6D.GZ=9Q+!;VMM&(XX8U&%15'
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M$TGW;:><6\[?2*7:Y_*O>HYAA<1_#J)_@_N>I^2YEPCGV47>-P<XI=;<T?\
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MM*LH-.TRRA6WMK2UC$<4,:C"HJC@  =*NT45^1MMN[.\****0!1110 4444
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M26DW?:<JX]&4\$?6OJWX?_%CPA\5-/\ M?A7Q!9:S&%W/'#)B:,?[<38=/\
M@0%<_P"//@5H_BCS+K3=ND:DW):-?W,A_P!I>WU'Y&OS/-O#ZI1:QW#]5W6J
MC?7_ +=E_G]YXF&XEE3F\#GE'EEL[Q:_\"B]5_6AG>!/V@M.UCR[37T72[PX
M N5SY#GW[I^.1[UZY'(LT:NC*Z,,JRG((]0:^,/%?@G6/!=Y]GU6T:$,?W<R
M_-')[JW?Z=?45L^ _BQK7@618HI/MNFY^:RG8[1Z[#_"?T]0:63<?XK+ZOU'
M/X.ZTYK6DO\ %'KZK7R9EF/"M#%0^LY5):ZVO=/T?3YZ>A]<45RW@GXD:+X[
MMMUA/Y=VJYDLYL"5/P[CW'Z5U-?NV%Q=#'48U\--3@]FM3\OKT*N&J.E6BXR
M71A111768!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5^0G_  5*_8[D^'OBJ?XM^$[$_P#"+ZU./[9MX$^6
MPO7/^MP.D<I/7H)"1_&HK]>ZR_$_AG2O&GAW4=!URPAU/1]1@>VN[.X7<DL;
M##*?P[CD=17MY1FE3*<4J\-5LUW7^?8SJ04XV/P7_8M_:TU;]E+XFKJ)$U_X
M0U0K!K>EQGF2,$[9HP>/-CR2/4%E)&<C]XO!GC+1?B%X5TSQ)X<U&'5M$U*$
M7%K>6[921#_(@Y!!Y!!! ((K\,?VW?V,]9_95\=--:)/J7@#5)6.DZJPW&(\
MG[-.>@E49P>CJ-PY#*MW]BC]NGQ!^RKKATN_CGU[X>WTN^]TE7_>6SG@SVV3
M@/CJIPKXY(.&'Z3G644L]H1S'+W>=O\ P)=O*2_X#..G4=-\DC]VZ*XSX3_&
M'PA\</"%MXF\%ZW;ZWI4W#-$<20OCF.5#\T;C^ZP!Z'H0:[.OQZI3G2DX35F
MMTSOWV"BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3 YBKX2M&?HTW\UNOF?(8C XG!NV(IN/JOU+-%%%>H<04444 %%%% !1110
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M&>JQ C#R#W5><E/VBT71=/\ #>CV6E:590:=IEE"MO;6EK&(XH8U&%15'
MZ5]EGF>4<JI?V;ENDEHVOL__ &W=]/4YZ=-S?/,-%T6P\-Z/9:5I5G!IVFV4
M*V]M:6T82*&-0 J*HX   &!5VBBOR-MMW9WA1112 **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#T9ZT<0TO-)_DT5]9?5']/5U>6]A"9KF>.WB!P9)7"K^9KB/$GQ]^&7@_?\
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MX@U34)-]UJ5Y<O\ WIIW<_J:^JO@W>W.H?#719[N:2XG995,DK%F($KA>3[
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M:8%U#8WR]R\11OS4@?I7UN%\3,HK:5X3@_1-?@[_ ('@UN#,?3UI2C+YM/\
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M^2\^[Z>NV-.DY/GF0:1I%CX?TNTTS3+2'3].LXE@M[6VC$<<,:C"HJC@
M"KE%%?DS;;NSN"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"Z9!!& ,8P-JKV'Z51N?V:-?3/D:EILH_P"FC2(?_0365<?L]^+X?N0VD_\
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M<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!^*G[26I>*OV'/^"CEW\5KG
M03K>D:E?SZM8-<$K%>P7$+1SQ)*5.R2,R,O&=N$)!5@#Z?\ \$TOB_\  '5/
M@OI7PO\ B<WAVY\4P:]<7VFV7BK34FMRTH14:*65#$LA*XP2&.1C-?5P_:R^
M '[2GQ7N_@3K>D/KVL"YN[1K+Q#I"_9?M-MO$B*9#D2 (Y4@ _*<$'BOR6N/
MV:]!G_81M?C9!J5Q;>(X/$[Z-<V4LBF"Y@(&TQKC<)%)R><%0W'&: /V"_;]
M\2VGPH_8C^(PTV"#3K=]*71+6UM4$4:)<R);%$5<  )(W XP#7Y4?L6_MN>(
M?V4? _BBP\,?#M?%EQJ%ZE]J&I332B."!(PJ(5C0[<$R'<S8^;&.]?H;\ OC
M-X"M_P#@G;\,M?\ VA7T^[\/W"-II.O:6^I13M!/<):[HQ'(2WE6X(8KDE<Y
MR:^B?V;-7^$_BGX3VFH_!VSTJW\#74\ZQQZ9IYLXVD5RDA>)D5@Q*_QJ"5VG
MH10!Y-^Q7_P4&\*_M>->:(VE2>$_&UC ;F72);@3Q7$((4RP2[5+8)7<I4%=
MPQN&37YX_ML7"?$K_@J5:^']2/GZ8NNZ!H@C?YU$+K;&1<>A::0X]S47P3LK
M/P[_ ,%;$LO L4,6DP>,=2@AAL_]2EOLG$ZIMXV*OF  <  =J=^VA"GPW_X*
MF0:[J6+?3#X@T#6?.<[5\E5M?,;)[!HI!GV- 'V]_P %AO#MMJW[(AOY($:?
M2M=LYX9-HW)O#Q, ?0B3H/0>E6?^"0/B:XU[]CNULYY&D31M<OK"$,2=J'RY
M\#VW3M^=0?\ !877H-)_9!>RDE"3:IKUE;11\9<J))3^ $7\JE_X(_\ ANXT
M+]CVWO)D9$UC7;Z^A+#&Y!Y<&1[;H&_*@#[;HHHH *\P_P";FO\ N4/_ &]J
MUJGP#\(:QJEY?W-M>M<W4SSRE;^9069BQP V ,D\"N8\&^"=+\!_M#RV&D1S
M1VTGA8SL)IGE.XW:J>6).,*.* /;**** "BBB@ HHHH **** "BBB@ HHHH
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M/QA\#WQNM&^)7B:U=FW-&^HR30L?>)RR'\J_?SQS\'? GQ.CV^+?!VA^)#C
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M\L_1V_.WYFBQ$'N?KA17Q#\._P#@KE\%_%DD5OXAM]=\%W#<-+>V@N;8'V>
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MT^_L<=2O]F SQCXR\1_%3QA>:]XAU&[\0>(M4FW2W$Q+RRN>%50.@'"JJ@
M    "OTR_83_ ."9<>CC3OB#\8M.674/EN--\)W"Y6#NLMVO=^XAZ+_'DY5?
M7OV*O^"<WA_]G<6?BWQ@UOXF^(>T/&P7=::43V@!'SR>LI QT4#DM]H5GGO$
MZJ1>#RYV@M'):7\H]EY_=IN4Z/VIB* H  P!P *6BBOS0[ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[;;>JOJD.[\MV37XS7_B#5-4S]MU*\O,]?M$[O\ S-9]>U3XDQEOWD(_*_\
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M+=)(7#J?Q%?70J0J:PDGZ'YOB,%BL&^7$TI0?]Y-?F3T445H<04444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO^??P[_X R?_ !VC_AXU\5O^??P[_P" ,G_QVO6O^'8.E_\ 10+O_P %:_\
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M)/#FD^+-9N=4U'2[+[9<-OE:TMTM49NY\N(*H)[D#FOU*_X=R_"G_GX\1?\
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M8?(L+[.M&=W+V<8>[9IJZU=VT[;:'T111170?B(4444 %%%% !1110 4444
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M#<6Q)]"%23 ]\FOURHKZ"EQ1FU)6]K=>:3_2YDZ,'T/QO_X<V_&G_H9_ ?\
MX,+W_P"1*MZ?_P $:?BU)(1?^,/!=LF1AK>XNYCCOP;=/Y\^U?L+174^+\T_
MF7W"]A _,[P9_P $6=+A:*3Q9\3KR[4X\RVT73$@(]0)9'?/UV#Z5]1?"K_@
MGK\"OA+-!=6/@N'7=3BY%_XBD-\^1T/EO^Z4]\J@/Z5]'T5Y&)SW,L6K5:SM
MV6GY6+C2A'9#(XTAC2.-%CC0!551@ #H /2GT45X)J%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>
M8?\ -S7_ '*'_M[7I]>8?\W-?]RA_P"WM 'I]%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7F'_-S7_<H?^WM>GUYA_S<U_W*'_M[0!Z?1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5YA_P W-?\ <H?^WM>GUYA_S<U_W*'_ +>T >GT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>8?\W-?]RA_[>UZ?7F'_-S7_<H?^WM 'I]%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7F'_ #<U_P!RA_[>UZ?7F'_-S7_<H?\ M[0!Z?1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5YA_S<U_W*'_M[7I]>8?\W-?]RA_[>T >GT444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %>8?\ -S7_ '*'_M[7I]>8?\W-?]RA_P"WM 'I]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?,'QT_P""
MAGPI^!OC?PWX8N-:LM?O-0U-=/U1M,OHY!H:[U5IKD#. NYB5'S?(>* /I^B
ML'P3X\\-_$GP_!KOA37=.\1Z/,2J7VF7*3Q%AU7<I(##N#R.]6?$WBK1?!6B
MW&L>(=8L-!TBW ,U_J=TEM!%DX&Z1R%')QR: -6BO//A_P#M$?"_XJ:D=.\(
M?$#PYXBU(;O]!T_4XI+@A?O,(PVXJ,?> Q[UZ'0 4444 %>8?\W-?]RA_P"W
MM>GUYA_S<U_W*'_M[0!Z?1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKS#_ (7I_P!4^\=_^"7_ .SH_P"%Z?\ 5/O'?_@E_P#LZ /3Z*\P_P"%Z?\
M5/O'?_@E_P#LZ/\ A>G_ %3[QW_X)?\ [.@#T^BO,/\ A>G_ %3[QW_X)?\
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M$O\ ]G1_PO3_ *I]X[_\$O\ ]G0!Z?17F'_"]/\ JGWCO_P2_P#V='_"]/\
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MZ /3Z*\P_P"%Z?\ 5/O'?_@E_P#LZ/\ A>G_ %3[QW_X)?\ [.@#T^BO,/\
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M^J?>._\ P2__ &= 'I]%>8?\+T_ZI]X[_P#!+_\ 9T?\+T_ZI]X[_P#!+_\
M9T >GT5YA_PO3_JGWCO_ ,$O_P!G1_PO3_JGWCO_ ,$O_P!G0!Z?17F'_"]/
M^J?>._\ P2__ &='_"]/^J?>._\ P2__ &= 'I]%>8?\+T_ZI]X[_P#!+_\
M9T?\+T_ZI]X[_P#!+_\ 9T >GT5YA_PO3_JGWCO_ ,$O_P!G1_PO3_JGWCO_
M ,$O_P!G0!O?"/QE>^/O =CK>H100W4\DR,ELK*@"2L@P&)/11WKL:^?_A'\
M0KWP#X#L=$U#P%XTFNH))G9[;1V9"'E9Q@LP/1AVKL?^%Z?]4^\=_P#@E_\
MLZ /3Z*\P_X7I_U3[QW_ ."7_P"SH_X7I_U3[QW_ ."7_P"SH ]/HKS#_A>G
M_5/O'?\ X)?_ +.C_A>G_5/O'?\ X)?_ +.@#T^BO,/^%Z?]4^\=_P#@E_\
MLZ/^%Z?]4^\=_P#@E_\ LZ /3Z*\P_X7I_U3[QW_ ."7_P"SH_X7I_U3[QW_
M ."7_P"SH ]/HKS#_A>G_5/O'?\ X)?_ +.C_A>G_5/O'?\ X)?_ +.@#H?B
MSXNO/ ?P]U?7=/B@FN[-8S&ERK-&=TB(<@$'HQ[UU<+F2&-SU903CZ5X+\6?
MB->>//A[J^A:?X"\:0W=XL8C>YT=EC&V1'.2&)Z*>U=7#\<#'#&A^'WCK*J
M<:+[?[] 'J5%>8?\+T_ZI]X[_P#!+_\ 9T?\+T_ZI]X[_P#!+_\ 9T >GT5Y
MA_PO3_JGWCO_ ,$O_P!G1_PO3_JGWCO_ ,$O_P!G0!Z?17F'_"]/^J?>._\
MP2__ &='_"]/^J?>._\ P2__ &= 'I]%>8?\+T_ZI]X[_P#!+_\ 9T?\+T_Z
MI]X[_P#!+_\ 9T >GT5YA_PO3_JGWCO_ ,$O_P!G1_PO3_JGWCO_ ,$O_P!G
M0!Z?7'2^,KV/XNP>%A%!_9\FBMJ)DVMYOF";R\9SC;CVSGO6#_PO3_JGWCO_
M ,$O_P!G7'2_$*]D^+L'BD> O&G]GQZ*VG&/^QV\WS#-YF<;L;<>^<]J /H"
MBO,/^%Z?]4^\=_\ @E_^SH_X7I_U3[QW_P""7_[.@#T^BO,/^%Z?]4^\=_\
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M1_PO3_JGWCO_ ,$O_P!G0!Z?17F'_"]/^J?>._\ P2__ &='_"]/^J?>._\
MP2__ &= '0_%GQ=>> _A[J^NZ?%!-=V:QF-+E6:,[I$0Y (/1CWKJX7,D,;G
MJR@G'TKP7XL_$:\\>?#W5]"T_P !>-(;N\6,1O<Z.RQC;(CG)#$]%/:NKA^.
M!CAC0_#[QUE5 .-%]O\ ?H ]2HKS#_A>G_5/O'?_ ()?_LZ/^%Z?]4^\=_\
M@E_^SH ]/HKS#_A>G_5/O'?_ ()?_LZ/^%Z?]4^\=_\ @E_^SH ]/HKS#_A>
MG_5/O'?_ ()?_LZ/^%Z?]4^\=_\ @E_^SH ]/HKS#_A>G_5/O'?_ ()?_LZ/
M^%Z?]4^\=_\ @E_^SH ]/HKS#_A>G_5/O'?_ ()?_LZ/^%Z?]4^\=_\ @E_^
MSH ]/KCI?&5['\78/"PB@_L^316U$R;6\WS!-Y>,YQMQ[9SWK!_X7I_U3[QW
M_P""7_[.N.E^(5[)\78/%(\!>-/[/CT5M.,?]CMYOF&;S,XW8VX]\Y[4 ?0%
M%>8?\+T_ZI]X[_\ !+_]G1_PO3_JGWCO_P $O_V= 'I]%>8?\+T_ZI]X[_\
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MBO,/^%Z?]4^\=_\ @E_^SH_X7I_U3[QW_P""7_[.@#T^BO,/^%Z?]4^\=_\
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M,[/;:.S(0\K.,%F!Z,.U=C_PO3_JGWCO_P $O_V= 'I]%>8?\+T_ZI]X[_\
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M/)X'<@<U[W0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOV[M'_9B\$W>A>&M3M;SXIZ@@6RLHPDW]G*2";BX4Y"_+G8K#+$@X*@FG?\
M!,G]HKQS^TK\%_$GB+Q]J4.J:K9>()+"&6"TCMPL(MK>0+MC4 G=(W/7F@#Z
M_HKXP_X*$?M_2?LCQ:/X;\,Z3:ZQXXUBV:\0ZAO^S6-MN*+*ZJ09&9E<*H88
MV$D] ?E36OV\?VR?@?8Z1XS^(W@:W'@_4I46./4]&^RQG<,B/?&P>%V"L0)
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M-'DI)$VY3E N =PW#BOU(H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K\<_\ @MIXV_M3XT> O"J/O31]#DOF /W9+F<J1]=MLA^A%?L9
M7RO\<OVC/V9O#7QKT[P=\1M.T?4O'\-U9Q12:IX9-P;1Y2A@D%S)%L55$@;<
MKG;\W0@B@#XT\._\%9OB/\*=.\,V>M_!6WTSP/%;0VFGK(;JVGEMXD5!Y<[K
MY<A"CL@'TK]+O@_\>_"/QM^$=C\1_#UZP\/7$$DTWVH!9;1H\^;',H)VLF#G
MD@C!!(()\<_X*=P:'-^Q5X_.MK 3&+5[ RXWB[^TQB/R^^[!8''\);MFO@;]
MDWXB:E\+_P#@F?\ M$ZI)(T5E?7XTC3>2"US=016\VP^JQR(W']V@#VG_@D?
MI]U\3/BQ\=/C3J,9^T:Q?_989&&3NN)GNITSV Q;\>X]*]!^/'_!-W6/VG?V
MLM7\<^-?%YL_ANBVD=EH]G*\EW(J6\2RHNX;+=&D5B2NXGDX!.ZO0/\ @EE\
M.A\/_P!C7PI/)%Y-YXBGN=;N 1C/F2>7$?QABA/XU];T ?A]_P $\M&L_#G_
M  4H_LG3X?L^GV%WKMK;P[BVR-(IU1<DDG  &2<U^H/[=GP'NOVBOV:?$WA7
M3KZWT_58O+U.RFO)!' 9(&W[)'/"JR[UW'A203P#7YE_L&_\I0K_ /["?B'_
M - N*^S?^"P_C37_  I^RK:66C2S6UGKFO0:=J<T)()M_)FE\LD= SQ)GL0"
M#]Z@#Y!_9'_X*76W[)OP7O\ X:ZSX(;7]2TF\NGT^\TW48O(E=W)*2NH8%0^
M[$D98,I&!QD^I_\ !'SX*ZAK/C;QC\<-2O\ 35CO89]-MM-L+J-Y%DFF665Y
M8T),*CRP$5\$AB<8"D^J_P#!-G]F7X.>,_V/M"UC5?!?A_Q5K.NM>+J]YJEE
M%=3HZ7$D:Q*S M$%1(R I!R0_4@U\H_L WTOPQ_X*5:QX+\$WTUQX*N=2UO2
M9%$N])[&W6X>WD8]&(:*+#]?F./O&@#]JZ*** "H[BW2ZMY89!F.12C ''!&
M#4E<I\6M>U+PM\*_&>M:-'YNKZ;HM[>6494'=/' [QC!Z_,!0!^-7PM\>77_
M  2K_:R\6Z3X@L+7QKH]Y9-9^9I5_$;E;<RK)#*R@GRY,)AH9-I^8$'&TM?T
M;6[O_@IG^WIH/B"SM;'P?H6E+9O):W=_']K>SMI#*VQ>&EE<EQ\BD("NXX7)
MU/\ @DC\,_!?QO\ C'\0M<^(EC9^,/$%C:17MI;:ZJW8FDFE?[1=,DF1(ZMY
M8W,#@RYZX-8G_!3[P3X9_9N_:H\)ZS\+K>V\'ZJ^FP:S):Z0JPQ6UTEQ(J2I
M&O$>X1C*@!3M)Q\QR ?>'_!63XB_\(+^QWK=A%-Y5WXFO[71X\'YMI<SR8]B
MD#*?][WKM?V1?A/??#_]ACPAX7T\&SUV^\.27F[>8W2[O$><98<@JTP7/;:/
M2OD?_@IUJ=_\;/C-^SG\'BK6NH:L8;W4K:,\1/>31P*3Z>6(K@_0FOU%M+6&
MPM8;:WC6&WA18XXT& J@8 'L * /QP^-G_!-&/\ 9Z_9)^(OQ*\>^)#XH^(<
M0L3;+9/)]DLWEO[>.5R[X>=V61UW,% W$[2<,/HO_@B?_P FV^,O^QMF_P#2
M.UKV#_@J/_R8G\3?^X9_Z=+2O'_^")__ ";;XR_[&V;_ -([6@#SO_@L-\"]
M3LO%/A3XXZ9?:?\ 9].MX-*O+"]N4CD,D<[RPO$C,#-GS6#(F6 0-C&XCRG]
MKC_@IM:_M5? ^V^&^D^"&T#4=6NK5]1O=1U"(P0M'('"Q,0H +A<R.5"J&!'
M.0?\%+-:N/'W_!0+P[X-\87\MGX(L9-)LHMTNR*&UN&C:ZG'. Q+N"W7$2YX
M45]9_P#!1#]EGX-^$_V._$VJZ5X)T#PKJ?AV&V;2M0TRSCMI]YGCC\MW4!I=
MX=@=Y8DMN^\,T >W?L&_ RY_9[_9E\+>&;^_M=2U.X\S5+N>QF$UOYD[;PL;
MCAE5-@W#AB"1P17T'7P+_P $9_&6O>)/V:]=TS5)I+G2]#UZ2TTR20Y\N-H8
MY7A'^RK/N'_73\OOJ@ KXT_;J_8I\7?MA>.? MO9>+(/#/@O28)CJ8E:25WE
M9UVF*W&$9@H8;F9<9[]*^RZ* /P1^,'P;\._L_\ _!1#PMX#\*I<+HNDZYX=
M6-KN4RRR.ZVLDDCMZL[LV  !G    K]V_$]K=W_AO5K:P<QWTUI-';NK["LA
M0A3N[<D<]J_%[]L__E+!9?\ 8P>&O_15G7[:4 ?C=\7O^"9[? ;]E?XD?$WX
MB^)O^$I^($,-J]K%92R&VM9)+R!))'D?#SR%7898*HR3AC@CWS_@B7_R0+QU
M_P!C,?\ TE@KW7_@II_R8Y\3_P#KC8_^E]M7A7_!$O\ Y(%XZ_[&8_\ I+!0
M!Z[_ ,%3OB*?A_\ L:^*H(IO)O/$5Q;:) <]?,?S)1^,,4H_&LO]G_X#^(K/
M_@F=I/@;PQ<+I/B[Q%X<EO(;MYVMS'/>LTRL[H"R[4D53@9PN,&O%O\ @K=J
M$WQ,^*WP)^"VGR-]IUC4/M5Q&G)'GS):P/CVQ<\G_&OTLTW3[?2=/M;&TB6"
MTM8EAAB7HB* JJ/8 "@#\4_VN/\ @GKI7[)/[+-EXIU;7&\3>/M1\1VMG-=P
M!H[2V@:"Y=XXU)RY+(I,CX/R@!5YW?>O_!)__DR7PA_U^ZC_ .E<M<5_P6>_
MY-0T3_L;;/\ ]);NNU_X)/\ _)DOA#_K]U'_ -*Y: /DG_@I/\.M7_9W_:\\
M+?M$V#Z;JVGWFHZ?>G2[J[2.?[59I$A01D[VC9(4/F(#L8G./EW>?_ME?MUQ
M?MWZ7X(^&_A;PJGAA?[7CO)+W7M2@B4W!C>)$\UBJ1Q@2N2S-\QV\#',GQ@:
M#XZ?\%7E\,_$Z1Y/#47B.+1HK&XE*1?98TS!".?E69]I.""3,Q')KZ)_X*R?
ML[_"GP3^SGIWB?0?">A^$?$5GJUO96<FBV45G]JC=7WPNL:@. J[QD979P0"
M00#[>_9K^$W_  HOX#^"? AO5U&;1M.2&>ZC)*2S,3)*R9YV;W;;G^'%>EU\
ME?\ !+7QAKWC+]C;PI-KUQ->26-Q=:?9W$[%G>UBE*QC)ZA.8QZ! .U?6M !
M7@'CS]AGX2?$;XU6GQ5UK1[V?QC;WMI?_:%U"7R9)+8((@T))3:!$F5  .#G
MJ<^_U\F?M_\ [<%C^R7X(AT_1A;ZC\1=;B;^S;*4[DM(N5-W,O=01A5/WV![
M*U 'D?\ P6(^/OA;0O@LGPJ66'4/%^N75O>-;(P+6%M%)O\ .?\ NERH11W!
M<]N?1?\ @EOX#O/@_P#L8V&I>(@^GIK-U=>(RMP3^YM61%1R.P:.$2#'9P>]
M?)O["W[!NN_M,>)D^.?QNN;G4]$U"Y-_:V%^Q:?7) >)9L_=MP0 J_QA< !,
M;OO/]O[X@1_"G]CGXCWT#+;2W.F?V-:)'\I#73+;X3'3:DC-QT"4 ?)W_!(_
M3+CXF_%SXY_&K4HS]IU:^-K!(W)S<3O=3K[8VV_'O[5Z'\>O^";VL_M/?M8:
MOXX\:^+VLOAO&MI'8Z/9RO+>2*EO$LJ+N&RW1I0Y)7<3R=H)#5WG_!*WX;_\
M*]_8W\,7,D7E7GB2YN=<G&.N]_+B/XPPQ'\:^NZ /Q&_8#T&Q\*_\%.+K1=+
M@^RZ9INH:_9VL&XMY<4:7"(N6))PH R23Q7U7_P6MTG4[S]GOP;>VPD?2[/Q
M(OVM44D*SVTPC=O0#YER>[@=Z^9/V(_^4J^N?]AGQ)_*YK]6OVD-4^&%G\)]
M5L/C!>Z=9>"-6*Z?<?VG(4CDD;+HJE?F#@IO4KR"F1C&: /&?^"?7Q \%+^P
MCX1O)-3TVUT?0=/N(-<\]U$=I(LLC3><#TW!M_/4.#SFOS6_X)@^*X]'_;T\
M/PZ46M]*UM-4LO+R1^X^SRSQJ1_O0Q\>H%?2?@/_ ()2_!+XG:7%X\\*_&#6
M-3^&LTDLNU((T8QQ2,)%:=@NT+M89:/MNZ&O ?\ @F1X5M/%W[?UOJWART:'
MPYH:ZMJD$7S,(;5XY+>%26R>/M,8Y.>* /W)HHHH ***JZIJ5OH^EWE_=EEM
M;6%YYC'&TC!%4LV$4%F. > "3T - '\_?A/]HS6?#_[</B3XL^&O#)\;Z[<Z
MSJMSI.F8D<$S^;'&VR,%G"1R<*,'@<C%?<'P/_X*_7%]\2(/!_QF\#Q^"FN)
MUM6U*S,L8L968!?M,$WS(G(RX;*]=I'(^D/V9/CY^S;\7/B1KMI\(--T6W\4
MQ6/GW=]9^'ETV:YM_,"D;VC1W 8H2#TW+WZ?#7_!;BWT&/XK_#J6T%N/$<FC
MW']H>7CS3;B9?LY?'.-WV@ GT/I0!]@?\%6_B-_P@O[&_B"TAF$5UXEO;71H
M64\E6?SI /8QP2*?9JZK]COX4WW@#]A/PCX;T[-IKNH^'9;\2!S&ZW5XKSKE
MARK*947/;8/2OA_]N"ZU7XK6W['GP2GDD36]2T72[G5$!Y66Y2WME<CMM,=R
M>?4U^N5C90:;96]G:Q+!;6\:Q11(,!$4 *H]@ * /QX^+W_!,Y/@#^RE\2/B
M5\0?$G_"5?$&&&U>V2RDD^RVCR7D"2.TCX>=RKL,L% W'@G!'T)_P1/_ .3;
M?&7_ &-LW_I':U[5_P %-/\ DQSXG_\ 7&Q_]+[:O%?^")__ ";;XR_[&V;_
M -([6@#YB_;&NH/A_P#\%8-(\1^,&\GPVNM>']3%Q.N(ULXX[97?GJJ/%+G'
M7:U?7?\ P5\\2^%6_9'AM;R\LKC5M2U6SGT-5=7>0J2TDL>,Y00LX+#C]XHS
M\PSO?MW>$?V;?C/JFC^#?BAXUM?"?C^ QQZ5=VKG[;"L[@*CKM96B=@.'QCD
M@KDD_'?[6G_!.WX?_LA_L[^(/%FH^,-1\6>*+N>UTK0(;F);6"&5YA)*WEJS
M%V$"3XRVT9)VDX( /H;_ ((J>)KC4OV>O%^BS2&2+3/$;20!CG8DMO$2H'8;
MD9OJQK]#*_/W_@B[X/N=%_9M\1Z[<QM&FM^(93;9'#PPPQ1[P?3S/-7_ ( :
M_0*@ HHHH ^;?^"@WP!O?VBOV9];T#2[VVL=6TV>/6K-KZ98;=WA5]R22,0J
M QO)AF(4':20,D?GC^RK_P %0K?]F']GU?AK?>!VUS6-$ENQIE]9WT8MIC+,
M\N)B <A9)&^9"P9=N,=3]0_\%F_&6O\ AW]G/P[I>ESS6NDZWKJVVIR0L5\U
M$ADD2%B/X69=V._E"M/_ ()]_LM_!;QC^QSX6O\ 4?!7A_Q5?^(+>=]6U'4;
M..XN3-YSHT:R$%HO+"A0$*X*[OO$D@'E/_!&GX$WUG-XL^,=_J&GM%JULVCV
M5C8W,<LB S)+,\R(3Y)W1QA4;#8+' !4LO[:R#X_?\%+/@G\+8_]*T[0EM[J
M_@Z@;G:[N5QVS;P1<^]>-?\ !,G6+KP'^WQX@\'>$M1GO/!=X=5LY?WN^.>V
MMVD:VG;'!;*H P[2L!PQKVG]A]/^%\_\%(/CG\59#]KT[0S<6=C/UQOD^S6S
M9][:VEX]Z /J7]O;]F[QA^U-\+_#_@SPEKMMH"?VY'=ZI<7DTB1M:+!,I4H@
M/FG>\9"' R,DC&:_*'_@H+^RGX:_9(U_X?\ A?0;NZU6[O-%>[U/5+KY6NI_
M.9=RQ@D1H   HR<=2QYK]]J_';_@MQ_R6CX>?]B_)_Z4O0!^F4FGZCJ_[*C6
M&D%AJUUX+\BS,8RWG-8[8\#UW$5^:7_!%'Q-HFB_%KXAZ#J4T5IXAU+3+<V$
M4Y"/(L,CF>-<]6^>-MHYPA./E./U7^%<BP_"?PA(YVHFB6;,?0"!*_/?QQ^Q
MO^S-^V=\8]:OOA3\5%T;Q=(CZKJECH<7VNU<F4![A VT*Q=QG8^,L#M&<D ^
M;?\ @K_X@\/:M^UQ#_PC]Q;RZAI^@VMKJTMHX)6]66=MKD?\M%B:$'G( 4<8
MK]GOA7X@F\6_"_P?KEPVZXU/1[.]D8]VD@1R?S:OP?\ VZOV=/!W[-_Q6\-_
M#7P1>WOB'5XM,CGU6\N6#32W<\K^7$(U^5,1B,A0,GS 23FOWG^'/AMO!OP]
M\,>'W(+Z5I=K8,1TS%$J?^RT =%1110!^;'B+_@F!=^.OC!\4OBK\6O%#:MI
M,]_JNI:/X?L[B5Y&M_,E>U2>=L&-%3;^ZCZ# WK@BO'?^"(__):/B'_V+\?_
M *4I7ZT_$+_D0?$W_8,N?_135^2W_!$?_DM'Q#_[%^/_ -*4H ^]_P!O3]G?
MQE^T]\(M%\$^#M<M_#[R:]#=:I=74\D<36*V]PKHRQ@F7,CQ$1G@D DC&1^5
M'_!0;]D?PS^R&OPST#0[RZU?4]0L+JXU75KKY3=3+)&!LC!*QH 3A1D\\LW6
MOWIK\B_^"X/_ "/WPL_[!E[_ .C8Z /T_P#@C_R1?P#_ -B_I_\ Z31U^>7_
M  4 7_A?7_!0/X%?")3]JTW3_(N;Z'KM$TWFW((]?LUJA_&OT-^"/_)%_ /_
M &+^G_\ I-'7YY_L@J/C[_P5$^,GQ+;_ $C3?#*W5M8S]1NRMC 1Z!H(IS^/
MUH ^A/V^OV/_ !E^U_??#G1M#\4V_ACPOI;W\VMR7#R/YA?[,("ENN%E==DV
M-S*%R>><'\R/VO/@#X9_9I_:P\&>!_"GVJ33[:UTJ>:YO)=\US.\S;Y6Z $X
M'RJ   ..]?OI7XK?\%0O^4@'AS_KRTC_ -'O0!^G/[;VCZEKW[(_Q7L])5WO
M6T"X<)&I9G1%WR* .I**P_&OC/\ X(B^*]!7P=\1_#?VF"+Q.VH07YMV8"6:
MU\K8K*.K!'#YQ]WS%SC<,_I;KVLZ=X=T/4-5U>ZAL=*L;>2YN[JX8+'#"BEG
M=R>BA023Z"OS'7_@GK^SC^U9XZ\0ZQ\&/BG-I=O9RQR:GI&DVWVFVMC,'($)
M?845MK\ NJX(X&% !\I_MR?$+0]+_P""@WB+Q=X+N[>2+2]8TZZ-W8N/+-Y;
MQ0><RLO&1+&P8CJP8\YK]\Z_GS^/_P"S_P"%?"O[8FC_  :^';W.IP6]WINB
M7%Y._FRW-[*R&=VXVC:9=I  5?+P>02?Z#* "J>LZ3;:]H]]IEXKM9WL$EM,
ML<C1L4=2K ,I#*<$\@@CL:N44 >%_ ']C+X6?LO^(-;USP)IEUIMUJELEM<&
M[O7N%2)3NPI<DJ"0">>P]*_+']OCQQ9?MJ_MI>'O"OPQ1-:>WMX?#4&H0?-'
M=S":62656'6&/S&^;IB-V!VD&O6O^"A7[=7B#XM^-IO@)\&9)[NUN+H:5J>H
M:8VZ;5KACL-G 1TB#':S _.01G8#O^G_ -@3_@G[I?[*^CKXG\2FWUCXF7\&
MR:XC^:'3(V^]! >['^.3O]T87)8 D_X*B^.%^%_[$^N:5;W#K<:Y-9^'[>21
MLNREO,D!/<F&"0'ZUN?LC?LZZ)+^P3X.^'GB>REET[Q%HWV[5((IWMY9/M;F
MXVET(8$*Z(1GHN#GFOF__@K7?3_%+XR? CX*Z?,RW&K7WVFX13T^TSI;0/[;
M=MP<^A-?I7#%8>&=$CC4PZ?I>GVX4%V"1P0QKCDG@*JCJ>@% 'DWP2_9T^&7
M['OA7Q/)X61M!T2[D_M+4KK5+TR)"D:'DR/]U$7<>3QDG-?E.VK)^VQ_P5$T
M_7_ ]I,=!77+"^:["F-OL-@(1)<L>J[Q#\N<'+QCK71?M;?M8>./V]OB_:_!
M;X/Q3R>#9+PP1)"QC.L.AW-=3M_!;H%+JI[#>V6VJOZ'?L6_L6>&OV0_!#P6
M[QZSXSU.-3K&NE,;R.1#"#RL*GIW8_,W8* ?FM_P5+O)/'G[>=AX<N69K:UL
M]*TE%#8PLK>:V/3FX-??_P#P5+\-6FH?L-^-BMO&O]DRZ=<VJ*H"Q$7D,1VC
MMB.1QQZXK\__ /@J?I]QX!_;NLO$UPDGV6\L]+U:%@.JPGRF /KF _F*^]_^
M"IGC+3[/]ACQ6T5U'(FOS:;;6,J."LV;J*?Y?4&*%SQVYH \Y_X(K>(I]0_9
MQ\6:3,[.FG>)I&AW$G8DMM =H]!N5C]6-?H17Y^?\$6_"]QI7[-?B;6)XVC3
M5O$DOD;AP\<5O"FX>V\R+]5-?H'0 4444 ?+W_!3#QQ_P@_[%WQ"D239<ZI%
M!I,(SC=Y\Z)(/^_7FG\*_+O]C3]LCXB?LR_#/Q%8^!?AG'XKM9]2.H:IK5Q;
MW,T<,8BC1(SY6!'MP[;F8_ZSH,9/[%_M,?%GX6?"'X?PZC\74MI?"]Y>):1P
MWFD2:C#+<%6=5*+&X!VHY!; ^4\YJ;]FGQY\,OB5\)+#6/A-9:?I_@QIYX(K
M'3]/2QC@E5R)%:!5 0D_-TY#@]Z /'/V(O\ @H3X=_:Z:\T"[TD^%?'-C ;J
M33?/$L%U"&"F2!R 202NY&&1N&"PR1\Z?MR+_P +\_X*0_!#X4H?M6FZ,MO=
M7T'7&^1KFZ7'O;6\1_&O /V7K>RM_P#@K'Y7@<0_V%'XJUQ;7['@P"S$5V#L
M(X\O9G;VQMKZ _8E4?'S_@I3\;OBHW^E:;H7VBUL9^O+N+2V;/;-O;R\>] '
MVO\ M$_L@_#7]J1]'D\?:=?7L^D)+'92VFH2V_E"0H7^53M)/EKR03Q]*YC]
MJKXI>!?V1_V4[W2[H0K:C16\.Z!H;N#)>-]G\E(\=U5<%VZ >Y /??M*?M$>
M&OV8?A3J?C7Q(_FK#^YL=.C<++?W3 [(4SZX))P=JJS=J_);X1_"+XI?\%4_
MCAJ'C7QMJDNE^"--F$-S=P@B&TBSN6QLD.1OP02QSC=O?<2JL >K?\$9_ ^I
M^'=)^*WQ1N;>1-'AL5TVT9B0ES)'NGFP.^P"(9_Z:$#O7G?_  1SLSXI_:[\
M2:WJ/^E7EOX:O;T3R8+>?)=6R,W/<K))S[U^N_AWX3^'O WPK3P#X5L(=#T&
MWT^2PM8(1D1JRD%R3RS$L69CDL2222:_(+_@C]J1\%?MB:[X?U4&TO[WP_?:
M8MO)PWVF*X@E9,>H6"7CV- &Q_P6KT>#3_VAO!.KVX\F[N_#:I*T8VDF*YFV
MMD=\/C/HH]*_7/X8Z_+XK^&WA/6YVWS:EI-I>.P.<M)"CD_FU?D5_P %I-:A
MUG]H[P9H=G_I%[9>'8_,2+YF#RW,VU,#^+"J<>CBOUX^''A^3PC\//"^AR@"
M73-+M;)@O3,<*H<?]\T =%1110 5^4__  5P^">K>$?B=X4^/FE7FFS6EJ+2
MTNM-OKE(Y?M$$I>)HXV8&9&! 94RR[2Q&TDK^K%?BO\ \%!-2E^)O_!230_!
M7C:^EM/!-GJ&BZ5&&EV1PV5P+=[F4'.%):63+^B+G[HH /VP/^"DEK^UY\)=
M)^&VA>"F\/7NI:A;37MYJVI0^3$Z$[4C=@JJI9@3+(4"J#D8)(_2_P#8P^#8
M_9M_9?\ "OAK4M4M;ZXMK:74K^^MI1);!YF:9O+?H8U5@ PX;;N[U\]?\%*O
MV8O@]X1_9!US7-(\&:#X4UK0'LUTF[TFRBM9I&>XCC:%R@!E#(\C88DY!?L:
M\7_9E^.VN^%O^"3?Q;O=6O9I4TN[N_#>B2R.2\:745O&(TSSB-[J1AZ#(Z+0
M!U/_  2AL9OBQ\?/CO\ &R^1C)J%VUK:NXZ?:KA[B11Z;5B@'T;%?7FE_L+_
M  DT;X\+\7[32+Y?&GV^XU-YI=1EEA>XF#AG,;D@8WDJ!@*0,#@5YW_P2?\
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MV!6:+1?$ME?SE1D!&CGMP3Z#?<(/Q% &G_P2)T.#2_V-=,NHXE1]3UB_NIF
M'SL)!""?^ PJ.?2OA7]@>9?AW_P4WE\.Z<?(TV;4M>T8HORCR8X[B1%QZ;K>
M/CV%?<G_  2'\26NI_L;V=JMPA?1]8OK:X4L/W19A,,^@VR@\U\._P#!/FV_
MX6=_P4LN/%.FQF;3;>]UW768#<HAE2>)&)_WKF/GU(H _;RBBB@#R_\ :<\!
M^)OBA\!?&7A/P=?KI?B35K06MG>27+VZQ$R)N+2("RKLW9P"2"1@YK\F?VR/
M^"?NB?LA_LLZ)XAO=9D\2^/=3\46UE=7\8:*U@MVM+N1H8HR<MEXT)=N3M&
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M!K>N6_[;'_!3S3-5\#6DIT277+&4WB*49[*Q6+SKIC@%=R0DKG!^:->M=?\
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M_L@Z!XIG\)1/H6E7[+?:G=:G?&1(DA5L$R.?E1%9SR>,DDU^4WB/7(?VW/\
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M4 C'QZ_X* _ GX1)_I.GZ?Y-U?P]0%FF\VY&/7[/:H?QKQC_ ()XZA-\-/\
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MV2/%<W\:\A5N;@";<.Y6"U+?1O>OO;]F7_DVWX4?]BEI/_I'%7P3^S6H^/\
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M4?$MK<+X=\?2C3(H5F>%I[6*.:*61&4@KN:>1-RD',9] :^O?@#^R/\ "_\
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M9_\ V9?"OAJ?5+36;^<2:G=WFGS":U:2=MX$3CAD5=B[APQ4L.#7T#7YT?\
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M;8CRI8_LUSM3&UV8S#>,$^4.>*_5GX!^(-8\6_ OX=ZYXA).O:EX=T^\OV(
M+3R6T;R$@< EB3CMG% '>4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7QY^W9_P3UTK]KAK+Q'HVK0^&/'FGV_V9;N>(O;7T()*13;?F4J2
MV)%!(#$%6^7;]AT4 ?D@W_!+?]I7XER:1X=^)'Q>L;KP;I3J(%DUB]U,0J,C
M,$$B(N0I(&YEP,#H,5]!?M3?L%:_KW[+?@7X*?!D:99Z-I&I_P!H:A<:W=M%
M+<N(Y!O9EC;<SO,['@ ;5    'W;10!@^ ?"-I\/_ OAWPO8#%CHNG6^FP8&
M/W<,2QK^BBMZBB@#\_/V;_\ @G1XU^"_[7]S\7-4\2Z#?:++=ZG<"QM#/]I"
MW*RA!\T87(\P9Y['%?87QY^"'AK]HCX7ZQX&\4P-)IVH)F.XBQYMK,O,<\9/
M1U//H1D'()%>@T4 ?D?#_P $M_VE_A?/J^A?#;XOV%IX3U1RDWD:S?:89TP!
MNG@CC=02/E^5G.,CH<5]4_L(_P#!/+3/V29+WQ+KFJP>)O'E];_93<V\16VL
M(2V62#=\S%L+N<@'    W;OL>B@ HHHH *9-#'<0R12QK+%(I5XW *LI&""#
MU%/HH _+OXM?\$F_'/@_XH7'C3]GKQ[;^%$EEDFBL+F\N+"XT_?UA@N(5<O'
MR1A]N%P"6ZUJ? '_ ()3>*KCXLVWQ#^/_C6W\97MM/'>#3K>YFOFO94P5%U/
M.BDHNU1L4,& QN &#^F%% 'Q;)^R%XY\4?\ !1=/CAXBET@^!])M_*TFTCN7
M>ZW+:>2FY-@ _>R2R_>X.*^TJ** /&OVPO@EJO[1G[.?BWX>:)?V>F:GK'V3
MR;J_W^2GDWD,[;M@+<K$0,#J17#?\$__ -E7Q#^R/\*=>\+>(]7TS6;S4-:?
M4XYM+,GEJC00QA3O53NS$3TQ@BOIZB@#Y"_;L_X)]Z1^UU#8Z_I.J0^&?'NF
MP&VBOIHB]O>PY++#/M^9=K%MKJ"0&8%6XQ\E2?\ !+G]IOXA0:5X7\>?%W3K
MCP7IDB"&&;6K_4(X4 V[H+>2-5)5<@!BF!P"!7ZY44 >;_L]_ ?PU^S;\*])
M\"^%DD-C9[I)KN?'G7<[G,DTA  +$X'LJJHX KTBBB@ HHHH _/SX]_\$Z/&
MOQ8_;1M_C)IWB70;/0H]3TF^-A=&?[3MM$@5Q\L97)\EL<]QG%?H'110!Y!^
MUO\ !G5/VA/V>?%_P^T:^M--U/6H[=(;J^W>2GEW,4QW;03R(R.!U(KSK_@G
M[^R=XB_9%^&OB/PWXDUC2]9NM3U<ZA'+I9DV*GDQQ[3O53G*$\#N*^I** /C
M#7/V1/''C;_@HIIGQJUV726\!:%:I#IEJMR[799+5E3='LP,3RR2?>[+7V?1
M10!\W?M[?LQZ]^UC\%]/\&^'=5T[1[ZWUJ#4VN-4,GE%$AG0J-BL=V91VQP:
MW_V+O@+J_P"S3^S[H?@'7=0L=4U*PN+J5[G3]_DL)9WD4#>JG@, >*]RHH ^
M&/VYO^":=O\ M+>*%\>^!]:M/"OCPQI'=K>HXM-0* +'([Q@O%(J@+N"MD*H
MP,9KY_B_X)8_M"_&#7M)B^,7Q>M[_P /Z:QC1WU:\U6YCCXSY"3(J*6P!N+
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MD_9'\0?LG?#7Q-9>+Y=.G\3:WJHN))-,F:6,6T<2K$I9E4E@S3'I_$*^MZ*
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M /;NOOCG>>)-!N?#UQKVM:LNG0&?[6([U+I8U.8PFY3<+GYL<'&:]:_X*'?
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MBQXM\;:AX\\)FXUS4IKT)(UT3'&S'RX^(>B)M4>RBOUAHH _&O\ X<E_%/\
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M\9:U\6K;Q]^T)XWM?&,MO-'=-IT%U/?R7SI@HES/.BXC& "BA@1QD"OTWHH
M^+/$7[(/CCQQ_P %$])^-&N2:0? &@V\<6FVJW+-=EH[5@FZ/9M&+B5W^]T
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MF?C#\9OBWXM\;ZAX]\*M<:YJ4UXJS/=%HHF8^5%Q#T2,(@]E%?J_10!^-?\
MPY+^*?\ T/7@_P#[ZNO_ (S7TIXJ_P""?_Q-U/\ 8=\%_ ?2_&&@65WIVK3W
M^L7C/.+>[B,\TT42XC+$!I48Y ^:,=:_0"B@#\:_^')?Q3_Z'KP?_P!]77_Q
MFO7_ -DC_@EC\0/V>_VAO"'Q!UGQ;X;U+3-%DN'FM;$W'G/YEM+"-NZ,#@R
M\GH#7Z:T4 %%%% !1110!^9GQ\_X)/\ BBW^*US\0/@%XTM?!]W/<27BZ;<W
M,]D]C*P);[+<0JQ"L2V$(4*#C<1P*OP=_P""4/C7Q7\4+?QQ^T/XYA\6M%*L
MTFFV]Y/>S7VPC9'/<3*NV/C[B@Y7@%>WZ>T4 ?%GBK]D#QQX^_X*(:#\9-:D
MTC_A7GAVVBATZU6Y8W9,5L_EYCV;5 N97?[W11W-?07[3GP[\3_%SX#^,/!?
M@_5;/1=<UVT%BE]?%Q%'"[J)P=BL?FB\Q.!U:O4:* /QK_X<E_%/_H>O!_\
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M]*\7>']+\/:;IL=C96&H-/YB-N9Y7(2(C+,P'4\(OTKYL_X<E_%/_H>O!_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXM_MP_%?_A!OAY_:UIX7OKEK72/#&DN8IK]!D^;=,I&XE5+E6;RXP/\ 9+D
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MOF[E 8[550< DT ?LE:^,M OM1;3[;7--N+]<9M8KN-I1GI\H.:V*_&74O\
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M.C_A]G_U1G_RZ?\ [CKR_P#X<V_&G_H9_ ?_ (,+W_Y$H_X<V_&G_H9_ ?\
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MW%G_ -BS9?\ HVXH _5SQ]\9M,_9]_9=;Q_JT?VBVT;0K:2.U#[3<3-&B0Q
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M$-C;WD]U':6]PJM&UT?))R,@$/@@X[$9%3V=];ZA")K6>*YA)P)(7#J<>XH
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M=Y_P]&_ZIG_Y7_\ [FH_X>C?]4S_ /*__P#<U<'_ ,.T?B=_T'?"7_@9=?\
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M/"$"V"00?/YNH7&UYMH'4X\F/'7=&WK63\.I/VZ/A+X.T_PIX1\.^.M#\/V
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M@ZK>^,/!6AZ25A>:X\06*)IUQ;@ DS-,FT';U_>;EXY!% &#^QW^TO\ !?\
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M"R7QQ_X0OX'Z-\.["XV:EXON_-NU5N18VY5V![C=*8<>H1QZUI?\$;OAG?\
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M?6/[97[>Q_9#\=>#]-NO >I>(_#VJV[SW^K0LT$<)W[42"1D,<L@"R,T992
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M7/'VC_MD^(K?X8W'V3QOJ_B'4]'T^X& T37,TL3.K'A"%=OG_AZCD U]8_\
M!$'0=0D\??$[6EC<:7#IEK9O)CY3,\K.H'J0L;_3(]:\2_90C6;_ (*@:4KC
M<!XNU9OQ"W1'ZB@#4_;0_P""=WBS]F'P'9?$N_\ B$/&]Q=:A'!J4K6LD%Q!
M<2!F602M*YE&Y,;CM;)7CTWOV>O OQW_ ."E/A6+PMX@^)=QH_P^\&01VDM[
M<1-<->3LS,GFQAT-Q(J<;G8!55?XF8G[:_X*\_\ )FVH_P#8:L/_ $-JX?\
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MXP7/Q[_X)K>+?'M]:)8W^L?#[67NH8@0@F2TN(I"@/(4O&S <X!')ZU\0?\
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MY9KT[XB^"D\>^&9=,,WV:4.LT,I&0KC(&1Z$$C\:\2/[-7B;M?Z3C_KM+_\
M&Z_*.*\3Q51Q<8Y-']UR[I1D[ZWOS)VZ6/NLBHY'4P\GF,O?OU;6GE:QN_\
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MGQBMO@'\"O&?CNX*>9I.GN]I')TENGQ';H?9I70'V)-?EO\ \$2_^2^^.O\
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MF*YS_@B3XCN;SX+_ ! T.1RUKI^NQW4*G^$S0*K 'T_<@X]SZUX3_P %#O\
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M3)!/S@?=$9Q]!0![7X=_X)1_&OX-^#[?XC>$/B):Z?\ $O3(/MJ:#ID4BMP
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MV'_"A/':Y&X>)LD=_P#CUA_PH _1:BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$7X$_ 6S\!_$:73;F\T>[F739],NFG4V;D2!&+(I#+(TH';;M Z5\X_MC?\
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MX];Q3\!/%2_98Y3/96LVHO8:II[$'Y8KA<*X'0,61L$ YP6/ZVT4 ?CKH/\
MP2\_:+^/7C6WU+XT^,C8V<&(Y+[5-7;5[[RLY*0*&95')^\Z@$YP:_3_ ,._
MLZ^!?"_P)'PAL]('_"$MILFF2VLC9DF20'S)'< ?O&9F<N,88Y&,#'I=% 'Y
M':C_ ,$R?VA/V<_B)=>(/@+XYAN;6172*5;T6-YY.X,(9XW'E2CA><X)7.U>
M*6;_ ()R_M._M.>,-,O_ (Z>.[>RTVS5E$D]XM[/"C,-ZP00@1*6VKD[EZ+G
M.,5^N%% 'DOC#X'VMC^ROXE^$O@B"*R@D\)WOA_2H[J4[5>2UDBC,CX)Y9@6
M;!/).*^5_P#@F]^PO\1_V4?B)XLUOQK/H<MGJFE+90#2[QYG\P3*_P P:-<#
M />OT"HH ^'/^"E7[#/B3]JN#PMXB\$75BGB70XYK2:QU"4Q)=V[LK+LDP0K
M(P;@\$.>1C!YG_@GC^S'^T/\&_'5\WQ8U.6;P'#X?ET>QT&\UXW\4+-+"R&*
M ,\:*$21>HX;&"*_0FB@#\G?BY_P2G^*'PO^*4OC7]GKQ1%;VRS/<65F]^UC
MJ&GELYA27&R2/!(RS*<':P;ECCZ3_P $S_VC/VB/B!I^K?'?QE]FTVVVQRW%
MSJ@U"\$.[+16Z)F.//)R2 "<[6.17Z]44 87@;P5H_PW\&Z+X6\/VBV.BZ/:
M1V5I;J<[(T4*,GN3C))Y)))Y-;M%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?.?[?'P!\3?M*?L]W?@KPE)81ZQ+J-K=*VI3-%%LC8
MEOF56.>?2OHRB@#Y7_X)S_LT^+OV5_@CK?A/QG)ILNJ7GB&?5(VTNX::/R7M
MK:(9+(IW;H7XQTQS4_[?W['B?M;_  JM[326M+/QQHLWVC1[V[)2-E8@302,
M 2$=0&X!PT:=LU]0T4 ?GM_P3A_81^)/[*?Q2\3>(?&D^ARV&HZ,;"$:7>/,
M_F>?&_(:-<#"'G/I7F?QW_X)K_&K]HK]J+6/'7B2_P##MMX6U36(E9(]1E>X
MM]+1EC553R@/,$*@X! +D\\YK]5:* *]A8V^EV-M96D*6UI;1K###&,+&B@!
M5 [   5Y9^U;\#HOVC/@#XO\"9ACO]0M?,TZ><D)%>1D20,2 2%WJ%8@$[6;
M@]*];HH _/3_ ()T_L8?&C]DGXE:]<>)[CP]<>#]=L!#=PZ=J$DDJ7$3;H)
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MT_2O!_D:/::E#:&QF>54YMGMU4(#&@3)4)@,@VG)(^WZ:L:JS%5"ECEB!U.
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M;P1I_@F728KC1[VXN+G^U;EX5*NB*NTJC9.5/I7V510!\G_"WX-Z_P#L_?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*** "BBB@ HKY!_X*6?M,^-_V7OA3X7U_P #3V5OJ&H:T+&=KZU$ZF+R)7P
M3P<H.:[/]@7XX>*/VAOV;])\:>,);6;7+F]NX)'M(!#'MCE*KA1["@#Z+HHK
MX&_X*<?MD?$?]E?7/ %KX#N=.MXM9MKR6[^W62W!+1M$$VY/'#M0!]\T5^*E
MI_P4C_:\U#2;35+70!<Z9=@M;WL/A21X9@#@E' PWX&N@^%__!9/XG>$O%$=
MA\3_  IIFMZ4DGEW8L;9[#48.>2 S%&*C^ JN<#YAUH _8NBN:^&_P 1= ^+
M7@71?%_A>_34M!U>W%Q:W"\$@Y!5A_"RL"K*>0RD'I72T %%%% !1110 451
MURYFL]%U"XMQFXBMY)(QC.6"DCCOS7YW_L%_MA?'_P"-WQX7PW\2-)^Q^&SI
M=Q<^9_83V?[Y"FP>81[GCO0!^CU%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%> ?MG?M=:)^R#\,HM?O+/^V=?U*9
MK71]($GE_:) ,N[M@E8T!!8@$Y95XW9'YHZ?^WE^VK\;9+C6/ .F:FVE1LP=
M/"O@]+VUC(&=GF2PS-G .!OR?>@#]K:*_'_X/_\ !73XH_#OQX/#WQN\.Q7]
M@MPL%_(M@VG:GIV3\S&+ 5]H.?+**3C[PK]<]%UJQ\1Z/8:MIEU'?:;?V\=U
M:W4+;DFB=0R.I[@J01]: +M%?"/_  4<_P""@VK?LN:AI?@?P/8VL_C+4K'[
M?/J-_'YD-A;L[I&43(#RLT;GYOE4*"0V[CYFUK]K3]NCX*^%]+^)/C?3DN?!
M%\\,J+J6DV(@V/RBR"V"SPAL@ R%3G'<\@'[#T5Y'^RO^T-IG[4'P6T7QYIU
MFVFRW)>WOM/=M_V6ZC.)$#8&Y>C*<#*L,@'('F?_  4=_:(\8?LS? ?3?%?@
MF:S@U>?7[?3W:]MA.GDO!<.PVD]<QKS]: /JBBOQ-T'_ (*9?M9^*-)FU71=
M)AU?2X9?(EO;#PN\\*284[&=05#893@G/S#UJ?2?^"NW[0/@7Q'%%XOT'1-0
MA4J\VFW^ER6,YC.?NLK J3V)5AQTH _:NBO,_P!G/X]^'_VE?A+HWCSPXLD%
MK?!H[BRF8&6SN$.)(7QU(/(/&Y65L#->F4 %%>(?MH_'2_\ V<OV</%?CK1U
MM9-;LA;PV$5ZA>)YI9XX_F4$$@*S-C(^[7Y7_P##Y+X]_P#/GX/_ /!7+_\
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M[17PH^,T/@72O VK:=XIU[39IYKS5].7>D,#*H6#SL8?<P+;02%V]MU2:O\
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M5_+2&,YCC78%Y<$LV0H&W+>A_P#!;S_DEGPT_P"PS<?^B!7JG_!(C0=*TO\
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M^- $<'_!1S]J7]FOQMIMA\:O#?\ :5C< 2/9ZOI,>GSSP[AN>WF@54+#..C
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ME?6NA_X*?_%.Z_:2_:J\*_#SPA,NK6>F06NGZ<L+92XO;[RY"P/NKVZ>Q0T
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MG=17FO3W$NIZI);G,2W,NT%$..0B)&N>Y4GC.!X3_P %GO\ DU#1/^QML_\
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MX?\ V)_@7HOPY3PA;?#;P[=Z1):^1)=7-C'->3@C_6M<D>87SR'# @XVX
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MYX#-H^)8H&93BSML\@8K]SZ* /(OVOH9+C]E7XO111M+*_A34U5$!+,3;28
M ZFOSI_X(HZ-J&E_%'XD->6-S:*VC6X5IX60$^>>!D5^N=% 'X%^,-(\=_\
M!/?]M >,=4\--JL&GZO=W>FW%XK"UU6UG6124FVD"3RY3G )1QR#CGUW]J_]
MIKXM?MX?!>_E\+?"F^\.?#+PS)%JVJ:A).;A[N7/EHJ.40,%\TL40,< ,2
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MBWX4>+)9[NUDE:18[6[BD:"3]Z@/E,?)&4=<, I4C#5]4?\ !:[2[S5/A?\
M#9;.TGNV76;@LL$;.0/(')P*]Q_X);V<]C^Q'X$@NH)+>99M2W1S(589O[@\
M@^U 'YDVOAWXO?\ !4;]HVWUV[TAK+2/W5K<ZA;1,FGZ/IZ.255W)WR?-(0N
M2S.QX"@[?W2\+^&['P;X9TC0-+C,.F:59PV-K&S;BL42!$!/?"J*T884MXDB
MB18XD4*J(,!0.  .PI] !7X=?'#0=3E_X*L+=)IUV]K_ ,)]H[^<L#%-HEML
MG=C&*_<6B@#\N/\ @M?\)KK5(OAMXZTVQFNI8VN=$O&@B+G!Q- .!T&+C\ZV
M?^"*?PGN- \%_$3QQJ-C+:W.HWT&D6WVB,HXCA3S9" 1G:S3Q_C'[5^EU% '
MX=?L,:#J=K_P4TT6YGTZ[AMAK.ODS20,J8-G>X.2,<Y'YU](_P#!6K]C7Q)\
M1]0TKXL^!=(N-<O+.S^P:[IUDIDN#$A+0W$<8&7VAG5P.0 AQ@,1^FE% 'XR
MZ'_P6"^)OASX41>";KP9:7?CFUMAIL?B2XN)%DW!=BR26NSYIAP2=X!8?=YQ
M7U!_P3(T']HS5K?4?%OQ?\4>)#X4>V^SZ3HGB,EKJYD)4FY8RKYJH%!"Y8;R
MQ/0#/WH;.!KH71@C-R$\L3;!O"YSMSUQGM4U 'Y._P#!6+]C;Q5??$+_ (75
MX(TJ[UBSN[:)->AL 9)[2:%5CCN @^8H8UC4E0=IC). W',^#O\ @J%^T#\7
M?"$7PT\)^!;;6/B)>0?8!K^GQR&=<C8T[0CY(Y ,DR%@BGDJ ,5^Q%1QV\4+
MR/'$D;R-N=E4 N<8R?4X _*@#\'/V(?ACXB^&_\ P4*\(:!K-E,UUH>NZAIU
MW=11NT#210W$;,KD#*EE.#W!%?1/_!;?1[_5/%'PF-G97%V$L]1#&")GVY>W
MQG XK]7J* /G7]D_P;9^,OV%? ?A37;>7^S]6\)#3+ZW.4<Q2Q-'(O/0[6-?
ME4WA/XV?\$NOC[<^(;/1'U'16$UI%J4L#R:=J]B7!P[(?W<GRHVTD,C =5^]
M^[]% 'X0?'3]I#XR?\%*O$'AOPGH'@8BRTV5IHM+T1))D\YP%,]Q,WRHJJ<
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MN0/LL_/ Z5Z1_P $GK*XT_\ 8TT"&Z@EMIAJ=^3',A1AF<]C7V)10 5^4/\
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MOVDO"NC^,/!$'V[QIX<B>W;2PRJ=0LV;<51F('F1MN95S\P=QR=H/P;\%_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8^NP?:K[6;U5DBTFW(=@=K J&"(TA+*V%V@*S.,>7_%&\_:X_8HTB#XD:O\
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MVNO''[4W[1'Q7O/$%S-8^&X[""XTKP[N!BT]#)M7!P"SE0"S'J22 !@#]"*
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MUA2!);K&UN@1#@["[W*9<#("G')R/5_V4?@/\3_@NOB%OB1\7M0^*+:@MO\
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ME<3SR?>DD>!&9C[DDG\: .KHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXZ>--=U+P_&VIZGH7B"Z:XM[^)%)F<1Y*.0NYMCJQ(SA@P&8_P!CN\A\$?\
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M -H_QAH+BX\,I!/9FXMSF&25KN(1O[[OLT[ ],$^M #M9\<?%3]O[]IOQQX
M\$>.]0^&WPC\"SFTU#5-#=DNK^8.T?\ K$8%O,>*4H-P0(F2"QP9/B%^S_\
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M+X5_'#Q=XJU_187U#4?#OB6=[BRU>)%)E CW\/L!VYRW&%=20:Q]0GC^&_\
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MRS\>OV"? FI^/OAA\<KK6/!^@A)[GP_JRLB+"9%7"P.TD+GYADCRVQG;S@$
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MJ& ! %?3O_!(557]C?3R% +:U?DX'4[E&?R K@/&2@_\%I/ 9(SCPS(1_P"
M-[0!PG[57[+?Q3_9#^'<_P :?"/Q_P#&.OZSH]W;/JR:O<N5N!+*L2N%+LK@
M/(@,4@8%6//&#]B^-/VN+7P'^Q7IWQQU"RB>]O\ P_97T&FQ[O+>^N8TV0YZ
M[!(_)Z[5)ZU@?\%1_P#DQ/XF_P#<,_\ 3I:5\T_M1:'?:Q_P2!^&%Q9^88M-
ML]#N[I8USF+RS%\WH \J'/L* .D^#_[)_P 7_P!K/P+8?$_XK_'+QAX<NO$4
M*ZEI'A_PS<FVMK&!QN@D*!M@W+M8*JAL8W.6)QT?[/\ \6_B9^S;^U9!^SK\
M6O%DWQ TC7K)K_PKXJO0S7C??(CF=B6(;R9E(9F*LJX;:PQB_ /]A/2OBO\
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MZ!?WRVUM#J^H-?1R7 5F!$0A?&%#?.1@9Y(R,@'2_P#!4[XZ>+_A*GP,\1>
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M9C[510!\&-_P3K^(7P?\4:[>_L^_&V\^'GA_6)C<2^&[^S^U6\+D_P #$D'
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M,$5]_44 >6?LX_LW^#OV7_AW%X1\'6TH@,AN+R_NV#W-[.0 9)&  S@
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ME?V;Y'V+=,9<>;YK>9UQ]Q?7VKZ*HH ^=?V-_P!D/_ADG2_&5G_PEG_"5?\
M"1:F-1W_ -F_8_L^%(V8\V3=UZ\?2C]LC]D/_AK;2_!MG_PEG_"*_P#".ZF=
M1W_V;]L^T94#9CS8]O3KS]*^BJ* "HKFVBO+>6WN(DF@E0QR1R*&5U(P00>H
M(J6B@#X,;_@G7\0O@_XHUV]_9]^-MY\//#^L3&XE\-W]G]JMX7)_@8D@X&%!
M*;]H +-7;? /]@N[\'_%R+XN?%OX@WWQ6^(]O&4L9KB+RK/3\AAF-"3D@,VW
M 15+L0F[##Z]HH ^2?VO/V%+S]H;XE>%OB1X0\?W?PZ\<Z%;"R34+>!I0\(=
MW0J4D1D=3+(,Y.Y6P0,5UWC/]CW3?C5^S?H7PS^+&OW7B_6],C#KXLA4PW8N
MAN"SKN9\G:VU@Q(;&2 <8^B** /@,?L'_M%IH*>"Q^U1J+>!O)^S-_Q+&%[Y
M.-IC#>:7V[>,>;C'&,5]0_LS_LR>#?V5_AZGA;PC!*YF<7&H:G=D-<WT^ -[
MD   #A5'"CW))];HH ^2_P!H3]@I/B1\5(_BO\-O'>H_"CXF;0EUJ=A%YT%Z
MH0)^\C#J0Q4*"<E6"\H3S7'^&?\ @GEXN^('Q"T+Q3^T/\6[KXJ6^@N)=/\
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M &<?@NOP ^!_A?X=MJP\0KHL$D!U!K7[.)P\KR9\K>^W[^,;CT_"OF;X&_\
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MS^S?M?VO<T1V9\V/9_JNOS?>Z<<_15% %#7M#LO$VAZCH^I6ZW6G:A;26ES
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*)<JJMYB \A'5@P!SC++D[<D ^@:*K:AJ=GI%H]U?W<%E;1C+S7$BQHOU8G
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M0D("6D]W&DK$] $)R>H[4 :]%%5M0U*TTFREO+ZZALK2$;I+BXD$<:#U+$X
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M 45G6/B/2=3OI[*SU2SN[RWYFMX+A'DC_P!Y0<C\:T: "BF331V\+RRNL42
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S
MW_X+5:Y=V/[.'A/38&D2WO\ Q-&;@J<*RQVTY5&]1N(;ZI[5]N?"30K/PO\
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M(8HBQJ2.,J<<8KT#]IKQ)>>#_P!G+XH:WISR1ZAI_AC4KBVDC^]'*MM(4?\
MX"<'\*]+K$\<>$[+Q]X+\0>&-2W?V=K6GW&FW.WKY4T;1OCWVL: /C3_ ((Z
M^&['2/V2I-2MT3[9JVO7<US(/O901Q(I/H%3('^T3W->]_M(?M>?#S]E3_A'
M?^$]N=0M_P"WOM'V+[#9FXSY'E>9NP>/]<F/7GTKXF_X)T_'"U_9/\9>-?V<
MOB]>0^%=3M=7:ZTF_OW\NUFD=45HQ(<!5D58Y8V. V]AD$J#^C_BKP/X/\?6
MUI<>)/#^B>([>U1I+:;5;*&Z2)7"EF0NI"A@JDD==H]* /E+P_\ \%,OV;_'
MWC[P_;6T>H77B6\N8M-T^\N="_>QM+(%51*>44LPS@X[UYY_P5<_Y*G^R[_V
M,T__ */L*\?_ &W-;^%&J?M@?L_Z)\+$\-O=Z9KMNNKQ^%K6)8UD>]MO+5WA
M4*[@(_ )*]\9KV#_ (*N?\E3_9=_[&:?_P!'V% %K]M?QUXS_:"_:D\(_LN>
M#M=NO"FBW=M_:'B?5+*4K++ 8VD:(X()01+]S.':5=PPM:_CG_@D/\+8?!+'
MX>:AKWA?QYI\?GZ9KK:D\A>Y3YD,HX"@D#YH]A7J,XP>+^(6JVWP'_X*]Z1X
MJ\3L=.\.^-M'CL[;4[D@0+*;9;<#<3A?WD$:GICS03PV3^AWC/QAH_P^\)ZM
MXDU^^BTW1=+MGNKNZF8!8XU&3]3V ZDD <F@#Y;_ .":/[2?B+X_?!G4],\:
M2277C/P??_V7?WLQ4O=(03%(^/XQAT8]_+#9)8U\*?\ !.S]E6;]J:'QI8>+
MO$&J6OPJT?55N)M TZ?R1J>HNA"M(PYVQHJGGNXVXRU?2?\ P1VT>_U72?C/
M\0YK5[73?%/B");0,NT,8O/D?:.F!]J5<CC*D=JP?^"+_P 2-%71_B9X$EO(
M8-?_ +7&KP6LC!9+B!D$3L@SE@AC7=CIYB^M &'^TU\"&_X)I^)?"/QG^#&J
MZI9>%Y]4BTSQ!X7NKLS17,;!I N6Y9&6.1?FRR-M93Z?9?[6G_"U?B1^SND'
MP(=(]?\ $ @?^T&O4M)H+%XR[-#(2-LK?(H(/ 9B"" :\$_X+#>.+.;X->%/
MAGIY&H^,O%&O6[V>E0 /.T2!UW!>H+2O&B_WB6 Z&F_\% ?C!XU_9=_9G^$_
M@'P;J<GA[6-7AM]#N->C<J]I%;6\2.$E'W&8LOSCD*KXYY !IZ;_ ,$H?@1H
M/@&%O'U_JFH^(Y(0VH^)[K6FM]UP5S(R!CL"Y#$!PQQU)ZUP7_!+OQ)=^!OC
M[\9/@MIGBW_A,? .A[KW1;P7"SQ*J3B/=$R,4&]95W!>-R9&.<^B>&?^"37P
MBM[6'6/B)XE\3_$/5EA$M]J&J:L8;=R%R[#9AU3J?FE8CUKQ7_@FG-X-_P"&
M\/CA#X BAM_!L>F7$6D1V[LT;6T=Y BNA8EBK8# DY.X9H [W]@+_D^[]K3_
M +#,W_I?<5^BM?G5^P%_R?=^UI_V&9O_ $ON*_0&P\5:+JFJ7.F66KV%YJ5K
MN\^SM[E'FBVG:V] <K@D Y'4T :E%%?/O[>7QP_X4%^R[XR\0V]Q]GUJ\@_L
MC2B#AOM5QE R^Z)YDO\ VS- 'R[^R_)_PUE_P4:^)7Q@ES=^%? </]C:"YYC
MWD/!&Z9ZAE%U+[&93QQ5/X[S_P##'/\ P4R\'?$E/]"\%?$N#^S]7<?+&LI,
M<,Y/LKBTN">^6K,_95_X)2^$?'/P%\(>*_%_BOQOH?B'7K-=2FLM"U"WM[>.
M*0EH/E>W=MQB,9.6ZDC Q5;]K;_@E7X3^'WP#\5>,/!OBGQKKVO^'[;^T%LM
M>OX+F!X$(-QA4MT8,(M[ @_P8QSP ?H#^TU_R;;\5_\ L4M6_P#2.6OS@\#_
M /*$OQ?_ -?K?^G:"OICX0?';_AH+_@F=XKUVZN!<:[I_@[5M'U8YRWVF"RD
M7>WO)&8Y3_UTKYG\#_\ *$OQ?_U^M_Z=H* /O7]A7_DS_P"$G_8OV_\ *O=:
M\*_85_Y,_P#A)_V+]O\ RKW6@#\8O /P%U+]J+]N;]H3X:S^([[P[X&G\1WV
MM>(/[.VB:[^S7LL=O"I8$??N6;# K\F<$JM>E?MU?LI^%?V2?V%KSPWX4O\
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M_P""CWA74OB-X>\/ZGX8U6>_FM[^ZT^6.ROEN!@EYH%:6'+A@^XKN;=DG.:
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M G6=4_8G_;0T?X$VOBVZ\8?"3QI9FYT)+R=9I-*N"9-J!AP/FA9650H;S4;
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M^-W_  3+\*?"CX4Z_P"*_@GK&O\ A3QOHNE7,I9M0,\>JVXB;S[>56&,R)N
MQA<XRO<=;_P1Z_Y,_3_L8+[^45?3/[1?Q&T?X4? [QMXGURZBM;*STJXV^81
M^]E:-ECB4'JSN54#U-?,W_!'K_DS]/\ L8+[^45 'V_1678>*M%U35+G3++5
M["\U*UW>?9V]RCS1;3M;>@.5P2 <CJ:U* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&WQLN_B;I_B/Q/X2UF^OUU.[M='N8E@EN1()'D&^-F!=QN89(R20!TK["HH
MY'XI?"7P?\:O"-QX9\;Z!:>(=$G(8V]TI!1AT>-U(:-QD_,I!Y//-?-4?_!.
M.V\.1_8/!7QU^+G@KP]R%T33O$;?9X%Z[81M!09"<G<< C/S<?8=% '@_P "
M_P!BGX8_ +7)O$6DV-]XA\93[A-XJ\379OM1?(P<.0%0D<$HJDC@DBO>***
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M ()E^&[J2QB^(?Q1^(GQ0T>QE62#0-=UM_[.X.0'B&6.#_=91[5]ET4 >'?
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M@KKW@E]#O9_$T^LS:BFI77C";48YM:N75'4(\TD3*(R'R55%R50G)45]CT4
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M*_%GXB?$+0]1UJZUKQQ=-=ZE!J$\+V\3M,\I$*I$K*-TA'S,W 'UK/\ A/\
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M]JVGZ7'?1:@)M&FBBG\R-74#,D<B[<2'/RYX'->L44 ?*G[67Q'^#OPM\,>
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M) 9V S@ # 'VW10!X%^S)^Q1\.OV67U#4/#<5]K'B?4E*7OB+6YA/>2J6W%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760805200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001275187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--05-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-50761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AngioDynamics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3146460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">14 Plaza Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Latham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">12110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">795-1400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANGO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,329,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,671,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">DOCUMENTS INCORPORATED BY REFERENCEThe information required for Part III of this Annual Report on Form 10-K is incorporated by reference to the registrant&#8217;s Proxy Statement for its 2023 Annual Meeting of Stockholders to be filed within 120 days of the registrant's fiscal year ended May&#160;31, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760182128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759915136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 338,752,000<span></span>
</td>
<td class="nump">$ 316,219,000<span></span>
</td>
<td class="nump">$ 291,010,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales (exclusive of intangible amortization)</a></td>
<td class="nump">164,506,000<span></span>
</td>
<td class="nump">150,487,000<span></span>
</td>
<td class="nump">134,222,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">174,246,000<span></span>
</td>
<td class="nump">165,732,000<span></span>
</td>
<td class="nump">156,788,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">29,883,000<span></span>
</td>
<td class="nump">30,739,000<span></span>
</td>
<td class="nump">36,390,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">104,249,000<span></span>
</td>
<td class="nump">95,301,000<span></span>
</td>
<td class="nump">81,306,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">40,003,000<span></span>
</td>
<td class="nump">38,451,000<span></span>
</td>
<td class="nump">35,918,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">18,790,000<span></span>
</td>
<td class="nump">19,458,000<span></span>
</td>
<td class="nump">18,136,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">14,549,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_ChangeInFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">2,320,000<span></span>
</td>
<td class="nump">1,212,000<span></span>
</td>
<td class="nump">89,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AcquisitionRestructuringAndOtherItemsNet', window );">Acquisition, restructuring and other items, net</a></td>
<td class="nump">15,633,000<span></span>
</td>
<td class="nump">9,042,000<span></span>
</td>
<td class="nump">20,232,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">225,427,000<span></span>
</td>
<td class="nump">194,203,000<span></span>
</td>
<td class="nump">192,071,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(51,181,000)<span></span>
</td>
<td class="num">(28,471,000)<span></span>
</td>
<td class="num">(35,283,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(2,702,000)<span></span>
</td>
<td class="num">(688,000)<span></span>
</td>
<td class="num">(861,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(554,000)<span></span>
</td>
<td class="num">(790,000)<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_OtherNonoperatingIncomeExpenseAndInterestExpense', window );">Total other expenses, net</a></td>
<td class="num">(3,256,000)<span></span>
</td>
<td class="num">(1,478,000)<span></span>
</td>
<td class="num">(769,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax benefit</a></td>
<td class="num">(54,437,000)<span></span>
</td>
<td class="num">(29,949,000)<span></span>
</td>
<td class="num">(36,052,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(1,995,000)<span></span>
</td>
<td class="num">(3,402,000)<span></span>
</td>
<td class="num">(4,504,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (52,442,000)<span></span>
</td>
<td class="num">$ (26,547,000)<span></span>
</td>
<td class="num">$ (31,548,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (usd per share)</a></td>
<td class="num">$ (1.33)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (usd per share)</a></td>
<td class="num">$ (1.33)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">39,480,367<span></span>
</td>
<td class="nump">39,009,419<span></span>
</td>
<td class="nump">38,342,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">39,480,367<span></span>
</td>
<td class="nump">39,009,419<span></span>
</td>
<td class="nump">38,342,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_AcquisitionRestructuringAndOtherItemsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition Restructuring And Other Items Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_AcquisitionRestructuringAndOtherItemsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_ChangeInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings in the period resulting from remeasurement to fair value of contingent earn out liabilities related to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_ChangeInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_OtherNonoperatingIncomeExpenseAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income (Expense) And Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_OtherNonoperatingIncomeExpenseAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760080480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (52,442)<span></span>
</td>
<td class="num">$ (26,547)<span></span>
</td>
<td class="num">$ (31,548)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), before tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign currency translation gain (loss)</a></td>
<td class="num">(6,080)<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
<td class="nump">4,494<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Other comprehensive income (loss), before tax</a></td>
<td class="num">(6,080)<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
<td class="nump">4,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income tax benefit (expense) related to items of other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(6,080)<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
<td class="nump">4,494<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss, net of tax</a></td>
<td class="num">$ (58,522)<span></span>
</td>
<td class="num">$ (28,343)<span></span>
</td>
<td class="num">$ (27,054)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759741408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 44,620<span></span>
</td>
<td class="nump">$ 28,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $2,150 and $1,939, respectively</a></td>
<td class="nump">52,826<span></span>
</td>
<td class="nump">52,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">55,325<span></span>
</td>
<td class="nump">51,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">4,617<span></span>
</td>
<td class="nump">10,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets held for sale</a></td>
<td class="nump">6,154<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">163,542<span></span>
</td>
<td class="nump">143,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">44,384<span></span>
</td>
<td class="nump">45,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">111,144<span></span>
</td>
<td class="nump">152,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">159,238<span></span>
</td>
<td class="nump">201,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">10,676<span></span>
</td>
<td class="nump">10,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Non-current assets held for sale</a></td>
<td class="nump">43,653<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">532,637<span></span>
</td>
<td class="nump">552,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">40,445<span></span>
</td>
<td class="nump">28,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">26,617<span></span>
</td>
<td class="nump">34,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">14,761<span></span>
</td>
<td class="nump">8,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">2,002<span></span>
</td>
<td class="nump">2,652<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">83,825<span></span>
</td>
<td class="nump">74,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">49,818<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent', window );">Deferred income taxes</a></td>
<td class="nump">12,813<span></span>
</td>
<td class="nump">16,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration, net of current portion</a></td>
<td class="nump">4,535<span></span>
</td>
<td class="nump">8,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">3,350<span></span>
</td>
<td class="nump">4,736<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">154,341<span></span>
</td>
<td class="nump">128,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 17)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.01 per share, 75,000,000 shares authorized; 39,981,422 and 39,541,173 shares issued and 39,611,422 and 39,171,173 shares outstanding at May 31, 2023 and 2022, respectively</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">599,206<span></span>
</td>
<td class="nump">586,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(210,855)<span></span>
</td>
<td class="num">(158,413)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 370,000 shares, at cost at May 31, 2023 and 2022, respectively</a></td>
<td class="num">(5,714)<span></span>
</td>
<td class="num">(5,714)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(4,723)<span></span>
</td>
<td class="nump">1,357<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">378,296<span></span>
</td>
<td class="nump">424,489<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 532,637<span></span>
</td>
<td class="nump">$ 552,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other tax liabilities expected to be paid after one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955763749712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowances</a></td>
<td class="nump">$ 2,150<span></span>
</td>
<td class="nump">$ 1,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (shares)</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (shares)</a></td>
<td class="nump">39,981,422<span></span>
</td>
<td class="nump">39,541,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (shares)</a></td>
<td class="nump">39,611,422<span></span>
</td>
<td class="nump">39,171,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares (shares)</a></td>
<td class="nump">370,000,000<span></span>
</td>
<td class="nump">370,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759561264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Restricted Stock Units</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Restricted Stock Units</div>
</th>
<th class="th"><div>Additional paid in capital</div></th>
<th class="th">
<div>Additional paid in capital </div>
<div>Restricted Stock Units</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, Shares at May. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,448,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at May. 31, 2020</a></td>
<td class="nump">$ 454,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 561,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100,318)<span></span>
</td>
<td class="num">$ (1,341)<span></span>
</td>
<td class="num">$ (5,714)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasure shares at May. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(370,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(31,548)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,548)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance/cancellation of common stock units, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance/cancellation of common stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under Employee Stock Purchase Plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">8,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">4,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at May. 31, 2021</a></td>
<td class="nump">439,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">573,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131,866)<span></span>
</td>
<td class="nump">3,153<span></span>
</td>
<td class="num">$ (5,714)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at May. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,920,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury shares at May. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(370,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(26,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance/cancellation of common stock units, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,371<span></span>
</td>
<td class="nump">299,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance/cancellation of common stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under Employee Stock Purchase Plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">1,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(1,796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at May. 31, 2022</a></td>
<td class="nump">$ 424,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158,413)<span></span>
</td>
<td class="nump">1,357<span></span>
</td>
<td class="num">$ (5,714)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at May. 31, 2022</a></td>
<td class="nump">39,171,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,541,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury shares at May. 31, 2022</a></td>
<td class="num">(370,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(370,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">$ (52,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="nump">47,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance/cancellation of common stock units, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,826<span></span>
</td>
<td class="nump">239,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance/cancellation of common stock units</a></td>
<td class="num">(312)<span></span>
</td>
<td class="num">$ (720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(312)<span></span>
</td>
<td class="num">$ (720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under Employee Stock Purchase Plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">2,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">11,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(6,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at May. 31, 2023</a></td>
<td class="nump">$ 378,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 599,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (210,855)<span></span>
</td>
<td class="num">$ (4,723)<span></span>
</td>
<td class="num">$ (5,714)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at May. 31, 2023</a></td>
<td class="nump">39,611,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,981,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury shares at May. 31, 2023</a></td>
<td class="num">(370,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(370,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759799808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (52,442,000)<span></span>
</td>
<td class="num">$ (26,547,000)<span></span>
</td>
<td class="num">$ (31,548,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">30,873,000<span></span>
</td>
<td class="nump">29,349,000<span></span>
</td>
<td class="nump">25,916,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">2,484,000<span></span>
</td>
<td class="nump">2,439,000<span></span>
</td>
<td class="nump">2,456,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">14,549,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">11,158,000<span></span>
</td>
<td class="nump">10,692,000<span></span>
</td>
<td class="nump">8,625,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_ChangeInFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">2,320,000<span></span>
</td>
<td class="nump">1,212,000<span></span>
</td>
<td class="nump">89,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_DeferredIncomeTaxRelatedToOperatingActivity', window );">Deferred income tax provision</a></td>
<td class="num">(2,311,000)<span></span>
</td>
<td class="num">(3,708,000)<span></span>
</td>
<td class="num">(4,805,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Changes in accounts receivable allowances</a></td>
<td class="nump">695,000<span></span>
</td>
<td class="nump">118,000<span></span>
</td>
<td class="nump">207,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Asset impairments and disposals</a></td>
<td class="nump">291,000<span></span>
</td>
<td class="nump">391,000<span></span>
</td>
<td class="nump">14,228,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(513,000)<span></span>
</td>
<td class="num">(93,000)<span></span>
</td>
<td class="num">(147,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,299,000)<span></span>
</td>
<td class="num">(17,151,000)<span></span>
</td>
<td class="num">(4,162,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(8,198,000)<span></span>
</td>
<td class="num">(2,796,000)<span></span>
</td>
<td class="nump">11,539,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="nump">332,000<span></span>
</td>
<td class="num">(5,012,000)<span></span>
</td>
<td class="num">(3,181,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued and other liabilities</a></td>
<td class="nump">2,139,000<span></span>
</td>
<td class="nump">3,912,000<span></span>
</td>
<td class="nump">4,876,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">78,000<span></span>
</td>
<td class="num">(7,194,000)<span></span>
</td>
<td class="nump">24,093,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="num">(3,812,000)<span></span>
</td>
<td class="num">(4,297,000)<span></span>
</td>
<td class="num">(5,187,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_IncreaseInPlacementAndEvaluationUnits', window );">Additions to placement and evaluation units</a></td>
<td class="num">(5,394,000)<span></span>
</td>
<td class="num">(11,410,000)<span></span>
</td>
<td class="num">(8,524,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired', window );">Cash paid for acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,600,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired', window );">Acquisition of intangibles</a></td>
<td class="num">(540,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(9,746,000)<span></span>
</td>
<td class="num">(19,307,000)<span></span>
</td>
<td class="num">(13,711,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from issuance of and borrowings on long-term debt</a></td>
<td class="nump">70,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(45,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from borrowings on long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Deferred financing costs on long-term debt</a></td>
<td class="num">(751,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised', window );">Proceeds from exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">1,171,000<span></span>
</td>
<td class="nump">2,683,000<span></span>
</td>
<td class="nump">3,014,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">25,420,000<span></span>
</td>
<td class="nump">7,683,000<span></span>
</td>
<td class="num">(16,986,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="num">(518,000)<span></span>
</td>
<td class="nump">330,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">15,795,000<span></span>
</td>
<td class="num">(19,336,000)<span></span>
</td>
<td class="num">(6,274,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">28,825,000<span></span>
</td>
<td class="nump">48,161,000<span></span>
</td>
<td class="nump">54,435,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">44,620,000<span></span>
</td>
<td class="nump">28,825,000<span></span>
</td>
<td class="nump">48,161,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Increase (decrease) in accounts payable for purchases of fixed assets</a></td>
<td class="nump">124,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="num">(139,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_CashPaidDuringPeriodAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="nump">2,577,000<span></span>
</td>
<td class="nump">562,000<span></span>
</td>
<td class="nump">731,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">$ 342,000<span></span>
</td>
<td class="nump">$ 329,000<span></span>
</td>
<td class="nump">$ 313,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_CashPaidDuringPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During Period [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_CashPaidDuringPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_ChangeInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings in the period resulting from remeasurement to fair value of contingent earn out liabilities related to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_ChangeInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_DeferredIncomeTaxRelatedToOperatingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash flows from operating activities related to components of deferred income tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_DeferredIncomeTaxRelatedToOperatingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_IncreaseInPlacementAndEvaluationUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase In Placement And Evaluation Units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_IncreaseInPlacementAndEvaluationUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of intangible assets, net of cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments), Issuance Of Shares, Share-Based Payment Arrangement, Including Option Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955764520208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Business Description and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION, BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BASIS OF PRESENTATION, BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Description of Business</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, (collectively, the "Company", "we", "our", or "us").  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving the quality of life for patients.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Principles</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements and accompanying notes have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP").</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of AngioDynamics and its subsidiaries (all of which are wholly owned).  All intercompany balances and transactions have been eliminated.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all unrestricted highly liquid investments with an initial maturity of less than three months at the date of purchase to be cash equivalents. The Company maintains cash and cash equivalent balances with financial institutions in the United States in excess of amounts insured by the Federal Deposit Insurance Corporation.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Instruments</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the Company's cash and cash equivalents, accounts receivable, accounts payable and long-term debt approximates fair value due to the short-term nature or market interest rates of these items. The Company bases the fair value of short-term investments on quoted market prices or other relevant information generated by market transactions involving identical or comparable assets. The Company measures and records derivative financial instruments at fair value. See Note 5, "Fair Value of Financial Instruments" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K, for further discussion of financial instruments that are carried at fair value on a recurring and nonrecurring basis.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, principally trade receivables, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for estimated sales returns and doubtful accounts. The Company performs ongoing credit evaluations of customers and adjusts credit limits based upon payment history and the customer&#8217;s current creditworthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers, and a provision for estimated credit losses is maintained based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they are determined to be uncollectible.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inventories are stated at the lower of cost or net realizable value based on the first-in, first-out cost method and consist of raw materials, work in process and finished goods.  The standard cost of finished goods and work-in-process inventory is composed of material, labor and manufacturing overhead, which approximates actual cost. In addition to stating inventory at the </span></div>lower of cost or net realizable value, we also evaluate inventory each reporting period for excess quantities and obsolescence, establishing reserves when necessary based upon historical experience, assessment of economic conditions and expected demand. Once recorded, these reserves are considered permanent adjustments to the carrying value of inventory. An increase to inventory reserves results in a corresponding increase in cost of revenue. Inventories are written off against the reserve when they are physically disposed.<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets.  Placement and evaluation units represent capital equipment placed at customer locations under placement or evaluation agreements for which depreciation expense is included in cost of sales on the Consolidated Statements of Operations.  Refer below for useful lives by category:</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated useful lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 to 39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 8 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placement and evaluation units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates property, plant and equipment for impairment periodically to determine if changes in circumstances or the occurrence of events suggest the carrying value of the asset or asset group may not be recoverable. Expenditures for repairs and maintenance are charged to expense as incurred. Renewals and betterments are capitalized.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill, indefinite lived intangible assets and in process research and development ("IP R&amp;D") are amortized over their estimated useful lives, which range between <span style="-sec-ix-hidden:f-412">two</span> to eighteen years, on a straight-line basis over the expected period of benefit.  The Company periodically reviews the estimated useful lives of intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Such conditions could include significant adverse changes in the business climate, current-period operating or cash flow losses, significant declines in forecasted operations, or a current expectation that an asset group will be disposed of before the end of its useful life.  When testing for impairment of definite-lived intangible assets held for use, the Company groups assets at the lowest level for which cash flows are separately identifiable.  Prior to the first quarter of fiscal year 2023, the Company managed its operations as one reporting unit.  At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as two operating segments and two reporting units, namely Med Tech and Med Device (see Note 18 "Segments and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K).  The Company operates as two reporting units and two asset groups.  If a triggering event is deemed to exist, the Company performs an undiscounted operating cash flow analysis to determine if an impairment exists.  If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise.  Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated costs were based on respective fair market values at the date of acquisition.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For goodwill, the impairment test requires a comparison of the estimated fair value of each reporting unit to which the goodwill is assigned to the carrying value of the assets and liabilities of those reporting units. The determination of reporting units also requires management judgment. The Company considers whether a reporting unit exists within a reportable segment based on the availability of discrete financial information. The Company operates as two operating segments with two reporting units and consequently evaluates goodwill for impairment based on an evaluation of the fair value of each reporting unit. If the carrying value of the reporting units exceed the fair value, the carrying value is reduced to its fair value through an adjustment to the goodwill balance, resulting in an impairment charge. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the liability for contingent consideration recorded on the acquisition date for a business combination is based on probability weighted estimated cash flow streams, discounted back to present value using a discount rate determined in accordance with accepted valuation methods and reflective of the risk associated with the estimated cash flow streams. The liability for contingent consideration is remeasured to fair value at each reporting period with changes recorded in earnings until the contingency is resolved.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers control of promised goods or services to its customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those goods and services.&#160;See Note 4, &#8220;Revenue from Contracts with Customers&#8221; set forth in the Notes to our consolidated financial statements included in this Annual Report on Form 10-K for further discussion on revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs, including salaries, consulting fees, building costs, utilities and administrative expenses that are related to developing new products, enhancing existing products, validating new and enhanced products, managing clinical, regulatory and medical affairs are expensed as incurred.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates income tax expense for each jurisdiction in which it operates. This involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. The Company periodically evaluates deferred tax assets, capital loss carryforwards and tax credit carryforwards to determine their recoverability based primarily on the Company's ability to generate future taxable income and capital gains.  Where it is more-likely-than-not these will not be recovered, the Company estimates a valuation allowance and records a corresponding additional tax expense in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes and measures uncertain tax positions taken or expected to be taken in a tax return utilizing a two-step approach. The Company first determines if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is that the Company measures the tax benefit as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes on the Consolidated Statements of Operations.</span></div>Stock-Based CompensationStock-based compensation expense reflects the fair value of stock-based awards measured at the grant date and recognized over the relevant service period.  The expense recognized includes the impact of forfeitures as they occur.  The Company estimates the fair value of each stock-based award on the measurement date using either the current market price of the stock, the Black-Scholes option valuation model, or the Monte Carlo Simulation valuation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or restricted stock units, a risk-free interest rate and dividend yield. The Company recognizes stock-based compensation expense related to options, restricted stock units and market based performance stock units on a straight-line basis over the service period of the award, which is generally 4 years for options and restricted stock units and 3 years for market based performance stock units.<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company's foreign subsidiaries is the local currency in which the subsidiary operates. For foreign operations where the local currency is considered to be the functional currency, the Company translates assets and liabilities into U.S. dollars at the exchange rate on the balance sheet date. The Company translates income and expense items at average rates of exchange prevailing during each period. The Company accumulates translation adjustments in accumulated other comprehensive loss, a component of stockholders&#8217; equity.</span></div><div style="text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Transaction gains or losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in Other income (expense), net in the Consolidated Statements of Operations as incurred.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to market risks, including changes in foreign currency and interest rates. The Company periodically enters into certain derivative financial instruments to hedge the underlying economic exposure. </span></div>Derivative instruments are presented in the consolidated financial statements at their fair value. Changes in the fair value of derivative financial instruments are either recognized periodically in income or in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss) depending on whether the derivative financial instrument qualifies for hedge accounting and, if so, whether it qualifies as a fair value or cash flow hedge. Generally, the changes in the fair value of derivatives accounted for as fair value hedges are recorded in income along with the portions of the changes in the fair value of hedged items that relate to the hedged risks. Changes in the fair value of derivatives accounted for as cash flow hedges, to the extent they are effective as hedges, are recorded in accumulated other comprehensive income (loss).  There were no derivative instruments held by the Company as of May 31, 2023 and 2022.<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various legal proceedings that arise in the ordinary course of business, including patent infringement and product liability matters. The Company records accruals for contingencies when it is probable the liability has been incurred and the amount can be reasonably estimated.  Legal fees are expensed as incurred. Insurance recoveries related to potential claims are recognized up to the amount of the recorded liability when coverage is confirmed and the estimated recoveries are probable of payment. These recoveries are not netted against the related liabilities for financial statement presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759757232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">ACQUISITIONSCamaro Support Catheter Asset AcquisitionOn July 27, 2021, the Company acquired the Camaro support catheter (rebranded as Syntrax) from QX Medical, LLC for an aggregate purchase price of $4.0&#160;million, which included an upfront payment of $3.6&#160;million and $0.4&#160;million in purchase price holdbacks, along with $1.0&#160;million of potential future contingent consideration related to revenue milestones. This acquisition supports the Auryon product family and the Company's strategic plan.  The Company accounted for this acquisition as an asset purchase.  The Company recorded the amount paid at closing as inventory and fixed assets of $0.1&#160;million and an intangible asset product technology of $3.9&#160;million.  The intangible asset will be amortized over 15 years.  The contingent consideration is comprised of revenue milestones and will be accounted for when the contingency is resolved or becomes probable and reasonably estimable.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759549344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets Held For Sale<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">ASSETS HELD FOR SALE</a></td>
<td class="text">ASSETS HELD FOR SALE <div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal year 2023, the Company was in discussions with Merit to sell the dialysis product portfolio and BioSentry tract sealant system biopsy businesses.  This qualified for held for sale accounting and the Company determined that the fair value of the net assets being sold exceeded the carrying value as of May&#160;31, 2023.  The transaction was finalized on June 8, 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the major classes of assets held for sale:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of May 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total current assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total non-current assets held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761647952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE FROM CONTRACTS WITH CUSTOMERS</a></td>
<td class="text">REVENUE FROM CONTRACTS WITH CUSTOMERS<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one primary revenue stream which is the sales of its products.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize net sales by Med Tech, Med Device and by geography: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,039&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,963&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,256&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:54.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,043&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,967&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,010&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings.  The Company's products are generally used in minimally invasive, image-guided procedures.  Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use.  The Company sells its products to its distributors and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts and Performance Obligations</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements.  The Company&#8217;s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights.  As part of its assessment of each contract, the Company evaluates certain factors including the customer&#8217;s ability to pay (or credit risk).  For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Price and Allocation to Performance Obligations</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction prices of products are typically based on contracted rates.  Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer, net of any variable consideration as described below. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation.  Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation.  The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company&#8217;s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company&#8217;s manufacturing site or delivery to the customer&#8217;s named location, based on the shipping terms of a contract.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company typically invoices customers upon satisfaction of identified performance obligations.  As the Company&#8217;s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company enters into agreements to place placement and evaluation units (&#8220;units&#8221;) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer&#8217;s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units.  In these arrangements, revenue recognized for the sale of the disposables is not allocated between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts between the Company and its customers.  These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and Allowances:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides certain customers with rebates and allowances that are explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.  The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets.  These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes.  The Company is also required to pay administrative fees to group purchasing organizations. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Returns: The Company generally offers customers a limited right of return.  Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge.  To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date.  The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized.  The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls.  During the year ended May&#160;31, 2023, such product returns were not material.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances with Customers</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A receivable is generally recognized in the period the Company ships the product.  Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition.  Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers.  In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company&#8217;s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company&#8217;s receivables, contract assets and contract liabilities with customers:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended May&#160;31, 2023 and 2022, the Company had additions to contract liabilities of $0.7 million and $2.2&#160;million, respectively.  This was offset by $0.7 million and $2.1&#160;million in revenue that was recognized during the years ended May&#160;31, 2023 and 2022, respectively.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs to Obtain or Fulfill a Customer Contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs.  The Company&#8217;s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time.  However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products.  Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer.  Amounts charged to customers for shipping are recorded in net sales.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760180432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE OF FINANCIAL INSTRUMENTS<div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value.  The three levels of the hierarchy are defined as follows:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs to the valuation methodology are unobservable inputs based on management&#8217;s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to their immediate or short-term maturities.  The recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements using inputs considered as:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at May 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration for acquisition earn outs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Financial Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements using inputs considered as:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at May 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration for acquisition earn outs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Financial Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, 2 and 3 for the years ended May&#160;31, 2023 and 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the changes in fair value components of Level 3 instruments:    </span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial&#160;Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in present value of contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency gain from remeasurement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial&#160;Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency loss from remeasurement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liability for Acquisition Earn Outs</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements which is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of May&#160;31, 2023:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:25.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue based payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80% - 100%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At May&#160;31, 2023, the amount of undiscounted future contingent consideration that the Company expects to pay as a result of all completed acquisitions is approximately $20.0 million.  The milestones, including revenue projections and technical milestones, associated with the contingent consideration must be reached in future periods ranging from fiscal years 2024 to 2029 in order for the associated consideration to be paid. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Items Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a goodwill impairment charge of $14.5 million for the year ended May&#160;31, 2023 to write down the carrying value of the Med Device reporting unit to fair value. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal year 2021, the Company made the decision to abandon the OARtrac product technology and trademark.  This resulted in an impairment charge of $14.0&#160;million.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other items measured at fair value on a nonrecurring basis during the year ended May&#160;31, 2023 or May&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955874733936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method).  Inventories consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,708&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,186&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,325&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,392&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The Company periodically reviews inventory for both obsolescence and loss of value.  The Company makes assumptions about the future demand for and market value of the inventory.  Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow moving inventory.  The total inventory reserve at May&#160;31, 2023 and 2022 was $3.1 million and $3.7 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955766969632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_PrepaidExpensesAndOtherTextBlock', window );">PREPAID EXPENSES AND OTHER</a></td>
<td class="text">PREPAID EXPENSES AND OTHERPrepaid expenses and other consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Retention Tax Credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade shows</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_PrepaidExpensesAndOtherTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_PrepaidExpensesAndOtherTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955766623968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT, NET</a></td>
<td class="text">PROPERTY, PLANT AND EQUIPMENT, NET<div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placement and evaluation units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,917&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,581&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,069)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,891&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,512&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,005&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Depreciation expense for fiscal years 2023, 2022 and 2021 was $11.9 million, $7.6 million and $5.7 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761673888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically performed its annual goodwill assessment during the third quarter of each fiscal year.  During the fourth quarter of fiscal year 2022, the Company changed its annual impairment assessment date from December 31 to April 30 to more closely align the impairment assessment date with the Company's long term planning and forecasting process.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the first quarter of fiscal year 2023, the Company managed its operations as one reporting unit.  At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as two operating segments and two reporting units, namely Med Tech and Med Device (see Note 18 "Segments and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K).  As a result of this change, goodwill was required to be allocated to each reporting unit and an interim goodwill impairment assessment was performed at the Company and reporting unit levels.  To determine the fair value of the individual reporting units and the entire company as of June 1, 2022, the Company utilized the income approach.  The income approach is based on the projected cash flows discounted to their present value using discount rates, that in the Company's judgment, consider the timing and risk of the forecasted cash flows using internally developed forecasts and assumptions.  Under the income approach, the discount rate used is the average estimated value of a market participant&#8217;s cost of capital and debt, derived using customary market metrics.  Other significant assumptions include revenue growth rates, profitability projections, and terminal value growth rates.  The market approach was also considered; however, the income approach was chosen as the Company determined it is a better representation of both the Med Tech and Med Device reporting units' projected long-term performance. The fair value of each </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting unit and the Company as a whole was assessed to determine if there was any impairment.  The Company compared each reporting unit's fair value to the adjusted carrying value to conclude that there was no impairment for either reporting unit or the Company as a whole.  The adjusted carrying value of each reporting unit was used to calculate the Company's book value to compare to its market capitalization at the assessment date.  Based on the results of this evaluation, there were no adjustments to goodwill for either reporting unit or the Company as a whole as of August 31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's annual testing for impairment of goodwill was completed as of April 30, 2023.  To determine the fair value of the two reporting units as of April 30, 2023, the Company utilized the income approach for Med Tech and a combination of the income approach and market approach for Med Device.  The income approach is based on the projected cash flows discounted to their present value using discount rates, that in the Company's judgment, consider the timing and risk of the forecasted cash flows using internally developed forecasts and assumptions.  Under the income approach, the discount rate used is the average estimated value of a market participant&#8217;s cost of capital and debt, derived using customary market metrics.  Other significant assumptions include revenue growth rates, profitability projections, and terminal value growth rates.  The market approach estimates fair values based on the determination of appropriate publicly traded market comparison companies and market multiples of revenue and earnings derived from those companies with similar operating and investment characteristics.  The market approach was also considered; however, the income approach was chosen as the Company determined it is a better representation of the Med Tech reporting units' projected long-term performance.  For Med Device, both the income and market approaches were considered.  The fair value of each reporting unit was assessed to determine if there was any impairment.  The Company compared each reporting unit's fair value to the adjusted carrying value to conclude that there was no impairment for either reporting unit.  Based on the results of this evaluation, there were no adjustments to goodwill for either reporting unit as of April 30, 2023.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the sale of the dialysis product portfolio and BioSentry tract sealant system biopsy businesses to Merit Medical Systems, Inc. was a triggering event for the Med Device report unit.  As the Company concluded that this was the sale of a business, goodwill was allocated to the sale based on the relative fair value of the dialysis and BioSentry businesses and is included in assets held for sale as of May&#160;31, 2023.  To determine the fair value of the remaining Med Device reporting unit as of May&#160;31, 2023, the Company utilized the income approach, as it was determined to be a better representation of the remaining Med Device reporting unit's projected long-term performance. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the results of this evaluation, the Company recorded a goodwill impairment charge of $14.5 million for the year ended May&#160;31, 2023 to write down the carrying value of the Med Device reporting unit to fair value. The impairment loss is disclosed separately on the face of the accompanying consolidated statements of operations.  </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no adjustments to goodwill for the Med Tech reporting unit for the year ended May&#160;31, 2023 other than foreign currency translation adjustments.  There were no adjustments to goodwill for the year ended May&#160;31, 2022 other than foreign currency translation adjustments.   </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill for each reporting unit is allocated as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended May 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance June 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets held for sale </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance May 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though the Company determined that there was no goodwill impairment as of April 30, 2023 for the Med Tech reporting unit, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of April 30, 2024.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definite Lived Intangible Assets</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill are amortized over their estimated useful lives on a straight-line basis. Useful lives range from <span style="-sec-ix-hidden:f-610">two</span> to eighteen years.  The Company periodically reviews, and adjusts, if necessary, the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the triggering event for the Med Device reporting unit as of May&#160;31, 2023, long-lived assets were tested for impairment.  As a result of the undiscounted cash flow analysis that was performed, there were no impairments identified as of May&#160;31, 2023.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal year 2021, the Company made the decision to abandon the OARtrac product technology and trademark.  This resulted in an <span style="-sec-ix-hidden:f-612">impairment charge</span> of $14.0&#160;million.  The impairment charge is recorded in "Acquisition, restructuring and other items, net", on the Consolidated Statements of Operations (see Note 19 "Acquisition, restructuring and other items, net" as set forth in the Notes to the consolidated financial statements in this Annual Report on Form 10-K).  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;carrying<br/>value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net&#160;carrying<br/>value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,314)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,547&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,403)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,144&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;carrying<br/>value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net&#160;carrying<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,369&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,989)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $18.8 million, $19.5 million and $18.1 million for fiscal years 2023, 2022 and 2021, respectively.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,144&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761687232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss before income tax benefit are as follows:</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,437)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,949)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,052)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit is comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,311)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,708)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,805)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,995)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,402)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,504)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences that give rise to deferred tax assets and liabilities are summarized as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state R&amp;D tax credit carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses incurred not currently deductible</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,822&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,535&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,759)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,765)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,988)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability in the U.S. as of May&#160;31, 2023 and 2022 principally relates to tax amortization of intangibles that have an indefinite reversal period for book purposes, also known as a &#8220;naked credit deferred tax liability&#8221;, that cannot be considered as a source of income to recover the deferred tax asset.  In addition, included in the net deferred tax liability as of May&#160;31, 2023 and 2022 is a net deferred tax liability of $5.8&#160;million and $8.8&#160;million, respectively that was related to the stock acquisition of Eximo Medical Ltd. primarily related to book intangibles partially offset by tax net operating losses and capitalized R&amp;D expenditures.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's U.S. Federal net operating loss carryforwards as of May&#160;31, 2023 after considering IRC Section&#160;382 limitations are $169.7 million. The expiration of the Federal net operating loss carryforwards are as follows: $5.2 million between 2023 and 2024, $79.4 million between 2028 and 2037 and $85.1 million indefinitely.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's state net operating loss carryforwards as of May&#160;31, 2023 after considering remaining IRC Section&#160;382 limitations are $24.1 million which expire in various years from 2029 to 2042.  The Company has Israel tax net operating losses of $16.3&#160;million that can be carried forward indefinitely.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2018, except for the Global Intangible Low-Taxed Income, the Company will no longer record United States federal income tax on its share of the income of its foreign subsidiaries, nor will it record a benefit for foreign tax credits related to that income.  Upon distribution of these earnings in the form of dividends or otherwise, the Company would be subject to withholding taxes payable, where applicable, to foreign countries, but would have no further federal income tax liability.  The Company intends to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of May&#160;31, 2023, as well as all subsequent earnings generated by all of our foreign subsidiaries.  Determining the amount of unrecognized deferred tax liability related to any additional outside basis difference in these entities is not practical.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly assesses its ability to realize its deferred tax assets.  Assessing the realization of deferred tax assets requires significant management judgment.  In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity.  Evidence the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal year 2016, except the naked credit deferred tax liability.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&amp;D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of May&#160;31, 2023.  The Company will continue to assess the level of the valuation allowance required.  If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company&#8217;s results of operations.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated income tax expense has differed from the amount that would be provided by applying the U.S. Federal statutory income tax rate to the Company's income before income taxes for the following reasons:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit at federal statutory tax rate of 21.0%, 21.0% and 21.0%, respectively</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,432)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,289)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,571)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of Federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Non-U.S. operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meals and entertainment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,995)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,402)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,504)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending amount of unrecognized tax benefits:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits balance at June 1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in gross amounts of tax positions related to prior years due to U.S. tax reform</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease due to lapse in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits balance at May 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above includes unrecognized tax benefits associated with the calculation of limitations placed on the utilization of tax attributes related to an acquired company. If recognized, $0.5 million would result in adjustments to other tax accounts. &#160; </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense. There are no accrued interest and penalties recognized in the Consolidated Balance Sheets as of May&#160;31, 2023 and May&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business the Company is subject to examination by taxing authorities throughout the world.  Fiscal years 2020 through 2022 remain open to examination by the various tax authorities. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not anticipate that the amount of unrecognized tax benefits will significantly change in the next twelve months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955766827776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED LIABILITIES</a></td>
<td class="text">ACCRUED LIABILITIES<div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued severance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and franchise taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,842&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761481104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long Term Debt</a></td>
<td class="text">LONG-TERM DEBT<div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Company repaid all amounts outstanding under its then existing credit agreement and entered into a new Credit Agreement (the "Credit Agreement") with its lenders, JPMorgan Chase Bank, N.A., as Administrative Agent, sole bookrunner, and sole lead arranger, and Bank of America, N.A. and KeyBank National Association, as Syndication Agents. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for a $75.0&#160;million secured revolving credit facility (the "Revolving Facility") and a $30.0&#160;million delayed draw term loan (the "Delayed Draw Term Loan"), and also includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0&#160;million.&#160; Each exercise of such expansion feature must be drawn in $5.0&#160;million increments.  The proceeds of the Revolving Facility may be used for general corporate purposes, including permitted acquisitions.  The proceeds of the Delayed Draw Term Loan may be used for general corporate purposes, including primarily to finance the manufacturing costs of the Auryon laser capital equipment.  </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement has a five-year maturity.  Interest on the Revolving Facility and  Delayed Draw Term Loan will be based, at the Company's option, on a rate equal to (i) the Secured Overnight Financing Rate ("SOFR") plus 0.10% (subject to a floor of 0%), or (ii) if the Company elects to treat a borrowing as an ABR Borrowing, an alternate base rate based on SOFR, plus, in each case, an applicable margin of 1.25%, 1.50% or 1.75%, depending on the leverage ratio.  If any amounts are not paid when due, such overdue amounts will bear interest at an amount generally equal to 2.0% plus the existing loan rate.  The Credit Agreement also carries a commitment fee in the case of the Revolving Facility, and a ticking fee, in the case of the Delayed Draw Term Loans of 0.20% to 0.25% per annum on the unused portion.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations under the Credit Agreement are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the &#8220;Guarantors&#8221;). All obligations of the Company and the Guarantors under the Credit Agreement are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows:&#160;</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than 3.00 to 1.00 (during certain periods following material acquisitions the ratio shall be increased to 3.50 to 1.00). </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures* to&#160;consolidated interest expense* paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* The definitions of consolidated total indebtedness, consolidated EBITDA, consolidated capital expenditures and consolidated interest expense are specifically defined in the credit agreement included as an exhibit to Form 8-K filed on August 31, 2022.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;31, 2023 there was $25.0&#160;million outstanding on the Revolving Facility and $25.0&#160;million outstanding on the Delayed Draw Term Loan and the interest rate at May&#160;31, 2023 applicable to each was 6.73%.  As of May&#160;31, 2023 and May&#160;31, 2022, the carrying value of long-term debt approximated its fair market value.  </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:85.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delayed Draw Term Loan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debit issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total long-term debt</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,818&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was in compliance with the Credit Agreement covenants as of May&#160;31, 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2023, AngioDynamics used a portion of the consideration received from the sale of the dialysis and BioSentry businesses to repay all amounts owed under AngioDynamics&#8217; existing Credit Agreement, and as a result, the Credit Agreement was extinguished.  Pursuant to the terms of the Credit Agreement, AngioDynamics had the option to repay this facility prior to the maturity date without penalty.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760803984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">RETIREMENT PLANS</a></td>
<td class="text">RETIREMENT PLANSThe Company has a 401(k) plan under which eligible employees can defer a portion of their compensation, part of which is matched by the Company. Matching contributions were $4.2 million, $4.3 million and $3.8 million in 2023, 2022 and 2021, respectively. There are also various immaterial foreign retirement plans.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955874733936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalization</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2014, the Board of Directors approved the Amended and Restated Certificate of Incorporation (the &#8220;Amended Certificate&#8221;). Under the Amended Certificate, the authorized capital stock is 80,000,000 shares, consisting of 75,000,000 shares of common stock, par value $.01 per share and 5,000,000 shares of preferred stock, par value $.01 per share. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common stock are entitled to one vote for each share held. Subject to preferences applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably dividends, if any, as may be declared by the Board of Directors out of funds legally available for dividend payments. If the Company liquidates, dissolves, or winds up, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities and liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no pre-emptive rights or rights to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Company may designate in the future.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has the authority to (i)&#160;issue the undesignated preferred stock in one or more series, (ii)&#160;determine the powers, preferences and rights and the qualifications, limitations or restrictions granted to or imposed upon any wholly un-issued series of undesignated preferred stock and (iii)&#160;fix the number of shares constituting any series and the designation of the series, without any further vote or action by the Company's stockholders.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2020, the Company's shareholders approved the 2020 Stock and Incentive Award Plan (the &#8220;2020 Plan&#8221;).  The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance share units, performance shares and other incentive awards to the Company's employees, directors and other service providers.  On November 3, 2022 the Company's shareholders approved an amendment to the 2020 Plan to increase the reserve of shares of common stock available for future grants by 1,950,000 shares.  As of May&#160;31, 2023, there remained approximately 2.9 million shares available for future grants under the 2020 Plan. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of the 2020 Plan, equity awards were issued under the 2004 Stock and Incentive Award Plan (the &#8220;2004 Plan&#8221;).  The adoption of the 2020 Plan did not impact the administration of equity awards issued under the 2004 Plan but following the adoption of the 2020 Plan, equity award grants are no longer made under the 2004 Plan.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock option activity for the fiscal year ended May&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year - June 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year - May 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.89</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at year-end</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408,208&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.77</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options expected to vest in future periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are granted at exercise prices equal to the quoted market price of common stock at the date of the grant. Options vest 25%&#160;per year over four years for employees.  Stock options granted prior to May 1, 2007 and after June 1, 2017 expire on the tenth anniversary of the grant date.  Stock options granted between May 1, 2007 through May 31, 2017 expire on the seventh anniversary of the grant date. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of each stock option grant at the date of grant using a Black-Scholes option pricing model.  The weighted average grant-date fair value of options granted during the years ended May&#160;31, 2023, 2022 and 2021 was $9.27, $9.57, and $3.97, respectively.  The following assumptions were used in arriving at the fair value of options granted during 2023, 2022 and 2021, respectively:  risk-free interest rates of 3.20%, 0.92% and 0.34%; expected volatility of 44%, 41%, and 39%; and expected lives of 5.14 years, 5.05 years, and 4.96 years.  The Company does not declare dividends therefore a dividend yield of zero was used for the years ended May&#160;31, 2023, 2022 and 2021.  Risk-free interest rates reflect the yield on zero-coupon U.S. Treasury bonds whose maturity period equals the expected term of the option.  Expected volatilities are based on the historical volatility of the Company's stock.  The expected option lives are based on historical experience of employee exercise behavior. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised during the years ended May&#160;31, 2023, 2022 and 2021 was $0.2 million, $1.6 million, and $0.8 million, respectively.  As of May&#160;31, 2023, there was $3.9 million of total unrecognized compensation cost related to non-vested options, which is expected to be recognized over a weighted average period of 2 years. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash received from option exercises during 2023, 2022 and 2021 was $0.3 million, $2.7 million and $1.9 million, respectively.  Due to the valuation allowance there was no tax benefit realized from stock option exercises during the years ended May&#160;31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit and Performance Share Awards</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock units to certain employees under the 2020 Plan, and historically under the 2004 Plan, which give the recipients the right to receive shares of Company stock upon vesting. The restricted stock unit awards vest in <span style="-sec-ix-hidden:f-877">four</span> equal annual installments beginning on the first anniversary of the grant date.  Restricted stock unit awards granted to directors vest&#160;over one year. Unvested restricted stock unit awards will be forfeited if the recipient ceases to be employed by the Company. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The following table summarizes information about restricted stock unit activity for the year ended May&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted&#160;Average Grant-Date&#160;Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at beginning of year, June 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275,007)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at end of year, May 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock unit is the market price of Company stock on the date of grant.  The weighted average grant date fair value of restricted stock units granted during the years ended May&#160;31, 2023, 2022 and 2021 was $19.99, </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$26.24 and $10.40, respectively.  The total intrinsic value of restricted stock units (meaning the fair value of the units on the date of vest) vesting during the years ended May&#160;31, 2023, 2022 and 2021 was $5.6 million, $8.5 million, and $2.1 million,&#160;respectively.  As of May&#160;31, 2023, there was $9.1 million of total unrecognized compensation cost related to non-vested restricted stock awards, which is expected to be recognized over a weighted average period of 2 years.   </span></div><div style="text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company grants performance share awards to certain employees under the 2020 Plan, and historically under the 2004 Plan, which gives the recipients the right to receive shares of Company stock if certain criteria is met.  </span></div><div style="text-indent:21.6pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The following table summarizes information about performance unit award activity for the year ended May&#160;31, 2023:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance Unit Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted&#160;Average Grant-Date&#160;Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at beginning of year, June 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at end of year, May 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,530&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2023, 2022 and 2021, the Company granted performance unit awards.  Performance unit awards subject to vesting are based on the Company's level of attainment of the performance targets which are set for each of the <span style="-sec-ix-hidden:f-908">three</span> performance years along with continued employment of the grantee.  At the end of the three year period, the vested shares are subject to modification based on the Company&#8217;s TSR targets relative to the percentage appreciation of a specified index of companies for the respective three-year period. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to estimate the fair value of such awards, a Monte Carlo Simulation valuation model on the date of the grant was used.  For the years ended May&#160;31, 2023, 2022 and 2021, the weighted average grant date fair market value for new grants was $23.71, $28.93 and $9.72, respectively.  Compensation cost is recognized over the performance period which is typically three years.  As of May&#160;31, 2023, there was $2.4 million of unrecognized compensation cost which is expected to be recognized over a weighted average period of 1 year. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represents the break out of stock-based compensation included in the Company's Consolidated Statement of Operations:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,692&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax benefit on the compensation expense recognized for all stock-based compensation arrangements was $2.6 million, $2.5 million and $2.0 million for the years ended May&#160;31, 2023, 2022 and 2021, respectively.  The income tax benefit for 2023, 2022 and 2021 are negated by the full valuation allowance recorded against the deferred tax assets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employee Stock Purchase Plan (the &#8220;Stock Purchase Plan&#8221;) provides a means by which employees (the &#8220;participants&#8221;) are given an opportunity to purchase the Company's common stock through payroll deductions.  A total of  5,000,000 shares of common stock have been reserved for issuance under the Stock Purchase Plan.  Shares are offered through two purchase periods, each with duration of approximately 6 months, commencing on the first business day of the first and third fiscal quarters. An employee is eligible to participate in an offering period if, on the first day of an offering period, he or she has been employed in a full-time capacity for at least six months, with a customary working schedule of 20 or more hours per week and more than five months in a calendar year. Employees who own stock possessing 5% or more of the total combined voting power or value of all classes of stock are not eligible to participate in the Stock Purchase Plan. The purchase price of the shares of common stock acquired on each purchase date will be the lower of (i)&#160;85% of the fair market value of a share of common </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock on the first day of the offering period or (ii)&#160;85% of the fair market value of a share of common stock on the last day of the purchase period, subject to adjustments made by the Board of Directors. The Stock Purchase Plan is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423 of the Internal Revenue Code.  During the years ended May 31, 2017, 2019 and 2021, an additional 500,000, 1,000,000 and 500,000 shares of the Company's common stock, respectively, were reserved for issuance under the Stock Purchase Plan.   On November 3, 2022 the Company's shareholders approved an amendment to the employee stock purchase plan to increase the reserve of shares of common stock available for future grants by 1,000,000 shares. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to calculate the purchase date fair value of the shares issued under the Stock Purchase Plan and recognize expense related to shares purchased ratably over the offering period.  During the years ended May&#160;31, 2023, 2022 and 2021, 149,778, 98,586 and 164,194 shares, respectively, were issued at an average price of $13.67, $19.02 and $7.95, respectively, under the Stock Purchase Plan.  As of May&#160;31, 2023, 3.2 million shares remained available for future purchases under the Stock Purchase Plan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761687232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text">EARNINGS PER SHARE<div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share are based on the weighted average number of common shares outstanding.  In addition, diluted earnings per share include the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive.  In periods with a net loss, stock options and restricted stock units are not included in the computation of basic loss per share as the impact would be anti-dilutive.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles basic to diluted weighted average shares outstanding:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,480,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,009,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,342,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,480,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,009,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,342,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities excluded as their inclusion would be anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,491,099&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,465,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,285,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955764504096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-bottom:9pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception of the contract.  The Company has operating leases for buildings, primarily for office space, R&amp;D, manufacturing and warehousing.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date.  Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised.  The Company recognizes lease expense for these leases on a straight-line basis over the lease term.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected the three practical expedients that permit an entity to (a) not reassess whether expired or existing contracts contain leases, (b) not reassess lease classification for existing or expired leases, and (c) not consider whether previously capitalized initial direct costs would be appropriate under the new standard. Further, the Company has elected to not recognize leases with terms of 12 months or less on the balance sheet, and elected to account for lease and non-lease components as a single component for certain classes of assets.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental balance sheet information related to leases:</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-972"><span style="-sec-ix-hidden:f-973">Other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-976"><span style="-sec-ix-hidden:f-977">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-980"><span style="-sec-ix-hidden:f-981">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.  The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term.  The following table presents the weighted average remaining lease term and discount rate:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the lease liabilities for each of the following fiscal years is:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,596&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended May&#160;31, 2023 and May 31, 2022, the Company recognized operating lease expense, which includes immaterial short-term leases, of $2.7&#160;million and $2.8&#160;million, respectively.  The expenses on the Consolidated Statement of Operations were classified as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,694&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow and other information related to leases:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955762646080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Contingencies </span></div><div style="margin-bottom:7pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's other future commitments and contingencies as of May&#160;31, 2023: </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028 and thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,280&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) The non-cancelable inventory purchase obligations are not reflected on the Consolidated Balance Sheets under accounting principles generally accepted in the United States of America.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) These are future minimum royalty payments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business.  The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated.  The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred.  However, the Company cannot predict the outcome of any litigation or the potential for future litigation.</span></div><div style="margin-bottom:0.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.R. Bard, Inc. v. AngioDynamics, Inc.</span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2012, C.R. Bard, Inc. (&#8220;Bard&#8221;) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 7,785,302 ("302"), 7,959,615 (&#8220;615&#8221;) and 7,947,022 ("022")).  The case was stayed pending reexamination in the US Patent and Trademark Office ("USPTO").  Following the reexamination proceedings, and the parties&#8217; related appeals to the Federal Circuit which resulted in further proceedings at the USPTO, certain claims of the 615 patent were held invalid, while the remaining claims of the 615 patent and the other two patents were upheld over the prior art references considered in the reexamination proceedings.  Thereafter, the case was transferred from the District of Utah to the United States District Court for the District of Delaware (&#8220;District of Delaware&#8221;).  On July 22, 2021, in another case against a different defendant, the District of Utah invalidated multiple claims of the &#8216;302, &#8216;022, and &#8216;615 Patents under 35 USC &#167;101, including claims asserted against the Company.  On December 27, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal from the Utah Decision.  On February 17, 2023, the Federal Circuit Reversed-in-Part, Vacated-in-Part, and Remanded the Utah Decision.  The District of Delaware lifted the stay on February 28, 2023 and held a status conference on March 23, 2023.  A scheduling order has been entered, and a jury trial is currently scheduled for April 29, 2024. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.  </span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 10, 2015, Bard and Bard Peripheral Vascular filed suit in the District of Delaware claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 8,475,417, 8,545,460, 8,805,478).  The case proceeded through trial which began on March 4, 2019.  At the close of Bard&#8217;s case, the Court granted the Company's oral motion for judgment as a matter of law as well as its motions for summary judgment on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed.  Bard appealed the judgment to the Federal Circuit and on November 10, 2020, the Federal Circuit reversed the judgment in part with respect to Section 101 (subject matter eligibility), and vacated and remanded the trial court&#8217;s invalidity and non-infringement judgments.  Following remand from the Federal Circuit, a jury trial commenced in the District of Delaware beginning November 14, 2022.  On November 22, 2022, a jury entered a verdict finding that certain of the Company&#8217;s implantable port products infringe certain claims of U.S. patents held by Bard. The issue of damages was bifurcated by the Court during trial and was not determined by the jury.  On Jun</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e 1, 2023, following post-trial briefing, the Court issued its decision on the Company&#8217;s Renewed Judgement as a Matter of Law.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Court held the asserted patent claims were invalid as anticipated, indefinite, ineligible, and not willfully infringed.  The Court entered Judgment the same day in favor of the Company.  Bard has filed a Notice of Appeal to the Federal Circuit. The Company maintains its belief that Bard&#8217;s claims are without merit.  The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.</span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2021, Bard filed suit in the District of Delaware asserting certain of the Company&#8217;s port products (including certain related infusion sets) infringe U.S. Patent Nos. 8,025,639, 9,603,992 and 9,603,993.   On December 27, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal of the Utah decision invalidating </span></div>multiple claims of the &#8216;302, &#8216;022, and &#8216;615 patents under 35 USC &#167;101. Following the Federal Circuit&#8217;s decision on appeal, the District of Delaware lifted the stay on February 28, 2023, and held a scheduling conference on March 23, 2023. A scheduling order has been entered, and a jury trial is currently scheduled for June 9, 2025. The Company maintains its belief that Bard's claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955762652448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS AND GEOGRAPHIC INFORMATION</a></td>
<td class="text">SEGMENTS AND GEOGRAPHIC INFORMATION<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly reviews its segments and the approach used by the chief operating decision maker, the President and Chief Executive Officer ("CEO"), and management to evaluate performance and allocate resources.  Prior to the first quarter of fiscal year 2023, the Company considered the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis.  Commencing with the first quarter of fiscal year 2023, the Company began to manage its operations through two segments, Med Tech and Med Device to align with the transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company.  The CEO evaluates these two segments based on net sales and gross margin to, among other items, allocate resources and assess performance.  Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions.  The CEO evaluates all other elements of profitability, investment and cash flow metrics on a consolidated global basis due to shared infrastructure and resources. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company manages its assets on a total company basis, not by operating segment; therefore, the CEO does not review any asset information by operating segment and, accordingly, asset information is not reported or evaluated by operating segment.  Total assets were $532.6 million as of May&#160;31, 2023. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes net sales and gross margin by Med Tech and Med Device including prior periods during which the Company considered the business to be a single operating segment, in order to conform to the current period presentation:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross Margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross Margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross Margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic information</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes net sales by geographic area based on external customer location:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales by Geography</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>For fiscal years 2023, 2022 and 2021, international sales as a percentage of total net sales were 17%, 16% and 19%, respectively. Sales to any one country outside the U.S., as determined by shipment destination, did not comprise a material portion of net sales in any of the last three fiscal years. In addition, no one customer represents more than 10% of consolidated net sales.  85% of long-lived assets are located within the United States.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761737440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Restructuring and Other Items, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">ACQUISITION, RESTRUCTURING AND OTHER ITEMS, NET</a></td>
<td class="text">ACQUISITION, RESTRUCTURING AND OTHER ITEMS, NET<div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition, restructuring and other items, net consisted of:</span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,161&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mergers and acquisitions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transition service agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible and other asset impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israeli Innovation Authority prepayment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing Relocation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,633&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Legal expenses related to litigation that is outside the normal course of business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5) During the fourth quarter of fiscal year 2021, the Company made the decision to abandon the OARtrac product technology and trademark.  This resulted in an impairment charge of $14.0&#160;million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6) I</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n the first quarter of fiscal year 2023, a $3.5&#160;million payment was made to the Israeli Innovation Authority to fully satisfy the obligation related to grant funds that were provided to Eximo for development of the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7) Expenses to relocate certain manufacturing lines from Queensbury, NY to Alajuela, Costa Rica. </span></div>Included in legal for fiscal year 2021 is a $1.0&#160;million settlement expense. The settlement received partially offset legal expenses paid related to the settlement proceedings.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761672272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHESIVE INCOME (LOSS)</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)<div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of accumulated other comprehensive income (loss), net of tax, are as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation gain (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,080)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,080)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,723)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761726864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTSOn June 8, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with Merit Medical Systems, Inc. pursuant to which Merit acquired the dialysis product portfolio and BioSentry tract sealant system biopsy businesses for $100.0&#160;million in cash.  The Company and Merit entered into various agreements to facilitate the transition to Merit, including a Transactions Services Agreement and Contract Manufacturing Agreement.  The Company determined that the sale of the businesses did not constitute a strategic shift that had a major effect on the Company&#8217;s operations or financial results and as a result, this transaction will not be classified as discontinued operations.On June 8, 2023, AngioDynamics used a portion of the consideration received in connection with the Transaction to repay all amounts owed under AngioDynamics&#8217; existing Credit Agreement, dated as of August 30, 2022, with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and KeyBank National Association, as co-syndication agents, and JPMorgan Chase Bank N.A., as sole bookrunner and sole lead arranger, and as a result, the Credit Agreement was extinguished. Pursuant to the terms of the Credit Agreement, AngioDynamics had the option to repay this facility prior to the maturity date without penalty.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955766870096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">VALUATION AND QUALIFYING ACCOUNTS</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SCHEDULE&#160;II&#160;-VALUATION&#160;AND&#160;QUALIFYING&#160; ACCOUNTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance&#160;at Beginning of&#160;Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions&#160;- Charged&#160;to costs and expenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance&#160;at End&#160;of&#160;Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended May&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for deferred tax asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns and doubtful accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,064)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended May&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for deferred tax asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns and doubtful accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended May&#160;31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for deferred tax asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns and doubtful accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759777696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Description of Business</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Description of Business</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, (collectively, the "Company", "we", "our", or "us").  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving the quality of life for patients.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Principles</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements and accompanying notes have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP").</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of AngioDynamics and its subsidiaries (all of which are wholly owned).  All intercompany balances and transactions have been eliminated.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all unrestricted highly liquid investments with an initial maturity of less than three months at the date of purchase to be cash equivalents. The Company maintains cash and cash equivalent balances with financial institutions in the United States in excess of amounts insured by the Federal Deposit Insurance Corporation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Instruments</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the Company's cash and cash equivalents, accounts receivable, accounts payable and long-term debt approximates fair value due to the short-term nature or market interest rates of these items. The Company bases the fair value of short-term investments on quoted market prices or other relevant information generated by market transactions involving identical or comparable assets. The Company measures and records derivative financial instruments at fair value. See Note 5, "Fair Value of Financial Instruments" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K, for further discussion of financial instruments that are carried at fair value on a recurring and nonrecurring basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, principally trade receivables, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for estimated sales returns and doubtful accounts. The Company performs ongoing credit evaluations of customers and adjusts credit limits based upon payment history and the customer&#8217;s current creditworthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers, and a provision for estimated credit losses is maintained based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they are determined to be uncollectible.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inventories are stated at the lower of cost or net realizable value based on the first-in, first-out cost method and consist of raw materials, work in process and finished goods.  The standard cost of finished goods and work-in-process inventory is composed of material, labor and manufacturing overhead, which approximates actual cost. In addition to stating inventory at the </span></div>lower of cost or net realizable value, we also evaluate inventory each reporting period for excess quantities and obsolescence, establishing reserves when necessary based upon historical experience, assessment of economic conditions and expected demand. Once recorded, these reserves are considered permanent adjustments to the carrying value of inventory. An increase to inventory reserves results in a corresponding increase in cost of revenue. Inventories are written off against the reserve when they are physically disposed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets.  Placement and evaluation units represent capital equipment placed at customer locations under placement or evaluation agreements for which depreciation expense is included in cost of sales on the Consolidated Statements of Operations.  Refer below for useful lives by category:</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated useful lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 to 39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 8 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placement and evaluation units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates property, plant and equipment for impairment periodically to determine if changes in circumstances or the occurrence of events suggest the carrying value of the asset or asset group may not be recoverable. Expenditures for repairs and maintenance are charged to expense as incurred. Renewals and betterments are capitalized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill, indefinite lived intangible assets and in process research and development ("IP R&amp;D") are amortized over their estimated useful lives, which range between <span style="-sec-ix-hidden:f-412">two</span> to eighteen years, on a straight-line basis over the expected period of benefit.  The Company periodically reviews the estimated useful lives of intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Such conditions could include significant adverse changes in the business climate, current-period operating or cash flow losses, significant declines in forecasted operations, or a current expectation that an asset group will be disposed of before the end of its useful life.  When testing for impairment of definite-lived intangible assets held for use, the Company groups assets at the lowest level for which cash flows are separately identifiable.  Prior to the first quarter of fiscal year 2023, the Company managed its operations as one reporting unit.  At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as two operating segments and two reporting units, namely Med Tech and Med Device (see Note 18 "Segments and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K).  The Company operates as two reporting units and two asset groups.  If a triggering event is deemed to exist, the Company performs an undiscounted operating cash flow analysis to determine if an impairment exists.  If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.  </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise.  Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated costs were based on respective fair market values at the date of acquisition.</span></div>  For goodwill, the impairment test requires a comparison of the estimated fair value of each reporting unit to which the goodwill is assigned to the carrying value of the assets and liabilities of those reporting units. The determination of reporting units also requires management judgment. The Company considers whether a reporting unit exists within a reportable segment based on the availability of discrete financial information. The Company operates as two operating segments with two reporting units and consequently evaluates goodwill for impairment based on an evaluation of the fair value of each reporting unit. If the carrying value of the reporting units exceed the fair value, the carrying value is reduced to its fair value through an adjustment to the goodwill balance, resulting in an impairment charge.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Contingent Consideration</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the liability for contingent consideration recorded on the acquisition date for a business combination is based on probability weighted estimated cash flow streams, discounted back to present value using a discount rate determined in accordance with accepted valuation methods and reflective of the risk associated with the estimated cash flow streams. The liability for contingent consideration is remeasured to fair value at each reporting period with changes recorded in earnings until the contingency is resolved.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers control of promised goods or services to its customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those goods and services.&#160;See Note 4, &#8220;Revenue from Contracts with Customers&#8221; set forth in the Notes to our consolidated financial statements included in this Annual Report on Form 10-K for further discussion on revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs, including salaries, consulting fees, building costs, utilities and administrative expenses that are related to developing new products, enhancing existing products, validating new and enhanced products, managing clinical, regulatory and medical affairs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates income tax expense for each jurisdiction in which it operates. This involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. The Company periodically evaluates deferred tax assets, capital loss carryforwards and tax credit carryforwards to determine their recoverability based primarily on the Company's ability to generate future taxable income and capital gains.  Where it is more-likely-than-not these will not be recovered, the Company estimates a valuation allowance and records a corresponding additional tax expense in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes and measures uncertain tax positions taken or expected to be taken in a tax return utilizing a two-step approach. The Company first determines if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is that the Company measures the tax benefit as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes on the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Based Compensation</a></td>
<td class="text">Stock-Based CompensationStock-based compensation expense reflects the fair value of stock-based awards measured at the grant date and recognized over the relevant service period.  The expense recognized includes the impact of forfeitures as they occur.  The Company estimates the fair value of each stock-based award on the measurement date using either the current market price of the stock, the Black-Scholes option valuation model, or the Monte Carlo Simulation valuation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or restricted stock units, a risk-free interest rate and dividend yield. The Company recognizes stock-based compensation expense related to options, restricted stock units and market based performance stock units on a straight-line basis over the service period of the award, which is generally 4 years for options and restricted stock units and 3 years for market based performance stock units.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company's foreign subsidiaries is the local currency in which the subsidiary operates. For foreign operations where the local currency is considered to be the functional currency, the Company translates assets and liabilities into U.S. dollars at the exchange rate on the balance sheet date. The Company translates income and expense items at average rates of exchange prevailing during each period. The Company accumulates translation adjustments in accumulated other comprehensive loss, a component of stockholders&#8217; equity.</span></div><div style="text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Transaction gains or losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in Other income (expense), net in the Consolidated Statements of Operations as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to market risks, including changes in foreign currency and interest rates. The Company periodically enters into certain derivative financial instruments to hedge the underlying economic exposure. </span></div>Derivative instruments are presented in the consolidated financial statements at their fair value. Changes in the fair value of derivative financial instruments are either recognized periodically in income or in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss) depending on whether the derivative financial instrument qualifies for hedge accounting and, if so, whether it qualifies as a fair value or cash flow hedge. Generally, the changes in the fair value of derivatives accounted for as fair value hedges are recorded in income along with the portions of the changes in the fair value of hedged items that relate to the hedged risks. Changes in the fair value of derivatives accounted for as cash flow hedges, to the extent they are effective as hedges, are recorded in accumulated other comprehensive income (loss).  There were no derivative instruments held by the Company as of May 31, 2023 and 2022.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various legal proceedings that arise in the ordinary course of business, including patent infringement and product liability matters. The Company records accruals for contingencies when it is probable the liability has been incurred and the amount can be reasonably estimated.  Legal fees are expensed as incurred. Insurance recoveries related to potential claims are recognized up to the amount of the recorded liability when coverage is confirmed and the estimated recoveries are probable of payment. These recoveries are not netted against the related liabilities for financial statement presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements - Adopted</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:20.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Consolidated Financial Statements</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ASU 2021-10,&#160; Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company adopted the new standard in the first quarter of fiscal year 2023 and it did not have an impact on the Company's consolidated financial statements.</span></td></tr></table></div><div style="margin-top:9pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:20.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Consolidated Financial Statements</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2021-08,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span></div><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">This ASU</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. </span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company plans to adopt the new standard in the first quarter of fiscal year 2024 and does not expect there to be a material impact to the consolidated financial statements.</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue from Contract with Customer</a></td>
<td class="text">REVENUE FROM CONTRACTS WITH CUSTOMERS<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts and Performance Obligations</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements.  The Company&#8217;s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights.  As part of its assessment of each contract, the Company evaluates certain factors including the customer&#8217;s ability to pay (or credit risk).  For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Price and Allocation to Performance Obligations</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction prices of products are typically based on contracted rates.  Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer, net of any variable consideration as described below. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation.  Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation.  The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company&#8217;s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company&#8217;s manufacturing site or delivery to the customer&#8217;s named location, based on the shipping terms of a contract.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company typically invoices customers upon satisfaction of identified performance obligations.  As the Company&#8217;s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company enters into agreements to place placement and evaluation units (&#8220;units&#8221;) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer&#8217;s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units.  In these arrangements, revenue recognized for the sale of the disposables is not allocated between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts between the Company and its customers.  These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and Allowances:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides certain customers with rebates and allowances that are explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.  The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets.  These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes.  The Company is also required to pay administrative fees to group purchasing organizations. </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Returns: The Company generally offers customers a limited right of return.  Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge.  To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date.  The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized.  The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls.  During the year ended May&#160;31, 2023, such product returns were not material.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances with Customers</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A receivable is generally recognized in the period the Company ships the product.  Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition.  Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers.  In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company&#8217;s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs to Obtain or Fulfill a Customer Contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs.  The Company&#8217;s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time.  However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products.  Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer.  Amounts charged to customers for shipping are recorded in net sales.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760860288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, plant and equipment</a></td>
<td class="text">Refer below for useful lives by category:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated useful lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 to 39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 8 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placement and evaluation units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr></table><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placement and evaluation units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,917&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,581&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,069)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,891&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,512&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,005&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements - Adopted</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:20.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Consolidated Financial Statements</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ASU 2021-10,&#160; Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company adopted the new standard in the first quarter of fiscal year 2023 and it did not have an impact on the Company's consolidated financial statements.</span></td></tr></table></div><div style="margin-top:9pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:20.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Consolidated Financial Statements</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2021-08,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span></div><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">This ASU</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. </span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company plans to adopt the new standard in the first quarter of fiscal year 2024 and does not expect there to be a material impact to the consolidated financial statements.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e725-108305<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761675264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets Held For Sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Assets Held For Sale</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the major classes of assets held for sale:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of May 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total current assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total non-current assets held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955762452496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize net sales by Med Tech, Med Device and by geography: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,039&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,963&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,256&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:54.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,043&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,967&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,010&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract with Customer, Asset and Liability</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company&#8217;s receivables, contract assets and contract liabilities with customers:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955763916832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair value of assets and liabilities measured on recurring basis</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements using inputs considered as:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at May 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration for acquisition earn outs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Financial Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements using inputs considered as:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at May 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration for acquisition earn outs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Financial Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the changes in fair value components of Level 3 instruments:    </span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial&#160;Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in present value of contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency gain from remeasurement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial&#160;Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency loss from remeasurement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of May&#160;31, 2023:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:25.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue based payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80% - 100%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955764411328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method).  Inventories consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,708&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,186&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,325&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,392&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955764025136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_PrepaidExpensesAndOtherTableTextBlock', window );">Prepaid expenses and other</a></td>
<td class="text">Prepaid expenses and other consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Retention Tax Credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade shows</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_PrepaidExpensesAndOtherTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_PrepaidExpensesAndOtherTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761646736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, plant and equipment</a></td>
<td class="text">Refer below for useful lives by category:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated useful lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 to 39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 8 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placement and evaluation units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr></table><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placement and evaluation units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,917&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,581&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,069)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,891&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,512&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,005&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955764473408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill for each reporting unit is allocated as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended May 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance June 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets held for sale </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance May 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_ScheduleOfIntangibleAssetsTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;carrying<br/>value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net&#160;carrying<br/>value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,314)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,547&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,403)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,144&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;carrying<br/>value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net&#160;carrying<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,369&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,989)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Expected amortization expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,144&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_ScheduleOfIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_ScheduleOfIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761329552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of income (loss) before income tax provision</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss before income tax benefit are as follows:</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,437)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,949)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,052)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Income tax (benefit) provision analyzed by category</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit is comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,311)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,708)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,805)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,995)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,402)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,504)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of deferred tax asset and liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences that give rise to deferred tax assets and liabilities are summarized as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state R&amp;D tax credit carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses incurred not currently deductible</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,822&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,535&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,759)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,765)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,988)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Income tax rate reconciliation</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated income tax expense has differed from the amount that would be provided by applying the U.S. Federal statutory income tax rate to the Company's income before income taxes for the following reasons:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit at federal statutory tax rate of 21.0%, 21.0% and 21.0%, respectively</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,432)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,289)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,571)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of Federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Non-U.S. operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meals and entertainment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,995)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,402)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,504)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of unrecognized tax benefits reconciliation</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending amount of unrecognized tax benefits:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits balance at June 1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in gross amounts of tax positions related to prior years due to U.S. tax reform</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease due to lapse in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits balance at May 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759760512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued severance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and franchise taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,842&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761663600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text">As of May&#160;31, 2023 there was $25.0&#160;million outstanding on the Revolving Facility and $25.0&#160;million outstanding on the Delayed Draw Term Loan and the interest rate at May&#160;31, 2023 applicable to each was 6.73%.  As of May&#160;31, 2023 and May&#160;31, 2022, the carrying value of long-term debt approximated its fair market value.  <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:85.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delayed Draw Term Loan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debit issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total long-term debt</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,818&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761535792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule summarizes stock option activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock option activity for the fiscal year ended May&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year - June 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year - May 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.89</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at year-end</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408,208&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.77</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options expected to vest in future periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Share based compensation arrangement by share based payment award nonvested shares and weighted average grant date fair value</a></td>
<td class="text">The following table summarizes information about restricted stock unit activity for the year ended May&#160;31, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted&#160;Average Grant-Date&#160;Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at beginning of year, June 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275,007)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at end of year, May 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The following table summarizes information about performance unit award activity for the year ended May&#160;31, 2023:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance Unit Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted&#160;Average Grant-Date&#160;Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at beginning of year, June 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at end of year, May 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,530&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represents the break out of stock-based compensation included in the Company's Consolidated Statement of Operations:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,692&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761775728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Weighted Average Number of Shares</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles basic to diluted weighted average shares outstanding:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,480,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,009,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,342,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,480,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,009,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,342,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities excluded as their inclusion would be anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,491,099&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,465,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,285,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761027904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Supplemental balance sheet information</a></td>
<td class="text">The following table presents supplemental balance sheet information related to leases:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-972"><span style="-sec-ix-hidden:f-973">Other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-976"><span style="-sec-ix-hidden:f-977">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-980"><span style="-sec-ix-hidden:f-981">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Supplemental cash flow information</a></td>
<td class="text">The following table presents the weighted average remaining lease term and discount rate:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table>The expenses on the Consolidated Statement of Operations were classified as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,694&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow and other information related to leases:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lease liability schedule</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the lease liabilities for each of the following fiscal years is:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,596&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761734176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsTableTextBlock', window );">Other commitments and contingencies</a></td>
<td class="text"><div style="margin-bottom:7pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's other future commitments and contingencies as of May&#160;31, 2023: </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028 and thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,280&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) The non-cancelable inventory purchase obligations are not reflected on the Consolidated Balance Sheets under accounting principles generally accepted in the United States of America.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) These are future minimum royalty payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about obligations resulting from other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760182080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_ScheduleOfNetRevenueByProductGroupTableTextBlock', window );">Summary of total net sales by product category</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross Margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross Margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross Margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Summary of net sales for geographic areas</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes net sales by geographic area based on external customer location:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales by Geography</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_ScheduleOfNetRevenueByProductGroupTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of net revenue by product group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_ScheduleOfNetRevenueByProductGroupTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761695392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Restructuring and Other Items, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Acquisition, Restructuring and Other Items, net</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition, restructuring and other items, net consisted of:</span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended May 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,161&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mergers and acquisitions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transition service agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible and other asset impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israeli Innovation Authority prepayment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing Relocation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,633&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Legal expenses related to litigation that is outside the normal course of business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5) During the fourth quarter of fiscal year 2021, the Company made the decision to abandon the OARtrac product technology and trademark.  This resulted in an impairment charge of $14.0&#160;million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6) I</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n the first quarter of fiscal year 2023, a $3.5&#160;million payment was made to the Israeli Innovation Authority to fully satisfy the obligation related to grant funds that were provided to Eximo for development of the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020. </span></div>(7) Expenses to relocate certain manufacturing lines from Queensbury, NY to Alajuela, Costa Rica.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761672272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>May 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of accumulated other comprehensive income (loss), net of tax, are as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation gain (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,080)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,080)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,723)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759329264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th">
<div>May 31, 2023 </div>
<div>segment</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>unit</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>unit</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_ShortTermInvestmentsMaturityPeriod', window );">Maturity period</a></td>
<td class="text">less than three months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognition for costs not yet recognized (years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognition for costs not yet recognized (years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognition for costs not yet recognized (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AccountsReceivableDuePeriod', window );">Accounts receivables period due</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets other than goodwill (years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AccountsReceivableDuePeriod', window );">Accounts receivables period due</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets other than goodwill (years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and building improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and building improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (years)</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer software and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer software and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ango_PlacementAndEvaluationUnitsMember', window );">Placement and evaluation units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_AccountsReceivableDuePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable due period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_AccountsReceivableDuePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_ShortTermInvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term investments maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_ShortTermInvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ango_PlacementAndEvaluationUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ango_PlacementAndEvaluationUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761055360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 27, 2021</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">$ 526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember', window );">QX Medical, LLC Camaro Support Catheter Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Aggregate purchase price</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customer, liability, current</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Potential future contingent consideration</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AssetAcquisitionInventoryAndFixedAssets', window );">Inventory and fixed assets</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Product technology | QX Medical, LLC Camaro Support Catheter Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible asset product technology</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_AssetAcquisitionInventoryAndFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Inventory And Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_AssetAcquisitionInventoryAndFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760075712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets Held For Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventories</a></td>
<td class="nump">$ 4,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets held for sale</a></td>
<td class="nump">6,154<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property, plant and equipment, net</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="nump">17,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent', window );">Goodwill</a></td>
<td class="nump">25,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Non-current assets held for sale</a></td>
<td class="nump">43,653<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ango_DialysisProductPortfolioAndBioSentryBiopsyMember', window );">Dialysis Product Portfolio And BioSentry Biopsy | Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets held for sale</a></td>
<td class="nump">6,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Non-current assets held for sale</a></td>
<td class="nump">$ 43,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ango_DialysisProductPortfolioAndBioSentryBiopsyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ango_DialysisProductPortfolioAndBioSentryBiopsyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759670544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 338,752<span></span>
</td>
<td class="nump">$ 316,219<span></span>
</td>
<td class="nump">$ 291,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">282,713<span></span>
</td>
<td class="nump">265,963<span></span>
</td>
<td class="nump">237,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">56,039<span></span>
</td>
<td class="nump">50,256<span></span>
</td>
<td class="nump">53,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ango_MedTechMember', window );">Med Tech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">96,687<span></span>
</td>
<td class="nump">78,717<span></span>
</td>
<td class="nump">55,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ango_MedTechMember', window );">Med Tech | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">84,332<span></span>
</td>
<td class="nump">69,939<span></span>
</td>
<td class="nump">46,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ango_MedTechMember', window );">Med Tech | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">12,355<span></span>
</td>
<td class="nump">8,778<span></span>
</td>
<td class="nump">9,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ango_MedDeviceMember', window );">Med Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">242,065<span></span>
</td>
<td class="nump">237,502<span></span>
</td>
<td class="nump">235,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ango_MedDeviceMember', window );">Med Device | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">198,381<span></span>
</td>
<td class="nump">196,024<span></span>
</td>
<td class="nump">190,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ango_MedDeviceMember', window );">Med Device | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 43,684<span></span>
</td>
<td class="nump">$ 41,478<span></span>
</td>
<td class="nump">$ 44,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ango_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ango_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ango_MedDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ango_MedDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955756209392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval', window );">Right of return period (days)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_ContractwithCustomerRightofReturnRestockingCharge', window );">Restocking charge (percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn', window );">Restocking charge period (months)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination', window );">Additions to contract liabilities</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod', window );">Revenue recognized, including current period.</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_RevenuePerformanceObligationPaymentTerm', window );">Performance obligation payment term (days)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_RevenuePerformanceObligationPaymentTerm', window );">Performance obligation payment term (days)</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Right of Return, Minimum Remaining Product Life Prior to Return</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Right of Return, Product Return Period After Purchase Date Requiring Pre-Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_ContractwithCustomerRightofReturnRestockingCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Right of Return, Restocking Charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_ContractwithCustomerRightofReturnRestockingCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer With Customer, Liability, Revenue Recognized, Including Current Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_RevenuePerformanceObligationPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Payment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_RevenuePerformanceObligationPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760826176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue from Contracts with Customers Revenue from Contracts with Customers - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 52,826<span></span>
</td>
<td class="nump">$ 52,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">$ 526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759214688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments Fair Value of Financial Instruments (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration for acquisition earn outs</a></td>
<td class="nump">$ 19,296<span></span>
</td>
<td class="nump">$ 16,948<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Financial Liabilities</a></td>
<td class="nump">19,296<span></span>
</td>
<td class="nump">16,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration for acquisition earn outs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Financial Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration for acquisition earn outs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Financial Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration for acquisition earn outs</a></td>
<td class="nump">19,296<span></span>
</td>
<td class="nump">16,948<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Financial Liabilities</a></td>
<td class="nump">$ 19,296<span></span>
</td>
<td class="nump">$ 16,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759210032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 16,948<span></span>
</td>
<td class="nump">$ 15,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Change in present value of contingent consideration (1)</a></td>
<td class="nump">2,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement', window );">Currency gain from remeasurement</a></td>
<td class="nump">28<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_ChangeInFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">2,320<span></span>
</td>
<td class="nump">1,212<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 19,296<span></span>
</td>
<td class="nump">$ 16,948<span></span>
</td>
<td class="nump">$ 15,741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_ChangeInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings in the period resulting from remeasurement to fair value of contingent earn out liabilities related to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_ChangeInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Currency Gain (Loss) From Remeasurement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759930016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 3)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ango_RadiaDyneMember', window );">RadiaDyne | OarTrac trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Summary showing the recurring fair value measurements of the contingent consideration liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Summary showing the recurring fair value measurements of the contingent consideration liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Revenue based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,296<span></span>
</td>
<td class="nump">$ 16,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,296<span></span>
</td>
<td class="nump">16,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Summary showing the recurring fair value measurements of the contingent consideration liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure', window );">Potential amount of undiscounted future contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Summary showing the recurring fair value measurements of the contingent consideration liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Revenue based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,296<span></span>
</td>
<td class="nump">16,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,296<span></span>
</td>
<td class="nump">$ 16,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ango_RevenueBasedPaymentMember', window );">Revenue based payments | Valuation Technique, Discounted Cash Flow | Level 3 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Summary showing the recurring fair value measurements of the contingent consideration liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Revenue based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ango_RevenueBasedPaymentMember', window );">Revenue based payments | Valuation Technique, Discounted Cash Flow | Level 3 | Recurring | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Summary showing the recurring fair value measurements of the contingent consideration liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate used in fair value calculation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ango_RevenueBasedPaymentMember', window );">Revenue based payments | Valuation Technique, Discounted Cash Flow | Level 3 | Minimum | Recurring | Measurement Input, Probability of Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Summary showing the recurring fair value measurements of the contingent consideration liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate used in fair value calculation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ango_RevenueBasedPaymentMember', window );">Revenue based payments | Valuation Technique, Discounted Cash Flow | Level 3 | Maximum | Recurring | Measurement Input, Probability of Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract', window );"><strong>Summary showing the recurring fair value measurements of the contingent consideration liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate used in fair value calculation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Liabilities Measured On Recurring Basis [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted contingent consideration fair value fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ango_RadiaDyneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ango_RadiaDyneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ango_OarTracTrademarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ango_OarTracTrademarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ango_RevenueBasedPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ango_RevenueBasedPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ango_MeasurementInputProbabilityofPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ango_MeasurementInputProbabilityofPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955756185664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 28,679<span></span>
</td>
<td class="nump">$ 28,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">6,708<span></span>
</td>
<td class="nump">7,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">19,938<span></span>
</td>
<td class="nump">15,955<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">55,325<span></span>
</td>
<td class="nump">51,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation reserve</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759791792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_PrepaidDeposits', window );">Deposits</a></td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">$ 2,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_PrepaidEmployeeTaxCredit', window );">Employee Retention Tax Credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_SoftwareLicenses', window );">Software licenses</a></td>
<td class="nump">1,501<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_PrepaidLicenseeFees', window );">License fees</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_TradeShows', window );">Trade shows</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Rent</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_PrepaidIncomeandOtherTaxes', window );">Other prepaid taxes</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">2,201<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 4,617<span></span>
</td>
<td class="nump">$ 10,824<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_PrepaidDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_PrepaidDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_PrepaidEmployeeTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Employee Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_PrepaidEmployeeTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_PrepaidIncomeandOtherTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Income and Other Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_PrepaidIncomeandOtherTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_PrepaidLicenseeFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of prepaid licensee fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_PrepaidLicenseeFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_SoftwareLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of payments made for software licenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_SoftwareLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_TradeShows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of payments made in advance related to trade shows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_TradeShows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759270368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">$ 102,917<span></span>
</td>
<td class="nump">$ 95,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(59,026)<span></span>
</td>
<td class="num">(51,069)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements', window );">Property, plant and equipment excluding land and land improvements</a></td>
<td class="nump">43,891<span></span>
</td>
<td class="nump">44,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandAndLandImprovements', window );">Land and land improvements</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, Net</a></td>
<td class="nump">44,384<span></span>
</td>
<td class="nump">45,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">11,900<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and building improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">29,660<span></span>
</td>
<td class="nump">29,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer software and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">27,435<span></span>
</td>
<td class="nump">27,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">17,023<span></span>
</td>
<td class="nump">15,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ango_PlacementAndEvaluationUnitsMember', window );">Placement and evaluation units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">26,355<span></span>
</td>
<td class="nump">21,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">$ 2,444<span></span>
</td>
<td class="nump">$ 2,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment excluding land and land improvements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandAndLandImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandAndLandImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ango_PlacementAndEvaluationUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ango_PlacementAndEvaluationUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759853920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Goodwill Rollforward (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance June 1, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(14,549,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,980,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,291,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance May 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,238,000<span></span>
</td>
<td class="nump">201,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ango_MedTechMember', window );">Med Tech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance June 1, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,291,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance May 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,238,000<span></span>
</td>
<td class="nump">160,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ango_MedDeviceMember', window );">Med Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance June 1, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,549,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,980,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance May 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 40,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ango_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ango_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ango_MedDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ango_MedDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759675744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>segment</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>unit</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>unit</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,458,000<span></span>
</td>
<td class="nump">$ 18,136,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Total<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets other than goodwill (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets other than goodwill (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759661872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160;carrying value</a></td>
<td class="nump">$ 281,547<span></span>
</td>
<td class="nump">$ 314,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(170,403)<span></span>
</td>
<td class="num">(161,989)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net&#160;carrying value</a></td>
<td class="nump">111,144<span></span>
</td>
<td class="nump">152,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ango_ProductTechnologiesMember', window );">Product technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160;carrying value</a></td>
<td class="nump">211,751<span></span>
</td>
<td class="nump">239,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(118,314)<span></span>
</td>
<td class="num">(112,141)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net&#160;carrying value</a></td>
<td class="nump">93,437<span></span>
</td>
<td class="nump">127,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160;carrying value</a></td>
<td class="nump">57,509<span></span>
</td>
<td class="nump">60,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(40,755)<span></span>
</td>
<td class="num">(38,003)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net&#160;carrying value</a></td>
<td class="nump">16,754<span></span>
</td>
<td class="nump">22,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160;carrying value</a></td>
<td class="nump">7,450<span></span>
</td>
<td class="nump">9,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(6,660)<span></span>
</td>
<td class="num">(7,185)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net&#160;carrying value</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">2,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseAgreementTermsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160;carrying value</a></td>
<td class="nump">4,837<span></span>
</td>
<td class="nump">4,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(4,674)<span></span>
</td>
<td class="num">(4,660)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net&#160;carrying value</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ango_ProductTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ango_ProductTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955756290048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Expected Future Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Expected amortization expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 14,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">14,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">14,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">14,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">10,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2029 and thereafter</a></td>
<td class="nump">43,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net&#160;carrying value</a></td>
<td class="nump">$ 111,144<span></span>
</td>
<td class="nump">$ 152,380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955762635840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (45,240)<span></span>
</td>
<td class="num">$ (28,495)<span></span>
</td>
<td class="num">$ (31,595)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non-U.S.</a></td>
<td class="num">(9,197)<span></span>
</td>
<td class="num">(1,454)<span></span>
</td>
<td class="num">(4,457)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before tax expense</a></td>
<td class="num">$ (54,437)<span></span>
</td>
<td class="num">$ (29,949)<span></span>
</td>
<td class="num">$ (36,052)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760950256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">U.S.</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Non U.S.</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S.</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(3,415)<span></span>
</td>
<td class="num">(3,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Non U.S.</a></td>
<td class="num">(2,104)<span></span>
</td>
<td class="num">(293)<span></span>
</td>
<td class="num">(1,430)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(2,311)<span></span>
</td>
<td class="num">(3,708)<span></span>
</td>
<td class="num">(4,805)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">$ (1,995)<span></span>
</td>
<td class="num">$ (3,402)<span></span>
</td>
<td class="num">$ (4,504)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759228912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 40,460<span></span>
</td>
<td class="nump">$ 40,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">4,263<span></span>
</td>
<td class="nump">4,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state R&amp;D tax credit carryforward</a></td>
<td class="nump">7,311<span></span>
</td>
<td class="nump">6,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventories</a></td>
<td class="nump">724<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Expenses incurred not currently deductible</a></td>
<td class="nump">6,986<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Accrued liabilities</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="nump">59,822<span></span>
</td>
<td class="nump">54,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">46,828<span></span>
</td>
<td class="nump">50,320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liability</a></td>
<td class="nump">46,828<span></span>
</td>
<td class="nump">50,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(25,759)<span></span>
</td>
<td class="num">(20,203)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">$ (12,765)<span></span>
</td>
<td class="num">$ (15,988)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955756458288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,549,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Additional unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ango_EximoMedicalLtd.Member', window );">Eximo Medical, Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment', window );">Deferred tax liability, purchase accounting adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse', window );">Net operating loss carryforwards after considering limitations of use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=ango_TaxPeriodOneMember', window );">Tax Year 2022 and 2023 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal and State net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=ango_TaxPeriodTwoMember', window );">Tax Year 2028 and 2037 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse', window );">Net operating loss carryforwards after considering limitations of use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=ango_TaxPeriodFourMember', window );">Indefinite | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse', window );">Net operating loss carryforwards after considering limitations of use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=ango_TaxPeriodFourMember', window );">Indefinite | Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal and State net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=ango_TaxPeriodThreeMember', window );">Tax Year 2020 To 2040 | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal and State net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Purchase Accounting Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes (Textual) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Amount After Limitation Of Use</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ango_EximoMedicalLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ango_EximoMedicalLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ango_TaxPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ango_TaxPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ango_TaxPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ango_TaxPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ango_TaxPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ango_TaxPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ango_TaxPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ango_TaxPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955756297120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reasons for consolidated income tax provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at federal statutory tax rate of 21.0%, 21.0% and 21.0%, respectively</a></td>
<td class="num">$ (11,432)<span></span>
</td>
<td class="num">$ (6,289)<span></span>
</td>
<td class="num">$ (7,571)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of Federal tax benefit</a></td>
<td class="num">(353)<span></span>
</td>
<td class="num">(536)<span></span>
</td>
<td class="num">(462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_IncomeTaxReconciliationEffectOfForeignOperations', window );">Impact of Non-U.S. operations</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="num">(293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credit</a></td>
<td class="num">(991)<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="num">(1,303)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals and entertainment</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill impairment</a></td>
<td class="nump">3,055<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount', window );">Non-deductible executive compensation</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">5,556<span></span>
</td>
<td class="nump">3,168<span></span>
</td>
<td class="nump">3,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool', window );">Stock based compensation</a></td>
<td class="nump">505<span></span>
</td>
<td class="num">(1,616)<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">$ (1,995)<span></span>
</td>
<td class="num">$ (3,402)<span></span>
</td>
<td class="num">$ (4,504)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_IncomeTaxReconciliationEffectOfForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference, between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to the impact of non US operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_IncomeTaxReconciliationEffectOfForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Effect of Elimination of ASC 718 APIC Pool</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955756345632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, beginning balance</a></td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease in gross amounts of tax positions related to prior years due to U.S. tax reform</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Decrease due to lapse in statute of limitations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, ending balance</a></td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761327520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 9,232<span></span>
</td>
<td class="nump">$ 20,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Outside services</a></td>
<td class="nump">7,088<span></span>
</td>
<td class="nump">3,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties</a></td>
<td class="nump">2,874<span></span>
</td>
<td class="nump">2,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AccruedResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">1,525<span></span>
</td>
<td class="nump">1,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued severance</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Sales and franchise taxes</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">4,687<span></span>
</td>
<td class="nump">5,294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 26,617<span></span>
</td>
<td class="nump">$ 34,842<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955755972400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 03, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>covenant</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_DebtInstrumentFloorInterestRate', window );">Debt Instrument, Floor Interest Rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,818<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_DebtInstrumentDebtDefaultInterestRateIncrease', window );">Debt default interest rate increase (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio', window );">Debt instrument, maximum leverage ratio of total indebtedness to adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions', window );">Debt instrument, maximum leverage ratio of total indebtedness to adjusted EBITDA, following material acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio', window );">Minimum fixed charge coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Issuance of Long-term Debt</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Stated interest rate (percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Minimum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Maximum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature', window );">Possible increase in borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_LineOfCreditFacilityNumberOfCovenants', window );">Number of financial covenants | covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate at period end (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Borrowings outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio, Subsequent To Material Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Minimum Fixed Charge Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_DebtInstrumentDebtDefaultInterestRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Interest Rate Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_DebtInstrumentDebtDefaultInterestRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_DebtInstrumentFloorInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Floor Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_DebtInstrumentFloorInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Maximum Borrowing Capacity, Accordian Feature</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_LineOfCreditFacilityNumberOfCovenants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Number Of Covenants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_LineOfCreditFacilityNumberOfCovenants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760018752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long Term Debt - Long Term Debt Schedule (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debit issuance costs</a></td>
<td class="num">$ (182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">49,818<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans Payable | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ango_RevolvingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ango_RevolvingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955762659104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_RetirementPlansTextualAbstract', window );"><strong>Retirement Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Matching contributions</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_RetirementPlansTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retirement Plans (Textual) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_RetirementPlansTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955754324000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 03, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 29, 2014 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>working_hour </div>
<div>Employees </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsLineItems', window );"><strong>Other Ownership Interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_CapitalStockSharesAuthorized', window );">Authorized capital stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_CommonStockVotesPerShare', window );">Common stock, votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Option grants in the period, weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.27<span></span>
</td>
<td class="nump">$ 9.57<span></span>
</td>
<td class="nump">$ 3.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">0.92%<span></span>
</td>
<td class="nump">0.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 1 month 20 days<span></span>
</td>
<td class="text">5 years 18 days<span></span>
</td>
<td class="text">4 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">The total intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation not yet recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grants in the period, weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.24<span></span>
</td>
<td class="nump">$ 10.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Average price of share issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.67<span></span>
</td>
<td class="nump">$ 19.02<span></span>
</td>
<td class="nump">$ 7.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognition for costs not yet recognized (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsLineItems', window );"><strong>Other Ownership Interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage', window );">Percentage of grants to employees vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1', window );">Option grants to employees vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognition for costs not yet recognized (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsLineItems', window );"><strong>Other Ownership Interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grants in the period, weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service, compensation cost not yet recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested compensation, weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested compensation (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">736,020<span></span>
</td>
<td class="nump">670,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognition for costs not yet recognized (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ango_PerformanceShareAndRestrictedStockUnitAwardsMember', window );">Performance Share and Restricted Stock Unit Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsLineItems', window );"><strong>Other Ownership Interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of restricted stock awards vesting | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ango_PerformanceSharesIncludingThreeYearMarketConditionMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsLineItems', window );"><strong>Other Ownership Interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation not yet recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested compensation, weighted average grant date fair value (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.71<span></span>
</td>
<td class="nump">$ 28.93<span></span>
</td>
<td class="nump">$ 9.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod', window );">Performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognition for costs not yet recognized (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember', window );">2004 Stock and Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsLineItems', window );"><strong>Other Ownership Interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Total number of common stock available to be issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ango_StockPurchasePlanMember', window );">Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsLineItems', window );"><strong>Other Ownership Interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Total number of common stock available to be issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares to be offered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_NumberOfSharePurchasePeriod', window );">Share purchase periods | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_SharePurchasePeriod', window );">Duration of purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_EmployeePlanParticipatingEligibilityPeriod', window );">Employee eligible in participating in offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible', window );">Number of working hours to be eligible (working hour) | working_hour</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible', window );">Number of working months to be eligible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_EmployeePlanParticipatingEligibilityThresholdPercentage', window );">Employees ownership threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod', window );">Percentage of fair market value of a share of common stock on the first day of the offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of fair market value of a share of common stock on the last day of the offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for issuance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Maximum number of shares to be offered under the Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,778<span></span>
</td>
<td class="nump">98,586<span></span>
</td>
<td class="nump">164,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ango_StockAndIncentiveAwardPlan2020Member', window );">Stock And Incentive Award Plan 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsLineItems', window );"><strong>Other Ownership Interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</a></td>
<td class="nump">1,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ango_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsLineItems', window );"><strong>Other Ownership Interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_CapitalStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital stock shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_CapitalStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_CommonStockVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Votes Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_CommonStockVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_EmployeePlanParticipatingEligibilityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee plan participating eligibility period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_EmployeePlanParticipatingEligibilityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_EmployeePlanParticipatingEligibilityThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership threshold for participating plan eligibility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_EmployeePlanParticipatingEligibilityThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_NumberOfSharePurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share purchase period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_NumberOfSharePurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award award granted to employees vesting percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award award granted to employees vesting period1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_SharePurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share purchase period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_SharePurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award purchase price of common stock percent on first day of offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Compensation Cost Probable Recognition Performance Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Working Hours Per Week to be Eligible</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Working Months Per Year to be Eligible</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOwnershipInterestsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOwnershipInterestsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ango_PerformanceShareAndRestrictedStockUnitAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ango_PerformanceShareAndRestrictedStockUnitAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ango_PerformanceSharesIncludingThreeYearMarketConditionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ango_PerformanceSharesIncludingThreeYearMarketConditionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ango_StockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ango_StockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ango_StockAndIncentiveAwardPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ango_StockAndIncentiveAwardPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ango_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ango_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955755512256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Schedule summarizes stock option activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Outstanding at beginning of year (shares) | shares</a></td>
<td class="nump">2,346,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Granted (shares) | shares</a></td>
<td class="nump">187,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares Exercised (shares) | shares</a></td>
<td class="num">(47,824)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares Forfeited (shares) | shares</a></td>
<td class="num">(79,701)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Shares Expired (shares) | shares</a></td>
<td class="num">(200,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Outstanding at end of year (shares) | shares</a></td>
<td class="nump">2,206,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares Options exercisable at year-end (shares) | shares</a></td>
<td class="nump">1,408,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares Options expected to vest in future periods (shares) | shares</a></td>
<td class="nump">798,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at beginning of year (usd per share) | $ / shares</a></td>
<td class="nump">$ 17.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price Granted (usd per share) | $ / shares</a></td>
<td class="nump">21.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price Exercised (usd per share) | $ / shares</a></td>
<td class="nump">14.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price Forfeited (usd per share) | $ / shares</a></td>
<td class="nump">20.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price Expired (usd per share) | $ / shares</a></td>
<td class="nump">12.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at end of year (usd per share) | $ / shares</a></td>
<td class="nump">17.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable at year end (usd per share) | $ / shares</a></td>
<td class="nump">17.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Options expected to vest in future periods (usd per share) | $ / shares</a></td>
<td class="nump">$ 19.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 10 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, Option exercisable at year end</a></td>
<td class="text">4 years 9 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, Option expected to vest in future periods</a></td>
<td class="text">7 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding at end of year | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Options exercisable at year end | $</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Option expected to vest in future periods | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955756422784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160;Average Grant-Date&#160;Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-Date Fair Value, Granted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.24<span></span>
</td>
<td class="nump">$ 10.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-Vested Stock Award Units Beginning Balance (shares)</a></td>
<td class="nump">670,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Non-Vested Stock Award Units, Granted (shares)</a></td>
<td class="nump">379,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Non-Vested Stock Award Units, Vested (shares)</a></td>
<td class="num">(275,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Non-Vested Stock Award Units, Cancelled (shares)</a></td>
<td class="num">(38,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-Vested Stock Award Units Ending Balance (shares)</a></td>
<td class="nump">736,020<span></span>
</td>
<td class="nump">670,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160;Average Grant-Date&#160;Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-Date Fair Value Beginning Balance (usd per share)</a></td>
<td class="nump">$ 18.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-Date Fair Value, Granted (usd per share)</a></td>
<td class="nump">19.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-Date Fair Value, Vested (usd per share)</a></td>
<td class="nump">20.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-Date Fair Value, Cancelled (usd per share)</a></td>
<td class="nump">19.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-Date Fair Value Ending Balance (usd per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-Vested Stock Award Units Beginning Balance (shares)</a></td>
<td class="nump">449,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Non-Vested Stock Award Units, Granted (shares)</a></td>
<td class="nump">175,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Non-Vested Stock Award Units, Vested (shares)</a></td>
<td class="num">(45,008)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Non-Vested Stock Award Units, Cancelled (shares)</a></td>
<td class="num">(31,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-Vested Stock Award Units Ending Balance (shares)</a></td>
<td class="nump">548,530<span></span>
</td>
<td class="nump">449,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160;Average Grant-Date&#160;Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-Date Fair Value Beginning Balance (usd per share)</a></td>
<td class="nump">$ 17.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-Date Fair Value, Granted (usd per share)</a></td>
<td class="nump">21.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-Date Fair Value, Vested (usd per share)</a></td>
<td class="nump">20.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-Date Fair Value, Cancelled (usd per share)</a></td>
<td class="nump">20.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant-Date Fair Value Ending Balance (usd per share)</a></td>
<td class="nump">$ 19.23<span></span>
</td>
<td class="nump">$ 17.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955755588304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation pre tax amount</a></td>
<td class="nump">$ 11,158<span></span>
</td>
<td class="nump">$ 10,692<span></span>
</td>
<td class="nump">$ 8,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation pre tax amount</a></td>
<td class="nump">793<span></span>
</td>
<td class="nump">827<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ango_ResearchAndDevelopmentMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation pre tax amount</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ango_SalesandMarketingMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation pre tax amount</a></td>
<td class="nump">2,922<span></span>
</td>
<td class="nump">2,568<span></span>
</td>
<td class="nump">1,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation pre tax amount</a></td>
<td class="nump">$ 5,984<span></span>
</td>
<td class="nump">$ 5,999<span></span>
</td>
<td class="nump">$ 5,064<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ango_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ango_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ango_SalesandMarketingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ango_SalesandMarketingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759751376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">39,480,367<span></span>
</td>
<td class="nump">39,009,419<span></span>
</td>
<td class="nump">38,342,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">39,480,367<span></span>
</td>
<td class="nump">39,009,419<span></span>
</td>
<td class="nump">38,342,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded as their inclusion would be anti-dilutive</a></td>
<td class="nump">3,491,099<span></span>
</td>
<td class="nump">3,465,738<span></span>
</td>
<td class="nump">3,285,354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760020240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 5,113<span></span>
</td>
<td class="nump">$ 6,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">2,694<span></span>
</td>
<td class="nump">2,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 5,238<span></span>
</td>
<td class="nump">$ 7,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955762230512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 5,113<span></span>
</td>
<td class="nump">$ 6,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of lease obligations</a></td>
<td class="nump">1,922<span></span>
</td>
<td class="nump">2,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease obligations</a></td>
<td class="nump">3,316<span></span>
</td>
<td class="nump">4,703<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease obligations</a></td>
<td class="nump">$ 5,238<span></span>
</td>
<td class="nump">$ 7,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term (in years)</a></td>
<td class="text">3 years 18 days<span></span>
</td>
<td class="text">3 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760174192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Liability Maturity Schedule (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 2,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">2028 and thereafter</a></td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">5,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed Interest</a></td>
<td class="nump">358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease obligations</a></td>
<td class="nump">5,238<span></span>
</td>
<td class="nump">$ 7,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of lease obligations</a></td>
<td class="nump">1,922<span></span>
</td>
<td class="nump">2,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease obligations</a></td>
<td class="nump">$ 3,316<span></span>
</td>
<td class="nump">$ 4,703<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759789280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Statement of Operations Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">$ 2,694<span></span>
</td>
<td class="nump">$ 2,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">$ 1,458<span></span>
</td>
<td class="nump">$ 1,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955762439616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 2,742<span></span>
</td>
<td class="nump">$ 2,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760926256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract', window );"><strong>Purchase Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Total</a></td>
<td class="nump">$ 3,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">3,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFourthYear', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_PurchaseObligationToBePaidAfterYearFour', window );">2028 and thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvanceRoyaltiesAbstract', window );"><strong>Royalties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_Royalties', window );">Total</a></td>
<td class="nump">39,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_RoyaltiesDueInFirstYear', window );">2024</a></td>
<td class="nump">3,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_RoyaltiesDueinSecondYear', window );">2025</a></td>
<td class="nump">3,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_RoyaltiesDueinThirdYear', window );">2026</a></td>
<td class="nump">3,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_RoyaltiesDueinFourthYear', window );">2027</a></td>
<td class="nump">3,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_RoyaltiesDueAfterFourthYear', window );">2028 and thereafter</a></td>
<td class="nump">25,280<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">43,006<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">6,806<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">3,640<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">3,640<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2027</a></td>
<td class="nump">3,640<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_ContractualObligationToBePaidAfterYearFour', window );">2028 and thereafter</a></td>
<td class="nump">$ 25,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_ContractualObligationToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_ContractualObligationToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_PurchaseObligationToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_PurchaseObligationToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_Royalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_Royalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_RoyaltiesDueAfterFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Due After Fourth Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_RoyaltiesDueAfterFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_RoyaltiesDueInFirstYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Due In First Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_RoyaltiesDueInFirstYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_RoyaltiesDueinFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Due in Fourth Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_RoyaltiesDueinFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_RoyaltiesDueinSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Due in Second Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_RoyaltiesDueinSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_RoyaltiesDueinThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Due in Third Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_RoyaltiesDueinThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760171408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - unit<br></strong></div></th>
<th class="th"><div>Mar. 10, 2015</div></th>
<th class="th"><div>Jan. 11, 2012</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ango_CrBardIncMember', window );">C.R. Bard, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_NumberOfPatentsAssertedForReexamination', window );">Number of petitions filed for reexamination of patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_NumberOfPatentsUpheldOverPriorArtReferences', window );">Number of patents upheld over prior art references</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ango_TheDelawareActionMember', window );">The Delaware Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_NumberOfPatentsAssertedForReexamination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patents asserted for reexamination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_NumberOfPatentsAssertedForReexamination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_NumberOfPatentsUpheldOverPriorArtReferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Patents Upheld Over Prior Art References</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_NumberOfPatentsUpheldOverPriorArtReferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ango_CrBardIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ango_CrBardIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ango_TheDelawareActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ango_TheDelawareActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955759522176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments and Geographic Information - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>unit</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>unit</div>
</th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 532,637<span></span>
</td>
<td class="nump">$ 532,637<span></span>
</td>
<td class="nump">$ 532,637<span></span>
</td>
<td class="nump">$ 552,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International | Revenue from Contract with Customer Benchmark | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Net Assets, Geographic Area | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_NetAssetsGeographicAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_NetAssetsGeographicAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955756485152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments and Geographic Information - Sales by Product Category (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 338,752<span></span>
</td>
<td class="nump">$ 316,219<span></span>
</td>
<td class="nump">$ 291,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">$ 174,246<span></span>
</td>
<td class="nump">$ 165,732<span></span>
</td>
<td class="nump">$ 156,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_GrossMarginPercentage', window );">Gross Margin</a></td>
<td class="nump">0.514<span></span>
</td>
<td class="nump">0.524<span></span>
</td>
<td class="nump">0.539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ango_MedTechMember', window );">Med Tech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 96,687<span></span>
</td>
<td class="nump">$ 78,717<span></span>
</td>
<td class="nump">$ 55,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">$ 61,966<span></span>
</td>
<td class="nump">$ 52,584<span></span>
</td>
<td class="nump">$ 39,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_GrossMarginPercentage', window );">Gross Margin</a></td>
<td class="nump">0.641<span></span>
</td>
<td class="nump">0.668<span></span>
</td>
<td class="nump">0.710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ango_MedDeviceMember', window );">Med Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 242,065<span></span>
</td>
<td class="nump">$ 237,502<span></span>
</td>
<td class="nump">$ 235,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">$ 112,280<span></span>
</td>
<td class="nump">$ 113,148<span></span>
</td>
<td class="nump">$ 117,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_GrossMarginPercentage', window );">Gross Margin</a></td>
<td class="nump">0.464<span></span>
</td>
<td class="nump">0.476<span></span>
</td>
<td class="nump">0.498<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_GrossMarginPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Margin, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_GrossMarginPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ango_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ango_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ango_MedDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ango_MedDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955762223264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments and Geographic Information - Sale for Geographic Areas (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 338,752<span></span>
</td>
<td class="nump">$ 316,219<span></span>
</td>
<td class="nump">$ 291,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">282,713<span></span>
</td>
<td class="nump">265,963<span></span>
</td>
<td class="nump">237,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=ango_InternationalMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 56,039<span></span>
</td>
<td class="nump">$ 50,256<span></span>
</td>
<td class="nump">$ 53,967<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ango_InternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ango_InternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955755426032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Restructuring and Other Items, net - Schedule (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AcquisitionRestructuringAndOtherItemsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,633<span></span>
</td>
<td class="nump">$ 9,042<span></span>
</td>
<td class="nump">$ 20,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForPreviousAcquisition', window );">Payments for acquisition</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ango_RadiaDyneMember', window );">RadiaDyne | OarTrac trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ango_LegalCostsMember', window );">Legal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AcquisitionRestructuringAndOtherItemsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,998<span></span>
</td>
<td class="nump">7,625<span></span>
</td>
<td class="nump">6,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ango_MergersandAcquisitionsMember', window );">Mergers and acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AcquisitionRestructuringAndOtherItemsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ango_TransitionServiceAgreementMember', window );">Transition service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AcquisitionRestructuringAndOtherItemsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,032)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ango_DivestitureMember', window );">Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AcquisitionRestructuringAndOtherItemsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ango_IntangibleImpairmentMember', window );">Intangible and other asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AcquisitionRestructuringAndOtherItemsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ango_IsraeliInnovationAuthorityPrepaymentMember', window );">Israeli Innovation Authority prepayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AcquisitionRestructuringAndOtherItemsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,544<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ango_ManufacturingRelocationMember', window );">Manufacturing Relocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AcquisitionRestructuringAndOtherItemsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AcquisitionRestructuringAndOtherItemsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 632<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
<td class="nump">$ 756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_AcquisitionRestructuringAndOtherItemsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition Restructuring And Other Items Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_AcquisitionRestructuringAndOtherItemsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPreviousAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow representing an adjustment to the purchase price of a previous acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPreviousAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ango_RadiaDyneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ango_RadiaDyneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ango_OarTracTrademarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ango_OarTracTrademarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ango_LegalCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ango_LegalCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ango_MergersandAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ango_MergersandAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ango_TransitionServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ango_TransitionServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ango_DivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ango_DivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ango_IntangibleImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ango_IntangibleImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ango_IsraeliInnovationAuthorityPrepaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ango_IsraeliInnovationAuthorityPrepaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ango_ManufacturingRelocationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ango_ManufacturingRelocationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955760965744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition, Restructuring and Other Items, net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AcquisitionRestructuringAndOtherItemsNet', window );">Acquisition, restructuring and other items, net</a></td>
<td class="nump">$ 15,633<span></span>
</td>
<td class="nump">$ 9,042<span></span>
</td>
<td class="nump">$ 20,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ango_SettlementExpenseMember', window );">Settlement Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ango_AcquisitionRestructuringAndOtherItemsNet', window );">Acquisition, restructuring and other items, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ango_AcquisitionRestructuringAndOtherItemsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition Restructuring And Other Items Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ango_AcquisitionRestructuringAndOtherItemsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ango_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ango_SettlementExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ango_SettlementExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955762335136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="nump">$ 424,489<span></span>
</td>
<td class="nump">$ 439,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="nump">378,296<span></span>
</td>
<td class="nump">424,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="nump">1,357<span></span>
</td>
<td class="nump">3,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="num">(6,080)<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total comprehensive loss, net of tax</a></td>
<td class="num">(6,080)<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">$ (4,723)<span></span>
</td>
<td class="nump">$ 1,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761516800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 08, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherAssets1', window );">Proceeds from sale of assets</a></td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of other assets as part of operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139955761039136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation and Qualifying Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Allowance for deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Valuation and Qualifying Accounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance&#160;at Beginning of&#160;Year</a></td>
<td class="nump">$ 20,203<span></span>
</td>
<td class="nump">$ 17,035<span></span>
</td>
<td class="nump">$ 13,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions&#160;- Charged&#160;to costs and expenses</a></td>
<td class="nump">5,556<span></span>
</td>
<td class="nump">3,168<span></span>
</td>
<td class="nump">3,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance&#160;at End&#160;of&#160;Period</a></td>
<td class="nump">25,759<span></span>
</td>
<td class="nump">20,203<span></span>
</td>
<td class="nump">17,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember', window );">Allowance for sales returns and doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Valuation and Qualifying Accounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance&#160;at Beginning of&#160;Year</a></td>
<td class="nump">1,939<span></span>
</td>
<td class="nump">1,919<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions&#160;- Charged&#160;to costs and expenses</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(246)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="num">(2,064)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance&#160;at End&#160;of&#160;Period</a></td>
<td class="nump">$ 2,150<span></span>
</td>
<td class="nump">$ 1,939<span></span>
</td>
<td class="nump">$ 1,919<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>ango-20230531_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ango="http://www.angiodynamics.com/20230531"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ango-20230531.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <instant>2023-08-02</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ango:PlacementAndEvaluationUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-27</startDate>
            <endDate>2021-07-27</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-27</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-27</startDate>
            <endDate>2021-07-27</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ango:DialysisProductPortfolioAndBioSentryBiopsyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ango:RevenueBasedPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ango:RevenueBasedPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ango:RevenueBasedPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ango:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ango:RevenueBasedPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ango:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ango:RadiaDyneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ango:OarTracTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ango:PlacementAndEvaluationUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ango:PlacementAndEvaluationUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ango:MedDeviceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ango:ProductTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ango:ProductTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ango:EximoMedicalLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ango:EximoMedicalLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ango:TaxPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ango:TaxPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ango:TaxPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ango:TaxPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ango:TaxPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-03</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-30</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-30</startDate>
            <endDate>2022-08-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-03</startDate>
            <endDate>2019-06-03</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-30</startDate>
            <endDate>2022-08-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <startDate>2022-08-30</startDate>
            <endDate>2022-08-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ango:RevolvingFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <instant>2014-10-29</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <startDate>2014-10-29</startDate>
            <endDate>2014-10-29</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockAndIncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-03</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:TwoThousandAndFourStockAndIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceShareAndRestrictedStockUnitAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceShareAndRestrictedStockUnitAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceShareAndRestrictedStockUnitAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceSharesIncludingThreeYearMarketConditionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceSharesIncludingThreeYearMarketConditionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceSharesIncludingThreeYearMarketConditionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ango:PerformanceSharesIncludingThreeYearMarketConditionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ango:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ango:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ango:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ango:SalesandMarketingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ango:SalesandMarketingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ango:SalesandMarketingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-03</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ango:StockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ango:CrBardIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-11</startDate>
            <endDate>2012-01-11</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ango:TheDelawareActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-10</startDate>
            <endDate>2015-03-10</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ango:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ango:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ango:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:NetAssetsGeographicAreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:LegalCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:LegalCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:LegalCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:MergersandAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:MergersandAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:MergersandAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:TransitionServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:TransitionServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:TransitionServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:DivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:DivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:DivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:IntangibleImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:IntangibleImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:IntangibleImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:IsraeliInnovationAuthorityPrepaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:IsraeliInnovationAuthorityPrepaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:IsraeliInnovationAuthorityPrepaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:ManufacturingRelocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:ManufacturingRelocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:ManufacturingRelocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ango:SettlementExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-08</startDate>
            <endDate>2023-06-08</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001275187</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ango:AllowanceForSalesReturnsAndDoubtfulAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>ango:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="unit">
        <measure>ango:unit</measure>
    </unit>
    <unit id="covenant">
        <measure>ango:covenant</measure>
    </unit>
    <unit id="vote">
        <measure>ango:vote</measure>
    </unit>
    <unit id="employees">
        <measure>ango:Employees</measure>
    </unit>
    <unit id="working_hour">
        <measure>ango:working_hour</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-31">0001275187</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-32">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-51" id="f-412">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-51" id="f-610">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-120" id="f-612">http://www.angiodynamics.com/20230531#AcquisitionRestructuringAndOtherItemsNet</us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-44" id="f-877">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-166" id="f-908">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-8" id="f-972">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-7" id="f-973">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-7" id="f-976">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-8" id="f-977">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-7" id="f-980">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-8" id="f-981">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-05-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--05-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">0-50761</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">AngioDynamics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">11-3146460</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">14 Plaza Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Latham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">12110</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">518</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">795-1400</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">ANGO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-27">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-1" id="f-28" unitRef="usd">450329930</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-29" unitRef="shares">39671221</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-30">DOCUMENTS INCORPORATED BY REFERENCEThe information required for Part III of this Annual Report on Form 10-K is incorporated by reference to the registrant&#x2019;s Proxy Statement for its 2023 Annual Meeting of Stockholders to be filed within 120 days of the registrant's fiscal year ended May&#160;31, 2023.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-35">34</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-36">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-37">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-38" unitRef="usd">338752000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">316219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-40" unitRef="usd">291010000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-41" unitRef="usd">164506000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">150487000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-5" decimals="-3" id="f-43" unitRef="usd">134222000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-44" unitRef="usd">174246000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">165732000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-5" decimals="-3" id="f-46" unitRef="usd">156788000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-47" unitRef="usd">29883000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">30739000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">36390000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-1" decimals="-3" id="f-50" unitRef="usd">104249000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">95301000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-5" decimals="-3" id="f-52" unitRef="usd">81306000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-53" unitRef="usd">40003000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">38451000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">35918000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-56" unitRef="usd">18790000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">19458000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-3" id="f-58" unitRef="usd">18136000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-59" unitRef="usd">14549000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <ango:ChangeInFairValueOfContingentConsideration contextRef="c-1" decimals="-3" id="f-62" unitRef="usd">2320000</ango:ChangeInFairValueOfContingentConsideration>
    <ango:ChangeInFairValueOfContingentConsideration contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">1212000</ango:ChangeInFairValueOfContingentConsideration>
    <ango:ChangeInFairValueOfContingentConsideration contextRef="c-5" decimals="-3" id="f-64" unitRef="usd">89000</ango:ChangeInFairValueOfContingentConsideration>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-1" decimals="-3" id="f-65" unitRef="usd">15633000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">9042000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">20232000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-68" unitRef="usd">225427000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">194203000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-70" unitRef="usd">192071000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-71" unitRef="usd">-51181000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">-28471000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">-35283000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-74" unitRef="usd">2702000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">688000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-5" decimals="-3" id="f-76" unitRef="usd">861000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-77" unitRef="usd">-554000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">-790000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">92000</us-gaap:OtherNonoperatingIncomeExpense>
    <ango:OtherNonoperatingIncomeExpenseAndInterestExpense contextRef="c-1" decimals="-3" id="f-80" unitRef="usd">-3256000</ango:OtherNonoperatingIncomeExpenseAndInterestExpense>
    <ango:OtherNonoperatingIncomeExpenseAndInterestExpense contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">-1478000</ango:OtherNonoperatingIncomeExpenseAndInterestExpense>
    <ango:OtherNonoperatingIncomeExpenseAndInterestExpense contextRef="c-5" decimals="-3" id="f-82" unitRef="usd">-769000</ango:OtherNonoperatingIncomeExpenseAndInterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-83" unitRef="usd">-54437000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">-29949000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">-36052000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-86" unitRef="usd">-1995000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">-3402000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">-4504000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-89" unitRef="usd">-52442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-90" unitRef="usd">-52442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">-26547000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">-31548000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-93"
      unitRef="usdPerShare">-1.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-4"
      decimals="2"
      id="f-94"
      unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-95"
      unitRef="usdPerShare">-0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-96"
      unitRef="usdPerShare">-1.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-4"
      decimals="2"
      id="f-97"
      unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-98"
      unitRef="usdPerShare">-0.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-99" unitRef="shares">39480000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-4" decimals="-3" id="f-100" unitRef="shares">39009000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-101" unitRef="shares">38342000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-102" unitRef="shares">39480000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-4" decimals="-3" id="f-103" unitRef="shares">39009000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-104" unitRef="shares">38342000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">-52442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-106" unitRef="usd">-26547000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-107" unitRef="usd">-31548000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">-6080000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="c-4" decimals="-3" id="f-109" unitRef="usd">-1796000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="c-5" decimals="-3" id="f-110" unitRef="usd">4494000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-111" unitRef="usd">-6080000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-4" decimals="-3" id="f-112" unitRef="usd">-1796000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">4494000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-4" decimals="-3" id="f-115" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">-6080000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-118" unitRef="usd">-1796000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">4494000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">-58522000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-4" decimals="-3" id="f-121" unitRef="usd">-28343000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-122" unitRef="usd">-27054000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-123" unitRef="usd">44620000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-3" id="f-124" unitRef="usd">28825000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-7" decimals="-3" id="f-125" unitRef="usd">2150000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-8" decimals="-3" id="f-126" unitRef="usd">1939000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-7" decimals="-3" id="f-127" unitRef="usd">52826000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-8" decimals="-3" id="f-128" unitRef="usd">52304000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-7" decimals="-3" id="f-129" unitRef="usd">55325000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-8" decimals="-3" id="f-130" unitRef="usd">51392000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-131" unitRef="usd">4617000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-8" decimals="-3" id="f-132" unitRef="usd">10824000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-7" decimals="-3" id="f-133" unitRef="usd">6154000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-8" decimals="-3" id="f-134" unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="-3" id="f-135" unitRef="usd">163542000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-8" decimals="-3" id="f-136" unitRef="usd">143345000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-137" unitRef="usd">44384000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-3" id="f-138" unitRef="usd">45005000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-7" decimals="-3" id="f-139" unitRef="usd">111144000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-8" decimals="-3" id="f-140" unitRef="usd">152380000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-141" unitRef="usd">159238000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-8" decimals="-3" id="f-142" unitRef="usd">201058000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-7" decimals="-3" id="f-143" unitRef="usd">10676000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-8" decimals="-3" id="f-144" unitRef="usd">10963000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent contextRef="c-7" decimals="-3" id="f-145" unitRef="usd">43653000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent contextRef="c-8" decimals="-3" id="f-146" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-7" decimals="-3" id="f-147" unitRef="usd">532637000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-8" decimals="-3" id="f-148" unitRef="usd">552751000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-149" unitRef="usd">40445000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-8" decimals="-3" id="f-150" unitRef="usd">28047000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-151" unitRef="usd">26617000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-152" unitRef="usd">34842000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-7" decimals="-3" id="f-153" unitRef="usd">14761000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-8" decimals="-3" id="f-154" unitRef="usd">8783000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-155" unitRef="usd">2002000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-156" unitRef="usd">2652000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-157" unitRef="usd">83825000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-158" unitRef="usd">74324000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt contextRef="c-7" decimals="-3" id="f-159" unitRef="usd">49818000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-8" decimals="-3" id="f-160" unitRef="usd">25000000</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-161" unitRef="usd">12813000</us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent contextRef="c-8" decimals="-3" id="f-162" unitRef="usd">16037000</us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-163" unitRef="usd">4535000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-164" unitRef="usd">8165000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-165" unitRef="usd">3350000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-8" decimals="-3" id="f-166" unitRef="usd">4736000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-7" decimals="-3" id="f-167" unitRef="usd">154341000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-8" decimals="-3" id="f-168" unitRef="usd">128262000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-7" id="f-169" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-8" id="f-170" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-171"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-172"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-173" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-174" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-7" decimals="INF" id="f-175" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-176" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-177" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-8" decimals="INF" id="f-178" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-7" decimals="-3" id="f-179" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-8" decimals="-3" id="f-180" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-181"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-182"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-183" unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-184" unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-7" decimals="INF" id="f-185" unitRef="shares">39981422</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-8" decimals="INF" id="f-186" unitRef="shares">39541173</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-187" unitRef="shares">39611422</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-188" unitRef="shares">39171173</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-7" decimals="-3" id="f-189" unitRef="usd">382000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-8" decimals="-3" id="f-190" unitRef="usd">380000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-7" decimals="-3" id="f-191" unitRef="usd">599206000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-8" decimals="-3" id="f-192" unitRef="usd">586879000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-193" unitRef="usd">-210855000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-8" decimals="-3" id="f-194" unitRef="usd">-158413000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares contextRef="c-7" decimals="INF" id="f-195" unitRef="shares">370000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-8" decimals="INF" id="f-196" unitRef="shares">370000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-7" decimals="-3" id="f-197" unitRef="usd">5714000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-8" decimals="-3" id="f-198" unitRef="usd">5714000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-3" id="f-199" unitRef="usd">-4723000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-8" decimals="-3" id="f-200" unitRef="usd">1357000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-201" unitRef="usd">378296000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-202" unitRef="usd">424489000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="-3" id="f-203" unitRef="usd">532637000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-8" decimals="-3" id="f-204" unitRef="usd">552751000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-205" unitRef="shares">38448536</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-206" unitRef="usd">374000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-207" unitRef="usd">561871000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-208" unitRef="usd">-100318000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-209" unitRef="usd">-1341000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-13"
      decimals="INF"
      id="f-210"
      unitRef="shares">370000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-211" unitRef="usd">-5714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-212" unitRef="usd">454872000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-213" unitRef="usd">-31548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-214" unitRef="usd">-31548000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-16"
      decimals="INF"
      id="f-215"
      unitRef="shares">123536</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-16" decimals="-3" id="f-216" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-17" decimals="-3" id="f-217" unitRef="usd">1929000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-3" id="f-218" unitRef="usd">1930000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-18"
      decimals="INF"
      id="f-219"
      unitRef="shares">184685</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-19" decimals="-3" id="f-220" unitRef="usd">-223000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-20" decimals="-3" id="f-221" unitRef="usd">-223000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-16"
      decimals="INF"
      id="f-222"
      unitRef="shares">164194</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-16" decimals="-3" id="f-223" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-17" decimals="-3" id="f-224" unitRef="usd">1305000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-5" decimals="-3" id="f-225" unitRef="usd">1307000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-17" decimals="-3" id="f-226" unitRef="usd">8625000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-227" unitRef="usd">8625000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-21" decimals="-3" id="f-228" unitRef="usd">4494000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-229" unitRef="usd">4494000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-22"
      decimals="INF"
      id="f-230"
      unitRef="shares">38920951</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-231" unitRef="usd">377000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-232" unitRef="usd">573507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-233" unitRef="usd">-131866000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-234" unitRef="usd">3153000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-26"
      decimals="INF"
      id="f-235"
      unitRef="shares">370000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-236" unitRef="usd">-5714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-237" unitRef="usd">439457000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-3" id="f-238" unitRef="usd">-26547000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-239" unitRef="usd">-26547000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-29"
      decimals="INF"
      id="f-240"
      unitRef="shares">162721</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-29" decimals="-3" id="f-241" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-30" decimals="-3" id="f-242" unitRef="usd">2706000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-4" decimals="-3" id="f-243" unitRef="usd">2707000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-31"
      decimals="INF"
      id="f-244"
      unitRef="shares">299544</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-32" decimals="-3" id="f-245" unitRef="usd">-1900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-33" decimals="-3" id="f-246" unitRef="usd">-1900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-29"
      decimals="INF"
      id="f-247"
      unitRef="shares">59371</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-29"
      decimals="INF"
      id="f-248"
      unitRef="shares">98586</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-29" decimals="-3" id="f-249" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-30" decimals="-3" id="f-250" unitRef="usd">1874000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-4" decimals="-3" id="f-251" unitRef="usd">1876000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-30" decimals="-3" id="f-252" unitRef="usd">10692000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-4" decimals="-3" id="f-253" unitRef="usd">10692000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-34" decimals="-3" id="f-254" unitRef="usd">-1796000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-255" unitRef="usd">-1796000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-35"
      decimals="INF"
      id="f-256"
      unitRef="shares">39541173</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-257" unitRef="usd">380000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-258" unitRef="usd">586879000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-259" unitRef="usd">-158413000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-260" unitRef="usd">1357000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-39"
      decimals="INF"
      id="f-261"
      unitRef="shares">370000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-262" unitRef="usd">-5714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-263" unitRef="usd">424489000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">-52442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-265" unitRef="usd">-52442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">-52442000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-40"
      decimals="INF"
      id="f-267"
      unitRef="shares">21617</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-40" decimals="-3" id="f-268" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-41" decimals="-3" id="f-269" unitRef="usd">155000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">156000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-42"
      decimals="INF"
      id="f-271"
      unitRef="shares">239028</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-43" decimals="-3" id="f-272" unitRef="usd">-720000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-44" decimals="-3" id="f-273" unitRef="usd">-720000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-40"
      decimals="INF"
      id="f-274"
      unitRef="shares">29826</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-41" decimals="-3" id="f-275" unitRef="usd">-312000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">-312000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-40"
      decimals="INF"
      id="f-277"
      unitRef="shares">149778</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-40" decimals="-3" id="f-278" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-41" decimals="-3" id="f-279" unitRef="usd">2046000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">2047000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-41" decimals="-3" id="f-281" unitRef="usd">11158000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">11158000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-45" decimals="-3" id="f-283" unitRef="usd">-6080000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">-6080000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-46"
      decimals="INF"
      id="f-285"
      unitRef="shares">39981422</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-286" unitRef="usd">382000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-287" unitRef="usd">599206000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-288" unitRef="usd">-210855000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-289" unitRef="usd">-4723000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-50"
      decimals="INF"
      id="f-290"
      unitRef="shares">370000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-291" unitRef="usd">-5714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-292" unitRef="usd">378296000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">-52442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-294" unitRef="usd">-52442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-295" unitRef="usd">-26547000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-296" unitRef="usd">-31548000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">30873000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-298" unitRef="usd">29349000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-299" unitRef="usd">25916000</us-gaap:DepreciationAndAmortization>
    <ango:NoncashLeaseExpense contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">2484000</ango:NoncashLeaseExpense>
    <ango:NoncashLeaseExpense contextRef="c-4" decimals="-3" id="f-301" unitRef="usd">2439000</ango:NoncashLeaseExpense>
    <ango:NoncashLeaseExpense contextRef="c-5" decimals="-3" id="f-302" unitRef="usd">2456000</ango:NoncashLeaseExpense>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">14549000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-4" decimals="-3" id="f-304" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-5" decimals="-3" id="f-305" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">11158000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-4" decimals="-3" id="f-307" unitRef="usd">10692000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-308" unitRef="usd">8625000</us-gaap:ShareBasedCompensation>
    <ango:ChangeInFairValueOfContingentConsideration contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">2320000</ango:ChangeInFairValueOfContingentConsideration>
    <ango:ChangeInFairValueOfContingentConsideration contextRef="c-4" decimals="-3" id="f-310" unitRef="usd">1212000</ango:ChangeInFairValueOfContingentConsideration>
    <ango:ChangeInFairValueOfContingentConsideration contextRef="c-5" decimals="-3" id="f-311" unitRef="usd">89000</ango:ChangeInFairValueOfContingentConsideration>
    <ango:DeferredIncomeTaxRelatedToOperatingActivity contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">-2311000</ango:DeferredIncomeTaxRelatedToOperatingActivity>
    <ango:DeferredIncomeTaxRelatedToOperatingActivity contextRef="c-4" decimals="-3" id="f-313" unitRef="usd">-3708000</ango:DeferredIncomeTaxRelatedToOperatingActivity>
    <ango:DeferredIncomeTaxRelatedToOperatingActivity contextRef="c-5" decimals="-3" id="f-314" unitRef="usd">-4805000</ango:DeferredIncomeTaxRelatedToOperatingActivity>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">695000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-4" decimals="-3" id="f-316" unitRef="usd">118000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-5" decimals="-3" id="f-317" unitRef="usd">207000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">291000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-4" decimals="-3" id="f-319" unitRef="usd">391000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-5" decimals="-3" id="f-320" unitRef="usd">14228000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">513000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-4" decimals="-3" id="f-322" unitRef="usd">93000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-5" decimals="-3" id="f-323" unitRef="usd">147000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">1299000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-4" decimals="-3" id="f-325" unitRef="usd">17151000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-5" decimals="-3" id="f-326" unitRef="usd">4162000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">8198000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-4" decimals="-3" id="f-328" unitRef="usd">2796000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-5" decimals="-3" id="f-329" unitRef="usd">-11539000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">-332000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-4" decimals="-3" id="f-331" unitRef="usd">5012000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-332" unitRef="usd">3181000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">2139000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-4" decimals="-3" id="f-334" unitRef="usd">3912000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-5" decimals="-3" id="f-335" unitRef="usd">4876000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">78000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-4" decimals="-3" id="f-337" unitRef="usd">-7194000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-338" unitRef="usd">24093000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">3812000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-340" unitRef="usd">4297000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-341" unitRef="usd">5187000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <ango:IncreaseInPlacementAndEvaluationUnits contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">5394000</ango:IncreaseInPlacementAndEvaluationUnits>
    <ango:IncreaseInPlacementAndEvaluationUnits contextRef="c-4" decimals="-3" id="f-343" unitRef="usd">11410000</ango:IncreaseInPlacementAndEvaluationUnits>
    <ango:IncreaseInPlacementAndEvaluationUnits contextRef="c-5" decimals="-3" id="f-344" unitRef="usd">8524000</ango:IncreaseInPlacementAndEvaluationUnits>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-345" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired contextRef="c-4" decimals="-3" id="f-346" unitRef="usd">3600000</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired contextRef="c-5" decimals="-3" id="f-347" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <ango:PaymentsToAcquireIntangibleAssetsNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">540000</ango:PaymentsToAcquireIntangibleAssetsNetOfCashAcquired>
    <ango:PaymentsToAcquireIntangibleAssetsNetOfCashAcquired contextRef="c-4" decimals="-3" id="f-349" unitRef="usd">0</ango:PaymentsToAcquireIntangibleAssetsNetOfCashAcquired>
    <ango:PaymentsToAcquireIntangibleAssetsNetOfCashAcquired contextRef="c-5" decimals="-3" id="f-350" unitRef="usd">0</ango:PaymentsToAcquireIntangibleAssetsNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">-9746000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-4" decimals="-3" id="f-352" unitRef="usd">-19307000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-353" unitRef="usd">-13711000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c-1" decimals="-3" id="f-354" unitRef="usd">70000000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c-4" decimals="-3" id="f-355" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c-5" decimals="-3" id="f-356" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-357" unitRef="usd">45000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-4" decimals="-3" id="f-358" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-5" decimals="-3" id="f-359" unitRef="usd">20000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-1" decimals="-3" id="f-360" unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-4" decimals="-3" id="f-361" unitRef="usd">5000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-5" decimals="-3" id="f-362" unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">751000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-4" decimals="-3" id="f-364" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-5" decimals="-3" id="f-365" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <ango:ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">1171000</ango:ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised>
    <ango:ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised contextRef="c-4" decimals="-3" id="f-367" unitRef="usd">2683000</ango:ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised>
    <ango:ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised contextRef="c-5" decimals="-3" id="f-368" unitRef="usd">3014000</ango:ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-369" unitRef="usd">25420000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-4" decimals="-3" id="f-370" unitRef="usd">7683000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-371" unitRef="usd">-16986000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">43000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-373" unitRef="usd">-518000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-374" unitRef="usd">330000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-375" unitRef="usd">15795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-4" decimals="-3" id="f-376" unitRef="usd">-19336000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-377" unitRef="usd">-6274000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-378" unitRef="usd">28825000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-3" id="f-379" unitRef="usd">48161000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-14" decimals="-3" id="f-380" unitRef="usd">54435000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-381" unitRef="usd">44620000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-382" unitRef="usd">28825000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-3" id="f-383" unitRef="usd">48161000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="c-1" decimals="-3" id="f-384" unitRef="usd">124000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="c-4" decimals="-3" id="f-385" unitRef="usd">14000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="c-5" decimals="-3" id="f-386" unitRef="usd">-139000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:InterestPaid contextRef="c-1" decimals="-3" id="f-387" unitRef="usd">2577000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="c-4" decimals="-3" id="f-388" unitRef="usd">562000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="c-5" decimals="-3" id="f-389" unitRef="usd">731000</us-gaap:InterestPaid>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-390" unitRef="usd">342000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-4" decimals="-3" id="f-391" unitRef="usd">329000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-5" decimals="-3" id="f-392" unitRef="usd">313000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-393">BASIS OF PRESENTATION, BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, (collectively, the "Company", "we", "our", or "us").  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving the quality of life for patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Principles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements and accompanying notes have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of AngioDynamics and its subsidiaries (all of which are wholly owned).  All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all unrestricted highly liquid investments with an initial maturity of less than three months at the date of purchase to be cash equivalents. The Company maintains cash and cash equivalent balances with financial institutions in the United States in excess of amounts insured by the Federal Deposit Insurance Corporation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of the Company's cash and cash equivalents, accounts receivable, accounts payable and long-term debt approximates fair value due to the short-term nature or market interest rates of these items. The Company bases the fair value of short-term investments on quoted market prices or other relevant information generated by market transactions involving identical or comparable assets. The Company measures and records derivative financial instruments at fair value. See Note 5, "Fair Value of Financial Instruments" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K, for further discussion of financial instruments that are carried at fair value on a recurring and nonrecurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, principally trade receivables, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for estimated sales returns and doubtful accounts. The Company performs ongoing credit evaluations of customers and adjusts credit limits based upon payment history and the customer&#x2019;s current creditworthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers, and a provision for estimated credit losses is maintained based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they are determined to be uncollectible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inventories are stated at the lower of cost or net realizable value based on the first-in, first-out cost method and consist of raw materials, work in process and finished goods.  The standard cost of finished goods and work-in-process inventory is composed of material, labor and manufacturing overhead, which approximates actual cost. In addition to stating inventory at the &lt;/span&gt;&lt;/div&gt;lower of cost or net realizable value, we also evaluate inventory each reporting period for excess quantities and obsolescence, establishing reserves when necessary based upon historical experience, assessment of economic conditions and expected demand. Once recorded, these reserves are considered permanent adjustments to the carrying value of inventory. An increase to inventory reserves results in a corresponding increase in cost of revenue. Inventories are written off against the reserve when they are physically disposed.&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets.  Placement and evaluation units represent capital equipment placed at customer locations under placement or evaluation agreements for which depreciation expense is included in cost of sales on the Consolidated Statements of Operations.  Refer below for useful lives by category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated useful lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 to 39 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 8 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Placement and evaluation units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates property, plant and equipment for impairment periodically to determine if changes in circumstances or the occurrence of events suggest the carrying value of the asset or asset group may not be recoverable. Expenditures for repairs and maintenance are charged to expense as incurred. Renewals and betterments are capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets other than goodwill, indefinite lived intangible assets and in process research and development ("IP R&amp;amp;D") are amortized over their estimated useful lives, which range between &lt;span style="-sec-ix-hidden:f-412"&gt;two&lt;/span&gt; to eighteen years, on a straight-line basis over the expected period of benefit.  The Company periodically reviews the estimated useful lives of intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Such conditions could include significant adverse changes in the business climate, current-period operating or cash flow losses, significant declines in forecasted operations, or a current expectation that an asset group will be disposed of before the end of its useful life.  When testing for impairment of definite-lived intangible assets held for use, the Company groups assets at the lowest level for which cash flows are separately identifiable.  Prior to the first quarter of fiscal year 2023, the Company managed its operations as one reporting unit.  At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as two operating segments and two reporting units, namely Med Tech and Med Device (see Note 18 "Segments and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K).  The Company operates as two reporting units and two asset groups.  If a triggering event is deemed to exist, the Company performs an undiscounted operating cash flow analysis to determine if an impairment exists.  If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and other intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise.  Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated costs were based on respective fair market values at the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  For goodwill, the impairment test requires a comparison of the estimated fair value of each reporting unit to which the goodwill is assigned to the carrying value of the assets and liabilities of those reporting units. The determination of reporting units also requires management judgment. The Company considers whether a reporting unit exists within a reportable segment based on the availability of discrete financial information. The Company operates as two operating segments with two reporting units and consequently evaluates goodwill for impairment based on an evaluation of the fair value of each reporting unit. If the carrying value of the reporting units exceed the fair value, the carrying value is reduced to its fair value through an adjustment to the goodwill balance, resulting in an impairment charge. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the liability for contingent consideration recorded on the acquisition date for a business combination is based on probability weighted estimated cash flow streams, discounted back to present value using a discount rate determined in accordance with accepted valuation methods and reflective of the risk associated with the estimated cash flow streams. The liability for contingent consideration is remeasured to fair value at each reporting period with changes recorded in earnings until the contingency is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers control of promised goods or services to its customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those goods and services.&#160;See Note 4, &#x201c;Revenue from Contracts with Customers&#x201d; set forth in the Notes to our consolidated financial statements included in this Annual Report on Form 10-K for further discussion on revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs, including salaries, consulting fees, building costs, utilities and administrative expenses that are related to developing new products, enhancing existing products, validating new and enhanced products, managing clinical, regulatory and medical affairs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates income tax expense for each jurisdiction in which it operates. This involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. The Company periodically evaluates deferred tax assets, capital loss carryforwards and tax credit carryforwards to determine their recoverability based primarily on the Company's ability to generate future taxable income and capital gains.  Where it is more-likely-than-not these will not be recovered, the Company estimates a valuation allowance and records a corresponding additional tax expense in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes and measures uncertain tax positions taken or expected to be taken in a tax return utilizing a two-step approach. The Company first determines if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is that the Company measures the tax benefit as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;Stock-Based CompensationStock-based compensation expense reflects the fair value of stock-based awards measured at the grant date and recognized over the relevant service period.  The expense recognized includes the impact of forfeitures as they occur.  The Company estimates the fair value of each stock-based award on the measurement date using either the current market price of the stock, the Black-Scholes option valuation model, or the Monte Carlo Simulation valuation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or restricted stock units, a risk-free interest rate and dividend yield. The Company recognizes stock-based compensation expense related to options, restricted stock units and market based performance stock units on a straight-line basis over the service period of the award, which is generally 4 years for options and restricted stock units and 3 years for market based performance stock units.&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company's foreign subsidiaries is the local currency in which the subsidiary operates. For foreign operations where the local currency is considered to be the functional currency, the Company translates assets and liabilities into U.S. dollars at the exchange rate on the balance sheet date. The Company translates income and expense items at average rates of exchange prevailing during each period. The Company accumulates translation adjustments in accumulated other comprehensive loss, a component of stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Transaction gains or losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in Other income (expense), net in the Consolidated Statements of Operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to market risks, including changes in foreign currency and interest rates. The Company periodically enters into certain derivative financial instruments to hedge the underlying economic exposure. &lt;/span&gt;&lt;/div&gt;Derivative instruments are presented in the consolidated financial statements at their fair value. Changes in the fair value of derivative financial instruments are either recognized periodically in income or in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss) depending on whether the derivative financial instrument qualifies for hedge accounting and, if so, whether it qualifies as a fair value or cash flow hedge. Generally, the changes in the fair value of derivatives accounted for as fair value hedges are recorded in income along with the portions of the changes in the fair value of hedged items that relate to the hedged risks. Changes in the fair value of derivatives accounted for as cash flow hedges, to the extent they are effective as hedges, are recorded in accumulated other comprehensive income (loss).  There were no derivative instruments held by the Company as of May 31, 2023 and 2022.&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to various legal proceedings that arise in the ordinary course of business, including patent infringement and product liability matters. The Company records accruals for contingencies when it is probable the liability has been incurred and the amount can be reasonably estimated.  Legal fees are expensed as incurred. Insurance recoveries related to potential claims are recognized up to the amount of the recorded liability when coverage is confirmed and the estimated recoveries are probable of payment. These recoveries are not netted against the related liabilities for financial statement presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-394">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, (collectively, the "Company", "we", "our", or "us").  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving the quality of life for patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Principles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements and accompanying notes have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of AngioDynamics and its subsidiaries (all of which are wholly owned).  All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-395">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all unrestricted highly liquid investments with an initial maturity of less than three months at the date of purchase to be cash equivalents. The Company maintains cash and cash equivalent balances with financial institutions in the United States in excess of amounts insured by the Federal Deposit Insurance Corporation.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <ango:ShortTermInvestmentsMaturityPeriod contextRef="c-1" id="f-396">less than three months</ango:ShortTermInvestmentsMaturityPeriod>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-397">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of the Company's cash and cash equivalents, accounts receivable, accounts payable and long-term debt approximates fair value due to the short-term nature or market interest rates of these items. The Company bases the fair value of short-term investments on quoted market prices or other relevant information generated by market transactions involving identical or comparable assets. The Company measures and records derivative financial instruments at fair value. See Note 5, "Fair Value of Financial Instruments" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K, for further discussion of financial instruments that are carried at fair value on a recurring and nonrecurring basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c-1" id="f-398">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, principally trade receivables, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for estimated sales returns and doubtful accounts. The Company performs ongoing credit evaluations of customers and adjusts credit limits based upon payment history and the customer&#x2019;s current creditworthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers, and a provision for estimated credit losses is maintained based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they are determined to be uncollectible.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <ango:AccountsReceivableDuePeriod contextRef="c-51" id="f-399">P30D</ango:AccountsReceivableDuePeriod>
    <ango:AccountsReceivableDuePeriod contextRef="c-52" id="f-400">P90D</ango:AccountsReceivableDuePeriod>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-401">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inventories are stated at the lower of cost or net realizable value based on the first-in, first-out cost method and consist of raw materials, work in process and finished goods.  The standard cost of finished goods and work-in-process inventory is composed of material, labor and manufacturing overhead, which approximates actual cost. In addition to stating inventory at the &lt;/span&gt;&lt;/div&gt;lower of cost or net realizable value, we also evaluate inventory each reporting period for excess quantities and obsolescence, establishing reserves when necessary based upon historical experience, assessment of economic conditions and expected demand. Once recorded, these reserves are considered permanent adjustments to the carrying value of inventory. An increase to inventory reserves results in a corresponding increase in cost of revenue. Inventories are written off against the reserve when they are physically disposed.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-402">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets.  Placement and evaluation units represent capital equipment placed at customer locations under placement or evaluation agreements for which depreciation expense is included in cost of sales on the Consolidated Statements of Operations.  Refer below for useful lives by category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated useful lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 to 39 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 8 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Placement and evaluation units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates property, plant and equipment for impairment periodically to determine if changes in circumstances or the occurrence of events suggest the carrying value of the asset or asset group may not be recoverable. Expenditures for repairs and maintenance are charged to expense as incurred. Renewals and betterments are capitalized.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-403">Refer below for useful lives by category:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated useful lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 to 39 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 8 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Placement and evaluation units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Placement and evaluation units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-53" id="f-404">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-54" id="f-405">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-55" id="f-406">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-56" id="f-407">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-57" id="f-408">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-58" id="f-409">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-59" id="f-410">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-411">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets other than goodwill, indefinite lived intangible assets and in process research and development ("IP R&amp;amp;D") are amortized over their estimated useful lives, which range between &lt;span style="-sec-ix-hidden:f-412"&gt;two&lt;/span&gt; to eighteen years, on a straight-line basis over the expected period of benefit.  The Company periodically reviews the estimated useful lives of intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Such conditions could include significant adverse changes in the business climate, current-period operating or cash flow losses, significant declines in forecasted operations, or a current expectation that an asset group will be disposed of before the end of its useful life.  When testing for impairment of definite-lived intangible assets held for use, the Company groups assets at the lowest level for which cash flows are separately identifiable.  Prior to the first quarter of fiscal year 2023, the Company managed its operations as one reporting unit.  At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as two operating segments and two reporting units, namely Med Tech and Med Device (see Note 18 "Segments and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K).  The Company operates as two reporting units and two asset groups.  If a triggering event is deemed to exist, the Company performs an undiscounted operating cash flow analysis to determine if an impairment exists.  If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and other intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise.  Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated costs were based on respective fair market values at the date of acquisition.&lt;/span&gt;&lt;/div&gt;  For goodwill, the impairment test requires a comparison of the estimated fair value of each reporting unit to which the goodwill is assigned to the carrying value of the assets and liabilities of those reporting units. The determination of reporting units also requires management judgment. The Company considers whether a reporting unit exists within a reportable segment based on the availability of discrete financial information. The Company operates as two operating segments with two reporting units and consequently evaluates goodwill for impairment based on an evaluation of the fair value of each reporting unit. If the carrying value of the reporting units exceed the fair value, the carrying value is reduced to its fair value through an adjustment to the goodwill balance, resulting in an impairment charge.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-52" id="f-413">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-414"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportingUnits
      contextRef="c-1"
      decimals="INF"
      id="f-415"
      unitRef="segment">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-416"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportingUnits
      contextRef="c-1"
      decimals="INF"
      id="f-417"
      unitRef="segment">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-60" decimals="-5" id="f-418" unitRef="usd">14500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-419">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the liability for contingent consideration recorded on the acquisition date for a business combination is based on probability weighted estimated cash flow streams, discounted back to present value using a discount rate determined in accordance with accepted valuation methods and reflective of the risk associated with the estimated cash flow streams. The liability for contingent consideration is remeasured to fair value at each reporting period with changes recorded in earnings until the contingency is resolved.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-420">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers control of promised goods or services to its customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those goods and services.&#160;See Note 4, &#x201c;Revenue from Contracts with Customers&#x201d; set forth in the Notes to our consolidated financial statements included in this Annual Report on Form 10-K for further discussion on revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-421">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs, including salaries, consulting fees, building costs, utilities and administrative expenses that are related to developing new products, enhancing existing products, validating new and enhanced products, managing clinical, regulatory and medical affairs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-422">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates income tax expense for each jurisdiction in which it operates. This involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. The Company periodically evaluates deferred tax assets, capital loss carryforwards and tax credit carryforwards to determine their recoverability based primarily on the Company's ability to generate future taxable income and capital gains.  Where it is more-likely-than-not these will not be recovered, the Company estimates a valuation allowance and records a corresponding additional tax expense in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes and measures uncertain tax positions taken or expected to be taken in a tax return utilizing a two-step approach. The Company first determines if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is that the Company measures the tax benefit as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-423">Stock-Based CompensationStock-based compensation expense reflects the fair value of stock-based awards measured at the grant date and recognized over the relevant service period.  The expense recognized includes the impact of forfeitures as they occur.  The Company estimates the fair value of each stock-based award on the measurement date using either the current market price of the stock, the Black-Scholes option valuation model, or the Monte Carlo Simulation valuation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or restricted stock units, a risk-free interest rate and dividend yield. The Company recognizes stock-based compensation expense related to options, restricted stock units and market based performance stock units on a straight-line basis over the service period of the award, which is generally 4 years for options and restricted stock units and 3 years for market based performance stock units.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-61" id="f-424">P4Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-62" id="f-425">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-426">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company's foreign subsidiaries is the local currency in which the subsidiary operates. For foreign operations where the local currency is considered to be the functional currency, the Company translates assets and liabilities into U.S. dollars at the exchange rate on the balance sheet date. The Company translates income and expense items at average rates of exchange prevailing during each period. The Company accumulates translation adjustments in accumulated other comprehensive loss, a component of stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Transaction gains or losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in Other income (expense), net in the Consolidated Statements of Operations as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-427">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to market risks, including changes in foreign currency and interest rates. The Company periodically enters into certain derivative financial instruments to hedge the underlying economic exposure. &lt;/span&gt;&lt;/div&gt;Derivative instruments are presented in the consolidated financial statements at their fair value. Changes in the fair value of derivative financial instruments are either recognized periodically in income or in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss) depending on whether the derivative financial instrument qualifies for hedge accounting and, if so, whether it qualifies as a fair value or cash flow hedge. Generally, the changes in the fair value of derivatives accounted for as fair value hedges are recorded in income along with the portions of the changes in the fair value of hedged items that relate to the hedged risks. Changes in the fair value of derivatives accounted for as cash flow hedges, to the extent they are effective as hedges, are recorded in accumulated other comprehensive income (loss).  There were no derivative instruments held by the Company as of May 31, 2023 and 2022.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to various legal proceedings that arise in the ordinary course of business, including patent infringement and product liability matters. The Company records accruals for contingencies when it is probable the liability has been incurred and the amount can be reasonably estimated.  Legal fees are expensed as incurred. Insurance recoveries related to potential claims are recognized up to the amount of the recorded liability when coverage is confirmed and the estimated recoveries are probable of payment. These recoveries are not netted against the related liabilities for financial statement presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-429">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements - Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect on the Consolidated Financial Statements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;ASU 2021-10,&#160; Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The Company adopted the new standard in the first quarter of fiscal year 2023 and it did not have an impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect on the Consolidated Financial Statements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASU 2021-08,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;This ASU&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The Company plans to adopt the new standard in the first quarter of fiscal year 2024 and does not expect there to be a material impact to the consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="c-1" id="f-430">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements - Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect on the Consolidated Financial Statements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;ASU 2021-10,&#160; Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The Company adopted the new standard in the first quarter of fiscal year 2023 and it did not have an impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect on the Consolidated Financial Statements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASU 2021-08,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;This ASU&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The Company plans to adopt the new standard in the first quarter of fiscal year 2024 and does not expect there to be a material impact to the consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-431">ACQUISITIONSCamaro Support Catheter Asset AcquisitionOn July 27, 2021, the Company acquired the Camaro support catheter (rebranded as Syntrax) from QX Medical, LLC for an aggregate purchase price of $4.0&#160;million, which included an upfront payment of $3.6&#160;million and $0.4&#160;million in purchase price holdbacks, along with $1.0&#160;million of potential future contingent consideration related to revenue milestones. This acquisition supports the Auryon product family and the Company's strategic plan.  The Company accounted for this acquisition as an asset purchase.  The Company recorded the amount paid at closing as inventory and fixed assets of $0.1&#160;million and an intangible asset product technology of $3.9&#160;million.  The intangible asset will be amortized over 15 years.  The contingent consideration is comprised of revenue milestones and will be accounted for when the contingency is resolved or becomes probable and reasonably estimable.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-63" decimals="-5" id="f-432" unitRef="usd">4000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:ContractWithCustomerLiability contextRef="c-64" decimals="-5" id="f-433" unitRef="usd">3600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-64" decimals="-5" id="f-434" unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ango:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-64" decimals="-5" id="f-435" unitRef="usd">1000000</ango:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <ango:AssetAcquisitionInventoryAndFixedAssets contextRef="c-63" decimals="-5" id="f-436" unitRef="usd">100000</ango:AssetAcquisitionInventoryAndFixedAssets>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-65" decimals="-5" id="f-437" unitRef="usd">3900000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-63" id="f-438">P15Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-439">ASSETS HELD FOR SALE &lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of fiscal year 2023, the Company was in discussions with Merit to sell the dialysis product portfolio and BioSentry tract sealant system biopsy businesses.  This qualified for held for sale accounting and the Company determined that the fair value of the net assets being sold exceeded the carrying value as of May&#160;31, 2023.  The transaction was finalized on June 8, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the major classes of assets held for sale:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total non-current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="c-1" id="f-440">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the major classes of assets held for sale:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total non-current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent contextRef="c-7" decimals="-3" id="f-441" unitRef="usd">4154000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-442" unitRef="usd">2000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-66" decimals="-3" id="f-443" unitRef="usd">6154000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent contextRef="c-7" decimals="-3" id="f-444" unitRef="usd">44000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent contextRef="c-7" decimals="-3" id="f-445" unitRef="usd">17629000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent contextRef="c-7" decimals="-3" id="f-446" unitRef="usd">25980000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent contextRef="c-66" decimals="-3" id="f-447" unitRef="usd">43653000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-448">REVENUE FROM CONTRACTS WITH CUSTOMERS&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one primary revenue stream which is the sales of its products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize net sales by Med Tech, Med Device and by geography: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Tech&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Device&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Tech&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Device&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings.  The Company's products are generally used in minimally invasive, image-guided procedures.  Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use.  The Company sells its products to its distributors and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts and Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements.  The Company&#x2019;s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights.  As part of its assessment of each contract, the Company evaluates certain factors including the customer&#x2019;s ability to pay (or credit risk).  For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transaction Price and Allocation to Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction prices of products are typically based on contracted rates.  Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer, net of any variable consideration as described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation.  Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation.  The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company&#x2019;s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company&#x2019;s manufacturing site or delivery to the customer&#x2019;s named location, based on the shipping terms of a contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company typically invoices customers upon satisfaction of identified performance obligations.  As the Company&#x2019;s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company enters into agreements to place placement and evaluation units (&#x201c;units&#x201d;) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer&#x2019;s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units.  In these arrangements, revenue recognized for the sale of the disposables is not allocated between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contracts between the Company and its customers.  These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates and Allowances:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides certain customers with rebates and allowances that are explicitly stated in the Company&#x2019;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.  The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets.  These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes.  The Company is also required to pay administrative fees to group purchasing organizations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product Returns: The Company generally offers customers a limited right of return.  Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge.  To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date.  The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized.  The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls.  During the year ended May&#160;31, 2023, such product returns were not material.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Balances with Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A receivable is generally recognized in the period the Company ships the product.  Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition.  Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers.  In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company&#x2019;s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the Company&#x2019;s receivables, contract assets and contract liabilities with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended May&#160;31, 2023 and 2022, the Company had additions to contract liabilities of $0.7 million and $2.2&#160;million, respectively.  This was offset by $0.7 million and $2.1&#160;million in revenue that was recognized during the years ended May&#160;31, 2023 and 2022, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Costs to Obtain or Fulfill a Customer Contract&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs.  The Company&#x2019;s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time.  However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products.  Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer.  Amounts charged to customers for shipping are recorded in net sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-449">REVENUE FROM CONTRACTS WITH CUSTOMERS&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts and Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements.  The Company&#x2019;s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights.  As part of its assessment of each contract, the Company evaluates certain factors including the customer&#x2019;s ability to pay (or credit risk).  For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transaction Price and Allocation to Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction prices of products are typically based on contracted rates.  Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer, net of any variable consideration as described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation.  Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation.  The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company&#x2019;s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company&#x2019;s manufacturing site or delivery to the customer&#x2019;s named location, based on the shipping terms of a contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company typically invoices customers upon satisfaction of identified performance obligations.  As the Company&#x2019;s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company enters into agreements to place placement and evaluation units (&#x201c;units&#x201d;) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer&#x2019;s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units.  In these arrangements, revenue recognized for the sale of the disposables is not allocated between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contracts between the Company and its customers.  These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates and Allowances:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides certain customers with rebates and allowances that are explicitly stated in the Company&#x2019;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.  The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets.  These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes.  The Company is also required to pay administrative fees to group purchasing organizations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product Returns: The Company generally offers customers a limited right of return.  Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge.  To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date.  The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized.  The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls.  During the year ended May&#160;31, 2023, such product returns were not material.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Balances with Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A receivable is generally recognized in the period the Company ships the product.  Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition.  Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers.  In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company&#x2019;s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Costs to Obtain or Fulfill a Customer Contract&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs.  The Company&#x2019;s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time.  However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products.  Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer.  Amounts charged to customers for shipping are recorded in net sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-450">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize net sales by Med Tech, Med Device and by geography: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Tech&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Device&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Tech&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Device&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-67" decimals="-3" id="f-451" unitRef="usd">84332000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-68" decimals="-3" id="f-452" unitRef="usd">12355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-69" decimals="-3" id="f-453" unitRef="usd">96687000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-70" decimals="-3" id="f-454" unitRef="usd">69939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-71" decimals="-3" id="f-455" unitRef="usd">8778000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-72" decimals="-3" id="f-456" unitRef="usd">78717000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-73" decimals="-3" id="f-457" unitRef="usd">198381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-74" decimals="-3" id="f-458" unitRef="usd">43684000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-60" decimals="-3" id="f-459" unitRef="usd">242065000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-75" decimals="-3" id="f-460" unitRef="usd">196024000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-76" decimals="-3" id="f-461" unitRef="usd">41478000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-77" decimals="-3" id="f-462" unitRef="usd">237502000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-78" decimals="-3" id="f-463" unitRef="usd">282713000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-79" decimals="-3" id="f-464" unitRef="usd">56039000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-465" unitRef="usd">338752000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="-3" id="f-466" unitRef="usd">265963000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-81" decimals="-3" id="f-467" unitRef="usd">50256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="-3" id="f-468" unitRef="usd">316219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="-3" id="f-469" unitRef="usd">46440000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-83" decimals="-3" id="f-470" unitRef="usd">9291000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-84" decimals="-3" id="f-471" unitRef="usd">55731000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-85" decimals="-3" id="f-472" unitRef="usd">190603000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-86" decimals="-3" id="f-473" unitRef="usd">44676000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-3" id="f-474" unitRef="usd">235279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-88" decimals="-3" id="f-475" unitRef="usd">237043000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-89" decimals="-3" id="f-476" unitRef="usd">53967000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-477" unitRef="usd">291010000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ango:RevenuePerformanceObligationPaymentTerm contextRef="c-51" id="f-478">P30D</ango:RevenuePerformanceObligationPaymentTerm>
    <ango:RevenuePerformanceObligationPaymentTerm contextRef="c-52" id="f-479">P90D</ango:RevenuePerformanceObligationPaymentTerm>
    <ango:ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval contextRef="c-1" id="f-480">P30D</ango:ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval>
    <ango:ContractwithCustomerRightofReturnRestockingCharge contextRef="c-1" decimals="INF" id="f-481" unitRef="number">0.20</ango:ContractwithCustomerRightofReturnRestockingCharge>
    <ango:ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn contextRef="c-1" id="f-482">P12M</ango:ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-483">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the Company&#x2019;s receivables, contract assets and contract liabilities with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-7" decimals="-3" id="f-484" unitRef="usd">52826000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-8" decimals="-3" id="f-485" unitRef="usd">52304000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-7" decimals="-3" id="f-486" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-8" decimals="-3" id="f-487" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability contextRef="c-7" decimals="-3" id="f-488" unitRef="usd">499000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-8" decimals="-3" id="f-489" unitRef="usd">526000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination contextRef="c-1" decimals="-5" id="f-490" unitRef="usd">700000</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination contextRef="c-4" decimals="-5" id="f-491" unitRef="usd">2200000</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <ango:CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod contextRef="c-1" decimals="-5" id="f-492" unitRef="usd">700000</ango:CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod>
    <ango:CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod contextRef="c-4" decimals="-5" id="f-493" unitRef="usd">2100000</ango:CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-494">FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value.  The three levels of the hierarchy are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Inputs to the valuation methodology are unobservable inputs based on management&#x2019;s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to their immediate or short-term maturities.  The recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements using inputs considered as:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value at May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration for acquisition earn outs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements using inputs considered as:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value at May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration for acquisition earn outs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level 1, 2 and 3 for the years ended May&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the changes in fair value components of Level 3 instruments:    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financial&#160;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;Measurements Using Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in present value of contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency gain from remeasurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financial&#160;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;Measurements Using Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency loss from remeasurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Liability for Acquisition Earn Outs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements which is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of May&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.946%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue based payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 - 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At May&#160;31, 2023, the amount of undiscounted future contingent consideration that the Company expects to pay as a result of all completed acquisitions is approximately $20.0 million.  The milestones, including revenue projections and technical milestones, associated with the contingent consideration must be reached in future periods ranging from fiscal years 2024 to 2029 in order for the associated consideration to be paid. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Items Measured at Fair Value on a Nonrecurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a goodwill impairment charge of $14.5 million for the year ended May&#160;31, 2023 to write down the carrying value of the Med Device reporting unit to fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of fiscal year 2021, the Company made the decision to abandon the OARtrac product technology and trademark.  This resulted in an impairment charge of $14.0&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no other items measured at fair value on a nonrecurring basis during the year ended May&#160;31, 2023 or May&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-495">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements using inputs considered as:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value at May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration for acquisition earn outs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements using inputs considered as:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value at May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration for acquisition earn outs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-90" decimals="-3" id="f-496" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-91" decimals="-3" id="f-497" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-92" decimals="-3" id="f-498" unitRef="usd">19296000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-93" decimals="-3" id="f-499" unitRef="usd">19296000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-90" decimals="-3" id="f-500" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-91" decimals="-3" id="f-501" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-92" decimals="-3" id="f-502" unitRef="usd">19296000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-93" decimals="-3" id="f-503" unitRef="usd">19296000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-94" decimals="-3" id="f-504" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-95" decimals="-3" id="f-505" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-96" decimals="-3" id="f-506" unitRef="usd">16948000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-97" decimals="-3" id="f-507" unitRef="usd">16948000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-94" decimals="-3" id="f-508" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-95" decimals="-3" id="f-509" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-96" decimals="-3" id="f-510" unitRef="usd">16948000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-97" decimals="-3" id="f-511" unitRef="usd">16948000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-512">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the changes in fair value components of Level 3 instruments:    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financial&#160;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;Measurements Using Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in present value of contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency gain from remeasurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financial&#160;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;Measurements Using Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency loss from remeasurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-8" decimals="-3" id="f-513" unitRef="usd">16948000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-1" decimals="-3" id="f-514" unitRef="usd">2320000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <ango:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement contextRef="c-1" decimals="-3" id="f-515" unitRef="usd">28000</ango:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-7" decimals="-3" id="f-516" unitRef="usd">19296000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-27" decimals="-3" id="f-517" unitRef="usd">15741000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <ango:ChangeInFairValueOfContingentConsideration contextRef="c-4" decimals="-3" id="f-518" unitRef="usd">1212000</ango:ChangeInFairValueOfContingentConsideration>
    <ango:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement contextRef="c-4" decimals="-3" id="f-519" unitRef="usd">-5000</ango:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-8" decimals="-3" id="f-520" unitRef="usd">16948000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-521">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of May&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.946%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue based payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80% - 100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 - 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-98" decimals="-3" id="f-522" unitRef="usd">19296000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-99" decimals="2" id="f-523" unitRef="number">5</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-100" decimals="2" id="f-524" unitRef="number">0.80</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-101" decimals="2" id="f-525" unitRef="number">1</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <ango:UndiscountedContingentConsiderationFairValueFairValueDisclosure contextRef="c-102" decimals="-5" id="f-526" unitRef="usd">20000000</ango:UndiscountedContingentConsiderationFairValueFairValueDisclosure>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-60" decimals="-5" id="f-527" unitRef="usd">14500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:AssetImpairmentCharges contextRef="c-103" decimals="-5" id="f-528" unitRef="usd">14000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-529">INVENTORIES&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method).  Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company periodically reviews inventory for both obsolescence and loss of value.  The Company makes assumptions about the future demand for and market value of the inventory.  Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow moving inventory.  The total inventory reserve at May&#160;31, 2023 and 2022 was $3.1 million and $3.7 million, respectively.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-530">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method).  Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c-7" decimals="-3" id="f-531" unitRef="usd">28679000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c-8" decimals="-3" id="f-532" unitRef="usd">28251000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c-7" decimals="-3" id="f-533" unitRef="usd">6708000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c-8" decimals="-3" id="f-534" unitRef="usd">7186000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c-7" decimals="-3" id="f-535" unitRef="usd">19938000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-8" decimals="-3" id="f-536" unitRef="usd">15955000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c-7" decimals="-3" id="f-537" unitRef="usd">55325000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-8" decimals="-3" id="f-538" unitRef="usd">51392000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves contextRef="c-7" decimals="-5" id="f-539" unitRef="usd">3100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c-8" decimals="-5" id="f-540" unitRef="usd">3700000</us-gaap:InventoryValuationReserves>
    <ango:PrepaidExpensesAndOtherTextBlock contextRef="c-1" id="f-541">PREPAID EXPENSES AND OTHERPrepaid expenses and other consisted of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Retention Tax Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade shows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ango:PrepaidExpensesAndOtherTextBlock>
    <ango:PrepaidExpensesAndOtherTableTextBlock contextRef="c-1" id="f-542">Prepaid expenses and other consisted of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Retention Tax Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade shows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ango:PrepaidExpensesAndOtherTableTextBlock>
    <ango:PrepaidDeposits contextRef="c-7" decimals="-3" id="f-543" unitRef="usd">894000</ango:PrepaidDeposits>
    <ango:PrepaidDeposits contextRef="c-8" decimals="-3" id="f-544" unitRef="usd">2106000</ango:PrepaidDeposits>
    <ango:PrepaidEmployeeTaxCredit contextRef="c-7" decimals="-3" id="f-545" unitRef="usd">0</ango:PrepaidEmployeeTaxCredit>
    <ango:PrepaidEmployeeTaxCredit contextRef="c-8" decimals="-3" id="f-546" unitRef="usd">4194000</ango:PrepaidEmployeeTaxCredit>
    <ango:SoftwareLicenses contextRef="c-7" decimals="-3" id="f-547" unitRef="usd">1501000</ango:SoftwareLicenses>
    <ango:SoftwareLicenses contextRef="c-8" decimals="-3" id="f-548" unitRef="usd">1255000</ango:SoftwareLicenses>
    <ango:PrepaidLicenseeFees contextRef="c-7" decimals="-3" id="f-549" unitRef="usd">217000</ango:PrepaidLicenseeFees>
    <ango:PrepaidLicenseeFees contextRef="c-8" decimals="-3" id="f-550" unitRef="usd">172000</ango:PrepaidLicenseeFees>
    <ango:TradeShows contextRef="c-7" decimals="-3" id="f-551" unitRef="usd">448000</ango:TradeShows>
    <ango:TradeShows contextRef="c-8" decimals="-3" id="f-552" unitRef="usd">328000</ango:TradeShows>
    <us-gaap:PrepaidRent contextRef="c-7" decimals="-3" id="f-553" unitRef="usd">191000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent contextRef="c-8" decimals="-3" id="f-554" unitRef="usd">240000</us-gaap:PrepaidRent>
    <ango:PrepaidIncomeandOtherTaxes contextRef="c-7" decimals="-3" id="f-555" unitRef="usd">264000</ango:PrepaidIncomeandOtherTaxes>
    <ango:PrepaidIncomeandOtherTaxes contextRef="c-8" decimals="-3" id="f-556" unitRef="usd">328000</ango:PrepaidIncomeandOtherTaxes>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-7" decimals="-3" id="f-557" unitRef="usd">1102000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-8" decimals="-3" id="f-558" unitRef="usd">2201000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-559" unitRef="usd">4617000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-8" decimals="-3" id="f-560" unitRef="usd">10824000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-561">PROPERTY, PLANT AND EQUIPMENT, NET&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Placement and evaluation units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation expense for fiscal years 2023, 2022 and 2021 was $11.9 million, $7.6 million and $5.7 million, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-104" decimals="-3" id="f-562" unitRef="usd">29660000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-105" decimals="-3" id="f-563" unitRef="usd">29425000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-106" decimals="-3" id="f-564" unitRef="usd">27435000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-107" decimals="-3" id="f-565" unitRef="usd">27292000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-108" decimals="-3" id="f-566" unitRef="usd">17023000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-109" decimals="-3" id="f-567" unitRef="usd">15453000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-110" decimals="-3" id="f-568" unitRef="usd">26355000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-111" decimals="-3" id="f-569" unitRef="usd">21009000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-112" decimals="-3" id="f-570" unitRef="usd">2444000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-113" decimals="-3" id="f-571" unitRef="usd">2402000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-7" decimals="-3" id="f-572" unitRef="usd">102917000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-8" decimals="-3" id="f-573" unitRef="usd">95581000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-574" unitRef="usd">59026000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-575" unitRef="usd">51069000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <ango:PropertyPlantAndEquipmentExcludingLandAndLandImprovements contextRef="c-7" decimals="-3" id="f-576" unitRef="usd">43891000</ango:PropertyPlantAndEquipmentExcludingLandAndLandImprovements>
    <ango:PropertyPlantAndEquipmentExcludingLandAndLandImprovements contextRef="c-8" decimals="-3" id="f-577" unitRef="usd">44512000</ango:PropertyPlantAndEquipmentExcludingLandAndLandImprovements>
    <us-gaap:LandAndLandImprovements contextRef="c-7" decimals="-3" id="f-578" unitRef="usd">493000</us-gaap:LandAndLandImprovements>
    <us-gaap:LandAndLandImprovements contextRef="c-8" decimals="-3" id="f-579" unitRef="usd">493000</us-gaap:LandAndLandImprovements>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-580" unitRef="usd">44384000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-3" id="f-581" unitRef="usd">45005000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-582" unitRef="usd">11900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-4" decimals="-5" id="f-583" unitRef="usd">7600000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="-5" id="f-584" unitRef="usd">5700000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-585">GOODWILL AND INTANGIBLE ASSETS&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has historically performed its annual goodwill assessment during the third quarter of each fiscal year.  During the fourth quarter of fiscal year 2022, the Company changed its annual impairment assessment date from December 31 to April 30 to more closely align the impairment assessment date with the Company's long term planning and forecasting process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the first quarter of fiscal year 2023, the Company managed its operations as one reporting unit.  At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as two operating segments and two reporting units, namely Med Tech and Med Device (see Note 18 "Segments and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Annual  Report on Form 10-K).  As a result of this change, goodwill was required to be allocated to each reporting unit and an interim goodwill impairment assessment was performed at the Company and reporting unit levels.  To determine the fair value of the individual reporting units and the entire company as of June 1, 2022, the Company utilized the income approach.  The income approach is based on the projected cash flows discounted to their present value using discount rates, that in the Company's judgment, consider the timing and risk of the forecasted cash flows using internally developed forecasts and assumptions.  Under the income approach, the discount rate used is the average estimated value of a market participant&#x2019;s cost of capital and debt, derived using customary market metrics.  Other significant assumptions include revenue growth rates, profitability projections, and terminal value growth rates.  The market approach was also considered; however, the income approach was chosen as the Company determined it is a better representation of both the Med Tech and Med Device reporting units' projected long-term performance. The fair value of each &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reporting unit and the Company as a whole was assessed to determine if there was any impairment.  The Company compared each reporting unit's fair value to the adjusted carrying value to conclude that there was no impairment for either reporting unit or the Company as a whole.  The adjusted carrying value of each reporting unit was used to calculate the Company's book value to compare to its market capitalization at the assessment date.  Based on the results of this evaluation, there were no adjustments to goodwill for either reporting unit or the Company as a whole as of August 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's annual testing for impairment of goodwill was completed as of April 30, 2023.  To determine the fair value of the two reporting units as of April 30, 2023, the Company utilized the income approach for Med Tech and a combination of the income approach and market approach for Med Device.  The income approach is based on the projected cash flows discounted to their present value using discount rates, that in the Company's judgment, consider the timing and risk of the forecasted cash flows using internally developed forecasts and assumptions.  Under the income approach, the discount rate used is the average estimated value of a market participant&#x2019;s cost of capital and debt, derived using customary market metrics.  Other significant assumptions include revenue growth rates, profitability projections, and terminal value growth rates.  The market approach estimates fair values based on the determination of appropriate publicly traded market comparison companies and market multiples of revenue and earnings derived from those companies with similar operating and investment characteristics.  The market approach was also considered; however, the income approach was chosen as the Company determined it is a better representation of the Med Tech reporting units' projected long-term performance.  For Med Device, both the income and market approaches were considered.  The fair value of each reporting unit was assessed to determine if there was any impairment.  The Company compared each reporting unit's fair value to the adjusted carrying value to conclude that there was no impairment for either reporting unit.  Based on the results of this evaluation, there were no adjustments to goodwill for either reporting unit as of April 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the sale of the dialysis product portfolio and BioSentry tract sealant system biopsy businesses to Merit Medical Systems, Inc. was a triggering event for the Med Device report unit.  As the Company concluded that this was the sale of a business, goodwill was allocated to the sale based on the relative fair value of the dialysis and BioSentry businesses and is included in assets held for sale as of May&#160;31, 2023.  To determine the fair value of the remaining Med Device reporting unit as of May&#160;31, 2023, the Company utilized the income approach, as it was determined to be a better representation of the remaining Med Device reporting unit's projected long-term performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the results of this evaluation, the Company recorded a goodwill impairment charge of $14.5 million for the year ended May&#160;31, 2023 to write down the carrying value of the Med Device reporting unit to fair value. The impairment loss is disclosed separately on the face of the accompanying consolidated statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no adjustments to goodwill for the Med Tech reporting unit for the year ended May&#160;31, 2023 other than foreign currency translation adjustments.  There were no adjustments to goodwill for the year ended May&#160;31, 2022 other than foreign currency translation adjustments.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill for each reporting unit is allocated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.508%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Tech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Device&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance June 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets held for sale &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Even though the Company determined that there was no goodwill impairment as of April 30, 2023 for the Med Tech reporting unit, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of April 30, 2024.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Definite Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets other than goodwill are amortized over their estimated useful lives on a straight-line basis. Useful lives range from &lt;span style="-sec-ix-hidden:f-610"&gt;two&lt;/span&gt; to eighteen years.  The Company periodically reviews, and adjusts, if necessary, the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the triggering event for the Med Device reporting unit as of May&#160;31, 2023, long-lived assets were tested for impairment.  As a result of the undiscounted cash flow analysis that was performed, there were no impairments identified as of May&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of fiscal year 2021, the Company made the decision to abandon the OARtrac product technology and trademark.  This resulted in an &lt;span style="-sec-ix-hidden:f-612"&gt;impairment charge&lt;/span&gt; of $14.0&#160;million.  The impairment charge is recorded in "Acquisition, restructuring and other items, net", on the Consolidated Statements of Operations (see Note 19 "Acquisition, restructuring and other items, net" as set forth in the Notes to the consolidated financial statements in this Annual Report on Form 10-K).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;carrying&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&#160;carrying&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;carrying&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&#160;carrying&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense was $18.8 million, $19.5 million and $18.1 million for fiscal years 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c-4" decimals="INF" id="f-586" unitRef="unit">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportingUnits contextRef="c-4" decimals="INF" id="f-587" unitRef="unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:NumberOfOperatingSegments contextRef="c-1" decimals="INF" id="f-588" unitRef="unit">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments contextRef="c-1" decimals="INF" id="f-589" unitRef="unit">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments contextRef="c-1" decimals="INF" id="f-590" unitRef="unit">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-60" decimals="-5" id="f-591" unitRef="usd">14500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-592">&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill for each reporting unit is allocated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.508%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Tech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Device&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance June 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assets held for sale &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-114" decimals="-3" id="f-593" unitRef="usd">160529000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-115" decimals="-3" id="f-594" unitRef="usd">40529000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-8" decimals="-3" id="f-595" unitRef="usd">201058000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-69" decimals="-3" id="f-596" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-60" decimals="-3" id="f-597" unitRef="usd">14549000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-598" unitRef="usd">14549000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillOtherIncreaseDecrease contextRef="c-69" decimals="-3" id="f-599" unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease contextRef="c-60" decimals="-3" id="f-600" unitRef="usd">-25980000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease contextRef="c-1" decimals="-3" id="f-601" unitRef="usd">-25980000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-69" decimals="-3" id="f-602" unitRef="usd">-1291000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-60" decimals="-3" id="f-603" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-1" decimals="-3" id="f-604" unitRef="usd">-1291000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-116" decimals="-3" id="f-605" unitRef="usd">159238000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-117" decimals="-3" id="f-606" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-607" unitRef="usd">159238000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-118" decimals="INF" id="f-608" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-119" decimals="INF" id="f-609" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-52" id="f-611">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-121" decimals="-5" id="f-613" unitRef="usd">14000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <ango:ScheduleOfIntangibleAssetsTableTextBlock contextRef="c-1" id="f-614">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;carrying&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&#160;carrying&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;carrying&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&#160;carrying&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ango:ScheduleOfIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-122" decimals="-3" id="f-615" unitRef="usd">211751000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-122" decimals="-3" id="f-616" unitRef="usd">118314000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-122" decimals="-3" id="f-617" unitRef="usd">93437000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-123" decimals="-3" id="f-618" unitRef="usd">57509000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-123" decimals="-3" id="f-619" unitRef="usd">40755000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-123" decimals="-3" id="f-620" unitRef="usd">16754000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-124" decimals="-3" id="f-621" unitRef="usd">7450000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-124" decimals="-3" id="f-622" unitRef="usd">6660000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-124" decimals="-3" id="f-623" unitRef="usd">790000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-125" decimals="-3" id="f-624" unitRef="usd">4837000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-125" decimals="-3" id="f-625" unitRef="usd">4674000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-125" decimals="-3" id="f-626" unitRef="usd">163000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-7" decimals="-3" id="f-627" unitRef="usd">281547000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-7" decimals="-3" id="f-628" unitRef="usd">170403000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-7" decimals="-3" id="f-629" unitRef="usd">111144000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-126" decimals="-3" id="f-630" unitRef="usd">239467000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-126" decimals="-3" id="f-631" unitRef="usd">112141000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-126" decimals="-3" id="f-632" unitRef="usd">127326000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-127" decimals="-3" id="f-633" unitRef="usd">60115000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-127" decimals="-3" id="f-634" unitRef="usd">38003000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-127" decimals="-3" id="f-635" unitRef="usd">22112000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-128" decimals="-3" id="f-636" unitRef="usd">9950000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-128" decimals="-3" id="f-637" unitRef="usd">7185000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-128" decimals="-3" id="f-638" unitRef="usd">2765000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-129" decimals="-3" id="f-639" unitRef="usd">4837000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-129" decimals="-3" id="f-640" unitRef="usd">4660000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-129" decimals="-3" id="f-641" unitRef="usd">177000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-8" decimals="-3" id="f-642" unitRef="usd">314369000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-8" decimals="-3" id="f-643" unitRef="usd">161989000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-8" decimals="-3" id="f-644" unitRef="usd">152380000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-645" unitRef="usd">18800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-4" decimals="-5" id="f-646" unitRef="usd">19500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-5" id="f-647" unitRef="usd">18100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-648">&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-7" decimals="-3" id="f-649" unitRef="usd">14399000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-7" decimals="-3" id="f-650" unitRef="usd">14380000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-7" decimals="-3" id="f-651" unitRef="usd">14199000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-7" decimals="-3" id="f-652" unitRef="usd">14057000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-7" decimals="-3" id="f-653" unitRef="usd">10827000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-7" decimals="-3" id="f-654" unitRef="usd">43282000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-7" decimals="-3" id="f-655" unitRef="usd">111144000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-656">INCOME TAXES&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of loss before income tax benefit are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit is comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,995)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Temporary differences that give rise to deferred tax assets and liabilities are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state R&amp;amp;D tax credit carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses incurred not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net deferred tax liability in the U.S. as of May&#160;31, 2023 and 2022 principally relates to tax amortization of intangibles that have an indefinite reversal period for book purposes, also known as a &#x201c;naked credit deferred tax liability&#x201d;, that cannot be considered as a source of income to recover the deferred tax asset.  In addition, included in the net deferred tax liability as of May&#160;31, 2023 and 2022 is a net deferred tax liability of $5.8&#160;million and $8.8&#160;million, respectively that was related to the stock acquisition of Eximo Medical Ltd. primarily related to book intangibles partially offset by tax net operating losses and capitalized R&amp;amp;D expenditures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's U.S. Federal net operating loss carryforwards as of May&#160;31, 2023 after considering IRC Section&#160;382 limitations are $169.7 million. The expiration of the Federal net operating loss carryforwards are as follows: $5.2 million between 2023 and 2024, $79.4 million between 2028 and 2037 and $85.1 million indefinitely.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's state net operating loss carryforwards as of May&#160;31, 2023 after considering remaining IRC Section&#160;382 limitations are $24.1 million which expire in various years from 2029 to 2042.  The Company has Israel tax net operating losses of $16.3&#160;million that can be carried forward indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in 2018, except for the Global Intangible Low-Taxed Income, the Company will no longer record United States federal income tax on its share of the income of its foreign subsidiaries, nor will it record a benefit for foreign tax credits related to that income.  Upon distribution of these earnings in the form of dividends or otherwise, the Company would be subject to withholding taxes payable, where applicable, to foreign countries, but would have no further federal income tax liability.  The Company intends to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of May&#160;31, 2023, as well as all subsequent earnings generated by all of our foreign subsidiaries.  Determining the amount of unrecognized deferred tax liability related to any additional outside basis difference in these entities is not practical.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly assesses its ability to realize its deferred tax assets.  Assessing the realization of deferred tax assets requires significant management judgment.  In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity.  Evidence the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal year 2016, except the naked credit deferred tax liability.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&amp;amp;D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of May&#160;31, 2023.  The Company will continue to assess the level of the valuation allowance required.  If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company&#x2019;s results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's consolidated income tax expense has differed from the amount that would be provided by applying the U.S. Federal statutory income tax rate to the Company's income before income taxes for the following reasons:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit at federal statutory tax rate of 21.0%, 21.0% and 21.0%, respectively&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of Federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of Non-U.S. operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Meals and entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,995)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending amount of unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits balance at June 1 &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in gross amounts of tax positions related to prior years due to U.S. tax reform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease due to lapse in statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits balance at May 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table above includes unrecognized tax benefits associated with the calculation of limitations placed on the utilization of tax attributes related to an acquired company. If recognized, $0.5 million would result in adjustments to other tax accounts. &#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense. There are no accrued interest and penalties recognized in the Consolidated Balance Sheets as of May&#160;31, 2023 and May&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business the Company is subject to examination by taxing authorities throughout the world.  Fiscal years 2020 through 2022 remain open to examination by the various tax authorities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not anticipate that the amount of unrecognized tax benefits will significantly change in the next twelve months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-657">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of loss before income tax benefit are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-658" unitRef="usd">-45240000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-4" decimals="-3" id="f-659" unitRef="usd">-28495000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-5" decimals="-3" id="f-660" unitRef="usd">-31595000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-661" unitRef="usd">-9197000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-4" decimals="-3" id="f-662" unitRef="usd">-1454000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-5" decimals="-3" id="f-663" unitRef="usd">-4457000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-664" unitRef="usd">-54437000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-665" unitRef="usd">-29949000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-666" unitRef="usd">-36052000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-667">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit is comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,995)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-668" unitRef="usd">129000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-669" unitRef="usd">120000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-670" unitRef="usd">100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-671" unitRef="usd">187000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-672" unitRef="usd">186000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-673" unitRef="usd">201000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-674" unitRef="usd">316000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-675" unitRef="usd">306000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-676" unitRef="usd">301000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-677" unitRef="usd">-207000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-678" unitRef="usd">-3415000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-679" unitRef="usd">-3375000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-680" unitRef="usd">-2104000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-681" unitRef="usd">-293000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-682" unitRef="usd">-1430000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-683" unitRef="usd">-2311000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-684" unitRef="usd">-3708000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-685" unitRef="usd">-4805000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-686" unitRef="usd">-1995000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-687" unitRef="usd">-3402000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-688" unitRef="usd">-4504000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-689">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Temporary differences that give rise to deferred tax assets and liabilities are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state R&amp;amp;D tax credit carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses incurred not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-7" decimals="-3" id="f-690" unitRef="usd">40460000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-8" decimals="-3" id="f-691" unitRef="usd">40759000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-7" decimals="-3" id="f-692" unitRef="usd">4263000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-8" decimals="-3" id="f-693" unitRef="usd">4617000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-7" decimals="-3" id="f-694" unitRef="usd">7311000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-8" decimals="-3" id="f-695" unitRef="usd">6320000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-7" decimals="-3" id="f-696" unitRef="usd">724000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-8" decimals="-3" id="f-697" unitRef="usd">853000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="c-7" decimals="-3" id="f-698" unitRef="usd">6986000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="c-8" decimals="-3" id="f-699" unitRef="usd">1914000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-7" decimals="-3" id="f-700" unitRef="usd">78000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-8" decimals="-3" id="f-701" unitRef="usd">72000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="-3" id="f-702" unitRef="usd">59822000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-8" decimals="-3" id="f-703" unitRef="usd">54535000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-704" unitRef="usd">46828000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-705" unitRef="usd">50320000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-7" decimals="-3" id="f-706" unitRef="usd">46828000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-8" decimals="-3" id="f-707" unitRef="usd">50320000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-708" unitRef="usd">25759000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-3" id="f-709" unitRef="usd">20203000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities contextRef="c-7" decimals="-3" id="f-710" unitRef="usd">12765000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-8" decimals="-3" id="f-711" unitRef="usd">15988000</us-gaap:DeferredTaxLiabilities>
    <ango:DeferredTaxLiabilitiesPurchaseAccountingAdjustment contextRef="c-130" decimals="-5" id="f-712" unitRef="usd">5800000</ango:DeferredTaxLiabilitiesPurchaseAccountingAdjustment>
    <ango:DeferredTaxLiabilitiesPurchaseAccountingAdjustment contextRef="c-131" decimals="-5" id="f-713" unitRef="usd">8800000</ango:DeferredTaxLiabilitiesPurchaseAccountingAdjustment>
    <ango:OperatingLossCarryforwardsAmountAfterLimitationOfUse contextRef="c-132" decimals="-5" id="f-714" unitRef="usd">169700000</ango:OperatingLossCarryforwardsAmountAfterLimitationOfUse>
    <us-gaap:OperatingLossCarryforwards contextRef="c-133" decimals="-5" id="f-715" unitRef="usd">5200000</us-gaap:OperatingLossCarryforwards>
    <ango:OperatingLossCarryforwardsAmountAfterLimitationOfUse contextRef="c-134" decimals="-5" id="f-716" unitRef="usd">79400000</ango:OperatingLossCarryforwardsAmountAfterLimitationOfUse>
    <ango:OperatingLossCarryforwardsAmountAfterLimitationOfUse contextRef="c-135" decimals="-5" id="f-717" unitRef="usd">85100000</ango:OperatingLossCarryforwardsAmountAfterLimitationOfUse>
    <us-gaap:OperatingLossCarryforwards contextRef="c-136" decimals="-5" id="f-718" unitRef="usd">24100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-137" decimals="-5" id="f-719" unitRef="usd">16300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-720">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's consolidated income tax expense has differed from the amount that would be provided by applying the U.S. Federal statutory income tax rate to the Company's income before income taxes for the following reasons:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit at federal statutory tax rate of 21.0%, 21.0% and 21.0%, respectively&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of Federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of Non-U.S. operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Meals and entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,995)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-721" unitRef="usd">-11432000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-4" decimals="-3" id="f-722" unitRef="usd">-6289000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-5" decimals="-3" id="f-723" unitRef="usd">-7571000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-724" unitRef="usd">-353000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-4" decimals="-3" id="f-725" unitRef="usd">-536000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-5" decimals="-3" id="f-726" unitRef="usd">-462000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <ango:IncomeTaxReconciliationEffectOfForeignOperations contextRef="c-1" decimals="-3" id="f-727" unitRef="usd">14000</ango:IncomeTaxReconciliationEffectOfForeignOperations>
    <ango:IncomeTaxReconciliationEffectOfForeignOperations contextRef="c-4" decimals="-3" id="f-728" unitRef="usd">199000</ango:IncomeTaxReconciliationEffectOfForeignOperations>
    <ango:IncomeTaxReconciliationEffectOfForeignOperations contextRef="c-5" decimals="-3" id="f-729" unitRef="usd">-293000</ango:IncomeTaxReconciliationEffectOfForeignOperations>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-1" decimals="-3" id="f-730" unitRef="usd">991000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-4" decimals="-3" id="f-731" unitRef="usd">-395000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-5" decimals="-3" id="f-732" unitRef="usd">1303000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="c-1" decimals="-3" id="f-733" unitRef="usd">258000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="c-4" decimals="-3" id="f-734" unitRef="usd">179000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="c-5" decimals="-3" id="f-735" unitRef="usd">116000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-1" decimals="-3" id="f-736" unitRef="usd">3055000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-4" decimals="-3" id="f-737" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-5" decimals="-3" id="f-738" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <ango:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount contextRef="c-1" decimals="-3" id="f-739" unitRef="usd">366000</ango:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount>
    <ango:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount contextRef="c-4" decimals="-3" id="f-740" unitRef="usd">686000</ango:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount>
    <ango:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount contextRef="c-5" decimals="-3" id="f-741" unitRef="usd">107000</ango:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-742" unitRef="usd">5556000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-743" unitRef="usd">3168000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-744" unitRef="usd">3921000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <ango:IncomeTaxReconciliationEffectofEliminationofASC718APICPool contextRef="c-1" decimals="-3" id="f-745" unitRef="usd">-505000</ango:IncomeTaxReconciliationEffectofEliminationofASC718APICPool>
    <ango:IncomeTaxReconciliationEffectofEliminationofASC718APICPool contextRef="c-4" decimals="-3" id="f-746" unitRef="usd">1616000</ango:IncomeTaxReconciliationEffectofEliminationofASC718APICPool>
    <ango:IncomeTaxReconciliationEffectofEliminationofASC718APICPool contextRef="c-5" decimals="-3" id="f-747" unitRef="usd">-526000</ango:IncomeTaxReconciliationEffectofEliminationofASC718APICPool>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-3" id="f-748" unitRef="usd">1027000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-4" decimals="-3" id="f-749" unitRef="usd">412000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-5" decimals="-3" id="f-750" unitRef="usd">455000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-751" unitRef="usd">-1995000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-752" unitRef="usd">-3402000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-753" unitRef="usd">-4504000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-754">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending amount of unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits balance at June 1 &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in gross amounts of tax positions related to prior years due to U.S. tax reform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease due to lapse in statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits balance at May 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-8" decimals="-3" id="f-755" unitRef="usd">464000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-3" id="f-756" unitRef="usd">464000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-14" decimals="-3" id="f-757" unitRef="usd">464000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-758" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-4" decimals="-3" id="f-759" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-5" decimals="-3" id="f-760" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-1" decimals="-3" id="f-761" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-4" decimals="-3" id="f-762" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-5" decimals="-3" id="f-763" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-3" id="f-764" unitRef="usd">464000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-8" decimals="-3" id="f-765" unitRef="usd">464000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-3" id="f-766" unitRef="usd">464000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible contextRef="c-7" decimals="-5" id="f-767" unitRef="usd">500000</us-gaap:IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-7" decimals="INF" id="f-768" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-8" decimals="INF" id="f-769" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-770">ACCRUED LIABILITIES&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and franchise taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-771">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and franchise taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-772" unitRef="usd">9232000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-773" unitRef="usd">20232000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="c-7" decimals="-3" id="f-774" unitRef="usd">7088000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="c-8" decimals="-3" id="f-775" unitRef="usd">3731000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-7" decimals="-3" id="f-776" unitRef="usd">2874000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-8" decimals="-3" id="f-777" unitRef="usd">2986000</us-gaap:AccruedRoyaltiesCurrent>
    <ango:AccruedResearchAndDevelopmentCurrent contextRef="c-7" decimals="-3" id="f-778" unitRef="usd">1525000</ango:AccruedResearchAndDevelopmentCurrent>
    <ango:AccruedResearchAndDevelopmentCurrent contextRef="c-8" decimals="-3" id="f-779" unitRef="usd">1279000</ango:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:RestructuringReserveCurrent contextRef="c-7" decimals="-3" id="f-780" unitRef="usd">262000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:RestructuringReserveCurrent contextRef="c-8" decimals="-3" id="f-781" unitRef="usd">59000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c-7" decimals="-3" id="f-782" unitRef="usd">480000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c-8" decimals="-3" id="f-783" unitRef="usd">750000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent contextRef="c-7" decimals="-3" id="f-784" unitRef="usd">469000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent contextRef="c-8" decimals="-3" id="f-785" unitRef="usd">511000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-786" unitRef="usd">4687000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-787" unitRef="usd">5294000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-788" unitRef="usd">26617000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-789" unitRef="usd">34842000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="c-1" id="f-790">LONG-TERM DEBT&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2022, the Company repaid all amounts outstanding under its then existing credit agreement and entered into a new Credit Agreement (the "Credit Agreement") with its lenders, JPMorgan Chase Bank, N.A., as Administrative Agent, sole bookrunner, and sole lead arranger, and Bank of America, N.A. and KeyBank National Association, as Syndication Agents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement provides for a $75.0&#160;million secured revolving credit facility (the "Revolving Facility") and a $30.0&#160;million delayed draw term loan (the "Delayed Draw Term Loan"), and also includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0&#160;million.&#160; Each exercise of such expansion feature must be drawn in $5.0&#160;million increments.  The proceeds of the Revolving Facility may be used for general corporate purposes, including permitted acquisitions.  The proceeds of the Delayed Draw Term Loan may be used for general corporate purposes, including primarily to finance the manufacturing costs of the Auryon laser capital equipment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement has a five-year maturity.  Interest on the Revolving Facility and  Delayed Draw Term Loan will be based, at the Company's option, on a rate equal to (i) the Secured Overnight Financing Rate ("SOFR") plus 0.10% (subject to a floor of 0%), or (ii) if the Company elects to treat a borrowing as an ABR Borrowing, an alternate base rate based on SOFR, plus, in each case, an applicable margin of 1.25%, 1.50% or 1.75%, depending on the leverage ratio.  If any amounts are not paid when due, such overdue amounts will bear interest at an amount generally equal to 2.0% plus the existing loan rate.  The Credit Agreement also carries a commitment fee in the case of the Revolving Facility, and a ticking fee, in the case of the Delayed Draw Term Loans of 0.20% to 0.25% per annum on the unused portion.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's obligations under the Credit Agreement are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the &#x201c;Guarantors&#x201d;). All obligations of the Company and the Guarantors under the Credit Agreement are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than 3.00 to 1.00 (during certain periods following material acquisitions the ratio shall be increased to 3.50 to 1.00). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures* to&#160;consolidated interest expense* paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* The definitions of consolidated total indebtedness, consolidated EBITDA, consolidated capital expenditures and consolidated interest expense are specifically defined in the credit agreement included as an exhibit to Form 8-K filed on August 31, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of May&#160;31, 2023 there was $25.0&#160;million outstanding on the Revolving Facility and $25.0&#160;million outstanding on the Delayed Draw Term Loan and the interest rate at May&#160;31, 2023 applicable to each was 6.73%.  As of May&#160;31, 2023 and May&#160;31, 2022, the carrying value of long-term debt approximated its fair market value.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.862%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolving Facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Delayed Draw Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized debit issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was in compliance with the Credit Agreement covenants as of May&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2023, AngioDynamics used a portion of the consideration received from the sale of the dialysis and BioSentry businesses to repay all amounts owed under AngioDynamics&#x2019; existing Credit Agreement, and as a result, the Credit Agreement was extinguished.  Pursuant to the terms of the Credit Agreement, AngioDynamics had the option to repay this facility prior to the maturity date without penalty.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-138" decimals="-5" id="f-791" unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-139" decimals="-5" id="f-792" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <ango:LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature contextRef="c-138" decimals="-3" id="f-793" unitRef="usd">75000000</ango:LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-140" decimals="-5" id="f-794" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentTerm contextRef="c-141" id="f-795">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-142"
      decimals="INF"
      id="f-796"
      unitRef="number">0.0010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ango:DebtInstrumentFloorInterestRate
      contextRef="c-143"
      decimals="INF"
      id="f-797"
      unitRef="number">0</ango:DebtInstrumentFloorInterestRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-144"
      decimals="INF"
      id="f-798"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-145"
      decimals="INF"
      id="f-799"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-146"
      decimals="INF"
      id="f-800"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ango:DebtInstrumentDebtDefaultInterestRateIncrease
      contextRef="c-147"
      decimals="INF"
      id="f-801"
      unitRef="number">0.020</ango:DebtInstrumentDebtDefaultInterestRateIncrease>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c-51"
      decimals="INF"
      id="f-802"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c-52"
      decimals="INF"
      id="f-803"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <ango:LineOfCreditFacilityNumberOfCovenants
      contextRef="c-148"
      decimals="INF"
      id="f-804"
      unitRef="covenant">2</ango:LineOfCreditFacilityNumberOfCovenants>
    <ango:DebtInstrumentCovenantTermsMaximumTotalLeverageRatio
      contextRef="c-147"
      decimals="INF"
      id="f-805"
      unitRef="number">3.00</ango:DebtInstrumentCovenantTermsMaximumTotalLeverageRatio>
    <ango:DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions
      contextRef="c-147"
      decimals="INF"
      id="f-806"
      unitRef="number">3.50</ango:DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions>
    <ango:DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio
      contextRef="c-147"
      decimals="INF"
      id="f-807"
      unitRef="number">1.25</ango:DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-808">As of May&#160;31, 2023 there was $25.0&#160;million outstanding on the Revolving Facility and $25.0&#160;million outstanding on the Delayed Draw Term Loan and the interest rate at May&#160;31, 2023 applicable to each was 6.73%.  As of May&#160;31, 2023 and May&#160;31, 2022, the carrying value of long-term debt approximated its fair market value.  &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.862%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolving Facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Delayed Draw Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized debit issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LineOfCredit contextRef="c-149" decimals="-5" id="f-809" unitRef="usd">25000000</us-gaap:LineOfCredit>
    <us-gaap:LongTermDebt contextRef="c-149" decimals="-5" id="f-810" unitRef="usd">25000000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="c-149"
      decimals="INF"
      id="f-811"
      unitRef="number">0.0673</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-150" decimals="-3" id="f-812" unitRef="usd">25000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-151" decimals="-3" id="f-813" unitRef="usd">25000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-7" decimals="-3" id="f-814" unitRef="usd">182000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-7" decimals="-3" id="f-815" unitRef="usd">49818000</us-gaap:LongTermDebt>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-816">RETIREMENT PLANSThe Company has a 401(k) plan under which eligible employees can defer a portion of their compensation, part of which is matched by the Company. Matching contributions were $4.2 million, $4.3 million and $3.8 million in 2023, 2022 and 2021, respectively. There are also various immaterial foreign retirement plans.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-5" id="f-817" unitRef="usd">4200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-4" decimals="-5" id="f-818" unitRef="usd">4300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-5" decimals="-5" id="f-819" unitRef="usd">3800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-820">STOCKHOLDERS&#x2019; EQUITY &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capitalization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 29, 2014, the Board of Directors approved the Amended and Restated Certificate of Incorporation (the &#x201c;Amended Certificate&#x201d;). Under the Amended Certificate, the authorized capital stock is 80,000,000 shares, consisting of 75,000,000 shares of common stock, par value $.01 per share and 5,000,000 shares of preferred stock, par value $.01 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of common stock are entitled to one vote for each share held. Subject to preferences applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably dividends, if any, as may be declared by the Board of Directors out of funds legally available for dividend payments. If the Company liquidates, dissolves, or winds up, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities and liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no pre-emptive rights or rights to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Company may designate in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board of Directors has the authority to (i)&#160;issue the undesignated preferred stock in one or more series, (ii)&#160;determine the powers, preferences and rights and the qualifications, limitations or restrictions granted to or imposed upon any wholly un-issued series of undesignated preferred stock and (iii)&#160;fix the number of shares constituting any series and the designation of the series, without any further vote or action by the Company's stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 13, 2020, the Company's shareholders approved the 2020 Stock and Incentive Award Plan (the &#x201c;2020 Plan&#x201d;).  The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance share units, performance shares and other incentive awards to the Company's employees, directors and other service providers.  On November 3, 2022 the Company's shareholders approved an amendment to the 2020 Plan to increase the reserve of shares of common stock available for future grants by 1,950,000 shares.  As of May&#160;31, 2023, there remained approximately 2.9 million shares available for future grants under the 2020 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the adoption of the 2020 Plan, equity awards were issued under the 2004 Stock and Incentive Award Plan (the &#x201c;2004 Plan&#x201d;).  The adoption of the 2020 Plan did not impact the administration of equity awards issued under the 2004 Plan but following the adoption of the 2020 Plan, equity award grants are no longer made under the 2004 Plan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about stock option activity for the fiscal year ended May&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year - June 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,346,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of year - May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,206,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at year-end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,408,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.77&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options expected to vest in future periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options are granted at exercise prices equal to the quoted market price of common stock at the date of the grant. Options vest 25%&#160;per year over four years for employees.  Stock options granted prior to May 1, 2007 and after June 1, 2017 expire on the tenth anniversary of the grant date.  Stock options granted between May 1, 2007 through May 31, 2017 expire on the seventh anniversary of the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of each stock option grant at the date of grant using a Black-Scholes option pricing model.  The weighted average grant-date fair value of options granted during the years ended May&#160;31, 2023, 2022 and 2021 was $9.27, $9.57, and $3.97, respectively.  The following assumptions were used in arriving at the fair value of options granted during 2023, 2022 and 2021, respectively:  risk-free interest rates of 3.20%, 0.92% and 0.34%; expected volatility of 44%, 41%, and 39%; and expected lives of 5.14 years, 5.05 years, and 4.96 years.  The Company does not declare dividends therefore a dividend yield of zero was used for the years ended May&#160;31, 2023, 2022 and 2021.  Risk-free interest rates reflect the yield on zero-coupon U.S. Treasury bonds whose maturity period equals the expected term of the option.  Expected volatilities are based on the historical volatility of the Company's stock.  The expected option lives are based on historical experience of employee exercise behavior. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised during the years ended May&#160;31, 2023, 2022 and 2021 was $0.2 million, $1.6 million, and $0.8 million, respectively.  As of May&#160;31, 2023, there was $3.9 million of total unrecognized compensation cost related to non-vested options, which is expected to be recognized over a weighted average period of 2 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Cash received from option exercises during 2023, 2022 and 2021 was $0.3 million, $2.7 million and $1.9 million, respectively.  Due to the valuation allowance there was no tax benefit realized from stock option exercises during the years ended May&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Unit and Performance Share Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants restricted stock units to certain employees under the 2020 Plan, and historically under the 2004 Plan, which give the recipients the right to receive shares of Company stock upon vesting. The restricted stock unit awards vest in &lt;span style="-sec-ix-hidden:f-877"&gt;four&lt;/span&gt; equal annual installments beginning on the first anniversary of the grant date.  Restricted stock unit awards granted to directors vest&#160;over one year. Unvested restricted stock unit awards will be forfeited if the recipient ceases to be employed by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The following table summarizes information about restricted stock unit activity for the year ended May&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted&#160;Average Grant-Date&#160;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at beginning of year, June 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at end of year, May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each restricted stock unit is the market price of Company stock on the date of grant.  The weighted average grant date fair value of restricted stock units granted during the years ended May&#160;31, 2023, 2022 and 2021 was $19.99, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$26.24 and $10.40, respectively.  The total intrinsic value of restricted stock units (meaning the fair value of the units on the date of vest) vesting during the years ended May&#160;31, 2023, 2022 and 2021 was $5.6 million, $8.5 million, and $2.1 million,&#160;respectively.  As of May&#160;31, 2023, there was $9.1 million of total unrecognized compensation cost related to non-vested restricted stock awards, which is expected to be recognized over a weighted average period of 2 years.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company grants performance share awards to certain employees under the 2020 Plan, and historically under the 2004 Plan, which gives the recipients the right to receive shares of Company stock if certain criteria is met.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:21.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The following table summarizes information about performance unit award activity for the year ended May&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance Unit Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted&#160;Average Grant-Date&#160;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at beginning of year, June 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at end of year, May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal years 2023, 2022 and 2021, the Company granted performance unit awards.  Performance unit awards subject to vesting are based on the Company's level of attainment of the performance targets which are set for each of the &lt;span style="-sec-ix-hidden:f-908"&gt;three&lt;/span&gt; performance years along with continued employment of the grantee.  At the end of the three year period, the vested shares are subject to modification based on the Company&#x2019;s TSR targets relative to the percentage appreciation of a specified index of companies for the respective three-year period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to estimate the fair value of such awards, a Monte Carlo Simulation valuation model on the date of the grant was used.  For the years ended May&#160;31, 2023, 2022 and 2021, the weighted average grant date fair market value for new grants was $23.71, $28.93 and $9.72, respectively.  Compensation cost is recognized over the performance period which is typically three years.  As of May&#160;31, 2023, there was $2.4 million of unrecognized compensation cost which is expected to be recognized over a weighted average period of 1 year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables represents the break out of stock-based compensation included in the Company's Consolidated Statement of Operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax benefit on the compensation expense recognized for all stock-based compensation arrangements was $2.6 million, $2.5 million and $2.0 million for the years ended May&#160;31, 2023, 2022 and 2021, respectively.  The income tax benefit for 2023, 2022 and 2021 are negated by the full valuation allowance recorded against the deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Employee Stock Purchase Plan (the &#x201c;Stock Purchase Plan&#x201d;) provides a means by which employees (the &#x201c;participants&#x201d;) are given an opportunity to purchase the Company's common stock through payroll deductions.  A total of  5,000,000 shares of common stock have been reserved for issuance under the Stock Purchase Plan.  Shares are offered through two purchase periods, each with duration of approximately 6 months, commencing on the first business day of the first and third fiscal quarters. An employee is eligible to participate in an offering period if, on the first day of an offering period, he or she has been employed in a full-time capacity for at least six months, with a customary working schedule of 20 or more hours per week and more than five months in a calendar year. Employees who own stock possessing 5% or more of the total combined voting power or value of all classes of stock are not eligible to participate in the Stock Purchase Plan. The purchase price of the shares of common stock acquired on each purchase date will be the lower of (i)&#160;85% of the fair market value of a share of common &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock on the first day of the offering period or (ii)&#160;85% of the fair market value of a share of common stock on the last day of the purchase period, subject to adjustments made by the Board of Directors. The Stock Purchase Plan is intended to qualify as an &#x201c;employee stock purchase plan&#x201d; within the meaning of Section&#160;423 of the Internal Revenue Code.  During the years ended May 31, 2017, 2019 and 2021, an additional 500,000, 1,000,000 and 500,000 shares of the Company's common stock, respectively, were reserved for issuance under the Stock Purchase Plan.   On November 3, 2022 the Company's shareholders approved an amendment to the employee stock purchase plan to increase the reserve of shares of common stock available for future grants by 1,000,000 shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option-pricing model to calculate the purchase date fair value of the shares issued under the Stock Purchase Plan and recognize expense related to shares purchased ratably over the offering period.  During the years ended May&#160;31, 2023, 2022 and 2021, 149,778, 98,586 and 164,194 shares, respectively, were issued at an average price of $13.67, $19.02 and $7.95, respectively, under the Stock Purchase Plan.  As of May&#160;31, 2023, 3.2 million shares remained available for future purchases under the Stock Purchase Plan.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ango:CapitalStockSharesAuthorized
      contextRef="c-152"
      decimals="INF"
      id="f-821"
      unitRef="shares">80000000</ango:CapitalStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-152"
      decimals="INF"
      id="f-822"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-152"
      decimals="INF"
      id="f-823"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-152"
      decimals="INF"
      id="f-824"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-152"
      decimals="INF"
      id="f-825"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <ango:CommonStockVotesPerShare contextRef="c-153" decimals="INF" id="f-826" unitRef="vote">1</ango:CommonStockVotesPerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="c-154" decimals="0" id="f-827" unitRef="shares">1950000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-155"
      decimals="-5"
      id="f-828"
      unitRef="shares">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-829">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about stock option activity for the fiscal year ended May&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year - June 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,346,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of year - May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,206,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at year-end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,408,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.77&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options expected to vest in future periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-8" decimals="INF" id="f-830" unitRef="shares">2346248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-8"
      decimals="2"
      id="f-831"
      unitRef="usdPerShare">17.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-832" unitRef="shares">187826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-833"
      unitRef="usdPerShare">21.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-834" unitRef="shares">47824</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-835"
      unitRef="usdPerShare">14.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-836" unitRef="shares">79701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-837"
      unitRef="usdPerShare">20.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-838" unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-839"
      unitRef="usdPerShare">12.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-7" decimals="INF" id="f-840" unitRef="shares">2206549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-7"
      decimals="2"
      id="f-841"
      unitRef="usdPerShare">17.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-842">P5Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-7" decimals="-3" id="f-843" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-7" decimals="INF" id="f-844" unitRef="shares">1408208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-7"
      decimals="2"
      id="f-845"
      unitRef="usdPerShare">17.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-846">P4Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-7" decimals="-3" id="f-847" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-7" decimals="INF" id="f-848" unitRef="shares">798341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-7"
      decimals="2"
      id="f-849"
      unitRef="usdPerShare">19.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-850">P7Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-7" decimals="-3" id="f-851" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <ango:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage contextRef="c-61" decimals="2" id="f-852" unitRef="number">0.25</ango:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage>
    <ango:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1 contextRef="c-61" id="f-853">P4Y</ango:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-854"
      unitRef="usdPerShare">9.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-4"
      decimals="2"
      id="f-855"
      unitRef="usdPerShare">9.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-5"
      decimals="2"
      id="f-856"
      unitRef="usdPerShare">3.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-1" decimals="4" id="f-857" unitRef="number">0.0320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-4" decimals="4" id="f-858" unitRef="number">0.0092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-5" decimals="4" id="f-859" unitRef="number">0.0034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-1" decimals="2" id="f-860" unitRef="number">0.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-4" decimals="2" id="f-861" unitRef="number">0.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-5" decimals="2" id="f-862" unitRef="number">0.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-863">P5Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-4" id="f-864">P5Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-5" id="f-865">P4Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-866" unitRef="usd">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-4" decimals="-5" id="f-867" unitRef="usd">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-5" decimals="-5" id="f-868" unitRef="usd">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-7" decimals="-5" id="f-869" unitRef="usd">3900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-870">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-5" id="f-871" unitRef="usd">300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-4" decimals="-5" id="f-872" unitRef="usd">2700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-5" decimals="-5" id="f-873" unitRef="usd">1900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-61" decimals="INF" id="f-874" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-156" decimals="INF" id="f-875" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-157" decimals="INF" id="f-876" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-44" id="f-878">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="c-1" id="f-879">The following table summarizes information about restricted stock unit activity for the year ended May&#160;31, 2023:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted&#160;Average Grant-Date&#160;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at beginning of year, June 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at end of year, May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The following table summarizes information about performance unit award activity for the year ended May&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance Unit Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted&#160;Average Grant-Date&#160;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at beginning of year, June 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at end of year, May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-158"
      decimals="INF"
      id="f-880"
      unitRef="shares">670017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-158"
      decimals="2"
      id="f-881"
      unitRef="usdPerShare">18.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-44"
      decimals="INF"
      id="f-882"
      unitRef="shares">379572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-44"
      decimals="2"
      id="f-883"
      unitRef="usdPerShare">19.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-44"
      decimals="INF"
      id="f-884"
      unitRef="shares">275007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-44"
      decimals="2"
      id="f-885"
      unitRef="usdPerShare">20.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-44"
      decimals="INF"
      id="f-886"
      unitRef="shares">38562</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-44"
      decimals="2"
      id="f-887"
      unitRef="usdPerShare">19.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-159"
      decimals="INF"
      id="f-888"
      unitRef="shares">736020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-159"
      id="f-889"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-44"
      decimals="2"
      id="f-890"
      unitRef="usdPerShare">19.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-4"
      decimals="2"
      id="f-891"
      unitRef="usdPerShare">26.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-5"
      decimals="2"
      id="f-892"
      unitRef="usdPerShare">10.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-160" decimals="-5" id="f-893" unitRef="usd">5600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-161" decimals="-5" id="f-894" unitRef="usd">8500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-162" decimals="-5" id="f-895" unitRef="usd">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-159" decimals="-5" id="f-896" unitRef="usd">9100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-44" id="f-897">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-163"
      decimals="INF"
      id="f-898"
      unitRef="shares">449473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-163"
      decimals="2"
      id="f-899"
      unitRef="usdPerShare">17.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-164"
      decimals="INF"
      id="f-900"
      unitRef="shares">175386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-164"
      decimals="2"
      id="f-901"
      unitRef="usdPerShare">21.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-164"
      decimals="INF"
      id="f-902"
      unitRef="shares">45008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-164"
      decimals="2"
      id="f-903"
      unitRef="usdPerShare">20.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-164"
      decimals="INF"
      id="f-904"
      unitRef="shares">31321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-164"
      decimals="2"
      id="f-905"
      unitRef="usdPerShare">20.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-165"
      decimals="INF"
      id="f-906"
      unitRef="shares">548530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-165"
      decimals="2"
      id="f-907"
      unitRef="usdPerShare">19.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-166" id="f-909">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-166" id="f-910">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-167"
      decimals="2"
      id="f-911"
      unitRef="usdPerShare">23.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-168"
      decimals="2"
      id="f-912"
      unitRef="usdPerShare">28.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-913"
      unitRef="usdPerShare">9.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <ango:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod contextRef="c-166" id="f-914">P3Y</ango:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-167" decimals="-5" id="f-915" unitRef="usd">2400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-166" id="f-916">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-917">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables represents the break out of stock-based compensation included in the Company's Consolidated Statement of Operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-170" decimals="-3" id="f-918" unitRef="usd">793000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-171" decimals="-3" id="f-919" unitRef="usd">827000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-172" decimals="-3" id="f-920" unitRef="usd">768000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-173" decimals="-3" id="f-921" unitRef="usd">1459000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-174" decimals="-3" id="f-922" unitRef="usd">1298000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-175" decimals="-3" id="f-923" unitRef="usd">1152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-176" decimals="-3" id="f-924" unitRef="usd">2922000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-177" decimals="-3" id="f-925" unitRef="usd">2568000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-178" decimals="-3" id="f-926" unitRef="usd">1641000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-179" decimals="-3" id="f-927" unitRef="usd">5984000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-180" decimals="-3" id="f-928" unitRef="usd">5999000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-181" decimals="-3" id="f-929" unitRef="usd">5064000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-930" unitRef="usd">11158000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-4" decimals="-3" id="f-931" unitRef="usd">10692000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-932" unitRef="usd">8625000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-5" id="f-933" unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-4" decimals="-5" id="f-934" unitRef="usd">2500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-5" decimals="-5" id="f-935" unitRef="usd">2000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-182"
      decimals="INF"
      id="f-936"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ango:NumberOfSharePurchasePeriod
      contextRef="c-183"
      decimals="INF"
      id="f-937"
      unitRef="employees">2</ango:NumberOfSharePurchasePeriod>
    <ango:SharePurchasePeriod contextRef="c-183" id="f-938">P6M</ango:SharePurchasePeriod>
    <ango:EmployeePlanParticipatingEligibilityPeriod contextRef="c-183" id="f-939">P6M</ango:EmployeePlanParticipatingEligibilityPeriod>
    <ango:SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible
      contextRef="c-183"
      decimals="INF"
      id="f-940"
      unitRef="working_hour">20</ango:SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible>
    <ango:SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible contextRef="c-183" id="f-941">P5M</ango:SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible>
    <ango:EmployeePlanParticipatingEligibilityThresholdPercentage contextRef="c-183" decimals="2" id="f-942" unitRef="number">0.05</ango:EmployeePlanParticipatingEligibilityThresholdPercentage>
    <ango:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod contextRef="c-183" decimals="2" id="f-943" unitRef="number">0.85</ango:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c-183" decimals="2" id="f-944" unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-184"
      decimals="INF"
      id="f-945"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-185"
      decimals="INF"
      id="f-946"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-186"
      decimals="INF"
      id="f-947"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="c-187" decimals="0" id="f-948" unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-183"
      decimals="INF"
      id="f-949"
      unitRef="shares">149778</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-186"
      decimals="INF"
      id="f-950"
      unitRef="shares">98586</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-188"
      decimals="INF"
      id="f-951"
      unitRef="shares">164194</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="c-7"
      decimals="2"
      id="f-952"
      unitRef="usdPerShare">13.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="c-8"
      decimals="2"
      id="f-953"
      unitRef="usdPerShare">19.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="c-27"
      decimals="2"
      id="f-954"
      unitRef="usdPerShare">7.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-182"
      decimals="INF"
      id="f-955"
      unitRef="shares">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-956">EARNINGS PER SHARE&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share are based on the weighted average number of common shares outstanding.  In addition, diluted earnings per share include the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive.  In periods with a net loss, stock options and restricted stock units are not included in the computation of basic loss per share as the impact would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles basic to diluted weighted average shares outstanding:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,480,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,009,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,342,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,480,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,009,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,342,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities excluded as their inclusion would be anti-dilutive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,491,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,465,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,285,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="c-1" id="f-957">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles basic to diluted weighted average shares outstanding:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,480,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,009,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,342,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,480,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,009,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,342,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities excluded as their inclusion would be anti-dilutive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,491,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,465,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,285,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-958" unitRef="shares">39480367</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-4" decimals="0" id="f-959" unitRef="shares">39009419</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-960" unitRef="shares">38342476</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="0" id="f-961" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-4" decimals="0" id="f-962" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-5" decimals="0" id="f-963" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-964" unitRef="shares">39480367</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-4" decimals="0" id="f-965" unitRef="shares">39009419</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-966" unitRef="shares">38342476</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-967" unitRef="shares">3491099</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-4" decimals="0" id="f-968" unitRef="shares">3465738</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="0" id="f-969" unitRef="shares">3285354</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-970">LEASES&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception of the contract.  The Company has operating leases for buildings, primarily for office space, R&amp;amp;D, manufacturing and warehousing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date.  Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised.  The Company recognizes lease expense for these leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company elected the three practical expedients that permit an entity to (a) not reassess whether expired or existing contracts contain leases, (b) not reassess lease classification for existing or expired leases, and (c) not consider whether previously capitalized initial direct costs would be appropriate under the new standard. Further, the Company has elected to not recognize leases with terms of 12 months or less on the balance sheet, and elected to account for lease and non-lease components as a single component for certain classes of assets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental balance sheet information related to leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.461%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-972"&gt;&lt;span style="-sec-ix-hidden:f-973"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-976"&gt;&lt;span style="-sec-ix-hidden:f-977"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-980"&gt;&lt;span style="-sec-ix-hidden:f-981"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.  The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term.  The following table presents the weighted average remaining lease term and discount rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturities of the lease liabilities for each of the following fiscal years is:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended May&#160;31, 2023 and May 31, 2022, the Company recognized operating lease expense, which includes immaterial short-term leases, of $2.7&#160;million and $2.8&#160;million, respectively.  The expenses on the Consolidated Statement of Operations were classified as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow and other information related to leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ango:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-971">The following table presents supplemental balance sheet information related to leases:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.461%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-972"&gt;&lt;span style="-sec-ix-hidden:f-973"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-976"&gt;&lt;span style="-sec-ix-hidden:f-977"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-980"&gt;&lt;span style="-sec-ix-hidden:f-981"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ango:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-974" unitRef="usd">5113000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-8" decimals="-3" id="f-975" unitRef="usd">6974000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-978" unitRef="usd">1922000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-8" decimals="-3" id="f-979" unitRef="usd">2560000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-982" unitRef="usd">3316000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-983" unitRef="usd">4703000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-984" unitRef="usd">5238000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-8" decimals="-3" id="f-985" unitRef="usd">7263000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-986">The following table presents the weighted average remaining lease term and discount rate:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;The expenses on the Consolidated Statement of Operations were classified as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow and other information related to leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-7" id="f-987">P3Y18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-8" id="f-988">P3Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-7" decimals="3" id="f-989" unitRef="number">0.041</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-8" decimals="3" id="f-990" unitRef="number">0.038</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-991">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturities of the lease liabilities for each of the following fiscal years is:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-7" decimals="-3" id="f-992" unitRef="usd">2097000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-7" decimals="-3" id="f-993" unitRef="usd">1621000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-7" decimals="-3" id="f-994" unitRef="usd">1329000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-7" decimals="-3" id="f-995" unitRef="usd">375000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ango:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-7" decimals="-3" id="f-996" unitRef="usd">174000</ango:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-7" decimals="-3" id="f-997" unitRef="usd">5596000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-7" decimals="-3" id="f-998" unitRef="usd">358000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-999" unitRef="usd">5238000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-1000" unitRef="usd">1922000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-1001" unitRef="usd">3316000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-5" id="f-1002" unitRef="usd">2700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-4" decimals="-5" id="f-1003" unitRef="usd">2800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-170" decimals="-3" id="f-1004" unitRef="usd">881000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-171" decimals="-3" id="f-1005" unitRef="usd">890000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-189" decimals="-3" id="f-1006" unitRef="usd">193000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-190" decimals="-3" id="f-1007" unitRef="usd">257000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-191" decimals="-3" id="f-1008" unitRef="usd">162000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-192" decimals="-3" id="f-1009" unitRef="usd">160000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-179" decimals="-3" id="f-1010" unitRef="usd">1458000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-180" decimals="-3" id="f-1011" unitRef="usd">1495000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-3" id="f-1012" unitRef="usd">2694000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-4" decimals="-3" id="f-1013" unitRef="usd">2802000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-1014" unitRef="usd">2742000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-4" decimals="-3" id="f-1015" unitRef="usd">2723000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-1016" unitRef="usd">840000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-1017" unitRef="usd">36000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1018">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments and Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's other future commitments and contingencies as of May&#160;31, 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase obligations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) The non-cancelable inventory purchase obligations are not reflected on the Consolidated Balance Sheets under accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2) These are future minimum royalty payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business.  The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated.  The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred.  However, the Company cannot predict the outcome of any litigation or the potential for future litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;C.R. Bard, Inc. v. AngioDynamics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2012, C.R. Bard, Inc. (&#x201c;Bard&#x201d;) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 7,785,302 ("302"), 7,959,615 (&#x201c;615&#x201d;) and 7,947,022 ("022")).  The case was stayed pending reexamination in the US Patent and Trademark Office ("USPTO").  Following the reexamination proceedings, and the parties&#x2019; related appeals to the Federal Circuit which resulted in further proceedings at the USPTO, certain claims of the 615 patent were held invalid, while the remaining claims of the 615 patent and the other two patents were upheld over the prior art references considered in the reexamination proceedings.  Thereafter, the case was transferred from the District of Utah to the United States District Court for the District of Delaware (&#x201c;District of Delaware&#x201d;).  On July 22, 2021, in another case against a different defendant, the District of Utah invalidated multiple claims of the &#x2018;302, &#x2018;022, and &#x2018;615 Patents under 35 USC &#xa7;101, including claims asserted against the Company.  On December 27, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal from the Utah Decision.  On February 17, 2023, the Federal Circuit Reversed-in-Part, Vacated-in-Part, and Remanded the Utah Decision.  The District of Delaware lifted the stay on February 28, 2023 and held a status conference on March 23, 2023.  A scheduling order has been entered, and a jury trial is currently scheduled for April 29, 2024. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.9pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 10, 2015, Bard and Bard Peripheral Vascular filed suit in the District of Delaware claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 8,475,417, 8,545,460, 8,805,478).  The case proceeded through trial which began on March 4, 2019.  At the close of Bard&#x2019;s case, the Court granted the Company's oral motion for judgment as a matter of law as well as its motions for summary judgment on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed.  Bard appealed the judgment to the Federal Circuit and on November 10, 2020, the Federal Circuit reversed the judgment in part with respect to Section 101 (subject matter eligibility), and vacated and remanded the trial court&#x2019;s invalidity and non-infringement judgments.  Following remand from the Federal Circuit, a jury trial commenced in the District of Delaware beginning November 14, 2022.  On November 22, 2022, a jury entered a verdict finding that certain of the Company&#x2019;s implantable port products infringe certain claims of U.S. patents held by Bard. The issue of damages was bifurcated by the Court during trial and was not determined by the jury.  On Jun&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;e 1, 2023, following post-trial briefing, the Court issued its decision on the Company&#x2019;s Renewed Judgement as a Matter of Law.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Court held the asserted patent claims were invalid as anticipated, indefinite, ineligible, and not willfully infringed.  The Court entered Judgment the same day in favor of the Company.  Bard has filed a Notice of Appeal to the Federal Circuit. The Company maintains its belief that Bard&#x2019;s claims are without merit.  The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.9pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 8, 2021, Bard filed suit in the District of Delaware asserting certain of the Company&#x2019;s port products (including certain related infusion sets) infringe U.S. Patent Nos. 8,025,639, 9,603,992 and 9,603,993.   On December 27, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal of the Utah decision invalidating &lt;/span&gt;&lt;/div&gt;multiple claims of the &#x2018;302, &#x2018;022, and &#x2018;615 patents under 35 USC &#xa7;101. Following the Federal Circuit&#x2019;s decision on appeal, the District of Delaware lifted the stay on February 28, 2023, and held a scheduling conference on March 23, 2023. A scheduling order has been entered, and a jury trial is currently scheduled for June 9, 2025. The Company maintains its belief that Bard's claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherCommitmentsTableTextBlock contextRef="c-1" id="f-1019">&lt;div style="margin-bottom:7pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's other future commitments and contingencies as of May&#160;31, 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase obligations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) The non-cancelable inventory purchase obligations are not reflected on the Consolidated Balance Sheets under accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2) These are future minimum royalty payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherCommitmentsTableTextBlock>
    <us-gaap:PurchaseObligation contextRef="c-7" decimals="-3" id="f-1020" unitRef="usd">3166000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths contextRef="c-7" decimals="-3" id="f-1021" unitRef="usd">3166000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear contextRef="c-7" decimals="-3" id="f-1022" unitRef="usd">0</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear contextRef="c-7" decimals="-3" id="f-1023" unitRef="usd">0</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligationDueInFourthYear contextRef="c-7" decimals="-3" id="f-1024" unitRef="usd">0</us-gaap:PurchaseObligationDueInFourthYear>
    <ango:PurchaseObligationToBePaidAfterYearFour contextRef="c-7" decimals="-3" id="f-1025" unitRef="usd">0</ango:PurchaseObligationToBePaidAfterYearFour>
    <ango:Royalties contextRef="c-7" decimals="-3" id="f-1026" unitRef="usd">39840000</ango:Royalties>
    <ango:RoyaltiesDueInFirstYear contextRef="c-7" decimals="-3" id="f-1027" unitRef="usd">3640000</ango:RoyaltiesDueInFirstYear>
    <ango:RoyaltiesDueinSecondYear contextRef="c-7" decimals="-3" id="f-1028" unitRef="usd">3640000</ango:RoyaltiesDueinSecondYear>
    <ango:RoyaltiesDueinThirdYear contextRef="c-7" decimals="-3" id="f-1029" unitRef="usd">3640000</ango:RoyaltiesDueinThirdYear>
    <ango:RoyaltiesDueinFourthYear contextRef="c-7" decimals="-3" id="f-1030" unitRef="usd">3640000</ango:RoyaltiesDueinFourthYear>
    <ango:RoyaltiesDueAfterFourthYear contextRef="c-7" decimals="-3" id="f-1031" unitRef="usd">25280000</ango:RoyaltiesDueAfterFourthYear>
    <us-gaap:ContractualObligation contextRef="c-7" decimals="-3" id="f-1032" unitRef="usd">43006000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="c-7" decimals="-3" id="f-1033" unitRef="usd">6806000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear contextRef="c-7" decimals="-3" id="f-1034" unitRef="usd">3640000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear contextRef="c-7" decimals="-3" id="f-1035" unitRef="usd">3640000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear contextRef="c-7" decimals="-3" id="f-1036" unitRef="usd">3640000</us-gaap:ContractualObligationDueInFourthYear>
    <ango:ContractualObligationToBePaidAfterYearFour contextRef="c-7" decimals="-3" id="f-1037" unitRef="usd">25280000</ango:ContractualObligationToBePaidAfterYearFour>
    <ango:NumberOfPatentsAssertedForReexamination
      contextRef="c-193"
      decimals="INF"
      id="f-1038"
      unitRef="unit">3</ango:NumberOfPatentsAssertedForReexamination>
    <ango:NumberOfPatentsUpheldOverPriorArtReferences
      contextRef="c-193"
      decimals="INF"
      id="f-1039"
      unitRef="unit">2</ango:NumberOfPatentsUpheldOverPriorArtReferences>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="c-194"
      decimals="INF"
      id="f-1040"
      unitRef="unit">3</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1041">SEGMENTS AND GEOGRAPHIC INFORMATION&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly reviews its segments and the approach used by the chief operating decision maker, the President and Chief Executive Officer ("CEO"), and management to evaluate performance and allocate resources.  Prior to the first quarter of fiscal year 2023, the Company considered the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis.  Commencing with the first quarter of fiscal year 2023, the Company began to manage its operations through two segments, Med Tech and Med Device to align with the transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company.  The CEO evaluates these two segments based on net sales and gross margin to, among other items, allocate resources and assess performance.  Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions.  The CEO evaluates all other elements of profitability, investment and cash flow metrics on a consolidated global basis due to shared infrastructure and resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company manages its assets on a total company basis, not by operating segment; therefore, the CEO does not review any asset information by operating segment and, accordingly, asset information is not reported or evaluated by operating segment.  Total assets were $532.6 million as of May&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes net sales and gross margin by Med Tech and Med Device including prior periods during which the Company considered the business to be a single operating segment, in order to conform to the current period presentation:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Tech Net Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gross Margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Device Net Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gross Margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gross Margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Geographic information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes net sales by geographic area based on external customer location:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales by Geography&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;For fiscal years 2023, 2022 and 2021, international sales as a percentage of total net sales were 17%, 16% and 19%, respectively. Sales to any one country outside the U.S., as determined by shipment destination, did not comprise a material portion of net sales in any of the last three fiscal years. In addition, no one customer represents more than 10% of consolidated net sales.  85% of long-lived assets are located within the United States.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c-1" decimals="INF" id="f-1042" unitRef="unit">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments contextRef="c-1" decimals="INF" id="f-1043" unitRef="unit">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:Assets contextRef="c-7" decimals="-5" id="f-1044" unitRef="usd">532600000</us-gaap:Assets>
    <ango:ScheduleOfNetRevenueByProductGroupTableTextBlock contextRef="c-1" id="f-1045">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Tech Net Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gross Margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Med Device Net Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gross Margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gross Margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ango:ScheduleOfNetRevenueByProductGroupTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-69" decimals="-3" id="f-1046" unitRef="usd">96687000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-72" decimals="-3" id="f-1047" unitRef="usd">78717000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-84" decimals="-3" id="f-1048" unitRef="usd">55731000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit contextRef="c-69" decimals="-3" id="f-1049" unitRef="usd">61966000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-72" decimals="-3" id="f-1050" unitRef="usd">52584000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-84" decimals="-3" id="f-1051" unitRef="usd">39544000</us-gaap:GrossProfit>
    <ango:GrossMarginPercentage contextRef="c-69" decimals="3" id="f-1052" unitRef="number">0.641</ango:GrossMarginPercentage>
    <ango:GrossMarginPercentage contextRef="c-72" decimals="3" id="f-1053" unitRef="number">0.668</ango:GrossMarginPercentage>
    <ango:GrossMarginPercentage contextRef="c-84" decimals="3" id="f-1054" unitRef="number">0.710</ango:GrossMarginPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-60" decimals="-3" id="f-1055" unitRef="usd">242065000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-77" decimals="-3" id="f-1056" unitRef="usd">237502000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-3" id="f-1057" unitRef="usd">235279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit contextRef="c-60" decimals="-3" id="f-1058" unitRef="usd">112280000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-77" decimals="-3" id="f-1059" unitRef="usd">113148000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-87" decimals="-3" id="f-1060" unitRef="usd">117244000</us-gaap:GrossProfit>
    <ango:GrossMarginPercentage contextRef="c-60" decimals="3" id="f-1061" unitRef="number">0.464</ango:GrossMarginPercentage>
    <ango:GrossMarginPercentage contextRef="c-77" decimals="3" id="f-1062" unitRef="number">0.476</ango:GrossMarginPercentage>
    <ango:GrossMarginPercentage contextRef="c-87" decimals="3" id="f-1063" unitRef="number">0.498</ango:GrossMarginPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-1064" unitRef="usd">338752000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="-3" id="f-1065" unitRef="usd">316219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-1066" unitRef="usd">291010000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-1067" unitRef="usd">174246000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-4" decimals="-3" id="f-1068" unitRef="usd">165732000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-5" decimals="-3" id="f-1069" unitRef="usd">156788000</us-gaap:GrossProfit>
    <ango:GrossMarginPercentage contextRef="c-1" decimals="3" id="f-1070" unitRef="number">0.514</ango:GrossMarginPercentage>
    <ango:GrossMarginPercentage contextRef="c-4" decimals="3" id="f-1071" unitRef="number">0.524</ango:GrossMarginPercentage>
    <ango:GrossMarginPercentage contextRef="c-5" decimals="3" id="f-1072" unitRef="number">0.539</ango:GrossMarginPercentage>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="c-1" id="f-1073">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes net sales by geographic area based on external customer location:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales by Geography&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-78" decimals="-3" id="f-1074" unitRef="usd">282713000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="-3" id="f-1075" unitRef="usd">265963000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-88" decimals="-3" id="f-1076" unitRef="usd">237043000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-195" decimals="-3" id="f-1077" unitRef="usd">56039000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-196" decimals="-3" id="f-1078" unitRef="usd">50256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-197" decimals="-3" id="f-1079" unitRef="usd">53967000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-1080" unitRef="usd">338752000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="-3" id="f-1081" unitRef="usd">316219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-1082" unitRef="usd">291010000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-198"
      decimals="2"
      id="f-1083"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-199"
      decimals="2"
      id="f-1084"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-200"
      decimals="2"
      id="f-1085"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-201"
      decimals="2"
      id="f-1086"
      unitRef="number">0.85</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-1087">ACQUISITION, RESTRUCTURING AND OTHER ITEMS, NET&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition, restructuring and other items, net consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mergers and acquisitions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transition service agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestiture &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible and other asset impairment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Israeli Innovation Authority prepayment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing Relocation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Legal expenses related to litigation that is outside the normal course of business.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5) During the fourth quarter of fiscal year 2021, the Company made the decision to abandon the OARtrac product technology and trademark.  This resulted in an impairment charge of $14.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6) I&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;n the first quarter of fiscal year 2023, a $3.5&#160;million payment was made to the Israeli Innovation Authority to fully satisfy the obligation related to grant funds that were provided to Eximo for development of the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7) Expenses to relocate certain manufacturing lines from Queensbury, NY to Alajuela, Costa Rica. &lt;/span&gt;&lt;/div&gt;Included in legal for fiscal year 2021 is a $1.0&#160;million settlement expense. The settlement received partially offset legal expenses paid related to the settlement proceedings.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-1088">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition, restructuring and other items, net consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended May 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mergers and acquisitions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transition service agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestiture &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible and other asset impairment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Israeli Innovation Authority prepayment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing Relocation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Legal expenses related to litigation that is outside the normal course of business.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5) During the fourth quarter of fiscal year 2021, the Company made the decision to abandon the OARtrac product technology and trademark.  This resulted in an impairment charge of $14.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6) I&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;n the first quarter of fiscal year 2023, a $3.5&#160;million payment was made to the Israeli Innovation Authority to fully satisfy the obligation related to grant funds that were provided to Eximo for development of the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020. &lt;/span&gt;&lt;/div&gt;(7) Expenses to relocate certain manufacturing lines from Queensbury, NY to Alajuela, Costa Rica.</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-202" decimals="-3" id="f-1089" unitRef="usd">9998000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-203" decimals="-3" id="f-1090" unitRef="usd">7625000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-204" decimals="-3" id="f-1091" unitRef="usd">6161000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-205" decimals="-3" id="f-1092" unitRef="usd">368000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-206" decimals="-3" id="f-1093" unitRef="usd">59000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-207" decimals="-3" id="f-1094" unitRef="usd">1000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-208" decimals="-3" id="f-1095" unitRef="usd">0</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-209" decimals="-3" id="f-1096" unitRef="usd">0</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-210" decimals="-3" id="f-1097" unitRef="usd">-1032000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-211" decimals="-3" id="f-1098" unitRef="usd">0</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-212" decimals="-3" id="f-1099" unitRef="usd">0</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-213" decimals="-3" id="f-1100" unitRef="usd">393000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-214" decimals="-3" id="f-1101" unitRef="usd">0</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-215" decimals="-3" id="f-1102" unitRef="usd">0</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-216" decimals="-3" id="f-1103" unitRef="usd">13953000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-217" decimals="-3" id="f-1104" unitRef="usd">3544000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-218" decimals="-3" id="f-1105" unitRef="usd">0</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-219" decimals="-3" id="f-1106" unitRef="usd">0</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-220" decimals="-3" id="f-1107" unitRef="usd">1091000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-221" decimals="-3" id="f-1108" unitRef="usd">644000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-222" decimals="-3" id="f-1109" unitRef="usd">0</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-223" decimals="-3" id="f-1110" unitRef="usd">632000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-224" decimals="-3" id="f-1111" unitRef="usd">714000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-225" decimals="-3" id="f-1112" unitRef="usd">756000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-1" decimals="-3" id="f-1113" unitRef="usd">15633000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-4" decimals="-3" id="f-1114" unitRef="usd">9042000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-5" decimals="-3" id="f-1115" unitRef="usd">20232000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <us-gaap:AssetImpairmentCharges contextRef="c-103" decimals="-5" id="f-1116" unitRef="usd">14000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:PaymentsForPreviousAcquisition contextRef="c-226" decimals="-5" id="f-1117" unitRef="usd">3500000</us-gaap:PaymentsForPreviousAcquisition>
    <ango:AcquisitionRestructuringAndOtherItemsNet contextRef="c-227" decimals="-5" id="f-1118" unitRef="usd">1000000</ango:AcquisitionRestructuringAndOtherItemsNet>
    <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="c-1" id="f-1119">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in each component of accumulated other comprehensive income (loss), net of tax, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1120">&lt;div style="margin-bottom:9pt;text-indent:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in each component of accumulated other comprehensive income (loss), net of tax, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at May 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity contextRef="c-228" decimals="-3" id="f-1121" unitRef="usd">3153000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-229" decimals="-3" id="f-1122" unitRef="usd">-1796000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-229" decimals="-3" id="f-1123" unitRef="usd">-1796000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-230" decimals="-3" id="f-1124" unitRef="usd">1357000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-231" decimals="-3" id="f-1125" unitRef="usd">-6080000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-231" decimals="-3" id="f-1126" unitRef="usd">-6080000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-232" decimals="-3" id="f-1127" unitRef="usd">-4723000</us-gaap:StockholdersEquity>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1128">SUBSEQUENT EVENTSOn June 8, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with Merit Medical Systems, Inc. pursuant to which Merit acquired the dialysis product portfolio and BioSentry tract sealant system biopsy businesses for $100.0&#160;million in cash.  The Company and Merit entered into various agreements to facilitate the transition to Merit, including a Transactions Services Agreement and Contract Manufacturing Agreement.  The Company determined that the sale of the businesses did not constitute a strategic shift that had a major effect on the Company&#x2019;s operations or financial results and as a result, this transaction will not be classified as discontinued operations.On June 8, 2023, AngioDynamics used a portion of the consideration received in connection with the Transaction to repay all amounts owed under AngioDynamics&#x2019; existing Credit Agreement, dated as of August 30, 2022, with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and KeyBank National Association, as co-syndication agents, and JPMorgan Chase Bank N.A., as sole bookrunner and sole lead arranger, and as a result, the Credit Agreement was extinguished. Pursuant to the terms of the Credit Agreement, AngioDynamics had the option to repay this facility prior to the maturity date without penalty.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromSaleOfOtherAssets1 contextRef="c-233" decimals="-5" id="f-1129" unitRef="usd">100000000</us-gaap:ProceedsFromSaleOfOtherAssets1>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="c-1" id="f-1130">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SCHEDULE&#160;II&#160;-VALUATION&#160;AND&#160;QUALIFYING&#160; ACCOUNTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance&#160;at Beginning of&#160;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&#160;- Charged&#160;to costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance&#160;at End&#160;of&#160;Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended May&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns and doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended May&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns and doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended May&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns and doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-234" decimals="-3" id="f-1131" unitRef="usd">13114000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-235" decimals="-3" id="f-1132" unitRef="usd">3921000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-235" decimals="-3" id="f-1133" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-236" decimals="-3" id="f-1134" unitRef="usd">17035000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-237" decimals="-3" id="f-1135" unitRef="usd">2150000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-238" decimals="-3" id="f-1136" unitRef="usd">1833000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-238" decimals="-3" id="f-1137" unitRef="usd">2064000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-239" decimals="-3" id="f-1138" unitRef="usd">1919000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-236" decimals="-3" id="f-1139" unitRef="usd">17035000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-240" decimals="-3" id="f-1140" unitRef="usd">3168000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-240" decimals="-3" id="f-1141" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-241" decimals="-3" id="f-1142" unitRef="usd">20203000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-239" decimals="-3" id="f-1143" unitRef="usd">1919000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-242" decimals="-3" id="f-1144" unitRef="usd">343000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-242" decimals="-3" id="f-1145" unitRef="usd">323000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-243" decimals="-3" id="f-1146" unitRef="usd">1939000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-241" decimals="-3" id="f-1147" unitRef="usd">20203000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-244" decimals="-3" id="f-1148" unitRef="usd">5556000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-244" decimals="-3" id="f-1149" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-245" decimals="-3" id="f-1150" unitRef="usd">25759000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-243" decimals="-3" id="f-1151" unitRef="usd">1939000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-246" decimals="-3" id="f-1152" unitRef="usd">457000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-246" decimals="-3" id="f-1153" unitRef="usd">246000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-247" decimals="-3" id="f-1154" unitRef="usd">2150000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>118
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MDV)#0V(E<JT#N99.O3>*12!V:$!B(!>B,?2N-_0[V:D(ZI4LR[*=;MN^Z:J
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MJJJ!OJHVM4M$ *>( ,Y9$6 <"\*R'2+R<2[>8U12TRM643.: $RIE3<;% G
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M;M\WYFZ^]Y(7E:A5(6O4B/7E[ J?9R2U!BWBKT(\JH-K9*G<2?G9WMSDE[/
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M>5*+B?T9<<7*:<@8!=HO!"5I"LB*#((: 11ZIF_00,2O@6Y>Q\M5+:<X34.
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M\3L@! FYU1D5:L,K$]!P L$/<33".37"7DPL&8PZG)%[!N\7*VL6*]KP/$5
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M0M5^ VM/E-@VGY&NA5*B: XWG %L;0#WUP*DROY$?YGJOD2N_@=02P,$%
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M,P0#:G0) $TUAOCZ0):EX[J5]/J(A/71[^?OX2#*Q!<T*1"\ &R:XKDOZ',
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M(*[A9SJEH1$M\QJXXR=4&@)$L+D).80Q R:#]C8W+$3*'67!T3;T\F'YL?\
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M%>GM_"2 @.:F<EOYIF_A*C NEVN#LEQR 7Y?.E<U-SR@_<CSW;\ 4$L#!!0
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M<UZ.-5M[D>9 A>;#Q3;<E&]<_M8F\8.:EVT-:]EP-67<'X*8>N=<H(5 %U2
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M32Q03TA">,YZ6>CJA&VN"@VW/!9<6Z']87$3TM1^[QS^\S+AP6S2E!;D,P1
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M%]TO"=D[IU&W*J\YJ ;G2./I5$SI ">>B4L4W7732#P,UBS*LBGV2J9S_%W
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M\I;KM6@,2%Q1:'PQZ 6@V_'3*E9M?,LOE:4!XL6*)C9JYT#G*Z7L07$7=/^
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M(;A,\QN??KL$/AF_IZ-#3]P1K,_M+;U[T+D* ID3F+PY/.@-P&!C:&=0646
M>?7@S,,*KE.9::/CLH;KIIW_7$\ ,-(3 O<&*P)S9>02 G,O%R)2$!D' ).4
MRWKRDB8YPKYBLK.;P) F.'@N,Q5IBTV5S5Q1Z!BQ13TB6#@#3Y6,1* XEY&B
MQBW"6CQ%%H+"$!2/1Q<!WXJ!+).@H4/R/J&2YQPK<*5%M0GDDE;W '&DC9P!
MTIF,J@Y385VDP]1CIJ#@&JX]\4EF<TPIGVGH 7FAXH'G5A1$C(EBO"R=]&;5
M/6Q(\>1<^)(.2PKB_:]N04Y>DKPJ0"?R.$)#>0"0.5\Z3^J7%9Z"0GPGL&E[
M"6L3T#+[L])!4UQM.72S%__?@[U&$=:&_3;5%@Y(;BNDK1"$ "DY+<16@7'E
MEP#'P,->9++4Y& %M4N":@L-P& $ZQ1,?;]4TD,^B8[+GOC"20-N@,PMH%)X
M;C%[ 5>1W522<P1R7 W&?T#G,E&6*K]@&* I](6Y.WJ7%]_6)/S^H+REZBT^
M,Q"DP@WMV.G<?O]\ \:5I@IBT!L.WHJ=4$W^0$LA.---C0/DP&?P%FS"XXZ&
M<#U=8P:W(($V1- #Y$&>\B@.=(YDQHTO;L1%,];EJ#< QY(29& R@$TE@TBK
M+BM%+A6*8C[#9-I9E@8):F+(EWZ&>:@W[(T.WG;Q=P 3H.:P=TCON4)SQ_%0
M^\ H8(%FC [4#CZ:"K*@*1 2S"'Z<>584%W(*YS*''/8B;=V;>T@N%PWCB;;
M;4/C.DX1@:UC1CUHQUB3+FW)X4Q&"&P),4Y@&3*\IORUDFC =D4 D33"9SM]
MZTPHHL[N:1P;NYMV;@Y&9LB@-X+VL&) 6!.S(=-610-M99FBX&3D3'6W'JX3
MHV=<54)=>N-&4[WB] RGI?H$^&:51/Z,BFCPAP/8)A$GL"^QHBLFRV?L  M1
M^8!ZKCT%,ZW7MG[)70%OZ0Q^G02=:\G <BGY\8>CT6AP\G,ZTOG  \.3W9X8
MP]VK5KAU$M )]/ZT]34[FQH)Y:?:!ZJHVE'J2#/TT$06UPK2%MU+U(P*]36U
M"C($%?^&0EO"JRV-J1W'U85Z)^K_;$RV=L6"^XO( 0BY&<B 3!)#'5=9AAS@
MZR8".*O"-ND-3K))N?HND1J'D.2V";M+M"&>0F7"#$.8C@LG0!X/%,RR3N.:
M<W]]/N67J>-B?9R<]^%$7,E'72 PU\E.*B"PT#+I7%)%2@6<M)W@U:H0WE%X
MKZWY=/'E[G+\CO927IA1?F/]P-B]WF! &X;TOY/7!47YB*LBT4.[O%&.9MJ0
M7*V$[*&D7IC+E/&;+H,TQ"$'[2$(PL;$S_H1\]D<"5 Q&B_8F6R@RQ42S]I,
M6^,>.4U2X[ !@S:]\;*@WJ7TB"Q;RB7G8=B+)#)/J8WNU7EE*!4 D4R7.  +
M4V.DZ:8;2F(AU%S%_B6VU.@;6L;04[IO4.F)=QS7""^TS2TW7W%U=Q-&W=?A
MJ</_!7@2MV&BGJ),$559,UZ9\NWS&T9-P+PNENIQKB>:"S!=S,71^]\0^B:5
MQN;*DRZ0(Z0EMG;U4DF'0(4%I+T9K79]J]>?EWN25_=M:5J:G--BPG4=97%-
MOY4*3GTN57=2]D/O<._M1H-([,I ?=&CBK@DG1ZDJ;B"&620]]Q@DZ/I'.^0
M"I*;$'U3J:E!\_<JIDT]]#-DD*L"S@B[Z\=N .>-&!UT!^#[%@#JV:^(L&-$
M-'(:JN%_Z=ZBR*4ZA(H[T=1W[@R/1KOBCH/SF>YOQ/Y/W:/AT6H9992(:W@U
MFN7PW7(C9]92Y#- >W1Y_K6R2ARE@:X8VYEVETMHK+.0FFW9U/*FLE#8X\:7
M\CQXG"ETO6C*O2MX/DC3-A*HJF89=.++A7:WT F%95(%3?13W"[2%7VY?D-?
M0&#*!&L:4=X;'IX\]4S/[:T+$?5'"#R4F>YF6 A"]4@BD(.1J'KBNO+D%.8;
MW^O@@Z=B^I=CUH&:RQ3PJ1M_L@D%+#S==;FP-_*;"X*@],$.!+]0+]#LX-:P
MZ3M+?^7S%R[T,_[(1ZD<D*4O8>UH^QUQG#Z?/2U/'R&ON&.F3Q%3;!V@2^X(
MGS[LI9?H2OZ8-G$1O0 _SI6$/V@!YJ?.Q>:%#FB_KI[_#U!+ P04    "  %
MB@-7+_ K1KD"  #6!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R5
M5&UOVC 0_BNGK)HVJ2(AH5W5023HF%:I5(AVVX=I'YSD(%8=.[.=IOS[G1W(
MF$29]@%RKX^?L^]NW"K]9$I$"R^5D&82E-;6UV%H\A(K9@:J1DF>M=(5LZ3J
M36AJC:SP294(XRBZ#"O&99".O6VIT[%JK. 2EQI,4U5,;V<H5#L)AL'>L.*;
MTCI#F(YKML$'M%_KI28M[%$*7J$T7$G0N)X$T^'U;.3B?< WCJTYD,%5DBGU
MY)3;8A)$CA *S*U#8/1YQAL4P@$1C5\[S* _TB4>RGOTS[YVJB5C!F^4^,X+
M6TZ"JP *7+-&V)5JO^"NG@N'ERMA_#^T76Q")^:-L:K:)9-><=E]V<ON'@X2
MKJ)7$N)=0NQY=P=YEI^89>E8JQ:TBR8T)_A2?3:1X](]RH/5Y.649],56JZ1
M;MG"4C!IQJ$E5.<+\QW"K$.(7T$8QK!0TI8&YK+ XF^ D.CTG.(]IUE\$G'!
MMI ,SR&.XN0$7-*7F'BXY-\ESE#BFEL#/Z:9L9I:XN>Q@CN\T7$\-R;7IF8Y
M3@*: X/Z&8/T[9OA9?3Q!-M1SW9T"CU=S1]O5_/%_/X1EG?3^X=C_/X/X;%$
MN%%5S>062F: P2@:OGMZ#S4].#3T:!K:DN<EH. ;G@D$K&JAMH@&<@JA)J<0
M!K72?I+4&FR)7$-.J#2?S%G/H6;:.E^'Q0VUJ:4=4D"V=?%[#@-8.#N7&\J7
M5O.L<?D&6M0(9Z-!3'TNA(<D+=EKP&0!9\G@JC=PZ5O$-TKLW210W]"CU.BG
M7=!I5#[A,O<31L$STUPU!C@M(8N:,P&TVFAXW8[I&\5=C1D<>\[P8-8JU!N_
M4>B>5"-M-W:]M5]:TVY6_X1W&V_!](93X0+7E!H-/EP$H+LMTBE6U7YR,V5I
M#WBQI,6+V@60?ZV4W2ON@'Z5I[\!4$L#!!0    (  6* U=/T+.G>!   / Q
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;+5;:Y/;N+']*ZB)G=A5
M'(Y(42^_JNRQDW5N-G8\]J92M^X'2(1&B"E"YF/DV5]_3S< /B1J[/'N5NW:
MDD@T&OTX?1J G^U-\;G<*%6)K]LL+Y^?;:IJ]^3BHEQMU%:6H=FI'$_6IMC*
M"E^+ZXMR5RB9\J!M=A&/1M.+K=3YV8MG_-O[XL4S4U>9SM7[0I3U=BN+VU<J
M,_OG9]&9_^&#OMY4],/%BV<[>:VN5/5I][[ MXM&2JJW*B^UR46AUL_/7D9/
M7B7T/K_PBU;[LO-9T$J6QGRF+V_3YV<C4DAE:E61!(F_;M2ERC(2!#6^.)EG
MS90TL/O92_\KKQUK6<I279KLWSJM-L_/YF<B56M99]4'L_])N?5,2-[*9"7_
M*?;VW1@SKNJR,ELW&-^W.K=_RZ_.#IT!\]&) ;$;$+/>=B+6\K6LY(MGA=F+
M@MZ&-/K 2^714$[GY)2KJL!3C7'5BZO*K#YO3):JHOR+>/.EUM7MLXL*DNGY
MQ<I)>66EQ">D1+'XV>35IA1O\E2E?0$74*G1*_9ZO8KOE/BSO!7C*!#Q*![?
M(6[<+'/,XL8GQ-F%B?]]N2RK I'P?T-KM"*281&4'4_*G5RIYV<(_U(5-^KL
MQ9__%$U'3^]0,&D43.Z2_N+JX[O+__GIW3]>O_EP!3_\Z]/;C_\9TO'[I?SY
M3_,XFCUULL2EW.E*9OI7R=GP#O^M*K-4A8@79.8H"42U4>*5D44JS%J\U@4R
MQQ2ED+M=86Y4RL]?(B/A8B'S5'Q0924K?+E41:77>H4O-/1MOC+%SA1VJD<T
MC+2)1T_]Z,X ?A(]?1R*3WA4]";IO&:UDW6U,87^%<]6=D&BI @6NA3S43 :
M\?^BW$BX*! K _0H*YU?DUJSR<$+]./*;+=0DJ4$8B<+<2.S6HD'X2@2.^C#
MK_)RAX8C%-:J**#/-R2$XB/T=YEV.+&@*51>Z2HC,QMA<B5N#*P)V!5*KC9.
MC8W*TE!<U<O_PC?THIU?Y2O%?LI@JV6FZ(G,;P50&![*4S+ '3I7]] ,0:&
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M6- +>+XVIO)?:(+F'WF\^']02P,$%     @ !8H#5ZR-C\1[ P  "P@  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULC57;DMHX$/V5+J<J3\[8V,#
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MD3$ 06^$1 %8*XNM0D5YH9V0(B,+A,1=$:N2B\1LA(>.&*$ET 8'&E/I!-C
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M]R;GRQ0]55E:@/<;8WQS0QNT?P5=_0E02P,$%     @ !8H#5_X]@_#B"0
MQ1D  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&ULW5E=;]LX%OTKA&<Q
MDP"J8\MVXC1M@#1M=UI,/I"DW8?%/M 2;;,CB1Z2BNO]]7ON)27+J9-9[,L
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M#TL<.X6A"?B>:^TV#^1@>Y ]_ =02P,$%     @ !8H#5[X<$WW_!   ^ H
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M&#G&4&K0P%^C.4D1A?Y^+P/!0?=]!ZZMSLR297C1H+XQJ)^P,?ST6]SO?#X
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M/+D#RK3]JNR+<K$@Z>3UZ4R=PP[E.I* QAOEN<:6<TL\;76IVOJJZ?S@C*(
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MZ>)@1M^5)7>+#G =\.X6%!4>=QG"<56X2+\1DDF,=$5 MD.?/GZ@$HQ>1F$
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MA5I/O)ZWV;CAJ]RZC2 9EVR%<[3?RIDF*^A0,EZ@-%Q)T+B<>-/>Z#1V\77
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M"[CH,84"\#V7TJPG:*"[.D[_ E!+ P04    "  %B@-7^H9B*+ "  #,!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R%5-MNVS ,_17"&X86\.I;
MG-N2 $VW8GTH4+3=^C#L0;&96*@L>9*<M/OZ47;B>4":O<0D11X>1CJ<[91^
M-@6BA9=22#/W"FNK:1"8K,"2F0M5H:23M=(EL^3J36 JC2QOBDH1Q&$X#$K&
MI;>8-;$[O9BIV@HN\4Z#J<N2Z=<E"K6;>Y%W"-SS36%=(%C,*K;!![3?JCM-
M7M"AY+Q$:;B2H'$]]RZCZ7+@\IN$[QQWIF>#FV2EU+-S;O*Y%SI"*#"S#H'1
M9XM7*(0#(AJ_]IA>U](5]NT#^G4S.\VR8@:OE'CBN2WFWMB#'->L%O9>[;[B
M?I[4X65*F.87=FUN$GN0U<:J<E],#$HNVR][V?\/O8)Q^$9!O"^(&]YMHX;E
M9V;98J;5#K3+)C1G-*,VU42.2W<I#U;3*:<ZN[B16Y16:8X&SA[92J YGP66
MD-UYD.U1EBU*_ 9*%,.MDK8P\$7FF/\+$!"ECE=\X+6,3R+>LE=((A_B,$Y.
MP"7=F$D#E_QGS%?XS$TFE*DUPH_+E;&:WL7/8Q.W@(/C@$XK4U.Q#.<>B<&@
MWJ*W^/ N&H:?3M =='0'I]#[MW*,VLGBX]3Z]\QH=F.9Q1R8!9(E:E!KR)2Q
MP&0.DG8!"5SPW^X]P):)&N&L-EQNP!8(:ZZ-_<BEO[=(ZU"B+51^?@']1IDB
M\1K7A^";2B6H'>%,X8Q+"JG:4$=S#OW[[CLQW+,=/7B+FC-AX#W$8W\XFK1&
MG$;P1*H' JNTRM 8&/JC< PC/QH/X9I+3MK(8:-4;B":^)-D#%'J3](4'I5E
M@G#2U$_BU!F1GTQB.'9_04]A)>I-LT?<@+6TK=BZ:+>J+EN%_DUO]]PMTQLN
M#0A<4VEX,4H]T.WN:!VKJD:O*V5)_8U9T+I%[1+H?*V4/3BN0;? %W\ 4$L#
M!!0    (  6* U=2/;TVXP(  "@&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;'U5;6_C-@S^*X3O<+@#C+.M."_72P*T:8<;L&)%VVT?AGU0;#H6
M3I8\4;FD^_6C;-?+@#1?9(DB'SXD17IYL.X[U8@>CHTVM(IJ[]NK)*&BQD;2
M9]NBX9O*ND9Z/KI=0JU#679&C4Y$FLZ21BH3K9>=[,&MEW;OM3+XX(#V32/=
MRPUJ>UA%6?0J>%2[V@=!LEZV<H=/Z']K'QR?DA&E5 T:4M: PVH576=7-WG0
M[Q1^5WB@DSV$2+;6?@^'G\M5E 9"J+'P 4'RYP=N4.L Q#3^'C"CT64P/-V_
MHO_4Q<ZQ;"7AQNH_5.GK5;2(H,1*[K5_M(=O.,0S#7B%U=2M<.AUY_,(BCUY
MVPS&S*!1IO_*XY"'$X-%^H:!& Q$Q[MWU+&\E5ZNE\X>P 5M1@N;+M3.FLDI
M$XKRY!W?*K;SZP>'K50EW!VYS(0$TI3PJZ_1P<=GN=5(GY:)9T=!/2D&T)L>
M5+P!F@FXM\;7!'>FQ/+_  DS'&F*5YHWXB+BO7R!21:#2,7D MQDC'K2P4W>
M@+O%"IW#$C:6/,6PD:WR4JM_L(QA2$E\DHIK(O0$MXH*;6GO$/Z\WI)W_*;^
M.I>>WGM^WGOHLRMJ98&KB!N)T/W :/WA739+OUZ(+1]CRR^ACQ7%TXK:$,8Y
MIA>QSC-]VP$4EKN5/"?65L 2J*SFME=F=P4?E6&1W1.KTR<XK>CI0< MMI84
MI_L]++[DO(HX2V=PU[3:OB#"(WHT74L_RR-LN(S*PX=W"Y&)KY#'&=L\V<H?
M))=)JZ+GF,73-.-53*?P2R^$"OE"9'/(Y@*>G2P1J+8'@CQ?P$0LV)/QD'W)
M0.3I\!+:(7@OC\%XEG>*_5W&/ 6S%>SIV?)[8NYY/&,'[R%+XX7(X5Q]DY/N
M;=#MNAE%G,N]\7TCC])Q#%[WW?^?>C]#[Z7;*4.@L6+3]/-\&H'KYU)_\+;M
M9L'6>IXLW;;F48XN*/!]9:U_/00'X\]A_2]02P,$%     @ !8H#5QWH*8D^
M P  ?0<  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&ULG55M;^,V#/XK
MA'<86L XOZ=QE@1HN@X;<!V"WEX^#/N@V$PLG"SY)+FY[->/DA,O'=+<L ^V
M*8E\^) FJ?E>Z4^F0;3PI172+(+&VFX61:9JL&7FO>I0TLE6Z9996NI=9#J-
MK/9&K8C2.)Y$+>,R6,[]WEHOYZJW@DM<:S!]VS)]6*%0^T60!*>-9[YKK-N(
MEO..[? CVE^[M:95-*+4O$5IN)*@<;L([I/9*G?Z7N$WCGMS)H.+9*/4)[?X
MJ5X$L2.$ BOK$!A]7O !A7! 1./S$3,873K#<_F$_H./G6+9,(,/2OS.:]LL
M@FD -6Y9+^RSVO^(QW@*AU<I8?P;]H-NG@=0]<:J]FA,#%HNAR_[<LS#F<$T
M?L,@/1JDGO?@R+/\GEFVG&NU!^VT"<T)/E1O3>2X=#_EH]5TRLG.+M>:_J^V
MAQ#6@DD+3-;P^+GG'27>AO SE<7-+VPCT-S.(TL.G5E4'<%7 WCZ!GB2PI.2
MMC'P*&NL7P-$Q'2DFY[HKM*KB$_L %D20AJGV16X;(P^\W#9_XD>_KC?&*NI
M;OZ\%/J G%]&=KTT,QVK<!%0LQC4+Q@LO_TFF<3?7>&=C[SS:^AGO+N1-YYX
M7R)[%>XRV6?<(E6\:UN@YH?>X+87(*B)#&P.4#&+.Z4/,W@TEE-_8/U:9]5S
M47.Y\^PVIP5O.ZU>T!$UD(-5D)5P0*8-/*BVZRTY-6IK]TSCZ[@@==K%4?F)
M50V%H0__4BJ<TO2H1'^U\JX&I1<F>N:'02\YN3]A74TG."+#S.)_48S,4#H$
M9<7,X(9+L(WJ#5F86SBOSO-%^E]R\0[2,IQ,XD'(T^+K^;@+\ZQPG[1,WTQ(
M<A<Z.DD1YD7VM8RDDS K"#()X[@D I(:H!_F)X5*;'=4'Z06YGGNWG$*29R&
M97('91$6TP0^N'-657W;"U\3-5)-57SP<E.4Q&9R2P*YF)2WD&?AM$P@S\."
MQL4'Q\H]PKU>UTJ9^>>=T\VFN1,*HEG I8:*SD9BBWKG![^!2O72#M-QW!WO
MEOMAI/ZC/EQ,3TSON#0@<$NF\?N[(@ ]#/MA857G!^Q&61K77FSH?D3M%.A\
MJY0]+9R#\<9=_@U02P,$%     @ !8H#5_C#R#9@!   H0H  !D   !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&ULK59M;]LV$/XK!W<H;("H1>H]=0SDI>LZ
M+$/09AN&81\8B;:Y2J1'4G&R7[\C92MNZ^C#L"_V'<5[?^YXBYTVG^U&" >/
M;:/L^63CW/9L/K?51K3<OM%;H?#+2IN6.V3->FZW1O Z"+7-G$51-F^Y5)/E
M(IS=FN5"=ZZ12MP:L%W;<O-T*1J].Y_0R>'@HUQOG#^8+Q=;OA:?A/ME>VN0
MFP]::MD*9:568,3J?')!SRXS?S]<^%6*G3VBP4=RK_5GSWRHSR>1=T@THG)>
M \>_!W$EFL8K0C?^WNN<#":]X#%]T/Y]B!UCN>=67.GF-UF[S?FDF$ M5KQK
MW$>]^T'LXTF]ODHW-OS"KK^;QA.H.NMTNQ=&#UJI^G_^N,_#D4 1O2# ]@(L
M^-T;"EY><\>7"Z-W8/QMU.:)$&J01N>D\D7YY Q^E2CGEN^UKG>R:8"K&CXH
MQ]5:WC<"+JP5SL+TCB-G9XNY0V->9%[M%5_VBMD+BBF#&ZW<QL([58OZ2P5S
M]')PE1U<O62C&F_X$\24 (M8/*(N'B*/@[KXOT5^+6W5:-L9 7]<W%MG$#]_
MGDI#;R4Y;<7WU)G=\DJ<3[!IK# /8K)\_8IFT=N1&)(AAF1,^Q##*;]&)4_[
M-:0$FQT$KS;8=EMMG%1KZ)1T("WPIM$5=Z(&;O$><CM[!K\+CA*^T'!<)IA*
M!6ZC.XM)MC.XP>]W O5ZXEH\R$K G7:\@4O><(7<CYT2T$LS^ XP3R1E)5+)
M@6 1)5%:P."L;+=<&AP4#EZ_*AAE;V%*$Y(FY>R9V%=U(YHZ1&<YEGJXSE)2
M%M'LF<".QWY6V('&"%4] =9?V8;WDZ3^"QO3&\0&H825='9DN></\7R1#8PG
M+0F+"Z0. L]G(WA(!SRDHW@X@C$/ 9\"QJB*T\#X1B]4&N>R]3#0*ZRPV$,!
MD7(VBH#W1EN4YL8\>51=5%77=DW T\_X! T?;HVNN\J!0[0HW>BU%-87GU*2
MIQ2I*:4%B6DR0[J,21+G<!7&I3"(VKY2=B.W%M*<I%$)4T10GJ8SQ!3^)W!G
M>(T/'#Y^D),DC6":D2S#VN=E!#\A,I5%DPDI4/,T(5F>>%%?1%90!%4>G,@C
MDD2Q=X*B:S1)CJ-G_W?T<4F2K#=,&5JCP3#+2<RRE\+'#J(TA6E<D,A[RE 0
MA_-1^"4I??@YH06FAY$\2T\EP.>&YMXZIIW$61G\R"AV3!G\2!F)BV@,Q]F
MXVP4Q^\>M_AJ^QG3^O'S3]]W D_1IU.8'E5W&M.#C57G_)0_9:I/)=YQ.H!<
M?M,'PZ3\N@U@A0\(#K8GG(PV#,ZC<?D5+! JB4\@9K4L/9<&&G.)=.9IVI_G
MGH[2W-,%T(@4+-!E>,30/NYE*X<02&+""G:$RE-%F1^M#8B;=5B.?&MWRO4;
MQ' Z[%\7_=KQ?+U?WFZX64MEH1$K%(W>Y#AD3+\0]8S3V["$W&N'( WD!G=(
M8?P%_+[2VAT8;V#82I?_ E!+ P04    "  %B@-7*6<!'XP&   /$0  &0
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M^+FI+;:.H7ZJ%+1("!TI.9WQDFO.U% F]XN_90 UB0H*/@?QK,Z!>/62:K*
M]D0PGT2+ =WJ1^4&B;:9<JRP/BA_R'6?3/L/_D/R>GH^@:/0]2754$J6#G(J
MY080NZ:R@'"'KA/&KATD449NM,B_O<7N6)BJ!#Q3TW1#QX\#N,9>0CZP F26
MQ@VE 0OD^@VM5N\NC.X<C(#T[BA*L"I([ 10BI?U'92GD.AXXH<DC0+RWC*'
M0IIJC!>U !&VDDL(,2L:Z/K0TT!(!J4+E>.%Y#3/9<-V8YFD()5\E.CL0-ZC
MS$DA6L K41#M!JTOY8)!*\BY]1W]I)60FG]O@Q&#D)1$KG%H]^DK+9MV&::0
M0ED *B*,+L+#=7P7\(*9*8:4;PPN?">)+3"\"/Q-]^$AZ?"0O(#J)*8/7!5U
M#NJ-X4-8V"\:6P_V.5IO?D8VJY4H>0&2BW[?:=L#64)]MY@IR%R*RE >!+@!
MUC( 6HNF!*)EEGX+2[ITM2HW6,<XVU#0M@ZQ!ANHJ$U?FW$,\*=W;&LG/&J*
M#"$G=[D7PD(5^/("#AZ@.W!K_LC>SE!(BN\=NC\Y]F9*KGT!6Y(5,UO>TA8'
M4JWERMCQ4]L1$R=*@'9O#!K[;CFD1A*8=\'JVS0.(N3N*(B1J6,0>@F!RLW\
MKCNW! *!(  Y+\M:RK^&K1*5^=+86C P3ZPJ;#P]$AAG&5@59!%R?8"%?\5H
M:0D0IC*IX;1A%OE12KP$FA7THX]"%&M>EH2#-5R:[P%T_(B\>97ZGO^NNZ.1
M/6Y@]RQO,%*[W!7$,8F1--R$G"]IO< 0D;L!H$9.%$$O=+PXA6L&F32$2 8(
M,7*-4[$'L8O\F/P.M2.!EUP_(2'LHD,P]W_L>FF'\O2Y*&]JQ/6B-CVE9X-Z
M!M[W*AG>,=_N8$?C 62+7TCX#SJW&YT96_"ZQ@6V) HSM%2PSX478/++D^&8
MT=)D'R#Z:U,SXF$_C,.=ZP7+D0Y,Y2Q,<[%6FHVVV;D+Q2U*)"L-]0'YP*X.
M6&4#I@+E-8:/#*8,[I&#JD<EO;UW"MMU)5U9[98]#&64O.*ZQ>93<I[EMHW@
M@-M#%3GI'5(K)A?F*(ZT#^&PY]7N;7?:/[6'W(?I]J^"*RHA_XJ4; Y+W<,$
M=L_2'K_M@Q8K<^2="0T':#-<,@I,AA/@^UP(O7U !=U_(--_ 5!+ P04
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M/?*U/<<HG@0Y3O$(,A2*ALU84 NP%<)"29I9T2POX4PTI%*MH;J9<SCLRJ'
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M46D4BQ9JX&U^= 2?'Z$:?51:BDJC6+1PLLQ[_1BVW_^A8=E#O-C=L,"1?75
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MP7WD/@NL3$'9"3B^D-)L&G:!KM9-_P-02P,$%     @ !8H#5V9LP]ML @
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M\$-VS1S_&Z L .=74II]QUY-S9\H_0-02P,$%     @ !8H#5^^DW\0W P
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M<VAE970U-RYX;6RM5FUOVS80_BL'K2@2(*TLR9:=U!90VPM68 &"9.D^#/U
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MYXGB\ZZ#=Q/)&M,$7YA4+=4,2W7I =< ]7[)F-Q-=%\=KM'L+U!+ P04
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MJ8)-"Y(H+?_S;]5 ' 7@<P&D"B!] T95P.AMP.1,P+@*&+\-&)T)\*L OV_
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M%QLV.X(O\_7HSUP('N6;"T:G+,D*R.]GG(OM3E9!^7K)Z']02P,$%     @
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MG@.RG50\KY,U@YP6QU_\HVY$)P'Z(PFH3D#/3?#K!+\J],BL*NL&*[R8"7X
MHHS6:.5!U9LJ6U=#B_)OO%="WZ4Z3RW><[X\4,8 +I;@ME"X6-,'1L"5E$1)
M<&&X]OJ&*$R9?*/O?KN_ :]?O0&O "W UPW?28TC9Z[2U,H'N%E-X]V1!AJA
M\0D_ A_^!I"'?$/V];.S43_;U>UH>H*:GJ *SA^!NRWT.* %5>2"Z3%FZLO?
M'W4.N%4DE_^8JCT^(# _H)R:EW*+,S)W]-R31.R)L_CU%QAYOYN*MP36ZX7?
M],*?0E^\%US*(UJ&A7BDQ1KL,=L14]5'J+""*M>/_0(E, SBF;OOUG,:YL/
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M*5<-#JQ* G3-F5I*](.ED.X*^+J$NH[@K8Y)T*IX35]12+ZA  >AP\_TP^S
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M,K5?@[$_T')3K1FXEEK+K-I=<V;NG[* ^7TII;X_*"MH5L(L_@=02P,$%
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M1'W5JAN*K\WEXYDKO,J8UQ5>3T%H ?Z_X%P=&OH#S85W\A]02P,$%     @
M!8H#5Z]_,O@R P  SPD  !D   !X;"]W;W)K<VAE971S+W-H965T-S$N>&UL
MK59=;]HP%/TK5E9-G=01"%]3!Y%*TVE]J(2@; _3'DQR :N.G=D.T/WZ73LA
M@RI0-O4%_''/R3WG^FNPD>I)KP ,V:9<Z*&W,B:[]GT=KR"ENB$S$#BSD"JE
M!KMJZ>M, 4T<*.5^T&SV_)0RX84#-S96X4#FAC,!8T5TGJ94/8^ R\W0:WF[
M@0E;KHP=\,-!1I<P!3/+Q@I[?L62L!2$9E(0!8NA=].ZCOHVW@5\8[#1>VUB
ME<RE?+*=^V3H-6U"P"$VEH'BWQIN@7-+A&G\*CF]ZI,6N-_>L7]QVE'+G&JX
ME?P[2\QJZ'WR2 (+FG,SD9NO4.KI6KY8<NU^R::,;7HDSK61:0G&#%(FBG^Z
M+7W8 [1Z1P!!"0A> MI' .T2T#X7T"D!'>=,(<7Y$%%#PX&2&Z)L-++9AC/3
MH5$^$[;L4Z-PEB'.A/<BEBF01[H%30XZ'\D$8BEBQAEU)9(+,A,*QY:"_8;$
MAI$1"%@PH\EE!(8RKC\@;C:-R.7%!W)!F""/*YEK*A(]\ WF:[_JQV5NHR*W
MX$ANK8 \2&%6FMR)!))# A^%5FJ#G=I1<)+Q@3Z3=NN*!,V@79//[=GHH 8=
MG8UNG9#2K@K7=G3M(W3_4)PK<K>->9XPL20WJ<P%UFL,"NLE[)"1.$]Q;96P
M"9A<"4U^3"3G!'?7AJKD9UWYB@P[]1G: ^M:9S2&H8<GD@:U!B]\_Z[5:WZN
M\_XMR:(W(CNH3*>J3.<4>WA0!X.&SJLZS&')A#-]3CD5,=2Y6K!W';L]M==A
MI]<9^.M]L\Z(B4[''$CK5M*Z)Z5%$./=HL%N[*626A-:KB=<?U9J)C6SZU'C
ME<"IL09(DBDF%7D&JC1)<K!#L\:TX0!XRN/Q76=#D4EO+_WF"Q->C8A.11P8
MT*L,Z)UG0*F#TZQP0QMJ<@/6!\Y29MRNK#WS>J_J>C4B.A5QH*M?Z>K_[YH%
MD;RR8/MG+-@S8J+3,84N?^^J2T$MW9-!D]BNPN(>J$:K5\F-NXQ?C(_PM5(\
M+O[2%$^=!ZIPEVK"88&4S48?,U+%\Z'H&)FY"W4N#5[/KKG"%Q<H&X#S"RG-
MKF,_4+WAPC]02P,$%     @ !8H#5SIE7XH0 P  TPD  !D   !X;"]W;W)K
M<VAE971S+W-H965T-S(N>&ULK99K;YLP%(;_BL6JJ9.V<@N7= E2FVK:I%6+
MFG;[[,!)L&HPLYW;OY\-"4V#0_MA7Q(;SGG/\]KX,MHP_BQR (FV!2W%V,JE
MK*YM6Z0Y%%A<L0I*]6;!>(&EZO*E+2H..*N3"FI[CA/:!2:EE8SJ9U.>C-A*
M4E+"E".Q*@K,=[= V69LN=;AP0-9YE(_L)-1A9<P _E43;GJV:U*1@HH!6$E
MXK 86S?N]<2M$^J(WP0VXJB-M)4Y8\^Z\R,;6XXF @JIU!)8_:UA I1J)<7Q
M=R]JM35UXG'[H/ZM-J_,S+& ":-_2";SL15;*(,%7E'YP#;?86\HT'HIHZ+^
M19LF-@@LE*Z$9,4^61$4I&S^\78_$$<)KG\FP=LG>.]-\/<)?FVT(:MMW6&)
MDQ%G&\1UM%+3C7ILZFSEAI1Z&F>2J[=$Y<GD)DWY"C+TD^ YH402$.CR#B0F
M5'Q"7]#3[ Y=7GQ"%XB4Z#%G*X'+3(QLJ6IK!3O=U[EMZGAGZMSC'?+=S\AS
M/-^0/7EWMO<ZVU9^6]->:]JKY?PW3-,7TR9'C<C +*+7U[6H< IC2RT@ 7P-
M5O+Q@QLZ7TT&_Y/8*[]^Z]?O4T^F>,<9I4A-G5IZ%$OE';9J)Q!FXXU:4*OI
M?6"=##U?#?SZV% W2,_M2]0KTD%+.N@E_;62@F2 ] B0U$S7*(1'A2,GCD_H
MND%^Y+MFN*"%"WKA'M@.TW,?2] IZ,71X(3*$#2,0S-5V%*%_53J<\$\S>O9
MS6"M=N9*[;/2!!EVZKN!%YQ &H*\:&B&C%K(J!?RL.*$XN.X3,%$%W5')SS]
MZKHQP1FTN$6+>]%FF*H]3P_>0I/E1 "2>&N>Y;A3?A [)XC=F"APS(S#EG'X
MQAS/U:(U$@V[1.'PA*@;$[AGUH+KO!P<3O]2E3EPXT'@&)#BZ(3)$!5XP\$9
MJJ/CS.VE>F024R.5V]VOPM#M8'7#_$$\.-W6[*,35U]W[C%?DE(@"@N5YUQ%
M2H W-XBF(UE5'\)S)M617C=S=>L"K@/4^P5C\M#1YWI[CTO^ 5!+ P04
M"  %B@-7>^!0';L'  !50@  &0   'AL+W=O<FMS:&5E=',O<VAE970W,RYX
M;6RUG%UOVS84AO\*X15#"[2Q/NQ\=(F!.%2P#$T;).EV,>R"L>B8JR2Z)&4G
MP'[\2%DV15MFH^+D)K%D\2'U'NN(+TGI=,G%-SFC5*&G/"OD66^FU/QCOR\G
M,YH3><#GM-#?3+G(B=*;XK$OYX*2M"J49_TH" [[.6%%;W1:[;L1HU->JHP5
M]$8@6>8Y$<]CFO'E62_LK7?<LL>9,COZH],Y>:1W5'V=WPB]U=]04I;30C)>
M($&G9[WS\&,RB$R!ZH@_&5W*QF=D3N6!\V]FXRH]ZP6F132C$V401/];T N:
M98:DV_&]AO8V=9J"S<]K^F5U\OID'HBD%SS[BZ5J=M8[[J&43DF9J5N^_)W6
M)S0TO G/9/47+>MC@QZ:E%+QO"ZL6Y"S8O6?/-5"- I$T9X"45T@>FF!N"X0
M;Q6(]S5I4!<8;-<0[BDPK M4I]Y?G7LE'":*C$X%7R)ACM8T\Z%2ORJM]6*%
M^:'<*:&_9;J<&GWBQ2.ZIR)'F#XH] %])D(0$SST%E-%6";?H3>(%>A^QDM)
MBE2>]I6NV!3O3^I*\*J2:$\E882N>:%F$B5%2E,7T-<MWC0[6C=[''F)Y^7C
M 8J#]R@*H@A]O</H[9MW+0V[\&/^*(L#%,0&$YYX,-B/N2;/* ZKQL1K"IKP
M!2U(H5IPR8MQ>\[-T2S>A#JNL/$>;!7@JT(J4>HK7:&_/^D#T)6BN?RGI9'C
M%6W03C,)[*.<DPD]Z^D,):E8T-[HUU_"P^"WMCA PC D+ &".2$9;$(R\-&W
M0_(>76:<"[U'45V90K=$T;;0K*B'%=7<"A:CX+2_:.KMK;>KWI"P! CFZ#W<
MZ#WTZGW/%<E0IG/>!V5R7JKU;]/72^GZTX>$X15LV(C\X.0X/':CG^P>%0V#
MP/Y&'/$.-^(=>L6[9@7+R[Q-+V_!KGI!PC D+ &".>H?;=0_ LW>1Y A@81A
M2%@"!'-"<KP)R;'W@KC@><Y4%8TIU?VE.143O:'[UVU]B+$7UC4BD#"\@H5A
M\WYR$ 315E8!JM/1^F2C]8D_^9"G?<G'6["KKI P# E+@&".^F%@;4( FGYJ
M'%!40&D8E)9 T=S -/Q;")F$_+3.<8&DX9JVFX>&6XD(JEI7\LA*'GDEKW[Z
M?(HN!$U9:__1#^BL,B0-@](2*)H;"FMI0UA/&X*:6E :!J4E4#0W,-;8AB]P
MMO6 '6)K/RNTG]5;$T&)?$&N@O2=%Z T7-..W52UW6."JM,-@G6[H=_N5D%@
MC>&%?-6+0AE=4*%E-P%AW.0R53EC5AA'3-."2JEW(9+^6TJ]C9+QU3T^;PT2
MJ%<&I>&:UAPGB;<C!%2A&R%KJ4._IX:.T'LTY5G&EZQXU"A]U3%=ADR^ETPR
M,S#?-G@[]K>Q<PA!_7M-,YTL&\.#G0[!:SCST%KST&LSUR,C:,J>="0F,R)T
MX,SXKXU@J^Z@'AV4AFN:HWMXL-L3>PW_'5H#'OH=^,[E4XWJO7VF1,CV6PJH
M"?]!ZX:H:DBKO)#M2*!H;A2L-0_]WOQ&\ FEJ413P7-T)65)BDG50_ZT&6G%
M>T9::W1SJ-(9J:R%!K7EH+0$BN;.@UEC'GG]Y9890?^AL>E:[9LX\,.Z_OY!
M:1B4ED#1W+!86QZ%H,8D O7EH#0,2DN@:&Y@K'F/_.;]3A'377(MR=J)M-XS
M_,#.H0$U\S5M>\@DW+Y/0]7JBFYM>N1UF[M)ZHY.2OT9?=%]I,*LY4"7K-!W
M#=-OO:TB<O?E\O9=X_LKW?%]0G=+,M^?W$#-/2@-@](2*)H;3FONHP%L<@,U
M\J T#$I+H&AN8*SAC_R&_R>2V[!]S#7<ZH'Y*^XL.B0M@:*YHEL/'_D]_$YR
M6]O!'_7%0&TW* V#TA(HFAL@:\\CV*GS"-27@](P*"V!HKF!L?8]\AODGTA7
MH/X=E(:C]FGT<&?0!*I:5W5KUR._7=_-5_68XX_R%>A$.R@-@](2*)J[3--:
M^AAVKCT&-?6@- Q*2Z!H;F"LJ8_]<^W=\Y4?V#DTH+8^;I]N#X^V\Q54M:[J
MUK''7:;;=9:ZI0N>+8Q5K'==D@G+F'INC0"H>P>E85!: D5SP]1870Z\O!QV
M?3GL G/8%>:OX=9CZ]9C_U1\?9%,ZXL$/7 A5C.$$Z*KW7?=@'KVFM8<YC_:
M'>?'H)4F4#17=VO&8[\9O^%2LH>LL>"!%2\5'W12/=Y=#MXJ/J@IAZ*YXEM3
M'OM-^><R?Z#"W#:FJX%%DFV>R)'Z'N)Y.F?L1W=6']28U[3FDH;M12=0%;K*
M6[<=^R?#KYS>$5%(]X\83Q$MTA^N^/&C.RL/ZKQKVG9WZ?!H>TD)5+6N_M94
MQWY3/5YG&(EXJ:0B1:HW6M4&-=.@-%S3]C_"4FO]&E8ZME8Z]EOIESY/Y,=T
M5AK4.L>[,_"M2K^&)QY83SSH.,V]GD':M[# S^LJ.2@-@](2*)H;&6N*![ S
MW0-02PQ*PZ"T!(KF!L;ZYH'?-^\^7*KK0N<Y+]N[/36NF0CB8'<MCK_6SHJ#
M6F HVDKQ?N.Q^IR*Q^I]!E)W';6 JR?L-WLW[TPXK]X4T+>'KUZX<$W$(RLD
MRNA4%PT.CK3*8O4.@]6&XO/J(?T'KA3/JX\S2E(JS 'Z^RGG:KUA*MB\26+T
M/U!+ P04    "  %B@-7N$X_M 0#  !S"P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970W-"YX;6RMEFU/VS 0Q[^*E:$))" /?>[:2*,5&A)(B,+V8MH+-[FV
M%D[<V4X+$Q]^YR1D#:09H+QI;<?WO_N=S\F-MD+>JQ6 )@\1C]786FF]'MJV
M"E80474JUA#CDX60$=4XE4M;K270,#6*N.TY3M>.*(LM?Y2N74M_)!+-60S7
MDJ@DBJA\/ ,NMF/+M9X7;MARI<V"[8_6= DST'?K:XDSNU )602Q8B(F$A9C
MZZL[G+B.,4AW?&>P53MC8E#F0MR;R44XMAP3$7 (M)&@^+>!"7!NE#".W[FH
M5?@TAKOC9_7S%!YAYE3!1/ ?+-2KL=6W2 @+FG!]([;?( ?J&+U <)7^DFVV
MM]>U2) H+:+<&".(6)S]TX<\$3L&;FN/@9<;>&\U:.4&K10TBRS%FE)-_9$4
M6R+-;E0S@S0WJ372L-@<XTQ+?,K03ON7(EZ26Y 1F<)<DQ/R8F&&=1,F',CA
M%#1E7!WAGKO9E!P>')$#PF)RNQ*)HG&H1K;&@(RL'>3.SS+GWA[G5_21M-QC
MXCE>J\)Z\F9KKVQM8Q**3'A%)KQ4KK5'+L6]B)66"9:I)C\O<0.YT!"I7U5H
MF5J[6LW<OJ%:TP#&%EXO!7(#EO_YD]MUOE21-B16 F\5X*TZ=?\2E!J2)*:1
MD)K]@1"OP9QIPI1*:!P "832E:>;Z7927?.^V/@G;A_/8K.+5NO\@VCM JU=
MBW8K-.6$8TF?:%/2"*:K0#*5[@Y(>]!W^R](VJ]PO8[C.,6N4HB=(L1.??9-
ME8D%F4@(,>E/Y 8V@F\8WL)S&C#.]&-5Q+6B[ZV^AL1*_-V"O]OHM>LV"=Z0
M6 F\5X#WZ@^^5)7'9"F%JKQEO5?%62Z[#*76V0=1^@5*_S\H-%;DFC[2.7XI
MGL@,@@3+.?V"5!'5JKWW#!L2*X$/"O!!H\4[:!*\(;$2N.O\ZQN<9LHWU]G_
MVLR_];7NWHMC[W1$IAV]HG+)L$8Y+%#>.>UA.#+K\+*)%NNT29H+C2U7.EQA
M5PS2;,#G"R'T\\3T746?[?\%4$L#!!0    (  6* U?/5@]&:@(  (4&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;*U576_3,!3]*U:8T"9!TR3=
M&*.-M*X@>*A4;0P>$ ]N<MM8<^Q@W[3;O^?:24,[VJD/>TE\[7O._7).AFMM
M'FP!@.RQE,J.@@*QN@I#FQ50<MO3%2@Z66A3<B33+$-;&>"Y!Y4RC/O]B[#D
M0@7IT._-3#K4-4JA8&:8K<N2FZ<Q2+T>!5&PV;@5RP+=1I@.*[Z$.\#[:F;(
M"CN67)2@K-"*&5B,@NOH:C)P_M[AAX"UW5HS5\E<ZP=G?,M'0=\E!!(R= R<
M7BNX 2D=$:7QI^4,NI .N+W>L'_QM5,M<V[A1LN?(L=B%%P&+(<%KR7>ZO57
M:.LY=WR9EM8_V;KQ/:>(66U1ERV8[%*HYLT?VSYL :*+ X"X!<3/ <D!0-("
MDF,!@Q;@6QTVI?@^3#CR=&CTFAGG36QNX9OIT52^4&[L=VCH5! .TUM 88#F
MB&PFN;+L= +(A;1G[#V[OYNPTY,S=L*$8E,A)4W*#D.DN X=9FV,<1,C/A C
MBME4*RPL^ZQRR'<)0DJXRSK>9#V.7V2<\B>61.]8W(^3/?G<'(V.]Z G1Z.C
M%TI)N@$DGBXY>@#?X1%K+L_8K^NY14-?QN]]/6]H!_MIG5I<V8IG, I(#BR8
M%03IVS?11?_3OH:])MGDE<AVVCGHVCEXB9VF@UDAU))E=..,F-=XZ,XV/!\]
MCQ/'53KHT758;;=EGT^RZS/YWR?I778^31'AU@=:@EEZH;.48ZVPN?7=;J>E
MUUY"GNV/26,;2?Q'TPCTE)NEH.LC84&4_=Z'\X"91O0: W7E96"ND43%+POZ
M3X!Q#G2^T!HWA@O0_7G2OU!+ P04    "  %B@-7AC:(9>0.  !HI0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6S-G?V/VC@>QO\5BUO=M5(7R L!
M>M.1VB:Q*UV[HW9W[X?3:94!,T2%A$W"3.>T?_PY+X-Q, [I/;.Z^:'EQ?[8
MA@?;^3ZV<_609E_S-><%^;;=)/F;P;HH=J]'HWRQYMLH'Z8[GHAW5FFVC0KQ
M-+L;Y;N,1\LJTW8SLL=C;[2-XF1P?56]=I-=7Z7[8A,G_"8C^7Z[C;+'=WR3
M/KP96(.G%S['=^NB?&%T?;6+[O@77ORRN\G$L]&!LHRW/,GC-"$97[T9O+5>
M,V]69JA2_!KSA_SH,2F;<INF7\LG'Y9O!N.R1GS#%T6)B,1_]_P]WVQ*DJC'
M[PUT<"BSS'C\^(D>5HT7C;F-<OX^W?PS7A;K-X/9@"SY*MIOBL_I ^--@R8E
M;Y%N\NI?\M"D'0_(8I\7Z;;)+&JPC9/Z_^A;\T$<9;"M,QGL)H/=RN!,SV1P
MF@Q.*X-GG\G@-AG<=@GS,QDF38;)I1F\)H/7;O2Y3VG:9)A>FF'69*CD,JJ_
MCNJ[]*,BNK[*T@>2E:D%K7Q0":+*+;["."FU^Z7(Q+NQR%=<?RG2Q==UNEGR
M+/\;"7[?Q\4C^9%\BK(L*E5%7OB\B.)-_O)J5(CRRERC1</V:[9]AFW9Y&.:
M%.N<!,F2+U7 2%3T4%O[J;;O;"/Q4WH_)&/G%;''MDWR=93Q7%.O]V;*3XMB
M2.QY2;%<<I\6G/Q 1@WN/-4W4S]&C\2QJJHYY)<O/GGQP\OJAQLG=[^MTWU&
M@NUNDSYR4<8EQ047%V<?BKN$&U[,M7IQZ<7<\7D(NQ1BS;00157.X3?@5%3G
MG!Z*-<_(3P^)^ VLXQWYD!1<D(N<_.L?(BGY4/!M_F]-;=_57%?/+8>=U_DN
M6O W S&NY#R[YX/KO_[%\L9_UXD6"?.1L  )"Y$PBH0Q$$S1H'O0H&NB7[_=
M%^LTB__#EV01[>(BVI"\[)K)BUKFNN[WG1'95WXUS*M@Y8SG_GHVKO^N1O?'
MTD*6&B!A(1)&D3 &@BG2FARD-3%*ZTO=<:<KLDBW6S%?[!:6$=A76),384TG
M6F%=FC"X-&&(; =%PA@(I@C".PC",PKB_9$,7I%=E)'[:+,74[U]OB0[,116
MRGA)_C@:]W4J,9;25R4U;'KTG8Z'8ZNED$L2!9<D"I%UIT@8 \$494P/RI@:
ME7$C+AQYEHE!J!%',^F+Y.ADZC:,\+Z"F)[\R/6]QH7I@@O3A<A&4"2,@6"*
M,F8'9<SZ*>/[NPUC07U5,KNDV[@D47!)HA!9=XJ$,1!,$<?\((YYCP&EO*#.
MI2"$'LI7=$HP4OLJ87[R^V[+ %E<@(2%2!A%PA@(ILC*&LO@U-@HK)]V58#S
M+HL2<34>)T1<J9?*BM/E*_)0Q25%CQ3=\RRZXW4RLHP*3E91_+W=D[E*?54)
MI?D-[;B3F@_M::LGTZ::M%*%FE3.<-Y*1:'U9RB:*J>C6*=EE-/G./]*5AGG
M0DIUB(=DD;YK,I-ZJP!)\QN:9:ECE6.W=:!/-Y[;;2F<2>BX;34@V\%0-%4-
MME2#;51#\&W'%V7_<9]NHB+>E)'OLW(PHGK+ 4GS&]I,^?)<MRT&;:KV_$:;
MRIFW98"L/T/15!G(X*]EC.M)&8@>8:O][J%17BC-[VC;A#SR*,N)1;:E$4/L
ML1@>'[5NPZ6DV3E"V$%PGPA-9<2CR3D6A7Y*#$53%29#NY8YMONSF+04:1G2
M%<-.%B=YO&CF)NF*I-44)R?\&\\6<2YT*"8H6AE"H[U0FM_0)D?=AJV[!M>D
M$TC-1;@FX4R3CD*;P5 T52<R3FN9 [7B,FK'DSRJYKQ)6H@?C)B@\$5ZEU2A
MEW/"@$9KH33?.@W5.G.M,I#%AE :A=(8BJ:*3,9^+7/P]R9+%YPO<S$/3K>-
M%7!Y'P0-^4)I?D-3I*95VFDZ>ZKM@TX36CKM4F@[&(JFZD-&@"US"/CGZ!NY
MY0E?Q<59%4#CO%":W]"4D4@WP@2ZA!.M##0)=8%C"FT(0]%4&<APKV6.]](_
M->0"#0E#:3Z4%EBG46;;&]IN6W.GR2QQM=86'#2 C**I@I,A9,L<0W[;*&J7
MQ8MJ8EP'C^,\W]?CD5E!T% RE.8W-.7+=(;>2=1.DVP^')_$:DZ338?S25L:
MT" PBJ:N^9-18-L<!;ZI>I]2$\UDN)H@K]*,+-)RE99FJORBNM;4FI3FPOI*
M!4KS.SX(N[Z$UBX61-8CA-(HE,90-%6,,H9LFV/(3XLX2;5REM0.A59GT @R
ME.9#:0&4%D)I%$IC*)JJ/1FQMNM0*'ZAJ@V-7T-I/I060&DAE$:A-(:BJ6*4
M<7/;',\5H_*")T4Y9Q,C<V/1%BGAAU7N]T*:<7*GU2,TI@ZE^0U-]4#LU@PK
M@)890FD42F,HFJHS&3VWS=%S=0V 3F#-Y:E69]"@.93F=[3;-4SVD/4(H30*
MI3$43=6>C,C;YHC\!<$P,Z&WPJ#1]X9V'+IJA\&ZDX3=22BTV@Q%4[]T&2&W
M.R+DV,M-:,@<2O,[/@A3#X2L1PBE42B-H6BJ&&4XWC:'XS^+(2Z+J_4)]07G
M+T*/VA"8&=1;:-"H/)060&DAE$:A-(:BJ>*3)H ]>Z[K36A$'TKSH;0 2@NA
M- JE,11-%:,T"&RS0?!K]V0?:@) :7Y'XZQJJ-7J"[K0'$JC4!I#T=0]X-)E
M<,S!]3_5\337I:]4H33?.5T8;LV'\]8BT !:: BE42B-H6BJ,*7CX%SH.)3H
M>,%?E?MXY4*Q\J*DQVHQ<V&]E0>U)1K:\97FW-(MWH 6&T)I%$IC*)JJ/>DX
M..8U\I_2I RRE:<2'&GN^;I%J$T!I?G?0R.Z$;T!*?WK;.AXK; +M/842F,H
MFJK*H_-:S-:#7I7&K<EF8F]E8<]JJ6G*>0:.-[9/>KW3=-YT/+;:.[N@M:-0
M&D/15.5(,\$Q!]6QL3US8;U%!747.CX(PU(2:#U"*(U":0Q%4\4HW06GXV"6
M>CYGN*(U WH+#&HN=#3.$#R&UB.$TBB4QE T56#2R7 ZG8SJ=,M$B*PZ!8A$
MR9)H0\KD[4.4+?63,JB# :7Y4%H I850&H72&(JF"E.Z&L[TF0++#M3E@-)\
M*"V TD(HC4)I#$53Q2A=#L>\U>'G:FOFT55K-3L\])'U%JFHZAX/*T[.!5>@
MM@>4YC>TX^#*1+LS1I-PIMT9HTEHZ\(U%-H0AJ*I<I$^A&,.U9\,JOI!$^I%
M0&D^E!9 :2&41J$TAJ*I!X1*@\(=/].@Z4+=!BC-A]("*"V$TBB4QE T58S2
ME'#-IL1W[E4W4WLK$>H^N*?N@^WJ!DAHL2&41J$TAJ*I(I/N@VMV'[HM?S.@
MMYZ@AD%'XYSS 1)H/4(HC4)I#$53!2:-!/=[C(1GL[?,M>FM5J@)T="4G<G.
M<-H^)5.7;#:<.ZU+ TVR^7#:[)NO_UID"FT.0]%481V=YM[I,QPN$@R]%]0_
M@-+\C@::>B^H?P"E42B-H6BJR*1_X)I#[%@SRUQ8;S%"O8:.#^+\ZCEH-4(H
MC4)I#$53M2BM!M=L-8BNW6WLA-)C^)"4>P/+^P=5O@*YV43:3=)F:F_10;T%
M*"V TD(HC4)I#$53E2B]!?>YO 47ZBU :3Z4%D!I(91&H32&HJEBE-Z">XFW
MD.RWMT*3[3NP1/=1O(EN-^7ID.3V<-:-\8X_4(,!2O,;FG*PFO:L/VBQ(91&
MH32&HJGJDU:%:[8JZO'X9I\MUE'.SP_"4*\"2O.AM !*"Z$T"J4Q%$V]XY3T
M*B;/Y55,H%X%E.9#:0&4%D)I%$IC*)HJ1NE53,Q>!7H0-A?76Z)0$Z.A*:>@
M:H]BAA8;0FD42F,HFJH^:6),S''^C]&W>+O?'NFON:E6K;=TM1(]HS8\: ;W
MUAG4W&AHW;?=@A8;0FD42F,HFJHSZ65,S%Y&O<!S]S39JZ/..?E#WG98JS&H
M)0&E^9/3_0[M6YQ "PRA- JE,11-59<T-";F>+^_SVJO7_1?!XT=^C*MLJ#F
M!I3F=S36:^Y0H9VU0=T-*(U":0Q%4Q5W=-=:<U#_L.V5;^*[N)R@Q4EYU\$B
M7L2[J%H7$"?U\&E>(V NI[<0H<9&QV=@%"+4VH#2*)3&4#15B-+:F)BMC4^'
MB=M#FGTMM;9.]]G3_.V@SA?'[Y9K 9KGOY7/M;J$>A]0FC_1W"3A9&8'=32@
M- JE,11-%:!T-";F,Z!.!=C<0$E5H%9C4$L#2O,[6CTQ]7U0_P)*HU :0]%4
MZ4G_8F+V+P[7#B0]Q/**M2AIG6[T@RW4H(#2_(:F'NPZ;A_L"BTSA-(HE,90
M-%5;TIV8=&ZD.#I N%I6MXVRK[R0VW"BYBX0[:!=6A_2LXJSO%R5]U@F*%^X
M9#8(-3N@-+^AJ0*=G0@4:F) :11*8RB:(E!/FAA>YWTG_D>!;J+>^C37J:\^
MH32_H77H$UIF"*51*(VA:*H^I:_AF7T-.2^,ELMJ\5^T>0HN-^4MJ^6 I:=1
M+44UN1KFPGH+#^IJ0&F!=^J1:/<W0DNEFE(M7<2<=5=/U8MT(CR$$T'VR5*\
M6W97%ZX?,!?;6SE0G\([]2DL=SZ=SMJ=UFFZ^6PR:Q_*I,-YKC5OWYH+V@B&
MHJFZD<Z"U^$L5#)X>V99)[&KDXHTLH!:"U":#Z4%4%H(I5$HC:%HJA*E"^&Y
MS[2LQ(.Z$5":#Z4%4%H(I5$HC:%HJABE0>%U'-]4#IX_OHO*^^4JVV'?9EF4
MW/&MZ"K)[2,Y3G<3/58O5]WGJ^;N8;EXL"_R(DJ6XMK@%6GV=8C.-N/EN/O"
MY_4C_;SM]!;+UGQR.J]X;VY.;]$B:0&4%D)I%$IC*)HJ6FEF>&8SHW7[NNZY
M'=2D@-)\*"V TD(HC4)I#$53)2CM#.^Y-FAX4#<#2O.AM !*"Z$T"J4Q%$T5
MHS0X/+/!\?\RB)_NG= &!]Z;F]-;M-!;84!I(91&H32&HM6B'>5KS@L_*J+K
MJRW/[OA[OMGD9)'N$X$OPSN'5TG&5^6]M%^_M0>CD]=]ZS6SRM='$G-]M8ON
M^,<HNXN3G&SX2B#'PZF8A63E&0=/3XIT]V9@#<AM6A3IMGJXYM&29V4"\?XJ
M38NG)V4!I1-=5?OZOU!+ P04    "  %B@-7UC:17^@$  "A%   &0   'AL
M+W=O<FMS:&5E=',O<VAE970W-RYX;6RUF-MNXS80AE^%4!=M%G LD98E.W4,
M.(<>+H(&FZ9[4?2"ML8V$4GTDI0=%WWXDI(L.;".!9J+6"?.?#,<SB]Q=N#B
M36X!%'J/PEC>6ENE=C>V+5=;B*@<\AW$^LZ:BX@J?2HVMMP)H$$Z* IMXCB>
M'5$66_-9>NU9S&<\42&+X5D@F401%<<["/GAUL+6Z<(7MMDJ<\&>SW9T R^@
M7G?/0I_9A96 11!+QF,D8'UK+?#-'?',@/2)/Q@<Y-DQ,J$L.7\S)[\&MY9C
MB""$E3(FJ/[9PSV$H;&D.;[E1JW"IQEX?GRR_E,:O YF227<\_ K"]3VUII8
M*( U34+UA1]^@3R@L;&WXJ%,_Z-#_JQCH54B%8_RP9H@8G'V2]_S1)P-&$UK
M!I!\ $FY,T<IY0-5=#X3_("$>5I;,P=IJ.EH#<=B,RLO2NB[3(]3\Q?%5V];
M'@8@Y _H\5O"U!%=/8"B+)2?T2=D([FE B1B,7J-F9(#?5$?_[[EB:1Q(&>V
MTAS&FKW*?=YE/DF-3TS0$X_55J+'.(#@HP%;!U!$04Y1W)%&BT_TB$9X@(A#
M1NCUY0%=??K GOTT.!H5Z1JECD9UZ=*K(DA"R*N8_6V,FQ0BOBNK3.>P*BN9
M:;?:M%E^-W)'5W!KZ?4E0>S!FG__'?:<'QO W0+<;;(^?\D2\5NBI-*SQN(-
MH@HM8</BV)SP-3H"%>@J2]5G]$]ETK) ,E=>ZLHL^_V<C%R/N).9O:]@'!>,
MXRZ,/PL:*PBZH8PO4/#$GQ"OFL0K2+PN)(_O(%9,=F7Q+EBN7<WB5K/X!8O?
MA47WH#6PSGGQ+UG\J>_@:I9)P3+IEI<=$UU))I<D6C+T7S7*M$"9_H>"ACCH
M5\K3RU(FCC=VI]5TV"G[JM.)+VT+$D%62G2I>X?F-(#7!K839.[J0Y6[SH0X
M-0L.GW5_W(]RI]52SZSB: ]2F4:_3E0B .U ,![(CL#X MB?3D9N3?EA4O*2
MYOYK7%X;&0[0/8_TNXFD:=]="-TU-J#?%W17.Z+SYY[I,;V\.% 1#$ZQ#LY+
M9X"^IO*MGU[L0>C7D6+MHV?!5H#^7"RE$KJ[_U49+_D?6CLN10DW2L>\@*<Y
M/)S@=P9^T*'M)S(P4YS-J9G<4CTK \Z _/.*](=X5#._I4KA9IEJB:34AKZ\
MF5NSD,J%CH?CFMZ,2\G"S9K5!GPF(7V1QY?(V!WZ=9VIU#;<+&YMR&=*TQ?9
MJ\BR,W1(#7(I@;A9 ]NSG M27V"_(L=DB.O*HM1)W"R4?5?D!]WJ&\2D(@A_
M6%<GI<#B9H5MCZ%>V]* >@<RK0P$UY0/*;68-&MQCTC:]:]G4#G:ATXY'9(:
MY2:E<I-FY;Z(28#Y"#?UM-(?5T:J$AJBD*VA$JO9^CB=18FP@Z+L4XTX**#'
MIF\H4JHX:=3#/NRGN:DKLLK8FKV[>6S34VA^:V2E$I.>2MPILK:BJPRR&<2_
MF,!I:Y2E2I-FE5YL-@(V5(%&58+%DJW0GH9)<U_3*Z4RD,S7^&R!U'P:D%*5
M2;,J-P&V-*TZRLL/S3K*4HA)LQ"W4G;I1W6\7FM6[;-=HPC$)MT;D[I.DUAE
M&TC%U6+_;9'M.I6/9YMW3U3H-TJ)0ECKH<[0UWY%MA^6G2B^2_>@EEPI'J6'
M6Z !"/. OK_F7)U.C(-B5W+^+U!+ P04    "  %B@-77KYK+WP%  ! )P
M&0   'AL+W=O<FMS:&5E=',O<VAE970W."YX;6R]FEM/XS@8AO^*E1WM,M+0
MQ,ZI9=M*M)G9W0M&"#3,M6E,&Y%#QW'I\.\W)^(Z24U2##>0I/;[V4\=V^]7
M3_<)?4PWA##P.PKC=*9M&-M>Z'JZVI (IZ-D2^+LDX>$1IAEMW2MIUM*L%]4
MBD(=&8:C1SB(M?FT>'9-Y]-DQ\(@)M<4I+LHPO1Y0<)D/].@]O+@)EAO6/Y
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M@AVV;,-H+K7R=@RF]AZ>!'%/@N2>1$4>H0HAYA&@F?_B(H)3:CY4J8G@N/E
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M#VEY7*N\8<FV.,!TGS"61,7EAF"?T+Q ]OE#DK"7FSQ ?6AN_C]02P,$%
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M?1S+D%C5#*QN!-WH]M@=%8(6^C(E."%,&<CG*TK%XXV:H&G)SG\ 4$L#!!0
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M,=<!ZOV*,?DVT1U;U:$'_P!02P,$%     @ !8H#5Y.0N .; P  3!   !D
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MPCR@[Z\Y5Z\+L[FL_AM$?P%02P,$%     @ !8H#5P]-?3_, @  XPD  !D
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M!(\4#Q9U6<5VHL:>AJXIZ8US[)349A-G9G/M)AG&_J:#<]QRCE_*62.0=54
MSXC<8'.E&-)296SN!86; #H9>V,<RSC^CS'J9IRTC)->QF\%D$O@=$L5D'-W
M$W1!])H<"W$BLSW>:<L[/?6YG9Z2_41F>^RSEGUVY'ZFG,,*,OY$F,B5G9(,
M]WCW%ICU'*^:K3?ZL6S^SA5LGS]XUZT8)AH..=H'@RD>!54_*>J*D96[E9?2
MX!WOB@6^PD#9#O@]E](\5^Q%W[[KDK]02P,$%     @ !8H#5Z7ASE_Z P
M514  !D   !X;"]W;W)K<VAE971S+W-H965T.#@N>&ULM9A?;^,V#,"_BN =
MACN@J_\D=M(N"=#4\59@+8IFW1Z&/:@V$QNUI4Q2DCM@'WZ2[/KLS/$EA>XE
ML67R1XFD*9F3/66O/ 40Z'.1$SZU4B$VU[;-XQ0*S"_I!HA\LJ*LP$+>LK7-
M-PQPHI6*W/8<)[ +G!%K-M%CCVPVH5N19P0>&>+;HL#LRQQRNI]:KO4V\)2M
M4Z$&[-ED@]>P!/&\>63RSJXI258 X1DEB,%J:MVXUY&K%;3$'QGL>>,:J:6\
M4/JJ;NZ2J>6H&4$.L5 (+/]V< MYKDAR'O]44*NVJ12;UV_T2"]>+N8%<[BE
M^9]9(M*I-;90 BN\S<43W?\*U8)\Q8MISO4OVE>RCH7B+1>TJ)3E#(J,E/_X
M<^6(AH)W=43!JQ2\0X7@B,*@4A@<*KA'%(:5PO!4"WZEX!\HN(,C"D&E$&C?
ME\[2G@ZQP+,)HWO$E+2DJ0L=+JTM'9P1E5E+P>333.J)V1+6,D\$1Y@DZ!>@
M:X8W:1:C.U)FK8K^3^@!,X95"J"/(0B<Y?P3^H R@GY/Z99+53ZQA9R-8MIQ
M97E>6O:.6'8]=$^)2#E:D 22-L"6RZC7XKVM9>[U$N_Q%S1P+Y#G> /TO S1
MQP^?$"\7V#&_VW?0MB3K0H7GHSHHBY,IWK<F%)V,<GL</ZB3:*!Q@_XD0D^P
MH4QD9-U*G[]^D^+H3D#!_^Y*DY(][&:KRGK--SB&J25+)P>V VOVXP]NX/S<
M%5.3L- D;&$2%AF"M:(]K*,][*//'K;%"S!$5TCN;ZHLR'A7;UEG&2AI@::I
MC6XW\R;VKAFT;TJ$O3,Z-Q+_-^>VS46&S+7<Z]?N]7O=>\,Y=#NRU/,;\_8'
M7C 8'7CS-+'P-+%%AYCOC?Q#C_6NZ9T>"VJ/!;T>NR,"&-'%!N?H7UF&=D"V
M@%:,%NA6[C%,GE_DOBI2=*MW5)F]<R!Q*L]2KU*^L>U)Z1B4@JY<3QE_[0I$
M[W3.K5@F8:%)V,(D+#($:R7(J$Z0T7?<GT8FHVT2%IJ$+4S"(D.P5K3'=;3'
MO>6@_0XS^0Y?(+E1J3'YK=05X5[>N1$V"0M+V+A1?9U+][!$=PH%!P6Z4^BJ
M%FIY^JKV]%6OIY_EX1,2M!18 )>%]$%^"9?;UT6SJ-[(3][WE-E>X^>&Q20L
M- E;F(1%AF"M='"=KQ^3SG<LM!7<4,"-TD*CM(516F2*U@YZHX/@&JZW_<"S
M VV2%E:T=J$<^P<EUZC-R!2M#*#=Z ;)H^Y:]^TXBNF6B+*94H_6O<$;W1$[
M&)^KGJ'N,GW%E W'>\S6&>$HAY5$.I<C>?QG90^OO!%THWM.+U3(\[:^3 $G
MP)2 ?+ZB5+S=* -U)W7V'U!+ P04    "  %B@-7,'SP4^P#   )$@  &0
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MH&C<[Y;;,;M:96>Z8+_K8J;LQ;H[HNI TJE ?"Z%J.8 SD)#>A>7H#0*2DM
M:0R*9LO<^30X/FB[!/5M0&D4E): TA@4S5:],V^PURSPM$M08P:41AO:9I<+
M^LWRIR',$?(!![L\:MP9)-COD-#TT5Q*J;F0G-Z(/WOOPD+2*"@M :4Q*)JM
M:F>DX/%!VR.HX0)*HZ"T!)3&H&CV_WQWI@OQ3N]WMT=_WKYZ@M)H0_.UQY^'
M,$=(. [=S9%T?@;Q^QE7A>;%/+W/1'WYE/7;%5PIH5':.LO.@H/Z': T"DI+
M0&D,BF;KW?DLA!RR;1)0ZP641D%I"2B-0=%LU3OKA7@G^9ZV"6JJ@-)H0_.V
MS9^&,$<(#L?1KL;9^1K$[VM<*<E%EJ*KHB@?>3T;/U_I12E3_8S,X2W7[T8X
MBP[J?(#2*"@M :4Q*)JM>.>[D.B@K1/4A@&E45!: DIC4#1;]<Z&(?[W97:W
M3E"#!91&&YKUK!B-1OWNN1VUU3U](79%.XN#^"V.:UZL'OC+=70KLG+*=[TU
MYD?M7610UP.4EH#2&!3-EKBS7,CQ05LEJ"4#2J.@M 24QJ!HMNJ=)4/\+[?L
M;I6@9@LHC38TZ_DP&.-^J]R.BOO]E#F"=C3+L#,\0K_A42]W<-74G[?W^^>@
MA@<H+0&E,2B:K6?GMX3XD)TQ!'5=0&D4E): TA@4S5:]<UU"_]LM.SNC/V]O
M/4']E(:V^:)G'/;6%22.H"/<;XRNH"CNM<;AQI*QO'H;J%K<I]"T7!5ZO:BG
MW=HN(#ROE\WUME_@DTOLV$[Q"5LO#^SPZ]6*UUS.TT*A3#R8704?C\Q(Y7H!
MX/J++I?U@K7[4NLRKS\N!)\)6068WQ_*4K]\J7;0+L.<_ ]02P,$%     @
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M!&D,\/M4"+V<F V:7C3Z#U!+ P04    "  %B@-7"YO1)ET#   W"P  &0
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MTB56M;G50-!CV?@]4B';R/(Q!A(!4P#Y?D^I. _4 LT_&[9_ 5!+ P04
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    (  6* U?R)>8^T08  #X^   /
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M>E)B]< H&_0W4N2>E-@]&--OAE+DGI38/1C3;X92Y)Z4V#T8TV^&4N2>E'Q
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M=_E.O8?Q\U"'6\_7FL__3JK'RW?K[?'7Y=?%R0MUQ;F]KQB>_@)02P,$%
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  %B@-7W%">WN\    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  %
MB@-7F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    (  6* U<D1[*JQ <  &<O   8
M  " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  %
MB@-7\-Q&+CX"  #"!0  &               @($($   >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ !8H#5^7G=TM@!@  7QT  !@
M         ("!?!(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   (  6* U=]U*J<? ,  '0,   8              " @1(9  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  %B@-7^[LQF=L&  "5'
M&               @('$'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ !8H#5^Y4]EM0 P  HPL  !@              ("!U2,  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (  6* U>^5$E(00L
M -U]   8              " @5LG  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    "  %B@-7FRY]\:T(   +*P  &               @('2
M,@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ !8H#5^51
M/I[R$0  O#   !@              ("!M3L  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    (  6* U<]@S)>RP,  % (   9
M  " @=U-  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M!8H#5R]I,T.T P  V0<  !D              ("!WU$  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    "  %B@-7_QF!W#D/  #P*0  &0
M            @('*50  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    (  6* U<<@/:RW@D  /<=   9              " @3IE  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ !8H#5W=6;W6W @
MSP4  !D              ("!3V\  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    "  %B@-7WQ1*K?0"   Y!@  &0              @($]
M<@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  6* U<,
M7X3@%P,  +$&   9              " @6AU  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ !8H#5ZM1V?$A#   LB4  !D
M     ("!MG@  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  6* U=/T+.G>!   / Q   9              "
M@;^@  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ !8H#
M5ZR-C\1[ P  "P@  !D              ("!;K$  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    "  %B@-7?M+'OET'   6$@  &0
M        @($@M0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   (  6* U?^/8/PX@D  ,49   9              " @;2\  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ !8H#5SF5MVU@!@  U X
M !D              ("!S<8  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    "  %B@-7OAP3??\$  #X"@  &0              @(%DS0
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  6* U?T/R&V
MVP(  ),&   9              " @9K2  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ !8H#5X)FU,.>!   _ D  !D
M ("!K-4  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  %
MB@-7?%XKHS\#  "F!P  &0              @(&!V@  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  6* U='A3$T@1T  %M=   9
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M970S-2YX;6Q02P$"% ,4    "  %B@-7^H9B*+ "  #,!0  &0
M    @(%?#0$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M  6* U=2/;TVXP(  "@&   9              " @480 0!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ !8H#5QWH*8D^ P  ?0<  !D
M             ("!8!,! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    "  %B@-7^,/(-F $  "A"@  &0              @('5%@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  6* U<I9P$?C 8
M  \1   9              " @6P; 0!X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ !8H#5S5!UE71 @  ! 8  !D              ("!
M+R(! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  %B@-7
M$>_9,>P"  ".!@  &0              @($W)0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    (  6* U=E%%!^7 4  %X-   9
M      " @5HH 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ !8H#5\A(Z5_) @  (08  !D              ("![2T! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  %B@-7R =7KFT$  #<"P
M&0              @('M, $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    (  6* U?WZ(0^*0,  !,'   9              " @9$U 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ !8H#5R7;C8^-
M P  2 @  !D              ("!\3@! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    "  %B@-7SY1.4ZX$  !O"@  &0
M@(&U/ $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (  6*
M U<NL8WUM0(  &\&   9              " @9I! 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ !8H#5UDZ/<@,!P  HT,  !D
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M=#4T+GAM;%!+ 0(4 Q0    (  6* U=F;,/;; (  )4&   9
M  " @:I< 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
M!8H#5^^DW\0W P  R \  !D              ("!35\! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    "  %B@-7RW4T16@#   &"P  &0
M            @(&[8@$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    (  6* U>K6TXZ4@4  'HG   9              " @5IF 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ !8H#5W/@,!*, @
M4@<  !D              ("!XVL! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    "  %B@-7N@</0O\"  # "0  &0              @(&F
M;@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (  6* U<,
MGHEEQP0  ( =   9              " @=QQ 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ !8H#5P(7C]L!!0  BB<  !D
M     ("!VG8! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  6* U>4KSJA,@,   D,   9              "
M@6N, 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ !8H#
M5S3AJJ.V P  P0P  !D              ("!U(\! 'AL+W=O<FMS:&5E=',O
M<VAE970V."YX;6Q02P$"% ,4    "  %B@-7G-M)0.T%   5,P  &0
M        @('!DP$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0
M   (  6* U>.Y^806 0  /P.   9              " @>69 0!X;"]W;W)K
M<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ !8H#5Z]_,O@R P  SPD
M !D              ("!=)X! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q0
M2P$"% ,4    "  %B@-7.F5?BA #  #3"0  &0              @('=H0$
M>&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    (  6* U=[X% =
MNP<  %5"   9              " @22E 0!X;"]W;W)K<VAE971S+W-H965T
M-S,N>&UL4$L! A0#%     @ !8H#5[A./[0$ P  <PL  !D
M ("!%JT! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    "  %
MB@-7SU8/1FH"  "%!@  &0              @(%1L $ >&PO=V]R:W-H965T
M<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    (  6* U>&-HAEY X  &BE   9
M          " @?*R 0!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#
M%     @ !8H#5]8VD5_H!   H10  !D              ("!#<(! 'AL+W=O
M<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    "  %B@-77KYK+WP%  !
M)P  &0              @($LQP$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM
M;%!+ 0(4 Q0    (  6* U>$S5LB @0  )X5   9              " @=_,
M 0!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ !8H#5\K+
MEL?B @  \0@  !D              ("!&-$! 'AL+W=O<FMS:&5E=',O<VAE
M970X,"YX;6Q02P$"% ,4    "  %B@-7/#3M89@"  #5!@  &0
M    @($QU $ >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    (
M  6* U?<0^NIE@,  %,,   9              " @0#7 0!X;"]W;W)K<VAE
M971S+W-H965T.#(N>&UL4$L! A0#%     @ !8H#5_,B/<4M P  K0L  !D
M             ("!S=H! 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"
M% ,4    "  %B@-7DY"X YL#  !,$   &0              @($QW@$ >&PO
M=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    (  6* U?GA4=;@0(
M %T&   9              " @0/B 0!X;"]W;W)K<VAE971S+W-H965T.#4N
M>&UL4$L! A0#%     @ !8H#5P9=O187 P  )PP  !D              ("!
MN^0! 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    "  %B@-7
M#TU]/\P"  #C"0  &0              @($)Z $ >&PO=V]R:W-H965T<R]S
M:&5E=#@W+GAM;%!+ 0(4 Q0    (  6* U>EX<Y?^@,  %45   9
M      " @0SK 0!X;"]W;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%
M  @ !8H#5S!\\%/L P  "1(  !D              ("!/>\! 'AL+W=O<FMS
M:&5E=',O<VAE970X.2YX;6Q02P$"% ,4    "  %B@-7T^N<D4\#  "<#0
M&0              @(%@\P$ >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+
M 0(4 Q0    (  6* U<+;&+9< 8  )(Y   9              " @>;V 0!X
M;"]W;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%     @ !8H#5ST<CC?@
M @  EPH  !D              ("!C?T! 'AL+W=O<FMS:&5E=',O<VAE970Y
M,BYX;6Q02P$"% ,4    "  %B@-7"YO1)ET#   W"P  &0
M@(&D  ( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    (  6*
M U=$X-+E#P(  +X$   9              " @3@$ @!X;"]W;W)K<VAE971S
M+W-H965T.30N>&UL4$L! A0#%     @ !8H#5[=4H\S< P  >!   !D
M         ("!?@8" 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"% ,4
M    "  %B@-7\=3*M3L#  #,$P  #0              @ &1"@( >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    (  6* U>7BKL<P    !,"   +
M  "  ?<- @!?<F5L<R\N<F5L<U!+ 0(4 Q0    (  6* U?R)>8^T08  #X^
M   /              "  > . @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  %B@-7^C"$:+D"  #D-P  &@              @ '>%0( >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  %B@-7*J)E^DD"   5-@
M$P              @ '/& ( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..9P!G $@<  !)&P(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>247</ContextCount>
  <ElementCount>448</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Basis of Presentation, Business Description and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation, Business Description and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Assets Held For Sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AssetsHeldForSale</Role>
      <ShortName>Assets Held For Sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Revenue from Contracts with Customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/RevenuefromContractswithCustomers</Role>
      <ShortName>Revenue from Contracts with Customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Prepaid Expenses and Other</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/PrepaidExpensesandOther</Role>
      <ShortName>Prepaid Expenses and Other</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Long Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/LongTermDebt</Role>
      <ShortName>Long Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Retirement Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/RetirementPlans</Role>
      <ShortName>Retirement Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Segments and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/SegmentsandGeographicInformation</Role>
      <ShortName>Segments and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Acquisition, Restructuring and Other Items, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnet</Role>
      <ShortName>Acquisition, Restructuring and Other Items, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/ValuationandQualifyingAccounts</Role>
      <ShortName>Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Assets Held For Sale (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AssetsHeldForSaleTables</Role>
      <ShortName>Assets Held For Sale (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/AssetsHeldForSale</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Revenue from Contracts with Customers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/RevenuefromContractswithCustomersTables</Role>
      <ShortName>Revenue from Contracts with Customers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/RevenuefromContractswithCustomers</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Fair Value of Financial Instruments Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/Inventories</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Prepaid Expenses and Other (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/PrepaidExpensesandOtherTables</Role>
      <ShortName>Prepaid Expenses and Other (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/PrepaidExpensesandOther</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/AccruedLiabilities</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/StockholdersEquity</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/EarningsPerShare</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/Leases</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Commitments And Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments And Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Segments and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/SegmentsandGeographicInformationTables</Role>
      <ShortName>Segments and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/SegmentsandGeographicInformation</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Acquisition, Restructuring and Other Items, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetTables</Role>
      <ShortName>Acquisition, Restructuring and Other Items, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnet</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Assets Held For Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AssetsHeldForSaleDetails</Role>
      <ShortName>Assets Held For Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/AssetsHeldForSaleTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Revenue from Contracts with Customers - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue from Contracts with Customers - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Revenue from Contracts with Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails</Role>
      <ShortName>Revenue from Contracts with Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/RevenuefromContractswithCustomersTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Revenue from Contracts with Customers Revenue from Contracts with Customers - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/RevenuefromContractswithCustomersRevenuefromContractswithCustomersContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenue from Contracts with Customers Revenue from Contracts with Customers - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Fair Value of Financial Instruments Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails2</Role>
      <ShortName>Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3</Role>
      <ShortName>Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/InventoriesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Prepaid Expenses and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails</Role>
      <ShortName>Prepaid Expenses and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/PrepaidExpensesandOtherTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Property, Plant, and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant, and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Goodwill and Intangible Assets - Goodwill Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Goodwill Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Goodwill and Intangible Assets - Expected Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Expected Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Income Taxes - Components of Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails</Role>
      <ShortName>Income Taxes - Components of Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Income Taxes - Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Income Taxes Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Long Term Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails</Role>
      <ShortName>Long Term Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Long Term Debt - Long Term Debt Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails</Role>
      <ShortName>Long Term Debt - Long Term Debt Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Retirement Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/RetirementPlansDetails</Role>
      <ShortName>Retirement Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/RetirementPlans</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/StockholdersEquityTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Stockholders' Equity (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/StockholdersEquityDetails2</Role>
      <ShortName>Stockholders' Equity (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/StockholdersEquityTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Stockholders' Equity - Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/EarningsPerShareTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/LeasesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Leases - Liability Maturity Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails</Role>
      <ShortName>Leases - Liability Maturity Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Leases - Supplemental Statement of Operations Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails</Role>
      <ShortName>Leases - Supplemental Statement of Operations Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Commitments and Contingencies - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Segments and Geographic Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails</Role>
      <ShortName>Segments and Geographic Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Segments and Geographic Information - Sales by Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails</Role>
      <ShortName>Segments and Geographic Information - Sales by Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Segments and Geographic Information - Sale for Geographic Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails</Role>
      <ShortName>Segments and Geographic Information - Sale for Geographic Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Acquisition, Restructuring and Other Items, net - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails</Role>
      <ShortName>Acquisition, Restructuring and Other Items, net - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Acquisition, Restructuring and Other Items, net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetNarrativeDetails</Role>
      <ShortName>Acquisition, Restructuring and Other Items, net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/SubsequentEvents</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="ango-20230531.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails</Role>
      <ShortName>Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angiodynamics.com/role/ValuationandQualifyingAccounts</ParentRole>
      <Position>95</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  ango-20230531.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="ango-20230531.htm">ango-20230531.htm</File>
    <File>ango-20230531.xsd</File>
    <File>ango-20230531_cal.xml</File>
    <File>ango-20230531_def.xml</File>
    <File>ango-20230531_lab.xml</File>
    <File>ango-20230531_pre.xml</File>
    <File>ex2105312023.htm</File>
    <File>ex23angio2023consentofdelo.htm</File>
    <File>ex3115312310-k.htm</File>
    <File>ex3125312310-k.htm</File>
    <File>ex3215312310-k.htm</File>
    <File>ex3225312310-k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ango-20230531_g1.gif</File>
    <File>ango-20230531_g2.jpg</File>
    <File>ango-20230531_g3.jpg</File>
    <File>ango-20230531_g4.gif</File>
    <File>ango-20230531_g5.jpg</File>
    <File>ango-20230531_g6.jpg</File>
    <File>ango-20230531_g7.jpg</File>
    <File>ango-20230531_g8.jpg</File>
    <File>ango-20230531_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="971">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>124
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ango-20230531.htm": {
   "axisCustom": 0,
   "axisStandard": 30,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 971,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 247,
   "dts": {
    "calculationLink": {
     "local": [
      "ango-20230531_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ango-20230531_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ango-20230531.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ango-20230531_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ango-20230531_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ango-20230531.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 716,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 11,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 15
   },
   "keyCustom": 68,
   "keyStandard": 380,
   "memberCustom": 36,
   "memberStandard": 48,
   "nsprefix": "ango",
   "nsuri": "http://www.angiodynamics.com/20230531",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "dei:DocumentPeriodEndDate",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:CurrentFiscalYearEndDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.angiodynamics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "dei:DocumentPeriodEndDate",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:CurrentFiscalYearEndDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Acquisitions",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.angiodynamics.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Assets Held For Sale",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.angiodynamics.com/role/AssetsHeldForSale",
     "shortName": "Assets Held For Sale",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Revenue from Contracts with Customers",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.angiodynamics.com/role/RevenuefromContractswithCustomers",
     "shortName": "Revenue from Contracts with Customers",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value of Financial Instruments",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.angiodynamics.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.angiodynamics.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ango:PrepaidExpensesAndOtherTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Prepaid Expenses and Other",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.angiodynamics.com/role/PrepaidExpensesandOther",
     "shortName": "Prepaid Expenses and Other",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ango:PrepaidExpensesAndOtherTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Property, Plant and Equipment, Net",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNet",
     "shortName": "Property, Plant and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.angiodynamics.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.angiodynamics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Accrued Liabilities",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.angiodynamics.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.angiodynamics.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Long Term Debt",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.angiodynamics.com/role/LongTermDebt",
     "shortName": "Long Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Retirement Plans",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.angiodynamics.com/role/RetirementPlans",
     "shortName": "Retirement Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.angiodynamics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Earnings Per Share",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.angiodynamics.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.angiodynamics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.angiodynamics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Segments and Geographic Information",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.angiodynamics.com/role/SegmentsandGeographicInformation",
     "shortName": "Segments and Geographic Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Acquisition, Restructuring and Other Items, net",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnet",
     "shortName": "Acquisition, Restructuring and Other Items, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Accumulated Other Comprehensive Income (Loss)",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLoss",
     "shortName": "Accumulated Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.angiodynamics.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Valuation and Qualifying Accounts",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://www.angiodynamics.com/role/ValuationandQualifyingAccounts",
     "shortName": "Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "31",
     "role": "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Assets Held For Sale (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.angiodynamics.com/role/AssetsHeldForSaleTables",
     "shortName": "Assets Held For Sale (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Revenue from Contracts with Customers (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersTables",
     "shortName": "Revenue from Contracts with Customers (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Fair Value of Financial Instruments Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.angiodynamics.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ango:PrepaidExpensesAndOtherTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Prepaid Expenses and Other (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.angiodynamics.com/role/PrepaidExpensesandOtherTables",
     "shortName": "Prepaid Expenses and Other (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ango:PrepaidExpensesAndOtherTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetTables",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements Comprehensive Income (Loss)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.angiodynamics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Accrued Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.angiodynamics.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Long-Term Debt (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.angiodynamics.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.angiodynamics.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Earnings Per Share (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.angiodynamics.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ango:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://www.angiodynamics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ango:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCommitmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Commitments And Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "46",
     "role": "http://www.angiodynamics.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments And Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCommitmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Segments and Geographic Information (Tables)",
     "menuCat": "Tables",
     "order": "47",
     "role": "http://www.angiodynamics.com/role/SegmentsandGeographicInformationTables",
     "shortName": "Segments and Geographic Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Acquisition, Restructuring and Other Items, net (Tables)",
     "menuCat": "Tables",
     "order": "48",
     "role": "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetTables",
     "shortName": "Acquisition, Restructuring and Other Items, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "menuCat": "Tables",
     "order": "49",
     "role": "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ango:ShortTermInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Details Textual)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
     "shortName": "Basis of Presentation, Business Description and Summary of Significant Accounting Policies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ango:ShortTermInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Acquisitions - Narrative (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-63",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Assets Held For Sale (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails",
     "shortName": "Assets Held For Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Revenue from Contracts with Customers - Disaggregation of Revenue (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails",
     "shortName": "Revenue from Contracts with Customers - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-79",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ango:ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Revenue from Contracts with Customers (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails",
     "shortName": "Revenue from Contracts with Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ango:ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Revenue from Contracts with Customers Revenue from Contracts with Customers - Contract Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersRevenuefromContractswithCustomersContractAssetsandLiabilitiesDetails",
     "shortName": "Revenue from Contracts with Customers Revenue from Contracts with Customers - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-93",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Fair Value of Financial Instruments Fair Value of Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-90",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-8",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 2)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails2",
     "shortName": "Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-103",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 3)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3",
     "shortName": "Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-102",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ango:UndiscountedContingentConsiderationFairValueFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Inventories (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.angiodynamics.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ango:PrepaidDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Prepaid Expenses and Other (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails",
     "shortName": "Prepaid Expenses and Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ango:PrepaidDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Property, Plant, and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails",
     "shortName": "Property, Plant, and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-8",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Goodwill and Intangible Assets - Goodwill Rollforward (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails",
     "shortName": "Goodwill and Intangible Assets - Goodwill Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-121",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ango:ScheduleOfIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ango:ScheduleOfIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Goodwill and Intangible Assets - Expected Future Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Expected Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Income Taxes - Components of Loss (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails",
     "shortName": "Income Taxes - Components of Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Income Taxes - Income Tax Benefit (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails",
     "shortName": "Income Taxes - Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-118",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-9",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-9",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-8",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Income Taxes Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-14",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-143",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ango:DebtInstrumentFloorInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Long Term Debt - Narrative (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails",
     "shortName": "Long Term Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-143",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ango:DebtInstrumentFloorInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Long Term Debt - Long Term Debt Schedule (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails",
     "shortName": "Long Term Debt - Long Term Debt Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Retirement Plans (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.angiodynamics.com/role/RetirementPlansDetails",
     "shortName": "Retirement Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-152",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ango:CapitalStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-152",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ango:CapitalStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-8",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.angiodynamics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-8",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-4",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Stockholders' Equity (Details 2)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.angiodynamics.com/role/StockholdersEquityDetails2",
     "shortName": "Stockholders' Equity (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-44",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Stockholders' Equity - Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.angiodynamics.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.angiodynamics.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Leases - Liability Maturity Schedule (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails",
     "shortName": "Leases - Liability Maturity Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Leases - Supplemental Statement of Operations Information (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails",
     "shortName": "Leases - Supplemental Statement of Operations Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-170",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCommitmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Commitments and Contingencies - Schedule (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails",
     "shortName": "Commitments and Contingencies - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCommitmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-7",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-193",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ango:NumberOfPatentsAssertedForReexamination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-193",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ango:NumberOfPatentsAssertedForReexamination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "unit",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Segments and Geographic Information - Narrative (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails",
     "shortName": "Segments and Geographic Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-198",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Segments and Geographic Information - Sales by Product Category (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails",
     "shortName": "Segments and Geographic Information - Sales by Product Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "3",
      "lang": "en-US",
      "name": "ango:GrossMarginPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Basis of Presentation, Business Description and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation, Business Description and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Segments and Geographic Information - Sale for Geographic Areas (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails",
     "shortName": "Segments and Geographic Information - Sale for Geographic Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-195",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ango:AcquisitionRestructuringAndOtherItemsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Acquisition, Restructuring and Other Items, net - Schedule (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails",
     "shortName": "Acquisition, Restructuring and Other Items, net - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-226",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForPreviousAcquisition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ango:AcquisitionRestructuringAndOtherItemsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Acquisition, Restructuring and Other Items, net - Narrative (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetNarrativeDetails",
     "shortName": "Acquisition, Restructuring and Other Items, net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-227",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ango:AcquisitionRestructuringAndOtherItemsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-8",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-228",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-233",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfOtherAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.angiodynamics.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-233",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfOtherAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-241",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Valuation and Qualifying Accounts (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails",
     "shortName": "Valuation and Qualifying Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ango-20230531.htm",
      "contextRef": "c-234",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 84,
   "tag": {
    "ango_AccountsReceivableDuePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable due period.",
        "label": "Accounts Receivable Due Period",
        "verboseLabel": "Accounts receivables period due"
       }
      }
     },
     "localname": "AccountsReceivableDuePeriod",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "ango_AccruedResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development, Current",
        "label": "Accrued Research And Development, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_AcquisitionRestructuringAndOtherItemsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Restructuring And Other Items Net.",
        "label": "Acquisition Restructuring and Other Items Net",
        "terseLabel": "Total",
        "verboseLabel": "Acquisition, restructuring and other items, net"
       }
      }
     },
     "localname": "AcquisitionRestructuringAndOtherItemsNet",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetNarrativeDetails",
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_AllowanceForSalesReturnsAndDoubtfulAccountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for Sales Returns and Doubtful Accounts [Member]",
        "label": "Allowance for Sales Returns and Doubtful Accounts [Member]",
        "terseLabel": "Allowance for sales returns and doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForSalesReturnsAndDoubtfulAccountsMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_AssetAcquisitionInventoryAndFixedAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Inventory And Fixed Assets",
        "label": "Asset Acquisition, Inventory And Fixed Assets",
        "terseLabel": "Inventory and fixed assets"
       }
      }
     },
     "localname": "AssetAcquisitionInventoryAndFixedAssets",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental balance sheet information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ango_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "xbrltype": "stringItemType"
    },
    "ango_CapitalStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital stock shares authorized.",
        "label": "Capital Stock Shares Authorized",
        "verboseLabel": "Authorized capital stock (shares)"
       }
      }
     },
     "localname": "CapitalStockSharesAuthorized",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ango_CashPaidDuringPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid During Period [Abstract]",
        "label": "Cash Paid During Period [Abstract]",
        "verboseLabel": "Cash paid during the year for:"
       }
      }
     },
     "localname": "CashPaidDuringPeriodAbstract",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ango_ChangeInFairValueOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense charged against earnings in the period resulting from remeasurement to fair value of contingent earn out liabilities related to acquisitions.",
        "label": "Change in Fair Value of Contingent Consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "ChangeInFairValueOfContingentConsideration",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_CommonStockVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Votes Per Share",
        "label": "Common Stock, Votes Per Share",
        "terseLabel": "Common stock, votes per share"
       }
      }
     },
     "localname": "CommonStockVotesPerShare",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ango_ContractualObligationToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Obligation, To Be Paid, After Year Four",
        "label": "Contractual Obligation, To Be Paid, After Year Four",
        "totalLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "ContractualObligationToBePaidAfterYearFour",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Right of Return, Minimum Remaining Product Life Prior to Return",
        "label": "Contract with Customer, Right of Return, Minimum Remaining Product Life Prior to Return",
        "terseLabel": "Restocking charge period (months)"
       }
      }
     },
     "localname": "ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Right of Return, Product Return Period After Purchase Date Requiring Pre-Approval",
        "label": "Contract with Customer, Right of Return, Product Return Period After Purchase Date Requiring Pre-Approval",
        "terseLabel": "Right of return period (days)"
       }
      }
     },
     "localname": "ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ango_ContractwithCustomerRightofReturnRestockingCharge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Right of Return, Restocking Charge",
        "label": "Contract with Customer, Right of Return, Restocking Charge",
        "terseLabel": "Restocking charge (percent)"
       }
      }
     },
     "localname": "ContractwithCustomerRightofReturnRestockingCharge",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ango_CrBardIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C.R. Bard, Inc. [Member]",
        "label": "Cr Bard Inc [Member]",
        "terseLabel": "C.R. Bard, Inc."
       }
      }
     },
     "localname": "CrBardIncMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer With Customer, Liability, Revenue Recognized, Including Current Period",
        "label": "Customer With Customer, Liability, Revenue Recognized, Including Current Period",
        "terseLabel": "Revenue recognized, including current period."
       }
      }
     },
     "localname": "CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio",
        "terseLabel": "Debt instrument, maximum leverage ratio of total indebtedness to adjusted EBITDA"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMaximumTotalLeverageRatio",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio, Subsequent To Material Acquisitions",
        "label": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio, Subsequent To Material Acquisitions",
        "terseLabel": "Debt instrument, maximum leverage ratio of total indebtedness to adjusted EBITDA, following material acquisitions"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Minimum Fixed Charge Coverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Minimum Fixed Charge Coverage Ratio",
        "terseLabel": "Minimum fixed charge coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ango_DebtInstrumentDebtDefaultInterestRateIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Debt Default, Interest Rate Increase",
        "label": "Debt Instrument, Debt Default, Interest Rate Increase",
        "terseLabel": "Debt default interest rate increase (percentage)"
       }
      }
     },
     "localname": "DebtInstrumentDebtDefaultInterestRateIncrease",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ango_DebtInstrumentFloorInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Floor Interest Rate",
        "label": "Debt Instrument, Floor Interest Rate",
        "terseLabel": "Debt Instrument, Floor Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentFloorInterestRate",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ango_DeferredIncomeTaxRelatedToOperatingActivity": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows from operating activities related to components of deferred income tax assets.",
        "label": "Deferred Income Tax Related To Operating Activity",
        "verboseLabel": "Deferred income tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxRelatedToOperatingActivity",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_DeferredTaxLiabilitiesPurchaseAccountingAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Purchase Accounting Adjustment",
        "label": "Deferred Tax Liabilities, Purchase Accounting Adjustment",
        "terseLabel": "Deferred tax liability, purchase accounting adjustment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPurchaseAccountingAdjustment",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_DialysisProductPortfolioAndBioSentryBiopsyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dialysis Product Portfolio And BioSentry Biopsy",
        "label": "Dialysis Product Portfolio And BioSentry Biopsy [Member]",
        "terseLabel": "Dialysis Product Portfolio And BioSentry Biopsy"
       }
      }
     },
     "localname": "DialysisProductPortfolioAndBioSentryBiopsyMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_DivestitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divestiture",
        "label": "Divestiture [Member]",
        "terseLabel": "Divestiture"
       }
      }
     },
     "localname": "DivestitureMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount",
        "terseLabel": "Non-deductible executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_EmployeePlanParticipatingEligibilityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee plan participating eligibility period.",
        "label": "Employee Plan Participating Eligibility Period",
        "verboseLabel": "Employee eligible in participating in offering period"
       }
      }
     },
     "localname": "EmployeePlanParticipatingEligibilityPeriod",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ango_EmployeePlanParticipatingEligibilityThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership threshold for participating plan eligibility.",
        "label": "Employee Plan Participating Eligibility Threshold Percentage",
        "verboseLabel": "Employees ownership threshold"
       }
      }
     },
     "localname": "EmployeePlanParticipatingEligibilityThresholdPercentage",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ango_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_EximoMedicalLtd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eximo Medical, Ltd. [Member]",
        "label": "Eximo Medical, Ltd. [Member]",
        "terseLabel": "Eximo Medical, Ltd."
       }
      }
     },
     "localname": "EximoMedicalLtd.Member",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_FairValueLiabilitiesMeasuredOnRecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Liabilities Measured On Recurring Basis [Abstract]",
        "label": "Fair Value Liabilities Measured on Recurring Basis [Abstract]",
        "verboseLabel": "Summary showing the recurring fair value measurements of the contingent consideration liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisAbstract",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ango_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Abstract]",
        "label": "Fair Value Liabilities Measured on Recurring Basis Unobservable Input Reconciliation [Abstract]",
        "verboseLabel": "Fair Value Measurements using Significant Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Currency Gain (Loss) From Remeasurement",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Currency Gain (Loss) From Remeasurement",
        "terseLabel": "Currency gain from remeasurement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_GrossMarginPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Margin, Percentage",
        "label": "Gross Margin, Percentage",
        "terseLabel": "Gross Margin"
       }
      }
     },
     "localname": "GrossMarginPercentage",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ango_IncomeTaxReconciliationEffectOfForeignOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the difference, between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to the impact of non US operations.",
        "label": "Income Tax Reconciliation Effect of Foreign Operations",
        "verboseLabel": "Impact of Non-U.S. operations"
       }
      }
     },
     "localname": "IncomeTaxReconciliationEffectOfForeignOperations",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_IncomeTaxReconciliationEffectofEliminationofASC718APICPool": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation, Effect of Elimination of ASC 718 APIC Pool",
        "label": "Income Tax Reconciliation, Effect of Elimination of ASC 718 APIC Pool",
        "negatedTerseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationEffectofEliminationofASC718APICPool",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_IncomeTaxesTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes (Textual) [Abstract]",
        "label": "Income Taxes (Textual) [Abstract]",
        "verboseLabel": "Income Taxes (Textual) [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxesTextualAbstract",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ango_IncreaseInPlacementAndEvaluationUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase In Placement And Evaluation Units",
        "label": "Increase In Placement And Evaluation Units",
        "negatedTerseLabel": "Additions to placement and evaluation units"
       }
      }
     },
     "localname": "IncreaseInPlacementAndEvaluationUnits",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_IntangibleImpairmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Impairment [Member]",
        "label": "Intangible Impairment [Member]",
        "terseLabel": "Intangible and other asset impairment"
       }
      }
     },
     "localname": "IntangibleImpairmentMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_InternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International [Member]",
        "label": "International [Member]",
        "verboseLabel": "International"
       }
      }
     },
     "localname": "InternationalMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_IsraeliInnovationAuthorityPrepaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Israeli Innovation Authority Prepayment",
        "label": "Israeli Innovation Authority Prepayment [Member]",
        "terseLabel": "Israeli Innovation Authority prepayment"
       }
      }
     },
     "localname": "IsraeliInnovationAuthorityPrepaymentMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_LegalCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Costs [Member]",
        "label": "Legal Costs [Member]",
        "terseLabel": "Legal"
       }
      }
     },
     "localname": "LegalCostsMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity, Accordian Feature",
        "label": "Line Of Credit Facility, Maximum Borrowing Capacity, Accordian Feature",
        "terseLabel": "Possible increase in borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_LineOfCreditFacilityNumberOfCovenants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Number Of Covenants",
        "label": "Line Of Credit Facility, Number Of Covenants",
        "terseLabel": "Number of financial covenants"
       }
      }
     },
     "localname": "LineOfCreditFacilityNumberOfCovenants",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ango_ManufacturingRelocationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Relocation",
        "label": "Manufacturing Relocation [Member]",
        "terseLabel": "Manufacturing Relocation"
       }
      }
     },
     "localname": "ManufacturingRelocationMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_MeasurementInputProbabilityofPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Probability of Payment [Member]",
        "label": "Measurement Input, Probability of Payment [Member]",
        "terseLabel": "Measurement Input, Probability of Payment"
       }
      }
     },
     "localname": "MeasurementInputProbabilityofPaymentMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_MedDeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Med Device",
        "label": "Med Device [Member]",
        "terseLabel": "Med Device"
       }
      }
     },
     "localname": "MedDeviceMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails",
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_MedTechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Med Tech",
        "label": "Med Tech [Member]",
        "terseLabel": "Med Tech"
       }
      }
     },
     "localname": "MedTechMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails",
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_MergersandAcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mergers and Acquisitions [Member]",
        "label": "Mergers and Acquisitions [Member]",
        "terseLabel": "Mergers and acquisitions"
       }
      }
     },
     "localname": "MergersandAcquisitionsMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_NumberOfPatentsAssertedForReexamination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patents asserted for reexamination.",
        "label": "Number of Patents Asserted for Reexamination",
        "terseLabel": "Number of petitions filed for reexamination of patents"
       }
      }
     },
     "localname": "NumberOfPatentsAssertedForReexamination",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ango_NumberOfPatentsUpheldOverPriorArtReferences": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Patents Upheld Over Prior Art References",
        "label": "Number Of Patents Upheld Over Prior Art References",
        "terseLabel": "Number of patents upheld over prior art references"
       }
      }
     },
     "localname": "NumberOfPatentsUpheldOverPriorArtReferences",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ango_NumberOfSharePurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share purchase period.",
        "label": "Number of Share Purchase Period",
        "verboseLabel": "Share purchase periods"
       }
      }
     },
     "localname": "NumberOfSharePurchasePeriod",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ango_OarTracTrademarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OarTrac Trademark [Member]",
        "label": "OarTrac Trademark [Member]",
        "terseLabel": "OarTrac trademark"
       }
      }
     },
     "localname": "OarTracTrademarkMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_OperatingLossCarryforwardsAmountAfterLimitationOfUse": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Amount After Limitation Of Use",
        "label": "Operating Loss Carryforwards, Amount After Limitation Of Use",
        "terseLabel": "Net operating loss carryforwards after considering limitations of use"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAmountAfterLimitationOfUse",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_OtherNonoperatingIncomeExpenseAndInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Nonoperating Income (Expense) And Interest Expense",
        "label": "Other Nonoperating Income (Expense) And Interest Expense",
        "totalLabel": "Total other expenses, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAndInterestExpense",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_PaymentsToAcquireIntangibleAssetsNetOfCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of intangible assets, net of cash acquired from the purchase.",
        "label": "Payments To Acquire Intangible Assets Net Of Cash Acquired",
        "negatedLabel": "Acquisition of intangibles"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssetsNetOfCashAcquired",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_PerformanceShareAndRestrictedStockUnitAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Share and Restricted Stock Unit Awards [Member]",
        "label": "Performance Share and Restricted Stock Unit Awards [Member]",
        "verboseLabel": "Performance Share and Restricted Stock Unit Awards"
       }
      }
     },
     "localname": "PerformanceShareAndRestrictedStockUnitAwardsMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_PerformanceSharesIncludingThreeYearMarketConditionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Shares, Including Three-Year Market Condition [Member]",
        "label": "Performance Shares, Including Three-Year Market Condition [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesIncludingThreeYearMarketConditionMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_PlacementAndEvaluationUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement And Evaluation Units",
        "label": "Placement And Evaluation Units [Member]",
        "terseLabel": "Placement and evaluation units"
       }
      }
     },
     "localname": "PlacementAndEvaluationUnitsMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_PrepaidDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Deposits",
        "label": "Prepaid Deposits",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "PrepaidDeposits",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_PrepaidEmployeeTaxCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Employee Tax Credit",
        "label": "Prepaid Employee Tax Credit",
        "terseLabel": "Employee Retention Tax Credit"
       }
      }
     },
     "localname": "PrepaidEmployeeTaxCredit",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_PrepaidExpensesAndOtherTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other [Table Text Block]",
        "verboseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherTableTextBlock",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ango_PrepaidExpensesAndOtherTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other.",
        "label": "Prepaid Expenses and Other [Text Block]",
        "verboseLabel": "PREPAID EXPENSES AND OTHER"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherTextBlock",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/PrepaidExpensesandOther"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ango_PrepaidIncomeandOtherTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Income and Other Taxes",
        "label": "Prepaid Income and Other Taxes",
        "terseLabel": "Other prepaid taxes"
       }
      }
     },
     "localname": "PrepaidIncomeandOtherTaxes",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_PrepaidLicenseeFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of prepaid licensee fees.",
        "label": "Prepaid Licensee Fees",
        "verboseLabel": "License fees"
       }
      }
     },
     "localname": "PrepaidLicenseeFees",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments), Issuance Of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "label": "Proceeds (Payments), Issuance Of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of stock options and employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsPaymentsIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_ProductTechnologiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product technologies.",
        "label": "Product Technologies [Member]",
        "terseLabel": "Product technologies"
       }
      }
     },
     "localname": "ProductTechnologiesMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment excluding land and land improvements.",
        "label": "Property Plant and Equipment Excluding Land and Land Improvements",
        "totalLabel": "Property, plant and equipment excluding land and land improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentExcludingLandAndLandImprovements",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_PurchaseObligationToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation, To Be Paid, After Year Four",
        "label": "Purchase Obligation, To Be Paid, After Year Four",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "PurchaseObligationToBePaidAfterYearFour",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "QX Medical, LLC Camaro Support Catheter Asset Acquisition",
        "label": "QX Medical, LLC Camaro Support Catheter Asset Acquisition [Member]",
        "terseLabel": "QX Medical, LLC Camaro Support Catheter Asset Acquisition"
       }
      }
     },
     "localname": "QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_RadiaDyneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RadiaDyne [Member]",
        "label": "RadiaDyne [Member]",
        "terseLabel": "RadiaDyne"
       }
      }
     },
     "localname": "RadiaDyneMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_ResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development.",
        "label": "Research and Development [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_RetirementPlansTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retirement Plans (Textual) [Abstract]",
        "label": "Retirement Plans (Textual) [Abstract]",
        "verboseLabel": "Retirement Plans (Textual) [Abstract]"
       }
      }
     },
     "localname": "RetirementPlansTextualAbstract",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/RetirementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ango_RevenueBasedPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Based Payment [Member]",
        "label": "Revenue Based Payment [Member]",
        "terseLabel": "Revenue based payments"
       }
      }
     },
     "localname": "RevenueBasedPaymentMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_RevenuePerformanceObligationPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Payment Term",
        "label": "Revenue, Performance Obligation, Payment Term",
        "terseLabel": "Performance obligation payment term (days)"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPaymentTerm",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "terseLabel": "Potential future contingent consideration"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_RevolvingFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Facility",
        "label": "Revolving Facility [Member]",
        "terseLabel": "Revolving Facility"
       }
      }
     },
     "localname": "RevolvingFacilityMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_Royalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties",
        "label": "Royalties",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "Royalties",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_RoyaltiesDueAfterFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": 3.0,
       "parentTag": "ango_Royalties",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties, Due After Fourth Year",
        "label": "Royalties, Due After Fourth Year",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "RoyaltiesDueAfterFourthYear",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_RoyaltiesDueInFirstYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractualObligationDueInNextTwelveMonths",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties, Due In First Year",
        "label": "Royalties, Due In First Year",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "RoyaltiesDueInFirstYear",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_RoyaltiesDueinFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": 5.0,
       "parentTag": "ango_Royalties",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties, Due in Fourth Year",
        "label": "Royalties, Due in Fourth Year",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "RoyaltiesDueinFourthYear",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_RoyaltiesDueinSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": 2.0,
       "parentTag": "ango_Royalties",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties, Due in Second Year",
        "label": "Royalties, Due in Second Year",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "RoyaltiesDueinSecondYear",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_RoyaltiesDueinThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": 4.0,
       "parentTag": "ango_Royalties",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties, Due in Third Year",
        "label": "Royalties, Due in Third Year",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "RoyaltiesDueinThirdYear",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_SalesandMarketingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and Marketing [Member]",
        "label": "Sales and Marketing [Member]",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SalesandMarketingMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_ScheduleOfIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of intangible assets.",
        "label": "Schedule of Intangible Assets [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ango_ScheduleOfNetRevenueByProductGroupTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of net revenue by product group.",
        "label": "Schedule of Net Revenue by Product Group [Table Text Block]",
        "verboseLabel": "Summary of total net sales by product category"
       }
      }
     },
     "localname": "ScheduleOfNetRevenueByProductGroupTableTextBlock",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ango_ScheduleofIncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Income Tax [Line Items]",
        "label": "Schedule of Income Tax [Line Items]",
        "verboseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "ScheduleofIncomeTaxLineItems",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ango_SettlementExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Expense",
        "label": "Settlement Expense [Member]",
        "terseLabel": "Settlement Expense"
       }
      }
     },
     "localname": "SettlementExpenseMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award award granted to employees vesting percentage.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Award Granted to Employees Vesting Percentage",
        "verboseLabel": "Percentage of grants to employees vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPercentage",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ango_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award award granted to employees vesting period1.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Award Granted to Employees Vesting Period 1",
        "verboseLabel": "Option grants to employees vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardGrantedToEmployeesVestingPeriod1",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ango_SharePurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase period.",
        "label": "Share Purchase Period",
        "verboseLabel": "Duration of purchase of shares"
       }
      }
     },
     "localname": "SharePurchasePeriod",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ango_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangement by sharebased payment award purchase price of common stock percent on first day of offering period.",
        "label": "Share based Compensation Arrangement by Share based Payment Award Purchase Price of Common Stock Percent on First Day of Offering Period",
        "verboseLabel": "Percentage of fair market value of a share of common stock on the first day of the offering period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercentOnFirstDayOfOfferingPeriod",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ango_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Compensation Cost Probable Recognition Performance Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Compensation Cost Probable Recognition Performance Period",
        "terseLabel": "Performance period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsCompensationCostProbableRecognitionPerformancePeriod",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Working Hours Per Week to be Eligible",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Working Hours Per Week to be Eligible",
        "terseLabel": "Number of working hours to be eligible (working hour)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingHoursPerWeektobeEligible",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ango_SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Working Months Per Year to be Eligible",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Working Months Per Year to be Eligible",
        "terseLabel": "Number of working months to be eligible"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardWorkingMonthsPerYeartobeEligible",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ango_ShortTermInvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term investments maturity period.",
        "label": "Short Term Investments Maturity Period",
        "terseLabel": "Maturity period"
       }
      }
     },
     "localname": "ShortTermInvestmentsMaturityPeriod",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "ango_SoftwareLicenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of payments made for software licenses.",
        "label": "Software Licenses",
        "verboseLabel": "Software licenses"
       }
      }
     },
     "localname": "SoftwareLicenses",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_StockAndIncentiveAwardPlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock And Incentive Award Plan 2020",
        "label": "Stock And Incentive Award Plan 2020 [Member]",
        "terseLabel": "Stock And Incentive Award Plan 2020"
       }
      }
     },
     "localname": "StockAndIncentiveAwardPlan2020Member",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_StockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Plan [Member]",
        "label": "Stock Purchase Plan [Member]",
        "terseLabel": "Stock Purchase Plan"
       }
      }
     },
     "localname": "StockPurchasePlanMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_TaxPeriodFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Period Four [Member]",
        "label": "Tax Period Four [Member]",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "TaxPeriodFourMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_TaxPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Period One [Member]",
        "label": "Tax Period One [Member]",
        "terseLabel": "Tax Year 2022 and 2023"
       }
      }
     },
     "localname": "TaxPeriodOneMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_TaxPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Period Three [Member]",
        "label": "Tax Period Three [Member]",
        "terseLabel": "Tax Year 2020 To 2040"
       }
      }
     },
     "localname": "TaxPeriodThreeMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_TaxPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Period Two [Member]",
        "label": "Tax Period Two [Member]",
        "terseLabel": "Tax Year 2028 and 2037"
       }
      }
     },
     "localname": "TaxPeriodTwoMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_TheDelawareActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Delaware Action",
        "label": "The Delaware Action [Member]",
        "terseLabel": "The Delaware Action"
       }
      }
     },
     "localname": "TheDelawareActionMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_TradeShows": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of payments made in advance related to trade shows.",
        "label": "Trade Shows",
        "terseLabel": "Trade shows"
       }
      }
     },
     "localname": "TradeShows",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ango_TransitionServiceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition Service Agreement",
        "label": "Transition Service Agreement [Member]",
        "terseLabel": "Transition service agreement"
       }
      }
     },
     "localname": "TransitionServiceAgreementMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_TwoThousandAndFourStockAndIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand and Four Stock and Incentive Award Plan [Member]",
        "label": "Two Thousand and Four Stock and Incentive Award Plan [Member]",
        "verboseLabel": "2004 Stock and Incentive Award Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourStockAndIncentiveAwardPlanMember",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ango_UndiscountedContingentConsiderationFairValueFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undiscounted contingent consideration fair value fair value disclosure.",
        "label": "Undiscounted Contingent Consideration Fair Value Fair Value Disclosure",
        "verboseLabel": "Potential amount of undiscounted future contingent consideration"
       }
      }
     },
     "localname": "UndiscountedContingentConsiderationFairValueFairValueDisclosure",
     "nsuri": "http://www.angiodynamics.com/20230531",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r702",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r702",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r702",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r702",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r702",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r476",
      "r600",
      "r616",
      "r640",
      "r641",
      "r674",
      "r688",
      "r697",
      "r767",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails",
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r476",
      "r600",
      "r616",
      "r640",
      "r641",
      "r674",
      "r688",
      "r697",
      "r767",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails",
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r335",
      "r602",
      "r676",
      "r695",
      "r762",
      "r763",
      "r769",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails",
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r335",
      "r602",
      "r676",
      "r695",
      "r762",
      "r763",
      "r769",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails",
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r459",
      "r476",
      "r506",
      "r507",
      "r508",
      "r599",
      "r600",
      "r616",
      "r640",
      "r641",
      "r674",
      "r688",
      "r697",
      "r757",
      "r767",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails",
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r459",
      "r476",
      "r506",
      "r507",
      "r508",
      "r599",
      "r600",
      "r616",
      "r640",
      "r641",
      "r674",
      "r688",
      "r697",
      "r757",
      "r767",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails",
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r286",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "verboseLabel": "VALUATION AND QUALIFYING ACCOUNTS"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ValuationandQualifyingAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r336",
      "r337",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r677",
      "r696",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Segment, Geographical [Domain]",
        "verboseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r336",
      "r337",
      "r624",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r642",
      "r643",
      "r677",
      "r696",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "verboseLabel": "ACCRUED LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r33",
      "r694"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Receivables",
        "verboseLabel": "Accounts receivable, net of allowances of $2,150 and $1,939, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets",
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersRevenuefromContractswithCustomersContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails",
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "auth_ref": [
      "r217",
      "r231"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.",
        "label": "Accrued Professional Fees",
        "terseLabel": "Outside services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r37",
      "r656"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "verboseLabel": "Royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r116",
      "r245"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r253",
      "r611",
      "r621",
      "r622"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r46",
      "r49",
      "r186",
      "r592",
      "r617",
      "r618",
      "r717",
      "r718",
      "r719",
      "r733",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r45",
      "r49",
      "r186",
      "r265",
      "r266",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r733",
      "r734",
      "r735",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r158",
      "r159",
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvanceRoyaltiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance Royalties [Abstract]",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "AdvanceRoyaltiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation pre tax amount"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r254",
      "r343",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, allowances"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r71",
      "r100",
      "r106"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense",
        "verboseLabel": "Amortization of intangibles"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Securities excluded as their inclusion would be anti-dilutive"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r692",
      "r805",
      "r806",
      "r807"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r71",
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r212",
      "r225",
      "r249",
      "r274",
      "r322",
      "r326",
      "r331",
      "r344",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r552",
      "r554",
      "r568",
      "r694",
      "r765",
      "r766",
      "r817"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r240",
      "r257",
      "r274",
      "r344",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r552",
      "r554",
      "r568",
      "r694",
      "r765",
      "r766",
      "r817"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r10",
      "r113",
      "r119",
      "r238",
      "r239"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Current assets held for sale",
        "totalLabel": "Current assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails",
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2",
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation and Description of Business"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Building and building improvements",
        "verboseLabel": "Building and building improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r549",
      "r686",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3",
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r549",
      "r686",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3",
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails",
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r179",
      "r180",
      "r551"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration for acquisition earn outs",
        "verboseLabel": "Revenue based payments"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r179",
      "r181"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Discount rate used in fair value calculation"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r179",
      "r181"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "verboseLabel": "Contingent consideration, net of current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r182",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r73",
      "r243",
      "r653"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r67",
      "r73",
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r67",
      "r206"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r218",
      "r230"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and Contingencies (Note 17)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r126",
      "r382",
      "r383",
      "r626",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r129",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r733",
      "r734",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (shares)",
        "verboseLabel": "Shares of common stock (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "verboseLabel": "Common stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24",
      "r694"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.01 per share, 75,000,000 shares authorized; 39,981,422 and 39,541,173 shares issued and 39,611,422 and 39,171,173 shares outstanding at May 31, 2023 and 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "verboseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "verboseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Summary of Income tax (benefit) provision analyzed by category"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r50",
      "r260",
      "r262",
      "r269",
      "r607",
      "r613"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r61",
      "r268",
      "r606",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "ACCUMULATED OTHER COMPREHESIVE INCOME (LOSS)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "verboseLabel": "Computer software and equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r88",
      "r89",
      "r204",
      "r205",
      "r339",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r88",
      "r89",
      "r204",
      "r205",
      "r339",
      "r623",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r88",
      "r89",
      "r204",
      "r205",
      "r339",
      "r625",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r88",
      "r89",
      "r204",
      "r205",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r88",
      "r89",
      "r204",
      "r205",
      "r339",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "verboseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Contract with Customer, Asset and Liability"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r435",
      "r437",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersRevenuefromContractswithCustomersContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r435",
      "r436",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails",
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersRevenuefromContractswithCustomersContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r435",
      "r436",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract with customer, liability, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": {
     "auth_ref": [
      "r675"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.",
        "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination",
        "terseLabel": "Additions to contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Four",
        "totalLabel": "2027"
       }
      }
     },
     "localname": "ContractualObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year One",
        "totalLabel": "2024"
       }
      }
     },
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Two",
        "totalLabel": "2025"
       }
      }
     },
     "localname": "ContractualObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Three",
        "totalLabel": "2026"
       }
      }
     },
     "localname": "ContractualObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r58",
      "r602"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales (exclusive of intangible amortization)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails",
      "http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails",
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails",
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r726",
      "r801"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "verboseLabel": "Non U.S."
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r172",
      "r534",
      "r542",
      "r726"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r726",
      "r801",
      "r803"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "verboseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r213",
      "r215",
      "r224",
      "r279",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r580",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Stated interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r20",
      "r215",
      "r224",
      "r415"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r208",
      "r210",
      "r398",
      "r580",
      "r670",
      "r671"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails",
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r39",
      "r279",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r580",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r39",
      "r137",
      "r140",
      "r141",
      "r142",
      "r207",
      "r208",
      "r210",
      "r222",
      "r279",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r580",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails",
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term (years)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r209",
      "r404",
      "r416",
      "r670",
      "r671"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: unamortized debit issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]",
        "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r726",
      "r802",
      "r803"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r172",
      "r726",
      "r802"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Non U.S."
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r71",
      "r172",
      "r535",
      "r541",
      "r542",
      "r726"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r21",
      "r22",
      "r214",
      "r223",
      "r529"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Gross deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other tax liabilities expected to be paid after one year or operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Tax Liabilities, Noncurrent",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r170",
      "r800"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r170",
      "r800"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r170",
      "r800"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r169",
      "r170",
      "r800"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Federal and state R&amp;D tax credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r170",
      "r800"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "auth_ref": [
      "r170",
      "r800"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "terseLabel": "Expenses incurred not currently deductible"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r163",
      "r799"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r170",
      "r800"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "verboseLabel": "Matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r71",
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r71",
      "r114"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "verboseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r455",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsHeldforsaleMember": {
     "auth_ref": [
      "r2",
      "r3",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations, Held-for-sale [Member]",
        "terseLabel": "Discontinued Operations, Held-for-sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsHeldforsaleMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r10",
      "r111",
      "r119",
      "r238",
      "r239"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Non-current assets held for sale",
        "totalLabel": "Non-current assets held for sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails",
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r10",
      "r111",
      "r119"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r10",
      "r111",
      "r119"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r10",
      "r113",
      "r119"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r10",
      "r113",
      "r119"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r10",
      "r111",
      "r119"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r15",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "ASSETS HELD FOR SALE"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSale"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r686",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r270",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r300",
      "r302",
      "r304",
      "r305",
      "r306",
      "r310",
      "r558",
      "r559",
      "r608",
      "r614",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "verboseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]",
        "terseLabel": "Weighted average shares outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r270",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r302",
      "r304",
      "r305",
      "r306",
      "r310",
      "r558",
      "r559",
      "r608",
      "r614",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Employee service, compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period of recognition for costs not yet recognized (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r796"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r136",
      "r237",
      "r264",
      "r265",
      "r266",
      "r287",
      "r288",
      "r289",
      "r291",
      "r297",
      "r299",
      "r313",
      "r345",
      "r434",
      "r512",
      "r513",
      "r514",
      "r537",
      "r538",
      "r557",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576",
      "r592",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r560",
      "r561",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r199",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r406",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r561",
      "r596",
      "r597",
      "r598",
      "r670",
      "r671",
      "r683",
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value By Fair Value Hierarchy Level [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r560",
      "r561",
      "r563",
      "r564",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Fair Value By Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r406",
      "r461",
      "r466",
      "r561",
      "r596",
      "r683",
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r406",
      "r461",
      "r466",
      "r561",
      "r597",
      "r670",
      "r671",
      "r683",
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r406",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r561",
      "r598",
      "r670",
      "r671",
      "r683",
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Change in present value of contingent consideration (1)"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r406",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r596",
      "r597",
      "r598",
      "r670",
      "r671",
      "r683",
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Measurements Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r565",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful life of intangible assets other than goodwill (years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r247",
      "r367"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "2029 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "verboseLabel": "2028"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r364",
      "r366",
      "r367",
      "r368",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails",
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "verboseLabel": "Expected amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r105",
      "r604"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Gross\u00a0carrying value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r101",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails",
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r105",
      "r603"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net\u00a0carrying value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Intangible asset product technology"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails",
      "http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r87",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r246",
      "r351",
      "r605",
      "r664",
      "r694",
      "r745",
      "r752"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance May 31, 2023",
        "periodStartLabel": "Balance June 1, 2022",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "GOODWILL AND INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r71",
      "r352",
      "r357",
      "r363",
      "r664"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Goodwill impairment",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r57",
      "r274",
      "r322",
      "r325",
      "r330",
      "r333",
      "r344",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r568",
      "r662",
      "r765"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.",
        "label": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r721",
      "r756"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r71",
      "r112",
      "r118"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Asset impairments and disposals"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r275",
      "r543"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r53",
      "r211",
      "r219",
      "r233",
      "r322",
      "r325",
      "r330",
      "r333",
      "r609",
      "r662"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income tax benefit",
        "totalLabel": "Income (loss) before tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations",
      "http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r275",
      "r543"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "verboseLabel": "Non-U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "verboseLabel": "Loss before tax expense:"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesComponentsofLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r686",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r11",
      "r12",
      "r13",
      "r14",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r370",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails",
      "http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails",
      "http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r276",
      "r522",
      "r527",
      "r533",
      "r539",
      "r544",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r277",
      "r298",
      "r299",
      "r321",
      "r520",
      "r540",
      "r545",
      "r615"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit",
        "totalLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations",
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxBenefitDetails",
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "verboseLabel": "Reasons for consolidated income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r263",
      "r518",
      "r519",
      "r527",
      "r528",
      "r532",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r797"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r521"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax benefit at federal statutory tax rate of 21.0%, 21.0% and 21.0%, respectively"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r797"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "auth_ref": [
      "r797"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount",
        "terseLabel": "Meals and entertainment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r797"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r797"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "verboseLabel": "State income taxes, net of Federal tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r797"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development tax credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Increase in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Additional unrecognized tax benefit"
       }
      }
     },
     "localname": "IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r99",
      "r103"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r209",
      "r221",
      "r267",
      "r320",
      "r579"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "ango_OtherNonoperatingIncomeExpenseAndInterestExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r722"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "verboseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r711"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r256",
      "r654",
      "r694"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.angiodynamics.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets",
      "http://www.angiodynamics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/InventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r242",
      "r255",
      "r312",
      "r348",
      "r349",
      "r350",
      "r601",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r713"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r97",
      "r714"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory valuation reserve"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r712"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Israel.",
        "label": "Israel Tax Authority [Member]",
        "terseLabel": "Israel"
       }
      }
     },
     "localname": "IsraelTaxAuthorityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LandAndLandImprovements": {
     "auth_ref": [
      "r709"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale.",
        "label": "Land and Land Improvements",
        "verboseLabel": "Land and land improvements"
       }
      }
     },
     "localname": "LandAndLandImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lease liability schedule"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r590"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r590"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r590"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r590"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r590"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r590"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r274",
      "r344",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r553",
      "r554",
      "r555",
      "r568",
      "r661",
      "r765",
      "r817",
      "r818"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r216",
      "r228",
      "r694",
      "r725",
      "r743",
      "r811"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r241",
      "r274",
      "r344",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r553",
      "r554",
      "r555",
      "r568",
      "r694",
      "r765",
      "r817",
      "r818"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total Financial Liabilities",
        "verboseLabel": "Total financial liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Financial Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Licenses"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r20",
      "r215",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Borrowings outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee (percentage)"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Interest rate at period end (percentage)"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails",
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loans Payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r20",
      "r215",
      "r226",
      "r405",
      "r417",
      "r670",
      "r671"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Total long-term debt",
        "totalLabel": "Total long-term debt",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets",
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails",
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "Long Term Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails",
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r39",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails",
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r127",
      "r128",
      "r384",
      "r385",
      "r386",
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "verboseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "verboseLabel": "Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetAssetsGeographicAreaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the total assets less the total liabilities of a designated geographic area ( such as a state, country, continent, or market) when it serves as a benchmark in a concentration of risk calculation.",
        "label": "Net Assets, Geographic Area [Member]",
        "terseLabel": "Net Assets, Geographic Area"
       }
      }
     },
     "localname": "NetAssetsGeographicAreaMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r67",
      "r69",
      "r72"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r54",
      "r72",
      "r220",
      "r232",
      "r239",
      "r258",
      "r261",
      "r266",
      "r274",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r303",
      "r322",
      "r325",
      "r330",
      "r333",
      "r344",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r559",
      "r568",
      "r662",
      "r765"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "verboseLabel": "Increase (decrease) in accounts payable for purchases of fixed assets"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive income, net of tax"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r322",
      "r325",
      "r330",
      "r333",
      "r662"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r814"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesDetails",
      "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities",
        "totalLabel": "Total lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesDetails",
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails",
      "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less: Current portion of lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails",
      "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails",
      "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r584",
      "r586"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesDetails",
      "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r589",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r588",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Federal and State net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "auth_ref": [
      "r132",
      "r193",
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of options indexed to an issuer's equity.",
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r16",
      "r80",
      "r90",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "verboseLabel": "BASIS OF PRESENTATION, BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table Text Block]",
        "terseLabel": "Other commitments and contingencies"
       }
      }
     },
     "localname": "OtherCommitmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), before Tax [Abstract]",
        "verboseLabel": "Other comprehensive income (loss), before tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r183",
      "r184",
      "r185"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss), before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r44",
      "r47"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "verboseLabel": "Foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r51",
      "r136",
      "r259",
      "r262",
      "r268",
      "r570",
      "r575",
      "r576",
      "r606",
      "r612",
      "r717",
      "r718"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss), net of tax",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r259",
      "r262"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total comprehensive loss, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r183",
      "r184",
      "r185"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedLabel": "Income tax benefit (expense) related to items of other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r694"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "ango_OtherNonoperatingIncomeExpenseAndInterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherOwnershipInterestsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Ownership Interests [Line Items]",
        "terseLabel": "Other Ownership Interests [Line Items]"
       }
      }
     },
     "localname": "OtherOwnershipInterestsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r715",
      "r744"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r665",
      "r666",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForPreviousAcquisition": {
     "auth_ref": [
      "r720"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow representing an adjustment to the purchase price of a previous acquisition.",
        "label": "Payments for Previous Acquisition",
        "terseLabel": "Payments for acquisition"
       }
      }
     },
     "localname": "PaymentsForPreviousAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Deferred financing costs on long-term debt"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": {
     "auth_ref": [
      "r720"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Two, Net of Cash Acquired",
        "negatedLabel": "Cash paid for acquisitions"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r459",
      "r460",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "verboseLabel": "RETIREMENT PLANS"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RetirementPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r23",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r23",
      "r694"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r716"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Total",
        "verboseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets",
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "verboseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidRent": {
     "auth_ref": [
      "r655",
      "r663",
      "r744"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Rent",
        "verboseLabel": "Rent"
       }
      }
     },
     "localname": "PrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/PrepaidExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from Issuance of Long-term Debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
        "label": "Proceeds from Issuance of Other Long-Term Debt",
        "terseLabel": "Proceeds from issuance of and borrowings on long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-Term Lines of Credit",
        "terseLabel": "Proceeds from borrowings on long-term debt"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfOtherAssets1": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the sale of other assets as part of operating activities.",
        "label": "Proceeds from Sale of Other Assets",
        "terseLabel": "Proceeds from sale of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfOtherAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r63",
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "verboseLabel": "Property, Plant and Equipment by Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r122",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r115",
      "r244"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "ango_PropertyPlantAndEquipmentExcludingLandAndLandImprovements",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r117",
      "r229",
      "r610",
      "r694"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets",
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesTables",
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life (years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r271",
      "r347"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "verboseLabel": "Changes in accounts receivable allowances"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "PurchaseObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "PurchaseObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Purchase Obligations"
       }
      }
     },
     "localname": "PurchaseObligationFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/CommitmentsandContingenciesScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r739",
      "r740",
      "r741",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "verboseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r160",
      "r236",
      "r825"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2",
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r371",
      "r373",
      "r376",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "ACQUISITION, RESTRUCTURING AND OTHER ITEMS, NET"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r372",
      "r373",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetNarrativeDetails",
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetNarrativeDetails",
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveCurrent": {
     "auth_ref": [
      "r710",
      "r758",
      "r759"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.",
        "label": "Restructuring Reserve, Current",
        "verboseLabel": "Accrued severance"
       }
      }
     },
     "localname": "RestructuringReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r143",
      "r227",
      "r620",
      "r622",
      "r694"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r237",
      "r287",
      "r288",
      "r289",
      "r291",
      "r297",
      "r299",
      "r345",
      "r512",
      "r513",
      "r514",
      "r537",
      "r538",
      "r557",
      "r617",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r318",
      "r319",
      "r324",
      "r328",
      "r329",
      "r335",
      "r336",
      "r339",
      "r454",
      "r455",
      "r602"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations",
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r339",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r458",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue from Contract with Customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE FROM CONTRACTS WITH CUSTOMERS"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomers"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "verboseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r587",
      "r693"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Sales and Excise Tax Payable, Current",
        "verboseLabel": "Sales and franchise taxes"
       }
      }
     },
     "localname": "SalesAndExciseTaxPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r49",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r174",
      "r175",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails",
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "verboseLabel": "Summary of Income tax (benefit) provision analyzed by category"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r39",
      "r137",
      "r140",
      "r141",
      "r142",
      "r207",
      "r208",
      "r210",
      "r222",
      "r670",
      "r672",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Summary of deferred tax asset and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r11",
      "r12",
      "r13",
      "r14",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Assets Held For Sale"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AssetsHeldForSaleTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Summary of Income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r154",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Fair value of assets and liabilities measured on recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r101",
      "r104",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r664",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "verboseLabel": "Components of income (loss) before income tax provision"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r17",
      "r30",
      "r31",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r81",
      "r82",
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "verboseLabel": "Share based compensation arrangement by share based payment award nonvested shares and weighted average grant date fair value"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherOwnershipInterestsTable": {
     "auth_ref": [
      "r144",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of other units or shares or classes of ownership in a partnership. This schedule ordinarily includes a description of the ownership interest detailing special or unusual rights; the capital contributed to and the capital account balance of the other unit holders for the partnerships; number of units of other ownership interest authorized to be issued, issued, and outstanding in the partnerships; aggregate cumulative cash distributions made to, and aggregate cumulative net income shared by, the other unit holders in the partnership.",
        "label": "Schedule of Other Ownership Interests [Table]",
        "terseLabel": "Schedule of Other Ownership Interests [Table]"
       }
      }
     },
     "localname": "ScheduleOfOtherOwnershipInterestsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "verboseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetNarrativeDetails",
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Acquisition, Restructuring and Other Items, net"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r56",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "verboseLabel": "Summary of net sales for geographic areas"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r52",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSaleforGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r148",
      "r150",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule summarizes stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r250",
      "r251",
      "r252",
      "r314",
      "r418",
      "r419",
      "r420",
      "r422",
      "r426",
      "r431",
      "r433",
      "r674",
      "r708",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r691",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Summary of unrecognized tax benefits reconciliation"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Number of Shares"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "verboseLabel": "Expected amortization expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtLongTermDebtScheduleDetails",
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r322",
      "r323",
      "r327",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r338",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "SEGMENTS AND GEOGRAPHIC INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationNarrativeDetails",
      "http://www.angiodynamics.com/role/SegmentsandGeographicInformationSalesbyProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Non-Vested Stock Award Units, Cancelled (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted Average Grant-Date Fair Value, Cancelled (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Non-Vested Stock Award Units, Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grants in the period, weighted average grant date fair value (usd per share)",
        "verboseLabel": "Weighted Average Grant-Date Fair Value, Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2",
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-Vested Stock Award Units Ending Balance (shares)",
        "periodStartLabel": "Non-Vested Stock Award Units Beginning Balance (shares)",
        "terseLabel": "Nonvested compensation (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2",
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "verboseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant-Date Fair Value Ending Balance (usd per share)",
        "periodStartLabel": "Weighted Average Grant-Date Fair Value Beginning Balance (usd per share)",
        "terseLabel": "Nonvested compensation, weighted average grant date fair value (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2",
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted\u00a0Average Grant-Date\u00a0Fair\u00a0Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Non-Vested Stock Award Units, Vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "verboseLabel": "Total fair value of restricted stock awards vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted Average Grant-Date Fair Value, Vested (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares reserved for issuance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum number of shares to be offered"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Total number of common stock available to be issued (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares Options exercisable at year-end (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Options exercisable at year end (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "The total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Shares Expired (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Shares Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Option grants in the period, weighted average grant date fair value (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Outstanding at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares Outstanding at end of year (shares)",
        "periodStartLabel": "Shares Outstanding at beginning of year (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "auth_ref": [
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Schedule summarizes stock option activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Outstanding at end of year (usd per share)",
        "periodStartLabel": "Weighted average exercise price, Outstanding at beginning of year (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value, Option expected to vest in future periods"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "verboseLabel": "Shares Options expected to vest in future periods (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price, Options expected to vest in future periods (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "verboseLabel": "Average price of share issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesDetailsTextual",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.angiodynamics.com/role/StockholdersEquityDetails2",
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price Expired (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price Forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r484",
      "r503",
      "r504",
      "r505",
      "r506",
      "r509",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/BasisofPresentationBusinessDescriptionandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value, Options exercisable at year end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, Option exercisable at year end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining contractual life, Option expected to vest in future periods"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "verboseLabel": "Percentage of fair market value of a share of common stock on the last day of the offering period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r43",
      "r136",
      "r237",
      "r264",
      "r265",
      "r266",
      "r287",
      "r288",
      "r289",
      "r291",
      "r297",
      "r299",
      "r313",
      "r345",
      "r434",
      "r512",
      "r513",
      "r514",
      "r537",
      "r538",
      "r557",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576",
      "r592",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r313",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r23",
      "r24",
      "r136",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Maximum number of shares to be offered under the Stock Purchase Plan",
        "verboseLabel": "Purchase of common stock under Employee Stock Purchase Plan, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.angiodynamics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r23",
      "r24",
      "r136",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Issuance/cancellation of common stock units, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r24",
      "r136",
      "r143",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Shares Exercised (shares)",
        "verboseLabel": "Exercise of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.angiodynamics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r23",
      "r24",
      "r136",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "verboseLabel": "Purchase of common stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r23",
      "r24",
      "r143",
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Issuance/cancellation of common stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r136",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r27",
      "r28",
      "r96",
      "r694",
      "r725",
      "r743",
      "r811"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r147",
      "r273",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r434",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r577",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r577",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r577",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r577",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r593",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Product technology"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "verboseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "negatedPeriodEndLabel": "Ending balance, treasury shares",
        "negatedPeriodStartLabel": "Beginning balance, treasure shares",
        "terseLabel": "Treasury stock, shares (shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r42",
      "r145",
      "r146"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, 370,000 shares, at cost at May 31, 2023 and 2022, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r372",
      "r373",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetNarrativeDetails",
      "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsnetScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r517",
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits, ending balance",
        "periodStartLabel": "Unrecognized tax benefits, beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Decrease in gross amounts of tax positions related to prior years due to U.S. tax reform"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Decrease due to lapse in statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/IncomeTaxesIncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r728",
      "r729",
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "verboseLabel": "Allowance for deferred tax asset"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r280",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance\u00a0at End\u00a0of\u00a0Period",
        "periodStartLabel": "Balance\u00a0at Beginning of\u00a0Year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "verboseLabel": "Additions\u00a0- Charged\u00a0to costs and expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Valuation Technique, Discounted Cash Flow"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/FairValueofFinancialInstrumentsFairValueofFinancialInstrumentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r736"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "verboseLabel": "Effect of dilutive securities"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r301",
      "r306"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Diluted",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations",
      "http://www.angiodynamics.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r300",
      "r306"
     ],
     "calculation": {
      "http://www.angiodynamics.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations",
      "http://www.angiodynamics.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2510-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(3)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r698": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r699": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r701": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r702": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r703": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r704": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r705": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r706": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r707": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e725-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e765-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>125
<FILENAME>0001628280-23-027335-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-027335-xbrl.zip
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M4KQE3E%8S\*SD *UF#B287+1FC<\#PT*YZ=X,1T6 \%*B@:%=9T\"UA?A#T
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M**SWLJ!3,)9$#(W"NHV*#X>%TD/A[/47BF8XA#"V$0!G/MS:#\$6+ \U%-;
M+SH4?H@6DJH-_&/VI!W\Q=S]])*-1J-P!OFJZH27Q;<*9V*OKAQP64=<.+.Y
M #B\4*Y?.+.X$#B\T"->NN'[7 \Q4&BKNE5_BH=XXM(?\A WEFY\/M]5WFAF
MP/RXJSQWZ0\=1'/I!F!)8@;-I5M@+R"-IQ[$ GLW-9J%-8&>'UW3S#N9/N3*
M\AA!S<(:02^: '44JR@8RO!:>CQF9^".2@2,PADP/S:.RX2;2P2!PEDX/P2!
M<U ;?27;_5"2S^Q&AL,2 :-PME!Y9,0B;=)FX4RFDLF(A0*CL%'%(LN(A4*@
ML"'%DLB(10)CJ["AQ<=SXTX>W&%@9JM&3JTT0GFKL#'$ AWX0C&\L)8R#WB]
M$0_M.!H$(6QM8O I_*HBUS[B+G#E0?'"VL1PUE?T)AG$3KZ[_&ZB[1JRA36P
M'X7LS7VPANQW(%M8PWVQ)[X8A#H-XK \H"VL&^!QHAV 0OU:9$N=/]N^<QZ
M>O./.'05*#JH 94'RH5U,GSO[,]4**27_7U-PU/0+:S7XCSP^Q&8O,>R.Z.?
MP3E8%)>]HQ#LAH75/O)JI\*FTLK\\Z[E7>#=N7X_?]$RX=S8IW:]6XN!<V%]
M(X^=>@=K23'-HKLP("\,K7[8$-W+9#/\$&Q;A76UK/*P)X/I>T_/,]E;5)Y)
MJ[ ^F:) 9I+)/0*9R4M_##*%==Y\$Z$KNI[$SCPSN>'EG0Q]MS^(3EU?^#;(
M)+RT$_3"Y)<SWY$/G7LQ6F1[GZ*@S,J(>>G>I[(<1&&=-?-I!_N9%)(8OOO$
MU^S8,(E=*YBLV6@5UF%40NPJ*PX4UK.T?!QX<=N;-78]%;L*Z]%Z]Y!9>Z.*
MY8U:"5(DA8AV<"?!Q)E3C&A^-:L\HR"Q55AOV#O%LR5YM[<+ZQE#^)Y1?3"5
MS.?Z+_*1/_&P2R%;E@7>PKK7BN74#H2OKL08]=;RP';I#KKG!6-:U4:]VMQ?
MS+L5S9,T^7:/>6$G+GVA:+\+(CE;K.,O+Q#IVX5U2F&SB LQS)8.=Z+ OFW[
MSIEOX_IWLGTO0@<OQ"F=2U?C&HVG>=PG+_TAW7Z[L'Z=&0"ZN0]N!D&LA.\
MF#"B/Q]DY6&IA?6JT%E."ZZ3X<@+QE+2V5^.EI,VDZ.-U0PM;FP7UB-1&,@T
MG@Z9199#;Q?6(S$',M<2C K7CJ1#L*'^6]>=KZ7)JM\NK&E>H -?I%38*:R-
M/''@7*XIPUX0#@5(X<Y A)A:.0, =.>RIZFOR$>Z4UBCM^#P6I$$V2ELIDG!
MX;4B76RGL$5&<P30),C*4R.Z4UB;?75'70@14UA3O1 DL%#MJRPV^4SIH,Y\
MVXMQ% (5U?Q;BO"+"&\ESIARW%>P"E=%(&6QUPL#M6613UG,\R("8J&BO"QF
M>Q$!T5@@('8+:\YSN1X51.*=6!&9MH)(FV:KZ++7$=Y;U:UV"VN^%PP^*S+7
M=PMKKA<,/BLRSW<+:YX_"A^=VZ,D#CMM^]@Y6GK!DJ;%%(+/%=:V+RB<5L7O
M"FOK%Q1.J^)[A744?!].)(Z$[[!._?W1P&5E>87U"A0/1*OB=H7U%Q0/1*MB
M=(7U)#Q) ?]%^C(4'HBDMC-T?5=%H<!TL9.'$7;S?)N<;Z_<3H?5PFQ%K'"O
MW(Z(U<)L1;QQK[#.B7E)SE<QZ.="R5(ERNX5UL>PFF->;16@U+FF:G:]@$E%
M56:=QXH&DD7O@_ 65*C_'01Q.'O=[!5/67H2APKK_U@]#C5VGXQ#C;U%LL_"
M^CH* )/]I]-U?9$P*:Q?8_4P69EJ6%A'Q@R8Y$H17E4.KJ2,:J^P'HP"T,NJ
MU/)RNRQFN]'?M,-BO]P.BU5";$4R:;_<[HJ.]#RP)MH9]^W;)K#">BJ*#:Y5
M45?A/![8]^S<C=P^0><(](>,7G$4?A8AEF(OV2:"(VZ [O84.W7BTA^#1N%\
M!X]"XV8@CZ4G[K%<:$FS#7)0V<;)R(VGM#V=O/3'H%(X[P%")6%DO\B@'XK1
M .=H98!S!N\0^@0VX;U165,X%T+1 +,JJ5(X/T+1 +,B@W6_L$Z$HX#ZJX1T
M_->NNOT\_BQ]>X"32*=ZTTD_EJ=A,(2;X X[^MV-!F:(['< ]R,;FJX_2S%I
MZO(?W<=W,-;LX"+PO[[1C/G]PGI7ULA:7&1=C<AKU@OK6%HC:W&1=35J -A'
MY4?6"QGQ(.T4@NU0BB4CA\TS(0^^=@I/!^64^K!:47&3^J'$=A2'V!@Y4!'W
M2)'A7=8I<B[[PL-?WZ96UJP7SF-84/BL2A$IG ^QH/!9E>PMG#?Q>?#Y(L.^
M#*E!JOUG["JJDG^KO*YP#L82P&I5?*]P/L<2P&I5/+"P;LBGP>HF%#X#J ._
MN+9L]T,I7Z$&=55\L+">N(+#:T6\L%%89U3!X;4B?M@HK#_F:? Z=N_@.A>N
M>IM93<U&R9T2KP>@57&\DGLE7@] JV)Q)7=+G/D1_-?M>O)L.!)N^':5O4;)
M'10K@-2JF%[)W1,K@-2JN%_)G1-G*A32<\]\/[CCK.DX&@0AO,A5*$=B_(:Y
M8<E=%06 W*JX8\F=%@6 W(JX9;/D[HLOPH][0E]U+3U=:?(V&62SY+Z+U0!K
M13RQ67(_QFJ M2HV6%Z?AKGP,AK(,'?U&V6"Y?5NK Q4JV*!Y75OK Q4JV*
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MH*>8*$7+>IA"!2LI2H\0(PRLNH ,$O;RGQJK3BF# >Z/?9=Q*E;.Q@22-3>
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M4SXX))Z,1D]<F51].@9Z>U;&P-:!!;ZCN0X%:// HQ3VM&(Y\WRKBF$OV!A
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M9$]#<VMMU."%VO>0N#%LS*+Q!.>>N:$=NU$NW=MXBX%OAYR9/N$4)B?A9/T
MZ(754V0\)F"3_?)_<M]>$0_OC$)A/,M<T3V2TCD?HWT)#("S:!+/]61B!NG
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ML0-]*F?I3G[3 R&^4%J&:]]:7\3#4^FE7GMA>&E]X_K&]8WO.HJZ_?:BJ%F
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MTI"FL&/,\)*HH?5 NZ$.V3:8WCY-"\I\S3Y'WP'*QG)3_DWW![$V3SK7QQ^
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M@KV324*^=E()H,=T$&M&X"9=&$&F>PY(@RLJHM22-K=1ED)IPZU[:H,PBM4
MNU+^E7'\WQ&>)7OA@G=0+_3X>1903]_2&<^SQV:R,Y]CVEWZV9'V7=FC\=YI
MDT^LIO!'J!^@T:GS@J7O3/0"59BUBL%*,C,=M&3CR"Q'.@5VLRM$D._1<J7K
MD\Y)^_KH5^N_Q7#TR3H^^79R?GGUY>3BII1J+ ;+^F%P'PWT#&M2N;AR>83#
M1O0(0$RP=OT8M3@S+=@X;-$"X"G"IBUR9M1:%/0EE;)H4Z(?(,+IF,:0U:B
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M47$+]2$S'+V#Y)TE;"M..ZW/.,N9R1UIU0OS\)ZX UN48U$Y28!Y).;MYS]
M]\XR^C?YNO@N6-(HWQ[5<^5%C8X'LBC(G$Y"7)&.YVO.+?P,I\Z!QLQ*0$+&
M0:PZ HZ5(J2>FAM<9?#?J2"JY[J,D%3G> VUCR8)9L")^#.1(A,F)%;1U$0Y
M#AR TS&6";AGZ=NPH9[KZ4[.;"50SH]^L5(R^U\S&2R5?' MVS5@GMFOVYW.
MXORE/ Z$9RK'58+P:1 ! *W[-:A<+26C?4:CS*)K.N0DF3*7>F+A<CAW'-\!
M7,Z6&>S&TDKT_F;]:7@O[A*[%(R8DVM0I1TBZ*;D26:'^1HOWB^70PJ:>$%!
M5WK7$8<F)MHM<4^I7$0$"=R$0M+V%$KGS24J<Q+0Y5X'S%C2.SC?1OLM\=UP
MZD=,YC\P*^J#90_DD%,*'-,B(M'Z0. 0>@AZ+\P]Q6K0D>D@E42KDXNLS4P
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M#D$!#)Y+Y1OGF=:>33*-/C?%1DR4/Y),*K+N3OBE,JT?(:D.)@I7'\S"XAN
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M-8\> ,M_$)[8AG;;!_3WC*.[]=IT6+Z>57,2Z_@I)0_ 7 =;4I= _\:AYDM
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M/INP"IKQ6\JLD$5F;,5&:?]#K%&5>G@%:S%IQFL<]NR,P,P+K>J(LI.UU 9
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MMW&A7,8 @5?%AK5$'AWD"/>V'H&MR44;IND@W"2<!_XJB! 1J3HX=:^U9=J
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MF1(QSW1KF9^5G%DTQTT]<,FA?>&L>=020#=/Q*$* #8A]);$#\?#L2<KE;.
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MKTJ+7(J^9QK9GA$/KNM9.2$U1PU8]SABA;FT[OPCGEA'DHR8Y;I1$"($3X(
MX,2<S\FA(91241)K6PK&LY/:<ET-A>8<A/CP6P+YK40\-XQ[%@6]M&7".%MQ
M?9;\]TN2AV?>71G>:9X^%H=\8^P^G:P733,A5 !XSHA+D$R]>'J<PR8Q5_U%
MFN:)YRHCI=!*:14;$HMI)SV4LM[.?4,DGB.Q<L\5Y>LD&5[Y OQN.&S6C".2
M0W8;!I;WWDNPG0KOVO]]L/,//W%6KEF"?TEPPL,_)SCAYJ0:#J\CL)$M0VZ#
MBIQ_C,D0TBI2)Z+C@4C1RQC#VVYG[D7&0D15="'NHSC4&2#=MM[GVGX0G*4"
M%/!%DV#CG_-1B0QO0_$403+;%9?]>P?H02HN 9D=J#J(K">.FE%X:RG6GQZ>
M4972F  <![\1F=*YBQ,=PD)<54&P5V];1=97>MP3>] L^=:G<44QN^&*7QW&
M-_<1KOIY?#!6+&E1EZNO<@4='(6A"E[+I##?C<.X\#BGT:^_1_SW/X=3(#OX
M+O_XNV4$+Z!R^4S3CW0M5Y%RSQ 3Z%U\&LEJ1\[_PYK$WK*SDMLB:G)8%]G!
M@[U_W+^56<!73K[;K_'^P8P#=TIH$K2B$*9A#E )7*46BFQA6_^',4<3XJX2
MV1I6$0@W;=,O$I2!*VT%/"=ZJ#V0RX\*4C,A5UF^&O5K8K^%0%U0FNL4XLK[
ME\YJ%0=>"<>[0F*,VS.2_]%"1W0^AP6A/-Y"0B#2 FNM;X.D#A;X<OHB$6NS
M9:Q @'-9E5?A2V(#A*@:67I6OB-%JYK;I9 4<4*=S#T.TD]8H54F%.I1SV#+
M\J$$QO=WZ1I1UBMT=C%GDW^MH2"PFH&V'=H:<ZE9RX1*4#J-$ B"'\U*%AF*
MK*:N8)$JC9)FX=BHT#[QD>&^KR@H&##$Y()%0V5:;3I=F"%QXV*.=3][(?E@
M/)<<%#B%)FA]*Y0?9]<;\;+8^4[]'67'%R&?S'W<,4,1+^84%SPHF5U9A%<2
MF<M4Y<@*E ;LXY"HCRZ7.)3T"K?;@-B,>F)U34-=1BXAXUO$4$B:4;@=O:C+
MM)?$P]K!5&JIR\T=8"IL9?9H<TT&1G!&#0BBQ)F>G2*'J2.]$GF-*UHVB,[Q
M-4GN.TXP4/8O"^',I93%*O@J- _[B=01CU0IR!KT+,I3\:VY 0+ZPNE#9U7G
M5Y:(?)J7@=6/FKCN!3<D6"64>I^+)50]MZ%5I_9R&KX]L+MNY0GUHVX5=\)O
M+0JW)&M=0;US2IM2])QB8= PH9SM;MF^"#&DFX ")_Y\8TW=TQ9-Y@20"F;1
M?5+L FI,;=517?\UY?44%S"MVK 2=[N"C_JN((%T)VA.]9NT0XMY"P^$YIX*
MK)0Q6@D$-$RD@E\^X:[A^T7M,,+;=U]=-2X?WI47L?Y$?TH?C!RQ @6&5^%5
MWI1C5GZB?SR'/K=W\9YF7YWSY?"A'TOCP3^I43*D9]CIU%D9^%.=NF&OCCUA
M7@6#V04^X+6LR9<]#%9ZSODQ@8T^M(.0B"*&+H2T'[;V%JUH.D7A#>4%[/A1
M&9O5[Z 'I])L.S3JKF -I=$:Z6DX,DKUZV::5X:N5V]9UP3I^H_E_Y \ 3<K
MJ=4@NQPCMB'KQA*\=/.MV[D=\H-Z!OP5:X3%&BA-3BL=;(MVBFM22QI$1;U9
M??WKR&*AZM>2I:(D_C6NT<Z78DT]'0TY?YB$2=^/.7^B,^S=6S36F)>T[B*$
MZL(;W:WC+"R"L1('N;HIIU85(N1.]39U)B6[EF+QMG/F.X1)K^GMOH49TBC]
MB<HEST OTRR[(U>0<8])VOY,I,71,$-7#.LIK,6K$,9TOIP=)PH<**HW>RL]
MA).SH^Q<>,8>/7TH"\3"O,NJ\SA!XN)1?F&N%M->!:G!M)P <A*9F @21C"%
M+J'W(Q5",Q"X$.+'BP;QL)) A#T=O.99M91 0JD@XI3A<'WOK*'ZI<5K[CT.
M#T9@=?2F=A&[5YAC.$'I1,2J^@\B%,XOY&W?_P##AU*&/*@YMO3E_DQXF"9Y
M6'\[^.:[_6^S-,GD6)3DZ3_XR2H\7#C;R)'_/OO;D_V'9H&5RL$?PH_S[&_?
M?K?_>.A#3^5#C[[%#W][^F3_P,F#JU=)I//,@ T9T\\X>/$0>^\P/GSLGHVM
M*$818:)*KW+K"@Q_N.-W&8JFCQ]2D570C[UUP7WOBM,K"_4B^X]#-@AH1JW4
M@(><S,B@R1'7R;^$1WWM(IVE9I_P( O'O2_WT0B9F: E)Z3+0),U6R]']5OS
M-!_DV5<G?(4WQ+?6<RH_WH^D;^S.#9H[\ $4\D(OHKP@D_"-M7 830=&FF*^
M6WGR'6;CS:AL]YB$* JN4HV%C!9>-A>E2]&':%J19NV)+*!MF>;[_Z6"M48*
M/C>NTHQ_#*/\K3Q&?T-R=)/!W%T[B-P0/L;00 ]D0=W:TC=/"5AB FV;&HP=
M\4JR32;%9F_5[$V*3<++<Q[LP[QHHXKN')XU**[WG#J6T84@[J%35(&AHAQI
MN;=KWX'0TAT;F!0K[5<E,*%A.<.>!C>X70O !H5 0&^H#<4)H-#&Y(PC1(9#
M&'A9C#=.3S@!_D2T#:/0_$+G\1Q:Y *\E/&"@(*<2?Z=]46M=ZBV5DYJUZU6
MFG&+6$_7LI\K>:LJN<R0CC97PTN="GP<;?QNB;PMRR7ISY32J! !/(GR7WQB
M65.PX#9A>8C,FOEE_YZ.YYS2LA,Z;'(OGT)?4!X">152V:NLJU)Y -P32.>1
M*A[:1U2=;ZN)HFHG)KN*4S%\+@170!'2C-W5V7V=_=&?L\[^A8:S +B4P7 X
M#V5W- Y>!J]#4-8[STS7-P.;Q6N06P1EQW19!*X%DU:"/=!MG(]ACKDY!]YA
MO3'<[V@3',Z/]382CA,>=]B9]QP]L)DTTDPL@K;%B#1@XM+T$*(SMED$CQJ@
M2#V&^CY3::C,V'BX0G&S6),R,S)LLFP 3QYZI7#-R^"9Z@'$Y$.,TG.%D=1J
MAIM,5]RY-D #'L[0JHOZ]>+)*GHC(1*D4SR\/O_(Z%&@OYJ=*R\3_3 Z1WV>
M6A:\!.D?.['[V:$':7/="WA4:IYBP5=/1S"G/;9-<I.SHVG,"0#;7C)E0HZD
MYIA_5(!K&T(87@/%>F+?[I8(\_D4C=?>^?3A[)YMNN"U%+4PM/$J87ZU# 1K
M5*5CN#!4W=+6FWEY0:[6O*ADM5I^*%?D73Q]C16T@:1X(001:%?7=T@ES2Q<
M5E*"7%*'1E) W8*LR*EE_;27O4B\*PL9VO>N1/ P("$J')_B^'OJX$%UM1L4
M,=R<""X,$W7DD6Q8)BU/.\GC!H^BBBP.#[#MX=W2,PERFJ-DWWWD2JCAO6_G
MD?0;M[51U6:;Y95,YH(HN(I^D_3_KLNP<4;K-BQQ>I)_-NW;//MQ'GZ9O0C&
MN_._C@8A=6##=8Z:,)K968A.\NRD:PNB?WQ9K"Z)(Q>$M^[+)%2CK5>KV,%G
MQBZ7[5Q=<H1&D[+'S0'B7"!TG(*=5R,0!JC7I;[?1FNGLEUU!W&+*/](]0^V
MT^ER2P>0HJ EEVEAUC?<$)827GCU\\+6]OXV&M]:VGRC&,?.&-0]&M2-7[UM
MYWK((H-A3^V2(@QM(Z05/BD65(05%T_LF'(Q<K%/0\@^U(+'4M_AFM8MH$Z@
M/FD=!8JZEFA6<=/T=0^NIR*$T2(P_0&9N3$)G//OJ-,,5K> OB7W(=9E?.U@
M^*LEI=7,'&!:F%I#^C, MN!@5U\GI_(7C121/S1,,X <_)[_K9NJ7LW$^L2Y
MJ3$\FZ@5AL6J:Q'I<SQ5XE2S;^##^/11$#E#2&@B"Y29KN-,,4UP[=O6&5F2
M]*3 (\70U9OKQLN3(_FG(N9;73A_65+@P[!8]ZCK#FO<%8-46M61Q%+W7C->
M1S3#\[!9R><FB0!F-:NZ,-HMJ--:]>4B4(SZF-B)R^$R"K#/@8.CF63X(HNG
M2_P6:4$&B:_L,X( XZ8K8,-8&4R>AE,0H#?O7U9D1:/M7#32P*($1 MC<KR5
M*4STM"\XL2YEXA4V']7/L#&X+$;% R9MT!"BV?7-T0;"T%H\=$O(<(,E]^"*
M^Z-,F!AK@K2G2$)M($\[W>B[/S1%"VCK\ZHM&9I(N+%Y./:9S;=K^)Z ,1%V
ML"0J.8MU!KY?:#*6WFH%RTO'L+WQ\"UCM)@CZ&C6H/MKDL7$^(Q+ZDGF1D&E
M]Z\ZXM"0&NAH7M1OP^N7X[=:_F1).X@+8#4CK&EI$KNL*VO#2SE?,:$7-'I6
M?0X^2,-R5TYG./,U4'?A$6?5B.KJ:-D'Z-57KL2[<+,:;JFUKH</'FE%TDS!
MC\)*<.36S\OB*G?]!GK/;1Z1\!ZCJC;!W_#>R>YLKE!Q.WCR/X8UDP$@^GW*
M<@(9TG "EKZI-"GN^5,[E8O',62N)#L0"V5IS(RCQWTV7=[;?#+I8_AN;![A
M2ID1JOJR[+#6S!H2U,0R3J8%KYRU8'$NVK(;6@]\'/??4I,,VZ:9O4Y9--M$
M*P,[PAOAR&!R#0%FM,RWDE$9P*S37T^>[QU\EQ&]&:C79T6WC=$I>RQX?>;=
MMEF+GWK5M/.).9+>B?0XXUUME]%_Z?5\;]&4?O2QQ8EQPL%7T\W-.<EV3X(J
MIPP7DJ2I7I6T;2\EBBH\TA\\HSO=P\$LQW:?<)=)HU./1C,[G-/A<C$SS/,8
MX;N]MP8Y463%.#9CO[G<SV"2&]&P2;36O!1Z^'D8;!97V<>]<9_,ZS9Z3C]3
MRSY5.;72FF>)@GLN>!=D R%1FVA;63L )_TL2]"G<$,'-CX5/@2D2LD56Z?E
M0'#+UE9>9+44#$6%? %2PYW.*^PZE8/!\N?7T#XW[<LU.?L6+QGSN$E#. 6#
MA8^I/4D0B222H5]2I:K+'0D#UT+#0<1E<6HX2.Z&0NHE4_W41!:LERP6I"7#
M*0Z1<\%2;LO1II^AJ >@DMM<1OO9J:)'C,^A27A*$A)'X%B^S^Y5][>(1!%V
MF@)!+ E @&+J^MM=341>'N:<RPV1]QVSV K0B8DE:/B9C#WXB-\]?A:> P\B
M.1*LH2CPOI& 12Z(3X>/\\##Q9X'F\/L4NJC<H>2Q0"5R#^Y-/:HF80XW^Y_
M&2Y8T4&DBZ!-\$M-;>SSOGP.S21X"[&D@1S1>.V0Q]M5BFAX8AEH5$K8-PTK
M8/RVEJX/([W/;#? 'EB*E3I'NXI=Q_AA@F%=-A57&<C>P?MDA(6TS83/+\LF
M1",Z")?].4 XB5ZZ55DL4E4C[A\+4T!0K9S02W/ZC:M1160$7Z.E'D'RTYF=
MVNX:YM)UXCN[D+!=V6516J#?$3=)^!:S"RE+<@S23&<IVGM? :)4BJBEW57M
MDZK]X[NJ_6<<SG$1EM][:AO8!632MG*[M&&*5GIH'&LC@N!+9+ZA,HD+)$91
MH3_=:CW1_''8?WL4IJ"I8P6EN5N9]4DB4:0[*C +-^-@OEHUS)I#LPI2>K!&
MAS*,EI#T#U/>'$!OQ!=3$ZFI[:@'N9-J90TN*_+@%7UE" M8Y,3U5=8"._L,
M %[0H[(,0$ICI'ERL7(*U*-A(.KD]4+KR.I6AP.@YC#6;IV2W[/3KNE(=J%C
MPW"_ERS-:PU<*@P>H/;1KE/ECA-.*^9FFJ#G9L')N%PZ4"+;*LK(2M^2\]SJ
MI%.Z@Y)+W#(<QHT\=9$%Y9%SJP+N27 [@I\K/)<HC6"T.7?/;IKP&^'X)(E?
MZHI2!6?&DX$!6-CC%M(D5=:75=O4,9OLN&SJJ628TCG7_)YV@D3/(G6['$MA
MXE@DZXIO0AT0LL @T^- #>_='UP?\^,1WG*U;&I.)JZPA8>BO>%@3_"=*C#2
M,SQ\-XM!@W,6MT)8%$V''N<NW4OTOE%](KXH%20KXN>&*Q@6;UDGRHQQX7=^
MY4M=1NU #":H38-BE0*K!$"_"UZ+-&@%03"5+*MTOGY$X?@%+F65Z!&;#F?B
M>F-.KB$]_KPEG=_7;.^@(;KU9\U"R#-H\\4EBJ &JUMF<1DV\:SH;R\!QK"@
M(;+AZ(+P!FIE'KXO]A?JW;)YYXAR./KU/GH_L!OTPC.XFG%/Q3OO,YT,)8U&
M9:E062X;@;R?@' 4RX;]\2_NH Z64"LA,70P^9*BTZB/H4##"F%4.VL9RWOE
M]TR(W2FN1Y+<( ?6T.N,KZ;(D]?'V--)PV/I$#S\D.'65&%>57/.**$(6$TA
M3O!Q^4CNW^\7S7LY3L<0=IOV @]L6-HD>Z3\:LDXX^6%L<3&0'MAPB)/NKXT
MRZFU%+;@?.SGECI&8=6N)=3,_NMRSL%%4K3:O'A7]K-):(@E3,JJV;.BF'R>
M""PG0_3-3!I0>-<IM?M4N%FO8GB/IMXFK,4BK,BUFG4Z-[IXPOD*P\!1D>0[
MN*X(S7-0U(YGO9W=JE1,(BD4/[&?'3+4PW8XEPJI+!;S84WKY"^%K]D21C'1
MI6F!>7-!^W>\W;6P+SU^*[$$/+>KP?0V[X;ND[:82!A2ZS6G&CVI/0\[:Z"9
MT@!R3[4 0Y9$B#E>I:1?9',2+*]5?,-,@(&>KE9KRUE'E#BJ0A^-,?V))U_S
MV4Z!?$##-N]-N'->!:DE6<]"<JM\<>352JJOL;9W@=Z-F%DD"YX(@ W/0=_9
M^-C9(#'UV"%HJ7BULE/C3ZTLY8D.%DI;C<-R"_N.$I^TY;&XB7!BQEC0"$O?
MXH;W1+D[N%9SN4+XS*Q::OW58#28,W]"W4:XRV^.&7RHM!,6W'$\&BFK?]Y@
M\D"W@:4(Z-F]X_,?[^?DQ2R@F<E%U+@03<L,""83Q5R@3Z;[8YS*X3/IDP_2
M+T0'S9[PCV8%D .6^GCNT=XQE^NF@9!-BAY@V6SM?9IO.#K$+O,:)6%FPY8@
M"Z2!):$%YHT([CE_$;NRZ+I&B-P8?[Z]))B<K; T,3PP.GZ9_HQ8@><;Z^*B
M2' 67"E6 "D+,6S<8,6'#]9I_T:M8X%SO+Y<7&)&GK%87C7#!  0F+;>R#&+
MJW69!1^6DD!H*6S"!I@T]&,('%>S?Z^I2Y!0,//)M,( 39#XH'D*JX<RSQGA
MK<@F*H?V=-XT$\#Z!T!<_6-5<SQ456+M:$^-[9F\'6A49HTO4V%ZNY5-YB<=
MTU^G'#^JICM<K[!EN2]:2M9Q1_/(Z N<47[1>25*NCO]CM=8OV=%Q\09<F_$
M^8],,Y8R:$]D[YC$ /<NZ+_WLR&Q:)9&V !FB2"#&%E"K ]$$2:07CG=-D+9
M08#LKF.?03$M F]@^C93 EDVU$4:7;K"'.05_+>E@)'H-F)%V9OF3=AZ!0Y]
M#<@6-D@&4G)H7((P;26'+OU5,E=$(<C<9K+5+1*]:.'>UKP9_ R!HPZM(9QW
M7HI3F[^_QV%'[B%J:?TWT<_O;J&'#]:SD_-_G&=GQR\/WQP_S]Z<9F]^.@[_
M_/&7\(O3LW]FQS__>G)V^O.KXY_?W(1W^7BWH4>\S;)+;3D3 +^00Q%[&'-S
M>#Q  A3( )=T+;I2XJY3W1+XRTH?,>WMVV!;:QA#JVU(9(/&9[K!6K=^\&^Y
M)TRE$+&M_[6>,"O9K8RK?RL-$ X2_6"8R/.W>!)5A=Q G G@JDQZ&*0KGN<J
M-WZ;'9/F/6PN;XS1<5AZEU&;'*5=.H0L(?A8\8][P>(;QAV_&)%'3UTIZ&CC
ME,X(Q(V4,V]7$3"]*MZIDV,$</)4RL%JS?0?T)0H!2X\*D(*5&N2KD5S=7(<
M,8;%!0--.,+S['F[9HS"4=,MRF#ZL\.P7.\)MO7%\Z-# ;4&7UE95UX\/QP8
M7[<7_#"GT _B7KF0+G87O>9$WH=. 9.8RM/FEAPA?ZL6VKL&N< 5%6TA1'&\
M>D8"NV0EMR16@ELERP4@^G]4X[>DF0RNYK7L?"7J>1%.BA!,<L,@QHAI5KZ]
M+Q(=5/)Y(3H<1[Q(LM=VG":C>O3:1I6?6$I:?CWQRD#FQ8]R DE*\0GA&?[!
M+_*#7.*0XF/_FC_Q&HD-.*]I2*5)@Y[D< P)$?W5(9NN@^^^^\:>_J>3UX=N
M42A:^#EU*[ZVC9.=V7*P;_[X_/59_.(DN%?DJ.&^=W@$CT=X<H='^(S#J>(X
MTD\;33M^T97!==3EK]VVM/=R=V*PE\F)3K3<XOOD#0. OA8]E1AF,M2(33C?
MQXQ]SV](CJ38::P'/ST+NKX05]X$Q^N]F%ZG,^957#D7VQ^"'KL)Y=DO8B0&
MGYT*TKA0Q73AK78%HJL/,;"36%[7;VNBFC1Y/MR\,*;0I&LR[!H@ OOA&9UP
MQ&RU]_CI(^I%T40"Q357+).2S4N.893V2E89>6B7X02B0VU:(>26 !6-V1WZ
M1>7UW!@8HL^R(]%3G)24B>)SLBNK_V@4WI9C:GSE 9"2VSV#/B!.G12U*?)V
M<E*-"B//+3C?2DR7U+A)])MT;#*6=*N5:JJ8#Y6Y+M"6 -).-P-N>"<BN"79
M@$GN.N/[N%%4C*M+#OA"A!HL%[MBM$.-NN9KWX*?^S@^HENDP)7VTVNN,%NN
M1Q2HVH[G96'M_\()( C- ?GC2-X%QXXP*/P5F6]!,M@C<N)BRLUHY:2*OIMO
M7XSAIZ(]^VO2AL3&R:R%]P-\N[BLO^ Y!:>!O5M)9X5/ _>)$A&O@6II%%;1
M,^8(NEC$7!(SY(JT'?^C8J]7'%#[!G7T5"+UD0B8"7Z+$*CC'I34M\@G /W/
M1E'P.[2"WIRPBLROFSSCPD>=<<+)08$W=>,V["JBAZ$E\-[HZ2)-W^IJZR=W
M[(XQD:2*Y90M-60LESK%:]_/CJ1@A<=(;O J! 1ANX43=K7JC)ICS!7Y)66G
M)IH@\D23X12I.G$_$XUN5BPHVR0[U6,-(:U;0^=K<3X]VR5BW2P4HD\L:YPJ
MU#%T9:\9Y#ODH8G<IA'4F_C][FE]EYWCPEV2B%W8%YR1H$/4]&YM&'-5 3'F
M#T-,<B)M^T"F@TX@P>Y[K#J-<%-/-7=2%5039B YH,3>EZ&46M@^Y9P-3WR2
M)404Z(KL6ET9)[#+R%RI )DQ.=,Y#,!2DO*D2'8@>>*_E9N=XC/OE. 3F+D0
M^RS1]6:1BZ0<$, ])Y$$ YA)N$0+X:=UF/+LG&5?W5BY6=:!Z3\?X^ZY.;,6
M0^ND0MP5MH 4LDF) 3#1MD"&DV!F7&XM5FDEW"*OI/K:0R&*4B"7&)Q_A?,J
M9N43Y%],-!M8 3LR99J1_@X]VGS+QIM(.V[K;H>_R/H &M@WK:%YDN4&O%]_
MC;G5FB#J/PAK-G@\7,MV$\^,VX_WLLSC:)/R5H4]*!R%5J9+BG=A[(.3V<0?
M\0$K/N=*N95O]]/D/=HJ=,):QW"J>M\_<&;-%2==F5$F\1LL$XLP@=:U=!?Q
M'YRGQ'6#+<^#UROTB5K%$#L1Y^L3L]Q<S/TG3C);.N1K#X^E*'2UFI=J=Q(0
MJ]9*;K('=&/2_%PV(F-!O,=;/$P?<@S^KV0B60+"Y;%PGOWO^9FG%W)&AY##
M>](X[:U./D :-50SD@6H^#L-3**_E*H.Z1HFIB^K/6R?J45XR>"#NS9$.E,'
MCL];Z>^>;HVL$*P:?9!0+ POAT4P7__M6F!WC4_93FC%PVTG)C:AAW3"W<16
M"'4!^2 2U-K;=D%\ ZP?Y?/@91Z+"0,)<R#FYOJ +%&/*\R+$;EDX:=E,7Y;
M7+"SR-DK3D#/JN52<@**[N? 7NM:3,PG#"K))U+I+*?>L54<4W?7G,JU+FWW
M4;:Y;I'RH(:QMHZ,=4V8MC7Z02IVY_B;STL"*+.OE#9@1O=&P],\Q@),NLPM
MMKZ*[8'*ZHASDM5H,-?B=M;EQ;RZ0(8F./IOYR7S-5G,#LP?<Q)+W8KNGG0Z
MDONXZJ3RS;YSO;UF<[9A!08DOGPNX'\J:K:MM <) P3),H=):I8K3[DT='&*
M$^DE(WE6;FXX3(OPM W8C\%:W;9MLT^ENQ89LO<0F/A]J> XY2&!,T;]"AW0
MY8O&@KV$3"\L''3+<LRH&A;3Z1XVB+*WK#NEWO:WW+W*G8.I.]U_<<='Z7FF
M%0F]Z8PU2K *NP_F(FI7L_V01)%(RWE82%A+,Q:5K &/M/@>B2I;_F;F:/W(
MXW;JP.\ZPGI,*-P3(*&B"LXK![=@0--UU3MRMWG_MJQ93 ICI'I&*8)=NTBI
MSL:^JIFP3O,.2>8IK$4R/OV"8<DUPF2]X.L-0B-YQ61KIGNRFV&EJWLQ"8NW
M09#+K=*&1TE8'S',>O_WWOS6.F,"0%8Z.H2-PB<<I\'2W["$TM+.IC4-8"7&
MYL&E<+G'>K<UEK?6K['%0,M\]_J/1A*89T!97 9@<!=(OZ$O6\2-7-41P,YM
M(5T(Q?;#)>:<C TW*A?"Q,+<@00EI)Q5ZA<P5P!-4S=S*W[PB>")D7&CQQ?-
MW"<'#^Z]O9\NC==MN?>*KW.HJT3+RZ]?Q:IZDD&23;]B%BQ8U[ HX2CCS8ZK
MV#<)S1'\C1H^5K.-X3\QM&:-S;QO/:4Y#3D?8UR."K9;'G/9EC(25%A2LH9<
M3Y^JTP?%PUR5'/*ICYA0V7F!7V8"PW?6':LYKJ#_@*&8PB4*-O*JG%\B<EW-
M7,9LPADIE''DX>XJ\KXB_\U=1?XS#J=?^+3@@Q$3QSCZ>MR&1%XG+>->)SNX
M1]NP<ZE3BF6F"C4[8D6Z)&>MMJ)::1N?MYR>&<=_RSDF:42OQ; >1(F%%$D4
M1/Y9EU>$(Z1'<L0LPIDJ7J'K?2&_2OT"?>+TQK$XH/+)VF2,*(^@R$T;,W?*
MA7 [$Y.OQ5A'BIO1QHQZ'+:M&H69<'(V)VUQ18Q=I0A)#J6:A[ (6M=/LW]K
M"GR"PUPZ@$$4Y6)T\3Q.GE1PH'R]YV@ND9B9A5=%I[8# ? GQAK"RS*+5:@B
M"Z><$(.[DCM.GW!=.8QX)_!919_7@R%I*>5\:)Z<<]8Z!L)KB;+2DP0$F[1+
MV[+T^FO),2)IL:']G4M/U5S;+6R_:T4!^QT]D+K-D^@#=8%F$G<3]-?H$GLZ
M#$..B.3+!KBP.5PJILB/*3M5L"#2#-9ZTB.J,7(WLW4!*_UBFSY5Q6$8)1C
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M/(IV%88-F(_G9RF379YTC#&:BPXTJKT9N)*=2DIQ-A-J\682JMQ8=6Q G4K
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M,NN0I5$"8#%AD7JE$$@ZF:@4/-1]376N2CFJ6/#6Y+VZ2_WNE^Q$T2N:1,A
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MU$YK_H'+T=9Z0'G4=N$5GG #*CSP28()%^O1O$*U/?6#DV^0AVIHU;KA%:>
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MP4?3.":SNI"J6F*SJ>[0'AX-MD=S+\'"_8:PP>LJ +7.@F=]?]9;?+-OUF
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M;EB)UC,5("ACR:,,IE4>/0>,8[@-B9".-@;8)^8%0(YX+2&(\&NX'F&D@:A
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M;\ U+[Y\MKY\L,XOW[^[^+:S&G3NA_1#4!\RTF%M*:YG48J=8-GGKOB6P9F
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MUO5G9J*S@73XRXA>W@KG.S$6PBA  %>1:*:DO/%R@,5T6)/AU;*G4>[A%WF
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M#;<B771-S*_=<;<[FBXM%=NOS;0,!D=EDG_9W_D[)!TVU5X!J;8N 7'<>BD
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M^USL[67(TW#); RT&$;HS<9-A;I[P-CH#L2$\X=E4V^J":Q0C]N(<<U'1W?
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M:BP=RSP(W.\G:9*">@/<J<[FK-J;VP9H6V[./@CDZM\H:/AA5(VAF^-PP+;
MM--H"JI"^C(!(AR#]:?7E2^;L?P:+59MMXTM5H5W^> #ZW9!(D=I(Q(=U*(!
MYI4OG#U_@5_^I#H,(X_E$8C" RG%_&5U%5!G3QKQEKLYA#I< Y"[JII.?5VX
M!F!WWATHPG:[-.&%TRU3FC8X&<9K7=EU5-G0%MVC3 ':-]9LN7.+[=PT5!DL
MJ4T4N7W?P$J=>H/#V.PPEGK$:]AE^P[;OFJOOXN2)BV15/J=O$NZ*DN:HNGL
MA/"#)DOPS3&%!U_IZ'T'A?L\\J$J%.[2)6>*TJ)"!%JU[K2I %EDS1U8H]X
M2UP%L:2#A2,GT KD"C:,P"8CT(P#_R(()8^,@Y2(V:/;-R4L8/H=0'H;7G.
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ML S55KV!3PT0=ZZBVT//4TR%:)YGTIY$06L8(P'%$]KK_WKU<,LJ?;[_N'F
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M3#A.QCF+F^TU4?"QZ7'8@7E&SQ/-_%!#K/2;GFM:9%':#=</,@AA9C>?!\@
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M.6GJY"O)H8L0O,4-\5Y%9'7@54!P3;LUC+TUP6V["!Q!H() CPW!10(]4)+
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M<!D9'K_RR[; #-=EUZK;F$]0H:#";E!A"ZQ_&V2AJ\J*6C-J<60JG$W+7$C
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M #T#X(L4B[##G5X!#R QXT\(*,(4DYS!4@(+Y?N6RPQ,HJ]D-,'42\D#J4\
M6D/X#G(-OD<$"7X_/V8!!C((1D'ZCHQE# SL ^S-BT&*I+"GY,^/L*6O\*<U
M;V;2B$D*_"N Z@58/BX'WPV3(2W !U?)EH&#9%?*^1ML$)=DG!:7"!!]@V&
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MO_Z.[ K+P<AB.8L8I\)7F,+O9V8'XT]T':A!AJ6,P4S/P..ERX!_4WM3)([
M;O_0LH,.G&?/JE;T^(;,]%E101;P46M/GQ&(@D)8_Y,//(&6 )3H!M<#G9L7
MUT$JK!T@?3+U:L 50;.4O) Z./^YA$?&L%M%X5Q&[HP""[+'XQP)P5J Q0$Z
MX)K*/T4G;0R.DH,'0#VGP/\G!'/P S!88*P1G%!P0"7X2R^F*GS,I>-AT/N*
MMX1.T'/Z.70!28AKLZ*$7S(C^<^E0QFN3]D&_"WFFT7N/+&7X.I]3_53;#N+
M*V+OHX?H4?_$0<*#,&?&EE$1SG(Y7U#E!!3XPTO>MD8'1L?"^N$=R*[,O;3
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ML@O^/,+H-W\>])D,_0]>^PORH>-0C1+1,@S"YLPE:Z=(7PB<^ Q,_$QAO!@
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MTMDM?7RD<:&&Y7E+&BF'P$0SBN24'_?FQ?-M@S#:></^L&V1R5T1;-]Q@0!
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M&S.U-Y)UK2^*Y4B03V]K$TN^54R UMFQHL =9,<T.M=-;FI& P_*]N"Q#UA
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MXCJ,WM,>2>'MXT5*0/)2A](0-SN,81U\V7!$_.D2, NX -Y!DBB$9XPDFJ3
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MVX0UI4QW'%"7O>^)<LP&R2F]2X:=?^'G&2CY_IBE_9ZSY)]<N&3>BBF9PE'
MQ<,;'VH&*;33.43"\QP.;$GYVI(9U9D_=B(;Y[;7FA4+S-D"DL9;R0X *?V0
MZ:\3&.I\E"R7MN./,YU'';\FDTCP)T"5>0BZ?B[O 4V*^<L$!.NYS*)FOI1L
MN6CSDV3(*,@C??("_!@UR(X/-@ _F\YHBI"\8<S6RH"%<'W-!.)88(UOP.WF
MVE]85+*]--/_K20&E91<%YI,9  IG)[S_75BG\+IO$QS$@8MC_$ +U-Y)G[I
MV<-ZI"%]A6O_ +RD$[[R;<Q7OI+7]D%JV15UH_U+A97T1S^6YS&P&;(6<,X<
MN9EAE;$%!EP0A:Z/US!^ZN'I@7$SRUM7<]/)RW-*_6/,35%O!?D+A#)B5C+Y
M&<5SE)KS8]03<Q_.'<@*EU'8)=?3B]GRK**)!C+2,1<W'5@^[7(6,2OH,HL$
MX("<&'1."=WYZ9Q[M$9JZYLHK57W&G)EQ\YM1X92&ZJJG%26ZZICU)F5'^^F
MK-SLOAPQ@#R&C,_A&,WW$TG#Y,JLUB>K1LO4P')R6J:LM1Q'9>26_X7FVO',
MXPP.S%P=\^ZQ&P&?N1@@6SJ?K9%CU>SE8]6J-"#M;>(@Q3 J'A:V?OC7?BZL
MP4H75GO.DSQ'-F..,*W0<)I909>;.'-:,]Z<B9=FM4>G=(<.Z)]4XNX<8QLI
M^]^KY&MMQ>OB',IY(;GA>$1%.=LH$E^-687VUK,*GRC3^QXI2DK Q94#"G5E
M?N"?*A/;ZQJJ;E)95SL=HE.CXQ#;ME2UV^VX\_/KGFY^FTPG_.WF_K?'RX??
M;Z^DV[LO]X_?+I]O[^]V&%.X?A6SJ[85PW.):FJJX^A=LTOTC@$G#QS#I$3!
M-.9ZC"G,#@^U%>;T H#LFCQR[&F!.9?AZ1QQ@+_]].DK9UH)WV@RCI@!YXXC
M AQUF$R,<;>'G"T:C\0>L_H^^9&'CQY >?*]//AVQ>ZX^47=(>HS67PREMZ=
M7=W<GV7^&]@?R6Q;8$\45"G /=318@9U9/",48/T06<"4\^&L4O11</";3E;
M[&)7)NG?(#TRV[CK8WX><$ 23X4KQDD6DS@9?ISGJ^#3.A1E#>P1N.!DOQF4
M0'Z\D)>)=\>C/VD0#?"K%FYFV,7,PIBO.B$!X]-]S.2 M<#%OINEO_S,'<B8
M2I8D+=QR[EP>?^?Y"1LMS_UMB#(O3$X2Z24 /AU('9+X"(HK[G7"A3)_V@X0
MX7Y2V#\_$H8:V?;13YF[5K=S0*]Q/^>1U/&DYHSHUL1-L\1+>8IYJDLBJ#ER
MMZ1O<&C/%+ :@8E_7+/3P!TSS7@".![\S(F>._X(.O88G-AE1.H B7C,!.I&
M@1]Q+V_\0H&X0(?*@Y ^D]QC&PG?)?4CS+2+7$9=.6JDL+*0GZ\[=@0PVKVY
M'Y-%DF5(5?0,M#5G@-C*DS!#4$N0.#C/>8EYDA3R4 !1"Y.W4'%CX5T_I7U,
M4%A@ )PO@*T*]TZQ"P#;F.6@-9>)WIQ-(#BYH8J)!!%3KY(!,@-4>I P)]ER
M4^@_3=M,J9SZ9BI)#I<$!!?D'N:Q*S6*81VX_.XP9%!)"H\7=IEMFP:4PPSP
M"M"G"V(K3\S#K-<D[>=L%FS:GM0%Y1QP"97LA#,(=SK'=9I;2-Z0(7W2(SQ+
MH!L3T,Z'$[8UQ6-KEBXYY?W+U?.0>:21F2&NI!ET4APS."9I!A<>,P%IM\#S
M/_$$0$"./"0$A^9%-%?9492RO#SVAFF%H?!Q".,6RS".T0\18*[EPHU^_G#$
M7R2:>(PF7N%3$9_8IK)M,L_F?^Z>,V_,\XE+]MS-4N+-*:Z@GUT8FMI>+"R7
MX.P#7-22P<.UP[ZQOL7#*V , E%.369>P?7@1)?)IXE;C2?\H)X0>4D>2.%!
MSC)4&Y95PZUEN!0M;#CIG&]FEG'V=DQ.!2F0,ES]N%6.^T8&%$NS>LI,\/ON
M'4TQK01,C,^C!RY+?P-M9+!LM+=N+(SV?MLAU(HLMV7NAMIV"K7AM%5[^=>[
M3LI5P 91=AMNO6ZLKUBLJ:H-&T)<7,TTWI-BU',")Q9^@86'#C@01Q)*HFTF
M<-;H +>>(KU-#_IJ'S+J%F5M>(,1M"<%.%4 ;C? *45\9"X4J.@,)"454V_S
MC-*.3"QRZT66-'N#E[4[ZZ4.'\)QC +NL84#^KSTA(;0/AU<3ZV0OVB+IU.0
M;SJK6VQD]MV7..KG]?G_\-/>U3"!_='XYE=F!%\RAQ_UGLFOK:OS=?/LPC%;
MIFU5J*%P2?VI!>6<*N58:@4HQ\+<G9:E",H1E%,;RK'U"E".?79A&"U+4RI$
M.?OV,*^/ROD;<[(_L #:MKUW3IGPB[9X.H2_3MED6,&18GN"=LXN3*7EF&5U
M2JY1_S5!$57:6YE*Y#X48<@@XM268>N"(@1%U(4BUBF'>U&$PD:&&GJ5*.*D
M_(Q+<WE7J8'?6"!_:02C89.]PJRD?Y7J--LXDT&1 _&!QAAF(2]TC/_GZA0!
MJ* DZ>V*V#S' /M?-@F4B2%T^Z#JK$ZS,ZKBX!.S;0M4%:AZ,%2=539V1E7]
M[,)2VA49AWA\5*U:%%T\8X-GG)0:NC;<G>7PBH!WXX(/IGS\X(-AG%VHNMJ2
M3:,:,D/$[03I;."L7#..Y4U(QP32T:R6(:N"= 3IU(5T["J0#@Y!T8R6:CD5
M(AT1\Q;QC%..9ZS3-_>*9]AG%XJBECC72(3X!$D<78_<BR0<) FMI>A[>XX%
M20B2J(I^N ])@ 0"DK!:J@A[B[!W98EB2=A;+B- 8RIG%[K9WAO]3R5 (V*)
MAPA[6Z6@J@JH:A5T91&H*E"UM+!W.:BJ :HZ(D-#A+UK_(R34D-7(BOO0B8B
MWHV+/2C'#SV8^MF%IMDMRQ!1.T$YM:&<"M2IF@90CF*V5*5*03M!.8)R5E*.
M40'*P4P11VG)2D42<T6X6P0R3CZ0L4;9W"N.89U=*);>4G51XBTHHC84<<!Z
M5A/S/TSL8K*W624H0E!$193#O2@"TS\,LV7954K_."DGHXAU'R@JHY01E+&P
MZ8<B0MTB?GA 3"VE:M92L#V-P%2!J0?$5*,43%5Q5$Z[(@[8XV,J4V<^L"$L
M%XN#*S<9-O/6JDGQ),G?:/02DT'/=Y</D]QNKNAX,D[FX$S0PWGS*Z5Q2(+<
MNYE<AM[7*'SYZO^D'I_>]'DT60L)+G&^Z[(9.I:V,$.G/@,OUPY@ZHRDE\FI
M$ #$9#@=S> HN1D@)39Z;NM)1V+D4,VF^-1JL6+DT.R>Q,BAJA^@&#E4RH:;
M-CE'C!PJ<^30O@'AZL:![Z:5NUS-'>UD^I[VP*%:+/*D7-DK\?9[Z.-,WZ<4
M)T"+;-FF9"Y9]O%3ERP=!(6MMBQ%JX;/223]"=+9H(BY JW5+&RM9AHMQQ2D
M(TBG/J13!:F3M5:3]2J13G,29F]#YM]&>)-@IU2)33.CZDTKBE.!['++.KLP
MS):L[1T5K%[FG<"U*5PS*X!K.*M.;JG&">8]"UR;PK4*-(FT',QU /5Y[XFB
M%<V?U*PJZP"L2'M;-2OSXF51:0TVZD5#C''GZ]W8?7ZB1D.) #HA=G-\9F/+
M99>%EW?2%3?U!<T+FJ]E0;NME%W0+FA>T+R@^2J7XMMJV:7XQZ?YV21HEG>Z
MD H-?^-9^.&0>?5F,E.S\]35MH5YI(,H\5DJ:TP#N/@GG:2/_F4VQ3?;LSRY
MA71@>\-T^2T+&3%'2@'&P0/3B;K3/WOCQFD#\D+/.S$E/\Y)%Q;[D02O9)2<
M?9C-[/7#\SD8SF^?;_+BKYT8;BUX<3WRIO\ZAT6,JGQ;,3R7J*:F.H[>-;M$
M[QA=UZ8>-2E1-./LXDL42UT?B5$:41(G$B:[M?"G*I'0PU^4EN1/.YVS/!T"
M_TF#<4V$%'6EE#4/F^1IO]*82MO6MSDS00YUGA,!^\$WQFPQCW[R8U*6H136
M9=@:-@18X"A_:6V_,J?DE>E8F+VX,@;X+1>GRG+)BP/D*%"^ &PQ30;41>X3
MC-J\31R</"QZ)$4AA74-X3WP^S!-?(]*:8]*W]M/[19BC$<!D8 HJ8=Y7DG/
M'_1A$?!Q IC+UM:2/.#!893"@_J#V$\HH!F($2 +P*U!%#-H +)-T,P/^<N[
M[%T!25+X):9T!K';TBU<!AR=OR2,^&+S(H&8#F!?L)9$ZD<QKAIH6)'_@D\%
M2#/)0##39_S:MK3]&2DEGY%Y=F$O#@=CBPZB\.4\P.(1@#M6CV"=!*^%@(]>
M07BSA%XXF^D,IO:B.)*DQ;H)QEQDUW9HU]!EU_)T0U$)<!:+4DWK=O2N0CM_
MJHI^MA$7S3Y!,7S0RI^5=3Z*,SG1#2MY'@%MXZ&;#F-4?4+O$:4R]2Z1. #/
M:'(-"!A$R3 NJM'!_JH9I.$>U),ZFJ?;M*/:&G5TU=4[-M7-CF(Z\)OEF>9\
M3<_EU=^^WS[=/M_>W[6DQYNGY\?O5\_?'V_O?I,N[ZZE^^??;QZEV^>;;T\M
MZ>[F>5'UF*MA6A0@ZU<TNP/+T16GV[$<*NNZ02@QJ4I=0E1-\USJVF=[U$H5
MPOHJ2M*D"+CV_-(,65.ZJB9W/=G4-:IVU([>H::L&K9#/*6N!5.7[K^'?I)Q
MM7@:2$R,1$#BL004WD]:C'<A,_,3I/BHNVE%E"XJHNI89%2KQ99;$;4T@"@*
MC42A464/610:B4*CNA4:%0?1-XN=C[TO;^T9_4I?P"[,-U[J"LRVL<$2"CQY
MB$WG6KM .<+:=GP \$;E_9R+:CM/:--]_HURZ0-M%SOU66.3*;MAWK2Z1YOA
M%DV&.[I]<S7;.;MP6HY3UL2/$XO+"1)L% EJQR!!1SZ[L%JFNN@:%"0H2+!I
M)+@DG>7 )*B<79@MQ53J0H)OVF'@:(K_-QJ_T#AAKE$R.?NDCK: NL06$,GR
M4\2_)*]E2^(OH&_U[$(SJ]0^6)1:E(\]2\IZ]L<>[>S"$#5AIXT\2^IT]D<>
M3!NI$.XTPV7X',/-[, D>,)/WZ42>8DI9?DK-=0>M'VTATT["=2=A)?4V^]A
M.G3]7]0[_U\:1X6D;6"G1%M5U$\5*JX7/:?+QRSGK3'+%)A55\QZMQ5J*0O]
M=1+8 ?SV1HX/G+_5D@MF#2W$\FO4&*3BRLDUB/TD]>$(:1UU$5UX,M:3]9)*
MW,-)#+LTB2$,U4IC5OEAXC68Y0C,:@9FE1/]7, @6,K9A>;LW8!,.$&V//W;
M,(6S\S$/?))<SLI+)+\_('Y<5V^((;PAZZFY_$#J2CFAR(JP69N!6>5$Z;;
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MJ1R$7\]XQ/_0$?ORCD$%& AP_P@X"?[%'NA&Y\DH]+*( G\@R$&\MV EDX4
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M'E^CV \]PHYC&+_0)!&2^NTE]8>4= *:DP#[P2_!-M.S]-&@+^>T%UUM6P8
M>A E?NI'X<>8!@2[=G]Z];VTEP%Y^D9^V!_ER2VD [0Z3)??4@&1H>*:;'V.
M+4[_[$3>"/[II?W@XO\#4$L#!!0    (  6* U<YY7G>OA<  +(? 0 1
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M\VF54OIY\]O+CZZF=WV0'JM^_L^_OWI7/N()B.E\M89YZ2]83?^RVOSPU:+
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MIL3H0++[&?>2PQL6AD:+<[:(#%8+BRT)\,$(D U!$RN*X?:A'@@+/^YIXL+
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M/! TWVG+^9ICW5Y/<3)GK9QPQG=BE"0ZR L.4:$AM]JGS!TJ_1Z61Q,YYT?
M@0S@3# \F6XR'?LB+\-FI2,S6L 4<A)%5=\O;ZU(6*2HI*YK<2[*P!V*>("<
M,=G8@T*#BR5#"HO60K.-?$C?,V)M"%HDXJ5P(7L-,D/-[!WTV!7?F^7Y'<7F
MT6>6*&@R*V0MHMA$C.LL) O4]UU6X%M6]$O^T-1-,L:D" _D_AWQJ(,VG57R
M+>97J'" QB@R7:-41EAMK0!KD59%*X2")30U@+B[2L.8U!\SWP_:;CZ?K]9-
M*UN8O8%I?3E_!I^F:YA=(6Z2/"836Z*E]4#9ID&5[A%14XO5T=E6N8O=OD_5
MF)0?,S"86<+86G@-TSG67V$Y)P6\(F?U]*3O.M;GV*9ENIXHA3'+*$4PF>16
MR8HL-B0_-05?$F(VCMM ^CY58XHC,4.%F25L4'F_1%B=+K]>D6X!;/;-]SA(
MZ\7H6HH,I=MM9,PC%%"9&QJWJ=@Q:C1LGBHS%@[<<\XHX@4&M\K$-5*6&%H0
MTO1XF<Q1)-5M'6^-0T<(9:^?WY'$,343Y=8U S)KB!CDY76*IF4F4\A6,H$4
MH"3'4F?R_51/ZJZI(+MI^KWLU?WC[6_@:P_U7L9YP209:5FI2CJU"4+OV4F^
M@.[Q+^]],=S%*'=3,B:GZT ,W!=H/V#K.07F\A3K77G#5F-(:$2P30G;?*]4
M0W(+FLQ)N69*Y8Y WDO,F#PQ?C P,. Q\R\OZ%5-*>MK$S;WSL\]986<@22T
M#KIB:48I[AR!_:D=DPO'C*@CL7"P[,L+8HKVWBE?A2D]!["X+ADQ"T2P3D/(
M@(/T,-Y/_#Q"FBX'6#@VGSE!::**REIZ<A6:I_4H:"(55P28G(+,/I?,G9!X
MUP2'/9%\]J@K::RA->)+M3VT1B>K5WZF2MS"DEHAI9YH74/@^"8A8[*H]N#T
MG<@]:+/9)P],')'MR;45VC1))AR1 -A]E6Q5BE5IR]YV_>+=8S*1&+B[UY;R
M%3=MGV-W"X$8H9K46QX[39*S%2/ 5R+8%>D<)FD:=[O2 \@=DQW$ )MC,8X-
M:6^6O=?\^NN;&<S73^>UAU4VT]IZEG"(!6FU9/+''EQ1-HMDH<]"]5;5DJPS
MW"[80_2,R0QBP K;UG..9K@V68D(N>RQ>RD030RQ)B5%U;V'1-):D+'N1/8^
MYFQCE)Z[FG8;NL:7$WD0.-A9,5"!4E'DE+7L13#]WA85(;8V%"F9;$TA"MCS
MIW<NTSE6>)J![?MO[F/U %VTGLW]8K;XPCIW^=M#!Q^[? _]3'TT>@XSO8"$
M_><I/>V7K_]8]3+HR]:Q3\MZ^OF\C+'46'3O[ L=.+XU\B(@BI"4-B9"D6J
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MCR8Y%0K9%-NUS+SYY!WG#OR0+#Y\2X\1B+F2@@C79QH?%(WY_F,90S([KN'
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MJ/CTS<MG;Q:+V02"!W)6(AD)/;4/R&9(H6J135066C16Z<--MP=IV#'&\.-
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MVU5L%N!<$]G)%ITK.DCNI/#OD#2F+,UA0,/)$VZI\W;Q%697%YIT!J^"%-D
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M"CV*S+U3^Y$Z)K?MF/B\U:_U")S>4GR>_[S_D6&%?_O3_P=02P,$%     @
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M;A,GQEA/9 G#LRXDHK*5##=EQE3M[:KEI<P!(1P??!A CRNGK:/H0P4(1/+
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MF9&0Z&>C^>/ .$*U\#RZJ!.O?96Q'LDE$*""C#N(37P6X_1Z.BBY!)N.7A9
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MVXG-MI'7-N;2/)-KB"7'!VTC*/A\+A7C7<ZKI;;.W\BLJNF*\NLRC//QP/@
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MD5FW9=J-A)"])%$6( "16,HLR3(Q%2#'Q%L=,#Z-,NU[*V]OF75[7K2Q$%7
M@7H73#'W<*!>XI YS20JEHSV+CK1F7=UR54%*YT45=%;!WW VI2L:@/Q>U7!
M U6[1VVX??1RHJJ"MG13I,82B#83J8(KEWKH-"H+DD;AL^NLAN\3K"K8-7-V
M4<>IJ@I21A7E7A/+&%K,$==<KW$)+@<7H*F7T=1.87VZ505W4N@^505WT48'
MT5BKF8@W(8;.IX!S(I6@>XEF=4XD -.$YY@IQ*RHKIU0LPG+MVWK5-'00^;H
M+IBSK '3 EE'=LUF5*<Q9^IHKP4E#A!]!QO1(P@38])3]/8H!R"219P+,0F2
M0LI@F,Y<URZG=&Q2;#%4CLV)721^!"XL0X+>^<GR,($JW/*\XT2451'-,D&L
M=@A8IJAED(KZVC78MJ,ZOD%22X=;J'&@ FI'8ZW">SMJPJ).0I-7PHM20"S,
MD!Q$+E*@Q%'!2_8["Y3&K./*^>B&\*SV[WSR+.A2QAW627D6_SGMC^>B+FLC
M!%4" W'H*J()%:TD5BE-0'$.3!EF6*O>LSLL$1N@?-OF: W]/*2-Z8(VY>,(
MEG.G#<".C-*MX$YCFU9190MZ'*Z'(ZTS]X$Z+A,WZ.L+5^(Q HLDL,R(R@@N
M1,6%KQTE>B*B;+%73\.37<1?/0O1I[Y_\75X<\$?% >)&ZUR#/==X659, T)
MSH.+I15TLJWLCI4'']^XJ"SWII+0NJCY7&0)K_N?(;T:3DK54MSZYEOGSU]_
M]?_3C)X// JB,%F*Z#,/AC ?.)&J5$HWR1&A/4TL)ZY#]<(>[>%]VP9'5WI\
M2#G;(>5N@?[FKY=3K0W<KN[_=H-ZHKO KE3?GF+5]-;%;<^.L'7D7ML<"3.^
M5,!,DO@D,]'>Y:2%YQ2J1S*< \VVW1N>*<MV45=M ^B-'WT8^8C_2W#M1_]8
M;.D9$J,Q:B*=+:>4@%MZ2)DDJX)(*>ELVA7O6__\$UP!=JF3IJY -]I(]:O:
MOQTU:"=,OKX=^"*5] M:B)_*&=%O,%F42;^/JEW)^C:/K56/?N<A/"@V+P25
MG">>M4P)@HE)!\XL32%S$7MM7G#8^G[O#<_NO.'U37TT[E6BS  Q,@HTU@4K
M^9:,6%RFLE%4.U$[_&,[JD/WM8UO0,G>-O@V&4  $,:9(U('1RP-@0#:E"$'
MJFBJ?8W4!M?QE[#*+%G=M:HKHP-7;R/&OXZ:\;@'G/JL+<+)"M&5IJ(XBW$-
MQZ6<*BDEX[6/CA]'=$8DV5N+;6FRNPJZ*!H;X_1Z.O 32"_@$WJH_5E"/'X>
MP$SPP_3LNAE-^O^:?7_C8'I1I.BM2R09@>/PGA&OA2!4:Y&"4=)Z7IE*M;!?
M(.E.HM:*Y8UFEN%&5+]\B8-IZ@\_OD;KHAR^X%^OKC^-FL_S2+*>CSE"=)(H
MQ4H(/M?$@]3$926<-M$PT:Y8Q=X0+HA31]1%!T4)-L(R)EHPEIA"9XE6+/$2
MV9VM=8H9Q.IJ1_%=/E5J"KUB/F>;<?>8$39*GDG.I7J[1(H&AEYG%!J,Y)&I
MZJ5/'L-S@:RH)OX.DE+N[I(]R7V0 1$PI2R1+AMBG37$.1LHD\%X6CL._.[[
MSTCU=3REO87;@<'[/EY!F@[@3=XXZ/G-#+.**ETR[G0*Q3"/Q"5#T?*Q6AJF
M&:O>+KXMMF-5K.^8%IVHXERJS&\<TIUBQ<&6Q!J12$P4B+1&X2R0F5!T"('1
M: ,<;<LY?:7Y;NC0=@_:4RT=K%";1W\;[M@&8D?WHRW@G>9.M+IJVU+G0+V<
MB$)HQ FEO2 AYXB>?<*5.P=-,J5HT,G '#W:XG/BM(-S8,XNZN@DZ*\_2/-(
ME>7'NY[;XE(N<MS.E>+$>XM"X$P2:\L:G!-(:H3BMG[@7PM@9V0Q[ZO2!U&
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M![**ZLWD"D:OAG$$?@PO8/YW3W.0UDD$ER.2DHE(O+&9@.6,4V!"Q-J6Z*.
M+H<%A\N[ Z]D"0X'"OV/P^?3T:A4-/LP\L/Q8.9"_15E-J-MBC';6.*41"C)
MGL401\.;2&.-<T%+ ;43']NCNQR:5-9$!T%#-QN8<9';D#BA(C(T;\"1X)0G
M6?*L&/>03>U>$.O-@$."'I9/G-^D)AWS[#A(1H]K,_!R2. -84ERYIW3+-:V
M;#9 .59(0UVKM89<3QVP4$I/OQTU:1HG;T;O8?2Y'^<W7@:8ES(EDDT)UD--
MDF"5(FC(,?!&1*M:F49;JG:O>_?I0Q .T&=34:Z5:^HO\)2$]06B\;+C70M0
M%5M<; 1R_(87A^OHH<(K"?AHVE=>^$"E+&99B=%6DGA-&6',*I]<*E';3T_K
MCW3).)+2=Y%K[43E7R&5MI:+0U_((G#'.,Z%4JW7H,&&#K?&M2QE-&>"!K:2
M#KFQ/MR=QQZWR4(E.3=5A%2_UE]Z 65,R_L;:0-GN&UE0Q&+QC]\")D(&BFD
ME /PM@7][CWX$E2VMZ VSK&C7F?\YD<C='$^0S>7& \>?X2KB\>'M')AD93.
M.M*<DC'2&.."0>,*E $I@C#AL0N+!R_JK%#(K8> Z%*RI9F=R%#J$?AR:(%^
M8$XY>Z4R\%C92VJ#ZU"G\+=IF3]O\COX5#(!AQ]GU\<]']&BE0(M7(T^MZ0N
MDY#1Z[4V4>-U!N%K)\ZO1W)6-2_V8\.JOUA!Y!U<="Q1O4%/R1=4[^<>91FK
ML5%1C6LKNL5H$3'B13GF*4NTE\ED6[LS_$8P%TR'PP1_O,L2D,"BXYPX*#&P
MPD;B.4>O."L>)%,YYZXNPDY]6=(Y%RJ(O(/;D\W#_GT,>3IXW<_0HY9ZD0TC
M63!=SH$#<8XQ$I6S$LTS[:$V+=K@ND"25%='!W<LMP1^DU>E,,<_*/A[*GMM
MP:.C;;(GTMN2%X[K7&2E7K>3*E9/?FH)[0*)TX52.KAKN5N3XB'07I2@= J1
M"(.DE@Y=\R $)S$*XVFVN%C6-L0?1W2!3*FH@@[2M!_A\1W)O)_X"2Q_"=U7
M>#,J8?,CN"I'@Y]A_LU?BE<Z+O_^E^'T>F:!-<.>2)Q3I02QZ&H3*8.87P>Y
M1$MU,[3"4NW<A<X'=8$T/2\B=-!$ZO8JZA%9+FZG$!Q53A!NT$60!;,3W!&J
MBPB!*DMK%WQKC^Y8%[N=,ZXCA9S#]>]MSW#A:3#:)H+H,Y')H>.173E;59ZR
M+#BTJ^S?ID'Z>5STUE7F:AOUG85:^<KO;E_J-C J7O'>>?7Q+W7W%/ZJ^@Z0
M7(>*U%)Y)PPEEE&TU*7#3Y S$2D)CQX>!=,J-.W4"GSD?K:N_G816&6]_8J2
MNFWJKEC@.N!:4I)XT+T*.!B6%+$FQ^R9XJQ=@]DMFKOWTN->^.TM]J:&S"H>
MCL^ ^"]W@63O#<^<6(T.CW2B5 "(FFAMN,@BQQ1:%03:IKR[+WV"RMM;9N=Q
M.;OZ=3=WM)O><H2KVE8#7+FQY3Q:85V.*EN9%;-H*B>=I*!!,LB/IIAM>M^!
M!P'#A7RVMR>X-?\#PM5<64*=*::<2&C*)4D2AT19<I*KVB6]]L'98?>+><UA
MY2,.V0=T:$594C,E/J@2YY(ME2P*YVH[C-LP'?^(HG,&[=#E8G>U'+<MU)UR
MPG?/!WLR >X%+A-=DC@D\Y8X]*_1J:8 / 3I>#X>D3:@_+:I54-UQ^W04ZJ!
M&B, K0U#7'0E:2RX$A&!-J ,7.#>8] K.!ZQ3E*.]9Q(M*M*.KB)OCVQV2*8
M^:F-C;;T3Q,E## 121DCUNM,/+.>X[>8IK6/\7=#>*QST:/3J$-%G?JLM,5,
M>= 72_,HC 5#%*>R7)A1$E2>-::VEBJPZ&@=;R4[EP:*79+D@"Z)NRCK'-K6
MM8#[O4MB!ZH_M'_='GH[ [I9*634/!/*B\FHH1P.E91<:0.B=@QR[3WU+&A6
ML4OB,5FVB[IJ)Q\M\CY*;LVP&30?9VUQ9R>"25IJ-"[EFD6#IH7DQ L5B?$*
M$EJ1&>+*&<SFUBSK7W%6T0Z':Z:I+M8N*H%.QY/F&D;O8)Z\/[[J?UI"LQS'
MA(8CT3@\(B-D8KD,Q,]J03 M9:Y]2/ (G,MD1VT]=+#;W#3X7.)QW//H)(Z.
M<HJ499PXRS6)P3M%=8YAM77\P;Q8Q7#99#A(XAVX\*_[$;=4>/9Q!#-_[ .,
MKF_*56K&6;*"1 ^X,?(L20#/2&DHPRE%CU/7/I)^!,YE\Z*6'C8&C]>_L)L'
MZGWP7Z!*]N1CCZMU!=<:\LI=6[31"0!#$_4R*QVBP-D9<_!6&Q9"[[$''V"R
M+5WR)M^\X/9 " !M"_"&H)T1B4RXA@1)'<F6 DM19H3:RFI[["T'69QWI/(!
M)3KU@YN>53%E R)'PIV#DLRMB//X1\E AG+R[8QO!7[S.XZW8-35U3WKLI((
M:V?&OX ,HQ&DV2!]Z ]0LC!^.QW%*X^K6(S-=%B2YYZE_T'K9]:U4C#KJ#..
M@'"X.D+TQ)H8\<MHO',NF]2NVL'N[SXR$VKIK#F>P&O[FC?9DR5A[CFNB%\7
ME6S'SZX+TF=Y J/7_>O^9)'4\/L8>C)I%VT0J'- 8UB4NU:!FZBWS#$A1(I)
MM&+(/F^_ (YT+O0.[,_-F'N2:K1R!"?9,RAE\DLI.Q-)IEY9'ZDPU;O%;T;S
MM.E16=H=5H%<2;7EU'-.@R)@TRPY(!%;1BR4-(XG'7 9J\R!4V<W=ZG_"E+N
M(,-P69'TU?#WX0AB\W'8_]=LI_L9ABCHR?C5^!W^O!GZ,/CZ%@$7/ZP7,T^X
MPUG"?$[H%8$C/J.39!*764MN.*]=^G$OH)?!G.YUU$%FXB:H2Q&]A:$?%#OJ
MV2Q$$D8PGJ I-9I"ZEF5LLH&#2=;G'GG18F7+0V23<J.>HBF]NYS -S+(-FQ
M]-5!:N -QE^^^.O^<&9@S>_)<\QH8:5$:,J62.HI<8DK$HT6:&D%W'9K5S/?
M"*;K )=N'.&Z,CZ7@)49GT?])LTN(3DSN%9*0[PNK;:9=R1HRW"EA,QH*IVV
M:W>LN ?@5$$GE72Z>LJ^MVR[N&19@ED<$[>!TU&$R J4TT2 '*"<36H^0+)'
M4#@%)R!J0X#;<@^,GRSP$N7+2_U*[GFH;:D>1=%;8C"ZT_,N JU]LG6#Y<UP
MF9:%EH53:-X0P!6+R! Y"<9YU(JWWEJOZ&JEW@WG5@^???Q+KX-DW=035.T3
MZQLX'_YH%G"X]D[(TJ1<!(;>"<>A!1M(TL)R)G& N^KMYMF7H+?]!-79?'O9
M3$?+.W,C;>E40S0$M/ M^I9>((^\UYK&+!1HOIOB;A]^"9K;4U2U>XW>,@F5
M<%,:V+O K ;"LRDEK<H:X!DC/.721H0&R]K%FJU[^B4H;U]A=5$V;FF</YM.
MKII1?_)UOI4[Y5$5$MTWBW\$JHBE41!OA>8"%*C5NN7U/-I[2"[+::D@[0XN
M:!ZB6AK;+7!UY,9LPG0:?Z:&WK92X0"A=^#A;,3G@J5&>4.,MT!DY!XM!6\)
MT"R\HP8DK1T_>%PR;/%YCLF%763= 0<0!8PG_?B\7"V/OBY+5*!- 4*B<Q=5
MV?\H?E(L$,M8Y%18;7/M<I!K@9PB-[2&GIK:0NX@L'Q6P>_9,+W&WQS\O^FH
M/T[]65OKI;N@DO!4X"9H1*$\U<27JV0F8BHMD!F3M4^\MT"Z$#;4%'P7N\)X
MY&%P=\Q+OS]HM&/1:U2Y5#_.P1$G-"/!"L%]H(R'ZO4[-V"Y$"94$74'UN+/
MTW%_"./QL_C/:7\\EVS9 (/@)AC%"#HS:!?'4L(S)TN8!6:,"M*GVDO"!BB7
MY3/4D'<'CN,Z6.4C>K8+\K<!V)'WL!7<:=R(*JIL08_#]=#!UK$=J+4>G#2!
M4(L[&MH\LG2KQH7-"^O 46Y][0O2$Q%EBXMQ&I[L(O[:1\"_?.E?-[\"VCI^
M\'J2_K2T=@R5EOM,0&O</U/.Q&6;"9<0'-54NM0N_V']\X]O*5360E-7A!L=
MB?J91:^;X<>2 /4"PJ1&:M&CSZN56]0>]$IRD99.)0:&&PTRJ&0IE\E!"<".
M(G+;>_3)!SKQ^,A7P_%D-)T%@]Z$Z220X%(4A./:021SI5JD3B0'9(L G12K
M?66] <KA"8Y#>).?CY#[DY<^EL2)KXMZF#\WHU'S1W_X\;G_A#^9?,7YH*1)
M)I/2\HY($#BUM,S$< <R!A=\]9/M7? =?TFJP8^'J8X=::3VE?$N0$L&SBCU
M_? E^,ET!#WC#(N\-(PS(LX=L0 IDJ0LT&A#4L*UVIT.0?&T"7-<)71Q1'I/
M&#_[<7_\_M,(W;DWP[_Y4;]X?^_\!%A/HGT&D$NS0:W*/5]QV!TEB7HM:#;4
MV=KK3EML3YM"G6JB]GWY?9#EJQ=SQVL9ZUP@+@/Q>P[-LQ!$*JHM)SU(:RNU
M1\N?LF@S2L3&5@O,3J]]VG3H6,P=G*2L6_Z>-]?7_5F.YTN MS"*^,E_A!Y
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M'KP*HK9EOP['J<+.#];MFN7@(!EW$&:QBFD9+-D"54<AYNL1G2:N_'"-;:'
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M!29F(3*J2\:K4D3FD$@(JA1BDHP925E@N97N-[S@Z2JXAL1J3^[-%$.%T 5
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M.6NL]LD:*7Q^I&;PB95&&.]U<;W\$/WTOFQ/:*JSF^Y-BXB&9V^49RX&R[1
MS3SDR&H74F^\,Z5Y"ZO&6SC:2UZMA/EQ(&ON74;IM(_&L.1]C9HZTOH@/3,9
MO8[>QZ)2:_>Y$[+QM>TI9?"!7]V>>T,4Y=W&(-K0;MU?S6D>M!4,4XA,6R [
MV]A">X3DC1/!9SU8 ++A1L8*1IZ3W)Y>(LXE2OEV0C<V_K:@0UP_]VZ]SZ4G
M"<%'7[O2!YM<?:KB+-0,ZJ(CIPT)6%[2327\"3BGCV">3%:FP_!L &=[![2-
M3=\!W$!!RB>!G2;:V(R-W<3C"!Z,+BC22&X!) N^)#H=03'P 6KO4D_8K)"I
MM;EW @'9$]8[C7ST(?T <E%5Y/OR&US?.NT!/):2%<M2!::#H:UZ$YD %4PP
MVMKFM] #$.-;^0V9-&U)X=:#A#[B'.EKGR\F^0U^P^OIU[K=37,PF4WBVK$<
M34WC7G7EI%T7+5P6.J+<>N/?T6?KJ55> F_;DK+YF*$J:S#)JY9<5Y-/&[DS
MM@[$M"RI@$S+# RTDDR&I-"JF P/G=B[8X$7P]D6!!P@,_KO.,$97).\7>0O
M1-OY8@9U\M':[=](7O%<)&D93X9 9ED8"$>7EL&4-$+0N76B3B=@+T$ZAN/$
MB,WOWM4)R//?;KY^7?FV<'U+HFEY3Y[:DDKSMY-E3'])L<-CX8<OUBHPWFB[
M6U%R$-(:;VT0&>D&=R$D4"# )>L2Q'1Y^++'*8EW.)\COEM-NYZGV=77-=W6
M89RDG4MUHCOFFM83,+#@O&)62R5CR5SFU@^P>R =/_=F2<S)I^4*FQAH@& #
MSYD5E0K3@K8(8EG*DD,*L6B7L/$^'P4ROMIK*0$/9]D<2^L!XLV/;W@5]RD\
M1[*J"0LJ@A:"(3O, ]W@*'+T(H-J+09/P!DK]CND"+2B]G.(R"KT6MJ<&$ =
M72@=L"!!L)BJVY^UY*%U.><91F2;<;Q'7+4/Y4</EW4!]U=<M3<;>\7-#N'!
M^((24*8L$\LFUXLQ91:=M<R)XH1.(@&XYR\@1\15!Y2/'J0?):[J2C'@O&8H
MM:]-"3WSJ!V+G$<=-%K1O ;Q[..JO9BT-Z[:A\+#C&%Y)![X8TB D,E"=R*+
M,0BF"18+2B?&?8HED#-95.LDA@ZP7I)8M.;"$ G]>$U_]>GB7H#Q1WPYQ)!K
MP]*"HDZ <56&R5 'XTK**HL8FO?UW(/I)8E(4_J?+,X+@J34F<A"#HHL[Q*9
M!S*_B1X $IQ2L75WBF<9YSU&4MIS8L0X[^OIER]7BV4^.$SR:_*>2=!QDJYP
M_BO,5ALY(K+;Y_.M8KD';VDK>LMY-D8&YTHTNB@73$2,B=,I1VDTO^RST)'!
MJ^E\_L/W[Z(T6D!0B6NF44J2W*QJ+;!@,A?,MLX%-JUK'':C.>I%<M4V\WWY
M0$>42'HQG^-L@?GGZ>PCXA_$Y,GRQ%XJLO<3D!-@O!!UWK%DL23!C+ <DQ<A
M;%]\.UXH.RYX@N!L&W;_\%PY!'5;YQUL8?S'U\]XG=]_P]F'V=5T=C%;D'+#
M&9$$YY?>%LBR*+IO>6T=6[O)I129PJ0=MZ($Z#91KL>B+U(2FE%Y "/XQ^U_
MW\CN]35^PGS]_>VDS.I?W<[&B$%G;0+#X(@D)I#L)H\UN5V@=Y#3]I3!QKIP
M'\)G+T C,&8 6_D!$=9A:1/(^BJ<<9T\";>2S!MGF,M1B*A$C*)U]^G'D8SV
MXC.&,!Q$WE._\\QGB\MW1/-/RTOP-<Q79=ODZY,?YTE:,SBB2K3,>^,9J)R+
M53[G;FDR]/E[TD&_NY.,QU<^V2M. U9.FY&TX8WR$$VM<%U[?UTP]7FJZ<7N
M.QSCOLRTX,].5A])W+$8#]IFH36P$A4YY:HZY0(RL\5%-")E*3KEN9P5PW>\
MM(S%[SXT;9W4^GKV"F;Y[23=3I8M')*GW8ALJS.C6,C>L""]+M%&K9SMY"1L
M?7@\.ZX=J:>-Z-3:Z?O],[[!:_@WS/ BU4VN,:DB(J+B3'!/9HF,=="=<,PY
MEWD$B6E[LNL.WNU8X+GSL 7=QNRGL#+0:J3L[SC]-(.OGZ_2O<3&%M'&WFLT
MZZMPU.:VLT8+)X8E':TR6O,0(ZEHYU#Z4'RHO17ZKG;L2]1RN8_X=3JKAN&]
ME>[Y#\9'9YQEKJ:^:X>9>6DYW2J:%PPVE>8I=%UP'>LY;F(EMRF-&]I?2L&+
MKT=6EMH '<E7(B<WLNA 68Q%:=/:>=P)Y@3=95K+Q+9/V8;P SS@U\ IH= N
MB6" U'9&,IL\(H,8(S/9D$.4$^;M*JCC>U\L5WZ!O#Z I(,DXTP2;7.5<O_Q
M:O[/#^0VUYS\3R@NK??:)NV8E/66KB^%D2QDQKDAH,D$U?R5Y2D\+U (FI%_
MB&D3=_U2=Y/AU??U7ZY")LXBEPB287*QSO"KZ2,@&"'5SI:03//2@@-@CM;T
M>&CQ&9I%YQ"@O$U>N+/ZX'KIQ(=HG:R/=G3WD>HL5I/J#,"2B1F3T"IVF\VW
M)XZQ$\#IVX ,Q/5I:^HWCFRM=W8?TMJO[ *J84QS)Y#Q@YJ-&#4=BLJCB8!2
M7$M!KC\JNYQJD5CP,C+'M2F);&9C.V4(GA?KGPAOCLGY/L0=P%K]=3KYQVVK
M",V]3EPQ'J1@6GM@ 0.IM<Q5L,(K(UOG"]];?MPX6B.&;'N;!U*SH7^9IC=D
M_7Z__,=OE]IG)WRU<4D\F9:U6;33BED#&+27BJZO)_@YQ_2?GZ;?_K;^XHJ=
MZ]_<<?)NO>?,P .I-H;[^.K[*YRDSU]@]L^E"G(B!NF#9UE*K'$+RX(3A2G/
MG1(AEZS;M\QY&M-+-]L&X<T _N5#?!MTZZ/1!=] M83[L)VFG+ M1_>*2P-V
MC*)RMG *S I3\4R+:OI (*M'ET!'*#N=4O"F>9>7TXC+GN+"TTI+'RX,,FKA
M&TYN\&>B2LWLF4%:_._5XO/KF_EB^@5G:ZN'FR@@2\T<DEFL.?WBK1<,..9L
MG%5:MZXFZ@1L_$AG6WX^*#QKS8P!GCA^Q<4J)']GI%W,$-;@HN?6E(+,^FB9
M3DHS^I/ C$=7"K?>V-:A\"<!O3 ):4?\<8S<VQ$WGB/7+EN6+"]D?]-^P6C)
M$CE.(+5/(K?6($_ ^1.;M@=Q9&?)64-AN9?UT@7:6 ;MJ1(PF[-PGV@<2?\Q
M],D]B%9FJ*T=&%=8ZG.PJDWX%./"%]!"Y* '?W(]4:KF*26C#]D'D(B[6^\!
MR,VL*9UL5";7^%Q@NM2(3S2>>>^-LD78S$MCN=@+Z@QLD$-9^*"8N27]=QJG
MX^<7+GN Q.\?9M-\DQ:O88&?IK/O R8;/KW@6)F'/;:]E89(3C!*;W-4D12-
M#4%X5VP*JB2)NMB]:8A/+SU"3F*4)I1:NZH=3[5J!1G94IQ95R3] !!MZ\9L
M8^0D[O$A?_HC7=_DVKJ"W CZ)_\.?UQR:7DBSV%-"JYK;E5 )B47"L%&3*VS
M%0^ >:9I37WDJ*?#?S2S!G#__SZ;SN=T:LO5XG)9F4E*@ 7DIO;%J)7 (3.+
M3FEE7%$^M+YL[Y9_@?)P*'%;5\HL<?P"LT]7D[M$NTMTG*Q'#2RXQ)F&FGQE
M"K"LE):N:"-UM^;OCW[^!;&S$0W/)%<13 Z* S!7.$'6D<"+7)B#H(12*13?
M^FGRN><J'J,#AF;1.>0JKJV^][/U7*Y5%@X4="%(YG4"IA,'%@6I/LL]CZ)
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MG=PM?7T]_3=,$L[OLFWG]]]Y0_%1(9U0@9(.K)*<>><-_5(*F.!E#*V+D ^
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M)2'MT-TADD.W H("XOA^ON_[K.>O>,\O]^Y[SMI[[;/N/>NJ::A*P.#,N"6
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MB?$Y ST=+<TS:BI*"G(R""F8Y.D38B(0(9  'P\7!QL+ )#Z?P!02P,$%
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M'Q-^Q^NC3D]UD>!^S;T.X'ZG.KQ5CF%-5)S(ENV6_5<4]C7+=&1K,^LQK_E
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M6V7 H#+4V%B-&?XSLH1Y1_034ENZ7[)+ P+(-" 0<K<:MB%TQ$?%:<D/[=&
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M>JOX'D@8T8#RHBQ"(=>  ]1N,,;:/#-M"(-^Q@O&XSY>Y3:YQO#?F##:Q/\
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M>TM$Q$B54:L<E"R/;*R2_O-99;/!,7[!Y:U"!<HI+B#KU+JIY.]2'G>29'5
MJV11$N#?JY?XMO>; 26?H(OEGYS2/4TD+_!^N=+HW<?B_]Y9\B5_%FO1FW]M
M*!./1?;Z[@)Y%>+K(OA/NL/F?LA7"S<&I<JB-66,1?R8A:(K.JK1K5W=88:)
M[4+01[\U]8O=?="I"MTV;S"+=O8+NK[!'C<$8IZU!XCZ\-EZ$SM>]5)]N-A!
MOK)U%JC^?#N'^TSK;U'%M_%UZTOTSRZ$N04+K9<FH[F3M=M(6;D-[^?>H.,F
M[Y;=&CK)X2-T352%0/8D,!-H8"_S;''MN,+'VI:OM5Z2J):OJ;(;QJVSF=C"
M0'AJ16V_*@TH[WT:W!#/"G/Y]& 1YC(CMAJIW8*EF4#DK"M_*?1@6FM^,R_J
M[&N)MZ O\UBZ%"CHN>WNHYROM&[_5$&Z3[VA1]#<,1I9JKOBF\@=R3*:>C(
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M%="K\9U*NBL*H*U!_;(<]\6GEUK2HZ2>6L6NO5J%MS@^%"WD/P<L?VP4;89
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M?NF,S@HB284LF&S[F]_,<47GJJA+Q Q]])]7A6$G^['G (SA?A3HXKKIT(*
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MF_\:27A+/M$@IJQ@$<E098P"+IKTNE6#%1$%-?](-!V5JQ5Q;T;S/G.6>//
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M63^+OG'_T'-Z%.0K!' .<$+$(FLA74,*+"'VG?QF#>^>)"5NW!;/^'J-T74
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M@UH#ZTFEKQTT3_E1T""" E0=G\-H%M#A*#!)?>VY8P_7V[,W%HS$G=:BEZI
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M<"D8DW?7T7)JT'3F]3L^]!]+ [5M9_8^52O#W!7HKO<C,1D>+[NIH#_I1L-
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M7%)A9,NAA@"H, Q&I1'F5N,7-!U!J.H'W%*I7S$$IGC!HU-Q;_'A24V1;;H
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MH8 F&B>^B<&VYX[#W<L;Y:UAC@"0A*OM&$( :+#[/[//.M8=N,/*6UW7 4<
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M#-SA$.Z N<X_>*>%KOWN4%PL -+M.E 7(:0+#:0[#;1@!K*%N_F=1[<K:_T
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M,A\)FJ#@C6X.B1[P. ^?:]$WB7<<>CS??FYTZ)1$WMB?=44350"\/PA87N8
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M>000;\'_/#?#B_D_NWX10$Q'69V1_[P:M6F]<;@0\BG_2_\3_I2VZ!-B*Q1
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M38_@X.%P1;)KVL_?T:N[$06G?@"NTY'XTTR9EFMOMQK .1[4'^X3%PEYR [
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M9IXSGHBVKS5=6<M*+-Y&.JD?^HULGCX,>8"GBLL0I090GT10:+(#]'?B&8Q
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M>>/ZX6O8+^Y=8@+KF>,2%;2Q*D;5$A'5P3,ZMOY=_ I=#?]^:1\GJN>QG$Q
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MW=;H!BFWWSJ<13##TD]*-\,XWL?)Y,8Z]-%:C(U);'#6V:ST?Y73=);$\,$
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M2.X'G'R3>X.(3[P#!W5+-N:U=(C$Y^\&J6;T :;Q.B@\J*1\,B8Y]--T0/%
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MC^)9R&^[]QV(@7G6^V-OR_?.(_=#2<1KZ%]R9$:OA;+8 ;V"C+CGSSY_?7'
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M@LFO9*E8SJU"Y+WBS O8U8_/)K)KY/WSN9)RG&>%SG=5@JQQLO$!-ZTND%?
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M5T_3:G&-LNAZ)_G<RW,C.I@#;Z9 YN2AI316XTT270@Q981F_$3I?=<3[)A
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MTW9+!#VCWMV&.6!RW).JXCBQ(-'?TW,3@ON7<_?+X>S!J&^PQ/%N@=DG#*#
M,@ZTQ^15:_4%Q^G6>/N60N7)Q0@GK&IHWZ3G>]XV84US0L>,W:_?&)P<I'D1
MU69]N:,*J\48^X<1&HS4"S)XTQ9"AHB595LP7K2@A3J932\LI*KKGF7J'<8E
M0;#QH'"R/WWDA".>DYX:Z_00+$^*]K?A^'VF!XM:@/ZWMDO#H&^5'1VD378-
M</\PCBVV=[:?SEE ,VW:L:7!BFF## /O,IS>>)-UL\S'=](O!6_0@SUS%"M8
M(ZL1LZ<D"RJS63$1)4"3:W&\WL4&UO5D?^NNIH,2X4BJ+<NU'S :QRS7<GJX
MI/.J+1M/3S+%DC>F.PL%OZ2LAT=S/MNX"/916^8E<;H2[@D!+1DG&V.Z,RG2
MJE-+U8^),P;!RR"=FQ"7B FS]!*1?:#D(+LC'IET;YGE%?!9.8E9C6"J"@B8
MQ'?FP!A\="_4I?'$&7<5/)*:8]&OCSL?1U*8H2NZB%XV7D6')PHL4"9 -"]^
M72%JF4Y\7([/F4\8H\FU#7UG& 'JM&YH/_K2WSV-,WJ,E&.UECIPTW8/)!R\
M&)-A[*UBNXF&6QF)CTJ@+GUQMA.F>.]7\ZNM^P:(Z;TMKXQN6KX+$+@"A"=#
M/9^IYZG]$,..36+G+'C6)RM6%^^$Z/V$;?EZ;9\3R[&?L;[HQ!M(R\8J.ZE0
MIII;8;K&,&+-8SX?K^ O0SGT6$B2Z<^9FF%[D[\S!"9@R']V!DX<\J^;V)IQ
M?8$;UU<>X&^+T5XFZZ0+&-%]]A<6_-*LP&)V-XNW=UX689TJS>@@@3N/ZG$)
M263.:VL06X*X%<4B:>)Q%]F&@6K 2$Z374U%CQ79[@"_"1]<%,^\62S=4@ 7
MZV3WX$-Z@/; T<P5>XZ'&*Z$(O'R<_OBHVL)[CI24E3#-Z<?_W$8>?4P./FR
M>=XWK9,K5;-GP'ZM\>Y+^:Z+_;$QU,"HY]>SD\K+UHO9X@N8:&O%**.9,G"Z
M[SF-)-I<N$?)<4PQ%TZ+ &77()'=<*C1?Z0,MEQ:MCP!HDS(#B'?"Z6:1D9;
M  C65EV&KD%&Z >^8+05U2!2JW;?*95+(.Y7+N_N JNUQJ MU4KI"YPKTE]^
M8?Z([G4_B2]M.2=R/='"(/\C+ >55AT@7,H2GLBR4/9-333ZZTIQT!6RC'-T
MS\<J..I":=D%V\6X^N++D7ORDUGQ/6=NH3GC=TG4_'N?O@DLPS/[%7_RLQ74
M-=&]9\J%(WO]G[K[@3D(9ZUK;EA"N@/P[,?@@0\YXY5N[KWE,C3D&3Z)PO+$
MM9@CK]? C8)D=+<:X*>UCD) !*J6\=5^/,%O+>Z"VJ2B#Y6QCH!P 0Q]JDR$
M=U.7!8(V+[\MF<M>&C%282NV!:%^3$GN)S .>7E)5=LKS[%4P62.I74>T1W6
MC6JQ;E%<./H*U $?FQ;W\;>3J!WE8Z5C?57-^G64"=:YOMJ1M.OK9I@^Z@_U
MJNOY,CZ57TZ>CV\+8,/ZX->NCFU_(77(@)TDU%IRCT;3CW3]+I<(7PR+4=W=
MF_-ZK-5QEDJ4)UMWO)$QOZJ@!G$E.[W_/S2<]5?3C^.V7^L-!HSN[A[=.F!T
M.#H$'-TAHB"B;)2 Q.@0D"Y1:5#P[>@4*2E!*1$!E3! 4;Z?\YSS_ WW.==]
M_73]-5)J,E &)-L-]Z$E0)L!]6>]-$TU8$&VR>Y^8 NP!>I1P1Q4<-AX1YIT
M V:#I\F+'XSSN1FOZ(7CQ\,_AB6X.DICQ:RS:V$OA=;_$WA\J"Y3)&F@N/>)
MKFP05X\R4D@6C**S_D?]=TI2^IXLY2CM=0AUSF7 K1E1B6,?.:7Z>22$W9\X
M[/A^+'-3^BD^9MCH[)'+[O)%UXL17>9F2+<[[-.H;,H_*?5M@HD@?\8N?RH<
M'D:=RI]U]WFXD18?U[!R_%HJBB4XOF+Z20AH+OO;#PV2*16ZLX24Q *TRD G
M<<*G5U?J'@>IVM'TYX5@1G)Y)9(J;(N# #@8'G##A($> Y<K'N*;QDW?D\*?
M;)N^H$+_PYM:A\$<L!!U7+<J@WF<Y&9TFFL)SKZ_KH-I=D/JJ^#OF?B2/M9>
MT(?G_E26;_U$N=TC(-N;:L74)+E4A<D.<<&/?;X'L^HWAB8@;8?K=BP\+=?Z
MN [VKZ37?+0.T!\Z'.;"17B3.+Q((E%&O)BA =@NBU' =/<D[>GN'=EOG/>%
M0;#K#8:$&*1-(^'9_R9ES=)OF-EJB0A=4W_$2=]P>@]_!E9\8H&[3[7I:7K&
M&O25O1WDNOOXO%8OU3T,5@!:HH_+-?W<K8<3\ST6P>N)7P9??CU*F;E(A;#@
M@'FRDHO9[^R,S&2@Q1D+NZ;(J('CL/6_H#]<VH$5\I4L;R;^/ WO[=^Q1/(K
M_C[0J5ZZ.?SU"PT2CT6^8JV@9T>P8'4+LHY>93V(3X"Z\P@8XYC,[A[:)V4%
M<([071Y&/_C(;*3 <>/@ZV]Q6PS.!4A#VP)%Z[B\O9&6!0I)P'PXQ-IH1I0+
MHLQ<7'+"]L@6'ZJ5R\K3=OTQ7X2TP!#O"<_,0N/CLY99^+'!+]9I$6JG*.Z;
M@9*OR(+2ZY'&>9S(X^I_UHKLQOX?/&@!Q[ /SJVY/B0QX3A@7X)[4'] $&?:
MJIL--"B<L]'7[YR.'2OFCH0O.[Q8&9/1N1@/&AT&YFKE]UL+*.\0"%MS.I0^
MT^AV",O(I2K;W/',T4<ONM?<O;BX6(+$5(/^\!E86'D7LH!NQ"70V[YG5+,%
M)<'C2*"J,J71S1#ZWQW.ABT.]Y/O%,.8.%39QG%FHJ!/DR0CN[38XBDE/0._
MPNLX3U49=SLVZ.L3-E@SNE#OSJUZ)V7U[99?4B,O@N4O-=:SF8O5[; :3JA>
M<\=)CH#^-:3CS@=R?-X9OCI>M#<UO_@9]DK9'!*V;NF/D'&%C.HCK*=,9 !H
M&I*@03X/UAOU'\&Y#!1ZZ:_O\5V#@^U&JY\?@X31AZZGQQT9M&_2^O6=ZMA#
M?9VMY? )<!/OBR&CK4CX#R#;BH6$\S8>[="Q!=#"U'.4.B.1:D96&ON9X3R0
M]Z%4Z8#TGJ'Q9/ V"[E;-\)N+..I7IW,S^Q-D'['#>?:*\#Y#9\J]1I&C*^-
M^Q:I\Y/UAER",RFEOB&+P*%XS>7+=2]#_@>;>T&0VVIYX3V3$*CM$%E',O2Q
M!?Q5J_9!:*6Q9 [SKUQF-?/(^#FF+/P!#FYD:?22K+8-5X_N8UO'00\-5?WH
M)*(\67CQ\!!>E8.MD*5CV_BPE7S@DH11.S"LPZNT\V*&#IP\I3W8]O[P0I"1
MZ4GI?E$'L_)8=C*IIS.W*V:-DC:XL91[YUX:UC[ <J-M7"+M]M\+#=:'HHD,
M/[^\QT5BTKAY1AR 42G*.),!:?/'M\'AR'+=(5=10NI^]*2B"B),@EN8]*MO
MY,?@Z?VI%OGNU'2SG*;LBC=W0R_MF1H@SMI'IK/'];MJ]GA^!>7^4W6M_L[6
M*P]KH\_+^2/]2IYI<$ 1:<+8D6KAS5CX)XG&%1]9^)S7F+4"Z;H@03$S_O"P
M0'""GB+[(9P&%\=P94'7;]++;U$S<%&,5=>DR> 1?N0?9FK+N,T4<X55*_Z$
MQ1A,8YOMTG=W%_<JA98Q--HV2E>GH=(Q^[0^,HAHICKY@(^G/16HYG[,/464
MLZ)=)=U-[G9X]YNVZ< [$.Q_H(F[7+SN=L%5*POZV6\DQ=K#$WA'7_P3[XD^
MXOTI>[G$TX1OW^G '?%W:>E((!;J)#[IG?^?BJN'LPW\ K\-<SVY%4E&SVVP
M>I5W&/L$=I35;F3%);O,@7_0\,WG2U85<4@<*U?L!BXV'/8^KT/H8U=U-\5A
M%3%5N2Y'[\*'';$%3#_*22P^;Z+T/[&-[#)/.:GI5OI4C9_6)L@DM%)(GK@W
MK:(F<>_$+!GKRS^ /A6U,3-_>_7O9D.;:*H(\/ABG&Z.(UA#MR=S7FJ>X(3+
M)G5JHT6>!7+]G9&7MY>\RV.F _;;O:..GV<>X6&/BIL1_K5WNG!RFBH4?#GI
M[I\_Z9!5@+4E>N7Q1;K)5JBIZLD];]P-81#2*WT .]A:LFO:CD<-T"^+GC )
MY.=5H\'M .3A))QD+I4YZED;/XHO3X(*DBS\.DI#ZE@]@X:]%!7C[86&O')Z
MML,5\CV_)Q'VH4QH$)P(%O7"%4XG$INKZN,I@X7QB205$\DB)9&&/&&6P[<@
MD@+AR/V[ O:PQ5U7("4ZU92((RA@%:ZG&M?W3+SK:>NA,:864.JCTDJ"W"=[
MT$W[J])KYMT\.JZEI[Z8]1>"&D=94F."?-P" AD<F*,^4G#3TKNC@H1;L<\2
M7KWY\/]#P$I$]62L(!R$AMD" M#DP106:>=<=10(?IU'ZR+Z',DD\OB!B%FQ
MMG]*MBD4K1?'<BB4-ED4^3.HT*3-O A[/E^_C"@OG:C /^#2255NF*TQ?ZAY
M=T49R CA^2E"2&&5CH,)^XQB([ "<"1M!"MR\<@.1L]S3O0#UGT>P'AWN5H?
M>_?9&19UFA\HB_FDJ'IOPM][BE!; 58I_"B&/;.VZ6IO3 JG[V31'?<3E>?^
ME8D?'SMI8K')@G1,V@:;_<_'MRQ;KATU<HA04=;V3_([M^M;Q"=XP!U!C!*^
M>UV)^9W]%J.@\JANNL-&WW=Y5.-TK:/<VU<,9:VB]O]K=1WX&6A_7ZI>:)U>
M(*3_CBU_*@SIX'Y4_^-3!6\@_*)(Y]]N3E( C#>9&$=S7$71HU/X3L!+6*CC
M13[C5'*E6$)&!0U[++(!:^9UO >:FPAR3M%\P@$'3N>WF,F_B,:>Z:K_+P0L
M-Z0+PLU;#WCQ-WK%.TBKESO P=!!@D(*RSI@\PQ-U84RRJ  U(#7C#[$_A^C
M(Y]NB-4RNP>>+5D0B%A'@_1+K47ST=#G5[T''),0()^@).<KD6G^*V5R?%!F
M?@44Q)!N@4<XQ;"!5=_*D--=.4'PSA&I+P7$D@V"H-J5: 0VO0@&8&3[C8D(
M;;R Z]WMOIP'<B"_3T.5']9^FRE/'42[QKYUU>>^C4*'5<IL @1SQ":1<&&>
MS(\L+VRK=@8^(!Z&[$W$]F(%!0B769%REV+DC$.>(U0+I^/I=><%33G36X4E
MX>UFWTST+>/RK23SC9E9HH][*BUE_^,@IFT9LH?VT\A/A@THRQ$ +?ZTV\],
MW13"JMT F13"9;1[H.X@ZE$XK=60W;I]7V3W.HQ=Q3B\Q$;DVME(2>W-OAI!
M4JM@CH_<?TO+3$_I<JB\3XK<!UD7;-L@8&=C4%;" [PUHTB^6ZLIU))-B.0/
MA F, ]#V$V[PH(4&N<'WG5[-LV=,E0-R5DV]"*'N][*94='[XVCEV4,:F=L+
MMB10"#QH^WTM=Z%BVO+F^72*^KY@^0$B@4A[D=;9$T$X?/-^',F)*_OD&?*Y
MMHHLI[>G6>W^4L0[]UD&A_%N]!<^^@9&Z\23!W.\N=\>>U#=6?J</BFDWJD8
M&)=_$W.BM8,1@MMGV2M 1)J:P?PADM^%$)9?"<#=*>&/IIX21H3,[,TM1S+[
M7.QN.)I(^LGI90[UV,FOKLD?UG7(ZXJW3$N_W)XS+2JUR9TB(F#36PCY1)GF
M ?'T^3OHVLE> @ 39+D=$,4=3>J 2YPSA(K,/_PPN57Z]1P1%G?5$ XG0$+*
M/2Q3D"/,+&U9-'@P4%O.9G8) PHA3EV^F\.:9OBI*#08GG)!W/Q<IDZ9;PBY
MR>I7^D4H\5D":OTBU<5\[#Y/9"[-X=-(=/,8!V0AB>-@*WGDW<CI>^2(^KB"
M;'+87$K,C6<P=1QL::Z,Q28>1(^A8$:+J@0OM_()*2?Y&!HSB[KX<,Y-@E#G
M\6EU/Z?)5,HP3?4$E55QI%X'(Q!_LI*']V.7U"%N,W,NS0O0JXEK >4*U:<6
M $=8ZG!ROVWW=CFBCK$)S]-GDWM#%)5YAF;A4PI=/'OK <?6:=X#(-'U<9)N
M2< -O ?+-X*YUL) K8^?)?N'WR5,7ZXGB?X+2B&(./JNC!5=?IIQ\V1O\\N+
MK.;SI;9;K /@L^&EGL?)(*(?SP!5W1,[+7A 00?7ZRLH@_ R3].\+AKGP-@D
M'993JU1X TZ&+8>TK3-/F3^K, M/N62V*<@0YV[!RP4FL77[0=P*!XI2<>8G
MYEX(>]Q"KU#+XP;>Z0=%NU"!]04QX6Z)VKOK@$%?'!EI3F3Y@ 26BIDSGOS-
M9F\1@H*T40D!<FT)=VQV'&]^5+W.A3.YT*?*OL EWPJBVL+]3*!"&TTT*9YN
M^R!O[,L [>NB$<TPF]>:BYQ/P_]FQ>:Y3'NPM[Y@?'OC45:]?:]4\Y5[]FC0
MH2*- "G2,)9\*PH&XSLB^&H_$@BM;@I^$GA9D631L9WAU>_)@%T9J53P:N$Y
M]0,6?ZVH6?NR;D;!SH+(K?.38S0J'-X7CI=H.6>B^F#ZMA68^HY: U$]IL[C
M3=&$A,1G>E+VJP']#DI$<2R6&HL_!>ROM]CY1[P%2AZ6L#7=L3_,?7OYS-O9
M.6<9!/)SYQPOWN\H@W%#R\$TZN=4#1FLU6][-8>7C@*[UEI+"7"_@6KN D_^
M!T\EX@H))[E!/K(;RHF?#P>_[_FR4,#,)/I,5H,M5_]?-U=$N-+X^[ZT9'*.
M WSF)*<YX3F#K%PKE8HK9398.%O"\=;134KX4&EV7OI5%JDG_LH=/P:]VS%S
MQ[8#_I8V!HP;/FJ"!(9J:E_<8CXH00$!8.",N*O)^28]RX.VO,9V-[ <U\[<
MA+4^=8?>NW[Q5OHJ[\HK6?,$<2-UD)^&)"]$E0U@&8AGV!ZY?^<CV?F""_:6
M*[]9DXU27Z&^.?1"Z:U-VH&6)4_*^)!TITR(PV7AR%S&L26\MTA<NMD=PKPW
MAP0UO;4E\R56=XH&4J88;M@V<K]>CNUN&ZB_F?)%V]IJF<7A:V=7RWEW?K$
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MGA$^_[UG/W&='ZD IP>09>OI/Y1HWR_! $ZOG9Z@>I$B)F-[Q976539:$JB
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MT=*GE:<2-B,E[Z%*;SBT)W- +D^KASJJOA]%"4$DA$5X^@ZE'=P"#H?VS*(
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M)SP<8 WA]DKPY[F5LX)0Q-1_C@K.5I6PC17)IOW]]HW5]_$/6C_5&JS[TD!
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M(5[IK<NVE<%\9YNB^%=0Q&(_^A+54)^W(5%!:L>O,6B>04HXR@;0GA60!_.
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M+//C$YK]LJ'49\DJ74 =@!4^G,"40B)PW;#NBPL=:WA<A\YGV5?]AN2.VQ7
M#@6V,52SBW^Q$NP3AX%8V T-E<6\JH!0KUCAL6DYN:\T=!N$Y %?[U19.[*U
MU/J_:4>C2]5/4R6?Y:8<YUA.=CFRF629G W<DZM,5 @JS/9?<D<]Y\71F=4R
MZ<<8I-,PBJY.Q]--^^5G<LN^&L$=5-276VRID06E' 5!"#;6&WW1\VJC$20;
M41[DSCRRB)6^LHT6B>436L(#TTR9A'M)4<I"'D\46<,".OJR!Q",FG>4EM68
M_Z0<>?6;3@;\E/WX,7./! /P?:&@R#LX057* (@OF4;0]4''S!:CS]4/&N_M
M55%+>5O73 :/0RGB]5G)\<K#N1?J6#J9L*J*#,';^#"J^-[6!=([O-+&-M\K
MG!>KE[;SXLS?D!_&PFMS:"I983N-.N"UNE7:I![M./=_N)R7QCY)?W(J_CVJ
M-.IW:M;TVK;O<'LU%[-XM(>0<'K1^S-%9K#4Y-E-0',8Z>P#MK (C$CHP5+(
M.]$45B(JS$/"M;='$CT;5.2LX@7A[/+/[M,*&@^,3:T3RJ=GG!B#T9(F4V__
M* DJ>#K&LK*G-LP]I86UANBP!NFD6]4#HB":;N0;2GG-;6[UEPTPHVY697'M
M<?AS)>$\T!R,7YZ$%+$VI696U6POG/>&IBW1DHV"3YA(Y -[L2OEC?+LL<QR
M[,^"O+DEGG@=6@NML:O8<,[['C*3D5.L?Y1UM#R7?EPOOXRR:C;=#+0M;RDJ
MO+Q>1X:6GS6H__-G^^X!:G'5;B@M+ZU.=B>'/BPJ?3'(45Y2J@*LD=3;B2/U
M_X&<4:'&C+@9<"^P>DS%WZW]^0. $L% _HZ"% $ZVFPP&OCKS91S.NSPBPVZ
M^J90EX#(VZ"VEUYGW'MCYLJFCLN1Y8E==RWFQ8)'5JW]<([#PA3*IZ2O40Q>
MP>4)]V;EZ0I!2#+E^IS(^0QX7@6'^WN>0MNEBL]\XD;< Q :TFW/=-2W>X4;
MM^PR ;.^5!N]WMOS$@;\Z:L,SILM%:N,.4Z5IYD"FECZ;9IE3QBD>IO%=[BT
M>D=&^GWF\#LV9NV?6;;K=$L5IF4HYCTU]>G3;"IHX5)#UYO%O>37.A!HL%[G
M72PD%V]AX>QB!2Q]2N+FAE,*8P%I#+'PO<RVV-=K)'''P#9M9JXN$7N#/@*;
M-HHTCVG(B/!)_GP4!R="B9*NQ>[E?V^_:Y&;=$3EDC1 &!^",TG_NS]:O41F
M:7J*LZUP!'I>OMF6WQ4K-'W'Z21'#_\95;V>_ES^<_&O(I?">"?% XK?\QQO
M"L'(> ?5[>%S6QCQ4I6*:MRT_(NU"VBFP<>WGF5B/RONH/:<T <AV(_?E["<
MS-A:6S3TR!1T3X\\.89=Y+W.O$O2M39;/87?O;NZM)A%30R)-9Z<!$/41BN0
MLP%+!U&$)=NYP]2;AV&^W%9+HRK)!:%]J,N7IM;V1:$-*S38=_K)>!;Y#[O(
M"D5I[2 F6Q/UPX"*DD#'N0C$HB7]J#C R<_#P7EWRHS-P/!#<7.*E4)MS0.M
M>>%D)YM_#TR^& GP3WZ;>P[U)&@3'?&P?DG\'F_W,+OTSC\M=N;,?%N;(%;F
M3)Z#&+2')C_8*!A&E,&;AP (#:D^AJ/3"'*[;1*"0@*X> D<"=67CE.BQ8,Q
M&$E_<F($EM81Q4J2+!RL2:R8RA@?X[9@M<(?^U2-"[Z7?T^14^PK^W0>OMM"
M_X%%HA(W727G_,^ V+Q<NV#%X^ 6ZHT+@-2:N2?/Z1+O>&?2PB"[C&@FK>"8
MG#^#+YRW-+RL3I%G.:+C,%5!P%8=H3S+1^>=Y+;Q<'KOL)@*^J>H]$_(LB*R
MN)B6]_ZT>RRU5X7[J)(HAOP=@(1B0)_X^^DR*)1KI1'X:9/JVJN"0H$MG3:\
M#H+P0M<3M"J!]U 'UJ5!8E1653(V[3AR)\W4=/1;F'#"+E[O!!]G&C\,3TDM
MK9@J/;9WMUK1)TFCQN7@%'2(Z]_RIH!,^M1I>CX)KFDH%&E3_[JOT)?>Y9LK
M)/CY>> )WP7#XY&W4M6.&T3Y.9E<-*4"A3@NF\M8J< FB]H)DJ-)V[)T]KG:
MD#FKT@B[5,:/[B'Y;-^Y,%\Y]8:S.>BK*]#>(_90J$FC9CU@$XR%]$Y",4"S
MO)?T_YLZF(X=?-1J3$I:AR(9U<@,/&J,,%6R6-=&;>D^"ZY4HMW)[:K(F7:=
M4:@)KH4V2Y/6*/2NFDR@P254.UI\UJ'/733_#8Z=,);PSA5\=Z4@;*%'ZR3G
M-8-I_IO S-U^RQI50+O;-U;V@&ZK0=LBMXG7A$.AV//UT,B#':.O?2?]OND#
ML>FNVS'>KC!@;S_J<XK::=7/L/RG-XGX">L\YQ?BW-[;Z)<6J-PK#[TG\D#"
MWA2\]$6:)AXZ]64I.)7/MQX<&Q\=2 M&X"!((N+>?%TUO%(T[:.AN,?U6?SS
M[V8C8T!,:6M'+\W:B$C)C[")L<MF6LL#((@%P"5!E)A*VN%KO)8<\]K4>DS>
MYT*%Y=W^P8ECBF.+1E &S4SW^TDSL%/R<6%.PUKEF4+MX:)/N<UKD0'B4;?(
MPP_WU*(^-]OON#A\=_'Y13A^>X_C:ZU]#Y/O/]Z#J4:.QV%OP+18PTD8-)E2
M1AKOX$FJU:'.%3I-[%A-/Q\_X)E*).V;[JC9Q)]F&@D\XL9#TW-LCX'5C&$H
M?[(%J_>CO!R!HAPW17L6V]U88%KU-.GMX'#[>C,1ULZZ-.TV_"."FP@,NF>J
M:>#?5?#$TZ5^F^Q@+7[$7VS-2"L\^IO'RYK%,_#''I'EXF7/=$S3G%#Z=DR,
MY1M@KF'HJULJRD<AN?1'">9IV;PC_"!P]1LU.1/PJ>G?NL2_>QD06PTH"EM%
M>G_S6J_LK\:_OTGL;\&0-[2D1\8\D?$/IW6\$3,TR91 +^:SW0R%@+KTY C4
MGY ?5])>'3F<._XU#<NN4Y^1HR?RU/ A;S75S$!\L4 )$S=6X',)GJY1<-SV
MVR #1;@WC\>W2]F M3)SVB"M2[=TQ2]&7YT#)">$8)J6RCN@U6Y.IF]-CH[D
M=\Z.AZ]\RL<<IK,M<<7 ]<:%_*O2I$G&*0P^5Q4M>$]3QG82YCW^)GIX6L="
MI>OC!^5 J(\1) J \8^ S\]A1\;CZP7/@[%OJ2?OLW7]CH^I7DNO-,T<1+Z9
M/3-QC8_=&TZ%,S7DPNE8O3%L?$=[>C[-\[0^,_&\9C&Z$CK6@6+=96Y"Y\P2
MK8\>[MG3#"U*,KRDYS*Z2>7@\DC:, N2JBY7F]O.!!%>.@RQ5EQ3RC.0*BB%
MO,I3 UX:@)2P''><$6VI,CKQ.15O^&\_\.YCB!$9$&\,A/:]5F0=N4#:8P2&
M;&U__31;EXI: 8$EM=OW7Z(BQY+EW:7H7/_Y"\,5&I['GH_OHJ]@P6'(V(08
MN5[&I/\,RUS446K=33\+>_"H2#U=!"GE7',L\>R;Q<Y/C)>$$%Z@?5M-575L
MF4A&RC5?[8AQDUWGV? FW\MYCSQUUH<!<-RE^8\>M@\38.F75QAL52,IM%<G
MGCAX]($FFG:V%T?.)%#4F-NM;5OVP^W>C);V)NT>2(X[D0>;5GWPK?*9-!D:
M?C]]-[#C->=LI^_L+G98OI60YBHM\1OL(C$C][.LZ10O[8%:_I50X3$7;/CG
M="+^TB8TW79:A'VK(:1PTVMS-^=45J:ZWF%:S"S-<FLGU%<[S"\H[+<K!G0D
M87.8DI-M V%-F$,T:N(RA)]B[KTO_A2EU@!@^J.V<ELX*=-BR,^Q[7W+=P?L
M"6,6<$;D*B9&GL6U1F^%_LG"Q2_?Q)^AJ=._HX):=]^]TO]/^F&K.;9!: +'
M17>_'=OJ$G,H+5&8%5G<4V+4&7>8Z(L-5A@;E:6D_XD/#[#R^84\P,P&O'A\
M5?;X?0QC^(S]V# &XT::(2_4J&FP0QX- /U8]K?\M?YZD*Z/JH1X:4(<(VK4
M#$IHC?2_</B S<W&,TSFEG&XUI &C#/.)9Z(_;G;E]M?()(A\&[_<9@,V]-O
MCR_#P[$KTM>IUUL4$,_'[<Q>PWP:4).F<*:@Q7*(IE_N!A.(IN2_=$6\Q"VH
MN>/'=??O=$:^+S#_#J0+MKH@]4';+^G<>B6'R0>GDYY#:H!+_)16?:UFD=5;
M5+PEA$+G1MK <-H=FZ1X5YKQD!&5WNCR)%8]O*D_0B2C^>7F.X4/$:/Z\S3P
M*RS!NY7E2APE+]WJ%*J)^;.^VR'2BSE-,:6$=;UI*\_!F\7]@%/^G=:>5I(E
M-^U[0X,R1S*<PW1JXY_/,)^JM0K?H+- "08 ("RJU4%@:<I03CW(ACB21IU:
M3]O')BD*CG9DD:!DW_X(G62XB"I(HK$YR7/I&XT;C!"E+]R4'M>H\\Q5>/-?
M(CO)@"#[G^(W=_\[L'HX'LI,J'H[_VWJ!Z?\2<^'/[=5MIJ/91DHYY)>KX$=
M#J?*UAS6WF$!TL"J3-=3,/5=5;7C$;LN4SB@F=20Z\X<.:=3B*$^:B_32^@F
M#&Y3 )W:9RY!%?Z"D=$G<JMO594R5-9LLM>T'WJ=6L0F>17WIZP_U7@D16G0
M%9"PN^T(\JUPZ[7HN3U6^@\3.7PW)5YSV%CG=)*F7H_WHOOC7XA6JOPN[-5,
M7<M_/'?C+<?VM%Z3PK$!'S<'4PA).JSI%@@.6)RHL<[=P#O_L1D#(8:4).([
M.JF:*SZ[$V#1++=581+3L8V;V=__*!'+B6/H@$0#09=WM3^8GNC6+37^>I#@
MCF:#[)!1I+UQ]4=A=2*73WO^D#^#"._?K*B_.GE[.$0@R%')D>"=PY*3CW*R
MMG*N"JW")@$LE=3S&)Y]J(G$%9Q94%'O@5=$:G'CZ^GU5,4Y?&\;!K4CWN]O
MB<1@VN;PIA(2RB;>" GD\);GIU/E<RHU? FKT[MAH)T>M+4U!VP#G%>F[< \
M,@M7-L>9-2^1W:;_D0KYK;CU_Q\!.WB!$QF2]5[*#V_-\3))>V]-4G%7CJ6H
MIA.LE"NYN:A%6,L];DBHJ^E!0=]/%3P/$&!CH*I($W[ 8Z""]?JGAARV(-91
M)@>UO5(S,]91)Y]R+#RNT@:)O%",(I5IM+"$N$N<'^ LXVQZZ;EUGN.&D^!S
MQ$BA2Y ZM@0ZIAI$?W;?NHL&;8&ES_Q4#*)#D6!E0X7B;=/# I#^[AHP*(A^
ME0L(:]R;RA7ZS7+NJV=,:UZ(:@B(BSMBK0PHK$U6#(E/>RGC=4KR\>Y"5M>C
M_["QH/:"(KX_*,>Y8.";N&32L_846S=B<W#B=R@&!? <9L?R*J9R<_,A\ON?
M$"BBOV!M$,SBF(LS2Q$PA3?&L6U6[86["\3[2IP C((IKC9;8K+P4;<5">5V
M5RF[$W;>)'-XRWF)'+QD\D4@V*6/A-$^D=F7D<[AV[M0(E)MB5P6CZK29.=4
MOL3:!VER;9;QCUJ'Z5_XR"Y,4#'T,SU,XC"*<K,-4$[,9@W$YXV 0IX!>+S*
M78&=Y\900S-XRKK*L%/^ ]\I)PA9F 8&?!@?I ]S=D:MBX.E^[#V$%&@1&(#
MH>-P#^0/6X'9R-!0.$Z1@&=$R*\"/RL"CHF)I(/2/8"YK2JI9W5%87<Q3Z^;
M/QC0C+=4JZ.K)Q&LIU0++DZ[LPJXD$ORJKEHRPUYL=!R;TNXL@TID,X1JW]M
M?]1\=[U:"Z-G>;A':#-3U4WA8;%;TW3-427SZ:H+F_K M!-Y#$#BW1R7K>,N
M),M)KK*),A#!ZC0QBDN,/V* 0V@;:S0K8#[K\$BZL!F2OOH<((:X^B>2G%U1
M8R,7V-/%D\8-LD:I9,3[8A :T.R=NC+[](")BOP#YT;PR]>F30_P>I*=AD>6
M3<T>4#(3Z.!ZS)NW$[</GG<^5VUPY4S?,BCELA!,2YF2:,OUG]?2GU:[[SR-
MYA4] _"@/G>Z72P(U!:SUKL1#5#*_$:WX>U/HW&K8$C)O!84^0E8+3[R'R^$
MR#D6JQ>R7>WDR6I_FWGE=OJ=YT$=Z[>M]L9$RFP6<AYZH_DM,690(&$2+0?2
MF,I_]#U>6JE6.-'/UUZV^IW4XE_8?-7YZ2?T9<4_6Y.[/)J5/.B '//-GDW?
MHJ$O^!2RS\C4*8!X]%1F $A7N EXM<^;-2SO+8X% .>J>WEKK/5NP--'!G.8
M,\]N&,9I?;TNELN]MFUX87UW-OJ/]="O9?%1VQ+GAGBNV<:: NSEU1N4,47"
M6_@<J7$;%*PIQ[JIT\J#8:9HEM?F7K@&W:_"8]MIG9\="^OJB?#'OZ>@ZH_A
M3Z"A#2Z'&Z^2(NJY "(=C?NLG11:W>/,$UD.4:0F$+!5G# '"8>Y(++5=@\J
M2H/"8AUC $AR CDK8!"'SLHDXJ^2."%D#1NO4PW0A/$ LAH5#/\E]S-;.LJ8
MKD(;__)Q 8'.6.\!PP/J-@62Z&%MD2D /([L5*K4C!U*81! ^ZN=8)(8ZO_@
M0A[XZR %U3SR@"HN#@42D.81O42\.<P]&QAHASGLU5=(L (M_RRVH'^MK83?
MA;9X(+&Q8'$,*)-6M"^&.N_,V>#GP@I(3QI+M*X.@%#P=XZ7,QI*%REC<Y."
M,OGM&>_B8VB670&5D3U+D0;@F3/OF]QSJORJ0@S*9JZ:@E8JQ%3=DL>*1]H7
M'E3*;\!L.3N'JQ7) )!;&.*A]CSBHW'A<DDR_FX0^?_B$,9J\J:"N"L1(>X8
M]<ACG\"D*L<H=NO^)";0[6=)'TB:'*=+<H16ND-J)GKAAA)$JO%8\"C(R'86
M$8UAJ#L;9J2EB<@I(AUEK\,2*0J=@<TNH_;)%!V-?#_X\4\/G6>"S8UA56ID
M_'B%7F?*$&F F6[RT%(<AVH)2!)&B.,#Q65,,#QXT.X\9_2R2;)HV1D9PI L
M<C8+,(X&,HGGCI>6\3'APE0-D6>/$M]]E^!-057],S^0O#\]\2X$5"OA(W2'
M!#6CM&J1*:\29PJ_F+DK'1M"&F '>]HSN28!\HH6.>M$B6=>ETJRGJPZNPSP
M 2_#N"!EDX!YLAH ^1\0QZ[P]RX#R;#Y#Y$(?@SX)V&YW*J:4^C?^CH48;)R
M[6]86]O<$C)>%1<CCJ/G^^#0A$Q;?9@?WYYN"G_[-R9F4L]R4*7Q]%#=U& V
MU#(DA3859G>H-L,(#JU@V_;0#]L GCX$O5U;M^SX;MEJE>S!.EEP'Z?UL8&N
MBJQ&,TWN)HY#DN@;3;NC?4RA%^]2X*-''"@ _-6<K]76$B_L&R!(405)N$0[
M<_P1#;M_ \W-7I&KW4WRCY6V)K%<?E+E08%.^D5S3&M&S9$[$I+\99/?_\VX
M17XZ]V.2C-4#(:&'5EBB!Y,S('$X8.^)3P;9I+?FNKW.8K*YBOB;2')JX'-U
MLQ]6'+]S \4]AWHMI#8AC@B8_RK ]1%4P8&>-M\R3R>$?6(/)FWLI8]H4>3Q
MNNQ,:>;0JP!:74GZYU4:P#6QS'_R9)S)+?@40[*(#W\=\8&)!2V[$5-"]M>I
M'\ FZ@D4J7C2P%^]2^VXD&!<BO5EXH]J%F\)"0^A49Z/&^>@-MWW?.!-Q^[N
MUHU$4F&*>TF\@!G]C(>[HA.QV$:[WK\!4KL+WF>G]XJ@QMZD?NZR);L6),];
M3;*0J<@@8XQ<#^$6#BMQ W<F\]G> CW22)([+ID4UA)S[AW5^JH6MWHPM'@,
MHRLCJ_7@(^EEM?=-D?"^OO19XJ_MXHEP@&T2Z'U+)(),FYOYF,KNTSM^!F53
M(ZS+?=I+>NO%[#J[;;%>A>Q\2'-=HOZIZO.;$;'HNJ[-(%ZUKJJH;V];*6#O
M/LGTOIK,%W/N[1>;DV2.KX5RH=I GXW(P<19]M9;4I:DO*-BE0U\+*SG"?V>
MC_:\Z['-4^OE\^?(D_C'[1CZE:QRU.L#.;^NAY+^^-+R/QR/[.1DG5(7>XMC
MI\HW'&&/$SL%KM-)<;?O&CKQ\#?T0^>09.:^D79>Y2(>SW3/!X!P&\A]E0Q"
MT>L,B9>34<-3F7CP8 0V'1'&)!")\)4ZL=<%LD^:HV_$^:B8.1)CTUO:+WS>
M*;!>\+OF"<]QI+7_W1=(,W_Z*N98@6SS2WZPGYG&!C]!=Q)Q4,)$A#8O/V^^
M0S;!AP<&NAF^95'T, !)SG"/8>X;=>,9GCLT<XR+$'XM&:#^%WGAGM/0!^!K
MVU,V#Y_+/6:../U[@5:?Y#!\4O825-%1 #+4-5KM4$B^)J+<T55]/UPM6RWA
M9_"]<]?;!*^K KCY04Q\ 82ZCIS<TLGE0ME_A/_Q@F@9AMHU1[>'+K*0\^XN
M6F;PKBG'G./:=TOX%O]N#+&&3F(,/>C&/<)IQZMC,4PI3.']SRA*:-S O#;!
MT5!,/JGJAR] 3*JKCC2\9,711V3BX"H>$>_ $+?D$!H4XK$,B$0=M8>%V*-Y
M/0! $0_$SI'//3<UY+Y#,-T%Z+3HTZUB=E',OT=(;@*5']X#"<?;II*D@=P%
M6K-9N"83M_:#Y1D@,U2&8_.^5&.Q!(QY_H2O7(+Y[HIA&4^$OI:?::#KM$Y$
MC3:D3AMCBC-JO_*;UE#Y0)^B$BQ#UP;JQ1(O9B6[7)"? *"9<6,.?TH(&O$D
MYL$>SC9]'D6SJF&4D'$=9B?M#'?:\5D*4_ ]2LS_80!J4P@_3PNJIE:_LEH8
M\PTOQ$3^U*]Q#([G]U+] /KNEGU#%\+L) FK>;:\++(7:XG51A'= YQ--1.<
M3)@.^<F7 4_L/9)[,I7),LIC*B=MH!9-"NYC.DYX;O0OL38)"!=)%N^5(.']
MTCV2E"R!79;[NY3@K:QQCW3J8/LZ*2_9>I+M3NL&%Z(%^8S?V@K^]+FB^9'0
M'! 9'J&Y2%0O#3+] /NW "=DBSA1)9(%47Q-OA]V5]?9U-8DA7[;)#\NW,)Y
MXMDYDI,G.;?-+,L> UL-CJ9*(8Y<);TC2T.9$AY9'>V-=#"JS5.M>&[L[, V
M%I><11630%2$4;C1+A3A12SCB:>W^+_)T^NZBD?_ALG[9VSX.])9(G0[C9LX
M298.Z-JD*=MR$<T-):=C($P]D13 0>@MA(9+ZE]G9>LF!2]1YH52KUCG56OD
M2_?&E<*>*B0'7\AEU1QDFR[KO#UVEL$G^[31$;#JTDR G3XWI42U?W2[RB",
M[U^L$WF/2DTNRY@"F>,B(&L"V->$?#W&X:61S9+(,UPA1W:90XI+F5,6++YH
M2\YPYY!2-)EZI2BKM#.I=BO)Z#)='YVLXN0P7Z^CY_BT0>$!XAJW/*XR-44<
MM\T_VDD,=P2I%]X_.2=B02'WD!3KZC9/.,6B.>7(N^E<QAFH]_7I'0''WB*Y
MQAIM+I:D/BGME(K%/F2_1RGW>J[4!<QZW3",)'M-5[&8WJ]:X:GF?+H*I&J@
MVJ]>MVJYOM:&U""0"]"$8'G7-,EE-+$QH/0Y=88WLC!U=XHVT?TYQO)8#B0#
MO:\X*(<6&_6ECE#*+$*#?3H+)W+?\>HMK"AHJW 73/)HI%8IH!Q=+?W<%UN]
MVX@SR194I-4KR Z-J-,(*79<KVF<:BB[N6NRQ."#XS"G+[]R@KA4B1E"&AB!
M%], 1<V232=>)9W1UOF'<J[NR\W7<MP!7B!:"([XI?/KNIY[M8WKM;R*X7_%
M86.K%>IOM.\+D%XD-9W#(JJNTY\6MDY];_IKJ64):^'(2]&_"2U*YNB":XY9
MTA=(TSLX0[P=V5TK5*9^DZ'=+1DO UY:MW$\DFZTSEA.!OU,;)&3]&V8;GEV
M79&S3$F'T^:^*96NJE52BV"&T[[\4;GK65RG2WU<#)<BZ1@>0^'6B0E?.S2;
M88R7FCEG@0G05[(&>SXN\\\?9XO4_[)A30-=B7?9/9)VKJ7M<%*CC>C@?P+7
MGZHXG6X4I"IK IHB'&N/^-2@++K@(L6#-2GE)R2<)+7<>]V<'WA[0BQ5EOAC
M&%XPS76Y7W"8T3+1*=&[.76;04%0U)/QWZ\*7HA_\F]Y%:/_PJ;'11 BV-1S
MUI@EM$B9)5,IJ=0DO=M>GE7)RI0<G_LJT"OYURN_>EZWPK=&TWCS1\38M^*B
M#$\2#9OXG+=YGK&0DRQP5->+_>CX'XCAKX4&YW?Z7@WGY?WH>^>L9EG<(_2Q
MA>2PN>$\J+WQM=&UKRPSZ>=XO_>F=1\D'*ZGP02/0A;\@ZI%(8.?P8G:;]FS
M^E6I@,CD5&#=Q$>'.75?'"&/$UL:(88R#%V>X+=!/=W9\#_%@Z;Y]?-[@P4]
ML*=;+M\%FW[J*4[RDU)]:AKK: HGZQ?$)C:BV_:O\)G20 !/<]R+?%W]AH_G
M_SW*(ILX43'AEOM5C3B:8X2OF\!176+I8Y\O7J\'#-()/X!D:S*]'):N8/UK
M$CU _:K)AKN;E/3[X^SBD.SC!A).^2H+C,)*X9A]-8>*9F0\BQAV5!.,R=EU
M$C=F)C?((X_-H=C$<YR+O_1$3(IX<-$,6!N5M# (CZ].P=:+*(_O#NVSQ%5+
M9=<X=@HV9E?H&M4<TQ!<(_M+.3O^5]1X?Y)I/;'<57-\,F_\,0Z2'9"P.TS[
M0_*18V#FAQ[0<];I5Z=R_$JQB>G]!0 @EC>YV43-N$.:#W_5V#@^Y=1:X:CF
M<%P9]B)X=F"*60(*>&:(8E[UOI-[Y&1LX#7M]TX\&EQ^=6%B6P@H@.[V9HEU
M6KY%OYSY)DRW)3_)QV<TH-PA.4<T_'+R:RKQ6B3I)VMBH1?O\)6UV.JI]Z 9
M;%A%I>Y$1&K$*N+]&21&(LFI5OG>$RH9Q@P$+IB8?'G^4YRN_X)R9QL]E<^"
M^?S4NE/'I?>$(>KU\"=[#R#O&MGZ)OT=RJ SH'BDG<7+!!RRX$U";C=15@(G
M^#Q9@'/I<HB/+OVH+UT2B#:CVZ>C_^%ONXUY=.<=R;_()1O#1?Z/W)\G%C1%
M( C'FAM$-LGA;*-_DFS4XH&^E%9I"/BZ:(N[O^IP'#,#7K*%#D:FV/HHW:E8
MTIV4Z?8O^$'#O^]F>T,%;&%TJ5G(GIZN9).3TF7ESILV.IUI%0#:[E'+9564
M?OK$GY7F9$ KDTD5.G7(&8^IQX.+0LH22QY!S4)K"Y4B,3/MCQ;H&=Z*&^:2
M2<XPQ@6(I&/@49(?QP<I!9K9F"P&G;] 69#C)6>^M2\HOQ!+@3,6I]JIE1+\
M[MQ:ZS_VJ^Z;Z_[#]&1C07<>/\$F,.3X<4V6?PWC32"8/NEPM(W-)G.0Y&]-
M_GQ=2LH-B2"[[3-LZV;T7I;((&ZL799\/EQEIUAG,E5<T<FWDE?Z*COL;)WF
M^4)NW- -N4BWRBCK6_)/>2S0%48'[06F$SH?-?>LYNTCPQ%9]6&G6RCQU)I8
MG+_@+#$N0[LR:F/2=-T/^RG(R^_6QX\SAB3<"_K0ZO-9WPYL%V##,@'YB(''
M='LQ<CN,P,N\;);)<?W9_0#'N1^G&X5G):XB6S>L&TL?2)?8YN!?E^]6?E"U
M3[YAWI8SVU.U@39E[S%]WL_* <'QR8"BK!^8DZ&>C.3\I3\UK^S08<[@IQ?G
M'S(R<XW;UJ0HXD@>;M4#G80/S;L^F:S:K+"9&"+-^;$VLT-)+ZI_'Q?TAH[>
MHQ\^I:H_=$Z0%.'X&OC(HDL:-+?;-+LO(CH\?;;)]Q;^7F4W[6_+2^SN4.^Q
MLKIBAPJ)0^:*V?<=6;,OOQY_T1E"BKX\R:FTZ#]#?)4D.VMOPUDP=D^0E)6=
M/3%::UO8+#R#]MT][H_U?QM)ZL6^[LT^-35\:F^?',=XUB-QMAOUY<Z)UFKT
MU^Q8 9B!]T,08[H5R!;$^04/I-J?1]_NZJF]=Z:(%Q<_GC,\]< =ZGR73'EW
M+)O]S1]U_D>5Z-:>A3#D4Q?='ZEX\3ZGX3\!@.)%($PX4^GYB<3[_?3K(V<C
MA?]L#PCNGR_8/I"^&;*?:DF::O]!UO'=#/>]:_B[R--#G3+:D>D?[R6UAL6U
M0N<%E'^*=24&4)?_BIXYD<_I[#L:>UABHT&YZ(KUEVHF_5FV:Q;Y#8O4B(KX
MWD/U2S/306N660[%D@>9=B/PQ_?09'DA/FV)IOE</?N/_.]&WDN[GH<#%ZQ/
M68><WA:R?T??X;Z+_H;#D[<N_$9=!&/?,R=)7(EC+K.^T8:8NJ1FIS*<W3RC
M/(92'0@/:HUD7O]%U/DV'5\._91IOZ[:.HUTF&P-O*FEX*JXZ&RT_E/.C(AC
MN,UZ7YB_L340.6&W?^GW_KW'W$\_S.])T;^C3_TO8TB?B/WJ\U,@1+!=5;3[
M<3C<_C FL( ;OZA>7Y9X%6S^06&30=;1?,6-)_>MT:PV4G8?@TM.GNBBU=#8
MR;94 1"JP5:RZ 6&;['$[$6AD"5N([ [VR\^3M<Y_4!*L=F^\^-7.671\L63
M2R75ULT??_[=<<1M.=II?G!:T%+71E?N<G&;3W"[4<<.&]8>O)LUAJO'EICP
MC1SP"GS1>6]L@L5_M*HV(]8 8G)/.2TM[XNM,B19,'$&M%](!'9\EPSJ_"$5
MW-5%Y2L*-/M,),K(R>V[5A+5"ERG&3V;T_J4>&UT;2CX1=!#=]RFVYOX?^8?
M_6JA16@P\G8'F3[9%4_*(.E]=,XYEDS-1_A^75"A@?7Y^"\@^*?AQ_& ;T:E
M-K^^D">%*D@[26Y)FBN;\0@# A);97+I+$J\4TCD*%[T/[Q_,N:"?Z%:KT#2
MY\M/SPXX*PWWEF?WM'862#,SWOK[XHQ<5;!KQ''.HXQ"Y?@Y;[KI&:PO \3V
MC$F\?JZ"ZE3M[.2WV!8^%D9S&3=FT\P?PO#[;^V>V?T<!4LB[.CL1D9GL4Q#
MJ6UJ'A+PVPFM>BT?A^T/&SS:M[F2.5WM>+C8,OC.H;KO-E3R:V$(2UQ!]G;4
M+[6MF7@C&6FI._H#G8@(=7D409ON]QU<X_V3#/%AV:OSG3?/Q0C%P<>-@R?_
M*%)"Y>NFFC3[=;&$<*T?!_853UMTT=XLK,$_XIV7L:-CQIAF7LSCS:+?J'@J
M/7G.A#B+<\J8U>:'6]J =Y8:^-OPJV6^+UW9,7IHX0*.H)*0"5TA$WR E>C-
M>14GNO>ZB^UQ!,B*,TN-5($[&SGAO*5ZZWUD8ZFB1KP9)(Z+PZ8\0OB7RPOW
M]#H('ES)05E[M^3'[WX)7QS+[!?N37AV]_4U;TG = .M-ALW_F/.Y[_Y\?(F
M6@W3?(BN;$RJD%=?D>O72'H7H*5= NO2(2S):ZE86WM0O'$KSU=7&G$C4!^)
M>S.##I>\GD\:3F%D2BEG?94($$\Z'E4DYU=5*OCDG=/;KK!>)<NN^2<37H2"
MFZ<>J%4(]@MWSB@^B>5,AC]J+&.+7HWQCYY@@"BJ!SONZTDO3:.;TJ(#<UC
M6E_F53F6KTZ$[["]W3+)5'TB-G3]Q8:]QNIX2:S;PYUG/(G3*TTC0%6ZD1AT
M-J?8TER+/P=7Y<T<">%5BO+?O[[XOKHK]N*KDN04SXM/2_7+WJSG_4_<VSX,
MDP1]% '_+*6*&;U2>UDS]FF"Q+V0C0--1,M$F7Y0,^"JF#O)IW0KO60J%U31
M1=3Q3J)Q13G<OZE<.'+":N>K;1/YH<6G8.8 N!T1\1_;YUP3;.C"GP.38"Z9
MS^$G@X\YM)<+72?NOSDK[(]R[Q$L, ME85[G$\\B/,IW.?Q]2))NQI3$&4AY
M&PB+UI?L/>B<LY,;=%Q]*_>EH6DH@C1&KKUC"\]^NTV\]N7TDY+=$T.LJ;!!
M5M->;QV_\3A(.G-B?L@L1DWDJYZD_W<5D(GP<>B3-XJ7:X\H0Z;[W!B5N.>>
MZ.CW[!V(;NZ@N;-B)MF2??XT>V6;2("/+DE5!CJQO4-WKN0$4D(;DX2)V?R>
M$"NCP(>T(MP;))'L5)O$A0_IR\8IH])H1OZ2M(&(^UII1W>?&8@F8^\/<X+_
M-8U1QXX#[V4.XJ^RP%[I]P8=2D1C9 <X*>+V7M.NPXTIJL'0C[)J/^Z9!##\
MC4_=D^KDDFRW&9>*8;5=O4- V-8Q;V55T@5084 +:6H4TYR,H_Q:WPW&#>Y
MT?\F,5A.HZ^1^MYHUEW^-UQHK&) /4!?@!](QR/3 ILT$73<>#&D?WJB,C<:
MSD7GN;&3CH&RD?+H]&0?^6;F#^SE>A/#$'NF$3U;U1P$JQ210 DPHM$);=XP
M?4_+-4;FIH!KGE$%T09QSNU"\09YZN+&06;1 \1T-,"T2>6<1/TVFL& *0;<
MT5$T&^DN&=H+71V73/!DY0!$G?3EF$T+/GM7WLHR31_W^2#&!M3)!#AU7"-B
M(._B>95W!8Q5)O>??(@LNV*FJ6S?H#;9_'OX-]I16^%JX9G+%;?$X]R[3FT$
M<WZ'$CY-+D%31>&<&+W7=3*MND;1EYTO@&Y7I.9<S.-*IT(S97Z00>JX4#(\
MB]RP5HE/<+%H@9:\:#>Q5#S5.&/![$6.E&VE\O 87[0Y%,%XQ,J+U.->50?X
M#)#ZB^$9!;P_*F0&!2W=4N/_[NM068[6T])(P+V)C.^(CM2P[CKU<@#XQB"K
M+S2,6Q9':O>4.DW*C.N_))!F23=%WPJA_Q0^>R#=42P24L%>;F*)+@NQ[ UD
M="^!I$:/25/:1'EYD?C7]35VMM@B:2:P#?>) _#-6!41+QJ!U4\_38I%6!XH
M&A<F^SBZM/?4X,@+?T"T2!S!45&C";;U">1(QP2"[G,GR1@G/:,><?LJE7T_
M<Z&-8V=*LVDR#J#>,\]AB#PG>0,(:VU_]C'GMXGT\1M)6,72:\')^/%Q $:\
MP*8N*=>C$B[J::B_<?O]_A.O74'+@2_KI;Q=S^"_D&&>_3$45UT#;J7"D54O
M>D FO2/T['@H+TZ4X 0::."L_8?.6SE,C&F]59%([>3+FW.JH6?PL8YQ00Q#
M^]- C"DE<6]KY:'!N"ZY=O]$<C-:\UIWLOXK!SIJX?Z),<L)#NLZ>WWA;5KS
MONDKTJ_KD[F+;(I];Z4LOW]DQ !*IC7O+(Z!XGD#K$QG$<@W5"IC5"F!?*!H
MUB=:JNP'XE ^KHC+/IH@&*C-DKCPH&\N,9$YW_KO@$C2M_>9/?3ECRM-M35?
M+^0/!5?O[VR8=*QT%J#;<RE%OIA^$YI/'3JIOOEU=.\M^4#(06>9R^!#8L?7
MRX&^/ZN4FD_LGKZLP(M+-,2)>+MO4[4+6&@Z"8U_<6MM6AZ]D>)3*JWU^/%Z
M??ES-TY#Y=0GJ-]\?':7FS$+2^>>NW80W:%W'''V6E!Z0KOL\O6NB)_!7>N/
M&T-R0VG52_%>LK%^2G)X2/3L[&S_%O&KT)ZSTF\)4I'J?WC=C68$SE/ZQ=>M
M03S=E"T7&4&LTV)$Q##LQGGV\P'E(8-7A!Z#B[RG5;NB3Q7>/3L)<*4>?\/S
MG\(L85@*2/LS;R1<+O\NCCW(GM_CX*J995)HZV.)U.!QVUIX?WE$-O_?DC7U
M_UZWW/'Y6154:BC#T+<X*GKYGWQ>#5WY:^/&KVXO*0=/?%L?+Q2H7O8M;@B$
M1<K]DT\YZ"IGV<UT5[*X<WLY3*,J%E >N$'3>O7P]"]?N+;2=*GWY>-.Z>_8
MSV'91 Y7,T%E*(??(CL,8C?S'"Z I-R?<4ZQ\'#MTE&2S8C#J+-?"^/1GD3P
MO@4!@YN-']&<5(YBKZ-\PU\;[>R/\\FW/O+[<RWYW_7LTW\_F/;"#\CZP'JP
MJ&^=K5$>TO8K2@O"@/R+W^D0]H]V?)*,>K#;7YW_W7Y]^G2&W)EP^RDI^L_E
M?W?8H\LC _R0^_O/'@L,EP.A;[+@12!V%)@7!Q9%060=P;.;O^XQ_C-$$3''
M'?.4HR?IKF\=ND4V@=G[IO(X$ED4=-H!KHXBK<61MJ#(6AP3W0JAECC$+ Z5
MK-8>1@\$8_1*V6$=#/:]FR3$3F04G%3TG*1&^%]VFV2BG#2R%322%0GS.%JC
M;0Y;'/T5BOB4C=+Y<_<MSAY:\;<(1T7ME&B]25/&R5Q;P>R\FM!=P3)4\=6T
M@G6V@MT"PP M U97B7TJ!CS+6L<=?F5L4Q57,#56<#*C648JT*)H+EEGQ (G
MMY8S&P(3^6O$CC&6XO/6Z[X-$T8"C@R]S9FX0ZV(%LBO%"C;X=*K%&Q!LYKL
M> 'CWS*8 .&"Z\&-LQ0GSM0=,N="OQCVHPJT.+&+0#1&\/\"[P(0_;*B,1ZC
M';ABC^3@"M&BO!#>%^+B&N[B+PJC-5[C,"*C-FZC'B@C7HB!C<TBD0V>\P7B
M_)UA(F*C.JYC-G*C.[XC057 ./I",*Q9!A"2H%D/")JC$C8A&\(@.P:D0!8C
M/!:D0;:!A@T%%Q0% +Q74?SA^AT@!$YC-0ZD15XD01ZD1AXDA@U9:P@ <470
M0RX((0$A AYA*&*D2EKC"63D1KXD3 Y !7@D4=@AG8GD2*K?^SW@1#YA.JXD
M4.K>A1'C*1(C3![_)5*F@$S29(DA :W=XTR:I *B)!0&)3L2)38295)N)5>F
M#1)ZHH9IPS; 5U12WU2FH!-:I4IB95>VI5ON 85]Y?4YE5WLQ4PZ(%JFI5HR
M(E;6WUO^)6#B05S&Y8>)UEXLH0I6Y5ZV9& VIF,BQ00X(YN$'$"JHU8^)F9F
MYGD 687]XF5J)FB&IFB.)FF6IFF>)FJFIFJN)FNVIFN^)FS&IFS.)FW6IFW>
M)F[FIF[N)F_VIF_^)G &IW .)W$6IW$>)W(FIW(N)W,VIW,^)W1&IW1.)W56
MIW5>)W9FIW9N)W=VIW=^)WB&IWB.)WF6IWF>)WJFIWJN)WNVIWN^)WS&_Z=\
MSB=]UJ=]WB=^YJ=^[B=_]J=__B> !JB #BB!%JB!'BB")JB"+BB#-JB#/BB$
M1JB$3BB%5JB%7BB&9JB&;BB'=JB'?BB(AJB(CBB)EJB)GBB*IJB*KBB+MJB+
MOBB,QJB,SBB-UJB-WBB.YJB.[BB/]JB/_BB0!JF0#BF1%JF1'BF2)JF2+BF3
M-JF3/BF41JF43BF55JF57BF69JF6;BF7=JF7?BF8AJF8CBF9EJF9GBF:IJF:
MKBF;MJF;OBF<QJF<SBF=UJF=WBF>YJF>[BF?]JF?_BF@!JJ@#BJA%JJA'BJB
M)JJB+BJC-JJC/BJD1JJD3BJE5JJE7BJF9JJF;B@JIW:JIWXJJ(:JJ(XJJ9:J
MJ9XJJJ:JJJXJJ[:JJ[XJK,:JK,YJ;(0  #M02P,$%     @ !8H#5X1PP,!P
M5   $5\  !0   !A;F=O+3(P,C,P-3,Q7V<U+FIP9^R[!U!3W]LNNBE*%Y N
M)2I-0$1 >HF*@(B(J'0D*DV(- 'IB8" ($5 0 &)2)<2D"HM=$1 .J'W7A-*
M"*3=_/[GG.^[YSMWYGSGSIE[Y\[<E;PSV=E[9];[KG<][_.LK$T9I\P#'/?T
M#/0 &AH:8)KZ BA3@ Y 1TO[SYO:Z*GO,XQGSM#3GV%F8#C+R,K,RLK"S,+"
M=NX\!]LYSG,L+!R\')Q<W#P\/*SL?/R\W/SGN7FX__D1&CKJ/?1GF,Z<8>)F
M8V'C_E]NE&: DY'F'NTG.IK+ "TG#1TG#:4=  $ S1F:?S7@OS8:6FH?SS(P
M,C&S4"^HX@!H:>CH:.GI_NDU]6PP]3Q SWGF_"7Y6V>Y3)XS7/;D5@A)R&(4
MO5W>PO-H$".F^.)U*!,S+Q^_P 5Q"<DK4M(WE)155-74=>[HZNG?-;CW^(FI
MF;F%I96=O8.CTTMG%R]OGS>^?OX!8>_"(R+?1T4G)GU*3DG]_"7M>W9.;EY^
M0>&/GQ655=4UM;_J6MO:.SJ[?G?_&1H>&1U#CT],+BPN+:^LKJUO;&+W#PZ/
M<,?XD]-__*(!Z&C^6_N_](N3ZA<M/3T=/<,_?M'0^OYS 2?]F4OR9\_?,F%X
M[LEU62&$D?MV0E9Y"Y.HXB,,SXO7@\R\8C<6Q+'_N/8OS_YSCH7^W_+LWQS[
M=[\F 58Z&NK@T7$"8(#T^'OT%>#_M_^]]N,T+LL]9^-8I>8UHZOKDG-N0IWT
ME6[)]3,6I9#%>&(2A(<"C$MO40!=)1N^&XF[][\F.9*_%DQNG@8W'B6W^YKY
M<A:7];.<->",T*%5#V6S1/: QWMPG;5X<,&M!3F>::VNL&OVM#(1/<H9[:2%
M+0$M?;?L1MAWBSGKS92'ME;&PGW%ZV+1+S\KU"5\O"6L&R 009M'BQ0[,G::
M7FY=S(J.O.&[^8';1-<_\J6)+C?P6'-$^"E</1@F QM2+]F&@#2#HOP]HNOZ
M?C/_+*-;TS[:=O@%Q\6LG'.SEMGQZN]\02[DN68]3<HW-R,4LP\,%RU \.(E
MR\<!?/&]!P;RUNGW_>.L05<SJXY-7]MYS#U&2O,UUA%+W2-+CJ+OY99X?(^6
M>;_!?.7[V_^I.64@YB!_BS;G]ID;*4"I' 7XED84KAV3(P_*G?KTSX+W)QIA
M5;LK7R"X>#"JI\<M=9;\\L#S\]R/UX2:7X3Q8GY[H7@7JY,*,M.>9BJH0OOC
M_N^A7TWU/1KGX6,BJTU)2!E._<VC_'O'*Z["E2Z!5IZ%T*=GN!^9JQ5PQ1G3
MIJ])'J,/D/WN4]FX+O5W-8AS06RP'I?(GM$C:Z]X^4@+4??=^,7GZ&]+:GA4
M:QT\2M-UD468_8[*9$1AX)5H%C_[%[U=V/ES.8> 8U,1R\<1I/Z4*4*<6.<;
M4"0B'C3$O1FHJO^9-&G)4\OZ3QP[X Y[$T/H>;ZP.RHJDD^P2ON1(W+326$4
M0#.[_PYDY. 0]^.D;O"=M.IPJL)35VAFH]H]DP<N_64FNCQ1W_X9RG^9K2'V
M )>&\=T^R)OJ661RK!\I#8&Z7NO0,9:.8WE]TY3A%_@^6@W#AQO 2':56%9"
M+_EF;8W+BB *SYSU$;[_*B="=#ALY^D'AO?)<F[?3@(S]C@-GN >V![;S;W\
MWB1&*@.[I:,B V:.0S7/+']UF0FJWWG>_-'JEU".B]\UC93?##$7KM?>J_V3
M^2<1O<]\M! 9J:477&DA]XAAZ?[!$@7(_' 2393%\G6P\^&K-W9]$%PN=3&E
MK^\?N^FO9#"W1Q!,ZKY>CEY<M<QY5A"];?D9 P@LHT>[(AS< Y +%( >,_L:
MF0,&X1GV/+[PSZLG'>6CNT'E<MO9X#;A:R !?(M]:D=J@N/D7Z>K-_#I(_!^
M/>%@!I&JH\:@%.ED=:6GZEZKAB4EIQ4SV6HCH9^6_LS=I&;DI^DKWZ.!_U63
M^8S/I@!BZ XXCKF. @P:/=7R G'#E]/P2'*+.>14JN@>7"CX+J*UOS7M]  G
M1_J9CS?U=YV?X[?I]EQ@FA8O&8FQV"@V)D>K+</9(58GYZ))23SA^1]R-DRM
M% \VE?)ONW@$(%"\-0_GK'4]76_X\NX7^*U$A<D4"M!SCEQ(0<E3@!?]4^J0
M"%_E)B9LR93A@IJUZ]=#A*+S;H ,Z&39F'1PB!PV#'R_^RWNI;WE\P2=G/>O
MBW/L.0*CB?F@D,*W1=U:==IKT\\]'W;HI&D<W?E$Q87\9^:+D!T9"B!.6&0@
M1;C!#Q4AU<GX+X1[\&X8/H0"/$]'D%C1XQ@T=C, EM^_!FJ++,2!B.=KR#?!
M'."MU6$*<#.Q"8.DINY\,FJ?YI][(,J(4_KDXW!_-32!9)RZ'+==3QH#@7NI
M<<2RW_W/1+NPB +\EC@FUX+)H5",WAI96YP"!%$ ==+N* 58Y@JD #8@"G!+
M"2_J10% YRE $_QK,)IUQWKE%*&800%Z4(AU6#D%:-&$+X\?PD_)]=0QRVM*
M0::!YS-!^Z\"P"3X4PJP/@PQ1/<X@O>2X>T40'&J%5X_?'@+P@&;GJN6)%[V
MF"%J8HS6R9/)]P/R\MTE8'_>>3%S#NED&F/BU#/5$5/6.-2'!9%4E3"BI'<B
M_L^N5L7?VN?Y>FU[H-.7M^;?; 8Z[>,,KBFQ=/HZ7W/+#TI1<TH8)]LG0M=_
MVN1/6O.\M]W3G>L?V/<2\A5?'PHX@F==2\^;V;(*;XR-;:A)12LP9H7R7-U7
M4P5H1I(@18CR_NUT* ;4ME6RE:#ON?0!C]5\&V&M^I<],1)-Z)O&J KMSY6#
MMF$(EL-U3=<E%B4XWU/]=&NU5/#$8,(TZ,1%'[(;%F]%H*WX6^'N-GLA[-AL
M#T5D[RVNI]L>*C&%#O>0&:D(L\_01*T9P'\SV!-XBUZEL),QZ=O:B/OBIXW4
ML>N"3.GBS#\6/HJT*QN =NAF&[)Q#@,^*(X@7XR-.NT]]^<C6;7.HOV[BWIL
MHO+;RF$GBRB[(%?,<1O\_ VO7#Q"MV*LV&#Z<GV,\O!F_@^$AZY3D!9>8QX5
M?KT/](ZH9O?]9&[+OB;^.'[;9N4]KB\X_.KI#0R4O7M/W%VTN3#EGE\\M"]W
M;]5[LF-]V#M]JF)HEB&5?/((G@L[!YW,.9W]5;"I\DC S6U7+--2L$A1_@5<
M$5*GK2T>Q+)X614\@091)RPFG'P0#$5&O"@QLT441KP^"CTBL5>"[5#C87?P
M;?/E2V !6VJ..-ITBYDI\RHP3N#DS1+FZ)<NOLT65LP</8IOFQN/7#!O@_!8
M^D7>'W(K]1%4GJ,9N7;_=_Q$:T)L6_FV?QZL59H/9X5Q/*MP+9Y\O\>69"MB
M]_E%[OLBXTDEP2IWV7A#IO#L"P]3I1N3:JF1GQ?Y=W#_7S1S.:P^V0 930&V
M>7PHP/>TNN@5\A4*T*V$A9!"2U&'C\T^D55/$\#AB'#3HS[$=L <%]R> C#Z
M$5JOKW5P6,\(;E'I2BI^:/.9 'SC>P'=-*"^V*2'')<;-R8;&3?/[5*#L6%_
M= KSB2X,RV:NS/QAN)8]@.^MBY'G$6?:<1\%?>32$:_LYRX8-!3DL?>,>*1Z
M,:ZSJ8\410%>;6B>\7*:-Q:<Y<-,_Q4M&UE[810F0JM&K1%WCLF@?..'I&H*
M8'<&ZVW>I(V1_?C4D\ZH<.-C#$L'G<3=+N*AT#*<#XU<H\O6VX[+%7[ 7-;"
M,%3*U>9D80W&2U$1QU\A]E5=%9IX-G[NO6/<*G>:I.6+!!W1K-_/ CB"I>\1
MI__IA*LDQCO%E@X[NF60I6;A/?/(L;M";%[_$GB_?X "L _G;S"K__ZQWI(<
MH2/U^S)*O>N9R[P+03W=.[B_I.W%\ZC(&["7/C )V!!J'])T$3[NN$8!=)0(
M3I H>"62F+KW'H03^$4!!OJ"&=C@(OGYF_Z679B%S> /U%)62@$^LK>SGYY4
M4B\00U8&.2V5,"RL1D_6O#]2]8Y5LM%#FPN,%P?0WE0E0A?G\.*^Q+>PBW!T
M7SXY1#P8M2C'[MQT=6#/.]CVKZR.44-45N:DPW3B)?Z+T0>*,,B.P,&.SXEH
M#0W\AWYJ,%S9/Y6HA&[I/[T2H$(B@1?T_[LC2 :BJFN[J #6/RNA,AG0[3_?
M=_LQ3J;X_-BV_[Z]=G:&R'S :E-@RR$R($(GK'W8U/F)*]AX7[/N2][EF&G)
M,SZ;L'X*T/8T2(B:9I'9\+EA,H\8J"JU92O*[ 8^\KN;V]D-7'QO--%F-;$.
M/%H,/NC!4 !1N9UHU!\4UW%JFZW"0(/#2[=*V1==%C6V/RT?_ PYFO0K22-*
MX?VQ,NT(9J*!>ZF?W9/T^ZAW^W9V/TW[KVP-?CJ]0(HF?27?L"3ZX:WS_#)G
M>%FJ>_G&OE& PMK[#""=-G9'G@/_3!/-1JF. UTR S*LJXO'K\I9Y(OMXP+R
M*(3IQM?;FYT'776ZC3/%):P##?FOU1.+\^.^A<J,%F%0B\?$Y/@+5+[N=DP!
M]!NOYE_+_WS/LU"BQ#4RKJ.'A;^V:)KTF@)$U.&I2:O+KD<!4/G$*__Q"QEL
M:,R%4\@1E)VX3P3_QE* :FD*($TTGBP"3:8OB'QO>88/SU(,4!HW)K'PS/H%
M=DR"/LCVGDH@[8KN--K^77"@VZK,,)_O>X4W[$S;>WM4X./.[E)CI9W-],?&
MZH])4Z2P?OG\F)*J(R]I1A]^PYEUT?QX(3^!T*T;A"+PD<<BE_XF:8<L<@II
MRP^_.!"YBRD,/'?S@!;W["XK0X$61OL;,KK]^>9SESI3TS3MZ%@+L] ,D1BI
MGW?+]?YN<W+;5P@!6D8><P(P13^O>?>P:YJZBS)?$Z3V=W;L1/_^^A0G>FN:
M<$B7!$E&":.@_<+$UPUUH6L/D_0P4^7[AU !YJZ*LH0(ULBMS@ :VSA(LEE7
MT\L-$0JP,KW<85>XX!W0U+6I\A[\<BY"A#?Y^ZBF3];4O?RSX*JB,B*?1-$Z
MJO*X-9[CGF@Y%A=Y]=V\S QC__(XLH,CMXXU3> >1H^],5C_M.KV7+OOB8@<
MKL.0R$C"5335C)38_:K,U$CW/[N<QG>N6.N6T(5,%!>,G3QHJXZ_5" V*SCF
M:"B\D#NTR]\-E=-<86J6)+0QS**>P!TIP*1Y&P6H- ^?W&]F UM7,BNQ2>BS
M8I(&/U& \R(>XSBE _\(8VO:7WM]YTB-QG8L\?G10?6&Y9N3*&*H.WR+RGO6
M)5#T;O"E1<AQ_P%R=@="OJ6".FJA (=<D% 5,!8K1U@[0?]JTS [@>5_^3=N
M F_1!/^?J$DQ;!Q4Y9/:#&;[*F.0J(&ZX,*9X'KN%F^TGN8& SFTL;\,R8R7
M)-QW!E6@MIUR^CXC@TR"?0/JW-*L$X-:-=%=E[C)3B$[F+T/#4^+_/;:4T]Q
MOP(ELG[,W7/(]']@H!TV0/.6X1F0S?ZIP4RY)*!G^A%<"WZQ* ['__)Q'FDU
MM8?,]-A\=*]!Y\>,BWKL"/HT?"3"LE3B1;]H4J+!+O20 <=#BON;6 WA)+J_
MZ EJ-LQQ]F4$>VL87P2WP]^)? U8$H)ORQ-$X*U/E?+;P1?&(P9%GTLDY_T%
M+VVT+)I#3E89YT$-_AOHP^ GTF_/ O,T>C[I5_+?M:',3^70NR)/0QJ+1D_@
MGRM-=(.D#K-LP/':*GCVA;C<LXA%)+?%2]^DCK4.MJEDI_L)M9[#%^-;ZZ.)
M5!0*_0[OML74D$(8R/&)C?=KF(3<+IFD_T3;?1"PM0AXD&/:7XE:*&TZ!Q_4
M&43M;5  9O!"*8QZ>)MZN 4/AUTWZ0N./*V*)/O#0,M^H"D>>#),<H<;7(6@
MPAFM9+L6ER?YD*"_JNLS*XC_-8_@O_]Q/5-F\$@-$1X]N:_\YI1U%<6R,?@'
M\_NGWHY0].OB?'K00Q?QMANNNR/P2")M=L83PD/]O1F>DR("B#QM-1?9H)N/
MU^DZ_926%^*WY0[]8:OF7#R=<<57L]+IHOU^@] BZI[.62#L(W0).WZAECGS
M;W[WL19168*_P.OF(C$0F]U, 5CV9%V#S!>MA9D7-UC+NMZLW(\^QR04,.;[
M#O42&=&DB2XYA+#CN^Z/^EC'SIKF-KRKWWG4)?0&0+0V25"#E@?_39J'$\X:
M48!L77_);2X*(*F_('?LACK,O'<L97_XXYEV]?*>XTYNY:_5D5YI'9[M\V9U
M$/]37VS](D-D$ V&8)K:;M58G2!\5(RK[O-H9W*05^8(3"/><F^ 59T^IP!G
M;M,313&=9^&+5()>:8M2+)I:F)3F=S+5HG(.T;Z^'VIF#W=.$?GP\N,= <QP
M\UQ%?[BW$;S3RC'YQ^2'>/6AQ=O"*L:BK#&^]*#.1D(KO%*_#2X"_;A.%L'"
M$$6;7K2/QD:_3+]5,'X '"$[YIC]C,VPJ/>O;FB=_V-(>G!JPLIQ1\$R?I^N
M4.LM$@V:,,=!AE!."*:(9+M&K.OALTWUM\OGR$]@[\&/^_,T8Y;HWK7^,OTT
ME9'N[(P^U-@G&@6,A4:OQ#^>*10(+714!>R3;)PZ^C]D"N-EYJ>0Y_T2MWY7
M?EB.YN]TJ/U(&A_PE3S<A.ZW+:%WDI=0L36I;[Z?4@?@^?C[PP\"S&<?M)H+
M_3;V\,,A07)_MNQFEG+,S4]]M5C-E#/Y](NV85GX,%P(WG7!TE;6O.N"<$:!
MQV#5)B_#,)#TQ!LQZ;6@]^MZ=$_7*?=/KK<E;PK@V&WSQ;BAON:K+^T="'_,
M-V4V^=A,JJN$R?H?2.6/* !M.6'#KL!J,R5AQG):U]?UXA\CED@]D6]Q;!9(
MZF0%5[+':3-N&GHMQ#J^E+5L,\J_WVEHB9J-P69.\&L?G182E,C#%]AW>!8<
MZRI8\K?&GNMEY52L?)?,+B2+2:J"0Y!?>Q4"QGG^(FYHX(ZT7EU[;GS^Y$VJ
MW015N6'8'_XOJ>K4_ZBJ=:DU]A]9[?<_R.H?I%#2.ZKX&]5D(Z_,D5.,(?%5
MA#,$)BK%_>$G2.I!D:YFHG06C8_O4H HV/V3^PC\_B')9,\4@]RI)_#%NLK!
M+N+/=9$EI%GK\N)=0:>8L_<'KY#!IG2K6VCDC'<RIE;3P8;'U"R).D."KUU^
M)\^Q_ 5_]H]I=-G%.$:MHEWC\53<D/8%J!S@MW],%F>]8^58HB8VE>AQ^2,%
M\!JL]];TGB75P%_,J>S,<32<>4$7TU?T$B,W2S[$7MF;^128,(L"0P]S,!-C
M?*=U</1L4*#IS\VYT30P;#1%ES5'H>SWL]>,R/:]27.RX7$[.X%UFEI;')MR
M25%@5\7<JGBJJH3P5KRX/'24_@4\@K-PL"-J)<<_B&BR).6,@[OZ03\SPHJG
M.?2-FZ"_NS&F'JIUGS;?#!Z/[/7*<[0/O%N8)G"1F:@<_B+H/>CHP)D"?#.
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M#0L;ZD=9&J<KGOD'L29!N)+L"AT.TDN"7P5+/(\HC(XQU8X\0W5N$:,2J6F
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M<MRFWW3VL&@FNYN&9)8U<]$SNU)"HWGO:ILCC_.8-U;.J%'@M%[7JXD%'[6
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MG@5(]3$QG3T6M14#.563F8'2=66>&6P2]S,CM*61*FR=57[P^IGIW6Z^_OQ
MBO[U&;N(@H*Q<(-7:7"O&R5\CS*^U>7!./7)Y;#O*#\B'P6X_":< MARP->K
MD!R@,LD6W8OQ+'T( J,Q50"B!Y25/9VKE7$?K_V67;+(MEEC_@8H'O+L.0DD
M"[7<>F3T>@ZNX9]I"PDK#'_M!;7M2B0/(2I@D80[?CK;*N&O?'IN6C\8Y7D]
M4+Y9#(YB]\1'$[]1^3FX$W1&:<-[CFM#T:K@E4[PA93J6N%H@P&2>MPBRD,Z
MKB++N>ER>6*/Z?".CXS:69'979X4Y=,B6AG6>M6B$-N^TI=O=M:A'YIU>/9D
MQ6 LEG,V&S4L6KGMU17(F42^*VWKN@8%+C5U#;,^1RL=VS.:/5%6>L1N))J=
M$]:".JNI&RR+)HJRY75?FN[)G^GF]L?=3X9\ YZH@[:9,':Z#7$+#6K:WW[K
M,.ZY.WC_/GIX4W0<"S$AES_;Z>N1.94[T(1L9^BAS:@8G7#BC^E:8/^@?1TZ
MZ*S-.[BK)/#EK7_H3@0G:4-,\\HIF><429"%]5B!MS<6)OB[1?(7TU<Z</D5
M=&ZO+\>(W*9E&(G); [DBR0JYO@]-C9DXS.L&'J5M#LU<;/\(I&;QLKG0"W.
MRURH,</\JH;OD5:,!(15<<UM7]J% NPS_?,8 ON_'D/@I.J@^"CX'/@O*C@O
MW.U2HJ2 _J-BK?<MR,PIW!G\E6T+_(M72=2:P\5$Y3]UPY*]!2ODX<F\DY*:
M9&)W[W4?>9N&6.?@7NI)R4ABN@A53D'0\-,;Z*&CGB 5/)0Z8=\U\42V-0E4
M0(4E!$2>A.<Z,SJJV?V*TH(6(OGXS)2P7$7"Z:\.7]X:SN77&F+6>_CGE@!#
M*)LLSV\WV"O8-*B\WD]B<:^+S%CNB"&6K+I8O6)!E,MK_GX+[U$(B%_0GM'6
MQ'1%'1F?Q8=V60^Z.PP?&4K1E]G<GK+DA]]68-QEXB%0:0?;3D/U,:<8YEZN
M6+0N:VG.LU!V$UL:'\(9(D_=KY0WF*+LNRM_NH+5"[K_ NQOM8IVK@L<.@_B
M+"I7W.IG_*=/ILW,UAYGAM4<#500KI!'TB [+ LF;-W1;1UCG 6H,K802?Z#
M;(8?7%-?<^9QDLL(O+0D,7F/!3Y.G1XG,ML0>G(7F*5)&)_6TRXB,EAZ.&/6
M=]RA&1"SMLDH&\JXR7ZVNDD&U@=B)RM!S=*0'RK]E02G++3[N*-\Q&[JUU9?
M+V8P4UI[COU\7T)CBSMIN6+8L(B(TY!>V$*W!4I5]<V=ZJ^AB5R^Y ?J8,*9
MI_#MJE.DK3ZF!V>*=\? V]L@F.HH\8B"2R\U5^M3;I67)T2\T& ^^K/<Y_D)
M.QX/-=*PE#4J4_5_7OC:.#!<-'CX,#=GJ\-O[1N,BWC_?V3!5"S2LOYO++A^
M%/P<$A;0F>L+]UTHS*FK2\Y/)L^I3F\;2-*0C +<6_O?P?CQ\@L;E<9,X]6(
M?",/M#%7[WZ2J'0A%:IT(7^:4 I]ZR\PT>$W]O+($,66EGFJ6P0#)5?C=ZCY
M0L0^V ]$;DF"KP_:ZA/H*4#W(-Z0-(4D22:B#)NNPOYJT^%G"L8A?BB#))-?
MY5%9(8FK=ZL+U429VS3'P&US$^P+\%8*P&N)3VI+XZZV:LS#LO;Y7PWQE3([
ML7ROR?4@SOUV)N3(#*$B\U2VA-CQF,;, N665C5,B-?#4@#B^R8JV2KSZ2)'
MNQ O_VL)_F#DU:51;T*Z3/*<NQ>7SN50/=,0>OO "QAV_#-P:"39P1^%L0-3
M #Z;"6T'?;F842J6UQ#5JI^'%49[>D!OSVU3:8Q$S3SJV U^F&=U/+D& ^$9
M=/%V"QH@-GS :/'A!]G9.[*B=\V]^,"*YXVO0K\C&;A,S)#J"1/59%R ][.-
MX1B1#=%V"N"\-Q&O1_I.O/KQ]T8>/O$W5_YFNH*YYN=I7YU3$7W4BGZ'<:BV
M EZIQ##?+UNW]B?S>!SV26-#6[D! \/&B"\/(=)425:ZQ[(R\.GMORQ;3@M9
MM5'V>J>A\K9-3S-,FY&.Z!L:;PY5Y?V#Y.6^:-PELJT$>!JNJAS'KT%^PJZ0
M8F'G_.K6IV?]1#HGO48K<8DC(#SKJZ)3,P;B=5"+\2G/*@5HB:$&\6FPIE\2
M,[I1 +)"=HK9CSX>,J3&5G1?2;-;V$1%L;S9M%OLU'Q#<AM,$(X_,SGI1^@<
M2S\Z27 8]IYZ1P4H'LTH(=#)2[_FKIZCC>TF+E(TF=-/IMU,??7+0I +[R/_
M,J6.D8K+M>MO%#GN;BJHHVO1\5_6$);YVV7=.<?N<!T40PI!@'"OKJKL?WP$
MX/\39LZ%U5D"O2.S;TC!%X.M!#D57X5.EQTXO?(V)><#OI>;U+%[1.XVL\H1
ML<@V6X8H5SNQX#SRVM]9K9OQ*Z#CP6_L3>O(<#*54[?<+_;9L6+3Z(2)/)5U
M] @][;R]_H6\+^*)1T^=NN6Z%COCCJN]Q#M*6IE$4Q23'40O1@,55)9,\R][
M35;&A^?[\8X8^K.M])3]Z7)V&P*UAX3@T[!:$%QKHL ]"[SE6X:]IS;S2Z2!
M!I@WS6$NSWPF&ZGD1JP+3L;(Z7[27>=S@^H&JUT(& W= =(:+NC<';;JIO/;
M8?DAPRW=)^6CLE6,;2W2M47>@(FE>O@H4>7,,V:[3CU=;IJ2?^O'_UOF!><,
M"LX+DL?8%BVZVCS 70C2,X\; RN8;_/H%ZH*?51;#H%(X[?(S)=R-D5 /],7
M-C>VBOTC=\Q$KIZWOG[?0]1>VU)MUY[_4.NM=F^B;I3 3*AT3(K=6X:2H$:L
M(6X+8XM8^.K&3@<UNY ?73+>]BJUO>U5KR#KPA1-LX!HAHB&>1>(5UO5KZ:#
M+ T_CX\@M,_RI*R*1[-O6]?N>J^/L#Z_G4S/E?BZUQ]\[Z"^_D.>P36GBD&B
M5]Y]%!:?T@^]<><TF;-ZKW3AZ!L;!8@%<1+UL> G84^QN['!7#\9EU##JWU-
M<SCNW0<SGQT;.I?NF4=;-UXXV=U9 %#IH*3+:^MWP2&E"*,!A^&][ZXB@5^^
MP>PK/WW-P*EVPCFMJYN8*ZIK5=0C4W[>]<*]/*NX$W+SK]RM@=(@$T_[[P.W
M>'Y)0//$*I;#NG%=6Y B2'DCJ6^O)=WT2YIA8."7BS4)%0>7$X:GU)"?M=G(
MO77][7(2QY;O\88M&Q'.>>VOIY''#T7"2-E=8TWU8#YM0:+L0$FEJSJ9[LRG
M%U=>>:\HJ C_5.W_=8-F\_ +\FP=Z5N026D7JDV$.?VW)DN)U2WF8']I\&5H
MVFA\3-"=^VE['8R5%N.[!,G(;PKJ\)^"+T%?P%;TP5II*N81>/-%>UNV 7.C
MZ"TK[(T_'4US)7V@M(F=_2N+J0_QW4C;SD>3@M"+\-@G]>R]2X??G"JG>PLB
M Q@>+/&T^U6T:;.@+WO^F)J8+*< *8EZ/^!@<J-_S.GQ>R4'"F XZB9@C(F8
M!%^*_ET;99=^W-O;A?^\FMSUI\=6'"\W'VZF;/4N[X5"!'K5!O?W 5C4O/*W
M?=FPZX[5(_(]^NG Q?07J"LVQ*+^!0OSS/LJCSK\?627OV&9:>'8P0Z9N"Z[
M;+\A+=[Y=Y__4@6K.><T_-YV-KYZ2/I=V<6E)%&O$^9]*+CR_/FY!_M<A(,R
MDQ/6M-T&@87XG?0LW*^)VT&=&M[,@N-)22<O0M+G,%77V(EM2^[![29/2YHB
M7=V9O]^Z4+!3'4WO,JC+<^<,M\G-_V<MIN66Y#=D'SP.5-/5+J497##II^QW
MXRGMGS<1'&/=8C4T%K&[%D).(&_OXV_L0Q'/&N^"K&XV[[/SG"0MP/%2^NW"
M$O87=I/SH-?C!%\Y\H&CL:?F]7Z&9&:I>0275;$OKN;T04[;A^#0.W;K_)RG
MT<!I$\$L<3HYCF-N1]'S20XZ/_'\(_E:'V8OB 0^"=<;&+J5_3+VXHYLVSSL
M=D-%^URE>:Q/KH^KR8W/4WA7F-FI4PD0'+N$$'3&;M3PGI:,-ERO6QCRIPW#
M7SBA6\R88SY:31 TBCM=MF>H^.#<3V@V3X%L);HD::::FUME=*4X"R6<HF4+
MB;>'*E/O9N)F^7P9RUL(:+$,N_@ !CM#8TQNQ(=@'^UD=S'>X=@\&?2Y^N!.
M->++FJ'#*1Y[9O$US^B9-WEP9E3N^G':P=6WBLW-'+V&7#LA;\&*ID<:PN;-
MI\T-8\5!.PRQ%3]@6X@%#W40\NQ;V8G(N@CCRW>O[BQ=U.X\$Q$8#!TC<_F]
MN9MM9'SGY_"U:V%V!,.'#E\7GP50[P6;]@=L$.7F9V1L,+W2*1S""C@>N)0H
M(_-/C-^Z1T"<2V0X^;Q*Z]<71K;",*^%]>'S$WV<O@_O JG]%YW$EC0?*E8V
M8&:S%J4T][CQT13 ^A,H4>ECSDLM^?Z-Z.'!PWHCVEL27YQX,IKM^F/!_A0@
M&)%^5%)[B/$ODGI1-/EQV[[A\5,U?X&O_69V28^Z\DZCT18\@4\2].R?_5"[
M4:HA@'6>?U&Y??C18_MZ59;[BX^Q_3VPY*XIXIV4)9\N7/!H'_+S6*%PC"U4
M\T=7X'+".]-)IB.Q-X7278\]JR]5!9J++S+UNN7/UL:?]>LQ3>J,_9[N=R!:
MB?YI<__G YA.G.\Y<Q=:GKL]H/JX0'8.*7_.X WNV!F!F(&NK:'JQ-%T@>X.
M4TQ*RGX;GX 6%.FJ+,C?7N.E_RHR^^YX__!8"'_"^%J,>3:>_2Y4PZSVH^M,
MZ]H)6D $E=>EH.O FA:S4O;C+#<%>'QB[I6S45=:4'2M4'+B(EE0]9PJ!7A)
M >[EW(_[?+=D,(3X,B?N1CCMY7"3 1I=RX^G_YF'T_]WFK14:5;-TZ$_"7(V
M]0#8ZF!/$#8@PHR1S6U/M6KPK6@-)_>_"!I3%590!45]8]=#]AA/!>H.$36P
M!Y;1G6."=_-"!;^(QMY&?NXY4-;J!S^&&/I]P&TZ#+BY'Z*8^YPYFJ.W3!RO
MS+VE Q^/!J5B#5O)8J2"J@ZLT5BA4ZZ-49GBU!W#RGO7L]UN;L0=TBRDIO*V
M(SZ!<FTP1'F+S8?3"I5<A6S\/O/Q5EN:$,)UOP]MN,+ +.-K54(W!4KL@?O!
MEO(M%, 7.=;(L, 0<A%;58*>O%IZ,;-CC.%@T;Y[DEU N.+6W8/?Q&#>PF*#
M/.L;QRJ<I9"7C!](\'L35)T+:9\<+;J&X%;VJIE)N=N+>)!_:EZU!:HX%X\T
MP/6\2;HW^@YF-3OUUH#NHX#Q+"CAN)30K,U34U&3JO>I1Q:7^E/*X2OMEY"'
M9K?"CHU%-W/>Y"@N48"S>'W+FK&22G>!*=N>0AL;!;%ZP]OS296E9V=JNU E
MP0#<29;+:EB[ ^Y8FJ&@'HL4/!>37\ZSN[?@YU21PMH@<<?^X++&T]?RR5KO
M"S19/*]E9=\P'_PT\LHQ4.-KVUZ=$!-#12D:M&?B4;Z,8"=S(]N$#:Y6L5D%
MWYMZG/JGPCF+N5R]4(.%[O@S71QP$NR)>%&#Z:55B#__,_.'WJU"37,[UT)G
M^$1)\)G8E1ZI2F?&F=5LAD<_[LJ&?IM_@B.+5=:A'8=,)+C:SSG(+TH\X_YY
M=K=9/>D(IYH>UZD7@9JPO8(:S'OS,B\&8LFG=J)8?4?DS]1=X7=OWY2F;8[-
M0M46:TVAOGJ6O _"[[;T5TL/M?T*F>J_?USJM?@T]W"69>39S_),LN&[_4P-
MWR?/!1C\>SC'.;LT!U\7Z^3,MLR3P'<&E31PM0T?_3F,RN..'O&PE/'3[^IV
M=UI@Q^KBKU:]-F_B&FG0"<[6F*B4/[G.DN\(JO7+CW[E%3I5S4//?.CGW1KX
MJ';;KJ1>R2\7':L4>TY*5B+EY6Y:8$^LY&/&F!*6>W\X4D]\+])[981^IL="
M[NID5V:<$0N6[OPP;UI>7EU9535QIN[5>Y_FT[2;?K"O"T^A'>JR#<?50RZ*
M+LS?<5IF"RGTG4>L'T/B&%F!J:_-1SQ3SG#VI9K0NV[7,@T-ONTOET?=\610
MG5WB!RLS;&W9EKO/6R($XUKVS)<PK($P9]2]@ \Z7?V1AZ1KCBF3?_@E)A_^
M*5#9$2L7K%L2RP@<97EZ-MC=].'[>W)F73P[ T1PI7-4;>S_T<QY/S6AMUD\
MB(JB$A$ITJ6)!$1 X(*1B%R(R.4&$ A-$! !(X02I(8@OO0F@G0)14 ,50@U
M%&FA*!U"E5"DEX0:( FO=W9F9W9F=V9G=^>^^\/Y"Y[OG/,YWWGFL88XJC%-
MFFRSQIS+0ZJK?A?R\X2".)[%0G0I,8O8K![)C^[I2P9E107L31LB2S330"S%
MH:1 E?]'L=Q4D4<7D'4'3/ID"+?7>.[@](-WD*Y14UX1R[/),&-*X9UR4J__
M;4CNAKG:*.M\ KB$ZN_-V3),%)$:%L0TI^QS[^@?$+>N(=3CD_1U-XKY,B;-
M7_.Q]@L^#](8D&4S.B,0JC0,)_I!.RZY#F[?M(V<%K?&*:::,\93$K#YH$FZ
M$C7;Z_@V_YFJ>L,='741]_M\35<ASFO(,*9$F&8UI:,0_4FOTW?.R<Z!N2UX
MA>Q-AB>MSN!)X6#=(HR#4P%L($HHW]GC)^8*<+O4;92@4S==;SG](.'W*0\U
M$:V)1A=:_#%D98+9)(6S=Y=*P#W,UI_2\NC.S4)U7A/.95N[OPY'AOE59?NZ
MHW&TCE_V7Y?N;D"N=*ZO_D;\C0[Z1E##(9@L5(=V;/BN@BPOKX9V0S-,72TA
M6E%%XW'7H1_5>HU<,U+D,&1M[D 8G++\T]'@6BP+O/G&SZ>:(O-/(/L6/==,
M!6\3!?GA0K%(DWXR:?>PJ+1X<+$7-2ZA>,NX4$C!VMV6DJ!/>RR^ID)*;M6J
M#!<W"Y+@A#9/F66\-^Q:=0-:[,ZPW"E$HG-G'@Y9KZB*."IVC_O:B=XQXIIZ
M+\JUFE_GG^(R,6%2<WY!\;V[E,I;']&EM4?SY2&.66T#'R/P[X.>]G2*'A3U
M\8YWS2X.>76J-C1\; %U7J7T/S0QIZZ&(="L?B.X)Z:3S?RN,3FK7/I>"F<E
MTJ3U9'3X9 AA-&/7&,_5P)HU0I-2<"U;>9Y'T8.DSIKFHFN\^L@K5FN77QA4
MIJ%Q$S.3;5^[HR-X?=AD>G8NGUM>K'M?+;=FC<X96TEK8TJ&Z82?=<+"3&+X
M-CV>/7^GTW'6JFQA*?K@:IC]9PJS%AA>E#9WSE5NOS9FMB[N67@S:ZA0C2CC
M7+'91M]O?!)+:X8^4)UZ2\MTW*26@Z<_)'.T:'51?CKGC*3NZ=F[5]1*<F9T
MGXM?P+:\[5.FAF)=5'!Y8M+JU2EQEQ&OWA(08A6?JW^'H!)(ITJ<-*XU)+0E
M3.LY]4_X;C_1%B\[0^_,?5+O^59GM!==GNF^.JK!FTF.*<>6@'*^4,R>Y#]G
M'7L\?.<WZ3LY,ZT6^]8"::\$[.RM7R.R)BSF.3?%ZTV#.\JC94*$6[ WP=.Q
MBD-?/5149S7PY8C9NT[NA"WE>FT-8Z@22"M_TK+D"K=(B)G)A7Z[I,CLOU [
M^+^[O?=_I72)X-_&QV:-GZ5Y>8IP*2]09EY[I1^XY(DZP%XA$X'?^MDZ(;S@
M/YG2U/>[[0>E*2:^RVP N*JMW9^*TN7X9*,ZWP6V6^,E^3V/9')CG3G:+2W!
MGG&#]4BV%AZ=NU5UV_P5<KL%+VV!/RW3O#_D=3SHR*H]7J\5BW^E?@*H$D1U
M,60:AM!9@*F-%9.7+M_FOWD[6_ZJFC\MW,TWQ2.URK^N\KRJDX_94 X=+GXI
MUE1]?'ITJ$:G-O&VTZ-GV\W7SJJ_;1VL*^*R8FN7DRO!(Z0)^?&;E9.3ED:7
M,ZPJFNV_K@>:JJU?)16TVKWZ!,[P?/33+*OJ!*!TV^!:788'(HV6^U$EFW)@
M=7\01WRQG1529C[,8TAT:7;_T7!*#IPY$CBC[5MVBF>__7HF? [),8-(:\G#
M?WRGJ5QA]ET)D".U(X:>(I=-"+SO$^=>=EOY60^WL2>O193]X<_+^+S\DBYP
M6@8\.H7F^9!2$K\T.J%7?_$6 @FCQ+1-BXTUUC27,&?TJ_ &XA'0)HN*0>Q-
M0:*"([EF_FOJ"8#%TK3N7MXG ;'31]7*?I$XKF]M[+Q!"GK:5[O^5KK\=WV4
MX("="N*)G"4@J4W-,QPC3=4!>O:(WU:<!7,L0X]T4I&#A+N_'+.Z*B1?QX[2
M%[:Y9SX9DFS@CA AN?)KG0 "(JGNYKVL;'D6GQE)I9O0)V!)OYG3YGLFSQ'6
M4H,!JB])_"4%S@7W<Z7T"I,4CM)HHZ2Y:J)-]"C3.LS1,W]2;U1?97)]X-,)
MH&3P&;;U+!Y\[YB/AFL[0&#FY3EEN11Z5)8(M1"**D2>C A5:[<R@IW1[-(H
MU68$#(SL20\Q[_U.J'8LI+7N=U)XP[2D4B5)$8YL;.N<+N%H!S3N\#D!.+>T
MP3O7%*,A4CN 0I^IG);70"6K!.LNW2<L>7>_V7YQI-J"^8)LW;KXL**O0+=X
M*N[0N?#ALVM[D\WTM5$4@[]5%V^) ('\];SX.+6NY,POGX%\7O0IG3<Q>)++
M",S><$L,/*<&49K#OCER&3D(0J5O>/QPVLJ+6YP6[G [S]*Y;@; \.^>,^V8
MNFA9KK&W)2Q*T2\^NI-$E?7 >.FPE*J/@&_L._/=,2/BT>Q1D;KU&:I&WFJ0
M#6G[X[<L!M]]2"^OWAKAQKEGA?2R6"3 *,O.K+JR[B68\)U#P\)''05A*&)-
MM8@<JBN[N*&^^P30 K)O5;\@]^5,1))X5Y)F-41SM*Y@L'@AQOY9-VN&'^-%
MD=8[<!U)*VDV=&P\;K!Z'<P%3E%DX3\F>7$3W&Z):QNNRSPJ,?*MYU,)Y,17
M?TU0%!G$D\N#Q^Q^>X]ASXQ\);8NG1-I]Z]YL"6>[3:<!'ER%+R&A&= 'L7X
M,?)G3>+*K!:P646KQB'2.\;O]/H>Y/+><,)]$.+>:8K$N,2=<WXQKU761 HG
M__EXO4PD5S<8.J#O:YU[_$> *2W5:Q]RP3GLSXA>;E2Z2DTZ-4FS$OT 'F6I
M_G7P5=1B(-0+?,9W=20Y=3]O/QN1-]'EZ>O)74RPEY?MY33V3[ VF>N;*)B=
M"9E]2RP2\D#-=PZ**V4<UQRRS8V0W9@],US,&_I"I*@]6$6^-W!#+[_N+5J<
MS8X)@.-H>OL*E,"WX@E6M03JQ9Y!-<ON(#0GIJ.VL3;5KC(;&N^=O'>DA+0-
MR:,_2D;'+VI(,>H"-'%6#<G_H,M=(GP1*E<>4IY:N@=,%N:%P$O< P2.->FN
MZ>IYO;FV=O2Y;5M;UUQF+3042?1"%\YB 33OK^7K RC+>W>C>8*Y.0*+AYE>
M35:*G>YFQ(! &7V,+,J&U%E:,IA+9]<;60V((Y\ QOA[>77IL#G=$L$=R<9D
MO@A8N8=B8$TIBN*X?DP&LGP^ 3C07/M[(3_G5@)6@(V6OW!J0+K4_D+\S[%[
MSD;PS3U,W+*'2<<<*,!H:%- $''EM/:YS[>Y=0 %AMK^!9?_VFLQN02%AAD\
MKK%M:H O9W'HP%B@$JE* ,ATL;YJ2Y6Z^Z6?15\XHN?S7 P?M=9?28J\&?X_
M.<SUOU;1=^^V"5C(^L06?+@8U>.P)C?<P\]\1HK[Y3VM%-[06<QZESP8YJ9^
M*YU#K(]0BE?8E:H%V5%H7GX5>D?K+G_&/&HZ[>K_07G!;+BBS(15HKR9F_JJ
MX=C!A]1^K8+2&(/(_WYS(O,/),9- ^O%<@)HQ%T*!-)?T(@",:YSC.O)16G3
MXY'<POW0US07Y5F3/KO-LL0\(VL+C(W[,E3^W6AEHN'N"2 :XXP,$SZ?NK$%
MUG/Q#2 (R*FJ/F9=-@7/4]M]D+$09+; O>I_T)62P7*CY1I3_N'V4T0JR$+X
M$N-U)4Y$C@"= Z4/K^ZGH>Q^B&]DH.B@:8(X!=0<>-:8V4GY'JTHKYL'4_GC
M:/-EVDZMSQN1^IASC*T]QB7(F+1W^G'\]M5,$"-+0ZU%;.@$@'=!'?IUV5\>
M<J%@5@IFQ)EG0;D4[W7QDE4C.5(D79LCTVSSW5UNI2G(\6!M+X;+YL7G$ #+
MZ^6;"(L ^0<>^RFK7W#RJ@X'2%J";+>[5:5=5IPH!;F.HQRT7!(L>*3>T,TA
M-9S10]LX;DHIA7\9*D:-F0KH.;G8&0:][>"$DF7:N?>,W2IO=P\_C5\T+C8J
MJ7C?$BE=DBOZK[X'F1,9O'\THX]_M[CIL^&2*Y#IG"$FO2=!N:F24[(O?"3F
M!R+2-8_- E3Z%]($7#R/ Q=O\0OQ*'GU93O\92MSC2!&[9[_N/5,J]^9_)3:
MEKY/WUR?GP":#-V (VN=Q>GD3UM&6STVG>L%;TH?.S&6QB5"KH'9YP,<J E?
MK5E"L%94R9#<V*0UZ7?/]SGSS9@FU/7]$X"@ANH)H(@YF0!+SG)D?J\4/0%\
M29'5*$+@*9CUNY^^%=X(IVMR9,;T3*PH!!#'.MT\#TD?&+C(MI4W61.;^\Q&
M1_CPBA'SGO9R;%2'2+5*5/[X-Z8(96\QIQOBK9(G6A'1L/_VF3B3U=I@II*M
MPR;R*')R.7Y:$ZG^\WJ_[$5;S(],?2(5 !]J!#*2&X5]P$41.5(%'I"?51\#
MYG^1!C9YM]00_Z6Z/,2N*OBN3^)3B8=7@<VF1CT[8*O2\#8/8B4F[RANC<\"
MTE+@/8WE6A'Y FP#7INYE3OG\N!'QRLU)9M>$DF<:G<?\@ T#I8[YJ?=@#HM
MCDH0J$*#>XA:%2)->AG"?U '&LA]1UYN=!1V7"JEL[*G'.T,W)47%VAMY.BG
M2[J*#E3B]%7 ]CQ4F82]>[!YRSN&UL/7^1%)[)WDQ(P/"YM7#;7-_[[*_E])
M4=>(KZ=SC9^CB B I].&]F-IOF1S?H$3 .?DU(]2>JWS>%T*5K]\2206Q/^^
M< !>*-&@%RVIZH3+3-8.2)V'3>8]?3W4FLF__<SURI)5#>?KK05B;=^<MJ_#
M4KM\#(8OUQ\M@WZ!2MG8WKV+++O/LI?XD[I5 W\3WE<VG+"O.XQ.MDE='NK!
MZ9D?X[X=Q_U;;#M=_-72"U9NG@!@</;HP*@,;#,\S*=G?Y7B&BT1USKQ*G?.
MG$TO*'B4Q&3J_972/C-O3@"V6*$U^*D#Z^%*!DN>6OQ756],5#GX!-",FPZ0
M/+Y,!_>;WQ@QVFDCO4E*-DC9N#$.A7TC)>Q].Q#)%X[,$]Z>V3P!!*'\!2\!
MYV ?#C$VA>1&"48Y4Y)VI&4[Z^^#RG]+EHIR(E6+P!0URP(O&%?.C/?-B[0O
MFA/NWQ(-B=VJ]$G:RX,8GCN$,G9L_'PP+7[R(2\'2=#!HMW.JT\EBT!\=#>U
MXA>(T-4YK(I]1"(]*8HIL!#"R&:WL%W)6^Q+ @./V98G3(G4&^%(KR# ][Q/
M/!3&[;N!)IN-W#0(N>^,V"61UBJ5H@^2"F$)&O7I-Y3'#6UT0[K+?*2W!_*3
MYP\ST59/_&8$?Q7)4N.%?PUY_<?:(-U%-C@U8"4?S53SN3![U+1_$%FY=M/
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M0GF$3Z5_:,NDZ*IQ]K'(?M/721YX+[B6,%=_&0M#T%>[K8@01KF)N''?HWK
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MN0F)%I ^XFR,;1]_K"I3GT@49'73=UC)75#+C6CZ0$,7_&98*S\#TI^%!9#
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M+L;=7; DQ(6C;GG7$/[4U+3.7V+:Q;6.9?[#>\1?3UY=KA.R7],=@AJ.N[$
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M1+\$: NH2)0A]RH]!+8QU(T/Y]JNLU#8+:])AEN=C$T<M%>R%'.>+BX1@5,
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MQ@(H7(,H>'*R0UCIWRU5MPC1\#-$/Y$D\3P[&K58W&\+'2<SOWXR0!]P[<
M2N7VD4"\FBBB+AJ^*M+'2YB<4O=MXQ6_-K4?K3=%PC!T2]]TUS6909?7"HJF
MPY<=>7,D8^AA&/)8?0%AF5YF&F0.;]<KX3ZUW+EQB7K"Q=9L>#!Q/6:=+T7:
MTZD? &_T5VNHZ9O/7F?5/;#H:XK-)1DPA3IOJ-2>81H5_,9$'D,[6=%RG5/C
M/B>3F7&]S2$>3Y06;)YD?-C)JH7'K@-A13EBZ^:(\TY:+63IO(J.X%RHD.75
MVXS3[_=I[ [;[=G.+'^[K#G\I<PM2AV:I;S\ZQ/.H3XJT:JQ/GO-648*(F6S
M."=2GH;?-";P3P8]:[OZD57I1KD<W&S0/%9@PEF;XK7_"1Y0(TWU_D?@],O[
M?H;[?>SX[/BJ(1.L&XNWX3Z?ZT_-W/,Z?=_^</4- 1XFSG:YI)!3]^5^OT>.
MT5>T)VJ/1SQG==T6_OF57@'S][Z?ND<3KG#[4$V(54%SC-UTBKK"8XUKF[B@
MYTPV:9/DO0\WWL4K6%X/>^$0N\J;+.'.KJ7(F*V,T:?#UU$,;]+B"CZ7^67(
M?DCL^5-VA7.JVJ;O-HZ':QF)FW]]8N'X:[(J>JBA3'!'A3904^];1UJ<^<^3
MA(C#=KZO\X[3Q3G:KOXVTO[<KB8S5]S)SG;1@KQ'1\/C=74XMI+8_3^N!16T
MMD6/T*?9DS#'IEGK+(-[2N;ESEI4)VU2S"GS(9YK0XFC;4+26H-4BGRMEY=E
MGUO5=5IYBVO,_3)7[DHJEBHO/SI^='%CJ#F=)*B1T)'WW.)51E'#[_NBC2J&
M P0S1EIN5A0-3A5A\;?[N?H&%C9.I8.UO0X8@L#W=>:879GUUIH!K3$A\2E\
MQO>@);E,F)+SJ\^/JJFS2S9;^_TFNDOV)+XW@K,]]F11\(<<T1<Q9@2ERGLT
M1Q&"9W@[@C.JY$\"##W]?+6<H0TL-F>>V6MUY<]_F?_Q$8_3$%0SWT23K)PY
M-FM_Y^B4*\@M7(![JP)T/HRG-7^DDSHM?*0VN!A.JV-ZGU9'"? ?"5W.&@5^
M3Q^ST%%*^7SQ5/B&,E-^HHU8[E2A:D# Q*NY?/',>I!(B$+(SQ!!I/_:KEY/
MF\42[*MY"D_#=&VZW\ 5*^4ZO,-O\ZJ;@W7>_O=)VC?8Y?9#3.K1<E-Z/]6G
M^T'Z*7^UNBCV,+N\Y^QF\<\$R6N9-#]BJ4_H*?;3![$K<,Y0?//;[J4NVX'-
MZ29=TT.;\@5.BQEXLT#BO1/=+]K7B;A3Y&$'(BA.-!/F3PN5&T*R_YZXSYXR
MRZMZ#-?!]CE:<*-R__J8VU^8+]F?<:,AWCAE?S@8? );/XI"U*LU(]\ATJ2!
MS^5"Y45ZG9[ZN@BR H9#M;@]D:QP#@3!I<8WI,O:T.'3WKS[[:"B^1>*/5MN
M@>FQIT6]7U.E+H"I,M'9115H+<3YN8S3N'<^DS:2/J?J9AG>>I:M,^3M2?M$
M4.Y42G4J((T/0!4$AX,:2N. D%!P_6A8"#7$V5P+NG<O3M$TJ=3.@4NNN&7[
M0\I/+,!^J14<,1X$0&JM4_!93@5I5"-_'75OVL4O+;^Z-Q=!'!'<6P_P'V 3
MG%40"!EAOW=;U^B,!;"B)9"1;".MXDYPYE=?G\]^" >0BUO'>MR]JJHTC"EG
MT '251_"\R<B\X'J3EFOW#1XF_9"O,U5M5JAK5C 2@8,'UB/N /Y)#.2],ZQ
M:-ZD/<"[K]N%1GT#_Q<5-]&HPL7VG$@/&"]D-.!<(H0O&A0%HUFRC1CM;B*6
M,)R@"3];1LY+7:MH;=Y8G&AUASSX@Q:AP )BCI7@42+:<M/3>UR-W[16FT-%
MNRMB;;*3/3S_D+^;@2YZ#-C#T;#?NT/NX$Z]7,3N/!R=H%P0+;A%5?L?%A__
M,WDD("U<D'"L^O76 =]4(,7IF\@+LUT#5^!4K'L^9 DH]]/'KH/'XXJ=1QH+
M,$NX\JN:;?PQG'.89S%%6:5C'GNT%U]=9>9P60WL"2?X>J3UM<9IM$]LWEYH
MNT1*UQ^]+VK5,BV,F0_J6L:8]*%%J1"%<[P-E)9K6CRC4:[A?2LVS7I?JNL'
M4,/'9FV6R:XL )=8;[<= 0L1-4GNI_C?;JZ<=@KCK+3+\I^=%XAV5KE:W$M\
MEH;X^#R<CH?6L,3JG_<5_2>%F SAO (+[Q3?X9BUY/UV-D6YX_I&EO=#A\[W
M8!GFZP%3+"#4#BFQ:X:2[;WI2,)0BZGP8UYT_BQH<UQSUC'\6!4O,R,G[SNL
M2U*_D1 &^G8+_;&H9X#0&.6(]=XW-MZY''\0?O\O5OJ1D+<K]HTA 4%>=8A&
M6*^FW=E 6_!F!,S?_73H\O-#LUP)]O!G/QBE?D 7!+;1X!-<)06Y]WA\HC>3
M+;[9-:[5NN.##6FP<H"1+7E0OJ1,])4<6MF(]/.4C$C:P,IP1]Q2N53HR)QS
M:U:1N[)%P@I1\"Z*"$V&8/@0)+(&^W1ER?$="_B8IF$W<2ZOL$O^6,/:ZZ/$
M$Y(YL< [%] ..?D5#@H_M1<[F7>RB@&BF$BG)(X_AA>.GW[G.)PJ2RC[F1=K
M9Y8_LBC<Q )FFR]%OR&MUYC0_NMD26LBGQCJY(YE/2D*I7G:OP4T2RU R(TF
M:74L+=23*X4=Z^>*E6FM!XEL<$G1YNU_)G/^>Z(]F9^I<TI3S_K>.;?%*"ZA
M^NT>\TJC1]GWZ.S[?B7SEJ;.ZCKI;W_8+Y]5%3O*FC=Z60$1\6*J_40>-^E1
MU6-1@5_@6_-#"1V[%Y4WQ>O4C[GO_5)%5V[ET?OYXDK6C^-^CP]K;&M3M!E6
M4U]-O8[)A<R1JZ )X10FC04RNWWR)@=&(&IQOV.>)IE8RR#GUL+%$=&\#4^#
MB]%/ 3YAF[<5AMI[T!9*_#2RO!)5J 1N1+!Q9]_G3,4*\T^;@27>^/0&_#U,
M(ZH$I=7.DA^\\^Z9FM04TG6TIR'\"04S"&-2N7.)=6'5'HM9'KT[+IW\/ .?
M'DRL&Q>:D+#;3! )10B&@]>D.7#L]^,;"TV0W[+ 2NH%-*\!_-%71OP/,+>(
MMH<[0B(33_#QVQ_AA#=>P\'4*[)&$4S&YS_,47!#=O3<%\/&!IDI[6A:<CP-
M);K=['_9A/??),2B:QI@ 3=1/Q.96Z?T\*"2R4^)29RQI: <KYN^O/G'-CI7
MDZ[@:O=WYL#JM;^R95C76K>/!I\Z[%4Y("M?//GK2N?P-/OTZ4_@T- ;,@##
MXT \LSI-A9+^O9MG=!XO7Z,K!,C(6'!TZ2^B:!8V>:U1;T[TZ$'AS33=_90Q
M5T>6XO+4V\_KTG]9IQRJ-SE5QU_ ]]/I32GS+AF),]S74R9OU2I".$XFYSXP
M,#P8H-*6H<<"]G4O V9=%8*%?P4H1_+F/S&&DZ!UJ7_48/I_R2LL6L6Z=]PZ
M7EZ.S?5R1>$_.! P/?A(2^FO]I._(/K/^__NO?I_2TE[#'/:&UK*K0HGF0;F
MM_Y)=;>)WL!A2POS?2'40A^QP^?3D$9APT>"Z4"M^W*_IV_\R /$!PINY9WQ
M-27,0UE\/<S*@;7.]LGWN1>6PKY6S[/Q"&'\%?PAS\^K6LVO!-#?6>6><GZC
MS _-/GS756T/%W$MO&?&.3!_I6$AEVE05-UZN&Z]IZ__9ZZ/^*9E"K3(6%+>
M."F=-+*#H2$3F7-+R!+1+LT;:;/5K@"LD)H*JO:IO&%Q<R^(%OCXOYH\_E\3
M?4]SGC9Z'U+Y?4Z4Z5PKQ49I.6I@1\ \><&GM?A=,-UW%SY/+,#;'YA4AHP:
M8G2AV3[F\C+=AEZ,*SY6>9-;G:NU;G!N5L[7:?QC&?:>PJ-M=RB5&24O/&Q\
MJ"&:9B^FNFCCMFN:9NJ\X!G&:EE:7CD=H#X0Q7N]_.U 4+F--C!QEJVCRN<G
M/? 'QEN(UO CT;]M'OSOEAQ!A2OC^,7VEH$LD2NCKS?C'>__V)&*#1 LU1T#
M?ZX;G?Y*U4E+BJ>#,)]"HI8;C,(46!>*2S\%/7>C_[J^6?LIW?;J]==$^6&_
MD'Q$>:>T0PC72=]!W.K\/F39=,'D55"KE5R?G*O"*6+8<Z0N_M.<^$*C?0':
M^+:T(8Y*DZLG,SP7ZBU>;7];E%S5=/DTEV98V[/9EPE*CN1!^/;"YHW@"D\Z
M_([BEF<:28 L!2-73-T#;J3GEBI2NY:.*Y#9/:WHN?Y2H:GLF[=P3E4WD<=9
M;]5\:0"LPNY##QZV'&>BS%9!!Q-%?JYKR\:=[RV=!=UHQ< C3[D^/_O^'G/_
MV<9%S9U2BQV?P,])4[NF%B/5G%4.9G(I,T;^!7ZN;"+W)8_Y,(C#\VH66<:W
M5M3='V@##**/BU^(7^R]4R],U%&B&[?Y;_=K WD-X[JQP]]7<!W3;IGV*EHC
M 1@3FHEG?%X%.CLLRU8@E?>.;R*:@NN5Q[3 MHNVA66?/9.C.?^MIGNN,'*B
MT,_W5W.=T;2W6DO\R)_-2-0 4F6Z'0MXB9PB_E32&KW_UK1*V&!EB4F/&!GL
M9+-@,)Q&7YD $HZLVL,\$'0]Q3%WNR:=/".WK]!(C$+(_!U9:2$T^6^*N-W&
MJ6KA>WV^FWGI0?Z'N5B ^@V#/H(;WAOZ>[Y#,Z@+X7EIES* D6N>\OI9V(AZ
M([9HCA?&&OU<311MTJ4K&&' VB >+MXL%Z,^?:02<Z=Y8Q2Z>*UN:J@EIH%Z
M1/E$Q9_K+7X@'(;FNDW?0!C&%:M5#/C:"PR[K_4SD1XV)5T]OD\]PYI-=?RF
MHW3EZF"J=$?4;/CR-7E@PIP-A^3(<_>P;]SV=.>&Z85S#I=K+,9I0#;$X,U$
M.(.0#4U%8=$K2!>,\OR89.8YN78_N1.=@1%I"R/ R$Q#R:=?0.#GFLN0(<[Z
MVO_\PLM_M1#:D9+(D9Z*Q.0UI$=T,LX-,K5H+*HP&G-*;V6@E(-46T^@$?];
M[5;^S@0#Q\?4"BE1SJCDG1#OL]+AFG*^-G*4<O8BQUQ[1<QRU=)A9H]CKN5*
MTC"]A1QC-'+&V,9JDV,JS0AES)'>]0^\[_N\QP^?G[X_?+X_?8[G^7X];88M
M!YZ&V/OC?%6"AX3($%$?EV:<F$:O1*6_#VF^54A7SU20 K]8H;].>KNO[M!
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M9(T^S^?DM^+1 /:&!WIXI4Y8[3T@@#6U!@.#O4H7'+]F;8S@U4X]W6>L, !
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MYFI\<'%)>6<PX-+]/D"Z-';BP'9GV[/!\9L=15B6P_U(,@?W6_&%6P +SWZ
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M'M[""A^3D2_H+K";W@V-$1I@W1OTL9'M_X. AG<6YB54/H5%U$3IN"X3!]Y
MF_XV#;^9_L/@H"&)LL9>"[!M,%^,-1-VS@TZ[9>+4J3=YDCY?)0.7L0+LC<*
M_UD,_I<8;?RJX#T#;\^AC8R>W[?)TFXF)E9R8YZCIC.0NQVU<QMY*V9PM7FW
MX-Z?M,BL;J?8Z3EH.XIV?6['X%.A8G(Y*'**$EE\MI\X>5X><I: AKNL74F7
MW1O\%G^4=R<KU+^3L].4%AU\@ !5C3G"!.I(1Y7T[@9XKS;QN;,*%7.WF+38
M3DRT3;:-ZT5&Z:*9:R.;3 O1C9H^!S8^&?-!WQ'3II6M>Q)N,)#=:NOG%)A=
M/O<]@RW7Z$JC<PI!#_4SWUK_.RWM5\+8[CGUSEM@.%Z]==\I6W5DE32DI,@^
MVQLZ'/4\A17QMH0QBJXF5RM'&][[<SW.:ZCW$6Q>4Q/*O[^BP.SR*EN;AIP8
M< <\BS[D-,;\\\JH$PL,UF1<4#<1G9ZN%AH;E@PWH^'6/<+IZY&3K:LX@%$?
M;3(,XHA_%2F=F7P$Z6*+2$N-@7-65@A8>K:;3TZ-W'-@A'6I@7*COQNFG*ZA
M8&_0AD@=+DO5]$^S;%[L&Y""VF8WU;3\^)E+@[O9J9US4].VE,C:W]([NF0N
M+O=MADWTZ1\&A!?!\IO$5EA$.FH<B*,KE5R.0=6.ECMJ=K-Z[07S>72H4I<'
M;=JT%C5?:&CCURPJX"ZN34L9P9%<)9*$_U:(]U]N:0?LFH/.Q.)V"4O"!\XY
M=8+TW@,6HN^RS$A.H14N48F5;&NQ;(K0^2;G%KTOSCYB*^<IS\*CX13'='<W
M,9&[#T?+_15\.9)$#F0$W4Q@*_(WVG-[$@8C)V(;?CAG7?N&T\N>R=Z?#*/U
M:^C;P! ARY?5@J7*5^9(>*EV N8QO!.:8M$O"N=R_R+FYS?0&6/UWU')J\\[
MQ8?$;W]72P+_#-/V&^C;6Q789 W.F?20+&5_'#L40^S,V-,L !5ZW<^>K\@?
M]<4HW#NQ6W-1*I+]A AN9>=+?@GMNR!/8/79:MF 5[.1]Q>I-MY_'FAWZYK8
M]V96?GM^!WLH<.JXD0PK$7-[IQ.A_A)Y\DSFP6^9S4,IMA]EOES%4AW_+!='
M<M\F%?:F >#IQ0Y4,STS#VJ/"L74K%Y\J<CJJ5<M2#A23Y?D#-I]7==SE2S&
M_P+\UJ9=6M9!MQ-+*Z&78J;)VK*/ Z;+9.D[=K)M&DP]8C$.^=JD !%A%,5
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ML;:2D!?<.Q0 >^[6^7!_*PK0)$H!.G(RB+J"4R-+,61Z"G#(N<DO.T< C5.
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M&O3!RC?VW':M35I&SY9G?&IN=Z@(Z\"C!WQ.NVM:]/4W&NZW;AAK6'ZP-7T
M#V*K@-?DE[A'0.#>M<F=V\I[]V["C?N5/(P"].6GGF@D7>M.T^!7;),M3OC0
M5 HR[T\1''9Y2O?(4$VIX*$R47:>%-RT<YBE@RIR[QXY<>U[X2K-5Z+GUM8C
MV.EZK-M7"G!\U>[)MSG\=H=8EL5;DX^KON<@,L0526X\-T&)ZL+H,2A2U !^
M9#>F;T3@6;K;\Q;C=Z^5KZVJ1A3OZ-V60RW!S.=RA).;+4IR:U]MA,N.]9IL
M.=505S9^AGA%*C<6^.^P[-(T3FJ$&"?,2P%0Q11@EP'UKG1IZZ@LEGSJ+V7=
M$7<H0#)$8 5,4J=;4^,E&]3 ;2C N^^'6O%9TB!CAUST0[.5J#R<-@40]VRF
M /N\GRE 7P<T;^CP*R8"WC:.J?Y7FR7![2,%*, "-($"",)WTV&2<]6$'C!1
M8>>2'I?-;M*AVG_7S_W_FVV&@M0";\O/;<\2OX0;9KG?I  L16+([Y:=QN?]
M4RITX^T?V.<P$0*)@3['ECEP9J;9+OMEPH21&S^L2;21MWZ3:4%E$4_MT9Q:
M 4%8V?:L@MI ^Q^#DA=D4LAE&F?@398T.&O>, J@%7%Y;K5>[[75MVK"YT/W
M\I]F9MDX9/9Z$LF@^5#P0GWCJ<"&@_?(4&WR1D8RBV(W]SJ\@G<=ASZE92.1
M7Z)OWX+7C9+)R?#?XXC4K*YBBD#0Q6P+.@2\O-'E:[Q3M+&0OM'8(0<]S$EW
MS[S>Y%@8VZJI+[NUGI$==EH'(+?CV]L(]RJU+^OW[?(NBCM/*O^D  4>\!A2
M7OL;Y=VM1W 7-!V.48R@$^,5ZMO@K1 S)N:TMA.11Z9E"*,_EU\O*^CQL?T4
M2TD>RYM X$8I(>.)ELSW"IGSE>+6U78I1E\H0)!F4?GP\'@57./W*[=,5V5P
MXZS9N[OK94O#9?B57V<$-%DC=4X+U9]KBGKX\<UU",T-X7NY:,-X2ZO<SSKF
M'=4/W#P:.?J#EO>GW<,BYW(&QM\A?]@<FYO^Q=2D(Z<_^;:]\.JD^,< &C"&
M8QOFZ9"I%ZJ> 5H,?1+J-QIB"9V*A\X-]8T_[3[_TJT[IE0*KX)()892 /JM
M^DI;"<Q4-7O_'L_!RB+ZIV$M/<G2YAGN8*8W5H>OLZOL7G6Z7Q0"XHJS7SFS
M"+<C\1=TL]QJ[?L>)^9]KK/E=$P-ZCLNJNELE$#H8G^Z,,QA%X+ATR3UFWPG
MQ*-:Z[M ]^:22\&0!]"P@:VKQ"9E/.??>J%A<"M\=.LKY$1$AXV9AMQZI@XL
MY\H=9 AYE@CH[$U$*&/NX$)GM!5T><$>MR_0 "\+>L\=QW6T_[XUQ8USR\(T
M!CPKC?-[+3WPV85W)%-3:7V@8L?!M=ZEK49KGL:8BS-^7O;SB(ERX# " ]-?
MY#*'-B*S&+C,+_ZW.&*2"D3Y*4"2$]7S[.U!R \K=Q,BJ-B#@>IGDJ MX+T]
M56K9(2H>O&TP'TG%B84BD3Y4@/+] +1*]6^98"FGV/,&80Y[1%JXR6M>JH\^
ME'7@H0 ?&@K)B<8D850/..HW67[D*7I=P9T"Y"6C#4KQX\O3%. ,T0<W3W6$
MG[ 0;O04%37.PK-8I'+1[Q =S;%2;VC_R?\8UW_:[\+:A]COPX>UJL8EWO6-
M%@LG3JLN/7H:]CKBD#J3)QON-?+?>S!#_.01_GUOG),*_*VP.F).A4]F(X)"
M?-;'J E P_0@7IBSI>3PF_"KJB6SS9%=G8O=4KDI^?#7A7LBE7@PAJF)@ZB$
M,\A=\7CDRK.FW=$NIYC0BWRKAJ>!YJ27%P<)J$Y:TY,4H84J%>_V^^KAJY.Z
M\MK,<^@"G00<->0[^27C9D_IA4JKJU+G/&_;C/LCMZ@!Z%+$!7^?(;&,I0YJ
M2"5_@'!35\##_YK?0SDC##$4((H;75E9IF F2U2<R#V/EU:'I#D]:S-_"W)W
M\#A_V]XH<KT_C3_-I>.:7&/'[6Q+FPQ/<!6TI>%T+ 7PB2R.\0RW=0;G3, J
M4Z>K8QY:??SMT;UYMA=2%M'@<T+-([76#9$/QQ_R'JJ$<^'<5++J?0>H0V5'
M[%L?M'DQ2IY @KPGSF8]W:L*[W*18")MLP<Y")-RB:"Y&*M/6)UD9WA=BLG"
M>2*8L>Y<A/N+NXM=T=_Z4]9+]*D.<]/IV?< &9D]WQT3M&SUM-/GW$R? *$)
M6;$+8A]K.BM4%AW7]70:TY2&^A8V\J@ZO_Q[JQW_%ZO]PT#_,-JT_\IHW?[.
M:#G:))4:[BE3C?;J:_"_:[343,.Z7H$".(:;D033\-K0X6EJQP]YY^'M8)(X
M\GE(&7DGA@*P$G^:ZW&3Q&#7N,SU@'_R/\9'V3>12_.:.YGGWH&QCGWD55FP
M:1^$ G!"+]IDDX=AQWWXB0PCC@DF9FZG&N-I4EX^<Z5FXJJ@;XVJK5<;0S;Y
MO\T6EW8,I)A\0=1G]+0W-..*9G?N:]MZ_4@Y7,$CZ8Z;TE\/X<J<0_>DX%_=
M<K:9AE:@6HO(XA&G^I?<51U6BL[*#R)?:MT!S A=GW\/(HUQ)QLD]UUQ6PI-
M6T+'"G;$^H+8=.$LVQ?!#_3 4[>016+!J,%ZT7GC".W7Q7=?%UG?2H%WE<TK
M$(*V2,.]B?,1CVT+H%UZL&U0ED[D2+?74M)!-[>]P;!<Q*5\^^F;$WI!;H&/
M#5T2JL_&AIWPZ(:'77[GQJVF65CBZ8I8^J77MMWEFQLK\_P_MOARWOG@#8:W
MQ./]]%E/D.Z#KA9>[\\X+G5MPNO0&^ 6R=B9'SM7)6Y'IRL*F=\H%+(/AW_U
MR;6KSM7P#=' E71&"\M;A(N38-K'!ZX/RNUF2\M[%T2/37%/BE747+FT:C1C
M$T6T(C7L@EGKTQL%*KW"5F#0S^?/CQ7O0ZA0 J#90[TBGR/_U#F#&RCZY)&A
M+\!UO\6)1I9>M\H JTHP35E)3&L5ECVTCR?"VT92/TQH@]W8&]XE^\/\XNIB
M][[LNJW7@J(#I?-ME"+ZR98;W*L'<%F%&S^)<()%R/B<Z/=JN\'A!R@*(#\L
MN8Y]M+)-_ &9DJC?-^(/M<W,S$PTDA3+NJ0'H\MT.[7^#575/IQF%)R:34!5
MYT*N-M_QQ=T,UU+BXG5.)CX5['>-[W-P'V3*DLI_PXX\%F$P4L_D*]Y7&:E[
M[8Z_-5]L7J3-)K+5IIJH2 $>/_;D-VGWF4O0$;*>?EM;12OP4-N8] W/7KE3
M[N\>9C-$C<H";J%G!RO6K^1F_&J8(=W= C>3W1"9&#+TI>S=8FD=@LF6'3(/
MP@Z[@ N8&XIY_7;U^J1&?(?WM!C5/=?'(-L+&X*X#U-R/:MS! =G&P8VR\]N
MR8T'!EQ>% )]Y-[C7=\C^+6_-V)$S.O'CLU^2/+P4&D_O2XNQ$4!/JOMT97!
MS3"2B2_/]OA]=7,W+]FU@+:D[#1^@)6AE#_B*,#)D(!GS7IS%_97+_F /S=N
M/0^S/00;FYLFZF4IN[BX.*;=\6?>XUHE$8D__BYMF_Z[%(V:ME'+1GNCM:C^
M#GJ# BRS0K-P5*\H!E/MA^#]F88Q"D2$+YDZ/T9)VS%AQ[H5/'R,R320@N,I
M,Q0 PD.4^QL_^0K"U$N\C6*%CSI0PX6!. QALU?=AR;KX::Q[=06W.8<9.'U
MLQ2 BKB4J,X ;@1.>?H7[VZ30.Z#5PYG8V)Z^G<KXRRQQ\]UO&IQC706+857
MJ.^)HN.0?HQTXE^[A#(MKS\FC"\G3U;_"ML(^-GE7W]-IZYE5K1;$B>_L6M0
MC$.VC4$?[Q8T#J$V @F6:V+;]/1XT(UU=10[[A$U5C#\5+))!H-6JNU^Q#7E
M..V'!*PSR\-/R"[V"A/UAQLEUKS@9:N<T[?.:P8+BND2BO*>"C=9\ZU!.R=N
M[#[J/J\86&$HHX0W-C+VZ>G!(O+S5V%=*2%.47G<6LW7WGV1+4(-X2?#A/OF
MS,:_M(<-U'S.,.UW\GX\-:I)LY<2O%U^[6#_%99$V$QILRM)H:9(K_0AXK0U
M5^=2WJ(ZSK_R:U6K#;#Y-@3?)R834DPP.M.@EMK;W!XA(527HWI0&5!E-J;9
MGO3!<:[;!UOK9)_%NY&!9=4-ZJE1X"5D6&._@^8 G^'Z+V6TM1@B-.=GAK:@
MRTVT#/5"BL:UPK?-_0??,J*;T=_QX4UHC+DT_7/>YTIB+C/*WW)PHM-= ;VD
M/0<"9GZ>-T9'=O1P3+B084#JQPO.BA#TE.YW_.X!JL>X,M<S(T=@Z#1U21=^
MJJ_VZNMF30W4:;59U5*8[PE_F!7M=E]/I]I8T:33R)8"C'=,U^E U##3\JUM
M74QA-PCS.V8^*0[Q)-7<QA!2%MJ+F>BHW1@UUQX]8OGBV<86SK <X>+7=PN_
MJ]/.AQ=&O\<YQ5:L4P#&C[7W#_,^F1GI[2<O4P"F.B]PK!N?BNS9<@RNYM=N
M)/\F$CI01(W(NP:I_QIL'(D&V%8(>SVH:"WC1)??\6S>+&SK13<^NGCL5+T9
M65AV=@L/>$(.)N#S#DD$2WA'8T@>N8&)'%UY2(#VP"Z$Q.7X[KL;L*9;FC\I
MWM'\=F$DR^3!%S%8<5.$;(;K2XVTCTG>QM;67N[.^##D;7A+6X0V!;A,_D0!
M(MO(2F@,U@Q$ 7ZBWU. :3\*D! 1&\K%0HPCBR)YX;U4'69JX$D'8.SQ"LCA
M/@7 2,,S\?8S*"Z#>3BS>U;K^0XVC?S/P48"\_Y,UYL$_7(\+6K!#R';ND0J
MK+F3[4/BJ7R+%9B[EH)!->]XC+5]KZZ.>VK^(P7M?&D200%NS01 Q]0$>S@Z
MB^>QG\P=>BZDODZVB?5J? Y^.'<N.:3#\0/6:T<I>6C+.>%+W+,-D5#7I#.)
MYVPGQSV*A(RT2]MTI&&3PCR8J\EVRVN2SU V\4WDVQ5(_/(E:N)$0Q\^TD,!
MA-#N&^'SM]=?9()-?PZA@QPY,2T?7U ])RSJPY:#VT^;'3-^DHALY[L/]>K<
MI\JTWZ>-[\0[/ _M4"&([I6#,3U9L6597] +USK"*DL/[8=R>N=ZQU'M=L3$
MLTL?^MYZ<WN5M7P0WI#8^LFR( ]QAPA/&M42;=_+@C?-/L!,'MU2$[1(ZH8)
M),Y[B[3U(CD22J9Q"QD=$LF'HKNW(*#%5-$NXR>\I+ILPECM2B,-Z1TQF (<
M@V6PAB ML_@VYQ*&;4XR6LQP[-"-CDRE'1;.0 Z%E:!X,A4!ZLO!TFUVJ_NV
ME+XYG:N9+AM*NV9[>:+?OW(0Y5GM>0A."7D;]?9R%7CTDOZJ384QOFS]R)_I
M@=/^\&?<B'D4V)VZ\#15BM]/&;BY@1XLOO/N+!UZB6<Y!%'#^4<4\5*ZIQQ#
MP<_ @+0?/G'%[81K.LLZ<8=9.!TEK(#4; E\(WFI9&C^FD;'86.2@T]/1Z73
MBAK\J=^O>@K@6\90G]-%G$X^',6'SQELL,^"G^KE#57>@XVBMU>8M@J)5K M
M(BMM_8UO$(RY]50?#M[2XG/:%9U!]0* &5FF\4ZR=;J^FZNK4[)1AU@_1Q;9
M<0XD'!(G)"D(DA<64K=(+?LM+8F30J(6<P060P)S)/9<EM8;C6!E.=7E,"K<
M/E$9[:-@\6E@D *P5V;YX6J<\".:082K(7AL-22V\BD%\(=2(\HEVAH/S9$E
M7+E2+_;"4EE""078%"L[<&@?ZOM^H=-X$(.![E-AN>AG\&>WQ)^_R2>[ [!U
M3G9AT TO+,C8Y3PN>?6ZIAF7/W5"(J65?X-#KE]C<#*(4ZPSR\JY4 *SDD#?
M,%JHC1@JO PB3R(.A7=F$3@IR;C *JO!]TJO+7061"^=)EJF4?&CY[ 6 R$L
MQ*!U\\7J1X=[BA^_K1B\9B+MUR/:+J+B/F5IL!"N9GSSENE:J/TH/*9=(BY+
M]5QC)A1 0@<.;E)7D78W23J(JYXM(8(&O#@=/F+E7PLM(4.](CVE.DWI'U_Q
M:?6S7ML);@)S!6U%\Q?5_]R3C>.[P)I;=3?[UT]B&2X6/[(?0:H([(V]T/)N
M+>YX4GDCC^(7GH.$Y7>D8<BD=CAG/SH7!_[VOE3SE6_(T%[8UI7L>C&"OIUM
M8ZS1 ]-/VSUGJ*A"(*-MI 7M;NKCLB6^]"4499VT\=E<#]8?\?^".XK_]_F&
MVU-YQY %JY %B_?OG,]IG7 ?O#XT]!+\F@((PTZ98A!ST?EY%1\J;11M:RE
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MKI/';<=):8+DU]1T<-:FA5UU%A0E%^@E#YEL5C51!.4LZ1Z\\PG LQU_C';
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ML/9;#J(Q?.(4H!J9'E(:8\9TN7J[X_]B[[VCFOJVM>'X0T51#"I($8D*@HJ
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M6"SW>%# PVS>-/G(08[43EZP+?>=9VQFGN8A<(-:R++R_,0R^GOZ(AB,Z&)
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M?G%<60FD&_,[Z&4TO70Q7Y#&>Z E2E2$_]K+\?VU/:O;HVZ,HN-!'[KX4P+
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M/)Z0779N_LZV]',8%-&.K#R#B5OQW%02'C5P*SY[N"'DU $1ZGNG[@?LXY5
MD260,/A0,')J;_*VP^,FEX?X52^AY2P^3AL7<.U5V'-8C[U%@XU!M)@ZVH=M
M):F?E!3JD$ON,UY5M3OGGKY:1)@1AP@Y5;O4MOEI:A@S[/(S87>Q8R!7?RY
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M&$FDX6)%+(LC\X>,V*ORFSOZ8GGFOW[\G];L^F]H@/C&O3@U7>?\DA02VWH
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MB4+.)0J,+]3SCQM'?!;UX; 8%O-G"?!SX[>QF^=A->AZ4VIL6&@3$],-_L1
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M[[H+-=ZR?G$DQB')VF0:-6/;GV^=4] 7]#K#DUY_]^^-^_^'363=G"7LQ#%
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M $\WN_Q2;_H"ON,8<AC@-*I4#P?Y>9\I6A..IK0<%_&_5_$Z89_T,-:O*4$
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M,JR+CN^>TVCL&G:^&WW'Y$YNL D7X 73R=X<!<9H2I3.-/>\!MG9FFPBGVM
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M[8P"L)RSJB/+%92$3 9?6+JA#'/)9QU=:SC?J)%U\M["=C2=Y[<#\O,X/[@
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M5F^\"V@OH;Q>-@4S%%Y\H_6*'OY5QOMY36,JCV@JS[.'"7S7G^@+   KY[;
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M OF8@'[D0D_OY,K"7(OT&(Z;\Y*_1II^Y"%)'4ET@>B5ENE([!,DEK6]B8H
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MUC;;)DQ)@>>E3+QP [673!:=,%)_'<$?07S0%:IZ9=<Z!Y69B6Z0D>OCDL_
MPG.EY7($TK+&<F!^$@X_FL'G*/.@>NY=?K1:@.\58WADO@#WN):)0*:>$K7B
M9S]85D@S2,$3A=YA9BWW(,G_5I$\(,OA984DO6E[PY:^2"3*%$3EK_/D[*8
M/S3J YY6'[(XJ,'C2?S4A%(BS&%S\.4UV.4>%D[&/Q+Z.,#$T7#09.47BP3G
M@Z\OAGF> DZZ:*LQX )8S3'&$WD&6.!'2CN(__J]NR>2N3N?#9.ZE/WCQ3E)
M4]R-"YQ/+QD^U:4YA%$8P['\%,X-S(UG:'ZKB'90/]>S=6>[ZZVOI/W#7_+&
MM@]Z<+\/^$7VL5C\+A S(-H.>4"9@&$?LR3S-6$<47*7(S1QJG,!9E2*YKC%
ME;Z%GPRMJ! ><$VN61:65H"^"8)7:?-"YNXAL,87"%G7AAHK"PBANTXNON^W
M6:&%AJU_5@\6-H^P"!(K>B4\PIE<(WU4/C ?">IZT5BGV3P0'AVD0T_!XQ6@
M"Z*W#R]!LB@3B/H_B%UCHJ)M2%*O8M,;Y0'A&--8;B^9"O#[$RVFJQE5NSJ=
M#U\HOH)J*9DN*.*KR'5:AJ5V(6PFSZ1W%S8:?WFAHJ?'U"6+W2\9.]:I2PC*
M@RVH<>JI34.(05$1=>WK=CZPKGGJXP^-) >'^<ZB595]7HMWU]<:KWR-&K=.
MT_%<VR>(QY,XCKL1M:#NX;%+!+C.E/BDK#+ME,A4P&^C:P8!^LX9*E+-S#%,
MEU_XQ43=OOQ5FX-:#G,AO\"UJCUKXQ!QO= *_7_H=51^)VZM -3/M/GY,"9.
M<^IM"+P1Y %+HR@38HC<FQ U EM+ Z4<;K=@<GYN:ROX1?:N&%NYP= *YPO.
MU,MT6C/74*.^>&?JS0L]6YB"ET05/>?-C9CS/MIIYX0*O_UVHV$JM%F2CL&6
M5[NX(XO @E75)7^"\+A3KF"'[/L+W2NE=)H4/WR]9,1G, S$O_^EB(6B@QK0
M@L%H@X9(M-O^5=R[XV=''-\;N0ZE9^TN)0,X5N0 #&0=:H=>I'OD@C9WG*==
M$Z'7&27E?4E&>-!E/BY),-EEX^<;@*"CN>TSB$+(( 9,0[6OW@D901&&SGJ#
M_M+M' MJ;YZ:B8ANR!&N^Y(X6$S(B5K\GA>+*C3ZDX]Z7"8KQ)Y?C;[YPD>\
M7_/<RO4N?[H+@+L$=AUR&<(3-B^N.<8:\ORP+S?N(]-KKO& (MN[ ZL%L6E,
MAL76[9YQU*'EDW1:" G$EX1MXT&[[J]+59D^S0-QUSG$ <?>F"-'L ?I.O6J
MG@A:PBWLPAUL1UH!87W!Y-<NNCZ6_7X3[_Q-*PHU71VS);Z)Y?^]M)$+Z5G&
M6H&XW4'L%20@+@K=5MWVG0LX7VLK4[F>(^]=./:$H2*J^?ECA0,CM:L=H]1[
MQT?8S%!HJ;Q8&F<8NX^H"VQ7LN7WA-VX=G"\V)-RT"SI7V%(3:7[T*[;$ V"
M*CZ#_%5.Z]G*1V9CT^K?TBO$YTL+7]F, SYFP3P4+S\T_.E_5QRAB_!$<"R&
M+%#H)B_#@T:.P^+C_EJO^_O;CV2WIJ'\H7SG-T80Y_]-%E#U3!&V"E$PZ.N'
M1@AX/K+M16);O)RE']-'X.5U$B=JR$N_-V\:J?%H!??*+3#BX03%ROEM!]EI
M+7=D8ULD?B>RR-#74W[[R</>M4_08-[S[:84.O;BA3&<;_^,N2Y3CL6\28N^
ME+#<%7?;%X^F7#TV!(,2B8P4ABRD)H@+\B/_EFVS8WH]T0J.F8N[K]"O<&5X
MT^\[)-DP3"->;ZT=2&$,KMP!UA4UI,#BT5/:-^WMJ:*TY^V"YMQ K*[M%[Z#
M";:@-U%]R-8]4@,*R@[U])V?62&O5;6CVA_U402C#^[_F&FYK>N"F7'IYLZ9
M)-S]*55%-3I;B*GI#,@=P>K!G?UVT<'ME-'(633YHVMHH4'@W^>Q.=K)D9[[
M8X3K:?$5)&,B6\2].#Q'OF8DFV=S-]-N-NNZ0?>B0HSAP]^?P"1V3?Q1)GZ,
M$%EJLY.-GX;(8\>3P=(T7JHUVK<?)$+V[KT='J"]\/0FS=80*?-?U]LO;2DS
M&FMEVB+?L>W==Q%+4B^]_YUF.3UTW^UZ0>+_C6]&_OLT$,>_H (=O/45/ -\
M+X%N=<PC'H'<QZ+D*1.@FJ4Z)%#&YN ,8)AJ>]YPL26!ZZYIH[V.]H@G"DJX
MGD-B#T<=4TGK_!F@%R*-1<1[^_Z]9>;56X_YMG![;&VNBYV4BHP3Y/%7[_/\
M6]>=G>%.$:IIR@H:9F[S:_[YXO8KCP1#I&DW>!YN0S B*D7H$QP%@NE9DJN\
M/X9Z(YX?S";%]ML-E/,!G;4;3I6I[-SLWPX]# @\^&-O\-O0L)(TV8ZIHOB1
MQG2?5%9"4RX%.=W&B*^G^DP_0@>WC/&N\H"P3.PBD$PXH8*<RJ"9ZEX\4"VN
MF3QY\SGK<#7#90/ 1B)9$>OZNB*"!LDLIS<IPG4:E.;.F57A2+B:<OXZZ=67
M:D-4&@8%0C_OH Z@)A%$+@+7 :F8O9I$0% Z<Q"G(CN',?AJ:I]NI.>$(J(3
M =9[*A>'\:D7-+8V;@U=>-R8DB]2)^&I]NP7UL#S;SDJ+NDE"AR7?W72"\WF
MX,'G/%I/9W4]5$C\":\64X:ZTGF0$&(E%7$ A5!I)=R>*K/NKL&I2C":1+K5
MH@IEB7@BX%QQV][]43-P>W5HF$>"_&4=3>Y^3/7C)R#V 3@)5C>#\:8R!,Z0
M\N[&%DB\HV]0YL_<O/J1.&-W5LAC_W[ISA=2^_!YB97+,403DMAO+2!*+:]"
M6>RB>-IY3Z.<=[D*80JPSN28MW<+3N/UNJ K5 G&M:L%)?)LA0FHLC:6K!#+
MD_B;%0\+VN!*IFE[M0,ZMX9N8AS*B8Z460B0G SAMR'$V#4U3^6?XKPP7C)%
M^LV?WEI_T .V?/8/]S%;M-R02T"LO$?4&^[6H0?W.P07P=MO5[_:P.(;Y%VU
M:H[.W_WP.^K(K/WEXF0;E6=>&"(7(#P0@@O+$08M4TK#@2)B4R2];Y%5(87;
M%M>SYNHV2YYO-!?J3)%9R4D(+V]5_"3VTC>4C(3>;R5C$Q72UIJO-<\(2LG_
M\;<^P NI T\\/PA7C: BU^S8&:#N%F0 \A,!4 +.I2&%<E;. )?[K\ZZEQF/
MRC+-O%254WH=Z )ZQ4,#. ?. ]>.D=CET!+=U,KZHT-V.D+5T_O+5LO&@H^K
MO<7\[70?Q[RRM32S3MXOYTX_@M^< ;!F:0S+$=Q4[T6%M.RYV9)%+=(<ZJ6U
MK3/LZ\[?BMD#E^62F^&?0"M?P%C3/$7\++8H;[1R54,NN?ZQ4S4BG5%?RVFU
MZZ; [I^!9QFO,\Y=B'X[MP=B[!#=@G)W"+DMB8_[B%*91NOCUN@[WK-,"H]/
M%3Y]$]2](*0/>0GM"H/(4P>7I,6]$J[Y9D^N7@EF/L7)HSHWTL4EYFL@F3J[
M$_=HT?*#VW(-'.--5&__F82TBK!W+;F_"MN5\8,,RH/ZS@^H9&X_,0E:KF,A
ML9;TP]A(D2QO(#?M!"7NN?>.KA4N)56:/E8?M R4OJ**DW].>26DQU5QVD2A
M.\8>['0"J]=CKJV:,'4(MW[_G<7S],2G2]27P&90<>N]91\0:[%,9X)EQU,F
M2-Z._'=R?UA[CFO\)>JWOEED@2X6 H]WC@J-)BKK!26G^X:6I&PUU;+I1!*"
MOLJ7,I1]#@   'AX)F*E$EH#30!YR@%"S-%=+9$=7U! EN6A%(X<UH6]A@_:
M+[\/T+((1+@24NBW56L.-DCL?=.^"Z(4AF!XA$%'4^:NAMT,M?IH^XK5''@_
ME_C-^2[M%&T#QEI#+SA$L)#A)&Z<GI%%G(F%FD]$+\\9P*0F75UB29'N#/ J
M]Q1,H5<F\A!B\/<)[BCKMF<E"UN4:SCF4QJ.8-9%KX984/#A%]%K2X^2__8&
M0+&/Y>;TGI K$*YBDUJJ[LP;"7_M#:3(VNKB=R/&1_R+\2(&9L/^!O<8Y$I;
M@%1^\0#J#2)(SA-J[XI1QO@:^A.LQ?B3;^J> 82VEPT.N! &__DZ@U/9-YI:
MF/I3V_2^C.#G&RHS=+TU(G>"<JV0A^=VA\3$A'H8L&D$,>@ND,J Y\"VN-16
M=*7LLLEOY>O"U9,3FJ55('_>?//[7IW.K_5HB<4=C811;/E] AH+=\"F5L/)
M'U&,JO59F?N]S1%5"(P4H/N//HM?9=H @G -M M#PN;1Z([J#L5<VU'-;KS>
MPTBM^^,=1:(#W!M/];S,_6>%,X84HU_B-S!%1&$2+4&$*!.R8.=[*<3R#B+I
M[O=XXV9)BT=A.(5.T9/:L75.4=Y-HQ4^PE@/ GL?/,^/=R=DS"S1-TPIR]76
MR>0W(,FZ3[/0H*7;.U?9Y+.$X=]W'+YA$13Z0%P2/BO[T)[P!R7S##+LJ+%E
M$[E7YK-7U.PV:]@<YQ1WDV@$V/-RI*D\KS5#H8. T,I.5*N%'9X!].(0#\\
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M((;85<1)X:T(_2A[V[YYP8Z<9Z6;RX[1=_=7FN7D8/QHUE;6@V_J6I8+8,X
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MNDV3 1_^\B=Q9-^ZO;3RP<&-UV!V,?^VJEH_YZF@T9Y:+(?9W6?_V_=+^/]
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MAM4O\6;6?> $B@.+>P,<8*D"XX<AB;<YL%%G^L-YL4^S=[N19X>A!S5^6V;
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M)&)CGK[84 S+D$B9_3B\I(D6AB*3!E#? %0=#JS?&II3]D,[M':!1SNZNA6
MI_O9Q8Z^I'I2> +)*\8?2[F"\3A935@[!L!TWT%2 UPR"99@7@R+OY5NP0U0
M7Z-%G,#/'9WXS1M>:Z\(NR&*;8!@7%^-U%JS,QJ\[MP$D$U9,!;ZX !BQ@!*
M1]*+=!^&"96[EXL\AN/ !%'=4!>XIXQNY?Z'81"-3P8^?;$A0.*%*9!X:&-Q
MJC/FE S3Y>HW: [DR1O9T02Y(R'(91AK:0%XG'S^._0D@ZN.U$J=[V*YK6<
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M>M#\P&0"J6K2B)@]/H^'"[45.3"W.?4"400,XS3\A,)-KJD==N? 5-GE0%%
M_2/@MR:U]RJF^=74%8P](DK;!X*' ]%0&&SO)9B#-TL@P?)@;]KM)*B_$#5
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M0X4#Q=--?%<XL/JR2%BP4R_P^QK@-B1GV$'EIH>16^I92OBI[ZJK4S,]!$^
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MD'.*9,OC]N0VUH7@2.OA*-;UGLZWW$+J>A.#BBW"RK7FIME^KU> :#6KC+R
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MLS#'):_=Q/6_I-NQMZT;W<,T7=*78"I4&^V^D?)?];%1PO[_ %!+ P04
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ML7]RO\$'"+$WE_*JT&>(_K*?=:^^R/Y0/+K4Z.=AMZG%?3]62#DPY\/C_19
MT'2T9E&Y62M!5!]&7+<UT#A-KDL,*3MG]#4S(JJ,;?OXQ<Q#?%TZP)-.G]4B
M(*\2;04ELR4B<%#_3)GWGE#,X[.J-7I%ZT2HC,*@,F+MN"?>0^IMQ["%#US4
MQ20VN>7XUA$UCM4,:)FK'N'@8*_-?Q)MOCAY 69G<A-,;!LWNQ_<H&409E?1
M%SS:73+M(\+)IN@P:QPF<R #6/QX!TGZ@>5&+KT!H7:$#>-I=Z(-]B7EYJZ.
M>SZL_A!I8S;HK^5_<D: 9R%Y55,=,#_B8@%CXVM9X7'),$DZ&7;M0;[RUT!@
M5Q-84>IE K.YAL*8/DL2A@$OPX +P:Y"Y%\)^F%27[/%R=)/B(*UBE6USR*%
M?CRH#4TX43'Q2M+SQX_]NT+=X$LB/E9?I"@%V69XXH>FTK;H4Z>5B +AK:=R
MT1,N+2TRVVN^EUH-57\T>1=*G6D='\:6CW(>,%T]WYA*E)G99W^'7YU%TK,>
M:G6%<K,V))3I62E;*PT7*-/!+N>.EU(B$LK8!!2N/SLBU2+&QM<9 6F)4@(\
M_*4Y.31+NC#7IU9W^.4A#\MOAK/R\4FOCO/>CXOET*<4[Q%2FO1F7SZM&]:B
MJYVK#]X6EEC],AMZ-;U^_S7S+[*&'=$GBTKI FU.]@_]75?-!]=VG=V#)*S<
M I_(!+(HGLO0B.4U:/>"</AO+/ZDO0XCU3C$D94^ ZD<NO]30_ RDF*[*03;
MJMB-_O#R,E59Q^O9(G#)!ZV*W:VQ'#*QNC\;-@71ETBHF%V.-;09D0XS:LXX
MI.OL\^*5<+^F^S->H5'^@I(#.]W8<\#*OP?5IYA_0@&PP_5O-BRD68ILFC+'
MHZ*E KM2,;RS>-.N::#<EBA\+= H6(X?[NK%:ITTJ]IL@%:O:'PQODA4N[^^
M<2@TU<%C1,6N+Z;ERO[SL1PM^W%@''$DIDG>H%I\,9F&S+<*VC=E+)U;;,QJ
MR<TO;,([=X>?5S0PT(NU-.\]6FF.< !<47J(UB*JR+>=F'COB#W7G#1_UMK\
M@)M;;&#$WI5=0-#.W]*VNF^'^I)*+?+S\W?S+FQL>&PF>+&H1Z]"1C&:4XYT
MXJI_82<N(2)^\&0MG@\M'Q2D47K[#&^=3Z_LD^ABUOD,<X +V%@JO]>.X=,_
M-G.R%@4)2#/2JLO^XSQ.#*5+JI.WQGX>GTKI@03D;BG\/]5-^?\ J@NPG(MV
M._33(_8#Z[C26]<_5C0^](S].6TL=Z?CDWKC<1T/F5B.F;@K$-U7[6X>7'85
MZO<<TOIHW6LVH$+Y/5*W77"PLR&V?/&.H,=?+$^Z9,+*D?_V'JZ8?X.(_T]T
M<&P6_\@01LY\0W\-B6VQ<(S+X$DQPYZW*X^O6E:'^#^8GW$/2MT=@FC,+1S7
MD8T@23\Y^H[H$F1%8KQ$$)J&5.=J[]_.=ODB-%]&#4(#EH,U2!%]E9_OOUR/
M>FM(1VVDON[=SH$'_9'#^VG&)'R;O[*/H1!9^AG1DA?9'_QR=,--;.W<"8 J
MOO1'YF#^PXKN_"_1&_)?JAF(8!=Z/DL0])H^WC]@^R/$5RK .M3#^9ON@NJA
MFS VV&ECF=V?U4M 7OU^>@Y#N.1@U)%P([X6F.O?2F32T75BY4J@R[B-T-";
M-E]EC<^S<^FB'HX.@<9L!\VN_F#;N7B544;F_CS.LY/IA'T8'*F[I2]2]P&?
M=$Q$AN_933;W@QAQ8$FA^(5KF5NY@TGDVVGG%6';Q9Z&FF<>*21S'0\YR8-F
M@^)UD!JY^$>12)73;H*8V<@KD6J.Y-Z$G13KR1BMUQ1<P(&^^?T2Z:_X'AO/
M!Q^.UA/_-XVKBQQGG0WN5[Y-,R<]^G"PN*1\/,-B"=A68&W.*_:.J$FMNYD5
M$;+PD9Y/'UOW<.1K3BZ(N_(G\O6P.>U6)L"]4K4<T9N*UB[P"9WG+-VLN1=^
M,PW20<F0#H++Y@J=^8]+4+$#2QZ8K<45.3N,0I50MKX[6,(F/+PW5)UA*7NP
M^$'NUE<+@*7K:+1>DA*6[-FFQ@7"U_"D)^%99J3-\;I(+!7J1I3>+6V_;=%;
M'0O?=6])U_3^N]W^]PB&^'=TUD:J2]4_-??2L1RM3>11:Q,FX;.4QUW6PHY)
MN.DYY!_D/=52FA(P9]:Z>6 E2_QFQ1R.Q]OI60/W_\I^!@L+E/T66/ITM)ZB
M8NK#\N7FH_WKNP:("S5#P1/13A(]8L->[L#C<XT9<)E4N,]'(W:AMA6LI*'D
M4D3*=VP1^$?'1=*K$XZMWZIYZ?7F84O+E2N!E^-&DU8U/U[IN3I05L.CNT6X
M\+XAV9)]J+1$V397[$!I00(;Y%)\DN9J",D$.$VMN/?-JN$ITG3ZNXG'1ZN:
MA]9G7^A'M][1B%7GT$^];_=O$2OP!.,'@OMMNEL:T>R^RVB\G4OH8(:-$>RY
M2W96B<-JJ'=8H:LS81PYE3ULERZQU&VNR7(K22EU)$H#C20UEQAFE8*+K1&F
MA;>,7GRGVM<E>&VQ\GSY#LF^+5T^(ZD4(6P.&&=)OO)L_[N\E2L1S<\-T24]
MG/WA[BV*H8T9O!RR<8/B/R A.1>"3T' FS2*KWJ_Z$QMTGKC<V5>>3AL_&.3
MAJDYVW[30#,V:;.(E>"I<[U.$&CN4(O42F_E.^8TUCZV$"QJ55SI-O\;-'^P
MOU!Z#<:0X:T8+IK272)*>(6R)QQW\Z(GOE'.3"R,X_DG \>G45JH67R[&B?M
M&FF4#(O3ZD$=7'KK62=2Z_X7K;UC89[7U&S12,KN[Z;[WWW80QU25]>VBKN/
MJ;1I\\?8U-]SL2H5L:E^H2HEUY N,UE8<5'VN$'M#]C/$9J@"(/+F(AXR% >
M:F(E]3J_-"4)W2_SO5WL75D=M*JZ?\3PQLP#C7KV2]MISRLY+LX26/$SV1B)
M9F1X*/S@DK18FC6)_H7'_]UJEI*WU.=7Z+YW7U/_.C4MXKUF=8<)5"1^=D:F
M(FI@K028SX5'*8K;%Z@F.RJO*R=:)"8MQ79XTX680(S]3I"_/\_KIBL4LMS!
ML[$ZQ)33Q0JB7, ,H'<!MIU.WJ:< FNHZIV^]^8"#G1YO[&>/32L?-/YI8U&
MT9G# A7U.KR"D*H4HM31^*D4&IEG)'F'$$?@J_%-\>FQE;9)W+TWIM^U_A-(
M]Y?-=I$\<$CNV;627P[^=#WP'8E@!K:0%MM<#XS,..Z4^71;G@J3<9->^/RE
M86EI-,3@N?$ZZC!-C G$FM".@HXX;T.9P9!>_O!\EP'5&TUUSS8RNSE^IL3E
M%Y]FC15E_9J8DP-O$(L]=O/0Y0,9$5RT<W0\?B8_^Q#XC?CZ4@N2M^9EBLCL
MMZ<I_D<6DE,$]P8.E'RHEWD /^2&"$=_>Q6/ZD> "IUM/6GQV(K--I[37>-Z
M=-,Q32\I"6]4=7V2*:SH\,G'R6&LJZA'J K/%F>;<5;*"Q(R3DO36]/WY=O&
M03L+B?6<E+?IG##9\+2>+_,!.3RH&-1[5 =V'&%B%?1Y6F@+C3QZUJFY+# S
M<_O:W*][J<O[C272S\5RR.M?P7<$@/+RG:@8AG3CR&X:MUG)TA6?_JN$)6W+
MT/>'=\.2;QC]Q98Y%@W[:H(Q&H_"^A:,3HPY.IMX>OJ+M_(T<?#KI)L*V9G]
M^=XJN-VZ6\Q<5H9DG .'6'PTB\%U; XQUMGVXE8<,>7<9AO^P,]TF?J*#^EO
ML\ZGZ6S[6YQBB?BK>14(9-$K^65O-E3:9%PPYO/"_VM88\@:9Y!_$/<MBQLA
M!U(+ZQ6-8=-X%HB2"@C[J@G1^!K#AD*O*P^OY_B&]OEFGDPO'XSQ4*T\G!IS
MMJ\G6H?+:!WU%D6R4'LX@CR(=+\G=9(2EKWX>?QU1W+9H9Z[,G)]!_84O[V/
M8&.M :)<(85GCIFG-!_#C*SC&1G&5Q%K^>3C- EZ@:$46#-_W-G!A\1=]WW2
M^1SZ'1/8$DQS6:0))C)L?(E9]*@))K L)_0E:@## U$4RY"A-*I=Y)DG,6#?
MDM.@$3SK=I6Y!^W\8SW$KR76O3.X5AM0::2M92Y@O-M_/V?8>/BE<[4#27'/
MM@OV$TVEP>>"3& $Z4/WHC\S5#$FGZ%<)<%2-F\]%:LV_YY[6S;P:,QY^P,V
MA<\%$_"<.P\V\+Z("?Y):[DG# &,2,!3Z0IGJZ &/-L#;(L7:Q=-G@G(7DEA
M JCW3&"I';?42VEC D\N@) *N)$)15)0:;\]],[T,<V],57KLLG(F-WE:X J
M+R!$YV*,8K=\$**8-=LAY$[F.8 1@H;-I*"(]BF:**ZE@RK#-:4NG1Z>W%\J
M2KK7A(QORO#:V/HN]V#!(VKKQ]C@A\,5O\]F%5Q<S31^N=QX :GABJ)"D75-
MH@]!\/ "$GNF91BS019:-[@]6]<6,%;7><$!?')NB 8G/KIZU?F\9/O14_O,
M;Z:\;STED?[@BZP6%3J1K85>H64S;C/;7#B+%W4I(Z305!:4LY*/_Z+<.B'9
MNWJXLK)!*NKT73=7#2; 7D^VC[])PK7V\OZF5('#$K]Q9\W/6 7<Z!/RIP^Y
M&DMK)/^V&@F0MH*N:U7[,6!<HF.$+Y'Q/>USKV0;/.N;[P<WZ4A*:3W-BY7B
MIC-/4OK]C5YGJ(,8YZ;\1<Y*RJFGFB9G(<?&+6!*%!U#\['(5PE/5@_AQ@B@
M0E8G KR(K*Q[I"7AFU:U&M&/N>X=;RUJ%5@J-?*CX+0];,@DRAS3HAVUSXD6
M22\*UI-R;5>C:>6V'JTJ-E;\>8I?7_EBW0UQ^T>RC0DYO'4,SC/D 8:0VCK2
M<Y8ZD:9TEER*'!/8KV/7" LIH690\Q"[DR,;[1A-K&2SI ^^"K/.0L1PF>D/
MCTR+#W6]_P#C%VWE]'\K?;_##=.!ST6,X>=X"CM[8YIYR5/OC,8_QEJ$2$8>
M;KQ:0*8+VP4:1.? TZ ^JT5L^3=#)5U1BZ#+-N*Z\='X*EPJQALE2 @/^Z3K
MI_NVQ,-]9-O$8#)T]CIO>N:4+&"]+)+:-+)22!-N95C5M> I)Z%**PBSVQ:A
M\8795@\@O0BB%G=#> K\9RV>ZF^QL=$K1Y*?#$?K_V)((:D6F!^YA="--P8@
MS6D?C[X,RI*U*>[DFUC_.168+2FT$M.O?"O33G'!O.?,;0'!&P7)ZW[EIK?3
M4?UFM".-HO.KNN&(W5T$.+*P21,^,S?2NBD>;M8RO9_$J"L$X]J%=7,'RPL&
MWC@.?X<?&>BY*Z(H-C94R_K*E)-5Z3'< P+[*XS1\<5UUAFZ9XOT2;S_I?9I
ML=13,X.+IUXPNE[>6H:3+23\;9E FY1&YJ2-_)\28P(9:J1M1@<G<N?Y:AMF
MYF$4W^"M9NWPU79.P7R+"M(O2G#&NJ'C"]^_W$UZSZ_7!251-D&53EHZ)A%+
M.6X!9:?72!K2KVQGH"N](ZLQ/M4R@3W]D6),BQ/2KY>/=KQ^P% @7.(2UF0P
M1.)0D:]NV=,$O0<S-SV2IK4E<_V3OYKIA0*!W[!*T/*A#NFZ#&8Q@6O.&+JT
M+[2)L5TTG:$F ^HY[V;53#'$6;)P.I?SE-N\XTRWI7#DZ;^PC/%(+];/3, 3
M-WII#K9N_.8;+MS>-):']6LX$ZBM>9D;$* 9MZD8V'OHN[&'+<L7.7$"2(66
M.P7V4?7#33?;=8>Q;U:SI:M^;C$!HR:-1QZ3@GKY>1;53W[%/D8^\K^'7(-6
MQGYZ .^)2M@+:\5(@C>W;4D;KY6_72]>^II 9,N\\BS#_&K1[68S_Y868,X;
M]T.-FS&)JL*N\^6L2(NA$,OOS4J=+*^'O/5MV5G,.'4AOT/\6E%;"=^61D@.
M_!L6/)JV7D%$WD<*Z2,A1M<MV$MKW3SH\O:UT,?!^(ZL(%G_)',+I)S'F-W(
MQNRC$$G&S$B[JS"4&DOTOA^W2D/TD*"%FJK*S]2-\16KJY)"AQZG/& 1 W8V
M4191/Y@ 7P%H1E+K;%:/OM78%^Q;\L%C[28?5@'AOQ!DA'B))]FF@0H=#;!'
M6JC[!&ZMN]7W7+3&1US)[$_^VO"HOY18&]-Y(H^O9O+Z\Y@+I^/PQ( 89"6\
MO7?\]D8 6F3V^:Z4[JESD[[V RH?BYZ\D_:[?S?M2_?;GV)LT:?*$;/(F%N,
M$^BKI,+[F43C$*+!C>F6C9>+[MMO[.Y:1\R<<-O!+;M]:H;U&8J#2',2/F$'
MK/X(/U=GZ6SI8+KO</*=>Q7SF?H9%J>.1B.YH@Y#)*?"!+R0B1&2>Q6DC[B'
M*OX#7Y_K(R/J-/+FY!Z8VZ.#/RM)Z[J]^(GT@$\\(B+6WA"=O=9PY5HXV-V7
M 4TJD1JB7$^VJV68P+LLW-<F@5]QO$I[$CB(4D!E^4^O-6:QG58B'4XJ>0YC
MX?W#WANS#T_F-L<_M9+I!!I[N!%7ICLS<^"CN 0L7[7:HVR6'S2WV9>]=5Y.
M[9533M^23PZT7$%\[OY4HG;35L]^+HTF?(]AC3\+X<\Y2-B>*U]=(H"'P]I6
M7P?,IJ6AN4/T>J3CBHR+'$M>W4]=OJJKE@-G\8OX8A.$.H5I\<3/K^[84 5+
MF<!.\4;T*21XU&;=DPD<6"7G:O)$_/I"DG_DJJ?W\UF%U.OOM]E[]178:T_-
M^/MWZK%'D>RW-LO"X4X_T$JS!'Y7QTJOQKU>"G?-@IR7^XGN^Q0//0OIU,*/
M42.8/^GT50-1&)A9W"ZU5[N# 4_2N^MTY6M6+3)4[/?"\]L+#8N/2ZU=HPW%
M_[0BIFO2$=)$51#2Y-]2VE%B<-HS@:.G9A![Z^\PRY'M41'0%KGCYS<@][OF
M6,D$^NJ$]B"AS%8"D;8D"4X/'<3O-!.C#6ORDA18T\"/9&<(7MFB)%:GM<DF
MK<Y>C09X[(GD6W=%'[\3Y]W8Z,Z)>-_%^H+&0B]"^JD]P-9@DX^\=&JNKR8Q
M 6R*QN=A=>TQ_Q&=\SE,P%E-_TNK7/;)9 4JGL%]FZQ.[&E%\J)9;JUE[L5_
MZZBZF_ IX,C9"[CZKY79]XH9?W.F'\CS!J02ZQXVRZR&WIYNG^6XEF:5Y#$9
MNW4'_(LW/M_\I=B2QQ7)(AE(B+!"\]_3<]'W<L^4( XX@G<XY[8/);KB+>\E
MBG[Y>B8HU^#XK$T1ZXMM> J^LK!]<\S^0@6>C$DLWS$7#U2NF3*<L?3S0*C'
M9Q\.1;+%^Y=M9>S?[[N'+/<DHEI?<Q,)T;MX&/BB2VW'RG6LK/S0[2^P_'=K
M*X'=K8^[.9:A/L60K#"@PL\Z8J_ ,IXS2G'%O]C%E;%XFGQD0."V,J'5-[!S
M,U.,\]#O1]>MB9_2!NC.#&-[_&X[5#\"J*^H1]52]K/P=AY/$Q%;9U]7T>&C
MU2(7%J3DZ_XJ"MG@</^"6X;/IJ4FML-C&"+D<!;K#SG.*^=SW'PM;Y7W@,*R
MI!SX3R=1)Z(7T3@KE"M_\I7]"):TS 3&+1GQ/'\^O C%TNXT6_1/N0V6B?VE
M6/K%\L0GUL"?^ (<Z(N(1>PX&D)&?_:B&Q/H]&(EX_[)E<N]- '[&7@*TA,>
MK8N-IX45GGGKJP'&$NF'$E;TXH\W"2^5-7"*34F01Y)V\?^XJ.]@[G/5PY#.
MSI"_T+UT1U3:&%:? ^LS$60!9R'PKB3740H[>O>%V\D1I--R#585].6R-"K3
M=R?\Q?;X4)*@#>4*V#J'YQWSG98"?8G^OB8?;2DC%">_C#/J"8KGWHO*RJ1]
M_@@Y3HNY - :[P]_*,)!78>L?_5?652\9_SAVTP (WP&'!E&<"-GRJ99P4.D
M)Y^RV?L,$:L1*UY.6F]2IM9&;CLI9W'S/\S6VG?Z<E=3RH1%K\P%6!N2U(Z4
MAM3MXS^BEEV="<1CS(:V$6L?H-^X0$>J[<J9,_WR3:3%1Z%B(F>&G]E:?$ZN
MB#6YD7$MJ.X0B7,BVBKRE!%[5 3$MWCW(#)R=@_M0/J6]9R(X9YX-G0H/LKW
MFR9_.WV<WQ$_Z;E:8Q(5/W 4(F#W)(=AAP);G$2TW=/D@\8K"JPD"09G#]4.
M,98U]Z;2Y]=-!"OX].WKTD0_.9A\5R-$IGZ=\M0T>;3]YOC[D ,%ZNF/S<Z@
MHA&DB_"QDS9C87/N3&#LY-=F=C+?O75A(TZ'4_3U=X8550<B\N5/?3<8F-VD
M">W;AICZ?7G^+"?N*%*H>BH;T:]V2MGOM83'6,#FYZ2^O8TMAT65:%YN!M<[
MZF7,9Q+8CQ;*=;T[S4MRSW#>_W!;:HH)6/R<BQ60MMVEEANWC@R@2.:H,02#
M#\/;1<:U49Q#_)V.UI+6--2..TG+-;0L]6\58^HYYRU0'%'0O2N'".LNY.X>
MTT:+Q/L[WQH3'Z@)IC\*G#PM4=5-4-C83UGTQBW96PWX!T?J#G_^/*ZD)^&0
MR:$R8Y3>+AY=G)0?#5E$718C! 3H-,$!ADT:$4,/K6 "_=P^)21(YHZ1>^;D
MHX/3Q,*=6Z^$->XOD;#POGVTQ%] MZ12,E_G^K9LB%3QR+^>2C](CT?ZH6()
MD%AU)R1F2Y"UVUPD3$?\5&Y:ED@\%[40D'CNP!K/6&4%?\ @5_J/UOM @/;A
M/#Z-L0\DDPAMX[WQI?X[D2)MC;?>W%/W%2ZWY;B5GV'*A5 ^_4Y'\@4=@N<$
M&CT;LU0:CF$P\$Q P$6[%3_> R$$3O#,;"\,I%J0]S=H!BB'GDSM,+TL=D,]
M/^=GM(%/)>TBT0K9TBPV5$-W"JGIK_Y@$5"^>"N]55PD%&EBZVO;#%FDV(]H
MJ!WB Z@ZK3,]2FE*#N2:D3&N=ZW<"N>Z @F/1-T,\TQSX)TVR02!&G@R0:C)
M;B[R0MV$UK?3SJT2DK_-OU'K6W;.<L6-F40N0JCK"D+1<FRV80302H.J)\?
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M0#D(#+-'[B-7>RY"<&;A^^LMGAT_\X0);-US/0A-53&#0/L(;OH% -HSN(]
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M'<*OC*R'?2F,NQ=8W&)3_N6L.V;DBE!7N @%NM/]1PS.0B(^"7%]BE@%K2G
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M\6:<KQ85[@0],9+.)2<R./*)D;H;Q-79K)1@^LW6(_D#36?+_._$57*Z7;&
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MIH.>W4&Z#PO3X%7HWYTL^]>E2C)>/X2ZX9X^<8JM/=UD6?I^16+I#W*W3J6
MOW0]I8(_W+\_PG9BL.:6^3[HQ9T,1@",P7&G <0,QRV\R]M$HEEL:;4&PWSA
M8(UKQ0&GU#K!R7 ^3:@4\.@7WOSM*G]3;5]XB;E4J[5)XOH-?O:7^OVN_[+Z
M.PX%%*%Q?[*ADU@"4ENBZ&]!A9P6CQ\'2W,9VE:6(%0@&I^-8N'JP*^#S&)/
MM7V0&/8-^CX84%3K\)O"4>.'F_P6^S#'>@KLIQP=&I8GABTN+)\\4W]+(-%U
MJQ^5BFZS>\,R=7?6#&@IV0=UIB-MWFJ M)+TTEH.+4,[([2\R2Q #*7T,45-
M27:+/&&Z&%TC\MM]T#T['^AIQ.OLV#\]F85W=VY?8V0QRIHU.V@&S(%<34IK
MBC6UK:-@9.QCR-RUJ_Z\(3(NI="U,IDQ^A9="7!8S,/,"VK.<R$>0$AJ MX"
M9D.,MX[OKQ68RS7F1IRIE!_D7*VC"\([YX\PV9A]#0KOJBBPEFGX\^WEPO$@
M"P<L_Y2QGNHI$:4<^\N]UO*8,Y?/='1J9+%TW=&@(L1)V+3S3D<N&\4FEGZC
M '@[K$M[-1AT44U@FH(.4<>][*^N;4_+?6?2=6UV'Q1KQ!R<_\-'W@<QCPG2
ME?. :!8Y; 9(Y(F6O5_QVSZ*YAD60^7RS8TB3U+[E&+.?YZR.N:?GY>OR;;3
M1>>?)]8=)(JQ!4% 7J)LV_ CCCYUUE -VV]VQ#W2B[^:\7TRZ<1_WIR&*['@
MYA)3!]WVG/%>3S4L!)KRQKN?$57Z@W U\%/<]SV.UU?;]T&/M<O#'?^+P#Z;
M5MA4R"*:).Q><9>N2VX$4E6%VM7HC3,>$G)*@6(\*G%P P?&8$#RD_@EI@)=
MD8)IQ?'71A']CGG)2(Q%<HO,,05RG678"\(G[D9JGY:331[;8W%Z#BU6.S:=
ML#U2(4L$:J=3820L[?0RO":V=:;_\+"DG[ GH>*/]'7#J,,MD)6IAMV;(.%8
M6GGD;99<FU]3IO$"+M2JAM!M:+R(CL6D^4\XPKES-ONV!QO[H^JG-V[_VBAY
M>?:RK& \HPEP(0_@T9Q(OB*$49N.ZQ.3I^],7&IKDA)<Y*LT- 3L,I\[MZ>:
M:]%G )?V.0U&#DK%L'1Y@\5PQ($'C)2"%_<)61>4Y6^JF=R*L;[5RI$<@WN#
MFXJE1@ZA/;%1.I#DQX]>]#S*-7GC7/[J4]-EO4D8\I#1:?T;+W;RP=8'@+&5
MP.0)X.@GPPA_>N=_+R^*FMX-<O$Y<6M7&16T "5?I76[,-XV>3YLYUXB5R=G
MKHNLS_BS4#]V"9X/(=_ /IV8ET&[P066[:\>674<FM,/;IN]764ISU;W]FG/
M@^=+1W4KV;^@SJ,ZH=7'&9E0#S\^8'SEM/O0BR_)Y1QR9\=3DRINA[CJNK)_
M3CRF<1DRU"$\ (@N<L8P%1$/!MH-A,;7F@S?SE8 ?BIN B>V.:7*CD5?Y[K$
MP0X71K?>1#^$@9': +2<KDZF5O']PNA=C>S]R2..-\CT,-/0G(%U?\L[^:;U
MY)593EG(DXGN//*=$KV-R=C.@;]#;>R]&>B1^W!&5K,,BP\YT1\"&Q0>(A5#
MX-(+^>"%.O(ITH+D-6\=\"3%_BV!7\:J7]Q30HM-'"&_R88= @-*L<]\D3XT
M4?K-D0^+GL4)US%61PL4?6K:;<Z:TH^(Y(-[P8 ";SRN]E=4U'$>NY43X0.3
M2]!N"<8J]I<@51GH?T=G8Q3K\1%]O/V''OJZ1NZ.\8@MY(K+AIYC4[R7@>)4
M]-6=^ ,CY EY,#4&25HYG+>KQA]GMPLXS-M^K3(ZD[MRD'A/@=%%+)B6,@/,
M3F\UAG  7 3=*C&63:UK/F'.0TAH,Y/FS/%51PM =?9XF#R7*$2\-@I$GF_K
M5[M3AZ/(C@M:C_J0W(X]),2+N]S.@ 3-ON,5VHK;-.$:2&,I7*1R8#AEM4M&
MCE_#SK-9BB;8DRQBM^[\&'*S=I-I$F$P^L]QC,UL!_$MRZ^F)TB7%GUTJ JY
MWS9:,\:WVF=EM.MKK&]M<TS,SY.MP;OJ<%$6K*_GL*AO@$TKFFP"V=5A^#$[
ME <89ZKSP7_3#[]W9/;B:L8SM8B?>A:PPHRL[0;1&,DH(2+SL!@*/8UU9K7T
M"0F#',=Y]]M<CW3+PK?MA5>D\)@\BH[/7((Z;J4K,IXNLPAOJTTS"VS:V&G.
MWA,4XR4[(*MSPCZ.;7/]S/T,BOKE-?0\]@B@L# SCX%70Z*:=$LLM!A=<=M]
M"&QQRO/@YX5'0A2GS_TBYX,KT+Y^,2R_4KH/N@^=BL(/B*8]KOP^[WA"S"WW
MIWQ]"JS>\QK+<7A/L20#=/,,W>$@[%%['V3\_4X>H/K#$XR?C[[1^3ZN(7WQ
M?4D+R$@&).SPS_&$((0B7<09K$BM'H%<VD*J/M@'P>:_8YE]<'?6P/ZP9J3Z
M1;ZX!N22M2LW?08V3S;?8W7##,+DYP#1)D+/ROF^6PDBO'HI#7(Z=>ZGN9C[
MA*BYXR\Z/Y::3*Z((L#YD:<F@BP<%1T^CR5C"QD5AA)SST_&GSYAHB=ZZ^C'
MN^OW3W0&_PU"%4\LU-&%HY@P;Q:=V%XJ1B_+WZ$U?O#60<=6-^98W&FN'=%<
MO:T."PU5[^ UTZEJ/"X4E@;_MD$:HT29 \NTV\!&QQSD[UD/;4&\MXL!ET '
M!W_KS[.ATR3)BP,/A-CV""R$?6,-G\2TMI>R8;4$N*5-9Q3$(7'0="3+?1_^
MR))5J60_1CQK^);=QE#1Z-:+>LJ!+$D\64R(3O]NR;LC<FOEXOT>BX3,XD3F
M^>[TW=5_O0T4;LAJYC;K1SL*C)$< M\S<H&C)WYET/EC[XY4ST^%=/ [>8G4
MIN:)S9XS_WE;/CR^W9WCSP+SS@Z.KI %81QAJ2OZ40S=@]W^8U,0456;,!]Y
MH"K5=R6L$UPNO E2#) R<ZQ<\3_'^<C8(;9]VGBT1TBG//'3Y^G*HC:-\W]
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M:YASPW<P,L[1R4N<G^&G(R!;_?V@< K-&]U30'?:!U4^H+$FFQ9*DMF&VT1
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M/L/(^Y,7O2-15)Z1B-36ZCV5H_=4H:GVE:>BG3/G!DE=_=S=]$EN6DM>G5X
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MX:5CKB.#_'R%%U_("9CP]"VYC)J,4;6$V'99C(1CC!'-/($PI;ZHH62T8X[
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MTUMXJGUN>JC?&Z3A\$F/#S4\T:=X2LQ5J:'43=$ A;N';K]:6-=B35DV^BI
MI(HP\IN%5P5, \DC[2$^[#D9<S*UX5=.GL\AD'9\Q+9;I8^!A5/\:-K,0;B
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MD>#-JHNKN#:UVF#YXH9"-T]<Q4L!]18VR1VYOHN$)'\HV1('8@[F54$ZB.^
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M\>[4B/,S-(+U27A&NPN\&EJYLU:4S^R!'B62OV5"J>\J0V4;Q[5B$N4<!^I
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M#"$,M.Z#1!'9>!U3*A57M+QY=\HS]W8JX]T=J5/=S <#;[<N2\\*_\C[A.T
MBR#= ,E\1%TG4VH?] S67C?PJ$X'-O4SJH?_N[F$=&H.\=&9.OT0UP"GNG^V
MIBZT$,X')H00I*Z0W5MHEF"S>C*S3KJLO^2K NTNRN-%3KU_TT.QWAU--JK"
M?V60P@2<.,X;SDN7!EK)&X3TCNCUTD6L^)PA7Y-_Q O[5OFY&UGFX)M<#T]&
M7I^[%LEWDU$/]4CRICH!X"!B#KOEQ[$@+C]2^>%FENI4ECL.Z^Y]='[ULLP^
MR-A__A ]/)1R:P'W%.E6XM#J&8[]7?OD;RIUIJEDSN/.E$V HH=*0*IEB.9_
MJ&*!"F!VHLEWLN>3<6(^2#X*C]$04HM1D6N=$OZN^CTF)/=$VM=@&O&$6=?7
M0UOU]]C_/(I7_@&9+J-^I4!;X-.W"(KX)+FKPT%\:IW:(BF.LW//D0!'7>21
M\R3_IM/=W7J#G!.C-^"7F+.0FMO[H$\A;<J.:/,14E">D%?#2YW@C&+'C?/=
M76IRZF]X+QO+1>WD&+QD^^,FO"6Z)D=SG$>--1^E: "8:U7D?5!BTZ72;%53
MBZHY8;G[KPOQJ2VO[*PBG[2'>R]/@Y2P"5!O,*#T+(^K6=Z47$8(B2H&TBA:
M;;NU+SZD&GJL-;:[G91<2GL@]C[]Z#$+U^-Z6>AI%^KNX(DT^U$4IT?=D[O>
MO\S=?)PWS:M*N5)FJS^SUXKM15V&%+VTZ4-7HDE$EEP?5[4PSC//:'/2'Y;;
M\JN^]&-+F,C+7Q3=S1'1?L0:5'KOTNK=>;J0+G6<XKZ&5L2WDVNC"KTQB[=*
M5/!W!/)46JD^V7IU3LUA[I=^*[&OQ2MOO5JEMC)J2+*><*IWE:O36V6'4LF*
MBW?^3@..%A,.2DQR)C1+ I_ZK@*[9)?;9$U1=W:KFAB$G9#_78=OG]/9Y!3D
MNZ79I8Z"&*?>?J*?7_11[,R5&:F9Y;&J&WL<;G+X<_67&G]*OR1OV>GR:ZQ.
MZD<+H5OMM!PYJ6G-Y!\H\6%7P/+^HNT?GCP![9Q?9]:GY%OQNZY'S%W9_90*
M<%I[US^(&W+*;G+E'WY;NBK1@8G]DSU[ZU9C#-[RT]-U7]\**7G_]GB[V==D
M(9"Y021.M\ES'W38E()MWY!Q F!4+\!1$>/ZR6?@PXH_3/YFYS&>.#F/KQ[7
M_3?-N+MW#1<CH*8>V'Y+!VHGHQK%/7D61U%>L$XK!:Q/_'+L*Y(+'3)-7"J,
M7 QZ;G+,HJM5;[&YD9&.]L:R,\=SCV58DYN&[;S&'6QN#6*Y:)9I%X+3DJ4E
M.;VQG&(792/8U@^6[X5L7J!&(#6*D5 W.#OF.-"V8I+UH]H^.-WC387?THW4
M$C"(-^E;^^'N]<M0B65HK1\IA3(M6(X\ P@6+3<+90O8W_4^T=23QK%N5YS+
MD6*VGK(MU@]"O1R"Y^3RL/ M&T$DA+0K0SA1(U!>R1:!^7I;K7[UTP)30B^T
MJWTWN>4XDH:-Y7Q^+>GCC%2P/MO*%\^2%.-7AA>U7HD3_"G=B>H?/ER4C>22
MJ_ X].2_=R39^R"?@6GV1>VUW04<V O'1P?O@[B_%:!+M&K&L),5ODVOGSUL
MI;!Q(%MX<R_E@PN5L*<8;Z$>^Z!CJ*]YW/ NE$I=4^[,U^1I266N.@O]K_$=
M+I)Q1PVL%5XO@)[\S3Z+-*#84GY%L,C:#6_JB0_+KZ;C:M1#<V$Y CU5P4?6
M?#O]-9(C([1_LP3804E>)6PR\S1J.E>)K$@:6QAX2LV220D@,'QU;;)OO+:@
MUM.'3NCZ$Q"3Y]/7O=>N_=LM_[@M%;J0MP^JU7Z.\TZ 0BP7]47-A[+Q$\'C
M5**%P*+QBVOFX>O?,2J/NV[!'0;_SRV(___Z?_""9T*D:[BAWE#@C&@$2MK>
M>:LMCX\Z[V6T8?RS\^8B,:3J7$V='*UEXK=:)^QY%KH5%VV@3&E^=WOJ]Y/'
M$^\N7-QRO+T;$+6R4</9>)0>R(C>!WDE8)[F*E#V0>VJ801L/!V]"!.'-:WL
MW?E\_DRFDWF+<['"TKWK8!G;?' 8+1#5"27?27CYDI'6"A%.M\W;??!I%LH;
M=J@N;GZ]Z_PV=E2'?ITUNYXR1V^@1N<$R1TD;!M&#*'M0.[XGG:JLN3R50N_
MDTF_;97.A!2J<.O=_^*]K4S5!X@0$C]-!]#M]#G97*Q?4C,FQ)_^Y=ENH&OP
M][XF\'K#(&>W$S_KN26(KO;IXB0]N7?TB[$=4'["N*0E>3SV3=<Y<T)BWZ^[
M=QLU[EN=]*__1MRYK'+:&TVVFI_6H 928F/W083\9O[?T]K/:C*#R[\EU%M(
MT!M[S>HT"M2C&GM]/H3^".XX.-,)>#*^2DUEO-'J>FJ_V1G@+M3.UYWF=%?C
MZ?8Y1<:64QT+)5]7QQ.IEB,**>SFG/$J<Q?6"UL?%?\Y%:&,R*-. 31*FM7H
M!O0!-HHZ=XI\-D>C1>_&HMKLNT*7A[H.)B.MZ=URH$89 HR]CA$#]2TWI69,
MT&$+,"G 68T+:49>U)RX8+UZLD//6S;^IER:JF#G6GSWUZDY+OW+U'W0E V>
MFBO"R&0*+[^Z8<I[''"Y[BQW^4VA]^-0J:>S.9F84F=OPD9D$M4/4,%U7$W8
M\3R5>6'[1L14795+'G!\8#S"8(;Q#N?IQ\WL@_ I4F+CLSS'BAP<I"^,'%FD
M$IZ>U.P!@=@USO\#5S8A+//PAL^8+JXG0!*;N,D0? #B+'+ 4Z3\DD-9R2-_
MJYX@;F0%5U#BD16-%\HO6=U78)\'04U JV(C:GR16NA0/ZG*SV>2J-G FVQY
MR+I)WE_;/W$P5=)B55T\UTDSV>=73*6\A&]<;@$= ['7@)#%-!GFG B\V@GW
M'@'NR)6J)XMVJ$H[KO_1S6F[E"[&>=Z/+3U#[O%#=;9N%8U$W(P<=>4+XR5*
M WF)S!C/+/Z.,+T;75$3MER0OEY., ^N2WW?(C+S]R'P16P>SL?"UH!%&EMO
M&+ !><:8M;U7C6<SCN77_BC[9D\AB6=+6UQI@P:("7/2A6'X8*8ZHYREX'(.
MD40L+*UM51[8B-],G>],!->*#7)ZEJ FX;7:[7PJP "AJX7/8*+E+YQ'E:.G
MO3>MA$L7WB=ZKC%&[/Y2>]C]UU)Y08P8M"\?E-I,7J_T"RU@T7MMHB5G'W-X
MQ-J2W)ULJ_(Q;<NG]W@O_HR9^*4CS6^2-6.T#@Y39#LX2U$'I+P%H8K58"Q9
MO9N'&KY0N[KD\'+,=7/B:5IIRZS!![0.:$^9.LAH5&4Q^20+8S(\&JFKF(Q2
M7'U?[O:VW;90:>VF]@O9LVO?N&PG#G^\OD0T@"F2GM)LZ:*541WSXLPCGHH$
MYE+XE5]MFU$AQ>V(L]UGW[5(:7\3"HQ<@4E!U[:.TDU9;;<A[<>T?H][X\!V
M\P9_GQ+?_'IJ^IMZ0>6F:^ ^Z)!B.2K+6T<_(^YQ&$GY9FWRSO7F2 N';,^8
MF[8YUQK.K1]-!;-,SYK!4L4/27!JTVCSJ1IJ6K'GM$VLFL_;$85/YM86<:>T
M)>VMUB9]/KYIZ9*?&*_9S=P'<;@-WQ\,PF"FW9IR'XK8O\OSD8KX]:C J00:
M)[SG?EDXR/+:A/&([S;/\O!X[[!H;NB/B[;$.RI?8?F@O+:#F/K[\".*I$S*
M #46:%UL-,G [VW7=,4\3+V?^N)[R<WX,#WKRK9G^Z 1^SU.YE$L!<\45ERK
M*OT];B-SO89X&ETI>W3ROJ_)ZKNN'63E4M[>FO)/R!0G=;:.D<$\[)%[&/9T
M3F=TXTVJ=R/C"L_-A*  N=2[AS);'.,TI@Z#0O9!9/,!B!?\&-*18D1]3/FK
M40O-MZ(Q;ROWV">5RS==@Z[[3%U)^FKR&/47295B804HDB&=N9>&RU6Q-7S'
M6BL(=4VS2V:M+^_7O@@8<(%C\@1Q7GEKZ)FHMGT0Y$_>(41""_61N6]61W(Y
MMQ%"F%=4\AA(MYR:B X-"<&.HF>P5K5C^R!G^/.)\5M%8SGC4;]:]=R5Y1]V
M][;L<!P<.;Z;=W">S4U((DZF2>WM<M[A9GX[H*J+?_HYW2@LX*=IH>>P9K)<
MM$6?C&VG<)TF/F>2KWIQHVW^X+C9?1 ;W7>H60PU# 6KT"%A'YK.V:TT.%=[
M),GM!O3(>KJ:GU1[X9K4<E?FV#%]028WA!!FR4/5&-(2.YET5JO\.I-*&//_
MUJ=Q65L&L!5INL7D<?26,"5?8]CX?+>/>2/1W21=O%:>R+AMQ7G@SA+FI !!
M\HP#!1>_GC5C//QV2WZSQ=/MT97"&Z5R@57'\UV/A<JZ3K0Q>1C54.\!3&T5
M2\+"6^;!$#:5)*K+A^_\^L.E>([T]7L"(;NI^OFEXO+W6O]QRJ<P(Z\-%FLO
MKY!Q'3=>W% _,]ATSB<1TN9^D4K%#F+8$?#K9-/(/Q"PY_&N(QE%MG@W;RDY
MKLK.IS:0""$V\A$63![^BV(:A])$G@?\U/#==+5%59A]K!'%*>=#8;-/(E8O
M(+;N1(9L0=7]"=ED(N_<0;3W$4:%GBGM!,#9MK<3\\='S:Y^+.A"Y2M]*_-*
MH:L#Z9.]@2ESS=Z,^B:Y=RPJ2+X%G1IPJ(JYZ%>335*:?T@H0F#;Y),VJKS<
MA\\O.W+218A,,QQ^@"8FOP\:=L\'8_=!'@/3@6UY5>"V **?B/B#K7A#MW=V
M"P-A_KVV)ID70:"OMG^#BDM;H H(.+6&Q>//_JX$^EKRV.C:HI&_OE)3O$;2
M&QIB%0_S9EAE]"[$VK;X%EPZ5)\'G(XNI>R0S&GJ"![K7WB;S6E3%=]K!>'O
MJ&(/>CAI*<4C^J'8T; PQ ?28B17*M=)JY0NB>C;5N= [!$@TF7(:687KBXZ
M@R2*7<EEI[C'GM4[3+$PM0G[<NR7?[*;"=M7AQ8WM^Y92=Z(1SR\Q)_P@^,N
MHU'LZ D?EWW0E9$5^,S-<7 LE'P;%H%2''*A&115]!7A2U0_G]EZU11F\J#K
MYN!'S'>3P\;_5L#J!;;%;X_T ?W;/AR$*K)YQ9(5;(]AT]"%^3BDZ =[0\T)
MZV][/J-E6W9.APW^ZITUD13ONJ-2'&G\).?.F):RCZ1EXZB:@JT*Z7[HS_1O
MATZ6/G!9 YV*@.J@%Q)PPEI0?J0"90)/^YR)B=YP;ABA;\L;20^^J$80E^SN
MA\C)95J&<:[9T#P1&<2-]OGGT&,H60\=FQBZ"^&TF8./6O^,NJF&D3_L]5>4
MN5Z%Z0U9[-^XA7B=\,XB+-*+HA3]]N/G5VU</;_OUGQ-Q-TYK,$DET.FXZ&
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M-@@KN?SU$Q#,8_:U(>9^X,E/9[?O& =_6^9RG%RY+/R#>G!":#Q:X!R.%_T
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M\T("&M\QBO,W:/QH8\CD?]EP79=#;GFL\:8W8&<V] [-__$J!=AM.+O8C12
M@KT.HKC.ISKVA#NZ>?W^NJ)DY:0W,V7-J)L_S#7]E!!6W'NOI6@_8CX"KMUX
MIR&"RR71SRM? +J@C-,X<+?L,J-C[L/QGT\"GBA(TTVKZ@N)_J0_0TH-$VN1
M:^*YE6!B'7RKW>H$@I,>)GRJ(9/L\Q] (G,Q93>)FC25*Z#NBM9ITV G9I.
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M>=&,GB]G=QS'I[3).UML"07)%OTT5^ZG.BU3M(I&8GKV"O'/MUH$&G#11<&
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M>?FHB:U.5UAD3&^:[8 ZI!G-A;(M:@-&:+"@9=,[!*._=;F+)L?3.W5O%5X
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MS *K.,O?N-E:!;>7@RPK,X^22\KY]^QMBG;M\4$!05@/'!S8EIMDEED;2GB
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M4S#G$K\<W@*7W]\^!2DGSPJ4W7,V/PD!7=A[X=B&Z/9F#0D+>@L%\ < Q@&
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M+YJJ -S8)")C(;Q&EI5T(UIP0P74]]J46A6B<5>4OO:C(=,2Y'_GV)TZ@00
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M8X!9H9I[ BSL*(-C>,FR ZBZH&]UI/C>/.G\XD4_$8/$:M5*L9#&-5N?/W;
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MD)0.U>?#DT&J;$81O[_)F"L6BTFM!)6VL)WO?7=AV;,,=MBK*-[?Q66]ANY
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MD^1O9L?=X'CBMWR"%8Y8NA5IDS6@!-WX=K:+W?)3TM+9P^K*46(+ZCK/@_3
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MM"3\T(B.P?3K9M!1'K[>;,X5/:&?Y-]^)0=QE&SM2=._<SC[OF>-CZF12.$
M<?1RG[00V2_EV/1L[&C]43P!I)YPS6'0J).;1VY>3U056GU817"A[L'/PQ<@
M$NU>.6H?5=$>D66,5//E[U&S9'".*YMAI*>>V( II$)H+Y?&L:9C($(71%%>
MU$[FZ&T0F=_/29JP(R.*) 0!C[@L13=3 92QA3#*'!G8A1*%^N(=N]]R8?L@
M0G0+P3YV7'N$Q8:#Q@V-N(W+IUKBRC_^')1IWW(DH>F"LEW[DATJTKJDR%3?
M1#5C"*?+?*?W^0L+?&E._\#+[,KS>D>L)3U7$?\+Y7>AG6KZ60CIQMC^*6/0
M 0!+1>RIQEY<IZ@PJNK',.OXRIFJ1NX"*LKBC?.Z 3@?/?BLRN[V(,<(3$>7
M)RZS?7-HCP#$_".@-F9I]]5Z;#/%IQNK27\A>UIJ?!G&$C?%!ZEQOO>G38_4
M"18P)B))!<'Y_ZL%^*H1)M<H'IFT/[#1%%T.[<8'AC-T?M@F5LG<F!R"4GF/
M9FI*O,^FX]AYAVYP'F5B(8V^R1U\_LMB5%=2ENRTL2HTFP!2U4I0Y7VA3#6Y
M^02B<:N3M[O 1V\X;S\?;_R<,"J"7T[R(U:&JIV"?@GJ\8^D4-;8531#1\1E
M2N=:,"<U+JUL!VRO,D\('  XQ](Z]*$#[N3EPN@R^MW$X;,3Z,847YW$"]DC
M$OJ+$T^W<VM.H7)/-V)G#?X_/VKS_\IQ'AIK<O3 5,F.Z7!1J$"?L=B$:D,"
MJ;%,JZG,5RP+GVEO4_M"\B4O'WMF_A.C4#FR[J9]&,V+V8N0=!GK=$$G-EQ4
MLTY=G+=IQ2VV)X%;N\_=Y9)6?V=NQ0"\CS6V9SW\[J]_^\ ->YRKBM4P\7I[
M9M"5+U^F; 33\M<&AS^S>_$AQ$E(JG))PBZ*?PW!D9A5#/'_R&NU]T%89TPW
MAVL!U_C]X??=G>H)<46V519,IE%\00V.G1=MNR-J/Z"3E5?=;EW-<U02;<MP
MNZ0/ZEZ32[8-ZOH<,3N$.-P<\]Y=CI$+$_ F$2FQ5 \BIW8U[_NUG/W^_ #)
M]W\$)>XM>CTR/QUX4\:00_1B%/CCBQL</VT3Z/;D20J-4=RN2<@07NA#<<*Y
MH>%30^<A=YPL2_LEM<I:-3H":W$*(R\R3%=07_:##L^T_RS9$,,'!1S>>IO,
MG,C+H&0AO$N6W /^HQ\M,?4NIME;<<6C5E_THG[U1*OB48D1/6T)_4W5 A9A
M0#'G/%Y?EDONX:DXK*.<GL65; [1A*A%E&AJ3\P'ZBWSZ5T$(.!Z^$79C1O6
M!I<T+IN>_0Z'I@FQ;]]\L2KWA$:\"H!ILY3O#3(37< <V8^,:]?^\-LELXRP
M5M38(BQ<:W6O[JER]DJ!820X^]5%>]3$E[\47:JJ,8 Y^HZ#!/N<'*X7F+#\
MH5]T^1IL_LE%2MT+CO%CT3:']\HK=(.XUEER/XDNN.#R?:/^HF6')'0X+$BJ
MK_(-,D!0U\LZ./)(PQ5-YDHVU&VUL'JZ59'MKP*EG)$/5V5^ ]7W83=%2!+6
MSWLO^ ?^#3 0JN<U2I/+O_*;= ZKI?&97PJE86Q[Y/+M9XBN^\^M:ZTO(G!5
M#=X$1 M%=%>J9A"'(\+.S+XA-WR&#JU#/MZ^P?'C;#X.E8X@W4)E+)\BFR-A
M8N">L7BX1/Y8XK<U-YMA3=E6LV^ED^T=+F=>G']__@WOHFXCHLO+Z&(Y-9?B
M2>JKROKH[M]TCLCM+"ZA%/FZFUOINU,".U&.AY9*ZV!-B,]4S__H.H/N024N
M"Y!0=,V09&W@AM3926N:+^4-.8IYY9S(Z[H-E::(KYM#_0^?SQ134V@.\&EL
MP\>DA[@QEEI@VT4DY?E4<KLN^\_&N3&M%4]^BC)ZT"=Z?L#0%':J/GYV5S45
ML#=)D6!D5QP O"!/9:_D$:3,^UR*X_[=F;K+,1)ETGU5[#1(]8(%>ZRE;R#O
M'$B6.=(A,HOPVZ*>X\A@JE.3S*:4VS7Q6;+WT1CA[$M5%X(JNC\]86GGWCK)
M1S#IO>HI T5 =3H"5WX  /PQUH2/:JR+7TW/798E)4S\=AAW[7?W"UHXM=A?
M$/;/:M!D?2659L!ZI\L4DRDBHPQ\+QK(1;<8K^;MC;#%9_C/WGR"R[G)7YKI
MO7ADT?,"^I6!A6BF0\=UTKM\F@FB2P5F4^GD!+4C$L:ZTFCQC^1KS(\+GU9[
M9:744)]_*7&Q4N+NW=6L_:ZK /@9)BM./BB:(W6RYYTL-1J'3A'GZ+,1%_I<
M'Z/S[QSG7ZE.I\*,8@VI@9\.EQ[SF0AN);3^+,%5+TAT,XT8M42R3CZ\\=GB
M_::\C^^,OYY-N__DQRGD2UG]>S555XHUG_SUI?QN&0/!]$A-?>"3HX50=,\^
M(D4K)2K QFK)QV3NM,8*K$+C00][A-:13X7K>8B4>E=>B&5[TLV)+9SU)]<1
M7Z#@N$&BN8,DGRD[Z/$7^T=?-":O3*IHK7-#-Y6#SEA'1T-S3PC>+[2_'0$
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MM?%':VL^!"]?N<COLG09[Z:C[_&:R^!"8[J0MU$<T-.]X2K@/S:O"?3LEZ2
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MX%VPUIFXP!5T+-RG@AE\?637]5.VAM^&,=^C%WGJ2AWQ1V=#KWR6_:ZX@DK
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MT*UP+H6_HJE;S"\Z6;8>8>2;SD3SQ5C;9A92@R+Q':P<]'**Z2\G!!I.4,2
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M@1)__N"GVN8NCI. !L*H%CK&S2^QZ&B2U/'\E(C"YM8T+#N':J,>;55(W/Z
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M/_B#/_B#/_B#/_B#/_A_!MC1GA/1: M2C6G/O=5[);=@HC3Q[YKQVLFT ?5
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M80".>UWW8@" K4=;*'#3_L!^80;R#!;[:,JCJ>I0W-UR3REO53B@(-_NM4.
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MD7*9Z_]?!_X_)?ZYL+!.^Y\S&FE R+?(\X#_PK_ A\]Z69]#3(2DO@#DEAB
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MV?%'\,&922K:<8(N!JI\;-8,+@9N5%9T.LRBPBMPKGIG!\HHB0V):>8%@@R
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M@YSWWY+ON%*_X6M]T FM,B=M<2$;;32UO%2/=$F8>FH*UU9=]JKQM*J6^XJ
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M9_G3I(WZ6]JKS/&#L_:HPD:'4D+O89N"UT %E6=+B9J=P 6R:'<M*QGSVT=
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M54W?F:7B1Q\P+V/>T[61C8;U8E0YYR/*CB5"84&:Z?Q*ZT4A82"MMI/(3-O
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M+C(  ]>N:1Y6&?_1<]["!D-+H($(EO'<7N4BU1]FKZI;2=(U\8,L#2>!^P\
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M/17":VQP\XC('1<85AW_E%E>D4"TMNC*D@KUY(K-^7X1)KD&5:<>V<(@.%6
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M16A'AF;P WI2!?((22LWZK#1-1-+@YJ[3W<2Q$4\8*]F[-?*@G(XS+I!%7&
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M4= 1E31",[37$*BW];V="[("R=%^$SL<MV!IM_#__<3%,H/Q%-@EF;W5TN!
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M0%_1^F+F6>/;^>F.@M-:^-4DBL$->46$Y,*554VH?:6&#<?CR(<Z,U))VVA
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ME.=:X$<Q!H/YC3"5PX8.M!1QDFJ0D]"7=$3(HRA+4NO]QF/M7[<<QUZBEI*
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MJ]B^KA+&SRQ5O"9:3R9 "<XX0&:B@@0N S!36R6(.#WK-KG@M2_B *?Q#/2
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M&@=K.D2$Q"WT:_R$?#.M2\*7 .YT388F\/ L^@1@V3Y!@R2];]C=L=@^A;=
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MW/]&JK <&(L MY9.F07>Z'O5X)0O*2V2$UCL\+QX+%CL3Y+()R/U=.PE[\:
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M:>Z!0J3I71$IU:)5%L9Y3:CD]/91WO[[<D L_0R/3SXH$;_C8P(GH;BO)/]
MN!%[I(>^82.8H.>0L6V<9(P3"7L?[:;Y76WD[>[JXJU%S'YS20O*#A7R,U.G
M%7+X.8<GH? B2I$7 8V$SN0V@2NO7H>SNYB_/P^:UN<M0-/F?KH#II]6\22C
M!+Y)1=0+0%EK8$3MU'YNG:C#01*_\_Z52:-3TX@T76I7AB7+ *5S\BJPWU#S
M-BNNGA0I@)-X;BY^E: 31GQZAOCR)=_?G<[CPME@:RM!LAB#79 $;_?9F#[W
MR9RDO@#UI5A4-53WTG15'*!O8ZR4OJ-:[C%DIAVZ7,_@,/2 4>[8'=K&%/3
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M4N83TA@;<.IZ 8JD Y5FG#\#D]MDW5(G8,&;-G&!\<EE$N6*#U7&0J#V8"%
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MY$P9)AJ7!OZUQE$50M!0"4JGDMZ@RY>7SP3YUS-!NXVKW_Y5[3O0E<W(T,A
MXTMIM+Y)"U%Z+-O^R,AU4UN/6 Z?;"QD6_W$G,I+GV]8_OWR.2S@DX"#4,\
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M 80!/*OX0RR ]=_0<.G1\@H!Y6"[/C7(S:.K8R-*Y1E LKCFOA;#S9@NM6M
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MO"?;0D</RJ$XW"8\<M"?7I.W$5NTK^M[;:!L/ _$6388=GHV^5"!;)B'>ZL
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M[$E'YRI"QH[4"R ?0)55 H0+G7NV_;_^6L6.N>E!FW!A'M=\.ZYET-\IS@G
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MRA%A<GO..H2D93"XU;4Z=_>"J+^I5)[#IE$@=MB?A8J@)1%@K378@Y,R:83
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MGPEX/]?LM61^:>]&^X[M8#-<P!>'9)Y7E:6KI?@_5?>\2^@?VKD8<PS;BOF
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M#V7U#64>E4H9D?(WIDAZGFHQ[4M84JUHQQ]S_/JA:&G("G6R@(M6WD\3G%-
MC[L2*FXD9+3S9R7%)7&(V!346U'8:J7VJ7FLK19Q:1,IBYO#-[[Y;'-Y3EVK
MU:XJ5W+$=63'8,1&UVQO?'LS"L:WSN*G&NQ3>@?IJ)8#BF9_?S[ZOOU;I[LN
MO.5-3,%ZWRFYUJ=4X ?-Z]3\EL#$)9-D 4NTQ.C>5;1613PUWLIZ?8=/<6O*
M>E+'[;"=5_PC@K%.GF00C#N:?/<$_(NKT)<=SU4VP+7=%$66"/AC<SRAJCBA
MH$:',4,#W7+"_<)^8"GXL0%/R*.M; "?T+K#DZ2>Q'8=@0>?$!V).J!KUPAW
M0_YJDM5'*ZA<!,C[>H%Q?U&AOG6O1>FRC8.;Z="]K-?%HF/M7[$PJB.IQHCZ
M+7-\-> UA?S*5,M+\/W[A#3Y:'+0WA#%K5KG8O(>D!M^D#3]KE-FI;[$HV[C
M]AF'<=EVYHZ^!_%*.]P]0;TM*Z^/94JO%"^WZ7%:[R]E0N\KIXL2V( ]KVRC
MZKUL-B!(@[^3@4ZOE9]%>+8.OAXHI;F>4W8L+E?8KR*25FUZ"*"Q^H'1%ZQ+
MM4IQWO0K>=*@/MPT)%1Z_%*HFE^B5*99AF'(O<< T;<G$ @;*&':-&D\![PW
MN#T H0)A*<BP[D5AR^A6F_,07Y ,BPW8*M;1[7]]2TB[;+" \.LMZK#4>9#G
M"J+')B.">3]-^4E$B,*+<KU[\'O95SN[#-9#SAN://B_PXC_\FUM<!.J-@$=
M-<V?I$76>#=UI_N.^V?S]:PVI18VH FEU?=.&<LAY7$AB@G9M$'COEXXT076
M-*!;/F%1H57Z@A0/9I2@L%S%ZD'[2\9E,HJ#9C\KBW'EH90N H^GY>1%O_DG
M-XT_D>[L*,PM7K 6AKON8%#;&\@OC0S_SZ0$FP?([5,S=4?9  '<+S: :_CU
M*'&I869<OG7F@#<:HE5--TB0#ZWIWPA7W-[_" DB,YSQAU2$39?1#9AQY\89
MT=)A5F<U_6B5X")1N];]AA@Q$4K[BUD'E]^-CZ"E4*(X_@6A+K': N(>Z@3U
MB$^+?&'93C+3\+ ]@:6^=+YZ"?OA6K$B7EO_C%4^N1VUV<J*6.AL5P/S)#SZ
MNH&2..97 1;8S/&PT 966/L+N.Q<*"]Q:R4=?S:Q$.SO_S3,>%QW7S?;;D\Q
M@K%!!;$!1\Z-P%7+]TU;])1&U_B/*43>S/<+'KE'L%_O&)_J)<+>P-6I5;.;
M$>.H<8;T'+>&+:^6+@^T_%40BZ$?!FTY0;<2M0]MPT[IV>!1JWTL^[D;W+V5
M+]U62RUS!]Z, )<&!TP<C+P=C^S6-/Y3'T"Y6>?:49/]X)':B99_VCB$*?1L
M_?%/5NCV_*SYJF0C;/^,#4;[ONVG64^S0'477H7%,ANT]Y9#%T&66L!3]7-8
M&*%(*\3\IMFUX [4&G[=C!L_/+S>3C9/K=?HV\;D..-S0@.%@H6+.]W4'1*\
MKW4AT^Y@JZ6EK4GEL7.OX(5&!A5U5L]N?5 "]U>C&T;GQS"ARDY)Z9;FC93$
M_,TIU'S[U&SE0*F,L+W"E:E7K'7,+!Q'P$9Q:'JDQ7(;]1JWU42]P#4[-@E1
MW47QL/K'%;_]DGD^XG+-J#$!$L@_&E2)U%DUKM6G*SJ.6B[T;<[_1&9P8Z9U
M=D[NA1&K:S$M,\<94(+UIG=.+84S2<&*F+I' :D>7$,G:&C'-JNK9)OL*VS
M&S$W6 2'D@YHU!N(XI%"=]U84TDT2,M^N^[HK?6 /U:.HS]MFIE_Q4^B[6+"
M_@RO4)V:#6L&-DSFNA:==4>S?JK<!WW ZI+PZ]QS,J 7 1&M!1,Q.7<6NM$O
M#X$^*^Q6P<(KKU%"[70'$:-UH!IO:OHII7?D\YO7Q8=&'3+9 $DJR,#0QI^
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M[:$Z[?.F_>G*_Z=!&A/3B%IP-G6B634W;+=&>?>DF%%YW,#&B.'6/]7Y8:Y
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M[.>(<J_:T,K=.ZOVJDK#9Y3TP8?>,SV6:#9T#9Z(- NQ@;9><RCK,&8>S7H
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M E^V^TP@E^X>9S#U9@IP&6,?</JLBU63B'/W'/"2:U@^^0V&SI6JD,I/3]B
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M38]#X(7!N9-\,2*U:Z4\!IYSS__ +RU@P24M/PK-T@/R%@,"]Y?"1*D@X/7
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MT'.AZ:0R(</_!2Y;.]L^*O=6UIX7XCFMZNLV:2D@JVS?J+EH,]7KJ/:STTM
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MI@U"$ 91 8+%T6HW#]BGLR/?6FY=EN]*ZM06;L32)M_, 99&+5@1O"DA7E3
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M<P,]SPN50HN4^N?/0-:U-0C!FI>++*;[>"8MHM Q9_B[$M_?D\0DAM]D9T=
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MNSF29C%=M>\-LC3,[4X'[E(!50<DGO(V"#/\O&H+XJ4%;U7UXH2-3. T,25
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M&O.<F*Y7XM9#AZ5SS81=*&3FNH&&=9X9[T& P.B\>2Z8)2YK=R%O<W<ATC?
MS3VGW%BW,!V_3C'8D7#*ZKH?9>#Q\<43N<TOB\'@.T[(;B0]HOFVMC*)E9!M
MMV R)=6\P9X!?N\NJ1Y0BJH*2_&8NBW_:_EJ^/?\F'=G+HKS'C7:!S#F.AZ?
M+2S0JFQSN7#WT_>ZB]]+\&>B 7];_W9,IN[A4[%FF_5HE@PN:!D%7%%V<;@"
MF@.I7.>F:]%+\WJM"IZ]_2R0'H<D<9O@9P@%Q%NP9SC3,$R:1=^V7N7 YQ&W
M(EE7L1??WUI?>17Q@/7*0_YG)E^7@\&&3I^[Q6AK4LGU.^\=U #/DTDUY'H$
M^FM=QDM-+_L%DY!D\ML?GP482XM9G-RW?IU58V$]WBISWK9:#?T: #[7Q;1N
MS-M&XL"I?,)XA%( N%-%Y_OSU^= P]N_ENZ?$'%VRTZ<D$8?ZX&>9C[<H# [
M$XV@*?BG!.[/3[5/CIKIXVQ*"W7MW7S<%E([F;.[91C>/03.Z"[=TNR3IM^H
MDUGHGV+"KXXAGGA,MBX40*/$<?$=\EQ.V)ENWI\N'@S/ FX,]UYJR5<IJ-'5
MG;)D2GP!D9F'SV54Q8>1Q-UP,F;8EPH$K@6[=W)R#6IWNSI6?CY;>!D=7WNM
MU/5T\<G^,Z!2'[-^5!EH*R03/C+/)-=@C[?'XC]EUU\M=MXQ:I05OH?X4'QE
M5DBJAUVME3ZM%LQ.&*8P!^#J,:AV-IV6^7+DB]=N*M,]+@'AJ>/5XQQ?I_%1
M])1?/!+%/,CCP1<,:4E3=@>2!"D?)_'2+X+#*2H6I$OD3YJJ[.^T1D?\V.!5
MQO:^>;V2FE7)<@\PC[MWI:T89]_S'KWZ6X7 >_@ %TAACJ)5V8@.%A0=I0_.
M%W&O*M3Y3#7JE&Q0 )P[/(TC(?$ZN\$%(/]CL[/702PH])>,4Q0.DD4%UFQ+
M8,%\TW49FE7;H,)F%_BXV%..&?C:J3XM7XWAJ]K4%;"9="%8 %K5WPP_.0XS
M\6NN($O=RKC[\5TXZYWK0PI,JY^;:/5>J =E",+9) L#$9)PJHLTMG**"FBM
M,YZ,&TVA07#<=QDHZ\$MS0\T"'X/;JPG/^R\G FL^X+LVK*C,$.(U^&#( YE
M8Q :%&HJ>WY$L:UD#>71N*-CZY V<WCGU[<6#"#5W>Z%30CQ'*+Y%LGM"^QI
M)>$.;KJUZDBN-.AYG8_@2U.DO7+N]"-]MC96$_;V^Q>G0W\D7)T!@&\Z(>-I
M/ )4W0 ID_OXV<F",8F]$C/[=+:XR*ZA?_)"4>OF;BZSSF4']OQ\/3\%B4>,
MA",,A5F : WCC;B.\VA#,+3+O]AWOM^2_#G2U>Z=P>Q2Y_E''4O/S'I8H5*L
M=+3"]X9,OS: Y#9  XCXEW5,\3#-,EW;_.M&EB:4LJDGCU^WS>5:FS_QU#N!
M'O_T;W?+[*#];6,4%BR\?E$(1=@?<I5"I4B!).Z45]-6-,+\)UI5\!#LC."Y
MT*F''0LI..%Y5D6=K6?.QCMVVEZM#PC1N0*JI-4T)IM@HBOL.6$-MSC<,L_1
M(..< WUFQ)(241NA4UMA*R8MK=GYK.'-\.GQK[0SWD(Y(WDHO6"&/:-^^O4?
MV5#DP[&[8T+9;FS-1CZQ<X^Y[OMJ1B:]HVB/T.&%>7>2.E!30[MX7?);DL B
M1/@4SJPMZ)Y)98B; ->$]3H;<\/F'X7VV?)*/?@#?ME$'"]J:X/H!'W38@;B
MVD,RM<"8@!]EK"P(/HT)L4(K;IL=UUZ%LH1_:WV"^\:T^8!W)V.3E_CL(65"
MA&=4=E]619BEXX@_9OV4:9_%R47XJ47AF?SWK#2,34,IS,@L(Z:X*<SV.)UV
ME!"2PD?I%Q&*OYO>L6X)V@*6I$S7=V=)W,#IIT5Q)<PK,G99M_T!LK2*#!%"
MXVO;4>DG"8,NV&E:?=6C;I7$QS%I^.5LRD-K<T-)%4.E@',2QK6W;LO1S:BR
MR^R+!?^'!M+_7X7D3<N0*>@T\1Y&/[CA?'RC4A"[T3* /"GG>%Y_W*T,](F7
M* "1(3TC9X,=/-A@+L,-PCBA6X/[\J!67T>>NT_3!509!Y>D'R58=9]J?\#%
M.%/L1YH](1:LK83=)O&F+();TC1:59[/-UL&*7[#6>HXYQ6&KT\%N"WJ7EWJ
MVUCJNA;7Q32$,FH"D@*Q\1WS+_W G"2MYZVMXQR&2O-/Z>PKG':7.R^%^I4]
M6GE]HIDA]"2NGW!N1O#T?*E9?%]5"3=_92"]G.HK5$6'^ [Q5_,C+]+9>H<F
M1O(;N-A3",OOAJ]40,6MKQ*QO._V"4-*<P:RWKX,IKNNV@6G(V<0?L%:>923
MH+Q9V$U"*6X8<RM;@*A7BL";/[%]4[?H6)>F.,%JB?NE)3, UT0TJ_K&3_GC
MRT9)WA@(7PHX?+4J<=()_ZPAZ=EYR[:RK%]"LH,YIA+%BP%J#+^05VB&?0A3
M!P&I #L(LXF$C?%*9%[MV"\Z_OZ/4DF<)-MH;L+XV!X=(8@*8-@9+"1=_EWI
M4+J'%XC:&;;^Q5/3K35574/G1ODD7GL"!*24CUX0_6!,=>0L&AWAAIK=:JH>
MWC=O:+SUW:6;P5/@C!M1PKNE0&Y_!GKWJB8]Y".BQ(.4RTP%4%K@HE3 @)S,
MYCSA CA6F0I@AG^O>F^A5&[Y<"-Y3] O3TDBU(WT,7>G6YA>TS"][1AP+A.8
M@'B"()SSK=Y,P=K0&&]Q.3I\?%]6<F=MC]BK>N=5U[O9[G,R7Q[=U]ZDE0??
M]9@$M&G$F %&D/GBHJV"B^]DNT$%&)MOVV885PV[RF4'G#+\_- ^P.[:S?.:
M)9P0AG I?F:3?%KBJR <("_2%<GQ%;)V#["0"-*#PHTB:%WC\E=[WI%5&OEW
MX2H_-GC\>DQPSND$LH'R3OPF?9!\*XV[FY:B40SSQE[H@C0CRZ$G=^3VTCMF
MW47F]+3XPZ,O@"$?,-N" '+!;[[_Y9?LT/J<^1.!.%WI;Z<]]=@,K?+:BP+O
M8JM;4 (;%DIP=^3GU>KJ]W?>,?G@OFWS-V_LTET!Q4)88 &^M%D5D L;+',(
MH2WC'75:2V\>'B8_(.DMN?442%PJ"X757OS@]&0*_NAJQ]#XGIO[-H79D?C<
M2?M,>64I%AZ6*YO2[>*/ $W-]4WIR+C:"#ZT2@*))0078\*Z1V@18D!2Q$(Z
M_@=K[QG5Y/-%"P=I2HLTZ02EJ8 (2E%*L-!%4*1(,2K2FXHT"0F"]!(!!0$U
M*" @)2)56NA%1)!. B0A%)&6 (9 "C?\_N^G>[^^:\%B+=939N:<L\_>,V?F
M.2Q?.%X[E)"E#3M/YDPM=*C+PORMF,HU+X+7N&J:I\N7A;L%L<><>XZ?4*:+
MT-H-)1AY:!_$L54P;\5Z,^A+:QY7M6+EJS(^^TGS)Z<*2R7)L@3Q'U$BZ\H@
MC3[N.1#)WCH!38IF]CZ??6D;[@!30M?^)K;OU65?Z$<\?*6)W&U9K66DPX1Q
M4# C3O\D(5)?RB"$UIEQ+V#.[5E3L^D[]WBYLAMB!G4(BST0DR>X%$?WHP[2
M+M%ESTXTQI4_:!FK*-"_OIMI>B1S93&A$CB<RS"NJ8WKF)#R#9N0"KOEEG91
MG"?_/ML:(!_8"TQ%DJS$#P">J&GE>?4NE"SU%;5@7OIJ%U8MLY]BJ9/%G+OD
MTD18#KDK$WK>1D>XYMWY?77F4>0!0 E+5*=)>1P 1O2<*$#J63#]+;(+1XN#
MKXR,-,/_GTL VVBJJDY;R\V!;D,1*O$SQ)OUTM$*_ A*53W@]B6^]%];'63Y
M\Q<\!^_WY=P_KJW1@#C#J 3C/T^@:QW::(%Q^];14D9CP;YE#F.!P3)7Y3G4
MI%]T='6=!C2X]"U>+;EO>HF;I=*<&LB[=!'>SE9^<BR]#G:T*M/\6_*SIE-Q
M$X0"W])>73[+!K5)P7-AMR!W60Y_'>R.C($),]+H5E]6[AT;UE<II89(>8S4
M\FO^TO/>S2$B!D)M)%T)4S*+B6I-FWS#W/6P=C3[.;@G>CJ[8TX"C:X=J]5#
M7+C3]*'G@18Z1R^05RI-PDZ;OS-.+KU==$<&R@(]#D]R5LN\]33*=53+O/#[
MR([!<TLK37,!: -&?#',E'9VJ $^:3VP^06@0K3&EE'.D$/78XG((]CIL&]
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MX8ZELS%26D_ !IAR$_^&CGAG._E/E/IE37)M_-L0/67;Q..2D?_JV/+7'=0
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MU%!*H^_@D4US0U'R8 K77RN=(:'VX*/W/YM)1YES5"X\2&^X_[4?=!DVDWP
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MLCP[AY3$TXQN9>Y2Y:</IX-9^<.8>9@_VD',3,5(%1;BLJ1#IAJU[ !PO_L
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M=>RP:!!E&,IF-10HB9V)20^D, U-!+Y<&$/4\,X:*(0=:T[*77R0J,CY95;
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MEEF0G1- 5LV-)CTD?T8[0EZBJPLW-0)P^JV-<:-ID:5[X;BI\B2$^X)8CK^
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M]D?K<V?@0^(M9SAN(KLNXE,6FW60\[RNQ^3M8;O8QRJG1'WFW9/:7L?E]ZQ
MY(DY^( YM32\\^QV5##4LK@@NV35PW'EN^Q"[7<-X7VM$^U3&D#@S%\]*SJI
M +,Z07^H.J:(-&74QB/C4!D!NQ)BI>-#!;PTYZ]0 ?.X8/_@L=-QVYN95. 8
M=UJ;TJT^^31"M1!G5;)LO3J"_I2GQ)X!%7!,$ZDK,R"_I'W2F?G9W@7CK=8-
MY.=O\-+I]2M=7&D<?>ON&I=UV:3 < ]ZAP #1:"M/8$F>+/.&2YO8\R\ZLE?
M/TW,=9,M"<MB1@Q-%Z\?MBO@I%NCK8C/W+WM\*KEMCX1W><N7ILP(^*Y:L:A
MJWG5MAI"K=>AX8%4@'B!T@OEAKDBGA_8I03AC_I)SNF_R')1O%L9/[IU;'$P
MJ5PT:99=4R!,3:7+]>I#2][QP1F<6<+AYFL(;.,Q;5ZULS[;4QBO//T4W*G&
MZS[FHFZ0B(\/'EHGO3)@6'S;\%>SA 5RR8?ALV,?''=U)I])<W<]TK&PZFSK
MJ1G J7=U/%[(\[IFX$PH)+0T@U4,7S:M9F9KD[WU!6:43#LO_&JEG[@^(?,C
MPO[A)0#S7B!T+D39'9X$QSWJ_Z,JS8;\*:M/!0:/H._"9G/1-3^*B.*DLY\:
M<*/5LGYU'8K2UH7]'CEY50]UA\PY590O&5S(DIE]%_(@)% >ETUAY,-K81^E
M!,VCHBCR::VF>Z,=>1N-K_.<ZH9?*P?V9/<;*+*Y^5X3II]N7B;<Q._'H6VH
MP&38'= >$J5+B8)%I;6?SL^L:0U@;A6=OO/]HQ[]<5NW=I9KAJV/@U)F81LE
M^!G"+AADCV>8AW2[F.GB"LHN]KH4:HG6';>-?Q2M3K#QRWG)HTD/9*>)6G/]
MAH0%"Z[.,")G<RW9<)8IR$N%A2NP4[M]:I(-A.V4WI$S]\T0?%]%Z(="U$9H
M:(9%?BW!I5#0WM)D'H2E,O$JI6N&"^V*>HZ1IZ#QPJ#.%S7HRU5+_J'@KO'+
M/ZQ$M<]'V6J8-]C*9'Z_+<Q:G/LYAL(<1^-'J#;] _((>M?B<Y B;:[:Z\R0
M/^WGHLO=!M=.>JYAXGI@/T)@T&!NDC;81SQ/LL)KM:./K,N:@<GK!MEMPZN$
MS:7)_F=+&5[)HD^EWT"/7SOQM5^%'5(1/):-T]T6#&0 M10[46RD&Y&=!U\:
M7ZR[5<O\J5 I_U@IU=XDUQT@<>XUY-K2)RF7H74*T]>O9(9.>V2G-WO[WA&T
M#GJV.'O'.DN-"I1C$)2TR0&&PXYU2>#JO#Y-IE51RO+!0H/ZT>UFZ:(8?F=B
MH;0DIOD./J_BFE7D=R![#J-L] 59A2+E*XU3NC.-: RP 56&G'V)W-%1.T?+
M W:TI7SK]!])@C<5>%5H2CORNYB6)7WEZ YHZ_?857)IC?Y$VNQ6=B%H.E=*
MLI_OR:^I^,S$6!4J'#%OV\_?_?8T*B>Q#C?>>O@O'(;ST,UG.#!0#R^>$!&;
M7O5MC-UI4.>CQ72XSZ-434?.W#36L%3QE%@V_5)DJ[M73.>X&KM3^-M2H<G[
MM0^[OR5+FE5<VWO<3@%1-;#9S!:QX<![Q-,DF33=U&O<_7H*/"<RK;/.\PD:
M^USC_]Q./S# T([^5)Y!U*9\1U8_ 7V+_> =!]OM&B-F.B-34O89=VI[E*5=
M[-Q.73]G4;OS];;M+YZG-/YKC,"H=V'T.\I$YO3B2J8=A+A=SBJ3KYM^Q65J
M+"7?FA21EF8JM5Y<,6ZYT8;=C-.B,''@K+7 T6>X6J+IB#!>HR5?*%'ELX+9
M2['&H.*S6B^O_=C_Z7&<5ZA=?@F&,Y!^ :^:Z8[I4VOOFN&LA@*!6D.C+BZN
M+1-'TZS.GUR(F!^I]TGPW((WWK!2?UQ[74VGAA;*]T%D-YP9H:*.*\2FIN A
M'3YC2.=(O>'->>-R47HU/;Q;'S/'3NCLDT^\E[2A]H?/8)LA1'62#"Z^9 X=
M9Q EY_#ZW."YYE'KSY]KKYV9M=,,[ [-]YBY=$* C:$5RH:>3:91CF"._DMU
M<ZSJ.OC[QA%9_''<?TJW$R5$/VDKS%5DG?J9%98EB8'-OIJI3>N OX1Q%()F
MV#BG]<YTK\:G=?X^.1^OI&Z-W8Y.CKORYX/F(U?S9*:/# R<= =%&@;-X]5]
M2@BQ[7O5-6E\.TN9]RK60YUV/MD>%0C[>C:$&WV$"C@C_FB+1\$V7#[1(,2?
MO(OZ@L9,4NYKS^L3^9_""-,A:J,T1_Q"]O" SZB ]='L@[M[OQ,V2H@7 XW)
M#2T,J^FZ^QVG9E'A:NS/JJ=DOBD;U?.D:6K6)VN%:/-ZL("_^>KG'OI9P[60
MK:ZPA1B2"A6H"-4GB_GO98.BG96M1$[P2;=)#>M-]:YK1!W4SKWKT%2[Y7G(
M83FD\I2[,:9)A8/2+@O-9GPF4MXQ/,QBX^JM$/Y38<EQ XLW4!.0R3Q"2@K!
MC)RUA^#Z>;9GGK\GY<Y@ZBV6T*V'/B>_[)U(^@JJL(?XHK[!0$E[&@5X"=O@
M*Z0MIN=P!V2K<W5,+VIBN;7QQ=VN'\,=7U.Z\D2D7=2ZU=Y@M$@G0]14R.E4
MP I]V"7.P&&O_Z60!)XTIN3EF_!4/NB)#3IK#>M45>J>9E#QT8;O%S#W0+!0
M,*T5'8&L[M^0)NJB(E5D<_P2NM78HM=X1G(&GVZ)#7GS7W-_>TW(W##\!^.9
MUXFQE1Q-ZVA0I#^J>LJ:H'W:HK0B@RQBUA2]<VI_Y.NC!U:J3+4T.6<3W_49
MCH725 T.,2O=R:C"@%5UVM<?G:^+6'(LVQ!M"#TE=B?O3=U5E_=7^/V5]OJ
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MMMBEZ["I!JY^9"L/10G*2J+1];:^FUB7M"@I*E!=/>(S:WD=W?Q0"'72F 9
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MYY>O^\!Y\1 '^G[8;'IVK5@^\3[IRJC<-I>,-A;)W'QY>DHSY]@N^_&=0@Q
M]YN_A*[K@9#BXV #/X0YGI! M &C9^;BNB=4$"5@I.'@+O%YR*#\]Z&.'Z5^
M-[DFERE">8FL0=8TO]T8\&94"<(KFQK_<G1;3:U%B*D9RG[[\=X_L0(]+#+6
MK$,PB+.C^>N]XQVLF]"ET0P\LY?6F@2](6& =M37KXKP!">8UM%$!5ZJ=^WS
MF+YP<[I?4YIH?L-=V,[D:)GD6\V%+FQ-I5&"[O;$^A>T( W:\M6X8MJFA<$T
M]SR2&L[F%$8GP)W#7'YAXWO/4I<@:T?T.U<?NH=&X-LHHC.%Z3<5$'.A\<Z?
M3C0B]M_8>_-PJ-_W;WBD$J4IDMU49%\J6PJC9$M"A;*-[$O(%C)F9,T>0A$3
MLH4F^Y(,688HV3.6&2/),LR(,<SB?OM\O\?SW/?O?OZXC^=Y[N,YCN?X_G']
MX3#SGO-]7>=YOEZO]_NZSE/7<PZX0#SE'.L[0N6ETKIPM[^,KYD\R1!2SOC#
M3C!^T!H,W-,B\^/Q9*\/]0,M6ELUL\SDUPKU7H+7C>KGI2 JOC\6G9*B,@]C
M[@$7^A\?T$S\;F3PR;%,,5VP+:PQ %/N%9NE+*YRP "-^?5=4LD>:"G\,PCA
MBNA&<B(4$6-BG!.LDR'&7=4T@[EO %FDCF,0YH-Y*M42YM<[#"\EZ1BFRF)"
M7Z6?.**MA1B$\@&_F(/A:=4@*G!TDR3XNZ=N4PZ_3.;J'9J'\Y^H=OG3ONJX
M_-74]H3V.V!J(32TL9TZ,3LVQ[UH/,=+2^^L%(\QZ(&XJUB!P(=PS8X5.U/&
MZ?DNZT H!P+B;JJ"Q&U;_YWM/HY 2LJ%\NAC2Y:*3K%M+D;LEZW@M6<F$6A_
MRZ<$%+PW0Q77*YV\W\W>^':T/7H/A C"15.#)#%2#/%"QF/@ATO@SF/BK903
M<;<^PNH'J>6B@9_/G7:LQIZ2&YLZ>%Q=;5Q^&K@> <A47NK_M)$Z&8[Z_N);
MJ&39B[(5K^/ED%P@H8G=2D>V>]UE'8F:%SU]B%8PYR$9"SEAJYI?=.S1SW3B
MS,&R!0,_X2N+K)8$T,[V_.)J&B61Q3D47A1"[]162_=6],IL$)J-';91N3OW
MVK$I.EU00"Y(OO3@!4$0*X/U'=GP!B6(<8+QP"VR39);[\YI7:'3K4R>F68K
MS-0WON$Z_DGB3G)*]VO_)[^;?6ERC8F;X1S4:Z-U7BO/K>Y-J,I=5EEY FU]
MDN*2HV_^IRR:]X<O>SG?+RC9(,Q&B9OU'7.J59<XE:B@WC&14V-C'%#Q-<V:
MS_# @-V[LT\@&J<R.C1.L5'0':G'L/10N..$#^LBP[>1'%NTL$--7[DE8EO;
M#(1S X]A6E=YQT_P]0/EOU)#L_=KPUP#KLU?9^)&X(^?ZFJQ_8$-8G[F_G4%
M?M,BY6%33,DY]]X.P@4'[+.$7(#4W$+&P43@QD0;]&3_/']<O4MUFG/3#\52
M]0L/.(^N6GR*"Y5Y^;A9_[+]_2TTJM5I#H(S8''V$TW$#":46N4.%TFD/S J
M7C8.*L&KA 7'1:0G)Z]T54?]=0XDL%/=J,^;QCY@G*#Q(U[C+^ZOI(=PW/.B
MVSS0["ULNA+8Y@@H Y[87HZF;H3O'N@?C5$'W]<8""A3YB8=L3Y_:!"+H4DV
M)L+#PMVSU'>QG227M8+G)R*=ZYH2KD=LG&I]U!X082!5!;_V[WW@0Q0PJYNV
M!]HLEF9?'*1)FZXNE;$&D9 @"$G4?L)R#Q1=8X,^T4&]/ZGY_'=+]LF&M<J+
MHWZPP/TV#WL@EQ74I'K'%106SQN2\QV0LM:#SWBMPN2N!O\E/70G?GZT&"O[
MW(J]''UR?S=/UPIEOMW_Y(9Z;$/4FF*)U$X"7;=;*(@*0.W!@H;&D7[F.X9,
M=<;)#\;G/*HU$SA:Y, ]$="K<%4OBB^+JYFNLYR5W2;)ZB+_1HED1PHV:N6G
MN3L?N#P?<S/>1:)LVE#A8WJ[-)]2S_HSS&DD(6L/= )^D>C+&4*IUQ*_E]9:
MT>^>CQ/.3O0("_MT9[6R^/[)OR))+^Y]\(IG/F.QA6138RFE\75*G R+5II+
MA?5/[!-$SPA'VW.C^KBUA:07,1D?$  R R[$<-OOMK%L?68(F(:$_3XX,>^L
MA@UW'VDKAMZX<^40CPHB?/R'3MHU* EL#6)>IH$ICOWSI1WX([2-+TJU'1_N
M&P2.TQM#>39JL/ET"2O;[2D[4@ARU8X<"7D&JT7'MD*\B/U*P@^LM4;'=[^_
M 36^/M^4;BLIVL/F?]GIN]?T_^U3!>S\W;/R-63[.+5R9&NW(%=USZ7OV,+4
MO[C6=%/<,]T7^<+RKPGU5/#"0L[F^O,V+E,QFJO=A6]4#]W*'U_UKS?U"HI%
M\T"%*.)TU9#<>E9&ZBY):0\DC/YZ&<W;?<_/+\4$,N._]M)YO6I](*_E/KTR
M(<7@+ECJ53\>8SF>;UD-X!&WWA[HSB#+%,C+[Z%S99AE@"_U[8%88_>AY&_V
M4GL@%$F*M0<"$GW/GSU0K"<%R@"4$'1[%\92A_%NK9^X"OP+5+H'ZD49;_F<
M6H<PN)"_?9&=YLC16D""[(&8[U-IGDJ[6<@-)+ TEF"&LE7\'FB1#M 1#*"K
M*"W0N9Q6X.>A.%,F*WL/E#STWU\T;JSI;BN2++,'>OWY_YFQ!A.M.B0EQ@'4
M'N@<Q'+N-F4/U%[*<MUFJ/(SC:$[T#T0#L#/V,(]4#G@3\"UZ!8.0 2IAJ!8
MR#H4G;D_L44LP8JN/=!?)@ ]^"4D;09B3V&OPY"YD(SGX38Q5_^UAR,73QZ%
M;<D#V6#_Z8]G$4LHD56,8@ _3+( A-"Q,2)RAS6,7-_$,'Q2::YHWCW0(!68
M*63Q'F@^,#RLZS@P+^W +6^<_3]F]"FR$Y-LC4Q5%2_5>IGC3;E.*3*4, (M
MLSL$I#P-/-RV#TFMP&3D>D*I0A_W0#]PGT?FW#J.#AZFQ00E6V[,>KRUO'^N
M7KY3GBOK?,2J8<_5+?31_^D[F(=S.<WUCSX;:R2_GZ&:8(W5LN)G]T!RD/Q%
ML_:[W5.*P3'9X0PTVFG#RYB9LP7A0?1F8P0W_12&_[1)H_3&O5\ZZWEZD\0$
ML1_3W?3W0.%@$"^L"%^-W3\D<W2>>I:62<"?L-^952,CH]=),PN/^L*<J$:G
M!7<67OLM-"^^2+IM#S"$#C'-JR6T3NIERN^XRLGN,H\KV0GH*D62I*!18;AV
MGQVX^F "@T%;(J_OMV-6(ITEBO(:-V>L\C]1-[MO=^OX-P.C3\E$V?D(PT,O
M=XU.S_VP&A<[N<GQ7W8GOT,,HP2JVM@87!14RAI7:,[M_'4/D;SS+7 #G[C)
MXD".GQFPK/U>4)@=I;8K0%9W!IC-/3[ L<C6@RG:)J@H;5Z/;8AFU\KN^_(_
M18&6O7[+<.J9/5 0-RADF\%C3.B'.S(+6W7G!T_J,LM+:4^^/G -*VBUA=ES
M)/ERQ ZX+J06<'D-! KW8VB OY$8CJ]+3,0[6^9M3-YD:*<]ONP(?<[,MW@,
M;2L:KF0<&D8^@D2W@?= B39S*$$/;<C$L:>OLK#7'MQ9U?2J,5OGY2E62XM*
M\;^20X!Z^'(QD..^193U'A0W+8'SC5Z)8FW%TO4AVPB2B/-[V:QVN-N;8T].
ML3'Y;:8-@@X&=)[K/Y8@*J&;Z2)^)FKZ)"P%0C8?_(DF0B*T-3PQ FT0#UQ^
MU=OE;*]*DZ B.=79-/@1-\?ROS&*;0XOC\DX<AX\@/=%=EQ@74%^669F;@I[
M]:.@]N1<I,/L&O2JA"?WI_Q? C<532T-T)QD)09?Q?T6YKM5EAAMNP.G%*4B
ML!6Z:6=J1G]4T^=QB3_>R)'O^L[7@G@!+B-2#FBG<2Z8<?KHO%O$?"RV^W2+
M>DK5PQTQD^L_<;,.?JEJ/!6H.T/56M_"A^@2K&G(02#B3/D-2M!1C^""%-%)
M]+DZ3'WDW: S_9]L9F0/K%VXOW;/YQU[I,$/)!!WKM!HC+!3EJD [>CU"1\I
M^Z##]??7>L7KN\*<(5%6<^K)K=!BN"BS 6)$LWEO7'[?'2'?:')Z6>-&U6_Y
MH30!OVUJWZN_#)NPWQ':VT T 72O-XI<R_H2C-F5O;)MNE^@DO%:*1JZLFT.
M,.5FKR\ N6V";IQA -GA8]XZ*R'E\PB+$\@]DL9SX%WF*'+S@S5H$SF%Z3R=
M+\],9<E;VU_/.-\6XU=FT,K>8.RW6 2^+G01]F;?+=$G3;TI4]@6GKY$+SPW
MLWY^RUVQ0 \:T83\WC8#&/,:[D_>_C(XZ=LC)#I>^DC3B!@&7:V"&O^U&LQT
M\:[IJRW32QTX7YU$$NSGVE%B'4DE][!,>>&ZM#AY$['7?&^><K?&O:OY]&[C
M&8N(/8Y<>?L6#&1T0B%>!#.GA_C:)H>I;]I0_>9W.*K$82ZZ-O8X@2ISY'7'
MEL46.@9#R,#7-.11O-HQ_  W,_;&N5:7]!/H,H+^=[]=.S_P'JQONNE=>36K
M$D*3#^Z9GT>GY"AUYEUQ4D3-">MLRPA^7UEY\:$SY9/CB6?3_'ZV5IU'?:>B
M"(-1I%8E N88;5'GA_>LD5-M5&=9^]5J5\=!3D<CK<&W?PZ!+/=K13/T1Y$N
ML"E/*%=(6ENW;]FLR9RHHYJ4<\#.IW.($&+@M:9-*Z=9C(^V5$@L\@A#E>+:
M_,@OH,2#/[A:Q.UW"K\?%F&)R?--G>6A=1;2.EF\D$2APY\*O78W?[N,UAN#
MJU5'JV4/N^#>?XJ023_L'S#Z&_,$XXI*.(VJ#UXM+O *#CC</+X9K_+9R4'0
M^&WR(6S_E/S19\P)F#6($0L8>#]$L1\+:0B.61B=,^[=3 RKLKOC$Z#BER9,
MSPRV$EOF1FQ;_9VA2]%V37\N4G\,.U/>*+@<3BVW_7-EUO_@$?K;T*?^9=W.
M!/\*K#D,C6S@("5A:F%?,,="%CO;1*$G5#Y;[ZIX)0KFKGJXFE5GDZ0_)-Q_
MR9DO+"6(<V?OP1!J[3D_3D!=O86[?'T%QU2TGO+%_F)NQ8;,G$\*4Y:71ZZ\
M^A# .I)!O)J[7__OA(J&2/T'U =L$!=J3EGG?3O$=#HJ-6#%?K\%[7'@=B)I
M4M1\&C=A_5C()>[K..K\7:'\:F\D?Q;5_I9/_'%]2QV2C,/7I_K*D8__$6U7
M&/(8,G1UJ(R6<><9Z1?%M7([Z_V\<-4YO01U+.QU5]?3Y'>/W=G7N1A/_O7"
MU'W_A:DC [5[9XO.N]^6UR9U1P$"AJ[" -B\:1^A"25V*2,&]D!UJ1U*S]6>
M_\#9A?A^F96V2'J\W/"QVS^?CN/TO\+Z.VWU T6V1B>DA41UXX\QP"7?%15(
M=3M!D_",9A?U8^)1E*/'HL.,UN]!"45X;M8D790UH*T5JY33J?-QR.>=>=^#
MRK-9\G3V@YC$B>^PVH&<"=)#NA-<JF9B< J>/:)P_O;;28^&7EM(L+&;(_+S
MV:VW1_9 [O@X.7(J]2-Y,:JU6J1%%15;Y0-:OUQ=IZP^?S: -D%2)V73;TBM
M=I+9N\144_B:QWJF1"4Y;(MFC=,$'S+'V-ZDS!U9]MH 5#Z@-V3.C0/9!! 9
MPS;6=#?64;T2O#VB'P%I;I@=ST+(-J0O61BQ6>.6^'Y2V5Y;+1,CM"_M5^QW
M6H_'D,U7,#QP?4IJEX;*BH"OT C=RJS1:]*M^>>'H6Y0R/CE(6OM:+9,KE(.
M7IHP4:IKG79^FZ3'\0RNAS:J"!$S>IA._2;QI.;3QU<$.UUAYV[9N=HDGJ&:
M]/Z^S_1C+&R;%K.@[:2]5SXWC5)&.XX;O)LUO'BMVBM"/,/QPLOG:R?@RYUY
MK21Q*;YA!J"'(_U_PD)VZF!BK/%\T>P>2[(^RIDBEQ%2?<*.[\:$3<)<(DC+
M:%T'X@_P 3VDI_%^RT\J\@HJMIB3B#EA^R'WW<S!!SP_,Y7.]X Y/&6.COH$
M2IS@1O@@O@+)T10%84T)B952E+O$KF9T4H/YTPU\WR^?WO#DSXE>#I!XT_M*
M9]&'V;5V[&)W.#?@QDED1$$AXQ!-[K>]\!^5L+@1'Y^3CS-NC5>3,LI[;O"<
M[*/WM,4!1IO3BDPF,(ZH(_<?& O;_6FTHEH-G?VM8;WV8$)\5J,(F@Q"&"-P
M]F :BOR)Z(,B@.-W_])RYCN?^MO\::E(Q[N/Y,T0S_[T<1#H;7*\F>ER,(9O
MMY0RPC)7PU!--Y%,/J_]XP)NFN8E7K#ZPW$E/[^);.= 8TFD]=;:C%-HS8U*
M[S7Q-,C2&70#@+5?)2=8?:S4/5!AE3M[.Y00"_UK UWCW ,U;@'<L\&*=);"
M3^UBEJ5V#,;E%"^@8A^.'8]Q*>EX/$Z!V8KSY2P3T/+/,I]_OU[HPWZ^=@5"
MUH7L5*&V 0R=VMU)I*J-GJ4Y 9-SECR-D'PCD34K,5KWNN2-][?1ZNDIR7#.
M+#W(71VQ9$H1B].4<I4:2A;1AI*129#NI[^S)2Z9/)RCRQ#:GKW^PM'@[!JJ
MEG7G\8EG&2ERF\K40[1X2D /A/U7(ZUSSMO7F&*?K)3F&U0Q65^Y6URMX_2$
MQV'G;:R^_.''T1M&:"\:EA+0B3_ $E[1ODRY-]Q1L&2(UGBF^[4[S]SB5%IS
MX@60:^O4')[43.XD+G:"14/P';LQU(J'A)DK)@86C3E?O-R2+07/<PF.BE^\
MCUJK=6*_W-O+L=B8A'3$X%*I/<RWJC((^;I9KB%H6)!O0%" *!7E=,3E/HGD
M&'NGF/IQ^5[>AX'@( H8UTF]1[%B\$Y@Q8Z/UH&?#Y9-+\>KC#_-SQ9>FGBR
MSIGZ.*0K-4;;H6-:U]M!!ZM=2L82 6('4/E#YVB-E32D 2U]#P16$;9Q;<N?
MNIEC;*C@W=JMEQ1Z.3WX/!8/%Q'3:4>K,S$8IT3(Y$7XB9&0W6VLMB1%L#5K
MUZ;WAAZ/TAGQF%G27Y642P,!C2FQ$=#[K;R42X!L@*R*M5T:NZE641$BN>PU
MGG3(ZHUU;_I']HBC%2)/OE^U^KW-.'F7=3NW&TJ5M$,N!26'C]$!1?/U8ETJ
MG5=5B7F8V,;W?W4J9F>"Q24*T!,;BA6K(W$/5$1$%U8LPFC2P8S7OMTP^F$E
M5FI"!%1P_XC2E-P#9LK6((^GM7K<(_CUW9E6M0V#<.4>\9.U%\1];=>8<LM0
M6OAB"O1/3@B@!=G=WN/)>IBC?V:E*!-=?[;RSF$M#0.GU))]J](=HOLE#8\=
ME]L*9O%!G^V!_IB0 9G'!? KHC1[-]0!C_MDR41KGU[)EQU7D8."ISUV^Y<2
M?9WD>E,J#E[R.=_\W46<S$<>9/!945LHP<_;%$W(NAW6,5NQR:65)SP_+OVJ
M;,E;+;![.(VYF&PQ+\S6J?$HJMYO=Z(P)-B(_*UVZL^N77ZFS_IO%36U)2YE
M!^XN:= ;D/*J'!E%3<\!QR')=[^9WJ5(8"@*-92VO/<SQE NA5LO3+]SS)Q\
M$WX(% :+0Q)>(H58W#1M/%$]6ON<]=(>B&>S5QN7<_SUJ81I4,^AYIEXD8A[
M!:E.D&P)D8D7R XUAE'HO!)-.BY.\UI9I4>99^V*^O91GLQK$@W!BG/7I-CE
M'\MM*]E23N?.8<"PE9;,5;4<O>2*V>G9JXBUR^;&M1E_3O'"8J%D$Y.;H@!:
MG)Q+OHY3JIV:Z:\T%=&E\56NW5<B')=F'X$2&E ;,#B@_QQ[ 2 I7]F2H@("
M+<.;!K!4QRP 4]_Y62U@&:>'U2!B\,._X,ES56_IB>6U#.PBK Q:\WGU2MQJ
M'SF+.*N7+DG.RHR]FZ_W3B>U[$S4FC0[I;\=4*Y982BZ[--45O8WF 7ROYY]
M3"1GV]91U!E\YR;N?\R4JA[5EIBUZY#W;K;74'()<@B+//*[K>5_HM.@3?3/
M;9:Y(H8J3\L%8-]WY>]1JNH02Y9Q@])33AZ9LT3O@8XP%Q,5;CQM>_]A2#A,
MP"A84F\GC=.%P[V?I^*%0-1N&%T,</KS$ZQN%"]RR80)M]H#'7Q,>9(]A\%]
MV>TTSY%6#!H\;G?_ODK<H47>:] LK8''O4B""ELV_0ZR0UO['*+[J5@N14Z/
M@J9N)5=-&VE7%'<K)/_.NPJ9Z7U,VN!G"X[]3FP-@ $TAWP;BLLP9Y:RV(]B
M3O8MTCH[MPU,QA0/'.2'28>4?HE@<[Y\!LESL?T@%V#W(1.*Y.NWK*ZV*PVC
MY^/=QERJJVMB=0=&F!]D'K<MIQE)#2O#-)$=8)7<)C@_!7;7'_^P>51>H? @
MO,W9;V P%6XBAHB,T#Y/*7W>ZC:72I.&IOJTB6*RY\-0HBO6/NGT>YE-+2U-
M#7?4X048^&-3$"'_T%,4"8".@PN4TG9(S#J "+24MLMC]AM\X]%9&^^&C&1P
M$@]F]3W:PBNR[D$O7"8V V;VU"(['GS@ZR%HR\(:B:J<SYEZB!< 0M^'_NJ#
MP_9 L)9@5F:W#H2-]5U;E$;9WQ5-'H5R;RD]W[YBU8D_//6V=531?#$49R I
ML&"V/*'X'MT8!JJ F!D.9H;T&U 6&;Q(:OD51!I1-SCLG=;G"=RC;=W#Y>X$
M:+;*C7R!TW?>O3EAJ,4=/@48KM>H1[M&$?+;QMO%@(>\.R"[)]%9&,)'S$8(
MH)(=F:E_LR*@-_8E"Z2^&[\Z0A8#J,&7C5"$(N4&RF5844PUJ$&G8*%)UI_3
M0A:DL?/N;B0;>A#@&1,L3LP\@(%7V^\R+"FF7;#5)^.2KRLE1ZO>C?KX?C7\
MNF'8<V_C1Z\(N/7V\)-G2;NIC-,!)FW(PXQ#H_QA'M4XO [M;OUY]]5)__ '
MYM6LN4KPI!65CY9)01.@L9HV<U"<N@5Y-C54I*SE?.[,HX^!F6/$+[;OHU[8
MK*4(B 3H .FT&H;= SW? ]4HD>ZCV+3/+ _C:?[S]^PX5Q>;/ IJFE\\\]:J
MO?!5?Z%H!V%F:=)UF&\50K:%[)Q G$;^O V(43T#>Y="8&6T L/0*0#Q@=9;
MQ6QAQ):>UG^RN^_)\:14@MS[S.GL6NN73L^RE12.XJ>^#'X.U@U(#(K*^WD/
M-&3^@R.!]1U9H]2-FNHDI,1H?Z*<U!0FXSL?YTEU[MH^2?7/YKEA^EKN^GF]
M/M<S7[MSST04Z* %:*%$,.2?;F2/],B_<NJ>XRS1OFZ5UKBO>.?1U>*?D])/
MUV+U@B1<C$2[$17[;0(>&F(>^L:N%AW6'YW\/$C-_,'2L?J-9)Q"L>X($F&[
MI*(]T))H/2A< ?"F%\S<( 7OJC:UDFJOTYE%2T^L#^;<U>\)E?!JQ@]P;U]G
M,?PF%E3_#C)X2ZG2XRPMKQQH%QW,X[%K$1?%L'#]^]/VR[H"]L6/:='*RX(<
MOEHKF[PLKLE]@"."Z9Q CM[5M'H-&,7S$_DEFH+[Y2,FV0?@W_PXA/P6/.3Y
MO^4X_K\&+_D;XBZPY@>_TCHHRM0/L'@(KV*KJE1</?@DTFOY24-+=$:O][C)
MRJ/WCJ /8X8M24K#&$OWMP=:CU+GF+D+S'*HVPRL8S?,NI,H71IG-JRH)%!I
M/MWS\^KS@Q%#=>5O_#!:%7CWM^ 8(")R437([O5)=3-*;,;\@TTY%)>7N5[0
M@:7L81,)];2\9MQ0&8Y2W3=X/R.E?@%S $EX@^%K$V'ALF!\03:IQQMCSTX$
M<1NES^X:-&^4//CR\)B.#Y/XRV<+/?)>FKT/ZJ7TS\G@28 G'2'3K4MJ*R<5
M/M?:]SI%7\@4_NW R<X5)K2SSN)$T85#MJE&>Z 8(!%Q=N$T,>072%=F*EUR
M:1&;1D4K(W[9(M&WG#1^M^$+(Z#*^V_B)WGG2DD:%#DS"G\$0HZFI$LKXDWD
M=M,94WW^PL[XR,7DY4KG6)>3T1W7!<[0FR1VL !M)V0A>9W(XP7E<'=:_*E9
M,+DGSR_,HV!IM[A[EIIPVL7,Q<)0?$LNJ]U![=>%3?#4((LSF)B:"#NE"HV'
M'/59E?PT1OU6_L<Z!OOB-P%4<E]"W$< =+/95LU00D0IG19%]0;0*H)A2/Y#
MAL4KJ7IH*LLC75_9AV1U?LTZBW--<9)_'RZ@%I8 6@1L2?S8)T6R0AN6#:31
M;JZ'L;5_&WLKB"Z"$@H@9%-D K1N&YN(% C1GM=)-$K5;_PH5S[;=ZS-T4A.
M_6OUQQ[1T,&J,+=5=OJ1;CKDS]/OQ56>X[O;R?5=*7+E)'$Y7S<NGMD;>FUN
M_:(#OQ2?O.52^\4,T!&I0W!4CR,$N^? )R>OE7ML"]U9RHEYAU*Y>_:YP3DJ
MX>_@88P\2QK9<5Y;#BY'&0G)($"3;HT/U:KFDXPV9ZP'3NAW7)H3<1)_["QU
M66YT8J7J%!MM:\Z4=CX5BT]!:$8]H,W-B[NX1I_OGEFKQ'UX1V%'*8H].!GJ
M<(EF^TL\$#VFQ,50&D((,V3JR4K1JQFWAS:9&JN/JOIYDRK@ S/&RA==?=Y5
M:ZW4 JO,&XBB24!)_'/TL=;A+<RQI49/KJKNDGJ_4Q%B1XY]C/KF"4-V2"$]
M4'QU:CF+277"%5J34F83:XLWMG$/?4)6Y:A/$T"T=:K$OL:D^5)-V[*[A3Z4
MM2E2?OUXQ0-0BHVJ5?&'?RN/&)W/+7CQXB;Y0&1'6U=AFQ.SM568@NW&@^':
M"/;EX :Q\_6C#]#G:D?/U2I;URD>49"331>19-/T&120C( J( D5^4=_M(K2
M'5<VW+/-^B6K7;S>>YY^L577$B2[/+M6EH&<\F1: U:$,TX!+LY'EZ4I&S0W
MTK5KRSN8C>61%_#N36Q?/K(V#!;TD2MY<*E_2D+(L61I*_.'&I.UM6:POJ4&
M3[)W8^J_OVN)+7C?>^2A<(MRV77]"<>%CQ>*\CJW\*7LSW0@9X&O&2)=8$*(
M,?QQAE1AB*R=HMR,DH77Y/?RQS\*DK[T;63J]_6)5F"8L=H<(:G4(&;N)I@]
MI'S5>;S21W$ALVXGY_Z3OJN )'UO>DRY>[]UTDXB/1BXK 9"#C$,J;.LF$=R
M3H<\T1):_CH^PV_>EB[3:'#"\NOS5T[B*5[+^"D4U2"1^IEF?/B95WEW44C&
MS1;ZD\SPQ\5O\745W=)FM[%WQZZ=>?]&Y 0B&5CBLZR3B!YHPQZH4^&*[X$0
MKVXJBYN</)HT/(VM["+KML+73X]Y%$DQ8V"Y;U+JSP%V2&HKP"_0)N=0?#2I
M+B'^^$>;QB2H%;_UM]&LVF]!1['R;PM[:'?/-7 Z/M;W]S==*3[%1O%EG"K=
MWZ]$<BN@'1_IN+1TH;_0UMXXB%GE_R/I9O6AJ7IA*>G))=SG4JHJ3?<#XQ S
MIY6? .7Y_"YG-E7TJVU]4HFA4?JRAY47WQW$ _Z/BZHD%3..WPHH!F\VL1Y#
M^HGG!Y0]AIP $38BBD;NFM:'O_Z0]/;11C7&8^F3X#KL(6L*?PBN2]=%?+.7
M(4-B\K]J^=Y)_T;POFZ9(*(7=*JJ.;(:(JMV>25A^ZGT_LDZ2?PJ:MYW4K=#
M^^(PW$LQ4V&\JJPSR">P(NOU=7F;V\3>)@TT)\UXG[31J@BH*7]PHE R-L[F
MRQ+1BV3[3GU8=3!#^9;9HXMLG[83TSY-Y#"O%$9HQE%+F+EP*/T>7'Q4D^_#
MU_%+M57C>>_U!$+E?3*N.H.8A&LN+KU?:X]%14(O!@[2I)1(H>0[?\U&  ;W
M:757C_$JW_<X+<=$6R-;0CZ]IT>Y2>FMXR4=28RK]%OP=^3/,!9G )(<0#R$
MZD(EY-3G5Q.-3ZL+/<EX*-[/][EC#Y3U]U9[:,JEQV\=>#_YG7%J8G[&$-Z<
M0(SB6K55R2E5_S2P[O9IF#B*$%[-27*'!G]^>3IYHH10E19A )J8/F7&\0N.
MK%4B[<Z>TN;P%>C5O.3=UOM@BP9>N^E]<:=)F81[,E\BMPS^R<'B7.=?S9 L
M(J)X/*F[VZFJ5V'56=66IQM.+V3F7^YWZ!WH?==L,:<#\K<A<0%2Y2_KJ#!9
MO,L2SUN)D-/<#26O%?#E/_/VK+WX.7W!TNURJH_:PZ=KRSI8U=VEMY-]I7^>
M!E6V&A^J\]/6LM"!?FVUPN*KUV.T9>'P(99D",9B7)46:%AP!1;SX8/1,,DG
M+5[]@.(OHB8:]++?IY=]UAV$[D>F0L@FR$08#_01-XSHDQ$PUTU>&/_D5:[?
MR+]Q'IL)R?PD?4X\N#=DL!CQSAR(;>3_IZ&]*3PO]<6.?1[5J85L9TD^*QE6
M30PXEBQV\$7#-2,GB1.B G('K@F:OS#@PP'&)H\@.R[N@3S6(]ID1WU8/"$]
M&E4^4/]&G%C#KL4 >>M R,_WY-M/UA\?Z44;,E\C"1DL!=\$M38HC8*>\AST
M#J;^'C[[*9TZ;Y9WVV+M@S!$D< )JG[D\$(9-9HCS?X+19/>7FV>5\+5SOG&
MPK4(S8%-Z$V2,VP@R#@V1A-S[@;AO=IM6[]4ZU7D0W $2X()Z$0W.[D.,?DP
M0=5<FZF*..\KKEFB-3<?/.Z^M\B1+_?'^G]+M4!V(I(FX[8:-H_!#6/G5NV/
MY!K&;PHJS:[3K9?F#MY2^/((EXS:,LG/J\ CG?$ 5^J 34ZTLXY0V*W;:HL>
MJ'[N?V#H'%V=.;7@R"9^["K75HLT^QR,)MW(X%TQ9Y:K<K-WS[)GW!IA>+AC
M'HX>+A+7Y5OXP*DO7X8=2*XY;"#+1.CQ#2,[-)$N* BB#\4%]RVBO7+?;ADO
M0E)7CE0JB<Z%?SQH$7RQW+:&RL&>0Q=* #&JF"CD_IYQ%3PN]P;M-<7*C$PM
M*.VHZ$?CF;%4HY*FUGYC0=P06ZIFD4A^1 +S3F$":,=WOV6XY#*D/KNC7U2J
ML\J)([$N7$])96G]U\4>IX<U(:^_5(/*+9?ZXO4<]ET.Z@9)0-;L@9XQS GK
MSWG=)YXJ=!,]A<Q'E,0"3J7D2NES"\W=[GWEU+8'LJ9S 5;5,"N@A-3=+,R\
M@G$W\G"]G=IW'&ON@S/Y>Z'UC,+]#;QKIBYW<<WU"V9%$5T.X--C4$(>L@&2
M]##U^@1Z3:G.>^[)<KX"+TX:UC(+>X5E9Q>XE7J3V5 8H:W$C$(2\BPA->%C
M@XF:1N^G0C*PVY:_QUQK]4_GP&_I;T5_/+;Z4S M\[:V69'"I^]00A'DHU07
M'E<T_R2>.'C8]&UW\23M*;>BWIB2O:#FK^;FEP3Y1VJDUQJ#MA18X:89Q_QY
M#(,'3RVOK4GX#A;V,+/6$TBX&L(P?E)=R!91<.,^Z/C%$3X<?/^YFV)(Y&+7
M^"ZJ>U!@J?.F$7QI$P/6K)VV^YN>JOD\4C._6#==.9*SE^E6&'%928P&>S"$
MX%K1%J$Y>90N71F]HKNT>^R21B3N&P.C*/FUO#WI801[WMM@=!3& 4F31*4@
M0/"G %,[J:AR]95*/^>$2>JM3Z%XDO\S,>J,4,1!$^FM?O!-IN)^SZ\,%I<1
M?;]43'T,)JH^]6!?\51(D8%'E:+-W=<%1I73ON;-YO$RY]X<0_9;H1O^O 7G
M81Z"HS$G$0<9AVK)D"Z/P*G<;V)K+B-N(XHY06H^-YX)U,@<JU%Y^V2J[GCF
MWU12,H!>KZIIGXG)!CV8HZHVD&->N]')?N&%RS?['P8HB[16MQQV?Y!B9%?Y
M#D58A.Y/))%['8!<:AOF!S;&ISA_I5-VN? +[+3XSXAWW@\YLP4$#L)?"XA8
M*5.@+$XL99[J,E)G*C:UM.N;D()2"<X @PM&A4TS!2X).F2=_7VF72(F4.!J
M4P>T]:49QW?\QU0L1(SU P]:A3O-,[GZ]=N:FM./&E5&%>([Q/A)AR6_#S0%
MS3V_:L2F?RB<U\3B_@17@8$M6T(0*$2*%$H7HQE36\F:0K<;Y9:$J/G6)E+V
MC4F:#4D_IRNC4R^IM4]'IT1$'OF&<+8#_%]Q#^2I%).S,(.)5#4.^Z3A#ZU3
M 9_(99,-9!O"J7&(&@QH#5HS:P"&!)!7MST033P[H=Z4_]H'AOO$:L%P41/O
M8-%2,#@@J$QD(>L!RURH>OFKW?/!F<N>S(?#@;D*'#=K1U2F#!^IK$C?P>'&
M9PX8'#,L,#]IP'8] B0*J@@TXU@8)!D "Y TK@H6LZ5-$)[4NKS+340U-,:M
M2WK===-F3E5)ZIVUTHSV_G2Q4PRT\1?X\"RS$J'IE1-4V@WE[Q/+=(G(;CM'
M.;I<PG?YV,-XT8U?;&]>SLQ44*T30!NHR5*J'[EQ]1.YI;\#P?] 4B\@(+QL
M&B39UNS _I5&>,QW/;7E?5&^$<V78+I/HQH[45-W^HD?*OSFQLE=5]8*RB_9
MX VWM>_U7[YU]CDWOM4V>;9^-T@/!%^DP^%L%'62#%UKAB;WY<Y]@TKC,MR,
MG.==%?-'R?&^KRU20C<_!+ X^^@70SJI%C0H$7*,-FQWR>[F'L@NX\[SI6!N
M%<1=FPZ!/F=;M3]328'=X3 ]$,*1-04AWX8EX.OX25<K:'N@+]MBHJG76U+Z
MQ.VN[QJ6#)CUI&:>O+!<*C+Q T.V,-VY. A!3GBK[X&,22LKUF2EJ0H"/EX;
MBAA R)*AT86-N?:CSK7N/,L/CSD;!)]"9VEIW_,$,3*9B7L@9Y@P(Y 61H2*
M,N0I22Q>6MQ<LKD"*7+F<^&TKH2&RX.BG2)$T9N*PQU8ZZW/[ "OHNLR@F@Q
M;A4,#\H=W&3Y_;4M;EVK*_EOO4<S%MH/+XC>5K]PM.F-6!P0L#1)W]7Z><RD
M;_NLRC CR-?)-_C]\H7IJ:/"!9>EJ[TUSCP.@+G^X% N8%PF+\:Q1!_0>":,
M(VB64R9"UY=JRD)F1PT67DU#6@7]CS_]M5B%L(7O=ZC39^C1PN?'*:;MIGQ*
MDTXO!UV\U JI0B7Y79 LN9@O3:+LI_4[0(N'4E>\ 4VX\A;P<B6H.R;57K5Q
MM$V%UOMSLN/YK[8QU2=CZZV5O]YQ"68:2*U?B;C]V&L3H/^86O0SN!)9 GZV
M=IB#<5:AI*_$V$O<U2A=!]XGV@YI=77UGQ=P2DLZ]M0.X"VB9?O5,I'NII.#
MQ/,3S[4/T'X+YS[@&Y:QW+P_&WHUZHA;,C93>B[T.Z<MR5YF?S^V/VL$4[>8
MI-*_!TK)O]I8,_)H[*61%G%VD$N9>^7@B6<\6;CFJ]F%BY>[$4WF.F+&\^!G
MU 9H#28>P4,[=Z3R;<:7X#;(<%'+2Y)5^KAAT25MSH57IQ_Q]EU&9^X_1?E?
M*B>)_B$+H/<@3<9J59EHBOL /AJ2V,%O*4.T.ZY1)5D]>O[B^9E/-36K&0?E
MQ \3R+KY^A="432IU%4LL/C"E+&_\/NC"[GMCVD(.S'LM=:)9(99K?'1LPF@
M02'I&VE/4X0%SF&NN[\%]^$34>2;R 3(49:,\3QL<J7[I,V4_*"?B^LVR:G,
M8Z'VU1W;1^F:/)<&2CF\#B^D:&< L3W(+(*ZISX70E11\#TPUQ'O!JQ"]_<R
MU:,=QU?K+/^\3M'<\#<$O2$YI<'0]\P.\S]KY2MBJ)-]$N=\P3B%E,0BG(&+
MAT_I57$]KDMA&4GIH1+IH:J?]/[58_[_S6'U'=F(;8?P(H91M3/XR-;SYZ.?
M=K4D5PTW%"OKG>[]F;63>7\1=7/W$L!*8/N;B%5HGZA6-/$JFFF/OT?-<G;^
M6=2]Y+I/L3G0\Z2J0D'YA&"?&!KV5L!=%AY?342,[X&XJD@J676UE)Y$=9Q*
MV%3-'37+,R8'D]C.BNKXL'7JY]7"S(9T(/EX\FW(3P.BZ6HIQ;AK]BSEW:Y(
M@U!*TJ.S0G;S RPWE/"&D&K[%[& )7LW"I[%B:944!.89?6IHB'I@,<WS)X>
M4WV>F:ZE;]74.#R4I6IA*@V^</TMX<31C$$-])BU]('/,<EMV4[>+AY<-M8V
M^A\[CSD=%9)FNW>\'70HU(UD0[ZBA%,F@!,9G*^<,*,*\&]70OLX^7XY&['S
ML)T-+K,\PUN?&S7\V0=@3YO[&V-9/1 AJ#,JWGH+&[^FJ>5'8#YIUPT^GE=F
M)%'NQ^L3J5/%$Q4Q7+[(LG:K?\!L1A*RS5@_M.4_4P!KOUEB.V<56RVNQ+Z&
M)V4]C8Y*O3J@<^M.6@3BCDC$[>$'J7_X@*A/DV+P=E)[:H:1<R*1NVNFX.>,
M9V[@Q,C)';?W._KF&W1O=,D>R!%".W\+?XCA5\+0H:'>__3<I6:?:1K>M)/^
M-#5U^\(=#Q>'XAG3&T?K3AS_30 /?044,8PFH[Z:,9^*PWZ9/3+"X%7,X.M)
M#?/S"V!6^)/+K6Y8X"R$I63#Y8AY4BQ.&[JYNYJ,2TE(I_Y(Y8_T!FK^N98$
M58E?+RI.L$MBW &MBD7M5PP31,B$5'0EAE*$L4\5<QV&78E>G*6COBZBMS6[
M] 27FJJQ=J4%S-LT W)B)XI-6W"I[1C9/H\:+G<K)OIB[_Q TXM?=>EM&L$^
MQDX8$ BT!ESXJV_L'HA\"Y:(6R19E#!NTBI"YSY]/F<7OL6TE!->DDJW.CXB
M<3.9)S)6)^&:."?JEM7R-T#6?L,T3JPV!]$M&5S(X^Y5;AP)=?0_0=R288L7
MNT1$TXM:RL]:2R&PO^_MIFH#*^G#&H"=1KJ80+IGA2BCN^<GXE0%"T?EH37K
M]FZQBSY]_E5"Y#_G%C4%F"ND*X &V0-- =*\<6X=AS+SY0\),T_\@CQA>3[%
MIOR<DD>Y[(>3;A8+ML?89".?)/$]4L3'[('FIC#U^*A*7X9ZP6Q=/J1)/]9=
M)94O]+25>4.P3/SLI:_^_H(:WQ#3@-2+GMWOU6L,#R7[=O8Q3*D*$-O6QO[^
M.:88:1%S\EF_["KG6<BTOJNF V]W^!:0:=H :*48S"L]"YKAQ]J+5H]LHCEV
MA+1*BKD+JE\OW/L]21J[SBYTL,_LU;$HCSYQTJYGS_L!B^M9&HX<=R,N(4%0
M65 0 O'/DZZ'R.< /PWN,N5<07"A=!,&C8=SOOJ]M]=4^BWXFF56W:!_9!WV
M]IX91S]&&..2YT9L7)4J@9^U^FC*[X$3R_#VU:SYV&#<KQ=]$=QX];Y$8MYG
M2'$(X,/]+,X) $!+YRT+YGW%OA5,ZXEE*.2_R;$;&5C13!5;O%IDRR;4L@=J
M7]E\ D37 +-ROP<PDD];#3&!B^L:!-N&A&IJ:/7DRBJ0-M.FO2./\-QZ^SRE
MND%C,8%YB%9/QERGC9'Q,+)!O(/'IIWGSZG;XF>N^ M*7+_&-A39DGZ<*X4[
M:!00#IM0(,?@LJG>%)_2 +)3SV-[CPE4"]TRMSR1L^0YCQ7IA''TM$:/("4C
M\I)7/3,/2<ALNTKAZ"Y#G&7]R&%<J=4-S*Y90GI[T:OTG7%FM@.=[DD.!]Y6
M.WQ"F']#E !(YT>_SCCZ ^F^'MVR'L'0;9$ST;_PL#5>U\CC<6G@7<FP"C:L
MX*'L M4=NT)DASK2"_JL3?)SU!PZ\5Q=-<9/!)<?1>0?&;X_^B)9Q<W+^; 4
M2'OZ#2^>Z@A,2Q@-P,:#0;3B\-(_P3A88B"&E]:P:1I$--&UPKP^,7U5QB(^
MZ=$&V]^L-/+]-X1 =)NVY#ZS2\0\?$A.Z#%F(U;/V4'U\2H##6UP&:YF?%U>
M<_+')[M^,'W [TX@.P#'<_(58_5!R=6 RU[.-<AF\8!7\< ?SC.:M WML=^^
MTXFI6TM);IH3$'H(LN."DK96R#+R.8H[2 MJ1%$@FY),E.XH\'T>33@0/Y_&
MUV!XC[L]24WY1<"G36W@#CP ^1GY!/$3PI^"FL.+T;I_DQ=>=G[-L*?<R";?
MT& 2;QQ-;^<YK'/YC/-Q5!&JMG$U; X\"?@"]W;GD0=;N>&>@A, "80I;'%*
M)GY]0>K;F'#EN\<;<27=2'L+H)Q7E1B\,.IK9BY+>L8+=0BNZQ5V?")VXEX]
M)F$XN#& ]8$HV*9/?V^XDWW6\)??9XKN?H_TE7G^N(P>[4NTQ-(0%#%S;-3/
MV"W<GS@\WB41Y_E5G#[WU5%%[UKS=R/5W0F +H_1-1C'*?C./=#/SRR^$#1=
MGI8S=6NT[M.#2A]KXU >7Y4O#Q)D!/X^R0=SY@? M/?5^1[(P30>4X/I(?EV
MYRNCKF4;MY(W=VV]BF=;AT,' [RE>]U'O:>._LUO(F+T_KP]T)I!K:'95#(\
MF7EPOW^7@/V6/C6ENAI[69?3O,T5].)":37:!M S?"I0F@2:)#,7?S[#@,(?
M5Y?]ZE!:9=#4*^-G/W@^)HUC&%?YJ35[H *Z*<# "P'9D3RQ6GR*C8QD\/ZE
MZM'&Z)J,FQ2Q>HIR5T/+>$;X.^&K[@[C4JTRZGG":U/G0-H6#],&52OV0(>.
M['>Z1>%JC,'\(==9@P:4-92/@JC2,QOOFZ!)BV"SFU=<&AJ$SY N"XB36J39
M-R!S^/V7A>\HHVIB;+34>?HZF"%7YVQ4F=T%?IK*)5+YV*:"C_"LSJC>*I)-
MW(,"H4GJO7SJ2V+."1LF"E1-6<8?%7FCD-DKN$W$A%9L3%%5]GN8,^QIY^FV
M?_ G6DU=WG7/]3]0/9UN[*WGDLUK\TWH(8BUF8BZ"=I59G$)TH]/(R;R3_]8
M;]4HPWG8JY)W,KVM]T#^4[/7)(?)O<M'90[IRCE$&!_0]N[?X/^B]!-"_=(X
M!)LC+:86D\&=Y:^+6E*T J?US[I*ZD4*O$+E2KQ4$&J8;]KPVEH&?/D##9C0
M@]4 F'\!X_H[[2\,*P6&LB!_K*>M'JM^H^?N*&307A^\%IQ_FPVKN@EEG,JE
M&E&P)*<YWX,>+,YLHX1Y@\]-3<VLL>:0>Q6%LB39Y(Q,[4RJQ2FV#>07?-33
M/= J<_\PX3B<G1A<FV$[#%=&_[NL[$3K:[5J"ZE?F0'MBZH[XG0>UD VOEXJ
MA6%2\*=-/./+[/FAP+M5'D*164<4G9J?\=EE+^K<B#O^IAQ$F.?8[B?BXY3@
M3N32GJ>'WY3A8BL*9W].R2?7WZII_Q.1WRFO@8["$'+V0!\'NY4FD?-2SUN-
MYG--+G%?HNMDF,94^F8%*PL_EP"5B7!7-T)O@LAVP2Q.+-T6_IAR*":[*_6T
M05C)TOI"1]G*[+DP&O&Z3G#"A0>-)]A^R3P"F98N6ZW.D_FO,7-8)_^T'233
M5;M.RP[;X@V?.;<V![R6=+C"$\(NQ<7G[V>?NR\A:5[_M%,Q8GZ2I'W6PL:9
MQ@CW3"#.'LD>%D;7&@5)O%<+O8^O[]%?=?L<'DH/  (30N*CJZ^P#I,K?F*K
M8+;6QKR>O"IFI)3 M)J.^RFGYA.VEZ79?RG1)+=7*^9-)PWF\(DJID+]Q?UA
M[STKPMB&UX2<3SZWT';L;=+@J ^)8YP"Q.(\Q9B:0V/,*I-CL''$X>.9WBZ-
M=]K29>"]_6L[EI(".W%/F?*%$9I>\\"BC12PAB%L^#E\O(N7^HG.\R5%/@6S
M7]<DOMQZ._]XX66*NMS'WN\&OW_'T-D1DY#:55Q^(KF_&W"CA[!>:Z- K1#K
M'H8WCTK (QG):><2PQYU$2[F<R#0+^\?S9<\7D_N)[I@NB%)0MT?:HE>1CAJ
MIW%]WMKUF6HIDKKR9>%?![- ;K_/)O)<M"_=/R;/3(?[T>_3;#J$D)$NPXY-
M0^L^BHK(>A][/MD_"9]N%CDOF!:'9^J!0I"K=\F^,"8*XPH[3./H6G>3;'['
M;"1Q/Y3)XOT].WC)V_&]:9_LXK/O7O.PJ:/_+,M\*>EA)=R O("-N]NY[>^Q
M+H2'&8G08F<%\++GQ-?U?RZ6R&T"L;*AA,,0KK"&,6QP<S(#)ODZN-Q )"L[
M7<8Y(:3X@9,\QU4CDU+15_,YC.\T8<#GZ<Q*UG'&]9%S0UN&FV#N9,OA[3O>
MT*X>.;G16!U\:X)RV[6D))7P%>J5!)!TX7_&?\9_QG_&?\9_QG_&?\9_QO]_
M!D892BA$-6*[4R?1\UN8Z%:^T.)K16V)WG#+OZ8/\-]"SUM>C5^*MI=FW_R>
MP+#? \7%L28ADQ\](>2$;U3.(>>$%=:)'7@Y7ZQ%)I40J7%0S$-3&:#%SVA+
M!!A/<6.*IFK!RNG>99]*1?GS(VMC1SB.='R,3KGF/H6^"6(6%C:E1F+XZ\"I
MD&,J8-$05ZL,P_$S?\W/@XR.1EH:OCF@$QCD<EG"^;%A![H/]1Q/OKN.$S>A
M#1$Q1T*\-S]1W#[,>K2$OQ$ZDQ]Z6F/FI,X=XX93@8(J;/2K>@@93Q3YSAX(
M-]$II]"#+M!]>*C6-0 YYW%6K^//KWG?WW++T)]H%E>5!V6D1P@9P9)PIVH+
M4?0+B:+J]T;LLGHVG-Y<[UW]QMO(AG ]=EO[;H0.]'I9(49]#_1HG28G >6"
MWRVC0>:T\YS07BV!W[S+5G O/.0)F2'N<S<<G(,T#O5Q<:7%K;+M7M-#G)UB
M3>,;?A>4-L9[%TV4D'=+_OJ!(Q]ZG?ED-.U"OS@/>K-.6K+?II]!=MBA-5WF
M194Z, *!S"N=='W3VJF0HMN'!88M+^LU/4\_D/YD)T$'EBV7]!'$O/:O]HY0
MC"^:)I.T!ZI%)TK00LE_3:K'6IV.>4@6ERV??=<XLEWF'.]TYUCZ2P>LA.Q"
MB*,A+#.;VL/\1-KLH=QKL8K/[<R'X30G-8\*U)[TYL8,G.YH<,J;H@Q:@YCO
M"S%7,0Y[()JL*!:;*G2?<9666?+3PU[RL[Z03VUI5LKLKH7@AKWD8/99,T.'
MJ?M)H'=ET$*5__(.!&$#/[,'BHQFV%-0I&\<7V9N_C7RY<3$KV\6B3SUKYR]
M87+AVF\WC2ZO;R#$NR$8\-D.8Z@'2IC5C^>"*Z%I0F%RX;IFXS%)I'!/J;O\
M:7*$ R$:U[X]07Y4PH)/(7[@:Q$9\Z8"QEYJS0%AP0=3/4"Q6M5?+1X7_33C
M& JT:D<U\C/XCF.I893S^ @6Q*,!<9Y2C.XO@\&4A14T>@\:U!^Y])7MUV&S
M.%"Z?]%\*-(7/&5C-@SK;AA>20NQ9=-H;23;<I=6ALRPFJM2^^MX\YB7 G0@
M38%6BU*K6H"WWT4FM5T::8,P[GS\.,30+6N*NC6APNCV#KY(_]@OS+O0.\/W
MDN1Z]O&[)%;RCW\W6_WWX-OAH]LA.XRU51G"S'>:P00,-]Y]R/VIUG*'9[:0
M8]^9NSSJ\J::U6_!$];[A1DET21O(A17,5>:H*CIHO"F3?K'EEZ"KA,HAKNR
M^G!T)L>'7V_<VH8> +&B-,7;#:E!1S/XP)&2-7%=3[=6UP;#?*0LZF,OB'A+
M1=J[?T1.>H+HMQ,8;YG[>XV+8(((3<2H/1=9*6$],+2.VXJ$\3"V4W5\L6-Y
M=^"50\C./*Q3=1>C<VB_?>H_+51WO,F\+"Y>2AB1G_39B=QYOW48]J76:S<V
M?ZBS5-;DUY?:E\)_W[!(_F%_]RNB'A)AEK1=8@WN3CRK8O$MX7T:QQ36?F&@
MD]SA]6F%)S<X^CO5)\AOP4UE:#5F+MR%"'D.8V-P$TWY.G^%9-P=)C9C4E=_
M<]=>V(G+0JP/?Y;\/S>BR_V"T&3<2,KSR,FP.=.8K3T0NZF+;YFGT(_J/'35
MC67'C?-PD"F'M,:'0>HAVAPQ%2=,]1V&>\QS>KM.*/KZ$-)(9TY@&S1N?C@5
MQ@7:54R0(_C29+"D- J$:C6AR>9%N)IW95;!%;=A@VE\H-"A('R#U\=4Y*H9
M!U[%BEA<RCB52FT=5<DUN3.APW_%Y:>";Q@X1B+$%41X^?@"_MF'J#DDX[0I
M,3BZU5PTKFL/Q.61,_LR/338L6=R555 XU?$@'E"*D&VN7TG#@B\Q,)F=.P>
MZ&0@.-'^T! <-A>V.5HG:C]M:SVM=##JA44<N>:C[-?08^_$,H?_.X\RGU!T
MK1T*.IKHE_N\ZE?ZQ:2%R/3+Z]\0P:P.9 ,_=@^4C!?C[T3RJ*"J:8^6@OFU
MW:B\DZP=KD=B#\464S;9=K7^!^?\7QDA'*0\NIT[J@;<*5U/[X>2\I!W7E<%
MAI\Q6F 6ZEQ:(T5:JAP\?88WRV+^B<'O%!0]%('#"#LWC6NREWAZ%^L/B&K*
M$38_UR<]R\MW_C@PV7Y9>"/\#SNU(8&!I$$!EPFD%9'7L5&=>.'6JWS,R&EY
M_@V%* ]<?E[&WXN);#!WC8VO,I?I7S"VFW:>V*ZG6K%5)78&X27X*6R05]!1
M'Z/"H&,II4VRUR#6H$]Z</%])P22490GON9W03$-TDY5JZ7UWZFFPW>3&0AG
MM=.K:VDO;T5LU.HO_MZY)RVAMJ;M.H[Q,ITJ(J!C-C'QVNHCZ8L=_(/'REJR
M,AS/_&04]BI$#AYY%'$LYK;?] 8;':P7"EE%TW4]4/4<'=[\V)R@7(^:Z>S&
MMI&91F;6LG+\";7#"W^^/KY4>8FM5VR_^J<HLU#S(5T9SC$"MR*\KB2,+4Z0
M-K>]IAY>"54ZU/D19VK;T\IT9U].D*.H7]NOCX 81T@/NXX%VDF*PHQC8>=L
MIL!'6\GO7MVMSKMF]M/ELA3TPE;Y)HHFUTAB)\!.=O,G;HKRFL7<;,5YL[+/
M)_U61K5\;2_7BK<4"7P+QK7(#>R!W*"I" BS&,'S9U:33.P[5$5V7Y,O<7"I
M;=*-/PL/.K,!%L[,_*AL_QH(>B*D(76_@-ID/_4Q!992%U2?85-SFOQ3[VD,
M,;0X_S++Y2#/@5JU2]HDA-4>J/-7&Y C!U%1>R"RE=(>"/(6/+4K]]>4Q;E?
M9.;0<5HQW02.@!T.:<-W4I8X;C9_GBGYV7>JS=E%C?%-[A@<6Q\N3 ]@3;48
MK(815B"2/5IA/2W#O2I5B@93/+(.*G]?!!_I.'-(0-&?3<#5#%SZ!]W=NU_[
M#5;'BN)&)=4CN99\"?0=S8HGS61FUQ5XEW\_=_MC8R=F [88\1;Q%5.W& ?U
M7(^Q9%W\\3##-%_#>L1\^(.(9H.5+)NS1/C"V2@Y!^>3[1H@]I]_T D8WT&:
M=#)FM4BU-+I5K@2WL@<ZH:0POI1%R_ HO6[$-?S^@MN3#ES$!XZ!VQ>$YTE2
M ,6@&S!4QP.K[A+!48_6X*KO:Z9U?<,+OY4*DO[^%3:J8=L#A49' :Q%0>\Q
M_B#B(BUL?KV3^RC6GC_+2"7/FF=%I)W3(<WHP;D7!W2"'.X1TGJNG8FR^P8Z
M9;5_8-P<CQ/O@=2JMX>K=R,X<[YSVX<C\*9//C?PEJ:3;:]RO]L:\!H<WS^N
MI(9T7Q=$C.#9@P9/T8AA&EM>T).#)3?&+;\<W+@S/J[SW]A[SZBFNJ]?-'1I
M1NF($ 04E28=I01%*2($4*0)49$FTE0$)"0(TIN @H 2$&D"AA) BL30$>F]
MDR =) $,@11.^+_WC''/\XYQQSCCWC/&_?!\F!_8[.R]UEQKSOF;:Z\U?USA
M73.J.[N[.<#2\RA%6I&>Y!K#32'<," R1C_0>?2YUSG/;L-L92E. ;\ZB.4F
M5.:(!Q+A!8E!5LLF-KKE!ZZMFWU##Z+'O;TB$E)^&* ;S(UUXBTX5G3_9[SX
MOV(&A9GQRVMP)4;H1D>FSF-$G%95W0,T;)YUIF4^;3FW@I?_=C_D1D@MQ1H^
M.LM-2X&)>90%EOGX^*C+IBBHFI;'/:]]*LD6N?/ZAEBZ? >&*4F :7/8Y@V]
M"W%:">Q^" C5$R7'A>1C\^YY6CDARQTZ!V4N"&X0)*=];3=B3+1$9>:9?I!O
MMX (%LBX2=3FEF9ST-;S5!P;L6<I5,KQ\O4YE\0UX[=!&;V;17J/ 323_]H<
M^VC(R(<GY>>Z@&6Q6W(GUQ=VD_]0?\MMYY$^,:SRA^=)<OU6,X9EMULNR_B<
MQAPA9:YY#!AT[L72Z'' O5VWF0;P\P"BK@&)2JNBG\Y'1>M8'51_C9&#;U&"
ML?V3$STIOI^N^HA)1.4MQP)H+9^:KM%>8^9S7AIM^GD&Y:P=/-<3([\JU%<\
M5QYY;72O_#=[YIS?M$:*IC2?X>*9]VX@I_[_/<_]KQP)QTFB](+;*_J)#N]9
M1:+@U\0] -JB/,C5_[30R?;25K?X!<'E.<+T'"MBY<4AX*?9WB% !)5Q=)XK
M%'-"YRHQ$B+@/BF4CW>4.!@5^43_51N<7N,^Y&G8&5K.&K;??GRG-Q"5A<!=
MI9H? CX]P\]13\X@B/7D1E>?Q%RG.ZN#=R%?O.DO50_<(JE7<$^&+N8FM"TL
M;LH*3,:OMMWXFY OJEV67;AJ0]74Q((.Q#';J2&'@/;SAX#(I2,.=X-:NI4/
MAMP&?WP(: X_JLI^?;D-0Y:N/RK(A?CG%?\.6MU[AB_.9YA(-[6OX! 0;8/%
M[(+ 5#&&.W\#OHG!U34=.P3T;QX"WF9MT96-_M?7RNW8T 5 K5L'LGH*1]RE
M8_^I+/;?KE">*1\"D(PG,J7O1U&O'=5*S]EGN.1)*/75@?4A@+>'8$2/\J%^
MGD,08\'_>"4T$T/(H<LB!BX3?>C'_F#(,Z!__CV5D40]@))Y,+_ >$&"#XV#
M@2S9!P\!OX&#*+*W3QAX5QNQ>(YR"(BW_,?+J".'@ @.HC8]IB\.03#R_Z]R
M:_^\0I_^A5@^JF3F0G_ <.^H<,2*'H*LD7X(D(2_0[0\@YT\!.1.'0(N:,Y1
M'WZ.(LV39?U4VILT+7[Y<J^F1V-B+H6"3U$'_ON#08 F63X.JAQ2"#&?R(@<
MT?]357_2]V/(-M@9Y1V&$M]B]EE(D*MCNW,"[J3ZK\DA/L4>M29+5_T])0-_
M.V6P!H?I1DMA^!D*K81N!P@A2/(3B)6I6-H-6FR3*#D)!\6*J/7QMY/J(T9V
MQ[J<I9E'*Z[DV/9JL;Y5-/(BZ_RV61RC"IG2S?%]]+8L)9J8']0OJO@*VMG*
M;]'K"4)^6>2**-P9RAE1LGFAV<S0] LD1(V"#E$#&]$YZ.-05C5P6!-@J!H8
MVR10A:DBT)$^?CX:Q7R-5F?1CSM_9!^3#-,MP4')<E&;@H2\!34]ML%&WA*/
MV0MCZ(G"S!V;H?27!BP7(\)[VT'/F*>NGGE!FK%B3%Z"$:4L>%XB;@'!1/[I
M!6FMK5>H0='"BR:_G&TQ8?[9WW:Q]N><AK O5HOUZU.]0%I4=5+8K!BYRRL/
M]HS@_/BD6> ;^\?"8WQ&7@73[%,U?^;...E.*\,BL-.?'Z&N+B"+0023+?9U
MB1.TQ.>:([B4.8JS1?V(_,+;^[2,GU\T=,4>^*V=EGAMLQ2%1>V;D)"' )=3
MC!$R/8N:I7@&>GGAPV;5(H_UR_BUYUK?X0$ Y@':-O/_O#<'."?[?Z])#S^.
MP)KK\7@@J_HV[WG#SH@,E*IW:\%N>/JX4:HKOZET)DJQB'%D<+YA:M[Z\0,
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MV'B]X\CM;@726ZPU/3?"\NP#3T6[2<?MNR4=1R5!]M6!X7.D"QZ( U/Q8#;
M$1GX51UI/&3B$$!:&];Q]"\HFWE'+_/">TEX_MY10%T3F<'?O_(Z^=:3J(\-
M$$-66A>AD,Y]@1#>-C!U=4%7SH$@3F%:^ME/:^H"HI.!:@Q#OQ7Q$AP/]DB:
M\"1E$%UJL:@3<Y.!+=;?,2E8M:D9J>V3;,./PDJTV[,=%NT,I'EV^W3V.=J
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MOH0D.$#V)9W8#@$5[Q&K\G]7$003\+[*') !^2 6AX"!I5"]GZ@N*%E1DYH
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M.B8Y*R0-^]),4^P746I[\IE(JY9'3S3P_N+/WGBN(M@96COA[SJB,->&Y-_
M#UF_[3F>4*C=(TD_:Y,<:K#2YD";!.PR\FLIK^P\X ^$^+U;B?7W9J7;*KP3
MI*9N+"631=I#OI?LVM<!7Q\"N&"J!%,</7F^[]CJ>L&*_:/@,W':'\=3^J0K
M%C^^3Y,=)IVV@>J#/B()]EMBAX!'U&,$:,1"ZJ/ZT4;OCU<7\341M<""?3PX
M%/6!\5\@^4(ZXZ$N/J\R@:^,0JO-7M*\O_JHFZYL2=5"5$P2YQ1>5,"N2XMZ
M-89=>09E9$;HCHU40C?I0_6@&SF&#7?EXJVT@!?U<5,A'V[>#FI_P7?+HYME
M,(,QM\:1\TYQA$6=,UZ$J9;:E]?3FJZGVV@H]P1I2=,\[R4O"?>=:6$^KC$/
M + PWC\WQ8W;VW3!365M'9OI\_PR_HJ6F[MV4;JANNN,;>C-^M.^:\8;OH&H
M+@3YXEZ,DLX#BO>ZO4R2M%&>[>JD8V7VM=(W9[&3X-FZQ[VTF#];<$X$]OHN
MXKA[[5"/"RA:J5'=U_);0\V,O$'@Z9-UTJEKH:0"QJC<+(-$8>9S))0;/]YT
M,-%X%UB6721?%@ZBK(*V<X"C4(8Q)<;X44Y0;Q#0&B<54W/)=^U*O4;T3]!B
M01KB35FP=ZNKL60C^K%P_%06 D0U([23--)?NM1\/H%\YR1Z*TCB=<S^WTE=
MN=W;).RP]!!#X8> >/Z&(B-"6O$)5QW^LZ71F(P'265P=P26[WF&*WEQ8?.6
MX2TA^FFA'MG[@X[7?X)/<L/O,/W&\"]"$Y"$.W$]8 >#8)=G1"%>OD 7L?#)
MJ9G\XEN(YQU">I$8(T9\+7,Z64GDV(#B%6[B9Q[5]:MS<Z_;75+EUVUV4 99
M?WN05)@/]UZM81@7 V1A[[+:F"Z>)Y=2 D"X="L].ZI!,=5S=X'.E8\01VYH
M+I _OK-?\](0X F2>2RT]6KK-3@Y!RC <+]G VN6+<B7B2PM*0VZ3>EE;0''
MG-\@W:,\S^^*AFO]=5Z'YOW=9[R!56?0)0J+$/RK*GKBWF,AH6[9AP,=JI>H
MK-W[8ZLC@*-R9_\T?0+JB"E],X,00 H@LZ'(/GCA># .-/JUT<ROR,"+EA'T
MK)Z]&IT ?7ZI/AYMQ<./3"\XUL>P6JP;YO>P&H0B]N00L)OVI\GZZ.PW JNK
M)PX?A;+]10D'-M@3#3\6VP6&>5W40IN6N.<JGZU&YT:GS!HT/._K]0O56C/F
M&,)4(Z@"VJ00\CN*)O4ZH3:2BJ#EH1Y/ZHS6W$6.3[YV>E*JY;CE_05S5]+F
M%0)[@H$OOL!,#P'E"AAZDOH4?1!*,)E[C>" LY"7VR<UHQL]GWU9>7FOMJ9_
M#FJO<WQ-Z[C0B&U2'LO6/2/J22#]9F$KAL(\=0A8V=&7V*<$'VW45M)C(F.;
M3E'5AKS4$:<,D[-H-XFW^L>K0JU88XQ5;MTI.?VQI,Y0)$5X.<23-$ZKT0,D
M:+=A^& ZVV3[ VMNGS+W2PY3.WWI2_K%,N;Z6GRG][#M<DO15&=\)\:[S+GM
M%#"2(U['63B^FIMBQA[HA-##>9_US1*(U%9.#F_'KD*A5%_R(8!B3WU)ML&#
MF!BPL.I.A<?+7\RBY\(-OZNT6H\,7I_^[7W76C*9D1&L@#<:*,:!P:1"LNF#
M!2]FS4K7Y#)U7@U7WK,)@P"G<P]:>%0J:T5M;H<^Y<""T>E4@74\(D9/<Y:J
M2D.BW;]F_OR[P7<@!ZR=75-MM;WY(.FM[=6[V,G6+W^F<_ -8+(,L+DO!GD,
M@7-===(B1%;C0E3V-H3O0B='DP!!-GUV&MZG/Q;HT(0JZ9<0V)N-"@6PQ^D&
M9$$"PHP<M? HH"*JM6+"U2%#F=)::^R\DV]^W.%E./H-%ZZ(I8UJ27E&GP15
MF9?DWX-9#K6FV22VB_AO'I\\KZC/92?D8)W$P]2K^<C[M\2[@WR*%O5).>U3
M$Q?9 2_TT7WTQ+K&QJ!=0Y3&CI'T#?G@AE=26APLTAPL6JB.OBE,.Z(:V J*
M@HN/PC7(#UN:)4YZW?;.*K3'\BB0\O@_O%4QN1+ZJET\=#E72WI7D\ZIAUC@
MA)TY*IJ?1'_7K0_Z #I:O=)5.EJ]4CU:O6*O1Y#E($E-Y\CA"]=GQ8EZ<?XN
M\[Q"#%2-$QT^.SA[[&OMU ^WB<MBKBWWQ3]OKM[KH/)!Z!#3ED, B6<8O'L5
M57A$.#:W?9%ZM+HZPYBS-Z;ZV3FH?"7XO8[+_A F,I\/#Q2%/3\_G"WNNZ(2
M]R)DZ*?^]ZGR0\!GH7MN15/#-EU-\N0,#X(GG>OL O@TU*ZGR'X%?.*OYQZZ
M]CY*HWNB4Q_"(LNB6S^_BQKU(9_MH+Y'MBA18AB9\^ ?C )Z[OAD8 F=ZV-(
M_M%68A?--L\6]<:?HC+6P[^?EA[#<G@?TSF-#]5%X6LWL93'*U=@X)-?J1<T
M7^FPR15'SE#!8I.OG[+"GZ?*W=)\!)C0;R5<9FX:.S)S^J0-N'HOU#\/96NW
MFJU,V!BX@1"/Q+&U6D4JWXIM?=>5>$,N-:RNDP>PJS3U<E8.-0'$KYF=Z@QO
M"4@4C#1<C*]$%DF"FC%Z# U%E2)PNN2B.FWSC(?&F_0:*#$'.'9E7Y7.E4"\
MLH-#;@3@D1O[3K-[K?S87)E.W[N78SRBJ%PBBQ"R8(@;E.$0L ]T-/V_TCL&
MG:;R=.PU,,X(7R-">[.#+X3*A>-8T ==9MPC!#^VXB0YHN-!5+I;$7L(N#VP
M&'5K,)[(X6#CKV)ZT>WS^^WA2UA [5[)7X<V">%!F!=NQNCJ&)H2PD@;[WMZ
M-LA]!IX>*,=:@7OE=I+HQZ+PW1?H8E1C0N<[PWS/DJO%(EW[F1<>;&-9OO$R
M]17@UN1VO[^72GLHJ-\EFY,#C,.X)I'/SH4A7 \!,6D2NFAB4G1U2+!Y4%.7
MT,/:ZI.=\1$R^J5]VWIZ9-%E<>4&AJ-FHM7QD_0)!<D>GSQ&Z_L2U;>42[VV
M3,4\W9U_!"U9W__%>?]+3D*K<M_/JZMT7D87K^IQP?R(;PCI4513-0F9M"53
M3T>P156*:D!50)] J-J3SQ<>[+!W: GVPF=!U87-<Q-]5\N'8,XX4U"TT]GA
M/%6[P,=KQS["/E1FY >=;/7[PV;TT_2$[W&14&"4PB'@L<_4PCT"@BK/+:Y]
M1^*$T.:+LU$M0G!3++HV\\N J/VEQBT.$<#O'60Q8U0_( D69CZDHI%J)%O@
ME%E%#=$IPYF6QYY;D)LHURET/=&,F/*BLTS&;5'K?D?$5%^B$>4.? **E@UW
M ?/23ZYF<Q-<VE)#D%8IG5)QCJ^]$QUJ;3_K?]?YEE3CV8J83RBDJ^!WZ&U9
M?31Q'WW0C2.>*K!/4ARH"MJQCN ,O+AS,]PH1&B27+:4787)W+Y9&L _=*S1
MYEU@%IU+DV(&LR?'9Z*:R[B630B\[642607MDX#ZL&<R8>?3EA;SO+YN&%Y3
MF?_ LR ;S9CO78BN:3N&7ZAR.03D><O]72<](Y2E,W _5;M_E^P<-MJG7ZE?
M$<_NS"R,*%%VE:U[Z,ZR#)IJ^0]9/$_JYU4]X8&-TL8;1"6K2F'@TA\';59*
MT_/DR.FI<;W.O>,"*=. .4DHH_NU2N%4)1^BIMT  R^]%K(VB9K2N<P\$>25
M\)4BZ';=JX7G'DMRN),")7#]5 $C?K.Q$3_GW:*/-4795]14#RX92$U'XUY)
MQ;FOR4QJB0<@[0^6V^:J"S=#%B#'UB7$AC&N@JFW1IX4E'^+HPB1PP6B+2-Y
MWJ] +/5!#O!63(UA N4^5;=A&%=Y2C96+8B/U]F8S\=V JO<(^:OW#36'L0F
M<GI>-404FLIPEG-A8"$Z+[W??F-6GB ;K:..FS%MV;EZMK?06>92QFB@_9D4
MY0:)^RS]U?"J?[?U_K\1:,P<P=:1VVH8XREGXJ6V7E*$P9VJ@JJ(B([I>76(
M,F.>N.<<YR A$G!D7L+D9<'DL1;[QY7E6%;[CC<WX"X(K#W8F1,-/ID4/\LU
M..NH???= Z+@Q\\N\<)>S8YL+'^Z]AP&"$$JI^%U _J@XPBL_"' HPR"QS1'
M$CCB!O^ A<@W!1)G\=L:=YN&Z!L^*9<#OR5\;ZSJ.H=1@#WX2F[ 0389/EHL
M$&&8Z77;B!A!^YM15YEB;#>Z=JTAM-UFY0;B!MJ" Q^Q?,0(A1PI^UR)[M^-
M,RUYM=BFBXPJ"$I. GQJJ$S;93,FE2 K41O<1!O26W(/1RLBX26\N##0"R5L
M->Q"Y!)!^:=;<367E_-4?/S"?2+/C7,*A'YNP>:YJ3%F-?157G'S4UW%MYB<
MS-D[O*>3RR<[[Q"NLL:_M,$G;:I3 %0[VEOZA=HDO1-72]9F16OK@S=5+0CD
M()_=5RFPXN2GB]=2&GZXN'# 56[ IQB*B.%DV%<B>;]@I2??T<.)+^3FI9/5
M8@F*S[^Q^LN'/9!8H,^+!ZXF:0W"V>B#F-JQUF-4LR^KF35?O,../JT)-8A6
M#GG=[SKS\.RU#:O6C0C;Q9AV$W7*UMD$])CEO2X?_NGKQQ)=]1U5QSB*BE=8
M$LC*!!I= "9-@(;]_NYX$P)<(64ZS,K#;3-R8YP5A67=SSZ+_^#:</%\#K"]
MCWP^8./&PE;$(>!4-20>P?M\T]2*0,\-IM7IMK_)_XH.WI'-D-Z$(!\@9CD!
MS;\CVYF>Z*K2N16('4:$+9(U*0*G8& 3H9/ZQ7$<<KHMBNUSPKD[<V-_OGQ%
M1%704%_23]U(&!D.N&WGT/-,0L-,YF;OM\LB#U4N!>4 6Z 3&)(E&47Q@P4F
M=<R=>%(M0_B^N/WXU')T]7G>^MGV!L3 YBN6%XO6\4_$G"UTF9&-F/GR&F'[
M](TL#\%\])C5(:#9U'7VWGG'BL5[SUY!_1BZ9N2/8L\I99HDZ]%/#369H[?Q
M#36<:BYB(%?T,D>M(&&+*A"L/Z*$F,_)EOY6.^2]'-J3A[?-<;T=I_UDFUUN
M3^\_!60.1!7!+M"X@1MBIG+DV[>MK[-6\7N= [ 4HWJ19*G$A"(/A !<1GTQ
MH>=338*W8&'$&_[E;/8;_YGVK^"7!G4"&!G4'@W-$>\/X=4H84>6S,RLU@K'
M-H]95W]\9&7E]9E3I\[<E]/H='AB2  )12MH4F!$4K:M14)M<];6<9@*X5?R
MX\F"7)DEW)_%OK381$L6MAU3 ?T.@+(D0(YDCI^5^^8DBC?YY!>9>(.G5/>8
M[N.; .HV(\+(KR%=R?P+2-Y[4]/V:R_@,E?BD_OXSSW,'A7ICT^$>]J!+Y)W
M2$']ZL:(^:*T6BN/6@\OQB1K_S+[3!^KD5Z'[56.I?5_"@7K,&(O>M)KMI @
M]H,X,=GS8AUOT78_OHYEHVHG5&X0/)\Z:G,*L>&18^#/6C/$:TY]OW0M7O7R
MAN?&S?,LQ'#2,"U43Q+>AQ&4)7\D/.VP;"34-=*':NG-/&/U I3:DQ5ZSB>>
MO//G>$PMBV>>WF<T'0/O5\ 5$ C5A/Y1.[;R4>&;J9M88JTO1//GCNK4SW;(
M#&KJ('SC[B'@"<4F67BR)@C^ HOQ?E8;<"_8@F-!>$.6PD[5)\\0@R'D?**I
M^?#S.6Z'.<6:'4_CN\N.=3LZ;6*@I>V))M?D2)'3B@%\&$<$UJ&)B5RUH(D5
M9[E+2$0^*W,D.]%-2\H4>TZ9Y->F7"J3,F12[+0VY]"V2WI,^1(+H-K3$AF*
MR=>39N0I\&Z<(I+P!2JZ_H+?O/ZV[;2.58.9JK&5^UU9-Y<4@Y]OC)N)\6,)
MC^TAK8@H<,UR),R9Z*9?/U3=@B]3;;OR!<N9HI47_/ZKK6+S#[9[7Z=3&HQU
MY0[8'0+S,DW29.P> 71>Z;NR:+'NM4.6K2PXEE!4(<(R#MIR[3)H2A-T(&GS
M"U29OJE,S"*=)QMXX$T1;(5Q<(' 2KL_FX_>?;;=],8GYZ3N%0'?=G2)&MV[
MQ'4G7CW$DN&+O@YNJ4,8%L^;UCL87./H.E^)%;O,TGGZ ]<>B'SV^P<2N +T
M2K(^S#0HS<OT^;,S=T4QWW3"-_5!&1I-XN3OC"<8TO*\_DY]/U.*3IJQGUX3
M&E#Q.-#+3C2Q#I"%(=5>*YJJ5LR?UT8\;U3"-8#8R6[&_6K??EUQ?>?&FU#Z
M9"JVC8]5'P*[&#L0*5 ;(Q4CI)5\[8OD#PLMP/%FI#X;7!SFV^]_&3%?POT\
MTW]JDF'F(7F8#^7*9I\<GGP<;Y?;$V(,Q#?&C!FCGJL?D2)[+91IM'L6.WM^
MY"/F1-=A6_N/<UR-2^JM0<S'(CC_J '9CLCE\IP5RGKS0MB3O4C1/[42!78>
M29[\6#K40>[8A.8SLF'<V(9RSMH+#.&VF=!2R)4_8@]*UW_WR/ 4A[L%AZ<H
M]QHM0XT9Z- >XPSE@QD-JZ'B]-@&%=6[N[7!Y9[U_BD9BCS&I@9^I^^[D"+]
M?2\#SK2SG#SPN & JZP@"+9*,4VGR9;"8=Z-HAX!"UD.#PHZ\*9Q,4)FV!?R
M*?8;^P6G^0)";4-F_: 6"*R*&FA2]6[M,,R!B&B3D-$3"/:I6KTB&]WE69+!
M:>5M^[/I<8[%M<7([=9=%O!+,:U3*XXBTIIG="HTL(V*SVIU_;)'U %P\R-&
M-XRSCR 4=NT0$#$RGW!QR[:JH29&?>4)4TJP2:YUHG9H^-)Y9]OA=QP>\:FA
MT\_TCHB <^']8&'8&>$6""=9:,J6'!/$,<Z.*>PX\_&IAMKFL7WI-SRI9^['
M!ET$M,%;[_A-M7%W$EN3&Q/J)NXP+XMT_=5BV<X!8OO&HW!)T4UB__EJ?R;'
M4^.V^FC4U[53_C/#E@WZ@S=X6Y_\_,U3[**EBQ7<A5"%YHPP(SJ6A/<3$_<<
M7U<-&XA(N4VEU[;[:J%&ULZS+$,GP-@:N HM L:!,WLQ"]V@.30;W&JJO6RD
M;,IO)+73O^D,?6>& R<@"::HI%J],U4#(,L!6S,/H7QYX+F/)>/I',<[$0&R
M/Q/0;SI_^$._4S",H3D!>T[[K*=RM/IP%8?A7)%@E^HV>U<09SK 9Y+:ZRO0
MYZ<**_I2"/CX)3=+9JDIAU:)>= GNC)7OMSB R2'?*4ZXX&L]TR#2]L>/\IV
M0*&975/.7G8[J3%B&0HK-]>2PIB7;>9619P)DPD3$+%=L/BB%WH'S42NIH@?
MK6+"C AR\[3T9D<P[DZ3ZNC&N8_/"RJ^!>:_R'1]\[F_U+RW6R;JG61RQ((H
MZM0P&LE(((XCO/IXR!WXWE?^A9Y1;?9NL?[68?PR?H9[RO?*'2-"N>H<Z\Z^
M>//29I>GAFBDEBIO7-D)"&(._<7NR[D5C^S]G /L Y,5-+("OL#8""IV]O^+
M6_^QZI3,"%S9E=^&#@'.9LQB16=KWC\.^-VA(O @H\\9^M"289P6C)9[[0;3
M;K>!.!,^OFL;-]6]KAQV+J0N&.;&$DMS8H0.SJ:3".P-/3!,D.R3&RC=,GMZ
M$&HXD*-!Z@G^-&VB;/5K3I43("L?S%6"[T9-YM&YE/!FBKV4:\.HW3B/6H<.
M\5=#NYY"8#GCP4O8^YR+&7.B7-HV6^("3 O@2O#&3,'1M@[6W236B5OIDZ&N
MC2/^;(X8ST9?G0X62L[%3\L?B^J6U?=]*%!X'X@/[ R:_,0 -L#G65E([JXO
M&K6%:QH$]5:-IR9IV:._E<Z_1G]1T7>?BIP6 U4SO !^KPU%OAC0-C<);ID,
M"-,3(^OM->M)UF7*9FZU:*;.K GS)#0\8E:[FR"RV;G?!0CS-48-(L91S0@A
M'26">1==-3!EW8F8EGNAP3,X3TSC(Z<UIW?O%TTMK*O,!Z%)8'?JGS22KSVZ
MX)CTZY]+)CSNPL$2I7[#E.%A)H(158AE_C2&#\ZZFJTU6#JY[$ (F76QM4"G
MV)E;RP".FT^P*FQH9NZ#Z9S2%+TU/2W:)\7&(+RXWNKS.0[[H'+=C2<ZW1/6
MGU[SMGQ,CG%(JK\+?DPK_!2JTG@WOU&I%*!B]N$'$QV':D.2933"BU?GJ@?-
M @H=)]MHKU[J=.4\NK>DR("L,PP0\PY)L/893VIK.D?$D?L(%).&,;:V4D_4
MA&W8WB43YHM&STX!,\:Z[]SEXH0J!5R[N2^4SX@*C\G=7V *R!]\@3[F4*%[
M=C7OZ9+&2\)13S=4CJF^TAC:J_=>]GE,*R]JZ@%.\G:\S0Z"R'>CO:<^;/;=
M>[2; ^S!D&4P&U$+T(@J3S ?[)E;"&YKD_NVR^<5S09\NJ>*6KI5JU_YF]A8
M$6_LLU"-U)VQS1"*#LR8%H]X'*.G3-4=]/:&*9TKFIQ%%DW]&#LQT77./MCA
M3>,GOL&B+J8\;S'?)_ Q1HH:-R>$F2^>$T:X'P* 'K/'R#[SE+ECY+ E]VQ/
M#,\L)*#HGHK&YIMC _9JSK72RS+,G%@IS'6,"S0*(^*%<.W^KHWO2ZB^  OY
M:J!]P_]]YL)U$ZDIODAKL7P#2K-M.<^+;6'D)Z^-^6J/6R>,.-_]2A'I5R3I
MVBX4[Q47L1!=P9-@4@[M-?PRU(EZ%W(B<.=&\J,J]^HX2N20DO-TZ;FJ#Y&)
MFKB7Y_0?EH8NG.[;A% <CK9NR/KADHX%:LY3T^H3(@8^RE2^6;,93(EOT&F+
MT"F*M(N^S%KTT'"2UKV._7WG;LT;VZE2H?X.'Z[E)WZ2UJ*7M5BF^SE>TUL0
M '_@!(KD0Q@+K\YP3H?^JCUX$U$K\^S78OS-IU?'&TXD8R\:KSOM_S\7<F<B
MU%(%64@71S$>2EPK]$N$ZR!O8F&45/"+P9:+'Z_U9/G=<94,2JY9LN[[)=XA
MZPYFIPH?[1>$/:.]H>IACO]5X!NDMY@J"#9EX+M%\?7E8HD/[]H8CG."Y2([
MKH8J0QO\G;:;QZRB?C;41*[)_]E>TE]'WCL%H'(2]UJ5)EGH7-9$%N/:)/U4
MF\16M$;:*84\;/XJA;258B+^_H*DHKV1+(!IW&8#@05-1-TDVU#D[:BG&NLH
M(:639B.1Q0$ N>6NYZ!-GJRJ5QFVBL%L*,_(8YL/C',3'L:PCR0(7"S:!3PO
M/L]"L)HS) \PG$T#+4?Q[_CNN88A_12LOUB<FY>J;67 799?M[<OCR?4:B>'
M=DJ'EQ!W2&3R=XJO^R68^B!,T$TPXC>Q^UQZSGA72,#SM1^%O["Q@);+^H4I
MG-)2F.<%8=I%3A?R[![Z5>?Y_Q>&YQ8_UVTZ*U^ZN<FR$)#,5[#QO)=#UPR
M  MCV!'N2N-@/$<XS(T6$92[KJG-&S'R26$#*!/N:===]70_GO.VZ._EBQ#V
M)@I#T]EF"Q!A.);.VD!TB\(-4IW]4.-]Q1Y7;NNVOA@4<V@LTNH3%3T=(9/0
MD]"Q:^XN_<TBI;VRR,7W:T["3X,+!V%,$J^Y4D+UCLKP7EK=>^FST8"/1BD4
MH-^2VU?#(*+7C,9+#7V-S(&+T."!&P !2T8L/?H"8L.(&WT"U.<#C>"%0P"+
M;4_9>K9$;<K//<-:JZ'IR2H?FPA$S$#<(J";8^$==E\;UT<5=,./-8->OV#
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MB)Y$/KN4J/RMY@JSB@/ >2\RMQ8=-O1K^TPB2/E7TF*.XY^7%1U6(>XLRX>
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M7H0A6'=G%0QYMZ&H"KS7(#H_IC2R]J.]QMMUU_<NSHZ*056[(K5@'2K@M-P
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M%!YM#O@L6D8?+U\C\'=PW'3@'>=Y+M70-;[!Q<G9MA?P_K'*B0\! 7HPXFT
M3( N-@!1&$F$\ZB^;&U>+0WT('E'DNU!/W;@7/9D[<[07U>7Y4S07\[_Q 'P
MC%@$#"S[,R/GH54TT(MJ2V[G38S ! *[HZ?"=T*N=%8[>UDLXC0=]*:K6F!"
MNKY?$7IOEB#Q+OBY\MQBM7EQL_)$J'>M M^9!Y?GVGJ[(<_*0.%,_\TU;>!L
MRR9)-98QE0@)P@U]X9J1(^FLCE/J0S$[-IV?VMB-9[[;:2[O!:/SBD"?ZBT3
M[ O&X_#HKK"DQ!V?<(]/\[,&NJ@P+6Z6ARZ[K"QX=#9T\1V*I\F.\(+H"CL#
M'W1J(/!546I"_(G]74SD&JX=9]"B&S6(X:CF?\882S+/ 2XC01],_>&+ S/[
MU#F+CJ-JRQ2H4^XMT/0VB_X>71%P'R8!,/_JY(,Z318L6K@Y83N1J9#6<=![
MG)^Z:.RNO_(:)03:VOB_WACN_]_C8'":<2FG@I"P!(XEBWZ$EZ^WVD>7^1.?
ME$RW205=-3X4?_6T8=7,BI7]L4\ODI_:+@1I64C4YR?$M"^<F0,\3"M^\1M-
MJ,G>MTEQ]AQE+9=^M&CVVNZ=HADC4\#4WZ?Q(. .<8V2@Y2:)/OB+7<$\0$#
MZC00']R9J:H93[ 8# 2I1&ZHL.V:K22E/IZ\:"NC24B9.J:>OK"XQT@=IH$$
M@_<2Q$0F,");8FIOC"#W,\=VF3.)Z<[7(E%I4L*5Y=]C\3>?="%_C&$?)9TU
MI*#5]B+J_G+,I7\LLJ-\F7'\_MVH[GVB]-UK-]S67;^80506&3,/E-C(RGB/
MSMQI%+']%SDD_YYW WLN/O&]_1]^B@#*3:0O.33I;8#(&6-5>MC10.UBLL.Z
M7DLDT< KHSO!26)_SZF7';TMD5<]MUO*"7YR=-+VU2:V(K>-!$O.7.^<,S32
MIH&2:G3>[;K6CSF:<R1(F@G]X;HO*WX^>UOP^0K7,,;SWW-QOX6RUUL61+Q>
M._:'+%$T.GS%WDOFDQN7C%/O0AJT3%KV),36H1_5&/Z,T4 G_6F@5(=E&4IB
M/PV4IZY!93,(5U]HAT7EB!QDRNG=Z4B2_'B%U'O*"!J1C=4.(7-AJ4;^B;E$
M525JQ-A'.BJ]QS?O=+=@F>"5?:KG\'NQKWX\9DV2BHL(W%DS$:(XWF)9(#Y]
MM4E\93]C_&VF)8'G2=&2M3%(K.4T>0_/AY"C'R&3<%3S?+^L9I"C9+:#F1G9
MZW4.:D5@'B098Z_H2N&2H%WSO$-DP_R?==KN)1Z\1Z5]!F">6-&;)A6\>)86
M+5O<()GW\[),0O6X0Q*X7>C*\, /UX#PCU;3DU^6NLP[@TPJN:Z<0?;36?8I
M#S)O C%BW/_=0."7S==3,WN,*Z>D/H!2/AG5;71A!BA%U3ZH,\@!%*\:J8"#
MG<H_&B.A<\^^QSKF^WW68UY";JLO]A2=^:(AO-5.%E'5SBI#SK]O>+20KB4K
ME"MC#7A[_G;Y_(;.0+OY4&#H0\OXL.:57N8]\-S4%3<)CB=/!"-YCW^\5N)A
M6('@S<(?K-^E)""TF-KW+*"WL34Q>F\&O2[10.&F8X>H;HNKOTT!*<+IOUUK
M/G*_86#OLZV!_N>23?,=O 2=!$1*3C"<#&!%GZ9?;F= \7=K;H7_\\YM7XZN
MKQ/VZ/3^ZMC5[!\FLVHN A!CWAULM0SYE5(<BBB_A?IK+@5"_*MO>)R\1Y_)
M:S$M0M1$$L(H$/?[67VZ*-+7YBDVEJV'A^D#]AWSN$3TANG>'>1@+HBJ3)V%
MGB1K+8-CH4((BR48F$UMY-!7QC";W%]3)V;N/-<S^/[AZWMSR>2*E>A;5T1@
M;:@_5]<[('__%4<V+_N]FSO)9$U7VB^7[LI2N^ZT=$O-OOGSB^7'0J5ELKXL
MF8%2<S0X-=&-T1C5/[>A$18XO_$WO4!U0.V9ZUGCUGSWH#M"/4EBN(]O>9<E
M#\54@*1E\-0R];3/T@"=9-K4H_#=.*=7M14C2D>"7RHKFL(K=J)E'A3-(YZ$
M_U*NNR>6%E>*ZO-24R+Q.=! INYH8[KA2A#G&^@D:"5';<AZF:#13EJ94% \
M!VDV5>%;]MKF85V5H;Z[Q9)/78"(2 &,)$5X>P>?1LI#M'.'6I*TYX?\N&#]
MN]K**VI>:Z9@BBHZ'>% ^(W+W1XD720+X3FSRKQS9($C@OKXO3VR0;#4X?CY
MI8D'+W24.3&/N"[6WN62X/K]@G '=PV&O^6?G%L%C9 ?\\"O$QV=E0DWN$0Z
M7O/^&-_;K+Y*8/P=<&$!?Q?-WOZ$Y(!@;)X(GC-IH_*-2CA=MO"_^=9 ^D/_
M4_8W^?DNUTN'*O0BW2/TKD(!&7!'KQI#F07I)@ @;NPG4)K53U';*KER997>
MKX6&MJT_O42&M#OE;NO0\S(:!XU&G@=4<=;?&H%L_#C.P<*H]#-HZ]+'5,,(
MT!UI(/OF+X:^,_JNB300\#0Y%%*MU+D/W;Y/ VW[0(@:>'#+P@LHM[X"/*N5
M!N)'&"[/>9A69D+XS$H-)=LFC2Z$O.L3OR/G?@%T<? [<U?8+Y8$:C^5E0 E
M\W@O=(KI$@:[4[CAR+\+=SQ]FT27Y C>#4'B$MTRZ69MW"3KVI5WO8K=XN&,
M) VR"N43$H0<JIL_,UY#@>$R6N5F#.7%I";0GY]E:\/DW_TZ):62^UZWLN@T
M8@.X>>7 B^[A=(UW NOMXX6Y@& B$(L7Z^J;LQZ.OSF9ZQJ_ZG"<)?[*2,WQ
MPY*C(NOTI?A>P)=@LKRP[4^RAK,L[G4L")D03-J<53P7*YK>S_LTHE0,N<W6
M- \,;!D#&K6WH1=8-$'[N7&0*K\F+/Z.)0N<A<K/DL197+H9PH\'OB_T4@H+
M/]9AWO1$6Y#2=:_= :6D&XO^WAJ<85Q>3T0]Q$9#V9%< (MM(\&V,Y>G6EL]
MNKZ42EV-N,!5'[!2<F/?-(*_9[5W0[4#<8O23>9[L23<NR\'N/OF'P^D?_E\
MA/N.!2[:1KM\IY1A3L!\&G8_+Z6P;7&59TG7%YJOF!5JS[V0W+P@8'-;[9'E
M_?=YX%LIU%/M!!4+D,\=Y A&'W)6]Q,-Y&]Q%?6M]*5'']M::([SX_JY1!0+
M?L*'Q$X=%Q,'HI868IW!0)4\'Q4*> 1*U5:AA$XFK\VK;'EH,H3(&8H_R#MQ
M61ERJ<N?K&.BFS+-C_L#(2JCB.HM9": #5]XPW):K'_)I!/*A;A.V%F//A)E
MNQ=C8QR><;/R//2#BX'$>ZZWRD_9-<[<5+TB$M-*8<&AR3P+'<@+A/EZ@G '
MA(-Z=M(;7+@QS1_CH=Q[R:GLX,S5JHLJ?*DO'KZ+.LW,\HHZF\NF?X',24AI
M2V$%T-VV-!"W+I-TK5*0J*L=^S%Q>"_*O3;]JIDX1V*])-<'IE;>HT(RUV"G
MD%\Q26[>,WU/R#OS<G- 1NTB%1_Z-47XVZ'$17HTZT?7HP"YB3BUR8E%9,1P
MQW3'O Q_+U_@^98LKBS1YU[\:*="40X0,O[?GH,_>P0:"'?<0>?%+XCE#91L
M*C?PZ7>+/@1/J9O6M<8]$[=93XI*U[ 28%(2<;%^556UJV/D1KY/2:8J(OMS
MF+% !O[-<F&2^IQY.Z&VL'C#6;S!)^$9D&KVOB-4=D5Q;7*K(W'I!<,[&LBU
ML>=?8R,F=<IGA$99_ZJ/T&P&?T/(M(%MNL1CQ1,R1?L%QF(E8L^$2"AB#,$F
M8S$W@BYU@IO=[WT:\563Z\KXJ6DKS6=M&?"C+X_3[+XL8Q\20AV6(;Z@1!_M
MQ6F[FGWVR<4G>9L'U28/U623^?99+BEK,3[F?"D2T?_3 )U$/P/4";(OI1[#
MV9$C!_3C_-D!MO;CLUYMOOJ[9L%Z :NS Q*.CCJ[%X3,>;R% Y:NG&:5/,[%
M6X;ST4#7Z:#K2K[5T&3'A,G/$6^L4H0K)_"^3",>G,L@,#=#J:=.?\568'*N
M1CC88V48BV<_0U_Q,"PC69J  KH_3E-! *R4;#*N+X'0(#0H-.>'=0S*IZ_V
M&V=93S5],7NZ[C*],9M(61CY2MZBU&-7S^56UE&0[31000+L4S4# 4WF+>Q\
M X00+X\?DH)3\R>"Y?3TF@HDO\I'K_9V&R0$G-H<;(;30&U00>3T4R@3@I^_
M?? EE?=7D\2GC?%7]^[]KCL]'5TH=)6G;\LCQ7V?;4=.\$]#:B\)3/Q$^=JD
M0)("3,P(,@F'V2%6(^IRA$()SZ>$&P_>=@US4-TJ(DY_=CV9 ^;]W>!<[%7F
ME9Z9%-41\E3C<4%G<X?)!7F_CVEOCT^>,1F/T'>B)$!]ETC7G7VH' 3_F)1(
MC"S@#YVVE_.[FV9-U$V5(V]6X$N37C=FK#TB=*-:#;&XWPA32BZ5V8BTT70;
MYU+B_>OC'TR[9_UCD\\2/]KGE;P/H"?4]"_0[?\37DMJ:WPX<E@FNCR^7@OJ
M&E9X>ZNA0I3U_:<["T'NS3I+MVB@J FZBZD 'W%K UTI^,&K=?C.!+&$D$L*
M%\06*67@L<#I"/VV<;+@$@UTULGKV+XKZLM6G3:B1._#Q/B3'\1A.6;;I'?<
MB:PGN2)9F3&7*#78Q8]T,.%72M256U**#J-^+-HD%-21I?EO:6_R#9N?,&NV
MN_LG,>>^L)E!O:4D.R00^$."P4V(04#4(O@TO-!BK!W>M^%@[XW/A[K447#&
M:QY>C!Q?[DTNF4Y/#0J@?3%5M:./UFN:(N5*S)8]UR*#P"*QQH)VEB>Y7AGD
M@5.QB^DT$!M"%3]!=(^&T?',@I V7H>2_E@,\[K1)2 S&:O0$FQK%?O5-/A.
MAHS ^6;#;E@%NAT<#Q$NH\K"NXW]N7^GI]^RL[^WQ2G6QG6VL>3=DSB!]YS7
MHC*>[Z]G B3J*7^F\@S23>1P&.R%.S="HV;T^F3I37NNA/KQR:X  YBL*:.'
MU-6)S200,HC:UE?Q;_<IRCO8^G1)J.SISR!PK0;O7^%B;YMI_:P0U#.5F:GI
MCH,!U0\7SQ>[NVZ#I+&Z-)!+[A]3CYT[-!"L"K7I:HM%M1ICI*'MD"F6[L 9
M'<7"LBN9')E?0G3F--(773_$WOAQB3(-6D0MOA/R[8XGGR7(+4L7L)D4(TP)
M3G/DA]CU89G@.);*GF.VP]O.W5^H72BV':2V3RY_, ?/;^KE4;K&2%ZW?B)_
M63Y5TF?%*"(O(C[DFSO+*Y/KOU$>L&@SO,\B[#F"A\O*5]BTKJY^9JC\,G,V
M=M&J*K>KF2\"JHU=I*/%OAS"C0:J>(\Z9$87H/SV7OZ%=%E.Q71.2S?CY""G
M'&;RPUX*C7\A*91YQ+6?>W4T/=OU^-0?@/TQ> "&IY.T/[P8%=3D#^Q?QKM8
MO+V"X:TZ0!7_]\>@FIA0(T%,715L\S#JAZLH<'"/\_WM#66&->P)U&+AO!*>
MOR4KG!GU,K,P!=;V]//U.L+-^!'%K$ >N=5.R=+[4OK6CF_Z@\^9M1QA 2G_
MEV6ZMY"2"-_1)H=\>$)7SF7,@=+AG-0[E!MSZIIG@3%#VM3,\\B/#YQ*IS1)
M+UJT(3%-&HO9X!OX[)J"PFC?4IS%93F1T/,+GK*WDO,B.9^MZZYA]9!LF^/Z
M=+40V4R^\HL,.E^#GYM/DOR[FI1Z8OY"HK(I<+OE_-+;15>OU&Z1>!#E OH%
MRM4_3DR!8+(S1KKN*308'UP&NSKLM^JD8XX9E<X<_\%6>^M<W+M25Q%$WI/.
M\%58-NS;(#E?E5A, Z&GL(<518Q=6-<NX(CDHI&LRR;3!>8"_%OM%<ND=@O1
M"ML3VOD[&KN+%?&V;X(>%T7:GC-UK)\5EDN.P17&4&51K>H8)83Z>-!@/$:<
ML-"NA[(B\1(3RAUULYB/#N[TN[O-WJZ3+^*)MF+MGC^$ A(!:+($5-#!<Q9Q
M/:)62UQB$5EX4$"?;0^JIPSO3^URIX%^T=W R#N]IE@48HS%\NT[93F$RO#A
M$YNR[M:.B14*0.P;[:CB$Z4(N;PM^_%BZ%3U@/:T>6,Q4?7/$^."N=HB^<=Y
M'T"6] 0;3%(")#K^-5(M0?' #[JA8KIF2Z3?X18?:_$A+]&=7S=_1:2(Y-C)
ML)KOV,R\=I5L%'E^"-Y>P/<3XP &DO$"W-!^X@@5#SN)]F7_!L]PQB3M!FTB
M*EVO2+[M0[KM]^5=./B\I,4X4$B?P3/R:4IQV1>@ ,_?/5T8.;]&],VPO\$=
MGBR7YC__*-* 9R@@,.KQ=PG/+CF9I;I.2 JJ KMCO0AY@3V+\()T0D[!>S]'
M=NU[A);OD'O9S63>+0\P.7+T;?_^1LX76:1G7$GD0,,^'0 L=$47(8"CF)KV
MEZJ"65@[;ADE0\S)B9[_:WE>4&/W'H'KQ@E].X$0=#'TD5**F 8EDPHA*P)R
M^+U[6()29PK/'VUK=&S-(\O U1))8]Q5TO-,D_L:RN(,$F)7R@UQ,;O0Q6H(
MZ[QE*JQ=U5<&\ZA&'8+F-2%N-,6TH/"W+:?JNNRW,2;1]IJE37]:SQA>G#,5
M['\JL:-<L1Z1ER/+6 #%6\!BV]MC;&#3/MW]!/F6>UN,MS_8A>9[].,L-?KG
M4AM##+.S2_XU7$!01YV5@&J,.N!%,+*E\OD_5QPH6^WK.+OS*N;2GF^>XE$J
MJR1(0.6,/@%=47( (PI@$[IS\;?IE G:)<26D,*>?W8J*R'PG5M:.8X+B]FK
MNMERV*I?#=KQZ(;P0OWWIOV[Q4!XD^0C</0"*YE-JWI4W8)C2A&]QCE$ Y4:
M,S5UQUN]>'PE[C6;B*#^.>0@#22*>J#GTT95!K26H4+D^_C#C%Z/4KC276Z8
MCK'AI=2K*Q=%E.>_EB;>6GUQ1I0&.IG;$-.&Y:&!/+&,6U:ASM(U$S9/HUUJ
M[5R3?6+S$6%RE1[4!G19>"[)"#F4PT7)((-RE A9SJ(JYCW;K@F6<6XY9HZ7
M&*S?&S#<CEO/RP,GH19+^:&/)K#NC<]Y7OW!2+RV5'PXO9E>K>DRF8QK0$W[
M$#\0NKO]XUXC!Q>JHI8YGMS4M5SV,;,[-_2)(\9T#=;0@O^)58:>1_R96<_%
MV[Z@9S!&(TH.1^*;S=R9L+?4:V^ZK!Q06KZ7TQU75'8%!1>3:_KAV"7W?\5D
M<X&YQ=Q8,<&F4;(1_C,L4H&_X[<FLZ4F>^,."'23?2BDK^=]:R^((@M<PO^$
MO42!JQ<XY^"?G0G99#G,GB.![Z/ZZMAH!\? >]%:&8B\]^//HZLI#B7>Z=/2
M&:%%\Z;GJJJC=J5?'=XUDN_&@T;#F)L+@4+#D:/L\_L*AM='%98;:AJ?UYFH
MW?R8.DIG-2BA5:J69PA&&I A,)J,W'AQ>U17K\C>0< 8-O!Z^IK%Y_I98UG&
M QIH"0'A@RY^F9<CV";XZ9_WH<^9RK:9L5?H96\2LZ+LZ'S_PGEC*T9E8V/W
M\$75':,6M<'X5_^*AD<^!$K:YA5K@10TXC:@7KQ@\F4KTS*VP"=N&W/P0.7'
MU4L&YVPM(BIW@B4$_Y7&E<B-5QNX0[1N'/+-3PIV@C@U./Q&OE9ZQ[7\5.SE
M0P,:Z(O;4[4%0#XDOKI9@GBW9JB\((%D:3OAF]['!]7B8@D5-?F4>$$/"M<S
M CG2?_XKXNY$DQQ)%N[?03U)N%FVM%D#/F,G4*/ 3?2Y4%#W>GRU+2.QQ/?1
MN>EP%A';LW@8T0I8)V#M\;;=, %RP+B:8+!#EI,GW,3BV7-V;=>&ZPI6!IKW
MC@VK>?=GTO\D7+9P1;6:J3G00!RH5@U]\*;0UY[,G-S C_9.I=V*TBDWLATU
M,(N!L(\H]IU/58#_DCG\C F[O46^9\+0W:L1X+X(;7M @_@12,7]ZU[2:O)O
MP8I]$WEAG'[AO9^FUA!3/(HL>+.G5&?9^T]_,]&TABCKL13\)\G4=),+A(F^
M]"0C2P,=?EJ+T+),7CBK?WD+AK>"GD'( [[+OH:F"1W:%F4OS8.#Y<?M==VG
M!7>5SM4IK,9%&M&5UYIAI$ D>-J<J >4D)3)JF-4!0!"C"+4HLL],4YK)<S%
MS\0=>HXC?D+A?3,!A?VOE,4U]!BVJJ/^=9P:]G$KDD*HY;L%0>^_]-B7QJ13
ML-"5 8P\:E*0?CYJ><P(/4IQ'I82'[27K'^N]C0>"#Z2^WW/--$B\(SGG,3@
M'/?UEXIA_KS[MBV0B%Q^K!_=B-A.&B@.(M!T>W%.]6Y]6A/T(V"S5/8I4G/N
ME2G_T[%;6]9PQ=80_A6AZ6$R%(7S!\Z7V'E55-==R#-_:LVB?U<HRT*):ICT
M>\,?D-Z+KQ[D179!.84M7DMKA^=G!H_>SGF0<\%1V67RE34U&6QX!7(*0+=!
MSU)%4*W7J(QP*,XR;H7086^]S6) 4.CC"GSF*KE[)3M.*M^$LU RY\,KH_ W
M= ;.2"ENNHV_8XX/B: *=8M@SY)#$?)JO9*)FC57?T/>,2(PKF;G+^[V0"Y)
M/'>V(+G#WUA@Z09[1?V1J=Y485:\.2(YX1TCGR!/ S7:'$(; Y._/SKFI<^\
MU:I)E:-[QQ?/37*:"(:PPV&WDH*FU >T8><MM,:W!67,3-LJXSX_>'9R !3V
M$H6_"8E[[<EHGT7,)N"!]ZO\I##OLY0H-PG]6S#5'_L'43^W70%H="-D,H;X
MDJ"QP[#D'[MP&BEKJ5[8D<(T:_YI*S/YC9R]^1,N)7"N2.K.E$I3 ,=F'=7N
M6]=-NDNU5P?V4#XBE5+IXI*%/JSI5!?U$L5,9B%DX8SVVK'Q\^> )-QW5U^=
M#K-2">U.\=R]]XFRD@\(W]E%7W!T> CF@?4!!L(>?685ZSM2.&SD@EB35[$/
M4G T[0C& >_OR*B\>>-ZZ14O-\F705<+ E^FJ^2)_BF#3%5UP;BA?I;3KK;
MEQPI@LQ+?6; ?M%NXZ]8;M&@AUB5O$? GTUAIC=[H:_]!CE$'),Z'F/QM]E^
MI\P8$B/P@RW@:'N+:#0.RLZ617'H."NB\";4-;SNG6H-R^[QT8\D;OS=]5D:
M:#&#GHT.]_@1$.AI=0YI"!NPM[2[HW-[:/P<F[E0C^V.L/;>0EH&-1/1+=R2
M!Z[YMWBR1-7VYK<W:56*M1W74+6#V0//;N6P986R!QB=GS'MVVA9O7>&5>*5
M$3*<K (T+S?2(4TR)AGA$KP,XW($&N9W'\; LJRST;@3^TP,'DIK##6Q2PW<
M.A,+N?_SS6"D-UF&!GJKB##X1R+I\=0P'Z%C.76P".F"S,0LYL;HNA!8EBWC
MFN26EMPSD4GY&X'8]T]KEWM]9NH%#^0KS84K%M)U7_6Q,@82S0C=G9 (:"VF
MGJ0-''?]C>G08]Z[^6P.8C7Z)?1+RJ,'GI-JB3_C7>VX/L_>58EL<LO]@KK/
M>Y>2A#P;=>LS2="2420CP'(=IOX;LI]IP4;MI(NV8<$BQC)*/=33,G8ZI0O+
M2/V9RWS$^XOL@(-'C1>B9?[V"P<X1B2JW/$VDD]N\9L^ZW5R0H[ 2#U%(I@O
MP9X'0X00F@")P.@ I!1<\9\>)JZNQMAXCKXYW5T?]U3P-'J-6=.*.4 6P&U!
M&.B!\9 L4>3S.CRSOT.(N[5P4',ZQW5ZX,3YG-6"Q+SC5Z<IIPD>\6KT_ HX
MW"-PEBFE%FQ>#H0YF7?W\W@Z#4IRQGLRXI2F;;OG+P%I]$^5$6SJ"8SMMCEG
M"6_3G[[:"O-=+9G1R,Q,:_A3(@RR=KN%3IZ)W<G<1TVSX5CB]?^5)+J 9-[*
MX29(HY=\;YH=SH0T#_D75+W_?+GNVD?XU+WBBX6"77?#;"N0XS"(KA;I.IVV
M(R7A,VWIT]FU23H.#L;J#D_82X>V^%IC&=[Q_C0VV&+=<68DV1GOHUHED,R5
MQ0_-FQ7>/?\5GK[M1I4$=T5 K<AL3Q36(W7U=/>;#OH+'9I>FW:^G^S(?VUI
M91D&%!*O_TL9W*A6 Z@GFG.+>F&\QA*\B?285,N:N^I5)D\(B B]K<J;$FG2
MQ\*,Z05LBQR\%]@1Y\(]5!SM'3>(@89J'A<W?GVT8?D5*;<(F[1UK"#(D'D<
MB.]'U6;>[3UZJ!J[>^Y^K_1,I]7=9-:^#URM(K^84[K1<:BS6!^E:3I-)H8#
M'KC?:!  ;>?#+7=@Q$=$T]=L&'0[;:V$3P_G7U7N3S]@XP8Q1E JH ]1\9 J
MI>T]7 (-=(I\C\"?HLL8^BC=^3S^.-Y-0YIU_NY,H%]@U'F+^I:3C*_ON3?0
M0)/$+>B)?^TMH9Z#'#Y9OC5)3\J5Z Q!<ZD@=E:A[5/8FF :85/P4/VPF\PC
MUY'I'TV7:?'<6P&=0DY>[EU,KPXD]QORO>D,AAY!$6]^"8&6:"!WIZN_3>E0
M?-\KY+]&K]R=_Q:]9>URGQG3[E\13S;@7<2R8Y3@NS00]=2YY5P!)_A$AZV^
M8EWC>Y>)M3$/'R"BZ?D5N_X_$;X/-/U>)A_MPJK0Y$]=$]0.7UL:Z$H].H-Z
ME@;JX]<7IX$FMFF@OT[^5T0+M__@P<O@G7:\97N.,O""4-@QSXO'5UE C8>#
MM!9^-#H\6:G9F4W\DVXGE32YUR]F^O D0SU)$EC&I;1 9F".E&S$L^5P0YS8
MBY!"O=V48N\[NB,FM9?4'@D9>QA=*HT=VKTH:."L8CD"_7;Z*[(+>ZJMZ#8E
ML?!YLGF]S $Z\RCECX5T% WTH!^UR3[*,(R<7A"A2@#+RS302Z@[]L5T/^#A
M.*Y G4'#X]GC'I7UN)\NU_<D=B5)\+9?!L;NN:W+=.56#'9BIQ):&V(ZE*)0
M(KI.N#*44=01ATD[1BI[5[X&GFKVEO483V*8^5 G8&ME4!I^%4[]%S[NKTG.
MJ,HI 'LU653Q6>I++X[,JU]CQO)K@R [^CKQI,9EF<1J= SV%!F&TPOP7!JN
MGKN(PSW-^,P@V/8L7?,6B^0WQC(0HH8>O&G <UQ*'*1*$?T57M>1B8T/UB1;
M!OME-(P=UKV1?S _^A(LH<K$]&Y9LQ]B3[+'_%N+4Z:!>HM\4,3+\ZA-A8+P
MWU<@:9!J2 <X"4,'V<AD>/<2N#U7;.NOI+[$2)G:!N_1A<XOJ5Q5M?7?&R+%
M9UPSW*R2^AB11[6O?G \@\60S^(@@#2Z%14WKT](Z=2#X1K,_/TR];.+XI;C
ME)SF'M]>R]AK[+)K9?&&"G8&.)^MC4<!"M DL6OL>"! 2T(&<"#I#P5 F5V
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M[Z$J5NKIFJ.B_5$2GN*9?<-D Y(A]2>JFEI,4H5;XM0'XT8ZS[0T2-?CSD^
M\]OZU_5^>*]^&^K(.'V+.[_H/@/(=@2+-[6VIB0=[O.<F![[HREZ<U60'%'.
MV'4=3.9[T^*6N-RNPD4G"QK5#&W(,5CE0B=T"KQ$%PI"" D"#=2E3:WZ/#>C
M7YK9W)_VG;NO0BY*L6]1-Y;=BIGIWD$7>!*C1BE70+"0>#<71(+99'.(= U%
MM/WE5;&[/_]W36V*,VR;&RI3/B93=A_52L>#E0ZJ- TTJTH#W4Q/.[#<,?JX
MX /!FT*B^?F0+@D65;]V=]/5?S[8_P'3R -?%"&=!FWJ@ZF]-! _#>0#/3&)
ML 30A/XN,9$& H]<L9<8!#_06UM;\;QK0U)6^/YLX[V+18]< ]-E1"%T#D+P
MQWELSY!L#$C:9'N"V\(9M:2P7C19#E?R:P"^@(A=>RH5ZR_]\-S[^,IR81_V
M!V1&RLM#=#Q=[B+.XN;XB9% ,7/N5Z_+!PIER9B3E]'?Y%_)LG6G+WWN?O!N
MQSB%)$<6!EQ)#@CHR-%>,E6+(-,9KF\:+"IC-%[@L_9:^6>KD 'C22ONJW<;
MLNO]& 9  3!1C#3"=Q2[F(\4!^SP,UW3T:G\L4%9#JSI6UMVI=7P@6K566=#
M/X?^LR?CKP@+_H@Y>>DDI#IC^QG!EN@">)20'?#0';9E7YCC$*)QP(;#BGBE
M+G6/X0.2D%:[:IDA?O^*7QCCF-?I,OH<\L=[;UT'O$Q[-I"MK(,K%N$*)"2J
M-PMQCX[*=/MO>%T1Z<P>KR)Y(#N0_!,XPM,:_/&]T<,C;-.HKH:.0]]^FV2R
MYW.;DT82):+UF\DU^S%DNJ<LIJ-QEJS8#AU4+%5FZ+ ,TG%L4P6_W+<S<GU4
M>-MF?2!3O-6.!D(TI4&WW@QCRBG//WMA%W.IC->$LZN?K8)"I'&XIBPJ:^'Y
MW"G_3D_6>=V'0=>/09.3RW\@?1'0*SX]*&\::/K$!/$AP(^#BEGZ$$F-U^[)
MRP_.Y6P95DKYF?0([#X*K'$0P36'82#TZ&KWU)CNWH[T>T0>X7R/8Y/KKQ!:
M"35Z&+.V_!SC^>?H1(0FY 5=C2]T8J<36AI".@834**Z'A^]Y\7I5$+#"$]I
MK8ULDP&U=2E?O7#1T-?(BD'P0<=X;HM2(H0']7!ONFV$& HTXAK1$/BS#F7A
M%';X)T WP^A=A=%K8ZD>5Y'4M >K,'=A%W0ERB.7UPMY&>#"TT .0P_CG2[O
M&59Y-KW9_W+.VHUXL:_/8(7W/$:04N6/(Q22>0:)C_'ST;AE^R&/ZJ91IOH_
MR[&.6=$FAQW*C:D3/J1XT($2<(&EQ=>C/;?:HY7TGBH#H&TMA8%/A%*7IJ:G
MEAR[#54M%4R#&2EZ3^K\_[ZC:%*D*#E(CBTL(YG_V4>Z&<\TF1&DUY9O/1L;
M:[H==,Q_2<)$B)7W_;N7S"HM'J5)OV&BJ%8K[ J&V@LAJCJB-FTR_BU.=R,>
M .\+Z;YMAT.+>,>Z5_X*^H/.Y+U?IGK^=>J),'[?KWJ3MNO=_Q_N8/UMI)X6
M7B+10&>1]*_PRE=/3CN\';':_LJ)*)*)]T+MB_C?12UF82Z.Z%J3!,B:OI=-
MWVT27WM-W#8.C8<7/&Z->6!@^U=3CP.$D,%A6<F6P!.ZHY\%.!;I)Z O\Z:;
MR\OVFRA+1YVLT<!.XIOZ$T\ETU-%M#^\#@LPX#W,(/,RXDP2D!#@S:*(,S_A
M9LW2]R.E,_U,^UY"+\<_;2D3\R0_71:>6/,3EEC3K_E)G<J1'/&GNWP^M$HZ
MR5_>RCLLJ%=]^F/_^7[H[E@S>'=VN5Q8KU.&S%M'-<Z=ZJ=V>:$.=:Z#9@@9
M'?X"R$$(_@Z,T^OO1'Q-/PT4#>7>CJI)?H\J&E!/2UK>27ET28?7^& Y8?=Y
M5$/+(3J(@M'7-,>S$!T),;'R_F+]SLVQ7D(WAK3,N+<014$N/9XC/UY!_GHX
M^])G; ,8!2^CIWIUO3Z5=./\8XY[R^T=KT+#7KDI=(U,RG+U65*4T2>!8L)Y
M)4!6H]MR*K>%S[L*""0I*@G O[ F/S [O>83<CA]#O[\J)Z'(8E0X@A4X"T7
M_;=SF3\2(%V&'53)L17,A)_41/F/D=)![TU?.4&5?A&_LRZ2C$W+:^J[D-J%
M;J4XL<L W3Q[4^A%8O6\P/A1XY-GY?!H9CGU_),ZCVQAF7H57<.7'%7]D@P$
MM=91BV4?X)^)3QB?TP6Q&O:O:('56/EG /6O2U9MXT3MC#WPF2Z5+H;^Y*FH
MY)*]LS7LT/-BKF+VUDDZ^D,?T!G60A6Z#786WK@TT;7 "V"V)F[4OW'$K\<5
M^"18W)SZY/*X)RMYZ@1W_X<Z$4W-01^Z<(K#O+A!27S8U/#*T->_W)N[7R+H
MKG5B!?0*1[@K 4U7T"^18&#&;EPJ7E2EW[@Q\^F[I>NQ#JO',GF,KTU/8&3I
M\.*S<9QSGOX_$.B_/O)^XA8FPZ&FSK/KGBFQK^C*;H 1*!#&L8N11[5:Z'KA
M!KE:"<*.@!/>W&@4<F.D%*$EX3#G+0_RGZ_\UO_(<RYAUUKQ:\EQ; ;N.OG.
M?U8*/K<AY>CBY$TYXA:@\'7KTJ;]ES<X,R'<;\M9P?:KYF<X.U*?6\3;/:W<
MYPA5(I]-(3J,H#PM7VK/XLG.A./(X&P)VV?/YEC:,[_51O%^-DX.%)N-!()[
MMQ[X7S_"3LL1SP%F^/:V,,2"P+]*KG'*&_S'_;Z^G.@B]<, 1R;WD]?.(5P,
M$2OW/5ZKJ# ,T[GO'8PV'+MT$<%.X(\XHEP?\!@K;'RFPS:U^.+N-9)::KNV
M<?]:UY1X\?9*2'$P%)#I[E**S60E^,=#/0=Y)\E6.6>#1800@\SO770N^%=U
MG7_%>V72B1 EPLUS6*Y!/>WQ>=JSP7_[<X&]I3HEZ4M1>H4E/.MAIIJ#E$VJ
MJ< #D.09+9GGL"]!# 1_,C<-1(PDY'8I1><HX!<ZV#9K4#QP)6LA1.:'%;6J
MMM9:^41]4HF)K&*HA%] @.6K7APX#HN_G3NMT8T4Q*^GU$!C8$QDKL>/W',-
MTC[G6F4$YCWH,Z:!E+LE.+J]Q6%O*WIG_G5:1_6,D.@O3P[P4V-"[F(77X7<
M!NXX IMT&+>>\<<-J#K9E=]_A;.]Z^42F+PD&MIM*'[TK] R_M9@!(P'ZDX_
M!G'Z.MEL'"E!EAX+EN7*(T@([JEE]8P;)[B]UTR:@"^SO6*>?>6SHS3-N(S$
MDO3^]9H\Q K G:6T#\.84SU\ B6=']BK];(C R\L[K _79<(O1&I E:@QT8$
M03HKG]H3N%D7T*%TY.3^4UCV'7F[I\OVH=CS,Y%AB/91VV)X=Q?D-%F*) +8
M0!.K6L'/U7U9;H[XI>/&0\=-GED'.5Y-W%IHE"]5-I05?Q$/^H-='-PV+*,K
MB=MY9/K$H_,(.^L)1R6\S=3AH2-W'P>M%>M SE^D V'1TH^_5L.DE?6C*-&N
MP,$G0!6&G^C6T5)4K/898D[ 7=A=RG&RFE$LA;EF2%V_ !:W>?C60_(L3!>&
M:I7%#;DE=&*KZ"PRY0QPWKS':FW,/6U:R_6^("B'.:GMC,&?M)]@K?(9ZBD:
MB&2&N$W0Z/2/Q9[45W2R!UYTS+/;IJJ3KD##BE4Z"(T7BYYD&!M?1"?-5(:!
MPD?^;S>)^?_Y8!G(K3G>-EQ:F"X+\G4)SAID!@ZN+IL3%',:\Y,,_>\&LQ>D
MP>0+[.SNO09+0A(03*3S9"^@D="]/-A.9PWDX,R?<C:_%@GN!:XN[X,G<[J#
M&T1XQ.6UC/O/=*R^F/BMP,/00N8 ))904^M+Y6F+*%8',^8W]P43J[YY[3YT
MS4BW ?D]U<.#_OUQ_HW_5YI^<H%H2/<TLV'R0X__//TN!<.G>KO>7J!D$:%5
M2Z93*9<MYL((AVAW( E_? 6H6 SW:!.3_>9D>65L9Z!FKN224Y^I>+1(R0E&
M9I%(!E&Y_$\14&@I:C$'*H01V3AVY@1\2=>][?G;^V,RW+-""OWJJY)Z=212
M8<6]_><2)-\\S_SK0[2EI)$OD&3(^BA.>(#9D?#O7LS85Q^-B-#C$5>&6)&+
M13UW11DD7YM?(H;13QHZ/4)4^ 7UAFSK^7'X';1"SR#T^Z9-XH/&E.1!^OCD
MYQEAT?T7V$M+ SC9F EF]%28C>+&*/M,ZZ+$D-H+ *GUKU%+C@)SU\CVIXUR
MY8?WKYQ,C)ST:#WGZ*%^W,S#X& QXAOD>WG$LJ(N>;AK6#*2#7[WHI%0D;4U
M8QX(Q%+CAKB*+R3+Y# 0E**18T3(3IG*^DV2;<9:J'Z0A1BE7KBB4;/GIW;\
MAFP>^'63#(F>*-N42'Q S"(+60;J11U_OT8#O8PA27BD-<!7NZ?(!XUBSM!Q
MSOJ=^&-8!/0T:LF8+(S/C<#60&OIHN!15"XQ9HHZN+X4-[>ZY]L<YJ>^0?>E
MGW6YE9!I&LA7#IQ" ^'3'Y$4WP7M 2:HJL!&95T'ZM :X?@@1:E6=;YYS_G7
M=I/%QRUM_0*_.ONG'WVE"GZ C]WBC62WPN-?0X6P1B#$&]*_.RSZ0;F3>QWS
M%R<R.GUQ%)-[D3HZ=FXC1A\KZSB=E@>SI/>WSTN2L5O=(A.5R"%L50J=P7N#
M8^[ #;LN'PB[R-97-U<_SN"[$W6QLJN#ZX/J"5;Q%SV;S@7TXS-YD%BH0PU*
M,?RM]AX[MU'\D2\A[D[3=]AZ/FZN?@XM&+N*OR3;L@B2VX1.I1 M\+;;=?CY
M];8<L7@+BR.^@V!?RUO67C4L%VW70??%K:[F+9X(2W?7'Z,?66 !?Q,;"V,A
MWRZ?IPYBA?WUQ>"H>^]FS9<:2= :A[85&HB1VZ"E+?(.\A>#>_G,(F2;/X3.
M3!-2$8Y '8&9A*OK> ;ONS?PA#_-HW!%^8>G62]#EM^)BQD/SCX5"'_V'^,X
M(]LR<JLU.M!L"%-\3,HN512^?K66SZS(H64XYJ5. ^^%\RK:[]T$>V?+(IGE
MJ@@>VW&%"'=*5I!E-)2O9@8MZ#V-H#-_?-HU=OX'FR%1V2'\?VHQPP+?_ *T
MEC>T91D7Y:"34&+2$$(3<WH$ZIT -/&(DU1VA]\Y&X$M%80'%+_R/X\S9@$Q
MP,RI_=#*.KKEW?9 T&BRHG130]-;1^^PSC7]H7!9 :9ORD5YKXHT03GY51#W
M3Q'ZDL ;.N4ZF*A&)0AU=Z B<L_N8L[^#IM1W<J$39%)PC'NLS\^:]ZZES[9
ML\C]=$?$5@EG"4CYE1#X2#<(T&1]=6^D-!#%7,@T^W=N-]TM9KN"O>R#,EL4
M5])*!2)UA!5[>>^7]G_VV#*N64Z7$(6'4)YH+D_JY2%=\R*$#I#]^:0YA,?+
MVZY6@L_ZM?+&O:2!:!L;P=99D/V^Z!WJJ4U"X++D>!BL"SLM;$6 19;)V-U,
M*)A,< VI)F-<W63]L)?L6 =9FL,/C$"/ZQ98@QQ0D0TQ[9:<[> 8-:T@LT-S
MHTBE2[ZNK_D2+P^WU O7B=3>6Y>14>]&]J"J4&25PM9&?P94FQ$=WDS>/--;
M)\9,(GMSE5_4]1](;B8WUA_R[@31PPDK0K<H%'""5&NT8>.A^'24*SUN.50L
M*&F4K'5*W:,VQU",]Y_P2\?"$].8^'\+L/J7R?QX[ XC?L$&;Y*P(_3;9)0'
M@?]F5[9RYVVFM/A.L.Z+2.U(5DE(<A!V\M]]"]1'5)OH(FSZ*<D"?_X-#]^$
M]A.21?Y)2L^LE@2CYB0AY4K]\B%S/ CO/P4E0O&YVUE+X5<GC+Y_GV@R*U'I
M+P$2;K7D$+I,;S$_-6:[Q/8ZH"/=U8+R"NM.,2&&X+$)&1U"G>A8A#4.?6;.
MYV]Z@8_P>1WS.E;&P C#NK&!9W,\#"NPZH7M=KKW3Y<L+<,=.E,'& UEIN75
MS?4^K?4]<@W@9KUHPEX8+?;RA+YS!I&-\LF?K(W@"B7=\08OPN2V9^Z8^]?J
M,J8H9 V J]$"*JG)RD;A%"-0J,?V,DD#T"'"@!#^EPA17]F('C\EI=U)O8'M
M%9!;:@2CYG^2#HOCW^Q_V(5EA-)M;44#56MT6O['V(]0;8&J _]LO1*>$-1%
MM[5/:/:38_Z):31U)+<JNH!D""]9T@I_,-[?EG.6<-KG[Y<LM4=[1;H.B'S'
MQ\RZ8Y+$-_''#?_%#_\/\IH5,(3W;Z.!(/HB6YA3A*@WSAL-D>5[%VK-V>,#
M7G<!.DZF/9H21>*1!KMT.'^NIC0)6=YKUQ-%2-%I*/$#9AAQ.NG\S+23ET'Y
M(]P#4].94(G7H<:)'I(,'VR;J;W8BKHHU$,]&>O,[EM-!).$HUIN'S'IT9:#
MW2RI6.O>R:BX!VR7)%???[MTR,0#LOT_,@S="2/T@RE)__%;MVRE_X>]]XQJ
MLNNZ1H,@2)?>Q*" ]"((*"VB(B B@A2I4>D@("(2,"04Z6 $!6X0" J(U-"1
M&NDH33J$$A*P41-*B*1PPOV>,\8[OC_GG#_?=\HS!HM?R57VGGNN.==U9>T^
M.SCC\UVVQQNO?=22/ +,H=THAH*I_^RZ+\Z@@+= CQ%SO'3Q>7."/Y(JBR0D
M,?"M5YIG B<%SAN.93![ZL^2]M9'QX^/RY'T$Z,T&.:_==ZL((/KJ<GY.'MK
M=2.V3^>+&>?D"B3+@7O48NCR,X%P+VQJ$Y)7'U1Q.T"6L$A#8BIQ3^%1B5++
M#XT4T-Z .GM_ B^)LY4 [QWH4(4ZD6,BB$YX@S8/9<_/R=_J)G9$/2_)K$8.
M-S$)F=>PMW(9MC-.8$9#@1Z:CV(D\/:Q'3*0Z_T'<)ZVX/=.G#*3*LL^U[LD
M%SG>IHE)WJ[E6MVRZV06FH&,D@PF8%JPX4.1;E"R.&TF>;]=0WT=/V#3_5PU
M;KFNZB<TK[(AAE]"3.J,VV\&0I8O'J<CGX*2Z/Y-JT]-46W(.AVJN:CKW\L8
M-^Z?6?--*6&?^T5[(ZY3-.E#^=RT#/K9DM@V:98JSZ"@3[ZA[EK#>V3F%Z\9
MD!8RX3#X*C?]FY'KCP#>EK,*AC)0&P0>W1THN0;B,+S@SQY2.FO\RRC\_0G8
MCOK:=2$.]J]VG-\$AH/H8@R'$@9IQ;/UJ'#V@NI!O:VHI,Q#SL1G1P">7E^5
M#>CPW%#R@<,=D:=E"H\!0S8/:%\9R>@/Q8G!;(3)G)+NY$[\*/DF6\R^]B04
MO8%MH*&";SSW&D8,,AS2S$_*XN5?4QV:4)GOAKK0BT2V**HY6UZQ+ZE/^ $3
M1.9,OX9786'LPZTVHDNE(!,.7LN[L8GGG8/CDB$2ML1MJERX;4.W>?' H55M
M^C?MKY#@7X/M.NG='\>')T^++,HSIDGQW\Q"/&ZRGI33U ./ @F@Z'R0F/L:
MYF4^Q'G:A[XM._\?C5L2@C7*MADS<HHBHI_HDO!.O1 ++WQ<!I%W!=LSB$W&
M_'Q]_0_&/9-N'-L:Q\7NTO\T[F_C26,9[LYX(=*P(-,RNA&^P? KW&&$_,%.
M,(%QTBXYDK^CY+U-[!Q# "W^Z+T$<QW5UO<:'MG$=D_D&Y1WMUB2>./WAC6'
M=^F]?D)-[YH": DBSS6"<I\->UM=/0E=)P8?$T1L*<6*JDWN/:8($IAZKKH"
M-(N>ZPB=ORB#0NH-@]5H 88K$=CP0T6&/9L>)5VGR&T6PXE' #K_,$/Z3+#F
M'0%.;9,"M/$LR7",_A+L9]"/@[X7,\50&/G>$8!S<!F;K'^25DI+I+6[/V:L
M:L-1$D):F6=;+7SKS\03U-4/D?K=I%"R-.\79)2A!-DOJ+0DL6!<I;@Q?<?\
MXHF%BO2!5='DS\S\_GTKN2_P'<[OZ.RC*ZB7'>I3^[QS!RL6!]V!O'Z:?YM<
MS[;64YS5SX:E9)ZKYA%YN@4 .,\LV=QEZS[+RT#9P^.E3DS^@A38!R7E9"5"
MW0I]_<O6P^-*2[*!#F^>_O4N&J6_2BBOYS*;W&.RB5"BW*2/&/+2/AE*6N!X
M1>>'_%]^^#E.&NMR=K@C6#8H<?KFDZ%34M&\TL7A&8),!"'D!I!R\W?'&?!)
M'V2#,=65XW1$=JC/;;7S\269J3^S;#F_]!0R1P)0$60@Y=P?8)UEIX%?)Y*[
M(6Z\S;RL;Q24W*!DW)I7=2O#(4=J@*./?>[L<F'I@KGPX0G&N$^0KM!2]A!S
M:M>)3/[/P6*05G"KCFY6HFHE--'SKIEI5[:,U(FAGDS9[$0#@"C\]!'@(6D:
MY.LOLE(220UD3!!OP@,;%]<>']#CIJG(OTX0 >,F*%PZ9&3J89P8Z-[852"W
M*QET=YQA%,H.[8H_DO';SHU3E\SS+.T(;;(]XF>L9KO]V-_P:]3D6.9Z"(@!
M7TC-+#1DN.%<1&[/-!@$C)K5-$R'7!3'^IZ>_[#@<FKF\2,SP +./I)]^5FE
M(^ 7_1SD'EU@%$#.Z@;Y4GA)T]G!)1'E@[OZ2-T+"-A"ZNQBKKN7I#%T"@>:
ME:/SP6>;>D  $.X*Q9)4/ZI#E0'-2>A73O2K&H[^RIO=(=*K0T8?VT_7WV5#
M4IF.4<:ALXQ]23U&61,MQEWYOU &!W'=V59[X;\^$832:J.]IL]0?.Y#X0SC
M4><U]ZR[!-ZE1WN7-Q>%QY(0.@AT;EA$3?[^GBUCM6$;$!MP'!C3W1W^6+QR
M$QO?9O&AU:(0DGSG" #VD/:74TIK9[\A^[1$D:,VW^_7HA^)B?R'J-NGQDXU
MI7W4,GB!(Z09CGEXE?S5L:]!Z;D_[9>3 BZ)W;QZ68:#LL40-Z@D<.WSJ!6U
M.6O*,CAVZTUG#E=F)BFSR<R/A)(R#CKS(UNGY)^1@="+#\R>]AO@X7,BW8>_
M-C)*H.Q$[4)55#'FSY,_# $S3> ,>YFF[KTE?6V$+P;PQ/R$!H^1UC8#\[]0
M<:#E7+0$5*'(>-F/%Q-\OY[LR=I75U>7+E'T\M>SB["]O[ZA?-V;OV1Y;Y'
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MTJ=GOYZY_5#S8OYU)58I+O]'IH#E99HTQ0K69\A)*XU#?/(]",^*U[=G#,V
M9D^XS >E3ZS+G4Y26W>[GYP1DLF0EC.4"V&DJN[)MB"#O)*>;8P 7J1'C<NI
M9>"9>6N)Z:K'%>MAF=I7J_PBSWFYY$]@J7S;W0?B.AL1DJMCM2;E?@<SU1?I
MEZP$61!D01X0!P56 Y587A3!;<<^0W%#@N_$FWW?:PUIK*MM8G.W^O1%3";]
M1;J9#./OC9,-TVY5*N4<0Z31,8[;Q]OAF.MC-RTN_I=7?_[W?K1H$ZUP^!?M
M3M /1'L*\<U6AR*A(V,%SK66#YQ1+IRL][?&F.L-FL4/*M\I=KAS955@8/5Y
MI2-#PT3HT-FQ1,OEJO>E\U1.6H$6D(U\A[XR*LY:^4@U<T8J0'$UPW-E^]18
M D#X\E=&P@@F\4W 6,B_;,@(/%883+U-+BPME^F0FOQ>T&0G^I!?^)%HE6"S
MVTYJF2 _[]2Q4&^$UP+G0/Y*1X!_BPR!%+M_+OU[X4%-IV6.BPR[!YH(M0[-
M)404LA9(58 S-%M)+Y!L#FID,%CV3_HW^O".86^+FZH^5JMMY#,E>7T3;&QU
M]:P"PU(S4BAA"LZZ!3W)@)4(]3P]9$,$B0$^I+CJU][!J@TAJL*W5K[/%%,-
M""54*1@38>:XWK*]X:(Q?UQO^?%WZ;;Y65JS7G#3Y:]]X3G']997#/ANDR\<
M >)!W@B,4O<10%"5:D)[$^BK(F+_O2]'SL7AP1O]P9^HK!;U&F3:Y[M^&V(/
M7WF[*D@[G ]1'*L^Z6#:R1)^CZ'F7AY7T=F2Z,+DF?M$M@TBD2&7<2&9%=<7
M($]_SFP^?[@39GT_M0#X]M+CP1$@&W,968*!,%I6-U#T'+F!&(KG/NA% 3$K
M%$.GS_KOS(6!(>D:PYG.-7>URS)E5#?4*?R,U/:"5$&+?XSV5A/^[6K(,'"!
M'1+4.V.GC?WP*EJ<86G1MRJ2Q)RD@R._=<>?B^%B6CV<V6 F-JU<C;].'J08
M+Y%COA"'ZBR*?F/"YPU^3K,HI37<5#^E7/O@%6L8JH.QPJ7(>11UL@E>;0/[
M@N!ZZMU50JL/879.XF)S!373)+9O9?<UL?1Q;M/PFUT!5QV*'KWG"' :=AHB
MTI?/003V^:%$($[W"7L8GNR283<IQ*VEBNC[8R4/(ZMN=J80!WHCXHT!D)*-
M>(K.$:!;$2K12!"ARH );\-TZI;@WA'Q&]F[I_2@:(T[_ZRW(HWNBX]NQ-,J
M*3[>8"!C+)5WT+5[?1-HG"1]>/'G3_8/_V:B_;G^3-B6YHC)&(/(,V"3R!.,
MCQ8;LI#?X?I)6*HT<A[L<01(1,X93JW^U;&RI)>'!XQF-&US!8Q>[FPB'"S#
M,G#@.<H-LF65&3#IDI\!]R6EKQ=BOCK-OG1UXH_ZYR,NGYE?[^S^'\;AOQP&
M4@70>&2GR_5[3601RE5?0UY"'JT__Q*W8X^+2M75!=NOBL/]2WR%IP'*06_6
M@+6_-J0_4MF)(Z5$8&^',IJ<332Y9V<&-2I];Q10H=XEH]QST5GA:?\/"1MY
M&6 9 X]YCX_=62T,8\^PF,<WC255JOM@"0R<>JX$2)G^N_2WO,Z"H5[MX?;]
MV[$@0EL'-[GN"QB#G$7.3]\<I5S?8&!Z1^/+ULY!U5:>#L<>ASSST!' "QB]
M3F!>AL?2)1LK]*^U*/-?#6%MH%S.U4==@%9N-VVO2" LNSH\_X7E&C%PXQ<Q
M2<6/0<QB#9S >!-;^O?/A)>9Z4+-R2QA&M7_2%=;BPPIY#/UBZ*:O0M.U% ?
MXB2E^Y>$IMIT4+/]I=XME?69H9GIOQ[7Z&8\3!NXK,\7S7-**FF680/8)HZ;
M*,"%Z=R#GWS0+'!O%_,N&'?;9Y][1E./C?OGF",V$>G%==1;"99B,BE(1UHF
M_&&$ .D%T;!R)0_>$XKE@\FM=<9B$QML%0<J4]<9-,3YX,1&SVMU[928O7U!
MIEW4IODQ@W:;0R@X8"(:Q] X+X/IIR7O6)ALH.?0OI3G?_W=YUJ'+=6 'GU/
ML/"2,S0A8T$FH>%ZG<R=^84;;SH515>3C+FJBAZ4LD6?V@2S'^_W\XLXTP46
M]3V,WZ 0/U)P3?$-V=1Y%*\+)J)*E%>_S_ST+!MG<R@ H.JWK2C/C$.P'0$Z
MU1ES*$GN7;9,/$3V6ICW=%P<:]">"FF_;C,QA*CXV@RMM_8Z IC<L,6PRJR%
M \H,0DF-M->,+Y4V6,:+((_]^46&(H5]/'PU^M\,F]=A%5IGZ4\_B$&-@EJ;
M/(,]F+.%A6MVZR$EOL+CCLZ,:7MN6F3]JF2V5)J(R@0]0I+E1MY0),GO>AUW
MR)5MX$_KITV\_)1SO.NU[7"#;6&[[DLN+V\@LVCW5W(.,0RFF?F_=1W::#_X
M[*]N8$-<5''RYK7U;D/E,1F-WW29B1E-QQJI#(]OV[?+&G446$Y47!G]SD@4
M7=+'CXN(?GC_"EU@7R!&Y!X1$5T)AGROJ$@!^BORO@V0Y1&+]*^PV9([HY&K
M?K ]>T!B#%2<)=E0GY/!_D"J[.5)N0X*?!;63Z^6G_OQ-_W9_$SHE3^N.(;E
M=2!:TMD7H6CA!F BEIDNBZ6>)][YY)YUKR%N8<'!U72S^5T L5K3(]O!W?K)
MM:HKA<N,-"MWIWV%-S%'[17<&YB4A10.V+-&E?Q&>PB3^#Y+4==S-;8X;I5=
MP!<&/<Q ?69P91[<+_"X/O+.AAP4]F_-2!I(B%\+_+1!'Z: ,0>73#RALR1X
MV?INQ%9N,$,J']>Q:BTWXH\ 7'5E4).V8VU-YX>3;VM=FGP.]Z2]V7CG>*_.
M\/&[(\#T_E_8]AW("L@[</8L^"SU/E"X0PBRM8NS[_EHD16:62.F@J+?;0[A
MXJBYRPS,=O*6U4R'M7^(!!E"&0:&I8,([U?AV%K'C_:[F/2Z7MS!)YNWZX(/
MA=]&=5O4+MR.OOD:T-IQF^O'_4VE?60*V@O!#;U%9N;M0@BS3ET*&=_<^]F2
M""VU,[6R597^T7C9G8M-NF9!@[>4X7V8?L.KT9M PHPQHJN#A5:BJMPF"?"N
M]$?5MT]@NB"G4LS3&L)/>@!>G9CI@'U%UHS&PSU<-)T^Q]AW$$-3H$;R2 >B
M=FG/P6WVQXI;_LG-V:\<LK-KAYY\_M>[C2[W;[ROA"K0"@VEH'?:R1EPO(M>
M+]!O1U_+H+"?)^^7B\R*7_:"]I=85FGGN%%)I=_?Y/^'YHO_B?\C>)5H'SL,
M&=ZG3JV39M]_F)\17.DP:\&BXN5SONB51X8;B_!*]!Q5:>4S?+F6#FR)E8T_
M?L[AD=CW(TTV-2/^T[DPU/TC0'0U_&LZ&4U'/]NF*26UVY,4C@!O3,C7CP"/
MAA'T)$? W^0;QWO:>[=,-SPL077QBER=">7[(AMJ4=H<O4IM9_7[_6\?D_IQ
MN">W^1?M\(\Q+RJ;DAN$)PK\KEB=;%6ZH:.]57A06/(>%89Z!WJLABF;(/E,
M=8@[ND N $6!0FN(DJ(W8,[ ZM??$>K,7,?K8X^Q/EPA@,,[27^S2!]I#>?)
MG"MJO%!#0DE,"&\B4&#_=\>8%XYF,/3H\M,O9M*QCS1KKP'.G)JML8J&(H[O
M*1%J298+*[(D3I!@DU )7.JUWT[ TSXYZ8O] 7=,6=6+-!]X^:29<?0:]<DS
M;_LJ19-3B?V=:$Y#@06JZ4P#9(60JUVSV!\&T)"(?:OV]KS50?:!O-7VFZAT
M0\-Q^'(!\@Q=^H\&I GW:Z._;-V5Y>JVT(_I KN?.Q>I5E*(GZMGI?G#F:\"
MX5:NYRCRL&E7(5JE/E]8Q6_M _&;E1]O-V(:XZ%&^=^LV9W3#M(:&Z>_C$RS
MG#AU5@5O29;/;%H!)BR=)]A_"7SIB.QMS3LY)'*(P:KDO;1FE?[QJ$+2S)[#
MX4V0M?T3,2G@8_L8V 2PX>,;BB;Y#:X/4?I;IV4H7VL2?*<I?=S&Z/$WPH5?
MW),PZC/Z'Q0; 4P5C.GM$"(W%T!!9"(A;AN7-]*N.S^[SO[,O5%UA,^,J]5!
M1YW[O.G\4XV+P\%P@NWH7T5X[38MA9'4?U,X #2A#TF[O!C[%=9B N\R.H$:
M\1'B1N<_&),V3]RK>4&ZZ:U3]E7JS>";+241Z4!C_>]L)6.N(11]JO<$VAL<
M8RA,COKH%!''[3LSG#XXLFM1\:U7]F6'R/-^.Y?YFU?9F"^C](@SFPQS=NK7
MIO_R=I0N\"4C2YV?W$\&-:TYHDB(USDVE].^>E-+EI:<C:L=--M980$ P\0/
M'5KDX]<I.9KC\8V%A,%E5+>+^0I;\K-&R/Z532^*5FI*TO/:;&WMS0J.]%OR
M^JQNO4!.QCQB(LFE1=1+Y$7"H#79")_WH,+19;&W'Z.L]L,3(P1^,)]YSNCD
MC+ZP<Q* HIA$1&#>D4H)B(UWRZ?:S/ AG]'-;>\V6@+2W.H77"U27FM<M;&*
M'@EWY^*W >:&8.>#2=DU8Q.]I^G?'&.;8J=!]6:"AX46+WXPI=_V.YUVF667
MKQ<0L6X,06R\H=A!@DF?R9YTA>^;%\;55%2Y\XN+G =JS7RTOW=S 9921(6@
M7,LI)TZAWBC#EU'BR%2J[C2,C:Q22H['<V4="/_!T71W_(A"169\(G<>-?+,
MY]\T$D>==>)?B;P*,O5&:=#>T14@\2N@+DF&6)4C^(]&-KR8R9894Y/QS%13
MM4,$L][P6+C[NJ(9\*K=;\(;\#]G2/].D#[3:NJ/ '-J]\A/<QJCM2R4>AW?
MS;FL<4,?B+O+CP7F%B1=5Q6VGK\YL>.F3\0='E %K^-I]'=JJ?I"%"T_#+J+
M;%4E8#^I>I8S>? !NPBG>-^\@+?*9W:1,S\C#2D?VMQ(=VF?J%<HCE UL(BW
M<-V?X,XGTXYQ&<_6=AR=%<O]%PP/A3P49\78"J2B5N'U;%3!$Y8L5.? EV@.
M_9,OB&"\C*+%9D-NGYZ?0/U%NP<5#F_Y6K?*5D_,UQ8PS\)]41AS"UH&3 AY
MQK=%:[K55^U]#44E-UEBZ[6VA$H?*W:Z@GJ']O[2\<N%=1FCO>N5%]8.[L2;
M-TR.O.-*JA/*[3D1H.\>5@BZ#F8P7],18#,(#TH  [8,&=Z/#"Z#JA*QI-2/
MA5Z"X[2/HU91^KUI^+?R@-*'???A#?E*VV!AJ'/\LN6&R4?(SLHU1,_WWTNB
MXS_\+YCU< 8U2R%.?C-<"!Q=- ") _9&HT%"*C =J!RA_U7%8\\)?ZUYHU#)
MXNZX="DS49DGEI+EGU%I'>?HBV-0==HK?2%B"R^@>-*1.DU0BW>;NJ'T6)8_
M-[&'[;E^5?[]D:W97Z]F0,L%6/ZV8)7I$H+)LG #D;E3V[K>'V\>#W%#RS\?
M4'%C;XY\'/FE9N7MO;2KP! K\&5Z'[JQ*H;B^CMG.^W](L2R5YRK]&SQ^\6A
M"Q?+,T_]N3"EW'SS7H9UT8-71E?@#9:;PQ_IHW35L38F')(3##4A(RL4VYOB
MG\W(G[\IHW0+=S_Z><TIP=P39G>-I(!65N"3?D""M9HD56Q\JXB!0&D;@OZ;
MN07S0K 35JP"596N0<28KDN$*9/G6U6-KL@#9"+,*1I4ABN+2R%+X. )Z%DL
M 0'W+]JFO2.AZO\:NO2\7AF:?5?W8XM2*-;_^#O;)_N>)5U&@BDFJ^&PFWRA
MA')[0GZY ,;OHH^(.!;SB*+_8DYPR(8Z+P*SA#*#'\_@#OHM8TI6Y#:-*<Z=
M@;QY963X+62/MK/[5M/G>HVHM=O<NE%KQ@#8\DP:;!)=GQE/4:3*?2;VM7H$
ME?:HXFJ:JAM"S%0OO$9FF#]13Y:FG9X"SO:OL%'5+.>ROKBJ9,)!UN\LG2R,
M$_^F+K!T:P(MAF+[ZY+^BM Y9*7IWT'U7B]AO/-Z@Q_()MV'B)3]_13J^_1%
MC""<0DK>:Z5&&G;0WAP!?/(T22@R6"WU69[P]K4&A-6[.]I-Z16O'+5NJF2L
ML T!,UX8'+?>9/$_U@8,:5N3<W $,'::SDH$+7]PQ*; I"')G6"F#CY?N/#6
M,Q%U\+H?M/$YGZDH(B.I.D366<'3HM?,Y8M[9$2-,51R&4U68$N&*A&#KY+A
MQ!4<-[9;+R\\I*EFFO_WU\<NN>?3Q9[7!CP0OY'6N.KNEK._G0)L-"*K42RI
M!F3[*LAU<9&4*?Z)WIA[F)J1D;&$U.;X=)F=*,,'7[(M']]E&W]FZV]NW3"V
M-]]*F1O'?)N6RP\KNGQ_Q59Y*"*2A2Z$ ]:@-ZU"*,X0S9ZS2I:LZ)=[>BI6
M]?/L'R<-QP_F;30'[+]9*@-^JW,^O>_U8Y7Y-\=?^Y5^JN"]+T#6#BFS94DE
MXQFZ-&3I3'*>=!?I0V"=NMB<])N#9C$;[J:\67W[R9WR^@!I!H Y>MR99U?:
MH>L4)?H ["PM#4^LJ@$ES/>TS"2@AG_\2@@QY5]R3_Z4^"Z(14QLH6GP<_7
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MZX1//^X@$8V$='<MB<3CMIH)K<L="&A.YOMR2)P ]_"*OZ*XE@=3[LT=Q;*
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ML6@%YC2X%O/8'X@F9!-@*19B$]W6)9N/]CY3&_/SU^*R1V6>GWUK[_P>"0H
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M1D>WON83SYHCEFJFV:P,Z> #,(GS3ONI;1@,#EF\ DVHVA. ]K0,*ULYWPU
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MC6UOZ!W9_<T)E7T616H?(-]-( ^O"FVMO_XYKUV,K43I3OWQW [96NW/T7X
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MW\6;R8Q]>K.U,D[ZO@+IW7#=@+)E4=Q'K=C1C1$0.N#?22[#%Q[=+;M;M,I
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M??>&Y@?L>@YL6P-("/G!R#?+UE&\4,Q-_X",[G?7M-F4-/7C!$UG9O&B%C(
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MEEW*;#-KC*16N,YXU#Y96%Z(Q^;=@K6UY59WZUP**X9_\\(3,OSX;OE(M6L
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ML+Y4;YDQ\RAJ%IZ4"[ 8>>:_+6L0# 9#G,POL7!PF%R R41^DA>?B&\/\@D
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M,HA3LX3@2$ 6I1E,5!C)))4LLSMR[N]F;G;T7@:!Q\>RH/R^)HFMS(/RDY]
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MH)-UK\2!5?:, 0"ZUXKP N3$%2/D/J"%D=I7"7E;4&R*1IQN9/+2$6?U.59
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M*)8019)!EG "$XHBS,.0(FI5]FU0[[/;5KQ_"SHKX J$$0S(%=AJ55N7.[U
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MMV?__CKYY?<._E_D,GC_0Y8\K^1-F7-Y6RR7JBC-BPMS&P7A3$$]?\V-59I
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ME4]YM5ZD 8Y(&(<P8\048=5_,)[$,),B4"Q!,M0=.QB*'F6;&]'VV3<[_:[
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MLIQ+&M!0F,OPB2G?E4(2)2%,I4H9BZ,TLLNEU-/'W,B[EA*T8EX!(Z@#BYS
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M=JH?'--9OC8P;90L395.XQVIS9S.MQ<E*%$A$QI3*2$*PD#O4[1!DB82A4&
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M+!;+J^7JB]UI5$;+<DI(1A$1V&8J8$AD%,&<Y2F,$V6C5R35$CD;8QX#C\U
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M7<UEFS[]L+"_NENORA6KCF$V!_UQ1E*J*(-*2+MS&PO(XRB!!"/*:)8)JOE
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MSL2A,0;>A3BAYOZ.PZF+.WHORV]LWM35N%[,R\6LD&US\GOSYK0%K.[TYI!
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MYYXQG(/AJ,T+7\'UG@[D^DE]8[/K1;DJF[<UXHB0E'+(4X4@R5)B;/38-F[
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M[3!VM#_0":-% %00C* %1K<Y>^L&%YY2_SG:5W2;BF#-*3H.?\E)%YML^-$
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MF"TWJAQF#GHFS%8)L*/%!&SU "\4F8"-*CV4 ;\<T$!,>H$@@_+IY8"]9M4
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M0-GK)+C1?6!@^^;\Q?P;_%3\J++[Y]^J%-PJ5>(<BMZ,[X%+(-IW&7%0[O>
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MQ6(VC3A)C1UIW&F:&[;*D(0LQQ+B+,J9)''",M1:F ^.6T#=Q>E@53X,T4?
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M8*.*C1!ME0&U-BY<P6WGI-DJ=H-TQP:P.Y"=C: _;DWV3C]MQ];I?VWMG,=
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M\N).OCCB +W.]%H6K4-0W6Q=4*@ZMFLG^;*TB6(2?*$3,2K]PH<?\RY)LL[
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M=HDBI7*68K]L$:_QAY<.4HMJR,PK64> UCIYEKGXS86;I>H,WXY-U@;8KSO
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MRRAY;Z@'#;MW+_4;Q/%[FXK3B0']#=^21VAWP.;Q#KF-/NMIJ%+I*,LD1KB
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M5YL&DE)!%,MA)F.]3^-)!(N$:]M!<B(EC9,B1WZ9%1ZC#R_C8B.S#9Z).A_
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M._#MZO/''JU67*;(C-&&!#XPVQTV7%E?[KBRGH1O6>4+WQ"-5US$>;O>*SW
MZVR_TN>YKA6]=9_!S\MU=5[[NAY2C;\;\[V0RY78Z_?Z0?VPWLS85,0R9ZG:
M349,-[5B-(>8<@EC63*>TS*/R]*VT+>S-#8?_S ED7[[T[?S 5+ODV%&L0,!
M')A=FV:I[[0>O]2%*':J['&JVNEK90[:4RN>;13R63:\-ZK>JHF[2S)PD?'>
MD!W7'N__2-?#Y MQ*Z]7@L\VGPBK4J:NEX^/LRI^_TGHPD0Z6$0>Q)23/$-4
M[:RS(L40I7$."9,1+.,895$N222I57*F^=AC,TQW8@(IU.?\M)74\J2/#?YF
M/!D(U<"\6.VAEQ+4<H-6\ G80UK)#G;"^SS0;HV8MY/NYB,/? 3>&I+CL_'V
MCW"(.6NRU-68_YAMOK>U>NYF#]\W2WDGU.9_H?T RMC43H#O9*4^(TRC$A%M
M[+$DAXC&)<1I7BHK,!*(LC1+4J-N"V[#CXW)=O(!5@FX)3-#)G.<!8.H=E!L
M _-9*SO0PF]+C$U )7]=C$QK, %[^-=*!$7=(FP>%/V!HNH!9L$N\.X,8F=<
MWOZIPX7MG34^B.J[/\4UO%15?FNM;SWT7_>&;I.9<))(7@J(1<PA2K"R?24B
M4+MP298BA)G5P7NC4<>W8%1"[_:NQQ^8CK>R[X]D]7?;$)/)+)C&F#QC&SS(
M9 %K@-.15GAY"SB9C#EPQ,D"AN.0D\W-?GJ(O2?K&:M.;^X\K+L^.%E)1<DR
M#M.(I!#%40%)J:S>5#%6P8LL37,KQK(:?6S,]5>A5Q#! ?DA5FK;4?<;6X/E
M[A!\O]YCW7-AQEO!$ [,7Z?ZE%6R3T!]O'L_1A2@A9$3;H$:FW6/_:;MSHQ@
MN=0$S>PA#IOY#X)N;A8Z;J\W!_IO'X0DS_--VQ3^CFQ$6Z)B6LHH+>)<:']D
MI+;OK("4) P6-)68H)+GI?E&WFKHL3&;%A?P6EXP:P0&*R6Q^EM;=L;:1^DP
M)0:[^F! AXZ+:XQW@D] ]8M&=ATE;U#7XF^+_00#VF(C'PSP@3;Q?H&WV[\[
M8=>Y=[=[XG#[=B=-#_;L;D\(4%>D/71:U6??9?+("&<19VJEX'$&$8YR6%*U
MCX]9&45$TCS#5EUV'608V[I1R;RMGOP"UDTI?(\U1\Y,AF$L*RS$H6-:!K5'
MMD?]ZRX3($CV5 \8ARA#<D:"\90BZ8;(JAS)A4?9L2$7L^G'Q48][HIS]>:N
MF__IT%L\E06)<*E[B4=E E&9J)]*G,$<DQ03S#(NC9)+.T<9&Z/5@H)&Q$G[
M ZCBR[<+0V;K!K:;N[S!%7K#[HJ4,?T8(7&"8-:"_>EA^>/_JOMK;E$_["BE
M^ZF#D(:18BTMF%WLL%G^**5@^A3W-BM(&UBZA=A"1]LKJ_S+<L'5BJXN4W3S
M\:>N$*G^)]BSON^@9.3C\GFQF1*>Y04C3'%&H?N/ZT..*8HA(QG*::'^PZ7Q
MECJ @&.C&R4^W,D/1"NY0R/)8'-JL"=_XYD*S72M=GO9E/5N\5##"3C0$31*
M3L!6S8/"P(HR*TW?>'HM/ %O/,T#^0O>:KKM/ L!YZ+3_Q!BW.&\% %1._!E
MA!RGSVD')<C5\^;[4F\A/BP?R4Q]\1$M<%DDL"BU6X,C":DL,JAFGHL(IX@Q
M;./6.#?0V);>O8][*RGXO9;5\FCK66S-O!0^$ N\!+J!Y7B:X#P27H\*G!CF
M#<X!G%?V=))_Q_7.'22/,@VV[H8IYRG)!).0"*H,>I(*B+%D,)<)RY-$9)1:
ML4/G:&.CB&T:C7-_N&YPS>C!&V2!.>)<LN165J\M)"]#XJ^)9,=80[>1O*SV
MB4:2!C<Y^ ]^%?Q>L.]-5AV5*4TP22$E$8(HRTN(F4B@2'(I<ARG$39J-GO\
MZ+&QPJ^Z*(R2SF+?=@B5P8;:&8# WWBKNTL5MD,0++:=SF ,M&&\^$+8[>Q.
MJMNY)SN\8[C=U$E)#_9!IZ^P(YOU:C/]NEKJG=+MZIM8_9BQNOFRB"*&LK2$
M>4DD1#(AD-)(_90A)@7"*"%& 8IS XR->!H9J^(QC9A6#:W/ ME-2#[@"4Q+
M#L@8?Y.7U.\R,]2]>R:&^MO.O#C[V$$^WTM*M1_QQ>L<[(:[Y0N9:U/ZP[.8
M+;YIGPC7-4^G*4T%13R!G+ "HA1AB",6P93B)$5Y$4M2&)L0YT89VT=MWJ*E
M&SP#H\(')($_Y*V($Z"$!+,%J,6LBN+Z@,G"[/ !UT 6B!ML=F;))3@Z+92S
M-P]GK%R2_\!NN7BQFZ_E$YFM_D+FS^)4?G]9DBQ&4D!1D!@B7!"(99+ B(I8
MLCR6I;#J7=4UV-A84,L**F'W\OS7)HG^]CB;>5U\H1>8,-V!LW:ZF"#BR>?2
M.=2@+A<3I5][7(SN<8WBU*FP3;AHFF$FBR**(,>9X@PNU!:(H13RDJ RRU"6
MQ&2Z$ ]D(PRK&[\:P>A5Q_6KOC].R%!$DZ\MVGCK0AC&T,^A:!JFL4=FJ.A,
M TDCFL^ S$F=O<5A#I\^</CEI&K'49?3ESD&6P[*F=1>#%GD I<4EB66$,5J
MPT,CB2$B21;K7NPQ3:PB+$=#C&VQ?U6CQ\J'T0&D832E%SRA0RAVR-C'3<XJ
M[RM8<CS L!&2LPH>A47.7^GV:7]KSC[<RBO&5L]J'=P%#5\=7A YSI(\5I:^
MY#E$LM0=QF@!:<D1$H(S(BRK1YH/;O.V#U,LLI'8/<AJ@;P91X1!,S!WM$+K
MLC0MI'MR!ST@8@^8)[ZQ&'A0'K('Y#4_.3S!=4OQ0RS4]+[H+4OEIVJJG*^G
MG,LH$@1#ENHJMXDH(8ED"LN,I 6F291+R]2P<T.-S4392@I^M**"52VK[5;C
M++JFNPX?F 7?@+1P;:5LVQMX[)ER&0IO^Y*S PV\1;FD\/%NY>(=/5GB5(W[
M*,.)9!%3>Y98V3-Q&L$R91C&,H\I20E*D)7GLFNPT3'%E[]\_')_>W?S\9LC
M,[AW#?"%TV#L$+S.OPDBODGBS>OSFRA]EBC\U]7?62Z')_K7N]>[0 I-01(8
MI;J$:A:K#5":8%B6-$EIG*1E9D48EX<<&VWL6^N?EXL'6#5QU]*[[GW.@FV[
MY_$!X8![G4/T]@I]#+7EN827]ZW.V0'?:(MS"8#S6YN+=SK6N/N?9^W3:0-^
M.98Q+9"$));ZA$N1P[)0Y),4>99CC/(,9U9%[ X>/S9FJ:5S#IV^PLZ,/-P1
M"4P4YF#8%XP[J;.OBG"'#Q^VY-M)Q8YJNIV^RNV#_96P[[.%6+U<+;A^\).F
M@[9H;APS$1<9Q#(J(&)Z<Z$^6\AED469)&F4%';.TH[1QN<=W0I;)3>*5ER[
MC[H+7[,OW!-F@3_W0["V<@8H=VN AR<JZ!II4%XP4/DU29C<XKC)>*9K]3&H
MQWW4&YG*T)L618I2)@C,8YT0GF<E+!,A88R+/,U(+'ADU0[QU"!C6^YW,H)*
MR,;HM5SU3\)IN''H"5+HK8(M/O8[@0X ?-G^IX88UMKO4/+(ON^ZUO%S;\K&
M"GYP,'ZU4E,M-*F\?]E=\I6\Z%]=_4%6O#93]O885=G9^^]D<?M4-<;ZBUAO
M!+]9?*U:LD\Y1T6!$8*%E @BRC$LHSB&DA:9VB;0-,IBNX2JH40W^N8&S=32
MQ6UJ&<$WW6P!5&J!WQ95 _KF7][51;0MVUX-]CX8<N"8YG@@7M7ZP$JA@S(G
M8$]K0%_ _G6-YO5[, '-YFS?8U.7^MXH_4$#P/9%F2U #8)'YAYXVGRM!D.)
M/>P*,_!D'*U:0X_O+1"W<W2Q",<HBB&J4@D35D*"LPC*N$@Y0CPO[5().\8:
MFQE\.L;DZ /KPM@Y,C="[Y@K:#["<H$<9UTCO750[I)+S>06-]+X(*18K32S
MK3?K:_(TVY#Y[!^*QE;BB<RXVIU7G'6U7HO-^L1+3S I.9481AG*($JS7"<L
MEI#I:!WCG"O+TH98>LHS-O)IU0&5/A.PI]$$-#I-*I=4;=_4>OE@JKX3:\9F
M TY78,8;9*:LZ=$3OIXHM*\T@]*L)^A>4[&OQ[K6X[XG/V^X6@QF<L;J8H'/
ME;,^)P5)(YI!3HL4HB)!D+"XA%G$LD+$3-#,J,K.Q9'&1K%-M6E=@.Y07%#+
M:UN7^QS W83H%;;0H4]7Q!SJ<U] HT>-[G-/'KA.]P4%CVMU7[IA8#=H/?JM
MK/YUW1005'PV92GE@L<$4I0J0L$E@R4O"BB%I"R7I$2E7<C$MX1C(Z)?R<_9
MX_,C6%3RZ@2DI@O@9@FH3DA2"X<X[Z,::%H#NRU]3-;X_9-?ME-<ZPEVBH[
M!WEI#M[:V7A6OO\=7L5+\'IS'UX<R&VI^*H^I.]JK%LZGSU4LGQX%C>+^^^S
M55T)IXSS+"M1# FB.40YRR%-<P2CG&24)[F0L;!A_DL#CHW(U9N>V]'T14C-
M6-<G4(%)M!45[&2=- O=UVJGK.4%]XIJ/-8<,,7'$\%='&Y0OC)5_C7]&-_7
M-Z?_RW+QHXIG5'QUI8O<'W=GRZF,<$PXS!%G$&4Z$%$4$DJ6X91Q'&51XGK
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M(+-%T]//7QN_/A-MX0QZV\D;Q)/4V>ZOG=A64["G:A4SV5,6[+3=[Q,X3'-
M#S,R0,/ /E*.IHF@!ZAM&@OZ&,[Q:(1:UCXIH[&)*]]4S8?TBK;@)U:W$\GZ
M@J"BB#,",=*YBYP6$ N$89D5D<RQS'B9VZTH?44:W]+Q[?GI:5YYUL@<\*W
M.D"[6"Y@E3 R:]6L*,>#\=Y[9LV6D"%G*_!:41GU6I?)-HWGYF!63IKV.Y7"
M'.3PA*^OTQU]Q1GVR(<G\([.@?AZKL\.L5.9E;%(LPBF.6$0R5+7FY<9I)((
MEB"641[94?'I@49(L#I!%M2=@]B>I#[:HO;J3CHB=CO9E6?7;F7'>=[K@71#
M$[1KYAB:5YY-\.Z^>N#FT4W[R:K-Y/IF49?YN]B#<EHD94YI&L.TJ'RQ10(I
M+Y0UR%DJ4L4Y,K4Z+CNP_&/+\:NU  ^5%CH37&T:F@JW$_!'VW&7-!UWJ\L
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MG_[CG]K?J#^T8?T?__3_ 5!+ P04    "  &B@-7TQL1M9W*  #E'0D %0
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MXM?Q)&W^ZSR?7=;0WG)64Y8KC2'=?_@%V<\PGT-ZOU+87BX[%I=H?:'[R7/
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MU2:@:X,Q44C:$N\0V"!M]/*\[-C]%8]++-%V87"6")M0_R>X&!<A3)>_^4O
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MCNUYZK%F)U'GF(N.,.MR*<+/!$]N28S +>0IAAC5>QX?)&C88H/Z *HG_2;
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MHP)"AL?:_3V?1&"]T'*S[-;ISB0UAB+;1N@R#S40#&$X"8PYQ[13,=>N83]
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M/YZ.M$Z&(_TDFH@B2QBJ!4,M29Y*896AT=9^V',$68VVLSX5"D<WM#Y-+PU
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M@%>T?TCL%D]6\)Q28$0G9$<F&PB:TD"$I31[I@6K/A;@&+J&]9)Z0UEUE30
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MZ^T#G8_3SU]6M3YX=;F8;1?N]B_K*1"O"KW\P^4B?8$E_@PK_(AU?$F=RK3
M5]^^+>9_PL7$0E9*BRH%\B!H)Y(LZ%!]B6)#/>M#M5]_U<%('-><C@#@/I3=
M/>0_(GTS_8M8?/T%%I]QHM&)Z*$P@:86_;C"HO*:665\AERXOS_?XE@HWW_U
MN#FJ'B%ZDG*ZA]XV_KH9<[=9D+],"WZ@U;A8S3>_-RE>JB)\#<A2'6<G.0M)
M(_. QD<(%+4U@N2^)(U[ ZM'J ZBS XRLD^._GPW2PNL6P5N_GP[7US]_M64
MLW>SJ[%6K^=?XW2VUM6$]HADDC!,F%Q'MZ\;!=&7K*7@,HH"NO4=H$$8&7=(
MXGG703^(&-VR;[E^5 +7PTO3_/-L^C^5WVW^>]M,:.-J36B[\B$B9](HM2DN
M]DI&)D'ZE!R4H/>KR&Y!S;A3&,>PY^=6X<LN8GCV%ZX7^?J^,<SRE3"G.&@%
M1!/"SE@^T5Z0YZZ]R)XGB8H)H>J4;P_D@>?$'!>1@RXN8'R9M1>OTKI.EU24
M</IG/:_\#5?7_0R33;SX1(%'S8Z@%,Q+FYAQBO8KK8+1K4^.GZ+GA51"'("5
M!^W)6FFC4Q]ZO;Z)I8F46B@*7ID"29L([2+,1^M9*I+81"4PM2ZK?HJ><<_)
MSH&L9MKH%%G7;LQ$)#0":''(DK">EE0IH6,V1&,Y+Q!D:UO])$'C'G"-A:WC
M]-&UO_@6IHM_PL4ESLM;"N!F:0H7[V8DO\N:%UD^\^,3_,$V+V[G[PT@B$;^
MW/6K;_49O8:XB=J6#(*A<[1_ZA!84(KB&([::K".J]:MYY^BY^3!]%?/WCC-
MK^XXS;\BU)?E]Q11UB9(M1!]EG^;SQ97?_T)EM-M@EIG-#+S>A.'XCAM*;*,
MUA0F V@3M B6MQY.T8SX<7W"9GA[,+Q^%.5VL+=?,_[3]RV;U6B\7>"_+W&6
MOF\J_@QP'D---T=B*5O)0!&'N= .QIV0&%KO\'N0U0D2SPN87;!MI+V> /D8
M0U>]%Q"LK>TQ@@]0C\0X Q]#=7;0 K'DK1T*D+O)Z@20K:"P"VJ-]-(IU);7
M*_;JVJQU@G.=*4*KA[\!/8O.<Y;1NVBD,<JW3B+M0U<G8&L%ACW =I)FNB@I
MO;5$KS_^[RDNB*POWW^AP''3!8(;4P>;<!;LID"6-@1)&X(/JDA>2HG-K\#O
M1]FXIS;=[;BM=-BK)7S(WW9EAVR"#;5!HG*):>ZPKG'-/!8-&3$[UWH8S4$$
M=F(;&R)D'_/81%T]8?'=[-OE:KF6F+BZ12!45D9D9F6AG:1VR0'E@26*[G*,
M*8K]&E(>@[R'Y'2"L_8@V 6W$S72UR9\BQFY948693)JR2S4D<A& (N"5J>S
M@$48KT /9M@>DM/)=CL*O([12+?P4EMF2$)<*&(F@[9D\IUAT9#S(32 5,58
MK<YAO=0!\!HL3S(NO([12%_P.L$)_N6ZL,EI;63A@AFOR0>1')DOQ;*@$91*
MR1;9NJE-4P8Z@7 ? <G9$=&!KWB+U4=2 S>9 0\N&F%9C-DQ[2$S\%8QGB('
MKFUQ&1KC?#_*.O$@SP^=^>!Z[,)</U*#_'H]/>4SJ8<^+:=Y.T+E)G^//!AN
M4# >Z(L6BC,O(S"NC$7DR2O9^OCG"#+'1>X0>)F?5W7=6\^)DPX0"F=6U1MX
M6*N4H  SKC@O/,IB]NKIW,QJCAL0G0%S#172]52E)@4M]Z:BG;&T1_96VW-/
M%.<H[A$@-6IP3$(AE]7K"OA@F*!@W9DBDQDNEFU8W+.^IG']X*?=G[6_\\=L
M'I>X6-<*KP/*>G^#U'(QW1BB*_E$[W*V%*>JG&2-6".MU>18DA9 ^&)$>A:L
M0Q'7B==Y*JSN7+496X==N)L-A? :+M+EQ>:.U/SBXNU\\1<L\B2FG%%8QV#=
M1#KQ0OHQ)"&I9$J^H!JNIF\HIL99#GV@=M=A0A< ZL!%?NR8LI9=/V!^>9?[
MY<=[4?(V1%@_:R*XUJ6@9L;DPK0-NO8EELQ;X!FDE#RWGM(W"".=;"1]@'6/
M'.UYD7/T\OFVOGCZ^PH6JU$7T0Y)7+6.J?-2BA:Q6*8P4D"4R&_P-2KBP@51
M#&C)6Y_K#<5+)\F^'VHI-<7/V.T &@MA<\DQ??\'3&>_S)?+>F'I(SWT^MD3
M:5TV%B2+4M;!Y(*$DZUE&3 EK10$<(=%,&>BO).L4%=+J7\(C;V^7G^I/4_?
MS:Z%]+[L..^=*"&B*BHR)VRHXY42*8#8,MJ5G)3,H>PWTW+_=X[;"JEC3 ^D
MMK["^:8NI*,5B0KJIE>O28F,#"(HEI"#%K: M#].\#%85Z0^ET0_R#DQ^'@S
MRR\A!W&/W3/F(%1O.8A[HCA'#@*44TI[7_UU"H952BQ($9G,J?:Y2T8+.90E
MZ_J"<<"BA%>>N5(;6$KRP$@PA8G:_3ISXZ0;[,+F#WS!^!"\#7?!^!#E=G""
MNL,;^^G[)WK ^B:$*5PE'@WCSFC:5NJ!==0D5L4EV<R0DVD]R/%9HCI!X7G!
M\DB;D7::ZQ>*E9UMG;$/-D!,R(@512$"10=>%L\D@LH<2K%YB(ZA3Q(U+A0;
M@V _B!VID;&/$+:]?VCY8=YV[]_6F5O@DCLMF8JNCJ00M'.(;!G:$()+66HE
MGW,;GWY%ER@Y5H^/C$@X4:@=6)]JT#=2P?1E-OWWY6;YQ"(,DB5FP;C:J3ER
M%K/-#"$D\BMT(@O>V.0\3DDG&8A1M[P&.NH2:5=7\I-U607-@N:T"'F]04-1
M.Q-!6V6SXR6VWMYVT3*NO6JAYV>A<X30^P0/A4*U2R;FU[#\\O9B_M?6 &N;
MP!=>&*\E6IJG>KR?"E/"<,5S#%(-;[IV4=<;P(Y!P_,0:Z&:?MTFL#Z55"23
M%E/M\$$[/%9^H-09':&4^T/W!G&;!MOTFJ*DH2P[,$-[=E&(: RA6S,K8ZY'
M,I+%")Y<PI"D],9C&JP3U.F]4E[ U<13O*D!=-@3,O>ZN:R]SY8;9*;DVN?5
M ?,D3Q9X2-H5L#F<HT3I9?=*.0@A)_5*.41=/6'QD;OMRO&4/ 7;:&P=H$:F
M'QS%R-(GKIW/.L!@C<N.[#;02:^4@T!P0+>!0S0R:@'"W8'?PA@3G!;5YDNF
MG:&HR*!GP;D2!=3_;S'Z^/J%G=2ZC+)U'B_YD:=EWYX8':*(*H-C4&<F:%LL
M@Y"KYYETY$J!NC_<\'C =#$B_7!EW5?W$9(;>SSZG;GN,@AG4W8L>*2 I7C.
M @4J3%GEHG->V/TRSL^-1[_]TI&5?HS*YBWD-_K6<&^RN],8"VB6="4=*;#T
M7'A6=!8F8DE9[G4*])SJ;[]TG+"]F>J/EE]?98E/=!J.)!H(T547BD0#NI:Q
M\<*2$=E9""FHP<*>$UN&#U\RV$M0WD1[/45!3W0C]G7"(W>>8?*%:1-#/=HG
MWYN"1PHM%90PV,R%E]PR_" H'-$R_!"]= JU!XVIN>"&2[ 4-0KR!!.M3+"T
M4&O@B):#3JYUXY0?HV7X06 XIF7X(9KI8J^]Q<SZ0.&ZZB9 CK0",].AGE&4
MDEE$8>O0I\(Q%<.M:(RQ7;2,.]:UCUVUB9XZL&^/\;%=G%D(#9Q<5"X1F1:)
MQ).R8CGF@D[8(FWKCB^[J1G7EK71]AX0.D+T'8+H*DO]$597H1,W9'8A2*;J
M"B.W0C%O S&H<[(Z:L.A=:?EYZGJ#U3'Z/\96)VHC+&+!>ZS\V$QC]M+2O-R
M+^.=(]$N'"M1E2HUS@)7DOQ7)2+GJ=AT[TQJ1_7 _N\<MYR@,8*&E'<'5NJJ
MP>.K]._+Z7*Z5E*UX1A-K9$A49E$;D#RFGEC+$,C)0KCA+N9]MZX_^8]4O9"
MD_NQ':L66NH4;/7C J]6:) Z2T?!C@HU.1A%8E$407$W%HC)2 6M*UF>)6K<
M#;&)ZO> T_%Z&'LS_ AY"C]_GUUMY"(:B9K,N@F"K+P"71>:8S$ AN2$-MGO
MM>/=>W!_.#A!9_-& NS JKR=SJ8K_&7Z)^9WI)#9YRF9VXVY_NG[K_!_YXO7
M%T""JZM&JP1%1L<$1,FTJ?.&7 Y,U<Y1HF1I8_,[H?N3MQ?"_(^]U0VES;Z!
M>L/8;_#U:D';),'ZDIAPD(@]"J8AZ\(LA)*M LFQ>?KH,!)'/DP="BK[0_)D
MO8V]>;Z'Q:<%)/I?QJ^P^-=V"RB8!4_),AU\/<=!V@(H2&+9FZARSK8XN]<>
M^OCSN\7-Z?J<MQ5N#V:KZ8 ,KI(U*5KF?,!Z0AA9R!H9IV]'F50VT&-7AE\.
MFK83?O ]>C1$C&TN#VEX=-TQ(R?(8)5F*FE51<U)U*[>:+%29">\NW_AL$$7
M],[:G)\?*<?V13]*;5VD28\:UJ(Q<,N!95-GRAF;602KF1.T9QEK:ROZ@0Y<
MNI^S<R;HM!BY<X 67RI4[Y_!3\"$&!Q&9DUM1.3(+L3L TO!<8A*:;"MPZ,&
M9(^3''DQ4#Y)RQTXR\\,+_)0O/"^#O7 ]>674A-#B?&@-=;[-L*W'FO68)I4
M\QN:X\"QH6Y&-:)KZ?TQRS?7WA]?5-=,/L9M\26GNJ2L]!2)6AU9]!2$IDR[
M!4_.FKQ?A'\B(2^_X4H#__2<RNQB_U^+^]W7;\1+-?6OO\#B,RXG,FA?@M1D
M[&MS8L43@V(RRZI^UB4C;UW/]S@E+__B^FFH;*BG9IOR$/UOW\W^I&?-%R37
M;0?7NV3OU\OVD:>TZTO['(F->LQ>O>;[(],<G1 B<T5&Q5E"$'#.O-&<<6L!
MG)$<FK>X>8*<4VW/]:-_P]7-R+4,48)7K$BL]Q9]JB-[.2M6"_ 2#;K!6+Q%
MQ[BG-:TP<-^*G"SQ+O:L:RX^PE^_ EFG*5PL)RJY)%THS.G$:S&]8L'4Z:0R
MQJ(Y9NY;]VU]E)!.D'.TAG=!YFAA]X69_YXO_O5N]F$Q3Q0/3Z20'E)2S(HZ
M<H<GP0)%-11Y>!UI#PU!MQX@^#@EXWK?PZ'F>''W!9N:JEQ^P?R/^3PO)Y[B
M4&,],.YL(4_.9N8U)&:4\3$"_3"WOGSP."7CNL?#P>9X<?<%&Q+,!)4.Q4K#
M:OC'- (R .D9!8>F>-0EF-:EE+??/V[_DN$@<JAHFXT@;P"+ZTY['['./Z%
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M4S/=GYJ;DO65^'>SM$!8XL^X^7-B)6H?M*PN&ZT&H1(#1TXV>BDD1Z%4:GW
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M;O#X<G E=@#4)];W9G" @42D0V3!J5JB7#B#:&KCH^*Y%DF%T-H8/D?3N,'
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MSQ0XWB=MO_0'_T%1.Z0>^SJ8NS>&62-W&&)D7-6;24(&%B#4J<PJF2"<]'S
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M30]^_@32U?M H9$\3SY)3;^Y_=AO-7"2^O$%CYNDWI+QH9/4*<LDDO2UOL6
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MGQZW=<4 2#A,>&.K_AT)?_YU2B[YN^]_ANGR!H(9#RR7]0M\4?M9D[D+7#%
MG6-.NBAIMS,.CZ^Q%1CT"8&AD3A'1\5J&7 V?3>?+WY<J./\[-MB.3W[^7&)
M?X:?-]C*,>H2LP(1&8DJ$^Q]463G,%CM9?+I;B.!QU"R]9I;H<:<$FJ&$??8
M*/HMS,]+V,CH$Z[_]?4LQNBE$,%Z2-+7H:["@ MT5$:#)7IAN$Y\.]_TJ66V
MPHH](:RT$VH'J8]UAOV6>"Z]IQA4=-9 C(7B^>0+1"%(1BS:2$PJ'UNGUAZC
M92L$N=- 4%.Y=X"?7\Y7TSFN5C?BM(N!T=J9J P"D9UK0IL">.80N-9&2\6B
M;MY#ZQ%2^KGV'S(CVT(/G<*I_I(BN\VF\RIZC\J CIGL:T0),>4(QG"5 D;.
M^#& =8NH<?-Q352_!9SVU\/8;M"GD*?AS<_Y97A8(OG]!AF4HBD0L$D!B:H
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M :Z5V]]EW[N^>U]QKO^'%Z[/_(O>_P-02P,$%     @ !HH#5WY1#Y3;!P
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M[+MVV'M+MOVN[NQ.U%WAOU!+ P04    "  &B@-75>+"-KP$   V%   $@
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M-3,Q+GAS9%!+ 0(4 Q0    (  6* U>=E@ZHNC   #/H 0 5
M  "  9"? @!A;F=O+3(P,C,P-3,Q7V-A;"YX;6Q02P$"% ,4    "  %B@-7
ME"7/S;QJ   4DP0 %0              @ %]T ( 86YG;RTR,#(S,#4S,5]D
M968N>&UL4$L! A0#%     @ !8H#5^6^AY8<+0  (BX  !0
M ( !;#L# &%N9V\M,C R,S U,S%?9S$N9VEF4$L! A0#%     @ !8H#5Y4R
MX(?N,0  J30  !0              ( !NF@# &%N9V\M,C R,S U,S%?9S(N
M:G!G4$L! A0#%     @ !8H#5]B G5.V-0   C@  !0              ( !
MVIH# &%N9V\M,C R,S U,S%?9S,N:G!G4$L! A0#%     @ !8H#5YLW@^,^
M P$ RP0! !0              ( !PM # &%N9V\M,C R,S U,S%?9S0N9VEF
M4$L! A0#%     @ !8H#5X1PP,!P5   $5\  !0              ( !,M0$
M &%N9V\M,C R,S U,S%?9S4N:G!G4$L! A0#%     @ !HH#5R I7#&"1P
M/U   !0              ( !U"@% &%N9V\M,C R,S U,S%?9S8N:G!G4$L!
M A0#%     @ !HH#5VX<[]NY+P  OS4  !0              ( !B' % &%N
M9V\M,C R,S U,S%?9S<N:G!G4$L! A0#%     @ !HH#5QCSDK>A&0$ R&(!
M !0              ( !<Z % &%N9V\M,C R,S U,S%?9S@N:G!G4$L! A0#
M%     @ !HH#5P-..A:#* 4 +% & !0              ( !1KH& &%N9V\M
M,C R,S U,S%?9SDN:G!G4$L! A0#%     @ !HH#5[MTE;=K60$ =C0. !4
M             ( !^^(+ &%N9V\M,C R,S U,S%?;&%B+GAM;%!+ 0(4 Q0
M   (  :* U?3&Q&UG<H  .4="0 5              "  9D\#0!A;F=O+3(P
M,C,P-3,Q7W!R92YX;6Q02P$"% ,4    "  &B@-7KIS8ZEX#   Y&@  $
M            @ %I!PX 97@R,3 U,S$R,#(S+FAT;5!+ 0(4 Q0    (  :*
M U?-II$*"0,  /8(   >              "  ?4*#@!E>#(S86YG:6\R,#(S
M8V]N<V5N=&]F9&5L;RYH=&U02P$"% ,4    "  &B@-7N5J9_]0'  #O+0
M$@              @ $Z#@X 97@S,3$U,S$R,S$P+6LN:'1M4$L! A0#%
M  @ !HH#5WY1#Y3;!P  2BX  !(              ( !/A8. &5X,S$R-3,Q
M,C,Q,"UK+FAT;5!+ 0(4 Q0    (  :* U??ODBSP 0  #(4   2
M      "  4D>#@!E>#,R,34S,3(S,3 M:RYH=&U02P$"% ,4    "  &B@-7
M5>+"-KP$   V%   $@              @ $Y(PX 97@S,C(U,S$R,S$P+6LN
9:'1M4$L%!@     5 !4 9@4  "4H#@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
